Treatment Department,Deidentified,Plan Provider,Plan Date,Plan Name,Line of Treatment,Plan Start Date,Plan Status,Disease,Unnamed: 10
NBR BMSCH 2 PED HEMONC,33818,"Sharma, Archana, DO",10/20/2023,ARST2032 Regimen VA,_1. First Line,10/19/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Sharma, Archana, DO",10/20/2023,ARST2031 Regimen A (VAC + VINO-C Maintenance),_1. First Line,10/19/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Sharma, Archana, DO",10/20/2023,PEDS AEWS1031 Regimen A Induction & Consolidation,_1. First Line,10/19/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Sharma, Archana, DO",10/20/2023,ARST2031 Regimen A (VAC + VINO-C Maintenance),_1. First Line,10/19/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Cole, Peter David, MD",10/25/2023,AALL1731 Non-DS SR B-ALL Induction,Induction,10/24/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Cole, Peter David, MD",11/14/2023,PEDS AALL1331 Blinatumomab,Induction,11/13/2023,Inactive,Pediatrics,
NBR BMSCH 2 PED HEMONC,33818,"Drachtman, Richard, MD",12/1/2023,ARST2032 Regimen M (VAC),_1. First Line,11/30/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Drachtman, Richard, MD",12/1/2023,ARST2032 Regimen VA,_1. First Line,11/30/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Drachtman, Richard, MD",12/1/2023,ARST2031 Regimen A (VAC + VINO-C Maintenance),_1. First Line,11/30/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Drachtman, Richard, MD",12/1/2023,PEDS AALL0434 Arm B (CMTX + Nel) Maintenance,_1. First Line,11/30/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Drachtman, Richard, MD",12/1/2023,AALL0434 - Maintenance Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,11/30/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33818,"Moerdler, Scott, MD",1/8/2024,AGCT1532 Arm A (Standard BEP),_1. First Line,1/7/2024,Inactive,,
CINJ PEDS HEMONC ,33818,"Sharma, Archana, DO",7/10/2024,AALL1732 HR B-ALL Arm C Delayed Intensification,Consolidation,7/9/2024,Inactive,,
HAM OP INFUSION,89879,"Yogarajah, Meera, MD",5/6/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,5/6/2024,Active,,
CINJ OP INFUSION,83892,"Boland, Patrick M, MD",5/7/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/2/2025,Active,Malignant neoplasm of cardia of stomach (CMS/HCC),"C16.0 - Malignant neoplasm of cardia; R05.9 - Cough, unspecified; E03.9 - Hypothyroidism, unspecified"
CINJ OP INFUSION,51798,"Boland, Patrick M, MD",2/2/2024,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,1/4/2024,Inactive,,
CINJ OP INFUSION,51798,"Boland, Patrick M, MD",2/5/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/1/2024,Inactive,,
CINJ OP INFUSION,51798,"Boland, Patrick M, MD",4/19/2024,FOLFIRI + trastuzumab + pembrolizumab,_2. Second Line,4/18/2024,Inactive,,
CINJ OP INFUSION,51798,"Boland, Patrick M, MD",2/21/2025,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_3. Third Line,2/20/2025,Active,Malignant neoplasm of cardia of stomach (CMS/HCC),C16.0 - Malignant neoplasm of cardia; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
CINJ OP INFUSION,23849,"Ghodoussipour, Saum Bobak, MD",1/29/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/29/2024,Inactive,,
CINJ OP INFUSION,39616,"Haigentz, Missak, MD",9/25/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,9/24/2023,Inactive,,
CINJ OP INFUSION,39616,"Haigentz, Missak, MD",1/17/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,1/17/2024,Inactive,,
CINJ OP INFUSION,46947,"Gulhati, Prateek, MD PhD",3/30/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,3/30/2023,Inactive,,
CINJ OP INFUSION,46947,"Gulhati, Prateek, MD PhD",6/15/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,6/14/2023,Inactive,,
CINJ OP INFUSION,15138,"Jang, Thomas L, MD",1/13/2025,BCG (TICE) Induction 42 Day Cycle - Upper Tract,Induction,1/12/2025,Active,,
CINJ OP INFUSION,63266,"Berim, Lyudmyla, MD",8/1/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/28/2024,Active,,
CINJ OP INFUSION,63266,"Berim, Lyudmyla, MD",12/16/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,12/16/2024,Active,,
CINJ OP INFUSION,53599,"Berim, Lyudmyla, MD",4/23/2025,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,Maintenance,4/23/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),C25.1 - Malignant neoplasm of body of pancreas
CINJ OP INFUSION,59328,"Packiam, Vignesh, MD",1/8/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,1/8/2024,Inactive,,
CINJ OP INFUSION,59328,"Packiam, Vignesh, MD",4/8/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,3/21/2024,Inactive,,
CINJ OP INFUSION,59328,"Ghodoussipour, Saum Bobak, MD",8/19/2024,BCG Induction (TICE) 42 Day Cycle,Induction,8/16/2024,Inactive,,
CINJ OP INFUSION,59328,"Packiam, Vignesh, MD",8/19/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,8/18/2024,Inactive,,
CINJ OP INFUSION,59328,"Packiam, Vignesh, MD",12/10/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,12/9/2024,Active,,
SOM OUTPT INFUSION,90411,"Toomey, Kathleen C, MD",10/2/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,10/2/2024,Inactive,,
CINJ OP INFUSION,87201,"Omene, Coral Oghenerukevwe, MD",2/13/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,2/12/2023,Inactive,,
NBI OP INFUSION,85019,"Schleicher, Lori, MD",8/30/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,8/29/2023,Inactive,,
NBI OP INFUSION,85019,"Schleicher, Lori, MD",1/24/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,1/4/2024,Inactive,,
NBI OP INFUSION,85019,"Schleicher, Lori, MD",3/14/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_2. Second Line,3/5/2024,Inactive,,
NBI OP INFUSION,85019,"Schleicher, Lori, MD",5/15/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/14/2024,Active,,
CINJ OP INFUSION,49585,"Berim, Lyudmyla, MD",12/8/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,11/9/2023,Active,,
CINJ OP INFUSION,31135,"Ghodoussipour, Saum Bobak, MD",12/5/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,12/2/2023,Inactive,,
CINJ OP INFUSION,6502,"Toppmeyer, Deborah L, MD",9/13/2023,Palbociclib 28 Day Cycles - Breast,,9/13/2023,Inactive,,
CINJ OP INFUSION,6502,"Toppmeyer, Deborah L, MD",10/7/2023,"PACLitaxel D1, D15 28 Day Cycles - Breast",_1. First Line,10/5/2023,Inactive,,
CINJ OP INFUSION,61452,"Berim, Lyudmyla, MD",2/6/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/3/2023,Inactive,,
CINJ OP INFUSION,56200,"Toppmeyer, Deborah L, MD",12/16/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/15/2024,Active,Squamous cell carcinoma of mandible (CMS/HCC),
NBR CINJ OP INFUSION,21636,"Tiger, Yun Kyoung, MD",5/10/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,5/9/2025,Active,Primary CNS lymphoma (CMS/HCC),"C83.390 - Primary central nervous system lymphoma; D32.9 - Benign neoplasm of meninges, unspecified; G93.89 - Other specified disorders of brain"
NBI OP INFUSION,45494,"Cheng, Yan Ho, MD",11/7/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,11/2/2023,Active,,
CINJ OP INFUSION,37196,"Boland, Patrick M, MD",2/6/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,2/1/2024,Inactive,,
CINJ OP INFUSION,21079,"Jang, Thomas L, MD",6/2/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,6/2/2023,Inactive,,
HAM OP INFUSION,90603,"Patel, Malini M, MD",5/2/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",First Line,5/1/2023,Inactive,,
NBI OP INFUSION,79399,"Shah, Maya M, MD",9/6/2023,"Albumin-Bound PACLitaxel D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_4. Fourth Line,9/5/2023,Inactive,,
NBI A5 PEDIATRICS,68649,"Batra, Surabhi, MD",4/3/2024,PEDS AHOD1331 Bv-AVE-PC,_1. First Line,3/27/2024,Active,,
NBI A5 PEDIATRICS,68649,"Batra, Surabhi, MD",4/22/2024,PEDS AHOD1331 Bv-AVE-PC,_1. First Line,3/27/2024,Inactive,,
CINJ OP INFUSION,47546,"Patankar, Sonali, MD",5/10/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,5/8/2024,Active,,
CINJ OP INFUSION,47546,"Patankar, Sonali, MD",3/31/2025,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,3/31/2025,Active,Primary peritoneal carcinomatosis (CMS/HCC),"C48.2 - Malignant neoplasm of peritoneum, unspecified; C56.9 - Malignant neoplasm of unspecified ovary"
NBI OP INFUSION,64176,"Shah, Maya M, MD",11/8/2023,Carfilzomib 27 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/7/2023,Inactive,,
NBI OP INFUSION,64176,"Shah, Maya M, MD",9/18/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_3. Third Line,9/17/2024,Active,,
CINJ OP INFUSION,6511,"Gulhati, Prateek, MD PhD",4/21/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,4/12/2023,Inactive,,
CINJ OP INFUSION,6511,"Gulhati, Prateek, MD PhD",3/28/2024,CISplatin + Gemcitabine 28 Day Cycles - Pancreatic Adenocarcinoma,_1. First Line,3/28/2024,Inactive,,
MSC OP INFUSION,36879,"Eltoukhy, Hussam, MD",10/9/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/9/2024,Active,,
CBMC OP INFUSION 2FL,71890,"Dharmapuri, Sirish, MD",2/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/27/2025,Active,Colon adenocarcinoma (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CBMC OP INFUSION 2FL,71890,"Dharmapuri, Sirish, MD",3/4/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/28/2025,Active,Colon adenocarcinoma (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
MSC OP INFUSION,50520,"Cohen, Seth D, MD",5/30/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,5/29/2023,Inactive,,
MSC OP INFUSION,50520,"Cohen, Seth D, MD",10/28/2024,Bevacizumab 21 Day Cycles - Primary Peritoneal Cancer,_3. Third Line,10/27/2024,Inactive,,
MSC OP INFUSION,30332,"Cohen, Seth D, MD",10/3/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,10/19/2023,Inactive,,
MSC OP INFUSION,30332,"Cohen, Seth D, MD",2/20/2024,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/12/2024,Inactive,,
MSC OP INFUSION,30332,"Cohen, Seth D, MD",5/14/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,5/7/2024,Inactive,,
MMC BBR2 ONCOLOGY,30332,"Cohen, Seth D, MD",6/26/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,6/26/2024,Inactive,,
NBR 5N ONCOLOGY,3378,"Shah, Mansi R, MD",12/9/2023,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,12/9/2023,Inactive,,
NBR 5N ONCOLOGY,3378,"Shah, Mansi R, MD",5/31/2024,Talquetamab  28 Day Cycles- Multiple Myeloma,_9. Ninth Line,5/31/2024,Inactive,,
NBR 5N ONCOLOGY,3378,"Shah, Mansi R, MD",11/20/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_8. Eighth Line,8/19/2024,Active,,
CINJ OP INFUSION,85883,"Haigentz, Missak, MD",10/10/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,10/9/2023,Inactive,,
CINJ OP INFUSION,85883,"Haigentz, Missak, MD",12/8/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,12/8/2023,Active,,
NBR BMSCH 2 PED HEMONC,44465,"Masterson, Margaret, MD",10/25/2023,Dasatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,10/25/2023,Active,,
CINJ OP INFUSION,63000,"Omene, Coral Oghenerukevwe, MD",8/1/2023,Palbociclib 28 Day Cycles - Breast,,8/1/2023,Active,,
SOM OUTPT INFUSION,46734,"Patel, Eshan, MD",3/7/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/21/2024,Inactive,,
SOM OUTPT INFUSION,46734,"Patel, Eshan, MD",7/18/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,7/10/2024,Active,,
CINJ OP INFUSION,85618,"Aikins, James K, MD",9/23/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Uterus,_1. First Line,9/20/2023,Inactive,,
NBR CINJ OP INFUSION,8625,"Eltoukhy, Hussam, MD",3/9/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,,2/26/2023,Inactive,,
CINJ OP INFUSION,8625,"Stephenson, Ruth D, DO",1/12/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,1/11/2024,Active,,
CINJ OP INFUSION,8625,"Stephenson, Ruth D, DO",9/11/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,9/11/2024,Inactive,,
NBR CINJ OP INFUSION,68792,"Rhodes, Joanna Meehan, MD",5/8/2025,RiTUXimab 168 Day Cycles - Indolent Lymphoma Maintenance,_1. First Line,5/8/2025,Active,"CLL (chronic lymphocytic leukemia) (CMS/HCC)
Malignant neoplasm of right ovary (CMS/HCC)","C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; C56.1 - Malignant neoplasm of right ovary; D69.6 - Thrombocytopenia, unspecified; Z90.721 - Acquired absence of ovaries, unilateral; Z23 - Encounter for immunization"
CMC OP INFUSION,97972,"Pompa, Tiffany Ann, MD",12/26/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,11/20/2024,Active,,
MMC OP VP INFUSION,3388,"Lee, Patrick C, MD",4/12/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/10/2024,Inactive,,
MMC OP VP INFUSION,3388,"Lee, Patrick C, MD",8/2/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/24/2024,Active,,
CINJ OP INFUSION,89370,"Haigentz, Missak, MD",5/8/2025,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,_1. First Line,5/8/2025,Active,Thyroid cancer (CMS/HCC),
SOM OUTPT INFUSION,5873,"Patel, Eshan, MD",8/21/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,7/25/2023,Inactive,,
MMC OP INFUSION,19641,"Lee, Patrick C, MD",4/8/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,4/8/2025,Active,Thrombocytopenia (CMS/HCC),
CINJ OP INFUSION,39474,"Groisberg, Roman, MD",5/19/2023,SORAfenib 28 Day Cycles- Hepatobiliary Cancers,,5/19/2023,Active,Stage IV breast cancer in female (CMS/HCC),
CBMC OP INFUSION 2FL,78970,"Wagmiller, Jennifer Ann, MD",10/14/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,10/13/2024,Active,,
CBMC 2W ONCOLOGY,78970,"Wagmiller, Jennifer Ann, MD",11/27/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,11/26/2024,Active,,
CMC OP INFUSION,36883,"Talwar, Sumit, MD",5/3/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,5/2/2023,Active,,
NBR CINJ OP INFUSION,38523,"Matasar, Matthew J, MD",1/24/2024,R-CHOP / R-DHAX (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab / Cytarabine / Oxaliplatin) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/22/2024,Inactive,,
NBR CINJ OP INFUSION,38523,"Matasar, Matthew J, MD",7/2/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,7/1/2024,Active,Oropharyngeal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,20767,"Wagmiller, Jennifer Ann, MD",8/27/2024,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_2. Second Line,8/11/2024,Active,,
CINJ OP INFUSION,85765,"Gulhati, Prateek, MD PhD",2/23/2023,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",,2/23/2023,Inactive,,
CINJ OP INFUSION,85765,"Gulhati, Prateek, MD PhD",9/28/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,9/28/2023,Inactive,,
NBR 4N BMTU/IMCU,85266,"Matasar, Matthew J, MD",7/3/2024,BMT Autologous BEAM,_2. Second Line,7/2/2024,Inactive,,
NBR CINJ OP INFUSION,85266,"Matasar, Matthew J, MD",5/30/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_3. Third Line,5/30/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
CINJ OP INFUSION,38923,"George, Mridula A, MD",11/22/2023,"PACLitaxel D1, D8 21 Day Cycles - Breast",_1. First Line,11/21/2023,Inactive,,
CINJ OP INFUSION,38923,"George, Mridula A, MD",11/22/2023,"Albumin-Bound PACLitaxel D1, D8 / Trastuzumab 21 Day Cycles - Breast",_1. First Line,11/21/2023,Inactive,,
CINJ OP INFUSION,38923,"George, Mridula A, MD",11/22/2023,Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel weekly 21 Day Cycles - Breast,_1. First Line,11/21/2023,Inactive,,
CINJ OP INFUSION,38923,"George, Mridula A, MD",11/22/2023,"Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel D1, D8 21 Day Cycles - Breast",_1. First Line,11/21/2023,Inactive,,
CINJ OP INFUSION,38923,"George, Mridula A, MD",4/1/2024,CINJ 042109 SGNTUC-028 Trastuzumab / Pertuzumab + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,_1. First Line,3/31/2024,Active,,
TRMC TCCC OP INFUSION,18601,"Capo, Gerardo, MD",3/13/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,3/12/2024,Active,"Primary lung adenocarcinoma, left (CMS/HCC)
Malignant neoplasm metastatic to both lungs (CMS/HCC)",
CINJ OP INFUSION,40555,"Boland, Patrick M, MD",2/29/2024,Imatinib 30 Day Cycles - Sarcoma,Adjuvant,2/29/2024,Active,,
CBMC OP INFUSION 2FL,90103,"Wagmiller, Jennifer Ann, MD",12/7/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/27/2023,Inactive,,
MMC OP VP INFUSION,40846,"Talwar, Sumit, MD",12/8/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,11/27/2023,Inactive,,
NBR CINJ OP INFUSION,40846,"Assal, Amer, MD",4/17/2024,BMT Autologous Melphalan Day -1  200mg/m2,_1. First Line,4/4/2024,Inactive,,
CINJ OP INFUSION,9265,"Goel, Sanjay, MD",5/12/2025,CINJ 052404 Dose Escalation XL309 / Olaparib 28 Day Cycles Research- Advanced Solid Tumors,_7. Seventh Line,5/9/2025,Active,Primary malignant neuroendocrine neoplasm of stomach (CMS/HCC),
CBMC OP INFUSION 2FL,83672,"Wagmiller, Jennifer Ann, MD",4/15/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,4/10/2024,Active,,
CBMC OP INFUSION 2FL,83672,"Wagmiller, Jennifer Ann, MD",3/10/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,3/10/2025,Active,"Endometrial ca (CMS/HCC)
On antineoplastic chemotherapy
Encounter for screening for other viral diseases
Other problems related to lifestyle
Other abnormal tumor markers
Antineoplastic chemotherapy induced anemia",R97.8 - Other abnormal tumor markers; C54.1 - Malignant neoplasm of endometrium; Z79.899 - Other long term (current) drug therapy; Z11.59 - Encounter for screening for other viral diseases; Z72.89 - Other problems related to lifestyle
CINJ OP INFUSION,55313,"George, Mridula A, MD",4/4/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,4/4/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)","C50.912 - Malignant neoplasm of unspecified site of left female breast; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; E78.5 - Hyperlipidemia, unspecified; N63.42 - Unspecified lump in left breast, subareolar; Z17.1 - Estrogen receptor negative status (ER-)"
CBMC OP INFUSION 2FL,61101,"Scoppetuolo, Michael, MD",8/10/2023,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,8/10/2023,Inactive,,
CBMC OP INFUSION 2FL,61101,"Scoppetuolo, Michael, MD",12/6/2023,DOCEtaxel 21 Day Cycles - Prostate,_2. Second Line,12/4/2023,Inactive,,
CBMC OP INFUSION 2FL,61101,"Scoppetuolo, Michael, MD",4/3/2024,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,3/31/2024,Inactive,,
CBMC OP INFUSION 2FL,15872,"Radovich, Delia, MD",1/19/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/18/2024,Inactive,,
CINJ OP INFUSION,15872,"Goel, Sanjay, MD",10/30/2024,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,10/30/2024,Active,,
CINJ OP INFUSION,75858,"Haigentz, Missak, MD",3/12/2024,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/12/2024,Inactive,,
NBR 4N BMTU/IMCU,49601,"Braunschweig, Ira, MD",5/14/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,5/13/2023,Inactive,,
CINJ OP INFUSION,14531,"Stephenson, Ryan D, DO",3/10/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,3/9/2023,Inactive,,
SOM OUTPT INFUSION,18827,"Toomey, Kathleen C, MD",1/8/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/2/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,82853,"Boland, Patrick M, MD",8/29/2023,Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 480 mg D1 28 Day Cycles- Gastrointestinal Cancers,,8/22/2023,Inactive,,
CBMC OP INFUSION 2FL,32267,"Dharmapuri, Sirish, MD",12/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/19/2024,Active,,
SOM OUTPT INFUSION,39302,"Toomey, Kathleen C, MD",5/6/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/6/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,14185,"Groisberg, Roman, MD",2/7/2025,AD (DOXOrubicin / Dacarbazine) 21 Day Cycles - Sarcoma,_1. First Line,2/6/2025,Active,Malignant solitary fibrous neoplasm (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; K59.00 - Constipation, unspecified"
CINJ OP INFUSION,14185,"Groisberg, Roman, MD",5/9/2025,Gemcitabine 21 Day Cycles - Sarcoma,_2. Second Line,5/9/2025,Active,Leiomyosarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified"
MMC OP VP INFUSION,8625,"Lee, Patrick C, MD",12/21/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/12/2023,Inactive,,
MMC OP VP INFUSION,8625,"Lee, Patrick C, MD",2/26/2024,Weekly Fluorouracil IV Push / Leucovorin IV Push 7 Day Cycles- Colon Cancer,Neoadjuvant,2/23/2024,Inactive,,
NBI D7 MED-SURG/TELE,30576,"Shah, Shailja S, MD",12/17/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/16/2024,Active,,
NBI OP INFUSION,93196,"Shah, Shailja S, MD",5/6/2025,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/6/2025,Active,Malignant poorly differentiated neuroendocrine carcinoma (CMS/HCC),"C7A.8 - Other malignant neuroendocrine tumors; K65.2 - Spontaneous bacterial peritonitis; R18.0 - Malignant ascites; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; N17.9 - Acute kidney failure, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z59.71 - Insufficient health insurance coverage; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z80.9 - Family history of malignant neoplasm, unspecified; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.3 - Family history of diabetes mellitus; Z85.43 - Personal history of malignant neoplasm of ovary; Z79.899 - Other long term (current) drug therapy"
NBI OP INFUSION,54979,"Jacoby, Sari H, MD",7/24/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,7/23/2023,Active,,
NBI OP INFUSION,54979,"Jacoby, Sari H, MD",1/8/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/5/2025,Active,,
NBI OP INFUSION,54979,"Jacoby, Sari H, MD",4/7/2025,Rucaparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,4/7/2025,Active,Adenocarcinoma of head of pancreas (CMS/HCC),
CINJ OP INFUSION,63269,"Girda, Eugenia, MD",10/13/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Neoadjuvant,10/12/2023,Inactive,,
NBR 5N ONCOLOGY,63269,"Girda, Eugenia, MD",11/18/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Uterine Serous",_1. First Line,11/17/2023,Inactive,,
CINJ OP INFUSION,63269,"Girda, Eugenia, MD",5/22/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/21/2024,Inactive,,
CINJ OP INFUSION,63269,"Girda, Eugenia, MD",6/7/2024,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Stage IVB UTerine Serous",Adjuvant,6/5/2024,Inactive,,
CINJ OP INFUSION,63269,"Girda, Eugenia, MD",10/17/2024,Trastuzumab 21 Day Cycles (Continuation) - Uterine,Maintenance,10/16/2024,Inactive,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,63269,"Girda, Eugenia, MD",2/21/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Uterine Cancer,_2. Second Line,2/21/2025,Active,Endometrial cancer (CMS/HCC),
NBI OP INFUSION,8729,"Schleicher, Lori, MD",11/15/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,11/2/2023,Active,,
CINJ OP INFUSION,4337,"Mayer, Tina M, MD",7/11/2023,Temozolomide 28 Day Cycles - CNS,,7/11/2023,Active,"Adenocarcinoma of breast metastatic to liver (CMS/HCC)
Hypothyroidism, unspecified type
End stage renal disease (CMS/HCC)",
CBMC OP INFUSION 2FL,46779,"Litvak, Anna M, MD",11/30/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,11/23/2023,Active,Overlapping malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,89443,"Packiam, Vignesh, MD",1/26/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,1/25/2024,Inactive,,
CINJ OP INFUSION,89443,"Packiam, Vignesh, MD",1/26/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,1/26/2024,Inactive,,
NBR 5N ONCOLOGY,89443,"Stephenson, Ryan D, DO",4/17/2024,Gemcitabine 21 Day Cycles - Bladder,_1. First Line,4/16/2024,Inactive,,
CBMC OP INFUSION 2FL,21963,"Dharmapuri, Sirish, MD",12/9/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Consolidation,12/8/2024,Inactive,,
CBMC OP INFUSION 2FL,21963,"Dharmapuri, Sirish, MD",2/3/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/2/2025,Active,Malignant neoplasm of rectum (CMS/HCC),"E86.1 - Hypovolemia; C19 - Malignant neoplasm of rectosigmoid junction; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; R62.7 - Adult failure to thrive; E87.1 - Hypo-osmolality and hyponatremia; K27.9 - Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation; F31.9 - Bipolar disorder, unspecified; I10 - Essential (primary) hypertension; Z68.1 - Body mass index (BMI) 19.9 or less, adult; G70.9 - Myoneural disorder, unspecified; I95.1 - Orthostatic hypotension; E87.6 - Hypokalemia; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; F51.05 - Insomnia due to other mental disorder; G51.0 - Bell's palsy; F41.9 - Anxiety disorder, unspecified; G89.29 - Other chronic pain; Z79.899 - Other long term (current) drug therapy; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z80.3 - Family history of malignant neoplasm of breast; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z87.891 - Personal history of nicotine dependence; Z88.2 - Allergy status to sulfonamides; Z98.891 - History of uterine scar from previous surgery; Z98.890 - Other specified postprocedural states; Z88.3 - Allergy status to other anti-infective agents"
CINJ OP INFUSION,49000,"Gulhati, Prateek, MD PhD",3/21/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/20/2024,Inactive,,
CINJ OP INFUSION,74435,"Weiss, Sarah, MD",5/15/2023,CINJ 092204 [Fianlimab (1600mg=arm A or 400mg=arm B) + Cemiplimab 350mg] or [pembrolizumab 200mg= arm C ] - 21 Day Cycles Research- Melanoma,Adjuvant,5/14/2023,Active,,
CINJ PEDS HEMONC ,28918,"Botwinick, Marissa, DO",1/12/2023,AALL1731 All SR-Fav B-ALL - Consolidation,First Line,1/12/2023,Inactive,,
CINJ PEDS HEMONC ,28918,"Botwinick, Marissa, DO",2/7/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,,2/7/2023,Inactive,,
CINJ PEDS HEMONC ,28918,"Botwinick, Marissa, DO",4/6/2023,"AALL1731 SR-Fav B-ALL, SR-Avg Arm A & B B-ALL, and B-LLy (including DS patients) Delayed Intensification",First Line,4/4/2023,Inactive,,
CINJ PEDS HEMONC ,28918,"Botwinick, Marissa, DO",6/13/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,,6/13/2023,Inactive,,
CINJ PEDS HEMONC ,28918,"Botwinick, Marissa, DO",8/10/2023,AALL1731 Non-DS SR Fav  B-ALL - Maintenance,First Line,8/9/2023,Inactive,,
CINJ PEDS HEMONC ,28918,"Botwinick, Marissa, DO",8/29/2023,AALL1731 Non-DS Fav B-ALL - Maintenance,First Line,8/10/2023,Active,,
CINJ OP INFUSION,99154,"Goel, Sanjay, MD",4/10/2024,"CINJ 052208 Part 1c,e,f,g,h AMG-193 28 Day Cycles Research- Solid Tumors",_3. Third Line,4/10/2024,Inactive,,
CBMC 2W ONCOLOGY,75119,"Wagmiller, Jennifer Ann, MD",7/4/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/3/2024,Inactive,,
NBI OP INFUSION,52260,"Anderson, Patrick S, MD",11/3/2023,"PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles , Followed by additional 4 cyc les of Paclitaxel anfd Carboplatin Q 2 1 days. - Serrous Ensdmetrial Adenocarcinoma",_1. First Line,11/2/2023,Inactive,,
NBI OP INFUSION,52260,"Anderson, Patrick S, MD",12/1/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/30/2023,Inactive,,
MSC OP INFUSION,93393,"Cohen, Seth D, MD",5/1/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,4/28/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
MMC OP VP INFUSION,39126,"Cohen, Seth D, MD",5/7/2024,RomiDEPsin 28 Day Cycles - Cutaneous T-Cell Lymphoma,_2. Second Line,5/5/2024,Inactive,,
MSC OP INFUSION,39126,"Cohen, Seth D, MD",7/3/2024,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_3. Third Line,7/2/2024,Active,,
CBMC OP INFUSION 2FL,69455,"Brown, Andrew Bennett, MD",11/9/2023,Nivolumab 480 mg D1 28 Day Cycles- Head and Neck Cancers,Maintenance,11/8/2023,Active,,
CBMC OP INFUSION 2FL,67534,"Brown, Andrew Bennett, MD",10/18/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/17/2023,Inactive,,
NBR CINJ OP INFUSION,88394,"Rhodes, Joanna Meehan, MD",2/7/2024,RiTUXimab 28 Day Cycle - Indolent Lymphoma,_1. First Line,2/6/2024,Inactive,,
CINJ OP INFUSION,45351,"Omene, Coral Oghenerukevwe, MD",6/26/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,6/25/2023,Inactive,,
CINJ OP INFUSION,49045,"Hochster, Howard S, MD",5/1/2025,CINJ 072402 Quemliclustat or Placebo / Nab-PACLitaxel / Gemcitabine 28 Day Cycles Research- Pancreatic Adenocarcinoma,_1. First Line,5/1/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),
NBR CINJ OP INFUSION,87690,"Matasar, Matthew J, MD",1/9/2023,Zanubrutinib (160 mg) 30 Day Cycles - Marginal Zone Lymphoma,Second Line,1/9/2023,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
SOM OUTPT INFUSION,21419,"Patel, Eshan, MD",3/19/2024,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Adjuvant,3/19/2024,Active,,
NBI OP INFUSION,78524,"Schleicher, Lori, MD",4/5/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,3/28/2024,Active,,
CINJ OP INFUSION,95657,"Boland, Patrick M, MD",10/10/2023,CINJ 072304 Cohort 1 ME-344 + Bevacizumab - Colorectal Cancer,_4. Fourth Line,10/10/2023,Inactive,,
CINJ OP INFUSION,71620,"Packiam, Vignesh, MD",12/3/2024,BCG Induction (TICE) 42 Day Cycle,Adjuvant,12/2/2024,Active,,
CINJ OP INFUSION,71620,"Packiam, Vignesh, MD",3/11/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,3/11/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),N30.01 - Acute cystitis with hematuria; N30.81 - Other cystitis with hematuria; Z85.51 - Personal history of malignant neoplasm of bladder; Z87.442 - Personal history of urinary calculi; Z87.891 - Personal history of nicotine dependence; Z98.890 - Other specified postprocedural states; Z91.048 - Other nonmedicinal substance allergy status
CBMC OP INFUSION 2FL,75281,"Wagmiller, Jennifer Ann, MD",11/3/2023,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,10/29/2023,Inactive,,
CINJ OP INFUSION,66962,"Stephenson, Ryan D, DO",12/6/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,12/6/2024,Active,,
MMC OP VP INFUSION,32063,"Lee, Patrick C, MD",2/17/2025,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,2/9/2025,Active,"Malignant neoplasm of unspecified part of unspecified bronchus or lung (CMS/HCC)
Non-small cell lung cancer (CMS/HCC)
Chemotherapy-induced fatigue",
MMC BBR2 ONCOLOGY,16388,"Lee, Patrick C, MD",4/8/2025,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/7/2025,Inactive,"Malignant neoplasm of unspecified part of unspecified bronchus or lung (CMS/HCC)
Non-small cell lung cancer (CMS/HCC)
Chemotherapy-induced fatigue",
CINJ OP INFUSION,39171,"Hochster, Howard S, MD",8/15/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Anal Cancer,Induction,8/14/2024,Inactive,,
CINJ OP INFUSION,39171,"Hochster, Howard S, MD",10/2/2024,PACLitaxel/CARBOplatin 21 Day Cycles- Esophageal and Esophagogastric Junction Cancers,_1. First Line,10/1/2024,Active,,
NBI VALERIE FND HEMONC,82797,"de Benedictis, Marianna, MD",8/16/2023,AALL1731 Non-DS SR (Fav or Avg) B-ALL - Maintenance,_1. First Line,8/15/2023,Active,,
NBR 4N ONCOLOGY,67965,"Groisberg, Roman, MD",8/17/2024,MAP (High-Dose Methotrexate / DOXOrubicin / CISplatin) - Bone Cancer,_1. First Line,8/16/2024,Active,,
SOM OUTPT INFUSION,44192,"Patel, Eshan, MD",5/8/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,5/7/2023,Inactive,,
SOM 1PAV ONCOLOGY,44192,"Patel, Eshan, MD",5/31/2023,DHAP (Dexamethasone / CISplatin / Cytarabine) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,5/31/2023,Inactive,,
SOM OUTPT INFUSION,44192,"Patel, Eshan, MD",11/1/2023,RiTUXimab 56 Day Cycles -  Lymphoma  Maintenance,Maintenance,10/29/2023,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,73995,"Omene, Coral Oghenerukevwe, MD",1/31/2023,Trastuzumab/Pertuzumab 21 Day Cycles (Initiation) - Breast,Neoadjuvant,1/30/2023,Inactive,,
CINJ OP INFUSION,73995,"Omene, Coral Oghenerukevwe, MD",4/11/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Second Line,4/6/2023,Inactive,,
CINJ OP INFUSION,73995,"Omene, Coral Oghenerukevwe, MD",5/2/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,5/1/2023,Inactive,,
CINJ OP INFUSION,73995,"Omene, Coral Oghenerukevwe, MD",8/1/2023,PACLitaxel Every Two Weeks - Breast,,8/1/2023,Inactive,,
CINJ OP INFUSION,73995,"Omene, Coral Oghenerukevwe, MD",1/2/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,1/2/2024,Inactive,,
CINJ OP INFUSION,59280,"Haigentz, Missak, MD",11/21/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Anaplastic Thyroid Cancer,Adjuvant,11/20/2023,Inactive,,
CINJ OP INFUSION,59280,"Haigentz, Missak, MD",1/27/2024,Dabrafenib / Trametinib 30 Day Cycles - BRAF V600E Anaplastic Thyroid Cancer,Consolidation,1/27/2024,Active,,
CMC OP INFUSION,67337,"Eltoukhy, Hussam, MD",1/27/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/26/2024,Inactive,,
NBR 5N ONCOLOGY,76391,"Palmisiano, Neil David, MD",7/24/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,7/24/2024,Inactive,,
NBR CINJ OP INFUSION,76391,"Palmisiano, Neil David, MD",10/29/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,Consolidation,10/28/2024,Inactive,,
NBR CINJ OP INFUSION,76391,"Palmisiano, Neil David, MD",12/2/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,_1. First Line,12/2/2024,Inactive,,
NBR CINJ OP INFUSION,76391,"Palmisiano, Neil David, MD",2/24/2025,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,_1. First Line,2/24/2025,Active,B-cell lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,19706,"Drachtman, Richard, MD",2/7/2023,Peds AALL0434 - Delayed Intensification Arm B (CMTX+Nel) and  Arm D (HDMTX+Nel) 63 Day Cycle - Acute Lymphoblastic Leukemia,First Line,2/3/2023,Inactive,,
CINJ PEDS HEMONC ,19706,"Drachtman, Richard, MD",4/25/2023,PEDS AALL0434 Arm B (CMTX + Nel) Maintenance,_1. First Line,4/24/2023,Inactive,,
JCMC CP INFUSION,38076,"Sekhri, Arunabh, MD",2/22/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/21/2023,Inactive,,
JCMC CP INFUSION,77982,"Cruz, Allan Louie E, MD",12/11/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/6/2024,Active,,
MSC OP INFUSION,92723,"Cohen, Seth D, MD",8/5/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,7/29/2024,Inactive,,
CINJ OP INFUSION,50439,"Mayer, Tina M, MD",1/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,1/18/2023,Active,,
CMC OP INFUSION,35314,"Talwar, Sumit, MD",4/10/2025,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_2. Second Line,4/10/2025,Active,Hepatocellular carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,42101,"Kovtun, Jeanette Muniz, MD",8/20/2024,DOXOrubicin Liposomal 28 Day Cycles - Endometrial,_3. Third Line,8/18/2024,Inactive,"Endometrial adenocarcinoma (CMS/HCC)
Other acute kidney failure (CMS/HCC)",
CINJ OP INFUSION,42101,"Stephenson, Ruth D, DO",2/24/2025,Albumin-Bound PACLitaxel  21 Day Cycles- Uterine,_4. Fourth Line,2/23/2025,Active,"Endometrial adenocarcinoma (CMS/HCC)
Hypothyroidism (acquired)","C54.1 - Malignant neoplasm of endometrium; E03.9 - Hypothyroidism, unspecified"
CINJ OP INFUSION,29233,"Mayer, Tina M, MD",8/22/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,8/22/2023,Active,,
CMC OP INFUSION,43104,"Talwar, Sumit, MD",9/11/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,8/27/2024,Active,,
CMC OP INFUSION,17030,"Tang, Horace, MD",4/6/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/29/2023,Inactive,,
CINJ OP INFUSION,37371,"Hochster, Howard S, MD",5/8/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Maintenance,5/8/2023,Inactive,,
CINJ OP INFUSION,37371,"Hochster, Howard S, MD",8/3/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,8/2/2023,Inactive,,
CINJ OP INFUSION,37371,"Hochster, Howard S, MD",10/12/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,10/11/2023,Inactive,,
NBR 4N ONCOLOGY,10185,"Matasar, Matthew J, MD",9/6/2023,RiTUXimab 90 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,9/6/2023,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
NBR CINJ OP INFUSION,10185,"Matasar, Matthew J, MD",12/7/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),Maintenance,12/6/2023,Inactive,,
NBR 4N ONCOLOGY,10185,"Matasar, Matthew J, MD",2/23/2024,RiTUXimab / Ibrutinib 56 Day Cycles - Mantle Cell Lymphoma (Maintenance),_2. Second Line,2/22/2024,Inactive,,
NBR CINJ OP INFUSION,10185,"Matasar, Matthew J, MD",3/3/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,3/2/2024,Inactive,,
CINJ OP INFUSION,20120,"Stephenson, Ryan D, DO",1/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,1/18/2023,Active,,
CINJ OP INFUSION,20120,"Stephenson, Ryan D, DO",6/14/2024,Sipuleucel-T 14 Day Cycles - Prostate,_2. Second Line,6/14/2024,Inactive,,
CINJ OP INFUSION,62193,"Toppmeyer, Deborah L, MD",7/25/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,7/24/2024,Inactive,,
CINJ OP INFUSION,56565,"Stephenson, Ryan D, DO",2/22/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,2/21/2024,Inactive,,
CBMC OP INFUSION 2FL,33928,"Radovich, Delia, MD",11/14/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/13/2023,Inactive,,
CBMC OP INFUSION 2FL,33928,"Scoppetuolo, Michael, MD",8/13/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,8/12/2024,Active,,
CINJ OP INFUSION,40715,"Haigentz, Missak, MD",4/10/2023,CINJ 032013 (EA5181) ARM B PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,4/2/2023,Inactive,,
CINJ OP INFUSION,40715,"Haigentz, Missak, MD",6/7/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,First Line,6/6/2023,Active,,
CINJ OP INFUSION,28488,"Haigentz, Missak, MD",2/26/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,2/25/2024,Inactive,,
CINJ OP INFUSION,28488,"Haigentz, Missak, MD",5/13/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/13/2024,Active,,
CINJ OP INFUSION,63007,"Muralikrishnan, Sivraj, MD",3/18/2025,CINJ 032405 Cohort 1 Amivantamab Monotherapy (pt weight < 80 kg) 21 Day Cycles Research- Head and Neck Cancers,_3. Third Line,3/18/2025,Inactive,Head and neck cancer (CMS/HCC),
CBMC 2W ONCOLOGY,49824,"Grossman, I Robert, MD",6/25/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,6/25/2024,Inactive,,
CBMC OP INFUSION 2FL,49824,"Grossman, I Robert, MD",7/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,7/17/2024,Inactive,,
NBR CINJ OP INFUSION,49824,"Grossman, I Robert, MD",1/2/2025,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,1/1/2025,Active,,
CBMC 2W ONCOLOGY,49824,"Grossman, I Robert, MD",1/2/2025,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 14 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,1/1/2025,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC 2W ONCOLOGY,1389,"Grossman, I Robert, MD",3/13/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_4. Fourth Line,3/13/2025,Inactive,Richter's syndrome (CMS/HCC),"A41.89 - Other specified sepsis; D61.810 - Antineoplastic chemotherapy induced pancytopenia; T83.518A - Infection and inflammatory reaction due to other urinary catheter, initial encounter; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; D65 - Disseminated intravascular coagulation (defibrination syndrome); J18.9 - Pneumonia, unspecified organism; G93.41 - Metabolic encephalopathy; J96.91 - Respiratory failure, unspecified with hypoxia; D76.1 - Hemophagocytic lymphohistiocytosis; E87.20 - Acidosis, unspecified; R64 - Cachexia; D70.1 - Agranulocytosis secondary to cancer chemotherapy; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; E44.0 - Moderate protein-calorie malnutrition; B19.10 - Unspecified viral hepatitis B without hepatic coma; D63.1 - Anemia in chronic kidney disease; I10 - Essential (primary) hypertension; F32.A - Depression, unspecified; I34.0 - Nonrheumatic mitral (valve) insufficiency; I47.20 - Ventricular tachycardia, unspecified; Z16.21 - Resistance to vancomycin; E87.0 - Hyperosmolality and hypernatremia; I47.19 - Other supraventricular tachycardia; B37.0 - Candidal stomatitis; E87.1 - Hypo-osmolality and hyponatremia; Z68.1 - Body mass index (BMI) 19.9 or less, adult; I27.20 - Pulmonary hypertension, unspecified; I48.91 - Unspecified atrial fibrillation; A41.81 - Sepsis due to Enterococcus; B97.0 - Adenovirus as the cause..."
NBI OP INFUSION,9384,"Schleicher, Lori, MD",6/26/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,6/25/2023,Inactive,,
NBI OP INFUSION,9384,"Schleicher, Lori, MD",2/1/2024,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,2/1/2024,Active,,
CINJ OP INFUSION,87894,"Berim, Lyudmyla, MD",7/15/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,6/30/2024,Inactive,,
CINJ OP INFUSION,87894,"Berim, Lyudmyla, MD",7/15/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,6/17/2024,Inactive,,
CINJ OP INFUSION,87894,"Berim, Lyudmyla, MD",9/16/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,8/27/2024,Active,,
HAM OP INFUSION,13541,"Yogarajah, Meera, MD",9/26/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/18/2024,Active,,
HAM OP INFUSION,13541,"Yogarajah, Meera, MD",12/19/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,12/18/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
NBI OP INFUSION,77024,"Schleicher, Lori, MD",1/31/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,1/31/2024,Active,,
CINJ OP INFUSION,7601,"George, Mridula A, MD",5/17/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,5/9/2024,Active,,
CINJ OP INFUSION,89011,"Stephenson, Ruth D, DO",7/5/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,7/3/2023,Inactive,,
CINJ OP INFUSION,89011,"Stephenson, Ruth D, DO",11/15/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,11/15/2023,Active,,
CINJ OP INFUSION,89011,"Stephenson, Ruth D, DO",7/5/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/4/2024,Inactive,,
CBMC OP INFUSION 2FL,31135,"Scoppetuolo, Michael, MD",11/7/2023,Pembrolizumab / Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,11/6/2023,Active,,
CBMC OP INFUSION 2FL,54398,"Wagmiller, Jennifer Ann, MD",1/22/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,12/17/2023,Inactive,,
CBMC OP INFUSION 2FL,54398,"Wagmiller, Jennifer Ann, MD",4/15/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/14/2024,Active,,
NBI OP INFUSION,58474,"Shah, Maya M, MD",2/1/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,2/1/2024,Active,"Endometrial cancer (CMS/HCC)
Encounter for screening for other viral diseases
On antineoplastic chemotherapy",
CINJ OP INFUSION,51654,"Berim, Lyudmyla, MD",8/9/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,8/1/2023,Inactive,,
CINJ OP INFUSION,51654,"Berim, Lyudmyla, MD",4/8/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/7/2024,Inactive,,
CINJ OP INFUSION,51654,"Berim, Lyudmyla, MD",4/22/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,4/21/2024,Inactive,,
NBI OP INFUSION,77712,"Shah, Maya M, MD",11/10/2023,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,_4. Fourth Line,11/9/2023,Inactive,,
NBI OP INFUSION,77712,"Shah, Shailja S, MD",3/15/2024,"DOCEtaxel D1, D8, D15  28 Day Cycles-Non-Small Cell Lung Cancer",_4. Fourth Line,3/14/2024,Inactive,,
HAM OP INFUSION,52734,"Yogarajah, Meera, MD",3/4/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/3/2024,Inactive,,
CINJ OP INFUSION,36099,"Aikins, James K, MD",4/7/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/5/2023,Inactive,,
CINJ OP INFUSION,36099,"Aikins, James K, MD",8/16/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_2. Second Line,8/11/2024,Active,,
CINJ OP INFUSION,36099,"Aikins, James K, MD",3/14/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,3/14/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),C54.1 - Malignant neoplasm of endometrium (CMS/HCC)
NBR CINJ OP INFUSION,49975,"Schaar, Dale, MD PhD",1/23/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,1/22/2023,Inactive,,
NBR CINJ OP INFUSION,49975,"Schaar, Dale, MD PhD",8/28/2023,"CINJ 022204 LYT- 200 28 Day Cycles Research -  Acute Myeloid Leukemia (AML), & MDS",,8/28/2023,Inactive,,
NBR CINJ OP INFUSION,49975,"Schaar, Dale, MD PhD",11/6/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,11/5/2023,Inactive,,
CINJ OP INFUSION,11303,"Gulhati, Prateek, MD PhD",1/20/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/16/2023,Inactive,,
CINJ OP INFUSION,11303,"Gulhati, Prateek, MD PhD",7/27/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,7/26/2023,Inactive,,
CINJ OP INFUSION,11303,"Gulhati, Prateek, MD PhD",10/19/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,10/19/2023,Inactive,,
CINJ OP INFUSION,11303,"Gulhati, Prateek, MD PhD",1/25/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,1/24/2024,Inactive,,
CINJ OP INFUSION,11303,"Gulhati, Prateek, MD PhD",4/18/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_5. Fifth Line,4/18/2024,Inactive,,
CINJ PEDS HEMONC ,19737,"Moerdler, Scott, MD",7/10/2023,Dabrafenib / Trametinib ,_1. First Line,7/10/2023,Active,,
CBMC OP INFUSION 2FL,7570,"Grossman, I Robert, MD",6/6/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,6/5/2023,Inactive,,
CINJ OP INFUSION,70041,"Haigentz, Missak, MD",2/13/2023,CINJ 032111 (EA3161) ARMS A and B CISplatin with Concurrent Radiation 7 Day Cycles Research- Oropharyngeal Carcinoma,First Line,2/12/2023,Inactive,,
CINJ OP INFUSION,70041,"Haigentz, Missak, MD",5/1/2023,CINJ 032111 (EA3161) ARM A Maintenance Nivolumab 480 mg 28 Day Cycles Research- Oropharyngeal Carcinoma,First Line,5/1/2023,Active,,
CINJ OP INFUSION,51852,"Stephenson, Ryan D, DO",12/16/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,12/16/2024,Active,,
NBR CINJ OP INFUSION,47491,"Evens, Andrew M, DO",6/27/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,6/26/2024,Inactive,,
NBR CINJ OP INFUSION,47491,"Evens, Andrew M, DO",11/7/2024,BMT Autologous Carmustine / Thiotepa,_1. First Line,11/6/2024,Active,,
CBMC OP INFUSION 2FL,26200,"Wagmiller, Jennifer Ann, MD",4/4/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/3/2023,Inactive,,
CMC OP INFUSION,77986,"Cohen, Seth D, MD",10/2/2024,PEDS ACNS0332 - Other than Average Risk Medulloblastoma / PNET ,_1. First Line,9/22/2024,Active,,
CINJ OP INFUSION,53505,"Weiss, Sarah, MD",4/11/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,3/24/2024,Active,,
NBR 4N ONCOLOGY,10388,"Stephenson, Ruth D, DO",1/4/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,Second Line,12/25/2022,Inactive,,
NBR 5N ONCOLOGY,86324,"Palmisiano, Neil David, MD",6/29/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,6/29/2024,Inactive,,
NBR CINJ OP INFUSION,86324,"Shah, Mansi R, MD",10/24/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,10/10/2024,Active,,
CINJ OP INFUSION,57836,"Aikins, James K, MD",9/8/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/5/2023,Inactive,,
CINJ OP INFUSION,57836,"Aikins, James K, MD",3/14/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,3/13/2024,Inactive,,
CINJ OP INFUSION,57836,"Aikins, James K, MD",3/21/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,3/21/2024,Active,,
NBI VALERIE FND HEMONC,24184,"de Benedictis, Marianna, MD",12/20/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,12/20/2024,Inactive,,
NBR 4N BMTU/IMCU,82287,"Schaar, Dale, MD PhD",3/2/2024,BMT Allogeneic TBF + Post Cy ,Consolidation,3/1/2024,Inactive,,
CMC OP INFUSION,40808,"Cohen, Seth D, MD",4/3/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,7/21/2024,Active,,
CINJ OP INFUSION,117,"Boland, Patrick M, MD",11/10/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,37872,"Leitner, Stuart P, MD",1/20/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/15/2025,Active,,
CBMC OP INFUSION 2FL,2646,"Leitner, Stuart P, MD",4/30/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/30/2025,Active,Cancer of central portion of right breast (CMS/HCC),C50.111 - Malignant neoplasm of central portion of right female breast
CBMC OP INFUSION 2FL,35380,"Raptis, George, MD",5/20/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,5/20/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,17234,"Dharmapuri, Sirish, MD",5/6/2025,Irinotecan D1 of 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/6/2025,Inactive,Adenocarcinoma of rectum metastatic to lung (CMS/HCC),
CINJ OP INFUSION,52950,"Haigentz, Missak, MD",12/10/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,12/10/2024,Active,,
CBMC OP INFUSION 2FL,60455,"Dharmapuri, Sirish, MD",1/21/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/6/2025,Active,,
NBR 4N BMTU/IMCU,2484,"Evens, Andrew M, DO",9/12/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,9/12/2024,Inactive,,
NBR CINJ OP INFUSION,2484,"Evens, Andrew M, DO",12/4/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_3. Third Line,12/3/2024,Active,,
CBMC OP INFUSION 2FL,33941,"Ligresti, Louise G, MD",7/29/2024,Palbociclib 28 Day Cycles - Breast,_3. Third Line,7/29/2024,Active,,
NBR 4N ONCOLOGY,16524,"Tiger, Yun Kyoung, MD",6/6/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,6/6/2024,Inactive,,
CINJ OP INFUSION,3113,"Omene, Coral Oghenerukevwe, MD",9/19/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/11/2023,Inactive,,
CINJ OP INFUSION,3113,"Omene, Coral Oghenerukevwe, MD",11/28/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,11/27/2023,Inactive,,
HAM OP INFUSION,87214,"Yogarajah, Meera, MD",10/9/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,10/8/2024,Active,,
CINJ OP INFUSION,30683,"Girda, Eugenia, MD",5/23/2025,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,5/23/2025,Inactive,Endometrial carcinoma (CMS/HCC),
JCMC CP INFUSION,22550,"Sekhri, Arunabh, MD",9/13/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,8/25/2024,Inactive,,
NBI OP INFUSION,86724,"Shah, Shailja S, MD",9/26/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,9/25/2023,Inactive,,
NBI OP INFUSION,86724,"Shah, Shailja S, MD",12/5/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,11/8/2023,Active,,
NBR CINJ OP INFUSION,44255,"Egini, Ogechukwu, MD",7/26/2024,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,7/23/2024,Active,,
NBI OP INFUSION,2331,"Cheng, Yan Ho, MD",2/20/2024,"DOCETAXEL / DAROLUTAMIDE, 21 DAY CYCLES - PROSTATE CANCER",Induction,2/19/2024,Inactive,,
TRMC TCCC OP INFUSION,90254,"Salerno, Vincent E, MD",11/21/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/20/2024,Inactive,,
CINJ OP INFUSION,81572,"Patel, Eshan, MD",4/12/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,4/9/2024,Inactive,,
CINJ OP INFUSION,81572,"Patel, Eshan, MD",8/2/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/1/2024,Inactive,,
NBI OP INFUSION,2491,"Anderson, Patrick S, MD",4/11/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,4/10/2024,Inactive,,
NBI OP INFUSION,2491,"Anderson, Patrick S, MD",6/20/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,6/12/2024,Inactive,,
NBI OP INFUSION,2491,"Anderson, Patrick S, MD",10/10/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles -  Clear cell Metastatic Endometrial cancer ( ERBB2 ) positive,_3. Third Line,9/25/2024,Active,,
CINJ OP INFUSION,81909,"Haigentz, Missak, MD",6/23/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,First Line,6/22/2023,Inactive,,
CINJ OP INFUSION,81909,"Haigentz, Missak, MD",8/16/2023,Cetuximab / PACLitaxel 80 mg/m2 -  28 Day Cycles- Head and Neck Cancers,Second Line,8/15/2023,Inactive,,
MMC OP VP INFUSION,16152,"Cohen, Seth D, MD",3/6/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,3/5/2024,Inactive,,
MMC OP VP INFUSION,16152,"Lee, Patrick C, MD",6/12/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,6/11/2024,Active,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
CMC OP INFUSION,33889,"Taff, Jessica, MD",11/27/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,11/25/2023,Active,,
CINJ OP INFUSION,24103,"George, Mridula A, MD",3/15/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,3/14/2024,Inactive,,
CINJ OP INFUSION,24103,"George, Mridula A, MD",6/7/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,6/7/2024,Active,,
CINJ OP INFUSION,4499,"Toppmeyer, Deborah L, MD",3/19/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/18/2024,Inactive,,
CINJ OP INFUSION,4499,"Toppmeyer, Deborah L, MD",7/25/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,7/25/2024,Active,,
CINJ OP INFUSION,10553,"Leiser, Aliza, MD",5/8/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,5/7/2023,Inactive,,
CINJ OP INFUSION,10553,"Leiser, Aliza, MD",9/25/2023,Pembrolizumab 21 Day Cycles ,,9/24/2023,Inactive,,
NBR 4N BMTU/IMCU,26245,"Matasar, Matthew J, MD",7/25/2024,Cyclophosphamide 2000 mg/m2 Once for Stem Cell Mobilization,_1. First Line,7/24/2024,Inactive,,
NBR CINJ OP INFUSION,26245,"Matasar, Matthew J, MD",8/23/2024,BMT Autologous Carmustine / Thiotepa,_2. Second Line,8/22/2024,Active,,
NBR BMSCH 2 PED HEMONC,97333,"Cole, Peter David, MD",6/29/2023,per AALL1731 Non-DS SR B-ALL Induction,Induction,6/28/2023,Inactive,,
CINJ PEDS HEMONC ,97333,"Drachtman, Richard, MD",8/3/2023,"AALL1731- SR-Avg B-ALL, Consolidation",First Line,8/3/2023,Inactive,,
CINJ PEDS HEMONC ,97333,"Drachtman, Richard, MD",9/1/2023,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,First Line,9/1/2023,Inactive,,
CINJ PEDS HEMONC ,97333,"Drachtman, Richard, MD",10/26/2023,"AALL1731 SR-Fav B-ALL, SR-Avg Arm A & B B-ALL, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,10/26/2023,Inactive,,
CINJ PEDS HEMONC ,97333,"Drachtman, Richard, MD",1/4/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,1/4/2024,Inactive,,
CINJ PEDS HEMONC ,97333,"Drachtman, Richard, MD",2/29/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,2/29/2024,Active,,
NBI OP INFUSION,30299,"Shah, Shailja S, MD",5/14/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/13/2024,Inactive,,
SOM OUTPT INFUSION,32916,"Toomey, Kathleen C, MD",2/14/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/13/2024,Active,,
JCMC CP INFUSION,4635,"Sekhri, Arunabh, MD",4/7/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/7/2025,Active,"Overlapping malignant neoplasm of colon (CMS/HCC)
Adenocarcinoma of colon (CMS/HCC)","C18.2 - Malignant neoplasm of ascending colon; C18.8 - Malignant neoplasm of overlapping sites of colon; C18.9 - Malignant neoplasm of colon, unspecified; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); I50.30 - Unspecified diastolic (congestive) heart failure; R59.0 - Localized enlarged lymph nodes"
MSC OP INFUSION,2817,"Cohen, Seth D, MD",12/9/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Salivary Gland,_1. First Line,12/9/2024,Active,,
MSC OP INFUSION,2817,"Cohen, Seth D, MD",2/10/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Salivary Gland,Maintenance,2/9/2025,Future,Salivary duct carcinoma (CMS/HCC),
CINJ OP INFUSION,6984,"Ghodoussipour, Saum Bobak, MD",1/13/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/13/2023,Inactive,,
NBI OP INFUSION,73092,"Shah, Shailja S, MD",10/31/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/30/2023,Inactive,,
NBI OP INFUSION,73092,"Shah, Shailja S, MD",3/26/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,3/25/2024,Inactive,,
NBI OP INFUSION,73092,"Shah, Shailja S, MD",5/28/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/27/2024,Inactive,,
NBI OP INFUSION,73092,"Shah, Shailja S, MD",12/17/2024,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,12/17/2024,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
NBI OP INFUSION,73092,"Shah, Shailja S, MD",1/7/2025,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,12/17/2024,Active,H/O autologous stem cell transplant (CMS/HCC),
NBR 4N ONCOLOGY,60544,"Matasar, Matthew J, MD",3/19/2023,Cytarabine (100 mg/m2) / DAUNOrubicin (90 mg/m2) / Gemtuzumab (7 + 3 + GO) - Acute Myeloid Leukemia (Induction),First Line,3/19/2023,Inactive,,
NBR CINJ OP INFUSION,60544,"Palmisiano, Neil David, MD",5/15/2023,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,5/15/2023,Inactive,,
NBR CINJ OP INFUSION,60544,"Palmisiano, Neil David, MD",5/15/2023,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,5/14/2023,Inactive,,
NBR 5N ONCOLOGY,44718,"Chen, Xiaoyi",4/29/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,4/29/2025,Active,CML (chronic myelocytic leukemia) (CMS/HCC),"C92.12 - Chronic myeloid leukemia, BCR/ABL-positive, in relapse; E43 - Unspecified severe protein-calorie malnutrition; J96.01 - Acute respiratory failure with hypoxia; I50.33 - Acute on chronic diastolic (congestive) heart failure; B19.10 - Unspecified viral hepatitis B without hepatic coma; E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy; D63.0 - Anemia in neoplastic disease; I11.0 - Hypertensive heart disease with heart failure; F25.0 - Schizoaffective disorder, bipolar type; J44.9 - Chronic obstructive pulmonary disease, unspecified; E66.01 - Morbid (severe) obesity due to excess calories; E89.0 - Postprocedural hypothyroidism; Z51.11 - Encounter for antineoplastic chemotherapy; J98.4 - Other disorders of lung; F43.10 - Post-traumatic stress disorder, unspecified; G47.00 - Insomnia, unspecified; F41.1 - Generalized anxiety disorder; R45.1 - Restlessness and agitation; F41.0 - Panic disorder (episodic paroxysmal anxiety); I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; G89.29 - Other chronic pain; M10.9 - Gout, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; E78.00 - Pure hypercholesterolemia, unspecified; Z68.33 - Body mass index (BMI) 33.0-33.9, adult; Z91.81 - History of falling; Z91.52 - Personal history of nonsuicidal self-harm; Z88.0 - Allergy status to penicillin; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z91.030 - Bee allergy status; Z91.040 - ..."
JCMC CP INFUSION,37962,"Cruz, Allan Louie E, MD",6/13/2024,Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,6/12/2024,Inactive,,
NBI D7 MED-SURG/TELE,70279,"Jacoby, Sari H, MD",8/3/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/2/2024,Active,,
JCMC CP INFUSION,30373,"Sekhri, Arunabh, MD",1/20/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,1/12/2025,Active,,
CMC OP INFUSION,43672,"Cohen, Seth D, MD",3/28/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/27/2024,Inactive,,
NBI VALERIE FND HEMONC,22069,"Rao, Harini, MD",4/19/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,4/19/2024,Inactive,,
NBI VALERIE FND HEMONC,22069,"Rao, Harini, MD",4/25/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,4/25/2024,Inactive,,
NBI VALERIE FND HEMONC,22069,"Rao, Harini, MD",5/24/2024,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,5/24/2024,Inactive,,
NBI VALERIE FND HEMONC,22069,"Rao, Harini, MD",7/22/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,7/22/2024,Inactive,,
NBI VALERIE FND HEMONC,22069,"Rao, Harini, MD",9/26/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,9/26/2024,Inactive,,
NBI VALERIE FND HEMONC,22069,"Rao, Harini, MD",11/26/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,11/26/2024,Active,,
NBR CINJ OP INFUSION,75696,"Matasar, Matthew J, MD",10/4/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,10/3/2023,Inactive,,
CINJ OP INFUSION,49273,"Toppmeyer, Deborah L, MD",8/14/2023,Palbociclib 28 Day Cycles - Breast,First Line,8/14/2023,Active,,
CINJ OP INFUSION,10709,"Toppmeyer, Deborah L, MD",3/18/2025,Ribociclib 28 Day Cycles - Breast,_2. Second Line,3/18/2025,Active,"Malignant neoplasm of lower-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)",
CINJ OP INFUSION,54236,"Haigentz, Missak, MD",6/6/2023,Dabrafenib/Trametinib 28 Day Cycles- Anaplastic Thyroid Cancer,First Line,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,99584,"Shah, Mansi R, MD",2/13/2024,Carvykti with Fludarabine / Cyclophosphamide with Dr. Paul Chung from 2/7-2/9 - Multiple Myeloma,Lymphodepletion,2/6/2024,Inactive,,
NBI OP INFUSION,27860,"Anderson, Patrick S, MD",3/28/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - endometrial cancer,_1. First Line,3/27/2024,Inactive,,
NBI OP INFUSION,27860,"Anderson, Patrick S, MD",7/22/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,7/10/2024,Active,,
CINJ OP INFUSION,52966,"Toppmeyer, Deborah L, MD",8/7/2023,Palbociclib 28 Day Cycles - Breast,First Line,8/7/2023,Inactive,,
CINJ OP INFUSION,52966,"Toppmeyer, Deborah L, MD",10/5/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,First Line,10/4/2023,Inactive,,
CINJ OP INFUSION,52966,"Toppmeyer, Deborah L, MD",8/14/2024,Gemcitabine / CARBOplatin 28 Day Cycles - Breast,_3. Third Line,8/13/2024,Inactive,,
CINJ OP INFUSION,52966,"Toppmeyer, Deborah L, MD",8/14/2024,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",_4. Fourth Line,8/13/2024,Inactive,,
NBI D7 MED-SURG/TELE,65635,"Shah, Shailja S, MD",12/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,12/17/2024,Inactive,,
NBI OP INFUSION,19357,"Shah, Shailja S, MD",9/10/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,9/9/2024,Active,,
CBMC OP INFUSION 2FL,8077,"Leitner, Stuart P, MD",4/11/2024,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,Neoadjuvant,4/10/2024,Inactive,,
CBMC OP INFUSION 2FL,8077,"Leitner, Stuart P, MD",8/1/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,7/25/2024,Active,,
NBI OP INFUSION,88189,"Shah, Maya M, MD",5/14/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,5/14/2025,Active,Secondary malignant neoplasm of bone and bone marrow (CMS/HCC),"C50.412, Z17.0 - Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)"
NBI OP INFUSION,68645,"Jacoby, Sari H, MD",4/8/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/31/2024,Inactive,,
NBI OP INFUSION,68645,"Jacoby, Sari H, MD",4/22/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/14/2024,Inactive,,
NBI OP INFUSION,68645,"Jacoby, Sari H, MD",7/3/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,7/2/2024,Active,,
CBMC OP INFUSION 2FL,80312,"Grossman, I Robert, MD",11/15/2023,PACLitaxel 28 Day Cycles - Melanoma,_2. Second Line,11/14/2023,Active,,
NBR 5N ONCOLOGY,77060,"Palmisiano, Neil David, MD",9/19/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,9/18/2024,Inactive,,
NBR 5N ONCOLOGY,77060,"Palmisiano, Neil David, MD",9/19/2024,Glofitamab / Gemcitabine / Oxaliplatin / Obinutuzimab 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,9/18/2024,Inactive,,
NBR 4N ONCOLOGY,77060,"Tiger, Yun Kyoung, MD",10/12/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,10/11/2024,Inactive,,
NBR CINJ OP INFUSION,77060,"Rhodes, Joanna Meehan, MD",12/26/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,12/25/2024,Active,,
NBR 4N ONCOLOGY,76099,"Jang, Thomas L, MD",10/27/2023,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,10/27/2023,Inactive,,
MMC OP VP INFUSION,89077,"Lee, Patrick C, MD",11/26/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,10/16/2024,Active,,
NBI OP INFUSION,8688,"Schleicher, Lori, MD",4/26/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,4/25/2023,Inactive,,
NBI OP INFUSION,8688,"Schleicher, Lori, MD",8/2/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,8/1/2023,Inactive,,
CINJ OP INFUSION,84715,"Berim, Lyudmyla, MD",6/12/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,,6/11/2023,Inactive,,
CBMC OP INFUSION 2FL,10787,"Grossman, I Robert, MD",2/24/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/16/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C25.0 - Malignant neoplasm of head of pancreas
NBI OP INFUSION,17860,"Shah, Maya M, MD",11/30/2023,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/30/2023,Inactive,,
NBI OP INFUSION,17860,"Jacoby, Sari H, MD",5/31/2024,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,_2. Second Line,5/9/2024,Inactive,,
CINJ OP INFUSION,52272,"Mayer, Tina M, MD",7/23/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,7/17/2024,Inactive,,
CBMC OP INFUSION 2FL,97330,"Kulkarni, Aditya A, MD",5/22/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,5/22/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
CBMC OP INFUSION 2FL,10149,"Kulkarni, Aditya A, MD",1/20/2025,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,1/15/2025,Active,,
MMC OP VP INFUSION,68723,"Meghal, Trishala, MD",8/28/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,8/12/2024,Inactive,,
JCMC CP INFUSION,80941,"Cruz, Allan Louie E, MD",3/14/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Cervical ,,3/13/2023,Inactive,,
JCMC CP INFUSION,80941,"Cruz, Allan Louie E, MD",11/8/2023,"Gemcitabine D1, D8, 21 Day Cycles- cervical cancer",_3. Third Line,11/8/2023,Inactive,,
JCMC CP INFUSION,80941,"Cruz, Allan Louie E, MD",12/14/2023,Topotecan 28 Day Cycles - Cervical,_4. Fourth Line,12/14/2023,Inactive,,
JCMC CP INFUSION,7899,"Cruz, Allan Louie E, MD",1/3/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/2/2024,Inactive,,
JCMC CP INFUSION,7899,"Cruz, Allan Louie E, MD",9/23/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/22/2024,Active,,
CINJ OP INFUSION,68561,"Omene, Coral Oghenerukevwe, MD",3/27/2023,Palbociclib 28 Day Cycles - Breast,,3/27/2023,Inactive,,
NBR 4N ONCOLOGY,68561,"Omene, Coral Oghenerukevwe, MD",4/24/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_2. Second Line,4/23/2024,Inactive,,
CINJ OP INFUSION,86483,"Haigentz, Missak, MD",9/20/2024,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/19/2024,Active,,
NBR CINJ OP INFUSION,35703,"Shah, Mansi R, MD",3/27/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/27/2025,Active,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; D84.9 - Immunodeficiency, unspecified; M89.9 - Disorder of bone, unspecified; I49.8 - Other specified cardiac arrhythmias; D64.9 - Anemia, unspecified; D47.2 - Monoclonal gammopathy; Z91.89 - Other specified personal risk factors, not elsewhere classified"
CINJ OP INFUSION,10163,"Mayer, Tina M, MD",8/15/2023,Enzalutamide 28 Day Cycles - Prostate,,8/15/2023,Active,,
CINJ OP INFUSION,97005,"Saraiya, Biren P, MD",10/29/2024,"DAROLUTAMIDE, 28 DAY CYCLES - PROSTATE CANCER",_1. First Line,10/28/2024,Active,,
NBI VALERIE FND HEMONC,66508,"Rao, Harini, MD",5/7/2025,PEDS AHOD1331 Bv-AVE-PC,_1. First Line,5/7/2025,Active,Hodgkin lymphoma (CMS/HCC),"C81.10 - Nodular sclerosis Hodgkin lymphoma, unspecified site"
CINJ OP INFUSION,68530,"Stephenson, Ruth D, DO",8/30/2023,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,8/22/2023,Inactive,,
CINJ OP INFUSION,68530,"Stephenson, Ruth D, DO",3/20/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,3/12/2024,Active,,
SOM OUTPT INFUSION,94889,"Patel, Eshan, MD",10/12/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,10/4/2023,Inactive,,
SOM OUTPT INFUSION,94889,"Patel, Eshan, MD",3/21/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,3/20/2024,Active,,
SOM OUTPT INFUSION,58438,"Toomey, Kathleen C, MD",12/6/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,12/5/2024,Inactive,,
SOM OUTPT INFUSION,15009,"Yin, Faye, MD",3/4/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/3/2024,Inactive,,
CMC OP INFUSION,72827,"Taff, Jessica, MD",7/9/2024,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Thymic Carcinoma,_1. First Line,7/7/2024,Inactive,,
CMC OP INFUSION,72827,"Taff, Jessica, MD",10/15/2024,Pembrolizumab 21 Day Cycles- thymic carcinoma,_2. Second Line,10/14/2024,Active,,
CMC OP INFUSION,71684,"Easaw, Sarah, MD",9/12/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",First Line,9/11/2023,Inactive,,
MMC OP INFUSION,20428,"Cohen, Seth D, MD",12/28/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,12/27/2023,Inactive,,
MMC OP VP INFUSION,20428,"Cohen, Seth D, MD",7/25/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma,Maintenance,7/24/2024,Active,Endometrial cancer (CMS/HCC),
MMC OP VP INFUSION,36098,"Lee, Patrick C, MD",4/29/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/28/2024,Active,,
CINJ OP INFUSION,4419,"Hochster, Howard S, MD",3/22/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/20/2023,Inactive,,
CINJ OP INFUSION,4419,"Hochster, Howard S, MD",12/6/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/6/2023,Inactive,,
CINJ OP INFUSION,74124,"Omene, Coral Oghenerukevwe, MD",2/10/2025,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,Neoadjuvant,2/9/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,36201,"Omene, Coral Oghenerukevwe, MD",5/5/2025,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,5/5/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,70972,"Eltoukhy, Hussam, MD",6/3/2024,Cladribine / RiTUXimab 56 Day Cycle - Hairy Cell Leukemia,_1. First Line,5/30/2024,Inactive,,
MMC OP INFUSION,70972,"Eltoukhy, Hussam, MD",11/18/2024,Cladribine / RiTUXimab 56 Day Cycle - Hairy Cell Leukemia,_1. First Line,10/27/2024,Active,,
JCMC CP INFUSION,57512,"Sekhri, Arunabh, MD",5/22/2023,EP (Etoposide / CISplatin) 21 Day Cycles - Testicular,First Line,5/21/2023,Inactive,,
CINJ OP INFUSION,38796,"Berim, Lyudmyla, MD",2/6/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,1/29/2023,Inactive,,
CINJ OP INFUSION,38796,"Berim, Lyudmyla, MD",10/9/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/1/2023,Inactive,,
CINJ OP INFUSION,38796,"Berim, Lyudmyla, MD",10/9/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/5/2023,Inactive,,
CINJ OP INFUSION,54737,"Boland, Patrick M, MD",12/3/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,10/21/2024,Active,,
NBR CINJ OP INFUSION,72162,"Egini, Ogechukwu, MD",3/20/2025,BMT Allogeneic TBF + Post Cy,_2. Second Line,3/19/2025,Active,Myelofibrosis (CMS/HCC),"D47.1 - Chronic myeloproliferative disease; E03.9 - Hypothyroidism, unspecified; Z94.84 - Stem cells transplant status; Z01.818 - Encounter for other preprocedural examination; D75.81 - Myelofibrosis"
JCMC CP INFUSION,34820,"Sekhri, Arunabh, MD",2/23/2023,PACLitaxel / CISplatin + Bevacizumab+Keytruda  21 Day Cycles - Cervical,First Line,2/22/2023,Inactive,,
JCMC CP INFUSION,34820,"Sekhri, Arunabh, MD",11/10/2023,Bevacizumab 21 Day Cycles - Metastatic Cervical Cancer,_2. Second Line,11/2/2023,Inactive,,
JCMC CP INFUSION,34820,"Sekhri, Arunabh, MD",7/3/2024,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_3. Third Line,6/12/2024,Inactive,,
JCMC CP INFUSION,34820,"Sekhri, Arunabh, MD",11/1/2024,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 50 mg/m2 D1 21 Day Cycles- cervical",_4. Fourth Line,10/27/2024,Inactive,,
NBR 4N ONCOLOGY,42581,"Palmisiano, Neil David, MD",4/1/2025,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,Induction,3/31/2025,Active,B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; B17.9 - Acute viral hepatitis, unspecified; D61.818 - Other pancytopenia; C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site; D62 - Acute posthemorrhagic anemia; K12.30 - Oral mucositis (ulcerative), unspecified; R16.2 - Hepatomegaly with splenomegaly, not elsewhere classified; C92.00 - Acute myeloblastic leukemia, not having achieved remission; D53.9 - Nutritional anemia, unspecified; E53.8 - Deficiency of other specified B group vitamins; K06.8 - Other specified disorders of gingiva and edentulous alveolar ridge; R59.0 - Localized enlarged lymph nodes; R73.9 - Hyperglycemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z59.71 - Insufficient health insurance coverage"
NBR BMSCH 2 PED HEMONC,19485,"Sharma, Archana, DO",7/7/2023,per AALL1731 Non-DS SR B-ALL Induction,Induction,7/6/2023,Inactive,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",8/16/2023,AALL1731 SR-High B-ALL and DS-High B-ALL Consolidation,,8/16/2023,Inactive,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",8/17/2023,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",First Line,8/17/2023,Inactive,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",11/3/2023,AALL1731 SR-High B-ALL Arm C Interim Maintenance I HDMTX,_1. First Line,10/19/2023,Inactive,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",1/4/2024,AALL1731 SR-High B-ALL Arms C & D Delayed Intensification,_1. First Line,1/4/2024,Inactive,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",3/14/2024,AALL1731 SR-High B-ALL Arms C & D - Interim Maintenance II CMTX,_1. First Line,3/14/2024,Inactive,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",5/16/2024,AALL1731 SR-High B-ALL Arm C - Maintenance,Maintenance,5/16/2024,Active,,
CINJ PEDS HEMONC ,19485,"Botwinick, Marissa, DO",11/8/2024,PEDS Blinatumomab,_1. First Line,11/7/2024,Inactive,,
CINJ OP INFUSION,58549,"Stephenson, Ryan D, DO",5/23/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,5/23/2025,Active,Renal cell carcinoma (CMS/HCC),"C64.1 - Malignant neoplasm of right kidney, except renal pelvis; C79.51 - Secondary malignant neoplasm of bone; G89.3 - Neoplasm related pain (acute) (chronic); M84.451A - Pathological fracture, right femur, initial encounter for fracture; L29.89 - Other pruritus; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; S22.050A - Wedge compression fracture of T5-T6 vertebra, initial encounter for closed fracture; S32.010A - Wedge compression fracture of first lumbar vertebra, initial encounter for closed fracture; S32.020A - Wedge compression fracture of second lumbar vertebra, initial encounter for closed fracture; S32.030A - Wedge compression fracture of third lumbar vertebra, initial encounter for closed fracture; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z90.5 - Acquired absence of kidney"
MMC OP INFUSION,70542,"Meghal, Trishala, MD",10/13/2023,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",,10/10/2023,Inactive,,
NBI VALERIE FND HEMONC,64712,"Rao, Harini, MD",9/4/2023,"AALL1731 SR-Fav B-ALL, SR-Avg Arm A & B B-ALL, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,9/4/2023,Inactive,,
NBI VALERIE FND HEMONC,64712,"Rao, Harini, MD",11/10/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,_1. First Line,11/10/2023,Inactive,,
NBI VALERIE FND HEMONC,64712,"Rao, Harini, MD",1/8/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,1/8/2024,Active,,
CINJ OP INFUSION,70702,"Stephenson, Ryan D, DO",12/6/2024,"DOCETAXEL / DAROLUTAMIDE, 21 DAY CYCLES - PROSTATE CANCER",_1. First Line,10/18/2024,Active,,
NBI OP INFUSION,43774,"Jacoby, Sari H, MD",2/12/2024,Dabrafenib/Trametinib 28 Day Cycles- Recurrent GBM,_2. Second Line,2/12/2024,Active,,
CMC OP INFUSION,57016,"Pompa, Tiffany Ann, MD",1/30/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/20/2025,Active,,
JCMC CP INFUSION,35167,"Sekhri, Arunabh, MD",5/7/2024,CISplatin (Split-Dosing) 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/6/2024,Inactive,,
JCMC CP INFUSION,35167,"Sekhri, Arunabh, MD",6/17/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,6/16/2024,Inactive,,
NBI A5 PEDIATRICS,54649,"Rao, Harini, MD",4/17/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,4/17/2024,Inactive,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",5/23/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,5/23/2024,Inactive,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",6/21/2024,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,6/20/2024,Inactive,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",8/23/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,8/23/2024,Inactive,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",8/28/2024,PEDS Asparaginase Erwinia (Rylaze),_1. First Line,8/28/2024,Inactive,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",10/25/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,10/25/2024,Active,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",10/28/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,10/28/2024,Inactive,,
NBI VALERIE FND HEMONC,54649,"Rao, Harini, MD",12/20/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,12/20/2024,Active,,
CBMC OP INFUSION 2FL,22920,"Litvak, Anna M, MD",11/16/2023,Palbociclib 28 Day Cycles - Breast,_2. Second Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,8659,"Leitner, Stuart P, MD",12/5/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/4/2024,Active,,
NBI VALERIE FND HEMONC,96711,"Batra, Surabhi, MD",12/26/2024,AALL1732 Consolidation,_1. First Line,12/26/2024,Active,,
NBI VALERIE FND HEMONC,96711,"Batra, Surabhi, MD",12/26/2024,AALL1732 Consolidation,_1. First Line,12/26/2024,Inactive,,
NBI VALERIE FND HEMONC,96711,"Rao, Harini, MD",1/10/2025,PEDS Asparaginase Erwinia (Rylaze) - ALL,_1. First Line,1/10/2025,Active,,
NBI VALERIE FND HEMONC,77704,"Batra, Surabhi, MD",3/11/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,3/11/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
NBI OP INFUSION,80761,"Schleicher, Lori, MD",3/17/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,3/17/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,41193,"Hochster, Howard S, MD",3/31/2025,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,3/31/2025,Active,"Hepatocellular carcinoma (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",C22.0 - Liver cell carcinoma; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; Z11.59 - Encounter for screening for other viral diseases
JCMC CP INFUSION,25058,"Cruz, Allan Louie E, MD",11/1/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/31/2023,Inactive,,
CINJ OP INFUSION,21976,"Girda, Eugenia, MD",8/28/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/27/2024,Active,,
NBR 5N ONCOLOGY,21976,"Girda, Eugenia, MD",11/13/2024,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Consolidation,11/13/2024,Inactive,,
CINJ OP INFUSION,63163,"Patel, Eshan, MD",8/2/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/19/2024,Active,,
MMC OP INFUSION,67750,"Meghal, Trishala, MD",7/15/2024,Olaparib 30 Day Cycles - Breast,Adjuvant,7/15/2024,Active,,
NBR 5N ONCOLOGY,49712,"Sridharan, Ashwin, MD",9/22/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,9/21/2023,Inactive,,
NBR CINJ OP INFUSION,49712,"Palmisiano, Neil David, MD",10/24/2023,AzaCITIDine Oral 28 Day Cycles - Acute Myeloid Leukemia,Maintenance,10/24/2023,Active,,
CBMC OP INFUSION 2FL,82769,"Gurubhagavatula, Sarada, MD",5/14/2025,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_3. Third Line,4/23/2025,Active,Ovarian cancer (CMS/HCC),
MMC OP INFUSION,70551,"Meghal, Trishala, MD",12/20/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,11/30/2023,Inactive,,
MMC OP VP INFUSION,70551,"Meghal, Trishala, MD",3/13/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/12/2024,Inactive,,
MMC OP VP INFUSION,70551,"Meghal, Trishala, MD",6/28/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,6/6/2024,Active,Aplastic anemia (CMS/HCC),
CBMC OP INFUSION 2FL,89829,"Scoppetuolo, Michael, MD",4/3/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/26/2024,Active,,
NBI OP INFUSION,42241,"Cheng, Yan Ho, MD",8/29/2023,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,8/28/2023,Active,,
NBI OP INFUSION,42241,"Cheng, Yan Ho, MD",12/10/2024,Acalabrutinib 30 Day Cycles - Small Lymphocytic Lymphoma,_1. First Line,8/29/2023,Active,,
NBR CINJ OP INFUSION,62996,"Matasar, Matthew J, MD",5/21/2025,CINJ 112305 AVD Arm E (Doxorubicin / Vinblastine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/21/2025,Active,Hodgkin lymphoma (CMS/HCC),"C81.90 - Hodgkin lymphoma, unspecified, unspecified site"
NBR CINJ OP INFUSION,62996,"Matasar, Matthew J, MD",3/19/2025,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,3/19/2025,Inactive,Hodgkin lymphoma (CMS/HCC),
CMC OP INFUSION,54655,"Tang, Horace, MD",6/19/2023,RiTUXimab 28 Day Cycles - Chronic Lymphocytic Leukemia /,,6/14/2023,Inactive,,
CINJ OP INFUSION,2972,"Ganesan, Shridar, MD PhD",6/4/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,6/3/2024,Inactive,,
CINJ OP INFUSION,2972,"Omene, Coral Oghenerukevwe, MD",12/9/2024,Olaparib 30 Day Cycles - Breast,_2. Second Line,12/9/2024,Active,,
CINJ OP INFUSION,41171,"Omene, Coral Oghenerukevwe, MD",4/1/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/1/2025,Active,"Malignant neoplasm of nipple of right breast in female, unspecified estrogen receptor status (CMS/HCC)
Carcinoma of breast metastatic to bone (CMS/HCC)","C50.911 - Malignant neoplasm of unspecified site of right female breast; C79.51 - Secondary malignant neoplasm of bone; C78.00 - Secondary malignant neoplasm of unspecified lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z90.11 - Acquired absence of right breast and nipple; C50.011 - Malignant neoplasm of nipple and areola, right female breast; Z17.0 - Estrogen receptor positive status (ER+)"
NBR CINJ OP INFUSION,98410,"Matasar, Matthew J, MD",12/18/2024,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,12/17/2024,Inactive,,
NBR CINJ OP INFUSION,98410,"Matasar, Matthew J, MD",1/14/2025,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,1/13/2025,Active,,
NBR CINJ OP INFUSION,98410,"Matasar, Matthew J, MD",2/5/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,2/4/2025,Active,"Grade 2 follicular lymphoma of lymph nodes of multiple regions (CMS/HCC)
Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC)",
CINJ OP INFUSION,79205,"Berim, Lyudmyla, MD",1/11/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,1/9/2024,Active,,
CBMC OP INFUSION 2FL,86106,"Dave, Manish, MD",8/23/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,8/22/2023,Inactive,,
CINJ OP INFUSION,5318,"Weiss, Sarah, MD",5/3/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Second Line,5/3/2023,Inactive,,
CINJ OP INFUSION,85578,"Ghodoussipour, Saum Bobak, MD",5/23/2024,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Adjuvant,5/22/2024,Inactive,,
CINJ OP INFUSION,85578,"Ghodoussipour, Saum Bobak, MD",10/21/2024,BCG Induction (TICE) 42 Day Cycle,Adjuvant,10/20/2024,Inactive,,
CMC OP INFUSION,85578,"Patel, Neel H, MD",12/9/2024,BCG Induction (TICE) 42 Day Cycle,Induction,12/8/2024,Active,,
HAM OP INFUSION,61398,"Yogarajah, Meera, MD",7/21/2023,Capecitabine 21 Day Cycles - Breast,First Line,7/21/2023,Inactive,,
HAM OP INFUSION,61398,"Yogarajah, Meera, MD",9/25/2023, Pembrolizumab / Gemcitabine / CARBOplatin 21 Day Cycles -TNBC,First Line,9/10/2023,Inactive,,
CBMC OP INFUSION 2FL,94777,"Wagmiller, Jennifer Ann, MD",8/23/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/22/2024,Active,,
MMC OP VP INFUSION,5368,"Cohen, Seth D, MD",5/9/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,5/7/2024,Active,,
MSC OP INFUSION,66263,"Cohen, Seth D, MD",7/11/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,,7/10/2023,Inactive,,
MSC OP INFUSION,66263,"Cohen, Seth D, MD",11/21/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,11/20/2023,Inactive,,
NBI OP INFUSION,37917,"Shah, Maya M, MD",6/27/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),First Line,6/26/2023,Inactive,,
NBI OP INFUSION,37917,"Shah, Maya M, MD",10/18/2023,Palbociclib 28 Day Cycles - Breast,_2. Second Line,10/18/2023,Inactive,,
NBI OP INFUSION,37917,"Shah, Maya M, MD",8/14/2024,Alpelisib 28 Day Cycles - Breast,_3. Third Line,8/14/2024,Active,,
NBI OP INFUSION,87434,"Jacoby, Sari H, MD",6/13/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/12/2023,Inactive,,
NBI OP INFUSION,87434,"Jacoby, Sari H, MD",2/13/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/12/2024,Active,,
NBI OP INFUSION,87434,"Jacoby, Sari H, MD",9/10/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/10/2024,Active,Prostate cancer (CMS/HCC),
CINJ OP INFUSION,49187,"Saraiya, Biren P, MD",1/11/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/7/2024,Inactive,,
CINJ OP INFUSION,28877,"Boland, Patrick M, MD",11/19/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,11/18/2024,Active,,
MMC OP VP INFUSION,70237,"Lee, Patrick C, MD",8/2/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/31/2024,Active,,
MMC OP VP INFUSION,84440,"Lee, Patrick C, MD",4/18/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/18/2025,Active,"Malignant neoplasm of cardia of stomach (CMS/HCC)
Chemotherapy-induced fatigue",
NBI OP INFUSION,30819,"Jacoby, Sari H, MD",3/24/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/24/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; N94.9 - Unspecified condition associated with female genital organs and menstrual cycle; R92.8 - Other abnormal and inconclusive findings on diagnostic imaging of breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,93736,"Haigentz, Missak, MD",4/16/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/16/2025,Active,Malignant neoplasm of right upper lobe of lung (CMS/HCC),
MMC OP VP INFUSION,32307,"Lee, Patrick C, MD",3/19/2024,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,3/19/2024,Active,,
NBR 5N ONCOLOGY,34110,"Rhodes, Joanna Meehan, MD",6/24/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Induction,6/24/2024,Inactive,,
NBR 5N ONCOLOGY,34110,"Rhodes, Joanna Meehan, MD",6/24/2024,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 14 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,6/23/2024,Inactive,,
NBR 5N ONCOLOGY,34110,"Rhodes, Joanna Meehan, MD",6/24/2024,DHAX (Dexamethasone / Cytarabine / OXALIplatin) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,6/24/2024,Inactive,,
NBR 5N ONCOLOGY,34110,"Rhodes, Joanna Meehan, MD",7/24/2024,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,7/23/2024,Inactive,,
NBR CINJ OP INFUSION,34110,"Rhodes, Joanna Meehan, MD",10/9/2024,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,Lymphodepletion,10/8/2024,Inactive,,
CBMC OP INFUSION 2FL,68696,"Dharmapuri, Sirish, MD",4/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/28/2025,Active,Malignant neoplasm of ampulla of Vater (CMS/HCC),C24.1 - Malignant neoplasm of ampulla of Vater
CINJ OP INFUSION,10178,"Berim, Lyudmyla, MD",3/21/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,3/19/2023,Inactive,,
CINJ OP INFUSION,10178,"Berim, Lyudmyla, MD",8/7/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,8/7/2023,Inactive,,
CINJ OP INFUSION,10178,"Berim, Lyudmyla, MD",2/14/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,2/13/2024,Inactive,,
CINJ OP INFUSION,32460,"Stephenson, Ryan D, DO",7/23/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,7/23/2024,Inactive,,
HAM OP INFUSION,68059,"Patel, Malini M, MD",4/17/2023,Trastuzumab 21 Day Cycles- Gastrointestinal Cancers,First Line,4/16/2023,Inactive,,
HAM OP INFUSION,68059,"Patel, Malini M, MD",5/8/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,Maintenance,5/8/2023,Inactive,,
HAM OP INFUSION,68059,"Patel, Malini M, MD",8/14/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,8/13/2024,Active,,
NBR CINJ OP INFUSION,10372,"Evens, Andrew M, DO",4/19/2023,Liposomal DOXOrubicin 28 Day Cycles - Cutaneous T-Cell Lymphoma,,4/18/2023,Inactive,,
NBR 4N BMTU/IMCU,10372,"Braunschweig, Ira, MD",6/23/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/23/2023,Inactive,,
CINJ OP INFUSION,98534,"Boland, Patrick M, MD",9/7/2023,CINJ 072304 Cohort 1 ME-344 + Bevacizumab - Colorectal Cancer,,9/7/2023,Inactive,,
NBI D7 MED-SURG/TELE,6318,"Shah, Shailja S, MD",12/15/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/14/2023,Inactive,,
NBI OP INFUSION,6318,"Shah, Shailja S, MD",3/26/2024,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,3/25/2024,Inactive,,
CMC OP INFUSION,3895,"Tang, Horace, MD",3/7/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles with radiation- Small-Cell Lung Cancer,First Line,3/7/2023,Inactive,,
CINJ OP INFUSION,28743,"Stephenson, Ryan D, DO",4/17/2025,Enzalutamide 28 Day Cycles - Prostate,_3. Third Line,4/17/2025,Active,Metastatic castration-resistant adenocarcinoma of prostate (CMS/HCC),"C61, Z19.2 - Metastatic castration-resistant adenocarcinoma of prostate (CMS/HCC)"
SOM OUTPT INFUSION,55830,"Yin, Faye, MD",6/30/2023,Dasatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,First Line,6/30/2023,Inactive,,
NBR CINJ OP INFUSION,55830,"Palmisiano, Neil David, MD",5/14/2024,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_2. Second Line,4/29/2024,Inactive,,
CINJ OP INFUSION,39906,"Girda, Eugenia, MD",12/13/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/12/2024,Active,,
CINJ OP INFUSION,45947,"Haigentz, Missak, MD",6/5/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,6/4/2023,Inactive,,
CBMC OP INFUSION 2FL,85218,"Scoppetuolo, Michael, MD",11/3/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/2/2023,Inactive,,
CINJ OP INFUSION,60679,"Haigentz, Missak, MD",1/23/2023,Brigatinib 28 Day Cycles- Non-Small Cell Lung Cancer,,1/23/2023,Inactive,,
CINJ OP INFUSION,60679,"Haigentz, Missak, MD",11/3/2024,Lorlatinib 28 Day Cycles- Non-Small Cell Lung Cancer,_4. Fourth Line,11/3/2024,Active,,
CMC OP INFUSION,48797,"Taff, Jessica, MD",5/30/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/30/2025,Active,Right upper lobe pulmonary nodule,
CMC OP INFUSION,24354,"Eltoukhy, Hussam, MD",5/4/2023,Daratumumab 28 Day Cycles- Multiple Myeloma,Maintenance,5/3/2023,Inactive,,
CMC OP INFUSION,24354,"Eltoukhy, Hussam, MD",11/19/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,11/18/2024,Active,,
MMC OP VP INFUSION,52863,"Lee, Patrick C, MD",11/14/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,10/30/2024,Active,,
MMC OP VP INFUSION,68017,"Lee, Patrick C, MD",5/29/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/28/2025,Active,"Carcinoma of biliary duct or passage (CMS/HCC)
Chemotherapy-induced fatigue
Other specified abnormalities of plasma proteins",
MMC OP VP INFUSION,82499,"Talwar, Sumit, MD",9/15/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,Second Line,9/14/2023,Inactive,,
CBMC OP INFUSION 2FL,99328,"Litvak, Anna M, MD",5/30/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,5/30/2025,Active,Breast cancer (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,84509,"Omene, Coral Oghenerukevwe, MD",4/4/2024,"PACLitaxel D1, D15 28 Day Cycles - Breast",_1. First Line,4/3/2024,Inactive,,
CINJ OP INFUSION,84509,"Omene, Coral Oghenerukevwe, MD",4/4/2024,Pertuzumab / Trastuzumab Q 21 Days - Breast,_1. First Line,4/3/2024,Active,,
NBI D7 MED-SURG/TELE,98448,"Jacoby, Sari H, MD",12/6/2024,Bortezomib Twice Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_2. Second Line,12/5/2024,Inactive,,
CBMC OP INFUSION 2FL,25674,"Ligresti, Louise G, MD",7/22/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,7/22/2024,Active,,
NBR CINJ OP INFUSION,40018,"Evens, Andrew M, DO",4/26/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,4/25/2023,Active,Primary EGFR-positive NSCLC (CMS/HCC),
JCMC CP INFUSION,54615,"Cruz, Allan Louie E, MD",10/26/2023,Trastuzumab 21 Day Cycles - Breast,Adjuvant,10/11/2023,Active,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),
CINJ OP INFUSION,42525,"Saraiya, Biren P, MD",1/23/2023,Enzalutamide 30 Day Cycles - Prostate,First Line,1/23/2023,Inactive,,
CINJ OP INFUSION,42525,"Saraiya, Biren P, MD",8/1/2023,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,Second Line,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,25780,"Matasar, Matthew J, MD",6/28/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Second Line,6/27/2023,Inactive,,
NBR 4N ONCOLOGY,25780,"Matasar, Matthew J, MD",8/2/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,8/1/2023,Inactive,,
NBI OP INFUSION,40194,"Shah, Maya M, MD",5/12/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/8/2025,Active,Breast cancer (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBI OP INFUSION,37112,"Shah, Maya M, MD",2/12/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,1/21/2025,Active,Malignant neoplasm of left female breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,8991,"Brown, Andrew Bennett, MD",11/15/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,11/14/2023,Inactive,,
SOM OUTPT INFUSION,80411,"Patel, Eshan, MD",5/7/2025,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,5/7/2025,Active,Squamous cell carcinoma of perianal region,"C44.520 - Squamous cell carcinoma of anal skin; I10 - Essential (primary) hypertension; I48.0 - Paroxysmal atrial fibrillation; E78.2 - Mixed hyperlipidemia; Z92.3 - Personal history of irradiation; K21.9 - Gastro-esophageal reflux disease without esophagitis; E78.5 - Hyperlipidemia, unspecified; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; Z87.891 - Personal history of nicotine dependence; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
SOM OUTPT INFUSION,53811,"Toomey, Kathleen C, MD",2/7/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,2/5/2024,Inactive,,
NBR CINJ OP INFUSION,79835,"Schaar, Dale, MD PhD",7/8/2024,CINJ 022204 LYT- 200 / Azacitadine 28 Day Cycles Research- Myelodysplastic Syndromes ,_3. Third Line,7/8/2024,Inactive,,
NBR CINJ OP INFUSION,79835,"Schaar, Dale, MD PhD",7/8/2024,CINJ 022204 LYT- 200 / Decitabine 28 Day Cycles Research- Myelodysplastic Syndromes,_3. Third Line,7/8/2024,Inactive,,
NBR CINJ OP INFUSION,79835,"Schaar, Dale, MD PhD",7/8/2024,"CINJ 022204 Cohort 3 Combination Agents Part 2 of 2 Decitabine 28 Day Cycles Research - Myleodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)",_3. Third Line,7/8/2024,Inactive,,
NBR CINJ OP INFUSION,79835,"Schaar, Dale, MD PhD",7/8/2024,"CINJ 022204 Cohort 3 Combination Agents Part 1 of 2 LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_3. Third Line,7/8/2024,Inactive,,
CINJ OP INFUSION,79835,"Schaar, Dale, MD PhD",7/11/2024,"CINJ 022204 LYT- 200 28 Day Cycles Research -  Acute Myeloid Leukemia (AML), & MDS",_1. First Line,7/11/2024,Inactive,,
NBR CINJ OP INFUSION,79835,"Schaar, Dale, MD PhD",12/23/2024,"CINJ 022204 Cohort 3 Combination Agents Part 1 of 2 LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_3. Third Line,12/23/2024,Inactive,,
NBI OP INFUSION,21568,"Schleicher, Lori, MD",7/10/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,7/10/2024,Active,,
CBMC OP INFUSION 2FL,29631,"Leitner, Stuart P, MD",7/18/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/10/2024,Active,"Colorectal cancer, stage IV (CMS/HCC)",
CBMC OP INFUSION 2FL,29631,"Leitner, Stuart P, MD",11/21/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,11/20/2024,Active,,
CINJ OP INFUSION,87945,"Patel, Eshan, MD",1/19/2024,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 80 mg/m2 D1 21 Day Cycles- Head and Neck Cancers",_1. First Line,1/18/2024,Active,,
CINJ OP INFUSION,10655,"Gulhati, Prateek, MD PhD",12/21/2023,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/13/2023,Inactive,,
CBMC 2W ONCOLOGY,21943,"McKenna, Marshall, MD",9/6/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,9/6/2024,Inactive,,
CBMC 2W ONCOLOGY,21943,"McKenna, Marshall, MD",9/7/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_1. First Line,9/5/2024,Active,,
CBMC 2W ONCOLOGY,21943,"McKenna, Marshall, MD",10/2/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,10/1/2024,Inactive,,
CBMC OP INFUSION 2FL,21943,"McKenna, Marshall, MD",4/8/2025,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_1. First Line,4/8/2025,Inactive,ATLL (adult T-cell leukemia/lymphoma) (CMS/HCC),"C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site"
CBMC OP INFUSION 2FL,15155,"Wagmiller, Jennifer Ann, MD",8/2/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,8/1/2023,Inactive,,
CBMC OP INFUSION 2FL,15155,"Wagmiller, Jennifer Ann, MD",11/15/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,11/14/2023,Inactive,,
CBMC OP INFUSION 2FL,15155,"Wagmiller, Jennifer Ann, MD",11/15/2023,PACLitaxel / CARBOplatin/trastuz/pembro 21 Day Cycles - Uterine,_1. First Line,11/15/2023,Inactive,,
CBMC OP INFUSION 2FL,15155,"Wagmiller, Jennifer Ann, MD",1/4/2024,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,1/3/2024,Inactive,,
CBMC OP INFUSION 2FL,15155,"Wagmiller, Jennifer Ann, MD",6/10/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/27/2024,Active,,
CBMC OP INFUSION 2FL,87517,"Brown, Andrew Bennett, MD",10/24/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/11/2023,Inactive,,
CBMC OP INFUSION 2FL,87517,"Brown, Andrew Bennett, MD",4/26/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/26/2024,Active,,
CBMC OP INFUSION 2FL,87517,"Brown, Andrew Bennett, MD",5/24/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/23/2024,Active,,
CMC OP INFUSION,21043,"Talwar, Sumit, MD",11/8/2024,Isatuximab/ Bortezomib / Dexamethasone / Lenalidomide- Multiple Myeloma,_1. First Line,11/7/2024,Active,,
CMC OP INFUSION,21043,"Talwar, Sumit, MD",11/29/2024,Isatuximab-irfc/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/28/2024,Inactive,,
CMC OP INFUSION,21043,"Talwar, Sumit, MD",12/3/2024,Isatuximab-irfc,_1. First Line,11/28/2024,Active,,
NBR 4N ONCOLOGY,21121,"Schaar, Dale, MD PhD",6/23/2023,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,,6/20/2023,Inactive,,
NBR CINJ OP INFUSION,1151,"Matasar, Matthew J, MD",10/18/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,Third Line,10/10/2023,Inactive,,
NBI OP INFUSION,96101,"Shah, Maya M, MD",9/13/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Third Line,9/13/2023,Inactive,,
NBI OP INFUSION,96101,"Shah, Maya M, MD",5/1/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,4/30/2024,Active,,
NBI OP INFUSION,96101,"Shah, Shailja S, MD",7/31/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_6. Sixth Line,7/31/2024,Active,"Soft tissue sarcoma of upper extremity, right (CMS/HCC)
Malignant neoplasm metastatic to both lungs (CMS/HCC)",
NBR CINJ OP INFUSION,56367,"Palmisiano, Neil David, MD",7/9/2024,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,7/5/2024,Active,,
CMC OP INFUSION,10293,"Taff, Jessica, MD",6/8/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,6/5/2023,Active,,
CBMC OP INFUSION 2FL,17953,"Derosa, William T, DO",11/22/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/21/2024,Active,,
CINJ OP INFUSION,4664,"Patel, Eshan, MD",5/8/2023,Pembrolizumab 21 Day Cycles - lung,,5/8/2023,Inactive,,
CINJ OP INFUSION,79577,"Patel, Eshan, MD",10/14/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,10/13/2024,Active,,
CINJ OP INFUSION,20425,"Stephenson, Ryan D, DO",4/29/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,4/29/2024,Inactive,,
CBMC OP INFUSION 2FL,28770,"Litvak, Anna M, MD",10/13/2023,CINJ 042102 Amendment 33 EOP B ARV-471 / Letrozole 28 Day Cycles Research- Breast Cancer,_1. First Line,10/12/2023,Active,,
CBMC OP INFUSION 2FL,28770,"Leitner, Stuart P, MD",1/18/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,1/10/2024,Inactive,,
CBMC OP INFUSION 2FL,28770,"Ligresti, Louise G, MD",4/10/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,4/8/2024,Active,,
CBMC OP INFUSION 2FL,28770,"Litvak, Anna M, MD",11/6/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,11/6/2024,Active,"Cancer of appendix (CMS/HCC)
Metastasis to peritoneal cavity (CMS/HCC)",
CBMC OP INFUSION 2FL,25986,"Wagmiller, Jennifer Ann, MD",7/27/2023,Albumin-Bound PACLitaxel weekly Pembro 21 Day Cycles - Breast,First Line,7/26/2023,Inactive,,
CBMC OP INFUSION 2FL,25986,"Wagmiller, Jennifer Ann, MD",11/10/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_3. Third Line,11/10/2023,Inactive,,
CBMC OP INFUSION 2FL,25986,"Wagmiller, Jennifer Ann, MD",3/27/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,3/25/2024,Active,,
CINJ OP INFUSION,89104,"Leiser, Aliza, MD",1/24/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,1/23/2023,Inactive,,
CINJ OP INFUSION,89104,"Leiser, Aliza, MD",12/18/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,12/14/2023,Inactive,,
NBI D7 MED-SURG/TELE,40139,"Anderson, Patrick S, MD",7/29/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,7/28/2024,Active,,
CBMC OP INFUSION 2FL,92640,"Ligresti, Louise G, MD",2/5/2024,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,2/5/2024,Inactive,Secondary malignant neoplasm of bone (CMS/HCC),
CBMC OP INFUSION 2FL,92640,"Litvak, Anna M, MD",1/28/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,1/28/2025,Active,,
NBR 4N BMTU/IMCU,21122,"Braunschweig, Ira, MD",10/19/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,10/17/2023,Inactive,,
TRMC TCCC OP INFUSION,21122,"Salerno, Vincent E, MD",2/16/2024,Carfilzomib 36 mg/m2 Post-Transplant Maintenance - Multiple Myeloma,_3. Third Line,2/15/2024,Active,,
CINJ OP INFUSION,57344,"Boland, Patrick M, MD",2/14/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,2/14/2023,Inactive,,
CINJ OP INFUSION,94411,"Hochster, Howard S, MD",6/5/2023,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,First Line,6/2/2023,Inactive,,
CINJ OP INFUSION,50069,"Hochster, Howard S, MD",9/19/2024,FLOT + Nivo (Fluorouracil IVCI 2400 mg/m2 over 46 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/13/2024,Inactive,,
CINJ OP INFUSION,66601,"Packiam, Vignesh, MD",1/15/2025,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Adjuvant,1/14/2025,Active,,
TRMC TCCC OP INFUSION,77555,"Capo, Gerardo, MD",2/4/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/4/2025,Active,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; D63.8 - Anemia in other chronic diseases classified elsewhere; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); C18.5 - Malignant neoplasm of splenic flexure"
MMC OP VP INFUSION,16639,"Cohen, Seth D, MD",2/7/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,1/9/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,3761,"Moerdler, Scott, MD",6/10/2024,PEDS Carboplatin - Low Grade Glioma,_1. First Line,6/10/2024,Active,,
CINJ PEDS HEMONC ,3761,"Moerdler, Scott, MD",5/7/2025,PEDS Erdafitinb 28 Day Cycles - CNS,_3. Third Line,5/7/2025,Active,"Low grade glioma of brain (CMS/HCC)
Glioma (CMS/HCC)","R53.1 - Weakness; M79.606 - Pain of lower extremity, unspecified laterality; C71.9 - Glioma (CMS/HCC)"
CINJ PEDS HEMONC ,3761,"Moerdler, Scott, MD",3/18/2025,PEDS Vinblastine - Low Grade Glioma,_2. Second Line,3/18/2025,Inactive,"Low grade glioma of brain (CMS/HCC)
Glioma (CMS/HCC)","R53.1 - Weakness; M79.606 - Pain of lower extremity, unspecified laterality; C71.9 - Glioma (CMS/HCC)"
NBI OP INFUSION,34975,"Jacoby, Sari H, MD",10/16/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/15/2023,Inactive,,
NBI OP INFUSION,34975,"Jacoby, Sari H, MD",3/25/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/24/2024,Inactive,,
NBI OP INFUSION,34975,"Jacoby, Sari H, MD",8/12/2024,Weekly Fluorouracil IV Push / Leucovorin IV Push 7 Day Cycles- Colon Cancer,_3. Third Line,8/11/2024,Inactive,,
NBI OP INFUSION,34975,"Jacoby, Sari H, MD",8/26/2024,Roswell Park Leucovorin/Fluorouracil/MVASI 56 Day Cycles- Colon Cancer,_3. Third Line,8/25/2024,Active,Urothelial cancer (CMS/HCC),
TRMC TCCC OP INFUSION,8088,"Capo, Gerardo, MD",5/16/2025,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,_1. First Line,5/16/2025,Active,Carcinoma metastatic to liver with unknown primary site (CMS/HCC),
MMC OP VP INFUSION,55830,"Cohen, Seth D, MD",6/8/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,5/31/2023,Inactive,,
MMC OP VP INFUSION,55830,"Cohen, Seth D, MD",6/8/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,5/31/2023,Inactive,,
MMC OP VP INFUSION,55830,"Cohen, Seth D, MD",11/2/2023,Nivolumab 28 Day Cycles - Non Small Cell Lung Cancer,_1. First Line,11/2/2023,Inactive,,
NBR CINJ OP INFUSION,42596,"Evens, Andrew M, DO",3/9/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,Second Line,3/8/2023,Inactive,,
CINJ OP INFUSION,87925,"Girda, Eugenia, MD",1/4/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/4/2024,Active,,
NBR 4N ONCOLOGY,45556,"Kennedy, Timothy, MD",10/4/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,10/4/2023,Inactive,,
CINJ OP INFUSION,32431,"Ghodoussipour, Saum Bobak, MD",1/3/2023,Mitomycin for Pyelocalyceal Instillation (Ureteral Gel) - Urothelial ,Induction,1/2/2023,Inactive,,
CINJ OP INFUSION,89970,"Saraiya, Biren P, MD",10/28/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,10/27/2024,Active,,
SOM OUTPT INFUSION,290,"Toomey, Kathleen C, MD",10/5/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Third Line,9/26/2023,Inactive,,
SOM OUTPT INFUSION,290,"Toomey, Kathleen C, MD",5/31/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,5/23/2024,Inactive,,
SOM OUTPT INFUSION,290,"Toomey, Kathleen C, MD",10/25/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_3. Third Line,10/24/2024,Active,,
MMC OP VP INFUSION,79108,"Cohen, Seth D, MD",6/17/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,_1. First Line,6/14/2024,Inactive,,
MMC OP VP INFUSION,79108,"Cohen, Seth D, MD",10/21/2024,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,10/21/2024,Active,,
CINJ OP INFUSION,79108,"Packiam, Vignesh, MD",5/9/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/8/2025,Active,Malignant neoplasm of left renal pelvis (CMS/HCC),Z51.89 - Encounter for other specified aftercare; C65.2 - Malignant neoplasm of left renal pelvis
CBMC OP INFUSION 2FL,92593,"Scoppetuolo, Michael, MD",10/25/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,10/24/2023,Inactive,,
NBR 5N ONCOLOGY,17406,"Berim, Lyudmyla, MD",6/16/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/16/2024,Active,,
CINJ OP INFUSION,17406,"Berim, Lyudmyla, MD",10/31/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,10/31/2024,Active,,
CINJ OP INFUSION,17406,"Berim, Lyudmyla, MD",1/30/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/26/2025,Active,,
CBMC OP INFUSION 2FL,99219,"Brown, Andrew Bennett, MD",2/6/2025,"Gemcitabine D1, D8 21 Day Cycles- Cholangio Carcinoma ",_2. Second Line,2/6/2025,Active,Cholangiocarcinoma determined by biopsy of biliary tract (CMS/HCC),
CBMC OP INFUSION 2FL,99219,"Brown, Andrew Bennett, MD",2/6/2025,Pembrolizumab 21 Day Cycles - Cholangio carcinoma ,_2. Second Line,1/21/2025,Active,Cholangiocarcinoma determined by biopsy of biliary tract (CMS/HCC),
NBI OP INFUSION,99818,"Schleicher, Lori, MD",12/24/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,12/24/2024,Active,,
SOM OUTPT INFUSION,70096,"Yin, Faye, MD",3/12/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/10/2024,Inactive,,
TRMC TCCC OP INFUSION,18505,"Capo, Gerardo, MD",2/25/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/24/2025,Active,Cancer of lesser curvature of stomach (CMS/HCC),
HAM OP INFUSION,28457,"Patel, Malini M, MD",3/8/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,3/2/2023,Inactive,,
HAM OP INFUSION,28457,"Patel, Malini M, MD",6/26/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,6/25/2023,Inactive,,
CINJ OP INFUSION,951,"Weiss, Sarah, MD",5/21/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,5/21/2025,Active,Malignant melanoma of right lower extremity (CMS/HCC),"C43.71 - Malignant melanoma of right lower limb, including hip; C79.2 - Secondary malignant neoplasm of skin"
CINJ OP INFUSION,57349,"Saraiya, Biren P, MD",4/17/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,First Line,4/2/2023,Inactive,,
JCMC 7W MED-SURG 2,74213,"Cruz, Allan Louie E, MD",9/20/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,9/19/2023,Inactive,,
NBR 4N ONCOLOGY,98403,"Jang, Thomas L, MD",2/21/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/21/2025,Active,"Bladder mass
Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC)",
CINJ OP INFUSION,98403,"Jang, Thomas L, MD",5/1/2025,CINJ 082404 Group B Gemcitabine 2000 mg 7 Day Cycles Research- Bladder Cancer,Induction,5/1/2025,Active,Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC),
TRMC TCCC OP INFUSION,70736,"Capo, Gerardo, MD",10/8/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/8/2024,Inactive,,
CINJ OP INFUSION,16602,"Aikins, James K, MD",8/4/2023,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,8/4/2023,Inactive,,
NBR 5N ONCOLOGY,90132,"Goel, Sanjay, MD",5/9/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,First Line,5/9/2023,Inactive,,
CINJ PEDS HEMONC ,83428,"Moerdler, Scott, MD",5/21/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,5/20/2024,Inactive,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",6/28/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,6/28/2024,Inactive,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",7/25/2024,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,7/25/2024,Inactive,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",9/26/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,9/26/2024,Inactive,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",9/26/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,9/26/2024,Inactive,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",11/28/2024,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,11/28/2024,Inactive,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",12/5/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,12/5/2024,Active,,
CINJ PEDS HEMONC ,83428,"Sharma, Archana, DO",12/5/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,12/5/2024,Inactive,,
CINJ PEDS HEMONC ,32,"Sharma, Archana, DO",2/13/2025,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,2/13/2025,Active,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),"C91.01 - Acute lymphoblastic leukemia, in remission; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; I15.8 - Other secondary hypertension"
CBMC OP INFUSION 2FL,30028,"Brown, Andrew Bennett, MD",10/13/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,30028,"Brown, Andrew Bennett, MD",8/1/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,7/31/2024,Inactive,,
CBMC OP INFUSION 2FL,30028,"Brown, Andrew Bennett, MD",9/5/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,9/4/2024,Active,,
CINJ OP INFUSION,89839,"Aikins, James K, MD",11/11/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - GERM CELL,Adjuvant,11/10/2024,Active,,
NBR 4N ONCOLOGY,47279,"Palmisiano, Neil David, MD",1/18/2023,HyperCVD Mini + Ponatinib (Cycle 1) (Cyclophosphamide / VinCRIStine / Dexamethasone) 28 Day Cycles - Acute Lymphoblastic Leukemia (Induction),,1/17/2023,Inactive,,
NBR 5N ONCOLOGY,47279,"Palmisiano, Neil David, MD",3/3/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia - (Induction),,3/3/2023,Inactive,,
NBR 4N ONCOLOGY,31667,"Rhodes, Joanna Meehan, MD",11/23/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,11/22/2024,Inactive,,
JCMC CP INFUSION,293,"Cruz, Allan Louie E, MD",3/25/2024,PACLitaxel 7 Day Cycles x 12 weeks - Hormone Receptor (+) Breast Cancer,Adjuvant,3/24/2024,Inactive,,
CINJ OP INFUSION,697,"Stephenson, Ruth D, DO",10/4/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,10/3/2024,Active,,
CINJ OP INFUSION,29939,"Omene, Coral Oghenerukevwe, MD",2/20/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,2/17/2023,Inactive,,
CINJ OP INFUSION,30840,"Boland, Patrick M, MD",4/11/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/4/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I26.99 - Other pulmonary embolism without acute cor pulmonale"
CINJ OP INFUSION,824,"George, Mridula A, MD",1/31/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/30/2025,Active,"Hepatocellular, cholangiocarcinoma combined (CMS/HCC)",
SOM OUTPT INFUSION,8698,"Patel, Eshan, MD",7/12/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/11/2023,Inactive,,
SOM OUTPT INFUSION,8698,"Patel, Eshan, MD",6/10/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/6/2024,Inactive,,
CINJ OP INFUSION,93504,"Berim, Lyudmyla, MD",3/10/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/10/2025,Active,Colorectal cancer (CMS/HCC),C18.9 - Stage IV carcinoma of colon (CMS/HCC)
NBR 5N ONCOLOGY,1382,"Mayer, Tina M, MD",3/15/2025,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,3/14/2025,Active,Testicular cancer (CMS/HCC),"C62.12 - Malignant neoplasm of descended left testis; C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes; C78.00 - Secondary malignant neoplasm of unspecified lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; D84.9 - Immunodeficiency, unspecified; R04.2 - Hemoptysis; K59.00 - Constipation, unspecified; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.49 - Family history of malignant neoplasm of other genital organs; Z80.8 - Family history of malignant neoplasm of other organs or systems; Z87.891 - Personal history of nicotine dependence; Z98.890 - Other specified postprocedural states; F41.9 - Anxiety disorder, unspecified; Q53.20 - Undescended testicle, unspecified, bilateral"
NBI OP INFUSION,37779,"Cheng, Yan Ho, MD",5/29/2025,RiTUXimab 28 Day Cycle - CLL,_1. First Line,5/29/2025,Active,"Autoimmune hemolytic anemia (CMS/HCC)
CLL (chronic lymphocytic leukemia) (CMS/HCC)",
CINJ PEDS HEMONC ,28521,"Botwinick, Marissa, DO",11/18/2024,per AALL1731 Non-DS SR B-ALL Induction,Induction,11/16/2024,Inactive,,
CINJ PEDS HEMONC ,28521,"Botwinick, Marissa, DO",12/26/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",Consolidation,12/26/2024,Active,,
CINJ PEDS HEMONC ,28521,"Drachtman, Richard, MD",1/24/2025,PEDS Blinatumomab,_1. First Line,1/23/2025,Active,,
CINJ PEDS HEMONC ,28521,"Botwinick, Marissa, DO",2/27/2025,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,1/23/2025,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),C91.01 - Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC)
CINJ PEDS HEMONC ,28521,"Drachtman, Richard, MD",5/29/2025,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,5/29/2025,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CINJ PEDS HEMONC ,28521,"Botwinick, Marissa, DO",4/25/2025,PEDS Blinatumomab,_1. First Line,4/24/2025,Inactive,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
SOM 1PAV ONCOLOGY,41655,"Patel, Eshan, MD",10/10/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,10/10/2024,Inactive,,
SOM OUTPT INFUSION,41655,"Patel, Eshan, MD",11/11/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/10/2024,Active,,
CBMC 2W ONCOLOGY,27740,"Grossman, I Robert, MD",12/28/2023,Venetoclax 42 Day Cycles - Mantle Cell Lymphoma,_1. First Line,12/28/2023,Active,"Rectal cancer (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
CBMC 2W ONCOLOGY,27740,"Grossman, I Robert, MD",8/30/2024,HiDAC-123 + Midostaurin (High-Dose Cytarabine / Midostaurin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),_2. Second Line,8/30/2024,Active,,
CBMC OP INFUSION 2FL,27740,"Grossman, I Robert, MD",2/4/2025,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_3. Third Line,1/27/2025,Active,AML (acute myeloblastic leukemia) (CMS/HCC),
CBMC OP INFUSION 2FL,12678,"Grossman, I Robert, MD",3/26/2025,MEC (MitoXANTRONE / Etoposide / Hight-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia,_4. Fourth Line,3/26/2025,Inactive,"AML (acute myeloblastic leukemia) (CMS/HCC)
Acquired coagulation factor deficiency (CMS/HCC)",
NBR CINJ OP INFUSION,53453,"Shah, Mansi R, MD",3/14/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,2/26/2024,Inactive,,
CINJ OP INFUSION,60780,"Weiss, Sarah, MD",3/31/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,3/31/2025,Inactive,Malignant melanoma metastatic to brain (CMS/HCC),"C43.9 - Malignant melanoma of skin, unspecified; C79.31 - Secondary malignant neoplasm of brain"
CBMC OP INFUSION 2FL,30327,"Wagmiller, Jennifer Ann, MD",7/13/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,7/12/2023,Inactive,,
NBR 5N ONCOLOGY,33247,"Mayer, Tina M, MD",12/14/2024,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,12/13/2024,Inactive,,
CINJ OP INFUSION,33247,"Groisberg, Roman, MD",2/28/2025,DOXOrubicin 21 Day Cycles - Sarcoma,_1. First Line,2/27/2025,Active,Undifferentiated pleomorphic sarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified"
CINJ OP INFUSION,43327,"Weiss, Sarah, MD",8/4/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,7/31/2023,Active,,
MMC OP VP INFUSION,31162,"Cohen, Seth D, MD",4/1/2024,CARBOplatin / Gemcitabine 21 Day Cycles + Nivolumab 360 mg - Bladder,Neoadjuvant,4/1/2024,Active,,
NBI OP INFUSION,52429,"Jacoby, Sari H, MD",9/4/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/4/2024,Inactive,,
CINJ OP INFUSION,33492,"Mayer, Tina M, MD",9/26/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - urothelial cancer,Neoadjuvant,9/25/2024,Active,,
NBR MEDICAL SAME DAY,33492,"Ghodoussipour, Saum Bobak, MD",2/3/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/3/2025,Active,Urothelial carcinoma (CMS/HCC),
CMC OP INFUSION,66142,"Lee, Patrick C, MD",4/19/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/18/2023,Inactive,,
NBR CINJ OP INFUSION,32307,"Shah, Mansi R, MD",7/30/2024,Talquetamab 28 Day Cycles,_6. Sixth Line,7/30/2024,Inactive,,
NBR CINJ OP INFUSION,32307,"Shah, Mansi R, MD",12/5/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_4. Fourth Line,12/4/2024,Active,,
MMC OP VP INFUSION,29332,"Cohen, Seth D, MD",6/7/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,,6/6/2023,Active,,
CBMC OP INFUSION 2FL,33691,"Dharmapuri, Sirish, MD",4/16/2025,Atezolizumab (Bevacizumab on Hold) 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,4/14/2025,Active,HCC (hepatocellular carcinoma) (CMS/HCC),
CBMC OP INFUSION 2FL,16954,"Brown, Andrew Bennett, MD",2/28/2025,Cemiplimab-rwlc 21 Day Cycles - Lung Cancer,Maintenance,2/27/2025,Active,Malignant neoplasm of upper lobe of left lung (CMS/HCC),
NBI VALERIE FND HEMONC,53755,"Ford, Maegan C, MD",10/23/2023,AALL1732 Consolidation,Consolidation,10/9/2023,Inactive,,
NBI VALERIE FND HEMONC,53755,"Ford, Maegan C, MD",10/31/2023,PEDS AALL02P2 Radiation and Chemotherapy (Weeks 51-54 or 53-56),Consolidation,10/29/2023,Inactive,,
NBI VALERIE FND HEMONC,53755,"Ford, Maegan C, MD",12/3/2023,PEDS AALL02P2 Maintenance for Isolated CNS Relapse ONLY (Weeks 55-104 or 57-106),Maintenance,12/1/2023,Active,,
CINJ OP INFUSION,97435,"Hochster, Howard S, MD",2/15/2023,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Second Line,2/14/2023,Inactive,,
CINJ OP INFUSION,97435,"Hochster, Howard S, MD",4/26/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Gastric Adenocarcinoma,Third Line,4/26/2023,Inactive,,
NBI OP INFUSION,20269,"Jacoby, Sari H, MD",1/15/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/14/2025,Active,,
NBI D7 MED-SURG/TELE,20269,"Jacoby, Sari H, MD",1/31/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,1/30/2025,Active,,
CBMC OP INFUSION 2FL,55347,"Leitner, Stuart P, MD",3/9/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/8/2023,Inactive,,
CINJ OP INFUSION,41705,"Ghodoussipour, Saum Bobak, MD",4/16/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,4/15/2024,Inactive,,
CINJ OP INFUSION,41705,"Ghodoussipour, Saum Bobak, MD",7/29/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,7/29/2024,Active,,
CINJ OP INFUSION,25097,"Toppmeyer, Deborah L, MD",7/1/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,3/13/2024,Active,,
CMC OP INFUSION,27281,"Pompa, Tiffany Ann, MD",10/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/16/2024,Active,,
NBR CINJ OP INFUSION,1710,"Shah, Mansi R, MD",9/2/2024,Teclistamab Weekly 28 Day Cycles,_6. Sixth Line,8/28/2024,Active,"Mass of upper outer quadrant of right breast
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,13310,"Stephenson, Ryan D, DO",10/28/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/28/2024,Active,,
CINJ OP INFUSION,97446,"Patel, Eshan, MD",6/6/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,,5/29/2023,Inactive,,
CINJ OP INFUSION,97446,"Patel, Eshan, MD",9/15/2023,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,,9/14/2023,Inactive,,
CINJ OP INFUSION,26812,"Jang, Thomas L, MD",3/20/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,3/18/2023,Inactive,,
CINJ OP INFUSION,26812,"Jang, Thomas L, MD",8/28/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,8/27/2023,Active,,
CINJ OP INFUSION,56188,"Leiser, Aliza, MD",6/17/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,6/16/2024,Active,,
CBMC OP INFUSION 2FL,84721,"Brown, Andrew Bennett, MD",6/28/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/27/2023,Inactive,,
CBMC OP INFUSION 2FL,84721,"Brown, Andrew Bennett, MD",8/8/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/8/2024,Inactive,,
CBMC OP INFUSION 2FL,84721,"Brown, Andrew Bennett, MD",12/11/2024,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/10/2024,Active,,
CINJ OP INFUSION,78435,"Saraiya, Biren P, MD",2/6/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,2/6/2023,Inactive,,
CINJ OP INFUSION,78435,"Saraiya, Biren P, MD",10/25/2023,CINJ 082107 (CURLU177PSM001) Enzalutamide 28 Day Cycles Research Prostate Cancer,_2. Second Line,9/27/2023,Inactive,,
CINJ OP INFUSION,78435,"Saraiya, Biren P, MD",1/23/2024,Enzalutamide 28 Day Cycles - Prostate,_3. Third Line,1/23/2024,Inactive,,
CINJ OP INFUSION,2349,"Berim, Lyudmyla, MD",8/16/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,8/15/2023,Inactive,,
NBR CINJ OP INFUSION,60632,"Evens, Andrew M, DO",4/10/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_1. First Line,4/9/2024,Inactive,,
SOM 1PAV ONCOLOGY,57406,"Patel, Eshan, MD",1/11/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/8/2024,Inactive,,
CBMC OP INFUSION 2FL,13970,"Gurubhagavatula, Sarada, MD",1/10/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/9/2025,Active,,
NBR CINJ OP INFUSION,60661,"Palmisiano, Neil David, MD",5/6/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,5/3/2023,Inactive,,
NBR 4N ONCOLOGY,60661,"Palmisiano, Neil David, MD",5/12/2023,CINJ 022105 (Part 1 of 2) Magrolimab or Placebo 28 Day Cycles Research- Acute Myeloid Leukemia,,5/11/2023,Inactive,,
NBR 4N ONCOLOGY,60661,"Palmisiano, Neil David, MD",5/12/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,,5/11/2023,Inactive,,
CBMC OP INFUSION 2FL,36503,"Leitner, Stuart P, MD",11/1/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/31/2023,Active,"Cancer of sigmoid (CMS/HCC)
Colon cancer metastasized to liver (CMS/HCC)",
CINJ OP INFUSION,9995,"Aikins, James K, MD",10/24/2023,CISplatin 21 Day Cycles - Cervical,_1. First Line,10/22/2023,Inactive,,
CINJ OP INFUSION,9995,"Aikins, James K, MD",10/24/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,10/23/2023,Inactive,,
NBR 5N ONCOLOGY,50821,"Zayac, Adam, MD",3/26/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,3/26/2024,Inactive,,
NBR CINJ OP INFUSION,50821,"Rhodes, Joanna Meehan, MD",3/28/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/28/2024,Inactive,,
CMC OP INFUSION,6854,"Pompa, Tiffany Ann, MD",7/24/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/11/2024,Active,,
CMC OP INFUSION,6854,"Pompa, Tiffany Ann, MD",1/9/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/8/2025,Active,,
CMC OP INFUSION,60681,"Pompa, Tiffany Ann, MD",3/14/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/14/2025,Active,Esophageal cancer (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C15.5 - Malignant neoplasm of lower third of esophagus
MMC BBR2 ONCOLOGY,64941,"Lee, Patrick C, MD",8/29/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,8/28/2023,Inactive,,
MSC OP INFUSION,87107,"Cohen, Seth D, MD",3/14/2023,DOCEtaxel 75 mg/m2/ CISplatin 75 mg/m2/ Fluorouracil Continuous Infusion (5 Days) 21 Day Cycles- Head and Neck Cancers,Neoadjuvant,3/13/2023,Inactive,,
MSC OP INFUSION,87107,"Cohen, Seth D, MD",6/6/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,6/5/2023,Inactive,,
NBR 5N MED-SURG OVRF,51737,"Alexander, Henry Richard, MD",2/10/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,2/10/2025,Active,"Peritoneal carcinomatosis (CMS/HCC)
Mucinous adenocarcinoma metastatic to gastrointestinal tract (CMS/HCC)",
SOM OUTPT INFUSION,76076,"Patel, Eshan, MD",10/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/20/2024,Active,,
CINJ OP INFUSION,93618,"Saraiya, Biren P, MD",8/11/2023,Enzalutamide 28 Day Cycles - Prostate,Second Line,8/11/2023,Inactive,,
CINJ OP INFUSION,93618,"Saraiya, Biren P, MD",8/11/2023,CINJ 082107 (CURLU177PSM001) Enzalutamide 28 Day Cycles Research Prostate Cancer,Second Line,7/14/2023,Inactive,,
HAM OP INFUSION,52048,"Patel, Malini M, MD",5/30/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,5/29/2023,Inactive,,
HAM OP INFUSION,52048,"Patel, Malini M, MD",9/5/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,8/27/2023,Active,,
SOM OUTPT INFUSION,72236,"Yin, Faye, MD",8/19/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,7/23/2024,Inactive,,
SOM OUTPT INFUSION,72236,"Toomey, Kathleen C, MD",4/30/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,4/30/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",C50.511 - Malignant neoplasm of lower-outer quadrant of right female breast; Z51.11 - Encounter for antineoplastic chemotherapy; Z17.0 - Estrogen receptor positive status (ER+)
NBI OP INFUSION,25953,"Shah, Shailja S, MD",8/6/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/29/2024,Active,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",8/8/2023,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,,8/7/2023,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",9/19/2023,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,,9/18/2023,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",1/2/2024,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,Neoadjuvant,1/1/2024,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",6/18/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,6/18/2024,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",8/26/2024,CINJ 042211 Arm B Capecitabine / Pembrolizumab 21 Day Cycles Research- Breast Cancer,Adjuvant,8/23/2024,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",9/17/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,9/17/2024,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",10/11/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,10/7/2024,Inactive,,
CINJ OP INFUSION,16106,"Omene, Coral Oghenerukevwe, MD",2/17/2025,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,2/10/2025,Active,"Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor negative (CMS/HCC)
Estrogen receptor negative status (ER-)
Secondary malignant neoplasm of bone (CMS/HCC)",
CBMC 2W ONCOLOGY,55227,"Litvak, Anna M, MD",3/15/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_3. Third Line,3/14/2025,Inactive,"Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor negative (CMS/HCC)
Estrogen receptor negative status (ER-)
Secondary malignant neoplasm of bone (CMS/HCC)","C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; A41.9 - Sepsis, unspecified organism; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; G93.5 - Compression of brain; I62.00 - Nontraumatic subdural hemorrhage, unspecified; E43 - Unspecified severe protein-calorie malnutrition; C79.31 - Secondary malignant neoplasm of brain; K82.0 - Obstruction of gallbladder; K81.0 - Acute cholecystitis; C79.49 - Secondary malignant neoplasm of other parts of nervous system; R18.8 - Other ascites; C79.51 - Secondary malignant neoplasm of bone; C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast; D63.0 - Anemia in neoplastic disease; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; E05.00 - Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm; D68.59 - Other primary thrombophilia; R47.01 - Aphasia; E87.1 - Hypo-osmolality and hyponatremia; K82.1 - Hydrops of gallbladder; N39.0 - Urinary tract infection, site not specified; G40.409 - Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D69.6 - Thrombocytopenia, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; F41.9 - Anxiety disorder, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); H02.401 - Unspecified ptosis of right eyelid; H54.61 - Unqualified visual loss, right eye, normal vision ..."
MMC OP VP INFUSION,58941,"Lee, Patrick C, MD",6/8/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,,6/7/2023,Inactive,,
MMC BBR2 ONCOLOGY,58941,"Lee, Patrick C, MD",8/25/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",,8/24/2023,Inactive,,
CINJ OP INFUSION,82868,"George, Mridula A, MD",7/14/2023,Abemaciclib 28 Day Cycles - Breast ,Maintenance,7/14/2023,Inactive,,
CINJ OP INFUSION,82868,"George, Mridula A, MD",6/5/2024,CINJ 042209 Arm A Imlunestrant 5 Year Treatment Research- Breast Cancer,Adjuvant,6/5/2024,Active,,
CINJ OP INFUSION,86493,"Girda, Eugenia, MD",9/11/2024,CINJ 052008 / R7075-ONC-2009 Dose level 10 Schedule C Expansion Q3W REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research,_5. Fifth Line,8/19/2024,Active,,
CBMC OP INFUSION 2FL,12206,"Wagmiller, Jennifer Ann, MD",5/27/2025,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Adjuvant,5/27/2025,Active,Malignant neoplasm of left ovary (CMS/HCC),
JCMC CP INFUSION,7500,"Cruz, Allan Louie E, MD",5/4/2023,RiTUXimab - week 4 of 4,,5/4/2023,Inactive,,
CINJ OP INFUSION,69997,"Hochster, Howard S, MD",1/30/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,First Line,1/30/2023,Inactive,,
CINJ OP INFUSION,69997,"Hochster, Howard S, MD",3/14/2024,Ivosidenib (Tibsovo) - Cholangiocarcinoma,_3. Third Line,3/12/2024,Active,,
CBMC OP INFUSION 2FL,69997,"Dharmapuri, Sirish, MD",2/21/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,2/18/2025,Active,"Cholangiocarcinoma of biliary tract (CMS/HCC)
Cholangiocarcinoma metastatic to liver (CMS/HCC)",
NBR CINJ OP INFUSION,43443,"Matasar, Matthew J, MD",10/25/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,_2. Second Line,10/24/2023,Inactive,,
NBR CINJ OP INFUSION,43443,"Matasar, Matthew J, MD",2/9/2024,RiTUXimab / Lenalidomide 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,2/8/2024,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
HAM OP INFUSION,54320,"Patel, Malini M, MD",3/20/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,3/19/2023,Inactive,,
HAM OP INFUSION,54320,"Patel, Malini M, MD",6/22/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,6/21/2023,Inactive,,
HAM OP INFUSION,54320,"Patel, Malini M, MD",12/11/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,12/10/2023,Inactive,,
CMC OP INFUSION,35309,"Talwar, Sumit, MD",11/1/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/31/2023,Inactive,,
CMC OP INFUSION,35309,"Talwar, Sumit, MD",5/1/2024,Nivolumab 480 mg 28 Day Cycles,Maintenance,4/30/2024,Active,,
CMC OP INFUSION,35309,"Talwar, Sumit, MD",5/2/2025,Zolbetuximab-clzb 14 Day Cycles,_2. Second Line,5/2/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),
CMC 4B ONCOLOGY,35309,"Talwar, Sumit, MD",3/14/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/14/2025,Inactive,Malignant neoplasm of pyloric antrum (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; E44.0 - Moderate protein-calorie malnutrition; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; K56.690 - Other partial intestinal obstruction; Z93.4 - Other artificial openings of gastrointestinal tract status; D63.0 - Anemia in neoplastic disease; Z68.25 - Body mass index (BMI) 25.0-25.9, adult; E87.6 - Hypokalemia; Z98.51 - Tubal ligation status; Z79.890 - Hormone replacement therapy; Z59.71 - Insufficient health insurance coverage; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z92.21 - Personal history of antineoplastic chemotherapy; Z87.891 - Personal history of nicotine dependence; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system"
CINJ OP INFUSION,89498,"Boland, Patrick M, MD",1/25/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,1/25/2024,Inactive,,
CINJ OP INFUSION,89498,"Boland, Patrick M, MD",8/16/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/15/2024,Inactive,,
CINJ OP INFUSION,20359,"Berim, Lyudmyla, MD",6/21/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/20/2023,Inactive,,
CMC OP INFUSION,46692,"Cohen, Seth D, MD",1/15/2024,5FU-Leucovorin 14 days gastric CA,_1. First Line,1/14/2024,Active,,
CINJ OP INFUSION,26155,"Patankar, Sonali, MD",6/10/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Neoadjuvant,6/6/2024,Active,,
HAM OP INFUSION,64142,"Yogarajah, Meera, MD",1/9/2024,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,12/13/2023,Inactive,,
CINJ OP INFUSION,80317,"Berim, Lyudmyla, MD",2/15/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,2/14/2023,Inactive,,
CINJ OP INFUSION,80317,"Berim, Lyudmyla, MD",2/15/2023,"Gemcitabine D1, D15/Albumin-Bound PACLitaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,2/14/2023,Inactive,,
CINJ OP INFUSION,80317,"Berim, Lyudmyla, MD",5/2/2024,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/29/2024,Inactive,,
CINJ OP INFUSION,76237,"Muralikrishnan, Sivraj, MD",1/8/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/29/2024,Active,,
CBMC OP INFUSION 2FL,45497,"Wagmiller, Jennifer Ann, MD",12/2/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,12/1/2024,Active,,
NBR CINJ OP INFUSION,52972,"Berim, Lyudmyla, MD",5/6/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/5/2024,Active,,
CMC OP INFUSION,34318,"Tang, Horace, MD",2/7/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,2/6/2023,Inactive,,
CMC OP INFUSION,34318,"Talwar, Sumit, MD",4/29/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/28/2024,Inactive,,
CINJ OP INFUSION,61107,"Stephenson, Ryan D, DO",1/12/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,1/12/2024,Active,,
CINJ OP INFUSION,61107,"Stephenson, Ryan D, DO",2/2/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,2/1/2024,Inactive,,
NBR 5N ONCOLOGY,70751,"Saraiya, Biren P, MD",8/8/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,8/8/2023,Inactive,,
MMC OP VP INFUSION,18596,"Meghal, Trishala, MD",11/25/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,11/11/2024,Inactive,,
MMC OP VP INFUSION,18596,"Meghal, Trishala, MD",1/6/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,12/9/2024,Active,,
MMC OP VP INFUSION,18596,"Meghal, Trishala, MD",2/18/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/10/2025,Active,Malignant neoplasm of lower-inner quadrant of right female breast (CMS/HCC),
CINJ OP INFUSION,58769,"Berim, Lyudmyla, MD",6/1/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/31/2023,Inactive,,
CINJ OP INFUSION,58769,"Berim, Lyudmyla, MD",7/20/2023,FOLFIRI + Avastin 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/4/2023,Inactive,,
CINJ OP INFUSION,58769,"Berim, Lyudmyla, MD",3/22/2024,CINJ 072110 Simplified Biweekly Infusional Fluorouracil / Leucovorin + Bevacizumab 14 Day Cycles- Colon Cancer,_2. Second Line,3/21/2024,Inactive,,
CINJ OP INFUSION,58769,"Berim, Lyudmyla, MD",4/5/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/3/2024,Active,,
CINJ OP INFUSION,58769,"Berim, Lyudmyla, MD",6/17/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_3. Third Line,6/17/2024,Inactive,,
CINJ OP INFUSION,78125,"Mayer, Tina M, MD",4/29/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,4/29/2025,Active,Malignant neoplasm of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; R91.1 - Solitary pulmonary nodule; M85.9 - Disorder of bone density and structure, unspecified; E88.810 - Metabolic syndrome; D64.9 - Anemia, unspecified; I71.40 - Abdominal aortic aneurysm, without rupture, unspecified"
CBMC OP INFUSION 2FL,35557,"Scoppetuolo, Michael, MD",3/1/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/8/2024,Inactive,,
CINJ OP INFUSION,86829,"Haigentz, Missak, MD",3/27/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,3/26/2023,Inactive,,
CBMC OP INFUSION 2FL,92762,"Wagmiller, Jennifer Ann, MD",5/19/2025,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_2. Second Line,5/19/2025,Active,Ovarian ca (CMS/HCC),
NBR CINJ OP INFUSION,10867,"Shah, Mansi R, MD",4/5/2023,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,,4/4/2023,Inactive,,
JCMC CP INFUSION,62684,"Cruz, Allan Louie E, MD",4/23/2024,PACLitaxel / Trastuzumab 21 Day Cycles - Breast,Adjuvant,4/22/2024,Inactive,,
JCMC CP INFUSION,62684,"Cruz, Allan Louie E, MD",5/29/2024,Trastuzumab 21 Days Cycles - HER2 (+)Breast Cancer,Adjuvant,4/22/2024,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
MDS (myelodysplastic syndrome) (CMS/HCC)",
NBR 5N MED-SURG OVRF,50422,"Alexander, Henry Richard, MD",5/8/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,First Line,5/8/2023,Inactive,,
CINJ OP INFUSION,50422,"Hochster, Howard S, MD",6/15/2023,Nivolumab/Ipilimumab 42 Day Cycles- Malignant Pleural Mesothelioma,Third Line,6/14/2023,Inactive,,
CINJ OP INFUSION,61783,"Omene, Coral Oghenerukevwe, MD",5/6/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Neoadjuvant,5/3/2024,Inactive,,
CINJ OP INFUSION,61783,"Omene, Coral Oghenerukevwe, MD",6/18/2024,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,6/17/2024,Inactive,,
CINJ OP INFUSION,61783,"Omene, Coral Oghenerukevwe, MD",11/11/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,11/11/2024,Active,,
CINJ OP INFUSION,84065,"Omene, Coral Oghenerukevwe, MD",4/1/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,4/1/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)","C50.111, Z17.1 - Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)"
CINJ OP INFUSION,43829,"Leiser, Aliza, MD",8/26/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,8/11/2024,Active,,
HAM OP INFUSION,26147,"Gendy, Mina, DO",9/25/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,9/17/2024,Inactive,,
CINJ OP INFUSION,26147,"Saraiya, Biren P, MD",2/18/2025,CINJ 082401 Arm 3 Cohort B Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,Adjuvant,2/18/2025,Active,Bladder cancer (CMS/HCC),
HAM OP INFUSION,26147,"Gendy, Mina, DO",3/12/2025,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",Adjuvant,3/4/2025,Active,"Bladder cancer (CMS/HCC)
Protein-calorie malnutrition, unspecified severity (CMS/HCC)
Abnormal levels of other serum enzymes
Disorder of bone density and structure, unspecified","C67.9 - Malignant neoplasm of urinary bladder, unspecified site (CMS/HCC)"
CBMC OP INFUSION 2FL,65100,"Dharmapuri, Sirish, MD",12/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/17/2024,Active,,
CBMC OP INFUSION 2FL,65037,"Dharmapuri, Sirish, MD",5/1/2025,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/1/2025,Active,Adenocarcinoma of sigmoid colon (CMS/HCC),
MMC OP VP INFUSION,88779,"Cohen, Seth D, MD",1/8/2025,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/11/2024,Active,,
MMC OP VP INFUSION,98948,"Meghal, Trishala, MD",8/27/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/26/2024,Active,,
MMC OP VP INFUSION,35265,"Cohen, Seth D, MD",8/20/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/19/2024,Active,,
CINJ OP INFUSION,36654,"Berim, Lyudmyla, MD",10/9/2024,Imatinib 30 Day Cycles - Sarcoma,_1. First Line,10/9/2024,Active,,
HAM OP INFUSION,73759,"Patel, Malini M, MD",7/24/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,7/1/2024,Active,,
HAM OP INFUSION,90846,"Patel, Malini M, MD",8/12/2024,Cladribine / RiTUXimab 56 Day Cycle - Hairy Cell Leukemia,_1. First Line,7/23/2024,Active,,
SOM OUTPT INFUSION,7205,"Patel, Eshan, MD",7/6/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,,6/21/2023,Inactive,,
SOM OUTPT INFUSION,7205,"Patel, Eshan, MD",5/23/2024,CINJ 032304 Arm B Pembrolizumab / Ramucirumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,5/20/2024,Inactive,,
SOM OUTPT INFUSION,7205,"Patel, Eshan, MD",8/22/2024,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,8/21/2024,Active,,
CINJ OP INFUSION,36423,"Mayer, Tina M, MD",6/5/2023,Apalutamide 30 Day Cycles - Prostate,,6/5/2023,Inactive,,
CINJ OP INFUSION,36423,"Mayer, Tina M, MD",9/12/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,9/12/2023,Active,,
CINJ OP INFUSION,3817,"Omene, Coral Oghenerukevwe, MD",10/2/2023,Abemaciclib 28 Day Cycles - Breast ,Maintenance,10/2/2023,Active,,
HAM OP INFUSION,13290,"Yogarajah, Meera, MD",8/14/2023,Ribociclib 28 Day Cycles - Breast,First Line,8/14/2023,Inactive,,
MMC OP VP INFUSION,75156,"Cohen, Seth D, MD",6/22/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,6/21/2023,Inactive,,
MMC OP VP INFUSION,75156,"Cohen, Seth D, MD",2/1/2024,Temsirolimus 28 Day Cycles - Uterine,_4. Fourth Line,1/24/2024,Inactive,,
NBI A5 PEDIATRICS,57655,"de Benedictis, Marianna, MD",7/26/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,7/24/2024,Inactive,,
NBI VALERIE FND HEMONC,57655,"de Benedictis, Marianna, MD",8/29/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,8/29/2024,Inactive,,
NBI VALERIE FND HEMONC,57655,"de Benedictis, Marianna, MD",10/10/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,9/30/2024,Inactive,,
NBI VALERIE FND HEMONC,57655,"de Benedictis, Marianna, MD",11/15/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,11/15/2024,Inactive,,
NBI VALERIE FND HEMONC,57655,"de Benedictis, Marianna, MD",11/18/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,11/15/2024,Inactive,,
NBI VALERIE FND HEMONC,57655,"de Benedictis, Marianna, MD",1/13/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,1/10/2025,Inactive,,
NBI VALERIE FND HEMONC,51367,"de Benedictis, Marianna, MD",2/17/2025,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,2/17/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
NBI VALERIE FND HEMONC,51367,"de Benedictis, Marianna, MD",5/1/2025,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,5/1/2025,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CINJ OP INFUSION,51607,"Gulhati, Prateek, MD PhD",3/2/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,3/1/2023,Inactive,,
CINJ OP INFUSION,57609,"Boland, Patrick M, MD",5/9/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,5/9/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),
NBI OP INFUSION,99493,"Cohen, Alice, MD",10/20/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/19/2023,Inactive,,
CINJ OP INFUSION,10746,"Gulhati, Prateek, MD PhD",1/27/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,1/27/2023,Inactive,,
CINJ OP INFUSION,93625,"Stephenson, Ryan D, DO",1/13/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Second Line,1/13/2023,Inactive,,
CINJ OP INFUSION,84539,"Omene, Coral Oghenerukevwe, MD",1/29/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,1/29/2024,Inactive,,
CINJ OP INFUSION,33941,"Hochster, Howard S, MD",2/15/2023,Nivolumab q21d / Ipilimumab q42 Day - Pleural Mesothelioma,Second Line,2/15/2023,Inactive,,
MSC OP INFUSION,68016,"Cohen, Seth D, MD",11/26/2024,Pemetrexed / CARBOplatin (AUC 5) / Nivolumab 21 Day Cycles- Lung Cancer,_1. First Line,11/18/2024,Active,,
MSC OP INFUSION,68016,"Cohen, Seth D, MD",2/19/2025,Nivolumab 480 mg 28 Day Cycles- Thoracic Cancers,Maintenance,2/18/2025,Future,Adenocarcinoma of left lung (CMS/HCC),
NBI OP INFUSION,5092,"Anderson, Patrick S, MD",5/24/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles -  Endometrial Cancer,_1. First Line,5/2/2024,Inactive,,
NBI OP INFUSION,5092,"Anderson, Patrick S, MD",10/10/2024,CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Endometrial adenocarcinoma,_2. Second Line,10/9/2024,Active,,
NBI OP INFUSION,97408,"Anderson, Patrick S, MD",1/23/2025,CISplatin 21 Day Cycles - Vulvar Cancer,_1. First Line,1/22/2025,Active,,
NBR CINJ OP INFUSION,64574,"Palmisiano, Neil David, MD",8/1/2023,DAUNOrubicin Liposomal - Cytarabine (VYXEOS) - Induction 14 Day Cycle - Acute Myeloid Leukemia,,8/1/2023,Inactive,,
NBR 4N BMTU/IMCU,64574,"Braunschweig, Ira, MD",12/2/2023,BMT Allogeneic TBF + Post Cy ,_4. Fourth Line,12/1/2023,Inactive,,
JCMC CP INFUSION,98218,"Sekhri, Arunabh, MD",9/16/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Left tonsil squamous cell carcinoma,_1. First Line,8/4/2024,Inactive,,
JCMC CP INFUSION,98218,"Sekhri, Arunabh, MD",4/21/2025,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,4/21/2025,Active,Tonsil cancer (CMS/HCC),"D70.1 - Agranulocytosis secondary to cancer chemotherapy; C09.9 - Malignant neoplasm of tonsil, unspecified; F41.9 - Anxiety disorder, unspecified; R79.89 - Other specified abnormal findings of blood chemistry; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits"
CINJ OP INFUSION,12009,"Goel, Sanjay, MD",2/21/2023,"CINJ 052203 Phase 2 Cohort A, B, C E7386 / Pembrolizumab 21 Day Cycles Research- Solid Malignancies",Third Line,1/20/2023,Active,,
MSC OP INFUSION,9393,"Cohen, Seth D, MD",6/15/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,5/31/2023,Inactive,,
MSC OP INFUSION,9393,"Cohen, Seth D, MD",10/19/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/18/2023,Active,,
CINJ OP INFUSION,58638,"Salacz, Michael E, MD",3/6/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Adjuvant,3/6/2023,Inactive,,
CINJ OP INFUSION,58638,"Mayer, Tina M, MD",6/5/2023,Bevacizumab 42 Day Cycles - CNS,Second Line,6/5/2023,Inactive,,
HAM OP INFUSION,15107,"Patel, Malini M, MD",8/16/2023,DOXOrubicin 21 Day Cycles - Uterine Sarcoma,Second Line,8/15/2023,Inactive,,
CINJ OP INFUSION,15107,"Groisberg, Roman, MD",8/31/2023,Imatinib 30 Day Cycles - Sarcoma,Second Line,8/31/2023,Inactive,,
NBR 5N ONCOLOGY,15107,"Groisberg, Roman, MD",11/3/2023,Gemcitabine / DOCEtaxel 21 Day Cycles - Uterine Sarcoma,_3. Third Line,11/2/2023,Inactive,,
HAM OP INFUSION,15107,"Yogarajah, Meera, MD",1/18/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_4. Fourth Line,1/14/2024,Inactive,,
CINJ OP INFUSION,15107,"Groisberg, Roman, MD",3/7/2024,Ifosfamide / Mesna 21 Day Cycles - Sarcoma,_4. Fourth Line,3/6/2024,Inactive,,
CBMC 2W ONCOLOGY,71073,"Phillips, Adrienne A, MD",12/26/2023,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,12/25/2023,Inactive,,
CBMC OP INFUSION 2FL,71073,"Phillips, Adrienne A, MD",9/5/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,9/4/2024,Inactive,,
CBMC OP INFUSION 2FL,71073,"Phillips, Adrienne A, MD",9/12/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_3. Third Line,9/10/2024,Inactive,,
CBMC 2W ONCOLOGY,71073,"McKenna, Marshall, MD",11/4/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,Adjuvant,11/3/2024,Inactive,,
JCMC CP INFUSION,27531,"Sekhri, Arunabh, MD",11/9/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,10/20/2023,Inactive,,
NBR CINJ OP INFUSION,39311,"Egini, Ogechukwu, MD",6/20/2024,BMT Autologous Melphalan Day -1 140MG/M2,Consolidation,6/19/2024,Inactive,,
JCMC CP INFUSION,40663,"Sekhri, Arunabh, MD",12/7/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,11/26/2023,Inactive,,
CBMC OP INFUSION 2FL,3148,"Wagmiller, Jennifer Ann, MD",2/21/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,2/21/2024,Inactive,,
CBMC OP INFUSION 2FL,3148,"Wagmiller, Jennifer Ann, MD",6/7/2024,PACLitaxel IV / CISplatin IP / PACLitaxel IP - 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,6/6/2024,Inactive,,
NBI OP INFUSION,57304,"Anderson, Patrick S, MD",9/20/2023,PACLitaxel Weekly / CARBOplatin with Radiation therapy -  Endometrial Cancer,_1. First Line,9/19/2023,Inactive,,
NBI OP INFUSION,57304,"Anderson, Patrick S, MD",1/11/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab(MVASI) 21 Day Cycles - Endometrial,_2. Second Line,1/10/2024,Active,,
NBI OP INFUSION,64894,"Anderson, Patrick S, MD",5/8/2025,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,5/8/2025,Active,"Malignant neoplasm of cervix (CMS/HCC)
Endometrial cancer determined by uterine biopsy (CMS/HCC)",
CINJ OP INFUSION,96427,"Mayer, Tina M, MD",6/7/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,6/7/2023,Inactive,,
NBR 4N ONCOLOGY,74926,"Omene, Coral Oghenerukevwe, MD",2/7/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,,2/6/2023,Inactive,,
CBMC OP INFUSION 2FL,49993,"Litvak, Anna M, MD",11/13/2023,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,_1. First Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,49993,"Brown, Andrew Bennett, MD",1/4/2024,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,Neoadjuvant,1/2/2024,Inactive,,
CBMC OP INFUSION 2FL,49993,"Wagmiller, Jennifer Ann, MD",4/4/2024,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,Neoadjuvant,3/26/2024,Inactive,,
CBMC OP INFUSION 2FL,49993,"Wagmiller, Jennifer Ann, MD",6/6/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,6/3/2024,Active,,
JCMC CP INFUSION,79496,"Sekhri, Arunabh, MD",12/15/2023,Pembrolizumab 42 Day Cycles - Recurrent Uterine,Adjuvant,10/15/2023,Active,,
CINJ OP INFUSION,93730,"Saraiya, Biren P, MD",5/9/2023,CINJ 081603 ARM 2 Apalutamide / Abiraterone / Prednisone / GnRH Agonist 90 Day Cycle Research- Prostate Cancer,Neoadjuvant,5/8/2023,Active,,
JCMC CP INFUSION,38295,"Sekhri, Arunabh, MD",4/29/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,4/21/2024,Inactive,,
CINJ OP INFUSION,96050,"Muralikrishnan, Sivraj, MD",4/7/2025,CINJ 032409 Cohort 2 (< 80 kg) PEMEtrexed / CARBOplatin / Amivantamab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,4/7/2025,Active,NSCLC metastatic to adrenal gland (CMS/HCC),
CINJ OP INFUSION,29351,"Patankar, Sonali, MD",1/24/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,1/21/2025,Active,,
SOM OUTPT INFUSION,92229,"Toomey, Kathleen C, MD",11/15/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,11/14/2023,Inactive,,
CINJ OP INFUSION,81935,"Haigentz, Missak, MD",3/27/2023,CINJ 032209 PART 8 Dose 5.1 Maintenance Tarlatamab Q2W Plus Durvalumab,Maintenance,3/27/2023,Active,,
CINJ OP INFUSION,58796,"George, Mridula A, MD",3/29/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,3/29/2023,Inactive,,
CINJ OP INFUSION,58796,"George, Mridula A, MD",5/24/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,First Line,5/23/2023,Inactive,,
CINJ OP INFUSION,58796,"George, Mridula A, MD",12/22/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,12/19/2023,Inactive,,
CINJ OP INFUSION,58796,"George, Mridula A, MD",4/15/2024,"CINJ 042314 Cohort 2 BB-1701 D1, D8 21 Day Cycles Research- Breast Cancer",_4. Fourth Line,4/15/2024,Inactive,,
NBR 5N ONCOLOGY,58796,"George, Mridula A, MD",5/4/2024,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,5/4/2024,Inactive,,
SOM OUTPT INFUSION,29314,"Patel, Eshan, MD",3/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/17/2024,Inactive,,
SOM OUTPT INFUSION,29314,"Patel, Eshan, MD",7/30/2024,Cemiplimab / PACLitaxel / CARBOplatin 21 Day Cycles - lung,_1. First Line,7/16/2024,Active,,
SOM OUTPT INFUSION,29314,"Patel, Eshan, MD",10/25/2024,cemiplimab - NSCLC,Maintenance,10/18/2024,Active,,
NBI OP INFUSION,85190,"Shah, Maya M, MD",5/12/2025,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - BREAST CANCER,_1. First Line,5/12/2025,Active,"Malignant neoplasm of upper-outer quadrant of breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC 2W ONCOLOGY,96798,"Grossman, I Robert, MD",7/16/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,7/16/2024,Active,,
CBMC 2W ONCOLOGY,96798,"Grossman, I Robert, MD",7/18/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,7/18/2024,Active,,
CINJ OP INFUSION,96088,"Berim, Lyudmyla, MD",4/25/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,,4/24/2023,Inactive,,
CINJ OP INFUSION,96088,"Berim, Lyudmyla, MD",8/17/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,8/15/2023,Active,,
SOM OUTPT INFUSION,61510,"Patel, Eshan, MD",5/20/2025,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,_1. First Line,5/20/2025,Active,Rectal cancer (CMS/HCC),
SOM OUTPT INFUSION,61510,"Patel, Eshan, MD",3/11/2025,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,_1. First Line,3/11/2025,Inactive,Rectal cancer (CMS/HCC),
CBMC 2W ONCOLOGY,58149,"Grossman, I Robert, MD",2/22/2024,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,2/22/2024,Inactive,,
CBMC 2W ONCOLOGY,58149,"Grossman, I Robert, MD",3/26/2024,HiDAC-135 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,3/26/2024,Inactive,,
SOM OUTPT INFUSION,3734,"Yin, Faye, MD",5/26/2023,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,Third Line,5/11/2023,Inactive,,
SOM OUTPT INFUSION,3734,"Yin, Faye, MD",11/17/2023,Irinotecan Liposome/Capecitabine  14 Day Cycles- Pancreatic Adenocarcinoma,_4. Fourth Line,11/16/2023,Inactive,,
SOM OUTPT INFUSION,3734,"Yin, Faye, MD",12/26/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_4. Fourth Line,12/19/2023,Inactive,,
NBI OP INFUSION,9506,"Anderson, Patrick S, MD",5/13/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - High Grade sererous Carcinoma of gyn Origin,Neoadjuvant,5/13/2025,Active,"Malignant neoplasm of other specified female genital organs (CMS/HCC)
High grade serous carcinoma (CMS/HCC)","C57.7 - Malignant neoplasm of other specified female genital organs; I26.99 - Other pulmonary embolism without acute cor pulmonale; C78.00 - Secondary malignant neoplasm of unspecified lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C77.4 - Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes; D63.0 - Anemia in neoplastic disease; N17.9 - Acute kidney failure, unspecified; Z79.01 - Long term (current) use of anticoagulants"
CINJ OP INFUSION,34053,"Leiser, Aliza, MD",1/13/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/13/2023,Inactive,,
CINJ OP INFUSION,34053,"Leiser, Aliza, MD",9/11/2023,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,9/10/2023,Inactive,,
CINJ OP INFUSION,34053,"Leiser, Aliza, MD",8/21/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,8/11/2024,Active,,
NBI OP INFUSION,40173,"Shah, Maya M, MD",12/4/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/3/2024,Active,,
NBI OP INFUSION,40173,"Shah, Maya M, MD",1/29/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/3/2024,Active,,
NBI OP INFUSION,40173,"Shah, Maya M, MD",4/9/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/4/2024,Active,Metastatic non-small cell lung cancer (CMS/HCC),"C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung"
CINJ OP INFUSION,55867,"Ghodoussipour, Saum Bobak, MD",6/6/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,6/5/2023,Inactive,,
CINJ OP INFUSION,55867,"Ghodoussipour, Saum Bobak, MD",9/26/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,9/25/2023,Inactive,,
MMC OP VP INFUSION,28431,"Cohen, Seth D, MD",1/31/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,1/30/2024,Inactive,,
NBI OP INFUSION,79126,"Shah, Maya M, MD",10/20/2023,Gemcitabine 28 Day Cycles - Breast,_1. First Line,10/19/2023,Inactive,,
CINJ OP INFUSION,42599,"Patel, Eshan, MD",5/20/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,5/12/2024,Inactive,,
CINJ OP INFUSION,95816,"Toppmeyer, Deborah L, MD",7/18/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_3. Third Line,7/10/2024,Inactive,,
CINJ OP INFUSION,95816,"Toppmeyer, Deborah L, MD",9/12/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_3. Third Line,9/11/2024,Inactive,,
CINJ OP INFUSION,95816,"Toppmeyer, Deborah L, MD",10/24/2024,"Sacituzumab Govitecan Day 1, Day 15 q 28 days - Breast",_4. Fourth Line,10/23/2024,Active,Malignant neoplasm of left female breast (CMS/HCC),
CINJ OP INFUSION,95816,"Toppmeyer, Deborah L, MD",12/3/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_3. Third Line,12/2/2024,Inactive,,
CMMC OP INFUSION,86964,"Siu, Karleung, MD",5/2/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/2/2025,Active,Malignant neoplasm of right upper lobe of lung (CMS/HCC),
MMC OP VP INFUSION,90653,"Lee, Patrick C, MD",9/30/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/30/2024,Active,Marginal zone lymphoma (CMS/HCC),
JCMC CP INFUSION,53264,"Sekhri, Arunabh, MD",5/3/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast x4,Neoadjuvant,4/21/2024,Active,,
CINJ OP INFUSION,43881,"Omene, Coral Oghenerukevwe, MD",7/23/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,7/23/2024,Inactive,,
CINJ OP INFUSION,43881,"Omene, Coral Oghenerukevwe, MD",11/11/2024,Capecitabine 21 Day Cycles - Breast,_1. First Line,11/11/2024,Inactive,,
CINJ OP INFUSION,43881,"Omene, Coral Oghenerukevwe, MD",11/11/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,11/11/2024,Active,,
CMC 4B ONCOLOGY,22228,"Patel, Neel H, MD",4/10/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/10/2024,Inactive,,
CMC OP INFUSION,22228,"Taff, Jessica, MD",6/10/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,5/6/2024,Inactive,,
CINJ OP INFUSION,52261,"Saraiya, Biren P, MD",5/12/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/12/2025,Active,Prostate cancer (CMS/HCC),C61 - Prostate cancer (CMS/HCC)
NBR CINJ OP INFUSION,17748,"Evens, Andrew M, DO",10/9/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/8/2024,Active,,
CINJ OP INFUSION,13349,"Patel, Eshan, MD",10/16/2023,Temozolomide 28 Day Cycles - CNS,_1. First Line,10/16/2023,Inactive,,
SOM OUTPT INFUSION,13349,"Patel, Eshan, MD",3/15/2024,Bevacizumab 21 Day Cycles - CNS tumor ,_2. Second Line,3/14/2024,Active,,
CINJ OP INFUSION,4607,"Boland, Patrick M, MD",6/25/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,5/31/2024,Active,,
CBMC OP INFUSION 2FL,67126,"Wagmiller, Jennifer Ann, MD",4/23/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,4/21/2024,Inactive,,
SOM OUTPT INFUSION,16561,"Patel, Eshan, MD",10/10/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/30/2024,Active,,
NBI A5 PEDIATRICS,65217,"Bhatla, Teena, MD",7/11/2024,PEDS R-CHOP - B-Cell Lymphoma,_1. First Line,7/10/2024,Active,,
NBI VALERIE FND HEMONC,65217,"Batra, Surabhi, MD",8/30/2024,"PEDS Nivolumab D1, D15 28 Day Cycles  - Hodgkin Lymphoma",_2. Second Line,8/29/2024,Active,,
CMC OP INFUSION,75997,"Cohen, Seth D, MD",12/26/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,12/26/2023,Inactive,,
CMC OP INFUSION,75997,"Cohen, Seth D, MD",3/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/8/2024,Inactive,,
NBR CINJ OP INFUSION,29851,"Rhodes, Joanna Meehan, MD",12/18/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/17/2023,Inactive,,
CBMC OP INFUSION 2FL,39854,"Grossman, I Robert, MD",11/17/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/16/2023,Active,,
TRMC TCCC OP INFUSION,42446,"Capo, Gerardo, MD",10/17/2024,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/15/2024,Active,,
CINJ OP INFUSION,29991,"Saraiya, Biren P, MD",6/20/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,6/20/2023,Inactive,,
CINJ OP INFUSION,29991,"Saraiya, Biren P, MD",8/14/2024,CINJ 082307 Arm 1 MK-5684 / Hormone Replacement Therapy 28 Day Cycles- Prostate Cancer,_3. Third Line,8/14/2024,Inactive,,
CINJ OP INFUSION,29991,"Saraiya, Biren P, MD",8/29/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,8/29/2024,Inactive,,
CINJ OP INFUSION,29991,"Saraiya, Biren P, MD",10/14/2024,CINJ 082304 Cohort 2 ONC-392 / Lutetium Lu 177 Vipivotide Tetraxetan 42 Day Cycles Research- Prostate Cancer,_2. Second Line,10/13/2024,Active,,
CBMC OP INFUSION 2FL,56555,"Brown, Andrew Bennett, MD",11/15/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,11/14/2023,Inactive,,
SOM OUTPT INFUSION,69125,"Toomey, Kathleen C, MD",5/4/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,First Line,5/3/2023,Inactive,,
SOM OUTPT INFUSION,69125,"Toomey, Kathleen C, MD",9/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,9/24/2024,Active,,
CBMC OP INFUSION 2FL,79167,"Niranjan, Usha, MD",4/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/7/2024,Inactive,,
CBMC OP INFUSION 2FL,79167,"Niranjan, Usha, MD",7/9/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,7/2/2024,Inactive,,
CBMC OP INFUSION 2FL,79167,"Dharmapuri, Sirish, MD",12/10/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - BTC,_2. Second Line,12/8/2024,Active,,
MMC OP INFUSION,66003,"Meghal, Trishala, MD",1/18/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/17/2023,Inactive,,
CBMC OP INFUSION 2FL,68870,"Brown, Andrew Bennett, MD",12/26/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/18/2024,Active,,
CINJ OP INFUSION,62039,"Berim, Lyudmyla, MD",6/18/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,6/17/2024,Active,,
CINJ OP INFUSION,8126,"Saraiya, Biren P, MD",1/9/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_4. Fourth Line,1/2/2024,Inactive,,
CINJ OP INFUSION,89464,"Haigentz, Missak, MD",1/30/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,First Line,1/30/2023,Inactive,,
CMC OP INFUSION,21288,"Cohen, Seth D, MD",8/1/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,7/31/2024,Inactive,,
CMC OP INFUSION,21288,"Cohen, Seth D, MD",11/13/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_2. Second Line,11/11/2024,Active,,
CINJ OP INFUSION,19835,"Weiss, Sarah, MD",3/12/2025,"CINJ 052408 Part 2.2A, B, C, and D Expansion AB248 / Pembrolizumab 200 mg 21 Day Cycles Research- Solid Tumors",_3. Third Line,3/12/2025,Active,Malignant melanoma of overlapping sites (CMS/HCC),Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C43.8 - Malignant melanoma of overlapping sites of skin
JCMC CP INFUSION,33808,"Cruz, Allan Louie E, MD",5/29/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,5/28/2024,Inactive,,
NBR CINJ OP INFUSION,77844,"Tiger, Yun Kyoung, MD",1/10/2025,Carfilzomib 56 mg/m2 Weekly / Pomalidomide (Day 1-21) Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,1/9/2025,Active,,
NBR CINJ OP INFUSION,77844,"Tiger, Yun Kyoung, MD",3/5/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_4. Fourth Line,3/5/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; D61.818 - Other pancytopenia; M89.9 - Disorder of bone, unspecified; C90.02 - Multiple myeloma in relapse"
JCMC CP INFUSION,29645,"Sekhri, Arunabh, MD",1/8/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/7/2024,Inactive,,
HAM OP INFUSION,50185,"Yogarajah, Meera, MD",1/20/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,1/11/2023,Inactive,,
HAM OP INFUSION,50185,"Yogarajah, Meera, MD",6/19/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Second Line,6/14/2023,Inactive,,
CINJ OP INFUSION,63758,"George, Mridula A, MD",10/22/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,10/22/2024,Active,,
CBMC OP INFUSION 2FL,61708,"Brown, Andrew Bennett, MD",7/17/2023,Atezo / CISplatin / Etoposide (1200/30/40) 21 Day Cycles - High Grade Neuroendocrine,Second Line,7/16/2023,Inactive,,
CBMC OP INFUSION 2FL,61708,"Brown, Andrew Bennett, MD",11/28/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,11/20/2023,Inactive,,
CINJ OP INFUSION,16148,"George, Mridula A, MD",2/5/2025,CINJ 042403 Tirzepatide Weekly 28 Day Cycles (3 Month Dispense Cycle 6 and Beyond) Research- Breast Cancer,Adjuvant,2/5/2025,Inactive,"Lobular breast cancer, right (CMS/HCC)",
NBR 4N ONCOLOGY,8844,"Tiger, Yun Kyoung, MD",12/4/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,12/3/2024,Inactive,,
CBMC OP INFUSION 2FL,67397,"Leitner, Stuart P, MD",2/1/2024,Sipuleucel-T 14 Day Cycles - Prostate,_2. Second Line,2/1/2024,Inactive,,
CBMC OP INFUSION 2FL,67397,"Leitner, Stuart P, MD",6/19/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,6/18/2024,Inactive,,
NBI A5 PEDIATRICS,36448,"Batra, Surabhi, MD",5/17/2024,PEDS DD-4A - Renal,_1. First Line,5/15/2024,Inactive,,
NBI VALERIE FND HEMONC,36448,"Batra, Surabhi, MD",7/9/2024,PEDS UH-1 Renal,_1. First Line,7/8/2024,Active,,
NBI OP INFUSION,28105,"Schleicher, Lori, MD",10/25/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,10/4/2023,Active,,
CINJ OP INFUSION,53008,"Stephenson, Ryan D, DO",4/22/2024,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,Neoadjuvant,4/21/2024,Active,,
CINJ OP INFUSION,58511,"Gulhati, Prateek, MD PhD",10/2/2023,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,,8/23/2023,Inactive,,
NBI OP INFUSION,76103,"Jacoby, Sari H, MD",3/11/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/11/2024,Inactive,,
CINJ OP INFUSION,94644,"Saraiya, Biren P, MD",11/25/2024,CISplatin Weekly with Concurrent Radiation 35 Day Cycle- Bladder,Induction,11/18/2024,Active,,
CINJ OP INFUSION,57796,"Jang, Thomas L, MD",5/22/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/22/2025,Active,Bladder cancer (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified; C67.8 - Malignant neoplasm of overlapping sites of bladder"
CINJ OP INFUSION,119,"Boland, Patrick M, MD",1/31/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,1/30/2025,Active,,
NBI D7 MED-SURG/TELE,27637,"Cohen, Alice, MD",3/13/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,3/13/2024,Inactive,,
TRMC TCCC OP INFUSION,76710,"Capo, Gerardo, MD",5/28/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/27/2024,Active,,
TRMC TCCC OP INFUSION,76710,"Capo, Gerardo, MD",10/1/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/12/2024,Inactive,,
NBR CINJ OP INFUSION,91276,"Evens, Andrew M, DO",1/25/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,,1/24/2023,Inactive,,
CBMC OP INFUSION 2FL,36927,"Dharmapuri, Sirish, MD",9/30/2024,Irinotecan / Bevacizumab 14 Day Cycles - CRC,_5. Fifth Line,9/15/2024,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",7/14/2023,"PACLitaxel D1, D15 28 Day Cycles - Breast",First Line,7/13/2023,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",8/11/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,First Line,8/10/2023,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",12/22/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,12/21/2023,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",5/6/2024,CINJ 042103 (BRE 354) Part A/B U3-1402 21 Day Cycles Research- Metastatic Breast Cancer,_3. Third Line,4/28/2024,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",7/10/2024,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,7/10/2024,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",10/3/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_4. Fourth Line,10/1/2024,Inactive,,
CINJ OP INFUSION,74205,"George, Mridula A, MD",12/6/2024,Talazoparib 28 Day Cycles ,_4. Fourth Line,12/6/2024,Inactive,,
NBR 4N ONCOLOGY,74205,"George, Mridula A, MD",12/22/2024,EriBULin 21 Day Cycles - Breast,_5. Fifth Line,12/19/2024,Active,,
CINJ OP INFUSION,40280,"Goel, Sanjay, MD",3/6/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_4. Fourth Line,2/15/2024,Inactive,,
CINJ OP INFUSION,49743,"Stephenson, Ruth D, DO",3/27/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,3/26/2024,Inactive,,
CINJ OP INFUSION,49743,"Stephenson, Ruth D, DO",12/11/2024,"CINJ 102302 ARM 2 PHASE 1B ACR-368 + ULDG DOSE LEVEL 1 - OVARIAN, ENDOMETRIAL, UROTHELIAL CANCER",_3. Third Line,12/11/2024,Inactive,,
CINJ OP INFUSION,53337,"Stephenson, Ruth D, DO",2/12/2025,"Albumin-Bound PACLitaxel D1, D8, D15/ CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_4. Fourth Line,2/11/2025,Inactive,Serous carcinoma of body of uterus (CMS/HCC),"C54.9 - Malignant neoplasm of corpus uteri, unspecified"
CINJ OP INFUSION,53337,"Stephenson, Ruth D, DO",2/12/2025,"Albumin-Bound PACLitaxel D1, D8, D15  28 Day Cycles-",_4. Fourth Line,2/11/2025,Inactive,Serous carcinoma of body of uterus (CMS/HCC),"C54.9 - Malignant neoplasm of corpus uteri, unspecified"
NBI OP INFUSION,28284,"Anderson, Patrick S, MD",3/21/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/6/2024,Active,,
NBI OP INFUSION,28284,"Anderson, Patrick S, MD",4/15/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/15/2025,Active,Cancer of ovary (CMS/HCC),
NBI OP INFUSION,48026,"Shah, Maya M, MD",3/25/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,3/13/2024,Inactive,,
CBMC OP INFUSION 2FL,52759,"Freeman, Benjamin B, MD",4/25/2025,DOXOrubicin Liposomal 28 Day Cycles - Breast,_7. Seventh Line,4/18/2025,Active,"Breast cancer metastasized to lung, right (CMS/HCC)",
CMMC OP INFUSION,52759,"Freeman, Benjamin B, MD",3/7/2025,Datopotamab deruxtecan-dlnk 21 Day Cycles- Breast Cancer,_9. Ninth Line,3/7/2025,Inactive,"Breast cancer metastasized to lung, right (CMS/HCC)",
MMC OP VP INFUSION,33525,"Eltoukhy, Hussam, MD",9/12/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/9/2024,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Immunocompromised state due to drug therapy (CMS/HCC)
History of peripheral stem cell transplant (CMS/HCC)
Encounter for vaccination",
MMC OP INFUSION,70085,"Meghal, Trishala, MD",8/18/2023,Abemaciclib 28 Day Cycles - Breast ,,8/18/2023,Inactive,,
CINJ OP INFUSION,96591,"Haigentz, Missak, MD",9/20/2023,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/20/2023,Active,,
CINJ OP INFUSION,49328,"Boland, Patrick M, MD",1/24/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,1/23/2023,Inactive,,
CINJ OP INFUSION,49328,"Boland, Patrick M, MD",6/4/2024,CINJ 052002 (10276) Phase 2 ARM B M3814 / Avelumab 28 Day Cycles Research,_3. Third Line,6/3/2024,Inactive,,
CINJ OP INFUSION,49328,"Boland, Patrick M, MD",9/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,9/9/2024,Inactive,,
MMC BBR2 ONCOLOGY,3920,"Lee, Patrick C, MD",12/12/2024,"mFOLFOX6 Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/9/2024,Inactive,,
JCMC CP INFUSION,57575,"Sekhri, Arunabh, MD",5/15/2023,DOCEtaxel 21 Day Cycles - Prostate,First Line,5/14/2023,Inactive,,
JCMC CP INFUSION,3734,"Sekhri, Arunabh, MD",3/10/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_2. Second Line,3/10/2025,Inactive,Metastasis from malignant neoplasm of prostate (CMS/HCC),
JCMC CP INFUSION,72372,"Sekhri, Arunabh, MD",3/9/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/8/2023,Inactive,,
JCMC CP INFUSION,21702,"Cruz, Allan Louie E, MD",10/18/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,10/15/2024,Active,,
NBR CINJ OP INFUSION,55675,"Rhodes, Joanna Meehan, MD",4/17/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,4/16/2024,Inactive,,
NBR 5N ONCOLOGY,55675,"Rhodes, Joanna Meehan, MD",4/22/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/22/2024,Inactive,,
NBR CINJ OP INFUSION,55675,"Rhodes, Joanna Meehan, MD",5/8/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/7/2024,Inactive,,
CBMC OP INFUSION 2FL,23650,"Wagmiller, Jennifer Ann, MD",1/3/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,Adjuvant,12/22/2024,Active,,
CINJ OP INFUSION,57356,"Aikins, James K, MD",4/4/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Metastatic Lymph Node favoring Mullerian Origin,_1. First Line,4/3/2024,Active,,
CINJ OP INFUSION,97162,"Girda, Eugenia, MD",6/1/2023,Pembrolizumab 21 Day Cycles - Cervical,,4/17/2023,Inactive,,
CINJ OP INFUSION,97162,"Girda, Eugenia, MD",8/14/2024,Abemaciclib 28 Day Cycles - Breast,_4. Fourth Line,8/14/2024,Active,,
CINJ OP INFUSION,97162,"Girda, Eugenia, MD",4/24/2025,Palbociclib 28 Day Cycles - Breast,_3. Third Line,4/24/2025,Active,"Malignant neoplasm of endometrium (CMS/HCC)
Pruritus, unspecified","C54.1 - Malignant neoplasm of endometrium; L30.9 - Dermatitis, unspecified; L40.8 - Other psoriasis; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; M54.16 - Radiculopathy, lumbar region"
CMC OP INFUSION,50783,"Meghal, Trishala, MD",4/25/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,4/24/2023,Inactive,,
CMC OP INFUSION,50783,"Meghal, Trishala, MD",5/23/2023,Albumin-Bound PACLitaxel/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,5/22/2023,Inactive,,
CBMC OP INFUSION 2FL,27335,"Raptis, George, MD",4/12/2024,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,Neoadjuvant,4/11/2024,Inactive,,
CBMC OP INFUSION 2FL,27335,"Raptis, George, MD",8/14/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,8/13/2024,Inactive,,
CBMC OP INFUSION 2FL,27335,"Raptis, George, MD",1/3/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,11/1/2024,Active,,
CBMC OP INFUSION 2FL,90145,"Dave, Manish, MD",1/12/2023,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,1/11/2023,Active,,
TRMC TCCC OP INFUSION,53326,"Meghal, Trishala, MD",4/8/2025,Anastrozole 30 Day Cycles - Breast,Adjuvant,4/8/2025,Active,Malignant neoplasm of central portion of right female breast (CMS/HCC),"C50.111 - Malignant neoplasm of central portion of right female breast; M85.80 - Other specified disorders of bone density and structure, unspecified site"
NBR CINJ OP INFUSION,80202,"Shah, Mansi R, MD",1/22/2024,Daratumumab/ Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,1/14/2024,Active,,
NBR CINJ OP INFUSION,80202,"Shah, Mansi R, MD",6/3/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,5/31/2024,Inactive,,
NBI OP INFUSION,95946,"Jacoby, Sari H, MD",4/29/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,Neoadjuvant,4/29/2025,Active,Rectal cancer (CMS/HCC),C20 - Malignant neoplasm of rectum
CINJ OP INFUSION,18571,"Haigentz, Missak, MD",8/11/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,,8/8/2023,Inactive,,
SOM OUTPT INFUSION,5003,"Patel, Eshan, MD",4/9/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/9/2025,Active,Mixed cellularity Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),"C81.70 - Other Hodgkin lymphoma, unspecified site"
CMC OP INFUSION,10462,"Cohen, Seth D, MD",3/31/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/31/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
CMC 4B ONCOLOGY,43089,"Easaw, Sarah, MD",11/7/2023,FOLFIRI Inpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/25/2023,Inactive,,
CINJ OP INFUSION,43,"Stephenson, Ryan D, DO",4/14/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,4/14/2023,Inactive,,
CBMC 2W ONCOLOGY,61829,"Grossman, I Robert, MD",7/27/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,7/26/2024,Inactive,,
CBMC 2W ONCOLOGY,61829,"McKenna, Marshall, MD",9/11/2024,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_2. Second Line,9/11/2024,Inactive,,
CBMC 2W ONCOLOGY,61829,"McKenna, Marshall, MD",9/11/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/10/2024,Inactive,,
CBMC OP INFUSION 2FL,61829,"Grossman, I Robert, MD",9/30/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,9/29/2024,Inactive,,
NBR CINJ OP INFUSION,61829,"Shah, Mansi R, MD",10/4/2024,Talquetamab 28 Day Cycles,_5. Fifth Line,10/3/2024,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CBMC OP INFUSION 2FL,67142,"Dave, Manish, MD",1/30/2024,RiTUXimab Initial Infusion Single Day (Outpatient),Maintenance,1/19/2024,Inactive,,
MMC OP VP INFUSION,42195,"Meghal, Trishala, MD",11/20/2023,Palbociclib 28 Day Cycles - Breast,_1. First Line,11/20/2023,Inactive,,
MMC OP VP INFUSION,42195,"Meghal, Trishala, MD",12/9/2024,Abemaciclib 28 Day Cycles - Breast,_2. Second Line,12/9/2024,Active,,
NBI OP INFUSION,38057,"Schleicher, Lori, MD",5/7/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,5/7/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)","C50.911, Z17.0 - Malignant neoplasm of right breast in female, estrogen receptor positive, unspecified site of breast (CMS/HCC)"
SOM OUTPT INFUSION,29817,"Patel, Eshan, MD",4/24/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,3/13/2023,Active,,
SOM OUTPT INFUSION,29817,"Patel, Eshan, MD",4/3/2025,Teclistamab Weekly 28 Day Cycles,_2. Second Line,4/3/2025,Inactive,Metastatic multiple myeloma to bone (CMS/HCC),
SOM OUTPT INFUSION,29817,"Patel, Eshan, MD",4/3/2025,Carfilzomib 27 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/3/2025,Inactive,"Metastatic cancer to bone (CMS/HCC)
Multiple myeloma not having achieved remission (CMS/HCC)
Multiple myeloma (CMS/HCC)",
JCMC CP INFUSION,21633,"Sekhri, Arunabh, MD",12/25/2023,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,12/24/2023,Inactive,,
CBMC 2W ONCOLOGY,48903,"Wagmiller, Jennifer Ann, MD",1/30/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,1/27/2025,Active,Serous carcinoma of body of uterus (CMS/HCC),
MMC OP VP INFUSION,42802,"Cohen, Seth D, MD",5/31/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/15/2024,Active,,
NBI OP INFUSION,42568,"Jacoby, Sari H, MD",11/7/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,89786,"Wagmiller, Jennifer Ann, MD",4/21/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/20/2023,Inactive,,
CBMC OP INFUSION 2FL,89786,"Wagmiller, Jennifer Ann, MD",12/8/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,12/7/2023,Active,,
CBMC OP INFUSION 2FL,89786,"Wagmiller, Jennifer Ann, MD",5/15/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/15/2025,Active,"Recurrent carcinoma of endometrium (CMS/HCC)
Thyroid toxicity, exogenous",E05.80 - Other thyrotoxicosis without thyrotoxic crisis or storm; C54.1 - Malignant neoplasm of endometrium
CINJ OP INFUSION,95835,"Muralikrishnan, Sivraj, MD",5/15/2025,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,_1. First Line,5/15/2025,Active,"Malignant neoplasm of thyroid gland (CMS/HCC)
Secondary malignant neoplasm of mediastinal lymph nodes (CMS/HCC)
Malignant neoplasm metastatic to lung (CMS/HCC)",
CINJ OP INFUSION,95835,"Haigentz, Missak, MD",5/2/2025,Dabrafenib/Trametinib 28 Day Cycles- Thyroid Cancer,_1. First Line,5/2/2025,Inactive,"Malignant neoplasm of thyroid gland (CMS/HCC)
Secondary malignant neoplasm of mediastinal lymph nodes (CMS/HCC)
Malignant neoplasm metastatic to lung (CMS/HCC)",
NBI D7 MED-SURG/TELE,77722,"Jacoby, Sari H, MD",4/25/2025,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,4/24/2025,Inactive,Pancreatic cancer metastasized to liver (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; A41.9 - Sepsis, unspecified organism; Z66 - Do not resuscitate; K72.00 - Acute and subacute hepatic failure without coma; E43 - Unspecified severe protein-calorie malnutrition; G93.41 - Metabolic encephalopathy; J96.01 - Acute respiratory failure with hypoxia; N17.0 - Acute kidney failure with tubular necrosis; R65.21 - Severe sepsis with septic shock; I81 - Portal vein thrombosis; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; D84.821 - Immunodeficiency due to drugs; I69.354 - Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; D63.0 - Anemia in neoplastic disease; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; K86.1 - Other chronic pancreatitis; K80.51 - Calculus of bile duct without cholangitis or cholecystitis with obstruction; E87.20 - Acidosis, unspecified; Z59.811 - Housing instability, housed, with risk of homelessness; R18.8 - Other ascites; Z79.4 - Long term (current) use of insulin; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; Z78.1 - Physical restraint status; E86.0 - Dehydration; Z11.52 - Encounter for screening for COVID-19; E87.6 - Hypokalemia; F17.210 - N..."
NBI OP INFUSION,77722,"Jacoby, Sari H, MD",4/21/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/21/2025,Inactive,Pancreatic cancer metastasized to liver (CMS/HCC),
CBMC OP INFUSION 2FL,8136,"Scoppetuolo, Michael, MD",10/5/2023,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,10/4/2023,Inactive,,
CINJ OP INFUSION,89042,"Haigentz, Missak, MD",4/22/2025,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/22/2025,Active,"Malignant neoplasm of right upper lobe of lung (CMS/HCC)
Primary adenocarcinoma of right lung (CMS/HCC)
EGFR-related lung cancer (CMS/HCC)","C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; I48.0 - Paroxysmal atrial fibrillation; R60.0 - Localized edema; L98.9 - Disorder of the skin and subcutaneous tissue, unspecified"
CBMC OP INFUSION 2FL,35374,"Brown, Andrew Bennett, MD",4/3/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,4/3/2025,Active,Laryngeal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,41809,"Grossman, I Robert, MD",6/11/2024,RiTUXimab Rapid Infusion Single Day (Outpatient),_1. First Line,6/11/2024,Inactive,,
CBMC OP INFUSION 2FL,41809,"Grossman, I Robert, MD",6/17/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,6/10/2024,Active,Colon cancer metastasized to liver (CMS/HCC),
CBMC OP INFUSION 2FL,41809,"Grossman, I Robert, MD",5/29/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,5/29/2025,Active,Vasculitis (CMS/HCC),
CMC OP INFUSION,16618,"Taff, Jessica, MD",10/13/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) q21 Day Cycles (adjusted 7/2024)- Gastrointestinal Cancers,First Line,9/25/2023,Active,,
CINJ OP INFUSION,17922,"Goel, Sanjay, MD",7/22/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,7/22/2024,Inactive,,
CINJ OP INFUSION,17922,"Goel, Sanjay, MD",9/24/2024,CINJ 052401 Part A Escalation GIM-122,_4. Fourth Line,9/24/2024,Inactive,,
CINJ OP INFUSION,40768,"Jang, Thomas L, MD",9/6/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/5/2024,Inactive,,
CINJ OP INFUSION,40768,"Jang, Thomas L, MD",1/3/2025,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/3/2025,Active,,
CBMC 2W ONCOLOGY,41742,"Grossman, I Robert, MD",2/15/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/14/2024,Active,,
CMC OP INFUSION,10378,"Taff, Jessica, MD",4/8/2025,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,4/8/2025,Active,Primary malignant neoplasm of anal canal (CMS/HCC),
SOM OUTPT INFUSION,73641,"Khalid, Aysha, MD",2/3/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Second Line,2/1/2023,Inactive,,
CINJ OP INFUSION,45543,"Ghodoussipour, Saum Bobak, MD",11/14/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,11/13/2023,Inactive,,
SOM OUTPT INFUSION,83546,"George, Roshini, DO",2/6/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/5/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified"
MMC OP VP INFUSION,77893,"Lee, Patrick C, MD",8/2/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_2. Second Line,5/22/2024,Active,,
CINJ OP INFUSION,62739,"George, Mridula A, MD",3/26/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_1. First Line,3/26/2025,Inactive,Malignant neoplasm of overlapping sites of right female breast (CMS/HCC),C50.912 - Malignant neoplasm of unspecified site of left female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; N18.6 - End stage renal disease; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; R44.0 - Auditory hallucinations; Z17.1 - Estrogen receptor negative status (ER-)
CMC OP INFUSION,78595,"Taff, Jessica, MD",6/7/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,6/1/2023,Active,,
CMC OP INFUSION,87467,"Cohen, Seth D, MD",3/7/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,3/6/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),
NBI OP INFUSION,75396,"Schleicher, Lori, MD",1/3/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,1/2/2025,Active,,
CBMC OP INFUSION 2FL,39767,"Brown, Andrew Bennett, MD",10/17/2023,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,10/17/2023,Inactive,,
MSC OP INFUSION,52152,"Cohen, Seth D, MD",6/29/2023,Methotrexate 7 Day Cycles - Gestational Trophoblastic Neoplasia,Adjuvant,6/27/2023,Inactive,,
MMC OP INFUSION,52152,"Cohen, Seth D, MD",8/21/2023,Methotrexate 14 Day Cycles - Gestational Trophoblastic Neoplasia ,First Line,8/20/2023,Inactive,,
MSC OP INFUSION,52152,"Cohen, Seth D, MD",8/22/2023,DACTINomycin 14 Day Cycles - Gestational Trophoblastic Neoplasia ,,8/16/2023,Inactive,,
JCMC CP INFUSION,16616,"Cruz, Allan Louie E, MD",6/4/2024,"mFOLFOX6 for cycles 1-7. Then, capectabine-avastin",_1. First Line,6/3/2024,Active,,
HAM OP INFUSION,56072,"Yogarajah, Meera, MD",11/18/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,11/10/2024,Active,,
CBMC OP INFUSION 2FL,28417,"Grossman, I Robert, MD",12/17/2023,EA (Etoposide / High-Dose Cytarabine) 28 Day Cycle - CNS Lymphoma,_3. Third Line,12/17/2023,Inactive,,
CINJ OP INFUSION,547,"Haigentz, Missak, MD",1/6/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,1/6/2023,Inactive,,
JCMC CP INFUSION,57473,"Cruz, Allan Louie E, MD",3/29/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,First Line,3/28/2023,Inactive,,
CINJ OP INFUSION,69780,"Omene, Coral Oghenerukevwe, MD",2/17/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,,2/5/2023,Inactive,,
CINJ OP INFUSION,81345,"Leiser, Aliza, MD",10/18/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,10/17/2024,Inactive,,
NBI OP INFUSION,77872,"Shah, Maya M, MD",1/17/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/16/2024,Inactive,,
MMC OP VP INFUSION,91029,"Lee, Patrick C, MD",2/10/2025,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant; Adjuvant),Induction,2/9/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
NBI OP INFUSION,63615,"Cohen, Alice, MD",12/2/2024,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,11/30/2024,Active,,
MMC OP INFUSION,25969,"Meghal, Trishala, MD",11/1/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/31/2023,Inactive,,
MMC OP VP INFUSION,25969,"Meghal, Trishala, MD",5/1/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,Neoadjuvant,4/30/2024,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
TRMC TCCC OP INFUSION,23117,"Capo, Gerardo, MD",9/30/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,9/29/2024,Active,,
NBR MEDICAL SAME DAY,98493,"Golombos, David, MD",2/13/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/13/2025,Active,Malignant neoplasm of bladder (CMS/HCC),
MSC OP INFUSION,75182,"Talwar, Sumit, MD",4/22/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/22/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),
NBI VALERIE FND HEMONC,54154,"Rao, Harini, MD",3/27/2024,PEDS ARST0332 Arm D,_1. First Line,3/26/2024,Active,,
NBI VALERIE FND HEMONC,51882,"Rao, Harini, MD",3/20/2025,Nivolumab / Ipilimumab 21 Day Cycles - Sarcoma,_2. Second Line,3/20/2025,Inactive,"Triton tumor, malignant (CMS/HCC)",
CINJ OP INFUSION,16492,"Toppmeyer, Deborah L, MD",5/15/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/15/2025,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,96858,"Sekhri, Arunabh, MD",10/30/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,39260,"Grossman, I Robert, MD",10/3/2023,Bortezomib / Dexamethasone 21 Day Cycles - Multiple Myeloma,_1. First Line,10/3/2023,Inactive,,
NBR 4N ONCOLOGY,52809,"Patel, Vimal D, MD",4/30/2024,RiTUXimab 28 Day Cycle - ITP/TTP,_2. Second Line,4/29/2024,Inactive,,
TRMC TCCC OP INFUSION,33705,"Capo, Gerardo, MD",1/8/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/7/2025,Active,,
TRMC TCCC OP INFUSION,33705,"Capo, Gerardo, MD",2/4/2025,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/3/2025,Active,"Malignant neoplasm of splenic flexure (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
TRMC TCCC OP INFUSION,33705,"Capo, Gerardo, MD",5/27/2025,"Cetuximab D1, D15 28 Day Cycles with Sotorasib- Colon Cancer",_1. First Line,5/20/2025,Active,"Rectal cancer (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
CINJ OP INFUSION,24187,"George, Mridula A, MD",8/19/2024,CINJ 042316 Neoadjuvant Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles x 4 Cycles followed by Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles x 4 Cycles Research- Breast Cancer,Neoadjuvant,8/18/2024,Active,,
CINJ OP INFUSION,13641,"Patankar, Sonali, MD",10/21/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,10/16/2024,Active,,
CMC OP INFUSION,14359,"Easaw, Sarah, MD",5/22/2023,Bevacizumab 28 Day Cycles - CNS,First Line,5/22/2023,Inactive,,
HAM OP INFUSION,72558,"Patel, Malini M, MD",10/29/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,10/13/2024,Active,,
HAM OP INFUSION,98604,"Patel, Malini M, MD",3/11/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/11/2025,Active,"Non-small cell cancer of right lung (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",C34.91 - Non-small cell cancer of right lung (CMS/HCC); C61 - Prostate cancer (CMS/HCC)
CINJ OP INFUSION,10782,"Haigentz, Missak, MD",10/11/2023,Atezolizumab PLUS Albumin-Bound PACLitaxel/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/11/2023,Inactive,,
CINJ OP INFUSION,10782,"Haigentz, Missak, MD",5/29/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/29/2024,Inactive,,
CBMC OP INFUSION 2FL,5431,"Dharmapuri, Sirish, MD",9/30/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,9/23/2024,Active,,
CBMC OP INFUSION 2FL,31448,"Phillips, Adrienne A, MD",7/15/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,6/30/2024,Inactive,,
CBMC OP INFUSION 2FL,31448,"Phillips, Adrienne A, MD",12/30/2024,"Bortezomib D1, D8, D15, D22 / Selinexor 100 mg / Dexamethasone 35 Day Cycles- Multiple Myeloma",_3. Third Line,12/27/2024,Inactive,,
CBMC OP INFUSION 2FL,6631,"Phillips, Adrienne A, MD",1/6/2025,Elotuzumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_3. Third Line,1/5/2025,Inactive,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,77853,"Mayer, Tina M, MD",1/9/2025,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,Adjuvant,1/8/2025,Active,,
CINJ OP INFUSION,79069,"Boland, Patrick M, MD",12/27/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/19/2024,Active,,
NBI OP INFUSION,79069,"Jacoby, Sari H, MD",3/7/2025,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/7/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),"C18.7 - Malignant neoplasm of sigmoid colon; D70.1 - Agranulocytosis secondary to cancer chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E28.2 - Polycystic ovarian syndrome; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); E66.9 - Obesity, unspecified; Z85.038 - Personal history of other malignant neoplasm of large intestine; Z86.711 - Personal history of pulmonary embolism; Z86.718 - Personal history of other venous thrombosis and embolism; Z98.84 - Bariatric surgery status; Z98.890 - Other specified postprocedural states; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,76097,"George, Mridula A, MD",12/13/2023,Palbociclib 28 Day Cycles - Breast,_1. First Line,12/13/2023,Inactive,,
CINJ OP INFUSION,76097,"George, Mridula A, MD",10/14/2024,Abemaciclib 28 Day Cycles - Breast,_2. Second Line,10/14/2024,Active,,
CINJ OP INFUSION,76097,"George, Mridula A, MD",3/19/2025,CINJ 042305 Phase 1B Cohort 4  Elacestrant / Ribociclib 28 Day Cycles Research- Breast Cancer,_2. Second Line,3/19/2025,Inactive,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,76097,"George, Mridula A, MD",3/19/2025,CINJ 042305 Phase 2 Arm D Elacestrant / Palbociclib OR Abemaciclib OR Ribociclib 28 Day Cycles Research- Breast Cancer,_2. Second Line,3/19/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,31347,"Doraiswamy, Anupama, MD",3/6/2023,Nilotinib (Newly Diagnosed) 28 Day Cycles - Chronic Myeloid Leukemia,,3/6/2023,Active,,
MMC OP VP INFUSION,17959,"Meghal, Trishala, MD",1/15/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,1/14/2024,Inactive,,
MMC OP VP INFUSION,17959,"Meghal, Trishala, MD",3/11/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,3/10/2024,Inactive,,
CINJ OP INFUSION,84985,"Dasgeb, Bahar, MD",10/30/2023,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,10/29/2023,Active,Malignant neoplasm of central portion of right female breast (CMS/HCC),
NBR 5N ONCOLOGY,26399,"Tiger, Yun Kyoung, MD",12/24/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/24/2023,Inactive,,
NBR CINJ OP INFUSION,26399,"Tiger, Yun Kyoung, MD",11/19/2024,STARGLO (Glofitamab / Gemcitabine / Oxaliplatin / Obinutuzumab) 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,11/18/2024,Active,Malignant neoplasm of endometrium (CMS/HCC),
NBR CINJ OP INFUSION,26399,"Tiger, Yun Kyoung, MD",1/8/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,1/7/2025,Active,,
NBR 5N ONCOLOGY,28465,"Girda, Eugenia, MD",10/22/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,10/21/2024,Inactive,,
CINJ OP INFUSION,42436,"Hochster, Howard S, MD",9/25/2023,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,First Line,9/24/2023,Inactive,,
CINJ OP INFUSION,42436,"Hochster, Howard S, MD",10/2/2023,CINJ 072006 (EA2182) ARM B Fluorouracil IVCI / Mitomycin 10 mg/m2 with 20 or 23 Day Concurrent Radiation 1 Cycle Research- Anal Carcinoma,First Line,8/28/2023,Inactive,,
CINJ OP INFUSION,12260,"Toppmeyer, Deborah L, MD",4/28/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,4/28/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,12260,"Toppmeyer, Deborah L, MD",3/24/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,3/24/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,12260,"Toppmeyer, Deborah L, MD",3/17/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/17/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,40071,"Patel, Eshan, MD",2/16/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,2/16/2023,Inactive,,
CINJ OP INFUSION,41031,"Haigentz, Missak, MD",8/23/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,First Line,8/15/2023,Inactive,,
CINJ OP INFUSION,41031,"Haigentz, Missak, MD",9/4/2023,Selpercatinib 28 Day Cycles- Non-Small Cell Lung Cancer,Second Line,9/4/2023,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,41031,"Haigentz, Missak, MD",2/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,2/5/2024,Inactive,,
JCMC CP INFUSION,92418,"Cruz, Allan Louie E, MD",10/23/2023,AC + Leuprolide (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/8/2023,Inactive,,
NBR 4N ONCOLOGY,11916,"Goel, Sanjay, MD",9/20/2024,PACLitaxel/CARBOplatin 21 Day Cycles,_1. First Line,9/19/2024,Active,,
SOM OUTPT INFUSION,40764,"Patel, Eshan, MD",12/10/2024,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 80 mg/m2 D1 21 Day Cycles- Head and Neck Cancers",_1. First Line,12/9/2024,Active,,
SOM OUTPT INFUSION,40764,"Patel, Eshan, MD",4/29/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,4/29/2025,Active,Head and neck cancer (CMS/HCC),
NBR CINJ OP INFUSION,21429,"Shah, Mansi R, MD",10/30/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,10/27/2024,Inactive,,
SOM OUTPT INFUSION,25322,"Toomey, Kathleen C, MD",7/3/2023,Abemaciclib 28 Day Cycles - Breast ,First Line,7/3/2023,Active,,
HAM OP INFUSION,92990,"Patel, Malini M, MD",4/13/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,4/12/2023,Inactive,,
TRMC TCCC OP INFUSION,4367,"Meghal, Trishala, MD",5/9/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,5/9/2025,Active,"Malignant neoplasm of gallbladder (CMS/HCC)
Encounter for drug therapy
Encounter for follow-up surveillance of biliary cancer",K82.8 - Other specified diseases of gallbladder; C23 - Malignant neoplasm of gallbladder; G89.3 - Neoplasm related pain (acute) (chronic); Z79.899 - Other long term (current) drug therapy; Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm; Z85.09 - Personal history of malignant neoplasm of other digestive organs
CBMC OP INFUSION 2FL,36891,"Wagmiller, Jennifer Ann, MD",10/2/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,10/1/2023,Inactive,,
CINJ OP INFUSION,23971,"Aikins, James K, MD",6/27/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/23/2024,Inactive,,
CINJ OP INFUSION,23971,"Aikins, James K, MD",10/29/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,10/29/2024,Active,,
CINJ OP INFUSION,23971,"Aikins, James K, MD",10/31/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,10/31/2024,Active,,
CMC 4B ONCOLOGY,67183,"Taff, Jessica, MD",11/29/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/26/2024,Inactive,,
CINJ OP INFUSION,9021,"Stephenson, Ruth D, DO",9/8/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Second Line,8/24/2023,Active,,
SOM OUTPT INFUSION,1683,"Yin, Faye, MD",1/12/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/11/2024,Inactive,,
NBI OP INFUSION,21079,"Shah, Maya M, MD",3/8/2023,Sacituzumab Govitecan 21 Day Cycles - Breast,Second Line,3/7/2023,Inactive,,
NBI OP INFUSION,21079,"Shah, Maya M, MD",8/28/2024,Olaparib 30 Day Cycles - Breast,_3. Third Line,8/28/2024,Inactive,,
NBI OP INFUSION,21079,"Shah, Maya M, MD",1/15/2025,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,1/15/2025,Active,,
NBI OP INFUSION,51783,"Shah, Maya M, MD",5/14/2025,Gemcitabine / CARBOplatin 28 Day Cycles - Breast,_4. Fourth Line,5/14/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)","C50.411, Z17.1 - Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)"
CINJ OP INFUSION,63812,"Berim, Lyudmyla, MD",3/6/2023,mFOLFOX6 Nivolumab - GEJ cancer,,2/28/2023,Inactive,,
CMC OP INFUSION,63812,"Taff, Jessica, MD",10/20/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- GEJ cancer,Second Line,9/24/2023,Inactive,,
CMC OP INFUSION,63812,"Taff, Jessica, MD",11/10/2023,IROX (Irinotecan/OXALIplatin) 21 Day Cycles- GEJ cancer,_2. Second Line,11/9/2023,Inactive,,
CMC OP INFUSION,63812,"Taff, Jessica, MD",11/14/2023,mXeliri (Capecitabine + Irinotecan) + Nivolumab 21 Day Cycles- GEJ cancer,_2. Second Line,11/9/2023,Inactive,,
CMC OP INFUSION,63812,"Taff, Jessica, MD",2/13/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- GEJ cancer",_2. Second Line,2/12/2024,Inactive,,
CMC OP INFUSION,9442,"Tang, Horace, MD",10/24/2023,CISplatin With Concurrent Radiation 7 Day Cycles - vulva,Neoadjuvant,10/24/2023,Inactive,,
CMC OP INFUSION,81278,"Talwar, Sumit, MD",10/9/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,9/3/2024,Active,,
CBMC OP INFUSION 2FL,68862,"Freeman, Benjamin B, MD",2/21/2025,AD (DOXOrubicin / Dacarbazine) 21 Day Cycles - Sarcoma,_3. Third Line,2/20/2025,Active,Fibrosarcoma (CMS/HCC),
CBMC 2W ONCOLOGY,27078,"Freeman, Benjamin B, MD",4/8/2025,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_4. Fourth Line,4/8/2025,Active,Fibrosarcoma (CMS/HCC),
CBMC OP INFUSION 2FL,27078,"Freeman, Benjamin B, MD",4/4/2025,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_4. Fourth Line,4/4/2025,Inactive,Fibrosarcoma (CMS/HCC),
CBMC OP INFUSION 2FL,27078,"Freeman, Benjamin B, MD",4/1/2025,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_4. Fourth Line,4/1/2025,Inactive,Fibrosarcoma (CMS/HCC),
CMMC OP INFUSION,27078,"Freeman, Benjamin B, MD",4/1/2025,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_4. Fourth Line,4/1/2025,Inactive,Fibrosarcoma (CMS/HCC),
HAM OP INFUSION,19207,"Patel, Malini M, MD",11/15/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/13/2023,Active,,
MMC BBR2 ONCOLOGY,8418,"Lee, Patrick C, MD",4/15/2025,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,4/15/2025,Active,Glioblastoma multiforme of brain (CMS/HCC),"I61.9 - Nontraumatic intracerebral hemorrhage, unspecified; G93.5 - Compression of brain; G93.6 - Cerebral edema; E44.0 - Moderate protein-calorie malnutrition; R18.8 - Other ascites; C71.9 - Malignant neoplasm of brain, unspecified; C50.911 - Malignant neoplasm of unspecified site of right female breast; D64.9 - Anemia, unspecified; I10 - Essential (primary) hypertension; L97.529 - Non-pressure chronic ulcer of other part of left foot with unspecified severity; E78.5 - Hyperlipidemia, unspecified; L84 - Corns and callosities; M81.0 - Age-related osteoporosis without current pathological fracture; N32.81 - Overactive bladder; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; Z79.810 - Long term (current) use of selective estrogen receptor modulators (serms); Z79.899 - Other long term (current) drug therapy; Z85.42 - Personal history of malignant neoplasm of other parts of uterus; Z90.722 - Acquired absence of ovaries, bilateral; Z92.3 - Personal history of irradiation; Z96.651 - Presence of right artificial knee joint; Z90.710 - Acquired absence of both cervix and uterus; I87.2 - Venous insufficiency (chronic) (peripheral); Z88.1 - Allergy status to other antibiotic agents; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z91.018 - Allergy to other foods; Z98.890 - Other specified postprocedural states; Z68.24 - Body mass index (BMI) 24.0-24.9, adult"
CINJ PEDS HEMONC ,23256,"Botwinick, Marissa, DO",1/23/2025,"PEDS LCH-IV Stratum I Group 1 MS-LCH, Group 2 SS-LCH (IC-1) Initial Course 1  - Langerhans Cell Histiocytosis",_1. First Line,1/22/2025,Active,,
CINJ PEDS HEMONC ,23256,"Botwinick, Marissa, DO",5/1/2025,"PEDS LCH-IV Stratum I Group 1 MS-LCH, Group 2 SS-LCH Continuation Arm A - Langerhans Cell Histiocytosis",_1. First Line,5/1/2025,Inactive,Langerhan's cell histiocytosis (CMS/HCC),
CINJ PEDS HEMONC ,23256,"Botwinick, Marissa, DO",4/25/2025,"PEDS LCH-IV Stratum I Group 1 MS-LCH, Group 2 SS-LCH Continuation Arm A - Langerhans Cell Histiocytosis",_1. First Line,4/25/2025,Active,Langerhan's cell histiocytosis (CMS/HCC),
CINJ PEDS HEMONC ,23256,"Botwinick, Marissa, DO",3/13/2025,"PEDS LCH-IV Stratum I Group 1 MS-LCH, Group 2 SS-LCH Continuation Arm A - Langerhans Cell Histiocytosis",_1. First Line,3/13/2025,Inactive,Langerhan's cell histiocytosis (CMS/HCC),
CMC OP INFUSION,64517,"Pompa, Tiffany Ann, MD",11/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,11/21/2024,Active,Non-small cell cancer of left lung (CMS/HCC),
CMC 4B ONCOLOGY,62785,"Pompa, Tiffany Ann, MD",4/11/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,4/11/2025,Active,"Carcinoma of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,20406,"Gurubhagavatula, Sarada, MD",5/6/2025,CINJ 032212 Cohort 4 Amivantamab-vmjw / Lazertinib 28 Day Cycles Research- Non-Small Cell Lung Cancer,_3. Third Line,5/6/2025,Active,Lung cancer (CMS/HCC),
CBMC OP INFUSION 2FL,20406,"Gurubhagavatula, Sarada, MD",4/15/2025,CINJ 032212 Cohort 4 Amivantamab-vmjw / Lazertinib 28 Day Cycles Research- Non-Small Cell Lung Cancer,_4. Fourth Line,4/15/2025,Inactive,Lung cancer (CMS/HCC),C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
HAM OP INFUSION,58468,"Yogarajah, Meera, MD",5/11/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,First Line,5/7/2023,Inactive,,
HAM OP INFUSION,58468,"Yogarajah, Meera, MD",8/17/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,First Line,7/30/2023,Inactive,,
CINJ OP INFUSION,24657,"George, Mridula A, MD",9/13/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/12/2023,Inactive,,
CINJ OP INFUSION,24657,"George, Mridula A, MD",2/7/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,2/6/2024,Inactive,,
CINJ OP INFUSION,87825,"Hochster, Howard S, MD",11/2/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/31/2023,Active,,
CINJ OP INFUSION,20391,"Hochster, Howard S, MD",5/22/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/22/2025,Active,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,32149,"Berim, Lyudmyla, MD",5/30/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,,5/27/2023,Inactive,,
CBMC OP INFUSION 2FL,98602,"Wagmiller, Jennifer Ann, MD",6/5/2023,A011801 / CINJ 042106 Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,Adjuvant,6/4/2023,Inactive,,
CINJ OP INFUSION,37782,"Haigentz, Missak, MD",1/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,1/22/2024,Inactive,,
NBR CINJ OP INFUSION,19760,"Evens, Andrew M, DO",2/21/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_5. Fifth Line,2/20/2024,Inactive,,
NBR 4N ONCOLOGY,19760,"Evens, Andrew M, DO",3/8/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,3/8/2024,Inactive,,
CBMC OP INFUSION 2FL,67433,"Brown, Andrew Bennett, MD",1/22/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_2. Second Line,1/21/2024,Inactive,,
CBMC OP INFUSION 2FL,67433,"Brown, Andrew Bennett, MD",7/2/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,7/2/2024,Inactive,,
CINJ OP INFUSION,67433,"Haigentz, Missak, MD",10/1/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_4. Fourth Line,10/1/2024,Inactive,,
NBR 5N ONCOLOGY,67433,"Haigentz, Missak, MD",10/31/2024,PACLitaxel Weekly 56 Day Cycles- Small Cell Lung Cancer,_5. Fifth Line,10/30/2024,Inactive,,
NBR 5N ONCOLOGY,74207,"Shah, Mansi R, MD",4/20/2023,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),First Line,4/20/2023,Inactive,,
NBR CINJ OP INFUSION,74207,"Shah, Mansi R, MD",5/11/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,5/7/2023,Active,,
NBR CINJ OP INFUSION,74207,"Shah, Mansi R, MD",1/16/2025,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_2. Second Line,1/15/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,14327,"Cheng, Yan Ho, MD",3/3/2025,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,3/3/2025,Inactive,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,6842,"Boland, Patrick M, MD",5/7/2024,mFOLFOX6 + nivolumab - gastric cancer,_1. First Line,5/3/2024,Active,,
CINJ OP INFUSION,19249,"Packiam, Vignesh, MD",11/19/2024,BCG Induction (TICE) 42 Day Cycle,Induction,11/18/2024,Active,,
CINJ OP INFUSION,19249,"Packiam, Vignesh, MD",2/18/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,2/17/2025,Active,Malignant neoplasm of lateral wall of bladder (CMS/HCC),C67.2 - Malignant neoplasm of lateral wall of bladder
HAM OP INFUSION,64781,"Patel, Malini M, MD",9/17/2024,RiTUXimab 180 Day Cycles (Initial & Maintenance) - Hodgkin Lymphoma,_1. First Line,9/16/2024,Active,Malignant neoplasm of ampulla of Vater (CMS/HCC),
HAM OP INFUSION,64781,"Patel, Malini M, MD",1/28/2025,RiTUXimab 180 Day Cycles (Initial & Maintenance) - Hodgkin Lymphoma,_1. First Line,9/16/2024,Active,Malignant neoplasm of lower-outer quadrant of right female breast (CMS/HCC),
CINJ OP INFUSION,15458,"Stephenson, Ryan D, DO",3/3/2023,CINJ 082201 (NRG-GU010) ARM 3 Androgen Deprivation Therapy 6 Months Cycle (180 Days) Research- Prostate Cancer,Adjuvant,2/2/2023,Inactive,,
CINJ OP INFUSION,26171,"Girda, Eugenia, MD",1/20/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/17/2023,Inactive,,
CINJ OP INFUSION,26171,"Leiser, Aliza, MD",1/8/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,12/25/2023,Inactive,,
CINJ OP INFUSION,26171,"Girda, Eugenia, MD",6/4/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Endometrial Cancer,_3. Third Line,6/3/2024,Inactive,,
CINJ OP INFUSION,26171,"Girda, Eugenia, MD",12/24/2024,Abemaciclib 28 Day Cycles - endometrial cancer,_5. Fifth Line,12/24/2024,Active,,
CINJ OP INFUSION,58305,"Toppmeyer, Deborah L, MD",1/30/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,1/27/2023,Inactive,,
CINJ OP INFUSION,58305,"Toppmeyer, Deborah L, MD",10/9/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Adjuvant,10/9/2023,Active,,
CINJ OP INFUSION,54873,"Boland, Patrick M, MD",4/9/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,3/27/2024,Inactive,,
NBR CINJ OP INFUSION,21154,"Evens, Andrew M, DO",7/7/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,7/7/2023,Inactive,,
NBR CINJ OP INFUSION,21154,"Evens, Andrew M, DO",10/25/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,10/24/2023,Active,Malignant neoplasm of breast (CMS/HCC),
JCMC CP INFUSION,16014,"Cruz, Allan Louie E, MD",8/29/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,8/29/2024,Active,,
CMC OP INFUSION,91749,"Taff, Jessica, MD",4/2/2025,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,4/2/2025,Active,Malignant melanoma of left upper extremity including shoulder (CMS/HCC),
SOM OUTPT INFUSION,65561,"Toomey, Kathleen C, MD",8/16/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,8/8/2023,Inactive,,
SOM OUTPT INFUSION,65561,"Toomey, Kathleen C, MD",12/20/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,12/19/2023,Active,Leukemia not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,45137,"Wagmiller, Jennifer Ann, MD",5/14/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,5/7/2025,Active,Endometrial cancer (CMS/HCC),C55 - Uterine carcinosarcoma (CMS/HCC)
CINJ OP INFUSION,84744,"Saraiya, Biren P, MD",2/13/2023,Lenvatinib 28 Day Cycles- Papillary Carcinoma,,2/13/2023,Inactive,,
CINJ OP INFUSION,11950,"Ghodoussipour, Saum Bobak, MD",12/28/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,12/26/2023,Inactive,,
CINJ OP INFUSION,11950,"Packiam, Vignesh, MD",3/22/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Adjuvant,3/21/2024,Active,,
MMC OP VP INFUSION,29858,"Meghal, Trishala, MD",11/2/2023,Enfortumab Pembrolizumab 21 Day Cycles - Bladder,_1. First Line,10/18/2023,Inactive,,
NBR CINJ OP INFUSION,50266,"Evens, Andrew M, DO",8/14/2023,mini CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) + Obinutuzumab 21 Day Cycles,Third Line,8/13/2023,Inactive,,
NBR CINJ OP INFUSION,50266,"Evens, Andrew M, DO",9/6/2023,Obinutuzumab 28 Day Cycles - Low Grade Indolent Lymphoma ,,9/5/2023,Inactive,,
CINJ OP INFUSION,77819,"George, Mridula A, MD",10/23/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,9/25/2024,Active,,
CINJ OP INFUSION,77819,"George, Mridula A, MD",10/23/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/15/2024,Active,Nodular lymphocyte predominant Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),
TRMC TCCC OP INFUSION,14947,"Capo, Gerardo, MD",4/30/2025,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,4/30/2025,Active,"Fallopian tube cancer, carcinoma (CMS/HCC)",
NBR 5N ONCOLOGY,97879,"Tiger, Yun Kyoung, MD",10/15/2024,Cytarabine (200 mg/m2) / DAUNOrubicin (60 mg/m2) (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,10/15/2024,Inactive,,
NBR 5N ONCOLOGY,97879,"Rhodes, Joanna Meehan, MD",11/7/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Adjuvant,11/7/2024,Active,,
NBR CINJ OP INFUSION,97879,"Palmisiano, Neil David, MD",12/3/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),_1. First Line,12/3/2024,Active,,
CBMC OP INFUSION 2FL,69375,"Wagmiller, Jennifer Ann, MD",8/23/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,8/22/2023,Inactive,,
CINJ OP INFUSION,52236,"Boland, Patrick M, MD",9/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/16/2024,Active,,
CINJ OP INFUSION,1783,"Boland, Patrick M, MD",3/25/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/25/2025,Active,Colon cancer (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon
NBR 5N ONCOLOGY,78352,"Braunschweig, Ira, MD",2/6/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,2/3/2023,Inactive,,
CINJ OP INFUSION,6680,"Mayer, Tina M, MD",2/28/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,,2/28/2023,Inactive,,
CBMC OP INFUSION 2FL,83487,"Scoppetuolo, Michael, MD",6/12/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/2/2024,Active,,
CBMC OP INFUSION 2FL,83487,"Scoppetuolo, Michael, MD",5/13/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/12/2025,Active,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,97261,"Jang, Thomas L, MD",7/17/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/17/2023,Inactive,,
MMC OP VP INFUSION,46267,"Cohen, Seth D, MD",2/10/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/2/2025,Active,"Malignant neoplasm of unspecified part of right bronchus or lung (CMS/HCC)
End stage renal disease (CMS/HCC)",
CINJ OP INFUSION,89850,"Ghodoussipour, Saum Bobak, MD",3/12/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Adjuvant,3/12/2024,Inactive,,
CBMC OP INFUSION 2FL,85024,"Scoppetuolo, Michael, MD",11/14/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_2. Second Line,11/13/2023,Inactive,,
CBMC OP INFUSION 2FL,85024,"Scoppetuolo, Michael, MD",2/6/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,2/5/2024,Inactive,,
CBMC OP INFUSION 2FL,85024,"Scoppetuolo, Michael, MD",5/3/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Prostate,_3. Third Line,4/28/2024,Inactive,,
NBR 5N ONCOLOGY,38654,"Rhodes, Joanna Meehan, MD",8/29/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/28/2024,Inactive,,
CINJ OP INFUSION,27999,"Omene, Coral Oghenerukevwe, MD",5/1/2023,Palbociclib 28 Day Cycles - Breast,First Line,5/1/2023,Inactive,,
NBR CINJ OP INFUSION,54900,"Rhodes, Joanna Meehan, MD",4/14/2025,R-MPV (High-Dose Methotrexate / VinCRIStine / Procarbazine / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,4/14/2025,Active,CNS lymphoma (CMS/HCC),"C83.390 - Primary central nervous system lymphoma; B20 - Human immunodeficiency virus (HIV) disease; F02.80 - Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety; N50.9 - Disorder of male genital organs, unspecified; B58.01 - Toxoplasma chorioretinitis; R91.8 - Other nonspecific abnormal finding of lung field"
NBR 4N ONCOLOGY,7513,"Chen, Xiaoyi",2/13/2025,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,2/13/2025,Active,ALL (acute lymphoblastic leukemia) (CMS/HCC),"C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; G93.6 - Cerebral edema; I62.9 - Nontraumatic intracranial hemorrhage, unspecified; K71.9 - Toxic liver disease, unspecified; C91.00 - Acute lymphoblastic leukemia not having achieved remission; E87.1 - Hypo-osmolality and hyponatremia; E83.39 - Other disorders of phosphorus metabolism; S00.03XA - Contusion of scalp, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z59.71 - Insufficient health insurance coverage; Z79.899 - Other long term (current) drug therapy"
NBR CINJ OP INFUSION,7513,"Chen, Xiaoyi",5/12/2025,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,5/12/2025,Active,ALL (acute lymphoblastic leukemia) (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia
CINJ OP INFUSION,47657,"Haigentz, Missak, MD",4/30/2024,Lenvatinib 28 Day Cycles- Papillary Carcinoma,_1. First Line,4/30/2024,Inactive,,
NBI VALERIE FND HEMONC,41542,"Bhatla, Teena, MD",11/3/2023,PEDS AREN0533 Regimen M - Renal,_1. First Line,11/1/2023,Inactive,,
CINJ OP INFUSION,6538,"Stephenson, Ryan D, DO",2/12/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,2/11/2024,Inactive,,
NBR 4N ONCOLOGY,7812,"Hinrichs, Christian, MD",7/4/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/3/2024,Inactive,,
NBI OP INFUSION,75647,"Jacoby, Sari H, MD",9/15/2023,Irinotecan D 1 & 8 / Panitumumab D 1 Q 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/15/2023,Active,,
NBI OP INFUSION,75647,"Jacoby, Sari H, MD",10/8/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/30/2024,Active,,
CMC OP INFUSION,54773,"Taff, Jessica, MD",9/11/2023,Abraxane / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,9/8/2023,Active,,
CINJ OP INFUSION,42539,"Saraiya, Biren P, MD",3/12/2024,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,3/11/2024,Inactive,,
CMC OP INFUSION,19864,"Taff, Jessica, MD",11/29/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,11/28/2023,Inactive,,
MMC OP VP INFUSION,10520,"Meghal, Trishala, MD",9/30/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,9/30/2024,Active,,
CINJ OP INFUSION,40677,"Ghodoussipour, Saum Bobak, MD",1/5/2023,Mitomycin for Pyelocalyceal Instillation (Ureteral Gel) - Urothelial ,Induction,1/4/2023,Inactive,,
CINJ OP INFUSION,13494,"Omene, Coral Oghenerukevwe, MD",7/23/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,7/21/2024,Inactive,,
CINJ OP INFUSION,13494,"Omene, Coral Oghenerukevwe, MD",9/17/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,9/17/2024,Inactive,,
CINJ OP INFUSION,13494,"Omene, Coral Oghenerukevwe, MD",1/7/2025,CINJ 042403 Tirzepatide Weekly 28 Day Cycles (3 Month Dispense Cycle 6 and Beyond) Research- Breast Cancer,Adjuvant,1/7/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,56921,"Eltoukhy, Hussam, MD",10/24/2024,RiTUXimab for ITP,_1. First Line,10/21/2024,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
NBI OP INFUSION,11121,"Jacoby, Sari H, MD",2/6/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/5/2024,Inactive,,
CBMC OP INFUSION 2FL,91763,"Gallinson, David Herschel, DO",5/13/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,5/13/2025,Active,Lymphoproliferative disorder (CMS/HCC),
TRMC TCCC OP INFUSION,9640,"Salerno, Vincent E, MD",2/5/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,2/4/2025,Active,Multiple myeloma (CMS/HCC),Z00.00 - Encounter for general adult medical examination without abnormal findings; C90.00 - Multiple myeloma not having achieved remission
CINJ OP INFUSION,12576,"Stephenson, Ryan D, DO",12/11/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Penile Cancer ,Adjuvant,12/10/2023,Active,,
CINJ OP INFUSION,1743,"Boland, Patrick M, MD",2/26/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,2/25/2024,Inactive,,
CINJ OP INFUSION,1743,"Boland, Patrick M, MD",5/24/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Adjuvant,5/23/2024,Active,,
MMC OP VP INFUSION,78666,"Cohen, Seth D, MD",7/6/2023,Atezolizumab / Albumin-Bound PACLitaxel 28 Day Cycles - Breast,,7/5/2023,Inactive,,
MMC OP VP INFUSION,78666,"Cohen, Seth D, MD",7/10/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,,7/5/2023,Inactive,,
MMC OP VP INFUSION,78666,"Cohen, Seth D, MD",10/16/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,_3. Third Line,10/15/2023,Inactive,,
MMC OP VP INFUSION,78666,"Cohen, Seth D, MD",11/20/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_3. Third Line,11/19/2023,Inactive,,
MMC OP INFUSION,90338,"Eltoukhy, Hussam, MD",6/19/2023,"EWALL Induction (Vincristine, Dexamethasone, Methotreate, Cytarabine, Dasatinib) - Ph+ Acute Lymphoblastic Leukemia",Induction,6/18/2023,Inactive,,
NBR 5N ONCOLOGY,90338,"Eltoukhy, Hussam, MD",8/1/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,Consolidation,8/1/2023,Inactive,,
NBR CINJ OP INFUSION,90338,"Eltoukhy, Hussam, MD",8/2/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,8/2/2023,Inactive,,
CINJ OP INFUSION,35403,"Hochster, Howard S, MD",6/13/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) and Nivo -  14 Day Cycles- Gastrointestinal Cancers,Maintenance,6/12/2024,Inactive,,
CINJ OP INFUSION,47857,"Ghodoussipour, Saum Bobak, MD",3/11/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,3/11/2024,Inactive,,
CINJ OP INFUSION,47857,"Stephenson, Ryan D, DO",5/24/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,5/23/2024,Inactive,,
CINJ OP INFUSION,47857,"Stephenson, Ryan D, DO",11/22/2024,CINJ 082401 Arm 1 Cohort A Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,Adjuvant,11/22/2024,Active,,
CINJ OP INFUSION,47857,"Stephenson, Ryan D, DO",5/14/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/14/2025,Active,Urothelial carcinoma of bladder with invasion of muscle (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C61 - Malignant neoplasm of prostate; R91.1 - Solitary pulmonary nodule; D64.9 - Anemia, unspecified; I89.0 - Lymphedema, not elsewhere classified; M25.551 - Pain in right hip; M54.9 - Dorsalgia, unspecified; Z51.11 - Encounter for antineoplastic chemotherapy; Z51.12 - Encounter for antineoplastic immunotherapy; Z92.21 - Personal history of antineoplastic chemotherapy; Z90.79 - Acquired absence of other genital organ(s)"
SOM OUTPT INFUSION,90293,"Toomey, Kathleen C, MD",4/26/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Maintenance,4/26/2023,Inactive,,
SOM OUTPT INFUSION,90293,"Toomey, Kathleen C, MD",6/27/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,6/27/2023,Inactive,,
HAM OP INFUSION,98921,"Yogarajah, Meera, MD",3/23/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,3/20/2023,Inactive,,
CBMC OP INFUSION 2FL,78461,"Dharmapuri, Sirish, MD",1/6/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2025,Active,,
CBMC OP INFUSION 2FL,78461,"Dharmapuri, Sirish, MD",1/6/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,12/8/2024,Inactive,Pancreatic adenocarcinoma (CMS/HCC),
HAM OP INFUSION,42698,"Yogarajah, Meera, MD",5/25/2023,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,,5/24/2023,Inactive,,
CBMC OP INFUSION 2FL,44807,"Leitner, Stuart P, MD",11/8/2023,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_2. Second Line,11/7/2023,Active,,
CINJ OP INFUSION,75518,"Hochster, Howard S, MD",5/17/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/16/2023,Inactive,,
CINJ OP INFUSION,75518,"Hochster, Howard S, MD",2/28/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/27/2024,Active,,
CINJ OP INFUSION,17847,"Hochster, Howard S, MD",5/7/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,5/7/2025,Inactive,"Malignant neoplasm of splenic flexure (CMS/HCC)
Cirrhosis (CMS/HCC)","K74.60 - Unspecified cirrhosis of liver; C18.5 - Malignant neoplasm of splenic flexure; R18.8 - Other ascites; E11.9 - Type 2 diabetes mellitus without complications; G25.81 - Restless legs syndrome; G47.00 - Insomnia, unspecified"
CINJ OP INFUSION,17847,"Hochster, Howard S, MD",3/6/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,3/6/2025,Active,"Malignant neoplasm of splenic flexure (CMS/HCC)
Cirrhosis (CMS/HCC)","K74.60 - Unspecified cirrhosis of liver; C18.5 - Malignant neoplasm of splenic flexure; R18.8 - Other ascites; E11.9 - Type 2 diabetes mellitus without complications; G25.81 - Restless legs syndrome; G47.00 - Insomnia, unspecified"
CINJ OP INFUSION,48977,"Stephenson, Ryan D, DO",2/24/2023,Avelumab 14 Day Cycles - Bladder ,First Line,2/19/2023,Inactive,,
CINJ OP INFUSION,48977,"Stephenson, Ryan D, DO",6/23/2023,Erdafitinib 28 Day Cycles - Bladder,_3. Third Line,6/23/2023,Inactive,,
CINJ OP INFUSION,48977,"Stephenson, Ryan D, DO",12/27/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,_4. Fourth Line,12/19/2023,Inactive,,
CINJ OP INFUSION,48977,"Stephenson, Ryan D, DO",3/20/2024,Sacituzumab Govitecan 21 Day Cycles - Bladder,_5. Fifth Line,3/19/2024,Inactive,,
NBR CINJ OP INFUSION,53133,"Evens, Andrew M, DO",8/21/2024,Mosunetuzumab-axgb 21 Day Cycles - Follicular Lymphoma,_4. Fourth Line,8/20/2024,Active,,
CINJ OP INFUSION,96333,"Boland, Patrick M, MD",1/30/2023,Pembro q6 weeks- Esophageal and Esophagogastric Junction Cancers,Maintenance,1/29/2023,Active,,
CMC OP INFUSION,72777,"Pompa, Tiffany Ann, MD",2/26/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,2/25/2025,Active,Head and neck cancer (CMS/HCC),
CMC OP INFUSION,72777,"Pompa, Tiffany Ann, MD",3/12/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,2/26/2025,Active,Head and neck cancer (CMS/HCC),
CBMC OP INFUSION 2FL,55363,"Wagmiller, Jennifer Ann, MD",11/21/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/20/2023,Active,,
CINJ OP INFUSION,50604,"Leiser, Aliza, MD",1/11/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/11/2024,Active,,
CBMC OP INFUSION 2FL,93840,"Leitner, Stuart P, MD",5/6/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/5/2024,Inactive,,
CBMC OP INFUSION 2FL,93840,"Leitner, Stuart P, MD",8/21/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/19/2024,Active,Anti-NMDA receptor encephalitis,
MSC OP INFUSION,74208,"Cohen, Seth D, MD",6/18/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,6/17/2024,Inactive,,
CINJ OP INFUSION,81449,"Boland, Patrick M, MD",4/4/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,4/2/2023,Inactive,,
CINJ OP INFUSION,7754,"Haigentz, Missak, MD",2/13/2024,CISplatin 75 mg/m2/ Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/13/2024,Inactive,,
CINJ OP INFUSION,7754,"Haigentz, Missak, MD",5/20/2024,Trametinib 28 Day Cycles - Neuroendocrine cancer (NF1 loss),_2. Second Line,5/20/2024,Inactive,,
CINJ OP INFUSION,7754,"Haigentz, Missak, MD",6/28/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_3. Third Line,6/28/2024,Inactive,,
CINJ OP INFUSION,7754,"Haigentz, Missak, MD",8/14/2024,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",_4. Fourth Line,8/14/2024,Inactive,,
CINJ OP INFUSION,47176,"Haigentz, Missak, MD",1/28/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_5. Fifth Line,1/28/2025,Inactive,"Primary malignant neuroendocrine neoplasm of lung (CMS/HCC)
Secondary cancer of brain (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
CINJ OP INFUSION,64557,"Muralikrishnan, Sivraj, MD",1/31/2025,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,1/30/2025,Inactive,"Malignant neoplasm of lung (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,64557,"Muralikrishnan, Sivraj, MD",2/3/2025,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,1/30/2025,Active,"Malignant neoplasm of lung (CMS/HCC)
Encounter for screening for other viral diseases","C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; Z51.89 - Encounter for other specified aftercare; R19.7 - Diarrhea, unspecified; M79.10 - Myalgia, unspecified site; Z11.59 - Encounter for screening for other viral diseases"
CINJ OP INFUSION,80970,"Muralikrishnan, Sivraj, MD",5/20/2025,"PACLitaxel 80 mg/m2 D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_4. Fourth Line,5/20/2025,Active,"Malignant neoplasm of lung (CMS/HCC)
Encounter for screening for other viral diseases","Z51.11 - Encounter for antineoplastic chemotherapy; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; R22.41 - Localized swelling, mass and lump, right lower limb; M79.10 - Myalgia, unspecified site; Z11.59 - Encounter for screening for other viral diseases; Z87.891 - Personal history of nicotine dependence"
CINJ OP INFUSION,80970,"Muralikrishnan, Sivraj, MD",4/8/2025,"PACLitaxel 80 mg/m2 D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_4. Fourth Line,4/8/2025,Inactive,"Malignant neoplasm of lung (CMS/HCC)
Encounter for screening for other viral diseases","Z51.11 - Encounter for antineoplastic chemotherapy; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; R22.41 - Localized swelling, mass and lump, right lower limb; M79.10 - Myalgia, unspecified site; Z11.59 - Encounter for screening for other viral diseases; Z87.891 - Personal history of nicotine dependence"
MMC OP INFUSION,91619,"Lee, Patrick C, MD",4/2/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/25/2024,Active,,
CINJ OP INFUSION,12460,"Berim, Lyudmyla, MD",3/6/2024,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,_1. First Line,3/6/2024,Inactive,,
CINJ OP INFUSION,12460,"Berim, Lyudmyla, MD",5/15/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/14/2024,Active,,
JCMC CP INFUSION,43175,"Cruz, Allan Louie E, MD",9/16/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,9/12/2024,Active,,
MMC OP VP INFUSION,34894,"Lee, Patrick C, MD",7/20/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/26/2023,Inactive,,
MMC OP VP INFUSION,34894,"Lee, Patrick C, MD",4/4/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,4/4/2025,Inactive,Malignant neoplasm of rectum (CMS/HCC),
CINJ OP INFUSION,54842,"Stephenson, Ryan D, DO",1/15/2025,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,1/14/2025,Active,,
HAM OP INFUSION,52288,"Patel, Malini M, MD",7/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/26/2024,Inactive,,
CBMC OP INFUSION 2FL,87252,"Grossman, I Robert, MD",6/27/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,6/23/2024,Inactive,,
CBMC OP INFUSION 2FL,87252,"Grossman, I Robert, MD",12/21/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,12/20/2024,Active,,
CINJ OP INFUSION,1333,"Berim, Lyudmyla, MD",5/30/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/30/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); K59.03 - Drug induced constipation; T40.2X5A - Adverse effect of other opioids, initial encounter; R53.81 - Other malaise; K86.9 - Disease of pancreas, unspecified; Z51.5 - Encounter for palliative care; Z79.891 - Long term (current) use of opiate analgesic"
MMC OP VP INFUSION,3827,"Meghal, Trishala, MD",8/16/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,8/16/2024,Active,,
NBR 5N ONCOLOGY,85519,"Matasar, Matthew J, MD",8/23/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,8/22/2023,Inactive,,
MMC OP VP INFUSION,73824,"Lee, Patrick C, MD",3/23/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,3/22/2023,Inactive,,
CINJ OP INFUSION,66590,"Stephenson, Ruth D, DO",12/9/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/17/2024,Active,,
CINJ OP INFUSION,5540,"Omene, Coral Oghenerukevwe, MD",3/5/2024,CINJ 042106 (A011801)  Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,Adjuvant,3/4/2024,Active,,
CINJ OP INFUSION,27219,"Mayer, Tina M, MD",11/3/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,10/30/2023,Inactive,,
CINJ OP INFUSION,50928,"Toppmeyer, Deborah L, MD",5/15/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,5/15/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)","C50.111, Z17.1 - Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)"
CBMC OP INFUSION 2FL,73750,"Wagmiller, Jennifer Ann, MD",8/20/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/11/2024,Inactive,,
CBMC OP INFUSION 2FL,73750,"Wagmiller, Jennifer Ann, MD",1/20/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,1/19/2025,Active,Skin cancer,
JCMC CP INFUSION,53132,"Cruz, Allan Louie E, MD",12/17/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/15/2024,Inactive,,
NBR 5N ONCOLOGY,5818,"Gulhati, Prateek, MD PhD",4/18/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,4/12/2023,Inactive,,
CINJ OP INFUSION,5818,"Boland, Patrick M, MD",6/5/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,,5/29/2023,Inactive,,
CINJ OP INFUSION,5818,"Boland, Patrick M, MD",9/15/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,,9/7/2023,Inactive,,
CINJ OP INFUSION,5818,"Boland, Patrick M, MD",12/15/2023,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/14/2023,Inactive,,
CINJ OP INFUSION,31382,"Toppmeyer, Deborah L, MD",6/19/2023,Olaparib 30 Day Cycles - Breast,Adjuvant,6/19/2023,Active,,
CINJ OP INFUSION,13074,"Hochster, Howard S, MD",1/12/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,1/4/2023,Inactive,,
CINJ OP INFUSION,13074,"Hochster, Howard S, MD",11/23/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,11/22/2023,Inactive,,
CINJ OP INFUSION,1502,"Toppmeyer, Deborah L, MD",3/23/2023,Palbociclib 28 Day Cycles - Breast,First Line,3/23/2023,Inactive,,
CINJ OP INFUSION,1502,"Toppmeyer, Deborah L, MD",9/30/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,First Line,9/13/2023,Inactive,,
CINJ OP INFUSION,1502,"Toppmeyer, Deborah L, MD",3/4/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_3. Third Line,3/3/2024,Inactive,,
CINJ OP INFUSION,20162,"Ghodoussipour, Saum Bobak, MD",10/27/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,10/27/2023,Active,,
HAM OP INFUSION,79530,"Patel, Malini M, MD",9/3/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,9/3/2024,Inactive,,
HAM OP INFUSION,79530,"Patel, Malini M, MD",11/25/2024,Temozolomide 28 Day Cycles - CNS,_1. First Line,11/25/2024,Active,"MGUS (monoclonal gammopathy of unknown significance)
End stage renal disease (CMS/HCC)",
HAM OP INFUSION,42705,"Yogarajah, Meera, MD",4/29/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/28/2024,Inactive,,
CINJ OP INFUSION,29958,"Stephenson, Ryan D, DO",3/7/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,First Line,2/23/2023,Inactive,,
CINJ OP INFUSION,61394,"Omene, Coral Oghenerukevwe, MD",2/20/2023,retire:  CINJ 042102 Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,,2/19/2023,Inactive,,
CINJ OP INFUSION,61394,"Omene, Coral Oghenerukevwe, MD",5/23/2023,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,,5/22/2023,Inactive,,
HAM OP INFUSION,19470,"Yogarajah, Meera, MD",3/21/2023,Pembrolizumab 21 Day Cycles - bladder,First Line,3/21/2023,Inactive,,
NBI A5 PEDIATRICS,13098,"Rao, Harini, MD",9/6/2024,PEDS AHOD1331 Bv-AVE-PC,_1. First Line,8/28/2024,Active,,
CINJ OP INFUSION,5743,"Stephenson, Ryan D, DO",1/13/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,1/13/2025,Active,,
SOM OUTPT INFUSION,43779,"Patel, Eshan, MD",1/3/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/2/2024,Inactive,,
SOM OUTPT INFUSION,43779,"Patel, Eshan, MD",3/27/2024,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,Consolidation,3/26/2024,Inactive,,
SOM OUTPT INFUSION,43779,"Patel, Eshan, MD",4/1/2024,Topotecan 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,3/31/2024,Inactive,,
CINJ OP INFUSION,43779,"Haigentz, Missak, MD",8/27/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,8/27/2024,Inactive,,
CBMC OP INFUSION 2FL,36480,"Brown, Andrew Bennett, MD",2/26/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,2/26/2024,Active,,
CBMC OP INFUSION 2FL,46343,"Dharmapuri, Sirish, MD",1/13/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/6/2025,Active,,
HAM OP INFUSION,39698,"Gendy, Mina, DO",10/4/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,9/27/2024,Active,,
CINJ OP INFUSION,30492,"George, Mridula A, MD",12/22/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/21/2023,Inactive,,
CINJ OP INFUSION,30492,"George, Mridula A, MD",6/17/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/23/2024,Active,,
NBR 4N BMTU/IMCU,25147,"Braunschweig, Ira, MD",3/30/2023,BMT Autologous Carmustine / Thiotepa,,3/29/2023,Inactive,,
CINJ OP INFUSION,67056,"Patel, Eshan, MD",1/20/2023,PACLitaxel / CARBOplatin  7 Day Cycles - Non-Small Cell Lung Cancer,,1/19/2023,Inactive,,
CINJ OP INFUSION,67056,"Patel, Eshan, MD",5/26/2023,Atezolizumab 28 Day Cycles- Non-Small Cell Lung Cancer,,4/27/2023,Inactive,,
CINJ OP INFUSION,14991,"Stephenson, Ryan D, DO",5/28/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,5/26/2024,Active,,
SOM OUTPT INFUSION,19647,"Patel, Eshan, MD",12/9/2024,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,12/8/2024,Inactive,,
CINJ OP INFUSION,4356,"Weiss, Sarah, MD",9/16/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Adjuvant,9/15/2024,Active,,
NBI OP INFUSION,29406,"Schleicher, Lori, MD",1/6/2025,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,1/5/2025,Active,,
CINJ OP INFUSION,37158,"Boland, Patrick M, MD",2/13/2023,CINJ 071702 (MK-3475-535) Pembrolizumab 21 Day Cycles Pre-Operative Research- Gastric Cancer,,1/16/2023,Inactive,,
CINJ OP INFUSION,27593,"Groisberg, Roman, MD",4/14/2023,SORAfenib 28 Day Cycles- Hepatobiliary Cancers,,4/14/2023,Active,Malignant melanoma of left lower extremity including hip (CMS/HCC),
CINJ OP INFUSION,46580,"Saraiya, Biren P, MD",5/20/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_2. Second Line,5/20/2024,Inactive,,
CINJ OP INFUSION,46580,"Saraiya, Biren P, MD",1/30/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,_2. Second Line,12/9/2024,Active,,
CINJ OP INFUSION,13567,"Saraiya, Biren P, MD",2/11/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,_2. Second Line,12/9/2024,Active,Primary malignant neoplasm of kidney with metastasis from kidney to other site (CMS/HCC),
CBMC OP INFUSION 2FL,73768,"Grossman, I Robert, MD",12/7/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,12/6/2023,Active,,
MMC OP INFUSION,39649,"Meghal, Trishala, MD",4/28/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/27/2023,Inactive,,
MMC OP INFUSION,39649,"Meghal, Trishala, MD",7/21/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,7/20/2023,Inactive,,
MMC OP INFUSION,39649,"Meghal, Trishala, MD",8/11/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,8/11/2023,Inactive,,
MMC OP VP INFUSION,39649,"Meghal, Trishala, MD",1/31/2024,CINJ 042211 Arm B Capecitabine / Pembrolizumab 21 Day Cycles Research- Breast Cancer,Adjuvant,1/30/2024,Inactive,,
MMC OP VP INFUSION,39649,"Meghal, Trishala, MD",2/2/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,2/2/2024,Inactive,,
CINJ OP INFUSION,2059,"Boland, Patrick M, MD",9/1/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,8/31/2023,Inactive,,
CINJ OP INFUSION,2059,"Boland, Patrick M, MD",2/2/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/1/2024,Inactive,,
CMC OP INFUSION,31496,"Patel, Neel H, MD",4/22/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/21/2024,Active,,
CMC OP INFUSION,31496,"Patel, Neel H, MD",8/13/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,8/11/2024,Active,,
CINJ OP INFUSION,8659,"Girda, Eugenia, MD",10/18/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,10/17/2023,Inactive,,
CINJ OP INFUSION,8659,"Girda, Eugenia, MD",1/26/2024,Pembrolizumab 42 Day Cycles - Cervical,Maintenance,1/25/2024,Inactive,,
CINJ OP INFUSION,8659,"Girda, Eugenia, MD",3/4/2025,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,2/26/2025,Active,Cervical cancer (CMS/HCC),
CINJ OP INFUSION,5054,"Berim, Lyudmyla, MD",2/19/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,2/16/2024,Inactive,,
CINJ OP INFUSION,93199,"Haigentz, Missak, MD",5/15/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,5/10/2023,Inactive,,
CINJ OP INFUSION,93199,"Haigentz, Missak, MD",5/24/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_4. Fourth Line,5/24/2024,Active,,
SOM OUTPT INFUSION,54321,"Toomey, Kathleen C, MD",5/3/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,5/2/2023,Inactive,,
SOM OUTPT INFUSION,54321,"Toomey, Kathleen C, MD",8/30/2023,"Gemcitabine (D1, D8, D15) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",Third Line,8/28/2023,Inactive,,
SOM OUTPT INFUSION,54321,"Toomey, Kathleen C, MD",2/28/2024,PACLitaxel 28 Day Cycles -  Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,2/27/2024,Inactive,,
CINJ OP INFUSION,18642,"Saraiya, Biren P, MD",8/15/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Second Line,8/15/2023,Inactive,,
CINJ OP INFUSION,18642,"Saraiya, Biren P, MD",9/12/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,Third Line,8/30/2023,Inactive,,
CINJ OP INFUSION,18642,"Saraiya, Biren P, MD",1/30/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,1/29/2024,Inactive,,
CBMC OP INFUSION 2FL,3998,"Dharmapuri, Sirish, MD",10/22/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/21/2024,Inactive,,
CBMC OP INFUSION 2FL,3998,"Dharmapuri, Sirish, MD",11/4/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/22/2024,Active,,
CBMC OP INFUSION 2FL,3998,"Dharmapuri, Sirish, MD",11/18/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/20/2024,Active,,
SOM OUTPT INFUSION,51268,"Patel, Eshan, MD",3/28/2023,"DOCEtaxel D1, D8, D15 /Ramucirumab 28 Day Cycles- Non-Small Cell Lung Cancer",First Line,3/27/2023,Inactive,,
SOM OUTPT INFUSION,51268,"Patel, Eshan, MD",2/19/2024,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,2/18/2024,Inactive,,
MMC OP INFUSION,78375,"Meghal, Trishala, MD",12/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,11/27/2024,Inactive,,
MMC OP VP INFUSION,78375,"Meghal, Trishala, MD",12/4/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,12/3/2024,Active,,
MMC OP INFUSION,21754,"Talwar, Sumit, MD",3/7/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/7/2025,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
CMC OP INFUSION,42635,"Talwar, Sumit, MD",4/25/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,4/2/2024,Active,,
NBR 4N ONCOLOGY,67101,"Tiger, Yun Kyoung, MD",5/21/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,5/21/2025,Inactive,AML (acute myeloid leukemia) (CMS/HCC),"E87.79 - Other hypervolemia; C92.00 - Acute myeloid leukemia not having achieved remission (CMS/HCC); I50.9 - Acute congestive heart failure, unspecified heart failure type (CMS/HCC)"
CMC OP INFUSION,95997,"Easaw, Sarah, MD",7/12/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,7/10/2023,Inactive,,
CMC OP INFUSION,95997,"Cohen, Seth D, MD",11/29/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,11/9/2023,Inactive,,
CINJ OP INFUSION,52916,"Leiser, Aliza, MD",3/25/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,3/19/2023,Inactive,,
CBMC OP INFUSION 2FL,68688,"Scoppetuolo, Michael, MD",10/18/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/17/2023,Inactive,,
CBMC OP INFUSION 2FL,68688,"Scoppetuolo, Michael, MD",8/14/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/5/2024,Active,,
CBMC OP INFUSION 2FL,34151,"Raptis, George, MD",2/5/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,2/4/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,52703,"Evens, Andrew M, DO",5/7/2025,CINJ 012503 Arm 1 Rituximab 56 Day Cycles Research - Follicular Lymphoma,_1. First Line,5/7/2025,Active,Follicular lymphoma (CMS/HCC),
CMC OP INFUSION,52597,"Cohen, Seth D, MD",4/9/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/8/2024,Inactive,,
HAM OP INFUSION,61292,"Yogarajah, Meera, MD",4/18/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/18/2024,Active,,
SOM OUTPT INFUSION,21846,"Toomey, Kathleen C, MD",5/5/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,5/5/2025,Inactive,"Rectal cancer (CMS/HCC)
Malignant neoplasm metastatic to both lungs (CMS/HCC)","A41.9 - Sepsis, unspecified organism; E11.10 - Type 2 diabetes mellitus with ketoacidosis without coma; I26.99 - Other pulmonary embolism without acute cor pulmonale; I81 - Portal vein thrombosis; E43 - Unspecified severe protein-calorie malnutrition; K56.690 - Other partial intestinal obstruction; C78.00 - Secondary malignant neoplasm of unspecified lung; K63.3 - Ulcer of intestine; C19 - Malignant neoplasm of rectosigmoid junction; C50.911 - Malignant neoplasm of unspecified site of right female breast; D50.9 - Iron deficiency anemia, unspecified; I10 - Essential (primary) hypertension; I36.1 - Nonrheumatic tricuspid (valve) insufficiency; Z68.32 - Body mass index (BMI) 32.0-32.9, adult; M48.56XA - Collapsed vertebra, not elsewhere classified, lumbar region, initial encounter for fracture; I48.20 - Chronic atrial fibrillation, unspecified; D62 - Acute posthemorrhagic anemia; N39.0 - Urinary tract infection, site not specified; E87.1 - Hypo-osmolality and hyponatremia; N17.9 - Acute kidney failure, unspecified; D68.69 - Other thrombophilia; I48.0 - Paroxysmal atrial fibrillation; I82.462 - Acute embolism and thrombosis of left calf muscular vein; R65.20 - Severe sepsis without septic shock; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; K63.5 - Polyp of colon; I95.9 - Hypotension, unspecified; E55.9 - Vitamin D deficiency, unspecified; E78.5 - H..."
CBMC OP INFUSION 2FL,36133,"Derosa, William T, DO",10/23/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,10/22/2024,Active,,
CINJ OP INFUSION,31743,"Stephenson, Ryan D, DO",1/13/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,1/5/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,15350,"Packiam, Vignesh, MD",2/4/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Induction - Bladder Cancer,Induction,2/3/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,15350,"Packiam, Vignesh, MD",5/16/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,5/16/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CBMC OP INFUSION 2FL,23724,"Leitner, Stuart P, MD",11/13/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,11/12/2023,Inactive,,
NBI OP INFUSION,21288,"Schleicher, Lori, MD",2/15/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/7/2024,Active,,
MMC OP VP INFUSION,65930,"Talwar, Sumit, MD",8/22/2023,RiTUXimab 168 Day Cycles - Wegners granulomatosis,,8/14/2023,Active,Malignant neoplasm of exocervix (CMS/HCC),
CINJ OP INFUSION,57833,"Boland, Patrick M, MD",3/28/2023,CINJ 072213 Nivolumab / Ipilimumab 21 Day Cycles Followed by Nivolumab 28 Day Cycles Research- Hepatocellular Carcinoma,,2/27/2023,Inactive,,
CINJ OP INFUSION,57833,"Boland, Patrick M, MD",3/19/2024,Nivolumab 480 mg 28 Day Cycles- hcc,_2. Second Line,3/18/2024,Inactive,,
CINJ OP INFUSION,57833,"Goel, Sanjay, MD",2/10/2025,CINJ 052401 Part A Enrichment GIM-122,_3. Third Line,2/10/2025,Active,Hepatocellular carcinoma (CMS/HCC),
CINJ OP INFUSION,46561,"Leiser, Aliza, MD",4/3/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,4/2/2023,Inactive,,
CINJ OP INFUSION,46561,"Leiser, Aliza, MD",6/29/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,First Line,6/29/2023,Inactive,,
CINJ OP INFUSION,46561,"Leiser, Aliza, MD",1/21/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,1/20/2025,Inactive,"Peritoneal carcinomatosis (CMS/HCC)
Elevated cancer antigen 125 (CA 125)
Encounter for antineoplastic chemotherapy
Malignant neoplasm of ovary (CMS/HCC)",
CINJ OP INFUSION,46561,"Leiser, Aliza, MD",1/24/2025,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,1/13/2025,Active,,
CINJ OP INFUSION,99914,"Leiser, Aliza, MD",5/8/2025,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,5/8/2025,Active,"Peritoneal carcinomatosis (CMS/HCC)
Elevated cancer antigen 125 (CA 125)
Encounter for antineoplastic chemotherapy
Malignant neoplasm of ovary (CMS/HCC)",
CINJ OP INFUSION,81102,"Hochster, Howard S, MD",10/4/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/3/2023,Inactive,,
CINJ OP INFUSION,81102,"Hochster, Howard S, MD",1/29/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,1/29/2024,Active,,
MSC OP INFUSION,97207,"Talwar, Sumit, MD",6/19/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,6/17/2024,Active,,
JCMC CP INFUSION,93149,"Cruz, Allan Louie E, MD",3/13/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/12/2023,Inactive,,
NBI OP INFUSION,18170,"Schleicher, Lori, MD",5/16/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,5/15/2024,Active,,
SOM OUTPT INFUSION,61976,"Toomey, Kathleen C, MD",5/8/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/8/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
NBR 5N ONCOLOGY,84444,"Palmisiano, Neil David, MD",6/21/2023,EWALL Induction (Vincristine / Dexamethasone / Dasatinib / IT Methotrexate / IT Cytarabine)- Acute Lymphocytic Leukemia,First Line,6/21/2023,Inactive,,
NBR CINJ OP INFUSION,84444,"Palmisiano, Neil David, MD",8/7/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,,8/7/2023,Inactive,,
NBR CINJ OP INFUSION,84444,"Palmisiano, Neil David, MD",9/14/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,9/14/2023,Inactive,,
CINJ OP INFUSION,25695,"Haigentz, Missak, MD",7/31/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,7/30/2023,Inactive,,
MSC OP INFUSION,58824,"Taff, Jessica, MD",11/6/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,11/1/2023,Active,,
CINJ OP INFUSION,89604,"Golombos, David, MD",4/2/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,4/2/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
MSC OP INFUSION,99141,"Cohen, Seth D, MD",8/24/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,8/16/2023,Inactive,,
CINJ OP INFUSION,18706,"Weiss, Sarah, MD",3/13/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,3/12/2023,Inactive,,
CMC OP INFUSION,97425,"Taff, Jessica, MD",5/4/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,4/26/2023,Inactive,,
CMC OP INFUSION,97425,"Taff, Jessica, MD",4/1/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,3/18/2024,Inactive,,
CINJ OP INFUSION,97425,"Berim, Lyudmyla, MD",9/9/2024,CINJ 072305 Cohort D ASP2138 14 Day Cycles Research- Gastrointestinal Cancers,_3. Third Line,9/8/2024,Inactive,,
CINJ OP INFUSION,70868,"Boland, Patrick M, MD",12/21/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,11/20/2023,Inactive,,
CINJ OP INFUSION,63122,"Berim, Lyudmyla, MD",9/9/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/5/2024,Active,,
CINJ OP INFUSION,63122,"Berim, Lyudmyla, MD",5/12/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Adjuvant,5/12/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),"C15.9 - Malignant neoplasm of esophagus, unspecified; C15.5 - Malignant neoplasm of lower third of esophagus"
CBMC OP INFUSION 2FL,74829,"Scoppetuolo, Michael, MD",2/19/2024,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,_1. First Line,2/11/2024,Inactive,,
CBMC OP INFUSION 2FL,74829,"Scoppetuolo, Michael, MD",4/8/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_2. Second Line,4/7/2024,Active,,
CBMC OP INFUSION 2FL,64775,"Litvak, Anna M, MD",3/21/2025,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,_1. First Line,3/21/2025,Inactive,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
NBI A5 PEDIATRICS,86969,"Ford, Maegan C, MD",9/24/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,9/23/2024,Inactive,,
NBI VALERIE FND HEMONC,86969,"Ford, Maegan C, MD",10/30/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",Consolidation,10/30/2024,Inactive,,
NBI VALERIE FND HEMONC,86969,"Ford, Maegan C, MD",12/2/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,Maintenance,12/2/2024,Inactive,,
NBI VALERIE FND HEMONC,86969,"Ford, Maegan C, MD",12/23/2024,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,Maintenance,12/2/2024,Active,,
NBI VALERIE FND HEMONC,86969,"Batra, Surabhi, MD",2/18/2025,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,2/18/2025,Active,Acute lymphoblastic leukemia (ALL) in child (CMS/HCC),
NBI VALERIE FND HEMONC,86969,"Batra, Surabhi, MD",5/19/2025,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,5/19/2025,Active,Acute lymphoblastic leukemia (ALL) in child (CMS/HCC),
NBI VALERIE FND HEMONC,86969,"Batra, Surabhi, MD",3/14/2025,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,2/18/2025,Inactive,Acute lymphoblastic leukemia (ALL) in child (CMS/HCC),
CMC OP INFUSION,92604,"Tang, Horace, MD",10/26/2023,Bevacizumab 14 Day Cycles - Glioblastoma,_2. Second Line,10/26/2023,Inactive,,
NBR 5N MED-SURG OVRF,26300,"Alexander, Henry Richard, MD",3/21/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,3/21/2024,Active,,
CINJ OP INFUSION,52308,"Haigentz, Missak, MD",3/12/2024,CINJ 052011 Cohort 9 Enfortumab Vedotin / Pembrolizumab Phase 2 21 Day Cycles Research- Solid Malignancies,_1. First Line,3/11/2024,Inactive,,
CINJ OP INFUSION,52308,"Haigentz, Missak, MD",11/19/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,11/19/2024,Active,,
SOM OUTPT INFUSION,9413,"Patel, Eshan, MD",3/10/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/10/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),"C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; J44.89 - Other specified chronic obstructive pulmonary disease; J98.59 - Other diseases of mediastinum, not elsewhere classified; Z79.51 - Long term (current) use of inhaled steroids; Z95.828 - Presence of other vascular implants and grafts"
CINJ OP INFUSION,43023,"Berim, Lyudmyla, MD",3/18/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/18/2025,Inactive,"Gastric cancer (CMS/HCC)
Mesothelioma, malignant (CMS/HCC)","C16.9 - Malignant neoplasm of stomach, unspecified; C45.9 - Mesothelioma, unspecified"
CINJ OP INFUSION,43023,"Berim, Lyudmyla, MD",3/18/2025,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_1. First Line,3/18/2025,Active,"Gastric cancer (CMS/HCC)
Mesothelioma, malignant (CMS/HCC)",
NBI OP INFUSION,64605,"Anderson, Patrick S, MD",2/8/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Endometrial adenocarcinoma,Neoadjuvant,2/7/2024,Inactive,,
NBI OP INFUSION,64605,"Anderson, Patrick S, MD",4/11/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles -Advanced Endometrial Cancer,_2. Second Line,4/10/2024,Inactive,,
NBI OP INFUSION,64605,"Anderson, Patrick S, MD",9/26/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles -Serrous endometrial cancer Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,9/25/2024,Active,,
NBI VALERIE FND HEMONC,31825,"Batra, Surabhi, MD",2/26/2025,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",_1. First Line,2/25/2025,Inactive,Acute lymphoid leukemia in remission (CMS/HCC),P09.9 - Abnormal findings on newborn screening
NBI D7 MED-SURG/TELE,73669,"Cheng, Yan Ho, MD",12/18/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_3. Third Line,12/18/2023,Inactive,,
NBR 5N ONCOLOGY,73669,"Rhodes, Joanna Meehan, MD",12/21/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/20/2023,Inactive,,
NBR CINJ OP INFUSION,73669,"Rhodes, Joanna Meehan, MD",3/27/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,3/19/2024,Inactive,,
NBR CINJ OP INFUSION,73669,"Rhodes, Joanna Meehan, MD",9/10/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_4. Fourth Line,9/4/2024,Active,,
NBR CINJ OP INFUSION,10465,"Shah, Mansi R, MD",3/25/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_2. Second Line,3/25/2025,Active,"Multiple myeloma (CMS/HCC)
Hx of autologous stem cell transplant (CMS/HCC)",
CMC OP INFUSION,94304,"Cohen, Seth D, MD",4/8/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/7/2024,Inactive,,
CMC OP INFUSION,62678,"Tang, Horace, MD",8/4/2023,RiTUXimab 28 Day Cycle - MS,,8/4/2023,Active,"Malignant neoplasm of larynx (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)",
MMC OP VP INFUSION,75583,"Lee, Patrick C, MD",3/13/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/12/2024,Active,,
CINJ OP INFUSION,99307,"Stephenson, Ruth D, DO",6/30/2023,Pembrolizumab 21 Day Cycles - Uterine,Third Line,6/15/2023,Inactive,,
CINJ OP INFUSION,99307,"Stephenson, Ruth D, DO",9/13/2023,Topotecan 21 Day Cycles - Uterine,Third Line,9/10/2023,Inactive,,
CINJ OP INFUSION,99307,"Stephenson, Ruth D, DO",1/31/2024,Megestrol / Tamoxifen (GOG 3007) 42 Day Cycles - Uterine,_5. Fifth Line,1/31/2024,Inactive,,
CINJ OP INFUSION,54174,"Ghodoussipour, Saum Bobak, MD",1/5/2023,CINJ 081603 ARM 1 Apalutamide 90 Day Cycle Research- Prostate Cancer,Neoadjuvant,12/6/2022,Inactive,,
CINJ OP INFUSION,54174,"Patel, Eshan, MD",10/9/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,,9/21/2023,Inactive,,
CINJ OP INFUSION,54174,"Patel, Eshan, MD",5/10/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/28/2023,Active,,
NBR 4N ONCOLOGY,79788,"Matasar, Matthew J, MD",5/19/2023,CINJ 022105 (Part 1 of 2) Magrolimab or Placebo 28 Day Cycles Research- Acute Myeloid Leukemia,,5/18/2023,Inactive,,
NBR 4N ONCOLOGY,79788,"Palmisiano, Neil David, MD",5/19/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,5/19/2023,Inactive,,
MSC OP INFUSION,86537,"Eltoukhy, Hussam, MD",3/13/2025,Bendamustine / RiTUXimab 28 Day Cycles - Waldenstroms,_4. Fourth Line,3/13/2025,Active,Waldenstrom macroglobulinemia (CMS/HCC),
CINJ OP INFUSION,70458,"Berim, Lyudmyla, MD",7/10/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,7/9/2024,Active,,
CINJ OP INFUSION,70458,"Berim, Lyudmyla, MD",12/2/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,12/2/2024,Active,,
CINJ OP INFUSION,53281,"Berim, Lyudmyla, MD",5/5/2025,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,Maintenance,5/5/2025,Active,Malignant neoplasm of bile ducts (CMS/HCC),C24.0 - Malignant neoplasm of bile ducts (CMS/HCC); C25.0 - Malignant neoplasm of head of pancreas (CMS/HCC)
CINJ OP INFUSION,54552,"Jang, Thomas L, MD",5/14/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/14/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
CBMC 2W ONCOLOGY,6043,"Grossman, I Robert, MD",8/28/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_2. Second Line,8/26/2024,Inactive,Malignant neoplasm of female breast (CMS/HCC),
CBMC OP INFUSION 2FL,6043,"Grossman, I Robert, MD",1/31/2025,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,1/26/2025,Active,,
SOM OUTPT INFUSION,8107,"Yin, Faye, MD",12/27/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,12/17/2023,Inactive,,
SOM OUTPT INFUSION,8107,"Toomey, Kathleen C, MD",7/3/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,7/2/2024,Inactive,,
SOM OUTPT INFUSION,8107,"Toomey, Kathleen C, MD",11/6/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,11/5/2024,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),
SOM OUTPT INFUSION,44105,"Patel, Eshan, MD",3/12/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles  Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,3/12/2025,Active,"Squamous carcinoma of lung, unspecified laterality (CMS/HCC)",C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung
MMC OP VP INFUSION,51909,"Meghal, Trishala, MD",4/15/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,4/14/2024,Inactive,,
MMC OP VP INFUSION,51909,"Meghal, Trishala, MD",6/10/2024,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,6/7/2024,Inactive,,
MMC OP VP INFUSION,51909,"Meghal, Trishala, MD",7/8/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,7/8/2024,Active,,
MMC OP VP INFUSION,51909,"Meghal, Trishala, MD",8/5/2024,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,8/4/2024,Inactive,,
HAM OP INFUSION,80044,"Yogarajah, Meera, MD",8/31/2023,Irinotecan + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,Second Line,8/9/2023,Inactive,,
CMC OP INFUSION,25098,"Taff, Jessica, MD",6/18/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,6/17/2024,Inactive,,
CINJ OP INFUSION,45922,"Hochster, Howard S, MD",9/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/28/2024,Active,,
MSC OP INFUSION,54644,"Cohen, Seth D, MD",8/2/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,7/30/2024,Inactive,,
MSC OP INFUSION,54644,"Cohen, Seth D, MD",10/8/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/7/2024,Inactive,,
CINJ OP INFUSION,41021,"Groisberg, Roman, MD",7/1/2024,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_1. First Line,6/30/2024,Inactive,,
CINJ OP INFUSION,41021,"Groisberg, Roman, MD",7/2/2024,PEDS AEWS1031 Regimen A Induction & Consolidation,_1. First Line,6/30/2024,Inactive,,
CBMC OP INFUSION 2FL,41021,"Scoppetuolo, Michael, MD",10/28/2024,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_1. First Line,10/27/2024,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
NBI OP INFUSION,31145,"Schleicher, Lori, MD",10/17/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,10/17/2024,Active,,
CINJ OP INFUSION,90082,"Saraiya, Biren P, MD",7/29/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,7/29/2024,Active,,
CINJ OP INFUSION,8847,"Haigentz, Missak, MD",3/13/2023,CINJ 032013 (EA5181) ARM A Durvalumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,,3/5/2023,Inactive,,
CINJ OP INFUSION,8847,"Haigentz, Missak, MD",5/9/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,Consolidation,5/8/2023,Inactive,,
CINJ OP INFUSION,8847,"Haigentz, Missak, MD",6/5/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,6/5/2024,Inactive,,
CINJ OP INFUSION,8847,"Goel, Sanjay, MD",9/25/2024,CINJ 052401 Part A Enrichment GIM-122,_4. Fourth Line,9/25/2024,Inactive,,
CINJ OP INFUSION,8847,"Haigentz, Missak, MD",12/2/2024,PACLitaxel (50mg/m2) / CARBOplatin with Concurrent Radiation  7 Day Cycles - Non-Small Cell Lung Cancer,_3. Third Line,12/2/2024,Active,,
CINJ OP INFUSION,8847,"Haigentz, Missak, MD",12/6/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_3. Third Line,12/5/2024,Inactive,,
CINJ OP INFUSION,88988,"Goel, Sanjay, MD",4/14/2025,CINJ 052402 Phase 1 MBRC-101 Dose Escalation 21 Day Cycles Research- Solid Malignancies,_3. Third Line,4/14/2025,Inactive,Primary cancer of left lower lobe of lung (CMS/HCC),
CINJ OP INFUSION,45802,"Girda, Eugenia, MD",6/27/2023,CINJ 052202 Dose Expansion Cohort 1 RGX104 / Ipilimumab 28 Day Cycles Research- Solid Tumor Malignancies,Third Line,6/4/2023,Inactive,,
CINJ OP INFUSION,72815,"Gulhati, Prateek, MD PhD",1/9/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/8/2025,Active,,
CINJ OP INFUSION,6846,"Gulhati, Prateek, MD PhD",5/27/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,5/27/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
NBR CINJ OP INFUSION,39240,"Shah, Mansi R, MD",5/12/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/12/2023,Inactive,,
NBI D7 MED-SURG/TELE,15490,"Jacoby, Sari H, MD",6/5/2024,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,6/4/2024,Inactive,,
NBR CINJ OP INFUSION,46878,"Chowaniec, Wayne B, NP",4/19/2023,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,First Line,4/18/2023,Inactive,,
NBR 4N ONCOLOGY,46878,"Braunschweig, Ira, MD",7/12/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,7/11/2023,Inactive,,
NBR 4N BMTU/IMCU,46878,"Assal, Amer, MD",11/8/2023,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,11/6/2023,Inactive,,
NBR CINJ OP INFUSION,46878,"Assal, Amer, MD",5/16/2024,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,5/14/2024,Inactive,,
NBR CINJ OP INFUSION,46878,"Shah, Mansi R, MD",10/3/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,10/2/2024,Active,,
NBR CINJ OP INFUSION,72764,"Schaar, Dale, MD PhD",2/14/2023,Decitabine (3 day) 56 Day Cycles - Myelodysplastic Syndromes,,2/13/2023,Inactive,,
CINJ OP INFUSION,91243,"Jang, Thomas L, MD",8/3/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,8/3/2023,Inactive,,
CINJ OP INFUSION,91243,"Jang, Thomas L, MD",9/19/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,9/19/2023,Inactive,,
CINJ OP INFUSION,91243,"Jang, Thomas L, MD",12/27/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,12/27/2023,Active,,
CINJ OP INFUSION,60187,"George, Mridula A, MD",11/22/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Adjuvant,11/19/2024,Active,,
CMC OP INFUSION,28126,"Cohen, Seth D, MD",9/9/2024,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_1. First Line,9/8/2024,Inactive,,
NBR CINJ OP INFUSION,24048,"Rhodes, Joanna Meehan, MD",5/10/2023,RiTUXimab q12 weeks Cycles - Lymphoma Maintenance,Maintenance,5/9/2023,Inactive,,
NBR CINJ OP INFUSION,24048,"Rhodes, Joanna Meehan, MD",8/19/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,Maintenance,8/18/2024,Inactive,,
NBR CINJ OP INFUSION,24048,"Rhodes, Joanna Meehan, MD",11/4/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,11/1/2024,Active,"Breast cancer metastasized to lung, unspecified laterality (CMS/HCC)",
NBR BMSCH 2 PED HEMONC,35841,"Murphy, Susan, MD",6/26/2023,Cytarabine Intrathecal (IT) 1 Day Induction,Induction,6/26/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,35841,"Cole, Peter David, MD",6/27/2023,AALL1732 Induction,Induction,6/27/2023,Inactive,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",8/1/2023,AALL1732 Consolidation,Consolidation,7/31/2023,Inactive,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",9/29/2023,Asparaginase Erwinia (Rylaze) 14 Day Cycles Replacement for each missed calaspargase dose ,_1. First Line,9/29/2023,Inactive,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",10/24/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,10/4/2023,Inactive,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",12/26/2023,AALL1732 Delayed Intensification,_1. First Line,12/26/2023,Inactive,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",3/4/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,3/4/2024,Inactive,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",5/6/2024,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,5/6/2024,Active,,
CINJ PEDS HEMONC ,35841,"Cole, Peter David, MD",5/6/2024,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,5/6/2024,Inactive,,
JCMC CP INFUSION,82420,"Cruz, Allan Louie E, MD",4/25/2024,"PACLitaxel D1, D8 21 Day Cycles - Metastatic Breast Cancer",_5. Fifth Line,4/23/2024,Inactive,,
JCMC CP INFUSION,82420,"Cruz, Allan Louie E, MD",6/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_6. Sixth Line,6/12/2024,Inactive,,
SOM OUTPT INFUSION,58426,"Patel, Eshan, MD",3/18/2024,Imatinib 30 Day Cycles - Sarcoma,Neoadjuvant,12/4/2023,Active,,
SOM OUTPT INFUSION,38567,"Patel, Eshan, MD",11/9/2023,Enfortumab Vedotin + Pembrolizumab 21 Day Cycles - Bladder,_1. First Line,11/7/2023,Active,,
SOM OUTPT INFUSION,38567,"Patel, Eshan, MD",5/15/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,_1. First Line,5/15/2025,Active,"Malignant neoplasm of overlapping sites of bladder (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",N32.89 - Other specified disorders of bladder; M04.8 - Other autoinflammatory syndromes; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; C67.8 - Malignant neoplasm of overlapping sites of bladder; Z72.89 - Other problems related to lifestyle; Z11.59 - Encounter for screening for other viral diseases
CINJ OP INFUSION,30682,"Stephenson, Ryan D, DO",8/21/2023,CINJ 082104 (EA8191) ARM A Short Term Androgen Deprivation GnRH Therapy 84 Cycles Research- Prostate Cancer,Adjuvant,8/21/2023,Inactive,,
JCMC CP INFUSION,19529,"Sekhri, Arunabh, MD",1/11/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,1/10/2023,Inactive,,
JCMC CP INFUSION,19529,"Sekhri, Arunabh, MD",8/25/2023,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,8/17/2023,Inactive,,
SOM OUTPT INFUSION,4581,"Patel, Eshan, MD",9/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,9/27/2024,Inactive,,
HAM OP INFUSION,37108,"Yogarajah, Meera, MD",2/22/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,2/11/2024,Inactive,,
HAM OP INFUSION,37108,"Yogarajah, Meera, MD",5/16/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/15/2024,Inactive,,
HAM OP INFUSION,37108,"Yogarajah, Meera, MD",11/20/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/20/2024,Active,,
HAM OP INFUSION,32965,"Patel, Malini M, MD",6/29/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/22/2023,Inactive,,
CMC OP INFUSION,74391,"Cohen, Seth D, MD",2/29/2024,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/28/2024,Inactive,,
SOM OUTPT INFUSION,16297,"Patel, Eshan, MD",8/29/2023,CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,,8/21/2023,Inactive,,
CINJ OP INFUSION,47771,"Saraiya, Biren P, MD",12/10/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,12/10/2024,Active,,
CINJ OP INFUSION,42964,"Haigentz, Missak, MD",4/10/2023,CINJ 032111 (EA3161) ARM B CISplatin with Concurrent Radiation 7 Day Cycles Research- Oropharyngeal Carcinoma,First Line,4/8/2023,Active,,
CBMC OP INFUSION 2FL,75280,"Radovich, Delia, MD",10/30/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,75280,"Brown, Andrew Bennett, MD",9/27/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,9/27/2024,Active,,
CBMC OP INFUSION 2FL,54375,"Radovich, Delia, MD",11/7/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,54375,"Brown, Andrew Bennett, MD",12/20/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,12/20/2023,Inactive,,
CBMC OP INFUSION 2FL,54375,"Brown, Andrew Bennett, MD",1/9/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,1/9/2024,Inactive,,
CINJ OP INFUSION,70766,"Saraiya, Biren P, MD",1/26/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Prostate,_2. Second Line,1/25/2024,Inactive,,
CINJ OP INFUSION,70766,"Saraiya, Biren P, MD",3/28/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Prostate,_3. Third Line,3/18/2024,Inactive,,
CINJ OP INFUSION,22877,"Toppmeyer, Deborah L, MD",5/6/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,_1. First Line,5/3/2024,Inactive,,
CINJ OP INFUSION,22877,"Toppmeyer, Deborah L, MD",9/30/2024,"PACLitaxel 80 mg/m2 D1, D8, D15 28 Day Cycles-  Breast Cancer",_2. Second Line,9/30/2024,Inactive,,
CINJ OP INFUSION,86759,"Stephenson, Ryan D, DO",10/11/2023,CINJ 082203 (NCI#10466) ARM 1 Erlotinib / Atezolizumab / Bevacizumab 21 Day Cycles Research- Renal Cell Carcinoma,First Line,9/11/2023,Active,,
SOM OUTPT INFUSION,12706,"Yin, Faye, MD",5/6/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/3/2024,Inactive,,
SOM OUTPT INFUSION,12706,"Patel, Eshan, MD",7/1/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/28/2024,Active,,
HAM OP INFUSION,11706,"Yogarajah, Meera, MD",3/26/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,3/26/2025,Inactive,"Breast cancer metastasized to intrathoracic lymph node, unspecified laterality (CMS/HCC)","C50.912 - Malignant neoplasm of unspecified site of left female breast; C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; J90 - Pleural effusion, not elsewhere classified; R59.0 - Localized enlarged lymph nodes; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.31 - Chronic kidney disease, stage 3a; F32.A - Depression, unspecified; F41.9 - Anxiety disorder, unspecified; E78.5 - Hyperlipidemia, unspecified; K58.9 - Irritable bowel syndrome, unspecified; Z87.891 - Personal history of nicotine dependence; Z88.5 - Allergy status to narcotic agent; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
HAM OP INFUSION,11706,"Yogarajah, Meera, MD",3/26/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,3/26/2025,Active,"Breast cancer metastasized to intrathoracic lymph node, unspecified laterality (CMS/HCC)","C50.912 - Malignant neoplasm of unspecified site of left female breast; C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; J90 - Pleural effusion, not elsewhere classified; R59.0 - Localized enlarged lymph nodes; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.31 - Chronic kidney disease, stage 3a; F32.A - Depression, unspecified; F41.9 - Anxiety disorder, unspecified; E78.5 - Hyperlipidemia, unspecified; K58.9 - Irritable bowel syndrome, unspecified; Z87.891 - Personal history of nicotine dependence; Z88.5 - Allergy status to narcotic agent; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,58588,"Boland, Patrick M, MD",5/3/2023,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,,5/3/2023,Inactive,,
CBMC OP INFUSION 2FL,1721,"Brown, Andrew Bennett, MD",5/4/2023,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,5/3/2023,Inactive,,
NBR CINJ OP INFUSION,22713,"Matasar, Matthew J, MD",9/27/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,9/26/2024,Active,,
CINJ OP INFUSION,29709,"Hochster, Howard S, MD",5/14/2025,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 1500 mg/m2 d1-14 21 Day Cycles- adjuvant biliary cancer",Adjuvant,5/14/2025,Active,Malignant neoplasm of intrahepatic bile ducts (CMS/HCC),
CBMC OP INFUSION 2FL,23835,"Leitner, Stuart P, MD",9/19/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,9/18/2023,Inactive,,
CBMC OP INFUSION 2FL,23835,"Leitner, Stuart P, MD",6/11/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",Maintenance,6/10/2024,Inactive,,
CBMC OP INFUSION 2FL,23835,"Leitner, Stuart P, MD",11/21/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",_2. Second Line,11/20/2024,Active,,
CINJ OP INFUSION,35597,"Aikins, James K, MD",5/3/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/2/2024,Inactive,,
CINJ OP INFUSION,35597,"Aikins, James K, MD",11/4/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,10/31/2024,Active,,
CBMC OP INFUSION 2FL,28787,"Raptis, George, MD",8/30/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,8/29/2024,Active,,
CBMC OP INFUSION 2FL,28787,"Raptis, George, MD",9/13/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,9/13/2024,Active,,
NBR 5N ONCOLOGY,55870,"Girda, Eugenia, MD",8/31/2023,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Second Line,8/14/2023,Inactive,,
CINJ OP INFUSION,55870,"Girda, Eugenia, MD",9/27/2023,DOXOrubicin 21 Day Cycles - Uterine Sarcoma,,9/26/2023,Inactive,,
CBMC OP INFUSION 2FL,55449,"Wagmiller, Jennifer Ann, MD",11/10/2023,Gemcitabine + Margetuximab/both only Day 1/ w OBI/ 21 Day Cycles - Breast (was w navelbine),_1. First Line,11/10/2023,Inactive,,
CBMC OP INFUSION 2FL,55449,"Wagmiller, Jennifer Ann, MD",5/24/2024,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,_5. Fifth Line,5/13/2024,Inactive,,
CBMC OP INFUSION 2FL,55449,"Wagmiller, Jennifer Ann, MD",8/7/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_5. Fifth Line,8/6/2024,Inactive,Malignant neoplasm of cerebral meninges (CMS/HCC),
CBMC OP INFUSION 2FL,55449,"Wagmiller, Jennifer Ann, MD",9/27/2024,Albumin-Bound PACLitaxel / Trastuzumab 28 Day Cycles - Breast,_6. Sixth Line,9/26/2024,Inactive,,
CBMC OP INFUSION 2FL,55449,"Wagmiller, Jennifer Ann, MD",10/25/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_6. Sixth Line,10/24/2024,Active,,
CINJ OP INFUSION,4557,"Gulhati, Prateek, MD PhD",6/15/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,6/14/2023,Active,,
MMC OP VP INFUSION,27240,"Cohen, Seth D, MD",3/20/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/19/2024,Inactive,,
MMC OP VP INFUSION,27240,"Cohen, Seth D, MD",7/3/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,7/3/2024,Inactive,,
MMC OP INFUSION,39229,"Meghal, Trishala, MD",8/2/2023,Capecitabine 21 Day Cycles - Breast,First Line,8/2/2023,Inactive,,
MMC OP INFUSION,39229,"Meghal, Trishala, MD",5/29/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/28/2024,Inactive,,
MMC OP INFUSION,39229,"Meghal, Trishala, MD",7/24/2024,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,Maintenance,7/16/2024,Inactive,,
MMC OP VP INFUSION,39229,"Meghal, Trishala, MD",9/11/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_2. Second Line,9/11/2024,Inactive,,
MMC OP INFUSION,39229,"Meghal, Trishala, MD",9/12/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_1. First Line,9/12/2024,Inactive,,
MMC OP INFUSION,39229,"Meghal, Trishala, MD",10/3/2024,Sacituzumab Govitecan 21 Day Cycles - Breast,_2. Second Line,9/25/2024,Inactive,,
MMC OP VP INFUSION,39229,"Meghal, Trishala, MD",10/30/2024,Bevacizumab 28 Day Cycles - CNS,_1. First Line,10/30/2024,Inactive,,
JCMC CP INFUSION,72351,"Sekhri, Arunabh, MD",7/18/2024,RiTUXimab 60 Day Cycles - Follicular Lymphoma Maintenance,_1. First Line,6/19/2024,Active,"Secondary malignant neoplasm of bone (CMS/HCC)
Stage IV breast cancer in female (CMS/HCC)",
MMC OP VP INFUSION,75671,"Lee, Patrick C, MD",4/29/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/29/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
NBR 5N ONCOLOGY,81610,"Saraiya, Biren P, MD",7/2/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,,7/1/2023,Inactive,,
NBR 5N ONCOLOGY,81610,"Saraiya, Biren P, MD",4/8/2024,TI-CE (PACLitaxel / Ifosfamide) 14 Day Cycles - Germ Cell Tumors,_2. Second Line,4/8/2024,Inactive,,
JCMC CP INFUSION,28866,"Sekhri, Arunabh, MD",8/28/2024,CISplatin Keytruda With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,8/11/2024,Inactive,,
JCMC CP INFUSION,28866,"Sekhri, Arunabh, MD",11/26/2024,Pembrolizumab 42 Day Cycles - Cervical,Maintenance,10/8/2024,Active,,
CINJ OP INFUSION,39023,"Stephenson, Ruth D, DO",11/16/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,11/15/2023,Inactive,,
CINJ OP INFUSION,78443,"Gulhati, Prateek, MD PhD",7/6/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/20/2023,Inactive,,
CINJ OP INFUSION,78443,"Gulhati, Prateek, MD PhD",12/29/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/28/2023,Inactive,,
CINJ OP INFUSION,4869,"Weiss, Sarah, MD",3/20/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,3/20/2023,Active,,
CBMC OP INFUSION 2FL,91683,"Langan, Russell, MD",3/3/2025,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/3/2025,Active,"Ovarian cancer (CMS/HCC)
Carcinomatosis (CMS/HCC)",
CBMC OP INFUSION 2FL,68894,"Dave, Manish, MD",8/31/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/30/2023,Inactive,,
MMC OP VP INFUSION,80471,"Lee, Patrick C, MD",2/6/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,2/5/2025,Active,"Squamous cell carcinoma of lower lobe of left lung (CMS/HCC)
Chemotherapy-induced fatigue",
MMC OP VP INFUSION,80471,"Lee, Patrick C, MD",2/6/2025,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant; Adjuvant),Neoadjuvant,2/5/2025,Active,Squamous cell carcinoma of lower lobe of left lung (CMS/HCC),
CMC OP INFUSION,14963,"Cohen, Seth D, MD",6/25/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,6/24/2024,Inactive,,
NBI OP INFUSION,24449,"Shah, Shailja S, MD",8/7/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,8/7/2024,Active,,
CBMC OP INFUSION 2FL,66484,"Leitner, Stuart P, MD",11/10/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,_1. First Line,11/10/2023,Active,,
CINJ OP INFUSION,67751,"George, Mridula A, MD",10/11/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,10/11/2024,Active,,
CMC OP INFUSION,51288,"Cohen, Seth D, MD",2/6/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,2/5/2024,Inactive,,
NBR 4N ONCOLOGY,87604,"Berim, Lyudmyla, MD",5/8/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,5/7/2024,Inactive,,
CINJ OP INFUSION,4938,"Toppmeyer, Deborah L, MD",12/17/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Adjuvant,12/11/2024,Active,,
JCMC CP INFUSION,84338,"Sekhri, Arunabh, MD",8/29/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/18/2024,Inactive,,
JCMC CP INFUSION,84338,"Sekhri, Arunabh, MD",9/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/8/2024,Inactive,,
HAM OP INFUSION,75648,"Yogarajah, Meera, MD",12/5/2023,Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles - Multiple Myeloma,_1. First Line,11/21/2023,Inactive,,
CINJ OP INFUSION,4844,"Schaar, Dale, MD PhD",2/13/2024,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,2/12/2024,Active,Esophageal adenocarcinoma (CMS/HCC),
MMC OP VP INFUSION,39868,"Cohen, Seth D, MD",7/10/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,7/9/2023,Inactive,,
NBR CINJ OP INFUSION,28968,"Palmisiano, Neil David, MD",3/16/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,3/15/2023,Inactive,,
NBR CINJ OP INFUSION,28968,"Palmisiano, Neil David, MD",5/1/2023,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),Induction,5/1/2023,Inactive,,
NBR CINJ OP INFUSION,28968,"Palmisiano, Neil David, MD",2/26/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,2/26/2024,Inactive,,
CINJ OP INFUSION,68786,"Omene, Coral Oghenerukevwe, MD",2/11/2025,CINJ 042403 Tirzepatide Weekly 28 Day Cycles (3 Month Dispense Cycle 6 and Beyond) Research- Breast Cancer,Adjuvant,2/11/2025,Inactive,Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC),C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBR CINJ OP INFUSION,90630,"Tiger, Yun Kyoung, MD",5/31/2024,RiTUXimab / Lenalidomide + Lenalidomide 28 Day Cycles - Follicular Lymphoma,_2. Second Line,5/28/2024,Active,Malignant neoplasm of cerebral meninges (CMS/HCC),
NBR CINJ OP INFUSION,57339,"Evens, Andrew M, DO",1/29/2025,Daratumumab 21 Day Cycles,_1. First Line,1/28/2025,Active,,
NBR CINJ OP INFUSION,57339,"Evens, Andrew M, DO",1/31/2025,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE ) 21 Day Cycles -  Lymphoma (Inpatient Regimen),_1. First Line,1/31/2025,Active,,
CINJ PEDS HEMONC ,61980,"Drachtman, Richard, MD",1/5/2023,AALL1732 Interim Maintenance II (IM II) with CMTX,,1/5/2023,Inactive,,
CINJ PEDS HEMONC ,61980,"Drachtman, Richard, MD",3/10/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,First Line,3/9/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,61980,"Drachtman, Richard, MD",12/23/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,12/23/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,61980,"Drachtman, Richard, MD",12/23/2024,"PEDS AALL1331 Blocks 1,2,3",_1. First Line,12/23/2024,Active,,
CINJ PEDS HEMONC ,40097,"Drachtman, Richard, MD",3/4/2025,BRIDGE THERAPY PRIOR TO CAR T - FOLLOWING AALL1732 IM1 WITH HDMTX,Adjuvant,3/3/2025,Inactive,ALL (acute lymphoid leukemia) in relapse (CMS/HCC),
NBI VALERIE FND HEMONC,59084,"Batra, Surabhi, MD",2/25/2025,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",_1. First Line,2/25/2025,Active,ALL (acute lymphoid leukemia) in remission (CMS/HCC),
CINJ OP INFUSION,22652,"Omene, Coral Oghenerukevwe, MD",7/9/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/8/2024,Inactive,,
SOM OUTPT INFUSION,51531,"Toomey, Kathleen C, MD",4/3/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,First Line,3/31/2023,Inactive,,
NBR 4N BMTU/IMCU,51531,"Assal, Amer, MD",6/10/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/10/2023,Inactive,,
MSC OP INFUSION,39274,"Cohen, Seth D, MD",1/2/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/28/2023,Inactive,,
NBR CINJ OP INFUSION,59378,"Shah, Mansi R, MD",12/10/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,12/9/2024,Inactive,,
NBR CINJ OP INFUSION,59378,"Shah, Mansi R, MD",12/19/2024,CINJ 012310 Induction Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,Induction,12/19/2024,Active,,
NBR CINJ OP INFUSION,69096,"Shah, Mansi R, MD",4/15/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_1. First Line,4/15/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),C90.02 - Multiple myeloma in relapse
NBR 4N ONCOLOGY,20435,"Palmisiano, Neil David, MD",7/20/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,7/19/2023,Inactive,,
CINJ OP INFUSION,77716,"Hochster, Howard S, MD",8/8/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/6/2024,Active,,
JCMC CP INFUSION,26174,"Sekhri, Arunabh, MD",3/25/2024,Topotecan 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,3/17/2024,Inactive,,
JCMC CP INFUSION,26174,"Sekhri, Arunabh, MD",5/31/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,3/17/2024,Inactive,,
JCMC CP INFUSION,26174,"Sekhri, Arunabh, MD",10/18/2024,Bevacizumab / Pembrolizumab 21 Day Cycles -ovarian,_5. Fifth Line,9/26/2024,Active,,
JCMC CP INFUSION,36331,"Sekhri, Arunabh, MD",3/31/2025,Topotecan / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_6. Sixth Line,3/28/2025,Active,"Metastatic malignant neoplasm to ovary (CMS/HCC)
Malignant neoplasm of bilateral ovaries (CMS/HCC)","C56.9 - Malignant neoplasm of unspecified ovary; R14.0 - Abdominal distension (gaseous); F41.9 - Anxiety disorder, unspecified; D64.89 - Other specified anemias; N18.4 - Chronic kidney disease, stage 4 (severe); F32.A - Depression, unspecified; Z15.01 - Genetic susceptibility to malignant neoplasm of breast; Z15.09 - Genetic susceptibility to other malignant neoplasm"
CINJ OP INFUSION,69229,"George, Mridula A, MD",5/28/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,5/28/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,21166,"Lee, Patrick C, MD",1/23/2024,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,12/17/2023,Inactive,,
CINJ OP INFUSION,72082,"Stephenson, Ryan D, DO",5/6/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,5/6/2024,Active,,
TRMC TCCC OP INFUSION,36177,"Capo, Gerardo, MD",11/18/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/4/2024,Active,,
CINJ OP INFUSION,69678,"Ghodoussipour, Saum Bobak, MD",10/27/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,10/27/2023,Inactive,,
CINJ OP INFUSION,69678,"Ghodoussipour, Saum Bobak, MD",2/16/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,2/16/2024,Active,,
HAM OP INFUSION,9953,"Yogarajah, Meera, MD",8/15/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/14/2024,Active,,
JCMC CP INFUSION,66329,"Cruz, Allan Louie E, MD",7/12/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,First Line,7/11/2023,Inactive,,
NBR CINJ OP INFUSION,38696,"Evens, Andrew M, DO",1/4/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,,1/3/2023,Inactive,,
NBR CINJ OP INFUSION,38696,"Evens, Andrew M, DO",1/11/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,,1/10/2023,Inactive,,
NBR CINJ OP INFUSION,38696,"Evens, Andrew M, DO",7/26/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,7/25/2023,Active,"Squamous cell lung cancer (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Chronic fatigue
Thyroid disorder screen",
CBMC OP INFUSION 2FL,29732,"Gallinson, David Herschel, DO",4/2/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,4/2/2025,Inactive,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) of stomach (CMS/HCC),
CBMC OP INFUSION 2FL,29732,"Gallinson, David Herschel, DO",4/1/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,4/1/2025,Inactive,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) of stomach (CMS/HCC),"C88.40 - Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue (malt-lymphoma) not having achieved remission; M54.16 - Radiculopathy, lumbar region"
CBMC OP INFUSION 2FL,66968,"Wagmiller, Jennifer Ann, MD",5/3/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,5/2/2024,Inactive,,
CBMC OP INFUSION 2FL,66968,"Wagmiller, Jennifer Ann, MD",8/21/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,8/20/2024,Inactive,,
CBMC 2W ONCOLOGY,66968,"Wagmiller, Jennifer Ann, MD",11/27/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,11/27/2024,Inactive,,
MMC OP VP INFUSION,36078,"Cohen, Seth D, MD",6/14/2024,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_1. First Line,6/14/2024,Active,,
NBR CINJ OP INFUSION,62534,"Shah, Mansi R, MD",6/13/2024,Daratumumab/Pomalidomide/Dexamethasone  - Multiple Myeloma,_2. Second Line,6/12/2024,Active,,
NBI OP INFUSION,44850,"Anderson, Patrick S, MD",9/19/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer/ Mullarian Origin,_1. First Line,9/11/2024,Active,,
CMC OP INFUSION,79593,"Taff, Jessica, MD",7/11/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,6/24/2024,Active,,
NBI OP INFUSION,32177,"Anderson, Patrick S, MD",4/25/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/24/2024,Active,,
CBMC 2W ONCOLOGY,64395,"Grossman, I Robert, MD",11/3/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/2/2023,Inactive,,
HAM OP INFUSION,514,"Patel, Malini M, MD",2/13/2023,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,Induction,2/12/2023,Inactive,,
HAM OP INFUSION,514,"Patel, Malini M, MD",3/16/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,3/15/2023,Inactive,,
HAM OP INFUSION,514,"Patel, Malini M, MD",10/5/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Second Line,10/4/2023,Inactive,,
MMC OP VP INFUSION,32712,"Lee, Patrick C, MD",4/23/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/23/2025,Active,Rectal cancer (CMS/HCC),
MMC OP VP INFUSION,56968,"Lee, Patrick C, MD",1/9/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,1/8/2024,Active,,
NBR CINJ OP INFUSION,6490,"Matasar, Matthew J, MD",12/20/2023,Brentuximab Vedotin / Nivolumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,12/19/2023,Inactive,,
NBR CINJ OP INFUSION,6490,"Egini, Ogechukwu, MD",4/16/2024,BMT Autologous BEAM,Consolidation,4/16/2024,Inactive,,
CINJ OP INFUSION,62891,"Toppmeyer, Deborah L, MD",8/19/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,8/19/2024,Active,,
NBI OP INFUSION,966,"Shah, Maya M, MD",7/11/2024,SUNItinib 28 Day Cycles - Sarcoma,_2. Second Line,7/11/2024,Active,Malignant neoplasm of endometrium (CMS/HCC),
CBMC 2W ONCOLOGY,48313,"Grossman, I Robert, MD",2/14/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,2/13/2024,Inactive,,
CBMC 2W ONCOLOGY,48313,"Grossman, I Robert, MD",2/20/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,2/19/2024,Inactive,,
CBMC 2W ONCOLOGY,48313,"Grossman, I Robert, MD",10/2/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_2. Second Line,10/2/2024,Inactive,,
CBMC 2W ONCOLOGY,48313,"Grossman, I Robert, MD",10/15/2024,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_3. Third Line,10/14/2024,Inactive,,
CINJ OP INFUSION,52398,"Gulhati, Prateek, MD PhD",9/26/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,8/28/2024,Active,,
CINJ OP INFUSION,32132,"Gulhati, Prateek, MD PhD",4/24/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/24/2025,Inactive,Malignant neoplasm of body of pancreas (CMS/HCC),C25.1 - Malignant neoplasm of body of pancreas
CINJ OP INFUSION,76394,"Toppmeyer, Deborah L, MD",4/1/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,3/11/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,69845,"Boland, Patrick M, MD",6/18/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/6/2024,Active,,
TRMC TCCC OP INFUSION,37512,"Salerno, Vincent E, MD",1/8/2025,Fluorouracil Continuous Infusion over 7 days,_3. Third Line,1/7/2025,Inactive,"Malignant neoplasm of female breast, unspecified estrogen receptor status, unspecified laterality, unspecified site of breast (CMS/HCC)
H/O known metastasis to liver",
CINJ OP INFUSION,28011,"Toppmeyer, Deborah L, MD",8/26/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Neoadjuvant,8/18/2024,Inactive,,
CINJ OP INFUSION,20949,"Toppmeyer, Deborah L, MD",1/10/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,1/5/2025,Active,Acute leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,22320,"Schaar, Dale, MD PhD",9/9/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/8/2024,Inactive,,
CINJ OP INFUSION,77112,"Weiss, Sarah, MD",2/22/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/21/2023,Inactive,,
CINJ OP INFUSION,58893,"Stephenson, Ryan D, DO",3/18/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,3/18/2024,Active,,
NBI OP INFUSION,86253,"Schleicher, Lori, MD",9/5/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/13/2023,Inactive,,
CMC OP INFUSION,57196,"Tang, Horace, MD",6/8/2023,CISplatin 7 Day Cycles - Vulvar Cancer,First Line,6/6/2023,Inactive,,
CMC OP INFUSION,57196,"Tang, Horace, MD",9/21/2023,PACLitaxel / CARBOplatin + Bevacizumab - Vulvar Cancer,,9/21/2023,Active,,
NBI OP INFUSION,17327,"Shah, Shailja S, MD",8/9/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Squamous Cell Carcinoma,_1. First Line,8/8/2024,Inactive,,
CMC OP INFUSION,18106,"Cohen, Seth D, MD",2/5/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/28/2025,Active,"Lung cancer, middle lobe (CMS/HCC)
Hypothyroidism (acquired)
End stage renal disease (CMS/HCC)",
CBMC OP INFUSION 2FL,69365,"Wagmiller, Jennifer Ann, MD",6/8/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,6/7/2023,Inactive,,
NBR CINJ OP INFUSION,47322,"Patel, Vimal D, MD",6/14/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,6/12/2023,Inactive,,
TRMC TCCC OP INFUSION,57705,"Salerno, Vincent E, MD",6/6/2024,Nivolumab 480 mg D1 28 Day Cycles- Head and Neck Cancers,_2. Second Line,6/5/2024,Active,,
NBR CINJ OP INFUSION,52492,"Shah, Mansi R, MD",4/15/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,Induction,4/15/2025,Active,"Renal amyloidosis (CMS/HCC)  (CMS/HCC)
Multiple myeloma (CMS/HCC)","C90.00 - Multiple myeloma not having achieved remission; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; D63.1 - Anemia in chronic kidney disease; N18.6 - End stage renal disease; I95.1 - Orthostatic hypotension; E85.81 - Light chain (AL) amyloidosis; E85.4 - Organ-limited amyloidosis; E78.5 - Hyperlipidemia, unspecified; Z94.84 - Stem cells transplant status; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D64.9 - Anemia, unspecified; N18.9 - Chronic kidney disease, unspecified; D18.03 - Hemangioma of intra-abdominal structures; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I50.32 - Chronic diastolic (congestive) heart failure; I10 - Essential (primary) hypertension; E55.9 - Vitamin D deficiency, unspecified; E66.9 - Obesity, unspecified; E08.22 - Diabetes mellitus due to underlying condition with diabetic chronic kidney disease; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; E78.2 - Mixed hyperlipidemia; N28.1 - Cyst of kidney, acquired; R18.8 - Other ascites; N08 - Glomerular disorders in diseases classified elsewhere; Z99.2 - Dependence on renal dialysis; Z86.69 - Personal history of other diseases of the nervous system and sense organs; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
CMC OP INFUSION,57234,"Easaw, Sarah, MD",3/20/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Third Line,3/19/2023,Inactive,,
CBMC OP INFUSION 2FL,12170,"Brown, Andrew Bennett, MD",5/22/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/22/2025,Active,"Malignant neoplasm of central portion of left female breast (CMS/HCC)
Metastases to the liver (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast
NBI D7 MED-SURG/TELE,95087,"Anderson, Patrick S, MD",8/24/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,8/23/2024,Active,,
NBI OP INFUSION,95087,"Anderson, Patrick S, MD",5/14/2025,Dostarlimab-gxlyD1 & 22 x 4 then maint Q42 Day Cycles- Gynecologic Cancers,_3. Third Line,5/14/2025,Active,Malignant neoplasm of endometrium metastatic to lung (CMS/HCC),
SOM OUTPT INFUSION,38371,"Yin, Faye, MD",4/24/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,4/23/2023,Inactive,,
CINJ OP INFUSION,59520,"Dasgeb, Bahar, MD",10/11/2023,RiTUXimab 168 Day Cycles - Pemphigus,,10/9/2023,Active,Malignant neoplasm of female breast (CMS/HCC),
CMC OP INFUSION,6062,"Tang, Horace, MD",8/24/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,8/24/2023,Active,"Prostate cancer (CMS/HCC)
Malignant neoplasm metastatic to bone (CMS/HCC)",
SOM OUTPT INFUSION,11422,"Patel, Eshan, MD",12/10/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/24/2024,Active,,
SOM OUTPT INFUSION,34760,"Patel, Eshan, MD",4/9/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,4/9/2025,Inactive,"Small cell lung cancer, left (CMS/HCC)",
SOM OUTPT INFUSION,34760,"Patel, Eshan, MD",3/17/2025,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,Maintenance,3/17/2025,Inactive,"Small cell lung cancer, left (CMS/HCC)",C34.92 - Malignant neoplasm of unspecified part of left bronchus or lung
CINJ OP INFUSION,34674,"Salacz, Michael E, MD",3/6/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,First Line,3/6/2023,Active,Cancer of lower third of esophagus (CMS/HCC),
MMC OP VP INFUSION,32501,"Cohen, Seth D, MD",5/3/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,5/2/2024,Active,Malignant melanoma of other part of trunk (CMS/HCC),
CINJ OP INFUSION,22343,"Saraiya, Biren P, MD",9/6/2024,Relugolix 30 day Cycles - Prostate,_1. First Line,9/6/2024,Inactive,,
CINJ OP INFUSION,8993,"Saraiya, Biren P, MD",3/18/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,3/18/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate; Z31.62 - Encounter for fertility preservation counseling
CBMC OP INFUSION 2FL,62162,"Litvak, Anna M, MD",11/20/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,11/19/2023,Inactive,,
NBR 4N ONCOLOGY,35544,"Assal, Amer, MD",8/21/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,8/20/2023,Inactive,,
NBR 4N ONCOLOGY,35544,"Palmisiano, Neil David, MD",10/6/2023,Cytarabine Cytoreduction for Hyperleukocytosis,Reinduction,10/6/2023,Inactive,,
NBR CINJ OP INFUSION,35544,"Assal, Amer, MD",10/19/2023,CINJ 022303 Phase 1 DSP-5336 - Leukemia,_6. Sixth Line,10/19/2023,Inactive,,
CINJ OP INFUSION,55421,"Golombos, David, MD",9/24/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/23/2024,Active,,
CINJ OP INFUSION,55421,"Golombos, David, MD",2/4/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,2/2/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),C67.8 - Malignant neoplasm of overlapping sites of bladder
NBR CINJ OP INFUSION,95819,"Braunschweig, Ira, MD",3/6/2023,Alemtuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,,3/5/2023,Inactive,,
NBR 5N ONCOLOGY,95819,"Sridharan, Ashwin, MD",3/7/2023,HyperCVAD (Cycle A) Course (Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,,3/7/2023,Inactive,,
NBR 4N ONCOLOGY,95819,"Braunschweig, Ira, MD",3/20/2023,Alemtuzumab + Pentostatin - T-Cell Prolymphocytic Leukemia (T-PLL),,3/19/2023,Inactive,,
NBR CINJ OP INFUSION,95819,"Braunschweig, Ira, MD",5/10/2023,FMC (Fludarabine / Mitoxantrone / Cyclophosphamide)  28 Day Cycles - T-cell Prolymphocytic Leukemia,,5/8/2023,Inactive,,
CINJ PEDS HEMONC ,40757,"Moerdler, Scott, MD",7/11/2023,PEDS AEWS1031 Regimen A Induction & Consolidation,First Line,7/11/2023,Inactive,,
CINJ PEDS HEMONC ,40757,"Moerdler, Scott, MD",7/12/2023,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,First Line,7/11/2023,Inactive,,
CINJ PEDS HEMONC ,40757,"Moerdler, Scott, MD",7/17/2024,PEDS Relapsed Sarcoma VinCRIStine / Irinotecan /Temozolomide,_2. Second Line,7/16/2024,Inactive,,
CINJ PEDS HEMONC ,40757,"Moerdler, Scott, MD",7/18/2024,Vincristine/ Irinotecan / Temozolomide 21 Day Cycles - Relapsed Sarcoma per article Cancer Res Treat 2022,_2. Second Line,7/18/2024,Inactive,,
CINJ PEDS HEMONC ,40757,"Moerdler, Scott, MD",7/18/2024,PEDS VIT - Relapse Sarcoma ,_2. Second Line,7/17/2024,Active,,
MMC OP VP INFUSION,51298,"Talwar, Sumit, MD",3/4/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/4/2025,Active,"Malignant neoplasm of corpus uteri, unspecified (CMS/HCC)
Drug-induced thyroiditis",
CMC OP INFUSION,8949,"Cohen, Seth D, MD",7/11/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_7. Seventh Line,7/7/2024,Inactive,,
CMC OP INFUSION,8949,"Cohen, Seth D, MD",8/1/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_4. Fourth Line,7/31/2024,Inactive,,
MMC OP VP INFUSION,31281,"Cohen, Seth D, MD",12/13/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,12/13/2023,Inactive,,
MMC OP VP INFUSION,31281,"Cohen, Seth D, MD",2/12/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/5/2024,Inactive,,
MMC OP VP INFUSION,69576,"Cohen, Seth D, MD",3/12/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/12/2025,Inactive,Malignant neoplasm of rectum (CMS/HCC),
MMC OP VP INFUSION,69576,"Cohen, Seth D, MD",3/12/2025,CINJ 072201 Control ARM FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,3/12/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
CBMC OP INFUSION 2FL,38170,"Radovich, Delia, MD",11/9/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/8/2023,Inactive,,
MSC OP INFUSION,18105,"Taff, Jessica, MD",9/3/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/13/2024,Active,,
CINJ OP INFUSION,27467,"Saraiya, Biren P, MD",5/6/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/6/2025,Active,Urothelial cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; C67.9 - Malignant neoplasm of bladder, unspecified; G47.9 - Sleep disorder, unspecified; C67.8 - Malignant neoplasm of overlapping sites of bladder; C68.9 - Malignant neoplasm of urinary organ, unspecified; Z90.79 - Acquired absence of other genital organ(s)"
CBMC OP INFUSION 2FL,11500,"Kulkarni, Aditya A, MD",1/13/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/29/2024,Active,,
CINJ OP INFUSION,32457,"George, Mridula A, MD",1/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,12/20/2023,Active,,
CINJ OP INFUSION,96296,"Toppmeyer, Deborah L, MD",7/20/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,7/19/2023,Inactive,,
CINJ OP INFUSION,96296,"Toppmeyer, Deborah L, MD",7/31/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,7/30/2024,Active,,
CBMC OP INFUSION 2FL,93373,"Brown, Andrew Bennett, MD",11/13/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/12/2023,Active,,
CINJ OP INFUSION,18037,"Boland, Patrick M, MD",11/9/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_2. Second Line,11/8/2023,Active,,
CBMC OP INFUSION 1FL,71452,"Meelheim, Brooke A, DO",1/9/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,1/5/2025,Active,,
CBMC OP INFUSION 1FL,71452,"Meelheim, Brooke A, DO",5/8/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,5/8/2025,Inactive,Malignant neoplasm of endometrium (CMS/HCC),
CINJ OP INFUSION,37703,"Berim, Lyudmyla, MD",6/12/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,,5/15/2023,Inactive,,
CINJ OP INFUSION,37703,"Berim, Lyudmyla, MD",8/18/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,,8/3/2023,Active,,
NBR 4N BMTU/IMCU,82205,"Braunschweig, Ira, MD",10/25/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,10/23/2023,Inactive,,
NBR CINJ OP INFUSION,82205,"Shah, Mansi R, MD",3/7/2024,Elotuzumab/Bortezomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,3/7/2024,Active,,
NBR CINJ OP INFUSION,82205,"Shah, Mansi R, MD",1/23/2025,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,1/15/2025,Active,,
NBR CINJ OP INFUSION,82205,"Shah, Mansi R, MD",2/19/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,2/6/2025,Active,Multiple myeloma without remission (CMS/HCC),
CBMC OP INFUSION 2FL,42583,"Wagmiller, Jennifer Ann, MD",5/8/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Neoadjuvant,5/2/2024,Active,,
MMC OP VP INFUSION,69945,"Lee, Patrick C, MD",2/13/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/30/2025,Active,Adenocarcinoma of small bowel (CMS/HCC),
TRMC TCCC OP INFUSION,97864,"Salerno, Vincent E, MD",5/2/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,5/1/2024,Active,,
TRMC TCCC OP INFUSION,97864,"Salerno, Vincent E, MD",7/25/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,7/24/2024,Active,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),
JCMC CP INFUSION,35561,"Cruz, Allan Louie E, MD",5/1/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/30/2024,Inactive,,
SOM OUTPT INFUSION,3932,"Yin, Faye, MD",7/8/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,7/7/2024,Inactive,,
SOM OUTPT INFUSION,3932,"Toomey, Kathleen C, MD",7/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/7/2024,Inactive,,
SOM OUTPT INFUSION,3932,"Toomey, Kathleen C, MD",11/29/2024,Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,11/27/2024,Active,Malignant neoplasm of other parts of pancreas (CMS/HCC),
CINJ OP INFUSION,49296,"Toppmeyer, Deborah L, MD",11/1/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/31/2024,Active,,
CINJ OP INFUSION,91483,"Stephenson, Ruth D, DO",1/9/2023,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,First Line,12/13/2022,Inactive,,
CMC OP INFUSION,56416,"Cohen, Seth D, MD",11/27/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/27/2023,Inactive,,
HAM OP INFUSION,64376,"Patel, Malini M, MD",11/9/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/8/2023,Inactive,,
HAM OP INFUSION,64376,"Yogarajah, Meera, MD",2/1/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,1/31/2024,Inactive,,
CINJ OP INFUSION,71877,"Gulhati, Prateek, MD PhD",3/30/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,3/29/2023,Inactive,,
CINJ OP INFUSION,68576,"Gulhati, Prateek, MD PhD",5/9/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/30/2024,Active,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",1/4/2023,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,1/3/2023,Inactive,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",5/10/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Second Line,5/9/2023,Inactive,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",9/13/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,,9/13/2023,Inactive,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",12/1/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,11/28/2023,Inactive,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",8/28/2024,Temsirolimus 28 Day Cycles - Uterine,_4. Fourth Line,8/27/2024,Inactive,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",12/18/2024,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,_4. Fourth Line,12/10/2024,Active,,
MMC OP VP INFUSION,88127,"Cohen, Seth D, MD",5/28/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_8. Eighth Line,5/28/2025,Active,"Malignant neoplasm of overlapping sites of cervix (CMS/HCC)
Malignant neoplasm of uterine adnexa, unspecified (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,68110,"Weiss, Sarah, MD",7/10/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,7/9/2023,Inactive,,
CINJ OP INFUSION,68110,"Weiss, Sarah, MD",7/19/2023,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,7/18/2023,Inactive,,
CINJ OP INFUSION,68110,"Weiss, Sarah, MD",9/27/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,9/26/2023,Active,,
CINJ OP INFUSION,55698,"Leiser, Aliza, MD",10/11/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/25/2023,Inactive,,
MMC OP INFUSION,68534,"Meghal, Trishala, MD",3/3/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/2/2023,Inactive,,
NBR CINJ OP INFUSION,93795,"Evens, Andrew M, DO",7/31/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/30/2024,Active,,
NBR CINJ OP INFUSION,46201,"Patel, Eshan, MD",7/28/2023,CINJ 032006 (BTCRC-LUN18-153) ARM A Pembrolizumab 42 Day Cycles Research- Non-Small Cell Lung Cancer,,6/29/2023,Inactive,,
CINJ OP INFUSION,75557,"Stephenson, Ryan D, DO",6/12/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Penile Cancer,Second Line,6/11/2023,Inactive,,
CINJ OP INFUSION,75557,"Stephenson, Ryan D, DO",5/1/2024,PACLitaxel weekly 28 Day Cycles - Penile,_3. Third Line,4/30/2024,Inactive,,
CINJ OP INFUSION,75557,"Stephenson, Ryan D, DO",8/1/2024,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Penile Cancer,_3. Third Line,7/30/2024,Active,,
CBMC OP INFUSION 2FL,24189,"Grossman, I Robert, MD",7/3/2023,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,7/2/2023,Inactive,,
CBMC OP INFUSION 2FL,24189,"Grossman, I Robert, MD",11/20/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/19/2023,Inactive,,
NBR CINJ OP INFUSION,24189,"Shah, Mansi R, MD",1/21/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,1/6/2024,Inactive,,
NBR 4N BMTU/IMCU,24189,"Assal, Amer, MD",2/8/2024,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,2/6/2024,Inactive,,
CBMC OP INFUSION 2FL,24189,"Grossman, I Robert, MD",11/22/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,11/12/2024,Active,,
MMC OP VP INFUSION,16358,"Cohen, Seth D, MD",11/21/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,11/20/2024,Active,,
MMC BBR2 ONCOLOGY,43095,"Eltoukhy, Hussam, MD",11/5/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_4. Fourth Line,11/5/2024,Inactive,,
CBMC OP INFUSION 2FL,15051,"Radovich, Delia, MD",11/14/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,11/13/2023,Inactive,,
MMC OP INFUSION,72821,"Eltoukhy, Hussam, MD",6/27/2024,CINJ 012203 Lead-In Treatment for Fit and Non-Fit Treatments Cycle 42 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,6/26/2024,Inactive,,
NBI VALERIE FND HEMONC,81792,"Rao, Harini, MD",10/5/2023,Avastin/Everolimus every 21 days,_4. Fourth Line,10/4/2023,Inactive,,
NBI VALERIE FND HEMONC,81792,"Rao, Harini, MD",12/4/2023,PEDS ACNS1123 Stratum 2,_4. Fourth Line,11/22/2023,Inactive,,
NBI OP INFUSION,8679,"Shah, Shailja S, MD",5/30/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,5/30/2025,Inactive,"Bilateral malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)","C50.011, Z17.0 - Malignant neoplasm of nipple of right breast in female, estrogen receptor positive (CMS/HCC)"
NBI OP INFUSION,8679,"Shah, Shailja S, MD",5/30/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,5/30/2025,Active,"Bilateral malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)","C50.011 - Malignant neoplasm of nipple and areola, right female breast; C50.912 - Malignant neoplasm of unspecified site of left female breast; Z17.0 - Estrogen receptor positive status (ER+)"
NBR 5N ONCOLOGY,86542,"Sridharan, Ashwin, MD",3/11/2023,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),,3/11/2023,Inactive,,
SOM OUTPT INFUSION,97959,"Toomey, Kathleen C, MD",5/22/2024,Trastuzumab maintenance Q21 Day Cycles (start 9/25/24)  - Breast,_1. First Line,5/21/2024,Inactive,,
SOM OUTPT INFUSION,97959,"Toomey, Kathleen C, MD",10/16/2024,Hylecta Trastuzumab 21 Day Cycles - Breast,_1. First Line,10/9/2024,Active,,
SOM OUTPT INFUSION,41841,"Patel, Eshan, MD",10/23/2023,DOCEtaxel 21 Day Cycles - Prostate,Neoadjuvant,10/20/2023,Inactive,,
CBMC OP INFUSION 2FL,24590,"Wagmiller, Jennifer Ann, MD",1/15/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/12/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CBMC 2W ONCOLOGY,24590,"Wagmiller, Jennifer Ann, MD",5/6/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/6/2025,Active,"Malignant (primary) neoplasm, unspecified (CMS/HCC)
Malignant neoplasm of bilateral ovaries (CMS/HCC)
Encounter for screening for other viral diseases
Abdominal discomfort","K52.1 - Toxic gastroenteritis and colitis; E43 - Unspecified severe protein-calorie malnutrition; E87.3 - Alkalosis; D84.9 - Immunodeficiency, unspecified; C56.3 - Malignant neoplasm of bilateral ovaries; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D64.9 - Anemia, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; Z68.1 - Body mass index (BMI) 19.9 or less, adult; R11.2 - Nausea with vomiting, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; F17.210 - Nicotine dependence, cigarettes, uncomplicated; G89.3 - Neoplasm related pain (acute) (chronic); E87.6 - Hypokalemia; Z86.16 - Personal history of COVID-19; Z90.710 - Acquired absence of both cervix and uterus; Z98.890 - Other specified postprocedural states; Z91.048 - Other nonmedicinal substance allergy status; Z79.899 - Other long term (current) drug therapy; Z80.9 - Family history of malignant neoplasm, unspecified"
CINJ OP INFUSION,53945,"Stephenson, Ryan D, DO",11/20/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,11/20/2023,Inactive,,
CINJ OP INFUSION,53945,"Stephenson, Ryan D, DO",4/19/2024,DOCEtaxel 21 Day Cycles - Prostate,_3. Third Line,4/9/2024,Active,,
CINJ OP INFUSION,53945,"Stephenson, Ryan D, DO",2/26/2025,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_4. Fourth Line,1/26/2025,Active,Metastatic castration-resistant adenocarcinoma of prostate (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C61 - Malignant neoplasm of prostate; Z19.2 - Hormone resistant malignancy status; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; G89.3 - Neoplasm related pain (acute) (chronic); R39.89 - Other symptoms and signs involving the genitourinary system; L60.8 - Other nail disorders; E83.51 - Hypocalcemia; R63.4 - Abnormal weight loss; R63.0 - Anorexia; R53.1 - Weakness; E83.39 - Other disorders of phosphorus metabolism
CBMC OP INFUSION 2FL,52234,"Scoppetuolo, Michael, MD",5/5/2025,CINJ 032102 Arm B Osimertinib / Bevacizumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,5/5/2025,Active,Adenocarcinoma of left lung (CMS/HCC),"C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; C34.92 - Malignant neoplasm of unspecified part of left bronchus or lung; R94.31 - Abnormal electrocardiogram (ECG) (EKG)"
NBR 5N ONCOLOGY,12067,"Patel, Vimal D, MD",8/29/2023,RiTUXimab 28 Day Cycle - Acquired Hemophilia,,8/28/2023,Inactive,,
CINJ OP INFUSION,18897,"Groisberg, Roman, MD",5/3/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,,5/2/2023,Inactive,,
CINJ OP INFUSION,18897,"Groisberg, Roman, MD",12/24/2024,Gemcitabine 21 Day Cycles - Sarcoma,_2. Second Line,12/19/2024,Active,,
CINJ OP INFUSION,90315,"Boland, Patrick M, MD",12/28/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/25/2023,Inactive,,
CINJ OP INFUSION,90315,"Boland, Patrick M, MD",1/23/2024,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/22/2024,Inactive,,
CINJ OP INFUSION,90315,"Boland, Patrick M, MD",6/25/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,6/25/2024,Active,,
SOM OUTPT INFUSION,80116,"George, Roshini, DO",5/8/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,5/8/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",C50.111 - Malignant neoplasm of central portion of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBR 5N ONCOLOGY,11620,"Ghodoussipour, Saum Bobak, MD",4/27/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/27/2024,Inactive,,
CINJ OP INFUSION,5994,"Hochster, Howard S, MD",2/13/2025,Gemcitabine/CISplatin 21 Day Cycles- Hepatobiliary Cancers- Gemcitabine-CISplatin Sequencing,_1. First Line,2/12/2025,Active,Cholangiocarcinoma (CMS/HCC),C22.1 - Intrahepatic bile duct carcinoma
CINJ OP INFUSION,89297,"Stephenson, Ryan D, DO",5/2/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Adjuvant,5/1/2023,Inactive,,
CINJ OP INFUSION,89297,"Stephenson, Ryan D, DO",8/2/2024,Pembrolizumab 21 Day Cycles - Bladder,_2. Second Line,8/2/2024,Inactive,,
NBR 5N ONCOLOGY,26438,"Zayac, Adam, MD",12/15/2023,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Rituximab / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,Induction,12/15/2023,Inactive,,
NBR 5N ONCOLOGY,26438,"Rhodes, Joanna Meehan, MD",12/18/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,12/18/2023,Inactive,,
NBR CINJ OP INFUSION,26438,"Zayac, Adam, MD",4/5/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,4/4/2024,Inactive,,
NBR CINJ OP INFUSION,26438,"Zayac, Adam, MD",5/8/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,_1. First Line,5/8/2024,Inactive,,
NBR CINJ OP INFUSION,26438,"Zayac, Adam, MD",9/3/2024,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,_1. First Line,9/3/2024,Active,,
NBR CINJ OP INFUSION,26438,"Zayac, Adam, MD",11/6/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,11/6/2024,Active,,
NBR 5N ONCOLOGY,23907,"Haigentz, Missak, MD",12/5/2023,CISplatin/DOCEtaxel 21 Day Cycles- Head and Neck Cancers,Neoadjuvant,12/5/2023,Inactive,,
CINJ OP INFUSION,23907,"Haigentz, Missak, MD",3/11/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,3/11/2024,Inactive,,
JCMC CP INFUSION,53602,"Cruz, Allan Louie E, MD",5/20/2024,weekly PACLitaxel x 12 weeks - Hormone Receptor (+) breast cancer,Neoadjuvant,5/15/2024,Inactive,,
NBR CINJ OP INFUSION,57578,"Rhodes, Joanna Meehan, MD",11/13/2023,Sutimlimab q2w,Maintenance,11/13/2023,Inactive,,
NBR 4N ONCOLOGY,94791,"Braunschweig, Ira, MD",1/5/2023,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,,1/4/2023,Inactive,,
NBR 4N BMTU/IMCU,94791,"Schaar, Dale, MD PhD",10/12/2023,BMT Allogeneic rATG / Flu / Cy / TBI + Post Cy ,_3. Third Line,10/10/2023,Inactive,,
NBR 4N BMTU/IMCU,94791,"Braunschweig, Ira, MD",12/16/2023,Pentostatin GVHD Days 1-3 every 2 weeks (Bone Marrow Transplant. 2018 Mar; 53(3): 315–325.),_4. Fourth Line,12/16/2023,Inactive,,
NBR 4N BMTU/IMCU,94791,"Braunschweig, Ira, MD",1/5/2024,Basiliximab Days 1 and 3 - Graft Versus Host Disease,Adjuvant,1/5/2024,Inactive,,
CBMC OP INFUSION 2FL,7933,"Litvak, Anna M, MD",11/3/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_6. Sixth Line,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,7757,"Wagmiller, Jennifer Ann, MD",11/10/2023,Simplified BiWeekly Infusional Fluorouracil/Leucovorin 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/10/2023,Inactive,,
JCMC CP INFUSION,41662,"Sekhri, Arunabh, MD",7/8/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,6/30/2024,Active,,
CMC OP INFUSION,89238,"Taff, Jessica, MD",9/13/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,9/12/2023,Active,,
HAM OP INFUSION,54825,"Yogarajah, Meera, MD",6/3/2024,CISplatin With Concurrent Radiation 7 Day Cycles - vulvar,_1. First Line,5/27/2024,Active,,
NBI OP INFUSION,33842,"Jacoby, Sari H, MD",10/8/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/7/2024,Inactive,,
NBI OP INFUSION,59612,"Jacoby, Sari H, MD",1/27/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,1/26/2025,Active,,
CBMC OP INFUSION 2FL,88992,"Wagmiller, Jennifer Ann, MD",8/22/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/14/2023,Inactive,,
CBMC OP INFUSION 2FL,88992,"Wagmiller, Jennifer Ann, MD",1/2/2024,PEMEtrexed+ Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer (took out carbo),Maintenance,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,88992,"Wagmiller, Jennifer Ann, MD",9/10/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - BREAST CANCER,_1. First Line,9/9/2024,Active,,
CBMC OP INFUSION 2FL,88900,"Dharmapuri, Sirish, MD",1/22/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",_1. First Line,1/16/2025,Active,,
CINJ OP INFUSION,67758,"Hochster, Howard S, MD",11/13/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,10/16/2023,Inactive,,
CINJ OP INFUSION,67758,"Hochster, Howard S, MD",1/17/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,1/2/2024,Active,,
CINJ OP INFUSION,56265,"Groisberg, Roman, MD",7/5/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,First Line,7/4/2023,Inactive,,
CINJ OP INFUSION,56265,"Groisberg, Roman, MD",8/18/2023,DOXOrubicin 21 Day Cycles - Sarcoma,,8/10/2023,Inactive,,
CINJ OP INFUSION,47477,"Gulhati, Prateek, MD PhD",8/10/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,8/9/2023,Inactive,,
SOM OUTPT INFUSION,27788,"Patel, Eshan, MD",6/19/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,6/18/2023,Inactive,,
SOM OUTPT INFUSION,27788,"Patel, Eshan, MD",2/6/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/6/2024,Inactive,,
NBI OP INFUSION,16739,"Jacoby, Sari H, MD",1/2/2024,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,1/2/2024,Inactive,,
NBI OP INFUSION,16739,"Jacoby, Sari H, MD",5/19/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,5/19/2025,Active,"Breast cancer metastasized to liver, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,84369,"Radovich, Delia, MD",11/10/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_1. First Line,11/9/2023,Inactive,,
CMC OP INFUSION,28316,"Talwar, Sumit, MD",5/26/2025,Capecitabine 21 Day Cycles - Breast,_1. First Line,5/26/2025,Active,Breast cancer (CMS/HCC),
CINJ OP INFUSION,20891,"Dasgeb, Bahar, MD",12/19/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,12/18/2023,Active,,
HAM OP INFUSION,33988,"Yogarajah, Meera, MD",7/6/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,7/5/2023,Active,Diffuse large B cell lymphoma (CMS/HCC),
CMC OP INFUSION,43992,"Pompa, Tiffany Ann, MD",1/7/2025,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,1/3/2025,Active,,
CMC OP INFUSION,62036,"Taff, Jessica, MD",1/8/2024,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,1/7/2024,Inactive,,
CBMC OP INFUSION 2FL,2998,"Ligresti, Louise G, MD",8/29/2024,EriBULin 21 Day Cycles - Breast,_2. Second Line,8/7/2024,Inactive,,
CBMC OP INFUSION 2FL,2998,"Ligresti, Louise G, MD",11/21/2024,Sacituzumab Govitecan 21 Day Cycles - Breast,_3. Third Line,11/20/2024,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,21610,"Mayer, Tina M, MD",6/12/2023,Darolutamide 28 Day Cycles - Prostate,,6/12/2023,Active,,
TRMC TCCC OP INFUSION,2721,"Salerno, Vincent E, MD",10/21/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/6/2024,Active,,
NBI VALERIE FND HEMONC,82160,"Bhatla, Teena, MD",10/2/2023,"AALL1731 SR-Fav B-ALL, SR-Avg Arm A & B B-ALL, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,10/2/2023,Inactive,,
NBI VALERIE FND HEMONC,82160,"Bhatla, Teena, MD",12/4/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,_1. First Line,12/4/2023,Inactive,,
NBI VALERIE FND HEMONC,82160,"Bhatla, Teena, MD",2/16/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",Maintenance,2/15/2024,Active,,
NBI OP INFUSION,73071,"Anderson, Patrick S, MD",2/7/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,2/6/2025,Active,Endometrial adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,48770,"Brown, Andrew Bennett, MD",12/11/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/10/2023,Active,,
CINJ OP INFUSION,35725,"Boland, Patrick M, MD",6/4/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,6/3/2024,Inactive,,
CBMC OP INFUSION 2FL,40030,"Brown, Andrew Bennett, MD",11/10/2023,PACLitaxel/CARBOplatin + Bevacizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/9/2023,Active,,
MMC OP VP INFUSION,12444,"Cohen, Seth D, MD",2/5/2024,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,2/5/2024,Active,,
CBMC OP INFUSION 2FL,71015,"Scoppetuolo, Michael, MD",7/27/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/26/2023,Inactive,,
CBMC OP INFUSION 2FL,71015,"Scoppetuolo, Michael, MD",3/21/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/20/2024,Active,,
CINJ OP INFUSION,7596,"Omene, Coral Oghenerukevwe, MD",10/3/2023,Neratinib 28 Day Cycles - Breast,_3. Third Line,10/3/2023,Inactive,,
CINJ OP INFUSION,7596,"Omene, Coral Oghenerukevwe, MD",10/10/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_3. Third Line,10/9/2023,Inactive,,
CINJ OP INFUSION,7596,"Omene, Coral Oghenerukevwe, MD",2/15/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_4. Fourth Line,2/12/2024,Inactive,,
NBI OP INFUSION,43036,"Schleicher, Lori, MD",10/24/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/23/2024,Active,,
NBI OP INFUSION,43036,"Schleicher, Lori, MD",2/6/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/5/2025,Active,"Malignant neoplasm of ascending colon (CMS/HCC)
Encounter for screening for other viral diseases
Abnormal findings on diagnostic imaging of other abdominal regions, including retroperitoneum",
NBR 5N ONCOLOGY,21757,"Shah, Mansi R, MD",4/16/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,4/14/2023,Inactive,,
MMC OP INFUSION,8801,"Meghal, Trishala, MD",5/17/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Induction,5/16/2024,Inactive,,
TRMC TCCC OP INFUSION,24780,"Salerno, Vincent E, MD",8/28/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,8/27/2024,Active,,
NBR 5N ONCOLOGY,59221,"Goel, Sanjay, MD",7/28/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,7/23/2023,Inactive,,
CMC OP INFUSION,78488,"Easaw, Sarah, MD",6/1/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/18/2023,Inactive,,
CMC OP INFUSION,88794,"Talwar, Sumit, MD",7/23/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,7/23/2024,Inactive,,
CMC OP INFUSION,88794,"Talwar, Sumit, MD",11/1/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,10/31/2024,Active,,
MSC OP INFUSION,8230,"Pompa, Tiffany Ann, MD",8/30/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,8/29/2024,Inactive,,
MSC OP INFUSION,8230,"Pompa, Tiffany Ann, MD",10/3/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,10/2/2024,Active,Cancer of upper lobe of right lung (CMS/HCC),
CMC OP INFUSION,10476,"Pompa, Tiffany Ann, MD",5/17/2023,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,5/17/2023,Inactive,,
CMC OP INFUSION,10476,"Pompa, Tiffany Ann, MD",10/23/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,10/22/2024,Active,,
JCMC CP INFUSION,46920,"Cruz, Allan Louie E, MD",7/2/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,7/1/2024,Inactive,,
MMC OP VP INFUSION,5871,"Cohen, Seth D, MD",9/6/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,8/29/2023,Inactive,,
MMC OP VP INFUSION,5871,"Cohen, Seth D, MD",2/27/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/26/2024,Active,,
NBR CINJ OP INFUSION,38963,"Shah, Mansi R, MD",1/4/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Consolidation,1/4/2024,Active,,
NBR CINJ OP INFUSION,44416,"Tiger, Yun Kyoung, MD",12/4/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/3/2024,Active,Richter's syndrome (CMS/HCC),
CBMC OP INFUSION 2FL,78686,"Gallinson, David Herschel, DO",5/5/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,5/5/2025,Inactive,"AIHA (autoimmune hemolytic anemia) (CMS/HCC)
Splenic marginal zone b-cell lymphoma (CMS/HCC)","D59.10 - Autoimmune hemolytic anemia, unspecified; C83.07 - Small cell b-cell lymphoma, spleen"
CBMC OP INFUSION 2FL,78686,"Gallinson, David Herschel, DO",3/6/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,3/6/2025,Inactive,"AIHA (autoimmune hemolytic anemia) (CMS/HCC)
Splenic marginal zone b-cell lymphoma (CMS/HCC)","R16.1 - Splenomegaly, not elsewhere classified; D59.10 - Autoimmune hemolytic anemia, unspecified"
NBR 5N ONCOLOGY,40114,"Boland, Patrick M, MD",9/1/2024,Gemcitabine/CISplatin 21 Day Cycles- Hepatobiliary Cancers- Gemcitabine-CISplatin Sequencing,_1. First Line,8/31/2024,Active,,
NBR 5N ONCOLOGY,24832,"Matasar, Matthew J, MD",1/7/2023,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),Induction,1/7/2023,Inactive,,
NBR CINJ OP INFUSION,24832,"Palmisiano, Neil David, MD",2/13/2023,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,2/10/2023,Inactive,,
MMC BBR2 ONCOLOGY,11265,"Talwar, Sumit, MD",1/10/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,1/9/2024,Inactive,,
SOM OUTPT INFUSION,67223,"Toomey, Kathleen C, MD",10/18/2024,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",_1. First Line,10/18/2024,Inactive,,
CINJ OP INFUSION,77973,"Packiam, Vignesh, MD",7/25/2024,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Adjuvant,7/25/2024,Inactive,,
CINJ OP INFUSION,77973,"Packiam, Vignesh, MD",12/18/2024,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,12/18/2024,Active,,
CINJ OP INFUSION,40794,"Berim, Lyudmyla, MD",7/19/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_2. Second Line,6/19/2023,Inactive,,
CINJ OP INFUSION,40794,"Berim, Lyudmyla, MD",4/8/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/5/2024,Inactive,,
CINJ OP INFUSION,40794,"Berim, Lyudmyla, MD",1/16/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/15/2025,Active,,
CINJ OP INFUSION,40794,"Berim, Lyudmyla, MD",2/27/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,2/25/2025,Active,"Malignant neoplasm of tail of pancreas (CMS/HCC)
Malignant neoplasm of tail of pancreas (CMS/HCC)",
CINJ OP INFUSION,40794,"Goel, Sanjay, MD",5/15/2025,CINJ 052402 Phase 1 MBRC-101 Dose Escalation 21 Day Cycles Research- Solid Malignancies,_3. Third Line,5/15/2025,Active,"Malignant neoplasm of tail of pancreas (CMS/HCC)
Liver disease, unspecified",
CINJ OP INFUSION,40794,"Goel, Sanjay, MD",4/30/2025,CINJ 052402 Phase 1 MBRC-101 Dose Escalation 21 Day Cycles Research- Solid Malignancies,_5. Fifth Line,4/30/2025,Inactive,"Malignant neoplasm of tail of pancreas (CMS/HCC)
Liver disease, unspecified",
CINJ OP INFUSION,40794,"Berim, Lyudmyla, MD",4/9/2025,Selumetinib - NF1 Mutation Pancreatic Caner,_4. Fourth Line,4/9/2025,Inactive,Malignant neoplasm of tail of pancreas (CMS/HCC),
CBMC OP INFUSION 2FL,2858,"Litvak, Anna M, MD",12/6/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,_1. First Line,11/14/2024,Active,,
CBMC OP INFUSION 2FL,91817,"Wagmiller, Jennifer Ann, MD",10/24/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,10/23/2023,Inactive,,
NBI OP INFUSION,51663,"Cheng, Yan Ho, MD",8/8/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/7/2023,Inactive,,
NBI OP INFUSION,51663,"Cheng, Yan Ho, MD",11/14/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,11/14/2023,Inactive,,
NBI OP INFUSION,51663,"Cheng, Yan Ho, MD",4/30/2024,Capecitabine 1000 mg/m2 / Pembrolizumab Q21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/30/2024,Inactive,,
NBI OP INFUSION,34851,"Cheng, Yan Ho, MD",3/4/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/4/2025,Inactive,"Malignant neoplasm of rectum (CMS/HCC)
Triple negative breast cancer (CMS/HCC)",C20 - Malignant neoplasm of rectum; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast
CINJ OP INFUSION,91760,"Aikins, James K, MD",5/16/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles + Pembrolizumab - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/16/2025,Active,"Stage IV serous adenocarcinoma of uterus (CMS/HCC)
Malignant neoplasm of overlapping sites of female genital organs (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C55 - Malignant neoplasm of uterus, part unspecified; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; C54.1 - Malignant neoplasm of endometrium; C57.8 - Malignant neoplasm of overlapping sites of female genital organs; Z90.79 - Acquired absence of other genital organ(s)"
CINJ OP INFUSION,93926,"Aikins, James K, MD",6/24/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,6/13/2024,Active,,
CINJ PEDS HEMONC ,76626,"Masterson, Margaret, MD",4/25/2024,as per AALL1732 Induction,_1. First Line,4/25/2024,Inactive,,
NBR 5N ONCOLOGY,76626,"Masterson, Margaret, MD",4/25/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,4/25/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,76626,"Masterson, Margaret, MD",4/25/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,4/25/2024,Inactive,,
CINJ PEDS HEMONC ,76626,"Masterson, Margaret, MD",5/29/2024,AALL1732 Consolidation,Consolidation,5/29/2024,Inactive,,
NBI VALERIE FND HEMONC,76626,"Bhatla, Teena, MD",5/30/2024,AALL1732 Consolidation,_1. First Line,5/30/2024,Inactive,,
NBI A5 PEDIATRICS,76626,"Rao, Harini, MD",6/28/2024,AALL1732 HR B-ALL Arm C Inotuzumab ozogamicin Block 1,_2. Second Line,6/27/2024,Inactive,,
NBI VALERIE FND HEMONC,76626,"Bhatla, Teena, MD",8/29/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,8/28/2024,Active,,
NBI VALERIE FND HEMONC,76626,"Bhatla, Teena, MD",12/12/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,12/11/2024,Active,,
NBI VALERIE FND HEMONC,76626,"Bhatla, Teena, MD",2/4/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,1/14/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI VALERIE FND HEMONC,76626,"Bhatla, Teena, MD",5/19/2025,Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia (Relapsed and Refractory),_2. Second Line,4/30/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
NBI A5 PEDIATRICS,76626,"Rao, Harini, MD",3/24/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_3. Third Line,3/23/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),"A41.9 - Sepsis, unspecified organism; I26.93 - Single subsegmental thrombotic pulmonary embolism without acute cor pulmonale; J18.9 - Pneumonia, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; D70.1 - Agranulocytosis secondary to cancer chemotherapy; E88.819 - Insulin resistance, unspecified; C91.01 - Acute lymphoblastic leukemia, in remission; J91.8 - Pleural effusion in other conditions classified elsewhere; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I10 - Essential (primary) hypertension; J45.909 - Unspecified asthma, uncomplicated; Z79.4 - Long term (current) use of insulin; Z11.52 - Encounter for screening for COVID-19; D69.59 - Other secondary thrombocytopenia; G47.33 - Obstructive sleep apnea (adult) (pediatric); T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R79.1 - Abnormal coagulation profile; R50.81 - Fever presenting with conditions classified elsewhere; Z79.899 - Other long term (current) drug therapy; Z86.72 - Personal history of thrombophlebitis; Z86.718 - Personal history of other venous thrombosis and embolism; Z86.711 - Personal history of pulmonary embolism; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.42 - Fami..."
NBI C5 PEDS ICU,76626,"Bhatla, Teena, MD",3/13/2025,AALL1621 Cohort 2,_2. Second Line,3/11/2025,Active,Acute lymphoblastic leukemia (ALL) in pediatric patient (CMS/HCC),"A41.9 - Sepsis, unspecified organism; I26.93 - Single subsegmental thrombotic pulmonary embolism without acute cor pulmonale; J18.9 - Pneumonia, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; D70.1 - Agranulocytosis secondary to cancer chemotherapy; E88.819 - Insulin resistance, unspecified; C91.01 - Acute lymphoblastic leukemia, in remission; J91.8 - Pleural effusion in other conditions classified elsewhere; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I10 - Essential (primary) hypertension; J45.909 - Unspecified asthma, uncomplicated; Z79.4 - Long term (current) use of insulin; Z11.52 - Encounter for screening for COVID-19; D69.59 - Other secondary thrombocytopenia; G47.33 - Obstructive sleep apnea (adult) (pediatric); T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R79.1 - Abnormal coagulation profile; R50.81 - Fever presenting with conditions classified elsewhere; Z79.899 - Other long term (current) drug therapy; Z86.72 - Personal history of thrombophlebitis; Z86.718 - Personal history of other venous thrombosis and embolism; Z86.711 - Personal history of pulmonary embolism; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.42 - Fami..."
NBI C5 PEDS ICU,76626,"Narang, Shalu, MD",3/13/2025,PEDS AALL1821 VXLD Reinduction,_2. Second Line,3/13/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),"A41.9 - Sepsis, unspecified organism; I26.93 - Single subsegmental thrombotic pulmonary embolism without acute cor pulmonale; J18.9 - Pneumonia, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; D70.1 - Agranulocytosis secondary to cancer chemotherapy; E88.819 - Insulin resistance, unspecified; C91.01 - Acute lymphoblastic leukemia, in remission; J91.8 - Pleural effusion in other conditions classified elsewhere; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I10 - Essential (primary) hypertension; J45.909 - Unspecified asthma, uncomplicated; Z79.4 - Long term (current) use of insulin; Z11.52 - Encounter for screening for COVID-19; D69.59 - Other secondary thrombocytopenia; G47.33 - Obstructive sleep apnea (adult) (pediatric); T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R79.1 - Abnormal coagulation profile; R50.81 - Fever presenting with conditions classified elsewhere; Z79.899 - Other long term (current) drug therapy; Z86.72 - Personal history of thrombophlebitis; Z86.718 - Personal history of other venous thrombosis and embolism; Z86.711 - Personal history of pulmonary embolism; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.42 - Fami..."
JCMC CP INFUSION,26031,"Sekhri, Arunabh, MD",1/27/2025,PEMEtrexed/CARBOplatin/osimertinib (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/19/2025,Active,,
NBI OP INFUSION,57841,"Schleicher, Lori, MD",8/25/2023,"Cetuximab D1, D15 28 Day Cycles- Hypertrophic Gastropathy",Maintenance,8/24/2023,Inactive,,
NBI OP INFUSION,60268,"Cheng, Yan Ho, MD",10/29/2024,BV-CHP(Brentuximab vedotin / Cyclophosphamide / DOXOrubicin / PredniSONE) 21 Day Cycles - Acute T-cell Lymphocytic Lymphoma,_1. First Line,10/27/2024,Inactive,,
CINJ PEDS HEMONC ,51211,"Moerdler, Scott, MD",10/2/2023,PEDS IE - Osteosarcoma,Second Line,10/1/2023,Inactive,,
CINJ PEDS HEMONC ,51211,"Moerdler, Scott, MD",9/23/2024,Regorafenib 28 Day Cycles - Sarcoma,_2. Second Line,9/23/2024,Active,"Secondary malignant neoplasm of liver (CMS/HCC)
Malignant neoplasm of central portion of left female breast (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Antineoplastic drugs causing adverse effect, subsequent encounter
Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes (CMS/HCC)",
JCMC CP INFUSION,76609,"Cruz, Allan Louie E, MD",6/17/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,6/10/2024,Inactive,,
JCMC CP INFUSION,76609,"Cruz, Allan Louie E, MD",9/9/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,9/9/2024,Active,,
JCMC CP INFUSION,76609,"Cruz, Allan Louie E, MD",4/7/2025,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/7/2025,Active,Malignant neoplasm of right upper lobe of lung (CMS/HCC),"C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung"
CBMC OP INFUSION 2FL,98150,"Litvak, Anna M, MD",5/2/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,_3. Third Line,5/2/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,4072,"Ghodoussipour, Saum Bobak, MD",6/5/2024,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,6/4/2024,Inactive,,
NBR MEDICAL SAME DAY,4072,"Golombos, David, MD",2/13/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/13/2025,Inactive,Urothelial cancer (CMS/HCC),
CINJ OP INFUSION,85368,"Ghodoussipour, Saum Bobak, MD",3/18/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/18/2025,Inactive,Urothelial cancer (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified; R82.6 - Abnormal urine levels of substances chiefly nonmedicinal as to source"
MMC OP INFUSION,86167,"Meghal, Trishala, MD",10/13/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,10/12/2023,Inactive,,
MMC OP INFUSION,86167,"Meghal, Trishala, MD",12/15/2023,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,12/14/2023,Inactive,,
MMC OP INFUSION,86167,"Meghal, Trishala, MD",5/6/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,5/6/2024,Inactive,,
CINJ OP INFUSION,92453,"Weiss, Sarah, MD",1/30/2023,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,Second Line,1/17/2023,Inactive,,
CINJ OP INFUSION,92453,"Weiss, Sarah, MD",12/27/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,12/26/2023,Inactive,,
MMC OP VP INFUSION,15326,"Cohen, Seth D, MD",5/1/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/1/2024,Active,,
CMC OP INFUSION,59094,"Easaw, Sarah, MD",5/24/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/16/2023,Inactive,,
CINJ OP INFUSION,99691,"Berim, Lyudmyla, MD",7/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/15/2024,Active,,
CBMC OP INFUSION 2FL,76469,"Brown, Andrew Bennett, MD",4/3/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/2/2024,Active,,
CINJ OP INFUSION,87744,"Goel, Sanjay, MD",4/23/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,4/23/2025,Active,Malignant neoplasm of cecum (CMS/HCC),
TRMC TCCC OP INFUSION,14521,"Capo, Gerardo, MD",7/11/2024,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles + Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,7/10/2024,Inactive,,
TRMC TCCC OP INFUSION,14521,"Capo, Gerardo, MD",5/12/2025,Lenalidomide D1-D28 Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,5/12/2025,Active,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission; C79.51 - Secondary malignant neoplasm of bone; C90.01 - Multiple myeloma in remission; C79.52 - Secondary malignant neoplasm of bone marrow
MMC OP VP INFUSION,73293,"Lee, Patrick C, MD",4/20/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,4/19/2023,Inactive,,
NBR 5N ONCOLOGY,69080,"Hinrichs, Christian, MD",6/27/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Unknown Primary,_1. First Line,6/26/2024,Inactive,,
HAM OP INFUSION,69080,"Yogarajah, Meera, MD",8/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,7/28/2024,Active,,
CINJ OP INFUSION,58726,"Haigentz, Missak, MD",8/14/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/6/2024,Active,,
CMC OP INFUSION,12009,"Taff, Jessica, MD",5/1/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",_1. First Line,4/23/2024,Inactive,,
NBR CINJ OP INFUSION,25823,"Tiger, Yun Kyoung, MD",10/23/2024,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_2. Second Line,10/22/2024,Inactive,,
NBR CINJ OP INFUSION,25823,"Tiger, Yun Kyoung, MD",11/4/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Lymphoma,_2. Second Line,10/22/2024,Active,,
NBR 4N ONCOLOGY,25823,"Egini, Ogechukwu, MD",2/20/2025,BMT Flu / Cy / Thio / TBIx2,_3. Third Line,2/20/2025,Active,"Anaplastic large cell lymphoma, ALK-negative, unspecified site (CMS/HCC)",
NBR 5N ONCOLOGY,26838,"Palmisiano, Neil David, MD",5/10/2024,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),Induction,5/10/2024,Inactive,,
NBR CINJ OP INFUSION,26838,"Zayac, Adam, MD",6/24/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),_1. First Line,6/24/2024,Inactive,,
NBR CINJ OP INFUSION,26838,"Zayac, Adam, MD",12/6/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_2. Second Line,12/6/2024,Active,,
NBR CINJ OP INFUSION,26838,"Zayac, Adam, MD",2/3/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,1/28/2025,Active,AML (acute myeloid leukemia) in relapse (CMS/HCC),C92.00 - Acute myeloid leukemia in adult (CMS/HCC)
NBR CINJ OP INFUSION,20732,"Zayac, Adam, MD",3/17/2025,(CLAD/LDAC and Venetoclax) - Acute Myeloid Leukemia,_2. Second Line,3/17/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),
NBR 5N MED-SURG OVRF,49206,"Alexander, Henry Richard, MD",1/24/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,1/24/2024,Active,,
MMC OP VP INFUSION,62942,"Talwar, Sumit, MD",2/4/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/27/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,76473,"Patel, Eshan, MD",5/17/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- RCC",,5/15/2023,Inactive,,
SOM OUTPT INFUSION,88523,"Patel, Eshan, MD",7/18/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/17/2023,Inactive,,
NBR 5N ONCOLOGY,97652,"Doraiswamy, Anupama, MD",6/14/2023,HyperCVAD + RiTUXimab Starting with B Cycle (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate / RiTUXimab) - Acute Lymphoblastic Leukemia,,6/14/2023,Inactive,,
NBR 5N ONCOLOGY,97652,"Shah, Mansi R, MD",6/23/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,6/23/2023,Inactive,,
NBR CINJ OP INFUSION,97652,"Matasar, Matthew J, MD",6/28/2023,RiTUXimab Initial Infusion Single Day (Outpatient),First Line,6/23/2023,Inactive,,
NBR CINJ OP INFUSION,97652,"Matasar, Matthew J, MD",7/26/2023,HyperCVAD + RiTUXimab (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate / RiTUXimab) - Acute Lymphoblastic Leukemia,First Line,7/11/2023,Inactive,,
NBR CINJ OP INFUSION,97652,"Matasar, Matthew J, MD",1/30/2024,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,1/29/2024,Inactive,,
NBR CINJ OP INFUSION,97652,"Matasar, Matthew J, MD",3/4/2024,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_2. Second Line,1/15/2024,Inactive,,
NBR CINJ OP INFUSION,97652,"Matasar, Matthew J, MD",11/13/2024,Pola-R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab/Polatuzumab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,97652,"Matasar, Matthew J, MD",12/26/2024,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_5. Fifth Line,12/25/2024,Active,,
SOM 1PAV ONCOLOGY,73897,"Patel, Eshan, MD",5/30/2023,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,,5/29/2023,Inactive,,
CMC OP INFUSION,28915,"Taff, Jessica, MD",12/26/2023,Bevacizumab / PACLitaxel 21 Day Cycles - Endometrial,_2. Second Line,12/25/2023,Active,,
CMC OP INFUSION,28915,"Taff, Jessica, MD",4/10/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/10/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),
CMC OP INFUSION,69802,"Pompa, Tiffany Ann, MD",11/5/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/5/2024,Active,"Cholangiocarcinoma (CMS/HCC)
Abnormal tumor markers
Finding of unspecified substance, not normally found in blood
Abnormal results of thyroid function studies",
JCMC CP INFUSION,6340,"Cruz, Allan Louie E, MD",10/15/2024,CINJ 042315 Arm 2 Durvalumab / DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer,Neoadjuvant,10/15/2024,Active,,
CINJ OP INFUSION,20965,"George, Mridula A, MD",4/12/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,4/12/2023,Inactive,,
CINJ OP INFUSION,20965,"George, Mridula A, MD",12/8/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,12/8/2023,Active,"Cancer of cecum (CMS/HCC)
Metastasis to peritoneal cavity (CMS/HCC)",
MMC OP VP INFUSION,9532,"Meghal, Trishala, MD",7/14/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/9/2023,Inactive,,
NBI OP INFUSION,21419,"Schleicher, Lori, MD",2/9/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/9/2024,Inactive,,
NBI OP INFUSION,21419,"Schleicher, Lori, MD",12/2/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/1/2024,Active,,
NBI OP INFUSION,21419,"Jacoby, Sari H, MD",2/17/2025,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,_2. Second Line,2/9/2025,Active,Adenocarcinoma of colon metastatic to liver (CMS/HCC),"C18.4 - Malignant neoplasm of transverse colon; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C18.9 - Malignant neoplasm of colon, unspecified"
HAM OP INFUSION,62744,"Yogarajah, Meera, MD",2/24/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/16/2025,Active,Metastasis from pancreatic cancer (CMS/HCC),
CINJ OP INFUSION,81413,"Goel, Sanjay, MD",12/10/2024,CINJ 052405 Tazemetostat 28 Day Cycles Research- Advanced Malignancies,_3. Third Line,12/10/2024,Active,,
JCMC CP INFUSION,10079,"Cruz, Allan Louie E, MD",8/23/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,7/30/2024,Inactive,,
JCMC CP INFUSION,10079,"Cruz, Allan Louie E, MD",2/28/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/26/2025,Active,"Recurrent malignant neoplasm of ovary (CMS/HCC)
Pulmonary nodules/lesions, multiple",
NBR CINJ OP INFUSION,93515,"Evens, Andrew M, DO",1/3/2024,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,1/2/2024,Inactive,,
NBR 4N BMTU/IMCU,93515,"Braunschweig, Ira, MD",4/17/2024,BMT Autologous BEAM,_3. Third Line,4/16/2024,Inactive,,
NBR CINJ OP INFUSION,93515,"Evens, Andrew M, DO",6/26/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,Maintenance,6/25/2024,Active,,
CMC OP INFUSION,21439,"Cohen, Seth D, MD",2/26/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/26/2024,Active,,
JCMC CP INFUSION,58151,"Sekhri, Arunabh, MD",11/18/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,11/13/2024,Active,,
NBI OP INFUSION,19747,"Anderson, Patrick S, MD",7/1/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,6/30/2024,Active,,
CBMC OP INFUSION 2FL,90638,"Litvak, Anna M, MD",10/2/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,10/1/2023,Inactive,,
CINJ OP INFUSION,55414,"Stephenson, Ryan D, DO",3/6/2023,CINJ 082002 Pre-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,Neoadjuvant,3/5/2023,Inactive,,
CINJ OP INFUSION,55414,"Stephenson, Ryan D, DO",8/7/2023,CINJ 082002 Post-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,First Line,6/12/2023,Active,,
MSC OP INFUSION,45124,"Eltoukhy, Hussam, MD",4/5/2023,RiTUXimab 56 Day Cycles - Maintenance,Maintenance,4/4/2023,Inactive,,
CINJ OP INFUSION,87393,"Boland, Patrick M, MD",8/29/2023,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,,8/29/2023,Inactive,,
CINJ OP INFUSION,87393,"Goel, Sanjay, MD",12/11/2023,CINJ 052103 (TJ033721STM101) Dose Expansion Cohort 1 TJ033721 18 mg/kg 21 Day Cycles Research- Gastric Cancer / Gastroesophageal Junction Cancer / Esophageal Adenocarcinoma,_5. Fifth Line,12/11/2023,Inactive,,
CINJ OP INFUSION,87393,"Goel, Sanjay, MD",1/8/2024,CINJ 052301 Dose Finding JZP341 28 Day Cycles Research- Advanced Solid Tumors,_5. Fifth Line,1/7/2024,Inactive,,
CINJ OP INFUSION,87393,"Boland, Patrick M, MD",4/26/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_5. Fifth Line,4/4/2024,Inactive,,
CINJ OP INFUSION,74796,"Toppmeyer, Deborah L, MD",8/24/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Third Line,8/23/2023,Inactive,,
CINJ OP INFUSION,74796,"Toppmeyer, Deborah L, MD",5/2/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_5. Fifth Line,5/1/2024,Inactive,,
CINJ OP INFUSION,74796,"Toppmeyer, Deborah L, MD",6/13/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_4. Fourth Line,6/12/2024,Inactive,,
CINJ OP INFUSION,74796,"Toppmeyer, Deborah L, MD",6/27/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_3. Third Line,6/26/2024,Inactive,,
CINJ OP INFUSION,96898,"Stephenson, Ruth D, DO",6/13/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,5/29/2024,Active,,
CINJ OP INFUSION,3386,"Stephenson, Ryan D, DO",11/29/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,11/28/2023,Inactive,,
CMC OP INFUSION,66591,"Talwar, Sumit, MD",1/20/2025,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,1/19/2025,Active,,
NBR 5N ONCOLOGY,47674,"Girda, Eugenia, MD",4/19/2023,CINJ 052008 / R7075-ONC-2009 Dose Level 9W REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,,2/28/2023,Inactive,,
NBR 4N ONCOLOGY,89085,"Palmisiano, Neil David, MD",1/26/2023,Cytarabine / IDArubicin / Midostaurin (7 + 3) - Acute Myeloid Leukemia FLT3+ (Induction),,1/26/2023,Inactive,,
NBR CINJ OP INFUSION,89085,"Palmisiano, Neil David, MD",3/23/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,3/23/2023,Inactive,,
NBR CINJ OP INFUSION,89085,"Palmisiano, Neil David, MD",4/26/2023,Gilteritinib 30 Day Cycles - Acute Myeloid Leukemia,,4/26/2023,Active,,
NBR 4N BMTU/IMCU,89085,"Patel, Vimal D, MD",9/21/2023,BMT Allogeneic TBF + Post Cy ,Consolidation,9/21/2023,Inactive,,
NBI OP INFUSION,59393,"Cheng, Yan Ho, MD",2/18/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,2/18/2025,Active,Metastatic cancer to bone (CMS/HCC),"C61 - Malignant neoplasm of prostate; C78.00 - Secondary malignant neoplasm of unspecified lung; C79.31 - Secondary malignant neoplasm of brain; E44.0 - Moderate protein-calorie malnutrition; D61.818 - Other pancytopenia; N13.1 - Hydronephrosis with ureteral stricture, not elsewhere classified; C79.51 - Secondary malignant neoplasm of bone; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; E04.2 - Nontoxic multinodular goiter; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I16.0 - Hypertensive urgency; G89.29 - Other chronic pain; E78.49 - Other hyperlipidemia; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; M48.02 - Spinal stenosis, cervical region; K59.00 - Constipation, unspecified; E53.8 - Deficiency of other specified B group vitamins; R04.0 - Epistaxis; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; K05.323 - Chronic periodontitis, generalized, severe; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z68.23 - Body mass index (BMI) 23.0-23.9, adult"
CBMC OP INFUSION 2FL,44004,"Raptis, George, MD",8/7/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,8/6/2024,Active,,
CINJ OP INFUSION,86445,"Haigentz, Missak, MD",3/25/2023,CARBOplatin / Etoposide PLUS Atezolizumab  21 Day Cycles - Small Cell Lung Cancer,First Line,3/24/2023,Inactive,,
CINJ OP INFUSION,86445,"Haigentz, Missak, MD",7/5/2023,Atezolizumab Maintenance 21 Day Cycles- Small Cell Lung Cancer,Maintenance,7/5/2023,Inactive,,
CINJ OP INFUSION,86445,"Haigentz, Missak, MD",1/10/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,1/9/2024,Inactive,,
CINJ OP INFUSION,86445,"Haigentz, Missak, MD",7/30/2024,PACLitaxel (60mg/m2)/ CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Small Cell Lung Cancer,_3. Third Line,7/30/2024,Inactive,,
CINJ OP INFUSION,86445,"Haigentz, Missak, MD",8/20/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,8/20/2024,Inactive,,
CINJ OP INFUSION,56901,"Stephenson, Ryan D, DO",11/11/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,11/9/2024,Active,,
NBI OP INFUSION,68113,"Cohen, Alice, MD",10/12/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_2. Second Line,10/11/2023,Inactive,,
NBI OP INFUSION,68113,"Cohen, Alice, MD",11/20/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/19/2023,Inactive,,
NBI OP INFUSION,68113,"Cohen, Alice, MD",2/1/2024,Everolimus / Exemestane 28 Day Cycles - Breast,_3. Third Line,2/1/2024,Inactive,,
NBI OP INFUSION,61800,"Cohen, Alice, MD",4/3/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,_3. Third Line,4/3/2025,Active,Primary malignant neoplasm of breast with metastasis (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C50.912 - Malignant neoplasm of unspecified site of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,72654,"Leiser, Aliza, MD",11/29/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,11/26/2023,Inactive,,
SOM OUTPT INFUSION,17451,"Patel, Eshan, MD",2/17/2025,Pembrolizumab 21 Day Cycles -kidney,_1. First Line,2/17/2025,Active,Clear cell adenocarcinoma of kidney (CMS/HCC),"C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis"
CINJ OP INFUSION,40166,"Boland, Patrick M, MD",6/20/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,6/19/2023,Inactive,,
CINJ OP INFUSION,40166,"Boland, Patrick M, MD",9/24/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/23/2024,Active,,
NBR CINJ OP INFUSION,23149,"Schaar, Dale, MD PhD",9/6/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,9/5/2024,Active,Colon cancer (CMS/HCC),
CINJ OP INFUSION,57546,"Weiss, Sarah, MD",2/26/2024,Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,2/22/2024,Active,,
HAM OP INFUSION,9478,"Yogarajah, Meera, MD",7/8/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,6/19/2024,Active,Primary cancer of right lower lobe of lung (CMS/HCC),
MMC OP INFUSION,37276,"Lee, Patrick C, MD",6/12/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,,6/12/2023,Inactive,,
MMC OP INFUSION,37276,"Lee, Patrick C, MD",8/28/2023,Temozolomide 28 Day Cycles - CNS,First Line,8/28/2023,Inactive,,
MMC OP INFUSION,37276,"Lee, Patrick C, MD",5/9/2024,Irinotecan / Bevacizumab 14 Day Cycles - Glioblastoma,_2. Second Line,5/8/2024,Inactive,,
HAM OP INFUSION,12691,"Patel, Malini M, MD",9/4/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,8/6/2024,Active,,
NBR CINJ OP INFUSION,73259,"Zayac, Adam, MD",11/4/2024,Venetoclax / Decitabine 28 Day Cycles - Accelerated Chronic Myeloid Leukemia,_5. Fifth Line,10/29/2024,Active,"Multiple myeloma in relapse (CMS/HCC)
Hypogammaglobulinemia (CMS/HCC)
Encounter for vaccination",
NBR 4N ONCOLOGY,73259,"Egini, Ogechukwu, MD",2/20/2025,BMT Allogeneic Mel / Thio / Flu +Abatacept with Post Cy 80mg/kg,_3. Third Line,2/20/2025,Active,Accelerated phase chronic myeloid leukemia (CMS/HCC),
CINJ OP INFUSION,18328,"Saraiya, Biren P, MD",10/26/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/26/2023,Inactive,,
NBR 5N ONCOLOGY,77352,"Tiger, Yun Kyoung, MD",5/27/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,5/26/2024,Inactive,,
NBR 5N ONCOLOGY,77352,"Tiger, Yun Kyoung, MD",5/27/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,16510,"Wagmiller, Jennifer Ann, MD",9/25/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/18/2024,Active,,
CBMC OP INFUSION 2FL,79294,"Wagmiller, Jennifer Ann, MD",10/30/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/29/2023,Inactive,,
CINJ OP INFUSION,94154,"Omene, Coral Oghenerukevwe, MD",5/2/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/2/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,43836,"Hochster, Howard S, MD",2/29/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/27/2024,Active,,
JCMC CP INFUSION,42118,"Cruz, Allan Louie E, MD",11/7/2023,Durvalumab 28 Day Cycles- metastatic gallbladder cancer,_1. First Line,11/6/2023,Inactive,,
JCMC CP INFUSION,42118,"Cruz, Allan Louie E, MD",10/29/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/28/2024,Inactive,,
JCMC CP INFUSION,42118,"Cruz, Allan Louie E, MD",11/12/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/12/2024,Active,,
CINJ OP INFUSION,14408,"Patankar, Sonali, MD",11/11/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,11/10/2024,Active,,
JCMC CP INFUSION,5513,"Cruz, Allan Louie E, MD",12/29/2023,Nivolumab 360 mg/PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Neoadjuvant,12/20/2023,Inactive,,
CMC OP INFUSION,13903,"Taff, Jessica, MD",3/26/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/14/2024,Inactive,,
CBMC OP INFUSION 2FL,11388,"Grossman, I Robert, MD",9/8/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,9/7/2023,Inactive,,
HAM OP INFUSION,92505,"Gendy, Mina, DO",5/19/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/19/2025,Active,AML (acute myeloblastic leukemia) (CMS/HCC),
MMC OP VP INFUSION,72477,"Lee, Patrick C, MD",5/13/2025,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,5/13/2025,Active,Melanoma of flank (CMS/HCC),
CMC OP INFUSION,96864,"Ferretti, Mark J, MD",7/1/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,_1. First Line,6/30/2024,Active,,
CINJ OP INFUSION,96864,"Haigentz, Missak, MD",3/4/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,3/4/2025,Active,"Malignant neoplasm of head, face, and neck (CMS/HCC)
Pituitary adenoma (CMS/HCC)","C76.0 - Malignant neoplasm of head, face and neck; D35.2 - Benign neoplasm of pituitary gland"
MMC OP INFUSION,809,"Meghal, Trishala, MD",5/26/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,5/23/2023,Inactive,,
JCMC CP INFUSION,71596,"Sekhri, Arunabh, MD",6/8/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/4/2023,Inactive,,
JCMC CP INFUSION,71596,"Sekhri, Arunabh, MD",8/23/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,8/14/2023,Inactive,,
JCMC CP INFUSION,71596,"Sekhri, Arunabh, MD",2/7/2024,"PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES -  squamous Lung CANCER, geriatric",_2. Second Line,2/6/2024,Inactive,,
JCMC CP INFUSION,71596,"Sekhri, Arunabh, MD",2/15/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/8/2024,Active,,
CINJ OP INFUSION,30448,"Gulhati, Prateek, MD PhD",2/17/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/17/2023,Inactive,,
CINJ OP INFUSION,30448,"Gulhati, Prateek, MD PhD",2/17/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/17/2023,Inactive,,
CINJ OP INFUSION,30448,"Gulhati, Prateek, MD PhD",8/19/2023,"Encorafenib + Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",,8/16/2023,Inactive,,
CBMC OP INFUSION 2FL,29069,"Litvak, Anna M, MD",5/22/2025,CINJ 042102 Block B (TNBC) Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles Research- Triple Negative Breast Cancer,_1. First Line,5/22/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,21682,"Shah, Shailja S, MD",5/27/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/27/2025,Active,Metastatic non-small cell lung cancer (CMS/HCC),
NBR CINJ OP INFUSION,91058,"Evens, Andrew M, DO",4/16/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,4/16/2025,Active,Follicular lymphoma (CMS/HCC),
CINJ OP INFUSION,93234,"Mayer, Tina M, MD",12/22/2023,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,12/22/2023,Active,,
NBR 5N ONCOLOGY,5650,"Tiger, Yun Kyoung, MD",9/11/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,9/11/2024,Inactive,,
NBR CINJ OP INFUSION,5650,"Zayac, Adam, MD",9/13/2024,CINJ 022101 (EA9181) ARM A PONATinib / Prednisone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,9/12/2024,Inactive,,
NBR CINJ OP INFUSION,5650,"Zayac, Adam, MD",9/24/2024,CINJ 022101 (EA9181) ARM C Induction Ponatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,_1. First Line,9/23/2024,Inactive,,
NBR CINJ OP INFUSION,5650,"Zayac, Adam, MD",12/12/2024,CINJ 022101 (EA9181) ARM C Consolidation Ponatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,Consolidation,12/12/2024,Inactive,,
NBR CINJ OP INFUSION,5650,"Zayac, Adam, MD",12/12/2024,CINJ 022101 (EA9181) ARMS C High Dose Methotrexate 14 Day Cycles Inpatient Research,_1. First Line,12/11/2024,Inactive,,
NBR CINJ OP INFUSION,5650,"Zayac, Adam, MD",1/13/2025,CINJ 022101 (EA9181) ARM C Consolidation Ponatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,Consolidation,1/6/2025,Active,,
NBR CINJ OP INFUSION,5650,"Zayac, Adam, MD",4/10/2025,CINJ 022101 (EA9181) Arms B / C Maintenance Methotrexate Intrathecal / Ponatinib / VinCRIStine 28 Day Cycles Research- Acute Lymphoblastic Leukemia,Maintenance,4/10/2025,Active,Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) (CMS/HCC),
HAM OP INFUSION,26693,"Yogarajah, Meera, MD",5/1/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/30/2023,Inactive,,
NBR CINJ OP INFUSION,76742,"Shah, Mansi R, MD",1/16/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,1/2/2024,Inactive,,
CBMC OP INFUSION 2FL,85920,"Litvak, Anna M, MD",11/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,85920,"Litvak, Anna M, MD",11/7/2023,Intrathecal Trastuzumab - Breast,Maintenance,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,85920,"Wagmiller, Jennifer Ann, MD",8/27/2024,VinORELBine 21 Day Cycles - Breast,_4. Fourth Line,8/26/2024,Inactive,,
CINJ OP INFUSION,41306,"Girda, Eugenia, MD",7/27/2023,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,7/26/2023,Inactive,,
CINJ OP INFUSION,41306,"Girda, Eugenia, MD",9/14/2023,CISplatin + Bevacizumab 21 Day Cycles - Cervical,,9/13/2023,Inactive,,
CINJ OP INFUSION,41306,"Girda, Eugenia, MD",10/5/2023,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,10/2/2023,Inactive,,
CINJ OP INFUSION,41306,"Girda, Eugenia, MD",5/9/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_3. Third Line,5/6/2024,Inactive,,
CINJ OP INFUSION,41306,"Girda, Eugenia, MD",11/7/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,11/5/2024,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
CINJ OP INFUSION,39553,"Girda, Eugenia, MD",3/13/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,3/13/2025,Active,"Peritoneal carcinomatosis (CMS/HCC)
Malignant neoplasm of left ovary (CMS/HCC)
Malignant neoplasm of peritoneum, unspecified (CMS/HCC)
Other abnormal tumor markers",
CBMC OP INFUSION 2FL,90628,"Radovich, Delia, MD",11/6/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/5/2023,Active,,
MSC OP INFUSION,97789,"Cohen, Seth D, MD",3/21/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,,3/20/2023,Inactive,,
CBMC OP INFUSION 2FL,86879,"Dharmapuri, Sirish, MD",11/4/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,11/3/2024,Active,,
CBMC OP INFUSION 2FL,86879,"Dharmapuri, Sirish, MD",4/29/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/29/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CINJ OP INFUSION,4387,"Saraiya, Biren P, MD",8/20/2024,Enzalutamide - Prostate,_1. First Line,8/20/2024,Active,,
MMC OP INFUSION,43744,"Lee, Patrick C, MD",1/20/2025,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,Adjuvant,1/19/2025,Active,,
MMC OP INFUSION,26068,"Lee, Patrick C, MD",5/6/2025,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,Adjuvant,5/6/2025,Active,Malignant neoplasm of anterior floor of mouth (CMS/HCC),
CINJ OP INFUSION,86419,"Weiss, Sarah, MD",4/26/2023,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,Second Line,4/24/2023,Inactive,,
MMC OP INFUSION,63099,"Lee, Patrick C, MD",1/2/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/1/2024,Active,,
CMC OP INFUSION,49940,"Taff, Jessica, MD",4/24/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,First Line,4/23/2023,Active,,
NBR CINJ OP INFUSION,63837,"Doraiswamy, Anupama, MD",6/8/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,,6/7/2023,Inactive,,
CMC OP INFUSION,63837,"Easaw, Sarah, MD",9/11/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,First Line,8/29/2023,Inactive,,
CMC OP INFUSION,63837,"Eltoukhy, Hussam, MD",11/2/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_2. Second Line,11/1/2023,Inactive,,
JCMC CP INFUSION,59028,"Sekhri, Arunabh, MD",6/29/2023,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",Neoadjuvant,6/29/2023,Inactive,,
CINJ OP INFUSION,85153,"Jang, Thomas L, MD",2/2/2023,MitoMYcin Intravesical Weekly 42 Day Cycle - Bladder,Adjuvant,2/1/2023,Inactive,,
CINJ OP INFUSION,26761,"Mayer, Tina M, MD",8/4/2023,Pembrolizumab 21 Day Cycles - prostate cancer with high TMB,,8/4/2023,Inactive,,
MMC OP INFUSION,14615,"Talwar, Sumit, MD",12/23/2024,RiTUXimab 28 Day Cycle -Hemolytic anemia,_1. First Line,12/22/2024,Active,Squamous cell carcinoma of cervix (CMS/HCC),
MMC OP INFUSION,83452,"Talwar, Sumit, MD",1/6/2025,RiTUXimab 28 Day Cycle -Hemolytic anemia,_1. First Line,12/22/2024,Active,Urothelial carcinoma (CMS/HCC),
MMC OP VP INFUSION,83452,"Talwar, Sumit, MD",2/24/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,2/19/2025,Active,Chronic lymphocytic leukemia of B-cell type not having achieved remission (CMS/HCC),
HAM OP INFUSION,11782,"Yogarajah, Meera, MD",12/16/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/8/2024,Active,,
MMC OP VP INFUSION,57588,"Lee, Patrick C, MD",10/24/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/16/2024,Active,,
MMC OP VP INFUSION,6026,"Lee, Patrick C, MD",2/9/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,First Line,2/8/2023,Active,,
CMC OP INFUSION,81369,"Taff, Jessica, MD",1/16/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,1/15/2023,Inactive,,
CMC OP INFUSION,81369,"Taff, Jessica, MD",1/15/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/12/2024,Active,,
CINJ OP INFUSION,89929,"Haigentz, Missak, MD",10/8/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,10/8/2024,Inactive,,
CINJ OP INFUSION,89929,"Haigentz, Missak, MD",11/13/2024,CISplatin/DOCEtaxel 21 Day Cycles- Head and Neck Cancers,Neoadjuvant,11/13/2024,Inactive,,
CINJ OP INFUSION,89929,"Haigentz, Missak, MD",2/24/2025,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,_1. First Line,2/23/2025,Active,"Laryngeal squamous cell carcinoma (CMS/HCC)
Malignant neoplasm of larynx (CMS/HCC)
Chronic fatigue",
CINJ OP INFUSION,46835,"Haigentz, Missak, MD",5/28/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,5/28/2025,Active,"Laryngeal squamous cell carcinoma (CMS/HCC)
Malignant neoplasm of larynx (CMS/HCC)
Chronic fatigue and malaise
Screening for thyroid disorder",
CINJ OP INFUSION,46835,"Haigentz, Missak, MD",5/26/2025,Pembrolizumab 21 Day Cycles  - Head and Neck Cancers,_2. Second Line,5/26/2025,Inactive,"Laryngeal squamous cell carcinoma (CMS/HCC)
Malignant neoplasm of larynx (CMS/HCC)
Chronic fatigue and malaise
Screening for thyroid disorder",
CINJ OP INFUSION,75920,"Kennedy, Timothy, MD",8/25/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,,8/25/2023,Inactive,,
CBMC OP INFUSION 2FL,1477,"Litvak, Anna M, MD",4/3/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/3/2025,Inactive,Secondary malignant neoplasm of bone and bone marrow (CMS/HCC),
SOM OUTPT INFUSION,44039,"Toomey, Kathleen C, MD",5/27/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/27/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),C56.3 - Malignant neoplasm of bilateral ovaries
CINJ OP INFUSION,71681,"Omene, Coral Oghenerukevwe, MD",4/26/2023,CINJ 042102 (I-SPY 2 105139) Datopotamab Deruxtecan Appendix AG 21 Day Cycles - Breast Cancer,Neoadjuvant,4/25/2023,Inactive,,
CINJ OP INFUSION,71681,"Omene, Coral Oghenerukevwe, MD",5/18/2023,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,,5/17/2023,Inactive,,
CINJ OP INFUSION,71681,"Omene, Coral Oghenerukevwe, MD",8/25/2023,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,,8/24/2023,Inactive,,
CINJ OP INFUSION,71681,"Omene, Coral Oghenerukevwe, MD",1/29/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,1/29/2024,Inactive,,
CINJ OP INFUSION,1365,"Patel, Eshan, MD",10/30/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/30/2023,Active,,
MMC OP VP INFUSION,6667,"Cohen, Seth D, MD",3/25/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,3/20/2025,Inactive,"Malignant neoplasm of sigmoid colon (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,48150,"Jang, Thomas L, MD",1/26/2023,MitoMYcin Intravesical Weekly 42 Day Cycle - Bladder,Induction,1/25/2023,Inactive,,
CBMC OP INFUSION 2FL,58085,"Brown, Andrew Bennett, MD",2/4/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,2/3/2025,Active,"Squamous cell carcinoma, scalp/neck",
NBR 4N ONCOLOGY,58274,"Palmisiano, Neil David, MD",12/19/2024,CINJ 022305 Part 1 of 2 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,12/19/2024,Inactive,,
NBR CINJ OP INFUSION,58274,"Palmisiano, Neil David, MD",1/18/2025,CINJ 022305 Part 2 of 2 Non-Intensive Ziftomenib / Venetoclax 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,1/17/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,58274,"Palmisiano, Neil David, MD",1/22/2025,CINJ 022305 Part 2 of 2 Non-Intensive Outpatient Ziftomenib / Venetoclaz/ Azacitidine 28 Day Cycles Research,_1. First Line,1/14/2025,Active,,
NBR CINJ OP INFUSION,62989,"Eltoukhy, Hussam, MD",6/9/2023,Gemcitabine 28 Day Cycles,,6/8/2023,Inactive,,
SOM OUTPT INFUSION,62989,"Patel, Eshan, MD",6/12/2023,Bendamustine 28 Day Cycles - Hodgkin Lymphoma,,6/9/2023,Inactive,,
CMC OP INFUSION,14455,"Pompa, Tiffany Ann, MD",3/13/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/13/2025,Inactive,Ovarian cancer (CMS/HCC),
CBMC OP INFUSION 2FL,99252,"Dharmapuri, Sirish, MD",5/13/2025,Durvalumab + Gemcitabine /CARBOplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,5/12/2025,Active,Biliary tract cancer (CMS/HCC),"C24.9 - Malignant neoplasm of biliary tract, unspecified; D50.0 - Iron deficiency anemia secondary to blood loss (chronic)"
JCMC CP INFUSION,53485,"Sekhri, Arunabh, MD",3/3/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - serous carcinoma endometrium ,Adjuvant,3/2/2023,Inactive,,
CINJ OP INFUSION,94770,"Patel, Eshan, MD",1/30/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,1/29/2023,Inactive,,
CINJ OP INFUSION,60635,"George, Mridula A, MD",5/22/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/22/2024,Inactive,,
NBI OP INFUSION,66695,"Jacoby, Sari H, MD",8/22/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/21/2023,Inactive,,
NBI OP INFUSION,66695,"Jacoby, Sari H, MD",3/19/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/18/2024,Inactive,,
MMC OP VP INFUSION,84793,"Meghal, Trishala, MD",3/27/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,3/26/2023,Inactive,,
HAM OP INFUSION,35903,"Patel, Malini M, MD",8/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/19/2024,Active,,
SOM OUTPT INFUSION,13390,"Patel, Eshan, MD",6/25/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/9/2024,Inactive,,
SOM OUTPT INFUSION,13390,"Patel, Eshan, MD",11/19/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,11/17/2024,Active,,
NBR 4N ONCOLOGY,82448,"Evens, Andrew M, DO",1/26/2023,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,First Line,1/25/2023,Inactive,,
NBR CINJ OP INFUSION,82448,"Evens, Andrew M, DO",3/24/2023,MATRiX (High-Dose Methotrexate / Cytarabine / Thiotepa / RiTUXimab) - CNS Lymphoma,First Line,3/23/2023,Inactive,,
NBR 4N ONCOLOGY,82448,"Assal, Amer, MD",7/7/2023,BMT Autologous Carmustine / Thiotepa,,7/6/2023,Inactive,,
CINJ OP INFUSION,33812,"George, Mridula A, MD",7/14/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/12/2023,Inactive,,
CINJ OP INFUSION,90645,"George, Mridula A, MD",2/9/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/8/2024,Inactive,,
CINJ OP INFUSION,90645,"George, Mridula A, MD",9/6/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,9/5/2024,Active,,
CINJ OP INFUSION,49529,"Berim, Lyudmyla, MD",5/8/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/2/2023,Inactive,,
CINJ OP INFUSION,49529,"Berim, Lyudmyla, MD",7/10/2023,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,,6/11/2023,Inactive,,
CINJ OP INFUSION,49529,"Berim, Lyudmyla, MD",9/20/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/19/2023,Inactive,,
CINJ OP INFUSION,49529,"Berim, Lyudmyla, MD",6/26/2024,"Encorafenib + Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/14/2024,Inactive,,
CINJ OP INFUSION,49529,"Berim, Lyudmyla, MD",9/11/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_2. Second Line,9/11/2024,Inactive,,
CINJ OP INFUSION,49529,"Berim, Lyudmyla, MD",10/16/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,10/16/2024,Active,"B lymphoblastic leukemia (CMS/HCC)
Donor specific antibody (DSA) positive
Encounter for immunization",
CINJ OP INFUSION,41243,"Haigentz, Missak, MD",7/29/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,7/28/2024,Active,,
CINJ PEDS HEMONC ,52604,"Botwinick, Marissa, DO",5/1/2023,PEDS AAML1331 Standard Risk APL Consolidation ,,5/1/2023,Active,,
CINJ OP INFUSION,81807,"Berim, Lyudmyla, MD",7/13/2023,IROX (Irinotecan/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,7/12/2023,Inactive,,
CINJ OP INFUSION,81807,"Berim, Lyudmyla, MD",4/25/2024,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/23/2024,Active,,
TRMC TCCC OP INFUSION,79866,"Capo, Gerardo, MD",8/6/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/5/2024,Active,,
JCMC CP INFUSION,94486,"Sekhri, Arunabh, MD",9/18/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,9/10/2024,Active,,
CINJ OP INFUSION,99610,"Girda, Eugenia, MD",10/5/2023,CINJ 102201 ARM 1 Neoadjuvant Pembrolizumab / MK-4830 / CARBOplatin / PACLitaxel 21 Day Cycles Research- Ovarian Cancer,Neoadjuvant,9/6/2023,Inactive,,
CINJ OP INFUSION,99610,"Aikins, James K, MD",4/26/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/25/2024,Inactive,,
CINJ OP INFUSION,99610,"Aikins, James K, MD",8/9/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,8/8/2024,Active,,
CINJ OP INFUSION,99610,"Aikins, James K, MD",5/1/2025,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/24/2025,Active,Malignant neoplasm of bilateral ovaries (CMS/HCC),
CBMC 2W ONCOLOGY,14572,"Derosa, William T, DO",2/24/2025,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,2/24/2025,Active,Malignant lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; I10 - Essential (primary) hypertension; M19.90 - Unspecified osteoarthritis, unspecified site; C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site"
NBR CINJ OP INFUSION,14572,"Rhodes, Joanna Meehan, MD",5/28/2025,BMT Autologous BEAM,_3. Third Line,5/27/2025,Active,"Malignant lymphoma (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)",
CBMC OP INFUSION 2FL,14572,"Derosa, William T, DO",3/24/2025,Polatuzumab Vedotin/ RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/24/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
CBMC 2W ONCOLOGY,14572,"Derosa, William T, DO",3/4/2025,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,3/4/2025,Inactive,"Malignant lymphoma (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)","C83.30 - Diffuse large B-cell lymphoma, unspecified site; I10 - Essential (primary) hypertension; M19.90 - Unspecified osteoarthritis, unspecified site; C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site"
SOM OUTPT INFUSION,50619,"Yin, Faye, MD",12/6/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,12/5/2023,Inactive,,
CMC OP INFUSION,40450,"Ferretti, Mark J, MD",4/18/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,_1. First Line,4/18/2025,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),
TRMC TCCC OP INFUSION,90786,"Capo, Gerardo, MD",10/16/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,10/15/2024,Active,,
CINJ OP INFUSION,83621,"Stephenson, Ryan D, DO",3/6/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,First Line,3/6/2023,Inactive,,
NBI OP INFUSION,48173,"Schleicher, Lori, MD",1/29/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/28/2025,Active,,
NBI OP INFUSION,48173,"Schleicher, Lori, MD",1/29/2025,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/28/2025,Inactive,Cecum mass,
MMC OP INFUSION,88104,"Meghal, Trishala, MD",7/26/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,7/25/2023,Inactive,,
MMC OP INFUSION,88104,"Meghal, Trishala, MD",10/18/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,10/17/2023,Inactive,,
MMC OP INFUSION,88104,"Meghal, Trishala, MD",4/19/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,4/19/2024,Active,,
NBI OP INFUSION,39263,"Cohen, Alice, MD",6/21/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,6/20/2023,Inactive,,
NBI OP INFUSION,39263,"Cohen, Alice, MD",5/22/2024,Gemcitabine 28 Day Cycles - Breast,_4. Fourth Line,5/21/2024,Inactive,,
NBI OP INFUSION,39263,"Cohen, Alice, MD",10/21/2024,Elacestrant 28 Day Cycles - Breast,_4. Fourth Line,10/21/2024,Inactive,,
NBI OP INFUSION,39263,"Cohen, Alice, MD",1/13/2025,Alpelisib 28 Day Cycles - Breast,_6. Sixth Line,1/7/2025,Active,,
NBI OP INFUSION,200,"Jacoby, Sari H, MD",12/4/2023,PEGinterferon alfa-2a 28 Day Cycle - Myeloproliferative Neoplasms,_2. Second Line,12/3/2023,Inactive,,
NBI OP INFUSION,200,"Jacoby, Sari H, MD",1/8/2024,PEGinterferon alfa-2a 28 Day Cycle - Myeloproliferative Neoplasms,_2. Second Line,1/7/2024,Inactive,,
NBI OP INFUSION,200,"Jacoby, Sari H, MD",2/19/2024,PEGinterferon alfa-2a 28 Day Cycle - Myeloproliferative Neoplasms,_2. Second Line,2/18/2024,Active,,
NBI OP INFUSION,10945,"Shah, Shailja S, MD",1/21/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,1/13/2025,Active,,
CINJ OP INFUSION,66900,"Saraiya, Biren P, MD",9/2/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/2/2024,Active,,
CBMC OP INFUSION 2FL,15707,"Dharmapuri, Sirish, MD",1/24/2025,"PACLitaxel D1, D8, D15 28 Day Cycles- Esophageal and Esophagogastric Junction Cancers",_1. First Line,1/23/2025,Active,,
CBMC OP INFUSION 2FL,31459,"Dharmapuri, Sirish, MD",2/19/2025,"PACLitaxel D1, D8, D15 28 Day Cycles- Esophageal and Esophagogastric Junction Cancers",_1. First Line,1/23/2025,Inactive,Malignant neoplasm of esophagus (CMS/HCC),
MMC OP VP INFUSION,48030,"Lee, Patrick C, MD",8/4/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,7/19/2023,Inactive,,
CINJ OP INFUSION,29072,"Stephenson, Ruth D, DO",3/8/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/7/2023,Inactive,,
MMC OP VP INFUSION,20043,"Lee, Patrick C, MD",8/30/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/9/2024,Inactive,,
MMC OP VP INFUSION,20043,"Lee, Patrick C, MD",11/21/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/7/2024,Active,,
MMC OP VP INFUSION,62252,"Lee, Patrick C, MD",2/14/2025,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/13/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
MMC OP VP INFUSION,62252,"Lee, Patrick C, MD",5/8/2025,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/8/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
NBR 5N ONCOLOGY,19268,"Sridharan, Ashwin, MD",9/15/2023,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),Induction,9/15/2023,Inactive,,
NBR 5N ONCOLOGY,19268,"Sridharan, Ashwin, MD",9/25/2023,HiDAC-123 + Midostaurin (High-Dose Cytarabine / Midostaurin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Induction,9/25/2023,Inactive,,
MMC OP VP INFUSION,71309,"Lee, Patrick C, MD",6/26/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/26/2024,Active,,
CMC OP INFUSION,61069,"Cohen, Seth D, MD",11/7/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,11/7/2023,Inactive,,
CMC OP INFUSION,61069,"Cohen, Seth D, MD",5/30/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,5/30/2024,Active,"Oropharyngeal cancer (CMS/HCC)
Malignant neoplasm of faucial tonsil (CMS/HCC)",
NBR CINJ OP INFUSION,9969,"Rhodes, Joanna Meehan, MD",2/6/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,2/5/2025,Active,Nodular sclerosing Hodgkin's lymphoma (CMS/HCC),"R59.1 - Generalized enlarged lymph nodes; R59.0 - Localized enlarged lymph nodes; C81.10 - Nodular sclerosis Hodgkin lymphoma, unspecified site"
NBR 5N ONCOLOGY,86533,"Tiger, Yun Kyoung, MD",11/4/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,11/3/2024,Active,,
MMC OP VP INFUSION,36409,"Cohen, Seth D, MD",1/8/2024,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/7/2024,Inactive,,
MMC OP VP INFUSION,36409,"Cohen, Seth D, MD",4/9/2024,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/5/2024,Active,,
TRMC TCCC OP INFUSION,58517,"Capo, Gerardo, MD",10/8/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,10/8/2024,Active,,
CINJ OP INFUSION,12832,"Boland, Patrick M, MD",8/23/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,8/21/2024,Inactive,,
CINJ OP INFUSION,62830,"Patel, Eshan, MD",6/26/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,6/23/2023,Inactive,,
CINJ OP INFUSION,5427,"Stephenson, Ryan D, DO",5/14/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Adjuvant,5/13/2024,Inactive,,
CINJ OP INFUSION,5427,"Groisberg, Roman, MD",5/9/2025,DOXOrubicin 21 Day Cycles - Sarcoma,_1. First Line,4/25/2025,Inactive,Leiomyosarcoma (CMS/HCC),"S27.0XXA - Traumatic pneumothorax, initial encounter; C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; Z51.89 - Encounter for other specified aftercare; R91.8 - Other nonspecific abnormal finding of lung field; M89.8X9 - Other specified disorders of bone, unspecified site; C61 - Malignant neoplasm of prostate; E78.00 - Pure hypercholesterolemia, unspecified; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; Z93.9 - Artificial opening status, unspecified; Z87.891 - Personal history of nicotine dependence; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
NBR 5N ONCOLOGY,5427,"Groisberg, Roman, MD",5/9/2025,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_1. First Line,5/9/2025,Active,Leiomyosarcoma (CMS/HCC),
CINJ OP INFUSION,23001,"Stephenson, Ryan D, DO",1/5/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,1/5/2024,Active,,
CINJ OP INFUSION,23001,"Stephenson, Ryan D, DO",2/21/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,2/1/2024,Inactive,,
CBMC OP INFUSION 2FL,22764,"Wagmiller, Jennifer Ann, MD",1/9/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/9/2024,Inactive,,
CBMC OP INFUSION 2FL,22764,"Wagmiller, Jennifer Ann, MD",7/9/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,7/8/2024,Active,,
NBR CINJ OP INFUSION,71672,"Shah, Mansi R, MD",8/8/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,8/5/2024,Inactive,,
NBR CINJ OP INFUSION,38274,"Matasar, Matthew J, MD",4/16/2025,MATRiX (High-Dose Methotrexate / Cytarabine / Thiotepa / RiTUXimab) - CNS Lymphoma,_1. First Line,4/8/2025,Active,Primary CNS lymphoma (CMS/HCC),"C83.390 - Primary central nervous system lymphoma; D72.828 - Other elevated white blood cell count; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites"
NBR 4N ONCOLOGY,38274,"Rhodes, Joanna Meehan, MD",4/15/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/15/2025,Inactive,"Primary CNS lymphoma (CMS/HCC)
CNS lymphoma (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C83.390 - Primary central nervous system lymphoma; D84.821 - Immunodeficiency due to drugs; D63.0 - Anemia in neoplastic disease; E87.1 - Hypo-osmolality and hyponatremia; Z90.89 - Acquired absence of other organs; Z86.16 - Personal history of COVID-19; Z80.49 - Family history of malignant neoplasm of other genital organs; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.7 - Family history of other malignant neoplasms of lymphoid, hematopoietic and related tissues"
SOM OUTPT INFUSION,30122,"Patel, Eshan, MD",11/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/27/2024,Active,,
SOM OUTPT INFUSION,12452,"Patel, Eshan, MD",3/19/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Thoracic Cancers",_1. First Line,3/19/2025,Active,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Stage IV adenocarcinoma of lung, unspecified laterality (CMS/HCC)",
SOM OUTPT INFUSION,12452,"Patel, Eshan, MD",3/13/2025,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/13/2025,Inactive,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Stage IV adenocarcinoma of lung, unspecified laterality (CMS/HCC)","C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung"
NBR 5N ONCOLOGY,63868,"Palmisiano, Neil David, MD",12/19/2023,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,12/19/2023,Inactive,,
NBR CINJ OP INFUSION,63868,"Zayac, Adam, MD",1/26/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),_1. First Line,1/26/2024,Inactive,,
CINJ OP INFUSION,95869,"Boland, Patrick M, MD",8/8/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,8/7/2023,Inactive,,
MMC OP VP INFUSION,831,"Cohen, Seth D, MD",10/18/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,10/17/2023,Inactive,,
CINJ OP INFUSION,75295,"Weiss, Sarah, MD",1/22/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,Neoadjuvant,1/19/2024,Active,,
CINJ OP INFUSION,61680,"Berim, Lyudmyla, MD",3/4/2024,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,2/18/2024,Inactive,,
CBMC OP INFUSION 2FL,28898,"Brown, Andrew Bennett, MD",7/5/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Third Line,7/4/2023,Inactive,,
CMC OP INFUSION,73690,"Samuel, David, MD",3/10/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,3/10/2025,Active,Malignant neoplasm overlapping cervix uteri site (CMS/HCC),
NBI VALERIE FND HEMONC,76100,"Batra, Surabhi, MD",4/24/2025,PEDS AOST0331 MAP Arm (DOXOrubicin / CISplatin / Methotrexate),_1. First Line,4/24/2025,Active,Osteosarcoma determined by biopsy of bone (CMS/HCC),
CINJ PEDS HEMONC ,81731,"Moerdler, Scott, MD",12/12/2024,Imatinib 30 Day Cycles - Sarcoma,_1. First Line,12/12/2024,Active,,
SOM OUTPT INFUSION,82802,"Yin, Faye, MD",1/5/2024,Capecitabine 21 Day Cycles - Breast,Neoadjuvant,1/5/2024,Active,,
CMC OP INFUSION,15546,"Talwar, Sumit, MD",6/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/28/2024,Inactive,,
MMC OP INFUSION,61847,"Meghal, Trishala, MD",7/26/2023,Neratinib 28 Day Cycles - Breast,,7/26/2023,Inactive,,
CINJ OP INFUSION,54884,"Mayer, Tina M, MD",1/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,1/18/2023,Inactive,,
CINJ PEDS HEMONC ,47295,"Moerdler, Scott, MD",2/12/2024,PEDS AEWS1031 Regimen A Induction & Consolidation,_1. First Line,2/11/2024,Inactive,,
MMC OP VP INFUSION,60879,"Talwar, Sumit, MD",4/18/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),Maintenance,4/18/2023,Inactive,,
MMC OP VP INFUSION,21883,"Talwar, Sumit, MD",3/14/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/13/2023,Inactive,,
JCMC CP INFUSION,78458,"Cruz, Allan Louie E, MD",4/29/2024,Pembrolizumab Maintance Q21 Days --- Triple Negative Breast Cancer,Neoadjuvant,4/22/2024,Inactive,,
CBMC OP INFUSION 2FL,66288,"Dharmapuri, Sirish, MD",3/13/2025,CINJ 072311 Durvalumab / Bevacizumab 21 Day Cycles Research- Hepatocellular Carcinoma,_1. First Line,3/10/2025,Active,HCC (hepatocellular carcinoma) (CMS/HCC),C22.0 - Liver cell carcinoma
NBR CINJ OP INFUSION,19334,"Matasar, Matthew J, MD",5/9/2023,CINJ 012103 ARM 2 MINI-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles Research- Non-Hodgkin Lymphoma,First Line,4/26/2023,Inactive,,
NBR 4N ONCOLOGY,9555,"Elsamra, Sammy, MD",5/9/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,5/9/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
MMC OP INFUSION,2654,"Cohen, Seth D, MD",9/25/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,First Line,9/24/2023,Inactive,,
MMC OP VP INFUSION,2654,"Cohen, Seth D, MD",3/10/2025,Cetuximab / PACLitaxel 100 mg/m2 / CARBOplatin AUC 2.5 21 Day Cycles- Head and Neck Cancers,_1. First Line,3/10/2025,Inactive,Malignant neoplasm of overlapping sites of tonsil (CMS/HCC),
MMC OP VP INFUSION,2654,"Cohen, Seth D, MD",3/10/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Head and Neck,_1. First Line,3/10/2025,Active,Malignant neoplasm of overlapping sites of tonsil (CMS/HCC),
CBMC OP INFUSION 2FL,90766,"Scoppetuolo, Michael, MD",12/1/2023,CISplatin/Pembrolizumab/Fluorouracil Continuous Infusion 21 Day Cycles- Head and Neck Cancers,_1. First Line,11/30/2023,Inactive,,
CBMC OP INFUSION 2FL,90766,"Scoppetuolo, Michael, MD",12/1/2023,Pembrolizumab 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/30/2023,Active,,
CBMC OP INFUSION 2FL,611,"Brown, Andrew Bennett, MD",9/4/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,Neoadjuvant,9/4/2024,Active,,
CBMC OP INFUSION 2FL,66679,"Brown, Andrew Bennett, MD",3/5/2025,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,Induction,3/5/2025,Inactive,Atypical carcinoid lung tumor (CMS/HCC),
CBMC OP INFUSION 2FL,66679,"Brown, Andrew Bennett, MD",3/5/2025,CISplatin/Irinotecan 28 Day Cycles- Small Cell Lung Cancer,Consolidation,3/5/2025,Active,Atypical carcinoid lung tumor (CMS/HCC),
NBI A5 PEDIATRICS,46935,"de Benedictis, Marianna, MD",7/27/2024,AALL1732 Induction,_1. First Line,7/25/2024,Inactive,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",9/4/2024,AALL1732 Consolidation,_1. First Line,9/4/2024,Inactive,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",10/30/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,10/29/2024,Inactive,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",10/31/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,10/30/2024,Inactive,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",11/4/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,11/4/2024,Active,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",11/4/2024,PEDS Blinatumomab,_1. First Line,11/4/2024,Inactive,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",12/16/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,12/16/2024,Active,,
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",2/26/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,2/25/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
NBI VALERIE FND HEMONC,46935,"de Benedictis, Marianna, MD",4/2/2025,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy Delayed Intensification",_1. First Line,4/2/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
NBR CINJ OP INFUSION,52016,"Matasar, Matthew J, MD",10/1/2024,CINJ 012203 Lead-In Treatment for Fit and Non-Fit Treatments Cycle 42 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,9/30/2024,Inactive,,
CMC OP INFUSION,2019,"Taff, Jessica, MD",5/18/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/17/2023,Inactive,,
NBR 4N BMTU/IMCU,95819,"Sridharan, Ashwin, MD",3/30/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,3/30/2024,Inactive,,
NBR CINJ OP INFUSION,95819,"Zayac, Adam, MD",5/13/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,5/6/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,70861,"Wagmiller, Jennifer Ann, MD",11/10/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,70861,"Wagmiller, Jennifer Ann, MD",3/21/2025,"Carbo D1/Vinorelbine D1, D8 21 Day Cycles (original plan with cisplatin)",_3. Third Line,3/3/2025,Active,Malignant neoplasm of unspecified part of right bronchus or lung (CMS/HCC),
CINJ OP INFUSION,95478,"Mayer, Tina M, MD",4/19/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,4/19/2023,Inactive,,
CINJ OP INFUSION,95478,"Mayer, Tina M, MD",9/3/2024,Apalutamide 30 Day Cycles - Prostate,_3. Third Line,9/3/2024,Active,,
CMC OP INFUSION,16733,"Cohen, Seth D, MD",9/3/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,8/28/2024,Active,"Malignant neoplasm of connective and soft tissue of left lower limb, including hip (CMS/HCC)",
TRMC TCCC OP INFUSION,55235,"Capo, Gerardo, MD",5/9/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,_2. Second Line,5/8/2025,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),
JCMC 7W MED-SURG 2,11885,"Cruz, Allan Louie E, MD",4/5/2024,MitoMYcin Intravesical - Bladder,Adjuvant,4/4/2024,Inactive,,
CINJ OP INFUSION,60123,"Saraiya, Biren P, MD",6/7/2023,CINJ 081804 Cohort ARM A-2 BCG 21 Day Cycles Research- Bladder Cancer,First Line,6/6/2023,Active,,
CBMC OP INFUSION 2FL,1166,"Litvak, Anna M, MD",11/2/2023,Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel weekly 21 Day Cycles - Breast,_1. First Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,1166,"Litvak, Anna M, MD",1/18/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Neoadjuvant,1/17/2024,Inactive,,
CBMC OP INFUSION 2FL,1166,"Ligresti, Louise G, MD",5/9/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,5/8/2024,Active,,
CBMC OP INFUSION 2FL,93339,"Litvak, Anna M, MD",1/30/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_3. Third Line,1/29/2025,Active,,
NBR 5N ONCOLOGY,18241,"Palmisiano, Neil David, MD",6/28/2023,CINJ 022105 (Part 1 of 2) Magrolimab or Placebo 28 Day Cycles Research- Acute Myeloid Leukemia,First Line,6/28/2023,Inactive,,
NBR 5N ONCOLOGY,18241,"Shah, Mansi R, MD",6/28/2023,CINJ 022105 (Part 2 of 2) Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,,6/27/2023,Inactive,,
MMC OP INFUSION,18241,"Eltoukhy, Hussam, MD",1/9/2024,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,Maintenance,1/7/2024,Inactive,,
MMC OP INFUSION,18241,"Eltoukhy, Hussam, MD",10/21/2024,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_2. Second Line,10/10/2024,Inactive,,
MMC BBR2 ONCOLOGY,18241,"Eltoukhy, Hussam, MD",11/6/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_4. Fourth Line,11/5/2024,Inactive,,
CINJ OP INFUSION,57795,"George, Mridula A, MD",7/10/2023,CINJ 042301 Capecitabine 21 Day Cycles Research- Breast Cancer,Third Line,7/10/2023,Inactive,,
CINJ OP INFUSION,57795,"George, Mridula A, MD",3/13/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,3/12/2024,Inactive,,
CINJ OP INFUSION,57795,"George, Mridula A, MD",6/10/2024,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,6/10/2024,Active,,
MMC OP VP INFUSION,7578,"Cohen, Seth D, MD",5/6/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/5/2024,Inactive,,
MMC OP VP INFUSION,7578,"Cohen, Seth D, MD",7/15/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/14/2024,Inactive,,
CMC OP INFUSION,60692,"Talwar, Sumit, MD",8/16/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,8/16/2023,Inactive,,
CMC OP INFUSION,60692,"Talwar, Sumit, MD",10/22/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/21/2024,Inactive,,
CMC OP INFUSION,60692,"Talwar, Sumit, MD",11/19/2024,CISplatin + Gemcitabine 28 Day Cycles - Pancreatic Adenocarcinoma,_2. Second Line,11/19/2024,Active,,
CMC OP INFUSION,60692,"Talwar, Sumit, MD",2/25/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/24/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),
HAM OP INFUSION,53730,"Yogarajah, Meera, MD",5/7/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/28/2024,Active,,
MMC OP VP INFUSION,28585,"Cohen, Seth D, MD",6/9/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/7/2023,Inactive,,
MMC OP VP INFUSION,28585,"Cohen, Seth D, MD",11/10/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/9/2023,Inactive,,
MMC OP VP INFUSION,28585,"Cohen, Seth D, MD",3/8/2024,CINJ 032304 Arm B Pembrolizumab / Ramucirumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,3/7/2024,Inactive,,
NBI OP INFUSION,32167,"Shah, Shailja S, MD",1/7/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/6/2025,Active,,
NBI OP INFUSION,29621,"Shah, Shailja S, MD",5/7/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/6/2024,Inactive,,
NBI OP INFUSION,29621,"Shah, Shailja S, MD",11/26/2024,Weekly Fluorouracil IV Push / Leucovorin IV Push 7 Day Cycles- Colon Cancer,_1. First Line,11/25/2024,Inactive,,
NBI OP INFUSION,29621,"Shah, Shailja S, MD",12/17/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/16/2024,Inactive,,
CINJ OP INFUSION,20586,"Groisberg, Roman, MD",3/29/2024,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,3/28/2024,Active,,
CBMC OP INFUSION 2FL,6193,"Scoppetuolo, Michael, MD",2/20/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,2/2/2025,Active,Malignant neoplasm of lower-outer quadrant of right female breast (CMS/HCC),"C50.511, Z17.0 - Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)"
MMC OP VP INFUSION,66580,"Lee, Patrick C, MD",8/30/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,8/29/2023,Inactive,,
CINJ OP INFUSION,59229,"Stephenson, Ryan D, DO",8/9/2023,Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,8/9/2023,Inactive,,
CMC 4B ONCOLOGY,86531,"Tang, Horace, MD",4/17/2023,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Testicular,Second Line,4/17/2023,Inactive,,
NBI OP INFUSION,89571,"Anderson, Patrick S, MD",1/25/2024,Gemcitabine / CARBOplatin / Bevacizumab(Zirabev) 21 Day Cycles + Bevacizumab(Zirabev) 21 Day Cycles - Synchronous ovarian and endometrial cancer,_2. Second Line,1/24/2024,Inactive,,
NBI OP INFUSION,89571,"Anderson, Patrick S, MD",7/25/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,7/24/2024,Active,,
CMC 4B ONCOLOGY,9574,"Tang, Horace, MD",4/17/2023,VIP (Etoposide / Ifosfamide / Mesna / CISplatin) 21 Day Cycles - Gestational Trophoblastic Neoplasia,Second Line,4/16/2023,Active,Malignant neoplasm of esophagus (CMS/HCC),
TRMC TCCC OP INFUSION,5464,"Capo, Gerardo, MD",5/15/2025,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,5/15/2025,Inactive,Adenocarcinoma of right lung (CMS/HCC),C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; G89.3 - Neoplasm related pain (acute) (chronic); Z87.898 - Personal history of other specified conditions
TRMC TCCC OP INFUSION,5464,"Capo, Gerardo, MD",5/15/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/15/2025,Active,Adenocarcinoma of right lung (CMS/HCC),C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; G89.3 - Neoplasm related pain (acute) (chronic); Z87.898 - Personal history of other specified conditions
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",5/30/2024,AALL1731 Non-DS B-LLy - Induction,_1. First Line,5/28/2024,Inactive,,
NBI A5 PEDIATRICS,46616,"Bhatla, Teena, MD",5/31/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,5/30/2024,Inactive,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",7/8/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,7/8/2024,Inactive,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",7/8/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,7/8/2024,Inactive,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",8/6/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,8/4/2024,Inactive,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",9/12/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,9/12/2024,Inactive,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",11/12/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,11/11/2024,Inactive,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",12/19/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,12/19/2024,Active,,
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",2/28/2025,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,2/25/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI VALERIE FND HEMONC,46616,"Bhatla, Teena, MD",4/28/2025,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,4/28/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
TRMC TCCC OP INFUSION,62253,"Salerno, Vincent E, MD",10/3/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/6/2024,Active,,
CBMC OP INFUSION 2FL,42363,"Litvak, Anna M, MD",5/23/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/23/2025,Inactive,"Invasive ductal carcinoma of breast, female (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C79.51 - Secondary malignant neoplasm of bone
CBMC OP INFUSION 2FL,42363,"Litvak, Anna M, MD",5/23/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/23/2025,Active,"Invasive ductal carcinoma of breast, female (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C79.51 - Secondary malignant neoplasm of bone
CINJ OP INFUSION,39753,"Berim, Lyudmyla, MD",10/6/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,,10/5/2023,Inactive,,
JCMC CP INFUSION,35787,"Ghuman, Damanjit, MD",5/18/2023,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,5/16/2023,Inactive,,
CINJ OP INFUSION,64232,"Leiser, Aliza, MD",5/23/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,5/23/2025,Active,Carcinosarcoma of body of uterus (CMS/HCC),
MMC OP VP INFUSION,63873,"Cohen, Seth D, MD",6/6/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/5/2024,Inactive,,
MMC OP VP INFUSION,63873,"Cohen, Seth D, MD",9/13/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/13/2024,Active,,
CINJ OP INFUSION,25680,"Haigentz, Missak, MD",10/31/2024,Trametinib 28 Day Cycles - NRASmt Cancer,_3. Third Line,10/31/2024,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,25680,"Haigentz, Missak, MD",11/9/2024,Everolimus 28 Day Cycles - Thymic Neuroendocrine Carcinoma,_3. Third Line,11/9/2024,Active,,
CINJ OP INFUSION,36757,"Haigentz, Missak, MD",12/30/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,12/30/2024,Inactive,,
MMC OP INFUSION,45346,"Meghal, Trishala, MD",9/17/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Induction,8/12/2024,Inactive,,
MMC OP VP INFUSION,45346,"Meghal, Trishala, MD",12/18/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,11/25/2024,Inactive,,
MMC OP VP INFUSION,45346,"Meghal, Trishala, MD",1/8/2025,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/17/2024,Active,,
NBI OP INFUSION,47782,"Schleicher, Lori, MD",4/23/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,4/23/2025,Active,Follicular lymphoma grade I of intra-abdominal lymph nodes (CMS/HCC),"C82.03 - Follicular lymphoma grade i, intra-abdominal lymph nodes; R59.0 - Localized enlarged lymph nodes"
CINJ OP INFUSION,92324,"Mayer, Tina M, MD",5/22/2023,Bevacizumab 28 Day Cycles - CNS,Second Line,5/22/2023,Active,,
CINJ OP INFUSION,92324,"Mayer, Tina M, MD",7/24/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,,7/24/2023,Active,Malignant neoplasm of rectum (CMS/HCC),
JCMC CP INFUSION,13790,"Cruz, Allan Louie E, MD",1/7/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/5/2025,Active,,
MMC OP VP INFUSION,17622,"Cohen, Seth D, MD",7/20/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/14/2023,Inactive,,
CINJ OP INFUSION,62076,"George, Mridula A, MD",5/15/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/15/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,47350,"Meghal, Trishala, MD",9/5/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,9/5/2024,Inactive,,
NBR CINJ OP INFUSION,74167,"Matasar, Matthew J, MD",5/24/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,5/23/2023,Inactive,,
JCMC CP INFUSION,40839,"Cruz, Allan Louie E, MD",4/6/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles - Cervical,First Line,4/5/2023,Inactive,,
JCMC CP INFUSION,40839,"Cruz, Allan Louie E, MD",10/18/2023,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_2. Second Line,10/17/2023,Inactive,,
CBMC OP INFUSION 2FL,10251,"Leitner, Stuart P, MD",11/15/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/14/2023,Inactive,,
CBMC OP INFUSION 2FL,10251,"Leitner, Stuart P, MD",11/15/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/14/2023,Inactive,,
TRMC TCCC OP INFUSION,13758,"Salerno, Vincent E, MD",5/21/2025,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,_3. Third Line,5/21/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
TRMC TCCC OP INFUSION,13758,"Salerno, Vincent E, MD",5/9/2025,weekly cisplatin x 6 with concurrent xrt,_3. Third Line,5/9/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C68.0 - Malignant neoplasm of urethra; I10 - Essential (primary) hypertension; M79.605 - Pain in left leg; M79.89 - Other specified soft tissue disorders; Z86.39 - Personal history of other endocrine, nutritional and metabolic disease"
SOM OUTPT INFUSION,94031,"Toomey, Kathleen C, MD",3/14/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/14/2024,Active,AML (acute myeloid leukemia) in remission (CMS/HCC),
CINJ OP INFUSION,35027,"Muralikrishnan, Sivraj",12/17/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,12/5/2024,Active,,
CINJ OP INFUSION,87129,"Muralikrishnan, Sivraj, MD",2/25/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,2/24/2025,Active,Cancer of right lung (CMS/HCC),"C34.2 - Malignant neoplasm of middle lobe, bronchus or lung; C34.01 - Malignant neoplasm of right main bronchus; C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; K85.10 - Biliary acute pancreatitis without necrosis or infection; K85.00 - Idiopathic acute pancreatitis without necrosis or infection; C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; Z90.2 - Acquired absence of lung (part of)"
CINJ OP INFUSION,42969,"Stephenson, Ruth D, DO",11/27/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Uterine,_1. First Line,11/7/2023,Inactive,,
CINJ OP INFUSION,42969,"Stephenson, Ruth D, DO",2/14/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/13/2024,Inactive,,
NBR CINJ OP INFUSION,81112,"Rhodes, Joanna Meehan, MD",6/12/2024,BMT Autologous Carmustine / Thiotepa,_3. Third Line,6/12/2024,Active,,
MMC OP VP INFUSION,25905,"Lee, Patrick C, MD",1/3/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,12/26/2024,Active,,
MSC OP INFUSION,63899,"Cohen, Seth D, MD",2/2/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,2/1/2023,Inactive,,
CMC OP INFUSION,82741,"Easaw, Sarah, MD",5/11/2023,PACLitaxel / CARBOplatin Post Concurrent Radiation Consolidation 21 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,4/28/2023,Inactive,,
CINJ OP INFUSION,55007,"Stephenson, Ryan D, DO",11/1/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,10/31/2023,Inactive,,
NBR CINJ OP INFUSION,51215,"Rhodes, Joanna Meehan, MD",9/20/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,9/19/2024,Inactive,,
NBR CINJ OP INFUSION,51215,"Rhodes, Joanna Meehan, MD",9/20/2024,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,9/19/2024,Inactive,,
NBR CINJ OP INFUSION,51215,"Rhodes, Joanna Meehan, MD",11/22/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine)  28 Day Cycles - Hodgkin Lymphoma,_1. First Line,11/21/2024,Active,,
NBR CINJ OP INFUSION,51103,"Assal, Amer, MD",3/16/2024,BMT Autologous Melphalan Day -1 140MG/M2,Consolidation,3/14/2024,Inactive,,
CINJ OP INFUSION,52031,"Weiss, Sarah, MD",8/4/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,8/3/2023,Inactive,,
CINJ OP INFUSION,52031,"Weiss, Sarah, MD",3/20/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_3. Third Line,3/15/2024,Inactive,,
CINJ OP INFUSION,52031,"Weiss, Sarah, MD",10/21/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_4. Fourth Line,10/1/2024,Active,,
CINJ OP INFUSION,12472,"Berim, Lyudmyla, MD",4/3/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,4/2/2024,Inactive,,
CINJ OP INFUSION,77553,"Berim, Lyudmyla, MD",2/13/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,,2/12/2023,Inactive,,
CMC OP INFUSION,37667,"Easaw, Sarah, MD",4/10/2023,Pembrolizumab 21 Day Cycles -Kidney,First Line,4/10/2023,Inactive,,
HAM OP INFUSION,40288,"Gendy, Mina, DO",2/19/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,2/9/2025,Active,Multiple myeloma (CMS/HCC),Z23 - Encounter for immunization
CBMC OP INFUSION 2FL,93440,"Grossman, I Robert, MD",5/29/2025,"RiTUXimab D1, D15",_2. Second Line,5/21/2025,Active,CIDP (chronic inflammatory demyelinating polyneuropathy) (CMS/HCC),
CBMC OP INFUSION 2FL,93440,"Grossman, I Robert, MD",4/23/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,4/23/2025,Inactive,CIDP (chronic inflammatory demyelinating polyneuropathy) (CMS/HCC),
CINJ OP INFUSION,25604,"George, Mridula A, MD",3/29/2024,"CINJ 042315 Arm 1 PACLitaxel D1, D8 14 Day Cycles followed by DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer",Neoadjuvant,3/28/2024,Active,,
CINJ PEDS HEMONC ,73774,"Botwinick, Marissa, DO",5/31/2024,COG5961 - Group A (COPAD),_1. First Line,5/30/2024,Inactive,,
CBMC OP INFUSION 2FL,4950,"Brown, Andrew Bennett, MD",8/1/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/1/2024,Active,,
CINJ OP INFUSION,53902,"Weiss, Sarah, MD",11/4/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,10/20/2024,Active,,
JCMC CP INFUSION,94084,"Cruz, Allan Louie E, MD",5/15/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles - Cervical,,5/15/2023,Inactive,,
JCMC CP INFUSION,94084,"Cruz, Allan Louie E, MD",3/21/2024,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_4. Fourth Line,3/20/2024,Inactive,,
JCMC CP INFUSION,94084,"Cruz, Allan Louie E, MD",7/11/2024,Pembrolizumab 21 Day Cycles - Cervical,_3. Third Line,7/7/2024,Active,,
JCMC CP INFUSION,94084,"Cruz, Allan Louie E, MD",4/29/2025,"Gemcitabine D1, D8 21 Day Cycles- Cervical cancer",_3. Third Line,4/29/2025,Active,Malignant neoplasm of cervix uteri (CMS/HCC),"C53.9 - Malignant neoplasm of cervix uteri, unspecified; N18.4 - Chronic kidney disease, stage 4 (severe); D63.1 - Anemia in chronic kidney disease"
JCMC CP INFUSION,94084,"Cruz, Allan Louie E, MD",4/22/2025,PEMEtrexed 21 Day Cycles - Uterine,_4. Fourth Line,4/22/2025,Inactive,Malignant neoplasm of cervix uteri (CMS/HCC),"C53.9 - Malignant neoplasm of cervix uteri, unspecified; N18.4 - Chronic kidney disease, stage 4 (severe); D63.1 - Anemia in chronic kidney disease"
MMC OP VP INFUSION,5767,"Cohen, Seth D, MD",5/31/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/29/2023,Inactive,,
CINJ OP INFUSION,43758,"Berim, Lyudmyla, MD",1/4/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/3/2023,Inactive,,
CINJ OP INFUSION,43758,"Berim, Lyudmyla, MD",2/15/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/14/2023,Inactive,,
MMC OP INFUSION,24804,"Meghal, Trishala, MD",9/2/2023,Abemaciclib 28 Day Cycles - Breast ,,9/2/2023,Inactive,,
MMC OP INFUSION,24804,"Meghal, Trishala, MD",9/18/2023,Palbociclib 28 Day Cycles - Breast,,9/18/2023,Inactive,,
MMC OP INFUSION,24804,"Meghal, Trishala, MD",12/27/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,12/21/2023,Inactive,,
MMC OP INFUSION,24804,"Meghal, Trishala, MD",6/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,6/10/2024,Active,,
MSC OP INFUSION,24804,"Cohen, Seth D, MD",5/29/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/29/2025,Active,"Long term (current) use of aromatase inhibitors
Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC)",
CINJ OP INFUSION,56132,"Aikins, James K, MD",4/12/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,4/11/2024,Active,,
CMC OP INFUSION,68758,"Eltoukhy, Hussam, MD",2/12/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,2/12/2024,Active,Jejunal adenocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,37183,"Patel, Eshan, MD",12/19/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/18/2023,Inactive,,
SOM OUTPT INFUSION,18374,"Yin, Faye, MD",1/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/17/2023,Inactive,,
SOM OUTPT INFUSION,18374,"Toomey, Kathleen C, MD",1/17/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/16/2024,Active,,
SOM OUTPT INFUSION,18374,"Yin, Faye, MD",6/5/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/5/2024,Inactive,,
CINJ OP INFUSION,18374,"Kennedy, Timothy, MD",7/19/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,7/19/2024,Inactive,,
CINJ OP INFUSION,10040,"Stephenson, Ryan D, DO",1/27/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,1/26/2023,Inactive,,
SOM OUTPT INFUSION,80304,"Toomey, Kathleen C, MD",1/26/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,1/24/2023,Inactive,,
SOM OUTPT INFUSION,80304,"Toomey, Kathleen C, MD",10/2/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,9/25/2024,Inactive,,
SOM OUTPT INFUSION,80304,"Toomey, Kathleen C, MD",10/23/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,10/22/2024,Active,Malignant neoplasm of ascending colon (CMS/HCC),
NBR CINJ OP INFUSION,87101,"Evens, Andrew M, DO",11/29/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,87101,"Evens, Andrew M, DO",6/12/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,6/11/2024,Active,Urothelial cancer (CMS/HCC),
MMC OP VP INFUSION,29862,"Meghal, Trishala, MD",6/19/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/18/2023,Inactive,,
MMC OP VP INFUSION,29862,"Meghal, Trishala, MD",4/30/2024,Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,3/10/2024,Inactive,,
CMC OP INFUSION,80239,"Pompa, Tiffany Ann, MD",10/9/2024,Gemcitabine/CISplatin 21 Day Cycles- Hepatobiliary Cancers- Gemcitabine-CISplatin Sequencing,_1. First Line,9/16/2024,Active,,
CBMC OP INFUSION 2FL,79502,"Wagmiller, Jennifer Ann, MD",12/19/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,12/17/2023,Inactive,,
CBMC OP INFUSION 2FL,79502,"Wagmiller, Jennifer Ann, MD",4/15/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/14/2024,Active,,
NBI OP INFUSION,58612,"Cheng, Yan Ho, MD",4/1/2025,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,4/1/2025,Active,Carcinoma of breast metastatic to bone (CMS/HCC),
CINJ OP INFUSION,52615,"Hochster, Howard S, MD",11/30/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/22/2023,Inactive,,
CINJ OP INFUSION,66199,"Weiss, Sarah, MD",2/6/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_4. Fourth Line,2/5/2024,Inactive,,
NBR CINJ OP INFUSION,23716,"Palmisiano, Neil David, MD",7/23/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,7/22/2024,Inactive,,
NBR CINJ OP INFUSION,23716,"Palmisiano, Neil David, MD",9/3/2024,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/3/2024,Active,,
CINJ OP INFUSION,3177,"Ghodoussipour, Saum Bobak, MD",2/6/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,,2/6/2024,Inactive,,
CINJ OP INFUSION,26133,"Weiss, Sarah, MD",1/13/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,12/10/2024,Active,,
JCMC CP INFUSION,57683,"Sekhri, Arunabh, MD",4/7/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,4/7/2025,Inactive,Carcinoma submandibular gland (CMS/HCC),"C08.0 - Malignant neoplasm of submandibular gland; E78.5 - Hyperlipidemia, unspecified; R11.2 - Nausea with vomiting, unspecified; R45.89 - Other symptoms and signs involving emotional state; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
MMC OP INFUSION,67646,"Meghal, Trishala, MD",1/20/2023,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,,1/19/2023,Inactive,,
MMC OP INFUSION,67646,"Meghal, Trishala, MD",10/25/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,10/24/2023,Inactive,,
MMC OP INFUSION,67646,"Meghal, Trishala, MD",2/14/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_3. Third Line,2/13/2024,Inactive,,
NBR 4N ONCOLOGY,67646,"Zayac, Adam, MD",2/17/2024,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,2/17/2024,Inactive,,
MMC BBR2 ONCOLOGY,67646,"Meghal, Trishala, MD",2/28/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_3. Third Line,2/27/2024,Inactive,,
CINJ OP INFUSION,53787,"Patel, Eshan, MD",3/13/2023,CINJ 032003 Durvalumab 14 Day Cycles Group C Post-RT Research- Non-Small Cell Lung Cancer,Consolidation,3/12/2023,Active,,
SOM OUTPT INFUSION,83770,"Patel, Eshan, MD",2/19/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/11/2025,Active,Metastatic colon cancer to liver (CMS/HCC),
CBMC OP INFUSION 2FL,77261,"Brown, Andrew Bennett, MD",4/12/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",Neoadjuvant,4/12/2024,Active,,
NBR CINJ OP INFUSION,595,"Assal, Amer, MD",7/13/2024,BMT Autologous Melphalan Day -1  200mg/m2,_1. First Line,7/11/2024,Active,,
NBR CINJ OP INFUSION,595,"Assal, Amer, MD",7/24/2024,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_1. First Line,7/23/2024,Inactive,,
NBR CINJ OP INFUSION,595,"Shah, Mansi R, MD",4/17/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,4/17/2025,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,94513,"Hochster, Howard S, MD",8/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/27/2024,Active,,
CINJ OP INFUSION,94513,"Hochster, Howard S, MD",1/22/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,1/22/2025,Active,,
NBI OP INFUSION,76302,"Shah, Maya M, MD",8/14/2023,Elotuzumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_3. Third Line,8/13/2023,Inactive,,
NBI OP INFUSION,73129,"Shah, Maya M, MD",8/14/2023,Elotuzumab/Bortezomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,8/13/2023,Active,,
CBMC OP INFUSION 2FL,99125,"Wagmiller, Jennifer Ann, MD",1/8/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/7/2024,Inactive,,
CBMC OP INFUSION 1FL,1698,"Meelheim, Brooke A, DO",11/4/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,11/3/2024,Inactive,,
CBMC OP INFUSION 1FL,1698,"Meelheim, Brooke A, DO",11/18/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,11/10/2024,Active,,
NBI A5 PEDIATRICS,40335,"Ford, Maegan C, MD",5/8/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,5/7/2024,Inactive,,
NBI VALERIE FND HEMONC,40335,"Ford, Maegan C, MD",6/13/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,6/13/2024,Inactive,,
NBI VALERIE FND HEMONC,40335,"Ford, Maegan C, MD",7/11/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,7/11/2024,Inactive,,
NBI VALERIE FND HEMONC,40335,"Ford, Maegan C, MD",9/12/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,9/12/2024,Inactive,,
NBI VALERIE FND HEMONC,40335,"Ford, Maegan C, MD",11/12/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,Consolidation,11/12/2024,Active,,
NBI VALERIE FND HEMONC,40335,"Ford, Maegan C, MD",1/22/2025,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,1/22/2025,Active,,
CINJ OP INFUSION,92643,"Boland, Patrick M, MD",3/10/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/6/2023,Inactive,,
CINJ OP INFUSION,92643,"Boland, Patrick M, MD",8/25/2023,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,8/24/2023,Inactive,,
CINJ OP INFUSION,67749,"Patel, Eshan, MD",6/7/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,6/6/2024,Active,,
SOM OUTPT INFUSION,83869,"Toomey, Kathleen C, MD",11/10/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,10/31/2023,Inactive,,
SOM OUTPT INFUSION,83869,"Toomey, Kathleen C, MD",10/18/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,10/18/2024,Active,,
SOM 1PAV ONCOLOGY,61816,"Pan, Beiqing, MD",11/15/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,11/14/2023,Active,,
CINJ OP INFUSION,4620,"Gulhati, Prateek, MD PhD",12/7/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,12/5/2023,Inactive,,
NBI OP INFUSION,11302,"Cheng, Yan Ho, MD",7/2/2024,RiTUXimab x 2 doses every 6 months - Multiple Sclerosis,_1. First Line,7/1/2024,Inactive,,
MSC OP INFUSION,5937,"Cohen, Seth D, MD",5/22/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,5/15/2024,Inactive,,
MMC OP VP INFUSION,5937,"Cohen, Seth D, MD",8/28/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/23/2024,Active,,
MMC OP VP INFUSION,5937,"Cohen, Seth D, MD",4/7/2025,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_2. Second Line,4/7/2025,Active,Cholangiocarcinoma at hepatic hilum (CMS/HCC),
CBMC OP INFUSION 2FL,69101,"Freeman, Benjamin B, MD",2/3/2025,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,1/27/2025,Active,Chronic myelomonocytic leukemia (CMS/HCC),
CBMC OP INFUSION 1FL,69101,"Freeman, Benjamin B, MD",3/28/2025,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_4. Fourth Line,3/28/2025,Active,Chronic myelomonocytic leukemia (CMS/HCC),C61 - Malignant neoplasm of prostate; C93.10 - Chronic myelomonocytic leukemia not having achieved remission
CMMC OP INFUSION,69101,"Freeman, Benjamin B, MD",3/20/2025,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_4. Fourth Line,3/20/2025,Inactive,Chronic myelomonocytic leukemia (CMS/HCC),C61 - Malignant neoplasm of prostate; C93.10 - Chronic myelomonocytic leukemia not having achieved remission
CMC OP INFUSION,7426,"Pompa, Tiffany Ann, MD",9/24/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/4/2024,Active,,
TRMC TCCC OP INFUSION,72564,"Salerno, Vincent E, MD",4/2/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/2/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
CBMC OP INFUSION 2FL,91622,"Dharmapuri, Sirish, MD",9/16/2024,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/15/2024,Active,,
NBR CINJ OP INFUSION,85256,"Tiger, Yun Kyoung, MD",3/6/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,2/27/2024,Inactive,,
NBI OP INFUSION,31827,"Jacoby, Sari H, MD",10/9/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,10/8/2023,Active,,
CMC OP INFUSION,31218,"Talwar, Sumit, MD",10/24/2023,Cemiplimab-rwlc 21 Day Cycles - Basal Cell Skin Cancer,Adjuvant,10/24/2023,Active,,
MSC OP INFUSION,28791,"Pompa, Tiffany Ann, MD",11/7/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/21/2024,Active,,
MMC OP INFUSION,73175,"Lee, Patrick C, MD",5/2/2023,CISplatin/Cetuximab 28 Day Cycles- Head and Neck Cancers,,5/1/2023,Inactive,,
CBMC OP INFUSION 2FL,21190,"Grossman, I Robert, MD",2/9/2024,RiTUXimab Initial Infusion Single Day then Subsequent (Outpatient),_1. First Line,1/31/2024,Inactive,,
CMC OP INFUSION,90360,"Tang, Horace, MD",2/1/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/1/2024,Inactive,,
NBR 4N ONCOLOGY,68508,"Palmisiano, Neil David, MD",7/17/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,7/17/2023,Inactive,,
NBR CINJ OP INFUSION,68508,"Palmisiano, Neil David, MD",8/3/2023,"(IT) Cytar / MTX, D1 D15 Hematological Malignancies",,8/3/2023,Inactive,,
NBR CINJ OP INFUSION,68508,"Rhodes, Joanna Meehan, MD",8/29/2023,Intrathecal Chemotherapy Day 1/ Day 15 Hematological Malignancies,,8/29/2023,Inactive,,
NBR CINJ OP INFUSION,68508,"Chowaniec, Wayne B, NP",3/14/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,3/14/2024,Inactive,,
NBR CINJ OP INFUSION,68508,"Egini, Ogechukwu, MD",3/31/2024,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,Lymphodepletion,3/31/2024,Inactive,,
NBR 4N BMTU/IMCU,68508,"Palmisiano, Neil David, MD",4/12/2024,Cytarabine Cytoreduction for Hyperleukocytosis,Lymphodepletion,4/12/2024,Inactive,,
NBI OP INFUSION,64778,"Anderson, Patrick S, MD",5/21/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Vaginal Cancer,_1. First Line,5/9/2024,Active,,
CINJ OP INFUSION,93222,"Omene, Coral Oghenerukevwe, MD",2/4/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,2/3/2025,Active,Malignant neoplasm of female breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,4207,"Leiser, Aliza, MD",2/17/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,2/14/2025,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,61365,"Stephenson, Ryan D, DO",5/24/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,14916,"Shah, Mansi R, MD",4/20/2023,CINJ 011912 (54767414MMY3021) ARM A Daratumumab and Hyaluronidase-fihj / Lenalidomide 28 Day Cycles Research- Multiple Myeloma,,4/19/2023,Active,,
CINJ OP INFUSION,67965,"Mayer, Tina M, MD",4/24/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/24/2025,Active,Bladder cancer (CMS/HCC),
CINJ OP INFUSION,67965,"Mayer, Tina M, MD",4/21/2025,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,4/21/2025,Inactive,Bladder cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C68.9 - Malignant neoplasm of urinary organ, unspecified"
CINJ OP INFUSION,36999,"Stephenson, Ryan D, DO",5/27/2025,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Adjuvant,5/27/2025,Active,Sarcomatoid urothelial carcinoma of urinary bladder (CMS/HCC),"S31.109A - Unspecified open wound of abdominal wall, unspecified quadrant without penetration into peritoneal cavity, initial encounter; R60.0 - Localized edema; I87.1 - Compression of vein; M79.661 - Pain in right lower leg; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; H91.90 - Unspecified hearing loss, unspecified ear; Z85.51 - Personal history of malignant neoplasm of bladder; Z85.46 - Personal history of malignant neoplasm of prostate; Z92.3 - Personal history of irradiation; Z87.891 - Personal history of nicotine dependence; Z90.89 - Acquired absence of other organs; Z90.79 - Acquired absence of other genital organ(s); Z98.49 - Cataract extraction status, unspecified eye; Z79.01 - Long term (current) use of anticoagulants; Z79.52 - Long term (current) use of systemic steroids; Z79.899 - Other long term (current) drug therapy; C67.9 - Malignant neoplasm of bladder, unspecified; M25.461 - Effusion, right knee"
CBMC OP INFUSION 2FL,85496,"Brown, Andrew Bennett, MD",4/21/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,4/21/2025,Active,Squamous cell carcinoma of oropharynx (CMS/HCC),
CINJ OP INFUSION,19702,"Boland, Patrick M, MD",1/31/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,1/23/2023,Active,,
CINJ OP INFUSION,8140,"Stephenson, Ryan D, DO",7/17/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,First Line,7/16/2023,Inactive,,
CINJ OP INFUSION,79059,"Packiam, Vignesh, MD",3/27/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,3/27/2024,Inactive,,
CINJ OP INFUSION,79059,"Packiam, Vignesh, MD",6/19/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,6/18/2024,Active,,
CMC OP INFUSION,70181,"Taff, Jessica, MD",4/4/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer (substitute Cisplatin d/t carbo shortage),First Line,3/28/2023,Inactive,,
CMC OP INFUSION,70181,"Taff, Jessica, MD",7/20/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/11/2023,Inactive,,
CMC OP INFUSION,70181,"Taff, Jessica, MD",4/3/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/3/2025,Active,"NSCLC of left lung (CMS/HCC)
Thrombosis due to vascular prosthetic devices, implants and grafts, subsequent encounter
Malignant neoplasm of lung (CMS/HCC)",
CBMC OP INFUSION 2FL,15038,"Dharmapuri, Sirish, MD",10/14/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/13/2024,Inactive,,
CINJ OP INFUSION,71426,"Jang, Thomas L, MD",7/29/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/28/2024,Inactive,,
CINJ OP INFUSION,71426,"Jang, Thomas L, MD",1/15/2025,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/15/2025,Active,,
CINJ OP INFUSION,71426,"Jang, Thomas L, MD",2/28/2025,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,2/28/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; N32.9 - Bladder disorder, unspecified; I10 - Essential (primary) hypertension; G89.29 - Other chronic pain; E78.5 - Hyperlipidemia, unspecified; L40.9 - Psoriasis, unspecified; H91.90 - Unspecified hearing loss, unspecified ear; M19.90 - Unspecified osteoarthritis, unspecified site; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z95.828 - Presence of other vascular implants and grafts; Z95.5 - Presence of coronary angioplasty implant and graft; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.02 - Long term (current) use of antithrombotics/antiplatelets; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,45426,"Berim, Lyudmyla, MD",12/15/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,12/15/2023,Inactive,,
CINJ OP INFUSION,45426,"Berim, Lyudmyla, MD",3/20/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/18/2024,Active,,
CINJ OP INFUSION,6090,"Mayer, Tina M, MD",7/17/2024,CINJ 082307 Arm 2 Abiraterone + Prednisone 28 Day Cycles Research- Prostate Cancer,_2. Second Line,7/17/2024,Active,,
CMC OP INFUSION,81471,"Pompa, Tiffany Ann, MD",10/2/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,10/1/2024,Active,"Esophageal cancer (CMS/HCC)
Cancer of distal third of esophagus (CMS/HCC)",
MMC OP INFUSION,43586,"Lee, Patrick C, MD",2/11/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,2/10/2025,Active,Hepatocellular carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,3556,"Brown, Andrew Bennett, MD",8/14/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/14/2024,Inactive,,
CBMC OP INFUSION 2FL,14920,"Grossman, I Robert, MD",9/11/2024,RiTUXimab Initial and Subsequent Infusion Single Day (Outpatient),_1. First Line,8/27/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
MMC OP INFUSION,96425,"Meghal, Trishala, MD",4/26/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,4/25/2023,Inactive,,
MMC OP INFUSION,96425,"Meghal, Trishala, MD",5/10/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Cervical ,_1. First Line,5/9/2024,Inactive,,
MMC OP INFUSION,96425,"Lee, Patrick C, MD",5/15/2025,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,5/15/2025,Active,Vulvar carcinoma (CMS/HCC),
NBI OP INFUSION,1435,"Shah, Maya M, MD",4/15/2023,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,4/15/2023,Active,,
CINJ OP INFUSION,57059,"Haigentz, Missak, MD",11/4/2024,CINJ 032006 (BTCRC-LUN18-153) ARM A Pembrolizumab 42 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,10/6/2024,Inactive,,
CMC OP INFUSION,2420,"Talwar, Sumit, MD",3/3/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/3/2025,Inactive,"Metastatic small cell carcinoma involving mediastinum with unknown primary site (CMS/HCC)
Drug-induced thyroiditis",
HAM OP INFUSION,5344,"Patel, Malini M, MD",1/4/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,1/3/2023,Inactive,,
CINJ OP INFUSION,27355,"Groisberg, Roman, MD",7/5/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,Third Line,7/4/2023,Inactive,,
MMC OP INFUSION,52544,"Meghal, Trishala, MD",9/16/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/23/2024,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),
CINJ OP INFUSION,3447,"Haigentz, Missak, MD",7/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,7/21/2024,Active,,
CBMC OP INFUSION 2FL,57025,"Leitner, Stuart P, MD",4/26/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/25/2024,Active,,
NBR CINJ OP INFUSION,52182,"Eltoukhy, Hussam, MD",8/18/2023,CINJ 012207 Arm 1 Dose Level 2 Tazemetostat / Rituximab / Bendamustine 28 Day Cycles Research- Follicular Lymphoma,First Line,8/17/2023,Inactive,,
CINJ OP INFUSION,4282,"Mayer, Tina M, MD",11/30/2023,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,11/30/2023,Active,,
CBMC OP INFUSION 2FL,45657,"Scoppetuolo, Michael, MD",4/18/2024,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",_1. First Line,4/8/2024,Active,,
CMC OP INFUSION,32374,"Taff, Jessica, MD",2/12/2024,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,2/1/2024,Inactive,,
MMC OP VP INFUSION,75968,"Cohen, Seth D, MD",7/31/2023,Cetuximab / PACLitaxel 100 mg/m2 / CARBOplatin AUC 2.5 21 Day Cycles- Head and Neck Cancers,First Line,7/30/2023,Inactive,,
MMC OP VP INFUSION,75968,"Cohen, Seth D, MD",7/31/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,7/30/2023,Inactive,,
MMC OP VP INFUSION,75968,"Cohen, Seth D, MD",9/9/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/4/2024,Inactive,,
SOM OUTPT INFUSION,13648,"Patel, Eshan, MD",5/14/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,5/14/2025,Active,Gastric adenocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,13648,"Patel, Eshan, MD",5/6/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/6/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),"K31.89 - Other diseases of stomach and duodenum; C16.9 - Malignant neoplasm of stomach, unspecified"
HAM OP INFUSION,50859,"Yogarajah, Meera, MD",10/31/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,10/27/2024,Active,,
NBR 5N ONCOLOGY,40487,"Toppmeyer, Deborah L, MD",1/16/2023,VIP (Etoposide / Ifosfamide / Mesna / CISplatin) 21 Day Cycles - Gestational Trophoblastic Neoplasia,First Line,1/15/2023,Inactive,,
CINJ OP INFUSION,77885,"Saraiya, Biren P, MD",5/22/2024,CINJ 082210 Arm B ddMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles Research- Urothelial Cancer,Neoadjuvant,5/21/2024,Inactive,,
NBR 5N ONCOLOGY,77885,"Packiam, Vignesh, MD",8/6/2024,Gemcitabine Intravesical Single Dose - Bladder,Consolidation,8/6/2024,Active,,
CINJ OP INFUSION,14764,"Berim, Lyudmyla, MD",4/9/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,4/9/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C25.9 - Malignant neoplasm of pancreas, unspecified"
CMC OP INFUSION,48698,"Taff, Jessica, MD",7/10/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,6/30/2023,Inactive,,
CMC OP INFUSION,48698,"Taff, Jessica, MD",2/2/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,1/31/2024,Inactive,,
CINJ OP INFUSION,17742,"Haigentz, Missak, MD",2/13/2023,CINJ 032003 Durvalumab 14 Day Cycles Group C Post-RT Research- Non-Small Cell Lung Cancer,Consolidation,2/12/2023,Inactive,,
CINJ OP INFUSION,17742,"Haigentz, Missak, MD",9/9/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/8/2023,Inactive,,
CINJ OP INFUSION,17742,"Haigentz, Missak, MD",12/29/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/29/2023,Inactive,,
CBMC OP INFUSION 2FL,33773,"Scoppetuolo, Michael, MD",2/27/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,2/18/2024,Inactive,,
CBMC OP INFUSION 2FL,33773,"Scoppetuolo, Michael, MD",7/1/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,6/30/2024,Active,,
SOM OUTPT INFUSION,17186,"Yin, Faye, MD",9/13/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/12/2023,Inactive,,
HAM OP INFUSION,46662,"Patel, Malini M, MD",4/14/2025,RiTUXimab 28 Day Cycle - ITP,_1. First Line,4/14/2025,Active,Acute idiopathic thrombocytopenic purpura (CMS/HCC),"D69.3 - Immune thrombocytopenic purpura; E11.9 - Type 2 diabetes mellitus without complications; D69.59 - Other secondary thrombocytopenia; I34.0 - Nonrheumatic mitral (valve) insufficiency; E66.9 - Obesity, unspecified; E78.5 - Hyperlipidemia, unspecified; K06.8 - Other specified disorders of gingiva and edentulous alveolar ridge; N93.9 - Abnormal uterine and vaginal bleeding, unspecified; R04.0 - Epistaxis; K21.9 - Gastro-esophageal reflux disease without esophagitis; G47.33 - Obstructive sleep apnea (adult) (pediatric); F41.9 - Anxiety disorder, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I25.5 - Ischemic cardiomyopathy; Z95.5 - Presence of coronary angioplasty implant and graft; Z83.3 - Family history of diabetes mellitus; I25.2 - Old myocardial infarction; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.51 - Family history of malignant neoplasm of kidney; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.02 - Long term (current) use of antithrombotics/antiplatelets; Z79.899 - Other long term (current) drug therapy; Z98.891 - History of uterine scar from previous surgery; Z98.51 - Tubal ligation status; Z68.34 - Body mass index (BMI) 34.0-34.9, adult"
CBMC 2W ONCOLOGY,52175,"Grossman, I Robert, MD",11/7/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_2. Second Line,11/7/2023,Inactive,,
MSC OP INFUSION,10337,"Lee, Patrick C, MD",1/8/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,1/7/2024,Inactive,,
CINJ OP INFUSION,84215,"Aikins, James K, MD",2/2/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Cervical,Third Line,2/1/2023,Active,,
NBR 5N ONCOLOGY,959,"Shah, Mansi R, MD",8/17/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,First Line,8/17/2023,Inactive,,
NBR 5N ONCOLOGY,959,"Rhodes, Joanna Meehan, MD",8/21/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,8/21/2023,Inactive,,
NBR CINJ OP INFUSION,959,"Rhodes, Joanna Meehan, MD",10/5/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,10/5/2023,Inactive,,
NBR 5N ONCOLOGY,959,"Rhodes, Joanna Meehan, MD",4/8/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,Adjuvant,4/7/2024,Inactive,,
CINJ OP INFUSION,98214,"Boland, Patrick M, MD",7/11/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,7/5/2023,Inactive,,
CINJ OP INFUSION,98214,"Boland, Patrick M, MD",2/16/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,2/8/2024,Inactive,,
CINJ OP INFUSION,98214,"Boland, Patrick M, MD",8/9/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,8/8/2024,Inactive,,
CINJ OP INFUSION,98214,"Boland, Patrick M, MD",10/18/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,10/10/2024,Active,,
CINJ OP INFUSION,98214,"Boland, Patrick M, MD",2/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,2/13/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C61 - Malignant neoplasm of prostate"
CMC OP INFUSION,99494,"Taff, Jessica, MD",3/6/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,2/21/2024,Active,,
CINJ OP INFUSION,30278,"Aikins, James K, MD",4/27/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,4/26/2023,Inactive,,
CINJ OP INFUSION,44707,"Hochster, Howard S, MD",11/27/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/26/2024,Active,,
CINJ OP INFUSION,48116,"Hochster, Howard S, MD",3/24/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,3/24/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
CBMC OP INFUSION 2FL,53081,"Leitner, Stuart P, MD",11/1/2023,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,10/31/2023,Inactive,,
CBMC OP INFUSION 2FL,53081,"Leitner, Stuart P, MD",12/4/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,12/3/2024,Active,Diffuse large B-cell lymphoma (CMS/HCC),
NBR 4N ONCOLOGY,22069,"Braunschweig, Ira, MD",11/1/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,10/30/2023,Inactive,,
NBR 4N BMTU/IMCU,22069,"Egini, Ogechukwu, MD",2/10/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,2/8/2024,Inactive,,
CINJ OP INFUSION,54478,"Stephenson, Ryan D, DO",6/19/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,6/19/2024,Active,,
CBMC OP INFUSION 2FL,41969,"Wagmiller, Jennifer Ann, MD",10/18/2023,Gemcitabine / DOCEtaxel 21 Day Cycles - Uterine Sarcoma,_1. First Line,10/17/2023,Inactive,,
NBR 5N ONCOLOGY,79421,"Doraiswamy, Anupama, MD",2/7/2023,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,First Line,2/7/2023,Inactive,,
CINJ OP INFUSION,84884,"Golombos, David, MD",11/14/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,11/7/2023,Inactive,,
CINJ OP INFUSION,41881,"Desai, Sahaj, MD",5/22/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,5/22/2025,Inactive,Adenocarcinoma of gastroesophageal junction (CMS/HCC),C16.0 - Malignant neoplasm of cardia; E11.9 - Type 2 diabetes mellitus without complications; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; Z95.5 - Presence of coronary angioplasty implant and graft
CINJ OP INFUSION,41881,"Berim, Lyudmyla, MD",5/22/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/22/2025,Active,Adenocarcinoma of gastroesophageal junction (CMS/HCC),C16.0 - Malignant neoplasm of cardia; E11.9 - Type 2 diabetes mellitus without complications; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; Z95.5 - Presence of coronary angioplasty implant and graft
NBI OP INFUSION,85201,"Anderson, Patrick S, MD",11/30/2023,Pembrolizumab 21 Day Cycles- Ovarian cancer,_3. Third Line,11/29/2023,Active,,
CINJ OP INFUSION,67555,"Berim, Lyudmyla, MD",4/26/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,,3/29/2023,Inactive,,
CINJ OP INFUSION,67555,"Berim, Lyudmyla, MD",7/10/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/7/2023,Inactive,,
CINJ OP INFUSION,23530,"Boland, Patrick M, MD",4/23/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/22/2024,Active,,
JCMC CP INFUSION,71261,"Sekhri, Arunabh, MD",7/19/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Neoadjuvant,7/4/2023,Inactive,,
JCMC CP INFUSION,71261,"Sekhri, Arunabh, MD",1/18/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,12/19/2023,Inactive,,
CBMC OP INFUSION 2FL,97861,"Dharmapuri, Sirish, MD",10/1/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/1/2024,Active,,
CBMC OP INFUSION 2FL,97861,"Dharmapuri, Sirish, MD",10/22/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/1/2024,Active,,
NBI OP INFUSION,52291,"Cheng, Yan Ho, MD",10/15/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/18/2024,Inactive,,
CBMC OP INFUSION 2FL,46156,"Brown, Andrew Bennett, MD",7/30/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Neoadjuvant,7/30/2024,Active,,
CBMC OP INFUSION 2FL,46156,"Brown, Andrew Bennett, MD",3/17/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/17/2025,Active,SCC (squamous cell carcinoma) of supraglottis (CMS/HCC),
NBR 4N BMTU/IMCU,93443,"Assal, Amer, MD",7/15/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,7/13/2023,Inactive,,
TRMC TCCC OP INFUSION,75796,"Capo, Gerardo, MD",6/4/2024,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/3/2024,Inactive,,
TRMC TCCC OP INFUSION,75796,"Capo, Gerardo, MD",10/22/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,10/21/2024,Active,,
CINJ OP INFUSION,99291,"Stephenson, Ruth D, DO",6/27/2024,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_2. Second Line,6/11/2024,Inactive,,
CINJ OP INFUSION,99291,"Stephenson, Ruth D, DO",12/4/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,11/19/2024,Active,,
CINJ OP INFUSION,99291,"Stephenson, Ruth D, DO",4/10/2025,Abraxane / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_4. Fourth Line,4/10/2025,Active,Cervical cancer (CMS/HCC),"C53.1 - Malignant neoplasm of exocervix; C53.8 - Malignant neoplasm of overlapping sites of cervix uteri; E03.9 - Hypothyroidism, unspecified"
CINJ OP INFUSION,9322,"Patel, Eshan, MD",4/22/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/11/2024,Inactive,,
CINJ OP INFUSION,9322,"Patel, Eshan, MD",7/12/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,5/31/2024,Active,,
CINJ OP INFUSION,1006,"Weiss, Sarah, MD",11/26/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,11/17/2024,Active,,
TRMC TCCC OP INFUSION,60533,"Capo, Gerardo, MD",12/13/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/11/2024,Active,,
CINJ OP INFUSION,76750,"Patankar, Sonali, MD",11/20/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,10/22/2024,Active,,
SOM OUTPT INFUSION,49674,"Patel, Eshan, MD",3/24/2025,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Bile  Adenocarcinoma",Adjuvant,3/24/2025,Active,Primary cholangiocarcinoma of extrahepatic bile duct (CMS/HCC),C24.0 - Malignant neoplasm of extrahepatic bile duct
CINJ OP INFUSION,18799,"Packiam, Vignesh, MD",2/23/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,2/23/2024,Inactive,,
CINJ OP INFUSION,18799,"Packiam, Vignesh, MD",6/24/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,6/24/2024,Active,,
CINJ OP INFUSION,86808,"Ghodoussipour, Saum Bobak, MD",10/30/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,10/29/2024,Active,,
CINJ OP INFUSION,86808,"Ghodoussipour, Saum Bobak, MD",2/18/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,2/17/2025,Active,Urothelial cancer (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified"
NBR CINJ OP INFUSION,46993,"Tiger, Yun Kyoung, MD",3/21/2025,RiTUXimab 375 mg/m2 Weekly x 4 then Monthly,_1. First Line,3/21/2025,Active,Neuropathy associated with anti-MAG antibody,
HAM OP INFUSION,38605,"Patel, Malini M, MD",8/12/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,7/28/2024,Active,,
NBR CINJ OP INFUSION,51236,"Tiger, Yun Kyoung, MD",8/9/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/8/2024,Inactive,,
NBR CINJ OP INFUSION,51236,"Tiger, Yun Kyoung, MD",9/4/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/3/2024,Active,,
CINJ OP INFUSION,79036,"Goel, Sanjay, MD",4/17/2024,CINJ 052208 Part 1K AMG-193 28 Day Cycles Research  - Solid Tumors,_3. Third Line,4/17/2024,Active,,
JCMC CP INFUSION,22330,"Cruz, Allan Louie E, MD",3/7/2025,Pembrolizumab Q6 weeks - Cervical,Induction,3/7/2025,Active,Malignant neoplasm of cervix (CMS/HCC),C53.8 - Malignant neoplasm of overlapping sites of cervix uteri
NBR CINJ OP INFUSION,76933,"Shah, Mansi R, MD",4/3/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,4/3/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; I71.23 - Aneurysm of the descending thoracic aorta, without rupture; M89.9 - Disorder of bone, unspecified; R26.81 - Unsteadiness on feet"
NBR CINJ OP INFUSION,76933,"Shah, Mansi R, MD",3/12/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/12/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
CMC OP INFUSION,49141,"Taff, Jessica, MD",6/8/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Second Line,6/7/2023,Inactive,,
MMC OP INFUSION,71483,"Meghal, Trishala, MD",7/24/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,7/18/2024,Inactive,,
MMC OP INFUSION,71483,"Meghal, Trishala, MD",10/16/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,10/15/2024,Active,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)
Transitional cell carcinoma (CMS/HCC)",
CINJ OP INFUSION,4617,"Berim, Lyudmyla, MD",8/21/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,8/21/2023,Inactive,,
NBR 5N MED-SURG OVRF,90503,"Alexander, Henry Richard, MD",8/8/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,8/8/2024,Active,,
CINJ OP INFUSION,13327,"Berim, Lyudmyla, MD",11/13/2024,5FU CIVI + RT rectal adenocarcinoma,_2. Second Line,10/27/2024,Active,,
CINJ OP INFUSION,90295,"Berim, Lyudmyla, MD",5/22/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/22/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),"C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; R97.0 - Elevated carcinoembryonic antigen (CEA); C18.2 - Malignant neoplasm of ascending colon; Z41.9 - Encounter for procedure for purposes other than remedying health state, unspecified"
CINJ OP INFUSION,11588,"Toppmeyer, Deborah L, MD",4/1/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/31/2024,Inactive,,
SOM OUTPT INFUSION,19764,"Yin, Faye, MD",10/31/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/17/2023,Inactive,,
SOM OUTPT INFUSION,19764,"Toomey, Kathleen C, MD",3/12/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,3/11/2024,Active,,
JCMC CP INFUSION,15412,"Cruz, Allan Louie E, MD",11/7/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,90228,"Grossman, I Robert, MD",1/8/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,1/5/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
SOM OUTPT INFUSION,86011,"Patel, Eshan, MD",1/12/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,1/12/2023,Inactive,,
CBMC OP INFUSION 2FL,80783,"Wagmiller, Jennifer Ann, MD",11/2/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,51382,"Wagmiller, Jennifer Ann, MD",11/6/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,11/5/2023,Inactive,,
NBR 5N ONCOLOGY,31348,"Tiger, Yun Kyoung, MD",7/26/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,7/24/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR 5N ONCOLOGY,48888,"Zayac, Adam, MD",6/6/2024,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,6/6/2024,Inactive,,
NBR CINJ OP INFUSION,48888,"Zayac, Adam, MD",9/30/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,48888,"Zayac, Adam, MD",11/4/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,11/4/2024,Inactive,,
NBR CINJ OP INFUSION,48888,"Zayac, Adam, MD",11/13/2024,Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia ECOG ACRIN E1910 (Step 3) Blinatumomab SLOW TITRATION due to reaction,_1. First Line,11/13/2024,Active,,
JCMC CP INFUSION,27998,"Sekhri, Arunabh, MD",12/18/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,12/6/2023,Inactive,,
JCMC CP INFUSION,27998,"Sekhri, Arunabh, MD",6/3/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/31/2024,Active,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",6/30/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/29/2023,Inactive,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",7/21/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,7/13/2023,Inactive,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",7/26/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,7/25/2023,Inactive,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",8/2/2023,CINJ 032013 (EA5181) ARM A Durvalumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,7/25/2023,Inactive,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",10/2/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,Consolidation,9/24/2023,Inactive,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",8/16/2024,CINJ 032304 Arm B Pembrolizumab / Ramucirumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,8/6/2024,Inactive,,
JCMC CP INFUSION,74170,"Sekhri, Arunabh, MD",1/10/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,1/2/2025,Active,,
MMC OP VP INFUSION,83515,"Meghal, Trishala, MD",8/8/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,8/8/2023,Active,,
CBMC OP INFUSION 2FL,96980,"Freeman, Benjamin B, MD",5/9/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/9/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,2355,"Wagmiller, Jennifer Ann, MD",4/15/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,4/8/2024,Active,,
JCMC 7W MED-SURG 2,15796,"Sekhri, Arunabh, MD",5/30/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab+herceptin 14 Day Cycles- Gastrointestinal Cancers,First Line,5/21/2023,Inactive,,
JCMC CP INFUSION,15796,"Sekhri, Arunabh, MD",12/13/2023,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,12/5/2023,Inactive,,
JCMC CP INFUSION,15796,"Sekhri, Arunabh, MD",3/6/2024,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,2/18/2024,Inactive,,
CINJ OP INFUSION,6138,"Weiss, Sarah, MD",2/18/2025,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,2/14/2025,Active,Merkel cell carcinoma of left upper extremity (CMS/HCC),
HAM OP INFUSION,58170,"Patel, Malini M, MD",6/7/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,First Line,6/7/2023,Inactive,,
HAM OP INFUSION,58170,"Patel, Malini M, MD",9/20/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/5/2023,Inactive,,
HAM OP INFUSION,3516,"Patel, Malini M, MD",2/17/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/10/2025,Active,Rectal cancer (CMS/HCC),C20 - Rectal cancer (CMS/HCC); R41.3 - Memory change
HAM OP INFUSION,47582,"Patel, Malini M, MD",11/16/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,11/8/2023,Active,,
MMC OP VP INFUSION,47246,"Cohen, Seth D, MD",5/8/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,5/7/2023,Inactive,,
MMC OP VP INFUSION,47246,"Cohen, Seth D, MD",12/20/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/20/2023,Inactive,,
MMC OP VP INFUSION,47246,"Cohen, Seth D, MD",12/21/2023,"Irinotecan D1, D8 21 Day Cycles- Gastrointestinal Cancers",Maintenance,12/21/2023,Inactive,,
NBR CINJ OP INFUSION,50194,"Egini, Ogechukwu, MD",7/8/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Neoadjuvant,6/25/2024,Active,,
NBR CINJ OP INFUSION,50194,"Egini, Ogechukwu, MD",7/24/2024,BMT Autologous Melphalan Day -1  200mg/m2,_1. First Line,7/23/2024,Active,Malignant neoplasm of female breast (CMS/HCC),
CMC OP INFUSION,32771,"Ferretti, Mark J, MD",1/27/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,1/27/2025,Active,,
CMC OP INFUSION,32771,"Ferretti, Mark J, MD",2/24/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,_1. First Line,2/23/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
SOM OUTPT INFUSION,81099,"Yin, Faye, MD",9/22/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,9/18/2023,Inactive,,
SOM OUTPT INFUSION,81099,"Yin, Faye, MD",11/10/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/9/2023,Inactive,,
SOM OUTPT INFUSION,81099,"Patel, Eshan, MD",12/27/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/21/2023,Active,,
CINJ OP INFUSION,30764,"Ghodoussipour, Saum Bobak, MD",3/22/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,3/22/2023,Inactive,,
CINJ OP INFUSION,30764,"Ghodoussipour, Saum Bobak, MD",6/28/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,6/28/2023,Inactive,,
SOM OUTPT INFUSION,30512,"Toomey, Kathleen C, MD",11/1/2023,Acalabrutinib 30 Day Cycles - CLL,_1. First Line,11/1/2023,Active,,
CBMC OP INFUSION 2FL,34163,"Leitner, Stuart P, MD",7/29/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,7/28/2024,Active,,
CBMC OP INFUSION 2FL,50691,"Scoppetuolo, Michael, MD",5/22/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,5/22/2025,Active,MALT lymphoma (CMS/HCC),C88.40 - Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue (malt-lymphoma) not having achieved remission
CINJ OP INFUSION,41152,"Stephenson, Ryan D, DO",9/18/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,9/17/2023,Inactive,,
CMC OP INFUSION,41152,"Cohen, Seth D, MD",1/31/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,1/30/2024,Inactive,,
CINJ OP INFUSION,95104,"Omene, Coral Oghenerukevwe, MD",10/22/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,10/21/2024,Active,,
CMC OP INFUSION,16056,"Talwar, Sumit, MD",10/5/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/5/2023,Inactive,,
CBMC OP INFUSION 2FL,5363,"Grossman, I Robert, MD",11/28/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,11/28/2023,Active,Malignant neoplasm of endometrium (CMS/HCC),
CBMC OP INFUSION 2FL,78981,"Dharmapuri, Sirish, MD",12/2/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/1/2024,Active,,
CMC OP INFUSION,47493,"Tang, Horace, MD",5/10/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,Second Line,5/9/2023,Inactive,,
CMC 4B ONCOLOGY,47493,"Tang, Horace, MD",1/3/2024,"Albumin-Bound PACLitaxel D1, D8 - Breast",_3. Third Line,1/2/2024,Inactive,,
CMC OP INFUSION,47493,"Tang, Horace, MD",1/31/2024,EriBULin 21 Day Cycles - Breast,_3. Third Line,1/30/2024,Inactive,,
CMC OP INFUSION,47493,"Talwar, Sumit, MD",2/28/2024,Gemcitabine 28 Day Cycles - Breast,_3. Third Line,2/27/2024,Inactive,,
CBMC 2W ONCOLOGY,44910,"Brown, Andrew Bennett, MD",6/19/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,6/18/2024,Active,,
NBR 4N ONCOLOGY,4995,"Tiger, Yun Kyoung, MD",3/19/2025,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,3/19/2025,Active,"Anaplastic large cell lymphoma, ALK negative (CMS/HCC)","K57.21 - Diverticulitis of large intestine with perforation and abscess with bleeding; J96.01 - Acute respiratory failure with hypoxia; K75.0 - Abscess of liver; E44.0 - Moderate protein-calorie malnutrition; C78.01 - Secondary malignant neoplasm of right lung; I65.02 - Occlusion and stenosis of left vertebral artery; B37.0 - Candidal stomatitis; C84.79 - Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites; C22.8 - Malignant neoplasm of liver, primary, unspecified as to type; Z23 - Encounter for immunization; C81.91 - Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck; C78.02 - Secondary malignant neoplasm of left lung; C80.1 - Malignant (primary) neoplasm, unspecified; E11.649 - Type 2 diabetes mellitus with hypoglycemia without coma; D63.8 - Anemia in other chronic diseases classified elsewhere; E87.0 - Hyperosmolality and hypernatremia; N32.1 - Vesicointestinal fistula; E87.1 - Hypo-osmolality and hyponatremia; M84.48XA - Pathological fracture, other site, initial encounter for fracture; N17.9 - Acute kidney failure, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; E27.8 - Other specified disorders of adrenal gland; D50.9 - Iron deficiency anemia, unspecified; D35.02 - Benign neoplasm of left adrenal gland; G89.3 - Neoplasm related pain (acute) (chronic); B27.00 - Gammaherpesviral mononucleosis without complication; J38.4 - Edema of larynx; R74.8 - Abnormal levels of..."
CINJ OP INFUSION,84480,"Toppmeyer, Deborah L, MD",3/6/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,3/5/2023,Inactive,,
CINJ OP INFUSION,84480,"Toppmeyer, Deborah L, MD",5/18/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,5/17/2023,Inactive,,
CINJ OP INFUSION,84480,"Toppmeyer, Deborah L, MD",9/21/2023,"Capecitabine One Week on, One Week off",Adjuvant,9/21/2023,Inactive,,
CINJ OP INFUSION,66915,"Weiss, Sarah, MD",2/19/2025,CINJ 092302 Cohort 2 Propranolol / Naltrexone 4.5 mg + Nivolumab (1 mg/kg) / Ipilimumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research Melanoma,_1. First Line,2/9/2025,Active,Melanoma metastatic to brain (CMS/HCC),"C79.31 - Secondary malignant neoplasm of brain; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C78.01 - Secondary malignant neoplasm of right lung; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; C43.9 - Malignant melanoma of skin, unspecified"
CINJ OP INFUSION,66915,"Weiss, Sarah, MD",5/14/2025,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_2. Second Line,5/14/2025,Active,Metastasis to brain (CMS/HCC),"C79.31 - Secondary malignant neoplasm of brain; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified"
SOM OUTPT INFUSION,16948,"Patel, Eshan, MD",3/17/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,3/17/2025,Active,Triple negative malignant neoplasm of breast (CMS/HCC),
MMC OP INFUSION,65864,"Meghal, Trishala, MD",10/5/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/2/2024,Active,,
CBMC OP INFUSION 2FL,88443,"Brown, Andrew Bennett, MD",12/23/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,12/15/2024,Active,,
NBR CINJ OP INFUSION,12426,"Shah, Mansi R, MD",10/8/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,Induction,10/7/2024,Active,,
NBR 5N ONCOLOGY,22103,"Rhodes, Joanna Meehan, MD",12/15/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,12/15/2023,Inactive,,
NBR CINJ OP INFUSION,22103,"Tiger, Yun Kyoung, MD",12/22/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/18/2023,Inactive,,
NBR CINJ OP INFUSION,22103,"Tiger, Yun Kyoung, MD",5/8/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/7/2024,Inactive,,
CINJ OP INFUSION,46420,"Golombos, David, MD",12/12/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,12/12/2023,Inactive,,
CINJ OP INFUSION,46420,"Golombos, David, MD",4/15/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,4/15/2024,Active,,
NBR 5N ONCOLOGY,85303,"Egini, Ogechukwu, MD",11/22/2024,VD-PACE (Bortezomib / Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,_3. Third Line,11/21/2024,Active,Prostate cancer (CMS/HCC),
NBR CINJ OP INFUSION,85303,"Shah, Mansi R, MD",5/4/2025,Talquetamab 28 Day Cycles,_9. Ninth Line,5/2/2025,Active,Kappa light chain myeloma (CMS/HCC),
NBR CINJ OP INFUSION,85303,"Shah, Mansi R, MD",3/7/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,3/7/2025,Inactive,Kappa light chain myeloma (CMS/HCC),
SOM OUTPT INFUSION,97876,"Patel, Eshan, MD",7/11/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,7/8/2024,Active,,
SOM OUTPT INFUSION,97234,"Patel, Eshan, MD",1/3/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,1/2/2025,Active,,
NBR 5N ONCOLOGY,57481,"Palmisiano, Neil David, MD",6/19/2023,"ECOG - ACRIN E1910 (Step 1) Induction (Daunorubicin, Vincristine, Cytarabine, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab) - Acute Lymphoblastic Leukemia",Induction,6/19/2023,Inactive,,
NBR CINJ OP INFUSION,57481,"Palmisiano, Neil David, MD",9/26/2023,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,,9/25/2023,Inactive,,
NBR CINJ OP INFUSION,57481,"Palmisiano, Neil David, MD",10/25/2023,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,10/25/2023,Inactive,,
NBR 5N ONCOLOGY,57481,"Palmisiano, Neil David, MD",10/28/2023,Step 3 ECOG-1910 Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia,_1. First Line,10/28/2023,Inactive,,
NBR CINJ OP INFUSION,57481,"Palmisiano, Neil David, MD",12/5/2023,Intrathecal Chemotherapy (IT) - Hematological Malignancies,_1. First Line,12/5/2023,Inactive,,
NBR CINJ OP INFUSION,57481,"Palmisiano, Neil David, MD",1/29/2024,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,1/29/2024,Inactive,,
NBR CINJ OP INFUSION,57481,"Palmisiano, Neil David, MD",7/16/2024,CALGB 9111 (Maintenance Therapy) 28 Day Cycles + Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,7/14/2024,Active,,
CBMC OP INFUSION 2FL,23247,"Radovich, Delia, MD",11/1/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/31/2023,Inactive,,
CBMC OP INFUSION 2FL,23247,"Leitner, Stuart P, MD",5/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/16/2024,Inactive,,
CBMC OP INFUSION 2FL,23247,"Leitner, Stuart P, MD",12/11/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/10/2024,Active,,
CBMC OP INFUSION 2FL,59630,"Litvak, Anna M, MD",2/23/2023,CINJ 042111 (GO42784) ARM B Endocrine Therapy 28 Day Cycles Research- Breast Cancer,_1. First Line,2/23/2023,Active,,
CINJ OP INFUSION,46582,"Saraiya, Biren P, MD",9/10/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_3. Third Line,9/3/2024,Inactive,,
CINJ OP INFUSION,13218,"Saraiya, Biren P, MD",3/18/2025,Enzalutamide 28 Day Cycles - Prostate,_4. Fourth Line,3/18/2025,Inactive,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; I82.422 - Acute embolism and thrombosis of left iliac vein; E03.9 - Hypothyroidism, unspecified; K59.00 - Constipation, unspecified; D64.9 - Anemia, unspecified; M79.2 - Neuralgia and neuritis, unspecified; E78.5 - Hyperlipidemia, unspecified; R68.2 - Dry mouth, unspecified; R03.1 - Nonspecific low blood-pressure reading"
CINJ OP INFUSION,20477,"Salacz, Michael E, MD",6/1/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,6/1/2023,Inactive,,
SOM OUTPT INFUSION,60629,"Yin, Faye, MD",1/9/2023,A011801 / CINJ 042106 Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,Adjuvant,1/5/2023,Inactive,,
SOM OUTPT INFUSION,60629,"Toomey, Kathleen C, MD",6/11/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,5/23/2024,Inactive,,
NBR 5N ONCOLOGY,95885,"Rhodes, Joanna Meehan, MD",2/16/2025,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_1. First Line,2/15/2025,Active,Smoldering myeloma,"M79.10 - Myalgia; R53.1 - Weakness; M25.50 - Arthralgia, unspecified joint"
NBR 5N ONCOLOGY,95885,"Shah, Mansi R, MD",3/20/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/20/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; N17.9 - Acute kidney failure, unspecified; E88.819 - Insulin resistance, unspecified; M08.20 - Juvenile rheumatoid arthritis with systemic onset, unspecified site; E11.65 - Type 2 diabetes mellitus with hyperglycemia; D50.9 - Iron deficiency anemia, unspecified; D63.8 - Anemia in other chronic diseases classified elsewhere; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; J45.909 - Unspecified asthma, uncomplicated; I10 - Essential (primary) hypertension; E66.9 - Obesity, unspecified; Z79.4 - Long term (current) use of insulin; L50.9 - Urticaria, unspecified; K59.03 - Drug induced constipation; I95.89 - Other hypotension; Z11.52 - Encounter for screening for COVID-19; G89.3 - Neoplasm related pain (acute) (chronic); D57.3 - Sickle-cell trait; Z68.36 - Body mass index (BMI) 36.0-36.9, adult; E55.9 - Vitamin D deficiency, unspecified; G47.33 - Obstructive sleep apnea (adult) (pediatric); R79.82 - Elevated C-reactive protein (CRP); E86.1 - Hypovolemia; E78.5 - Hyperlipidemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T40.2X5A - Adverse effect of other opioids, initial encounter; Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons; Z87.891 - Personal history of nicotine dependence; Z86.16 - Personal history of COVID-19; Z83.3 - Family history of diabetes mellitus; Z82.61 - Family history o..."
CINJ OP INFUSION,78690,"Leiser, Aliza, MD",11/9/2023,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/29/2023,Inactive,,
CINJ OP INFUSION,78690,"Leiser, Aliza, MD",1/12/2024,"PACLitaxel weekly 28 Day Cycles, Avastin every 2 weeks 10mg/kg",_3. Third Line,1/11/2024,Inactive,,
CINJ OP INFUSION,78690,"Leiser, Aliza, MD",9/27/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,9/16/2024,Inactive,,
CINJ OP INFUSION,41692,"Haigentz, Missak, MD",1/9/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/8/2025,Active,,
CINJ OP INFUSION,56430,"Goel, Sanjay, MD",1/3/2024,CINJ 052212 Phase 1a Single Agent RO7502175 21 Day Cycles- Advanced or Metastatic Solid Tumors,_4. Fourth Line,1/3/2024,Inactive,,
CINJ OP INFUSION,34713,"Mayer, Tina M, MD",4/21/2023,Apalutamide 30 Day Cycles - Prostate,,4/21/2023,Inactive,,
CINJ OP INFUSION,34713,"Mayer, Tina M, MD",1/2/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,1/2/2024,Active,,
CINJ OP INFUSION,59306,"Weiss, Sarah, MD",6/21/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,6/20/2023,Inactive,,
NBR CINJ OP INFUSION,20706,"Shah, Mansi R, MD",8/29/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/7/2024,Active,,
NBR CINJ OP INFUSION,20706,"Shah, Mansi R, MD",1/16/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,12/31/2024,Active,,
CBMC OP INFUSION 2FL,29011,"Litvak, Anna M, MD",10/15/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/26/2024,Active,,
CBMC OP INFUSION 2FL,29011,"Litvak, Anna M, MD",1/14/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,1/13/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,60977,"Meghal, Trishala, MD",11/8/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/7/2023,Active,,
MMC OP VP INFUSION,24813,"Cohen, Seth D, MD",9/25/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/17/2023,Inactive,,
MMC OP VP INFUSION,24813,"Cohen, Seth D, MD",4/22/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,4/21/2024,Active,,
CBMC OP INFUSION 2FL,69551,"Phillips, Adrienne A, MD",11/29/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,11/28/2023,Active,,
MSC OP INFUSION,4851,"Meghal, Trishala, MD",5/23/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,,5/15/2023,Inactive,,
MSC OP INFUSION,4851,"Meghal, Trishala, MD",8/22/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/16/2023,Inactive,,
CINJ OP INFUSION,17202,"George, Mridula A, MD",1/8/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,1/7/2024,Inactive,,
CINJ OP INFUSION,17202,"George, Mridula A, MD",5/17/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/16/2024,Inactive,,
CINJ OP INFUSION,17202,"George, Mridula A, MD",7/24/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,7/24/2024,Inactive,,
CINJ OP INFUSION,17202,"George, Mridula A, MD",7/26/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_2. Second Line,7/25/2024,Inactive,,
JCMC CP INFUSION,99012,"Cruz, Allan Louie E, MD",11/19/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/1/2024,Active,,
CBMC OP INFUSION 2FL,61201,"Dave, Manish, MD",5/5/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/4/2023,Inactive,,
NBR 4N ONCOLOGY,61201,"Braunschweig, Ira, MD",6/23/2023,Cyclophosphamide for Stem Cell Mobilization,,6/23/2023,Inactive,,
CBMC 2W ONCOLOGY,61201,"Grossman, I Robert, MD",2/1/2024,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_3. Third Line,2/1/2024,Inactive,,
CBMC 2W ONCOLOGY,61201,"Grossman, I Robert, MD",5/17/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,5/16/2024,Inactive,,
CBMC OP INFUSION 2FL,4898,"Brown, Andrew Bennett, MD",4/8/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,4/8/2024,Active,,
CBMC OP INFUSION 2FL,75343,"Brown, Andrew Bennett, MD",3/26/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,3/26/2025,Active,"Malignant neoplasm of central portion of left breast in male, estrogen receptor positive (CMS/HCC)",C50.122 - Malignant neoplasm of central portion of left male breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,30426,"Brown, Andrew Bennett, MD",11/6/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/5/2023,Inactive,,
CBMC OP INFUSION 2FL,30426,"Brown, Andrew Bennett, MD",4/11/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/11/2024,Inactive,,
NBI OP INFUSION,24830,"Shah, Maya M, MD",7/8/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,7/8/2024,Inactive,,
NBI OP INFUSION,62333,"Shah, Maya M, MD",9/10/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,9/9/2024,Inactive,,
CBMC OP INFUSION 2FL,70927,"Leitner, Stuart P, MD",11/15/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/14/2023,Active,,
NBI OP INFUSION,78736,"Cheng, Yan Ho, MD",2/22/2024,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 80 mg/m2 D1 21 Day Cycles- Head and Neck Cancers",_1. First Line,2/21/2024,Inactive,,
NBI OP INFUSION,78736,"Cheng, Yan Ho, MD",5/2/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,4/22/2024,Active,,
CMMC OP INFUSION,82057,"Freeman, Benjamin B, MD",2/18/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,2/5/2025,Active,Malignant neoplasm of female breast (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast
JCMC CP INFUSION,39706,"Sekhri, Arunabh, MD",5/3/2024,Pembrolizumab Maintance Q21 Days --- Triple Negative Breast Cancer,Neoadjuvant,3/26/2024,Active,,
CMC OP INFUSION,57475,"Cohen, Seth D, MD",5/29/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/28/2024,Inactive,,
CMC OP INFUSION,57475,"Cohen, Seth D, MD",9/18/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/15/2024,Active,,
CINJ OP INFUSION,90199,"Golombos, David, MD",8/21/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,8/21/2023,Inactive,,
HAM OP INFUSION,46840,"Yogarajah, Meera, MD",4/8/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,4/8/2024,Inactive,,
HAM OP INFUSION,46840,"Yogarajah, Meera, MD",6/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/9/2024,Active,,
CINJ OP INFUSION,7848,"Goel, Sanjay, MD",5/22/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,5/22/2023,Inactive,,
JCMC CP INFUSION,79236,"Cruz, Allan Louie E, MD",4/24/2025,VDC (VinCRIStine / DOXOrubicin / Cyclophosphamide) 21 Day Cycles - MPNST with rhabdomyoblastic features,_1. First Line,4/24/2025,Active,Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation (CMS/HCC),"C47.9 - Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified"
JCMC CP INFUSION,79236,"Cruz, Allan Louie E, MD",4/10/2025,PEDS ARST1431  Regimen A - Rhabdomyosarcoma,_1. First Line,4/9/2025,Inactive,Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation (CMS/HCC),"C47.9 - Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified"
JCMC CP INFUSION,79236,"Cruz, Allan Louie E, MD",4/8/2025,PEDS ARST1431  Regimen A - Rhabdomyosarcoma,_1. First Line,4/7/2025,Inactive,Malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation (CMS/HCC),
CBMC OP INFUSION 2FL,37657,"Wagmiller, Jennifer Ann, MD",1/20/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,1/6/2025,Active,,
CBMC OP INFUSION 2FL,78884,"Wagmiller, Jennifer Ann, MD",3/11/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/11/2025,Inactive,Hepatocellular carcinoma (CMS/HCC),
CINJ OP INFUSION,40075,"Boland, Patrick M, MD",10/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/15/2024,Active,,
CINJ OP INFUSION,2518,"Boland, Patrick M, MD",1/28/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/27/2025,Inactive,"Malignant neoplasm of stomach, unspecified (CMS/HCC)",
SOM OUTPT INFUSION,7340,"Patel, Eshan, MD",9/6/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,9/5/2023,Inactive,,
NBI A5 PEDIATRICS,83597,"de Benedictis, Marianna, MD",2/28/2025,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,2/27/2025,Active,ALL (acute lymphocytic leukemia) (CMS/HCC),"D69.6 - Thrombocytopenia (CMS/HCC); T14.8XXA - Bruising; Z65.9 - Problem related to psychosocial circumstances; D72.829 - Leukocytosis, unspecified type"
NBI VALERIE FND HEMONC,59823,"de Benedictis, Marianna, MD",5/2/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,5/1/2025,Inactive,ALL (acute lymphocytic leukemia) (CMS/HCC),
NBI VALERIE FND HEMONC,59823,"de Benedictis, Marianna, MD",4/4/2025,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,4/4/2025,Inactive,ALL (acute lymphocytic leukemia) (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
CBMC OP INFUSION 2FL,4421,"Leitner, Stuart P, MD",11/13/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,11/10/2024,Active,,
CBMC OP INFUSION 2FL,6726,"Leitner, Stuart P, MD",2/11/2025,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,2/10/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
MMC OP VP INFUSION,51052,"Lee, Patrick C, MD",2/21/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Adjuvant,2/21/2025,Active,Rectal cancer (CMS/HCC),
MMC OP VP INFUSION,62730,"Lee, Patrick C, MD",5/12/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/12/2025,Active,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,54801,"Mayer, Tina M, MD",2/17/2025,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,2/16/2025,Active,Testicular cancer (CMS/HCC),"C62.92 - Malignant neoplasm of left testis, unspecified whether descended or undescended; R74.01 - Elevation of levels of liver transaminase levels; C62.90 - Malignant neoplasm of unspecified testis, unspecified whether descended or undescended; Z90.79 - Acquired absence of other genital organ(s)"
CINJ OP INFUSION,78658,"Omene, Coral Oghenerukevwe, MD",1/10/2023,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,,1/9/2023,Inactive,,
TRMC TCCC OP INFUSION,52989,"Salerno, Vincent E, MD",2/27/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,2/26/2024,Active,,
NBR CINJ OP INFUSION,65770,"Shah, Mansi R, MD",2/28/2023,Carfilzomib 56 mg/m2 l Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,,2/20/2023,Inactive,,
NBR CINJ OP INFUSION,65770,"Shah, Mansi R, MD",8/1/2023,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,65770,"Shah, Mansi R, MD",9/27/2023,CINJ 011909 Cohort D Lymphodepletion JNJ-68284528 7 Day Cycle Research- Multiple Myeloma,,9/26/2023,Inactive,,
CINJ OP INFUSION,5234,"Haigentz, Missak, MD",1/12/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/11/2024,Inactive,,
CINJ PEDS HEMONC ,42642,"Cole, Peter David, MD",12/5/2023,IT methotrexate ,_3. Third Line,12/5/2023,Inactive,,
CINJ OP INFUSION,62306,"Aikins, James K, MD",4/13/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/29/2023,Inactive,,
CINJ OP INFUSION,62306,"Aikins, James K, MD",9/21/2023,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,,9/20/2023,Inactive,,
CINJ OP INFUSION,16503,"Aikins, James K, MD",4/14/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/12/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,44436,"Moerdler, Scott, MD",1/12/2024,as per PEDS AEWS1031 Regimen A Induction & Consolidation,_1. First Line,1/11/2024,Inactive,,
CINJ OP INFUSION,65482,"Haigentz, Missak, MD",7/12/2024,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,_1. First Line,7/12/2024,Active,,
NBR 4N ONCOLOGY,65482,"Haigentz, Missak, MD",2/4/2025,PACLitaxel weekly with Concurrent Palliative Radiation - Head and neck cancer,_2. Second Line,2/3/2025,Active,"Oropharyngeal cancer (CMS/HCC)
Malignant neoplasm of tonsil metastatic to lung (CMS/HCC)
Metastasis to bone (CMS/HCC)","I26.93 - Single subsegmental thrombotic pulmonary embolism without acute cor pulmonale; J96.01 - Acute respiratory failure with hypoxia; J96.02 - Acute respiratory failure with hypercapnia; C78.02 - Secondary malignant neoplasm of left lung; C79.51 - Secondary malignant neoplasm of bone; E44.0 - Moderate protein-calorie malnutrition; I27.20 - Pulmonary hypertension, unspecified; J90 - Pleural effusion, not elsewhere classified; C09.9 - Malignant neoplasm of tonsil, unspecified; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; I31.1 - Chronic constrictive pericarditis; I31.39 - Other pericardial effusion (noninflammatory); E87.29 - Other acidosis; E87.1 - Hypo-osmolality and hyponatremia; Z11.52 - Encounter for screening for COVID-19; Z28.21 - Immunization not carried out because of patient refusal; M50.222 - Other cervical disc displacement at C5-C6 level; E78.00 - Pure hypercholesterolemia, unspecified; Z92.3 - Personal history of irradiation; Z79.890 - Hormone replacement therapy; Z85.818 - Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx; Z92.21 - Personal history of antineoplastic chemotherapy"
CINJ OP INFUSION,65482,"Haigentz, Missak, MD",3/20/2025,CINJ 032405 Cohort 4 Amivantamab Monotherapy (Pt. Weight < 80 kg) 21 Day Cycles Research- Head and Neck Cancers,_3. Third Line,3/20/2025,Active,"Oropharyngeal cancer (CMS/HCC)
Malignant neoplasm of tonsil metastatic to lung (CMS/HCC)
Malignant pleural effusion
Hypothyroidism, acquired",
CINJ OP INFUSION,5437,"Toppmeyer, Deborah L, MD",10/3/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,10/2/2024,Active,,
CINJ OP INFUSION,5437,"Toppmeyer, Deborah L, MD",1/16/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,1/15/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
SOM OUTPT INFUSION,95630,"Patel, Eshan, MD",9/9/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,8/28/2024,Active,,
NBR CINJ OP INFUSION,87734,"Shah, Mansi R, MD",3/28/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,3/28/2025,Active,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; D70.4 - Cyclic neutropenia; D75.89 - Other specified diseases of blood and blood-forming organs; E83.52 - Hypercalcemia; D64.9 - Anemia, unspecified; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; I27.20 - Pulmonary hypertension, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I25.2 - Old myocardial infarction; E11.9 - Type 2 diabetes mellitus without complications; Z85.46 - Personal history of malignant neoplasm of prostate; Z98.890 - Other specified postprocedural states; Z95.5 - Presence of coronary angioplasty implant and graft; Z87.891 - Personal history of nicotine dependence; Z79.02 - Long term (current) use of antithrombotics/antiplatelets; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
NBR 5N ONCOLOGY,78861,"Haigentz, Missak, MD",5/6/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,5/6/2024,Inactive,,
MSC OP INFUSION,80759,"Cohen, Seth D, MD",12/28/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,12/24/2023,Inactive,,
MSC OP INFUSION,80759,"Cohen, Seth D, MD",10/29/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,10/23/2024,Active,,
CBMC OP INFUSION 2FL,5903,"Litvak, Anna M, MD",2/27/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,2/26/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C50.819 - Malignant neoplasm of overlapping sites of unspecified female breast; D05.11 - Intraductal carcinoma in situ of right breast; C50.811 - Malignant neoplasm of overlapping sites of right female breast; Z11.59 - Encounter for screening for other viral diseases; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,13498,"Berim, Lyudmyla, MD",12/7/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,12/4/2023,Inactive,,
CINJ OP INFUSION,13498,"Berim, Lyudmyla, MD",7/5/2024,Enasidenib 30 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,7/5/2024,Inactive,,
CINJ OP INFUSION,13498,"Berim, Lyudmyla, MD",1/10/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,12/19/2024,Active,,
NBR CINJ OP INFUSION,7499,"Zayac, Adam, MD",11/21/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,11/18/2024,Active,Nodular sclerosis Hodgkin lymphoma of intrathoracic lymph nodes (CMS/HCC),
NBR 4N BMTU/IMCU,7499,"Rabinovich, Emma",2/25/2025,BMT Allogeneic Mel / Thio / Flu + Post Cy,_2. Second Line,2/24/2025,Active,Acute myeloid leukemia (AML) with prior myelodysplasia (CMS/HCC),"Z94.84 - Stem cells transplant status; Z01.818 - Encounter for other preprocedural examination; C92.00 - Acute myeloblastic leukemia, not having achieved remission; J98.4 - Other disorders of lung; R91.1 - Solitary pulmonary nodule; M41.9 - Scoliosis, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; D61.818 - Other pancytopenia; Z76.82 - Awaiting organ transplant status; Z87.891 - Personal history of nicotine dependence"
SOM OUTPT INFUSION,94785,"Yin, Faye, MD",8/13/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,8/13/2024,Active,,
CINJ OP INFUSION,27743,"Weiss, Sarah, MD",2/3/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/2/2025,Active,Acral lentiginous melanoma (CMS/HCC),"C43.9 - Malignant melanoma of skin, unspecified"
NBR CINJ OP INFUSION,45435,"Palmisiano, Neil David, MD",12/5/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,12/4/2023,Inactive,,
NBI A5 PEDIATRICS,9426,"Rao, Harini, MD",4/17/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,4/16/2024,Inactive,,
NBR CINJ OP INFUSION,9505,"Shah, Mansi R, MD",11/7/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,10/1/2024,Active,,
CINJ OP INFUSION,36577,"Haigentz, Missak, MD",2/10/2023,Maintenance PEMEtrexed  PLUS Osimertinib 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,2/2/2023,Active,,
MMC OP INFUSION,31038,"Meghal, Trishala, MD",7/26/2023,Neratinib 28 Day Cycles - Breast,Adjuvant,7/26/2023,Inactive,,
CBMC OP INFUSION 2FL,91414,"Wagmiller, Jennifer Ann, MD",8/4/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,8/3/2023,Inactive,,
CBMC OP INFUSION 2FL,91414,"Wagmiller, Jennifer Ann, MD",2/29/2024,Pembrolizumab 42 Day Cycles - Uterine,Maintenance,2/28/2024,Inactive,,
CBMC OP INFUSION 2FL,91414,"Wagmiller, Jennifer Ann, MD",6/5/2024,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,5/19/2024,Inactive,,
CBMC OP INFUSION 2FL,91414,"Wagmiller, Jennifer Ann, MD",6/5/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,6/4/2024,Active,,
CBMC OP INFUSION 2FL,91414,"Wagmiller, Jennifer Ann, MD",6/12/2024,Doxil/ cis/ OBI,_2. Second Line,6/9/2024,Active,,
NBR CINJ OP INFUSION,21214,"Schaar, Dale, MD PhD",7/15/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,7/10/2024,Inactive,,
NBR 4N BMTU/IMCU,21214,"Schaar, Dale, MD PhD",10/3/2024,BMT Allogeneic TBF + Post Cy,_4. Fourth Line,10/3/2024,Active,,
NBR CINJ OP INFUSION,21214,"Schaar, Dale, MD PhD",1/27/2025,Decitabine (Maintenance Phase - POST allogeneic stem cell transplant- Acute Myeloid Leukemia,Maintenance,1/26/2025,Active,,
CBMC 2W ONCOLOGY,21199,"Wagmiller, Jennifer Ann, MD",7/9/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_2. Second Line,7/8/2024,Active,,
CINJ OP INFUSION,66293,"Toppmeyer, Deborah L, MD",9/19/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_3. Third Line,9/18/2024,Active,"Follicular lymphoma (CMS/HCC)
Diffuse large B-cell lymphoma (CMS/HCC)",
SOM OUTPT INFUSION,60931,"Yin, Faye, MD",12/28/2023,Pembrolizumab 21 Day Cycles - Kidney,Adjuvant,12/28/2023,Active,,
CBMC OP INFUSION 2FL,21482,"Brown, Andrew Bennett, MD",3/24/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Induction,3/24/2025,Active,Anal cancer (CMS/HCC),
CINJ OP INFUSION,96838,"George, Mridula A, MD",12/12/2024,CINJ 042103 (BRE 354) Part A/B/Z U3-1402 21 Day Cycles Research- Metastatic Breast Cancer,_3. Third Line,12/4/2024,Active,,
JCMC CP INFUSION,69141,"Sekhri, Arunabh, MD",8/12/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/7/2024,Inactive,,
CBMC OP INFUSION 2FL,82460,"Scoppetuolo, Michael, MD",1/3/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/12/2024,Active,"CML (chronic myelocytic leukemia) (CMS/HCC)
AMML (acute myelomonocytic leukemia) (CMS/HCC)",
NBI OP INFUSION,25357,"Shah, Shailja S, MD",10/27/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles -sqaumous cell of face ,_1. First Line,10/26/2023,Inactive,,
NBI OP INFUSION,25357,"Shah, Shailja S, MD",10/31/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles -sqaumous cell of face ,_1. First Line,10/30/2023,Inactive,,
NBI OP INFUSION,25357,"Shah, Shailja S, MD",12/8/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,Maintenance,12/7/2023,Inactive,,
HAM OP INFUSION,68821,"Taha, Hesham, MD",3/4/2024,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,_1. First Line,3/3/2024,Inactive,,
HAM OP INFUSION,68821,"Patel, Eshan, MD",4/8/2024,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/11/2024,Inactive,,
CINJ OP INFUSION,87423,"Hochster, Howard S, MD",7/19/2023,Durvalumab D1  21 Day Cycles,First Line,7/19/2023,Inactive,"Cholangiocarcinoma (CMS/HCC)
Abnormal tumor markers
Finding of unspecified substance, not normally found in blood
Abnormal results of thyroid function studies",
CINJ OP INFUSION,87423,"Hochster, Howard S, MD",11/7/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Cholangiocarcinoma,_2. Second Line,11/6/2024,Inactive,"Cholangiocarcinoma (CMS/HCC)
Abnormal tumor markers
Finding of unspecified substance, not normally found in blood
Abnormal results of thyroid function studies",
CINJ OP INFUSION,87423,"Hochster, Howard S, MD",1/16/2025,Gemcitabine/CISplatin 21 Day Cycles- Hepatobiliary Cancers- Gemcitabine-CISplatin Sequencing,Maintenance,1/15/2025,Active,,
CINJ OP INFUSION,64692,"Hochster, Howard S, MD",4/13/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,First Line,4/12/2023,Inactive,,
CINJ OP INFUSION,64692,"Hochster, Howard S, MD",4/20/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Maintenance,4/19/2023,Inactive,,
CBMC OP INFUSION 1FL,87757,"Scoppetuolo, Michael, MD",9/18/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/17/2023,Inactive,,
CMC OP INFUSION,94775,"Pompa, Tiffany Ann, MD",5/15/2025,RiTUXimab 180 Day Cycles (Initial & Maintenance) - Hodgkin Lymphoma,_1. First Line,5/15/2025,Active,"Marginal zone lymphoma of intra-abdominal lymph nodes (CMS/HCC)
B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC)",
CMC OP INFUSION,42611,"Pompa, Tiffany Ann, MD",8/2/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,7/31/2024,Active,,
CMC OP INFUSION,42611,"Pompa, Tiffany Ann, MD",4/8/2025,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,4/8/2025,Active,Hepatocellular carcinoma (CMS/HCC),
MMC OP VP INFUSION,76084,"Cohen, Seth D, MD",8/30/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,8/29/2023,Inactive,,
NBR CINJ OP INFUSION,34841,"Matasar, Matthew J, MD",8/4/2023, Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Second Line,8/3/2023,Inactive,,
NBR CINJ OP INFUSION,34841,"Matasar, Matthew J, MD",9/13/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,9/12/2023,Inactive,,
NBR CINJ OP INFUSION,34841,"Matasar, Matthew J, MD",12/28/2023,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,12/26/2023,Inactive,,
CBMC OP INFUSION 2FL,97586,"Dave, Manish, MD",5/15/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/14/2023,Inactive,,
CBMC OP INFUSION 2FL,97586,"Phillips, Adrienne A, MD",7/31/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,7/23/2024,Active,,
CMC OP INFUSION,47122,"Pompa, Tiffany Ann, MD",8/13/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,8/12/2024,Active,,
CMC OP INFUSION,85261,"Taff, Jessica, MD",5/24/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,First Line,5/24/2023,Active,,
NBR CINJ OP INFUSION,33588,"Assal, Amer, MD",5/2/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,5/1/2024,Inactive,,
NBR CINJ OP INFUSION,33588,"Shah, Mansi R, MD",5/3/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_1. First Line,5/1/2024,Active,,
CBMC OP INFUSION 2FL,5066,"Litvak, Anna M, MD",4/11/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,4/11/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,53101,"Cruz, Allan Louie E, MD",4/29/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- metastatic colorectal adenocarcinoma,_1. First Line,4/29/2025,Active,Cecal cancer (CMS/HCC),C18.0 - Malignant neoplasm of cecum
CINJ OP INFUSION,55868,"Boland, Patrick M, MD",7/21/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,7/17/2023,Inactive,,
CINJ OP INFUSION,16359,"Mayer, Tina M, MD",3/27/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/27/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
MMC OP VP INFUSION,82088,"Meghal, Trishala, MD",10/29/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,Adjuvant,10/28/2024,Active,,
MMC OP VP INFUSION,82088,"Meghal, Trishala, MD",10/29/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,10/22/2024,Inactive,,
MMC OP VP INFUSION,82088,"Meghal, Trishala, MD",10/29/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,10/28/2024,Active,Primary carcinoma of middle third of esophagus (CMS/HCC),
CINJ OP INFUSION,19097,"Aikins, James K, MD",8/4/2023,Letrozole 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,6/12/2023,Inactive,,
CINJ OP INFUSION,19097,"Aikins, James K, MD",5/10/2024,DOXOrubicin 21 Day Cycles - Uterine Sarcoma,_2. Second Line,3/28/2024,Active,,
CMC 4B ONCOLOGY,10074,"Eltoukhy, Hussam, MD",6/14/2024,Daratumumab 28 Day Cycles- Multiple Myeloma,_1. First Line,6/13/2024,Inactive,,
CMC OP INFUSION,10074,"Eltoukhy, Hussam, MD",6/14/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,6/13/2024,Inactive,,
CINJ OP INFUSION,5571,"Weiss, Sarah, MD",9/16/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,9/10/2024,Active,,
SOM OUTPT INFUSION,63689,"Yin, Faye, MD",4/5/2023,Pembrolizumab / PACLitaxel 21 Day Cycles - Breast,Neoadjuvant,3/30/2023,Inactive,,
SOM OUTPT INFUSION,63689,"Toomey, Kathleen C, MD",6/27/2023,Pembrolizomib Q21 days maintanence - Breast,Neoadjuvant,6/22/2023,Inactive,,
CINJ OP INFUSION,24651,"Boland, Patrick M, MD",7/11/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,7/7/2023,Inactive,,
CINJ OP INFUSION,24651,"Boland, Patrick M, MD",4/9/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,4/4/2024,Active,,
CINJ OP INFUSION,24651,"Boland, Patrick M, MD",1/28/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,1/27/2025,Active,,
CINJ OP INFUSION,24651,"Boland, Patrick M, MD",2/11/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,1/27/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
JCMC CP INFUSION,20820,"Sekhri, Arunabh, MD",9/4/2024,Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,7/7/2024,Active,,
CINJ OP INFUSION,42282,"Patankar, Sonali, MD",4/10/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,4/10/2025,Inactive,Malignant neoplasm of exocervix (CMS/HCC),C53.1 - Malignant neoplasm of exocervix
CBMC OP INFUSION 2FL,98014,"Wagmiller, Jennifer Ann, MD",1/31/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/23/2024,Inactive,,
CINJ OP INFUSION,58146,"In, Haejin, MD",1/12/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,1/12/2024,Active,,
SOM OUTPT INFUSION,69336,"George, Mridula A, MD",1/3/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/2/2023,Inactive,,
SOM OUTPT INFUSION,69336,"Toomey, Kathleen C, MD",5/23/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,5/23/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)
Metastatic cancer to brain (CMS/HCC)
Cancer with leptomeningeal spread (CMS/HCC)",
CINJ OP INFUSION,76074,"Stephenson, Ruth D, DO",8/16/2024,Gemcitabine / CISplatin 21 Day Cycles - Unknown Primary,_4. Fourth Line,8/8/2024,Active,,
NBR 5N ONCOLOGY,31340,"Matasar, Matthew J, MD",1/4/2023,Cytarabine / IDArubicin / Midostaurin (7 + 3) - Acute Myeloid Leukemia FLT3+ (Induction),,1/4/2023,Inactive,,
NBR 5N ONCOLOGY,31340,"Palmisiano, Neil David, MD",3/7/2023,HiDAC-123 + Midostaurin (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia FLT3+ (Consolidation),,3/7/2023,Inactive,,
NBR 4N BMTU/IMCU,31340,"Braunschweig, Ira, MD",8/1/2023,BMT Autologous Busulfan / Melphalan (Busulfan PK levels measured) ,,7/31/2023,Inactive,,
NBR 4N BMTU/IMCU,31340,"Palmisiano, Neil David, MD",11/2/2023,CINJ 022301 Iadademstat / Gilteritinib 28 Day Cycles Research- Acute Myeloid Leukemia,_3. Third Line,10/31/2023,Inactive,,
CINJ OP INFUSION,31340,"Palmisiano, Neil David, MD",5/7/2024,CINJ 022305 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_3. Third Line,5/6/2024,Inactive,,
NBR CINJ OP INFUSION,31340,"Palmisiano, Neil David, MD",5/7/2024,CINJ 022305 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,Induction,5/6/2024,Inactive,,
CINJ OP INFUSION,65717,"Saraiya, Biren P, MD",5/8/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,5/7/2024,Inactive,,
CINJ OP INFUSION,65717,"Saraiya, Biren P, MD",1/16/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/8/2025,Active,,
CINJ OP INFUSION,94589,"Patel, Eshan, MD",7/19/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - thyroid,Maintenance,7/18/2024,Inactive,,
CBMC OP INFUSION 2FL,85537,"Kulkarni, Aditya A, MD",1/22/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/15/2025,Active,,
CINJ OP INFUSION,99101,"Toppmeyer, Deborah L, MD",10/10/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Adjuvant,10/9/2024,Active,,
CINJ OP INFUSION,99101,"Toppmeyer, Deborah L, MD",1/2/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,1/1/2025,Active,,
CINJ OP INFUSION,46937,"Ghodoussipour, Saum Bobak, MD",6/22/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,6/7/2023,Inactive,,
CINJ OP INFUSION,46937,"Ghodoussipour, Saum Bobak, MD",9/4/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,9/3/2024,Inactive,,
CINJ OP INFUSION,46937,"Ghodoussipour, Saum Bobak, MD",1/29/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,1/28/2025,Active,,
CINJ OP INFUSION,8276,"Boland, Patrick M, MD",11/7/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,11/6/2024,Active,,
SOM OUTPT INFUSION,12251,"Yin, Faye, MD",7/18/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,7/17/2023,Inactive,,
CMC OP INFUSION,68890,"Eltoukhy, Hussam, MD",6/11/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,6/4/2024,Active,,
CINJ OP INFUSION,70705,"Stephenson, Ruth D, DO",1/26/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,11/22/2022,Inactive,,
NBR 5N ONCOLOGY,46034,"Patel, Eshan, MD",9/14/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,,9/4/2023,Inactive,,
CINJ OP INFUSION,46034,"Patel, Eshan, MD",1/26/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,1/25/2024,Inactive,,
CBMC OP INFUSION 2FL,51705,"Wagmiller, Jennifer Ann, MD",12/28/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,12/12/2023,Inactive,,
CBMC OP INFUSION 2FL,51705,"Wagmiller, Jennifer Ann, MD",9/6/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/11/2024,Active,,
CINJ PEDS HEMONC ,72027,"Moerdler, Scott, MD",9/25/2024,PEDS IE - Osteosarcoma,_6. Sixth Line,9/23/2024,Active,,
NBI OP INFUSION,6489,"Shah, Maya M, MD",1/17/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) - 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/16/2024,Inactive,,
NBI OP INFUSION,6489,"Shah, Maya M, MD",1/17/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,1/16/2024,Inactive,,
CINJ OP INFUSION,88823,"Muralikrishnan, Sivraj",9/27/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,9/26/2024,Active,,
MMC OP VP INFUSION,97891,"Lee, Patrick C, MD",4/24/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/24/2025,Inactive,Adenocarcinoma of pancreas (CMS/HCC),
HAM OP INFUSION,20802,"Patel, Malini M, MD",8/24/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,8/22/2023,Inactive,,
CINJ OP INFUSION,20802,"Weiss, Sarah, MD",4/22/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_3. Third Line,4/16/2024,Active,,
CBMC OP INFUSION 2FL,64846,"Dharmapuri, Sirish, MD",12/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/8/2024,Active,,
CBMC OP INFUSION 2FL,64846,"Dharmapuri, Sirish, MD",4/30/2025,CINJ 072201 Treatment ARM NBT-NM108 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,4/25/2025,Active,Cancer of sigmoid (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon; Z00.6 - Encounter for examination for normal comparison and control in clinical research program
CINJ OP INFUSION,99839,"Ghodoussipour, Saum Bobak, MD",1/29/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,1/26/2025,Active,,
CINJ OP INFUSION,99839,"Ghodoussipour, Saum Bobak, MD",4/14/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Induction,4/14/2025,Active,Urothelial carcinoma (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; M19.90 - Unspecified osteoarthritis, unspecified site; M10.9 - Gout, unspecified; Z98.890 - Other specified postprocedural states; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z88.2 - Allergy status to sulfonamides; Z91.041 - Radiographic dye allergy status; Z91.018 - Allergy to other foods; Z88.6 - Allergy status to analgesic agent; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,30869,"Grossman, I Robert, MD",2/5/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/4/2025,Active,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs,
CBMC OP INFUSION 2FL,52636,"Brown, Andrew Bennett, MD",11/16/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/15/2023,Inactive,,
CBMC OP INFUSION 2FL,52636,"Brown, Andrew Bennett, MD",10/15/2024,"VinORELBine D1, D8, D15, D22  28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,10/15/2024,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
CBMC OP INFUSION 2FL,54565,"Ligresti, Louise G, MD",5/13/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,4/29/2024,Inactive,,
CINJ OP INFUSION,66346,"Berim, Lyudmyla, MD",4/9/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/9/2025,Active,Cancer of ascending colon (CMS/HCC),C18.2 - Malignant neoplasm of ascending colon
CMMC OP INFUSION,78775,"Siu, Karleung, MD",5/29/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,5/26/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),C25.1 - Malignant neoplasm of body of pancreas
CINJ OP INFUSION,18575,"Berim, Lyudmyla, MD",1/8/2024,Gemcitabine 28 Day Cycles - Bladder,_1. First Line,1/7/2024,Inactive,,
CINJ PEDS HEMONC ,9403,"Drachtman, Richard, MD",7/9/2024,DFCI 16-001 Consolidation II (LR),,7/8/2024,Inactive,,
MMC BBR2 ONCOLOGY,32600,"Lee, Patrick C, MD",2/20/2025,RiTUXimab / Lenalidomide 28 Day Cycles - Mantle Cell Lymphoma (Induction),_1. First Line,2/17/2025,Active,Mantle cell lymphoma (CMS/HCC),
CINJ PEDS HEMONC ,48201,"Moerdler, Scott, MD",7/27/2024,PEDS VAC (Extrapolated from COG D9803),_1. First Line,7/26/2024,Active,,
MMC OP VP INFUSION,74344,"Cohen, Seth D, MD",11/18/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/17/2024,Active,,
NBR 5N MED-SURG OVRF,27542,"Alexander, Henry Richard, MD",3/27/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,3/27/2025,Active,"Overlapping malignant neoplasm of colon (CMS/HCC)
Disseminated malignant neoplasm, unspecified (CMS/HCC)",
NBR CINJ OP INFUSION,42320,"Rhodes, Joanna Meehan, MD",12/15/2023,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,12/15/2023,Inactive,,
SOM OUTPT INFUSION,43415,"George, Roshini, DO",2/20/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/12/2025,Active,Malignant neoplasm of right ovary (CMS/HCC),C56.1 - Malignant neoplasm of right ovary
MMC OP INFUSION,65671,"Meghal, Trishala, MD",2/1/2023,Palbociclib 28 Day Cycles - Breast,First Line,2/1/2023,Inactive,,
MMC OP VP INFUSION,65671,"Meghal, Trishala, MD",5/28/2024,Alpelisib 28 Day Cycles - Breast,_2. Second Line,5/28/2024,Inactive,,
CMC OP INFUSION,86388,"Tang, Horace, MD",5/1/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,First Line,5/1/2023,Inactive,,
NBR 4N BMTU/IMCU,86388,"Assal, Amer, MD",8/30/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,8/29/2023,Inactive,,
HAM OP INFUSION,6840,"Yogarajah, Meera, MD",3/21/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,3/17/2024,Inactive,,
MMC OP VP INFUSION,27915,"Lee, Patrick C, MD",9/8/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,Third Line,9/7/2023,Inactive,,
MMC OP VP INFUSION,93890,"Lee, Patrick C, MD",11/7/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_1. First Line,10/28/2024,Active,,
CINJ OP INFUSION,79202,"George, Mridula A, MD",2/1/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,First Line,1/17/2023,Inactive,,
CINJ OP INFUSION,79202,"George, Mridula A, MD",5/24/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/23/2024,Inactive,,
CINJ OP INFUSION,79202,"George, Mridula A, MD",7/26/2024,EriBULin 21 Day Cycles - Breast,_3. Third Line,7/21/2024,Active,,
CINJ OP INFUSION,79202,"George, Mridula A, MD",1/17/2025,Capivasertib 28 Day Cycles - Breast,_4. Fourth Line,1/17/2025,Active,,
CBMC OP INFUSION 2FL,44677,"Derosa, William T, DO",10/28/2024,Pembrolizumab 42 Day Cycles - Hodgkin Lymphoma,_2. Second Line,10/24/2024,Active,,
CBMC OP INFUSION 2FL,23900,"Derosa, William T, DO",11/6/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,11/5/2024,Active,,
CBMC OP INFUSION 2FL,17235,"Litvak, Anna M, MD",11/20/2024,CINJ 042102 Amendment 36 Block A DAN-222 / Niraparib 7 Day Cycles Research- Breast Cancer,_1. First Line,11/7/2024,Inactive,,
CBMC OP INFUSION 2FL,17235,"Litvak, Anna M, MD",11/22/2024,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,_1. First Line,11/21/2024,Active,,
CBMC OP INFUSION 2FL,17235,"Litvak, Anna M, MD",1/17/2025,CINJ 042102 Block B (TNBC) Pembrolizumab 400 mg / PACLitaxel / CARBOplatin 21 Day Cycles Research- Triple Negative Breast Cancer,_1. First Line,11/21/2024,Active,,
CBMC OP INFUSION 2FL,17235,"Litvak, Anna M, MD",2/25/2025,CINJ 042102 Block C (TNBC) Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Triple Negative Breast Cancer,_1. First Line,2/24/2025,Inactive,"Malignant neoplasm of central portion of breast in female, estrogen receptor negative (CMS/HCC)",
TRMC TCCC OP INFUSION,28391,"Capo, Gerardo, MD",4/11/2025,(Capecitabine 850 mg/m2/OXALIplatin/DOCEtaxel) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/11/2025,Inactive,Malignant neoplasm of gastroesophageal junction (CMS/HCC),
TRMC TCCC OP INFUSION,28391,"Capo, Gerardo, MD",4/11/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/11/2025,Inactive,Malignant neoplasm of gastroesophageal junction (CMS/HCC),"C16.0 - Malignant neoplasm of cardia; R65.11 - Systemic inflammatory response syndrome (sirs) of non-infectious origin with acute organ dysfunction; E46 - Unspecified protein-calorie malnutrition; E87.0 - Hyperosmolality and hypernatremia; E87.20 - Acidosis, unspecified; D69.6 - Thrombocytopenia, unspecified; E87.1 - Hypo-osmolality and hyponatremia; J45.909 - Unspecified asthma, uncomplicated; N18.9 - Chronic kidney disease, unspecified; Z68.38 - Body mass index (BMI) 38.0-38.9, adult; N17.9 - Acute kidney failure, unspecified; E86.0 - Dehydration; R13.14 - Dysphagia, pharyngoesophageal phase; K22.2 - Esophageal obstruction; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; E87.6 - Hypokalemia; K22.89 - Other specified disease of esophagus; Z87.891 - Personal history of nicotine dependence"
NBR CINJ OP INFUSION,51610,"Shah, Mansi R, MD",10/31/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,10/8/2024,Inactive,,
SOM OUTPT INFUSION,69015,"Yin, Faye, MD",2/15/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,2/13/2023,Inactive,,
CINJ OP INFUSION,53744,"Berim, Lyudmyla, MD",8/16/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,8/13/2023,Inactive,,
CINJ OP INFUSION,53744,"Berim, Lyudmyla, MD",12/20/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Pancreatic Cancer,Neoadjuvant,12/20/2023,Inactive,,
NBI OP INFUSION,80298,"Anderson, Patrick S, MD",12/7/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Metastyatic high grade endometrial c ancer,_1. First Line,12/6/2023,Active,,
MMC OP VP INFUSION,50020,"Cohen, Seth D, MD",12/4/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,12/3/2023,Inactive,,
CINJ OP INFUSION,18848,"Stephenson, Ryan D, DO",2/22/2023,CARBOplatin / Gemcitabine / PACLlitaxel 21 Day Cycles - Bladder,First Line,2/20/2023,Inactive,,
CINJ OP INFUSION,18848,"Stephenson, Ryan D, DO",6/19/2023,Avelumab 14 Day Cycles - Bladder Cancer Maintenance,Maintenance,6/18/2023,Inactive,,
CINJ OP INFUSION,18848,"Stephenson, Ryan D, DO",8/22/2024,Enfortumab Vedotin 28 Day Cycles - Bladder,_3. Third Line,8/15/2024,Inactive,,
SOM OUTPT INFUSION,30053,"Toomey, Kathleen C, MD",6/20/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_4. Fourth Line,6/19/2024,Inactive,,
SOM OUTPT INFUSION,30053,"Toomey, Kathleen C, MD",10/7/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,10/7/2024,Active,,
SOM OUTPT INFUSION,30053,"Toomey, Kathleen C, MD",4/18/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,_5. Fifth Line,4/18/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Malignant pleural effusion
Breast cancer metastasized to bone (CMS/HCC)
Metastasis to lung (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; J91.0 - Malignant pleural effusion; C79.51 - Secondary malignant neoplasm of bone; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; C78.00 - Secondary malignant neoplasm of unspecified lung; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,97487,"Girda, Eugenia, MD",4/3/2023,CINJ 102203 ARM 3 Nemvaleukin 21 Day Cycles Research- Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,3/12/2023,Inactive,,
CINJ OP INFUSION,97487,"Girda, Eugenia, MD",7/25/2023,CINJ 102303 ARM B Nab-PACLitaxel 28 Day Cycles Research- Gynecological Malignancies,,7/16/2023,Inactive,,
CINJ OP INFUSION,97487,"Leiser, Aliza, MD",12/26/2023,Gemcitabine / CISplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,12/25/2023,Inactive,,
NBR 5N ONCOLOGY,22961,"Shah, Mansi R, MD",4/26/2023,CINJ 022101 (EA9181) ARM A PONATinib / Prednisone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,,4/25/2023,Inactive,,
NBR 4N ONCOLOGY,22961,"Doraiswamy, Anupama, MD",5/22/2023,CINJ 022101 ARM B Cycle 1 Ponatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,First Line,5/21/2023,Inactive,,
NBR 4N ONCOLOGY,22961,"Doraiswamy, Anupama, MD",6/12/2023,CINJ 022101 ARM B Cycle 2 Ponatinib / Methotrexate / Cytarabine 21 Day Cycles Research- Acute Lymphoblastic Leukemia,First Line,6/12/2023,Inactive,,
NBR CINJ OP INFUSION,22961,"Doraiswamy, Anupama, MD",7/5/2023,CINJ 022101 ARM B Cycle 2 Ponatinib / Methotrexate / Cytarabine 21 Day Cycles Research- Acute Lymphoblastic Leukemia,,7/5/2023,Inactive,,
NBR 5N ONCOLOGY,22961,"Palmisiano, Neil David, MD",7/26/2023,CINJ 022101 ARM B Cycle 2B Ponatinib / Methotrexate / Cytarabine 21 Day Cycles Research- Acute Lymphoblastic Leukemia,First Line,7/26/2023,Inactive,,
NBR 5N ONCOLOGY,22961,"Palmisiano, Neil David, MD",8/28/2023,CINJ 022101 ARM B Cycle 5 (3A) Ponatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,First Line,8/28/2023,Inactive,,
NBR CINJ OP INFUSION,22961,"Palmisiano, Neil David, MD",9/18/2023,CINJ 022101 (EA9181)  ARM B Cycle 6 Ponatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,,9/18/2023,Inactive,,
NBR 5N ONCOLOGY,22961,"Palmisiano, Neil David, MD",10/23/2023,CINJ 022101 (EA9181) ARM B Cycle 7 Ponatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,Induction,10/15/2023,Inactive,,
NBR CINJ OP INFUSION,22961,"Palmisiano, Neil David, MD",11/13/2023,CINJ 022101 (EA9181) ARM B Cycle 8 Ponatinib / Methotrexate / Cytarabine 21 Day Cycles Research- Acute Lymphoblastic Leukemia,Consolidation,11/13/2023,Inactive,,
NBR CINJ OP INFUSION,22961,"Palmisiano, Neil David, MD",12/19/2023,CINJ 022101 (EA9181) Arms B / C Maintenance Methotrexate Intrathecal / Ponatinib / VinCRIStine 28 Day Cycles Research- Acute Lymphoblastic Leukemia,Maintenance,12/19/2023,Active,,
CINJ OP INFUSION,68542,"Omene, Coral Oghenerukevwe, MD",6/12/2023,Palbociclib 28 Day Cycles - Breast,Maintenance,6/12/2023,Inactive,,
CMC OP INFUSION,5724,"Cohen, Seth D, MD",6/26/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/18/2024,Active,,
CMC OP INFUSION,5724,"Cohen, Seth D, MD",5/29/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/29/2025,Active,Colon cancer (CMS/HCC),
CBMC OP INFUSION 1FL,26498,"Derosa, William T, DO",7/9/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,7/9/2024,Active,,
CBMC OP INFUSION 2FL,1549,"Leitner, Stuart P, MD",4/11/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,4/11/2025,Active,"Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)
Breast cancer, stage 4 (CMS/HCC)
Carcinoma of breast metastatic to multiple sites (CMS/HCC)",
CINJ OP INFUSION,59258,"Muralikrishnan, Sivraj, MD",4/9/2025,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Adjuvant,4/9/2025,Active,"Papillary thyroid carcinoma (CMS/HCC)
Squamous cell carcinoma lung (CMS/HCC)",C73 - Malignant neoplasm of thyroid gland; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung
CINJ OP INFUSION,85019,"Boland, Patrick M, MD",4/28/2023,Cape + Panitumumab ,_1. First Line,4/27/2023,Inactive,,
CINJ OP INFUSION,85019,"Boland, Patrick M, MD",1/31/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/30/2025,Active,,
TRMC TCCC OP INFUSION,90624,"Capo, Gerardo, MD",8/20/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/19/2024,Active,,
MMC OP INFUSION,99193,"Meghal, Trishala, MD",3/17/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,3/17/2023,Inactive,,
CINJ OP INFUSION,94276,"Leiser, Aliza, MD",10/23/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Endometrial cancer,Adjuvant,10/17/2023,Inactive,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,94276,"Leiser, Aliza, MD",12/23/2024,Olaparib 30 Day Cycles -Endometrial Cancer,_2. Second Line,12/23/2024,Inactive,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,94276,"Leiser, Aliza, MD",1/10/2025,Durvalumab 1500 mg 28 Day Cycles- Endometrial Cancer,_1. First Line,1/2/2025,Active,,
NBI OP INFUSION,55058,"Jacoby, Sari H, MD",3/29/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,3/20/2024,Inactive,,
NBI OP INFUSION,55058,"Jacoby, Sari H, MD",4/5/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,4/4/2024,Active,,
CMC 4B ONCOLOGY,46793,"Taff, Jessica, MD",5/20/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,First Line,5/18/2023,Inactive,,
CINJ OP INFUSION,54946,"Ganesan, Shridar, MD PhD",1/9/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,1/9/2024,Inactive,,
TRMC TCCC OP INFUSION,1872,"Salerno, Vincent E, MD",2/12/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,Maintenance,2/11/2024,Active,,
CBMC OP INFUSION 2FL,60940,"Brown, Andrew Bennett, MD",12/23/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/22/2024,Active,,
CBMC OP INFUSION 2FL,47093,"Brown, Andrew Bennett, MD",5/13/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,5/13/2025,Active,Small cell carcinoma of upper lobe of left lung (CMS/HCC),
CBMC OP INFUSION 2FL,47093,"Brown, Andrew Bennett, MD",3/31/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/31/2025,Inactive,Small cell carcinoma of upper lobe of left lung (CMS/HCC),"C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung"
CBMC OP INFUSION 2FL,47093,"Brown, Andrew Bennett, MD",3/26/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,3/26/2025,Inactive,Small cell carcinoma of upper lobe of left lung (CMS/HCC),
CINJ OP INFUSION,48514,"Haigentz, Missak, MD",12/3/2024,CINJ 032006 (BTCRC-LUN18-153) ARM A Pembrolizumab 42 Day Cycles Research- Non-Small Cell Lung Cancer,Adjuvant,11/4/2024,Active,,
CINJ OP INFUSION,69873,"Goel, Sanjay, MD",4/11/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_4. Fourth Line,3/21/2024,Inactive,,
CINJ OP INFUSION,69873,"Goel, Sanjay, MD",8/14/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_4. Fourth Line,7/3/2024,Active,,
NBI OP INFUSION,91006,"Jacoby, Sari H, MD",12/12/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/10/2024,Active,,
CINJ OP INFUSION,25502,"Gulhati, Prateek, MD PhD",4/20/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,4/19/2023,Inactive,,
CBMC OP INFUSION 2FL,43830,"Wagmiller, Jennifer Ann, MD",12/16/2024,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,Adjuvant,12/15/2024,Active,,
CINJ OP INFUSION,69195,"Haigentz, Missak, MD",5/5/2023,Lenvatinib 28 Day Cycles- Thyroid Cancer,First Line,5/5/2023,Active,,
SOM OUTPT INFUSION,63348,"Yin, Faye, MD",10/20/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/18/2023,Inactive,,
CINJ OP INFUSION,63348,"Stephenson, Ryan D, DO",8/19/2024,Cabozantinib 28 Day Cycles- Renal cell carcinoma,_2. Second Line,8/19/2024,Active,,
CINJ OP INFUSION,34305,"Girda, Eugenia, MD",8/15/2023,CINJ 102303 ARM A Relacorilant / Nab-PACLitaxel 28 Day Cycles Research- Gynecological Malignancies,,8/14/2023,Inactive,,
SOM OUTPT INFUSION,34305,"Toomey, Kathleen C, MD",10/10/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,10/9/2024,Active,,
SOM OUTPT INFUSION,34305,"Toomey, Kathleen C, MD",10/10/2024,Pembrolizumab 21 Day Cycles - Uterine,_5. Fifth Line,10/9/2024,Active,,
MMC OP VP INFUSION,17124,"Meghal, Trishala, MD",8/22/2023,Nivolumab/Ipilimumab + PACLitaxel/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/23/2023,Inactive,,
MMC OP INFUSION,17124,"Meghal, Trishala, MD",2/14/2024,CINJ 032304 Arm B Pembrolizumab / Ramucirumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,2/13/2024,Inactive,,
MMC OP VP INFUSION,17124,"Meghal, Trishala, MD",5/28/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,4/28/2024,Inactive,,
MMC OP VP INFUSION,17124,"Meghal, Trishala, MD",7/9/2024,Pemetrexed/CISplatin + Bevacizumab 21 Cay Cycles- Non-Small Cell Lung Cancer,_3. Third Line,7/1/2024,Active,,
CBMC 2W ONCOLOGY,7839,"Scoppetuolo, Michael, MD",2/16/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Unknown Primary,_2. Second Line,2/15/2024,Inactive,,
JCMC CP INFUSION,52999,"Sekhri, Arunabh, MD",6/21/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 21 Day Cycles- Gastrointestinal Cancers,Second Line,6/20/2023,Inactive,,
JCMC CP INFUSION,52999,"Sekhri, Arunabh, MD",10/18/2023,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,_3. Third Line,10/18/2023,Inactive,,
CMC OP INFUSION,51483,"Tang, Horace, MD",6/14/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/13/2023,Inactive,,
MMC OP VP INFUSION,56233,"Lee, Patrick C, MD",12/27/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,12/9/2024,Active,,
MMC OP VP INFUSION,56233,"Lee, Patrick C, MD",1/3/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,12/9/2024,Active,,
MMC OP VP INFUSION,56233,"Lee, Patrick C, MD",2/11/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,12/9/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
CBMC OP INFUSION 2FL,11947,"Ligresti, Louise G, MD",7/10/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_3. Third Line,7/9/2024,Active,,
CBMC 2W ONCOLOGY,88493,"Grossman, I Robert, MD",6/26/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,6/26/2024,Inactive,,
CBMC OP INFUSION 2FL,88493,"Grossman, I Robert, MD",7/18/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,7/16/2024,Active,"Ovarian cancer (CMS/HCC)
On antineoplastic chemotherapy",
NBI OP INFUSION,18259,"Anderson, Patrick S, MD",3/7/2024,Pembrolizumab 21 Day Cycles- GTN Invasive/ Recurrent,_3. Third Line,3/6/2024,Active,,
NBI OP INFUSION,33506,"Schleicher, Lori, MD",6/28/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,6/27/2024,Active,,
MMC OP VP INFUSION,7926,"Cohen, Seth D, MD",3/12/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,3/10/2024,Active,,
NBR 5N ONCOLOGY,31667,"Chen, Xiaoyi",2/10/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_3. Third Line,2/9/2025,Active,AML (acute myeloid leukemia) in relapse (CMS/HCC),; C92.02 - AML (acute myeloid leukemia) in relapse (CMS/HCC)
NBR 5N ONCOLOGY,36313,"Tiger, Yun Kyoung, MD",3/1/2025,Cytarabine Cytoreduction for Hyperleukocytosis,_4. Fourth Line,3/1/2025,Active,Acute myeloid leukemia in adult (CMS/HCC),"C92.02 - Acute myeloblastic leukemia, in relapse; D61.810 - Antineoplastic chemotherapy induced pancytopenia; Z51.5 - Encounter for palliative care; E88.3 - Tumor lysis syndrome; N18.6 - End stage renal disease; D65 - Disseminated intravascular coagulation (defibrination syndrome); N17.0 - Acute kidney failure with tubular necrosis; J15.9 - Unspecified bacterial pneumonia; D70.9 - Neutropenia, unspecified; E83.39 - Other disorders of phosphorus metabolism; D84.9 - Immunodeficiency, unspecified; J90 - Pleural effusion, not elsewhere classified; C92.12 - Chronic myeloid leukemia, BCR/ABL-positive, in relapse; D75.81 - Myelofibrosis; E86.0 - Dehydration; E87.5 - Hyperkalemia; Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons; Z99.2 - Dependence on renal dialysis; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; I95.3 - Hypotension of hemodialysis; E87.6 - Hypokalemia; E87.70 - Fluid overload, unspecified; R50.81 - Fever presenting with conditions classified elsewhere; K59.00 - Constipation, unspecified; K38.1 - Appendicular concretions; Q99.8 - Other specified chromosome abnormalities; Z59.71 - Insufficient health insurance coverage; Z79.899 - Other long term (current) drug therapy; Z63.4 - Disappearance and death of family member"
JCMC CP INFUSION,62893,"Cruz, Allan Louie E, MD",12/5/2023,TH+P (DOCEtaxel / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/4/2023,Inactive,,
JCMC CP INFUSION,62893,"Cruz, Allan Louie E, MD",6/13/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,6/12/2024,Active,,
CBMC OP INFUSION 2FL,35472,"McKenna, Marshall, MD",5/23/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/22/2025,Active,Diffuse large B cell lymphoma (CMS/HCC),
CBMC 2W ONCOLOGY,35472,"McKenna, Marshall, MD",5/13/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/13/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C82.90 - Follicular lymphoma, unspecified, unspecified site; C83.30 - Diffuse large B-cell lymphoma, unspecified site; L89.152 - Pressure ulcer of sacral region, stage 2; E87.1 - Hypo-osmolality and hyponatremia; K52.1 - Toxic gastroenteritis and colitis; D63.0 - Anemia in neoplastic disease; I10 - Essential (primary) hypertension; N13.30 - Unspecified hydronephrosis; K21.9 - Gastro-esophageal reflux disease without esophagitis; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; F41.9 - Anxiety disorder, unspecified; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; Z74.09 - Other reduced mobility; G47.00 - Insomnia, unspecified; G89.29 - Other chronic pain; T50.8X5A - Adverse effect of diagnostic agents, initial encounter; D50.9 - Iron deficiency anemia, unspecified; I95.1 - Orthostatic hypotension; R91.8 - Other nonspecific abnormal finding of lung field; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence; I25.2 - Old myocardial infarction; Z79.899 - Other long term (current) drug therapy; Z79.82 - Long term (current) use of aspirin; Z98.890 - Other specified postprocedural states; Z91.048 - Other nonmedicinal substance allergy status; Z98.61 - Coronary angioplasty status"
CBMC 2W ONCOLOGY,35472,"McKenna, Marshall, MD",5/13/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/13/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C82.90 - Follicular lymphoma, unspecified, unspecified site; C83.30 - Diffuse large B-cell lymphoma, unspecified site; L89.152 - Pressure ulcer of sacral region, stage 2; E87.1 - Hypo-osmolality and hyponatremia; K52.1 - Toxic gastroenteritis and colitis; D63.0 - Anemia in neoplastic disease; I10 - Essential (primary) hypertension; N13.30 - Unspecified hydronephrosis; K21.9 - Gastro-esophageal reflux disease without esophagitis; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; F41.9 - Anxiety disorder, unspecified; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; Z74.09 - Other reduced mobility; G47.00 - Insomnia, unspecified; G89.29 - Other chronic pain; T50.8X5A - Adverse effect of diagnostic agents, initial encounter; D50.9 - Iron deficiency anemia, unspecified; I95.1 - Orthostatic hypotension; R91.8 - Other nonspecific abnormal finding of lung field; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence; I25.2 - Old myocardial infarction; Z79.899 - Other long term (current) drug therapy; Z79.82 - Long term (current) use of aspirin; Z98.890 - Other specified postprocedural states; Z91.048 - Other nonmedicinal substance allergy status; Z98.61 - Coronary angioplasty status"
CBMC 2W ONCOLOGY,35472,"McKenna, Marshall, MD",3/5/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,3/4/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),"C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; E44.0 - Moderate protein-calorie malnutrition; Z66 - Do not resuscitate; I47.20 - Ventricular tachycardia, unspecified; N17.9 - Acute kidney failure, unspecified; E87.1 - Hypo-osmolality and hyponatremia; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; E11.9 - Type 2 diabetes mellitus without complications; E78.5 - Hyperlipidemia, unspecified; G25.81 - Restless legs syndrome; I10 - Essential (primary) hypertension; J45.20 - Mild intermittent asthma, uncomplicated; E83.52 - Hypercalcemia; Z96.641 - Presence of right artificial hip joint; F41.1 - Generalized anxiety disorder; F41.9 - Anxiety disorder, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; N28.89 - Other specified disorders of kidney and ureter; G62.9 - Polyneuropathy, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R51.9 - Headache, unspecified; M16.11 - Unilateral primary osteoarthritis, right hip; G47.00 - Insomnia, unspecified; E87.5 - Hyperkalemia; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; Z95.5 - Presence of coronary angioplasty implant and gr..."
NBI OP INFUSION,94777,"Shah, Shailja S, MD",5/14/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/13/2024,Inactive,,
CMC OP INFUSION,18287,"Talwar, Sumit, MD",4/24/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/22/2024,Inactive,,
CMC OP INFUSION,18287,"Talwar, Sumit, MD",8/28/2024,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Maintenance,8/28/2024,Inactive,,
CMC OP INFUSION,65564,"Pompa, Tiffany Ann, MD",1/15/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/13/2025,Active,,
CMC 4B ONCOLOGY,62811,"Pompa, Tiffany Ann, MD",12/5/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - BREAST CANCER,_1. First Line,12/4/2024,Inactive,,
CINJ OP INFUSION,43492,"Weiss, Sarah, MD",1/18/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,1/17/2023,Inactive,,
CMC OP INFUSION,67050,"Eltoukhy, Hussam, MD",7/9/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,7/9/2024,Inactive,,
CINJ OP INFUSION,31668,"Saraiya, Biren P, MD",4/24/2023,Darolutamide 28 Day Cycles - Prostate,,4/24/2023,Inactive,,
CINJ OP INFUSION,31668,"Saraiya, Biren P, MD",5/28/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,5/28/2024,Active,,
CINJ OP INFUSION,98097,"Packiam, Vignesh, MD",1/29/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,1/28/2024,Inactive,,
CINJ OP INFUSION,98097,"Packiam, Vignesh, MD",4/15/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Adjuvant,4/14/2024,Active,,
CINJ OP INFUSION,86436,"Packiam, Vignesh, MD",4/21/2025,Nadofaragene Firadenovec 84 Day Cycles - Bladder,Induction,4/21/2025,Active,"Bladder cancer (CMS/HCC)
Malignant neoplasm of overlapping sites of bladder (CMS/HCC)",
CINJ OP INFUSION,15681,"Stephenson, Ryan D, DO",11/20/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,11/20/2023,Active,,
NBR 5N ONCOLOGY,89737,"Rhodes, Joanna Meehan, MD",11/16/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_2. Second Line,11/16/2024,Inactive,,
NBR CINJ OP INFUSION,89737,"Rhodes, Joanna Meehan, MD",11/21/2024,CHeP (Cyclophosphamide / DOXOrubicin / etoposide/ Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,11/20/2024,Inactive,,
NBR CINJ OP INFUSION,89737,"Rhodes, Joanna Meehan, MD",11/21/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,11/21/2024,Inactive,,
NBR CINJ OP INFUSION,89737,"Rhodes, Joanna Meehan, MD",12/9/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,Consolidation,12/8/2024,Active,Endometrial cancer (CMS/HCC),
NBR 5N ONCOLOGY,89737,"Rhodes, Joanna Meehan, MD",12/26/2024,Brentuximab Vedotin / Nivolumab 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,12/25/2024,Active,,
CINJ OP INFUSION,40693,"Gulhati, Prateek, MD PhD",12/28/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,12/27/2023,Inactive,,
CINJ OP INFUSION,40693,"Gulhati, Prateek, MD PhD",3/18/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/18/2024,Active,,
NBR CINJ OP INFUSION,89650,"Shah, Mansi R, MD",12/25/2023,Bortezomib/Dexamethasone/Cyclophosphamide PO 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,12/25/2023,Inactive,,
NBR CINJ OP INFUSION,89650,"Shah, Mansi R, MD",2/1/2024,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,1/31/2024,Inactive,,
NBR CINJ OP INFUSION,89650,"Shah, Mansi R, MD",3/20/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,3/20/2024,Inactive,,
SOM OUTPT INFUSION,16920,"Patel, Eshan, MD",11/9/2023,CapeOX/Irinotecan (Capecitabine 1000 mg/m2/OXALIplatin/Irinotecan) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/8/2023,Inactive,,
SOM OUTPT INFUSION,16920,"Patel, Eshan, MD",11/28/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,11/26/2023,Inactive,,
MMC OP VP INFUSION,34585,"Lee, Patrick C, MD",12/21/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/6/2023,Inactive,,
MMC OP INFUSION,72735,"Talwar, Sumit, MD",6/29/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/28/2023,Inactive,,
MMC OP VP INFUSION,72735,"Talwar, Sumit, MD",9/1/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,8/31/2023,Inactive,,
CINJ OP INFUSION,64424,"Hochster, Howard S, MD",2/12/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,2/11/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),
CINJ OP INFUSION,93856,"Berim, Lyudmyla, MD",11/4/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/3/2024,Active,,
NBI A5 PEDIATRICS,34066,"Narang, Shalu, MD",2/9/2024,AALL1731 Non-DS SR B-ALL Induction,Induction,2/9/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",3/15/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",Consolidation,3/15/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",4/18/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,4/18/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",6/21/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,6/21/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",6/26/2024,PEDS Asparaginase Erwinia (Rylaze),_1. First Line,6/26/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",8/27/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,8/26/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",10/1/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,9/30/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",11/25/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,11/25/2024,Inactive,,
NBI VALERIE FND HEMONC,34066,"de Benedictis, Marianna, MD",12/31/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,12/30/2024,Active,,
CBMC OP INFUSION 2FL,71179,"Leitner, Stuart P, MD",11/9/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,11/8/2023,Inactive,,
CINJ OP INFUSION,75397,"Packiam, Vignesh, MD",2/17/2025,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,2/17/2025,Active,Malignant neoplasm of dome of urinary bladder (CMS/HCC),
CINJ OP INFUSION,48388,"Packiam, Vignesh, MD",5/19/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,5/19/2025,Inactive,Malignant neoplasm of dome of urinary bladder (CMS/HCC),
CINJ OP INFUSION,48388,"Packiam, Vignesh, MD",5/19/2025,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,5/19/2025,Active,Malignant neoplasm of dome of urinary bladder (CMS/HCC),
NBR CINJ OP INFUSION,59157,"Rhodes, Joanna Meehan, MD",4/10/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/10/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of upper extremity (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; E83.110 - Hereditary hemochromatosis; C83.34 - Diffuse large b-cell lymphoma, lymph nodes of axilla and upper limb; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D49.9 - Neoplasm of unspecified behavior of unspecified site; R22.32 - Localized swelling, mass and lump, left upper limb"
MSC OP INFUSION,63759,"Cohen, Seth D, MD",8/17/2023,"Nivolumab D1, D15 28 Day Cycles - Bladder",,8/17/2023,Inactive,,
MSC OP INFUSION,63759,"Cohen, Seth D, MD",12/5/2023,Enfortumab Vedotin + Pembrolizumab  21 Day Cycles - Bladder,_1. First Line,11/30/2023,Inactive,,
MMC OP VP INFUSION,10975,"Eltoukhy, Hussam, MD",1/9/2024,CINJ 012203 Lead-In Treatment for Fit and Non-Fit Treatments Cycle 42 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,1/8/2024,Inactive,,
MMC OP VP INFUSION,57159,"Eltoukhy, Hussam, MD",8/8/2023,Lenalidomide / Low-Dose Dexamethasone 28 Day Cycles - Multiple Myeloma,,8/8/2023,Inactive,,
MMC OP VP INFUSION,57159,"Eltoukhy, Hussam, MD",9/14/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,First Line,9/13/2023,Active,,
SOM OUTPT INFUSION,35074,"Ghodoussipour, Saum Bobak, MD",2/3/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,1/31/2025,Active,Urothelial cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C68.9 - Malignant neoplasm of urinary organ, unspecified"
SOM OUTPT INFUSION,87914,"Ghodoussipour, Saum Bobak, MD",5/12/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,5/12/2025,Active,Urothelial cancer (CMS/HCC),"N30.00 - Acute cystitis without hematuria; N39.3 - Stress incontinence (female) (male); Z85.51 - Personal history of malignant neoplasm of bladder; Z87.440 - Personal history of urinary (tract) infections; Z98.890 - Other specified postprocedural states; I10 - Essential (primary) hypertension; K21.9 - Gastro-esophageal reflux disease without esophagitis; M81.0 - Age-related osteoporosis without current pathological fracture; M19.90 - Unspecified osteoarthritis, unspecified site; K58.9 - Irritable bowel syndrome, unspecified; M41.9 - Scoliosis, unspecified; H04.129 - Dry eye syndrome of unspecified lacrimal gland; E78.5 - Hyperlipidemia, unspecified; E03.9 - Hypothyroidism, unspecified; F41.9 - Anxiety disorder, unspecified; F32.A - Depression, unspecified; Z87.891 - Personal history of nicotine dependence; Z85.118 - Personal history of other malignant neoplasm of bronchus and lung; Z88.2 - Allergy status to sulfonamides; Z88.0 - Allergy status to penicillin; Z91.040 - Latex allergy status; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z91.09 - Other allergy status, other than to drugs and biological substances; Z79.891 - Long term (current) use of opiate analgesic; Z79.1 - Long term (current) use of non-steroidal anti-inflammatories (nsaid); Z79.890 - Hormone replacement therapy; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,30127,"Wagmiller, Jennifer Ann, MD",11/28/2023,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/28/2023,Active,,
MSC OP INFUSION,99423,"Talwar, Sumit, MD",5/14/2025,Bortezomib/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/14/2025,Active,Myeloma (CMS/HCC),
CINJ OP INFUSION,47869,"Stephenson, Ryan D, DO",10/18/2023,CINJ 081804 Cohort A ARM A-1 BCG / Pembrolizumab 21 Day Cycles Research- Bladder Cancer,_2. Second Line,10/17/2023,Active,,
MMC OP VP INFUSION,20623,"Lee, Patrick C, MD",10/10/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,10/10/2024,Active,,
MMC OP VP INFUSION,10100,"Lee, Patrick C, MD",3/28/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,3/28/2025,Active,"Malignant neoplasm of urinary bladder (CMS/HCC)
Malignant neoplasm metastatic to left lung (CMS/HCC)
Chemotherapy-induced fatigue",
NBR 4N ONCOLOGY,30820,"Patel, Vimal D, MD",4/12/2023,BMT Autologous BEAM,Consolidation,4/12/2023,Inactive,,
MSC OP INFUSION,54755,"Meghal, Trishala, MD",5/2/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/1/2023,Inactive,,
MSC OP INFUSION,54755,"Meghal, Trishala, MD",7/25/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,,7/24/2023,Inactive,,
CBMC OP INFUSION 2FL,80426,"Wagmiller, Jennifer Ann, MD",11/10/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,11/9/2023,Inactive,,
SOM OUTPT INFUSION,11872,"Patel, Eshan, MD",11/14/2023,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,11/14/2023,Active,,
MMC OP VP INFUSION,93642,"Talwar, Sumit, MD",3/28/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,First Line,3/27/2023,Inactive,,
CBMC OP INFUSION 2FL,35764,"Litvak, Anna M, MD",1/30/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,1/8/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
NBI OP INFUSION,15978,"Schleicher, Lori, MD",11/25/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/24/2024,Inactive,,
MMC OP VP INFUSION,31239,"Talwar, Sumit, MD",2/14/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/13/2023,Inactive,,
MMC OP VP INFUSION,39173,"Talwar, Sumit, MD",2/11/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/10/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
SOM OUTPT INFUSION,60322,"Patel, Eshan, MD",12/2/2024,CISplatin / PACLitaxel with Concurrent Radiation Day Cycle- Bladder Cancers,_1. First Line,11/29/2024,Active,,
NBI OP INFUSION,60548,"Shah, Shailja S, MD",4/22/2025,Bortezomib/Dexamethasone weekly- Amyloid,_1. First Line,4/22/2025,Inactive,Cardiac amyloidosis (CMS/HCC),E85.4 - Organ-limited amyloidosis; I43 - Cardiomyopathy in diseases classified elsewhere
NBI OP INFUSION,60548,"Shah, Shailja S, MD",4/22/2025,Bortezomib/Dexamethasone weekly for Amyloid,_1. First Line,4/22/2025,Active,Cardiac amyloidosis (CMS/HCC),E85.4 - Organ-limited amyloidosis; I43 - Cardiomyopathy in diseases classified elsewhere
CBMC OP INFUSION 2FL,95537,"Dharmapuri, Sirish, MD",5/1/2025,"Gemcitabine D1, D8/Albumin-Bound PACLitaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,5/1/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CBMC OP INFUSION 2FL,91745,"Wagmiller, Jennifer Ann, MD",12/23/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,12/15/2024,Inactive,,
CINJ OP INFUSION,26570,"Berim, Lyudmyla, MD",4/10/2024,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,_1. First Line,4/10/2024,Inactive,,
CINJ OP INFUSION,26570,"Berim, Lyudmyla, MD",4/24/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,4/23/2024,Active,,
NBI D7 MED-SURG/TELE,46198,"Shah, Shailja S, MD",7/24/2024,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,7/24/2024,Inactive,,
NBI OP INFUSION,84603,"Snyder, Rose, MD",4/22/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,4/22/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,57759,"Wagmiller, Jennifer Ann, MD",12/4/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,11/26/2023,Inactive,,
CBMC OP INFUSION 2FL,57759,"Wagmiller, Jennifer Ann, MD",2/27/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/25/2024,Active,,
MMC OP VP INFUSION,50209,"Cohen, Seth D, MD",4/2/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,_1. First Line,2/26/2024,Inactive,,
MMC OP VP INFUSION,50209,"Cohen, Seth D, MD",6/5/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,_1. First Line,5/22/2024,Inactive,,
NBI OP INFUSION,84611,"Shah, Maya M, MD",1/10/2024,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,1/10/2024,Inactive,,
JCMC CP INFUSION,12640,"Cruz, Allan Louie E, MD",6/26/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/25/2023,Inactive,,
CINJ OP INFUSION,97717,"Patankar, Sonali, MD",12/9/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/10/2024,Active,,
CINJ OP INFUSION,97717,"Patankar, Sonali, MD",12/23/2024,Pembrolizumab 21 Day Cycles - Maintenance Cervical,Maintenance,12/22/2024,Inactive,,
CINJ OP INFUSION,97717,"Patankar, Sonali, MD",2/17/2025,Pembrolizumab 42 Day Cycles - Cervical,Maintenance,2/16/2025,Active,Cervical cancer (CMS/HCC),C53.1 - Malignant neoplasm of exocervix
CINJ OP INFUSION,8545,"Patel, Eshan, MD",3/8/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/7/2024,Inactive,,
CBMC OP INFUSION 2FL,67577,"Wagmiller, Jennifer Ann, MD",4/4/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,Neoadjuvant,3/27/2025,Inactive,Malignant neoplasm of exocervix (CMS/HCC),
CINJ OP INFUSION,71652,"Girda, Eugenia, MD",2/13/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/12/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; Z51.89 - Encounter for other specified aftercare
TRMC TCCC OP INFUSION,27484,"Capo, Gerardo, MD",4/25/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/23/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
TRMC TCCC OP INFUSION,27484,"Capo, Gerardo, MD",4/23/2025,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,4/23/2025,Inactive,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),C53.8 - Malignant neoplasm of overlapping sites of cervix uteri; G89.3 - Neoplasm related pain (acute) (chronic); Z85.41 - Personal history of malignant neoplasm of cervix uteri
NBR 5N MED-SURG OVRF,16656,"Alexander, Henry Richard, MD",4/14/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,4/14/2025,Active,"Overlapping malignant neoplasm of colon (CMS/HCC)
Pseudomyxoma peritonei (CMS/HCC)",
CBMC OP INFUSION 2FL,10382,"Litvak, Anna M, MD",10/12/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,10/11/2023,Inactive,,
MMC OP INFUSION,43699,"Lee, Patrick C, MD",3/18/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,3/18/2025,Active,Mass of upper lobe of right lung,
CBMC OP INFUSION 2FL,4867,"Scoppetuolo, Michael, MD",8/7/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,8/4/2024,Active,,
CINJ OP INFUSION,26080,"Toppmeyer, Deborah L, MD",4/10/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,4/10/2023,Inactive,,
HAM OP INFUSION,26080,"Toppmeyer, Deborah L, MD",6/19/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Adjuvant,6/19/2023,Active,,
NBI OP INFUSION,46140,"Anderson, Patrick S, MD",1/27/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,1/26/2025,Active,,
MMC OP VP INFUSION,77151,"Cohen, Seth D, MD",5/7/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,5/7/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
MMC OP VP INFUSION,77151,"Cohen, Seth D, MD",5/7/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/7/2025,Inactive,Malignant neoplasm of urinary bladder (CMS/HCC),
NBR CINJ OP INFUSION,26574,"Tiger, Yun Kyoung, MD",9/20/2024,Mogamulizumab-kpkc 28 Day Cycle - Mycosis Fungoides / Sezary Syndrome ,_6. Sixth Line,9/19/2024,Inactive,,
NBR CINJ OP INFUSION,26574,"Tiger, Yun Kyoung, MD",12/20/2024,Pembrolizumab 21 Day Cycles - Mycosis Fungoides / Sezary Syndrome ,_7. Seventh Line,12/19/2024,Active,,
NBR CINJ OP INFUSION,26574,"Tiger, Yun Kyoung, MD",4/4/2025,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_7. Seventh Line,3/30/2025,Inactive,Cutaneous T-cell lymphoma involving lymph nodes of lower extremity (CMS/HCC),"C84.A5 - Cutaneous t-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb; L98.8 - Other specified disorders of the skin and subcutaneous tissue; Z94.81 - Bone marrow transplant status; D72.820 - Lymphocytosis (symptomatic); L40.50 - Arthropathic psoriasis, unspecified; D89.813 - Graft-versus-host disease, unspecified"
NBR CINJ OP INFUSION,26574,"Tiger, Yun Kyoung, MD",4/4/2025,Brentuximab Vedotin / Bendamustine 21 Day Cycles - Hodgkin Lymphoma,_7. Seventh Line,4/4/2025,Active,Cutaneous T-cell lymphoma involving lymph nodes of lower extremity (CMS/HCC),
NBR CINJ OP INFUSION,26574,"Tiger, Yun Kyoung, MD",3/30/2025,Bendamustine 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_7. Seventh Line,3/30/2025,Inactive,Cutaneous T-cell lymphoma involving lymph nodes of lower extremity (CMS/HCC),"C84.A5 - Cutaneous t-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb; L98.8 - Other specified disorders of the skin and subcutaneous tissue; Z94.81 - Bone marrow transplant status; D72.820 - Lymphocytosis (symptomatic); L40.50 - Arthropathic psoriasis, unspecified; D89.813 - Graft-versus-host disease, unspecified"
CBMC OP INFUSION 2FL,96958,"Raptis, George, MD",7/23/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,7/22/2024,Inactive,,
CBMC OP INFUSION 2FL,96958,"Raptis, George, MD",9/17/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,9/17/2024,Inactive,,
CBMC OP INFUSION 2FL,96958,"Raptis, George, MD",12/11/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,12/11/2024,Inactive,,
CINJ OP INFUSION,66528,"George, Mridula A, MD",4/26/2023,CINJ 042111 (GO42784) ARM A Giredestrant 30 mg 28 Day Cycles Research- Breast Cancer,Adjuvant,4/26/2023,Active,,
CINJ OP INFUSION,26747,"George, Mridula A, MD",3/31/2023,Talazoparib 28 Day Cycles ,Neoadjuvant,3/31/2023,Inactive,,
CBMC 2W ONCOLOGY,85566,"Grossman, I Robert, MD",8/9/2024,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,8/9/2024,Active,,
CBMC 2W ONCOLOGY,85566,"Grossman, I Robert, MD",9/23/2024,HiDAC-135 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,9/23/2024,Active,,
CMC OP INFUSION,90788,"Taff, Jessica, MD",5/26/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,Third Line,5/25/2023,Inactive,,
NBR CINJ OP INFUSION,14567,"Rhodes, Joanna Meehan, MD",5/6/2024,RiTUXimab 28 Day Cycle - Mantle Cell Lymphoma,_1. First Line,5/5/2024,Inactive,,
CINJ OP INFUSION,58356,"Packiam, Vignesh, MD",3/14/2025,CINJ 082404 Group A TAR-210 6 Week / 12 Week Cycles Research- Bladder Cancer,Induction,3/14/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,40670,"Dasgeb, Bahar, MD",9/17/2024,Methotrexate IntraLesional Weekly- Head and Neck Cancers,_2. Second Line,8/20/2024,Active,,
CINJ OP INFUSION,54961,"Toppmeyer, Deborah L, MD",7/3/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,7/3/2023,Inactive,,
CINJ OP INFUSION,54961,"Toppmeyer, Deborah L, MD",2/8/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,2/8/2024,Active,Primary liver adenocarcinoma (CMS/HCC),
MMC OP INFUSION,54688,"Lee, Patrick C, MD",1/4/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,12/17/2023,Inactive,,
MMC OP INFUSION,54688,"Lee, Patrick C, MD",4/16/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,4/15/2024,Inactive,,
JCMC CP INFUSION,95088,"Sekhri, Arunabh, MD",1/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/21/2023,Inactive,,
TRMC TCCC OP INFUSION,1138,"Capo, Gerardo, MD",1/16/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,1/15/2025,Active,,
MMC OP VP INFUSION,32796,"Meghal, Trishala, MD",6/11/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,6/9/2024,Inactive,,
MMC OP VP INFUSION,32796,"Meghal, Trishala, MD",12/3/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,11/26/2024,Active,,
MMC OP VP INFUSION,32796,"Meghal, Trishala, MD",2/11/2025,Olaparib 30 Day Cycles - Breast,Adjuvant,2/11/2025,Active,"Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC)
Malignant neoplasm of body of pancreas (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy
CINJ OP INFUSION,11130,"Weiss, Sarah, MD",6/28/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,6/27/2023,Inactive,,
JCMC CP INFUSION,66994,"Cruz, Allan Louie E, MD",10/17/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/16/2023,Inactive,,
JCMC CP INFUSION,66994,"Cruz, Allan Louie E, MD",10/17/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/17/2023,Inactive,,
CMC OP INFUSION,95962,"Pompa, Tiffany Ann, MD",12/4/2024,CARBOplatin 21 Day Cycle- Head and Neck Cancers,_1. First Line,12/3/2024,Inactive,,
CMC OP INFUSION,18871,"Eltoukhy, Hussam, MD",8/26/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,8/25/2024,Active,,
CBMC 2W ONCOLOGY,95119,"McKenna, Marshall, MD",3/28/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,3/28/2025,Inactive,Large B-cell lymphoma (CMS/HCC),"B20 - Human immunodeficiency virus (HIV) disease; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E88.3 - Tumor lysis syndrome; K68.3 - Retroperitoneal hematoma; N15.1 - Renal and perinephric abscess; N17.0 - Acute kidney failure with tubular necrosis; C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes; E44.0 - Moderate protein-calorie malnutrition; E87.0 - Hyperosmolality and hypernatremia; J90 - Pleural effusion, not elsewhere classified; N18.9 - Chronic kidney disease, unspecified; K56.7 - Ileus, unspecified; D62 - Acute posthemorrhagic anemia; E87.1 - Hypo-osmolality and hyponatremia; K92.1 - Melena; K91.89 - Other postprocedural complications and disorders of digestive system; F05 - Delirium due to known physiological condition; E87.20 - Acidosis, unspecified; E83.51 - Hypocalcemia; E83.39 - Other disorders of phosphorus metabolism; F41.9 - Anxiety disorder, unspecified; E87.70 - Fluid overload, unspecified; E87.6 - Hypokalemia; E87.5 - Hyperkalemia; E83.42 - Hypomagnesemia; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; R73.9 - Hyperglycemia, unspecified; D64.81 - Anemia due to antineoplastic chemotherapy; Z60.3 - Acculturation difficulty; I95.9 - Hypotension, unspecified; R09.02 - Hypoxemia; E86.0 - Dehydration; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; N32.0 - Bladder-neck obstruction; N28.89 - Other specified disorders of kidney and ureter; Z72...."
CBMC 2W ONCOLOGY,95119,"McKenna, Marshall, MD",3/28/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,3/27/2025,Inactive,Large B-cell lymphoma (CMS/HCC),"B20 - Human immunodeficiency virus (HIV) disease; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E88.3 - Tumor lysis syndrome; K68.3 - Retroperitoneal hematoma; N15.1 - Renal and perinephric abscess; N17.0 - Acute kidney failure with tubular necrosis; C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes; E44.0 - Moderate protein-calorie malnutrition; E87.0 - Hyperosmolality and hypernatremia; J90 - Pleural effusion, not elsewhere classified; N18.9 - Chronic kidney disease, unspecified; K56.7 - Ileus, unspecified; D62 - Acute posthemorrhagic anemia; E87.1 - Hypo-osmolality and hyponatremia; K92.1 - Melena; K91.89 - Other postprocedural complications and disorders of digestive system; F05 - Delirium due to known physiological condition; E87.20 - Acidosis, unspecified; E83.51 - Hypocalcemia; E83.39 - Other disorders of phosphorus metabolism; F41.9 - Anxiety disorder, unspecified; E87.70 - Fluid overload, unspecified; E87.6 - Hypokalemia; E87.5 - Hyperkalemia; E83.42 - Hypomagnesemia; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; R73.9 - Hyperglycemia, unspecified; D64.81 - Anemia due to antineoplastic chemotherapy; Z60.3 - Acculturation difficulty; I95.9 - Hypotension, unspecified; R09.02 - Hypoxemia; E86.0 - Dehydration; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; N32.0 - Bladder-neck obstruction; N28.89 - Other specified disorders of kidney and ureter; Z72...."
CBMC 2W ONCOLOGY,95119,"McKenna, Marshall, MD",3/27/2025,Dose-Adjusted R-EPOCH (For AIDS-Related) (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (AIDS-Related),_1. First Line,3/27/2025,Inactive,Large B-cell lymphoma (CMS/HCC),"B20 - Human immunodeficiency virus (HIV) disease; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E88.3 - Tumor lysis syndrome; K68.3 - Retroperitoneal hematoma; N15.1 - Renal and perinephric abscess; N17.0 - Acute kidney failure with tubular necrosis; C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes; E44.0 - Moderate protein-calorie malnutrition; E87.0 - Hyperosmolality and hypernatremia; J90 - Pleural effusion, not elsewhere classified; N18.9 - Chronic kidney disease, unspecified; K56.7 - Ileus, unspecified; D62 - Acute posthemorrhagic anemia; E87.1 - Hypo-osmolality and hyponatremia; K92.1 - Melena; K91.89 - Other postprocedural complications and disorders of digestive system; F05 - Delirium due to known physiological condition; E87.20 - Acidosis, unspecified; E83.51 - Hypocalcemia; E83.39 - Other disorders of phosphorus metabolism; F41.9 - Anxiety disorder, unspecified; E87.70 - Fluid overload, unspecified; E87.6 - Hypokalemia; E87.5 - Hyperkalemia; E83.42 - Hypomagnesemia; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; R73.9 - Hyperglycemia, unspecified; D64.81 - Anemia due to antineoplastic chemotherapy; Z60.3 - Acculturation difficulty; I95.9 - Hypotension, unspecified; R09.02 - Hypoxemia; E86.0 - Dehydration; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; N32.0 - Bladder-neck obstruction; N28.89 - Other specified disorders of kidney and ureter; Z72...."
CBMC OP INFUSION 2FL,9549,"Wagmiller, Jennifer Ann, MD",11/14/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/14/2023,Inactive,,
CBMC OP INFUSION 2FL,9549,"Wagmiller, Jennifer Ann, MD",4/29/2024,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_2. Second Line,4/28/2024,Inactive,,
CBMC OP INFUSION 2FL,9549,"Wagmiller, Jennifer Ann, MD",8/8/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,7/31/2024,Active,,
CINJ OP INFUSION,57013,"Goel, Sanjay, MD",7/26/2023,CINJ 052216 Stage 2 Ulixertinib / Hydroxychloroquine 28 Day Cycles Research- Gastrointestinal Malignancies,Third Line,7/26/2023,Inactive,,
MMC OP VP INFUSION,10816,"Lee, Patrick C, MD",11/27/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,11/26/2023,Active,,
CMC OP INFUSION,9018,"Taff, Jessica, MD",7/3/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/2/2023,Inactive,,
NBR 4N ONCOLOGY,6968,"Braunschweig, Ira, MD",3/30/2023,BMT Autologous BEAM,,3/30/2023,Inactive,,
MMC OP INFUSION,71375,"Talwar, Sumit, MD",5/11/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,5/3/2023,Inactive,,
MMC OP VP INFUSION,71375,"Talwar, Sumit, MD",5/25/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,First Line,5/24/2023,Inactive,,
CINJ OP INFUSION,98535,"Mayer, Tina M, MD",6/3/2024,Avelumab 14 Day Cycles - maintenance for urothelial Carcinoma,Maintenance,6/2/2024,Inactive,,
CINJ OP INFUSION,98535,"Mayer, Tina M, MD",12/2/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/1/2024,Active,,
NBR 5N ONCOLOGY,35850,"Shah, Mansi R, MD",5/5/2023,Triple Intrathecal - 1 Day Cycle- Hematological Malignancies,,5/5/2023,Inactive,,
NBR 5N ONCOLOGY,35850,"Palmisiano, Neil David, MD",5/12/2023,HyperCVAD (Cycle A) Course (Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,,5/7/2023,Inactive,,
NBR CINJ OP INFUSION,35850,"Palmisiano, Neil David, MD",8/31/2023,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,,8/27/2023,Inactive,,
NBR CINJ OP INFUSION,35850,"Palmisiano, Neil David, MD",11/13/2023,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,_1. First Line,11/13/2023,Inactive,,
NBR 5N ONCOLOGY,35850,"Palmisiano, Neil David, MD",1/22/2024,HyperCVD Mini + Venetoclax (Venetoclax/ High-Dose Methotrexate / Cytarabine / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_3. Third Line,1/22/2024,Inactive,,
NBR CINJ OP INFUSION,35850,"Palmisiano, Neil David, MD",6/12/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),Reinduction,6/11/2024,Inactive,,
NBR 4N BMTU/IMCU,35850,"Palmisiano, Neil David, MD",7/5/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,7/4/2024,Inactive,,
CINJ OP INFUSION,5684,"Ghodoussipour, Saum Bobak, MD",11/25/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Induction - Bladder Cancer,Induction,11/22/2024,Active,,
CINJ OP INFUSION,52571,"Packiam, Vignesh, MD",4/17/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,4/17/2025,Active,Bladder cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; Z00.6 - Encounter for examination for normal comparison and control in clinical research program"
CBMC OP INFUSION 2FL,85893,"Brown, Andrew Bennett, MD",10/9/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,10/8/2023,Inactive,,
CBMC OP INFUSION 2FL,85893,"Brown, Andrew Bennett, MD",11/13/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,85893,"Brown, Andrew Bennett, MD",3/4/2024,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,3/3/2024,Inactive,,
CBMC OP INFUSION 2FL,18498,"Leitner, Stuart P, MD",1/15/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/14/2025,Active,,
MMC OP VP INFUSION,65880,"Cohen, Seth D, MD",12/11/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/10/2024,Active,,
HAM OP INFUSION,34009,"Yogarajah, Meera, MD",9/12/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,9/8/2024,Active,,
MMC OP VP INFUSION,86977,"Talwar, Sumit, MD",5/13/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,5/13/2025,Active,"Malignant melanoma of skin of trunk, except scrotum (CMS/HCC)
Drug-induced thyroiditis",
CINJ OP INFUSION,96574,"Stephenson, Ryan D, DO",12/15/2023,Apalutamide 30 Day Cycles - Prostate,_1. First Line,12/15/2023,Inactive,,
MMC OP VP INFUSION,89687,"Cohen, Seth D, MD",8/2/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,8/1/2023,Active,,
MMC OP VP INFUSION,89687,"Cohen, Seth D, MD",2/19/2025,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,2/18/2025,Active,Malignant melanoma of overlapping sites (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
SOM OUTPT INFUSION,75497,"Yin, Faye, MD",4/11/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,4/9/2023,Inactive,,
SOM OUTPT INFUSION,75497,"Yin, Faye, MD",8/15/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/14/2023,Inactive,,
CINJ OP INFUSION,90281,"Patel, Eshan, MD",9/8/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Induction,9/7/2023,Inactive,,
CINJ OP INFUSION,90281,"Patel, Eshan, MD",11/18/2023,PEMEtrexed + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/9/2023,Inactive,,
CINJ OP INFUSION,90281,"Patel, Eshan, MD",2/9/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/8/2024,Inactive,,
HAM OP INFUSION,41546,"Patel, Malini M, MD",1/8/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/6/2025,Active,,
CMC OP INFUSION,30023,"Easaw, Sarah, MD",9/21/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/5/2023,Inactive,,
CINJ OP INFUSION,55953,"Jang, Thomas L, MD",1/12/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,1/9/2023,Inactive,,
CINJ OP INFUSION,66234,"Mayer, Tina M, MD",7/7/2023,Enzalutamide 28 Day Cycles - Prostate,First Line,7/7/2023,Inactive,,
NBR CINJ OP INFUSION,66234,"Mayer, Tina M, MD",11/22/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,11/22/2024,Active,,
CBMC OP INFUSION 2FL,7632,"Grossman, I Robert, MD",7/16/2024,Bendamustine / RiTUXimab 28 Day Cycles - Splenic Marginal Zone Lymphoma,_2. Second Line,7/8/2024,Active,,
CMC OP INFUSION,5974,"Taff, Jessica, MD",3/27/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/26/2024,Active,,
CMC OP INFUSION,5974,"Taff, Jessica, MD",3/24/2025,FOLFIRI Inpatient (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/24/2025,Inactive,Primary cancer of esophagus with metastasis to other site (CMS/HCC),
CMC OP INFUSION,5974,"Taff, Jessica, MD",3/24/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/24/2025,Active,Primary cancer of esophagus with metastasis to other site (CMS/HCC),
CINJ OP INFUSION,51662,"Muralikrishnan, Sivraj, MD",5/27/2025,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,5/27/2025,Active,"Malignant neoplasm of lung (CMS/HCC)
Other fatigue",C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; R53.83 - Other fatigue
CINJ OP INFUSION,51662,"Muralikrishnan, Sivraj, MD",5/6/2025,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,5/6/2025,Inactive,"Malignant neoplasm of lung (CMS/HCC)
Other fatigue",C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; R53.83 - Other fatigue
CINJ OP INFUSION,51662,"Muralikrishnan, Sivraj, MD",3/25/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/25/2025,Inactive,"Malignant neoplasm of lung (CMS/HCC)
Other fatigue","C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I50.9 - Heart failure, unspecified; I63.40 - Cerebral infarction due to embolism of unspecified cerebral artery; I95.9 - Hypotension, unspecified; E11.9 - Type 2 diabetes mellitus without complications; R53.83 - Other fatigue"
CINJ OP INFUSION,46750,"Stephenson, Ryan D, DO",4/3/2023,Relugolix 30 day Cycles - Prostate,Neoadjuvant,4/3/2023,Inactive,,
CINJ OP INFUSION,21545,"Goel, Sanjay, MD",8/7/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_4. Fourth Line,6/18/2024,Active,,
NBI D7 MED-SURG/TELE,29504,"Shah, Shailja S, MD",11/19/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,11/19/2024,Inactive,,
NBI OP INFUSION,15837,"Cheng, Yan Ho, MD",11/21/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,11/13/2023,Active,,
NBR 4N ONCOLOGY,59963,"Matasar, Matthew J, MD",3/20/2023,CHOPE (Cyclophosphamide / DOXOrubicin / VinCRIStine / Prednisone / Etoposide) 21 Day Cycles - Non-Hodgkin's Lymphoma,,3/19/2023,Inactive,,
NBR CINJ OP INFUSION,59963,"Matasar, Matthew J, MD",4/11/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,First Line,4/10/2023,Inactive,,
NBR 4N ONCOLOGY,59963,"Braunschweig, Ira, MD",9/2/2023,BMT Autologous BEAM,,9/1/2023,Inactive,,
NBR CINJ OP INFUSION,59963,"Matasar, Matthew J, MD",8/28/2024,RomiDEPsin 28 Day Cycles - Cutaneous T-Cell Lymphoma,_2. Second Line,8/20/2024,Inactive,,
NBR CINJ OP INFUSION,59963,"Matasar, Matthew J, MD",11/6/2024,PRALAtrexate 49 Day Cycle - Peripheral T-Cell Lymphoma,_3. Third Line,10/29/2024,Inactive,,
NBR CINJ OP INFUSION,66855,"Tiger, Yun Kyoung, MD",5/3/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,4/24/2024,Inactive,,
MMC OP VP INFUSION,65036,"Talwar, Sumit, MD",4/11/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,4/10/2023,Active,,
MMC OP VP INFUSION,65036,"Talwar, Sumit, MD",5/13/2025,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/13/2025,Active,Malignant neoplasm of overlapping sites of colon (CMS/HCC),
CINJ OP INFUSION,1583,"Hochster, Howard S, MD",2/27/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,2/26/2025,Active,"Hepatocellular carcinoma (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",C22.0 - Liver cell carcinoma; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures
CINJ OP INFUSION,26798,"Aikins, James K, MD",8/27/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/11/2024,Active,,
CINJ OP INFUSION,21173,"Leiser, Aliza, MD",4/17/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/7/2025,Inactive,Malignant neoplasm of both ovaries (CMS/HCC),C56.3 - Malignant neoplasm of bilateral ovaries; Z85.41 - Personal history of malignant neoplasm of cervix uteri
CINJ PEDS HEMONC ,45761,"Masterson, Margaret, MD",4/25/2024,Cytarabine Intrathecal (IT) 1 Day Cycle per AALL1732,_1. First Line,4/25/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Masterson, Margaret, MD",4/26/2024,AALL1732 Induction,_1. First Line,4/26/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Masterson, Margaret, MD",5/30/2024,AALL1732 Consolidation,Consolidation,5/30/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Masterson, Margaret, MD",8/2/2024,AALL1732 HR B-ALL Blinatumomab Block 1,_1. First Line,8/1/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Drachtman, Richard, MD",8/16/2024,PEDS AALL 1732  Blinatumomab cylce 1 per COG memo 07.18.2024,_1. First Line,8/1/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Drachtman, Richard, MD",9/20/2024,PEDS Blinatumomab,_1. First Line,9/19/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Drachtman, Richard, MD",9/24/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,9/19/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Drachtman, Richard, MD",12/4/2024,AALL1732  Blinatumomab Block 2 No IT Methotrexate,_1. First Line,12/2/2024,Inactive,,
CINJ PEDS HEMONC ,45761,"Drachtman, Richard, MD",1/6/2025,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy Delayed Intensification",_1. First Line,1/6/2025,Active,,
CINJ PEDS HEMONC ,45761,"Drachtman, Richard, MD",4/3/2025,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,4/3/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
TRMC TCCC OP INFUSION,75204,"Meghal, Trishala, MD",4/16/2025,Zanubrutinib (320 mg) 30 Day Cycles - Mantle Cell Lymphoma,_1. First Line,4/16/2025,Inactive,CLL (chronic lymphocytic leukemia) (CMS/HCC),
SOM OUTPT INFUSION,63663,"Toomey, Kathleen C, MD",1/24/2025,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,1/22/2025,Active,,
CBMC OP INFUSION 2FL,88231,"Wagmiller, Jennifer Ann, MD",10/25/2023,Pembrolizumab 21 Day Cycles - Breast,Adjuvant,10/25/2023,Inactive,,
CBMC 2W ONCOLOGY,88231,"Wagmiller, Jennifer Ann, MD",7/15/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_1. First Line,7/14/2024,Inactive,,
CBMC OP INFUSION 2FL,88231,"Wagmiller, Jennifer Ann, MD",9/11/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_2. Second Line,9/8/2024,Inactive,,
CBMC OP INFUSION 2FL,88231,"Wagmiller, Jennifer Ann, MD",10/30/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_3. Third Line,10/28/2024,Inactive,,
CBMC OP INFUSION 2FL,37988,"Kulkarni, Aditya A, MD",4/14/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/7/2025,Active,Bladder cancer (CMS/HCC),
CINJ OP INFUSION,97550,"Gulhati, Prateek, MD PhD",1/19/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,1/4/2023,Inactive,,
CMC OP INFUSION,36417,"Talwar, Sumit, MD",10/4/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,10/3/2023,Active,,
HAM OP INFUSION,35811,"Patel, Malini M, MD",6/19/2023,Capecitabine 21 Day Cycles - Breast,Third Line,6/19/2023,Inactive,,
HAM OP INFUSION,35811,"Patel, Malini M, MD",8/29/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,8/28/2024,Active,,
CBMC OP INFUSION 2FL,32713,"Wagmiller, Jennifer Ann, MD",4/24/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,4/15/2024,Inactive,,
CBMC OP INFUSION 2FL,32713,"Wagmiller, Jennifer Ann, MD",9/11/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,9/3/2024,Active,,
NBR 5N ONCOLOGY,29647,"Berim, Lyudmyla, MD",4/26/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,4/25/2024,Inactive,,
NBI OP INFUSION,78000,"Shah, Maya M, MD",10/18/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,10/17/2023,Inactive,,
CBMC OP INFUSION 2FL,347,"Wagmiller, Jennifer Ann, MD",5/27/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/20/2025,Active,Cholangiocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,36267,"Wagmiller, Jennifer Ann, MD",11/17/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,11/16/2023,Active,,
SOM OUTPT INFUSION,71625,"Patel, Eshan, MD",9/16/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/15/2024,Active,,
CBMC OP INFUSION 2FL,76733,"Wagmiller, Jennifer Ann, MD",7/10/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,7/9/2023,Inactive,,
CBMC OP INFUSION 2FL,76733,"Wagmiller, Jennifer Ann, MD",2/2/2024,Pembrolizumab 42 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,2/1/2024,Active,,
HAM OP INFUSION,61061,"Yogarajah, Meera, MD",4/11/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,4/8/2025,Active,"Malignant neoplasm of endometrium (CMS/HCC)
Hypothyroidism due to drugs","C54.1 - Malignant neoplasm of endometrium; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified"
NBR CINJ OP INFUSION,46742,"Matasar, Matthew J, MD",7/12/2023,Zanubrutinib (160 mg) 30 Day Cycles - Mantle Cell Lymphoma,,7/12/2023,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,46742,"Matasar, Matthew J, MD",8/14/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,Adjuvant,8/13/2024,Active,,
CINJ OP INFUSION,6801,"Muralikrishnan, Sivraj, MD",5/28/2025,CINJ 032501 PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,5/28/2025,Active,"NSCLC of right lung (CMS/HCC)
Malignant neoplasm of overlapping sites of right lung (CMS/HCC)",
CINJ OP INFUSION,6801,"Muralikrishnan, Sivraj, MD",5/5/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/5/2025,Inactive,Malignant neoplasm of overlapping sites of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,54367,"Brown, Andrew Bennett, MD",11/8/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,11/8/2023,Inactive,,
CBMC 2W ONCOLOGY,54367,"Brown, Andrew Bennett, MD",1/11/2024,PACLitaxel 28 Day Cycles - Thymic Carcinoma,_3. Third Line,1/10/2024,Inactive,,
CINJ OP INFUSION,83509,"Mayer, Tina M, MD",4/24/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,4/24/2024,Active,,
MMC BBR2 ONCOLOGY,85019,"Talwar, Sumit, MD",1/8/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,_1. First Line,1/2/2024,Inactive,,
MMC OP INFUSION,85019,"Talwar, Sumit, MD",1/30/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Neoadjuvant,1/29/2024,Inactive,,
MMC OP INFUSION,85019,"Lee, Patrick C, MD",9/24/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,9/23/2024,Inactive,,
MMC OP INFUSION,85019,"Lee, Patrick C, MD",1/7/2025,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,1/6/2025,Active,,
MMC OP INFUSION,85019,"Lee, Patrick C, MD",5/13/2025,Capecitabine 1250 mg/m2 21 Day Cycles-,_2. Second Line,5/13/2025,Inactive,"Malignant neoplasm of hypopharynx, unspecified (CMS/HCC)","C13.9 - Malignant neoplasm of hypopharynx, unspecified; Z85.820 - Personal history of malignant melanoma of skin; Z92.3 - Personal history of irradiation; Z92.21 - Personal history of antineoplastic chemotherapy; Z98.49 - Cataract extraction status, unspecified eye; Z79.620 - Long term (current) use of immunosuppressive biologic; Z79.899 - Other long term (current) drug therapy; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
CBMC OP INFUSION 2FL,38475,"Dave, Manish, MD",5/15/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/14/2023,Active,,
SOM OUTPT INFUSION,35344,"Toomey, Kathleen C, MD",5/30/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_4. Fourth Line,5/30/2025,Active,Colon cancer metastasized to lung (CMS/HCC),
CINJ OP INFUSION,67470,"Saraiya, Biren P, MD",3/21/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,3/21/2023,Inactive,,
CINJ OP INFUSION,67470,"Saraiya, Biren P, MD",3/10/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/10/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; E83.52 - Hypercalcemia; N17.9 - Acute kidney failure, unspecified; K59.00 - Constipation, unspecified; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; E78.00 - Pure hypercholesterolemia, unspecified"
MMC OP INFUSION,6645,"Lee, Patrick C, MD",3/31/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,3/30/2023,Inactive,,
CINJ OP INFUSION,2426,"Haigentz, Missak, MD",12/24/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,12/23/2024,Active,,
CINJ OP INFUSION,2426,"Haigentz, Missak, MD",4/8/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,4/8/2025,Inactive,"Adenocarcinoma of hilum of left lung (CMS/HCC)
Chronic fatigue","C34.02 - Malignant neoplasm of left main bronchus; C79.31 - Secondary malignant neoplasm of brain; B18.1 - Chronic viral hepatitis B without delta-agent; D69.6 - Thrombocytopenia, unspecified; E87.5 - Hyperkalemia; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; J44.9 - Chronic obstructive pulmonary disease, unspecified; I10 - Essential (primary) hypertension; F41.9 - Anxiety disorder, unspecified; F32.A - Depression, unspecified; Z98.890 - Other specified postprocedural states; Z86.711 - Personal history of pulmonary embolism; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z91.81 - History of falling; Z79.01 - Long term (current) use of anticoagulants; Z79.51 - Long term (current) use of inhaled steroids; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; R53.82 - Chronic fatigue, unspecified"
CINJ OP INFUSION,56511,"Omene, Coral Oghenerukevwe, MD",8/26/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,8/25/2024,Active,,
JCMC CP INFUSION,84369,"Cruz, Allan Louie E, MD",4/3/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Second Line,4/3/2023,Inactive,,
CINJ OP INFUSION,1904,"Toppmeyer, Deborah L, MD",5/22/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,5/22/2025,Active,Secondary malignant neoplasm of axillary lymph nodes (CMS/HCC),C50.811 - Malignant neoplasm of overlapping sites of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z90.11 - Acquired absence of right breast and nipple; Z79.811 - Long term (current) use of aromatase inhibitors; Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants
NBR BMSCH 2 PED HEMONC,59313,"Moerdler, Scott, MD",5/13/2023,"per article Vincristine, Irinotecan and Temozolomide for relapsed sarcoma",Adjuvant,5/12/2023,Inactive,,
CINJ PEDS HEMONC ,59313,"Moerdler, Scott, MD",5/15/2025,Regorafenib 28 Day Cycles - Sarcoma,_3. Third Line,5/15/2025,Active,"Malignant neoplasm of bone and articular cartilage, unspecified (CMS/HCC)
Ewing sarcoma (CMS/HCC)",
CBMC OP INFUSION 2FL,85326,"Derosa, William T, DO",11/26/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/25/2024,Active,,
CMC OP INFUSION,96992,"Cohen, Seth D, MD",7/22/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/21/2024,Inactive,,
MSC OP INFUSION,96992,"Cohen, Seth D, MD",10/21/2024,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,10/21/2024,Inactive,,
MMC BBR2 ONCOLOGY,47641,"Cohen, Seth D, MD",2/6/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,2/6/2025,Inactive,Primary malignant neoplasm of bronchus of left upper lobe (CMS/HCC),
CINJ OP INFUSION,44677,"Boland, Patrick M, MD",1/5/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,1/4/2024,Active,,
CINJ OP INFUSION,80431,"Patel, Eshan, MD",3/24/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,3/10/2023,Inactive,,
CINJ OP INFUSION,80431,"Patel, Eshan, MD",5/26/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,,5/3/2023,Inactive,,
SOM OUTPT INFUSION,80431,"Patel, Eshan, MD",2/9/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/8/2024,Inactive,,
NBR CINJ OP INFUSION,60715,"Shah, Mansi R, MD",6/20/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,6/19/2023,Inactive,,
CMC OP INFUSION,8518,"Taff, Jessica, MD",4/25/2024,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,_1. First Line,4/18/2024,Active,,
NBR 5N ONCOLOGY,44017,"Rhodes, Joanna Meehan, MD",8/5/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/5/2023,Inactive,,
NBI VALERIE FND HEMONC,61301,"Narang, Shalu, MD",5/6/2023,AALL0434 - Maintenance Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,5/5/2023,Inactive,,
NBI VALERIE FND HEMONC,61301,"Narang, Shalu, MD",10/31/2023,AALL0434 - Maintenance Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,10/30/2023,Inactive,,
NBI VALERIE FND HEMONC,61301,"Narang, Shalu, MD",1/23/2024,AALL0434 - Maintenance Continued After Cycle Three Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,1/22/2024,Active,,
NBI VALERIE FND HEMONC,61301,"Narang, Shalu, MD",1/24/2024,AALL0434 - Maintenance Continued After Cycle Three Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,1/23/2024,Inactive,,
NBR 5N ONCOLOGY,96855,"Omene, Coral Oghenerukevwe, MD",4/24/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,4/23/2024,Inactive,,
NBR 5N ONCOLOGY,37320,"Gulhati, Prateek, MD PhD",10/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/14/2024,Inactive,,
NBR CINJ OP INFUSION,84280,"Evens, Andrew M, DO",5/1/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/30/2024,Inactive,,
CINJ OP INFUSION,98496,"George, Mridula A, MD",1/27/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,1/27/2023,Inactive,,
NBR 4N ONCOLOGY,27261,"Rhodes, Joanna Meehan, MD",3/15/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,3/15/2024,Inactive,,
NBR CINJ OP INFUSION,27261,"Shah, Mansi R, MD",4/9/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/8/2024,Inactive,,
NBR CINJ OP INFUSION,27261,"Shah, Mansi R, MD",12/17/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,12/17/2024,Active,,
NBI OP INFUSION,97517,"Shah, Shailja S, MD",2/3/2025,Dasatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,2/3/2025,Active,CML (chronic myelocytic leukemia) (CMS/HCC),
HAM OP INFUSION,57597,"Patel, Malini M, MD",2/13/2023,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,Third Line,2/8/2023,Inactive,,
HAM OP INFUSION,57597,"Patel, Malini M, MD",6/19/2023,MitoXANTRONE / PredniSONE 21 Day Cycles - Prostate,Third Line,6/18/2023,Inactive,,
CBMC OP INFUSION 2FL,1519,"Leitner, Stuart P, MD",9/12/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,9/12/2023,Active,,
JCMC CP INFUSION,43200,"Cruz, Allan Louie E, MD",5/1/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/30/2023,Inactive,,
CINJ OP INFUSION,73106,"George, Mridula A, MD",1/31/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,1/30/2024,Inactive,,
JCMC CP INFUSION,16927,"Cruz, Allan Louie E, MD",12/5/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Triple positive Breast Cancer,_1. First Line,12/3/2024,Active,,
JCMC CP INFUSION,83548,"Cruz, Allan Louie E, MD",4/17/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,4/17/2025,Active,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,18464,"Haigentz, Missak, MD",8/26/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,8/25/2024,Active,,
CBMC OP INFUSION 2FL,85054,"Brown, Andrew Bennett, MD",4/16/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/14/2024,Active,,
NBR 4N ONCOLOGY,69324,"Assal, Amer, MD",3/21/2024,BMT Autologous Melphalan Day -1 140MG/M2,_2. Second Line,3/19/2024,Active,,
NBI OP INFUSION,82958,"Snyder, Rose, MD",5/6/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,5/6/2025,Active,Myeloma (CMS/HCC),C90.02 - Multiple myeloma in relapse (CMS/HCC)
MMC OP VP INFUSION,13531,"Talwar, Sumit, MD",6/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,6/17/2024,Inactive,,
CINJ OP INFUSION,7277,"Berim, Lyudmyla, MD",6/19/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,6/19/2023,Inactive,,
CINJ OP INFUSION,7277,"Berim, Lyudmyla, MD",10/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,10/1/2023,Inactive,,
CINJ OP INFUSION,38813,"Berim, Lyudmyla, MD",8/17/2023,5-FU/LV+ Nivolumab 14 Day Cycles- Gastrointestinal Cancers,,8/16/2023,Inactive,,
CINJ OP INFUSION,81227,"Mayer, Tina M, MD",10/10/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,10/9/2023,Inactive,,
JCMC CP INFUSION,44807,"Cruz, Allan Louie E, MD",5/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/28/2024,Inactive,,
NBI OP INFUSION,23380,"Anderson, Patrick S, MD",7/3/2024,"DOCEtaxel D8 / Gemcitabine D1, D8 21 Day Cycles - Uterine Sarcoma",_2. Second Line,7/2/2024,Active,,
CMC OP INFUSION,31124,"Pompa, Tiffany Ann, MD",9/12/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,9/11/2024,Active,,
CINJ OP INFUSION,48132,"George, Mridula A, MD",3/20/2023,Palbociclib 28 Day Cycles - Breast,Adjuvant,3/20/2023,Inactive,,
CINJ OP INFUSION,48132,"George, Mridula A, MD",8/23/2023,Ribociclib 28 Day Cycles - Breast,Second Line,8/23/2023,Inactive,,
CINJ OP INFUSION,48132,"George, Mridula A, MD",1/26/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,1/26/2024,Inactive,,
NBI OP INFUSION,12689,"Anderson, Patrick S, MD",2/1/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles -Endometrial adenocaercinoma,_1. First Line,1/31/2024,Inactive,,
NBI OP INFUSION,12689,"Anderson, Patrick S, MD",6/13/2024,Liposomal DOXOrubicin 28 Day Cycles - Recurrent Endometrial Ca,_3. Third Line,6/12/2024,Active,,
JCMC CP INFUSION,41434,"Cruz, Allan Louie E, MD",8/15/2023,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,First Line,8/14/2023,Inactive,,
NBR CINJ OP INFUSION,94393,"Shah, Mansi R, MD",2/13/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_6. Sixth Line,2/13/2024,Inactive,,
NBR CINJ OP INFUSION,94393,"Shah, Mansi R, MD",7/9/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,10. Tenth Line,7/8/2024,Inactive,,
NBR CINJ OP INFUSION,94393,"Shah, Mansi R, MD",2/24/2025,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_9. Ninth Line,2/23/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
MMC OP VP INFUSION,42719,"Cohen, Seth D, MD",11/28/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/27/2023,Active,,
MMC OP INFUSION,85376,"Eltoukhy, Hussam, MD",5/1/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,,4/30/2023,Inactive,,
CINJ OP INFUSION,96483,"Leiser, Aliza, MD",6/23/2023,Pembrolizumab 21 Day Cycles - Uterine,Second Line,6/23/2023,Inactive,,
NBR CINJ OP INFUSION,53561,"Shah, Mansi R, MD",3/23/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,3/9/2023,Inactive,,
NBR 4N BMTU/IMCU,53561,"Braunschweig, Ira, MD",10/19/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,10/17/2023,Inactive,,
CBMC OP INFUSION 2FL,77756,"Brown, Andrew Bennett, MD",1/4/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Induction,1/4/2024,Inactive,,
CBMC OP INFUSION 2FL,77756,"Brown, Andrew Bennett, MD",5/15/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Maintenance,5/12/2024,Active,,
CINJ OP INFUSION,1092,"Boland, Patrick M, MD",12/20/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/19/2024,Active,,
NBR 5N ONCOLOGY,93049,"Haigentz, Missak, MD",4/18/2025,"PACLitaxel D1, D8, D15 28 Day Cycles- Esophageal and Esophagogastric Junction Cancers",_2. Second Line,4/18/2025,Active,"Primary esophageal squamous cell carcinoma (CMS/HCC)
Metastases to the liver (CMS/HCC)
Malignant neoplasm of lower third of esophagus (CMS/HCC)","A41.9 - Sepsis, unspecified organism; E43 - Unspecified severe protein-calorie malnutrition; Z66 - Do not resuscitate; G93.41 - Metabolic encephalopathy; R57.1 - Hypovolemic shock; J96.01 - Acute respiratory failure with hypoxia; R65.21 - Severe sepsis with septic shock; E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; C78.02 - Secondary malignant neoplasm of left lung; D70.1 - Agranulocytosis secondary to cancer chemotherapy; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C15.5 - Malignant neoplasm of lower third of esophagus; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; D69.6 - Thrombocytopenia, unspecified; Z68.31 - Body mass index (BMI) 31.0-31.9, adult; R18.0 - Malignant ascites; E87.20 - Acidosis, unspecified; Z93.3 - Colostomy status; D64.81 - Anemia due to antineoplastic chemotherapy; E78.5 - Hyperlipidemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; F41.9 - Anxiety disorder, unspecified; I95.9 - Hypotension, unspecified; Z11.52 - Encounter for screening for COVID-19; Z53.8 - Procedure and treatment not carried out for other reasons; E86.0 - Dehydration; E86.1 - Hypovolemia; E87.70 - Fluid overload, unspecified; R13.10 - Dysphagia, unspecified; M71.22 - Synovial cyst of popliteal space (Baker), left knee; M71.21 - Synovial cyst of popliteal space (Baker), right knee; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; T45.1..."
CBMC OP INFUSION 2FL,26060,"Wagmiller, Jennifer Ann, MD",11/13/2023,Pembrolizumab 21 Day Cycles - Uterine,Maintenance,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,26060,"Wagmiller, Jennifer Ann, MD",11/14/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,11/13/2023,Inactive,,
CBMC OP INFUSION 2FL,26060,"Wagmiller, Jennifer Ann, MD",12/5/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,12/4/2023,Active,,
CINJ OP INFUSION,11538,"Toppmeyer, Deborah L, MD",7/25/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Adjuvant,7/25/2024,Active,,
CINJ OP INFUSION,11538,"Toppmeyer, Deborah L, MD",8/1/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,8/1/2024,Active,,
MMC OP VP INFUSION,6602,"Lee, Patrick C, MD",3/6/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/5/2023,Inactive,,
CBMC OP INFUSION 2FL,12509,"Scoppetuolo, Michael, MD",10/25/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/16/2024,Active,,
CBMC OP INFUSION 2FL,12509,"Scoppetuolo, Michael, MD",2/18/2025,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/5/2025,Active,Adenocarcinoma (CMS/HCC),"C80.1 - Malignant (primary) neoplasm, unspecified"
CBMC OP INFUSION 2FL,7566,"Leitner, Stuart P, MD",10/10/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/3/2024,Active,,
CBMC 2W ONCOLOGY,53333,"Dharmapuri, Sirish, MD",5/29/2025,"Pembrolizumab + Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/29/2025,Inactive,"Adenocarcinoma of stomach, stage 4 (CMS/HCC)","C16.9 - Malignant neoplasm of stomach, unspecified; A41.51 - Sepsis due to Escherichia coli (e. coli); Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; K76.7 - Hepatorenal syndrome; G93.41 - Metabolic encephalopathy; I50.31 - Acute diastolic (congestive) heart failure; R18.0 - Malignant ascites; E44.0 - Moderate protein-calorie malnutrition; C78.01 - Secondary malignant neoplasm of right lung; E87.20 - Acidosis, unspecified; E83.39 - Other disorders of phosphorus metabolism; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C78.02 - Secondary malignant neoplasm of left lung; C61 - Malignant neoplasm of prostate; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; I34.0 - Nonrheumatic mitral (valve) insufficiency; D69.59 - Other secondary thrombocytopenia; D50.9 - Iron deficiency anemia, unspecified; N13.6 - Pyonephrosis; I31.39 - Other pericardial effusion (noninflammatory); E87.1 - Hypo-osmolality and hyponatremia; I48.0 - Paroxysmal atrial fibrillation; E83.51 - Hypocalcemia; R62.7 - Adult failure to thrive; G47.33 - Obstructive sleep apnea (adult) (pediatric); H40.9 - Unspecified glaucoma; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E66.3 - Overweight; K59.00..."
CBMC OP INFUSION 2FL,53333,"Dharmapuri, Sirish, MD",3/19/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/19/2025,Inactive,"Adenocarcinoma of stomach, stage 4 (CMS/HCC)","C16.9 - Malignant neoplasm of stomach, unspecified; D50.0 - Iron deficiency anemia secondary to blood loss (chronic)"
CBMC OP INFUSION 2FL,53333,"Dharmapuri, Sirish, MD",3/19/2025,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/19/2025,Inactive,"Adenocarcinoma of stomach, stage 4 (CMS/HCC)",
MMC OP VP INFUSION,32371,"Cohen, Seth D, MD",7/10/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/2/2024,Inactive,,
MMC OP VP INFUSION,32371,"Cohen, Seth D, MD",9/4/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,9/3/2024,Inactive,,
MMC OP VP INFUSION,27370,"Cohen, Seth D, MD",7/16/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/15/2024,Active,,
CMC OP INFUSION,93724,"Talwar, Sumit, MD",1/14/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Head and Neck cancer,Induction,1/12/2025,Active,,
MMC OP INFUSION,33134,"Meghal, Trishala, MD",3/29/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,3/28/2023,Inactive,,
CBMC OP INFUSION 2FL,6399,"Wagmiller, Jennifer Ann, MD",7/21/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,7/20/2023,Inactive,Malignant neoplasm of right ovary (CMS/HCC),
CBMC OP INFUSION 2FL,6399,"Wagmiller, Jennifer Ann, MD",2/1/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,1/31/2024,Inactive,,
CMC OP INFUSION,10769,"Tang, Horace, MD",2/15/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,2/14/2023,Inactive,,
CMC OP INFUSION,10769,"Talwar, Sumit, MD",1/8/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/6/2025,Active,,
CBMC OP INFUSION 2FL,24676,"Wagmiller, Jennifer Ann, MD",9/1/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,8/31/2023,Inactive,,
CBMC OP INFUSION 2FL,24676,"Wagmiller, Jennifer Ann, MD",2/24/2025,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,2/23/2025,Active,Malignant neoplasm of bilateral ovaries (CMS/HCC),C56.3 - Malignant neoplasm of bilateral ovaries
CBMC OP INFUSION 2FL,24676,"Wagmiller, Jennifer Ann, MD",3/28/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/21/2025,Inactive,Malignant neoplasm of bilateral ovaries (CMS/HCC),
CINJ OP INFUSION,61351,"Ghodoussipour, Saum Bobak, MD",3/2/2023,Mitomycin for Pyelocalyceal Instillation (Ureteral Gel) - Urothelial ,Induction,2/23/2023,Inactive,,
CBMC OP INFUSION 2FL,4753,"Raptis, George, MD",6/18/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,6/13/2024,Active,,
CBMC OP INFUSION 2FL,4753,"Raptis, George, MD",5/16/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,5/16/2025,Inactive,"Breast cancer, stage 4, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,4753,"Raptis, George, MD",5/16/2025,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_1. First Line,5/16/2025,Active,"Breast cancer, stage 4, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,85345,"Haigentz, Missak, MD",3/20/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/20/2024,Inactive,,
SOM OUTPT INFUSION,10667,"Patel, Eshan, MD",1/8/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/5/2024,Inactive,,
SOM OUTPT INFUSION,10667,"Patel, Eshan, MD",4/10/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/31/2024,Inactive,,
SOM OUTPT INFUSION,10667,"Patel, Eshan, MD",6/12/2024,"DOCEtaxel D1, D8, D15 /Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,6/11/2024,Active,,
CBMC OP INFUSION 2FL,4642,"Brown, Andrew Bennett, MD",3/11/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/11/2024,Active,,
MMC OP VP INFUSION,77520,"Cohen, Seth D, MD",7/29/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,7/28/2024,Active,,
CBMC OP INFUSION 2FL,55306,"Litvak, Anna M, MD",3/14/2025,Capivasertib 28 Day Cycles - Breast,_3. Third Line,3/14/2025,Active,"Breast cancer, stage 4, unspecified laterality (CMS/HCC)",
SOM OUTPT INFUSION,52911,"George, Roshini, DO",3/14/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,3/14/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,79483,"Stephenson, Ryan D, DO",10/6/2023,"CINJ 102302 ARM 2 PHASE 1B ACR-368 + ULDG DOSE LEVEL 1 - OVARIAN, ENDOMETRIAL, UROTHELIAL CANCER",Third Line,10/6/2023,Inactive,,
CBMC OP INFUSION 2FL,16349,"Wagmiller, Jennifer Ann, MD",1/21/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/7/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBR 4N ONCOLOGY,74738,"Assal, Amer, MD",12/28/2023,BMT Autologous BEAM,_3. Third Line,12/27/2023,Inactive,,
NBR CINJ OP INFUSION,74738,"Evens, Andrew M, DO",4/17/2024,Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,Maintenance,4/17/2024,Inactive,,
NBR CINJ OP INFUSION,74738,"Evens, Andrew M, DO",4/17/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,4/16/2024,Inactive,,
NBR CINJ OP INFUSION,74738,"Evens, Andrew M, DO",6/26/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,Maintenance,6/25/2024,Active,,
CINJ OP INFUSION,59092,"Girda, Eugenia, MD",10/15/2024,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,_7. Seventh Line,10/15/2024,Active,,
SOM OUTPT INFUSION,49629,"Yin, Faye, MD",10/14/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,10/14/2024,Inactive,,
SOM OUTPT INFUSION,49629,"Patel, Eshan, MD",12/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/9/2024,Active,,
CBMC OP INFUSION 2FL,71609,"Leitner, Stuart P, MD",11/14/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,11/14/2023,Active,,
CBMC OP INFUSION 2FL,43862,"Radovich, Delia, MD",11/7/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/6/2023,Inactive,,
MMC OP VP INFUSION,50029,"Cohen, Seth D, MD",3/27/2024,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,3/27/2024,Active,,
JCMC CP INFUSION,80289,"Sekhri, Arunabh, MD",12/3/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,12/2/2024,Active,,
NBI OP INFUSION,15008,"Shah, Maya M, MD",9/23/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/22/2024,Active,,
CINJ OP INFUSION,20821,"Weiss, Sarah, MD",4/3/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,4/3/2023,Inactive,,
CINJ OP INFUSION,20821,"Weiss, Sarah, MD",1/16/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,1/12/2025,Active,,
NBR 5N ONCOLOGY,20821,"Weiss, Sarah, MD",2/26/2025,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_3. Third Line,2/26/2025,Active,Malignant melanoma of vulva (CMS/HCC),R06.02 - SOB (shortness of breath); R09.02 - Hypoxia; R79.89 - Elevated troponin
NBR 4N ONCOLOGY,90587,"Palmisiano, Neil David, MD",4/4/2025,Cytarabine Cytoreduction for Hyperleukocytosis,_3. Third Line,4/4/2025,Inactive,Mantle cell lymphoma (CMS/HCC),"R78.81 - Bacteremia; J96.21 - Acute and chronic respiratory failure with hypoxia; Z66 - Do not resuscitate; N17.0 - Acute kidney failure with tubular necrosis; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; R18.0 - Malignant ascites; C79.31 - Secondary malignant neoplasm of brain; C83.10 - Mantle cell lymphoma, unspecified site; E83.39 - Other disorders of phosphorus metabolism; C95.90 - Leukemia, unspecified not having achieved remission; D84.9 - Immunodeficiency, unspecified; C43.9 - Malignant melanoma of skin, unspecified; C51.9 - Malignant neoplasm of vulva, unspecified; J43.9 - Emphysema, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; D63.1 - Anemia in chronic kidney disease; E87.20 - Acidosis, unspecified; Z16.23 - Resistance to quinolones and fluoroquinolones; Z28.21 - Immunization not carried out because of patient refusal; F17.210 - Nicotine dependence, cigarettes, uncomplicated; F41.9 - Anxiety disorder, unspecified; Z99.81 - Dependence on supplemental oxygen; R53.81 - Other malaise; M19.90 - Unspecified osteoarthritis, unspecified site; K58.9 - Irritable bowel syndrome, unspecified; R16.1 - Splenomegaly, not elsewhere classified; T36.95XA - Adverse effect of unspecified systemic antibiotic, initial encounter; B37.9 - Candidiasis, unspecified; Z22.1 - Carrier of other intestinal infect..."
CINJ OP INFUSION,92113,"Mayer, Tina M, MD",12/4/2023,Darolutamide 28 Day Cycles - Prostate,_2. Second Line,12/4/2023,Active,,
CINJ OP INFUSION,9912,"Saraiya, Biren P, MD",12/18/2023,CINJ 082210 Arm A Durvalumab / ddMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles Research- Urothelial Cancer,Neoadjuvant,12/15/2023,Active,,
NBR 4N ONCOLOGY,9912,"Jang, Thomas L, MD",3/2/2024,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,3/2/2024,Inactive,,
CINJ OP INFUSION,27682,"Weiss, Sarah, MD",11/6/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_2. Second Line,11/5/2024,Inactive,,
CINJ OP INFUSION,34840,"Weiss, Sarah, MD",9/9/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,7/28/2024,Active,,
MMC OP VP INFUSION,75739,"Talwar, Sumit, MD",4/11/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/10/2023,Inactive,,
CBMC OP INFUSION 2FL,27791,"Scoppetuolo, Michael, MD",4/11/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/25/2024,Inactive,,
CBMC OP INFUSION 2FL,27791,"Scoppetuolo, Michael, MD",7/3/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/25/2024,Active,,
CBMC OP INFUSION 2FL,27791,"Scoppetuolo, Michael, MD",7/23/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,7/22/2024,Active,,
CINJ OP INFUSION,10653,"Boland, Patrick M, MD",9/24/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,9/23/2024,Active,,
CMC OP INFUSION,72555,"Taff, Jessica, MD",2/20/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_4. Fourth Line,2/19/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,72555,"Taff, Jessica, MD",3/5/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_4. Fourth Line,3/5/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,25690,"Shah, Mansi R, MD",3/26/2025,Talquetamab 28 Day Cycles,_5. Fifth Line,3/26/2025,Inactive,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; M85.9 - Disorder of bone density and structure, unspecified; Z29.9 - Encounter for prophylactic measures, unspecified; R41.82 - Altered mental status, unspecified; K13.70 - Unspecified lesions of oral mucosa; R49.0 - Dysphonia; E87.1 - Hypo-osmolality and hyponatremia; E87.6 - Hypokalemia; E83.42 - Hypomagnesemia; D64.9 - Anemia, unspecified; N17.9 - Acute kidney failure, unspecified; B19.10 - Unspecified viral hepatitis B without hepatic coma; D80.1 - Nonfamilial hypogammaglobulinemia; F25.9 - Schizoaffective disorder, unspecified; J02.9 - Acute pharyngitis, unspecified"
CINJ OP INFUSION,6798,"George, Mridula A, MD",7/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/24/2024,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,6798,"George, Mridula A, MD",8/23/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,7/19/2024,Active,,
TRMC TCCC OP INFUSION,8825,"Salerno, Vincent E, MD",10/21/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,10/17/2024,Active,,
CINJ OP INFUSION,17223,"Goel, Sanjay, MD",1/25/2023,CINJ 052101 (TT420X1103) ARM A TT-00420 12 mg 28 Day Cycles Research- Solid Tumors,Third Line,1/25/2023,Inactive,,
CINJ OP INFUSION,76047,"Haigentz, Missak, MD",4/8/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Thymic Carcinoma,Adjuvant,4/7/2024,Inactive,,
TRMC TCCC OP INFUSION,19531,"Salerno, Vincent E, MD",5/28/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/28/2025,Active,Cancer of bronchus of right upper lobe (CMS/HCC),
JCMC CP INFUSION,30653,"Sekhri, Arunabh, MD",11/10/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,11/5/2023,Active,Granulosa cell carcinoma (CMS/HCC),
JCMC CP INFUSION,30653,"Sekhri, Arunabh, MD",1/30/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,10/22/2024,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
JCMC CP INFUSION,30653,"Sekhri, Arunabh, MD",5/6/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,5/6/2025,Active,Follicular lymphoma (CMS/HCC),"C82.90 - Follicular lymphoma, unspecified, unspecified site; F41.9 - Anxiety disorder, unspecified; D64.9 - Anemia, unspecified; F17.200 - Nicotine dependence, unspecified, uncomplicated"
CBMC OP INFUSION 2FL,55078,"Wagmiller, Jennifer Ann, MD",1/16/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/14/2024,Inactive,,
NBI OP INFUSION,42369,"Anderson, Patrick S, MD",1/18/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/17/2024,Inactive,,
NBI OP INFUSION,42369,"Anderson, Patrick S, MD",12/13/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,12/12/2024,Active,,
NBI OP INFUSION,42369,"Anderson, Patrick S, MD",3/7/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,3/6/2025,Active,Ovarian cancer (CMS/HCC),"I10 - Essential (primary) hypertension; I50.33 - Acute on chronic diastolic (congestive) heart failure; E66.2 - Morbid (severe) obesity with alveolar hypoventilation; D27.9 - Benign neoplasm of unspecified ovary; M89.8X9 - Other specified disorders of bone, unspecified site; C56.9 - Malignant neoplasm of unspecified ovary; R18.0 - Malignant ascites"
CINJ OP INFUSION,5629,"Omene, Coral Oghenerukevwe, MD",9/14/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/13/2023,Inactive,,
NBR 4N ONCOLOGY,26940,"Evens, Andrew M, DO",6/9/2023,Mini-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) - 21 Day Cycles - Mycosis Fungoides,,6/9/2023,Inactive,,
NBR CINJ OP INFUSION,26940,"Evens, Andrew M, DO",1/23/2024,CINJ 012312 Tazemetostat / Belinostat 21 Day Cycles Research- Lymphoma,_4. Fourth Line,1/22/2024,Inactive,,
NBR 5N ONCOLOGY,63436,"George, Mridula A, MD",9/16/2024,PACLitaxel weekly / Trastuzumab (q21d) - 21 Day Cycles - Breast,_1. First Line,9/11/2024,Inactive,,
HAM OP INFUSION,63436,"Yogarajah, Meera, MD",11/25/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,10/27/2024,Active,,
CBMC OP INFUSION 2FL,9870,"Brown, Andrew Bennett, MD",1/31/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/23/2025,Active,,
CBMC OP INFUSION 2FL,9870,"Brown, Andrew Bennett, MD",2/7/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/24/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),"C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung"
NBR 5N ONCOLOGY,58853,"Haigentz, Missak, MD",1/31/2023,PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,First Line,1/31/2023,Inactive,,
CBMC OP INFUSION 2FL,63628,"Raptis, George, MD",5/2/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,5/2/2025,Inactive,"Breast cancer, left (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)",
CBMC OP INFUSION 2FL,63628,"Raptis, George, MD",5/2/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,5/2/2025,Active,"Breast cancer, left (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)",
CINJ OP INFUSION,96106,"Haigentz, Missak, MD",1/27/2023,Pembrolizumab/PEMEtrexed Maintenance --> Pembro alone (Adjuvant)  21 Day Cycles- Non-Small Cell Lung Cancer,First Line,1/19/2023,Inactive,,
CINJ OP INFUSION,46315,"Stephenson, Ryan D, DO",12/29/2023,Pembrolizumab 42 Day Cycles - Kidney,Adjuvant,12/26/2023,Active,,
CINJ OP INFUSION,34816,"Haigentz, Missak, MD",1/6/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,1/6/2024,Active,,
CINJ OP INFUSION,4755,"Aikins, James K, MD",6/8/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Adjuvant,5/31/2023,Inactive,,
CBMC 2W ONCOLOGY,19006,"Grossman, I Robert, MD",11/2/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,11/2/2023,Inactive,,
CINJ OP INFUSION,43303,"Berim, Lyudmyla, MD",3/20/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/17/2023,Inactive,,
CINJ OP INFUSION,43303,"Berim, Lyudmyla, MD",5/1/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,4/26/2023,Inactive,,
CINJ OP INFUSION,50661,"Hochster, Howard S, MD",5/18/2023,DOXOrubicin Conventional TACE - Hepatocellular Cancer,First Line,5/18/2023,Inactive,,
CMC 4B ONCOLOGY,68214,"Taff, Jessica, MD",5/23/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/22/2023,Inactive,,
SOM OUTPT INFUSION,93120,"Patel, Eshan, MD",4/23/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/23/2025,Active,Mass of head of pancreas,"C25.9 - Malignant neoplasm of pancreas, unspecified; K86.89 - Other specified diseases of pancreas; K21.9 - Gastro-esophageal reflux disease without esophagitis; H91.92 - Unspecified hearing loss, left ear; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,34969,"Litvak, Anna M, MD",10/30/2023,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,_1. First Line,10/30/2023,Inactive,,
CINJ OP INFUSION,91364,"Muralikrishnan, Sivraj",12/13/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/13/2024,Active,,
CINJ OP INFUSION,91364,"Muralikrishnan, Sivraj, MD",2/14/2025,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/13/2025,Active,Metastatic adenocarcinoma (CMS/HCC),
TRMC TCCC OP INFUSION,21069,"Capo, Gerardo, MD",5/31/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,5/30/2024,Active,,
MMC OP VP INFUSION,97003,"Cohen, Seth D, MD",11/13/2024,Cetuximab / PACLitaxel 100 mg/m2 / CARBOplatin AUC 2.5 21 Day Cycles- Head and Neck Cancers,_1. First Line,11/12/2024,Active,,
MSC OP INFUSION,37922,"Taff, Jessica, MD",5/10/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/2/2023,Active,,
HAM OP INFUSION,97208,"Yogarajah, Meera, MD",8/28/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),First Line,8/27/2023,Inactive,,
CINJ OP INFUSION,3885,"Leiser, Aliza, MD",7/11/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Granulosa Cell Tumor of Ovary,Third Line,7/10/2023,Inactive,,
MSC OP INFUSION,45280,"Pompa, Tiffany Ann, MD",10/24/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,10/22/2024,Active,,
NBI D7 MED-SURG/TELE,68401,"Anderson, Patrick S, MD",12/18/2024,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_1. First Line,12/17/2024,Active,,
CBMC OP INFUSION 2FL,23900,"Wagmiller, Jennifer Ann, MD",8/28/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,,8/27/2023,Inactive,,
HAM OP INFUSION,97181,"Yogarajah, Meera, MD",10/20/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,,9/28/2023,Active,,
JCMC CP INFUSION,77077,"Sekhri, Arunabh, MD",8/22/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,8/13/2023,Inactive,,
JCMC CP INFUSION,77077,"Sekhri, Arunabh, MD",11/27/2023,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/26/2023,Inactive,,
CINJ OP INFUSION,8755,"Berim, Lyudmyla, MD",5/7/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/7/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),C18.2 - Malignant neoplasm of ascending colon
CBMC OP INFUSION 2FL,2167,"Raptis, George, MD",5/1/2024,EriBULin 21 Day Cycles - Breast,_3. Third Line,5/1/2024,Inactive,,
CINJ PEDS HEMONC ,45051,"Botwinick, Marissa, DO",2/13/2025,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,2/13/2025,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CINJ PEDS HEMONC ,45051,"Botwinick, Marissa, DO",5/22/2025,AALL1731 All Arms - Interim Maintenance I EscMTX,_1. First Line,5/22/2025,Inactive,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CINJ PEDS HEMONC ,45051,"Botwinick, Marissa, DO",5/22/2025,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,5/22/2025,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CINJ PEDS HEMONC ,45051,"Botwinick, Marissa, DO",4/18/2025,PEDS Blinatumomab,_1. First Line,4/10/2025,Inactive,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
MMC OP INFUSION,75448,"Lee, Patrick C, MD",1/3/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,1/2/2023,Inactive,,
MMC OP INFUSION,75448,"Lee, Patrick C, MD",1/3/2023,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/26/2022,Inactive,,
MMC OP INFUSION,75448,"Lee, Patrick C, MD",2/13/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/12/2024,Active,,
NBR 4N ONCOLOGY,69029,"Palmisiano, Neil David, MD",3/17/2023,ECOG - ACRIN E1910 (Step 1) Induction - Acute Lymphoblastic Leukemia,First Line,3/17/2023,Inactive,,
NBR CINJ OP INFUSION,69029,"Palmisiano, Neil David, MD",6/29/2023,ECOG - ACRIN E1910 (Step 2) Intensification - Acute Lymphoblastic Leukemia,,6/27/2023,Inactive,,
NBR CINJ OP INFUSION,69029,"Palmisiano, Neil David, MD",7/27/2023,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,,7/27/2023,Inactive,,
NBR CINJ OP INFUSION,69029,"Palmisiano, Neil David, MD",10/24/2023,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,,10/24/2023,Inactive,,
NBI VALERIE FND HEMONC,27131,"Batra, Surabhi, MD",9/14/2023,ANBL1531 Induction,_1. First Line,9/13/2023,Inactive,,
NBI VALERIE FND HEMONC,27131,"Batra, Surabhi, MD",9/14/2023,ANBL1531 Induction,_1. First Line,9/13/2023,Inactive,,
NBI VALERIE FND HEMONC,27131,"Batra, Surabhi, MD",10/10/2023,ANBL1531 Induction,_1. First Line,10/9/2023,Inactive,,
CINJ PEDS HEMONC ,1649,"Drachtman, Richard, MD",10/16/2024,PEDS IE - Osteosarcoma,_4. Fourth Line,10/15/2024,Active,,
NBR CINJ OP INFUSION,68217,"Tiger, Yun Kyoung, MD",3/7/2025,CINJ 012320 Group 2 COP (Cyclophosphamide / VinCRIStine / PredniSONE) + Pralatrexate 21 Day Cycles Research- Peripheral T-Cell Lymphoma,_1. First Line,3/7/2025,Active,Peripheral T cell lymphoma of lymph nodes of multiple sites (CMS/HCC),
CINJ OP INFUSION,64966,"Ghodoussipour, Saum Bobak, MD",6/12/2024,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,6/4/2024,Active,,
CINJ OP INFUSION,64966,"Ghodoussipour, Saum Bobak, MD",1/28/2025,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,1/15/2025,Active,,
CINJ OP INFUSION,47799,"Boland, Patrick M, MD",5/19/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/18/2023,Inactive,,
SOM OUTPT INFUSION,205,"Yin, Faye, MD",5/15/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,5/10/2023,Inactive,,
SOM OUTPT INFUSION,205,"Toomey, Kathleen C, MD",12/20/2024,Pembrolizumab 42 Day Cycles - Melanoma,_2. Second Line,12/19/2024,Active,,
SOM OUTPT INFUSION,205,"Patel, Eshan, MD",5/1/2025,Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,5/1/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),"C77.0 - Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck; C54.1 - Malignant neoplasm of endometrium"
CBMC OP INFUSION 2FL,82539,"Litvak, Anna M, MD",9/11/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),,9/10/2023,Inactive,,
CINJ OP INFUSION,45232,"George, Mridula A, MD",9/13/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,9/10/2024,Active,,
CBMC OP INFUSION 2FL,44110,"Leitner, Stuart P, MD",11/9/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,44110,"Leitner, Stuart P, MD",11/27/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,9895,"Brown, Andrew Bennett, MD",6/8/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/7/2023,Inactive,,
CBMC OP INFUSION 2FL,9895,"Brown, Andrew Bennett, MD",11/2/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,9895,"Brown, Andrew Bennett, MD",5/2/2024,PACLitaxel/CARBOplatin + Bevacizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/1/2024,Active,,
CBMC OP INFUSION 2FL,2194,"Wagmiller, Jennifer Ann, MD",11/13/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/13/2023,Inactive,,
CINJ PEDS HEMONC ,21856,"Botwinick, Marissa, DO",10/29/2024,as per AALL1731 Non-DS SR B-ALL Induction,Induction,10/29/2024,Inactive,,
CINJ PEDS HEMONC ,21856,"Botwinick, Marissa, DO",12/5/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,12/5/2024,Inactive,,
CINJ PEDS HEMONC ,21856,"Botwinick, Marissa, DO",1/3/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,1/2/2025,Inactive,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CINJ PEDS HEMONC ,21856,"Botwinick, Marissa, DO",1/10/2025,PEDS Blinatumomab,_1. First Line,1/2/2025,Active,,
CINJ OP INFUSION,42355,"Haigentz, Missak, MD",11/1/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/1/2023,Inactive,,
CINJ OP INFUSION,27457,"Dasgeb, Bahar, MD",1/9/2024,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,1/8/2024,Active,Extramedullary plasmacytoma in relapse (CMS/HCC),
CINJ OP INFUSION,98327,"Stephenson, Ryan D, DO",5/10/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Second Line,5/10/2023,Active,,
CBMC OP INFUSION 2FL,73156,"Grossman, I Robert, MD",3/13/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,3/5/2025,Active,Splenic marginal zone b-cell lymphoma (CMS/HCC),"C83.07 - Small cell b-cell lymphoma, spleen"
NBR 5N ONCOLOGY,84814,"Mayer, Tina M, MD",3/6/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,,3/4/2023,Inactive,,
JCMC CP INFUSION,55950,"Cruz, Allan Louie E, MD",4/3/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/1/2024,Inactive,,
JCMC CP INFUSION,55950,"Cruz, Allan Louie E, MD",10/1/2024,CINJ 042106 (A011801)  Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,Adjuvant,10/1/2024,Inactive,,
JCMC CP INFUSION,55950,"Cruz, Allan Louie E, MD",1/8/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/8/2025,Active,,
CBMC OP INFUSION 2FL,71023,"Litvak, Anna M, MD",10/19/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_3. Third Line,10/18/2023,Inactive,,
TRMC TCCC OP INFUSION,95324,"Salerno, Vincent E, MD",1/17/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/16/2025,Active,,
SOM OUTPT INFUSION,76524,"Toomey, Kathleen C, MD",5/12/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/14/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)","C67.8 - Malignant neoplasm of overlapping sites of bladder; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; N32.89 - Other specified disorders of bladder; K86.89 - Other specified diseases of pancreas; I48.19 - Other persistent atrial fibrillation; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.2 - Chronic kidney disease, stage 2 (mild); I50.42 - Chronic combined systolic (congestive) and diastolic (congestive) heart failure; E78.2 - Mixed hyperlipidemia; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I25.5 - Ischemic cardiomyopathy; G47.33 - Obstructive sleep apnea (adult) (pediatric); E11.51 - Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene; K76.0 - Fatty (change of) liver, not elsewhere classified; K21.9 - Gastro-esophageal reflux disease without esophagitis; M10.9 - Gout, unspecified; E66.01 - Morbid (severe) obesity due to excess calories; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; Z87.891 - Personal history of nicotine dependence; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z86.711 - Personal history of pulmonary embolism; Z87.440 - Personal history of urinary (tract) infections; Z92.21 - Personal history ..."
CINJ OP INFUSION,76524,"Packiam, Vignesh, MD",3/17/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/17/2025,Inactive,"Malignant neoplasm of bladder, unspecified (CMS/HCC)","C67.9 - Malignant neoplasm of bladder, unspecified; C67.8 - Malignant neoplasm of overlapping sites of bladder; C68.9 - Malignant neoplasm of urinary organ, unspecified"
MMC OP VP INFUSION,23208,"Lee, Patrick C, MD",8/3/2023,RiTUXimab Initial Infusion Single Day (Outpatient),Maintenance,7/28/2023,Active,"Lung nodules
Mass of lower lobe of left lung",
SOM OUTPT INFUSION,26060,"Toomey, Kathleen C, MD",9/8/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Third Line,9/5/2023,Inactive,,
SOM OUTPT INFUSION,26060,"Toomey, Kathleen C, MD",3/14/2024,EriBULin 21 Day Cycles - Breast,_4. Fourth Line,3/13/2024,Inactive,,
SOM OUTPT INFUSION,26060,"Toomey, Kathleen C, MD",8/1/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_5. Fifth Line,7/31/2024,Inactive,,
SOM OUTPT INFUSION,26060,"Toomey, Kathleen C, MD",10/30/2024,Capecitabine 21 Day Cycles - Breast,_6. Sixth Line,10/30/2024,Active,,
TRMC TCCC OP INFUSION,40391,"Capo, Gerardo, MD",10/7/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/6/2024,Active,,
HAM OP INFUSION,4099,"Yogarajah, Meera, MD",1/9/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Second Line,1/8/2023,Active,Multiple myeloma in relapse (CMS/HCC),
NBI C5 PEDS ICU,39321,"Bhatla, Teena, MD",1/27/2025,RiTUXimab Initial Infusion Single Day,_1. First Line,1/27/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,71377,"Weiss, Sarah, MD",8/19/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,8/16/2024,Active,,
SOM OUTPT INFUSION,10379,"Yin, Faye, MD",2/27/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/26/2023,Inactive,,
SOM OUTPT INFUSION,10379,"Yin, Faye, MD",5/9/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/1/2023,Inactive,,
CINJ OP INFUSION,47291,"Berim, Lyudmyla, MD",12/20/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/19/2024,Active,,
MMC OP VP INFUSION,72956,"Cohen, Seth D, MD",6/6/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/6/2024,Active,,
MMC OP VP INFUSION,72956,"Cohen, Seth D, MD",6/10/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/2/2024,Active,,
MSC OP INFUSION,69760,"Cohen, Seth D, MD",8/22/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,First Line,8/14/2023,Inactive,,
JCMC CP INFUSION,1308,"Cruz, Allan Louie E, MD",11/21/2024,PACLitaxel Weekly / CARBOplatin Weekly  - Uterine. Daratumumab for multiple myeloma. 28 day cycle,_1. First Line,11/15/2024,Active,,
JCMC CP INFUSION,1308,"Cruz, Allan Louie E, MD",2/27/2025,Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,2/27/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; C90.00 - Multiple myeloma not having achieved remission
JCMC CP INFUSION,27108,"Cruz, Allan Louie E, MD",3/27/2025,PACLitaxel Weekly / CARBOplatin weekly / pembrolizumab 21 Day Cycles - Endometrial clear cell carcinoma // Daratumumab - multiple myeloma,_1. First Line,3/27/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; E87.5 - Hyperkalemia
CINJ OP INFUSION,49586,"Boland, Patrick M, MD",4/21/2023,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,,4/20/2023,Inactive,,
CINJ OP INFUSION,80305,"Haigentz, Missak, MD",1/23/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/22/2024,Inactive,,
CBMC OP INFUSION 2FL,19578,"Scoppetuolo, Michael, MD",5/8/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/7/2023,Active,,
CBMC OP INFUSION 2FL,28560,"Wagmiller, Jennifer Ann, MD",8/2/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,8/2/2023,Active,,
CINJ OP INFUSION,95098,"Stephenson, Ryan D, DO",10/24/2024,Relugolix 30 day Cycles - Prostate,Adjuvant,10/24/2024,Active,Colon cancer (CMS/HCC),
CBMC OP INFUSION 2FL,53692,"Wagmiller, Jennifer Ann, MD",11/1/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,10/31/2023,Active,,
CBMC OP INFUSION 2FL,41170,"Brown, Andrew Bennett, MD",9/21/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/20/2023,Inactive,,
CBMC OP INFUSION 2FL,41170,"Brown, Andrew Bennett, MD",2/21/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,2/19/2024,Inactive,,
JCMC CP INFUSION,25317,"Sekhri, Arunabh, MD",7/15/2024,Temozolomide 28 Day Cycles - CNS,_1. First Line,7/15/2024,Active,Malignant neoplasm of colon (CMS/HCC),
NBR CINJ OP INFUSION,28268,"Evens, Andrew M, DO",12/18/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,12/17/2024,Active,,
CINJ OP INFUSION,64019,"Berim, Lyudmyla, MD",11/6/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,11/6/2023,Inactive,,
CINJ OP INFUSION,64019,"Berim, Lyudmyla, MD",1/11/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/5/2024,Inactive,,
CINJ OP INFUSION,4348,"Weiss, Sarah, MD",8/14/2024,CINJ 092305 Nivolumab 480 mg 28 Day Cycles Research- Autoimmune Disorders and Advanced Malignancies,_1. First Line,8/13/2024,Active,,
SOM OUTPT INFUSION,3300,"Toomey, Kathleen C, MD",9/17/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/14/2024,Inactive,,
SOM OUTPT INFUSION,3300,"Toomey, Kathleen C, MD",1/23/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,1/22/2025,Active,,
NBR 4N ONCOLOGY,81148,"Palmisiano, Neil David, MD",9/20/2023,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),First Line,9/20/2023,Inactive,,
CBMC 2W ONCOLOGY,9532,"Grossman, I Robert, MD",3/11/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/11/2025,Inactive,"Acute myeloid leukemia (AML), M5 (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; A41.9 - Sepsis, unspecified organism; C92.00 - Acute myeloblastic leukemia, not having achieved remission; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; D61.810 - Antineoplastic chemotherapy induced pancytopenia; N17.0 - Acute kidney failure with tubular necrosis; J98.51 - Mediastinitis; J18.9 - Pneumonia, unspecified organism; R65.21 - Severe sepsis with septic shock; J96.01 - Acute respiratory failure with hypoxia; I65.02 - Occlusion and stenosis of left vertebral artery; E44.0 - Moderate protein-calorie malnutrition; D84.9 - Immunodeficiency, unspecified; I10 - Essential (primary) hypertension; Z68.30 - Body mass index (BMI) 30.0-30.9, adult; D63.0 - Anemia in neoplastic disease; I72.0 - Aneurysm of carotid artery; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; R04.2 - Hemoptysis; G47.00 - Insomnia, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; L25.9 - Unspecified contact dermatitis, unspecified cause; R53.81 - Other malaise; E83.51 - Hypocalcemia; E87.6 - Hypokalemia; E83.39 - Other disorders of phosphorus metabolism; E83.42 - Hypomagnesemia; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; I44.30 - Unspecified atrioventricular block; E87.70 - Fluid overload, unspecified; I95.89 - Other hypotension; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere cl..."
HAM OP INFUSION,69288,"Patel, Malini M, MD",4/3/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/3/2023,Inactive,,
HAM OP INFUSION,69288,"Patel, Malini M, MD",6/26/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/25/2023,Inactive,,
CINJ OP INFUSION,94982,"Stephenson, Ryan D, DO",1/20/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,First Line,1/17/2023,Inactive,,
CINJ OP INFUSION,94982,"Stephenson, Ryan D, DO",6/2/2023,Avelumab 14 Day Cycles - Bladder Carcinoma,Maintenance,6/2/2023,Inactive,,
CINJ OP INFUSION,94982,"Stephenson, Ryan D, DO",8/11/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,Third Line,8/10/2023,Inactive,,
NBR CINJ OP INFUSION,23215,"Schaar, Dale, MD PhD",9/6/2023,RiTUXimab 28 Day Cycle - Autoimmune Hemolytic Anemia,,9/5/2023,Inactive,,
CINJ OP INFUSION,23215,"Schaar, Dale, MD PhD",11/6/2023,Cyclophosphamide 750 mg/m2 - to stop hemolysis process in setting of AIHA,_1. First Line,11/5/2023,Inactive,,
NBR CINJ OP INFUSION,57119,"Schaar, Dale, MD PhD",3/31/2025,RiTUXimab 28 Day Cycle - Autoimmune hemolytic anemia,_1. First Line,3/31/2025,Active,Autoimmune hemolytic anemia (CMS/HCC),
CINJ OP INFUSION,49538,"Haigentz, Missak, MD",4/30/2024,PACLitaxel / CARBOplatin Post Concurrent Radiation Consolidation 21 Day Cycles - Non-Small Cell Lung Cancer,Induction,4/29/2024,Inactive,,
CINJ OP INFUSION,49538,"Haigentz, Missak, MD",5/7/2024,Albumin-Bound PACLitaxel/CARBOplatin with Concurrent Radiation Therapy 7 Day Cycles- Non-Small Cell Lung Cancer,Induction,5/6/2024,Inactive,,
CINJ OP INFUSION,49538,"Haigentz, Missak, MD",7/23/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/23/2024,Active,,
CBMC OP INFUSION 2FL,22123,"Leitner, Stuart P, MD",10/25/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,10/25/2024,Active,,
CBMC OP INFUSION 2FL,31936,"Scoppetuolo, Michael, MD",8/26/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,8/25/2024,Inactive,,
JCMC CP INFUSION,31650,"Cruz, Allan Louie E, MD",5/16/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,5/14/2023,Inactive,,
JCMC CP INFUSION,31650,"Cruz, Allan Louie E, MD",11/27/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/26/2023,Inactive,,
JCMC CP INFUSION,31650,"Cruz, Allan Louie E, MD",5/21/2024,Mirvetuximab Soravtansine 21 Day Cycles - serous ovarian cancer,_4. Fourth Line,5/21/2024,Inactive,,
JCMC CP INFUSION,31650,"Cruz, Allan Louie E, MD",8/15/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,8/14/2024,Inactive,,
JCMC CP INFUSION,31650,"Cruz, Allan Louie E, MD",10/22/2024,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_6. Sixth Line,10/21/2024,Active,,
CINJ OP INFUSION,79822,"Gulhati, Prateek, MD PhD",11/27/2023,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Induction,11/21/2023,Inactive,,
MMC OP INFUSION,44234,"Meghal, Trishala, MD",10/30/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,10/30/2023,Inactive,,
MMC OP VP INFUSION,87605,"Talwar, Sumit, MD",4/18/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,4/17/2023,Inactive,,
MMC OP VP INFUSION,87605,"Talwar, Sumit, MD",1/30/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/17/2024,Inactive,,
MMC OP VP INFUSION,87605,"Talwar, Sumit, MD",8/13/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,8/9/2024,Active,,
CBMC 2W ONCOLOGY,28090,"Wagmiller, Jennifer Ann, MD",9/4/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/3/2024,Active,,
CBMC OP INFUSION 2FL,28090,"Wagmiller, Jennifer Ann, MD",9/11/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/10/2024,Inactive,,
CBMC OP INFUSION 2FL,28090,"Wagmiller, Jennifer Ann, MD",2/28/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/27/2025,Active,Malignant neoplasm of right ovary (CMS/HCC),
CBMC OP INFUSION 2FL,28090,"Wagmiller, Jennifer Ann, MD",3/21/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/21/2025,Active,Malignant neoplasm of right ovary (CMS/HCC),
CINJ OP INFUSION,9851,"Goel, Sanjay, MD",8/14/2024,CINJ 052308 Cohort D Dose Escalation DCC3116 / Sotorasib 28 Day Cycles Research- Malignant Solid Tumors,_2. Second Line,8/14/2024,Active,,
NBR CINJ OP INFUSION,45708,"Evens, Andrew M, DO",5/1/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,4/30/2024,Inactive,,
CBMC OP INFUSION 2FL,89233,"Wagmiller, Jennifer Ann, MD",3/17/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/17/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",
SOM OUTPT INFUSION,88086,"Toomey, Kathleen C, MD",2/26/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,2/26/2024,Inactive,,
SOM OUTPT INFUSION,88086,"Toomey, Kathleen C, MD",7/5/2024,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,7/5/2024,Inactive,,
SOM OUTPT INFUSION,88086,"Toomey, Kathleen C, MD",12/5/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_6. Sixth Line,12/4/2024,Inactive,,
CMC OP INFUSION,21696,"Taff, Jessica, MD",5/9/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,First Line,5/8/2023,Inactive,,
CMC OP INFUSION,21696,"Taff, Jessica, MD",12/6/2023,RiTUXimab 56 Day Cycles - Mantle Cell maintenance,Maintenance,11/28/2023,Active,Metastatic melanoma (CMS/HCC),
CMC OP INFUSION,97134,"Pompa, Tiffany Ann, MD",10/21/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,Neoadjuvant,10/20/2024,Active,,
NBI OP INFUSION,85758,"Jacoby, Sari H, MD",7/23/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/7/2024,Inactive,,
NBI OP INFUSION,85758,"Jacoby, Sari H, MD",10/14/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/13/2024,Inactive,,
NBI OP INFUSION,85758,"Jacoby, Sari H, MD",12/30/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,12/29/2024,Inactive,,
CINJ OP INFUSION,49956,"Jang, Thomas L, MD",1/12/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,1/11/2024,Inactive,,
CINJ OP INFUSION,49956,"Jang, Thomas L, MD",4/24/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,4/23/2024,Active,,
NBR CINJ OP INFUSION,45759,"Shah, Mansi R, MD",6/25/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,6/24/2024,Inactive,,
MMC OP INFUSION,45759,"Eltoukhy, Hussam, MD",10/21/2024,Carfilzomib 27 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,10/13/2024,Active,,
HAM OP INFUSION,78630,"Patel, Malini M, MD",3/9/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,First Line,3/8/2023,Inactive,,
NBR CINJ OP INFUSION,51076,"Shah, Mansi R, MD",2/3/2025,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,2/2/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Thrombocytopenia, unspecified (CMS/HCC)","C90.00 - Multiple myeloma not having achieved remission; G62.9 - Polyneuropathy, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; D69.6 - Thrombocytopenia, unspecified; R80.9 - Proteinuria, unspecified; D64.9 - Anemia, unspecified; K86.1 - Other chronic pancreatitis; Z94.84 - Stem cells transplant status"
MMC OP VP INFUSION,33657,"Cohen, Seth D, MD",1/3/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/2/2024,Inactive,,
CINJ OP INFUSION,73654,"George, Mridula A, MD",8/23/2023,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 28 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,8/22/2023,Inactive,,
CINJ OP INFUSION,73654,"George, Mridula A, MD",11/22/2023,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,11/21/2023,Inactive,,
SOM OUTPT INFUSION,34263,"Yin, Faye, MD",1/17/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,1/17/2023,Active,,
SOM OUTPT INFUSION,34263,"Yin, Faye, MD",3/6/2023,DOCEtaxel 21 Day Cycles - Prostate,First Line,3/3/2023,Inactive,,
NBR CINJ OP INFUSION,3733,"Shah, Mansi R, MD",4/17/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma. Maitenance. Has been on this since 2022 at Fox Chase,_2. Second Line,4/17/2025,Active,"Multiple myeloma (CMS/HCC)
Thrombocytopenia, unspecified (CMS/HCC)","C90.00 - Multiple myeloma not having achieved remission; I48.91 - Unspecified atrial fibrillation; I10 - Essential (primary) hypertension; D80.1 - Nonfamilial hypogammaglobulinemia; D84.9 - Immunodeficiency, unspecified; Z94.84 - Stem cells transplant status; Z51.11 - Encounter for antineoplastic chemotherapy; D69.6 - Thrombocytopenia, unspecified; Z78.9 - Other specified health status"
CBMC OP INFUSION 2FL,64022,"Leitner, Stuart P, MD",10/25/2023,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_4. Fourth Line,10/24/2023,Inactive,,
CINJ OP INFUSION,72593,"Weiss, Sarah, MD",6/14/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,Second Line,6/13/2023,Active,,
MMC BBR2 ONCOLOGY,60759,"Eltoukhy, Hussam, MD",5/5/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/5/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C16.9 - Malignant neoplasm of stomach, unspecified; Z66 - Do not resuscitate; E44.0 - Moderate protein-calorie malnutrition; C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; D50.9 - Iron deficiency anemia, unspecified; C61 - Malignant neoplasm of prostate; C73 - Malignant neoplasm of thyroid gland; E11.319 - Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; Z68.38 - Body mass index (BMI) 38.0-38.9, adult; Z79.4 - Long term (current) use of insulin; E78.00 - Pure hypercholesterolemia, unspecified; G47.00 - Insomnia, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; H54.62 - Unqualified visual loss, left eye, normal vision right eye; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.890 - Hormone replacement therapy; Z80.0 - Family history of malignant neoplasm of digestive organs; Z82.3 - Family history of stroke; Z99.3 - Dependence on wheelchair; Z87.11 - Personal history of peptic ulcer disease; Z79.899 - Other long term (current) drug therapy; Z92.3 - Personal history of irradiation; Z85.850 - Personal history of malignant neoplasm of thyroid"
CBMC OP INFUSION 2FL,8040,"Leitner, Stuart P, MD",12/9/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,12/1/2024,Active,,
CINJ OP INFUSION,94615,"Boland, Patrick M, MD",3/20/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,2/21/2024,Inactive,,
CINJ OP INFUSION,94615,"Boland, Patrick M, MD",5/28/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,5/13/2024,Inactive,,
NBI OP INFUSION,93353,"Shah, Maya M, MD",9/6/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Third Line,9/6/2023,Inactive,,
NBI OP INFUSION,93353,"Shah, Maya M, MD",1/10/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,1/10/2024,Active,,
CINJ OP INFUSION,56695,"Goel, Sanjay, MD",9/11/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,9/11/2023,Inactive,,
CINJ OP INFUSION,56695,"Goel, Sanjay, MD",1/17/2024,CINJ 052208 Part 1K AMG-193 28 Day Cycles Research  - Solid Tumors,_4. Fourth Line,1/17/2024,Inactive,,
NBI OP INFUSION,72353,"Cheng, Yan Ho, MD",10/21/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Intrahepatic Cholangiocarcinoma Cancer,_1. First Line,10/21/2024,Inactive,,
NBI OP INFUSION,72353,"Cheng, Yan Ho, MD",12/31/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,12/16/2024,Active,,
CBMC OP INFUSION 2FL,16695,"Wagmiller, Jennifer Ann, MD",9/3/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/18/2024,Active,,
CBMC OP INFUSION 2FL,19562,"Brown, Andrew Bennett, MD",12/18/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,12/18/2024,Inactive,,
CINJ OP INFUSION,62599,"Weiss, Sarah, MD",2/20/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,2/19/2023,Inactive,,
CINJ OP INFUSION,62599,"Weiss, Sarah, MD",4/25/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Second Line,4/25/2023,Active,,
CBMC OP INFUSION 2FL,69764,"Radovich, Delia, MD",12/13/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,69764,"Radovich, Delia, MD",12/18/2023,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,12/12/2023,Inactive,,
NBR 5N ONCOLOGY,26225,"Tiger, Yun Kyoung, MD",5/31/2024,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,5/31/2024,Inactive,,
NBR CINJ OP INFUSION,26225,"Palmisiano, Neil David, MD",6/28/2024,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_1. First Line,6/27/2024,Active,,
TRMC TCCC OP INFUSION,68023,"Capo, Gerardo, MD",10/31/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/30/2024,Active,,
TRMC TCCC OP INFUSION,68023,"Capo, Gerardo, MD",2/20/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/19/2025,Active,"Secondary malignant neoplasm of liver (CMS/HCC)
Malignant neoplasm of right breast (CMS/HCC)",
CBMC OP INFUSION 2FL,54544,"Brown, Andrew Bennett, MD",9/3/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,9/3/2024,Active,,
CBMC OP INFUSION 2FL,54544,"Brown, Andrew Bennett, MD",1/16/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,1/6/2025,Active,"Mixed phenotype acute leukemia, B-myeloid (CMS/HCC)",
CINJ OP INFUSION,28733,"Berim, Lyudmyla, MD",3/17/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/17/2025,Active,Malignant neoplasm of overlapping sites of stomach (CMS/HCC),C16.8 - Malignant neoplasm of overlapping sites of stomach
CMC OP INFUSION,37617,"Eltoukhy, Hussam, MD",4/24/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/24/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
HAM OP INFUSION,65025,"Yogarajah, Meera, MD",3/25/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,3/10/2024,Active,,
CINJ OP INFUSION,44185,"Dasgeb, Bahar, MD",4/3/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,3/20/2023,Inactive,,
MMC OP VP INFUSION,22615,"Cohen, Seth D, MD",3/18/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/17/2024,Inactive,,
MMC OP VP INFUSION,22615,"Cohen, Seth D, MD",6/12/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/11/2024,Active,,
CBMC OP INFUSION 2FL,49298,"Litvak, Anna M, MD",5/23/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,5/23/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)","C50.512, Z17.0 - Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)"
NBR CINJ OP INFUSION,49440,"Palmisiano, Neil David, MD",9/26/2023,Gilteritinib 30 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,9/26/2023,Inactive,,
NBR 4N ONCOLOGY,98988,"Shah, Mansi R, MD",8/2/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,8/2/2024,Inactive,,
NBR 5N ONCOLOGY,98988,"Shah, Mansi R, MD",8/29/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,8/29/2024,Inactive,,
NBR CINJ OP INFUSION,98988,"Shah, Mansi R, MD",10/28/2024,Talquetamab 28 Day Cycles,_8. Eighth Line,10/25/2024,Inactive,,
NBR CINJ OP INFUSION,98988,"Shah, Mansi R, MD",11/22/2024,VD-PACE (Bortezomib / Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,_6. Sixth Line,11/22/2024,Active,Multiple myeloma (CMS/HCC),
NBR CINJ OP INFUSION,75037,"Shah, Mansi R, MD",5/15/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_6. Sixth Line,5/14/2025,Active,"IgG multiple myeloma (CMS/HCC)
Stem cells transplant status (CMS/HCC)
Antineoplastic chemotherapy induced pancytopenia (CMS/HCC)",
JCMC CP INFUSION,34556,"Sekhri, Arunabh, MD",3/23/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,First Line,3/23/2023,Inactive,,
JCMC CP INFUSION,34556,"Sekhri, Arunabh, MD",4/14/2023,Albumin-Bound PACLitaxel weekly + carboplatin 28 Day Cycles - Breast,Neoadjuvant,4/10/2023,Inactive,,
JCMC CP INFUSION,34556,"Sekhri, Arunabh, MD",7/6/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,7/5/2023,Inactive,,
JCMC CP INFUSION,34556,"Sekhri, Arunabh, MD",8/31/2023,Pembrolizumab 21 Day Cycles - Bladder TNBC,Adjuvant,8/31/2023,Inactive,,
CBMC OP INFUSION 2FL,15200,"Leitner, Stuart P, MD",11/17/2023,CINJ 042102 Block A Zanidatamab 14 Day Cycles Research- Breast Cancer,Neoadjuvant,11/16/2023,Active,,
CBMC OP INFUSION 2FL,15200,"Leitner, Stuart P, MD",3/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/26/2024,Inactive,,
CBMC OP INFUSION 2FL,15200,"Leitner, Stuart P, MD",9/19/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,9/18/2024,Active,,
CINJ OP INFUSION,42499,"Mayer, Tina M, MD",3/17/2023,PACLitaxel / CARBOplatin / Gemcitabine 21 Day Cycles - Unknown Primary,_4. Fourth Line,2/26/2023,Inactive,,
CINJ OP INFUSION,16720,"Stephenson, Ruth D, DO",5/10/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,5/9/2023,Inactive,,
CINJ OP INFUSION,16720,"Stephenson, Ruth D, DO",9/5/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,9/4/2024,Inactive,,
CINJ OP INFUSION,16720,"Boland, Patrick M, MD",10/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/24/2024,Active,,
CBMC OP INFUSION 2FL,29601,"Litvak, Anna M, MD",11/20/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,11/11/2024,Active,Malignant neoplasm of right ureter (CMS/HCC),
CBMC OP INFUSION 2FL,1815,"Brown, Andrew Bennett, MD",5/9/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/9/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
MSC OP INFUSION,47810,"Eltoukhy, Hussam, MD",6/12/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,6/12/2024,Inactive,,
MSC OP INFUSION,47810,"Tiger, Yun Kyoung, MD",10/2/2024,GLOFITAMAB / GEMCITABINE / OXALIPLATIN / OBINUTUZUMAB / 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,9/29/2024,Active,,
MMC OP INFUSION,957,"Meghal, Trishala, MD",7/14/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,7/13/2023,Inactive,,
SOM OUTPT INFUSION,86866,"Toomey, Kathleen C, MD",2/14/2024,Gemcitabine 28 Day Cycles - Breast,_3. Third Line,2/13/2024,Inactive,,
NBR 4N ONCOLOGY,81269,"Palmisiano, Neil David, MD",7/14/2023,Cytarabine for Cytoreduction - Acute Myeloid Leukemia ,,7/14/2023,Inactive,,
MMC OP VP INFUSION,21531,"Cohen, Seth D, MD",5/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/8/2024,Inactive,,
CINJ OP INFUSION,95492,"Weiss, Sarah, MD",11/25/2024,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,11/25/2024,Inactive,,
CINJ OP INFUSION,95492,"Weiss, Sarah, MD",12/4/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,12/3/2024,Active,,
CBMC OP INFUSION 2FL,44339,"Wagmiller, Jennifer Ann, MD",10/30/2023,"DOCEtaxel D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",Adjuvant,10/30/2023,Inactive,,
MMC OP VP INFUSION,14646,"Cohen, Seth D, MD",10/7/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/4/2024,Active,,
CMC OP INFUSION,57550,"Tang, Horace, MD",6/5/2023,CISplatin/Etoposide with Concurrent Radiation 28 Day Cycles - Non-Small Cell Lung Cancer,Neoadjuvant,6/4/2023,Inactive,,
CMC OP INFUSION,57550,"Tang, Horace, MD",7/7/2023,CISplatin 100 mg/m2/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Non-Small Cell Lung Cancer,,7/6/2023,Inactive,,
CMC 4B ONCOLOGY,57550,"Tang, Horace, MD",11/10/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/7/2023,Inactive,,
CINJ OP INFUSION,36642,"Saraiya, Biren P, MD",1/3/2024,CINJ 082106 Pembrolizumab / Belzutifan or Placebo 42 Day Cycles Research- Renal Cell Carcinoma,Adjuvant,1/2/2024,Active,,
CINJ OP INFUSION,74695,"Stephenson, Ryan D, DO",9/27/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,9/27/2023,Active,,
CINJ OP INFUSION,99528,"Hochster, Howard S, MD",8/24/2023,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,Third Line,8/24/2023,Inactive,,
CINJ OP INFUSION,99528,"Hochster, Howard S, MD",6/6/2024,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,6/5/2024,Active,,
CINJ OP INFUSION,23482,"Hochster, Howard S, MD",5/14/2025,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_4. Fourth Line,5/14/2025,Active,Colon cancer metastasized to bone (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon (CMS/HCC)
TRMC TCCC OP INFUSION,54866,"Salerno, Vincent E, MD",8/29/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Thoracic Cancers",_2. Second Line,8/28/2024,Active,,
CINJ OP INFUSION,21978,"Stephenson, Ryan D, DO",8/30/2023,CINJ 082201 (NRG-GU010) ARM 2 Androgen Deprivation Therapy 6 months Cycle (180 Days) Research- Prostate Cancer,Adjuvant,8/2/2023,Inactive,,
MMC OP VP INFUSION,22966,"Talwar, Sumit, MD",8/8/2023,CISplatin 75 mg/m2/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,Adjuvant,7/31/2023,Inactive,,
CBMC OP INFUSION 2FL,42314,"Brown, Andrew Bennett, MD",3/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,3/3/2024,Active,,
CBMC OP INFUSION 2FL,29099,"Wagmiller, Jennifer Ann, MD",4/18/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/18/2024,Inactive,,
CBMC OP INFUSION 2FL,29099,"Wagmiller, Jennifer Ann, MD",5/30/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/29/2024,Active,,
CBMC OP INFUSION 2FL,29099,"Wagmiller, Jennifer Ann, MD",5/30/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,5/29/2024,Inactive,,
MMC OP INFUSION,99899,"Lee, Patrick C, MD",5/25/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),,5/23/2023,Active,Malignant neoplasm of prostate (CMS/HCC),
HAM OP INFUSION,56142,"Yogarajah, Meera, MD",3/21/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/21/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor negative (CMS/HCC)","C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; M19.90 - Unspecified osteoarthritis, unspecified site; Z79.899 - Other long term (current) drug therapy; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z17.1 - Estrogen receptor negative status (ER-)"
TRMC TCCC OP INFUSION,88170,"Salerno, Vincent E, MD",12/20/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/28/2024,Active,,
MMC OP VP INFUSION,90663,"Cohen, Seth D, MD",9/30/2024,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,_1. First Line,9/27/2024,Inactive,,
MSC OP INFUSION,90663,"Cohen, Seth D, MD",12/10/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,12/9/2024,Active,Malignant neoplasm of descending colon (CMS/HCC),
CMC OP INFUSION,90663,"Cohen, Seth D, MD",2/10/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/7/2025,Active,Carcinoma metastatic to lymph node of head and neck region (CMS/HCC),
CINJ OP INFUSION,24847,"Patankar, Sonali, MD",3/14/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,Adjuvant,3/13/2024,Active,,
CINJ OP INFUSION,55507,"Stephenson, Ruth D, DO",5/26/2023,PACLitaxel / CARBOplatin/ Pembrolizumab 21 Day Cycles - Uterine,Adjuvant,5/16/2023,Inactive,,
CINJ OP INFUSION,55507,"Stephenson, Ruth D, DO",8/30/2023,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,Second Line,8/29/2023,Inactive,,
CINJ OP INFUSION,55507,"Stephenson, Ruth D, DO",2/23/2024,Albumin-Bound PACLitaxel / Avastin21 Day Cycles- Uterine,_3. Third Line,2/22/2024,Inactive,,
MMC OP VP INFUSION,55507,"Meghal, Trishala, MD",3/12/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/21/2024,Inactive,,
JCMC CP INFUSION,75502,"Sekhri, Arunabh, MD",4/22/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/21/2024,Inactive,,
JCMC CP INFUSION,75502,"Sekhri, Arunabh, MD",6/5/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,5/27/2024,Inactive,,
NBI A5 PEDIATRICS,96164,"Ford, Maegan C, MD",4/15/2024,"AALL2121 Regimen A, Cycle 1",Induction,4/11/2024,Inactive,,
NBI VALERIE FND HEMONC,96164,"Ford, Maegan C, MD",4/16/2024,AALL2121 Regimen A,Reinduction,4/15/2024,Inactive,,
NBI VALERIE FND HEMONC,96164,"Ford, Maegan C, MD",7/19/2024,Bridging chemotherapy prior to CAR-T,_2. Second Line,7/19/2024,Active,,
NBI VALERIE FND HEMONC,90929,"Bhatla, Teena, MD",5/9/2025,AALL1731 All Arms - Interim Maintenance I EscMTX,_3. Third Line,5/9/2025,Inactive,Acute lymphoblastic leukemia (ALL) in relapse (CMS/HCC),
NBI A5 PEDIATRICS,90929,"Bhatla, Teena, MD",4/2/2025,AALL2121 Regimen B,_3. Third Line,4/2/2025,Inactive,Acute lymphoblastic leukemia (ALL) in relapse (CMS/HCC),"C91.02 - Acute lymphoblastic leukemia, in relapse; D61.810 - Antineoplastic chemotherapy induced pancytopenia; D70.9 - Neutropenia, unspecified; L03.213 - Periorbital cellulitis; B97.10 - Unspecified enterovirus as the cause of diseases classified elsewhere; R50.81 - Fever presenting with conditions classified elsewhere; B97.89 - Other viral agents as the cause of diseases classified elsewhere; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; H00.031 - Abscess of right upper eyelid; H10.89 - Other conjunctivitis; Z11.52 - Encounter for screening for COVID-19; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z98.890 - Other specified postprocedural states; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
NBI A5 PEDIATRICS,90929,"Bhatla, Teena, MD",4/1/2025,AALL1621 Cohort 2,_3. Third Line,3/31/2025,Inactive,Acute lymphoblastic leukemia (ALL) in relapse (CMS/HCC),"C91.02 - Acute lymphoblastic leukemia, in relapse; D61.810 - Antineoplastic chemotherapy induced pancytopenia; D70.9 - Neutropenia, unspecified; L03.213 - Periorbital cellulitis; B97.10 - Unspecified enterovirus as the cause of diseases classified elsewhere; R50.81 - Fever presenting with conditions classified elsewhere; B97.89 - Other viral agents as the cause of diseases classified elsewhere; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; H00.031 - Abscess of right upper eyelid; H10.89 - Other conjunctivitis; Z11.52 - Encounter for screening for COVID-19; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z98.890 - Other specified postprocedural states; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
CINJ OP INFUSION,75495,"Patankar, Sonali, MD",12/10/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,12/8/2024,Active,,
SOM OUTPT INFUSION,27569,"Toomey, Kathleen C, MD",5/30/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/30/2025,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,92589,"Berim, Lyudmyla, MD",8/7/2023,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,,7/3/2023,Inactive,,
CINJ OP INFUSION,92589,"Berim, Lyudmyla, MD",10/5/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/1/2023,Active,,
CBMC OP INFUSION 2FL,57193,"Radovich, Delia, MD",11/7/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,57193,"Leitner, Stuart P, MD",4/23/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/22/2024,Inactive,,
CBMC OP INFUSION 2FL,57193,"Leitner, Stuart P, MD",11/6/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,11/5/2024,Active,,
JCMC CP INFUSION,24967,"Sekhri, Arunabh, MD",5/7/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Endometrial Clear Cell Carcinoma,Adjuvant,5/7/2025,Active,Endometrial cancer (CMS/HCC),
CMC OP INFUSION,95742,"Patel, Neel H, MD",9/17/2024,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,9/17/2024,Active,,
CMC OP INFUSION,95742,"Patel, Neel H, MD",1/7/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,1/6/2025,Active,,
CINJ OP INFUSION,70372,"Berim, Lyudmyla, MD",11/14/2024,Nivolumab/Ipilimumab + PACLitaxel/CARBOplatin (AUC 6) 42 Day Cycles,_2. Second Line,11/10/2024,Active,,
CINJ PEDS HEMONC ,8942,"Sharma, Archana, DO",1/5/2023,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,,12/29/2022,Inactive,,
CINJ PEDS HEMONC ,8942,"Sharma, Archana, DO",3/13/2023,AALL1731 Delayed Intensification,,3/13/2023,Inactive,,
CINJ PEDS HEMONC ,8942,"Sharma, Archana, DO",6/1/2023,AALL1731 ALL SR-Avg B-ALL (including DS patients) - Interim Maintenance II EscMTX,,6/1/2023,Inactive,,
CINJ PEDS HEMONC ,8942,"Sharma, Archana, DO",8/14/2023,AALL1731 Non-DS SR (Fav or Avg) B-ALL - Maintenance,Maintenance,8/4/2023,Active,,
CINJ OP INFUSION,25887,"Leiser, Aliza, MD",5/3/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_2. Second Line,5/2/2024,Active,,
SOM OUTPT INFUSION,42671,"Yin, Faye, MD",6/30/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,6/4/2023,Inactive,,
SOM OUTPT INFUSION,42671,"Yin, Faye, MD",7/22/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,7/21/2024,Inactive,,
SOM OUTPT INFUSION,42671,"Toomey, Kathleen C, MD",8/7/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Cancer head and neck,_1. First Line,7/23/2024,Active,,
SOM OUTPT INFUSION,73797,"Toomey, Kathleen C, MD",5/29/2025,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,_3. Third Line,5/29/2025,Active,Squamous cell carcinoma of base of tongue (CMS/HCC),
CBMC OP INFUSION 2FL,69072,"Leitner, Stuart P, MD",11/1/2023,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,69072,"Leitner, Stuart P, MD",1/10/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,1/9/2024,Inactive,,
NBR 4N ONCOLOGY,96100,"Patel, Vimal D, MD",4/12/2023,BMT Autologous BEAM,Consolidation,4/11/2023,Inactive,,
CINJ OP INFUSION,11188,"Berim, Lyudmyla, MD",12/26/2024,PACLitaxel / CARBOplatin with Concurrent Radiation - Esophageal SCC,Neoadjuvant,12/24/2024,Active,,
NBR 4N ONCOLOGY,47899,"Berim, Lyudmyla, MD",2/3/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/1/2025,Active,"Malignant neoplasm of esophagus, unspecified location (CMS/HCC)","C15.9 - Malignant neoplasm of esophagus, unspecified; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E44.0 - Moderate protein-calorie malnutrition; N17.9 - Acute kidney failure, unspecified; C18.9 - Malignant neoplasm of colon, unspecified; E86.0 - Dehydration; D63.0 - Anemia in neoplastic disease; Z68.30 - Body mass index (BMI) 30.0-30.9, adult; Z93.3 - Colostomy status; E87.5 - Hyperkalemia; R13.14 - Dysphagia, pharyngoesophageal phase; K20.80 - Other esophagitis without bleeding; Z88.1 - Allergy status to other antibiotic agents; Z88.5 - Allergy status to narcotic agent; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.5 - Acquired absence of kidney; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.3 - Personal history of irradiation; G47.30 - Sleep apnea, unspecified; Z79.899 - Other long term (current) drug therapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
CBMC OP INFUSION 2FL,21336,"Brown, Andrew Bennett, MD",4/1/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,4/1/2024,Inactive,,
CBMC OP INFUSION 2FL,21336,"Brown, Andrew Bennett, MD",7/24/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,7/23/2024,Active,,
CINJ OP INFUSION,42168,"Toppmeyer, Deborah L, MD",7/10/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,7/9/2023,Inactive,,
CINJ OP INFUSION,42168,"Toppmeyer, Deborah L, MD",10/12/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,10/11/2023,Inactive,,
JCMC CP INFUSION,6186,"Sekhri, Arunabh, MD",3/4/2024,mFOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,2/16/2024,Inactive,,
JCMC CP INFUSION,6186,"Sekhri, Arunabh, MD",7/16/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,6/17/2024,Inactive,,
CINJ OP INFUSION,40217,"George, Mridula A, MD",12/8/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/7/2023,Inactive,,
CINJ OP INFUSION,40217,"George, Mridula A, MD",2/19/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,2/19/2025,Active,"Carcinoma of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,32222,"Berim, Lyudmyla, MD",8/16/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,7/28/2024,Inactive,,
CINJ OP INFUSION,80766,"George, Mridula A, MD",3/22/2024,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/21/2024,Active,,
CINJ OP INFUSION,41430,"George, Mridula A, MD",4/10/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,4/10/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)
Breast carcinoma metastatic to intra-abdominal lymph nodes, unspecified laterality (CMS/HCC)",
CBMC 2W ONCOLOGY,17594,"Grossman, I Robert, MD",4/5/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,17594,"Grossman, I Robert, MD",4/29/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/28/2024,Active,Malignant neoplasm of lower-inner quadrant of right female breast (CMS/HCC),
JCMC CP INFUSION,23981,"Sekhri, Arunabh, MD",5/11/2023,Nivolumab 480 mg D1 28 Day Cycles- Head and Neck Cancers,Second Line,5/10/2023,Inactive,,
JCMC CP INFUSION,23981,"Sekhri, Arunabh, MD",7/17/2024,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,7/16/2024,Inactive,,
JCMC CP INFUSION,23981,"Sekhri, Arunabh, MD",8/30/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_2. Second Line,7/28/2024,Active,,
JCMC CP INFUSION,23981,"Sekhri, Arunabh, MD",2/18/2025,Nivolumab/Ipilimumab + PACLitaxel/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/17/2025,Active,"Head and neck cancer (CMS/HCC)
Squamous cell carcinoma of right lung (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)
Duodenal cancer (CMS/HCC)",
JCMC CP INFUSION,23981,"Sekhri, Arunabh, MD",3/28/2025,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/18/2025,Active,"Head and neck cancer (CMS/HCC)
Squamous cell carcinoma of right lung (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)
Duodenal cancer (CMS/HCC)",
NBI OP INFUSION,39148,"Cheng, Yan Ho, MD",6/18/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (28 Day) x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,6/17/2024,Inactive,,
NBI OP INFUSION,39148,"Cheng, Yan Ho, MD",7/9/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/8/2024,Inactive,,
NBI OP INFUSION,39148,"Cheng, Yan Ho, MD",7/9/2024,Gemcitabine/CARBOplatin 28 Day Cycles x 4 cycles with Pembrolizumab 21 days - Non-Small Cell Lung Cancer,_2. Second Line,7/8/2024,Inactive,,
MMC OP VP INFUSION,88185,"Cohen, Seth D, MD",3/14/2023,Bendamustine / RiTUXimab 28 Day Cycles - marginal zone lymphoma,,3/13/2023,Inactive,,
MMC OP VP INFUSION,88185,"Cohen, Seth D, MD",10/9/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,10/8/2023,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CINJ OP INFUSION,7005,"Boland, Patrick M, MD",5/20/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,5/20/2024,Active,,
CINJ OP INFUSION,59810,"Hochster, Howard S, MD",5/13/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/13/2025,Active,Malignant neoplasm of cecum (CMS/HCC),"C18.0 - Malignant neoplasm of cecum; C18.9 - Malignant neoplasm of colon, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C79.9 - Secondary malignant neoplasm of unspecified site; Z90.49 - Acquired absence of other specified parts of digestive tract"
CINJ OP INFUSION,59810,"Alexander, Henry Richard, MD",3/3/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,3/3/2025,Inactive,Malignant neoplasm of cecum (CMS/HCC),"C18.0 - Malignant neoplasm of cecum; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis"
NBI OP INFUSION,76596,"Anderson, Patrick S, MD",7/30/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,7/29/2024,Active,,
NBI OP INFUSION,78941,"Anderson, Patrick S, MD",4/23/2025,Dostarlimab-gxly Day 1 & 22 x4 then Maint. Q42 Day Cycles- Gynecologic Cancers,_2. Second Line,4/23/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),
CINJ OP INFUSION,97381,"Leiser, Aliza, MD",4/14/2025,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,4/14/2025,Active,"Peritoneal carcinomatosis (CMS/HCC)
Malignant neoplasm of other specified female genital organs (CMS/HCC)","C48.2 - Malignant neoplasm of peritoneum, unspecified; I67.9 - Cerebrovascular disease, unspecified; I21.3 - ST elevation (STEMI) myocardial infarction of unspecified site; I82.409 - Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C54.2 - Malignant neoplasm of myometrium"
MMC OP VP INFUSION,90933,"Meghal, Trishala, MD",7/30/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,7/29/2024,Active,,
HAM OP INFUSION,30736,"Yogarajah, Meera, MD",9/11/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,First Line,9/10/2023,Inactive,,
NBR CINJ OP INFUSION,30736,"Palmisiano, Neil David, MD",7/15/2024,DAUNOrubicin Liposomal - Cytarabine (VYXEOS) - Induction 14 Day Cycle - Acute Myeloid Leukemia,Induction,7/15/2024,Active,,
NBR CINJ OP INFUSION,67157,"Egini, Ogechukwu, MD",4/22/2025,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_3. Third Line,4/18/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
NBR CINJ OP INFUSION,67157,"Egini, Ogechukwu, MD",4/20/2025,BMT Allogeneic Flu / Bu + Post Cy (No Busulfan Pk levels) (Reduced Intensity),_3. Third Line,4/19/2025,Inactive,MDS (myelodysplastic syndrome) (CMS/HCC),
MMC OP INFUSION,42210,"Meghal, Trishala, MD",10/18/2023,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Adjuvant,10/17/2023,Inactive,,
MMC OP INFUSION,42210,"Meghal, Trishala, MD",5/8/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Adjuvant,5/7/2024,Inactive,,
MMC OP INFUSION,42210,"Meghal, Trishala, MD",5/8/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/7/2024,Active,"Secondary malignant neoplasm of brain (CMS/HCC)
Malignant neoplasm of lower lobe, right bronchus or lung (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,97463,"Muralikrishnan, Sivraj, MD",4/29/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/29/2025,Active,"Metastatic adenocarcinoma (CMS/HCC)
NSCLC metastatic to brain (CMS/HCC)","I26.09 - Other pulmonary embolism with acute cor pulmonale; G93.6 - Cerebral edema; I82.220 - Acute embolism and thrombosis of inferior vena cava; J96.01 - Acute respiratory failure with hypoxia; C79.31 - Secondary malignant neoplasm of brain; C34.92 - Malignant neoplasm of unspecified part of left bronchus or lung; D64.9 - Anemia, unspecified; E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; E11.51 - Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene; Z79.4 - Long term (current) use of insulin; Z11.52 - Encounter for screening for COVID-19; E78.5 - Hyperlipidemia, unspecified; Z86.16 - Personal history of COVID-19; Z87.891 - Personal history of nicotine dependence; Z79.52 - Long term (current) use of systemic steroids; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.3 - Family history of diabetes mellitus; Z80.52 - Family history of malignant neoplasm of bladder; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z80.0 - Family history of malignant neoplasm of digestive organs; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z86.72 - Personal history of thrombophlebitis"
NBI OP INFUSION,86165,"Cohen, Alice, MD",12/28/2023,Capecitabine 21 Day Cycles - Breast,_2. Second Line,12/28/2023,Inactive,,
NBI D7 MED-SURG/TELE,86165,"Shah, Maya M, MD",1/17/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,1/16/2024,Inactive,,
NBI OP INFUSION,86165,"Cohen, Alice, MD",6/13/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_4. Fourth Line,6/12/2024,Inactive,,
NBI VALERIE FND HEMONC,81377,"Bhatla, Teena, MD",10/4/2024,AALL1732 Induction,Induction,10/3/2024,Inactive,,
NBI VALERIE FND HEMONC,81377,"Bhatla, Teena, MD",11/11/2024,AALL1631 Induction IB All Patients,_1. First Line,11/11/2024,Inactive,,
NBI VALERIE FND HEMONC,81377,"Bhatla, Teena, MD",1/13/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,1/12/2025,Active,,
NBI VALERIE FND HEMONC,81377,"Bhatla, Teena, MD",1/13/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,1/10/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI VALERIE FND HEMONC,81377,"Bhatla, Teena, MD",2/17/2025,AALL1631 SR Arm A Interim Maintenance,_1. First Line,2/17/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI VALERIE FND HEMONC,81377,"Bhatla, Teena, MD",2/21/2025,AALL1631 SR Arm B High-Dose Methotrexate Interim Maintenance,_1. First Line,2/18/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI VALERIE FND HEMONC,76568,"Bhatla, Teena, MD",5/29/2025,AALL1631 SR Arm B Delayed Intensification,_1. First Line,5/27/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI C5 PEDS ICU,76568,"Bhatla, Teena, MD",5/28/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,5/27/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C91.00 - Acute lymphoblastic leukemia not having achieved remission; D80.1 - Nonfamilial hypogammaglobulinemia; D69.6 - Thrombocytopenia, unspecified; D89.839 - Cytokine release syndrome, grade unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
NBI VALERIE FND HEMONC,76568,"Bhatla, Teena, MD",4/23/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,4/22/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
TRMC TCCC OP INFUSION,79271,"Salerno, Vincent E, MD",10/23/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,10/22/2024,Active,,
TRMC TCCC OP INFUSION,79271,"Salerno, Vincent E, MD",4/7/2025,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,_1. First Line,4/7/2025,Active,"Carcinoma of breast upper inner quadrant, right (CMS/HCC)
Metastasis to spinal column (CMS/HCC)",
CINJ OP INFUSION,62768,"Goel, Sanjay, MD",11/4/2024,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,11/4/2024,Active,,
CINJ OP INFUSION,78107,"Boland, Patrick M, MD",2/4/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,2/4/2025,Inactive,Cancer of sigmoid colon (CMS/HCC),"C78.01 - Secondary malignant neoplasm of right lung; J96.01 - Acute respiratory failure with hypoxia; Z51.5 - Encounter for palliative care; R65.11 - Systemic inflammatory response syndrome (sirs) of non-infectious origin with acute organ dysfunction; E87.20 - Acidosis, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I42.9 - Cardiomyopathy, unspecified; C18.7 - Malignant neoplasm of sigmoid colon; C78.02 - Secondary malignant neoplasm of left lung; I10 - Essential (primary) hypertension; N13.30 - Unspecified hydronephrosis; Z93.2 - Ileostomy status; D72.829 - Elevated white blood cell count, unspecified; K59.00 - Constipation, unspecified; F41.9 - Anxiety disorder, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; G47.00 - Insomnia, unspecified; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; Z85.038 - Personal history of other malignant neoplasm of large intestine; Z98.890 - Other specified postprocedural states; Z11.52 - Encounter for screening for COVID-19; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,8412,"Saraiya, Biren P, MD",5/8/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,5/8/2024,Active,,
HAM OP INFUSION,64882,"Yogarajah, Meera, MD",2/13/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,2/5/2024,Inactive,,
CINJ OP INFUSION,39940,"Omene, Coral Oghenerukevwe, MD",4/18/2023,Palbociclib 28 Day Cycles - Breast,First Line,4/18/2023,Inactive,,
SOM OUTPT INFUSION,87916,"Patel, Eshan, MD",2/7/2023,DOCEtaxel 21 Day Cycles - Prostate,,1/17/2023,Inactive,,
SOM OUTPT INFUSION,87916,"Patel, Eshan, MD",7/25/2023,Pembrolizumab 21 Day Cycles - prostate ,,7/25/2023,Inactive,,
NBI OP INFUSION,58603,"Cheng, Yan Ho, MD",3/29/2024,CARBOplatin/Fluorouracil Continuous Infusion with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_2. Second Line,3/28/2024,Inactive,,
NBI OP INFUSION,58603,"Cheng, Yan Ho, MD",4/19/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_2. Second Line,3/28/2024,Inactive,,
CBMC OP INFUSION 2FL,59655,"Radovich, Delia, MD",11/7/2023,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,11/6/2023,Inactive,,
MMC OP VP INFUSION,92725,"Lee, Patrick C, MD",5/22/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,5/16/2023,Active,"Invasive ductal carcinoma of breast, stage 1, left (CMS/HCC)",
CINJ OP INFUSION,80708,"Patankar, Sonali, MD",5/21/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Uterine Cancer,Neoadjuvant,5/6/2025,Active,Endometrial cancer (CMS/HCC),"C54.1 - Malignant neoplasm of endometrium; D64.9 - Anemia, unspecified; I63.9 - Cerebral infarction, unspecified"
CINJ OP INFUSION,87316,"Omene, Coral Oghenerukevwe, MD",10/17/2023,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,Neoadjuvant,10/16/2023,Inactive,,
CBMC OP INFUSION 2FL,87316,"Litvak, Anna M, MD",11/27/2023,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,_1. First Line,11/27/2023,Inactive,,
CBMC OP INFUSION 2FL,87316,"Wagmiller, Jennifer Ann, MD",2/26/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,2/15/2024,Inactive,,
SOM OUTPT INFUSION,80701,"Patel, Eshan, MD",5/13/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/13/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),"C18.7 - Malignant neoplasm of sigmoid colon; C18.9 - Malignant neoplasm of colon, unspecified"
NBR CINJ OP INFUSION,68083,"Shah, Mansi R, MD",2/16/2023,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,,2/14/2023,Inactive,,
NBR CINJ OP INFUSION,68083,"Shah, Mansi R, MD",5/21/2024,Carfilzomib 56 mg/m2 Weekly / Pomalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,5/20/2024,Active,,
NBR CINJ OP INFUSION,68083,"Shah, Mansi R, MD",2/6/2025,"Bortezomib D1, D8, D15, D22 / Selinexor 100 mg / Dexamethasone 35 Day Cycles- Multiple Myeloma",_4. Fourth Line,2/5/2025,Active,"Multiple myeloma in relapse (CMS/HCC)
Hypogammaglobulinemia (CMS/HCC)",Z51.12 - Encounter for antineoplastic immunotherapy; C90.01 - Multiple myeloma in remission; D47.2 - Monoclonal gammopathy; Z23 - Encounter for immunization
NBR CINJ OP INFUSION,68083,"Shah, Mansi R, MD",3/20/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,3/20/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),
HAM OP INFUSION,20015,"Patel, Malini M, MD",12/20/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,12/18/2023,Inactive,,
HAM OP INFUSION,20015,"Patel, Malini M, MD",8/13/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/12/2024,Active,,
NBI OP INFUSION,75816,"Cheng, Yan Ho, MD",6/24/2024,Albumin-Bound PACLitaxel/CARBOplatin + Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,6/23/2024,Active,,
CINJ OP INFUSION,90403,"Berim, Lyudmyla, MD",3/21/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,3/20/2024,Inactive,,
NBR CINJ OP INFUSION,75815,"Shah, Mansi R, MD",5/7/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,5/6/2024,Inactive,,
NBR CINJ OP INFUSION,75815,"Shah, Mansi R, MD",9/18/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,9/17/2024,Inactive,,
CINJ OP INFUSION,28299,"Girda, Eugenia, MD",1/11/2023,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,,1/10/2023,Inactive,,
SOM OUTPT INFUSION,23268,"Patel, Eshan, MD",11/21/2023,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_3. Third Line,11/6/2023,Inactive,,
SOM OUTPT INFUSION,23268,"Patel, Eshan, MD",2/6/2024,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,1/29/2024,Inactive,,
CBMC OP INFUSION 2FL,77976,"Raptis, George, MD",11/22/2024,CINJ 042102 EOP E ARV-471 and Abemaciclib 28 Day Cycles Research,Neoadjuvant,11/21/2024,Active,,
CBMC OP INFUSION 2FL,30718,"Litvak, Anna M, MD",9/24/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,9/24/2024,Active,,
CBMC OP INFUSION 2FL,30718,"Litvak, Anna M, MD",3/3/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/3/2025,Active,Malignant neoplasm of central portion of right female breast (CMS/HCC),
CBMC OP INFUSION 2FL,55994,"Leitner, Stuart P, MD",11/27/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,11/24/2024,Inactive,,
CBMC OP INFUSION 2FL,13863,"Scoppetuolo, Michael, MD",8/30/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,8/26/2024,Active,,
CBMC OP INFUSION 1FL,67643,"Meelheim, Brooke A, DO",1/13/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,1/12/2025,Active,,
CINJ OP INFUSION,706,"Boland, Patrick M, MD",5/3/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/2/2024,Inactive,,
CINJ OP INFUSION,706,"Boland, Patrick M, MD",10/22/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/22/2024,Active,,
CBMC OP INFUSION 2FL,99313,"Chowaniec, Wayne B, NP",11/7/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/6/2023,Inactive,,
CBMC 2W ONCOLOGY,99313,"Scoppetuolo, Michael, MD",5/3/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,5/2/2024,Active,,
NBR 5N ONCOLOGY,70395,"Doraiswamy, Anupama, MD",6/12/2023,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),First Line,6/12/2023,Inactive,,
NBR 4N BMTU/IMCU,70395,"Schaar, Dale, MD PhD",12/1/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,11/29/2023,Inactive,,
NBR CINJ OP INFUSION,70395,"Shah, Mansi R, MD",12/26/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,12/9/2024,Active,,
NBR CINJ OP INFUSION,70395,"Shah, Mansi R, MD",1/9/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,12/9/2024,Active,,
NBI OP INFUSION,8090,"Anderson, Patrick S, MD",6/24/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Endometrial cancer,_1. First Line,5/2/2024,Active,,
CBMC OP INFUSION 2FL,26765,"Dharmapuri, Sirish, MD",12/9/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",Adjuvant,12/8/2024,Active,,
SOM OUTPT INFUSION,40188,"Toomey, Kathleen C, MD",1/15/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,1/8/2025,Active,,
CMC OP INFUSION,71357,"Talwar, Sumit, MD",1/8/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,1/7/2025,Active,,
CMC OP INFUSION,71357,"Talwar, Sumit, MD",5/22/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,5/21/2025,Active,"Malignant neoplasm of right ureter (CMS/HCC)
Disorder of thyroid, unspecified",
NBR 5N ONCOLOGY,71357,"Ghodoussipour, Saum Bobak, MD",4/15/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/15/2025,Active,Malignant neoplasm of right ureter (CMS/HCC),
TRMC TCCC OP INFUSION,37286,"Salerno, Vincent E, MD",4/25/2025,RiTUXimab 28 Day Cycle - kidney disease,_1. First Line,4/25/2025,Active,ARF (acute renal failure) (CMS/HCC),
SOM OUTPT INFUSION,93440,"Patel, Eshan, MD",5/6/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,5/6/2025,Active,"Invasive lobular carcinoma of breast, stage 3, right (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast
HAM OP INFUSION,16723,"Yogarajah, Meera, MD",12/4/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/26/2023,Inactive,,
HAM OP INFUSION,16723,"Yogarajah, Meera, MD",8/16/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,8/16/2024,Inactive,,
HAM OP INFUSION,16723,"Yogarajah, Meera, MD",12/31/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,12/8/2024,Active,,
HAM OP INFUSION,16723,"Yogarajah, Meera, MD",2/13/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/9/2025,Active,Primary high grade serous adenocarcinoma of ovary (CMS/HCC),
HAM OP INFUSION,16723,"Yogarajah, Meera, MD",4/18/2025,Pembrolizumab 21 Day Cycles - TMB high cancer,_2. Second Line,3/11/2025,Active,Primary high grade serous adenocarcinoma of ovary (CMS/HCC),
HAM OP INFUSION,16723,"Yogarajah, Meera, MD",3/6/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/10/2025,Inactive,Primary high grade serous adenocarcinoma of ovary (CMS/HCC),
MMC OP VP INFUSION,68404,"Cohen, Seth D, MD",10/25/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/24/2023,Inactive,,
CINJ OP INFUSION,65572,"Leiser, Aliza, MD",6/5/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,6/1/2023,Inactive,,
CINJ OP INFUSION,35568,"Mayer, Tina M, MD",3/18/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/18/2024,Active,,
MMC OP VP INFUSION,47105,"Lee, Patrick C, MD",5/22/2025,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_1. First Line,5/22/2025,Active,Angiosarcoma (CMS/HCC),
CBMC OP INFUSION 2FL,58798,"Wagmiller, Jennifer Ann, MD",11/15/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,11/13/2023,Inactive,,
CBMC OP INFUSION 2FL,58798,"Wagmiller, Jennifer Ann, MD",12/26/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,12/25/2023,Active,,
JCMC CP INFUSION,60672,"Sekhri, Arunabh, MD",11/3/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,10/22/2023,Inactive,,
TRMC TCCC OP INFUSION,8827,"Capo, Gerardo, MD",10/22/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,10/21/2024,Active,"Secondary malignant neoplasm of lung (CMS/HCC)
Malignant neoplasm oropharynx (CMS/HCC)",
MMC OP VP INFUSION,16644,"Cohen, Seth D, MD",4/18/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/18/2024,Inactive,,
NBI OP INFUSION,68672,"Cheng, Yan Ho, MD",1/2/2024,Enzalutamide 28 Day Cycles - Prostate,Adjuvant,1/2/2024,Active,,
JCMC CP INFUSION,95588,"Cruz, Allan Louie E, MD",4/10/2025,Pembrolizumab 21 Day Cycles - Recurrent Endometrial Cancer MSI-high,_1. First Line,4/10/2025,Active,"Malignant neoplasm of endometrium of corpus uteri (CMS/HCC)
Chronic fatigue, unspecified",
CBMC OP INFUSION 2FL,92187,"Dharmapuri, Sirish, MD",2/26/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/25/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas
HAM OP INFUSION,98773,"Patel, Malini M, MD",1/8/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,1/7/2024,Inactive,,
HAM OP INFUSION,98773,"Patel, Malini M, MD",9/9/2024,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,9/8/2024,Active,,
CINJ OP INFUSION,96430,"Berim, Lyudmyla, MD",1/25/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/24/2023,Inactive,,
CINJ OP INFUSION,96430,"Berim, Lyudmyla, MD",2/7/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Second Line,2/6/2023,Inactive,,
MMC OP VP INFUSION,83024,"Talwar, Sumit, MD",5/13/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,5/13/2025,Active,Malignant neoplasm of left kidney (CMS/HCC),
MMC OP VP INFUSION,39468,"Talwar, Sumit, MD",2/18/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,2/18/2025,Active,Malignant neoplasm of left kidney (CMS/HCC),
CBMC OP INFUSION 2FL,18275,"Wagmiller, Jennifer Ann, MD",3/6/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/5/2023,Inactive,,
MMC OP VP INFUSION,25002,"Talwar, Sumit, MD",5/8/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,First Line,5/7/2023,Inactive,,
MMC OP VP INFUSION,25002,"Talwar, Sumit, MD",7/10/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,First Line,6/14/2023,Inactive,,
MMC OP VP INFUSION,25002,"Talwar, Sumit, MD",9/6/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Second Line,8/25/2023,Inactive,,
CINJ OP INFUSION,11574,"Stephenson, Ryan D, DO",10/27/2023,Nivolumab (1 mg/Kg) / Ipilimumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,10/26/2023,Active,,
NBR CINJ OP INFUSION,57016,"Egini, Ogechukwu, MD",1/29/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,1/28/2025,Active,,
CBMC OP INFUSION 2FL,83408,"Scoppetuolo, Michael, MD",6/17/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/3/2024,Active,,
NBR CINJ OP INFUSION,13601,"Zayac, Adam, MD",11/27/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,11/27/2024,Active,,
NBR CINJ OP INFUSION,50460,"Shah, Mansi R, MD",2/2/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_6. Sixth Line,2/1/2024,Inactive,,
CBMC OP INFUSION 2FL,52451,"Grossman, I Robert, MD",6/13/2024,S1826 Arm 1 AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,6/12/2024,Inactive,,
CINJ OP INFUSION,35049,"Berim, Lyudmyla, MD",5/1/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/1/2025,Inactive,Secondary malignant neoplasm of skin of chest (CMS/HCC),"J98.4 - Other disorders of lung; J96.01 - Acute respiratory failure with hypoxia; Z66 - Do not resuscitate; C79.2 - Secondary malignant neoplasm of skin; C22.1 - Intrahepatic bile duct carcinoma; E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; D64.9 - Anemia, unspecified; F31.9 - Bipolar disorder, unspecified; J90 - Pleural effusion, not elsewhere classified; I10 - Essential (primary) hypertension; G89.3 - Neoplasm related pain (acute) (chronic); T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; I89.0 - Lymphedema, not elsewhere classified; R73.9 - Hyperglycemia, unspecified; R94.31 - Abnormal electrocardiogram (ECG) (EKG); L98.9 - Disorder of the skin and subcutaneous tissue, unspecified; Z79.52 - Long term (current) use of systemic steroids; Z86.16 - Personal history of COVID-19; Z11.52 - Encounter for screening for COVID-19; Z79.899 - Other long term (current) drug therapy; Z80.9 - Family history of malignant neoplasm, unspecified; Z81.8 - Family history of other mental and behavioral disorders; Z85.05 - Personal history of malignant neoplasm of liver; Z85.828 - Personal history of other malignant neoplasm of skin; Z87.01 - Personal history of pneumonia (recurrent); Z88.0 - Allergy status to penicillin; Z90.411 - Acquired partial absence of pancreas; Z90.49 - Acquired absence of other specified parts of digestive tract; Z92.3 - Personal history of irradiation"
CINJ OP INFUSION,35049,"Berim, Lyudmyla, MD",4/28/2025,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,4/28/2025,Inactive,Secondary malignant neoplasm of skin of chest (CMS/HCC),"J98.4 - Other disorders of lung; J96.01 - Acute respiratory failure with hypoxia; Z66 - Do not resuscitate; C79.2 - Secondary malignant neoplasm of skin; C22.1 - Intrahepatic bile duct carcinoma; E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; D64.9 - Anemia, unspecified; F31.9 - Bipolar disorder, unspecified; J90 - Pleural effusion, not elsewhere classified; I10 - Essential (primary) hypertension; G89.3 - Neoplasm related pain (acute) (chronic); T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; I89.0 - Lymphedema, not elsewhere classified; R73.9 - Hyperglycemia, unspecified; R94.31 - Abnormal electrocardiogram (ECG) (EKG); L98.9 - Disorder of the skin and subcutaneous tissue, unspecified; Z79.52 - Long term (current) use of systemic steroids; Z86.16 - Personal history of COVID-19; Z11.52 - Encounter for screening for COVID-19; Z79.899 - Other long term (current) drug therapy; Z80.9 - Family history of malignant neoplasm, unspecified; Z81.8 - Family history of other mental and behavioral disorders; Z85.05 - Personal history of malignant neoplasm of liver; Z85.828 - Personal history of other malignant neoplasm of skin; Z87.01 - Personal history of pneumonia (recurrent); Z88.0 - Allergy status to penicillin; Z90.411 - Acquired partial absence of pancreas; Z90.49 - Acquired absence of other specified parts of digestive tract; Z92.3 - Personal history of irradiation"
CINJ OP INFUSION,57156,"Saraiya, Biren P, MD",1/23/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,1/15/2024,Inactive,,
MMC OP VP INFUSION,66892,"Cohen, Seth D, MD",11/25/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/18/2024,Active,,
MSC OP INFUSION,81554,"Cohen, Seth D, MD",5/20/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/16/2024,Inactive,,
CINJ OP INFUSION,56939,"Patel, Eshan, MD",5/3/2024,Temozolomide 28 Day Cycles - CNS,Maintenance,5/2/2024,Inactive,,
CINJ OP INFUSION,48980,"Weiss, Sarah, MD",12/12/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,12/12/2023,Inactive,,
CINJ OP INFUSION,48980,"Weiss, Sarah, MD",4/29/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,4/26/2024,Active,,
CBMC OP INFUSION 2FL,67373,"Scoppetuolo, Michael, MD",11/20/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_1. First Line,11/17/2024,Active,,
CBMC OP INFUSION 2FL,67373,"Scoppetuolo, Michael, MD",11/20/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,11/17/2024,Active,,
CINJ OP INFUSION,11779,"Hochster, Howard S, MD",9/14/2023,"Cape plus Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",First Line,9/14/2023,Active,,
SOM OUTPT INFUSION,73150,"Toomey, Kathleen C, MD",1/29/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,1/29/2024,Active,,
CBMC OP INFUSION 2FL,75696,"Litvak, Anna M, MD",1/7/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,1/6/2025,Active,,
NBR 4N BMTU/IMCU,19164,"Braunschweig, Ira, MD",6/20/2023,BMT Autologous BEAM,,6/20/2023,Inactive,,
CINJ OP INFUSION,91442,"Dasgeb, Bahar, MD",10/17/2023,Dostarlimab-gxly  42 Day Cycles- Colon Cancer,Third Line,10/16/2023,Active,,
SOM OUTPT INFUSION,95057,"Yin, Faye, MD",5/6/2024,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/28/2024,Active,,
CINJ OP INFUSION,76908,"Weiss, Sarah, MD",8/26/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,8/23/2024,Active,,
NBR CINJ OP INFUSION,31130,"Shah, Mansi R, MD",10/3/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Consolidation,9/19/2024,Active,,
CMC OP INFUSION,6646,"Pompa, Tiffany Ann, MD",5/30/2025,Pembrolizumab 42 Day Cycles - Melanoma,Adjuvant,5/30/2025,Active,"Malignant melanoma of right lower limb, including hip (CMS/HCC)",
CMC OP INFUSION,9798,"Cohen, Seth D, MD",5/29/2024,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_1. First Line,5/27/2024,Inactive,,
NBR CINJ OP INFUSION,85255,"Evens, Andrew M, DO",1/8/2025,Nivolumab + AVD (DOXOrubicin / VinBLAStine / Dacarbazine)  28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/7/2025,Active,,
NBR CINJ OP INFUSION,85255,"Evens, Andrew M, DO",1/8/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/7/2025,Inactive,Hodgkin lymphoma (CMS/HCC),
SOM OUTPT INFUSION,67736,"Patel, Eshan, MD",4/17/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Bladder Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,4/17/2025,Active,Urothelial carcinoma of bladder (CMS/HCC),
CINJ OP INFUSION,81324,"Jang, Thomas L, MD",12/24/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,12/18/2024,Active,,
CINJ OP INFUSION,87675,"Jang, Thomas L, MD",4/4/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,4/4/2025,Active,Urothelial cancer (CMS/HCC),
SOM OUTPT INFUSION,74181,"Patel, Eshan, MD",4/10/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,4/7/2023,Inactive,,
NBR CINJ OP INFUSION,98718,"Matasar, Matthew J, MD",5/19/2025,CINJ 112305 AVD Arm E (Doxorubicin / Vinblastine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/19/2025,Active,Hodgkin lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,98718,"Rhodes, Joanna Meehan, MD",3/24/2025,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,3/24/2025,Inactive,Hodgkin lymphoma (CMS/HCC),
CINJ OP INFUSION,25661,"Haigentz, Missak, MD",5/22/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,5/22/2023,Inactive,,
CINJ OP INFUSION,25661,"Haigentz, Missak, MD",6/25/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/17/2024,Inactive,,
CBMC OP INFUSION 2FL,50280,"Litvak, Anna M, MD",10/12/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,10/11/2023,Inactive,,
CBMC OP INFUSION 2FL,50280,"Litvak, Anna M, MD",11/22/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/21/2023,Inactive,,
CBMC OP INFUSION 2FL,50280,"Ligresti, Louise G, MD",9/3/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,9/2/2024,Active,,
CMC OP INFUSION,4831,"Easaw, Sarah, MD",6/12/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,6/6/2023,Inactive,,
CINJ OP INFUSION,346,"Stephenson, Ryan D, DO",5/17/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,5/17/2024,Active,,
CINJ OP INFUSION,346,"Stephenson, Ryan D, DO",10/16/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,10/9/2024,Inactive,,
JCMC CP INFUSION,99335,"Cruz, Allan Louie E, MD",5/28/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,5/28/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,99335,"Cruz, Allan Louie E, MD",3/18/2025,"CINJ 042315 Arm 1 PACLitaxel D1, D8 14 Day Cycles followed by DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer",Neoadjuvant,3/18/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,99335,"Cruz, Allan Louie E, MD",3/18/2025,PACLitaxel weekly 28 Day Cycles - Breast (Neoadjuvant),Neoadjuvant,3/18/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
HAM OP INFUSION,35414,"Yogarajah, Meera, MD",1/3/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,First Line,12/12/2022,Inactive,,
HAM OP INFUSION,35414,"Yogarajah, Meera, MD",7/20/2023,Pembrolizumab 21 Day Cycles - Breast,First Line,7/20/2023,Inactive,,
MMC OP VP INFUSION,89723,"Meghal, Trishala, MD",8/13/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,7/30/2024,Inactive,,
CINJ OP INFUSION,4488,"Weiss, Sarah, MD",12/9/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/8/2024,Active,,
MMC OP VP INFUSION,56746,"Lee, Patrick C, MD",9/19/2024,Opdivo,_1. First Line,9/12/2024,Active,,
MMC OP VP INFUSION,56746,"Lee, Patrick C, MD",5/15/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Thoracic Cancers",_1. First Line,5/15/2025,Active,"Secondary malignant neoplasm of right lung (CMS/HCC)
Chemotherapy-induced fatigue",
CINJ OP INFUSION,8236,"Patel, Eshan, MD",8/14/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,,8/3/2023,Inactive,,
CINJ OP INFUSION,29493,"Omene, Coral Oghenerukevwe, MD",12/24/2024,Palbociclib 3 Weeks on 2 weeks off,_1. First Line,12/24/2024,Active,,
MMC OP INFUSION,42317,"Meghal, Trishala, MD",7/26/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/17/2024,Active,,
JCMC CP INFUSION,61809,"Sekhri, Arunabh, MD",8/21/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,7/21/2024,Inactive,,
JCMC CP INFUSION,61809,"Sekhri, Arunabh, MD",4/23/2025,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,4/23/2025,Active,Bladder cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; E53.8 - Deficiency of other specified B group vitamins; I10 - Essential (primary) hypertension; R45.89 - Other symptoms and signs involving emotional state; D50.0 - Iron deficiency anemia secondary to blood loss (chronic)"
CBMC 2W ONCOLOGY,75541,"Wagmiller, Jennifer Ann, MD",1/12/2025,Hydroxyurea 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,1/12/2025,Inactive,"Buccal mucosa squamous cell carcinoma (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)",
CBMC 2W ONCOLOGY,75541,"Grossman, I Robert, MD",1/23/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,1/22/2025,Active,Multiple myeloma (CMS/HCC),
CBMC 2W ONCOLOGY,28064,"Grossman, I Robert, MD",5/2/2025,Cytarabine Cytoreduction for Hyperleukocytosis,_2. Second Line,5/2/2025,Inactive,AMML (acute myelomonocytic leukemia) (CMS/HCC),"C92.02 - Acute myeloblastic leukemia, in relapse; E44.0 - Moderate protein-calorie malnutrition; I46.9 - Cardiac arrest, cause unspecified; K92.2 - Gastrointestinal hemorrhage, unspecified; I27.20 - Pulmonary hypertension, unspecified; E87.20 - Acidosis, unspecified; E83.39 - Other disorders of phosphorus metabolism; E87.1 - Hypo-osmolality and hyponatremia; E11.9 - Type 2 diabetes mellitus without complications; I11.0 - Hypertensive heart disease with heart failure; D63.0 - Anemia in neoplastic disease; D69.59 - Other secondary thrombocytopenia; I47.20 - Ventricular tachycardia, unspecified; I50.32 - Chronic diastolic (congestive) heart failure; N17.9 - Acute kidney failure, unspecified; T84.59XA - Infection and inflammatory reaction due to other internal joint prosthesis, initial encounter; I48.91 - Unspecified atrial fibrillation; E86.9 - Volume depletion, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; E83.42 - Hypomagnesemia; I49.3 - Ventricular premature depolarization; M10.9 - Gout, unspecified; N32.81 - Overactive bladder; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z82.3 - Family history of stroke; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.3 - Family history of diabetes mellitus; Z87.891 - Personal history of nicotine dependence; Z87.892 - Personal history of anaphylaxis; Z90.79 - Acquired absence of other genital organ(s); Z91..."
CINJ OP INFUSION,25486,"Boland, Patrick M, MD",1/24/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/23/2023,Inactive,,
JCMC CP INFUSION,4791,"Cruz, Allan Louie E, MD",7/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastric Cancer adenocarcinoma,Neoadjuvant,7/14/2024,Inactive,,
JCMC CP INFUSION,4791,"Cruz, Allan Louie E, MD",2/20/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,2/13/2025,Active,Malignant neoplasm of pyloric antrum (CMS/HCC),"C16.3 - Malignant neoplasm of pyloric antrum; N18.32 - Chronic kidney disease, stage 3b; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); D63.1 - Anemia in chronic kidney disease"
JCMC CP INFUSION,4791,"Cruz, Allan Louie E, MD",3/6/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/6/2025,Inactive,Malignant neoplasm of pyloric antrum (CMS/HCC),C16.3 - Malignant neoplasm of pyloric antrum
JCMC CP INFUSION,76152,"Cruz, Allan Louie E, MD",4/7/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/7/2025,Inactive,"Malignant neoplasm of overlapping sites of left lung (CMS/HCC)
Abnormal weight loss
Chronic fatigue",
NBR 5N ONCOLOGY,34784,"Boland, Patrick M, MD",9/18/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,9/17/2023,Inactive,,
SOM OUTPT INFUSION,78381,"Patel, Eshan, MD",5/6/2025,Pembrolizumab / PEMEtrexed / CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,5/6/2025,Inactive,Mass of lung,
MSC OP INFUSION,87612,"Cohen, Seth D, MD",9/25/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,First Line,9/24/2023,Inactive,,
MSC OP INFUSION,87612,"Cohen, Seth D, MD",12/12/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/11/2023,Inactive,,
MSC OP INFUSION,87612,"Cohen, Seth D, MD",12/12/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/11/2023,Inactive,,
MMC OP VP INFUSION,87612,"Cohen, Seth D, MD",9/19/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/10/2024,Inactive,,
CBMC OP INFUSION 2FL,13681,"Scoppetuolo, Michael, MD",11/12/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/4/2024,Active,,
CINJ OP INFUSION,81839,"Saraiya, Biren P, MD",2/19/2024,Gemcitabine / OXALIplatin 21 Day Cycles - Testicular,_5. Fifth Line,2/15/2024,Inactive,,
CBMC OP INFUSION 2FL,16052,"Dharmapuri, Sirish, MD",10/24/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/22/2024,Active,,
MMC OP VP INFUSION,54904,"Cohen, Seth D, MD",2/21/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/14/2024,Inactive,,
NBR CINJ OP INFUSION,68494,"Rhodes, Joanna Meehan, MD",11/27/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/26/2023,Inactive,,
TRMC TCCC OP INFUSION,25811,"Salerno, Vincent E, MD",8/15/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/14/2024,Active,Multiple myeloma (CMS/HCC),
TRMC TCCC OP INFUSION,25811,"Capo, Gerardo, MD",10/4/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,10/3/2024,Inactive,,
NBR CINJ OP INFUSION,25811,"Rhodes, Joanna Meehan, MD",4/2/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,4/2/2025,Inactive,Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC),
NBR CINJ OP INFUSION,25811,"Rhodes, Joanna Meehan, MD",3/12/2025,PolaR-ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,3/12/2025,Inactive,Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC),
CINJ OP INFUSION,76204,"George, Mridula A, MD",6/26/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,6/26/2024,Inactive,,
CINJ OP INFUSION,76204,"George, Mridula A, MD",1/3/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,1/3/2025,Active,,
CINJ OP INFUSION,45209,"Patankar, Sonali, MD",12/30/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,12/17/2024,Active,,
NBR CINJ OP INFUSION,92263,"Evens, Andrew M, DO",7/21/2023,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,First Line,7/20/2023,Inactive,,
NBI OP INFUSION,42734,"Anderson, Patrick S, MD",3/11/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/6/2024,Inactive,,
TRMC TCCC OP INFUSION,47099,"Salerno, Vincent E, MD",10/25/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,10/24/2024,Active,,
NBR 5N ONCOLOGY,40057,"Berim, Lyudmyla, MD",4/15/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,4/14/2023,Inactive,,
TRMC TCCC OP INFUSION,66327,"Capo, Gerardo, MD",12/2/2024,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,11/13/2024,Active,,
CINJ OP INFUSION,35532,"Toppmeyer, Deborah L, MD",10/9/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,10/9/2023,Active,Chronic lymphocytic leukemia of B-cell type not having achieved remission (CMS/HCC),
CMC OP INFUSION,399,"Ferretti, Mark J, MD",5/1/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,_1. First Line,4/30/2024,Inactive,,
CMC OP INFUSION,399,"Ferretti, Mark J, MD",9/2/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,_1. First Line,9/2/2024,Inactive,,
CMC OP INFUSION,399,"Ferretti, Mark J, MD",12/9/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,12/8/2024,Active,,
CINJ OP INFUSION,89325,"Patel, Eshan, MD",12/1/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles  Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,11/29/2023,Inactive,,
CINJ OP INFUSION,89325,"Patel, Eshan, MD",3/1/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/29/2024,Inactive,,
CINJ OP INFUSION,89325,"Patel, Eshan, MD",5/17/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - lung  CANCER,_2. Second Line,5/16/2024,Inactive,,
MMC OP VP INFUSION,53533,"Lee, Patrick C, MD",3/14/2024,PEMBROLIZUMAB + GEMCITABINE ,_1. First Line,3/12/2024,Inactive,,
NBR 5N ONCOLOGY,99160,"Palmisiano, Neil David, MD",5/3/2025,Cytarabine Cytoreduction for Hyperleukocytosis,Induction,5/3/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; D65 - Disseminated intravascular coagulation (defibrination syndrome); E88.3 - Tumor lysis syndrome; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; G93.49 - Other encephalopathy; N18.30 - Chronic kidney disease, stage 3 unspecified; E66.9 - Obesity, unspecified; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; N17.9 - Acute kidney failure, unspecified; T40.2X1A - Poisoning by other opioids, accidental (unintentional), initial encounter; I50.9 - Heart failure, unspecified; I48.91 - Unspecified atrial fibrillation; I46.2 - Cardiac arrest due to underlying cardiac condition; E78.00 - Pure hypercholesterolemia, unspecified; Z91.040 - Latex allergy status; G47.33 - Obstructive sleep apnea (adult) (pediatric); K59.00 - Constipation, unspecified; M17.11 - Unilateral primary osteoarthritis, right knee; M19.071 - Primary osteoarthritis, right ankle and foot; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; Z79.01 - Long term (current) use of anticoagulants; Z79.82 - Long term (current) use of aspirin; Z83.3 - Family history of diabetes mellitus; Z87.891 - Personal history of nicotine dependence; Z88.2 - Allergy status to sulfonamides; K21.9 - Gastro-esophageal reflux disease without esophagitis; R33.8 - Other ret..."
CMC OP INFUSION,35257,"Tang, Horace, MD",12/13/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,12/13/2023,Inactive,,
NBR CINJ OP INFUSION,60640,"Matasar, Matthew J, MD",12/30/2024,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,12/29/2024,Active,,
NBR CINJ OP INFUSION,60640,"Matasar, Matthew J, MD",3/5/2025,"CINJ 112305 Arms B,D,F,H (Brentuximab Vendotin + Nivolumab) 21 Day Cycles - Hodgkin Lymphoma",_1. First Line,3/5/2025,Active,Nodular sclerosis Hodgkin lymphoma of lymph nodes of neck (CMS/HCC),
CBMC 2W ONCOLOGY,32697,"Grossman, I Robert, MD",8/2/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,8/2/2024,Inactive,,
CBMC OP INFUSION 2FL,32697,"Grossman, I Robert, MD",8/27/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/25/2024,Active,"Endometrial cancer (CMS/HCC)
On antineoplastic chemotherapy",
MSC OP INFUSION,37821,"Cohen, Seth D, MD",11/20/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/18/2024,Active,,
CBMC OP INFUSION 2FL,55258,"Wagmiller, Jennifer Ann, MD",5/16/2023,Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,5/15/2023,Active,,
MMC OP VP INFUSION,31968,"Cohen, Seth D, MD",7/8/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_3. Third Line,7/2/2024,Active,Astrocytoma brain tumor (CMS/HCC),
CMC OP INFUSION,88689,"Talwar, Sumit, MD",6/27/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,6/23/2024,Inactive,,
NBR CINJ OP INFUSION,94966,"Shah, Mansi R, MD",6/20/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,6/15/2023,Active,,
MMC OP INFUSION,97305,"Meghal, Trishala, MD",1/18/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,First Line,1/17/2023,Inactive,,
MMC OP INFUSION,97305,"Meghal, Trishala, MD",6/26/2024,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_3. Third Line,6/23/2024,Inactive,,
MMC OP INFUSION,97305,"Meghal, Trishala, MD",1/31/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/29/2025,Inactive,Malignant neoplasm of endometrium (CMS/HCC),
MMC OP VP INFUSION,97305,"Meghal, Trishala, MD",1/31/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/30/2025,Inactive,Malignant neoplasm of endometrium (CMS/HCC),
MMC OP VP INFUSION,97305,"Meghal, Trishala, MD",1/31/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/30/2025,Inactive,Malignant neoplasm of endometrium (CMS/HCC),
MMC OP VP INFUSION,97305,"Meghal, Trishala, MD",2/19/2025,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Uterine",_2. Second Line,2/18/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),
CINJ OP INFUSION,25009,"Berim, Lyudmyla, MD",10/14/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/10/2024,Inactive,,
CINJ OP INFUSION,30926,"Groisberg, Roman, MD",1/20/2023,Pembrolizumab 42 Day Cycles - Melanoma,Third Line,1/19/2023,Inactive,,
SOM OUTPT INFUSION,25522,"Toomey, Kathleen C, MD",9/25/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/24/2024,Active,,
SOM OUTPT INFUSION,25522,"Toomey, Kathleen C, MD",2/18/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/13/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),
HAM OP INFUSION,31446,"Patel, Malini M, MD",9/21/2023,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,First Line,9/20/2023,Inactive,,
NBR 4N ONCOLOGY,74284,"Berim, Lyudmyla, MD",4/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/31/2024,Inactive,,
NBR CINJ OP INFUSION,56705,"Matasar, Matthew J, MD",4/14/2025,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_2. Second Line,4/9/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
MMC OP VP INFUSION,98690,"Meghal, Trishala, MD",12/9/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,12/9/2024,Active,,
CMC OP INFUSION,95766,"Tang, Horace, MD",4/13/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,4/12/2023,Inactive,,
CMC OP INFUSION,95766,"Tang, Horace, MD",6/21/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",,6/20/2023,Inactive,,
CBMC OP INFUSION 2FL,77187,"Scoppetuolo, Michael, MD",10/23/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/22/2023,Active,,
MMC OP INFUSION,96686,"Talwar, Sumit, MD",2/1/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/31/2024,Inactive,,
CBMC OP INFUSION 2FL,55175,"Litvak, Anna M, MD",11/22/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,11/21/2023,Inactive,,
NBR CINJ OP INFUSION,51730,"Evens, Andrew M, DO",8/30/2023,RiTUXimab Initial Infusion Single Day (Outpatient) - Follicular Lymphoma PRIMA Maintenance,,8/23/2023,Inactive,,
NBR 5N ONCOLOGY,5357,"Berim, Lyudmyla, MD",7/11/2024,CISplatin/DOCEtaxel 21 Day Cycles- Head and Neck Cancers,_1. First Line,7/9/2024,Inactive,,
CINJ OP INFUSION,5357,"Haigentz, Missak, MD",8/14/2024,Cetuximab/DOCEtaxel with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_2. Second Line,8/14/2024,Inactive,,
CINJ OP INFUSION,5357,"Haigentz, Missak, MD",11/12/2024,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,Maintenance,11/12/2024,Inactive,,
CINJ OP INFUSION,5357,"Haigentz, Missak, MD",12/10/2024,Nivolumab 480 mg D1 28 Day Cycles- Head and Neck Cancers,_1. First Line,12/9/2024,Inactive,,
MMC OP INFUSION,67057,"Lee, Patrick C, MD",5/2/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,5/1/2023,Active,,
CBMC OP INFUSION 2FL,46809,"Dharmapuri, Sirish, MD",12/13/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/12/2024,Active,,
CBMC OP INFUSION 2FL,16854,"Wagmiller, Jennifer Ann, MD",12/15/2023,Pembrolizumab 42 Day Cycles - Uterine,Maintenance,12/5/2023,Inactive,,
CMC 4B ONCOLOGY,15674,"Talwar, Sumit, MD",9/21/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,,9/20/2023,Inactive,,
TRMC TCCC OP INFUSION,36303,"Capo, Gerardo, MD",4/2/2024,"DOCETAXEL / DAROLUTAMIDE, 21 DAY CYCLES - PROSTATE CANCER",_1. First Line,4/1/2024,Active,,
TRMC TCCC OP INFUSION,36303,"Capo, Gerardo, MD",4/1/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,4/1/2025,Active,Malignant neoplasm of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
MMC OP INFUSION,46134,"Lee, Patrick C, MD",1/3/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,1/2/2023,Inactive,,
CINJ OP INFUSION,5088,"Toppmeyer, Deborah L, MD",1/6/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,1/6/2025,Active,Cholangiocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,70890,"Leitner, Stuart P, MD",8/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/5/2024,Active,Malignant neoplasm of overlapping sites of colon (CMS/HCC),
CBMC OP INFUSION 2FL,70890,"Leitner, Stuart P, MD",10/28/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,Adjuvant,10/27/2024,Active,,
CBMC OP INFUSION 2FL,46673,"Leitner, Stuart P, MD",9/23/2024,Avelumab 28 Day Cycles - Merkel Cell Carcinoma or Endometrial Carcinoma or Gestational Trophoblastic Neoplasia or Bladder Cancer,_1. First Line,9/22/2024,Active,,
MMC OP INFUSION,70001,"Lee, Patrick C, MD",7/6/2023,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Second Line,7/3/2023,Inactive,,
CBMC OP INFUSION 2FL,97357,"Grossman, I Robert, MD",5/13/2024,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,5/13/2024,Active,,
CBMC OP INFUSION 2FL,97357,"Grossman, I Robert, MD",10/29/2024,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,10/29/2024,Active,,
CINJ OP INFUSION,66063,"Aikins, James K, MD",11/1/2024,PACLitaxel / CARBOplatin / Pembrolizumab 21 Day Cycles -Advanced Uterine Serous,_1. First Line,10/31/2024,Active,,
CMC OP INFUSION,94891,"Pompa, Tiffany Ann, MD",9/25/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,9/24/2024,Active,,
SOM OUTPT INFUSION,48274,"Patel, Eshan, MD",1/17/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles  Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,1/16/2024,Inactive,,
NBR CINJ OP INFUSION,25904,"Rhodes, Joanna Meehan, MD",6/3/2024,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,6/2/2024,Inactive,,
NBR 4N BMTU/IMCU,25904,"Rhodes, Joanna Meehan, MD",9/6/2024,BMT Autologous BEAM,_3. Third Line,9/5/2024,Inactive,,
CBMC OP INFUSION 2FL,18774,"Brown, Andrew Bennett, MD",7/24/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,7/23/2023,Inactive,,
CBMC OP INFUSION 2FL,18774,"Brown, Andrew Bennett, MD",2/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/12/2024,Active,,
SOM OUTPT INFUSION,33143,"Toomey, Kathleen C, MD",11/15/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/6/2024,Active,,
CBMC OP INFUSION 2FL,81853,"Brown, Andrew Bennett, MD",4/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/2/2024,Active,,
NBR 5N ONCOLOGY,26245,"Rhodes, Joanna Meehan, MD",7/15/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,7/15/2024,Active,,
CBMC OP INFUSION 2FL,66037,"Litvak, Anna M, MD",7/27/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,7/26/2023,Inactive,,
NBI OP INFUSION,81696,"Anderson, Patrick S, MD",6/29/2023, Bevacizumab 21 Day Cycles - Endometrial adenocarcinoma,Maintenance,6/28/2023,Active,,
CBMC OP INFUSION 2FL,41094,"Grossman, I Robert, MD",6/21/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,6/9/2024,Active,,
MMC BBR2 ONCOLOGY,21053,"Lee, Patrick C, MD",12/21/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,12/20/2023,Inactive,,
MMC OP INFUSION,131,"Eltoukhy, Hussam, MD",6/17/2024,CINJ 012307 Part 1 Odronextamab / CHOP 21 Day Cycles Research- Diffuse Large B-Cell Lymphoma,_1. First Line,6/16/2024,Active,,
MMC OP INFUSION,131,"Eltoukhy, Hussam, MD",12/11/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Maintenance,12/10/2024,Active,,
CBMC OP INFUSION 2FL,15947,"Dharmapuri, Sirish, MD",1/3/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/21/2024,Active,,
CBMC OP INFUSION 2FL,321,"Litvak, Anna M, MD",10/9/2023,Pertuzumab Trastuzumab faslodex xgeva 21 Day Cycles - Breast metastatic ,_3. Third Line,9/27/2023,Inactive,,
CBMC OP INFUSION 2FL,321,"Raptis, George, MD",10/16/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_2. Second Line,10/16/2024,Active,,
HAM OP INFUSION,14838,"Patel, Malini M, MD",6/30/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/29/2023,Inactive,,
HAM OP INFUSION,14838,"Patel, Malini M, MD",10/4/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/3/2023,Inactive,,
MMC OP VP INFUSION,90744,"Lee, Patrick C, MD",12/8/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,12/5/2023,Inactive,,
MMC OP VP INFUSION,90744,"Lee, Patrick C, MD",10/4/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/26/2024,Active,,
MMC OP VP INFUSION,90744,"Lee, Patrick C, MD",5/23/2025,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/23/2025,Inactive,Overlapping malignant neoplasm of colon (CMS/HCC),
MMC OP VP INFUSION,90744,"Lee, Patrick C, MD",5/23/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/23/2025,Active,Overlapping malignant neoplasm of colon (CMS/HCC),
MMC OP VP INFUSION,90744,"Lee, Patrick C, MD",5/2/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/2/2025,Inactive,Overlapping malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,75947,"George, Mridula A, MD",6/14/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/6/2023,Inactive,,
CINJ OP INFUSION,75947,"George, Mridula A, MD",10/18/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,10/17/2023,Inactive,,
CINJ OP INFUSION,75947,"George, Mridula A, MD",1/31/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/30/2024,Active,,
TRMC TCCC OP INFUSION,56956,"Capo, Gerardo, MD",3/13/2025,"CARBOplatin & Durvalumab & 21 Day and Gemcitabine D1,D8 Q21day cycles - Bladder",_1. First Line,3/13/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; D05.12 - Intraductal carcinoma in situ of left breast"
TRMC TCCC OP INFUSION,56956,"Capo, Gerardo, MD",3/13/2025,Durvalumab 1500 mg q21days in combo with gem/carbo for Bladder Cancer stage 3,_1. First Line,3/13/2025,Inactive,Malignant neoplasm of urinary bladder (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; D05.12 - Intraductal carcinoma in situ of left breast"
CINJ OP INFUSION,98425,"George, Mridula A, MD",5/22/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,5/20/2024,Inactive,,
CINJ OP INFUSION,98425,"George, Mridula A, MD",6/25/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,5/27/2024,Active,,
CINJ OP INFUSION,98425,"George, Mridula A, MD",12/18/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,12/17/2024,Active,,
CINJ PEDS HEMONC ,83008,"Drachtman, Richard, MD",9/6/2023,PEDS AHOD2131 ABVD All Arms,First Line,9/4/2023,Active,,
CINJ PEDS HEMONC ,83008,"Drachtman, Richard, MD",11/10/2023,PEDS ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) - Hodgkin Lymphoma,_1. First Line,11/10/2023,Inactive,,
MMC OP VP INFUSION,91349,"Lee, Patrick C, MD",4/24/2025,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,4/24/2025,Active,"Ovarian cancer, unspecified laterality (CMS/HCC)",
NBR MEDICAL SAME DAY,65553,"Golombos, David, MD",5/22/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,5/22/2025,Active,Bladder mass,
CBMC OP INFUSION 2FL,31277,"Leitner, Stuart P, MD",2/10/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/6/2025,Active,"Breast cancer metastasized to brain, unspecified laterality (CMS/HCC)
Malignant neoplasm metastatic to both lungs (CMS/HCC)",
CINJ OP INFUSION,86116,"Omene, Coral Oghenerukevwe, MD",5/12/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/12/2025,Active,"Stage IV breast cancer in female (CMS/HCC)
Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; C79.51 - Secondary malignant neoplasm of bone; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+)
CMC OP INFUSION,22696,"Pompa, Tiffany Ann, MD",10/30/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/21/2024,Active,,
MMC OP VP INFUSION,50178,"Cohen, Seth D, MD",3/29/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",First Line,3/21/2023,Inactive,,
MMC OP VP INFUSION,50178,"Cohen, Seth D, MD",10/29/2024,Pemetrexed / CARBOplatin + Amivantamab Patients >/= 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/14/2024,Active,,
CINJ OP INFUSION,22915,"Haigentz, Missak, MD",1/23/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,1/22/2023,Inactive,,
CINJ OP INFUSION,22915,"Haigentz, Missak, MD",5/3/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,5/2/2023,Inactive,,
CINJ OP INFUSION,56123,"Boland, Patrick M, MD",10/22/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,10/21/2024,Inactive,Gastroesophageal cancer (CMS/HCC),
CINJ OP INFUSION,56123,"Boland, Patrick M, MD",1/16/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/15/2025,Active,,
CINJ OP INFUSION,46306,"Ghodoussipour, Saum Bobak, MD",1/14/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Induction - Bladder Cancer,Induction,1/13/2025,Active,,
CINJ OP INFUSION,46306,"Ghodoussipour, Saum Bobak, MD",4/21/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,4/21/2025,Active,Urothelial carcinoma (CMS/HCC),
JCMC CP INFUSION,21774,"Cruz, Allan Louie E, MD",8/19/2024,"mFOLFOX6 Outpatient, bevacizumab (starting cycle 2) (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- sigmoid colon adenocarcinoma",_1. First Line,8/11/2024,Active,,
JCMC CP INFUSION,78891,"Cruz, Allan Louie E, MD",2/10/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/9/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon
NBI OP INFUSION,52306,"Cheng, Yan Ho, MD",2/20/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,1/29/2024,Inactive,,
NBI OP INFUSION,52306,"Cheng, Yan Ho, MD",7/9/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,7/1/2024,Active,,
HAM OP INFUSION,57822,"Yogarajah, Meera, MD",5/29/2025,Capecitabine 21 Day Cycles - Breast,_1. First Line,5/29/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",
HAM OP INFUSION,62585,"Yogarajah, Meera, MD",5/30/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,5/12/2024,Inactive,,
HAM OP INFUSION,62585,"Yogarajah, Meera, MD",10/3/2024,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,_1. First Line,7/28/2024,Active,,
CBMC 2W ONCOLOGY,83435,"Grossman, I Robert, MD",5/30/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,5/30/2025,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),C92.00 - Acute myeloid leukemia not having achieved remission (CMS/HCC)
MMC OP VP INFUSION,10048,"Meghal, Trishala, MD",6/11/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,6/11/2024,Active,,
NBI VALERIE FND HEMONC,98406,"Bhatla, Teena, MD",10/5/2023,PEDS ANBL1821,_3. Third Line,10/4/2023,Inactive,,
HAM OP INFUSION,21494,"Patel, Malini M, MD",9/26/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,9/26/2024,Active,Primary malignant neoplasm of bronchus of right lower lobe (CMS/HCC),
CINJ OP INFUSION,68917,"Ganesan, Shridar, MD PhD",1/17/2023,Everolimus / Exemestane 28 Day Cycles - Breast,Third Line,1/17/2023,Active,,
CBMC OP INFUSION 2FL,89622,"Leitner, Stuart P, MD",9/15/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,9/14/2023,Inactive,,
CINJ OP INFUSION,35589,"Stephenson, Ryan D, DO",8/11/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,8/11/2023,Inactive,,
CINJ OP INFUSION,48872,"Girda, Eugenia, MD",5/9/2023,"CINJ 102103 Cohort 1 PACLitaxel / CARBOplatin / Oregovomab or Placebo 21 Day Cycles Research- Ovarian, Fallopian Tube, or Peritoneal Carcinoma-002",,5/8/2023,Inactive,,
MMC OP VP INFUSION,41159,"Cohen, Seth D, MD",4/15/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/14/2024,Inactive,,
MMC OP VP INFUSION,41159,"Cohen, Seth D, MD",10/28/2024,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/27/2024,Active,,
CINJ OP INFUSION,11821,"Hochster, Howard S, MD",4/3/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,4/2/2024,Active,,
SOM OUTPT INFUSION,42714,"Yin, Faye, MD",5/17/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/9/2023,Inactive,,
SOM OUTPT INFUSION,42714,"Yin, Faye, MD",9/20/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,9/5/2023,Inactive,,
CINJ OP INFUSION,91902,"Aikins, James K, MD",3/8/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Uterine Serous Cancer,_2. Second Line,3/7/2024,Inactive,,
CINJ OP INFUSION,91902,"Aikins, James K, MD",8/22/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,8/11/2024,Active,,
CMC 4B ONCOLOGY,285,"Eltoukhy, Hussam, MD",12/25/2024,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,12/25/2024,Inactive,,
NBR 5N ONCOLOGY,96795,"Rhodes, Joanna Meehan, MD",12/15/2023,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,12/14/2023,Inactive,,
NBR 4N ONCOLOGY,96795,"Rhodes, Joanna Meehan, MD",12/28/2023,Tretinoin (ATRA) / Arsenic / 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),Induction,12/15/2023,Inactive,,
NBR CINJ OP INFUSION,96795,"Zayac, Adam, MD",2/5/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,_1. First Line,1/29/2024,Active,"Myelodysplastic syndrome, unspecified (CMS/HCC)
Pancytopenia (CMS/HCC)",
NBR BMSCH 2 PED HEMONC,61776,"Murphy, Susan, MD",1/13/2023,AALL1732 B-ALL Induction,,1/13/2023,Inactive,,
CINJ PEDS HEMONC ,61776,"Murphy, Susan, MD",2/16/2023,AALL1732 Consolidation,,2/16/2023,Inactive,,
CINJ PEDS HEMONC ,61776,"Botwinick, Marissa, DO",5/5/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,First Line,4/20/2023,Inactive,,
CINJ PEDS HEMONC ,61776,"Botwinick, Marissa, DO",7/6/2023,AALL1732 HR - B-ALL Arm A - Delayed Intensification,First Line,7/6/2023,Inactive,,
CINJ PEDS HEMONC ,61776,"Botwinick, Marissa, DO",9/21/2023,AALL1732 Interim Maintenance II (IM II) with CMTX,First Line,9/21/2023,Inactive,,
CINJ PEDS HEMONC ,61776,"Botwinick, Marissa, DO",11/27/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,11/25/2023,Inactive,,
CINJ PEDS HEMONC ,61776,"Botwinick, Marissa, DO",11/28/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,11/25/2023,Active,,
CINJ OP INFUSION,92215,"Hochster, Howard S, MD",11/20/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/20/2024,Active,,
MMC OP INFUSION,89505,"Lee, Patrick C, MD",5/1/2023,Lenalidomide (D1-D21) Maintenance 28 Day Cycles - Multiple Myeloma,,5/1/2023,Active,,
SOM OUTPT INFUSION,38883,"Yin, Faye, MD",9/26/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,8/27/2023,Inactive,,
SOM OUTPT INFUSION,38883,"Patel, Eshan, MD",4/5/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,4/3/2024,Active,,
CBMC 2W ONCOLOGY,7866,"Dharmapuri, Sirish, MD",2/5/2025,mFOLFOX6 Inpatient (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/4/2025,Inactive,Colorectal cancer (CMS/HCC),"C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes; J18.9 - Pneumonia, unspecified organism; Z51.5 - Encounter for palliative care; K56.690 - Other partial intestinal obstruction; C79.51 - Secondary malignant neoplasm of bone; K59.39 - Other megacolon; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; G99.2 - Myelopathy in diseases classified elsewhere; C19 - Malignant neoplasm of rectosigmoid junction; Z95.828 - Presence of other vascular implants and grafts; J98.11 - Atelectasis; K91.89 - Other postprocedural complications and disorders of digestive system; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; D50.9 - Iron deficiency anemia, unspecified; E83.51 - Hypocalcemia; D12.3 - Benign neoplasm of transverse colon; D12.5 - Benign neoplasm of sigmoid colon; D75.839 - Thrombocytosis, unspecified; M48.04 - Spinal stenosis, thoracic region; I95.9 - Hypotension, unspecified; K59.09 - Other constipation; D63.0 - Anemia in neoplastic disease; E86.0 - Dehydration; E87.6 - Hypokalemia; F41.9 - Anxiety disorder, unspecified; I25.2 - Old myocardial infarction; K21.9 - Gastro-esophageal reflux disease without esophagitis; K64.9 - Unspecified hemorrhoids; M62.84 - Sarcopenia; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; Z59.71 - Insufficient health insurance coverage; Z86.0100 - Personal history of colon polyps, unspecified..."
CINJ OP INFUSION,37305,"Goel, Sanjay, MD",3/13/2023,CINJ 052101 (TT420X1103) ARM B IB-3 TT-00420 (tinengotinib) 12 mg / Nab-PACLitaxel 28 Day Cycles Research- Solid Tumors,Third Line,2/12/2023,Inactive,,
CINJ OP INFUSION,37305,"Goel, Sanjay, MD",12/4/2023,CINJ 052008 / R7075-ONC-2009 Dose Level 10A REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,_6. Sixth Line,11/13/2023,Inactive,,
CINJ OP INFUSION,37305,"Goel, Sanjay, MD",2/19/2024,CINJ 052302 (DF9001) Monotherapy - Solid Tumor,_9. Ninth Line,2/19/2024,Inactive,,
CINJ OP INFUSION,37305,"Toppmeyer, Deborah L, MD",8/5/2024,CINJ 042402 Parts 1 and 2 RLY-2608 Single Agent 28 Day Cycles Research- Breast Cancer,_5. Fifth Line,8/5/2024,Active,,
CINJ OP INFUSION,79582,"Toppmeyer, Deborah L, MD",2/24/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,2/17/2025,Active,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),
NBR CINJ OP INFUSION,93946,"Doraiswamy, Anupama, MD",2/23/2023,PONATinib 30 Day Cycles - Chronic Myeloid Leukemia,Second Line,2/23/2023,Active,,
NBR CINJ OP INFUSION,87847,"Braunschweig, Ira, MD",10/11/2023,Isatuximab-irfc/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,10/10/2023,Inactive,,
NBR CINJ OP INFUSION,87847,"Tiger, Yun Kyoung, MD",10/4/2024,Talquetamab 28 Day Cycles,_4. Fourth Line,10/2/2024,Inactive,,
NBR CINJ OP INFUSION,87847,"Tiger, Yun Kyoung, MD",11/7/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_4. Fourth Line,11/6/2024,Active,,
SOM OUTPT INFUSION,9056,"George, Roshini, DO",4/14/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,4/7/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CMC OP INFUSION,7282,"Taff, Jessica, MD",3/27/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/20/2024,Inactive,,
CMC OP INFUSION,7282,"Taff, Jessica, MD",10/21/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/16/2024,Inactive,,
CINJ OP INFUSION,13485,"Toppmeyer, Deborah L, MD",7/20/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,7/17/2023,Inactive,,
CINJ OP INFUSION,12475,"Weiss, Sarah, MD",4/29/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,4/26/2024,Active,,
MMC OP VP INFUSION,26037,"Cohen, Seth D, MD",6/5/2023,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,First Line,6/4/2023,Inactive,,
MSC OP INFUSION,50044,"Cohen, Seth D, MD",9/5/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,First Line,8/8/2023,Inactive,,
MSC OP INFUSION,50044,"Cohen, Seth D, MD",11/28/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,_1. First Line,11/13/2023,Active,,
CINJ OP INFUSION,27437,"Haigentz, Missak, MD",12/18/2023,Pembrolizumab 42 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/17/2023,Active,,
CINJ OP INFUSION,51789,"Patel, Eshan, MD",2/24/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,2/16/2023,Inactive,,
MMC OP VP INFUSION,73662,"Talwar, Sumit, MD",4/18/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,4/17/2023,Inactive,,
NBR 5N ONCOLOGY,42339,"Matasar, Matthew J, MD",12/22/2023,R-BAC-500 Bendamustine / Cytarabine /  RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,12/22/2023,Inactive,,
NBR CINJ OP INFUSION,42339,"Tiger, Yun Kyoung, MD",1/19/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_2. Second Line,1/9/2024,Inactive,,
CINJ OP INFUSION,40081,"Boland, Patrick M, MD",7/21/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/14/2023,Inactive,,
CINJ OP INFUSION,94495,"Weiss, Sarah, MD",3/20/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,3/18/2024,Active,,
CBMC OP INFUSION 2FL,26631,"Dharmapuri, Sirish, MD",2/24/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,2/16/2025,Active,Anal cancer (CMS/HCC),
SOM OUTPT INFUSION,97389,"Yin, Faye, MD",2/5/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/4/2024,Inactive,,
MMC OP INFUSION,90475,"Samuel, David, MD",1/14/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/13/2025,Active,,
CBMC OP INFUSION 2FL,27673,"Dharmapuri, Sirish, MD",4/2/2025,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 830 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",Adjuvant,4/2/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; D50.0 - Iron deficiency anemia secondary to blood loss (chronic)"
CINJ OP INFUSION,2816,"Mayer, Tina M, MD",2/9/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,2/9/2024,Inactive,,
CINJ OP INFUSION,2816,"Mayer, Tina M, MD",7/23/2024,Enzalutamide 28 Day Cycles - Prostate,_4. Fourth Line,7/23/2024,Active,,
MMC OP VP INFUSION,11570,"Cohen, Seth D, MD",4/16/2025,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/16/2025,Inactive,Malignant neoplasm of overlapping sites of lung (CMS/HCC),
MMC OP VP INFUSION,11570,"Cohen, Seth D, MD",4/16/2025,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,4/16/2025,Active,Malignant neoplasm of overlapping sites of lung (CMS/HCC),
CINJ OP INFUSION,48235,"Saraiya, Biren P, MD",1/6/2025,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Induction,1/5/2025,Inactive,Malignant neoplasm of urinary bladder (CMS/HCC),
CINJ OP INFUSION,48235,"Saraiya, Biren P, MD",1/13/2025,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,Consolidation,1/5/2025,Active,,
MMC OP VP INFUSION,44529,"Lee, Patrick C, MD",4/22/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/22/2025,Active,"Malignant neoplasm of stomach (CMS/HCC)
Hypothyroidism, unspecified type
Chemotherapy-induced fatigue",
NBR CINJ OP INFUSION,41120,"Eltoukhy, Hussam, MD",6/30/2023,PEDS AHOD2131 ABVD All Arms,First Line,6/29/2023,Inactive,,
NBR CINJ OP INFUSION,41120,"Eltoukhy, Hussam, MD",6/30/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,First Line,6/29/2023,Inactive,,
MMC OP VP INFUSION,41120,"Eltoukhy, Hussam, MD",6/21/2024,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,6/20/2024,Inactive,,
NBR CINJ OP INFUSION,41120,"Evens, Andrew M, DO",10/25/2024,BMT Autologous BEAM,_2. Second Line,10/24/2024,Inactive,,
CBMC OP INFUSION 2FL,74548,"Grossman, I Robert, MD",5/28/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,5/27/2024,Active,,
NBI OP INFUSION,25659,"Shah, Maya M, MD",3/8/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,3/7/2023,Active,,
CINJ OP INFUSION,7872,"Stephenson, Ryan D, DO",4/7/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,First Line,4/7/2023,Active,,
MMC OP INFUSION,53446,"Lee, Patrick C, MD",5/2/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,5/1/2023,Inactive,,
MMC OP VP INFUSION,97253,"Meghal, Trishala, MD",8/20/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,8/13/2024,Inactive,,
MMC OP VP INFUSION,97253,"Meghal, Trishala, MD",11/25/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,11/18/2024,Active,,
MMC OP VP INFUSION,97253,"Meghal, Trishala, MD",1/27/2025,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,1/23/2025,Active,,
CINJ OP INFUSION,16525,"Patel, Eshan, MD",8/12/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,8/11/2024,Inactive,,
SOM OUTPT INFUSION,16525,"Patel, Eshan, MD",9/30/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,9/28/2024,Active,,
CINJ OP INFUSION,16525,"Muralikrishnan, Sivraj, MD",2/4/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/3/2025,Active,Malignant neoplasm without specification of site (CMS/HCC),
NBR BMSCH 2 PED HEMONC,78260,"Moerdler, Scott, MD",4/4/2023,ARST2031 Regimen A (VAC + VINO-C Maintenance),,4/3/2023,Inactive,,
CBMC OP INFUSION 1FL,74243,"Meelheim, Brooke A, DO",3/20/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,3/20/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
MMC OP INFUSION,72797,"Meghal, Trishala, MD",1/10/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/20/2024,Inactive,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),
MMC OP VP INFUSION,72797,"Meghal, Trishala, MD",1/10/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/9/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,72797,"Meghal, Trishala, MD",1/31/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/30/2025,Inactive,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),
NBI OP INFUSION,63453,"Anderson, Patrick S, MD",10/5/2023,DOXOrubicin Liposomal 28 Day Cycles - Endometrial Carcinoma,_2. Second Line,10/4/2023,Inactive,,
NBI OP INFUSION,63453,"Anderson, Patrick S, MD",3/28/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,3/22/2024,Active,,
MMC OP VP INFUSION,58646,"Lee, Patrick C, MD",3/25/2025,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/25/2025,Active,Malignant neoplasm of colon (CMS/HCC),
NBI OP INFUSION,66183,"Anderson, Patrick S, MD",11/14/2023,Pembrolizumab 21 Day Cycles - Cervical,_3. Third Line,11/13/2023,Inactive,,
NBI OP INFUSION,66183,"Anderson, Patrick S, MD",6/11/2024,Nivolumab 480 mg 28 Day Cycles- Recurrent Cervical cancer,_4. Fourth Line,3/18/2024,Active,,
CINJ OP INFUSION,64496,"George, Mridula A, MD",11/15/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,11/12/2024,Active,"Carcinosarcoma of body of uterus (CMS/HCC)
Fallopian tube cancer, carcinoma, left (CMS/HCC)",
CINJ OP INFUSION,64496,"George, Mridula A, MD",3/19/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,3/19/2025,Active,Carcinoma of breast metastatic to bone (CMS/HCC),C50.811 - Malignant neoplasm of overlapping sites of right female breast; Z17.0 - Estrogen receptor positive status (ER+); C79.51 - Secondary malignant neoplasm of bone; G89.3 - Neoplasm related pain (acute) (chronic)
CBMC OP INFUSION 2FL,55584,"Wagmiller, Jennifer Ann, MD",6/13/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,6/3/2024,Active,,
NBR CINJ OP INFUSION,21462,"Braunschweig, Ira, MD",6/28/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,6/27/2023,Active,,
HAM OP INFUSION,55445,"Yogarajah, Meera, MD",10/16/2023,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,10/13/2023,Inactive,,
JCMC CP INFUSION,54126,"Sekhri, Arunabh, MD",11/15/2023,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/14/2023,Inactive,,
JCMC CP INFUSION,54126,"Sekhri, Arunabh, MD",12/7/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/14/2023,Inactive,,
JCMC CP INFUSION,81910,"Cruz, Allan Louie E, MD",2/13/2024,PEMEtrexed/CARBOplatin (AUC 5)/ Amivantamab 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,2/12/2024,Inactive,,
JCMC CP INFUSION,81910,"Cruz, Allan Louie E, MD",6/11/2024,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,6/3/2024,Inactive,,
CBMC OP INFUSION 1FL,424,"Meelheim, Brooke A, DO",2/12/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,2/10/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),
CBMC OP INFUSION 2FL,51071,"Dharmapuri, Sirish, MD",11/13/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/12/2024,Active,,
JCMC CP INFUSION,60794,"Sekhri, Arunabh, MD",4/3/2023,CARBOplatin / Etoposide/Durvalumab 21 Day Cycles - High Grade Neuroendocrine,First Line,4/2/2023,Inactive,,
CINJ OP INFUSION,94092,"Berim, Lyudmyla, MD",2/17/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/6/2025,Active,Malignant neoplasm of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); G89.29 - Other chronic pain"
HAM OP INFUSION,49876,"Patel, Malini M, MD",8/31/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,8/30/2023,Inactive,,
HAM OP INFUSION,49876,"Patel, Malini M, MD",11/29/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,42659,"Rhodes, Joanna Meehan, MD",4/3/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,4/3/2025,Active,Follicular lymphoma (CMS/HCC),"C82.90 - Follicular lymphoma, unspecified, unspecified site; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
SOM OUTPT INFUSION,57650,"Toomey, Kathleen C, MD",5/9/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/30/2024,Inactive,,
SOM OUTPT INFUSION,57650,"Toomey, Kathleen C, MD",8/15/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,7/31/2024,Inactive,,
SOM OUTPT INFUSION,57650,"Toomey, Kathleen C, MD",10/17/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,10/16/2024,Active,Acute lymphoid leukemia in remission (CMS/HCC),
CINJ OP INFUSION,11405,"Boland, Patrick M, MD",4/18/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,,4/18/2023,Inactive,,
NBR CINJ OP INFUSION,52111,"Tiger, Yun Kyoung, MD",3/13/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,3/5/2024,Inactive,,
CINJ OP INFUSION,89509,"Gulhati, Prateek, MD PhD",8/31/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_5. Fifth Line,8/22/2023,Inactive,,
CINJ OP INFUSION,89509,"Gulhati, Prateek, MD PhD",1/18/2024,"Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,1/17/2024,Inactive,,
CINJ OP INFUSION,89509,"Gulhati, Prateek, MD PhD",11/7/2024,"Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,11/6/2024,Active,,
CINJ OP INFUSION,89509,"Goel, Sanjay, MD",3/17/2025,CINJ 052008 / R7075-ONC-2009 Dose Level 11 Schedule C Escalation Q3W REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_4. Fourth Line,2/24/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
NBR CINJ OP INFUSION,91029,"Doraiswamy, Anupama, MD",1/12/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia ,,1/12/2023,Inactive,,
NBR 4N BMTU/IMCU,91029,"Schaar, Dale, MD PhD",3/2/2023,BMT Allogeneic Flu (D-7) / TBI + Post Cy - Myeloablative,,3/2/2023,Inactive,,
TRMC TCCC OP INFUSION,36582,"Capo, Gerardo, MD",11/18/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,11/14/2024,Active,,
CINJ OP INFUSION,60796,"Stephenson, Ryan D, DO",2/20/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,2/19/2023,Inactive,,
CBMC OP INFUSION 2FL,49516,"Leitner, Stuart P, MD",9/30/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Neoadjuvant,9/29/2024,Active,,
HAM OP INFUSION,5246,"Patel, Malini M, MD",7/11/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,7/10/2023,Inactive,,
HAM OP INFUSION,46202,"Yogarajah, Meera, MD",1/31/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin)+ Nivolumab  14 Day Cycles- Gastrointestinal CancersPDL-1 >5,First Line,1/27/2023,Inactive,,
HAM OP INFUSION,46202,"Yogarajah, Meera, MD",9/7/2023,"Irinotecan D1, D8 21 Day Cycles- Gastrointestinal Cancers",Second Line,9/6/2023,Inactive,,
MSC OP INFUSION,46426,"Taff, Jessica, MD",5/8/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/7/2023,Inactive,,
NBR CINJ OP INFUSION,97478,"Patel, Vimal D, MD",1/9/2023,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,Maintenance,1/9/2023,Active,,
HAM OP INFUSION,40136,"Patel, Malini M, MD",12/2/2024,DOCEtaxel 75 mg/m2/ CISplatin 75 mg/m2/ Fluorouracil Continuous Infusion (5 Days) 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/1/2024,Active,,
NBR 5N ONCOLOGY,90864,"Mayer, Tina M, MD",3/13/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_2. Second Line,3/13/2025,Active,Cancer of alveolus of mandible (CMS/HCC),"Z43.0 - Encounter for attention to tracheostomy; E43 - Unspecified severe protein-calorie malnutrition; C41.1 - Malignant neoplasm of mandible; C33 - Malignant neoplasm of trachea; D68.9 - Coagulation defect, unspecified; D62 - Acute posthemorrhagic anemia; E83.39 - Other disorders of phosphorus metabolism; D63.8 - Anemia in other chronic diseases classified elsewhere; Z68.32 - Body mass index (BMI) 32.0-32.9, adult; E87.1 - Hypo-osmolality and hyponatremia; E86.1 - Hypovolemia; R13.10 - Dysphagia, unspecified; D72.829 - Elevated white blood cell count, unspecified; R00.1 - Bradycardia, unspecified; F12.90 - Cannabis use, unspecified, uncomplicated; F41.9 - Anxiety disorder, unspecified; R73.9 - Hyperglycemia, unspecified; E83.42 - Hypomagnesemia; E83.52 - Hypercalcemia; Z53.20 - Procedure and treatment not carried out because of patient's decision for unspecified reasons; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; Z79.899 - Other long term (current) drug therapy; Z79.891 - Long term (current) use of opiate analgesic; Z90.49 - Acquired absence of other specified parts of digestive tract; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z87.891 - Personal history of nicotine dependence; Z90.89 - Acquired absence of other organs; Z98.890 - Other specified postprocedural states; Z80.3 - Family history of malignant neoplasm of breast; Z92.21 - Personal history of antineoplastic chemotherapy"
HAM OP INFUSION,90864,"Patel, Malini M, MD",3/4/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_2. Second Line,3/3/2025,Inactive,Cancer of alveolus of mandible (CMS/HCC),C03.1 - Cancer of alveolus of mandible (CMS/HCC); Z01.818 - Encounter for other preprocedural examination
NBI OP INFUSION,44228,"Anderson, Patrick S, MD",11/3/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/2/2023,Active,,
NBI OP INFUSION,59339,"Anderson, Patrick S, MD",3/21/2025,Bevacizumab 21 Day Cycles -Progressive Endometrial cancer,_2. Second Line,3/20/2025,Active,"Malignant neoplasm of endometrium (CMS/HCC)
Endometrial cancer determined by uterine biopsy (CMS/HCC)",
NBI OP INFUSION,59339,"Anderson, Patrick S, MD",3/20/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/20/2025,Inactive,"Malignant neoplasm of endometrium (CMS/HCC)
Endometrial cancer determined by uterine biopsy (CMS/HCC)",
TRMC TCCC OP INFUSION,78007,"Capo, Gerardo, MD",1/3/2025,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,1/2/2025,Active,,
NBI OP INFUSION,88264,"Shah, Maya M, MD",1/8/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,1/7/2025,Active,,
NBI OP INFUSION,54151,"Shah, Maya M, MD",5/21/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/21/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CMC 4B ONCOLOGY,73258,"Patel, Neel H, MD",4/10/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/10/2024,Inactive,,
HAM OP INFUSION,20781,"Yogarajah, Meera, MD",3/7/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,2/24/2025,Inactive,Metastasis from pancreatic cancer (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K86.89 - Other specified diseases of pancreas; R59.0 - Localized enlarged lymph nodes; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z91.030 - Bee allergy status; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,84745,"Cohen, Seth D, MD",1/18/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,1/10/2023,Inactive,,
MMC OP VP INFUSION,84745,"Cohen, Seth D, MD",8/18/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Second Line,8/17/2023,Inactive,,
CBMC OP INFUSION 2FL,76591,"Wagmiller, Jennifer Ann, MD",10/17/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,10/16/2023,Inactive,,
CBMC OP INFUSION 2FL,76591,"Wagmiller, Jennifer Ann, MD",4/19/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/18/2024,Inactive,,
CBMC OP INFUSION 2FL,76591,"Wagmiller, Jennifer Ann, MD",5/31/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/30/2024,Active,,
CINJ OP INFUSION,30364,"Saraiya, Biren P, MD",6/21/2023,DOCEtaxel / PredniSONE 14 Day Cycles - Prostate,Third Line,6/20/2023,Inactive,,
MSC OP INFUSION,84478,"Cohen, Seth D, MD",6/11/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,6/7/2024,Active,,
CMC OP INFUSION,9876,"Cohen, Seth D, MD",5/29/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,5/28/2025,Active,"Malignant melanoma of scalp and neck (CMS/HCC)
Hypothyroidism due to medication",
MMC OP VP INFUSION,68167,"Lee, Patrick C, MD",9/27/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,9/27/2024,Inactive,,
MMC OP VP INFUSION,68167,"Lee, Patrick C, MD",1/8/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/1/2025,Active,,
MSC OP INFUSION,93917,"Meghal, Trishala, MD",10/19/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/18/2023,Inactive,,
MMC OP VP INFUSION,93917,"Meghal, Trishala, MD",1/29/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_1. First Line,1/28/2024,Inactive,,
MMC OP VP INFUSION,93917,"Meghal, Trishala, MD",2/2/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - BREAST CANCER,_1. First Line,1/28/2024,Inactive,,
MMC OP INFUSION,14573,"Lee, Patrick C, MD",4/1/2025,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,3/25/2025,Active,Prostate cancer metastatic to bone (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; J43.9 - Emphysema, unspecified; J90 - Pleural effusion, not elsewhere classified; J98.11 - Atelectasis; K63.89 - Other specified diseases of intestine; R91.8 - Other nonspecific abnormal finding of lung field; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
NBI OP INFUSION,6962,"Anderson, Patrick S, MD",3/13/2025,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,3/13/2025,Inactive,Metastasis from cervical cancer (CMS/HCC),
NBI OP INFUSION,6962,"Anderson, Patrick S, MD",3/13/2025,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_1. First Line,3/13/2025,Active,Metastasis from cervical cancer (CMS/HCC),
CINJ OP INFUSION,12549,"Berim, Lyudmyla, MD",7/1/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Stomach Cancer,_1. First Line,6/27/2024,Inactive,Malignant neoplasm of stomach (CMS/HCC),
CINJ OP INFUSION,12549,"Berim, Lyudmyla, MD",11/4/2024,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Stomach Cancer,_2. Second Line,11/1/2024,Inactive,Malignant neoplasm of stomach (CMS/HCC),
CINJ OP INFUSION,12549,"Berim, Lyudmyla, MD",1/10/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,1/6/2025,Inactive,Malignant neoplasm of stomach (CMS/HCC),
CINJ OP INFUSION,93920,"Weiss, Sarah, MD",6/14/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,6/11/2024,Inactive,,
CINJ OP INFUSION,93920,"Weiss, Sarah, MD",7/29/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,7/12/2024,Inactive,,
SOM OUTPT INFUSION,55863,"Patel, Eshan, MD",6/26/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,6/17/2024,Inactive,,
SOM OUTPT INFUSION,55863,"Patel, Eshan, MD",12/18/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,12/10/2024,Active,,
NBR CINJ OP INFUSION,13519,"Rhodes, Joanna Meehan, MD",1/8/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,1/7/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
NBR CINJ OP INFUSION,13519,"Rhodes, Joanna Meehan, MD",1/29/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,1/28/2025,Active,,
CMC OP INFUSION,37466,"Meghal, Trishala, MD",4/25/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,4/24/2023,Inactive,,
CINJ OP INFUSION,70245,"Weiss, Sarah, MD",5/22/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,5/22/2025,Active,Melanoma metastatic to lymph node (CMS/HCC),C43.72 - Malignant melanoma of left lower extremity including hip (CMS/HCC)
MMC OP VP INFUSION,18131,"Cohen, Seth D, MD",1/15/2025,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/14/2025,Active,,
CBMC OP INFUSION 2FL,82558,"Wagmiller, Jennifer Ann, MD",1/2/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,1/2/2024,Inactive,,
CBMC OP INFUSION 2FL,82558,"Wagmiller, Jennifer Ann, MD",4/1/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/1/2024,Active,,
CBMC OP INFUSION 2FL,19316,"Wagmiller, Jennifer Ann, MD",3/11/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,3/11/2025,Active,Ovarian cancer (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C56.3 - Malignant neoplasm of bilateral ovaries; D53.9 - Nutritional anemia, unspecified; Z11.59 - Encounter for screening for other viral diseases; C56.9 - Malignant neoplasm of unspecified ovary; Z79.899 - Other long term (current) drug therapy"
MMC OP INFUSION,85199,"Cohen, Seth D, MD",3/29/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,3/28/2023,Inactive,,
CMC OP INFUSION,56202,"Pompa, Tiffany Ann, MD",9/24/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,9/23/2024,Active,,
HAM OP INFUSION,41395,"Patel, Malini M, MD",1/22/2025,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/21/2025,Inactive,Small cell carcinoma of overlapping sites of lung (CMS/HCC),
CINJ OP INFUSION,11643,"Berim, Lyudmyla, MD",8/9/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Pancreatic Cancers,Neoadjuvant,7/29/2024,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),
CINJ OP INFUSION,11643,"Berim, Lyudmyla, MD",9/9/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Cancers",Neoadjuvant,9/2/2024,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),
CINJ OP INFUSION,11643,"Berim, Lyudmyla, MD",1/13/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Pancreatic Cancers,_1. First Line,1/12/2025,Active,,
CMC OP INFUSION,94275,"Talwar, Sumit, MD",1/16/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/14/2025,Active,,
JCMC CP INFUSION,98610,"Sekhri, Arunabh, MD",1/10/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,11/3/2024,Active,,
JCMC CP INFUSION,98610,"Sekhri, Arunabh, MD",4/25/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/25/2025,Active,Breast cancer of upper-inner quadrant of right female breast (CMS/HCC),"C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; E66.812 - Obesity, class 2; R45.89 - Other symptoms and signs involving emotional state; F33.9 - Major depressive disorder, recurrent, unspecified; Z68.39 - Body mass index (BMI) 39.0-39.9, adult"
MSC OP INFUSION,25609,"Taff, Jessica, MD",6/4/2024,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,6/4/2024,Inactive,,
JCMC CP INFUSION,43313,"Cruz, Allan Louie E, MD",2/12/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,2/11/2024,Inactive,,
NBR CINJ OP INFUSION,43313,"Palmisiano, Neil David, MD",8/27/2024,HAM-Ven (High-Dose Cytarabine / MitoXANTRONE / Venetoclax) 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,8/27/2024,Inactive,,
NBR 5N ONCOLOGY,43313,"Rhodes, Joanna Meehan, MD",8/27/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),Neoadjuvant,8/27/2024,Inactive,,
MMC OP VP INFUSION,15022,"Cohen, Seth D, MD",3/10/2025,CAP (Cyclophosphamide / DOXOrubicin / CISplatin) 21 Day Cycles - Adrenal Gland,_1. First Line,3/10/2025,Active,Thymoma,
HAM OP INFUSION,63482,"Patel, Malini M, MD",1/11/2023,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,First Line,1/10/2023,Inactive,,
HAM OP INFUSION,63482,"Patel, Malini M, MD",5/31/2023,Enfortumab Vedotin and Pembrolizumab 21 Day Cycles - Bladder,Second Line,5/30/2023,Inactive,,
CINJ OP INFUSION,38637,"Mayer, Tina M, MD",10/7/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/4/2024,Active,,
CINJ OP INFUSION,40353,"Stephenson, Ryan D, DO",6/5/2023,Pembrolizumab 21 Day Cycles - Melanoma,Third Line,6/5/2023,Active,,
CINJ OP INFUSION,97849,"Ghodoussipour, Saum Bobak, MD",4/11/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,4/10/2024,Inactive,,
CINJ OP INFUSION,97849,"Ghodoussipour, Saum Bobak, MD",10/16/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,10/16/2024,Active,,
CBMC OP INFUSION 2FL,73620,"Grossman, I Robert, MD",9/15/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,9/14/2023,Active,,
CBMC OP INFUSION 2FL,77560,"Scoppetuolo, Michael, MD",11/26/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,11/12/2024,Active,,
MMC OP VP INFUSION,59826,"Cohen, Seth D, MD",3/27/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,3/27/2024,Inactive,,
CMC OP INFUSION,23016,"Talwar, Sumit, MD",4/19/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,4/18/2023,Inactive,,
CMC OP INFUSION,23016,"Talwar, Sumit, MD",2/2/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,1/2/2024,Active,,
CMC OP INFUSION,23016,"Talwar, Sumit, MD",4/8/2025,Bortezomib/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,4/8/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CINJ OP INFUSION,4620,"Dasgeb, Bahar, MD",5/21/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,5/20/2024,Inactive,,
CINJ OP INFUSION,4620,"Dasgeb, Bahar, MD",9/9/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,9/2/2024,Active,,
NBI OP INFUSION,47486,"Shah, Shailja S, MD",10/8/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/7/2024,Active,,
MMC OP VP INFUSION,65109,"Lee, Patrick C, MD",4/5/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",,4/4/2023,Inactive,,
TRMC TCCC OP INFUSION,4112,"Capo, Gerardo, MD",2/4/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/3/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
CMC OP INFUSION,3667,"Taff, Jessica, MD",5/5/2025,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,5/5/2025,Active,Primary adenocarcinoma of upper lobe of right lung (CMS/HCC),
NBR 5N ONCOLOGY,9225,"Palmisiano, Neil David, MD",2/14/2024,CINJ 022305 Induction Ziftomenib / Cytarabine / Daunorubicin (7 + 3) 28 Day Cycle Research- Acute Myeloid Leukemia,Induction,2/13/2024,Inactive,,
CINJ OP INFUSION,92543,"Hochster, Howard S, MD",3/4/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,3/4/2024,Active,,
CINJ OP INFUSION,92543,"Hochster, Howard S, MD",5/1/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/1/2025,Active,Malignant neoplasm of cecum (CMS/HCC),"C18.0 - Malignant neoplasm of cecum; R97.8 - Other abnormal tumor markers; Z45.2 - Encounter for adjustment and management of vascular access device; C44.91 - Basal cell carcinoma of skin, unspecified; B00.0 - Eczema herpeticum; B02.9 - Zoster without complications; Z79.899 - Other long term (current) drug therapy; Z85.820 - Personal history of malignant melanoma of skin; C43.9 - Malignant melanoma of skin, unspecified"
CINJ OP INFUSION,3372,"Haigentz, Missak, MD",1/4/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,1/4/2023,Inactive,,
CMC OP INFUSION,72743,"Taff, Jessica, MD",5/22/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,5/21/2024,Inactive,,
CBMC OP INFUSION 2FL,68597,"Dharmapuri, Sirish, MD",1/13/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,12/29/2024,Active,Uterine sarcoma (CMS/HCC),
MMC OP VP INFUSION,89320,"Lee, Patrick C, MD",10/5/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,10/3/2023,Inactive,,
MMC OP VP INFUSION,89320,"Lee, Patrick C, MD",2/8/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,2/7/2024,Inactive,,
MMC OP VP INFUSION,89320,"Lee, Patrick C, MD",6/10/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation on dates of XRT,Induction,6/10/2024,Inactive,,
MMC BBR2 ONCOLOGY,89320,"Lee, Patrick C, MD",7/8/2024,Fluorouracil Continuous Infusion with Concurrent Radiation pancreatic Carcinoma,Neoadjuvant,7/7/2024,Inactive,,
MMC OP VP INFUSION,89320,"Lee, Patrick C, MD",11/11/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/6/2024,Active,,
CINJ OP INFUSION,97299,"Berim, Lyudmyla, MD",12/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/8/2024,Inactive,,
CINJ OP INFUSION,97299,"Berim, Lyudmyla, MD",5/23/2025,CINJ 072207 (NRG-GI008) Cohort B ARM 4 MFOLFIRINOX (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Ressearch- Colorectal Cancer,Adjuvant,5/23/2025,Active,Malignant neoplasm of rectosigmoid junction (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon (CMS/HCC)
HAM OP INFUSION,81374,"Patel, Malini M, MD",11/29/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,10402,"Wagmiller, Jennifer Ann, MD",1/29/2025,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,_1. First Line,1/20/2025,Active,"Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC)
End stage renal disease (CMS/HCC)",
CBMC OP INFUSION 2FL,57374,"Grossman, I Robert, MD",6/4/2024,RiTUXimab Initial and subsequent Infusion (Outpatient),_1. First Line,5/29/2024,Inactive,,
CBMC OP INFUSION 2FL,41526,"Grossman, I Robert, MD",3/6/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,3/3/2025,Active,Autoimmune hemolytic anemia (CMS/HCC),
MSC OP INFUSION,56221,"Packiam, Vignesh, MD",5/1/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,4/28/2024,Inactive,,
MSC OP INFUSION,56221,"Packiam, Vignesh, MD",9/4/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,9/3/2024,Active,,
NBR 5N MED-SURG OVRF,5682,"Alexander, Henry Richard, MD",3/27/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,First Line,3/27/2023,Active,,
CINJ OP INFUSION,27756,"Leiser, Aliza, MD",8/12/2024,Methotrexate 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_1. First Line,8/11/2024,Active,,
CINJ OP INFUSION,29366,"Omene, Coral Oghenerukevwe, MD",3/31/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/31/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z90.12 - Acquired absence of left breast and nipple; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,95913,"Haigentz, Missak, MD",2/6/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,First Line,2/2/2023,Inactive,,
NBR CINJ OP INFUSION,81909,"Shah, Mansi R, MD",10/30/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,10/15/2024,Inactive,,
TRMC TCCC OP INFUSION,55138,"Salerno, Vincent E, MD",12/18/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/17/2024,Active,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",1/9/2023,Teclistamab Weekly 28 Day Cycles- Multiple Myeloma,,1/9/2023,Inactive,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",10/6/2023,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,,10/6/2023,Inactive,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",10/16/2023,"Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles- Multiple Myeloma",10. Tenth Line,10/16/2023,Inactive,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",3/1/2024,"Bendamustine 70 mg/m2 D1, D8 / Carfilzomib 20/56 mg/m2 plus Dexamethasone 28 Day Cycles - Multiple Myeloma",10. Tenth Line,2/29/2024,Inactive,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",3/1/2024,Selinexor/ Carfilzomib 56 mg/m2 Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,10. Tenth Line,3/1/2024,Inactive,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",3/5/2024,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,10. Tenth Line,3/4/2024,Inactive,,
NBR CINJ OP INFUSION,57089,"Shah, Mansi R, MD",4/22/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,10. Tenth Line,4/14/2024,Inactive,,
NBI OP INFUSION,92275,"Shah, Maya M, MD",10/3/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,_1. First Line,10/3/2023,Inactive,,
CINJ OP INFUSION,43168,"Groisberg, Roman, MD",1/9/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,,12/29/2022,Inactive,,
JCMC CP INFUSION,43168,"Cruz, Allan Louie E, MD",6/3/2024,DOXOrubicin 21 Day Cycles - Dedifferentiated Liposarcoma,_1. First Line,5/23/2024,Inactive,,
CINJ OP INFUSION,2681,"Stephenson, Ruth D, DO",9/1/2023,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Adjuvant,8/31/2023,Inactive,,
SOM OUTPT INFUSION,75661,"Patel, Eshan, MD",10/29/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/20/2024,Active,,
SOM OUTPT INFUSION,75661,"Patel, Eshan, MD",11/26/2024,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,Non-Oncology Research,11/26/2024,Inactive,,
SOM OUTPT INFUSION,75661,"Patel, Eshan, MD",1/28/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/27/2025,Active,,
NBR 5N ONCOLOGY,89573,"Palmisiano, Neil David, MD",12/22/2023,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,12/22/2023,Inactive,,
NBR CINJ OP INFUSION,89573,"Zayac, Adam, MD",2/23/2024,CINJ 022303 Phase 1 DSP-5336 - Leukemia,_1. First Line,2/23/2024,Active,,
JCMC CP INFUSION,80641,"Cruz, Allan Louie E, MD",8/14/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,8/11/2023,Inactive,,
JCMC CP INFUSION,80641,"Cruz, Allan Louie E, MD",10/22/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) - Cetuximab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/18/2024,Active,,
NBR 5N ONCOLOGY,58385,"Rhodes, Joanna Meehan, MD",9/23/2024,Brentuximab Vedotin / Nivolumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,9/22/2024,Inactive,,
NBR CINJ OP INFUSION,58385,"Rhodes, Joanna Meehan, MD",1/15/2025,BMT Autologous BEAM,_3. Third Line,1/15/2025,Active,,
CBMC OP INFUSION 2FL,15212,"Wagmiller, Jennifer Ann, MD",12/18/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,12/17/2024,Active,,
NBR CINJ OP INFUSION,44887,"Rhodes, Joanna Meehan, MD",4/2/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,3/28/2024,Active,Malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,97636,"Stephenson, Ryan D, DO",3/24/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Second Line,3/10/2023,Inactive,,
CINJ OP INFUSION,54540,"Groisberg, Roman, MD",2/3/2025,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,2/3/2025,Active,"Malignant peripheral nerve sheath tumor of upper extremity, right (CMS/HCC)","C47.11 - Malignant neoplasm of peripheral nerves of right upper limb, including shoulder; C47.9 - Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified"
CINJ OP INFUSION,49314,"Stephenson, Ryan D, DO",12/27/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,12/26/2023,Inactive,,
CINJ OP INFUSION,13390,"Groisberg, Roman, MD",3/22/2024,Gemcitabine 21 Day Cycles - Sarcoma,_1. First Line,3/21/2024,Inactive,,
CBMC OP INFUSION 2FL,9777,"Dharmapuri, Sirish, MD",11/12/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Consolidation,11/3/2024,Active,,
NBI OP INFUSION,25682,"Shah, Shailja S, MD",1/21/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/20/2025,Inactive,Malignant neoplasm of esophagus (CMS/HCC),
TRMC TCCC OP INFUSION,44768,"Salerno, Vincent E, MD",8/1/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,7/31/2024,Inactive,,
NBR CINJ OP INFUSION,18789,"Chowaniec, Wayne B, NP",4/24/2025,Decitabine (Maintenance Phase) 28 Day Cycles - Post allo transplant - Acute Myeloid Leukemia,Maintenance,4/24/2025,Inactive,"AML (acute myeloid leukemia) (CMS/HCC)
History of allogeneic stem cell transplant (CMS/HCC)",
CINJ OP INFUSION,79577,"Jang, Thomas L, MD",3/9/2023,BCG Maintenance (TICE) 3/9/23 Schedule - Bladder,Maintenance,3/9/2023,Inactive,,
CINJ OP INFUSION,31931,"Hochster, Howard S, MD",2/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/8/2024,Inactive,"Cancer of ampulla of Vater (CMS/HCC)
Malignant ascites",
CINJ OP INFUSION,31931,"Hochster, Howard S, MD",1/8/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/2/2025,Active,,
NBR CINJ OP INFUSION,88722,"Eltoukhy, Hussam, MD",1/12/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,1/11/2023,Inactive,,
MMC OP INFUSION,25252,"Eltoukhy, Hussam, MD",1/24/2025,RiTUXimab 28 Day Cycle,_1. First Line,1/23/2025,Active,"Malignant melanoma of right lower limb, including hip (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC)
Other specified hypothyroidism",
CINJ OP INFUSION,43603,"Boland, Patrick M, MD",9/6/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/1/2024,Active,,
CINJ OP INFUSION,30440,"Omene, Coral Oghenerukevwe, MD",11/27/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,11/27/2023,Inactive,,
CINJ OP INFUSION,30440,"Omene, Coral Oghenerukevwe, MD",12/4/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,12/4/2023,Active,,
CINJ OP INFUSION,75618,"Aikins, James K, MD",1/8/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,1/3/2024,Inactive,,
CINJ OP INFUSION,75618,"Aikins, James K, MD",7/25/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,7/17/2024,Active,,
MMC OP VP INFUSION,74060,"Cohen, Seth D, MD",12/6/2023,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/6/2023,Inactive,,
MMC OP VP INFUSION,74060,"Cohen, Seth D, MD",4/17/2024,Durvalumab 1500 mg 28 Day Cycles,Maintenance,4/17/2024,Inactive,,
MMC OP VP INFUSION,74060,"Cohen, Seth D, MD",6/24/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/21/2024,Inactive,,
MMC OP VP INFUSION,74060,"Cohen, Seth D, MD",8/12/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,8/12/2024,Active,Mixed germ cell tumor (CMS/HCC),
CINJ OP INFUSION,63523,"Boland, Patrick M, MD",1/17/2023,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/13/2023,Inactive,,
CINJ OP INFUSION,63523,"Boland, Patrick M, MD",12/7/2023,Capecitabine 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/24/2023,Active,,
CINJ OP INFUSION,77173,"Saraiya, Biren P, MD",10/1/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/1/2024,Active,,
MMC OP VP INFUSION,77173,"Cohen, Seth D, MD",12/10/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,12/6/2024,Active,,
NBI OP INFUSION,23342,"Jacoby, Sari H, MD",1/6/2025,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,1/6/2025,Active,"ER+ PR+ carcinoma of breast (CMS/HCC)
Hypothyroidism due to medication",
NBI OP INFUSION,57254,"Shah, Shailja S, MD",4/12/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,Induction,4/11/2024,Active,Peripheral T cell lymphoma of extranodal and solid organ sites (CMS/HCC),
CBMC OP INFUSION 2FL,9350,"Brown, Andrew Bennett, MD",4/9/2024,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,Neoadjuvant,4/7/2024,Inactive,,
CBMC OP INFUSION 2FL,9350,"Brown, Andrew Bennett, MD",7/22/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,7/18/2024,Active,,
CMC OP INFUSION,90634,"Pompa, Tiffany Ann, MD",2/25/2025,"mFOLFOX6 Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/18/2025,Active,"Malignant neoplasm of colon, unspecified part of colon (CMS/HCC)
Rectal cancer (CMS/HCC)",
CINJ OP INFUSION,6055,"Girda, Eugenia, MD",12/15/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,12/14/2023,Inactive,,
CINJ OP INFUSION,71665,"Omene, Coral Oghenerukevwe, MD",7/16/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,7/15/2024,Inactive,,
CINJ OP INFUSION,71665,"Omene, Coral Oghenerukevwe, MD",9/10/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,9/9/2024,Active,,
CMC OP INFUSION,36037,"Taff, Jessica, MD",6/10/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,6/9/2024,Active,,
CMC OP INFUSION,2419,"Cohen, Seth D, MD",7/30/2024,MitoMYcin / Fluorouracil with Concurrent Radiation 21 Day Cycle - Bladder,_1. First Line,7/29/2024,Inactive,,
MMC OP VP INFUSION,2419,"Cohen, Seth D, MD",1/16/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,1/16/2025,Active,,
HAM OP INFUSION,9421,"Yogarajah, Meera, MD",8/5/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,8/5/2024,Active,,
CINJ OP INFUSION,63111,"Gulhati, Prateek, MD PhD",7/21/2023,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) 28 Day Cycles- Gastroesophageal Cancer",_1. First Line,6/22/2023,Inactive,,
CINJ OP INFUSION,63111,"Gulhati, Prateek, MD PhD",1/25/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/24/2024,Inactive,,
CBMC OP INFUSION 2FL,1878,"Dave, Manish, MD",11/8/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,11/8/2023,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,40176,"Shah, Mansi R, MD",9/14/2024,Daratumumab and Hyaluronidase-fihj Monthly / Bortezomib Bi-Weekly 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/13/2024,Active,,
CINJ OP INFUSION,9890,"Muralikrishnan, Sivraj, MD",2/24/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,2/21/2025,Active,Oropharyngeal cancer (CMS/HCC),C10.9 - Oropharyngeal cancer (CMS/HCC)
CINJ OP INFUSION,97188,"Berim, Lyudmyla, MD",8/31/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/30/2024,Active,,
CINJ OP INFUSION,97188,"Berim, Lyudmyla, MD",10/21/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/16/2024,Active,,
CINJ OP INFUSION,59694,"Berim, Lyudmyla, MD",5/15/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/15/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),
CINJ OP INFUSION,59694,"Berim, Lyudmyla, MD",5/15/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/21/2024,Inactive,"Malignant neoplasm of pancreas, unspecified location of malignancy (CMS/HCC)","C25.2 - Malignant neoplasm of tail of pancreas; C25.9 - Malignant neoplasm of pancreas, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); G89.29 - Other chronic pain; K59.03 - Drug induced constipation; R63.0 - Anorexia; R53.81 - Other malaise"
CINJ OP INFUSION,59694,"Berim, Lyudmyla, MD",5/9/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_2. Second Line,5/9/2025,Inactive,Malignant neoplasm of pancreas (CMS/HCC),
CMC OP INFUSION,71081,"Taff, Jessica, MD",3/18/2024,Pembrolizumab 21 Day Cycles - SqCC Skin - Unresectable,_1. First Line,2/26/2024,Inactive,,
CINJ OP INFUSION,61280,"Weiss, Sarah, MD",3/8/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Second Line,3/8/2023,Active,,
CINJ OP INFUSION,54264,"Toppmeyer, Deborah L, MD",6/1/2023,EriBULin 21 Day Cycles - Breast,Third Line,5/31/2023,Inactive,,
CINJ OP INFUSION,54264,"Toppmeyer, Deborah L, MD",7/18/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Third Line,7/17/2023,Inactive,,
SOM OUTPT INFUSION,90959,"Toomey, Kathleen C, MD",4/7/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,3/30/2023,Inactive,,
SOM OUTPT INFUSION,90959,"Toomey, Kathleen C, MD",7/7/2023,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,7/6/2023,Inactive,,
CINJ OP INFUSION,82146,"Goel, Sanjay, MD",4/17/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,4/16/2023,Inactive,,
CINJ OP INFUSION,73666,"Girda, Eugenia, MD",6/29/2023,CARBOplatin 21 Day Cycles - Endometrial Cancer,,6/12/2023,Inactive,,
CINJ OP INFUSION,73666,"Girda, Eugenia, MD",12/20/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_4. Fourth Line,12/19/2024,Active,,
MMC OP VP INFUSION,55441,"Cohen, Seth D, MD",4/24/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Second Line,4/23/2023,Inactive,,
MMC OP VP INFUSION,55441,"Cohen, Seth D, MD",7/10/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,7/9/2023,Inactive,,
MMC OP INFUSION,19048,"Meghal, Trishala, MD",5/31/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,5/23/2023,Inactive,,
MMC OP VP INFUSION,31380,"Meghal, Trishala, MD",2/12/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,2/11/2024,Inactive,,
MMC OP INFUSION,31380,"Meghal, Trishala, MD",2/14/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,2/13/2024,Inactive,,
CINJ OP INFUSION,5042,"Stephenson, Ryan D, DO",2/12/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,2/12/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; E03.9 - Hypothyroidism, unspecified; I48.0 - Paroxysmal atrial fibrillation; E78.2 - Mixed hyperlipidemia; I10 - Essential (primary) hypertension; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits"
CBMC OP INFUSION 2FL,41860,"Brown, Andrew Bennett, MD",1/8/2024,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,1/7/2024,Inactive,,
NBR CINJ OP INFUSION,80859,"Mayer, Tina M, MD",12/12/2024,CINJ 082104 (EA8191) ARM B Short Term Androgen Deprivation GnRH Therapy / Apalutamide 84 Day Cycles Research- Prostate Cancer,Neoadjuvant,11/14/2024,Active,,
CINJ OP INFUSION,71045,"Haigentz, Missak, MD",5/20/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,5/14/2024,Active,,
MMC OP VP INFUSION,94028,"Cohen, Seth D, MD",10/21/2024,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/16/2024,Active,,
CINJ OP INFUSION,43688,"Patankar, Sonali, MD",3/28/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Neoadjuvant,3/28/2025,Inactive,Endometrial cancer (CMS/HCC),"C54.1 - Malignant neoplasm of endometrium; D64.9 - Anemia, unspecified"
MSC OP INFUSION,72444,"Cohen, Seth D, MD",4/16/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),Maintenance,4/15/2024,Inactive,,
MMC OP VP INFUSION,72444,"Cohen, Seth D, MD",5/7/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,5/6/2024,Inactive,,
MMC OP VP INFUSION,72444,"Cohen, Seth D, MD",10/1/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,9/30/2024,Active,,
MMC OP VP INFUSION,84782,"Cohen, Seth D, MD",3/29/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/24/2024,Inactive,,
CBMC OP INFUSION 2FL,76806,"Raptis, George, MD",8/9/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/8/2024,Inactive,,
CBMC OP INFUSION 2FL,76806,"Raptis, George, MD",10/4/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,10/4/2024,Active,,
CBMC OP INFUSION 2FL,92863,"Raptis, George, MD",3/7/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/7/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,92863,"Raptis, George, MD",3/7/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/7/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
HAM OP INFUSION,2790,"Yogarajah, Meera, MD",12/20/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,_1. First Line,11/22/2024,Active,,
HAM OP INFUSION,2790,"Yogarajah, Meera, MD",12/20/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,12/15/2024,Active,"Bladder cancer metastasized to intra-abdominal lymph nodes (CMS/HCC)
Abnormal results of thyroid function studies
Encounter for screening for other viral diseases",
NBI OP INFUSION,72023,"Shah, Shailja S, MD",9/10/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,9/9/2024,Active,,
CMC OP INFUSION,69507,"Taff, Jessica, MD",6/2/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,5/24/2023,Inactive,,
CMC OP INFUSION,69507,"Taff, Jessica, MD",5/7/2025,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,5/7/2025,Active,Malignant neoplasm of lung (CMS/HCC),
CMC OP INFUSION,69507,"Taff, Jessica, MD",4/10/2025,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/10/2025,Inactive,Malignant neoplasm of lung (CMS/HCC),
NBI OP INFUSION,54086,"Anderson, Patrick S, MD",3/14/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Advanced serous endometrial cancer,Neoadjuvant,3/6/2024,Inactive,,
NBI OP INFUSION,54086,"Anderson, Patrick S, MD",10/17/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,10/2/2024,Active,,
NBI OP INFUSION,34059,"Anderson, Patrick S, MD",3/20/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_2. Second Line,3/20/2025,Active,"Postmenopausal bleeding
Endometrial cancer (CMS/HCC)
Malignant neoplasm of body of uterus (CMS/HCC)",
CMC 4B ONCOLOGY,77431,"Taff, Jessica, MD",2/6/2024,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/5/2024,Active,,
CMC OP INFUSION,6359,"Pompa, Tiffany Ann, MD",10/3/2024,Pemetrexed / CARBOplatin (AUC 5) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/25/2024,Inactive,,
CMC OP INFUSION,6359,"Pompa, Tiffany Ann, MD",10/30/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,10/2/2024,Active,,
CMC OP INFUSION,6359,"Pompa, Tiffany Ann, MD",10/30/2024,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,_1. First Line,10/2/2024,Active,,
NBI OP INFUSION,507,"Cohen, Alice, MD",12/28/2023,Everolimus / Exemestane 28 Day Cycles - Breast,_2. Second Line,12/28/2023,Inactive,,
SOM OUTPT INFUSION,507,"Toomey, Kathleen C, MD",11/15/2024,Capecitabine / Ixabepilone 21 Day Cycles - Breast,_1. First Line,11/14/2024,Inactive,,
CBMC OP INFUSION 2FL,13305,"Brown, Andrew Bennett, MD",10/17/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,13305,"Brown, Andrew Bennett, MD",5/8/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,5/5/2024,Inactive,,
CBMC OP INFUSION 2FL,94202,"Brown, Andrew Bennett, MD",10/2/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,10/1/2023,Active,,
CINJ OP INFUSION,65792,"Stephenson, Ryan D, DO",4/2/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,4/2/2025,Active,Metastatic renal cell carcinoma (CMS/HCC),"D50.9 - Iron deficiency anemia, unspecified; N28.89 - Other specified disorders of kidney and ureter; E83.52 - Hypercalcemia; R74.8 - Abnormal levels of other serum enzymes; C64.2 - Malignant neoplasm of left kidney, except renal pelvis; R05.1 - Acute cough; K59.00 - Constipation, unspecified"
CINJ OP INFUSION,81591,"Boland, Patrick M, MD",1/23/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/22/2024,Inactive,,
CBMC OP INFUSION 2FL,38251,"Kovtun, Jeanette Muniz, MD",6/11/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,6/10/2024,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
CBMC 2W ONCOLOGY,38251,"Grossman, I Robert, MD",7/10/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,7/9/2024,Active,,
HAM OP INFUSION,37671,"Patel, Malini M, MD",1/7/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,1/5/2025,Active,,
HAM OP INFUSION,92597,"Patel, Malini M, MD",4/2/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,4/2/2025,Active,"Squamous cell carcinoma of overlapping sites of left lung (CMS/HCC)
Non-small cell cancer of left lung (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C34.92 - Non-small cell cancer of left lung (CMS/HCC); Z11.59 - Encounter for screening for other viral diseases; T80.90XS - Infusion reaction, sequela"
CINJ OP INFUSION,37656,"Patel, Eshan, MD",2/17/2023,CINJ 032003 Durvalumab 14 Day Cycles Group C Post-RT Research- Non-Small Cell Lung Cancer,,2/16/2023,Inactive,,
CINJ OP INFUSION,37656,"Haigentz, Missak, MD",6/9/2023,CINJ 032201 ARM 1 Paclitaxel / CARBOplatin + Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,6/9/2023,Inactive,,
CINJ OP INFUSION,37656,"Haigentz, Missak, MD",11/21/2023,CINJ 032201 Pembrolizumab Maintenance 21 Day Cycles Research- Non-Small Cell Lung Cancer,Maintenance,11/20/2023,Inactive,,
MMC OP INFUSION,85457,"Eltoukhy, Hussam, MD",11/20/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/19/2023,Inactive,,
CBMC OP INFUSION 2FL,42584,"Brown, Andrew Bennett, MD",10/8/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,9/29/2024,Active,,
NBR 5N MED-SURG OVRF,58938,"Alexander, Henry Richard, MD",8/7/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Second Line,8/7/2023,Active,,
NBR CINJ OP INFUSION,9183,"Palmisiano, Neil David, MD",6/18/2024,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_1. First Line,6/18/2024,Active,,
CINJ OP INFUSION,52309,"Haigentz, Missak, MD",3/9/2024,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,_1. First Line,3/9/2024,Active,,
MMC OP VP INFUSION,33959,"Eltoukhy, Hussam, MD",8/7/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,8/6/2024,Active,,
SOM OUTPT INFUSION,48235,"Toomey, Kathleen C, MD",1/24/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/23/2025,Active,,
HAM OP INFUSION,23665,"Yogarajah, Meera, MD",7/24/2023,Bortezomib Twice Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,First Line,7/23/2023,Inactive,,
HAM OP INFUSION,23665,"Yogarajah, Meera, MD",8/3/2023,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),First Line,8/3/2023,Inactive,,
HAM OP INFUSION,23665,"Yogarajah, Meera, MD",8/21/2023,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,First Line,8/13/2023,Inactive,,
CINJ OP INFUSION,41716,"Toppmeyer, Deborah L, MD",10/2/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,10/2/2023,Inactive,,
CINJ OP INFUSION,41716,"Toppmeyer, Deborah L, MD",10/30/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,10/30/2023,Active,,
CBMC OP INFUSION 2FL,49795,"Grossman, I Robert, MD",6/16/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,Consolidation,6/16/2023,Inactive,,
CBMC OP INFUSION 2FL,49795,"Grossman, I Robert, MD",11/2/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/1/2023,Active,,
CBMC OP INFUSION 2FL,60752,"Gallinson, David Herschel, DO",1/28/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/27/2025,Active,,
CBMC OP INFUSION 2FL,38435,"Gallinson, David Herschel, DO",4/10/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/28/2025,Active,Colon cancer (CMS/HCC),
CINJ OP INFUSION,8765,"Toppmeyer, Deborah L, MD",7/17/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,7/17/2023,Active,,
NBR 5N MED-SURG OVRF,20637,"Alexander, Henry Richard, MD",11/30/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,11/30/2023,Active,,
NBI OP INFUSION,32459,"Jacoby, Sari H, MD",4/22/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Gallbladder Cancer,_1. First Line,4/22/2025,Active,Malignant neoplasm of gallbladder (CMS/HCC),"C23 - Malignant neoplasm of gallbladder; Z90.49 - Acquired absence of other specified parts of digestive tract; E66.9 - Obesity, unspecified; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; Z87.81 - Personal history of (healed) traumatic fracture; Z98.891 - History of uterine scar from previous surgery; Z88.0 - Allergy status to penicillin; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; D18.03 - Hemangioma of intra-abdominal structures"
CINJ OP INFUSION,85228,"Mayer, Tina M, MD",6/26/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,6/25/2023,Inactive,,
CBMC OP INFUSION 2FL,77635,"Leitner, Stuart P, MD",4/18/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney ",_1. First Line,4/11/2024,Inactive,"Mass of spine
Clear cell renal cell carcinoma, unspecified laterality (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)",
CBMC OP INFUSION 2FL,77635,"Leitner, Stuart P, MD",1/20/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_3. Third Line,1/16/2025,Active,,
SOM OUTPT INFUSION,93252,"Patel, Eshan, MD",4/12/2023,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,4/11/2023,Inactive,,
CINJ OP INFUSION,92737,"Haigentz, Missak, MD",1/12/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,1/10/2023,Inactive,,
CINJ OP INFUSION,10793,"Weiss, Sarah, MD",3/31/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,1/29/2023,Inactive,,
MMC BBR2 ONCOLOGY,81900,"Eltoukhy, Hussam, MD",9/10/2024,"Bortezomib/Dexamethasone D1, D4, D8, D11 21 Day Cycles- Multiple Myeloma",_1. First Line,9/9/2024,Inactive,,
MMC OP INFUSION,81900,"Eltoukhy, Hussam, MD",10/7/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,Induction,10/6/2024,Active,,
NBR CINJ OP INFUSION,7247,"Evens, Andrew M, DO",11/25/2024,CINJ 012207 Arm 1 Dose Level 3 Tazemetostat / Rituximab / Bendamustine 28 Day Cycles Research- Follicular Lymphoma,_1. First Line,11/22/2024,Active,,
NBR 5N ONCOLOGY,46532,"Chen, Xiaoyi",5/28/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,5/28/2025,Active,Burkitt lymphoma of intra-abdominal lymph nodes (CMS/HCC),"K76.82 - Hepatic encephalopathy; E43 - Unspecified severe protein-calorie malnutrition; K83.1 - Obstruction of bile duct; D47.Z1 - Post-transplant lymphoproliferative disorder (PTLD); K56.609 - Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction; C83.73 - Burkitt lymphoma, intra-abdominal lymph nodes; I13.2 - Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease; Z94.0 - Kidney transplant status; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; R56.9 - Unspecified convulsions; D63.1 - Anemia in chronic kidney disease; E03.9 - Hypothyroidism, unspecified; E04.2 - Nontoxic multinodular goiter; Z68.34 - Body mass index (BMI) 34.0-34.9, adult; I48.20 - Chronic atrial fibrillation, unspecified; I50.22 - Chronic systolic (congestive) heart failure; Z79.4 - Long term (current) use of insulin; E86.0 - Dehydration; R55 - Syncope and collapse; K86.89 - Other specified diseases of pancreas; R62.7 - Adult failure to thrive; Z98.61 - Coronary angioplasty status; K21.9 - Gastro-esophageal reflux disease without esophagitis; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecified; Z74.09 - Other reduced mobility; R13.10 - Dysphagia, unspecified; G25.3 - Myoclonus; R05.9 - Cough, unspecified; K31.89 - Other diseases of stomach and duodenum; Z79.621 - Long term (current) use of calci..."
NBR 5N ONCOLOGY,46532,"Chen, Xiaoyi",5/25/2025,Cyclophosphamide 250mg/m2 x 3 days - Burkitt Lymphoma,_1. First Line,5/25/2025,Active,Burkitt lymphoma of intra-abdominal lymph nodes (CMS/HCC),"K76.82 - Hepatic encephalopathy; E43 - Unspecified severe protein-calorie malnutrition; K83.1 - Obstruction of bile duct; D47.Z1 - Post-transplant lymphoproliferative disorder (PTLD); K56.609 - Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction; C83.73 - Burkitt lymphoma, intra-abdominal lymph nodes; I13.2 - Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease; Z94.0 - Kidney transplant status; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; R56.9 - Unspecified convulsions; D63.1 - Anemia in chronic kidney disease; E03.9 - Hypothyroidism, unspecified; E04.2 - Nontoxic multinodular goiter; Z68.34 - Body mass index (BMI) 34.0-34.9, adult; I48.20 - Chronic atrial fibrillation, unspecified; I50.22 - Chronic systolic (congestive) heart failure; Z79.4 - Long term (current) use of insulin; E86.0 - Dehydration; R55 - Syncope and collapse; K86.89 - Other specified diseases of pancreas; R62.7 - Adult failure to thrive; Z98.61 - Coronary angioplasty status; K21.9 - Gastro-esophageal reflux disease without esophagitis; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecified; Z74.09 - Other reduced mobility; R13.10 - Dysphagia, unspecified; G25.3 - Myoclonus; R05.9 - Cough, unspecified; K31.89 - Other diseases of stomach and duodenum; Z79.621 - Long term (current) use of calci..."
MMC OP VP INFUSION,18844,"Cohen, Seth D, MD",1/11/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,1/3/2024,Inactive,,
MMC OP VP INFUSION,18844,"Cohen, Seth D, MD",5/23/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,5/22/2024,Inactive,,
CMC OP INFUSION,18844,"Cohen, Seth D, MD",8/15/2024,CINJ 042106 (A011801)  Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,_2. Second Line,8/11/2024,Active,,
CBMC OP INFUSION 2FL,62907,"Brown, Andrew Bennett, MD",12/13/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,12/5/2023,Inactive,,
CINJ OP INFUSION,73605,"Hochster, Howard S, MD",3/28/2024,mFOLFOX6  (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/26/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,67614,"Drachtman, Richard, MD",12/26/2024,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,12/25/2024,Active,,
CBMC OP INFUSION 2FL,9699,"Brown, Andrew Bennett, MD",2/28/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,2/27/2024,Inactive,,
CBMC OP INFUSION 2FL,9699,"Brown, Andrew Bennett, MD",9/27/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/10/2024,Inactive,,
CINJ OP INFUSION,17558,"Saraiya, Biren P, MD",6/20/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,6/20/2024,Active,,
CINJ OP INFUSION,17558,"Saraiya, Biren P, MD",8/19/2024,Olaparib 30 Day Cycles - Prosate BRCA2,_2. Second Line,8/19/2024,Active,,
CINJ OP INFUSION,42458,"Saraiya, Biren P, MD",2/17/2025,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,1/26/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; M89.8X9 - Other specified disorders of bone, unspecified site"
CINJ OP INFUSION,1263,"Stephenson, Ruth D, DO",5/12/2023,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,5/9/2023,Inactive,,
CINJ OP INFUSION,1263,"Stephenson, Ruth D, DO",12/1/2023,Trastuzumab 21 Day Cycles (Continuation) - Uterine,Maintenance,11/30/2023,Inactive,,
CINJ OP INFUSION,1263,"Stephenson, Ruth D, DO",2/28/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,2/15/2024,Inactive,,
CINJ OP INFUSION,1263,"Stephenson, Ruth D, DO",9/13/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_4. Fourth Line,9/12/2024,Active,,
NBR 5N ONCOLOGY,13754,"Shah, Mansi R, MD",5/17/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_3. Third Line,5/17/2024,Inactive,,
NBR CINJ OP INFUSION,13754,"Shah, Mansi R, MD",6/25/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_5. Fifth Line,6/25/2024,Inactive,,
NBR CINJ OP INFUSION,13754,"Shah, Mansi R, MD",6/27/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Selinexor Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,6/26/2024,Inactive,,
NBR 5N ONCOLOGY,13754,"Shah, Mansi R, MD",7/19/2024,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,7/17/2024,Inactive,,
NBR 5N ONCOLOGY,13754,"Shah, Mansi R, MD",7/29/2024,Nelarabine 21 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,7/28/2024,Inactive,,
NBR 4N BMTU/IMCU,44625,"Braunschweig, Ira, MD",7/20/2023,BMT Allogeneic TBF + Post Cy ,,7/19/2023,Inactive,,
CINJ OP INFUSION,20204,"Aikins, James K, MD",10/6/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,9/20/2023,Active,,
CMC OP INFUSION,23842,"Pompa, Tiffany Ann, MD",1/15/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,1/14/2025,Inactive,Neoplasm of uncertain behavior of left ovary,
CMC OP INFUSION,23842,"Pompa, Tiffany Ann, MD",1/24/2025,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/23/2025,Active,,
CINJ OP INFUSION,72933,"Weiss, Sarah, MD",2/13/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Third Line,2/13/2023,Active,,
CINJ OP INFUSION,75867,"Berim, Lyudmyla, MD",9/26/2023,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",,9/21/2023,Inactive,,
NBI OP INFUSION,52413,"Jacoby, Sari H, MD",10/9/2023,"Cetuximab D1, D15 28 Day Cycles- Colon Cancer",_1. First Line,10/8/2023,Inactive,,
NBI OP INFUSION,33911,"Shah, Shailja S, MD",3/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/28/2025,Active,Local recurrence of malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CINJ OP INFUSION,81763,"George, Mridula A, MD",11/29/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,11/28/2023,Inactive,,
JCMC CP INFUSION,10312,"Sekhri, Arunabh, MD",2/7/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,2/6/2025,Active,Hodgkin lymphoma (CMS/HCC),
CINJ OP INFUSION,18518,"Stephenson, Ruth D, DO",9/23/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,9/19/2024,Active,,
NBR CINJ OP INFUSION,25796,"Palmisiano, Neil David, MD",2/5/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,Induction,2/4/2024,Inactive,,
NBR CINJ OP INFUSION,25796,"Egini, Ogechukwu, MD",5/12/2024,BMT Allogeneic Flu / Cy / TBI + Post Cy ,Consolidation,5/11/2024,Inactive,,
NBR CINJ OP INFUSION,25796,"Egini, Ogechukwu, MD",9/23/2024,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,9/22/2024,Inactive,,
NBR CINJ OP INFUSION,25796,"Egini, Ogechukwu, MD",10/21/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,10/20/2024,Active,"History of autologous stem cell transplant (CMS/HCC)
Multiple myeloma (CMS/HCC)
Encounter for immunization
Encounter for administration of vaccine
Immunocompromised (CMS/HCC)",
NBR CINJ OP INFUSION,19389,"Egini, Ogechukwu, MD",3/26/2025,BMT Allogeneic TBF + Post Cy/Abatacept (Reduced Intensity),_3. Third Line,3/26/2025,Inactive,"Chronic myelomonocytic leukemia not having achieved remission (CMS/HCC)
H/O allogeneic bone marrow transplant (CMS/HCC)","C82.80 - Other types of follicular lymphoma, unspecified site; D69.6 - Thrombocytopenia, unspecified; Z23 - Encounter for immunization"
CMC OP INFUSION,66938,"Pompa, Tiffany Ann, MD",1/28/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,1/24/2025,Active,,
CINJ OP INFUSION,98743,"Berim, Lyudmyla, MD",7/18/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,7/13/2023,Inactive,,
NBR CINJ OP INFUSION,97561,"Tiger, Yun Kyoung, MD",9/25/2024,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_3. Third Line,9/23/2024,Inactive,,
CINJ OP INFUSION,97561,"Goel, Sanjay, MD",12/23/2024,CINJ 052401 Part A Enrichment GIM-122,_3. Third Line,12/23/2024,Active,,
CBMC OP INFUSION 2FL,13593,"Dharmapuri, Sirish, MD",5/27/2025,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,3/17/2025,Active,HCC (hepatocellular carcinoma) (CMS/HCC),C22.0 - Liver cell carcinoma
CINJ OP INFUSION,60047,"Gulhati, Prateek, MD PhD",6/8/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",,6/8/2023,Inactive,,
MSC OP INFUSION,97678,"Cohen, Seth D, MD",3/12/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,3/11/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,75225,"Moerdler, Scott, MD",1/20/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,1/20/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,75225,"Moerdler, Scott, MD",1/20/2023,AALL1732 B-ALL Induction,,1/20/2023,Inactive,,
CINJ PEDS HEMONC ,75225,"Moerdler, Scott, MD",3/2/2023,AALL1732 Consolidation,First Line,3/2/2023,Inactive,,
CINJ PEDS HEMONC ,75225,"Botwinick, Marissa, DO",3/20/2023,Asparaginase Erwinia (Rylaze) ,First Line,3/20/2023,Inactive,,
CINJ PEDS HEMONC ,75225,"Botwinick, Marissa, DO",5/26/2023,per AALL1732 Interim Maintenance I (IM I) with HDMTX  (off study),,5/25/2023,Inactive,,
CINJ PEDS HEMONC ,75225,"Botwinick, Marissa, DO",1/9/2024,Blinatumomab - bridge therapy prior to BMT,_4. Fourth Line,1/8/2024,Inactive,,
CINJ PEDS HEMONC ,75225,"Botwinick, Marissa, DO",1/9/2024,Blinatumomab - bridging therapy prior to BMT at CHOP,_4. Fourth Line,1/8/2024,Inactive,,
CINJ PEDS HEMONC ,75225,"Botwinick, Marissa, DO",2/29/2024,AALL1732 HR B-ALL Arm B Inotuzumab ozogamicin Block 1,_5. Fifth Line,2/26/2024,Inactive,,
HAM OP INFUSION,1943,"Gendy, Mina, DO",10/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/2/2024,Active,,
NBR 5N ONCOLOGY,63149,"Tiger, Yun Kyoung, MD",10/1/2023,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),,9/30/2023,Inactive,,
NBR 5N ONCOLOGY,63149,"Shah, Mansi R, MD",10/10/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,First Line,10/9/2023,Inactive,,
NBR CINJ OP INFUSION,63149,"Shah, Mansi R, MD",2/15/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,2/15/2024,Inactive,,
NBR 4N ONCOLOGY,63149,"Schaar, Dale, MD PhD",3/6/2024,BMT Autologous Melphalan Day -1 140MG/M2,Consolidation,3/4/2024,Inactive,,
NBR CINJ OP INFUSION,63149,"Shah, Mansi R, MD",6/27/2024,Daratumumab/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,6/26/2024,Inactive,,
NBR CINJ OP INFUSION,63149,"Shah, Mansi R, MD",8/1/2024,"Bortezomib D1, D15 Maintenance 28 Day Cycles- Multiple Myeloma",Maintenance,7/31/2024,Inactive,,
NBR CINJ OP INFUSION,63149,"Shah, Mansi R, MD",9/2/2024,Talquetamab 28 Day Cycles,_5. Fifth Line,9/2/2024,Active,"Neuroblastoma, high risk (CMS/HCC)",
NBR 4N ONCOLOGY,63149,"Shah, Mansi R, MD",9/20/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_5. Fifth Line,9/20/2024,Inactive,,
NBR CINJ OP INFUSION,63149,"Shah, Mansi R, MD",1/30/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,10/22/2024,Active,,
NBR 5N ONCOLOGY,63149,"Shah, Mansi R, MD",2/25/2025,Bortezomib Twice Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,,2/24/2025,Inactive,"Multiple myeloma not having achieved remission (CMS/HCC)
Other acute kidney failure (CMS/HCC)","C90.00 - Multiple myeloma not having achieved remission; I21.A1 - Myocardial infarction type 2; D69.2 - Other nonthrombocytopenic purpura; I47.10 - Supraventricular tachycardia, unspecified; I50.20 - Unspecified systolic (congestive) heart failure; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; D63.8 - Anemia in other chronic diseases classified elsewhere; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; M06.9 - Rheumatoid arthritis, unspecified; N18.30 - Chronic kidney disease, stage 3 unspecified; E03.8 - Other specified hypothyroidism; R63.4 - Abnormal weight loss; N17.9 - Acute kidney failure, unspecified; I48.0 - Paroxysmal atrial fibrillation; Z68.27 - Body mass index (BMI) 27.0-27.9, adult; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; E78.00 - Pure hypercholesterolemia, unspecified; R59.0 - Localized enlarged lymph nodes; E87.5 - Hyperkalemia; R91.1 - Solitary pulmonary nodule; H40.89 - Other specified glaucoma; D72.822 - Plasmacytosis; L98.9 - Disorder of the skin and subcutaneous tissue, unspecified; R50.9 - Fever, unspecified; R21 - Rash and other nonspecific skin eruption; K59.00 - Constipation, unspecified; G89.29 - Other chronic pain; M54.9 - Dorsalgia, unspecified; M25.562 - Pain in left knee; M25.561 - Pain in right knee; Z79.899 - Other long term (current) drug therapy; Z79.82 - Long ter..."
MMC OP INFUSION,14489,"Lee, Patrick C, MD",12/11/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,12/9/2024,Active,,
CBMC OP INFUSION 2FL,95911,"Brown, Andrew Bennett, MD",11/7/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/30/2023,Inactive,,
JCMC CP INFUSION,56985,"Sekhri, Arunabh, MD",1/10/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Squamous Non-Small Cell Lung Cancer,_1. First Line,12/27/2024,Active,,
NBR CINJ OP INFUSION,91461,"Evens, Andrew M, DO",10/25/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/24/2023,Inactive,,
NBR 4N ONCOLOGY,80956,"Doraiswamy, Anupama, MD",2/20/2023,CINJ 022101 ARM B Cycle 2 Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,First Line,2/20/2023,Inactive,,
NBR 5N ONCOLOGY,80956,"Doraiswamy, Anupama, MD",4/10/2023,HyperCVD Mini (Cycle 1) (RiTUXimab / Cyclophosphamide / VinCRIStine / Dexamethasone / Inotuzumab) 28 Day Cycles - Acute Lymphoblastic Leukemia (Induction),,4/10/2023,Inactive,,
NBR CINJ OP INFUSION,80956,"Doraiswamy, Anupama, MD",5/30/2023,HyperCVD Mini (Cycle 2) (RiTUXimab / High Dose Methotrexate / Cytarabine / Inotuzumab) 28 Day Cycles - Acute Lymphoblastic Leukemia,,5/10/2023,Inactive,,
NBR 4N ONCOLOGY,80956,"Doraiswamy, Anupama, MD",7/11/2023,HyperCVD Mini (Cycle 3) (RiTUXimab / Cyclophosphamide / VinCRIStine / Dexamethasone / Inotuzumab) 28 Day Cycles - Acute Lymphoblastic Leukemia,,6/22/2023,Inactive,,
NBR 4N ONCOLOGY,80956,"Palmisiano, Neil David, MD",8/14/2023,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,,8/14/2023,Inactive,,
NBR CINJ OP INFUSION,80956,"Palmisiano, Neil David, MD",10/4/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,,10/4/2023,Inactive,,
CBMC OP INFUSION 2FL,30704,"Dharmapuri, Sirish, MD",10/21/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/20/2024,Active,,
SOM OUTPT INFUSION,95869,"Toomey, Kathleen C, MD",10/23/2024,Nabpaclitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,10/8/2024,Inactive,,
CINJ OP INFUSION,95151,"Berim, Lyudmyla, MD",1/8/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2024,Inactive,,
CINJ OP INFUSION,7350,"Boland, Patrick M, MD",9/24/2024,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/23/2024,Inactive,,
SOM OUTPT INFUSION,32450,"Patel, Eshan, MD",9/23/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,9/17/2024,Active,,
NBR CINJ OP INFUSION,54199,"Rhodes, Joanna Meehan, MD",12/7/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,12/6/2023,Inactive,,
HAM OP INFUSION,27976,"Patel, Malini M, MD",4/16/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/16/2025,Active,"Malignant neoplasm of lateral wall of oropharynx (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",
NBR 5N ONCOLOGY,27976,"Mayer, Tina M, MD",3/6/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- head and neck Cancer",_1. First Line,3/6/2025,Inactive,Squamous cell carcinoma of oropharynx (CMS/HCC),"J95.830 - Postprocedural hemorrhage of a respiratory system organ or structure following a respiratory system procedure; E43 - Unspecified severe protein-calorie malnutrition; R04.2 - Hemoptysis; I50.42 - Chronic combined systolic (congestive) and diastolic (congestive) heart failure; C10.9 - Malignant neoplasm of oropharynx, unspecified; R13.10 - Dysphagia, unspecified; I11.0 - Hypertensive heart disease with heart failure; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; E11.51 - Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene; D72.829 - Elevated white blood cell count, unspecified; I34.0 - Nonrheumatic mitral (valve) insufficiency; K94.23 - Gastrostomy malfunction; D62 - Acute posthemorrhagic anemia; I25.810 - Atherosclerosis of coronary artery bypass graft(s) without angina pectoris; Z68.1 - Body mass index (BMI) 19.9 or less, adult; Z89.611 - Acquired absence of right leg above knee; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I25.5 - Ischemic cardiomyopathy; E83.42 - Hypomagnesemia; E87.6 - Hypokalemia; I49.3 - Ventricular premature depolarization; Z95.1 - Presence of aortocoronary bypass graft; Z98.890 - Other specified postprocedural states; E78.5 - Hyperlipidemia, unspecified; I35.1 - Nonrheumatic aortic (valve) insufficiency; Z87.891 - Personal history of nicotine dependence; Z53.8 - Procedure and treatment not ..."
CINJ OP INFUSION,21721,"Jang, Thomas L, MD",1/10/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,1/10/2023,Inactive,,
CINJ OP INFUSION,21721,"Jang, Thomas L, MD",7/7/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/7/2023,Inactive,,
CINJ OP INFUSION,21721,"Jang, Thomas L, MD",1/3/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/3/2024,Inactive,,
MMC OP VP INFUSION,52010,"Lee, Patrick C, MD",3/24/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,3/22/2023,Inactive,,
MMC OP VP INFUSION,52010,"Lee, Patrick C, MD",9/12/2024,"Gemcitabine (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_3. Third Line,9/5/2024,Inactive,,
CBMC OP INFUSION 2FL,73200,"Phillips, Adrienne A, MD",2/8/2024,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,2/8/2024,Inactive,,
CBMC OP INFUSION 2FL,73200,"Phillips, Adrienne A, MD",5/1/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_4. Fourth Line,4/30/2024,Inactive,"Diffuse large B-cell lymphoma, unspecified body region (CMS/HCC)",
CBMC OP INFUSION 2FL,73200,"Phillips, Adrienne A, MD",8/26/2024,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_5. Fifth Line,8/13/2024,Inactive,"Diffuse large B-cell lymphoma, unspecified body region (CMS/HCC)",
CBMC OP INFUSION 2FL,73200,"Phillips, Adrienne A, MD",1/8/2025,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_5. Fifth Line,1/8/2025,Inactive,"Diffuse large B-cell lymphoma, unspecified body region (CMS/HCC)",
NBI OP INFUSION,35789,"Shah, Maya M, MD",1/8/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,1/8/2025,Active,,
CMC 4B ONCOLOGY,20644,"Pompa, Tiffany Ann, MD",3/27/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/27/2025,Active,"Other diseases of stomach and duodenum
Adenocarcinoma of gastroesophageal junction (CMS/HCC)",K31.89 - Gastric mass
JCMC CP INFUSION,35469,"Sekhri, Arunabh, MD",2/26/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,2/11/2024,Inactive,,
JCMC CP INFUSION,35469,"Sekhri, Arunabh, MD",2/26/2024,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,2/11/2024,Active,,
NBR CINJ OP INFUSION,38521,"Braunschweig, Ira, MD",5/2/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,,5/1/2023,Inactive,,
NBR 4N ONCOLOGY,38521,"Assal, Amer, MD",11/9/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,11/7/2023,Inactive,,
NBR CINJ OP INFUSION,38521,"Braunschweig, Ira, MD",1/31/2024,Daratumumab and Hyaluronidase-fihj Monthly / Bortezomib Bi-Weekly 28 Day Cycles- Multiple Myeloma,Maintenance,1/30/2024,Inactive,,
NBR CINJ OP INFUSION,38521,"Shah, Mansi R, MD",4/23/2024,Carfilzomib 56 mg/m2 Weekly / POmalyst  Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,4/22/2024,Inactive,,
NBR CINJ OP INFUSION,38521,"Shah, Mansi R, MD",12/2/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,12/1/2024,Active,,
NBR CINJ OP INFUSION,60947,"Shah, Mansi R, MD",5/24/2025,Talquetamab 28 Day Cycles,_8. Eighth Line,5/24/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,99338,"Shah, Mansi R, MD",4/16/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/15/2024,Inactive,,
NBR 4N BMTU/IMCU,99338,"Shah, Mansi R, MD",8/21/2024,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,8/19/2024,Inactive,,
MMC OP VP INFUSION,97436,"Meghal, Trishala, MD",4/9/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/8/2024,Inactive,,
MMC OP VP INFUSION,97436,"Meghal, Trishala, MD",4/12/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,4/11/2024,Inactive,,
MMC OP INFUSION,97436,"Meghal, Trishala, MD",8/23/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/1/2024,Active,,
MMC OP VP INFUSION,97436,"Meghal, Trishala, MD",11/5/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,11/5/2024,Active,,
CMC OP INFUSION,60268,"Meghal, Trishala, MD",5/9/2023,Pembrolizumab 21 Day Cycles - Uterine,First Line,5/8/2023,Inactive,,
CMC OP INFUSION,60268,"Meghal, Trishala, MD",11/3/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,10/20/2023,Inactive,,
MMC OP VP INFUSION,60268,"Meghal, Trishala, MD",5/13/2024,Everolimus / Letrozole 28 Day Cycles - Uterine,_3. Third Line,5/13/2024,Inactive,,
CINJ OP INFUSION,60268,"Girda, Eugenia, MD",9/24/2024,CINJ 052401 Part A Enrichment GIM-122,_4. Fourth Line,9/24/2024,Inactive,,
MMC OP VP INFUSION,60268,"Meghal, Trishala, MD",11/29/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,11/26/2024,Active,,
CINJ OP INFUSION,68872,"Boland, Patrick M, MD",8/15/2023,CINJ 072304 Cohort 1 ME-344 + Bevacizumab - Colorectal Cancer,,8/15/2023,Inactive,,
CMC OP INFUSION,13077,"Talwar, Sumit, MD",3/13/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,3/13/2024,Inactive,,
CMC OP INFUSION,13077,"Talwar, Sumit, MD",8/14/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,8/13/2024,Active,,
MSC OP INFUSION,71782,"Taff, Jessica, MD",4/9/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/9/2025,Active,Malignant neoplasm of other parts of pancreas (CMS/HCC),
NBR 5N ONCOLOGY,35325,"Haigentz, Missak, MD",3/29/2024,Durvalumab PLUS CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/29/2024,Inactive,,
CINJ OP INFUSION,25339,"Groisberg, Roman, MD",10/21/2024,Atezolizumab 28 Day Cycles-Alveolar Soft part sarcoma,_1. First Line,10/17/2024,Active,,
CINJ OP INFUSION,25339,"Groisberg, Roman, MD",3/21/2025,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_2. Second Line,3/21/2025,Active,Alveolar soft part sarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified"
TRMC TCCC OP INFUSION,72099,"Capo, Gerardo, MD",7/8/2024,"DOCEtaxel D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_1. First Line,7/7/2024,Active,,
NBR BMSCH 2 PED HEMONC,79009,"Botwinick, Marissa, DO",4/27/2023,per AALL1731 Non-DS SR B-ALL Induction,,4/27/2023,Inactive,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",6/6/2023,AALL1731 SR-High B-ALL Consolidation,,6/6/2023,Inactive,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",6/6/2023,"AALL1731, SR-Avg B-ALL Consolidation",Consolidation,6/6/2023,Inactive,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",7/18/2023,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,,7/18/2023,Inactive,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",9/18/2023,"AALL1731, SR-Avg,  Arm A,  B-ALL,  Delayed Intensification",First Line,9/18/2023,Inactive,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",11/20/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,_1. First Line,11/20/2023,Inactive,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",2/8/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",Maintenance,2/8/2024,Active,,
CINJ PEDS HEMONC ,79009,"Sharma, Archana, DO",2/8/2024,AALL1731 DS SR-Fav B-ALL - Maintenance,Maintenance,2/8/2024,Inactive,,
CMC OP INFUSION,78188,"Taff, Jessica, MD",9/25/2023,mFOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,9/22/2023,Active,,
SOM 1PAV ONCOLOGY,19236,"Patel, Eshan, MD",8/7/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,,8/6/2023,Inactive,,
HAM OP INFUSION,47295,"Yogarajah, Meera, MD",12/9/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/9/2024,Active,,
CINJ OP INFUSION,1135,"Aikins, James K, MD",9/12/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/9/2024,Active,,
CBMC OP INFUSION 2FL,55933,"Scoppetuolo, Michael, MD",11/27/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,11/27/2023,Inactive,,
CINJ OP INFUSION,39216,"Muralikrishnan, Sivraj, MD",2/11/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,2/10/2025,Active,Small cell carcinoma (CMS/HCC),"C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; I42.2 - Other hypertrophic cardiomyopathy; E87.1 - Hypo-osmolality and hyponatremia; D35.02 - Benign neoplasm of left adrenal gland; C80.1 - Malignant (primary) neoplasm, unspecified"
CINJ OP INFUSION,39216,"Muralikrishnan, Sivraj, MD",5/13/2025,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/13/2025,Active,Small cell carcinoma of hilum of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,73994,"Wagmiller, Jennifer Ann, MD",4/10/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,4/9/2024,Inactive,,
CBMC OP INFUSION 2FL,73994,"Wagmiller, Jennifer Ann, MD",1/6/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,12/29/2024,Active,,
SOM OUTPT INFUSION,8913,"Patel, Eshan, MD",12/31/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/30/2024,Active,,
CINJ OP INFUSION,2704,"Stephenson, Ryan D, DO",9/3/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,9/2/2024,Inactive,,
NBR CINJ OP INFUSION,18778,"Berim, Lyudmyla, MD",5/16/2024,CINJ 072201 Control ARM FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,4/10/2024,Inactive,,
CINJ OP INFUSION,18778,"Berim, Lyudmyla, MD",5/16/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/15/2024,Active,,
CINJ OP INFUSION,18778,"Berim, Lyudmyla, MD",5/6/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/6/2025,Active,"Malignant neoplasm of colon, unspecified (CMS/HCC)","C18.1 - Malignant neoplasm of appendix; C18.9 - Malignant neoplasm of colon, unspecified; G60.0 - Hereditary motor and sensory neuropathy; J45.909 - Unspecified asthma, uncomplicated; C18.2 - Malignant neoplasm of ascending colon"
NBR BMSCH 2 PED HEMONC,23670,"Parikh, Nehal S, MD",11/14/2024,as per AALL1731 Non-DS SR B-ALL Induction,Induction,11/13/2024,Inactive,,
CINJ PEDS HEMONC ,23670,"Parikh, Nehal S, MD",12/19/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,12/19/2024,Active,,
CINJ PEDS HEMONC ,35124,"Parikh, Nehal S, MD",1/23/2025,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,1/23/2025,Active,,
CINJ PEDS HEMONC ,35124,"Parikh, Nehal S, MD",2/6/2025,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,1/23/2025,Active,Acute lymphoid leukemia in remission (CMS/HCC),"C91.01 - Acute lymphoblastic leukemia, in remission"
CINJ PEDS HEMONC ,35124,"Botwinick, Marissa, DO",4/14/2025,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,4/14/2025,Active,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),
JCMC CP INFUSION,12388,"Cruz, Allan Louie E, MD",5/22/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/14/2023,Inactive,,
JCMC CP INFUSION,12388,"Cruz, Allan Louie E, MD",9/20/2023,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,,9/20/2023,Inactive,,
MMC OP VP INFUSION,16547,"Lee, Patrick C, MD",10/10/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,Neoadjuvant,10/9/2024,Active,,
MMC OP VP INFUSION,40257,"Cohen, Seth D, MD",1/8/2025,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,1/8/2025,Active,,
NBI OP INFUSION,76783,"Jacoby, Sari H, MD",5/12/2025,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/12/2025,Active,Neoplasm of sigmoid colon,"C18.7 - Malignant neoplasm of sigmoid colon; D49.0 - Neoplasm of unspecified behavior of digestive system; D64.9 - Anemia, unspecified"
NBR 4N ONCOLOGY,26679,"Tiger, Yun Kyoung, MD",1/18/2025,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / ) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/17/2025,Active,,
NBR CINJ OP INFUSION,26679,"Tiger, Yun Kyoung, MD",1/22/2025,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - T-Cell Lymphoma,_1. First Line,1/21/2025,Inactive,Peripheral T cell lymphoma of inguinal region (CMS/HCC),
NBR 4N ONCOLOGY,19633,"Tiger, Yun Kyoung, MD",4/14/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/14/2025,Inactive,Peripheral T cell lymphoma of inguinal region (CMS/HCC),
NBR 5N ONCOLOGY,19633,"Tiger, Yun Kyoung, MD",4/14/2025,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - T-Cell Lymphoma,_1. First Line,4/14/2025,Inactive,Peripheral T cell lymphoma of inguinal region (CMS/HCC),"C84.45 - Peripheral t-cell lymphoma, not elsewhere classified, lymph nodes of inguinal region and lower limb"
CINJ OP INFUSION,57914,"Ghodoussipour, Saum Bobak, MD",12/12/2023,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,12/12/2023,Inactive,,
CBMC OP INFUSION 1FL,57282,"Meelheim, Brooke A, DO",5/27/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,5/27/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
CINJ OP INFUSION,38142,"Stephenson, Ryan D, DO",5/9/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,5/9/2025,Active,Metastatic renal cell carcinoma (CMS/HCC),"C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis"
CMMC 3SA MED-SURG/ONCO,64055,"Siu, Karleung, MD",5/7/2025,"Bortezomib D1, D4, D8, D11 21 Day Cycles- Multiple Myeloma",_1. First Line,5/7/2025,Inactive,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; I21.A1 - Myocardial infarction type 2; E46 - Unspecified protein-calorie malnutrition; N17.9 - Acute kidney failure, unspecified; E87.1 - Hypo-osmolality and hyponatremia; G95.29 - Other cord compression; M48.04 - Spinal stenosis, thoracic region; E86.9 - Volume depletion, unspecified; R63.4 - Abnormal weight loss; D63.0 - Anemia in neoplastic disease; M84.48XA - Pathological fracture, other site, initial encounter for fracture; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; R63.0 - Anorexia; K82.8 - Other specified diseases of gallbladder; E83.52 - Hypercalcemia; K59.00 - Constipation, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R79.89 - Other specified abnormal findings of blood chemistry; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; D72.829 - Elevated white blood cell count, unspecified; Z92.3 - Personal history of irradiation; Z91.010 - Allergy to peanuts; Z68.24 - Body mass index (BMI) 24.0-24.9, adult; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
MMC OP VP INFUSION,58057,"Cohen, Seth D, MD",6/30/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,6/28/2023,Inactive,,
MMC OP VP INFUSION,58057,"Cohen, Seth D, MD",11/17/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/16/2023,Inactive,,
MMC OP VP INFUSION,58057,"Cohen, Seth D, MD",11/17/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/13/2023,Inactive,,
CMC OP INFUSION,73505,"Cohen, Seth D, MD",11/20/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_3. Third Line,11/19/2024,Active,,
NBR CINJ OP INFUSION,93309,"Schaar, Dale, MD PhD",1/16/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,1/15/2023,Inactive,,
CINJ OP INFUSION,42445,"George, Mridula A, MD",4/17/2023,Palbociclib 28 Day Cycles - Breast,First Line,4/17/2023,Inactive,,
CINJ OP INFUSION,25671,"George, Mridula A, MD",3/10/2025,CINJ 042305 Phase 1B Arm E  Elacestrant / Capivasertib 28 Day Cycles Research- Breast Cancer,_2. Second Line,3/10/2025,Active,Malignant neoplasm of central portion of right female breast (CMS/HCC),
CINJ OP INFUSION,25671,"George, Mridula A, MD",3/3/2025,CINJ 042305 Phase 1B Cohort 4  Elacestrant / Ribociclib 28 Day Cycles Research- Breast Cancer,_2. Second Line,3/3/2025,Inactive,Malignant neoplasm of central portion of right female breast (CMS/HCC),C50.111 - Malignant neoplasm of central portion of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast; C41.2 - Malignant neoplasm of vertebral column; M99.84 - Other biomechanical lesions of sacral region; N13.2 - Hydronephrosis with renal and ureteral calculous obstruction; R53.1 - Weakness; Z79.811 - Long term (current) use of aromatase inhibitors; Z15.01 - Genetic susceptibility to malignant neoplasm of breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,83966,"George, Mridula A, MD",10/28/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/28/2024,Active,,
CINJ OP INFUSION,29311,"Boland, Patrick M, MD",4/15/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/15/2024,Inactive,,
CINJ OP INFUSION,29311,"Boland, Patrick M, MD",5/31/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/30/2024,Active,,
NBR 5N ONCOLOGY,19319,"Tiger, Yun Kyoung, MD",7/27/2024,Cytarabine (100 mg/m2) / DAUNOrubicin (90 mg/m2) (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,7/26/2024,Inactive,,
NBR 5N ONCOLOGY,19319,"Zayac, Adam, MD",7/29/2024,Cytarabine (200 mg/m2) / DAUNOrubicin (60 mg/m2) (7 + 3) + Midostaurin - FLT3-TKD Acute Myeloid Leukemia (Induction),_1. First Line,7/29/2024,Inactive,,
NBR CINJ OP INFUSION,19319,"Zayac, Adam, MD",9/16/2024,HiDAC-123 + Midostaurin (High-Dose Cytarabine / Midostaurin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,19319,"Egini, Ogechukwu, MD",12/7/2024,BMT UCB Fludarabine / Thiotepa / TBI,_2. Second Line,12/3/2024,Inactive,,
NBR CINJ OP INFUSION,19319,"Egini, Ogechukwu, MD",12/18/2024,BMT UCB Omidubicel / Fludarabine / Thiotepa / TBI  ,_2. Second Line,12/14/2024,Inactive,,
NBR CINJ OP INFUSION,19319,"Egini, Ogechukwu, MD",12/18/2024,BMT UCB Omidubicel / Fludarabine / Thiotepa / TBI  ,_2. Second Line,12/14/2024,Inactive,,
NBR CINJ OP INFUSION,19319,"Egini, Ogechukwu, MD",1/14/2025,BMT UCB  Fludarabine / Thiotepa / TBI,_2. Second Line,12/13/2024,Active,,
CINJ OP INFUSION,93869,"George, Mridula A, MD",3/5/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,3/5/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",C50.812 - Malignant neoplasm of overlapping sites of left female breast; C79.51 - Secondary malignant neoplasm of bone; Z17.21 - Progesterone receptor positive status; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,60919,"Omene, Coral Oghenerukevwe, MD",2/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,2/6/2023,Inactive,,
CINJ OP INFUSION,60919,"Omene, Coral Oghenerukevwe, MD",10/7/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_9. Ninth Line,10/6/2023,Inactive,,
NBI OP INFUSION,63468,"Schleicher, Lori, MD",9/15/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/14/2023,Inactive,,
NBI OP INFUSION,63468,"Schleicher, Lori, MD",9/19/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/18/2023,Inactive,,
NBI OP INFUSION,63468,"Schleicher, Lori, MD",10/31/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/30/2023,Inactive,,
NBI D7 MED-SURG/TELE,63468,"Schleicher, Lori, MD",5/17/2024,RiTUXimab / Lenalidomide 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/8/2024,Inactive,,
NBR CINJ OP INFUSION,63468,"Rhodes, Joanna Meehan, MD",12/3/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_4. Fourth Line,12/2/2024,Active,,
NBI OP INFUSION,63468,"Schleicher, Lori, MD",12/3/2024,Obinutuzumab 28 Day Cycles - Low Grade Indolent Lymphoma ,_3. Third Line,12/2/2024,Inactive,,
CINJ OP INFUSION,73879,"Berim, Lyudmyla, MD",6/24/2024,CINJ 072401 Quemliclustat / Zimberelimab / Gemcitabine / CISplatin 42 Day Cycles Research- Advanced Biliary Tract Cancers,_1. First Line,6/23/2024,Inactive,,
CINJ OP INFUSION,73879,"Berim, Lyudmyla, MD",6/24/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,6/23/2024,Inactive,,
CBMC OP INFUSION 2FL,44101,"Wagmiller, Jennifer Ann, MD",10/13/2023,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,10/13/2023,Inactive,,
CMC OP INFUSION,47685,"Taff, Jessica, MD",6/20/2023,Nivolumab 28 Day Cycles - Merkel Cell Carcinoma,Adjuvant,6/4/2023,Inactive,,
CINJ OP INFUSION,53212,"Boland, Patrick M, MD",4/16/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/15/2025,Active,Adenocarcinoma of sigmoid colon (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon; G89.3 - Neoplasm related pain (acute) (chronic)
CINJ OP INFUSION,98171,"Saraiya, Biren P, MD",7/9/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,7/9/2024,Active,,
CINJ OP INFUSION,98171,"Saraiya, Biren P, MD",1/23/2025,CINJ 082307 Arm 2 Abiraterone + Prednisone 28 Day Cycles Research- Prostate Cancer,_2. Second Line,1/23/2025,Active,,
NBR CINJ OP INFUSION,47419,"Assal, Amer, MD",11/30/2023,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,11/29/2023,Inactive,,
NBR CINJ OP INFUSION,47419,"Assal, Amer, MD",3/27/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,3/26/2024,Inactive,,
NBR CINJ OP INFUSION,47419,"Assal, Amer, MD",3/27/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,3/26/2024,Inactive,,
NBR CINJ OP INFUSION,47419,"Shah, Mansi R, MD",5/22/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_6. Sixth Line,5/22/2024,Inactive,,
NBR CINJ OP INFUSION,47419,"Shah, Mansi R, MD",10/2/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,9/24/2024,Inactive,,
CBMC OP INFUSION 2FL,49825,"Wagmiller, Jennifer Ann, MD",5/16/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,5/6/2024,Inactive,,
CBMC OP INFUSION 2FL,49825,"Wagmiller, Jennifer Ann, MD",5/21/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,49825,"Wagmiller, Jennifer Ann, MD",5/21/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,5/21/2024,Inactive,,
CBMC OP INFUSION 2FL,49825,"Wagmiller, Jennifer Ann, MD",6/10/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,5/28/2024,Inactive,,
CINJ OP INFUSION,19131,"Stephenson, Ryan D, DO",4/30/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,4/30/2025,Active,Malignant neoplasm of prostate (CMS/HCC),C61 - Malignant neoplasm of prostate; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels
NBR CINJ OP INFUSION,90836,"Matasar, Matthew J, MD",3/5/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,3/5/2025,Inactive,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,72355,"Goel, Sanjay, MD",5/28/2025,CINJ 052410 Arm 2 MK-0472 / Pembrolizumab 21 Day Cycles Research- Advanced / Metastatic Solid Tumors,_4. Fourth Line,5/28/2025,Active,Malignant neoplasm of body of stomach (CMS/HCC),
NBI OP INFUSION,12226,"Jacoby, Sari H, MD",2/13/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/12/2024,Active,,
TRMC TCCC OP INFUSION,26896,"Salerno, Vincent E, MD",10/16/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/14/2024,Inactive,,
NBI OP INFUSION,17581,"Shah, Maya M, MD",12/18/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/17/2024,Active,,
CINJ OP INFUSION,47324,"Weiss, Sarah, MD",4/4/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles- Cutaneous Melanoma,First Line,4/3/2023,Inactive,,
NBR 5N ONCOLOGY,53693,"Zayac, Adam, MD",5/13/2025,Cytarabine / IDArubicin (7 + 3) + Gemtuzumab ozogamicin (GO) - Acute Myeloid Leukemia (Induction),_1. First Line,5/13/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C95.00 - Acute leukemia not having achieved remission (CMS/HCC); C95.90 - Leukemia not having achieved remission, unspecified leukemia type (CMS/HCC)"
NBR 5N ONCOLOGY,53693,"Zayac, Adam, MD",5/13/2025,Cytarabine / DAUNOrubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),_1. First Line,5/13/2025,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C95.00 - Acute leukemia not having achieved remission (CMS/HCC); C95.90 - Leukemia not having achieved remission, unspecified leukemia type (CMS/HCC)"
MMC OP VP INFUSION,6921,"Cohen, Seth D, MD",5/14/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/14/2025,Active,Mediastinal lymphadenopathy,
NBR MEDICAL SAME DAY,25474,"Ghodoussipour, Saum Bobak, MD",2/5/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/5/2025,Active,Urothelial carcinoma (CMS/HCC),
MMC OP VP INFUSION,98922,"Lee, Patrick C, MD",10/18/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/17/2024,Inactive,,
MMC OP VP INFUSION,98922,"Lee, Patrick C, MD",1/10/2025,Keytruda 6 week cycle,_1. First Line,1/9/2025,Active,,
MMC OP VP INFUSION,72468,"Lee, Patrick C, MD",2/21/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/20/2025,Active,"Adenocarcinoma, lung, right (CMS/HCC)
On antineoplastic chemotherapy",
MMC OP VP INFUSION,72468,"Lee, Patrick C, MD",2/28/2025,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,2/27/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),
MMC OP VP INFUSION,15054,"Cohen, Seth D, MD",7/17/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/17/2024,Active,,
CINJ OP INFUSION,96339,"Stephenson, Ryan D, DO",4/26/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,4/25/2024,Inactive,,
NBR CINJ OP INFUSION,94031,"Mayer, Tina M, MD",2/25/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,2/25/2025,Active,Prostate cancer (CMS/HCC),
CINJ OP INFUSION,76261,"Ghodoussipour, Saum Bobak, MD",12/6/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,12/6/2023,Active,,
MSC OP INFUSION,88239,"Cohen, Seth D, MD",6/8/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,First Line,6/7/2023,Inactive,,
CINJ OP INFUSION,6281,"Patel, Eshan, MD",4/26/2024,durvalumab /CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/26/2024,Inactive,Small cell lung cancer (CMS/HCC),
CINJ OP INFUSION,6281,"Patel, Eshan, MD",8/9/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,8/8/2024,Inactive,Small cell lung cancer (CMS/HCC),
CINJ OP INFUSION,6281,"Haigentz, Missak, MD",11/22/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,11/21/2024,Inactive,Small cell lung cancer (CMS/HCC),
CINJ OP INFUSION,6281,"Haigentz, Missak, MD",1/14/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,1/14/2025,Active,,
HAM OP INFUSION,62094,"Yogarajah, Meera, MD",5/22/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/14/2023,Inactive,,
MMC OP VP INFUSION,56395,"Cohen, Seth D, MD",4/26/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,,4/25/2023,Inactive,,
CBMC OP INFUSION 2FL,87862,"Litvak, Anna M, MD",10/19/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,10/18/2023,Inactive,,
CBMC OP INFUSION 2FL,87862,"Ligresti, Louise G, MD",6/27/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,6/26/2024,Inactive,,
CBMC OP INFUSION 2FL,87862,"Ligresti, Louise G, MD",6/28/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,6/28/2024,Inactive,,
CBMC OP INFUSION 2FL,87862,"Litvak, Anna M, MD",10/18/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,9/26/2024,Active,Primary malignant neoplasm of glottis (CMS/HCC),
CBMC 2W ONCOLOGY,88193,"Grossman, I Robert, MD",4/25/2025,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,4/24/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),"D46.9 - Myelodysplastic syndrome, unspecified; Z66 - Do not resuscitate; D63.0 - Anemia in neoplastic disease; D75.81 - Myelofibrosis; F32.A - Depression, unspecified; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; Z11.52 - Encounter for screening for COVID-19; K59.00 - Constipation, unspecified; E87.6 - Hypokalemia; T50.2X5A - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter; E87.70 - Fluid overload, unspecified; G62.9 - Polyneuropathy, unspecified; G47.00 - Insomnia, unspecified; F41.9 - Anxiety disorder, unspecified; L29.89 - Other pruritus; R21 - Rash and other nonspecific skin eruption; Z86.16 - Personal history of COVID-19; Z80.0 - Family history of malignant neoplasm of digestive organs; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z96.653 - Presence of artificial knee joint, bilateral; Z98.41 - Cataract extraction status, right eye; Z91.041 - Radiographic dye allergy status; Z88.2 - Allergy status to sulfonamides; Z88.5 - Allergy status to narcotic agent; Z91.09 - Other allergy status, other than to drugs and biological substances; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.51 - Long term (current) use of inhaled steroids"
CINJ OP INFUSION,73065,"Stephenson, Ruth D, DO",5/28/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/27/2024,Active,,
CINJ OP INFUSION,73065,"Stephenson, Ruth D, DO",5/31/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/30/2024,Inactive,,
CMC OP INFUSION,77636,"Talwar, Sumit, MD",5/17/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/8/2023,Inactive,,
CMC OP INFUSION,77636,"Easaw, Sarah, MD",7/26/2023,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",First Line,7/25/2023,Inactive,,
SOM OUTPT INFUSION,43486,"Toomey, Kathleen C, MD",10/10/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/8/2024,Active,,
NBI OP INFUSION,26306,"Snyder, Rose, MD",2/12/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,_1. First Line,2/11/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,40898,"Snyder, Rose, MD",12/17/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,12/16/2024,Active,,
CMC OP INFUSION,53649,"Talwar, Sumit, MD",6/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/11/2024,Inactive,,
CBMC OP INFUSION 2FL,75023,"Litvak, Anna M, MD",11/17/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,72402,"Litvak, Anna M, MD",11/9/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,72402,"Litvak, Anna M, MD",11/20/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,11/19/2023,Inactive,,
CBMC OP INFUSION 2FL,72402,"Litvak, Anna M, MD",11/20/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,72402,"Litvak, Anna M, MD",11/20/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,11/19/2023,Inactive,,
CBMC OP INFUSION 2FL,72402,"Litvak, Anna M, MD",2/12/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,2/11/2024,Inactive,,
CBMC OP INFUSION 2FL,72402,"Ligresti, Louise G, MD",3/13/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,3/3/2024,Inactive,,
SOM OUTPT INFUSION,88246,"Patel, Eshan, MD",4/10/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,4/9/2024,Active,,
CBMC OP INFUSION 2FL,24220,"Grossman, I Robert, MD",6/2/2023,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,6/1/2023,Inactive,,
NBR 4N BMTU/IMCU,24220,"Braunschweig, Ira, MD",12/14/2023,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,12/12/2023,Active,,
CBMC OP INFUSION 2FL,24220,"Grossman, I Robert, MD",3/12/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,3/11/2024,Active,,
MMC OP VP INFUSION,35836,"Cohen, Seth D, MD",6/14/2023,Enfortumab Vedotin + Pembrolizumab (Keynote 869) 21 Day Cycles - Bladder,First Line,6/13/2023,Inactive,,
NBI OP INFUSION,72647,"Shah, Shailja S, MD",3/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/4/2024,Active,,
CINJ OP INFUSION,27772,"Jang, Thomas L, MD",11/16/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,11/16/2023,Active,,
NBI OP INFUSION,11422,"Anderson, Patrick S, MD",9/12/2024,PACLitaxel / CARBOplatin Post Concurrent Radiation Consolidation 21 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,8/28/2024,Inactive,,
NBI OP INFUSION,11422,"Anderson, Patrick S, MD",9/12/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - advanced High Grade Endometrial cancer Cancer,_1. First Line,9/11/2024,Inactive,,
CBMC OP INFUSION 2FL,13938,"Leitner, Stuart P, MD",9/11/2023,Avelumab 14 Day Cycles - Merkel Cell Carcinoma,_1. First Line,9/10/2023,Inactive,,
CBMC OP INFUSION 2FL,13938,"Leitner, Stuart P, MD",6/3/2024,Avelumab 14 Day Cycles - Merkel Cell Carcinoma,_1. First Line,6/2/2024,Active,,
CBMC OP INFUSION 2FL,13938,"Leitner, Stuart P, MD",11/18/2024,Avelumab 28 Day Cycles - Merkel Cell Carcinoma or Endometrial Carcinoma or Gestational Trophoblastic Neoplasia or Bladder Cancer,_1. First Line,11/17/2024,Active,,
CMC OP INFUSION,44891,"Talwar, Sumit, MD",5/15/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/14/2024,Inactive,,
CBMC OP INFUSION 2FL,72764,"Brown, Andrew Bennett, MD",12/27/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,12/23/2024,Active,,
CBMC OP INFUSION 2FL,72764,"Brown, Andrew Bennett, MD",5/20/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,5/20/2025,Active,"Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)",
CINJ OP INFUSION,18667,"Gulhati, Prateek, MD PhD",3/20/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/20/2025,Active,"Malignant neoplasm of colon (CMS/HCC)
Other abnormal tumor markers","C18.9 - Malignant neoplasm of colon, unspecified; T81.72XD - Complication of vein following a procedure, not elsewhere classified, subsequent encounter; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; E03.9 - Hypothyroidism, unspecified; G62.9 - Polyneuropathy, unspecified; R97.8 - Other abnormal tumor markers; Z90.89 - Acquired absence of other organs"
CMC 4B ONCOLOGY,93294,"Taff, Jessica, MD",4/11/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/10/2024,Inactive,,
CINJ OP INFUSION,72909,"Hochster, Howard S, MD",5/9/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/8/2024,Active,,
CINJ OP INFUSION,37389,"Boland, Patrick M, MD",9/8/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,9/7/2023,Inactive,,
CINJ OP INFUSION,37389,"Boland, Patrick M, MD",12/27/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,12/25/2024,Inactive,,
CINJ OP INFUSION,37389,"Boland, Patrick M, MD",12/27/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,12/26/2024,Active,,
CINJ OP INFUSION,17574,"Boland, Patrick M, MD",3/7/2025,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,3/7/2025,Active,Cancer of ampulla of Vater (CMS/HCC),C24.1 - Malignant neoplasm of ampulla of Vater
MMC OP VP INFUSION,21014,"Eltoukhy, Hussam, MD",3/15/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/14/2024,Inactive,,
NBR CINJ OP INFUSION,21014,"Tiger, Yun Kyoung, MD",6/18/2024,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,6/17/2024,Inactive,,
NBR CINJ OP INFUSION,21014,"Tiger, Yun Kyoung, MD",7/10/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,7/9/2024,Inactive,,
CBMC OP INFUSION 2FL,92166,"Brown, Andrew Bennett, MD",10/25/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/19/2023,Inactive,,
HAM OP INFUSION,16921,"Yogarajah, Meera, MD",7/9/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,7/8/2024,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),
MMC OP VP INFUSION,89198,"Cohen, Seth D, MD",2/19/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,1/19/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CINJ OP INFUSION,55761,"Mayer, Tina M, MD",6/9/2023,Enzalutamide 28 Day Cycles - Prostate,,6/9/2023,Active,,
NBR 4N BMTU/IMCU,12280,"Schaar, Dale, MD PhD",1/25/2023,BMT Autologous BEAM,,1/24/2023,Inactive,,
CMC OP INFUSION,12280,"Eltoukhy, Hussam, MD",6/20/2023,RiTUXimab 56 Day Cycles - Mantle cell Maintenance,Maintenance,6/19/2023,Active,"Malignant tumor of paranasal sinuses (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)
Secondary malignant neoplasm of right lung (CMS/HCC)
Secondary malignant neoplasm of mediastinal lymph nodes (CMS/HCC)",
HAM OP INFUSION,92178,"Yogarajah, Meera, MD",8/6/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/5/2024,Active,,
CINJ OP INFUSION,19815,"Haigentz, Missak, MD",7/12/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,7/12/2023,Active,,
NBR CINJ OP INFUSION,25373,"Shah, Mansi R, MD",1/16/2023,Teclistamab Weekly 28 Day Cycles- Multiple Myeloma,,1/13/2023,Inactive,,
NBR CINJ OP INFUSION,25373,"Shah, Mansi R, MD",3/14/2023,Elotuzumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,,3/13/2023,Inactive,,
NBR CINJ OP INFUSION,25373,"Shah, Mansi R, MD",3/14/2023,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,,3/13/2023,Inactive,,
CBMC OP INFUSION 2FL,77425,"Dave, Manish, MD",11/29/2023,Carfilzomib 27 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/28/2023,Inactive,Extramedullary plasmacytoma in relapse (CMS/HCC),
CBMC OP INFUSION 2FL,77425,"Phillips, Adrienne A, MD",1/27/2025,Ixazomib/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,1/27/2025,Active,,
HAM OP INFUSION,97844,"Yogarajah, Meera, MD",4/29/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/29/2025,Active,Malignant neoplasm of pyloric antrum (CMS/HCC),
NBR BMSCH 2 PED HEMONC,65190,"Moerdler, Scott, MD",2/23/2023,PEDS IE - Osteosarcoma,,2/22/2023,Inactive,,
CINJ PEDS HEMONC ,65190,"Moerdler, Scott, MD",9/27/2023,Cabozantinib 28 Day Cycles - Metastatic Osteosarcoma ,Third Line,9/27/2023,Inactive,,
MMC OP VP INFUSION,57507,"Cohen, Seth D, MD",1/15/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,1/15/2024,Active,,
HAM OP INFUSION,29434,"Yogarajah, Meera, MD",10/3/2024,Darolutamide 28 Day Cycles - Prostate,_3. Third Line,10/3/2024,Active,,
HAM OP INFUSION,90210,"Yogarajah, Meera, MD",10/24/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,10/23/2023,Active,,
CINJ OP INFUSION,23607,"Stephenson, Ryan D, DO",10/19/2023,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,10/19/2023,Inactive,,
CINJ OP INFUSION,86308,"George, Mridula A, MD",8/2/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,8/2/2024,Active,,
CINJ OP INFUSION,86308,"George, Mridula A, MD",2/5/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,2/5/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.0 - Estrogen receptor positive status (ER+)
NBR 5N ONCOLOGY,47449,"Goel, Sanjay, MD",7/25/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,,7/24/2023,Inactive,,
CINJ OP INFUSION,47449,"Berim, Lyudmyla, MD",3/6/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/5/2024,Inactive,,
CINJ OP INFUSION,47449,"Berim, Lyudmyla, MD",7/3/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,6/30/2024,Inactive,,
NBI OP INFUSION,92817,"Snyder, Rose, MD",5/28/2025,Ruxolitinib 30 Day Cycles - Myelofibrosis,_2. Second Line,5/28/2025,Active,Polycythemia vera (CMS/HCC),D45 - Polycythemia vera
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",6/7/2024,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,6/6/2024,Inactive,,
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",6/7/2024,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,6/6/2024,Inactive,,
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",7/31/2024,Bevacizumab / Pembrolizumab 21 Day Cycles - Ovarian with oral cyclophosphamide,_7. Seventh Line,7/31/2024,Inactive,,
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",8/9/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_7. Seventh Line,8/8/2024,Inactive,,
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",11/20/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_6. Sixth Line,11/19/2024,Active,,
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",12/2/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,12/2/2024,Active,,
CINJ OP INFUSION,4979,"Stephenson, Ruth D, DO",2/5/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_9. Ninth Line,2/4/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),C56.3 - Malignant neoplasm of bilateral ovaries
CINJ OP INFUSION,1318,"Haigentz, Missak, MD",4/22/2025,PACLitaxel/CARBOplatin + Bevacizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/22/2025,Active,"Malignant neoplasm of lower lobe of left lung (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)","C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; C79.51 - Secondary malignant neoplasm of bone"
JCMC CP INFUSION,26762,"Cruz, Allan Louie E, MD",12/18/2024,DOCEtaxel 28 Day Cycles - Prostate,_3. Third Line,12/18/2024,Active,,
CINJ OP INFUSION,58398,"Stephenson, Ryan D, DO",2/15/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,2/15/2024,Active,,
CINJ OP INFUSION,67594,"Girda, Eugenia, MD",5/13/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,5/12/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; Z85.42 - Personal history of malignant neoplasm of other parts of uterus
CINJ OP INFUSION,18058,"Hochster, Howard S, MD",4/23/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/23/2025,Inactive,Malignant neoplasm of pancreas (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K83.1 - Obstruction of bile duct; C25.9 - Malignant neoplasm of pancreas, unspecified; R79.1 - Abnormal coagulation profile"
CBMC OP INFUSION 2FL,62362,"Wagmiller, Jennifer Ann, MD",3/12/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,3/10/2024,Inactive,,
CBMC OP INFUSION 2FL,62362,"Wagmiller, Jennifer Ann, MD",6/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,6/3/2024,Inactive,,
CBMC OP INFUSION 2FL,62362,"Wagmiller, Jennifer Ann, MD",6/4/2024,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Neoadjuvant,6/4/2024,Active,,
CINJ OP INFUSION,36031,"Leiser, Aliza, MD",3/21/2023,"CINJ 102103 Cohort 1 PACLitaxel / CARBOplatin / Oregovomab or Placebo 21 Day Cycles Research- Ovarian, Fallopian Tube, or Peritoneal Carcinoma",First Line,3/20/2023,Inactive,,
CINJ OP INFUSION,36031,"Leiser, Aliza, MD",8/29/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/28/2023,Inactive,,
CINJ OP INFUSION,36031,"Leiser, Aliza, MD",10/18/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_3. Third Line,10/17/2023,Inactive,,
CINJ OP INFUSION,36031,"Leiser, Aliza, MD",10/19/2023,PACLitaxel weekly 28 Day Cycles,_3. Third Line,10/17/2023,Inactive,,
CBMC OP INFUSION 2FL,15767,"Litvak, Anna M, MD",10/30/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,15767,"Wagmiller, Jennifer Ann, MD",5/13/2024,Pembrolizumab 42 Day Cycles -  Breast,Neoadjuvant,5/6/2024,Inactive,,
CBMC 2W ONCOLOGY,15767,"Wagmiller, Jennifer Ann, MD",1/10/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,1/9/2025,Active,,
CBMC 2W ONCOLOGY,15767,"Wagmiller, Jennifer Ann, MD",2/12/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,2/3/2025,Active,"Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor negative (CMS/HCC)","C79.31, C79.49 - Secondary malignant neoplasm of brain and spinal cord (CMS/HCC); H53.8 - Blurred vision; R53.1 - Weakness; R73.9 - Hyperglycemia; G93.89 - Brain mass; Z85.3 - Hx of breast cancer; K76.9 - Liver lesion; G93.9 - Brain lesion; Z33.2 - Encounter for elective termination of pregnancy; C50.919, C79.31 - Malignant neoplasm of breast metastatic to brain, unspecified laterality (CMS/HCC); R51.9 - Acute intractable headache, unspecified headache type; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes (CMS/HCC); C50.311, Z17.1 - Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor negative (CMS/HCC); C50.919, Z17.421 - Triple negative breast cancer (CMS/HCC)"
CBMC OP INFUSION 2FL,96387,"Wagmiller, Jennifer Ann, MD",8/26/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,8/25/2024,Active,,
NBR 4N BMTU/IMCU,88662,"Desai, Sahaj, MD",1/29/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,1/29/2024,Inactive,,
NBR CINJ OP INFUSION,88662,"Rhodes, Joanna Meehan, MD",1/30/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/30/2024,Inactive,,
CBMC OP INFUSION 2FL,79193,"Wagmiller, Jennifer Ann, MD",8/4/2023,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,8/3/2023,Inactive,,
CBMC OP INFUSION 2FL,79193,"Wagmiller, Jennifer Ann, MD",5/31/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,79193,"Wagmiller, Jennifer Ann, MD",9/16/2024,Topotecan 21 Day Cycles - Uterine,_3. Third Line,9/15/2024,Inactive,,
CINJ OP INFUSION,79193,"Girda, Eugenia, MD",11/19/2024,CINJ 052401 Part A Enrichment GIM-122,_4. Fourth Line,11/19/2024,Active,,
CBMC OP INFUSION 2FL,68042,"Wagmiller, Jennifer Ann, MD",9/26/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/22/2024,Inactive,,
CBMC OP INFUSION 2FL,68042,"Wagmiller, Jennifer Ann, MD",1/30/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/29/2025,Active,Prostate cancer (CMS/HCC),
CMC OP INFUSION,93377,"Pompa, Tiffany Ann, MD",4/29/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,Adjuvant,4/29/2025,Active,High grade neuroendocrine carcinoma of lung (CMS/HCC),C34.11 - Malignant neoplasm of upper lobe of right lung (CMS/HCC)
MMC OP VP INFUSION,7101,"Cohen, Seth D, MD",7/31/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,First Line,7/31/2023,Inactive,,
MMC OP VP INFUSION,7101,"Cohen, Seth D, MD",6/3/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,6/3/2024,Inactive,,
CMC OP INFUSION,20877,"Cohen, Seth D, MD",2/13/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,2/7/2025,Active,"Squamous cell carcinoma of skin, unspecified
Hypothyroidism, unspecified type
End stage renal disease (CMS/HCC)",
CBMC OP INFUSION 2FL,27402,"Brown, Andrew Bennett, MD",2/27/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/26/2025,Active,Hypopharyngeal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,27402,"Brown, Andrew Bennett, MD",3/7/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,3/7/2025,Active,Hypopharyngeal cancer (CMS/HCC),
CINJ OP INFUSION,65893,"Groisberg, Roman, MD",6/14/2024,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,Induction,6/12/2024,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Encounter for immunization",
CINJ OP INFUSION,65893,"Groisberg, Roman, MD",6/15/2024,PEDS AEWS1031 Regimen A Induction & Consolidation,Induction,6/13/2024,Inactive,,
NBR 4N BMTU/IMCU,65893,"Girda, Eugenia, MD",9/4/2024,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_2. Second Line,9/3/2024,Inactive,,
CMC OP INFUSION,22631,"Taff, Jessica, MD",12/4/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/3/2023,Inactive,,
CMC OP INFUSION,22631,"Taff, Jessica, MD",3/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,2/29/2024,Inactive,,
CINJ OP INFUSION,79156,"Patel, Eshan, MD",6/7/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,5/30/2024,Active,,
CINJ OP INFUSION,79156,"Patel, Eshan, MD",10/4/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/5/2024,Active,,
NBR 5N ONCOLOGY,48325,"Palmisiano, Neil David, MD",1/23/2023,CINJ 022105 Magrolimab or Placebo / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,Induction,12/23/2022,Inactive,,
NBR CINJ OP INFUSION,48325,"Eltoukhy, Hussam, MD",1/24/2023,CINJ 022105 Magrolimab or Placebo Research- Acute Myeloid Leukemia,,12/23/2022,Inactive,,
NBR CINJ OP INFUSION,48325,"Eltoukhy, Hussam, MD",1/24/2023,CINJ 022105 Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,,1/24/2023,Inactive,,
NBR CINJ OP INFUSION,48325,"Eltoukhy, Hussam, MD",3/3/2023,CINJ 022105 Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,,3/3/2023,Inactive,,
MMC OP INFUSION,48325,"Eltoukhy, Hussam, MD",6/7/2023,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,48325,"Palmisiano, Neil David, MD",6/26/2023,DAUNOrubicin Liposomal - Cytarabine (VYXEOS) - Induction 14 Day Cycle - Acute Myeloid Leukemia,,6/26/2023,Inactive,,
NBR CINJ OP INFUSION,48325,"Palmisiano, Neil David, MD",7/6/2023,"CINJ 022204 LYT- 200 28 Day Cycles Research -  Acute Myeloid Leukemia (AML), & MDS",,7/6/2023,Inactive,,
MMC OP INFUSION,48325,"Eltoukhy, Hussam, MD",10/2/2023,Decitabine 10 day,,10/1/2023,Inactive,,
MMC OP INFUSION,48325,"Eltoukhy, Hussam, MD",10/2/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles,,10/1/2023,Inactive,,
MMC OP INFUSION,48325,"Eltoukhy, Hussam, MD",10/26/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,10/24/2023,Inactive,,
CINJ OP INFUSION,88023,"Berim, Lyudmyla, MD",11/8/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,11/3/2023,Inactive,,
CINJ OP INFUSION,88023,"Goel, Sanjay, MD",10/9/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,10/9/2024,Inactive,,
CINJ OP INFUSION,88023,"Berim, Lyudmyla, MD",12/4/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/2/2024,Active,,
NBR CINJ OP INFUSION,74237,"Evens, Andrew M, DO",8/16/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,Second Line,8/15/2023,Inactive,,
CINJ OP INFUSION,71605,"Leiser, Aliza, MD",2/26/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/24/2025,Active,Malignant neoplasm of left ovary (CMS/HCC),C56.2 - Malignant neoplasm of left ovary
CINJ OP INFUSION,82774,"Stephenson, Ryan D, DO",3/6/2024,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,3/6/2024,Inactive,,
NBI OP INFUSION,21670,"Cheng, Yan Ho, MD",9/30/2024,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,_1. First Line,9/22/2024,Inactive,,
NBI OP INFUSION,21670,"Cheng, Yan Ho, MD",9/30/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,9/29/2024,Active,,
CINJ OP INFUSION,13100,"Berim, Lyudmyla, MD",12/21/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/20/2023,Inactive,,
CINJ OP INFUSION,13100,"Berim, Lyudmyla, MD",1/8/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2024,Inactive,,
CINJ OP INFUSION,13100,"Berim, Lyudmyla, MD",7/22/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,7/22/2024,Active,,
CINJ OP INFUSION,61683,"Boland, Patrick M, MD",3/14/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,,3/13/2023,Inactive,,
MMC OP VP INFUSION,68065,"Lee, Patrick C, MD",10/18/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/9/2024,Active,,
CMC OP INFUSION,82635,"Shah, Mansi R, MD",11/6/2023,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,Maintenance,10/26/2023,Inactive,,
CINJ OP INFUSION,97839,"Ghodoussipour, Saum Bobak, MD",2/19/2025,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,2/18/2025,Active,Malignant neoplasm of left renal pelvis (CMS/HCC),C65.2 - Malignant neoplasm of left renal pelvis
NBR CINJ OP INFUSION,32854,"Shah, Mansi R, MD",11/17/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,11/16/2023,Inactive,,
NBR CINJ OP INFUSION,32854,"Shah, Mansi R, MD",10/24/2024,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,10/23/2024,Active,,
CBMC OP INFUSION 2FL,16187,"Scoppetuolo, Michael, MD",7/19/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/18/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57971,"Drachtman, Richard, MD",8/24/2023,PEDS AEWS1031 Regimen A Induction & Consolidation,First Line,8/24/2023,Inactive,,
CINJ PEDS HEMONC ,57971,"Moerdler, Scott, MD",7/25/2024,PEDS VIT - Relapse Sarcoma ,_2. Second Line,7/24/2024,Inactive,,
CINJ PEDS HEMONC ,57971,"Moerdler, Scott, MD",2/25/2025,PEDS VIT - Relapse Sarcoma ,_2. Second Line,2/24/2025,Active,Relapsed Ewing's sarcoma (CMS/HCC),
CINJ PEDS HEMONC ,57971,"Moerdler, Scott, MD",5/2/2025,PEDS Cyclophosphamide / Topotecan/Cabozantinib- Relapsed / Refractory Solid Tumors,_3. Third Line,5/2/2025,Active,Relapsed Ewing's sarcoma (CMS/HCC),"C41.9 - Malignant neoplasm of bone and articular cartilage, unspecified; C78.2 - Secondary malignant neoplasm of pleura; C79.51 - Secondary malignant neoplasm of bone; I10 - Essential (primary) hypertension; K59.00 - Constipation, unspecified; Z60.3 - Acculturation difficulty; Z11.52 - Encounter for screening for COVID-19; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z90.2 - Acquired absence of lung (part of); Z82.5 - Family history of asthma and other chronic lower respiratory diseases; Z84.89 - Family history of other specified conditions; Z87.01 - Personal history of pneumonia (recurrent)"
CINJ PEDS HEMONC ,57971,"Moerdler, Scott, MD",4/15/2025,Erlotinib 28 Day Cycles,_3. Third Line,4/15/2025,Inactive,Relapsed Ewing's sarcoma (CMS/HCC),
CINJ OP INFUSION,98221,"Muralikrishnan, Sivraj, MD",1/2/2025,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/31/2024,Inactive,"Primary lung adenocarcinoma, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,98221,"Muralikrishnan, Sivraj, MD",1/23/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/22/2025,Active,,
CINJ OP INFUSION,47240,"Patel, Eshan, MD",10/1/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/19/2024,Inactive,,
CBMC OP INFUSION 2FL,4501,"Brown, Andrew Bennett, MD",10/16/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,10/15/2023,Inactive,,
CBMC OP INFUSION 2FL,4501,"Brown, Andrew Bennett, MD",1/26/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,1/25/2024,Inactive,,
CBMC OP INFUSION 2FL,4501,"Brown, Andrew Bennett, MD",4/11/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/11/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
HAM OP INFUSION,9185,"Yogarajah, Meera, MD",4/4/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,Maintenance,4/4/2023,Inactive,,
MMC OP VP INFUSION,19882,"Lee, Patrick C, MD",1/19/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,1/18/2023,Inactive,,
CINJ OP INFUSION,55280,"Stephenson, Ryan D, DO",8/18/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,First Line,8/18/2023,Inactive,,
NBR 5N ONCOLOGY,55280,"Stephenson, Ryan D, DO",12/7/2023,TI-CE (PACLitaxel / Ifosfamide) 14 Day Cycles - Germ Cell Tumors,_2. Second Line,12/7/2023,Inactive,,
NBR 4N BMTU/IMCU,36742,"Zayac, Adam, MD",3/28/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,3/28/2024,Inactive,,
NBR 4N BMTU/IMCU,36742,"Zayac, Adam, MD",4/4/2024,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,4/2/2024,Inactive,,
NBR 4N BMTU/IMCU,36742,"Zayac, Adam, MD",4/4/2024,Methotrexate Intrathecal 12 mg IT / Cytarabine Intrathecal 70 mg IT - Hematological Malignancies,_1. First Line,4/4/2024,Inactive,,
NBR CINJ OP INFUSION,36742,"Zayac, Adam, MD",7/15/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,6/25/2024,Inactive,,
NBR CINJ OP INFUSION,36742,"Zayac, Adam, MD",8/13/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,8/13/2024,Inactive,,
NBR CINJ OP INFUSION,36742,"Zayac, Adam, MD",11/5/2024,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,11/5/2024,Active,,
NBR CINJ OP INFUSION,36742,"Zayac, Adam, MD",2/21/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_2. Second Line,2/21/2025,Inactive,"Leukemia not having achieved remission, unspecified leukemia type (CMS/HCC)
B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)",
NBI OP INFUSION,33683,"Shah, Maya M, MD",12/11/2023,Zanubrutinib (320 mg) 30 Day Cycles - Mantle Cell Lymphoma,_3. Third Line,12/11/2023,Inactive,,
NBI OP INFUSION,33683,"Jacoby, Sari H, MD",4/22/2024,Bortezomib-Rituximab 21 Day Cycles - Mantle Cell Lymphoma,_3. Third Line,4/21/2024,Inactive,,
TRMC TCCC OP INFUSION,90350,"Capo, Gerardo, MD",10/10/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,10/9/2023,Active,Renal cell carcinoma (CMS/HCC),
CINJ OP INFUSION,17663,"George, Mridula A, MD",11/1/2023,Capecitabine 21 Day Cycles - Breast,Maintenance,11/1/2023,Inactive,,
CINJ OP INFUSION,17663,"George, Mridula A, MD",2/14/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,2/13/2024,Active,,
JCMC CP INFUSION,12316,"Cruz, Allan Louie E, MD",3/18/2024,Fluorouracil Continuous Infusion/Mitomycin 12 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,Induction,2/27/2024,Inactive,,
CINJ OP INFUSION,55283,"Leiser, Aliza, MD",3/4/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,2/28/2024,Inactive,,
CINJ OP INFUSION,55283,"Leiser, Aliza, MD",9/13/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,9/13/2024,Active,,
CBMC OP INFUSION 2FL,70080,"Wagmiller, Jennifer Ann, MD",7/26/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,7/25/2023,Inactive,,
NBR 5N ONCOLOGY,20503,"Tiger, Yun Kyoung, MD",2/20/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Neoadjuvant,2/20/2024,Inactive,,
NBR CINJ OP INFUSION,20503,"Tiger, Yun Kyoung, MD",3/1/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,2/29/2024,Inactive,,
NBR CINJ OP INFUSION,20503,"Tiger, Yun Kyoung, MD",3/1/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/28/2024,Inactive,,
NBR CINJ OP INFUSION,20503,"Tiger, Yun Kyoung, MD",7/22/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_1. First Line,7/18/2024,Inactive,,
JCMC CP INFUSION,42283,"Sekhri, Arunabh, MD",10/16/2023,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,10/15/2023,Inactive,,
NBR CINJ OP INFUSION,14059,"Shah, Mansi R, MD",1/17/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,1/16/2023,Inactive,,
NBR CINJ OP INFUSION,14945,"Shah, Mansi R, MD",4/18/2025,Carfilzomib/POm,_5. Fifth Line,4/18/2025,Inactive,"Multiple myeloma, failed remission (CMS/HCC)",
NBR CINJ OP INFUSION,14945,"Shah, Mansi R, MD",4/1/2025,Carfilzomib 56 mg/m2 Weekly / Pomalyst Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_8. Eighth Line,4/1/2025,Inactive,"Multiple myeloma, failed remission (CMS/HCC)",
CINJ OP INFUSION,7883,"Groisberg, Roman, MD",1/10/2025,PACLitaxel 21 Day Cycles - Breast,_2. Second Line,1/9/2025,Active,,
CINJ OP INFUSION,5281,"Groisberg, Roman, MD",5/9/2025,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_3. Third Line,5/9/2025,Active,"Primary angiosarcoma of heart (CMS/HCC)
Metastasis to bone (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C38.0 - Malignant neoplasm of heart
TRMC TCCC OP INFUSION,89885,"Capo, Gerardo, MD",5/28/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,5/27/2024,Inactive,,
CINJ OP INFUSION,22804,"George, Mridula A, MD",3/21/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/21/2025,Active,Malig neoplasm of upper-inner quadrant of unsp female breast (CMS/HCC),C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z90.12 - Acquired absence of left breast and nipple; C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.219 - Malignant neoplasm of upper-inner quadrant of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBR CINJ OP INFUSION,25871,"Evens, Andrew M, DO",2/13/2025,CINJ 012321 Dose Escalation ABBV-101 28 Day Cycles Research- Non-Hodgkin's Lymphoma (B-Cell Malignancies),_2. Second Line,2/13/2025,Active,"Mantle cell lymphoma (CMS/HCC)
Other specified diseases of liver
Need for hepatitis B screening test",
NBR CINJ OP INFUSION,25871,"Evens, Andrew M, DO",5/1/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,5/1/2025,Active,"Mantle cell lymphoma (CMS/HCC)
Abnormal coagulation profile
Diffuse large b-cell lymphoma, intra-abdominal lymph nodes (CMS/HCC)",
NBR CINJ OP INFUSION,25871,"Evens, Andrew M, DO",4/2/2025,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_3. Third Line,3/26/2025,Active,Mantle cell lymphoma (CMS/HCC),"C83.10 - Mantle cell lymphoma, unspecified site; Z00.6 - Encounter for examination for normal comparison and control in clinical research program"
SOM OUTPT INFUSION,44042,"Toomey, Kathleen C, MD",6/12/2024,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,_1. First Line,6/11/2024,Inactive,,
SOM OUTPT INFUSION,44042,"Toomey, Kathleen C, MD",6/13/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,6/12/2024,Inactive,,
SOM OUTPT INFUSION,44042,"Toomey, Kathleen C, MD",12/5/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,11/14/2024,Active,,
CINJ OP INFUSION,49308,"Boland, Patrick M, MD",11/5/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/31/2024,Active,,
CINJ OP INFUSION,9099,"Boland, Patrick M, MD",3/7/2025,FOLFIRI Inpatient (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,3/7/2025,Inactive,Malignant neoplasm of body of stomach (CMS/HCC),C16.2 - Malignant neoplasm of body of stomach; I48.0 - Paroxysmal atrial fibrillation
CINJ OP INFUSION,9099,"Boland, Patrick M, MD",3/7/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,3/7/2025,Active,Malignant neoplasm of body of stomach (CMS/HCC),C16.2 - Malignant neoplasm of body of stomach; I48.0 - Paroxysmal atrial fibrillation
HAM OP INFUSION,11941,"Patel, Malini M, MD",5/29/2024,Ibrutinib 28 Day Cycles - Waldenstrom Macroglobulinemia / Lymphoplasmacytic Lymphoma,_2. Second Line,5/29/2024,Active,,
CMC OP INFUSION,56318,"Eltoukhy, Hussam, MD",7/23/2024,RiTUXimab weekly x4 for ITP,_1. First Line,7/22/2024,Active,Malignant neoplasm of prostate (CMS/HCC),
NBR CINJ OP INFUSION,75953,"Shah, Mansi R, MD",11/13/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,11/12/2024,Active,,
NBR CINJ OP INFUSION,24690,"Schaar, Dale, MD PhD",5/12/2025,"Axatilimab D1, D15 28 Day Cycles- Chronic Graft Versus Host Disease",_3. Third Line,5/12/2025,Active,"Graft-versus-host disease, unspecified (CMS/HCC)
Abnormal levels of other serum enzymes
Abnormal results of liver function studies
Abnormal coagulation profile",
JCMC CP INFUSION,54382,"Sekhri, Arunabh, MD",12/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/4/2024,Active,"Primary squamous cell carcinoma of supraglottis (CMS/HCC)
Encounter for screening for other viral diseases",
SOM 1PAV ONCOLOGY,15055,"Patel, Eshan, MD",4/11/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,4/4/2023,Inactive,,
SOM OUTPT INFUSION,15055,"Patel, Eshan, MD",4/11/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,4/10/2023,Inactive,,
SOM OUTPT INFUSION,15055,"Patel, Eshan, MD",4/11/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,4/10/2023,Inactive,,
CMC OP INFUSION,13052,"Tang, Horace, MD",3/27/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,Second Line,3/27/2023,Inactive,,
CBMC 2W ONCOLOGY,18517,"Scoppetuolo, Michael, MD",4/12/2024,Atezolizumab / Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,4/11/2024,Inactive,,
CBMC 2W ONCOLOGY,18517,"Scoppetuolo, Michael, MD",4/12/2024,"PACLitaxel D1, D15 28 Day Cycles - Breast",_1. First Line,4/11/2024,Inactive,,
CBMC 2W ONCOLOGY,18517,"Scoppetuolo, Michael, MD",4/12/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,4/11/2024,Inactive,,
CBMC OP INFUSION 2FL,18517,"Scoppetuolo, Michael, MD",5/29/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,5/29/2024,Inactive,,
CMC OP INFUSION,33070,"Cohen, Seth D, MD",1/18/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,1/17/2024,Inactive,,
CMC OP INFUSION,33070,"Cohen, Seth D, MD",6/7/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/6/2024,Inactive,,
CMC OP INFUSION,33070,"Cohen, Seth D, MD",6/21/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/20/2024,Inactive,,
CMC OP INFUSION,33070,"Cohen, Seth D, MD",1/10/2025,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,1/9/2025,Active,,
CMC OP INFUSION,30877,"Cohen, Seth D, MD",4/18/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/18/2025,Active,Primary carcinoma of middle third of esophagus (CMS/HCC),
CMC OP INFUSION,30877,"Cohen, Seth D, MD",4/18/2025,Trastuzumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/18/2025,Active,Primary carcinoma of middle third of esophagus (CMS/HCC),
TRMC TCCC OP INFUSION,60691,"Salerno, Vincent E, MD",10/21/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/20/2024,Active,,
CBMC OP INFUSION 2FL,98452,"Scoppetuolo, Michael, MD",5/21/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,52358,"Leitner, Stuart P, MD",9/19/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,9/18/2023,Inactive,,
CBMC OP INFUSION 2FL,52358,"Leitner, Stuart P, MD",12/19/2023,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/18/2023,Inactive,,
CINJ OP INFUSION,86845,"Haigentz, Missak, MD",5/30/2024,"PEMEtrexed/CARBOplatin (AUC 5), addition of Pembrolizumab in C2 -  21 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,5/30/2024,Inactive,,
CINJ OP INFUSION,86845,"Haigentz, Missak, MD",8/21/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/13/2024,Active,,
CINJ OP INFUSION,32990,"Gulhati, Prateek, MD PhD",3/7/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/6/2024,Inactive,,
CINJ OP INFUSION,32990,"Gulhati, Prateek, MD PhD",4/4/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/4/2024,Inactive,,
CINJ OP INFUSION,32990,"Gulhati, Prateek, MD PhD",7/19/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,6/20/2024,Inactive,,
CBMC OP INFUSION 2FL,99521,"Grossman, I Robert, MD",10/30/2023,ECOG - ACRIN E1910 (Step 4) Maintenance (VinCRIStine / Prednisone / Mercaptopurine / Methotrexate Oral / Methotrexate IT) - Acute Lymphoblastic Leukemia,Maintenance,10/29/2023,Inactive,,
HAM OP INFUSION,59975,"Yogarajah, Meera, MD",5/23/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/22/2023,Inactive,,
HAM OP INFUSION,59975,"Yogarajah, Meera, MD",5/24/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/23/2023,Inactive,,
TRMC TCCC OP INFUSION,23699,"Capo, Gerardo, MD",8/26/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,8/25/2024,Active,,
MMC OP INFUSION,38905,"Meghal, Trishala, MD",1/18/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,First Line,1/17/2023,Inactive,,
MMC OP VP INFUSION,38905,"Meghal, Trishala, MD",2/14/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/13/2024,Inactive,,
MMC OP INFUSION,38905,"Meghal, Trishala, MD",6/5/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_1. First Line,2/27/2024,Inactive,,
JCMC CP INFUSION,43809,"Cruz, Allan Louie E, MD",4/1/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/1/2025,Inactive,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),
NBR CINJ OP INFUSION,35325,"Shah, Mansi R, MD",8/27/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,7/22/2024,Inactive,,
CINJ OP INFUSION,59938,"Haigentz, Missak, MD",11/6/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Head and neck cancer,_1. First Line,11/5/2024,Active,,
MMC OP INFUSION,95794,"Lee, Patrick C, MD",10/2/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,10/2/2024,Inactive,,
MMC OP INFUSION,95794,"Lee, Patrick C, MD",12/16/2024,Temozolomide IV 28 Day Cycles - CNS,_1. First Line,12/15/2024,Inactive,,
MMC OP INFUSION,95794,"Lee, Patrick C, MD",12/16/2024,Temozolomide 28 Day Cycles - CNS,_1. First Line,12/16/2024,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
TRMC TCCC OP INFUSION,46125,"Salerno, Vincent E, MD",4/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,4/28/2024,Inactive,,
TRMC TCCC OP INFUSION,46125,"Salerno, Vincent E, MD",10/14/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,10/13/2024,Active,,
NBI OP INFUSION,11418,"Shah, Shailja S, MD",5/21/2024,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,5/21/2024,Active,,
TRMC TCCC OP INFUSION,84839,"Capo, Gerardo, MD",5/20/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,5/20/2025,Active,"Iron deficiency anemia secondary to blood loss (chronic)
Gallbladder cancer (CMS/HCC)",K82.8 - Other specified diseases of gallbladder; C23 - Malignant neoplasm of gallbladder; D50.0 - Iron deficiency anemia secondary to blood loss (chronic)
NBI OP INFUSION,56837,"Shah, Shailja S, MD",10/10/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/9/2023,Active,,
NBI OP INFUSION,51267,"Anderson, Patrick S, MD",5/9/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Endometrial Cancer Cancer,_1. First Line,5/1/2024,Inactive,,
NBI OP INFUSION,51267,"Anderson, Patrick S, MD",10/14/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,10/2/2024,Active,,
NBI OP INFUSION,84701,"Schleicher, Lori, MD",12/9/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/8/2024,Inactive,,
NBI OP INFUSION,84701,"Schleicher, Lori, MD",12/16/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/16/2024,Active,,
JCMC CP INFUSION,34247,"Cruz, Allan Louie E, MD",6/6/2023,Pembrolizumab 42 Day Cycles (remaining cycles 12-17),,6/6/2023,Inactive,,
JCMC CP INFUSION,34247,"Cruz, Allan Louie E, MD",6/7/2023,Pembrolizumab 21 Day Cycles - cycle 12-17,,6/7/2023,Inactive,,
JCMC CP INFUSION,31327,"Sekhri, Arunabh, MD",7/3/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,First Line,6/29/2023,Inactive,,
JCMC CP INFUSION,31327,"Sekhri, Arunabh, MD",12/18/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,12/3/2023,Inactive,,
HAM OP INFUSION,22637,"Yogarajah, Meera, MD",5/9/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_4. Fourth Line,5/8/2024,Inactive,,
HAM OP INFUSION,22637,"Yogarajah, Meera, MD",7/2/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,6/30/2024,Inactive,,
HAM OP INFUSION,22637,"Yogarajah, Meera, MD",10/15/2024,Elacestrant 28 Day Cycles - Breast,_4. Fourth Line,10/15/2024,Active,,
CINJ OP INFUSION,89994,"Boland, Patrick M, MD",1/3/2024,Imatinib 30 Day Cycles - Sarcoma,_1. First Line,1/3/2024,Active,,
CINJ OP INFUSION,81001,"Boland, Patrick M, MD",6/6/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Neoadjuvant,6/5/2024,Active,,
CINJ OP INFUSION,97102,"Stephenson, Ryan D, DO",12/18/2023,Relugolix 30 day Cycles - Prostate,Adjuvant,12/18/2023,Inactive,,
CINJ OP INFUSION,86775,"Berim, Lyudmyla, MD",2/27/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,2/27/2025,Active,Rectal cancer (CMS/HCC),
NBR 4N ONCOLOGY,86775,"Berim, Lyudmyla, MD",3/3/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,3/3/2025,Inactive,Rectal cancer (CMS/HCC),"C19 - Malignant neoplasm of rectosigmoid junction; G92.8 - Other toxic encephalopathy; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; I82.412 - Acute embolism and thrombosis of left femoral vein; I82.432 - Acute embolism and thrombosis of left popliteal vein; K56.699 - Other intestinal obstruction unspecified as to partial versus complete obstruction; E11.649 - Type 2 diabetes mellitus with hypoglycemia without coma; D50.9 - Iron deficiency anemia, unspecified; I10 - Essential (primary) hypertension; K86.1 - Other chronic pancreatitis; I82.442 - Acute embolism and thrombosis of left tibial vein; N39.0 - Urinary tract infection, site not specified; Z16.23 - Resistance to quinolones and fluoroquinolones; Z16.24 - Resistance to multiple antibiotics; I82.812 - Embolism and thrombosis of superficial veins of left lower extremity; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; E27.8 - Other specified disorders of adrenal gland; B96.20 - Unspecified Escherichia coli (E. coli) as the cause of diseases classified elsewhere; K62.7 - Radiation proctitis; E78.2 - Mixed hyperlipidemia; E83.42 - Hypomagnesemia; G56.03 - Carpal tunnel syndrome, bilateral upper limbs; F43.23 - Adjustment disorder with mixed anxiety and depressed mood; G89.3 - Neoplasm related pain (acute) (chronic); K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; K59.4 - Anal spasm; Z79.84 - Lon..."
NBI OP INFUSION,48558,"Anderson, Patrick S, MD",9/28/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/27/2023,Inactive,,
NBI OP INFUSION,48558,"Anderson, Patrick S, MD",3/1/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/29/2024,Inactive,,
NBI D7 MED-SURG/TELE,48558,"Anderson, Patrick S, MD",4/11/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/10/2024,Inactive,,
CMC OP INFUSION,52097,"Eltoukhy, Hussam, MD",3/29/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,First Line,3/29/2023,Active,Acute myeloid leukemia in relapse (CMS/HCC),
CMC OP INFUSION,11431,"Eltoukhy, Hussam, MD",2/21/2025,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,2/21/2025,Active,"Acute monocytic leukemia in remission (CMS/HCC)
Encounter for antineoplastic chemotherapy",
HAM OP INFUSION,10887,"Yogarajah, Meera, MD",1/28/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,1/19/2025,Active,Malignant neoplasm of anterior floor of mouth (CMS/HCC),
CBMC OP INFUSION 2FL,6723,"Wagmiller, Jennifer Ann, MD",12/6/2023,Topotecan 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,12/3/2023,Active,,
MMC OP VP INFUSION,12969,"Meghal, Trishala, MD",11/8/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,11/4/2024,Active,,
CBMC 2W ONCOLOGY,39454,"McKenna, Marshall, MD",12/2/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,11/26/2024,Active,"Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC)
Pleural effusion, left",
SOM OUTPT INFUSION,87694,"Patel, Eshan, MD",5/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/14/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,87694,"Patel, Eshan, MD",5/1/2025,CISplatin + Gemcitabine 28 Day Cycles - Pancreatic Adenocarcinoma,_1. First Line,5/1/2025,Inactive,Pancreatic adenocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,87694,"Patel, Eshan, MD",4/23/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/23/2025,Inactive,Pancreatic adenocarcinoma (CMS/HCC),
NBR 4N ONCOLOGY,65501,"Rhodes, Joanna Meehan, MD",3/11/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,3/11/2024,Inactive,,
NBR 5N ONCOLOGY,65501,"Tiger, Yun Kyoung, MD",3/12/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/12/2024,Inactive,,
CINJ OP INFUSION,39772,"Girda, Eugenia, MD",1/17/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/16/2025,Inactive,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,39772,"Girda, Eugenia, MD",2/4/2025,CINJ 102301 Arm 1 PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles Research - Endometrial Cancer,_1. First Line,2/3/2025,Active,Endometrial cancer (CMS/HCC),
SOM OUTPT INFUSION,44500,"Yin, Faye, MD",11/29/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,11/6/2023,Inactive,,
NBR 4N ONCOLOGY,68187,"Palmisiano, Neil David, MD",1/24/2023,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),Induction,1/24/2023,Inactive,,
CBMC OP INFUSION 2FL,79299,"Brown, Andrew Bennett, MD",11/29/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,79299,"Brown, Andrew Bennett, MD",4/9/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/8/2024,Inactive,,
CINJ OP INFUSION,98213,"Boland, Patrick M, MD",9/6/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/5/2024,Inactive,,
CINJ OP INFUSION,15278,"Mayer, Tina M, MD",2/25/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,2/25/2025,Active,Prostate cancer metastatic to multiple sites (CMS/HCC),C61 - Prostate cancer metastatic to multiple sites (CMS/HCC)
MMC OP VP INFUSION,22541,"Cohen, Seth D, MD",8/14/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,,8/13/2023,Inactive,,
CINJ OP INFUSION,43699,"Stephenson, Ryan D, DO",12/29/2023,Cemiplimab-rwlc 21 Day Cycles - Basal Cell Carcinoma,_2. Second Line,12/28/2023,Inactive,,
NBR CINJ OP INFUSION,24282,"Rhodes, Joanna Meehan, MD",9/3/2023,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),First Line,9/3/2023,Inactive,,
NBR CINJ OP INFUSION,24282,"Shah, Mansi R, MD",9/5/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,9/4/2023,Inactive,,
NBR CINJ OP INFUSION,24282,"Shah, Mansi R, MD",10/3/2023,ONCE INSURANCE APPROVED: Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,10/2/2023,Inactive,,
MSC OP INFUSION,35743,"Cohen, Seth D, MD",4/3/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/2/2024,Inactive,,
MSC OP INFUSION,35743,"Cohen, Seth D, MD",4/3/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/26/2024,Inactive,,
MSC OP INFUSION,35743,"Cohen, Seth D, MD",7/3/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/1/2024,Active,,
CINJ OP INFUSION,40328,"Mayer, Tina M, MD",4/27/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,4/27/2023,Active,,
MMC OP VP INFUSION,72009,"Cohen, Seth D, MD",5/22/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,5/21/2024,Inactive,,
MMC OP VP INFUSION,72009,"Cohen, Seth D, MD",10/2/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/1/2024,Inactive,,
MMC OP VP INFUSION,72009,"Cohen, Seth D, MD",10/31/2024,Nivolumab 480 mg 28 Day Cycles,_1. First Line,10/30/2024,Active,,
MMC OP VP INFUSION,57933,"Cohen, Seth D, MD",3/12/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/10/2024,Inactive,,
MMC OP VP INFUSION,57933,"Cohen, Seth D, MD",3/12/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Advanced, Recurrent, Metastatic)",_1. First Line,3/3/2024,Inactive,,
MMC OP VP INFUSION,57933,"Cohen, Seth D, MD",6/11/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/10/2024,Active,,
CINJ OP INFUSION,68395,"Berim, Lyudmyla, MD",1/4/2023,CINJ 071801 TAS-102 + Bevacizumab / OXALIplatin 14 Day Cycles Research- Colorectal Cancer,,12/20/2022,Inactive,,
NBR 5N MED-SURG OVRF,68395,"In, Haejin, MD",8/15/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,8/15/2023,Inactive,,
CINJ OP INFUSION,68395,"Berim, Lyudmyla, MD",10/9/2023,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,Maintenance,9/20/2023,Inactive,,
CINJ OP INFUSION,68395,"Berim, Lyudmyla, MD",11/13/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/12/2023,Inactive,,
NBR CINJ OP INFUSION,68395,"Berim, Lyudmyla, MD",5/1/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_4. Fourth Line,5/1/2024,Inactive,,
CINJ OP INFUSION,68395,"Berim, Lyudmyla, MD",8/2/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,8/1/2024,Inactive,,
MMC OP VP INFUSION,40280,"Cohen, Seth D, MD",8/8/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,8/6/2024,Inactive,,
NBR CINJ OP INFUSION,75254,"Shah, Mansi R, MD",4/11/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,4/10/2024,Inactive,,
CINJ OP INFUSION,44829,"Weiss, Sarah, MD",5/14/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,5/14/2025,Active,Metastatic melanoma (CMS/HCC),"C43.60 - Malignant melanoma of unspecified upper limb, including shoulder; C78.00 - Secondary malignant neoplasm of unspecified lung; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; C79.31 - Secondary malignant neoplasm of brain; C43.9 - Malignant melanoma of skin, unspecified"
SOM OUTPT INFUSION,10026,"Toomey, Kathleen C, MD",1/12/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,12/17/2023,Inactive,,
SOM OUTPT INFUSION,10026,"Toomey, Kathleen C, MD",7/24/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,7/23/2024,Inactive,,
SOM OUTPT INFUSION,10026,"Toomey, Kathleen C, MD",11/21/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_2. Second Line,11/5/2024,Active,,
CINJ OP INFUSION,20582,"Ghodoussipour, Saum Bobak, MD",2/7/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/7/2023,Inactive,,
CINJ OP INFUSION,20582,"Ghodoussipour, Saum Bobak, MD",5/15/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,5/15/2023,Active,,
JCMC CP INFUSION,84155,"Cruz, Allan Louie E, MD",5/21/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Recurrent Breast Cancer HER+ ER+,Neoadjuvant,5/21/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)
Malignant neoplasm of left breast in female, estrogen receptor positive, unspecified site of breast (CMS/HCC)","C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; I82.622 - Acute embolism and thrombosis of deep veins of left upper extremity; D63.8 - Anemia in other chronic diseases classified elsewhere; B35.9 - Dermatophytosis, unspecified; B86 - Scabies; F17.210 - Nicotine dependence, cigarettes, uncomplicated; I82.A12 - Acute embolism and thrombosis of left axillary vein; Z17.0 - Estrogen receptor positive status (ER+); Z71.6 - Tobacco abuse counseling; Z92.21 - Personal history of antineoplastic chemotherapy; Z79.01 - Long term (current) use of anticoagulants; Z17.31 - Human epidermal growth factor receptor 2 positive status; Z17.21 - Progesterone receptor positive status; Z80.3 - Family history of malignant neoplasm of breast; Z80.0 - Family history of malignant neoplasm of digestive organs; Z85.3 - Personal history of malignant neoplasm of breast"
NBR CINJ OP INFUSION,35524,"Rhodes, Joanna Meehan, MD",11/7/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/6/2024,Active,Sarcoma (CMS/HCC),
TRMC TCCC OP INFUSION,14073,"Capo, Gerardo, MD",11/5/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/4/2024,Active,Prostate cancer (CMS/HCC),
CINJ OP INFUSION,72635,"Omene, Coral Oghenerukevwe, MD",8/26/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,8/26/2024,Active,,
CINJ OP INFUSION,72635,"Omene, Coral Oghenerukevwe, MD",2/17/2025,Elacestrant 28 Day Cycles - Breast,_2. Second Line,2/17/2025,Active,Stage IV breast cancer in female (CMS/HCC),
CMC OP INFUSION,75706,"Cohen, Seth D, MD",10/21/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/17/2024,Inactive,,
CMC OP INFUSION,75706,"Cohen, Seth D, MD",12/17/2024,Enfortumab Vedotin 28 Day Cycles - Bladder,_1. First Line,12/16/2024,Active,,
MMC OP VP INFUSION,98689,"Cohen, Seth D, MD",8/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,8/27/2024,Inactive,,
CINJ OP INFUSION,98689,"Toppmeyer, Deborah L, MD",9/26/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,9/25/2024,Inactive,,
CINJ OP INFUSION,98689,"Toppmeyer, Deborah L, MD",10/24/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,9/26/2024,Active,,
CINJ OP INFUSION,98689,"Toppmeyer, Deborah L, MD",12/23/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,12/17/2024,Active,"Carcinoma of breast metastatic to liver (CMS/HCC)
Stage IV breast cancer in female (CMS/HCC)",
CBMC OP INFUSION 2FL,65898,"Wagmiller, Jennifer Ann, MD",7/12/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/25/2024,Inactive,,
CBMC OP INFUSION 2FL,65898,"Wagmiller, Jennifer Ann, MD",7/19/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,7/12/2024,Inactive,,
CINJ OP INFUSION,7414,"Omene, Coral Oghenerukevwe, MD",4/11/2023,CINJ 042102 (I-SPY 2 105139) Datopotamab Deruxtecan / Durvalumab Appendix AH 21 Day Cycles - Breast Cancer,Neoadjuvant,4/10/2023,Inactive,,
CINJ OP INFUSION,7414,"Omene, Coral Oghenerukevwe, MD",6/13/2023,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,,6/12/2023,Inactive,,
CINJ OP INFUSION,7414,"Omene, Coral Oghenerukevwe, MD",9/12/2023,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,,9/11/2023,Inactive,,
CBMC OP INFUSION 2FL,29983,"Grossman, I Robert, MD",10/4/2024,RiTUXimab 168 Day Cycles - Minimal Change Disease,_2. Second Line,8/25/2024,Active,Cholangiocarcinoma determined by biopsy of biliary tract (CMS/HCC),
HAM OP INFUSION,47097,"Yogarajah, Meera, MD",4/29/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,4/29/2025,Active,Malignant neoplasm of cecum (CMS/HCC),"C18.2 - Malignant neoplasm of ascending colon; R79.1 - Abnormal coagulation profile; I10 - Essential (primary) hypertension; E66.9 - Obesity, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; Z87.891 - Personal history of nicotine dependence; Z88.6 - Allergy status to analgesic agent; Z79.1 - Long term (current) use of non-steroidal anti-inflammatories (nsaid); Z79.51 - Long term (current) use of inhaled steroids; Z79.899 - Other long term (current) drug therapy"
CBMC 2W ONCOLOGY,16044,"Dharmapuri, Sirish, MD",2/24/2025,mFOLFOX6 Bevacizumab Outpatient 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/2/2025,Active,Metastasis to liver (CMS/HCC),"C18.7 - Malignant neoplasm of sigmoid colon; K63.1 - Perforation of intestine (nontraumatic); E44.0 - Moderate protein-calorie malnutrition; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K56.7 - Ileus, unspecified; R16.0 - Hepatomegaly, not elsewhere classified; D64.9 - Anemia, unspecified; N18.9 - Chronic kidney disease, unspecified; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; R53.81 - Other malaise; Z85.46 - Personal history of malignant neoplasm of prostate; D72.829 - Elevated white blood cell count, unspecified; G47.00 - Insomnia, unspecified; Z68.22 - Body mass index (BMI) 22.0-22.9, adult"
CBMC OP INFUSION 2FL,59656,"Brown, Andrew Bennett, MD",12/7/2023,Bevacizumab Maintenance 21 Day Cycles- CNS,_2. Second Line,12/6/2023,Active,,
CBMC OP INFUSION 2FL,21599,"Wagmiller, Jennifer Ann, MD",6/6/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,6/2/2024,Inactive,,
CBMC OP INFUSION 2FL,21599,"Wagmiller, Jennifer Ann, MD",11/14/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,11/14/2024,Active,,
CINJ OP INFUSION,81413,"George, Mridula A, MD",1/5/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,12/12/2023,Active,,
CINJ OP INFUSION,90931,"Dasgeb, Bahar, MD",2/6/2023,RiTUXimab 168 Day Cycles - Pemphigus,First Line,2/5/2023,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
CINJ OP INFUSION,73361,"Stephenson, Ruth D, DO",7/28/2023,Trastuzumab 21 Day Cycles (Initiation) - Uterine serous cancer,Consolidation,7/25/2023,Inactive,,
CINJ OP INFUSION,73361,"Girda, Eugenia, MD",11/29/2023,CINJ 102104 ZN-c3 400 mg 21 Day Cycles Research- Uterine Carcinoma,Consolidation,11/28/2023,Inactive,,
CINJ OP INFUSION,73361,"Stephenson, Ruth D, DO",11/29/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,11/28/2023,Inactive,,
CINJ OP INFUSION,73361,"Stephenson, Ruth D, DO",12/15/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,12/12/2023,Inactive,,
HAM OP INFUSION,72816,"Patel, Malini M, MD",11/20/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,11/19/2024,Inactive,,
HAM OP INFUSION,72816,"Patel, Malini M, MD",11/20/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,11/19/2024,Active,,
HAM OP INFUSION,4437,"Patel, Malini M, MD",5/6/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,5/6/2025,Active,Squamous cell carcinoma of ventral tongue (CMS/HCC),"J96.21 - Acute and chronic respiratory failure with hypoxia; I5A - Non-ischemic myocardial injury (non-traumatic); C02.9 - Malignant neoplasm of tongue, unspecified; E66.2 - Morbid (severe) obesity with alveolar hypoventilation; Z93.0 - Tracheostomy status; D53.9 - Nutritional anemia, unspecified; J44.9 - Chronic obstructive pulmonary disease, unspecified; Z95.828 - Presence of other vascular implants and grafts; F32.9 - Major depressive disorder, single episode, unspecified; J96.22 - Acute and chronic respiratory failure with hypercapnia; Z93.1 - Gastrostomy status; M81.0 - Age-related osteoporosis without current pathological fracture; Z59.71 - Insufficient health insurance coverage; Z79.82 - Long term (current) use of aspirin; Z79.890 - Hormone replacement therapy; Z87.442 - Personal history of urinary calculi; Z87.891 - Personal history of nicotine dependence; Z11.52 - Encounter for screening for COVID-19; Z74.01 - Bed confinement status; I87.8 - Other specified disorders of veins; Z88.1 - Allergy status to other antibiotic agents; Z79.899 - Other long term (current) drug therapy; Z88.2 - Allergy status to sulfonamides; Z88.8 - Allergy status to other drugs, medicaments and biological substances; F41.9 - Anxiety disorder, unspecified"
NBI OP INFUSION,37181,"Schleicher, Lori, MD",10/18/2023,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,10/17/2023,Inactive,,
CINJ OP INFUSION,78941,"Mayer, Tina M, MD",11/19/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,11/10/2024,Active,,
CINJ OP INFUSION,42298,"Mayer, Tina M, MD",5/7/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,5/7/2025,Active,"Urothelial carcinoma (CMS/HCC)
Drug-induced thyroiditis","C67.9 - Malignant neoplasm of bladder, unspecified; C68.9 - Malignant neoplasm of urinary organ, unspecified; E07.9 - Disorder of thyroid, unspecified"
NBI OP INFUSION,74741,"Jacoby, Sari H, MD",5/20/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/20/2024,Active,,
SOM OUTPT INFUSION,2241,"Patel, Eshan, MD",5/27/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,5/27/2025,Inactive,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)","N28.9 - Disorder of kidney and ureter, unspecified; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+)"
SOM OUTPT INFUSION,2241,"Patel, Eshan, MD",5/12/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,5/12/2025,Inactive,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)","N28.9 - Disorder of kidney and ureter, unspecified; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC OP INFUSION 2FL,12895,"Kulkarni, Aditya A, MD",4/16/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,4/16/2025,Active,Prostate cancer (CMS/HCC),
CINJ OP INFUSION,30941,"Haigentz, Missak, MD",2/13/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,2/12/2023,Inactive,,
CINJ OP INFUSION,30941,"Haigentz, Missak, MD",2/20/2023,CINJ 032013 (EA5181) ARM A Durvalumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,,2/12/2023,Inactive,,
CINJ OP INFUSION,30941,"Haigentz, Missak, MD",4/12/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,Consolidation,4/11/2023,Active,,
NBI OP INFUSION,44995,"Anderson, Patrick S, MD",1/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,1/17/2024,Inactive,,
MMC OP VP INFUSION,71831,"Meghal, Trishala, MD",10/16/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,10/15/2023,Inactive,,
CBMC OP INFUSION 2FL,5911,"Dharmapuri, Sirish, MD",9/23/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/17/2024,Inactive,,
CINJ OP INFUSION,19103,"Patankar, Sonali, MD",10/14/2024,CISplatin and Pembrolizumab With Concurrent Radiation 7 Day Cycles - Vulvar Cancer,_1. First Line,10/11/2024,Active,,
CBMC OP INFUSION 2FL,16468,"Dharmapuri, Sirish, MD",11/13/2024,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,10/22/2024,Active,Acute myeloblastic leukemia not having achieved remission (CMS/HCC),
CMC OP INFUSION,11309,"Talwar, Sumit, MD",6/26/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/25/2024,Inactive,,
CINJ OP INFUSION,46628,"Haigentz, Missak, MD",4/12/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,4/12/2024,Inactive,,
CMC OP INFUSION,48488,"Cohen, Seth D, MD",1/18/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,1/10/2024,Inactive,,
CMC OP INFUSION,48488,"Cohen, Seth D, MD",6/18/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/18/2024,Active,,
HAM OP INFUSION,33087,"Yogarajah, Meera, MD",12/30/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,11/24/2024,Active,Nodular sclerosis Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),
HAM OP INFUSION,33087,"Yogarajah, Meera, MD",1/17/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,11/24/2024,Active,"Malignant neoplasm of unspecified site of unspecified female breast (CMS/HCC)
Secondary malignant neoplasm of female breast (CMS/HCC)
Malignant pleural effusion",
CINJ OP INFUSION,6458,"George, Mridula A, MD",9/22/2023,CINJ 042209 Arm A Imlunestrant 5 Year Treatment Research- Breast Cancer,Adjuvant,9/22/2023,Active,,
CBMC OP INFUSION 2FL,94477,"Brown, Andrew Bennett, MD",1/9/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Advanced, Recurrent, Metastatic)",Adjuvant,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,1835,"Scoppetuolo, Michael, MD",11/12/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,11/4/2024,Active,,
CBMC OP INFUSION 2FL,50645,"Litvak, Anna M, MD",12/13/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,12/13/2024,Active,Pancreatic adenocarcinoma (CMS/HCC),
CMC OP INFUSION,18752,"Cohen, Seth D, MD",4/14/2025,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,4/14/2025,Active,Rectal cancer (CMS/HCC),
HAM OP INFUSION,80491,"Yogarajah, Meera, MD",3/4/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/25/2024,Active,,
CINJ OP INFUSION,70437,"Stephenson, Ryan D, DO",11/27/2023,CINJ 082003 (NRG-GU008) ARM 1 GNRH Agonist or Antagonist Therapy 84 Day Cycles Research- Prostate Cancer,Adjuvant,11/26/2023,Active,,
CINJ OP INFUSION,7072,"Toppmeyer, Deborah L, MD",6/12/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,6/12/2023,Inactive,,
CINJ OP INFUSION,7072,"Toppmeyer, Deborah L, MD",8/21/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,8/21/2023,Active,Adenocarcinoma of sigmoid colon (CMS/HCC),
SOM OUTPT INFUSION,96228,"Yin, Faye, MD",9/11/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/28/2023,Inactive,,
CBMC OP INFUSION 2FL,608,"Leitner, Stuart P, MD",3/21/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,3/21/2024,Active,,
CINJ OP INFUSION,67997,"Goel, Sanjay, MD",6/3/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10W Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_4. Fourth Line,5/13/2024,Inactive,,
CINJ OP INFUSION,67997,"Goel, Sanjay, MD",9/18/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,9/18/2024,Inactive,,
NBR 5N ONCOLOGY,14463,"Palmisiano, Neil David, MD",6/28/2024,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,6/27/2024,Inactive,,
HAM OP INFUSION,62628,"Yogarajah, Meera, MD",5/23/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,5/5/2024,Active,,
JCMC CP INFUSION,19699,"Sekhri, Arunabh, MD",5/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/28/2025,Active,Overlapping malignant neoplasm of colon (CMS/HCC),"C18.8 - Malignant neoplasm of overlapping sites of colon; I82.4Y2 - Acute embolism and thrombosis of unspecified deep veins of left proximal lower extremity; N17.9 - Acute kidney failure, unspecified; D53.9 - Nutritional anemia, unspecified; M79.89 - Other specified soft tissue disorders; R60.9 - Edema, unspecified; K31.84 - Gastroparesis; C79.9 - Secondary malignant neoplasm of unspecified site; Z92.21 - Personal history of antineoplastic chemotherapy"
CINJ OP INFUSION,4290,"Haigentz, Missak, MD",7/14/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/14/2024,Inactive,,
CMC OP INFUSION,61687,"Pompa, Tiffany Ann, MD",2/26/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,2/25/2025,Active,"Malignant neoplasm of pancreas, unspecified (CMS/HCC)
Malignant neoplasm of head of pancreas (CMS/HCC)",
CINJ PEDS HEMONC ,71641,"Parikh, Nehal S, MD",4/2/2025,PEDS ACNS0332 - Other than Average Risk Medulloblastoma / PNET ,_1. First Line,3/21/2025,Active,Group 4 medulloblastoma (CMS/HCC),C71.6 - Malignant neoplasm of cerebellum
NBR CINJ OP INFUSION,5781,"Evens, Andrew M, DO",5/7/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/7/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site"
CINJ OP INFUSION,72885,"George, Mridula A, MD",9/23/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/22/2024,Active,,
CINJ OP INFUSION,73228,"Muralikrishnan, Sivraj, MD",4/21/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,4/21/2025,Active,Squamous cell carcinoma of oropharynx (CMS/HCC),
NBR CINJ OP INFUSION,78339,"Shah, Mansi R, MD",5/25/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,78339,"Shah, Mansi R, MD",5/25/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,78339,"Shah, Mansi R, MD",9/22/2023,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,,9/22/2023,Inactive,,
NBR 4N ONCOLOGY,78339,"Schaar, Dale, MD PhD",10/12/2023,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,10/9/2023,Inactive,,
CMC OP INFUSION,27663,"Eltoukhy, Hussam, MD",7/19/2024,Rituximab for WAIHA and ITP,_1. First Line,7/18/2024,Active,Malignant melanoma of left lower extremity including hip (CMS/HCC),
CBMC 2W ONCOLOGY,29529,"Grossman, I Robert, MD",1/22/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/22/2025,Active,,
SOM OUTPT INFUSION,80338,"Patel, Eshan, MD",4/8/2025,Cetuximab with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,4/8/2025,Inactive,Malignant neoplasm of cheek mucosa (CMS/HCC),C06.0 - Malignant neoplasm of cheek mucosa
CMC OP INFUSION,34479,"Taff, Jessica, MD",1/11/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/1/2023,Inactive,,
CMC OP INFUSION,34479,"Taff, Jessica, MD",1/24/2024,Albumin-Bound PACLitaxel / Trastuzumab 28 Day Cycles - Breast,_1. First Line,1/17/2024,Inactive,,
CMC OP INFUSION,34479,"Taff, Jessica, MD",5/9/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/8/2024,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
CINJ OP INFUSION,26224,"Berim, Lyudmyla, MD",8/4/2023,mFOLFOX6+ Trastuzumab+Pembrolizumab 14 Day Cycles- Gastroesophageal Cancer,_1. First Line,7/30/2023,Inactive,,
CINJ OP INFUSION,26224,"Berim, Lyudmyla, MD",4/18/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,4/8/2024,Inactive,,
CINJ OP INFUSION,26224,"Berim, Lyudmyla, MD",6/26/2024,FOLFIRI + Trastuzumab Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,6/24/2024,Inactive,,
CINJ OP INFUSION,26224,"Berim, Lyudmyla, MD",7/24/2024,Capecitabine / Lapatinib 21 Day Cycles - Gastric,_3. Third Line,7/24/2024,Inactive,,
CINJ OP INFUSION,26224,"Berim, Lyudmyla, MD",7/24/2024,Trastuzumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/23/2024,Inactive,,
CINJ OP INFUSION,26224,"Berim, Lyudmyla, MD",8/14/2024,Tucatinib / Trastuzumab 21 Day Cycles- Colon Cancer,_3. Third Line,7/31/2024,Inactive,,
CBMC OP INFUSION 2FL,70114,"Grossman, I Robert, MD",11/2/2023,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_8. Eighth Line,11/1/2023,Active,,
CBMC OP INFUSION 2FL,21623,"Grossman, I Robert, MD",1/11/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_2. Second Line,12/17/2023,Inactive,,
CBMC OP INFUSION 2FL,21623,"Grossman, I Robert, MD",5/9/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,5/8/2024,Inactive,,
CBMC OP INFUSION 2FL,21623,"Grossman, I Robert, MD",5/9/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,5/8/2024,Inactive,,
CBMC OP INFUSION 2FL,21623,"Grossman, I Robert, MD",5/9/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,5/9/2025,Active,"Breast cancer metastasized to multiple sites (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Nutritional anemia, unspecified",
SOM OUTPT INFUSION,96576,"Patel, Eshan, MD",3/13/2025,Pembrolizumab 21 Day Cycles - kidney,Adjuvant,3/13/2025,Active,Renal cell carcinoma (CMS/HCC),"C64.1 - Malignant neoplasm of right kidney, except renal pelvis"
CINJ OP INFUSION,70618,"George, Mridula A, MD",1/15/2025,Abemaciclib 28 Day Cycles - Breast,Adjuvant,1/15/2025,Active,,
NBR CINJ OP INFUSION,1908,"Rhodes, Joanna Meehan, MD",3/3/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,3/3/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; I42.2 - Other hypertrophic cardiomyopathy
SOM OUTPT INFUSION,10910,"Patel, Eshan, MD",3/7/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,2/27/2023,Inactive,,
CINJ OP INFUSION,55385,"Berim, Lyudmyla, MD",7/27/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/26/2023,Inactive,,
CINJ OP INFUSION,55385,"Berim, Lyudmyla, MD",12/4/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,12/4/2023,Inactive,,
CINJ OP INFUSION,55385,"Berim, Lyudmyla, MD",3/14/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/6/2024,Inactive,,
CINJ OP INFUSION,55385,"Berim, Lyudmyla, MD",4/10/2024,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,2/28/2024,Inactive,,
CINJ OP INFUSION,55385,"Berim, Lyudmyla, MD",5/29/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/28/2024,Active,,
HAM OP INFUSION,76107,"Patel, Malini M, MD",8/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/19/2024,Active,,
CINJ OP INFUSION,51636,"Gulhati, Prateek, MD PhD",6/15/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/13/2023,Inactive,,
CINJ OP INFUSION,51636,"Gulhati, Prateek, MD PhD",12/5/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,12/4/2024,Active,,
CBMC OP INFUSION 2FL,45418,"Wagmiller, Jennifer Ann, MD",6/17/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Neoadjuvant,6/10/2024,Active,,
CINJ OP INFUSION,77133,"George, Mridula A, MD",7/31/2023,I-0012-196-08 / CINJ 042001 INCMGA00012 + Pelareorep 28 Day Cycles Research- Breast Cancer,Third Line,7/30/2023,Inactive,,
MMC OP INFUSION,77133,"Meghal, Trishala, MD",10/4/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,9/29/2023,Inactive,,
MMC OP VP INFUSION,77133,"Meghal, Trishala, MD",10/16/2024,EriBULin 21 Day Cycles - Breast,_4. Fourth Line,10/10/2024,Active,,
CBMC OP INFUSION 2FL,34379,"Dharmapuri, Sirish, MD",3/31/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/31/2025,Active,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; C18.4 - Malignant neoplasm of transverse colon; E61.1 - Iron deficiency"
TRMC TCCC OP INFUSION,23796,"Capo, Gerardo, MD",10/17/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,10/16/2024,Active,,
JCMC CP INFUSION,77267,"Cruz, Allan Louie E, MD",1/16/2024,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_5. Fifth Line,12/5/2023,Inactive,,
CINJ OP INFUSION,27498,"Boland, Patrick M, MD",3/7/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/6/2023,Inactive,,
CINJ OP INFUSION,27498,"Boland, Patrick M, MD",6/6/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,6/1/2023,Inactive,,
CINJ OP INFUSION,27498,"Boland, Patrick M, MD",7/21/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,7/20/2023,Inactive,,
CINJ OP INFUSION,64691,"Mayer, Tina M, MD",12/14/2023,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,12/14/2023,Active,,
MMC OP VP INFUSION,81836,"Cohen, Seth D, MD",5/14/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,4/28/2024,Inactive,,
MMC OP VP INFUSION,81836,"Cohen, Seth D, MD",8/6/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/5/2024,Inactive,,
CINJ OP INFUSION,37249,"Jang, Thomas L, MD",4/5/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,3/28/2023,Inactive,,
CINJ OP INFUSION,37249,"Jang, Thomas L, MD",11/3/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,11/2/2023,Active,,
NBR 4N BMTU/IMCU,38906,"Braunschweig, Ira, MD",3/29/2023,BMT Autologous BEAM,,3/28/2023,Inactive,,
NBR 4N BMTU/IMCU,38906,"Patel, Vimal D, MD",4/5/2023,BMT Autologous BEAM,,4/5/2023,Inactive,,
CMC OP INFUSION,24321,"Pompa, Tiffany Ann, MD",3/12/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,3/12/2025,Active,Ovarian cancer (CMS/HCC),
CMC OP INFUSION,94883,"Taff, Jessica, MD",5/1/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,4/30/2023,Active,,
CMC 4B ONCOLOGY,91198,"Eltoukhy, Hussam, MD",7/13/2023,Dose-Adjusted V-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / Bortezomib weekly) 21 Day Cycles - Plasmablastic Lymphoma (Inpatient Regimen),First Line,7/13/2023,Inactive,,
CMC 4B ONCOLOGY,91198,"Eltoukhy, Hussam, MD",7/13/2023,Dose-Adjusted V-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / Bortezomib Weekly) 21 Day Cycles - Plasmablastic Lymphoma (Inpatient Regimen),First Line,7/13/2023,Inactive,,
CMC OP INFUSION,91198,"Eltoukhy, Hussam, MD",10/31/2023,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone for Plasmablastic Lymphoma,_2. Second Line,10/30/2023,Inactive,,
CINJ PEDS HEMONC ,33137,"Cole, Peter David, MD",2/14/2023,DFCI 16-001 Continuation,_1. First Line,2/14/2023,Inactive,,
CINJ OP INFUSION,55220,"Haigentz, Missak, MD",9/25/2023,Pembrolizumab (C2) PLUS PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,First Line,9/24/2023,Inactive,,
CINJ OP INFUSION,55220,"Haigentz, Missak, MD",12/18/2023,Pembrolizumab/PEMEtrexed (discontinued 4/15/2024) Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/18/2023,Active,,
JCMC CP INFUSION,86646,"Cruz, Allan Louie E, MD",4/23/2024,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,3/31/2024,Inactive,,
CINJ OP INFUSION,23000,"Boland, Patrick M, MD",5/16/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Consolidation,5/16/2025,Active,Malignant neoplasm of rectum (CMS/HCC),C20 - Malignant neoplasm of rectum
MMC OP INFUSION,16377,"Lee, Patrick C, MD",12/12/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,Induction,12/3/2023,Inactive,,
MMC OP INFUSION,72679,"Meghal, Trishala, MD",7/24/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,7/17/2024,Active,,
MMC OP VP INFUSION,98900,"Lee, Patrick C, MD",4/1/2025,CINJ 042211 Arm B Capecitabine / Pembrolizumab 21 Day Cycles Research- Breast Cancer,Adjuvant,4/1/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,19132,"Leiser, Aliza, MD",4/24/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/23/2024,Inactive,,
CINJ OP INFUSION,19132,"Leiser, Aliza, MD",9/11/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,9/11/2024,Active,,
CINJ OP INFUSION,42735,"Girda, Eugenia, MD",4/17/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,4/17/2025,Active,Endometrial cancer (CMS/HCC),"C54.1 - Malignant neoplasm of endometrium; R59.9 - Enlarged lymph nodes, unspecified"
CINJ OP INFUSION,35326,"Ghodoussipour, Saum Bobak, MD",1/23/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,1/23/2023,Inactive,,
CINJ OP INFUSION,35326,"Ghodoussipour, Saum Bobak, MD",5/1/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,5/1/2023,Inactive,,
TRMC TCCC OP INFUSION,95289,"Salerno, Vincent E, MD",9/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/9/2024,Active,,
TRMC TCCC OP INFUSION,95289,"Salerno, Vincent E, MD",2/24/2025,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_2. Second Line,2/18/2025,Active,Malignant neoplasm of rectosigmoid junction (CMS/HCC),
CINJ OP INFUSION,95446,"Berim, Lyudmyla, MD",11/10/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/2/2023,Inactive,,
CINJ OP INFUSION,95446,"Berim, Lyudmyla, MD",11/10/2023,CINJ 071702 (MK-3475-535) Pembrolizumab 21 Day Cycles Pre-Operative Research- Gastric Cancer,Neoadjuvant,10/12/2023,Inactive,,
CINJ OP INFUSION,95446,"Berim, Lyudmyla, MD",12/23/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/21/2023,Inactive,,
CINJ OP INFUSION,95446,"Kennedy, Timothy, MD",7/8/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,7/8/2024,Inactive,,
CINJ OP INFUSION,95446,"Berim, Lyudmyla, MD",8/29/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,8/12/2024,Inactive,,
CINJ OP INFUSION,95446,"Berim, Lyudmyla, MD",12/27/2024,Zolbetuximab + mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/18/2024,Active,"Malignant neoplasm of bronchus and lung (CMS/HCC)
Metastasis from malignant neoplasm of lung (CMS/HCC)",
CINJ OP INFUSION,29196,"Saraiya, Biren P, MD",4/9/2025,"CINJ 192004 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + KK-LC-TCR-T Cells 6 Day Cycle Research- Cancers of the Stomach, Breast, Cervix and Lung",_3. Third Line,4/8/2025,Inactive,Malignant neoplasm of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C16.8 - Malignant neoplasm of overlapping sites of stomach"
CINJ OP INFUSION,29196,"Berim, Lyudmyla, MD",3/24/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/24/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,13460,"Wagmiller, Jennifer Ann, MD",3/18/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/17/2024,Active,,
NBI OP INFUSION,83244,"Anderson, Patrick S, MD",12/13/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,12/11/2024,Active,,
NBR CINJ OP INFUSION,4097,"Matasar, Matthew J, MD",1/16/2025,BMT Autologous BEAM,Consolidation,1/11/2025,Active,,
CBMC OP INFUSION 2FL,28889,"Radovich, Delia, MD",12/4/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/29/2023,Inactive,,
CBMC OP INFUSION 2FL,13951,"Leitner, Stuart P, MD",2/20/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/19/2024,Inactive,,
CBMC OP INFUSION 2FL,13951,"Leitner, Stuart P, MD",5/15/2024,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,5/15/2024,Active,,
NBR CINJ OP INFUSION,6652,"Shah, Mansi R, MD",5/16/2024,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,5/15/2024,Inactive,,
NBR CINJ OP INFUSION,6652,"Shah, Mansi R, MD",5/29/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,5/28/2024,Inactive,,
NBR CINJ OP INFUSION,6652,"Shah, Mansi R, MD",10/28/2024,Lenalidomide Desensitization - Multiple Myeloma,_6. Sixth Line,10/28/2024,Inactive,,
NBR CINJ OP INFUSION,6652,"Shah, Mansi R, MD",10/31/2024,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_6. Sixth Line,10/31/2024,Inactive,,
NBR CINJ OP INFUSION,6652,"Shah, Mansi R, MD",1/30/2025,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_6. Sixth Line,1/22/2025,Active,,
SOM OUTPT INFUSION,12071,"Toomey, Kathleen C, MD",7/15/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,7/14/2024,Inactive,,
CMC 4B ONCOLOGY,54157,"Pompa, Tiffany Ann, MD",1/17/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Unknown Primary,_1. First Line,1/16/2025,Inactive,"Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)
Metastatic cancer to spine (CMS/HCC)",
MMC OP VP INFUSION,91670,"Cohen, Seth D, MD",3/20/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,First Line,3/19/2023,Inactive,,
CMC OP INFUSION,66488,"Cohen, Seth D, MD",4/24/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,4/23/2024,Inactive,,
CINJ OP INFUSION,24235,"George, Mridula A, MD",1/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,1/11/2024,Inactive,,
CINJ OP INFUSION,24235,"George, Mridula A, MD",9/25/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,9/25/2024,Active,,
CINJ OP INFUSION,34859,"Stephenson, Ryan D, DO",7/28/2023,DOCEtaxel / CARBOplatin 21 Day Cycles - Prostate,First Line,7/27/2023,Inactive,,
MMC OP INFUSION,50448,"Lee, Patrick C, MD",8/5/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,Maintenance,8/4/2023,Inactive,,
MMC OP INFUSION,50448,"Lee, Patrick C, MD",12/5/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,Maintenance,12/4/2023,Inactive,,
MMC BBR2 ONCOLOGY,21762,"Meghal, Trishala, MD",1/24/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/23/2025,Inactive,Small cell carcinoma (CMS/HCC),
NBR CINJ OP INFUSION,84698,"Evens, Andrew M, DO",3/7/2023,Pembrolizumab 21 Day Cycles - Mycosis Fungoides / Sezary Syndrome ,,3/6/2023,Inactive,,
CINJ OP INFUSION,4692,"Weiss, Sarah, MD",9/16/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,Neoadjuvant,9/13/2024,Active,,
SOM OUTPT INFUSION,15489,"Patel, Eshan, MD",10/19/2023,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_1. First Line,10/10/2023,Inactive,,
CMC OP INFUSION,15489,"Cohen, Seth D, MD",2/13/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,2/4/2024,Inactive,,
CMC OP INFUSION,15489,"Cohen, Seth D, MD",2/13/2024,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/12/2024,Inactive,,
CINJ OP INFUSION,41451,"Goel, Sanjay, MD",7/13/2023,CINJ 052212 Phase 1a Single Agent RO7502175 21 Day Cycles- Advanced or Metastatic Solid Tumors,Third Line,7/10/2023,Inactive,,
CINJ OP INFUSION,18383,"Ghodoussipour, Saum Bobak, MD",3/14/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/14/2025,Active,Urothelial cancer (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified"
CBMC OP INFUSION 2FL,65687,"Brown, Andrew Bennett, MD",9/30/2024,Bevacizumab 28 Day Cycles - CNS,_1. First Line,9/30/2024,Active,,
CBMC OP INFUSION 2FL,75880,"Wagmiller, Jennifer Ann, MD",6/8/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,6/7/2023,Inactive,,
CBMC OP INFUSION 2FL,75880,"Wagmiller, Jennifer Ann, MD",6/8/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,6/7/2023,Active,,
CBMC OP INFUSION 2FL,75880,"Wagmiller, Jennifer Ann, MD",6/9/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,6/8/2023,Inactive,,
NBR CINJ OP INFUSION,60290,"Tiger, Yun Kyoung, MD",6/26/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,6/23/2024,Active,,
MMC OP VP INFUSION,31840,"Talwar, Sumit, MD",1/2/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Induction,12/23/2024,Active,,
MMC OP VP INFUSION,31840,"Meghal, Trishala, MD",2/4/2025,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,Induction,1/13/2025,Active,Cancer of lower third of esophagus (CMS/HCC),
CBMC OP INFUSION 2FL,62534,"Leitner, Stuart P, MD",4/25/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,4/24/2024,Inactive,,
CBMC OP INFUSION 2FL,62534,"Leitner, Stuart P, MD",6/13/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,6/12/2024,Active,Endometrial cancer (CMS/HCC),
CBMC OP INFUSION 2FL,91353,"Grossman, I Robert, MD",1/30/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,1/14/2025,Active,Cancer of sigmoid colon (CMS/HCC),
CMC OP INFUSION,80087,"Talwar, Sumit, MD",6/6/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,6/5/2024,Active,,
MMC BBR2 ONCOLOGY,33240,"Lee, Patrick C, MD",4/23/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2024,Inactive,,
MMC BBR2 ONCOLOGY,33240,"Lee, Patrick C, MD",4/23/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2024,Inactive,,
NBR CINJ OP INFUSION,4405,"Patel, Vimal D, MD",2/16/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Consolidation,2/16/2023,Inactive,,
NBR CINJ OP INFUSION,4405,"Patel, Vimal D, MD",2/16/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,2/16/2023,Inactive,,
NBI OP INFUSION,72510,"Shah, Shailja S, MD",2/6/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,2/5/2024,Inactive,,
NBI D7 MED-SURG/TELE,72510,"Shah, Shailja S, MD",2/14/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,2/13/2024,Inactive,,
NBI D7 MED-SURG/TELE,72510,"Shah, Shailja S, MD",2/14/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,2/13/2024,Inactive,,
NBI OP INFUSION,72510,"Shah, Shailja S, MD",4/12/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,4/11/2024,Inactive,,
NBI OP INFUSION,72510,"Shah, Shailja S, MD",4/12/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,4/11/2024,Active,,
NBI OP INFUSION,72510,"Shah, Shailja S, MD",11/22/2024,Capecitabine 21 Day Cycles - Breast,_1. First Line,11/22/2024,Active,,
SOM OUTPT INFUSION,26797,"Patel, Eshan, MD",1/30/2025,"Carboplatin/Paclitaxel D1, D8, D15- Q21 Day Cycles- with every 21 days Pembrolizumab-Head and Neck Cancers",_2. Second Line,1/13/2025,Active,,
SOM OUTPT INFUSION,26797,"Patel, Eshan, MD",2/6/2025,"Carboplatin/Paclitaxel D1, D8, D15- Q21 Day Cycles- with every 21 days Pembrolizumab-Head and Neck Cancers",_2. Second Line,1/13/2025,Active,"Malignant neoplasm of tonsil (CMS/HCC)
Malignant neoplasm of anterior two-thirds of tongue, part unspecified (CMS/HCC)","C02.3 - Malignant neoplasm of anterior two-thirds of tongue, part unspecified"
NBR CINJ OP INFUSION,78984,"Shah, Mansi R, MD",10/19/2023,Carfilzomib 56 mg/m2 / Pomalidomide 2mg x 21 days Oral Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,10/18/2023,Active,,
NBR CINJ OP INFUSION,84604,"Shah, Mansi R, MD",4/10/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,4/10/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Vitamin deficiency, unspecified
Abnormal coagulation profile",
CBMC OP INFUSION 2FL,17026,"Scoppetuolo, Michael, MD",8/27/2024,Pemetrexed / CARBOplatin (AUC 6) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/19/2024,Inactive,,
CBMC OP INFUSION 2FL,17026,"Scoppetuolo, Michael, MD",9/17/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/9/2024,Active,,
HAM OP INFUSION,12372,"Yogarajah, Meera, MD",8/17/2024,Capecitabine 21 Day Cycles - Breast,_1. First Line,8/16/2024,Inactive,,
HAM OP INFUSION,12372,"Yogarajah, Meera, MD",12/5/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - BREAST CANCER,_1. First Line,12/1/2024,Active,,
CINJ OP INFUSION,80370,"Omene, Coral Oghenerukevwe, MD",9/18/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,9/13/2023,Inactive,,
CINJ OP INFUSION,34266,"George, Mridula A, MD",8/16/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,8/16/2024,Active,,
CMC OP INFUSION,64660,"Taff, Jessica, MD",5/25/2023,Pembrolizumab 42 Day Cycles - Melanoma,Adjuvant,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,50091,"Shah, Mansi R, MD",4/18/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,4/17/2024,Inactive,,
MMC OP VP INFUSION,64566,"Cohen, Seth D, MD",10/30/2023,Capecitabine 21 Day Cycles - Breast,_2. Second Line,10/30/2023,Inactive,,
MMC OP VP INFUSION,64566,"Cohen, Seth D, MD",12/20/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_2. Second Line,12/19/2023,Inactive,,
MMC OP VP INFUSION,64566,"Cohen, Seth D, MD",12/27/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/19/2023,Inactive,,
NBI OP INFUSION,51327,"Jacoby, Sari H, MD",8/6/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,8/5/2024,Active,,
NBI OP INFUSION,91247,"Cohen, Alice, MD",12/28/2023,Asciminib 28 Day Cycles - Chronic Myeloid Leukemia (Two or More TKIs),_3. Third Line,12/28/2023,Active,,
NBR CINJ OP INFUSION,28145,"Tiger, Yun Kyoung, MD",7/23/2024,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Cycle 1 Regimen),_1. First Line,7/23/2024,Inactive,,
NBR CINJ OP INFUSION,28145,"Tiger, Yun Kyoung, MD",8/9/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,8/8/2024,Inactive,,
NBR CINJ OP INFUSION,28145,"Tiger, Yun Kyoung, MD",8/9/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,8/8/2024,Inactive,,
NBR CINJ OP INFUSION,28145,"Tiger, Yun Kyoung, MD",8/23/2024,Teclistamab Weekly 28 Day Cycles,_3. Third Line,8/22/2024,Inactive,,
NBR CINJ OP INFUSION,28145,"Tiger, Yun Kyoung, MD",8/23/2024,Daratumumab/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,8/22/2024,Inactive,,
CINJ OP INFUSION,46174,"Mayer, Tina M, MD",5/25/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,5/25/2023,Active,,
CINJ OP INFUSION,13180,"Haigentz, Missak, MD",8/23/2024,"PACLitaxel 200 mg/m2 /CARBOplatin PLUS Nivolumab, 21 Day Cycles Neoadjuvant - Non-Small Cell Lung Cancer",Neoadjuvant,8/23/2024,Inactive,,
CINJ OP INFUSION,13180,"Haigentz, Missak, MD",1/22/2025,Nivolumab 480 mg 28 Day Cycles- Thoracic Cancers,Adjuvant,1/21/2025,Active,,
CINJ OP INFUSION,79833,"Haigentz, Missak, MD",11/4/2024,"DOCEtaxel with RT D1, D8, D15 (15mg/m2 dose) 21 Day Cycles- Head and Neck Cancers",Induction,11/4/2024,Inactive,,
CINJ OP INFUSION,79833,"Haigentz, Missak, MD",11/4/2024,DOCEtaxel with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,11/3/2024,Active,,
CINJ OP INFUSION,80514,"Boland, Patrick M, MD",2/17/2023,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,,2/17/2023,Inactive,,
SOM OUTPT INFUSION,97383,"Patel, Eshan, MD",1/13/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,1/13/2023,Inactive,,
NBR CINJ OP INFUSION,36792,"Rhodes, Joanna Meehan, MD",11/8/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,_2. Second Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,48371,"Grossman, I Robert, MD",11/1/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,10/31/2023,Active,,
CBMC OP INFUSION 2FL,51778,"Grossman, I Robert, MD",3/28/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,3/28/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CINJ OP INFUSION,14159,"Omene, Coral Oghenerukevwe, MD",6/3/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,6/3/2024,Active,Metastasis to peritoneal cavity (CMS/HCC),
CBMC 2W ONCOLOGY,69413,"Wagmiller, Jennifer Ann, MD",1/12/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,1/12/2025,Active,,
CINJ OP INFUSION,95766,"Saraiya, Biren P, MD",10/10/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/10/2023,Active,,
CMC OP INFUSION,96524,"Pompa, Tiffany Ann, MD",1/28/2025,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant; Adjuvant),Adjuvant,1/22/2025,Active,,
CMC OP INFUSION,96524,"Pompa, Tiffany Ann, MD",5/21/2025,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,5/21/2025,Inactive,"Squamous cell lung cancer, left (CMS/HCC)
Malignant neoplasm of bronchus of left lower lobe (CMS/HCC)",
CMC OP INFUSION,96524,"Pompa, Tiffany Ann, MD",4/24/2025,Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/24/2025,Inactive,"Squamous cell lung cancer, left (CMS/HCC)
Malignant neoplasm of bronchus of left lower lobe (CMS/HCC)",
NBR 4N ONCOLOGY,53779,"Braunschweig, Ira, MD",1/3/2023,MATRiX (High-Dose Methotrexate / Cytarabine / Thiotepa / RiTUXimab) - CNS Lymphoma,,1/1/2023,Inactive,,
NBR 4N ONCOLOGY,53779,"Braunschweig, Ira, MD",3/3/2023,BMT Autologous Carmustine / Thiotepa,,3/2/2023,Inactive,,
HAM OP INFUSION,54224,"Patel, Malini M, MD",10/18/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,10/16/2023,Inactive,,
NBR CINJ OP INFUSION,49933,"Rhodes, Joanna Meehan, MD",4/8/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,3/31/2024,Inactive,,
NBR CINJ OP INFUSION,49933,"Rhodes, Joanna Meehan, MD",11/18/2024,Obinutuzumab Maintenance 56 Day Cycles - Follicular Lymphoma ,Maintenance,11/17/2024,Active,,
CBMC OP INFUSION 2FL,46136,"Scoppetuolo, Michael, MD",8/1/2023,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",_1. First Line,7/31/2023,Active,,
CINJ OP INFUSION,86252,"Haigentz, Missak, MD",8/8/2023,Cetuximab / PACLitaxel 80 mg/m2 - 28 Day Cycles- Head and Neck Cancers,Second Line,8/8/2023,Inactive,,
CINJ OP INFUSION,86252,"Haigentz, Missak, MD",8/10/2023,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,,8/9/2023,Inactive,,
CINJ OP INFUSION,19063,"Golombos, David, MD",11/11/2024,Gemcitabine Intravesical Weekly 42 Day Cycle - Bladder,Adjuvant,11/10/2024,Active,,
CMC OP INFUSION,18023,"Weiss, Sarah, MD",6/7/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,Neoadjuvant,6/6/2023,Inactive,,
CMC OP INFUSION,98585,"Pompa, Tiffany Ann, MD",8/13/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,8/12/2024,Active,,
CINJ OP INFUSION,29670,"Hochster, Howard S, MD",6/5/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,3/26/2024,Inactive,,
SOM OUTPT INFUSION,64478,"Yin, Faye, MD",7/19/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,First Line,7/19/2023,Active,,
NBR CINJ OP INFUSION,37543,"Tiger, Yun Kyoung, MD",3/19/2024,MATRiX (High-Dose Methotrexate / Cytarabine / Thiotepa / RiTUXimab) - CNS Lymphoma,_1. First Line,3/17/2024,Inactive,,
NBR CINJ OP INFUSION,37543,"Egini, Ogechukwu, MD",7/25/2024,BMT Autologous Carmustine / Thiotepa,_1. First Line,7/24/2024,Inactive,,
MMC OP VP INFUSION,52584,"Talwar, Sumit, MD",5/20/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,5/20/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)","C50.912, C77.3 - Breast cancer metastasized to axillary lymph node, left (CMS/HCC)"
CBMC OP INFUSION 2FL,87926,"Leitner, Stuart P, MD",5/15/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/15/2025,Active,"Malignant neoplasm of overlapping sites of tonsil (CMS/HCC)
Malignant neoplasm of lingula of left lung (CMS/HCC)",
NBR 4N ONCOLOGY,58642,"Jang, Thomas L, MD",2/20/2024,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,2/20/2024,Inactive,,
CBMC OP INFUSION 2FL,21294,"Grossman, I Robert, MD",11/3/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,11/2/2023,Inactive,,
NBR 4N BMTU/IMCU,7841,"Schaar, Dale, MD PhD",11/22/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,11/20/2023,Inactive,,
CBMC OP INFUSION 2FL,29331,"Brown, Andrew Bennett, MD",3/6/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/5/2024,Active,,
CINJ OP INFUSION,72725,"Mayer, Tina M, MD",6/12/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,,6/12/2023,Inactive,,
MMC OP VP INFUSION,11578,"Cohen, Seth D, MD",5/17/2023,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,Maintenance,5/16/2023,Inactive,,
CBMC OP INFUSION 2FL,34952,"Wagmiller, Jennifer Ann, MD",11/6/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/5/2023,Inactive,,
CBMC OP INFUSION 2FL,34952,"Wagmiller, Jennifer Ann, MD",11/8/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/7/2023,Active,,
CMC OP INFUSION,49996,"Pompa, Tiffany Ann, MD",12/27/2024,Nivolumab 360 mg D1 every 21 Day Cycles- Thoracic Cancers,Neoadjuvant,12/23/2024,Active,,
CMC OP INFUSION,49996,"Pompa, Tiffany Ann, MD",12/27/2024,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Neoadjuvant,12/23/2024,Active,,
SOM OUTPT INFUSION,33513,"Patel, Eshan, MD",1/17/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,1/17/2023,Active,Urothelial carcinoma (CMS/HCC),
CINJ OP INFUSION,24097,"Berim, Lyudmyla, MD",5/20/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/14/2024,Active,,
CINJ OP INFUSION,30580,"Berim, Lyudmyla, MD",3/19/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/3/2025,Active,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CINJ OP INFUSION,30580,"Berim, Lyudmyla, MD",3/3/2025,FOLFIRI Inpatient (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/3/2025,Inactive,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
SOM OUTPT INFUSION,9096,"Toomey, Kathleen C, MD",2/1/2024,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,Adjuvant,1/18/2024,Inactive,,
CINJ OP INFUSION,87987,"Haigentz, Missak, MD",7/16/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,7/16/2024,Active,,
CINJ OP INFUSION,75489,"Haigentz, Missak, MD",5/13/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/13/2025,Active,Oropharyngeal cancer (CMS/HCC),
CINJ OP INFUSION,25917,"Weiss, Sarah, MD",2/24/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,2/23/2023,Inactive,,
CINJ OP INFUSION,34141,"Hochster, Howard S, MD",4/4/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/2/2024,Active,,
CMC OP INFUSION,19933,"Easaw, Sarah, MD",5/4/2023,PACLitaxel weekly,First Line,4/27/2023,Inactive,,
CMC OP INFUSION,19933,"Easaw, Sarah, MD",6/9/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,First Line,6/8/2023,Inactive,,
CMC OP INFUSION,19933,"Easaw, Sarah, MD",6/9/2023,"PACLitaxel D1, D8 21 Day Cycles - Breast",First Line,6/8/2023,Inactive,,
CMC OP INFUSION,19933,"Easaw, Sarah, MD",6/9/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),First Line,6/8/2023,Inactive,,
CMC OP INFUSION,19933,"Easaw, Sarah, MD",6/15/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),First Line,6/14/2023,Inactive,,
CMC OP INFUSION,19933,"Talwar, Sumit, MD",11/2/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,10/26/2023,Active,Ovarian cancer (CMS/HCC),
CINJ OP INFUSION,9715,"George, Mridula A, MD",2/14/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,2/13/2024,Inactive,,
CINJ OP INFUSION,60746,"Haigentz, Missak, MD",12/14/2024,PEMEtrexed/CARBOplatin (AUC 5) PLUS PEMBROLIZUMAB (startring in C2) - 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/5/2024,Active,,
SOM OUTPT INFUSION,18964,"Patel, Eshan, MD",7/17/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,First Line,7/9/2023,Inactive,,
SOM OUTPT INFUSION,18964,"Patel, Eshan, MD",10/2/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,First Line,10/2/2023,Inactive,,
SOM OUTPT INFUSION,18964,"Patel, Eshan, MD",4/18/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Maintenance,4/18/2024,Inactive,,
CMC OP INFUSION,12386,"Taff, Jessica, MD",5/12/2023,Nivo-AVD,First Line,5/11/2023,Inactive,,
CMC OP INFUSION,12386,"Taff, Jessica, MD",12/29/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,11/9/2023,Active,,
NBI OP INFUSION,35562,"Jacoby, Sari H, MD",7/30/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,7/29/2024,Active,,
NBI OP INFUSION,60012,"Cheng, Yan Ho, MD",6/13/2024,RiTUXimab Initial Infusion Single Day,_1. First Line,6/13/2024,Inactive,,
MMC OP VP INFUSION,95925,"Lee, Patrick C, MD",2/23/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/22/2023,Inactive,,
MMC OP VP INFUSION,95925,"Lee, Patrick C, MD",11/3/2023,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/24/2023,Inactive,,
CINJ OP INFUSION,1116,"Stephenson, Ryan D, DO",9/6/2023,CINJ 082211 Dose Escalation HB-302 / HB-301 Alternating 2-Vector Therapy 42 Day Cycles Research- Prostate Cancer,Third Line,9/6/2023,Inactive,,
CINJ OP INFUSION,1116,"Stephenson, Ryan D, DO",2/12/2025,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_6. Sixth Line,2/11/2025,Active,Prostate cancer metastatic to bone (CMS/HCC),C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone
CINJ OP INFUSION,2466,"Toppmeyer, Deborah L, MD",7/24/2023,Palbociclib 28 Day Cycles - Breast,Second Line,7/24/2023,Inactive,,
MSC OP INFUSION,17835,"Easaw, Sarah, MD",5/17/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/9/2023,Inactive,,
MSC OP INFUSION,17835,"Easaw, Sarah, MD",8/9/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,8/1/2023,Inactive,,
MSC OP INFUSION,17835,"Cohen, Seth D, MD",9/6/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/2/2023,Active,,
CINJ OP INFUSION,9935,"Goel, Sanjay, MD",1/8/2025,CINJ 052403 Part B Mirdametinib / Lifirafenib 28 Day Cycles Research- Solid Malignanices,_3. Third Line,1/8/2025,Active,,
CINJ OP INFUSION,24748,"Berim, Lyudmyla, MD",1/16/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/14/2025,Active,,
CINJ PEDS HEMONC ,28806,"Moerdler, Scott, MD",3/1/2024,PEDS ARST0332 Arm D,_1. First Line,3/1/2024,Inactive,,
CINJ PEDS HEMONC ,28806,"Moerdler, Scott, MD",5/10/2024,PEDS Gemcitabine / DOCEtaxel - Relapsed Sarcoma,_2. Second Line,5/9/2024,Inactive,,
NBR CINJ OP INFUSION,86027,"Evens, Andrew M, DO",9/27/2023,AHOD2131 All Arms ABVD,First Line,9/26/2023,Inactive,,
NBR CINJ OP INFUSION,86027,"Evens, Andrew M, DO",9/27/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,,9/26/2023,Inactive,,
MSC OP INFUSION,74160,"Easaw, Sarah, MD",7/17/2023,RiTUXimab q2 weekly every 180 days,Maintenance,7/17/2023,Active,Metastatic clear cell carcinoma of kidney (CMS/HCC),
MSC OP INFUSION,74160,"Tang, Horace, MD",1/15/2024,RiTUXimab MS,Maintenance,1/15/2024,Active,Malignant neoplasm of both ovaries (CMS/HCC),
CBMC OP INFUSION 2FL,45138,"Litvak, Anna M, MD",12/14/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,11/27/2023,Inactive,,
CINJ OP INFUSION,23561,"Stephenson, Ruth D, DO",5/16/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,5/16/2023,Active,,
NBI OP INFUSION,28700,"Shah, Maya M, MD",10/23/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/22/2024,Inactive,,
NBI OP INFUSION,28700,"Shah, Maya M, MD",12/26/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/25/2024,Active,,
MMC OP INFUSION,26018,"Meghal, Trishala, MD",10/15/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,10/3/2024,Active,,
MMC OP VP INFUSION,26018,"Meghal, Trishala, MD",10/15/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,10/10/2024,Inactive,,
MMC OP VP INFUSION,26018,"Meghal, Trishala, MD",10/15/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,10/14/2024,Inactive,,
MMC OP INFUSION,26018,"Meghal, Trishala, MD",10/15/2024,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,10/3/2024,Inactive,,
MMC OP VP INFUSION,26018,"Meghal, Trishala, MD",11/5/2024,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/28/2024,Inactive,,
CINJ OP INFUSION,59573,"Toppmeyer, Deborah L, MD",2/6/2023,Neratinib 28 Day Cycles - Breast,Adjuvant,2/6/2023,Inactive,,
CINJ OP INFUSION,59573,"Toppmeyer, Deborah L, MD",2/6/2023,Neratinib 28 Day Cycles - Breast,Adjuvant,2/6/2023,Active,,
NBI D7 MED-SURG/TELE,4840,"Cheng, Yan Ho, MD",4/9/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,4/8/2024,Inactive,,
NBI OP INFUSION,4840,"Cheng, Yan Ho, MD",4/9/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,4/1/2024,Inactive,,
CINJ OP INFUSION,46439,"Omene, Coral Oghenerukevwe, MD",5/15/2023,Palbociclib 28 Day Cycles - Breast,,5/15/2023,Inactive,,
CINJ OP INFUSION,46439,"Omene, Coral Oghenerukevwe, MD",6/19/2023,Abemaciclib 28 Day Cycles - Breast,,6/19/2023,Active,,
NBR 5N ONCOLOGY,45116,"Berim, Lyudmyla, MD",1/13/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/12/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,45116,"Berim, Lyudmyla, MD",2/7/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/4/2025,Active,Gastric adenocarcinoma (CMS/HCC),"C16.0 - Malignant neoplasm of cardia; G93.41 - Metabolic encephalopathy; R57.8 - Other shock; E44.0 - Moderate protein-calorie malnutrition; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; J90 - Pleural effusion, not elsewhere classified; I82.411 - Acute embolism and thrombosis of right femoral vein; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; N18.30 - Chronic kidney disease, stage 3 unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; D63.8 - Anemia in other chronic diseases classified elsewhere; F10.96 - Alcohol use, unspecified with alcohol-induced persisting amnestic disorder; D62 - Acute posthemorrhagic anemia; K62.6 - Ulcer of anus and rectum; Z95.1 - Presence of aortocoronary bypass graft; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z86.718 - Personal history of other venous thrombosis and embolism; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z87.891 - Personal history of nicotine dependence; Z88.8 - Allergy status to other drugs, medicaments and biological substances; K59.00 - Constipation, unspecified; I95.9 - Hypotension, unspecifie..."
NBI OP INFUSION,34833,"Jacoby, Sari H, MD",7/22/2024,Capmatinib 28 Day Cycles,_1. First Line,7/22/2024,Active,,
NBI OP INFUSION,34833,"Jacoby, Sari H, MD",2/25/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/17/2025,Active,"Malignant neoplasm of upper lobe, right bronchus or lung (CMS/HCC)",
MMC OP VP INFUSION,79185,"Lee, Patrick C, MD",3/22/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,3/21/2024,Inactive,,
MMC OP VP INFUSION,79185,"Lee, Patrick C, MD",5/27/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,5/26/2024,Inactive,,
MMC OP VP INFUSION,79185,"Lee, Patrick C, MD",5/30/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,5/22/2024,Inactive,,
MMC OP VP INFUSION,79185,"Lee, Patrick C, MD",3/24/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/24/2025,Inactive,Pancreatic adenocarcinoma (CMS/HCC),
MMC OP VP INFUSION,79185,"Lee, Patrick C, MD",3/13/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/13/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),
CINJ OP INFUSION,67156,"Patankar, Sonali, MD",5/30/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,5/28/2024,Active,,
MMC OP VP INFUSION,12330,"Cohen, Seth D, MD",5/10/2023,"Nivolumab D1, D15 28 Day Cycles - Kidney  started 7/20/16",,5/3/2023,Inactive,,
MMC OP VP INFUSION,12330,"Cohen, Seth D, MD",8/16/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,,8/16/2023,Inactive,,
CINJ OP INFUSION,6946,"Haigentz, Missak, MD",6/9/2023,PEMEtrexed/CARBOplatin (AUC 4) 21 Day Cycles- Non-Small Cell Lung Cancer ,Adjuvant,6/1/2023,Inactive,,
CINJ OP INFUSION,6946,"Haigentz, Missak, MD",9/6/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,9/6/2023,Inactive,,
MMC OP INFUSION,74875,"Meghal, Trishala, MD",6/14/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,6/5/2024,Inactive,,
MMC OP INFUSION,74875,"Meghal, Trishala, MD",6/14/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,6/14/2024,Inactive,,
MMC OP VP INFUSION,74875,"Meghal, Trishala, MD",3/4/2025,Olaparib 30 Day Cycles - Breast,Adjuvant,3/4/2025,Active,Malignant neoplasm of lower-outer quadrant of left female breast (CMS/HCC),
SOM OUTPT INFUSION,91330,"George, Mridula A, MD",11/10/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,11/2/2023,Inactive,,
CINJ OP INFUSION,91330,"George, Mridula A, MD",3/25/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,3/25/2024,Inactive,,
CINJ OP INFUSION,91330,"George, Mridula A, MD",8/9/2024,"CINJ 042314 Cohort 2 BB-1701 D1, D8 21 Day Cycles Research- Breast Cancer",_3. Third Line,8/9/2024,Inactive,,
CINJ OP INFUSION,91330,"George, Mridula A, MD",11/27/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_3. Third Line,11/25/2024,Active,,
CINJ OP INFUSION,16402,"George, Mridula A, MD",2/5/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,2/4/2025,Inactive,"Carcinoma of breast metastatic to bone (CMS/HCC)
Malignant neoplasm of breast metastatic to brain (CMS/HCC)",
NBR BMSCH 2 PED HEMONC,33840,"Moerdler, Scott, MD",8/11/2023,AALL1732 Induction,Induction,8/10/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33840,"Moerdler, Scott, MD",8/11/2023,AALL1732 Induction,Induction,8/10/2023,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",9/14/2023,AALL1732 Consolidation,,9/14/2023,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",12/8/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,11/28/2023,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",3/7/2024,AALL1732 Delayed Intensification,_1. First Line,3/7/2024,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",5/30/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,5/22/2024,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",8/9/2024,AALL1732 B-ALL Blinatumomab Block,_1. First Line,8/8/2024,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",8/9/2024,PEDS AALL 1732 per  Children's Oncology Group memo 07.18.2024,_1. First Line,8/8/2024,Inactive,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",9/12/2024,"AALL1732 HR B-ALL Arm A & B, MPAL, B-LLy Maintenance",_1. First Line,9/11/2024,Active,,
CINJ PEDS HEMONC ,33840,"Drachtman, Richard, MD",12/17/2024,AALL1732 ALL SR-High B-ALL  Blinatumomab Block 2,_1. First Line,12/12/2024,Active,,
NBI VALERIE FND HEMONC,74543,"Bhatla, Teena, MD",9/7/2023,PEDS LCH-III Group 3 Continuation,Maintenance,9/6/2023,Active,,
CBMC OP INFUSION 2FL,35969,"Dharmapuri, Sirish, MD",9/24/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,9/10/2024,Inactive,Malignant neoplasm of body of pancreas (CMS/HCC),
CBMC OP INFUSION 2FL,35969,"Dharmapuri, Sirish, MD",1/14/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/17/2024,Active,,
SOM OUTPT INFUSION,26453,"Patel, Eshan, MD",6/26/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,,6/18/2023,Inactive,,
SOM OUTPT INFUSION,26453,"Patel, Eshan, MD",6/26/2023,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,,6/26/2023,Inactive,,
SOM OUTPT INFUSION,26453,"Patel, Eshan, MD",3/4/2024,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/3/2024,Inactive,,
SOM OUTPT INFUSION,26453,"Patel, Eshan, MD",7/8/2024,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,7/8/2024,Inactive,,
NBR 4N ONCOLOGY,43814,"Palmisiano, Neil David, MD",7/5/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Induction,7/5/2024,Inactive,,
NBR 4N ONCOLOGY,43814,"Rhodes, Joanna Meehan, MD",7/12/2024,HyperCVAD + RiTUXimab (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate / RiTUXimab) Starting with B Cycle,_2. Second Line,7/12/2024,Inactive,,
CMC OP INFUSION,60039,"Pompa, Tiffany Ann, MD",5/30/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,5/28/2025,Active,Secondary malignant neoplasm of bone and bone marrow (CMS/HCC),
MMC OP VP INFUSION,50418,"Talwar, Sumit, MD",4/10/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/9/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),
MMC OP INFUSION,68062,"Lee, Patrick C, MD",4/9/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/8/2024,Active,,
TRMC TCCC OP INFUSION,93972,"Salerno, Vincent E, MD",4/8/2024,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,Maintenance,4/8/2024,Active,,
NBR 4N ONCOLOGY,48640,"Leiser, Aliza, MD",7/3/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,7/3/2023,Active,,
CBMC OP INFUSION 2FL,78438,"Brown, Andrew Bennett, MD",2/20/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Head and Neck,_1. First Line,2/20/2025,Active,Malignant neoplasm of upper gum (CMS/HCC),C03.0 - Malignant neoplasm of upper gum (CMS/HCC)
NBI OP INFUSION,1456,"Schleicher, Lori, MD",5/19/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/11/2023,Inactive,,
NBI OP INFUSION,1456,"Schleicher, Lori, MD",8/11/2023,Pembrolizumab alternating with Pembro/Pemetrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/10/2023,Inactive,,
NBI OP INFUSION,1456,"Schleicher, Lori, MD",1/26/2024,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/25/2024,Inactive,,
NBI D7 MED-SURG/TELE,1456,"Schleicher, Lori, MD",5/3/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,5/2/2024,Inactive,,
MSC OP INFUSION,76788,"Cohen, Seth D, MD",3/21/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/20/2024,Inactive,,
MSC OP INFUSION,76788,"Cohen, Seth D, MD",3/21/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles ,_1. First Line,3/12/2024,Inactive,,
MSC OP INFUSION,91723,"Cohen, Seth D, MD",5/6/2025,PACLitaxel Weekly / CARBOplatin Weekly 28 Day Cycles,_2. Second Line,5/6/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),
CBMC 2W ONCOLOGY,78851,"Scoppetuolo, Michael, MD",8/16/2024,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,8/15/2024,Inactive,,
CBMC 2W ONCOLOGY,78851,"Scoppetuolo, Michael, MD",9/6/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_1. First Line,9/5/2024,Active,,
MMC OP VP INFUSION,70779,"Cohen, Seth D, MD",3/24/2025,CISplatin 75 mg/m2 / Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Cancers,_1. First Line,3/19/2025,Active,"Small cell lung cancer, right lower lobe (CMS/HCC)",
CINJ OP INFUSION,81630,"Haigentz, Missak, MD",2/5/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,2/5/2024,Inactive,,
CINJ OP INFUSION,81630,"Haigentz, Missak, MD",4/29/2024,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,4/28/2024,Inactive,,
CINJ OP INFUSION,81630,"Haigentz, Missak, MD",7/22/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_3. Third Line,7/21/2024,Inactive,,
MMC OP VP INFUSION,92507,"Cohen, Seth D, MD",1/17/2024,CISplatin (Recurrent/Metastatic) 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/16/2024,Inactive,,
CINJ OP INFUSION,37875,"George, Mridula A, MD",9/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,9/3/2024,Active,,
CBMC 2W ONCOLOGY,31666,"Scoppetuolo, Michael, MD",3/18/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,3/5/2024,Inactive,,
CBMC 2W ONCOLOGY,31666,"Scoppetuolo, Michael, MD",8/26/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,8/25/2024,Inactive,,
CBMC 2W ONCOLOGY,31666,"Scoppetuolo, Michael, MD",8/26/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,8/25/2024,Inactive,,
CINJ OP INFUSION,35451,"Gulhati, Prateek, MD PhD",6/6/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/5/2024,Inactive,,
CINJ OP INFUSION,35451,"Gulhati, Prateek, MD PhD",12/12/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/11/2024,Active,,
CINJ OP INFUSION,35451,"Gulhati, Prateek, MD PhD",5/29/2025,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,5/29/2025,Active,Rectal cancer metastasized to bone (CMS/HCC),"C20, C79.51 - Rectal cancer metastasized to bone (CMS/HCC)"
CINJ OP INFUSION,35451,"Gulhati, Prateek, MD PhD",3/6/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/6/2025,Inactive,Rectal cancer metastasized to bone (CMS/HCC),
NBR CINJ OP INFUSION,96710,"Shah, Mansi R, MD",7/31/2024,BMT Autologous Melphalan Day -1 140MG/M2,Consolidation,7/29/2024,Inactive,,
CBMC OP INFUSION 2FL,34091,"Brown, Andrew Bennett, MD",10/3/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,10/3/2024,Inactive,,
CBMC OP INFUSION 2FL,34091,"Brown, Andrew Bennett, MD",12/9/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,12/8/2024,Active,,
CBMC OP INFUSION 2FL,34091,"Brown, Andrew Bennett, MD",12/9/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,12/8/2024,Inactive,,
CBMC OP INFUSION 2FL,34091,"Brown, Andrew Bennett, MD",2/17/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,2/16/2025,Active,"Primary malignant neoplasm of left upper lobe of lung (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)","C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; M04.9 - Autoinflammatory syndrome, unspecified; Z11.59 - Encounter for screening for other viral diseases"
CMC OP INFUSION,9128,"Cohen, Seth D, MD",5/9/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,First Line,5/8/2023,Inactive,,
MMC OP INFUSION,99848,"Lee, Patrick C, MD",11/5/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,10/22/2024,Active,,
MMC OP INFUSION,99848,"Lee, Patrick C, MD",3/31/2025,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,3/31/2025,Active,Cervical cancer (CMS/HCC),
CBMC OP INFUSION 2FL,89614,"Dharmapuri, Sirish, MD",9/30/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,9/2/2024,Active,,
CBMC OP INFUSION 2FL,89614,"Dharmapuri, Sirish, MD",4/28/2025,"Gemcitabine D1, D8/Albumin-Bound PACLitaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/25/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),
NBR CINJ OP INFUSION,43100,"Assal, Amer, MD",1/18/2024,Cyclophosphamide for Stem Cell Mobilization,_1. First Line,1/18/2024,Inactive,,
MMC BBR2 ONCOLOGY,45765,"Cohen, Seth D, MD",2/26/2024,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,2/26/2024,Inactive,,
SOM OUTPT INFUSION,99009,"Yin, Faye, MD",7/18/2023,Nivolumab 480 mg Q28 Day Cycles- Gastrointestinal Cancers,Adjuvant,7/17/2023,Inactive,,
CBMC OP INFUSION 2FL,99800,"Litvak, Anna M, MD",9/25/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,9/24/2023,Active,,
CINJ OP INFUSION,92042,"Weiss, Sarah, MD",5/15/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,Third Line,5/14/2023,Inactive,,
CINJ OP INFUSION,92042,"Weiss, Sarah, MD",6/12/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Third Line,6/12/2023,Active,,
CINJ OP INFUSION,7848,"Haigentz, Missak, MD",7/31/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,7/31/2023,Inactive,,
CINJ OP INFUSION,7848,"Haigentz, Missak, MD",5/14/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/13/2024,Active,,
CINJ OP INFUSION,71995,"Gulhati, Prateek, MD PhD",7/27/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/25/2023,Inactive,,
CINJ OP INFUSION,71995,"Stephenson, Ruth D, DO",8/14/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Second Line,8/8/2023,Inactive,,
CINJ OP INFUSION,71995,"Stephenson, Ruth D, DO",12/20/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_2. Second Line,12/19/2023,Inactive,,
CINJ OP INFUSION,71995,"Stephenson, Ruth D, DO",5/22/2024,CINJ 102310 Cohort B MK-4280A or Pembrolizumab / Lenvatinib 21 Day Cycles Research Solid Tumors,_3. Third Line,5/22/2024,Inactive,,
CINJ OP INFUSION,71995,"Stephenson, Ruth D, DO",9/27/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,9/26/2024,Inactive,,
SOM 1PAV ONCOLOGY,42122,"Patel, Eshan, MD",3/12/2025,Fludarabine  28 Day Cycles - T LGL,_3. Third Line,3/12/2025,Active,T-cell large granular lymphocytic leukemia (CMS/HCC),"C91.90 - Lymphoid leukemia, unspecified not having achieved remission; J18.9 - Pneumonia, unspecified organism; D59.4 - Other nonautoimmune hemolytic anemias; D61.818 - Other pancytopenia; E87.1 - Hypo-osmolality and hyponatremia; D63.0 - Anemia in neoplastic disease; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; J02.9 - Acute pharyngitis, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z11.52 - Encounter for screening for COVID-19; Z86.711 - Personal history of pulmonary embolism; Z79.890 - Hormone replacement therapy; Z79.899 - Other long term (current) drug therapy; Z91.013 - Allergy to seafood"
SOM OUTPT INFUSION,42122,"Patel, Eshan, MD",3/11/2025,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,3/11/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
NBI OP INFUSION,46972,"Schleicher, Lori, MD",8/2/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/1/2024,Active,,
CINJ OP INFUSION,5911,"Toppmeyer, Deborah L, MD",8/14/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,Adjuvant,8/13/2023,Inactive,,
CINJ OP INFUSION,5911,"Toppmeyer, Deborah L, MD",11/7/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Adjuvant,8/16/2023,Inactive,,
CINJ OP INFUSION,5911,"Toppmeyer, Deborah L, MD",11/26/2024,Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel weekly 21 Day Cycles - Breast,Neoadjuvant,11/21/2024,Active,,
CINJ OP INFUSION,65349,"Toppmeyer, Deborah L, MD",3/20/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,3/20/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,70160,"Berim, Lyudmyla, MD",7/8/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,7/3/2024,Active,,
CINJ OP INFUSION,70160,"Berim, Lyudmyla, MD",3/24/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,3/21/2025,Active,Cancer of rectosigmoid (colon) (CMS/HCC),
HAM OP INFUSION,86562,"Patel, Malini M, MD",2/24/2025,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,2/23/2025,Active,"Merkel cell cancer (CMS/HCC)
Secondary malignancy of axillary node (CMS/HCC)
Skin cancer, basal cell",
HAM OP INFUSION,86562,"Patel, Malini M, MD",3/10/2025,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,3/10/2025,Active,"Malignant neoplasm of soft tissue of hand, right (CMS/HCC)
Secondary malignancy of axillary node (CMS/HCC)
Skin cancer, basal cell
Abnormal findings on diagnostic imaging of other specified body structures",
CINJ OP INFUSION,13238,"Weiss, Sarah, MD",11/20/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,11/12/2023,Active,,
HAM OP INFUSION,93377,"Patel, Malini M, MD",1/21/2025,Cetuximab/DOCEtaxel with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,1/20/2025,Active,,
CMC OP INFUSION,58250,"Taff, Jessica, MD",7/19/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/16/2023,Inactive,,
MMC OP INFUSION,82995,"Meghal, Trishala, MD",5/12/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,5/11/2023,Inactive,,
MMC OP INFUSION,82995,"Meghal, Trishala, MD",10/6/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Adjuvant,10/6/2023,Inactive,,
CMC OP INFUSION,73301,"Taff, Jessica, MD",4/17/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,4/16/2023,Active,,
MSC OP INFUSION,73301,"Taff, Jessica, MD",5/27/2025,PACLitaxel / CARBOplatin 21 Day Cycles -Thymic carcinoma,_1. First Line,5/27/2025,Active,Thymic carcinoma (CMS/HCC),
CMC OP INFUSION,54516,"Cohen, Seth D, MD",7/17/2023,Dostarlimab-gxly,_2. Second Line,7/17/2023,Active,,
CMC OP INFUSION,22274,"Taff, Jessica, MD",4/11/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,4/11/2025,Active,"Malignant melanoma of left upper limb, including shoulder (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,38465,"Saraiya, Biren P, MD",4/18/2023,CINJ 081603 ARM 1 Apalutamide 90 Day Cycle Research- Prostate Cancer,Neoadjuvant,3/19/2023,Active,,
CBMC OP INFUSION 2FL,83617,"Radovich, Delia, MD",11/17/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,11/16/2023,Active,,
CBMC OP INFUSION 2FL,16639,"Leitner, Stuart P, MD",3/17/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,3/13/2025,Active,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)
Secondary malignant neoplasm of right lung (CMS/HCC)
Secondary malignant neoplasm of mediastinal lymph node (CMS/HCC)
Thyroiditis, autoimmune",
SOM OUTPT INFUSION,76613,"Toomey, Kathleen C, MD",10/3/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,9/24/2024,Inactive,,
SOM OUTPT INFUSION,73458,"Toomey, Kathleen C, MD",1/2/2025,Herceptin Hylecta (Trastuzumab) 21 Day Cycles (Continuation) - Breast,Maintenance,12/31/2024,Active,,
CBMC OP INFUSION 2FL,4168,"Leitner, Stuart P, MD",6/6/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,6/5/2024,Inactive,,
CBMC OP INFUSION 2FL,4168,"Leitner, Stuart P, MD",8/1/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,7/31/2024,Active,,
NBR CINJ OP INFUSION,67914,"Evens, Andrew M, DO",2/8/2023,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,,2/7/2023,Inactive,,
NBR CINJ OP INFUSION,67914,"Evens, Andrew M, DO",3/27/2024,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_3. Third Line,3/26/2024,Active,,
NBR 4N ONCOLOGY,25478,"Zayac, Adam, MD",12/7/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/7/2024,Inactive,,
NBI OP INFUSION,6392,"Anderson, Patrick S, MD",11/2/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Endometrial Cancer,_1. First Line,11/1/2023,Inactive,,
NBI OP INFUSION,6392,"Anderson, Patrick S, MD",3/28/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,3/27/2024,Inactive,,
NBI OP INFUSION,6392,"Anderson, Patrick S, MD",6/20/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Endometrial adenocarcinoma,_2. Second Line,6/19/2024,Active,,
CINJ OP INFUSION,49653,"Haigentz, Missak, MD",7/9/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/9/2024,Inactive,,
JCMC CP INFUSION,32067,"Sekhri, Arunabh, MD",7/1/2024,PACLitaxel / CARBOplatin 21 Day Cycles  - Endometrial Cancer,_1. First Line,6/30/2024,Inactive,,
NBI OP INFUSION,41932,"Jacoby, Sari H, MD",1/7/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/6/2025,Active,,
CBMC OP INFUSION 2FL,49499,"Leitner, Stuart P, MD",2/29/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,2/27/2024,Inactive,,
CBMC OP INFUSION 2FL,89617,"Derosa, William T, DO",4/16/2025,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,4/15/2025,Inactive,"Multiple myeloma (CMS/HCC)
Antineoplastic chemotherapy induced anemia",C90.00 - Multiple myeloma not having achieved remission; C90.01 - Multiple myeloma in remission
CBMC OP INFUSION 2FL,89617,"Derosa, William T, DO",4/16/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/16/2025,Active,"Multiple myeloma (CMS/HCC)
Antineoplastic chemotherapy induced anemia",
CMC OP INFUSION,92370,"Tang, Horace, MD",1/31/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,1/30/2023,Inactive,,
CMC OP INFUSION,92370,"Tang, Horace, MD",9/22/2023,Irinotecan,,9/15/2023,Inactive,,
CMC OP INFUSION,92370,"Tang, Horace, MD",10/12/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,10/12/2023,Inactive,,
CMC OP INFUSION,92370,"Talwar, Sumit, MD",10/2/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,10/1/2024,Active,,
CBMC OP INFUSION 2FL,1475,"Radovich, Delia, MD",11/7/2023,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,1475,"Radovich, Delia, MD",11/7/2023,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,1475,"Dharmapuri, Sirish, MD",10/1/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,9/30/2024,Inactive,,
CBMC OP INFUSION 2FL,87872,"Dharmapuri, Sirish, MD",1/3/2025,Irinotecan + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,12/23/2024,Active,,
CINJ OP INFUSION,87829,"Boland, Patrick M, MD",5/6/2024,CINJ 072006 (EA2182) ARM A Capecitabine 825 mg/m2 / Mitomycin 12 mg/m2 with Concurrent 28 Day Radiation 1 Cycle Research- Anal Carcinoma,Neoadjuvant,4/7/2024,Active,,
HAM OP INFUSION,17219,"Yogarajah, Meera, MD",5/20/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/19/2024,Inactive,,
HAM OP INFUSION,17219,"Yogarajah, Meera, MD",11/18/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/17/2024,Active,,
CBMC OP INFUSION 2FL,36091,"Brown, Andrew Bennett, MD",10/31/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,10/30/2023,Inactive,,
CMC OP INFUSION,99505,"Tang, Horace, MD",6/16/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,,6/15/2023,Inactive,,
CMC OP INFUSION,99505,"Tang, Horace, MD",6/16/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,,6/16/2023,Inactive,,
CMC OP INFUSION,99505,"Tang, Horace, MD",6/20/2023,RiTUXimab 56 Day Cycles,,6/19/2023,Inactive,,
CINJ OP INFUSION,28865,"Boland, Patrick M, MD",4/16/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,4/15/2024,Inactive,,
CINJ OP INFUSION,95111,"Girda, Eugenia, MD",4/30/2024,Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,4/29/2024,Inactive,,
CINJ OP INFUSION,95111,"Girda, Eugenia, MD",8/1/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,7/31/2024,Active,,
NBR CINJ OP INFUSION,51456,"Shah, Mansi R, MD",5/24/2023,"AALL 0434, Make up missed PEG-aparginase doses",,5/24/2023,Inactive,,
CINJ OP INFUSION,81615,"Berim, Lyudmyla, MD",4/29/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/29/2024,Inactive,,
NBR CINJ OP INFUSION,81615,"Berim, Lyudmyla, MD",5/13/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,4/15/2024,Inactive,,
CINJ OP INFUSION,81615,"Berim, Lyudmyla, MD",7/25/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,7/10/2024,Inactive,,
CINJ OP INFUSION,81615,"Berim, Lyudmyla, MD",9/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/4/2024,Active,,
HAM OP INFUSION,9817,"Yogarajah, Meera, MD",4/8/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,4/8/2025,Active,"Malignant neoplasm of overlapping sites of right breast, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,7069,"Meghal, Trishala, MD",7/16/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,7/16/2024,Inactive,,
MMC OP VP INFUSION,7069,"Meghal, Trishala, MD",7/25/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,7/25/2024,Active,,
NBI VALERIE FND HEMONC,92281,"Rao, Harini, MD",2/10/2025,ACNS2021 Induction,_1. First Line,2/8/2025,Active,Nongerminomatous germ cell tumor of central nervous system (CMS/HCC),
CINJ OP INFUSION,14117,"Groisberg, Roman, MD",11/15/2024,Gemcitabine 21 Day Cycles - Sarcoma,_1. First Line,11/14/2024,Active,,
HAM OP INFUSION,91690,"Yogarajah, Meera, MD",4/8/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/7/2024,Inactive,,
HAM OP INFUSION,91690,"Yogarajah, Meera, MD",8/19/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/9/2024,Active,,
MMC OP VP INFUSION,34464,"Talwar, Sumit, MD",2/27/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/21/2024,Inactive,,
CMC OP INFUSION,77250,"Easaw, Sarah, MD",6/22/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,6/19/2023,Inactive,,
MSC OP INFUSION,3850,"Cohen, Seth D, MD",10/24/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,10/16/2023,Inactive,,
MSC OP INFUSION,3850,"Cohen, Seth D, MD",1/23/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/15/2024,Active,,
NBI OP INFUSION,12331,"Cohen, Alice, MD",12/21/2023,Everolimus / Exemestane 28 Day Cycles - Breast,_3. Third Line,12/21/2023,Active,,
SOM OUTPT INFUSION,72115,"Yin, Faye, MD",4/27/2023,Palbociclib 28 Day Cycles - Breast,First Line,3/29/2023,Active,,
TRMC TCCC OP INFUSION,21676,"Capo, Gerardo, MD",1/11/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,1/11/2024,Active,,
CBMC OP INFUSION 2FL,35920,"Wagmiller, Jennifer Ann, MD",11/17/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,35920,"Wagmiller, Jennifer Ann, MD",6/20/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Unknown Primary,_2. Second Line,6/19/2024,Active,,
NBI OP INFUSION,87856,"Schleicher, Lori, MD",1/10/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - Lung CANCER,_1. First Line,1/9/2024,Inactive,,
NBI OP INFUSION,87856,"Schleicher, Lori, MD",12/20/2024,Olaparib 30 Day Cycles - Breast,_2. Second Line,12/20/2024,Inactive,,
CINJ OP INFUSION,2186,"Mayer, Tina M, MD",2/7/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,2/7/2023,Active,,
CINJ OP INFUSION,35808,"Hochster, Howard S, MD",7/1/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,7/1/2024,Inactive,,
CINJ OP INFUSION,35808,"Hochster, Howard S, MD",9/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/9/2024,Active,,
CINJ OP INFUSION,79568,"Leiser, Aliza, MD",1/25/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/15/2023,Inactive,,
CINJ OP INFUSION,79568,"Leiser, Aliza, MD",1/25/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/24/2023,Inactive,,
CINJ OP INFUSION,79568,"Leiser, Aliza, MD",1/25/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/24/2023,Inactive,,
CINJ OP INFUSION,79568,"Leiser, Aliza, MD",1/25/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/24/2023,Inactive,,
CINJ OP INFUSION,79568,"Leiser, Aliza, MD",8/11/2023,Pembrolizumab 21 Day Cycles - Uterine,,7/11/2023,Inactive,,
MMC OP VP INFUSION,69773,"Cohen, Seth D, MD",8/21/2024,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,8/19/2024,Active,,
CINJ OP INFUSION,81664,"Stephenson, Ryan D, DO",10/23/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,10/22/2023,Inactive,,
TRMC TCCC OP INFUSION,12275,"Capo, Gerardo, MD",10/3/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Thoracic Cancers",_1. First Line,10/2/2024,Active,,
CINJ OP INFUSION,5939,"George, Mridula A, MD",5/17/2023,Ribociclib 28 Day Cycles - Breast,First Line,5/17/2023,Active,Malignant neoplasm of right ovary (CMS/HCC),
CINJ OP INFUSION,48320,"Hochster, Howard S, MD",4/2/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/2/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CBMC OP INFUSION 1FL,4297,"Gallinson, David Herschel, DO",1/23/2025,RiTUXimab / Lenalidomide 28 Day Cycles - Follicular Lymphoma,_2. Second Line,1/17/2025,Active,"Malignant neoplasm of endometrium (CMS/HCC)
Encounter for screening for other viral diseases
Encounter for follow-up surveillance of endometrial cancer
On antineoplastic chemotherapy",
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",11/13/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,11/2/2023,Inactive,,
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",2/26/2024,CINJ 042103 (BRE 354) Part A/B U3-1402 21 Day Cycles Research- Metastatic Breast Cancer,_5. Fifth Line,2/12/2024,Inactive,,
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",2/27/2024,Gemcitabine 21 Day Cycles - Breast,_6. Sixth Line,2/27/2024,Inactive,,
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",4/30/2024,Sacituzumab Govitecan 21 Day Cycles - Metastatic Breast Cancer,_5. Fifth Line,4/29/2024,Inactive,,
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",7/9/2024,"PACLitaxel D1, D15 28 Day Cycles - Breast",_8. Eighth Line,7/9/2024,Inactive,,
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",11/22/2024,VinORELBine Day 1 and Day 8 21 Day Cycles - Breast,_8. Eighth Line,11/21/2024,Active,Malignant neoplasm of brain (CMS/HCC),
JCMC CP INFUSION,79275,"Cruz, Allan Louie E, MD",2/17/2025,DOXOrubicin Liposomal 28 Day Cycles - Breast,_9. Ninth Line,2/16/2025,Active,Breast cancer (CMS/HCC),C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CMC OP INFUSION,70116,"Tang, Horace, MD",7/10/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,,6/6/2023,Inactive,,
MMC OP INFUSION,7199,"Meghal, Trishala, MD",5/3/2023,Abemaciclib 28 Day Cycles - Breast ,,4/20/2023,Active,,
CINJ OP INFUSION,37536,"Omene, Coral Oghenerukevwe, MD",2/1/2023,Olaparib 30 Day Cycles - Breast,,2/1/2023,Active,,
CBMC OP INFUSION 2FL,31216,"Dharmapuri, Sirish, MD",9/10/2024,CINJ 072311 Durvalumab / Bevacizumab 21 Day Cycles Research- Hepatocellular Carcinoma,_1. First Line,9/9/2024,Active,,
CINJ OP INFUSION,81644,"Packiam, Vignesh, MD",10/10/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,10/9/2024,Inactive,,
NBR 4N BMTU/IMCU,82895,"Patel, Vimal D, MD",6/9/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/9/2023,Inactive,,
CMC OP INFUSION,36073,"Cohen, Seth D, MD",7/25/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,7/25/2024,Inactive,,
CMC OP INFUSION,36073,"Cohen, Seth D, MD",11/7/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_2. Second Line,11/6/2024,Inactive,,
CINJ OP INFUSION,76999,"Golombos, David, MD",10/24/2024,Gemcitabine Intravesical 28 Day Cycles - Bladder,Induction,10/23/2024,Active,,
NBR CINJ OP INFUSION,6210,"Shah, Mansi R, MD",5/9/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,5/8/2024,Active,,
CINJ OP INFUSION,87955,"George, Mridula A, MD",12/13/2024,CINJ 042316 Experimental Arm Neoadjuvant Dato-DXd / Durvalumab 21 Day Cycles Research- Breast Cancer,Neoadjuvant,12/12/2024,Active,,
CINJ OP INFUSION,87955,"George, Mridula A, MD",12/13/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,12/12/2024,Inactive,,
CINJ OP INFUSION,87955,"George, Mridula A, MD",2/28/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,2/27/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor negative (CMS/HCC)",
SOM OUTPT INFUSION,2828,"Toomey, Kathleen C, MD",9/27/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Second Line,9/26/2023,Inactive,,
CBMC OP INFUSION 2FL,38754,"Wagmiller, Jennifer Ann, MD",3/19/2024,Methotrexate 14 Day Cycles - Gestational Trophoblastic Neoplasia ,Induction,3/17/2024,Inactive,Malignant neoplasm of right ovary (CMS/HCC),
CBMC OP INFUSION 2FL,38754,"Wagmiller, Jennifer Ann, MD",5/1/2024,EMA-CO (Etoposide / Methotrexate / DACTINomycin / Cyclophosphamide / VinCRIStine) 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_2. Second Line,4/30/2024,Inactive,,
CBMC OP INFUSION 2FL,38754,"Wagmiller, Jennifer Ann, MD",5/1/2024,Methotrexate 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_1. First Line,4/30/2024,Inactive,,
NBI OP INFUSION,39162,"Schleicher, Lori, MD",11/1/2023,Nivolumab 480 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/1/2023,Active,,
CINJ OP INFUSION,49118,"Berim, Lyudmyla, MD",10/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/13/2024,Inactive,,
CINJ OP INFUSION,49118,"Berim, Lyudmyla, MD",12/20/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Unknown Primary,_1. First Line,12/8/2024,Inactive,,
NBR 5N ONCOLOGY,49118,"Berim, Lyudmyla, MD",12/27/2024,PACLitaxel / CARBOplatin 28 Day Cycles,_1. First Line,12/26/2024,Active,,
NBR 5N ONCOLOGY,92826,"Berim, Lyudmyla, MD",1/24/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/22/2025,Active,,
CBMC OP INFUSION 2FL,80633,"Brown, Andrew Bennett, MD",8/6/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/5/2024,Inactive,,
CBMC OP INFUSION 2FL,80633,"Brown, Andrew Bennett, MD",10/29/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,10/28/2024,Active,,
CBMC OP INFUSION 2FL,34547,"Wagmiller, Jennifer Ann, MD",3/27/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,3/24/2024,Inactive,,
CBMC OP INFUSION 2FL,34547,"Wagmiller, Jennifer Ann, MD",5/28/2024,Topotecan Daily 28 Day Cycles - Cervical,_2. Second Line,5/27/2024,Active,,
NBR CINJ OP INFUSION,76646,"Rhodes, Joanna Meehan, MD",8/8/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,8/5/2024,Inactive,,
CBMC 2W ONCOLOGY,41167,"Grossman, I Robert, MD",11/27/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/27/2024,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)
Secondary malignant neoplasm of unspecified lung (CMS/HCC)",
CBMC OP INFUSION 2FL,41167,"Grossman, I Robert, MD",12/12/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,12/11/2024,Active,"Malignant neoplasm of tail of pancreas (CMS/HCC)
Malignant neoplasm of tail of pancreas (CMS/HCC)",
SOM OUTPT INFUSION,80774,"Toomey, Kathleen C, MD",6/14/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,Induction,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,77007,"Rhodes, Joanna Meehan, MD",8/10/2023,R-MPV (High-Dose Methotrexate /  RiTUXimab) 21 Day Cycles - CNS Lymphoma,First Line,8/9/2023,Inactive,,
NBR CINJ OP INFUSION,91814,"Evens, Andrew M, DO",5/24/2023,Bendamustine 28 Day Cycles - Hodgkin Lymphoma,,5/23/2023,Inactive,,
NBR CINJ OP INFUSION,91814,"Evens, Andrew M, DO",11/20/2024,"CINJ 012315 Arm B Gemcitabine D1, D8 21 Day Cycles Research- Hodgkin Lymphoma",_4. Fourth Line,11/19/2024,Active,,
NBR CINJ OP INFUSION,35392,"Evens, Andrew M, DO",4/2/2025,CINJ 012315 Arm A MK-4280A Single Agent 21 Day Cycles Research- Hodgkin Lymphoma,_3. Third Line,4/2/2025,Active,"Hodgkin lymphoma, unspecified, unspecified site (CMS/HCC)",
HAM OP INFUSION,96358,"Patel, Malini M, MD",6/2/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,First Line,6/1/2023,Inactive,,
SOM OUTPT INFUSION,50542,"Toomey, Kathleen C, MD",5/11/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/3/2023,Inactive,,
CINJ OP INFUSION,16334,"Hochster, Howard S, MD",1/5/2023,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,Second Line,12/1/2022,Inactive,,
CINJ OP INFUSION,16334,"Hochster, Howard S, MD",3/1/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,3/1/2023,Inactive,,
CINJ OP INFUSION,16334,"Hochster, Howard S, MD",7/12/2023,XELIRI Capecitabine/Irinotecan/Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,Maintenance,7/11/2023,Inactive,,
CINJ OP INFUSION,16334,"Hochster, Howard S, MD",12/6/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/5/2023,Inactive,,
CINJ OP INFUSION,16334,"Hochster, Howard S, MD",1/31/2024,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/30/2024,Active,,
CBMC OP INFUSION 2FL,76631,"Grossman, I Robert, MD",5/22/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/21/2023,Active,,
CINJ OP INFUSION,21361,"Jang, Thomas L, MD",2/24/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/24/2023,Inactive,,
CINJ OP INFUSION,21361,"Jang, Thomas L, MD",6/19/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,6/19/2023,Active,,
NBR 5N ONCOLOGY,18973,"Rhodes, Joanna Meehan, MD",11/25/2024,Dose-Adjusted R-EPOCH (For AIDS-Related) (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen) ,_1. First Line,11/25/2024,Inactive,,
NBR 5N ONCOLOGY,18973,"Rhodes, Joanna Meehan, MD",11/25/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/25/2024,Inactive,,
NBR 5N ONCOLOGY,18973,"Rhodes, Joanna Meehan, MD",11/25/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine--> polatuzumab vedotin/ PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/24/2024,Active,"Malignant neoplasm of nipple and areola, left female breast (CMS/HCC)
On antineoplastic chemotherapy",
SOM OUTPT INFUSION,92458,"Patel, Eshan, MD",11/15/2023,CISplatin 25 mg/m2 D1-D3 /Etoposide 80 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/13/2023,Inactive,,
SOM OUTPT INFUSION,92458,"Patel, Eshan, MD",1/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,1/15/2024,Inactive,,
SOM OUTPT INFUSION,92458,"Patel, Eshan, MD",6/27/2024,DOCEtaxel D1 /pembro 21 Day Cycles,_2. Second Line,6/26/2024,Active,,
MSC OP INFUSION,86405,"Cohen, Seth D, MD",3/28/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,,3/27/2023,Inactive,,
CMC OP INFUSION,41542,"Taff, Jessica, MD",9/13/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,9/13/2023,Inactive,,
CBMC OP INFUSION 2FL,88023,"Brown, Andrew Bennett, MD",11/18/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,11/17/2024,Active,,
CMC OP INFUSION,94066,"Taff, Jessica, MD",4/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/24/2024,Active,,
CINJ OP INFUSION,13373,"Packiam, Vignesh, MD",4/4/2025,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,4/4/2025,Active,Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC),
CINJ OP INFUSION,88444,"Mayer, Tina M, MD",9/21/2023,Enzalutamide 28 Day Cycles - Prostate,,9/21/2023,Active,,
CBMC OP INFUSION 2FL,7386,"Gallinson, David Herschel, DO",5/19/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/19/2025,Active,Cecal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,7386,"Gallinson, David Herschel, DO",5/12/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/12/2025,Inactive,Cecal cancer (CMS/HCC),
CINJ OP INFUSION,83585,"Dasgeb, Bahar, MD",4/25/2023,Cetuximab / PACLitaxel 100 mg/m2 / CARBOplatin AUC 2.5 21 Day Cycles- Head and Neck Cancers,First Line,4/10/2023,Inactive,,
CINJ OP INFUSION,83585,"Dasgeb, Bahar, MD",6/13/2023,Cetuximab q7 Day Cycles with q14 day Fluoruracil (beginning 1/30/24),First Line,6/12/2023,Inactive,,
CINJ OP INFUSION,83585,"Weiss, Sarah, MD",9/9/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_2. Second Line,9/8/2024,Inactive,,
CINJ OP INFUSION,37925,"Omene, Coral Oghenerukevwe, MD",10/29/2024,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,Neoadjuvant,10/28/2024,Active,,
CINJ OP INFUSION,37925,"Omene, Coral Oghenerukevwe, MD",1/28/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,1/27/2025,Active,,
SOM OUTPT INFUSION,64717,"Yin, Faye, MD",3/1/2023,DOCEtaxel/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,2/28/2023,Inactive,,
SOM OUTPT INFUSION,64717,"Yin, Faye, MD",3/28/2023,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Adjuvant,2/27/2023,Inactive,,
CINJ OP INFUSION,68530,"George, Mridula A, MD",5/19/2023,Abemaciclib 28 Day Cycles - Breast,Third Line,5/19/2023,Inactive,,
MSC OP INFUSION,5308,"Cohen, Seth D, MD",7/11/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,7/10/2024,Inactive,,
MSC OP INFUSION,5308,"Cohen, Seth D, MD",11/11/2024,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,10/31/2024,Inactive,,
JCMC CP INFUSION,22957,"Cruz, Allan Louie E, MD",6/5/2024,"Pembrolizumab Q3W / PACLitaxel d1, d8 and d15 21 Day Cycles - Triple Negative Breast Cancer",Neoadjuvant,6/4/2024,Inactive,,
JCMC CP INFUSION,22957,"Cruz, Allan Louie E, MD",9/19/2024,Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/19/2024,Active,,
JCMC CP INFUSION,22957,"Cruz, Allan Louie E, MD",4/9/2025,CINJ 042405 Arm 1 Pembrolizumab Every 6 Weeks,Adjuvant,2/25/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor negative (CMS/HCC)",C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
JCMC CP INFUSION,22957,"Cruz, Allan Louie E, MD",3/18/2025,CINJ 042405 Arm 1 Pembrolizumab Every 3 Weeks,Adjuvant,2/25/2025,Inactive,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor negative (CMS/HCC)",C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
SOM OUTPT INFUSION,52954,"George, Roshini, DO",2/21/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,2/5/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)","C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.0 - Estrogen receptor positive status (ER+); Z17.22 - Progesterone receptor negative status; Z17.410 - Hormone receptor positive with human epidermal growth factor receptor 2 positive status; R92.30 - Dense breasts, unspecified; Z98.890 - Other specified postprocedural states"
CINJ OP INFUSION,29031,"Weiss, Sarah, MD",11/6/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,10/22/2024,Active,,
CBMC 2W ONCOLOGY,32772,"Grossman, I Robert, MD",4/23/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,4/21/2024,Inactive,,
CINJ OP INFUSION,35064,"Hinrichs, Christian, MD",9/28/2023,"CINJ 192004 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + KK-LC-TCR-T Cells 6 Day Cycle Research- Cancers of the Stomach, Breast, Cervix and Lung",Third Line,9/26/2023,Active,,
CINJ OP INFUSION,50638,"Salacz, Michael E, MD",5/16/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Adjuvant,5/16/2023,Active,Small cell carcinoma of overlapping sites of lung (CMS/HCC),
NBR 5N ONCOLOGY,10588,"Girda, Eugenia, MD",6/30/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,6/26/2023,Active,,
CINJ OP INFUSION,8431,"Ghodoussipour, Saum Bobak, MD",4/11/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/11/2025,Active,Urothelial carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,12579,"Litvak, Anna M, MD",5/9/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/9/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C50.912 - Malignant neoplasm of unspecified site of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,75878,"Dharmapuri, Sirish, MD",10/2/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/29/2024,Active,,
MMC OP VP INFUSION,83851,"Cohen, Seth D, MD",9/27/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,9/21/2023,Inactive,,
NBR CINJ OP INFUSION,85860,"Matasar, Matthew J, MD",9/9/2024,Cladribine 5 Day Cycle - Hairy Cell Leukemia,_1. First Line,9/8/2024,Inactive,,
NBR CINJ OP INFUSION,85860,"Matasar, Matthew J, MD",11/19/2024,RiTUXimab 28 Day Cycle - Hairy Cell Leukemia,_1. First Line,11/18/2024,Active,"Recurrent BCC (basal cell carcinoma)
Squamous cell carcinoma of skin",
NBR CINJ OP INFUSION,85860,"Schaar, Dale, MD PhD",11/25/2024,RiTUXimab 28 Day Cycle - Hairy Cell Leukemia,_2. Second Line,11/24/2024,Inactive,,
CBMC OP INFUSION 2FL,49723,"Siu, Karleung, MD",2/5/2025,"Bortezomib  + Dexamethasone D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,2/4/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,22507,"Brown, Andrew Bennett, MD",11/14/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/13/2023,Active,,
MMC BBR2 ONCOLOGY,44842,"Meghal, Trishala, MD",2/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/8/2024,Inactive,,
NBR CINJ OP INFUSION,43692,"Rhodes, Joanna Meehan, MD",4/21/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/21/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site"
NBR 5N ONCOLOGY,23076,"Rhodes, Joanna Meehan, MD",7/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,7/19/2024,Inactive,,
NBR CINJ OP INFUSION,23076,"Rhodes, Joanna Meehan, MD",8/8/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/7/2024,Active,,
NBR CINJ OP INFUSION,23076,"Rhodes, Joanna Meehan, MD",8/15/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/14/2024,Inactive,,
CINJ OP INFUSION,50021,"Haigentz, Missak, MD",11/2/2023,BTCRC-LUN19-396 / CINJ 032007 CISplatin / PEMEtrexed / Atezolizumab 21 Day Cycles Research- Non-Squamous NSCLC,Adjuvant,11/2/2023,Active,,
MMC OP INFUSION,61,"Eltoukhy, Hussam, MD",8/9/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/5/2024,Inactive,,
MMC OP VP INFUSION,61,"Eltoukhy, Hussam, MD",1/17/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,1/16/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,61,"Eltoukhy, Hussam, MD",1/17/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,1/16/2025,Inactive,Grade 3b follicular lymphoma of lymph nodes of multiple regions (CMS/HCC),
SOM OUTPT INFUSION,39067,"Toomey, Kathleen C, MD",3/22/2023,Capecitabine 21 Day Cycles - Breast,Third Line,3/22/2023,Inactive,,
SOM OUTPT INFUSION,39067,"Toomey, Kathleen C, MD",3/29/2023,Gemcitabine 28 Day Cycles - Breast,Second Line,3/28/2023,Inactive,,
CINJ OP INFUSION,78747,"Saraiya, Biren P, MD",8/19/2024,Enzalutamide 30 Day Cycles - Prostate,_1. First Line,8/19/2024,Active,,
NBR BMSCH 2 PED HEMONC,59251,"Drachtman, Richard, MD",12/27/2024,AALL1732 Induction,_1. First Line,12/27/2024,Active,,
NBR BMSCH 2 PED HEMONC,59251,"Drachtman, Richard, MD",12/27/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,12/27/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,59251,"Drachtman, Richard, MD",2/3/2025,AALL1732 Consolidation,_1. First Line,2/3/2025,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),
CINJ PEDS HEMONC ,59251,"Drachtman, Richard, MD",4/25/2025,PEDS Blinatumomab per AALL1732 Blina block 1,_1. First Line,4/7/2025,Inactive,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),
CINJ PEDS HEMONC ,59251,"Drachtman, Richard, MD",4/8/2025,AALL1732 Arm A Blinatumomab cycle 1,_1. First Line,4/7/2025,Inactive,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),
CINJ OP INFUSION,79120,"Toppmeyer, Deborah L, MD",4/23/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,4/17/2024,Active,,
HAM OP INFUSION,79120,"Yogarajah, Meera, MD",2/20/2025,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,2/9/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,7372,"Brown, Andrew Bennett, MD",6/5/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/4/2023,Inactive,,
CBMC OP INFUSION 2FL,7372,"Brown, Andrew Bennett, MD",6/5/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,First Line,6/4/2023,Inactive,,
CBMC OP INFUSION 2FL,7372,"Brown, Andrew Bennett, MD",6/5/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,First Line,6/5/2023,Inactive,,
CINJ OP INFUSION,31433,"Toppmeyer, Deborah L, MD",10/30/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,10/30/2024,Active,Sarcoma of right thigh (CMS/HCC),
CINJ OP INFUSION,31433,"Toppmeyer, Deborah L, MD",3/20/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,3/20/2025,Inactive,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,31433,"Toppmeyer, Deborah L, MD",3/20/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,3/20/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,30133,"Tang, Horace, MD",4/19/2023,Oxaliplatin + 5FU + Leucovorin + Trazimera,First Line,4/17/2023,Inactive,,
CMC 4B ONCOLOGY,30133,"Tang, Horace, MD",11/8/2023,oxaliplatin 5FU Trastuzumab ,_1. First Line,11/7/2023,Inactive,,
CMC OP INFUSION,30133,"Tang, Horace, MD",12/6/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_2. Second Line,12/5/2023,Inactive,,
CMC OP INFUSION,30133,"Cohen, Seth D, MD",4/3/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,4/2/2024,Active,,
MMC OP INFUSION,53779,"Eltoukhy, Hussam, MD",3/10/2025,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,3/10/2025,Active,Mantle cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
MMC OP INFUSION,53779,"Eltoukhy, Hussam, MD",3/10/2025,Acalabrutinib 30 Day Cycles - Mantle Cell Lymphoma,_1. First Line,3/10/2025,Active,Mantle cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
CINJ OP INFUSION,42346,"Boland, Patrick M, MD",1/3/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,1/2/2023,Inactive,,
CINJ OP INFUSION,42346,"Boland, Patrick M, MD",6/28/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/24/2024,Inactive,,
CINJ OP INFUSION,74775,"Goel, Sanjay, MD",2/27/2023,CINJ 052210 Part B Dose Expansion PY159 / Pembrolizumab 21 Day Cycles Research- Advanced Solid Tumors,Third Line,1/29/2023,Inactive,,
CINJ OP INFUSION,74775,"Goel, Sanjay, MD",6/20/2023,CINJ 052214 Single Agent Part 1B XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,6/20/2023,Inactive,,
MMC OP VP INFUSION,37776,"Lee, Patrick C, MD",3/26/2024,RiTUXimab Infusion,_1. First Line,3/26/2024,Inactive,,
MMC OP INFUSION,31398,"Meghal, Trishala, MD",7/21/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,7/20/2023,Inactive,,
MMC OP INFUSION,31398,"Meghal, Trishala, MD",9/20/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,9/19/2023,Inactive,,
MMC OP INFUSION,31398,"Meghal, Trishala, MD",5/1/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_2. Second Line,4/30/2024,Inactive,,
MMC OP INFUSION,31398,"Meghal, Trishala, MD",5/1/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_2. Second Line,4/30/2024,Inactive,,
NBI OP INFUSION,82381,"Snyder, Rose, MD",5/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/14/2025,Inactive,Adenocarcinoma of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CINJ OP INFUSION,16426,"Haigentz, Missak, MD",9/9/2024,Pemetrexed / CARBOplatin + Amivantamab Patients >/= 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/8/2024,Inactive,,
CINJ OP INFUSION,16426,"Haigentz, Missak, MD",9/10/2024,Pemetrexed / CARBOplatin + Amivantamab Patients >/= 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/8/2024,Active,,
CBMC 2W ONCOLOGY,3822,"Grossman, I Robert, MD",5/12/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,5/12/2025,Active,High grade B-cell lymphoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; E11.9 - Type 2 diabetes mellitus without complications; E89.0 - Postprocedural hypothyroidism; I10 - Essential (primary) hypertension; I36.1 - Nonrheumatic tricuspid (valve) insufficiency; J98.11 - Atelectasis; N95.9 - Unspecified menopausal and perimenopausal disorder; E66.3 - Overweight; R59.1 - Generalized enlarged lymph nodes; Z79.890 - Hormone replacement therapy; R60.0 - Localized edema; G47.33 - Obstructive sleep apnea (adult) (pediatric); M47.894 - Other spondylosis, thoracic region; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.710 - Acquired absence of both cervix and uterus; Z98.890 - Other specified postprocedural states; Z88.0 - Allergy status to penicillin; Z91.040 - Latex allergy status; Z91.013 - Allergy to seafood; Z88.3 - Allergy status to other anti-infective agents; Z79.899 - Other long term (current) drug therapy; Z79.01 - Long term (current) use of anticoagulants; Z68.26 - Body mass index (BMI) 26.0-26.9, adult; Z80.42 - Family history of malignant neoplasm of prostate; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z82.69 - Family history of other diseases of the musculoskeletal system and connective tissue; Z83.3 - Family history of diabetes mellitus; Z85.850 - Personal history of malignant neoplasm of thyroid; Z87.891 - Personal history of nicotine de..."
CBMC OP INFUSION 2FL,3822,"Grossman, I Robert, MD",5/9/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/9/2025,Inactive,High grade B-cell lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; C85.10 - Unspecified B-cell lymphoma, unspecified site"
CBMC 2W ONCOLOGY,3822,"Grossman, I Robert, MD",4/18/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/18/2025,Inactive,High grade B-cell lymphoma (CMS/HCC),"C85.11 - Unspecified B-cell lymphoma, lymph nodes of head, face, and neck; I82.431 - Acute embolism and thrombosis of right popliteal vein; R13.10 - Dysphagia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; D50.9 - Iron deficiency anemia, unspecified; E89.0 - Postprocedural hypothyroidism; M06.9 - Rheumatoid arthritis, unspecified; I10 - Essential (primary) hypertension; I36.1 - Nonrheumatic tricuspid (valve) insufficiency; G47.33 - Obstructive sleep apnea (adult) (pediatric); R59.9 - Enlarged lymph nodes, unspecified; J31.0 - Chronic rhinitis; H69.90 - Unspecified eustachian tube disorder, unspecified ear; H91.10 - Presbycusis, unspecified ear; J34.2 - Deviated nasal septum; Z91.040 - Latex allergy status; Z88.0 - Allergy status to penicillin; Z91.013 - Allergy to seafood; Z90.710 - Acquired absence of both cervix and uterus; Z90.49 - Acquired absence of other specified parts of digestive tract; Z98.890 - Other specified postprocedural states; Z79.890 - Hormone replacement therapy; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z85.850 - Personal history of malignant neoplasm of thyroid; Z87.891 - Personal history of nicotine dependence; Z92.21 - Personal history of antineoplastic chemotherapy; Z80.42 - Family history of malignant neoplasm of prostate; Z82.49 - Family history of ischemic heart disease and other diseases of the circulato..."
CINJ OP INFUSION,761,"Boland, Patrick M, MD",12/17/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,12/16/2024,Active,,
CINJ OP INFUSION,58600,"Haigentz, Missak, MD",3/18/2025,Dabrafenib/Trametinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/18/2025,Active,Malignant neoplasm of right upper lobe of lung (CMS/HCC),
MMC OP INFUSION,55151,"Eltoukhy, Hussam, MD",9/18/2023,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,,9/17/2023,Inactive,,
NBR CINJ OP INFUSION,7551,"Evens, Andrew M, DO",3/5/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,3/5/2025,Active,CNS lymphoma (CMS/HCC),C83.390 - Primary central nervous system lymphoma
NBR CINJ OP INFUSION,98510,"Evens, Andrew M, DO",6/21/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,,6/20/2023,Inactive,,
MSC OP INFUSION,24862,"Cohen, Seth D, MD",2/9/2023,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,Third Line,2/8/2023,Inactive,,
MSC OP INFUSION,24862,"Cohen, Seth D, MD",10/5/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,_4. Fourth Line,10/5/2023,Inactive,,
MMC OP VP INFUSION,25980,"Cohen, Seth D, MD",1/22/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,1/21/2025,Active,,
CINJ PEDS HEMONC ,25559,"Cole, Peter David, MD",5/4/2024,PEDS ARST0332 Arm D,_1. First Line,5/4/2024,Inactive,,
CINJ PEDS HEMONC ,25559,"Moerdler, Scott, MD",6/2/2024,"PACLitaxel D1, D8, D15 28 Day Cycles- per JCO article 2008 for Unresectable Angiosarcoma",_2. Second Line,6/2/2024,Inactive,,
CINJ PEDS HEMONC ,25559,"Moerdler, Scott, MD",8/19/2024,Cabozantinib / Nivolumab 28 Day Cycles -AS per Alliance A091902,_2. Second Line,8/19/2024,Inactive,,
CBMC 2W ONCOLOGY,51678,"Grossman, I Robert, MD",11/14/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_3. Third Line,11/14/2023,Inactive,,
CBMC 2W ONCOLOGY,51678,"Grossman, I Robert, MD",12/5/2023,Obinutuzumab 28 Day Cycles - Low Grade Indolent Lymphoma ,_4. Fourth Line,12/5/2023,Inactive,,
NBR CINJ OP INFUSION,51678,"Braunschweig, Ira, MD",12/11/2023,"Obinutuzumab, Glofitamab 21 Day Cycles Research- Diffuse Large B-Cell Lymphoma",_3. Third Line,12/10/2023,Inactive,,
NBR CINJ OP INFUSION,51678,"Braunschweig, Ira, MD",2/8/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_4. Fourth Line,2/7/2024,Inactive,,
NBR 5N ONCOLOGY,51678,"Rhodes, Joanna Meehan, MD",4/1/2024,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_5. Fifth Line,3/31/2024,Inactive,,
CBMC 2W ONCOLOGY,51678,"Grossman, I Robert, MD",4/12/2024,DHAP (Dexamethasone / CISplatin / Cytarabine) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_6. Sixth Line,4/12/2024,Inactive,,
CBMC 2W ONCOLOGY,51678,"Grossman, I Robert, MD",5/17/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_6. Sixth Line,5/17/2024,Inactive,,
SOM OUTPT INFUSION,41968,"Patel, Eshan, MD",5/5/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- pancratic Cancers,Neoadjuvant,5/5/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),"C25.1 - Malignant neoplasm of body of pancreas; C25.9 - Malignant neoplasm of pancreas, unspecified"
CINJ OP INFUSION,48940,"Saraiya, Biren P, MD",6/19/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,6/19/2023,Active,,
CMC OP INFUSION,7514,"Pompa, Tiffany Ann, MD",8/5/2024,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,8/4/2024,Active,,
CBMC OP INFUSION 2FL,20211,"Litvak, Anna M, MD",4/22/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,4/22/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,20211,"Litvak, Anna M, MD",4/10/2025,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,_1. First Line,4/10/2025,Inactive,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,30615,"Mayer, Tina M, MD",2/20/2023,CARBOplatin / Gemcitabine 21 Day Cycles - upper tract urothelial cancer ,,2/16/2023,Inactive,,
CINJ OP INFUSION,33622,"Haigentz, Missak, MD",12/6/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/28/2023,Inactive,,
CINJ OP INFUSION,33622,"Haigentz, Missak, MD",12/13/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/30/2023,Inactive,,
CINJ OP INFUSION,33622,"Haigentz, Missak, MD",3/6/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/6/2024,Inactive,,
NBR 5N ONCOLOGY,33809,"Zayac, Adam, MD",6/10/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,6/9/2024,Active,Diffuse large B-cell lymphoma (CMS/HCC),
CINJ OP INFUSION,51512,"Weiss, Sarah, MD",1/8/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,1/7/2025,Active,,
MMC OP VP INFUSION,72039,"Talwar, Sumit, MD",5/23/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/22/2023,Inactive,,
MMC OP VP INFUSION,72039,"Talwar, Sumit, MD",6/2/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,5/25/2023,Inactive,,
NBR 4N ONCOLOGY,60571,"Braunschweig, Ira, MD",10/12/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,_3. Third Line,10/12/2023,Inactive,,
NBR 4N ONCOLOGY,60571,"Braunschweig, Ira, MD",10/27/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,10/16/2023,Inactive,,
NBR CINJ OP INFUSION,60571,"Shah, Mansi R, MD",5/30/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/28/2024,Active,,
NBR CINJ OP INFUSION,60571,"Shah, Mansi R, MD",11/21/2024,"Bortezomib D1, D15 Maintenance 28 Day Cycles- Multiple Myeloma",Maintenance,11/20/2024,Active,,
CBMC OP INFUSION 2FL,60225,"Leitner, Stuart P, MD",10/17/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,10/17/2024,Active,,
CBMC OP INFUSION 2FL,60225,"Leitner, Stuart P, MD",1/24/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,1/23/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
CMC OP INFUSION,71368,"Tang, Horace, MD",11/8/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/7/2023,Inactive,,
CMC OP INFUSION,71368,"Cohen, Seth D, MD",3/19/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/18/2024,Inactive,,
CMC OP INFUSION,37031,"Pompa, Tiffany Ann, MD",8/14/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,8/13/2024,Active,Colon cancer (CMS/HCC),
CINJ OP INFUSION,5013,"Boland, Patrick M, MD",4/25/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,4/10/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C25.9 - Malignant neoplasm of pancreas, unspecified; G89.3 - Neoplasm related pain (acute) (chronic)"
MMC OP VP INFUSION,82149,"Lee, Patrick C, MD",7/13/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,7/11/2023,Inactive,,
CINJ OP INFUSION,26567,"Toppmeyer, Deborah L, MD",2/26/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,2/26/2024,Inactive,,
CINJ OP INFUSION,26567,"Toppmeyer, Deborah L, MD",2/26/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,2/26/2024,Active,,
CINJ OP INFUSION,56921,"Gulhati, Prateek, MD PhD",12/14/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,12/13/2023,Inactive,,
CINJ OP INFUSION,56921,"Gulhati, Prateek, MD PhD",5/9/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,5/8/2024,Active,,
CINJ OP INFUSION,21695,"Berim, Lyudmyla, MD",8/16/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/15/2023,Inactive,,
CINJ OP INFUSION,21695,"Berim, Lyudmyla, MD",2/7/2024,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/6/2024,Inactive,,
CINJ OP INFUSION,21695,"Berim, Lyudmyla, MD",2/7/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/6/2024,Active,,
CINJ OP INFUSION,63078,"Stein, Stacey",4/24/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/24/2025,Active,Malignant neoplasm of overlapping sites of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C25.0 - Malignant neoplasm of head of pancreas; K86.89 - Other specified diseases of pancreas; C25.8 - Malignant neoplasm of overlapping sites of pancreas"
CBMC OP INFUSION 2FL,62199,"McKenna, Marshall, MD",2/26/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,2/26/2025,Active,"Mantle cell lymphoma, unspecified site (CMS/HCC)",
CINJ OP INFUSION,26433,"Toppmeyer, Deborah L, MD",4/14/2025,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,4/14/2025,Active,Breast cancer of upper-inner quadrant of left female breast (CMS/HCC),
CBMC OP INFUSION 2FL,5873,"Wagmiller, Jennifer Ann, MD",8/26/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,8/25/2023,Inactive,,
NBR 5N ONCOLOGY,81910,"Berim, Lyudmyla, MD",2/9/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,First Line,2/7/2023,Inactive,,
CINJ OP INFUSION,81910,"Berim, Lyudmyla, MD",3/14/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,3/13/2024,Inactive,,
CINJ OP INFUSION,81910,"Berim, Lyudmyla, MD",12/12/2024,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",_3. Third Line,12/11/2024,Active,,
CINJ OP INFUSION,4301,"Mayer, Tina M, MD",4/3/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/2/2024,Active,,
CINJ OP INFUSION,61882,"Mayer, Tina M, MD",5/28/2025,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_2. Second Line,5/28/2025,Active,Bladder cancer (CMS/HCC),
CINJ OP INFUSION,61882,"Mayer, Tina M, MD",5/6/2025,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,_2. Second Line,5/6/2025,Inactive,Bladder cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C79.89 - Secondary malignant neoplasm of other specified sites; C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes; N13.9 - Obstructive and reflux uropathy, unspecified; R21 - Rash and other nonspecific skin eruption; N13.30 - Unspecified hydronephrosis; Z93.6 - Other artificial openings of urinary tract status; Z90.79 - Acquired absence of other genital organ(s)"
HAM OP INFUSION,43318,"Yogarajah, Meera, MD",1/3/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,1/3/2025,Active,,
HAM OP INFUSION,17132,"Yogarajah, Meera, MD",4/8/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/8/2025,Active,"Rectal malignant neoplasm (CMS/HCC)
Encounter for screening for other viral diseases","C20 - Malignant neoplasm of rectum; I10 - Essential (primary) hypertension; I89.0 - Lymphedema, not elsewhere classified; E11.9 - Type 2 diabetes mellitus without complications; E78.2 - Mixed hyperlipidemia; E03.9 - Hypothyroidism, unspecified; F41.9 - Anxiety disorder, unspecified; F32.A - Depression, unspecified; G47.33 - Obstructive sleep apnea (adult) (pediatric); Z92.21 - Personal history of antineoplastic chemotherapy; Z92.3 - Personal history of irradiation; Z86.16 - Personal history of COVID-19; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z79.890 - Hormone replacement therapy; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CMC OP INFUSION,78276,"Cohen, Seth D, MD",11/6/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,11/5/2023,Inactive,,
MMC OP INFUSION,77605,"Eltoukhy, Hussam, MD",11/13/2023,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/7/2023,Inactive,,
MMC OP INFUSION,77605,"Eltoukhy, Hussam, MD",8/19/2024,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,8/18/2024,Inactive,,
MMC OP INFUSION,77605,"Eltoukhy, Hussam, MD",9/23/2024,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,9/22/2024,Active,,
NBR CINJ OP INFUSION,16738,"Rhodes, Joanna Meehan, MD",2/26/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,2/18/2025,Active,Diffuse large B cell lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site"
CMC OP INFUSION,6562,"Cohen, Seth D, MD",5/28/2025,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,5/28/2025,Active,Cardiac sarcoma (CMS/HCC),
CINJ OP INFUSION,35289,"George, Mridula A, MD",10/4/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/3/2024,Active,,
CMC OP INFUSION,14584,"Pompa, Tiffany Ann, MD",1/28/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,1/21/2025,Inactive,Endometrial cancer (CMS/HCC),
CMC OP INFUSION,14584,"Pompa, Tiffany Ann, MD",2/11/2025,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/7/2025,Active,Endometrial cancer (CMS/HCC),
CMC OP INFUSION,6705,"Pompa, Tiffany Ann, MD",3/12/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,3/12/2025,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,10808,"Berim, Lyudmyla, MD",9/11/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",,9/10/2023,Inactive,,
CINJ OP INFUSION,10808,"Berim, Lyudmyla, MD",9/18/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,,9/8/2023,Inactive,,
CINJ OP INFUSION,5911,"Berim, Lyudmyla, MD",2/7/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/6/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified"
NBR CINJ OP INFUSION,24370,"Matasar, Matthew J, MD",10/3/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,,10/2/2023,Inactive,,
MMC OP INFUSION,46577,"Meghal, Trishala, MD",9/30/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Induction,9/18/2024,Active,,
CBMC OP INFUSION 2FL,53964,"Wagmiller, Jennifer Ann, MD",9/11/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,9/10/2024,Inactive,,
CBMC OP INFUSION 2FL,53964,"Wagmiller, Jennifer Ann, MD",9/18/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,9/17/2024,Active,,
NBR CINJ OP INFUSION,60277,"Palmisiano, Neil David, MD",5/5/2023,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),,5/5/2023,Inactive,,
NBR 5N ONCOLOGY,60277,"Matasar, Matthew J, MD",7/5/2023,"CINJ 022204 LYT- 200 28 Day Cycles Research -  Acute Myeloid Leukemia (AML), & MDS",,7/5/2023,Inactive,,
NBR 5N ONCOLOGY,60277,"Matasar, Matthew J, MD",7/6/2023,"CINJ 022204 LYT- 200 28 Day Cycles Research -  Acute Myeloid Leukemia (AML), & MDS",,7/6/2023,Inactive,,
JCMC CP INFUSION,53659,"Sekhri, Arunabh, MD",5/30/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/30/2025,Active,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; C78.00 - Secondary malignant neoplasm of unspecified lung; I10 - Essential (primary) hypertension; R45.89 - Other symptoms and signs involving emotional state"
NBR 4N ONCOLOGY,63315,"Goel, Sanjay, MD",9/16/2024,DOXOrubicin Liposomal 21 Day Cycles - Sarcoma,_1. First Line,9/15/2024,Inactive,,
JCMC CP INFUSION,3748,"Cruz, Allan Louie E, MD",7/31/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,7/18/2023,Inactive,,
JCMC CP INFUSION,3748,"Cruz, Allan Louie E, MD",11/11/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/11/2024,Active,,
TRMC TCCC OP INFUSION,27794,"Capo, Gerardo, MD",12/20/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,12/19/2024,Active,,
TRMC TCCC OP INFUSION,27794,"Capo, Gerardo, MD",12/20/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,12/19/2024,Inactive,,
TRMC TCCC OP INFUSION,76844,"Meghal, Trishala, MD",5/20/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,5/20/2025,Inactive,Infiltrating ductal carcinoma of left female breast (CMS/HCC),
TRMC TCCC OP INFUSION,76844,"Meghal, Trishala, MD",5/20/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/20/2025,Active,Infiltrating ductal carcinoma of left female breast (CMS/HCC),
TRMC TCCC OP INFUSION,76844,"Meghal, Trishala, MD",5/17/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/17/2025,Inactive,Infiltrating ductal carcinoma of left female breast (CMS/HCC),
NBR 4N BMTU/IMCU,35436,"Braunschweig, Ira, MD",10/27/2023,BMT Autologous Melphalan Day -1  200mg/m2,_4. Fourth Line,10/26/2023,Inactive,,
HAM OP INFUSION,59352,"Patel, Malini M, MD",7/24/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,7/23/2023,Inactive,,
NBR 5N ONCOLOGY,85763,"Palmisiano, Neil David, MD",1/29/2023,FLAG-IDA (Fludarabine / Cytarabine / IDArubicin / Filgrastim) - Acute Myeloid Leukemia (Induction),,1/29/2023,Inactive,,
NBR CINJ OP INFUSION,85763,"Palmisiano, Neil David, MD",3/22/2023,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),,3/22/2023,Inactive,,
NBR 4N BMTU/IMCU,85763,"Schaar, Dale, MD PhD",6/11/2023,BMT Allogeneic TBF + Post Cy ,,6/10/2023,Inactive,,
MMC BBR2 ONCOLOGY,17285,"Meghal, Trishala, MD",9/8/2023,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,First Line,9/7/2023,Inactive,,
CINJ OP INFUSION,69077,"Haigentz, Missak, MD",6/8/2023,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/8/2023,Inactive,,
NBR 4N ONCOLOGY,69077,"Haigentz, Missak, MD",11/2/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,11/1/2023,Inactive,,
NBR 5N ONCOLOGY,23996,"Matasar, Matthew J, MD",8/30/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/30/2024,Active,Diffuse large B-cell lymphoma (CMS/HCC),
NBI OP INFUSION,60452,"Anderson, Patrick S, MD",12/26/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,12/25/2023,Inactive,,
NBI OP INFUSION,60452,"Anderson, Patrick S, MD",2/1/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/24/2024,Inactive,,
NBI OP INFUSION,55221,"Jacoby, Sari H, MD",6/26/2023,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,6/26/2023,Inactive,,
NBI OP INFUSION,55221,"Jacoby, Sari H, MD",11/13/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,11/6/2023,Inactive,,
NBI OP INFUSION,55221,"Jacoby, Sari H, MD",4/1/2024,PACLitaxel / CARBOplatin (weekly) 28 Day Cycles - Prostate,_3. Third Line,3/31/2024,Inactive,,
CBMC 2W ONCOLOGY,62298,"McKenna, Marshall, MD",1/21/2025,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,1/21/2025,Active,,
NBR 4N BMTU/IMCU,62298,"Phillips, Adrienne A, MD",4/17/2025,BMT Autologous BEAM,_2. Second Line,4/16/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
CBMC OP INFUSION 2FL,46022,"Leitner, Stuart P, MD",10/2/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,10/2/2023,Active,,
CINJ OP INFUSION,22398,"George, Mridula A, MD",1/8/2025,CINJ 042102 EOP E ARV-471 and Abemaciclib 28 Day Cycles Research,Neoadjuvant,1/7/2025,Active,,
JCMC CP INFUSION,96174,"Cruz, Allan Louie E, MD",3/28/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,3/27/2023,Inactive,,
JCMC CP INFUSION,96174,"Cruz, Allan Louie E, MD",12/27/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/26/2023,Inactive,,
SOM OUTPT INFUSION,20979,"Patel, Eshan, MD",5/1/2025,Daratumumab 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/1/2025,Active,"Aplastic anemia (CMS/HCC)
Pancytopenia (CMS/HCC)","D61.9 - Aplastic anemia, unspecified; K25.0 - Acute gastric ulcer with hemorrhage; G62.9 - Polyneuropathy, unspecified; E03.9 - Hypothyroidism, unspecified; D61.818 - Other pancytopenia; F22 - Delusional disorders; L98.9 - Disorder of the skin and subcutaneous tissue, unspecified; E78.5 - Hyperlipidemia, unspecified; R41.3 - Other amnesia"
CMC 4B ONCOLOGY,51974,"Ferretti, Mark J, MD",10/25/2024,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,10/25/2024,Inactive,,
CMC OP INFUSION,51974,"Taff, Jessica, MD",12/2/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,11/17/2024,Active,,
NBR 5N ONCOLOGY,70187,"Boland, Patrick M, MD",4/2/2025,"mFOLFOX6 Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/2/2025,Active,Rectal cancer (CMS/HCC),"C19 - Malignant neoplasm of rectosigmoid junction; E43 - Unspecified severe protein-calorie malnutrition; B37.81 - Candidal esophagitis; N13.6 - Pyonephrosis; Z59.01 - Sheltered homelessness; K83.8 - Other specified diseases of biliary tract; F11.20 - Opioid dependence, uncomplicated; E11.9 - Type 2 diabetes mellitus without complications; D50.9 - Iron deficiency anemia, unspecified; I10 - Essential (primary) hypertension; Z16.12 - Extended spectrum beta lactamase (ESBL) resistance; Z16.19 - Resistance to other specified beta lactam antibiotics; M85.80 - Other specified disorders of bone density and structure, unspecified site; D75.838 - Other thrombocytosis; R63.4 - Abnormal weight loss; B96.20 - Unspecified Escherichia coli (E. coli) as the cause of diseases classified elsewhere; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z80.3 - Family history of malignant neoplasm of breast; Z80.41 - Family history of malignant neoplasm of ovary; Z88.0 - Allergy status to penicillin; Z68.24 - Body mass index (BMI) 24.0-24.9, adult"
NBR 5N ONCOLOGY,70187,"Boland, Patrick M, MD",4/2/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/2/2025,Inactive,Rectal cancer (CMS/HCC),"C19 - Malignant neoplasm of rectosigmoid junction; E43 - Unspecified severe protein-calorie malnutrition; B37.81 - Candidal esophagitis; N13.6 - Pyonephrosis; Z59.01 - Sheltered homelessness; K83.8 - Other specified diseases of biliary tract; F11.20 - Opioid dependence, uncomplicated; E11.9 - Type 2 diabetes mellitus without complications; D50.9 - Iron deficiency anemia, unspecified; I10 - Essential (primary) hypertension; Z16.12 - Extended spectrum beta lactamase (ESBL) resistance; Z16.19 - Resistance to other specified beta lactam antibiotics; M85.80 - Other specified disorders of bone density and structure, unspecified site; D75.838 - Other thrombocytosis; R63.4 - Abnormal weight loss; B96.20 - Unspecified Escherichia coli (E. coli) as the cause of diseases classified elsewhere; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z80.3 - Family history of malignant neoplasm of breast; Z80.41 - Family history of malignant neoplasm of ovary; Z88.0 - Allergy status to penicillin; Z68.24 - Body mass index (BMI) 24.0-24.9, adult"
NBR 5N ONCOLOGY,70187,"Boland, Patrick M, MD",4/1/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/1/2025,Inactive,Rectal cancer (CMS/HCC),"C19 - Malignant neoplasm of rectosigmoid junction; E43 - Unspecified severe protein-calorie malnutrition; B37.81 - Candidal esophagitis; N13.6 - Pyonephrosis; Z59.01 - Sheltered homelessness; K83.8 - Other specified diseases of biliary tract; F11.20 - Opioid dependence, uncomplicated; E11.9 - Type 2 diabetes mellitus without complications; D50.9 - Iron deficiency anemia, unspecified; I10 - Essential (primary) hypertension; Z16.12 - Extended spectrum beta lactamase (ESBL) resistance; Z16.19 - Resistance to other specified beta lactam antibiotics; M85.80 - Other specified disorders of bone density and structure, unspecified site; D75.838 - Other thrombocytosis; R63.4 - Abnormal weight loss; B96.20 - Unspecified Escherichia coli (E. coli) as the cause of diseases classified elsewhere; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z80.3 - Family history of malignant neoplasm of breast; Z80.41 - Family history of malignant neoplasm of ovary; Z88.0 - Allergy status to penicillin; Z68.24 - Body mass index (BMI) 24.0-24.9, adult"
CINJ OP INFUSION,39944,"Stephenson, Ruth D, DO",5/18/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Cervical ,Second Line,5/16/2023,Inactive,,
CINJ OP INFUSION,39944,"Stephenson, Ruth D, DO",7/12/2023,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,Third Line,7/11/2023,Inactive,,
CINJ OP INFUSION,39944,"Stephenson, Ruth D, DO",10/23/2023,Topotecan Daily 28 Day Cycles - Cervical,_5. Fifth Line,10/22/2023,Inactive,,
CBMC OP INFUSION 2FL,73384,"Brown, Andrew Bennett, MD",4/9/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/9/2025,Active,Malignant neoplasm of transverse colon (CMS/HCC),C18.4 - Malignant neoplasm of transverse colon; R79.1 - Abnormal coagulation profile
CINJ OP INFUSION,90195,"Packiam, Vignesh, MD",3/13/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/12/2025,Inactive,Malignant neoplasm of posterior wall of bladder (CMS/HCC),
NBI VALERIE FND HEMONC,52287,"Bhatla, Teena, MD",12/23/2023,AALL1732 Induction,_1. First Line,12/21/2023,Inactive,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",1/29/2024,AALL1732 Consolidation,_1. First Line,1/29/2024,Inactive,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",4/24/2024,AALL1732 HR B-ALL Arm C Inotuzumab ozogamicin Block 1,Consolidation,4/23/2024,Inactive,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",5/23/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,5/22/2024,Inactive,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",8/5/2024,AALL1732 HR B-ALL Arm C Delayed Intensification,_1. First Line,8/5/2024,Inactive,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",9/10/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,9/9/2024,Active,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",10/15/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,10/15/2024,Inactive,,
NBI VALERIE FND HEMONC,52287,"Bhatla, Teena, MD",10/15/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,10/15/2024,Inactive,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",12/23/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,12/20/2024,Active,,
NBI VALERIE FND HEMONC,52287,"Batra, Surabhi, MD",1/29/2025,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",_1. First Line,1/28/2025,Active,,
CBMC OP INFUSION 2FL,39052,"Scoppetuolo, Michael, MD",5/1/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,4/28/2025,Inactive,Melanoma (CMS/HCC),"C43.71 - Malignant melanoma of right lower limb, including hip"
CINJ OP INFUSION,69291,"Berim, Lyudmyla, MD",2/23/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/21/2023,Inactive,,
CINJ OP INFUSION,52618,"Muralikrishnan, Sivraj, MD",3/6/2025,CINJ 032409 Cohort 1 (>/=80kg) Amivantamab / Lazertinib 28 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,3/6/2025,Active,EGFR-related lung cancer (CMS/HCC),
CINJ OP INFUSION,35557,"George, Mridula A, MD",3/17/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,3/17/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; C50.811 - Malignant neoplasm of overlapping sites of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,99764,"Ghodoussipour, Saum Bobak, MD",2/17/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/17/2023,Inactive,,
CINJ OP INFUSION,99764,"Ghodoussipour, Saum Bobak, MD",10/4/2024,BCG Induction (TICE) 42 Day Cycle,Induction,10/3/2024,Inactive,,
CINJ OP INFUSION,99764,"Ghodoussipour, Saum Bobak, MD",1/24/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,1/23/2025,Active,,
CINJ OP INFUSION,8816,"George, Mridula A, MD",11/17/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/3/2023,Inactive,,
CINJ OP INFUSION,46334,"Omene, Coral Oghenerukevwe, MD",1/9/2024,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,1/9/2024,Active,,
NBR 5N MED-SURG OVRF,99696,"Alexander, Henry Richard, MD",10/19/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,10/19/2023,Active,,
MMC OP VP INFUSION,92571,"Cohen, Seth D, MD",8/9/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,73421,"Matasar, Matthew J, MD",5/2/2023,Duvelisib 28 Day Cycles - PTCL,Third Line,5/2/2023,Inactive,,
NBR CINJ OP INFUSION,73421,"Matasar, Matthew J, MD",7/18/2023,RomiDEPsin 28 Day Cycles - Cutaneous T-Cell Lymphoma,,7/17/2023,Inactive,,
CINJ OP INFUSION,16533,"Packiam, Vignesh, MD",7/18/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,7/16/2024,Inactive,,
CINJ OP INFUSION,16533,"Packiam, Vignesh, MD",10/15/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,10/14/2024,Active,,
CMC OP INFUSION,4313,"Cohen, Seth D, MD",1/12/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,1/11/2024,Inactive,,
CBMC OP INFUSION 2FL,71987,"Phillips, Adrienne A, MD",12/5/2023,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_3. Third Line,12/3/2023,Inactive,,
CBMC OP INFUSION 2FL,71987,"Phillips, Adrienne A, MD",12/18/2023,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_3. Third Line,10/17/2023,Active,,
CBMC OP INFUSION 2FL,70910,"Brown, Andrew Bennett, MD",1/21/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,1/21/2025,Active,,
CINJ OP INFUSION,28856,"Leiser, Aliza, MD",2/9/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,2/1/2023,Inactive,,
CINJ OP INFUSION,28856,"Leiser, Aliza, MD",3/29/2023,Liposomal DOXOrubicin / CARBOplatin/Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,3/12/2023,Inactive,,
CINJ OP INFUSION,28856,"Leiser, Aliza, MD",7/21/2023,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,7/16/2023,Inactive,,
CINJ OP INFUSION,28856,"Leiser, Aliza, MD",10/16/2023,Cyclophosphamide Oral / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,9/24/2023,Inactive,,
CINJ OP INFUSION,28856,"Leiser, Aliza, MD",12/11/2023,Temsirolimus 28 Day Cycles - Uterine,_3. Third Line,12/10/2023,Inactive,,
CINJ OP INFUSION,28856,"Leiser, Aliza, MD",12/28/2023,Albumin-bound Sirolimus 21 Day Cycles - Malignant Perivascular Epithelioid Cell Tumor (PEComa),_3. Third Line,12/25/2023,Inactive,,
NBI OP INFUSION,44764,"Jacoby, Sari H, MD",7/17/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,7/16/2023,Inactive,,
NBI OP INFUSION,44764,"Jacoby, Sari H, MD",11/13/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,11/12/2023,Inactive,,
NBI OP INFUSION,44764,"Jacoby, Sari H, MD",3/4/2024,DOCEtaxel 21 Day Cycles- Esophageal/Esophagogastric Junction Cancers,_6. Sixth Line,3/3/2024,Inactive,,
NBI OP INFUSION,99953,"Schleicher, Lori, MD",12/16/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Adjuvant,12/16/2024,Active,"Renal cell carcinoma (CMS/HCC)
Chemotherapy-induced fatigue",
NBI OP INFUSION,99953,"Schleicher, Lori, MD",3/5/2025,Temozolomide 28 Day Cycles - CNS,_1. First Line,3/5/2025,Active,Mass of right temporoparietal region,C71.3 - Malignant neoplasm of parietal lobe; G93.89 - Other specified disorders of brain
CINJ OP INFUSION,1838,"Berim, Lyudmyla, MD",10/29/2024,Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 480 mg D1 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/28/2024,Active,,
MMC OP VP INFUSION,77923,"Eltoukhy, Hussam, MD",1/9/2024,RiTUXimab / Lenalidomide 28 Day Cycles - Mantle Cell Lymphoma (Induction),_1. First Line,12/30/2023,Active,Adenocarcinoma of lung (CMS/HCC),
MMC OP INFUSION,77923,"Eltoukhy, Hussam, MD",1/29/2024,RiTUXimab / Lenalidomide 28 Day Cycles - Mantle Cell Lymphoma (Induction),_1. First Line,1/28/2024,Inactive,,
MMC OP VP INFUSION,91286,"Lee, Patrick C, MD",8/17/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,8/11/2023,Inactive,,
MMC OP VP INFUSION,91286,"Lee, Patrick C, MD",8/31/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,8/30/2023,Inactive,,
MMC OP VP INFUSION,91286,"Lee, Patrick C, MD",1/18/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/17/2024,Inactive,,
MMC OP VP INFUSION,91286,"Lee, Patrick C, MD",5/22/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,5/9/2024,Active,,
CINJ OP INFUSION,33335,"Patankar, Sonali, MD",5/10/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,5/8/2024,Active,,
CINJ OP INFUSION,33335,"Patankar, Sonali, MD",2/26/2025,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,2/25/2025,Active,Uterine cancer (CMS/HCC),"C54.1 - Malignant neoplasm of endometrium; N13.4 - Hydroureter; M54.50 - Low back pain, unspecified"
CINJ OP INFUSION,32963,"Toppmeyer, Deborah L, MD",2/7/2023,Olaparib 30 Day Cycles - Breast,Adjuvant,2/7/2023,Active,,
SOM OUTPT INFUSION,76677,"Patel, Eshan, MD",2/5/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/3/2025,Active,Primary malignant neoplasm of breast with metastasis (CMS/HCC),
JCMC CP INFUSION,28454,"Cruz, Allan Louie E, MD",5/12/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Mesothelioma Epithelioid,_1. First Line,5/12/2025,Active,"Mesothelioma (pleural) (CMS/HCC)
Neoplasm of uncertain behavior of unspecified endocrine gland",
MMC OP INFUSION,60093,"Lee, Patrick C, MD",6/28/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,6/28/2023,Inactive,,
CMC OP INFUSION,45052,"Taff, Jessica, MD",12/5/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,12/4/2023,Inactive,,
CMC OP INFUSION,45052,"Taff, Jessica, MD",12/7/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,12/3/2023,Inactive,,
CMC OP INFUSION,45052,"Taff, Jessica, MD",6/21/2024,CINJ 082401 Arm 3 Cohort A Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,Adjuvant,6/21/2024,Active,,
SOM OUTPT INFUSION,34599,"Toomey, Kathleen C, MD",11/22/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_1. First Line,11/21/2024,Active,,
SOM OUTPT INFUSION,34599,"Toomey, Kathleen C, MD",3/7/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,_2. Second Line,3/7/2025,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor negative (CMS/HCC)
Breast cancer metastasized to axillary lymph node, right (CMS/HCC)
Breast cancer, stage 4 (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; Z17.1 - Estrogen receptor negative status (ER-)
MMC OP INFUSION,95047,"Talwar, Sumit, MD",8/8/2023,CISplatin with Concurrent Radiation 7 Day Cycles,First Line,7/26/2023,Inactive,,
CMC OP INFUSION,95047,"Talwar, Sumit, MD",8/14/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,8/13/2024,Inactive,,
CBMC OP INFUSION 2FL,85107,"Litvak, Anna M, MD",5/29/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,5/29/2025,Active,"Malignant neoplasm of unspecified site of right female breast (CMS/HCC)
Breast cancer, stage 4, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,63081,"Litvak, Anna M, MD",10/23/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,10/22/2023,Inactive,,
CBMC OP INFUSION 2FL,63081,"Raptis, George, MD",8/9/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,10. Tenth Line,8/9/2024,Active,,
MSC OP INFUSION,92108,"Cohen, Seth D, MD",7/11/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/5/2024,Active,,
HAM OP INFUSION,49910,"Gendy, Mina, DO",9/10/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,8/30/2024,Active,,
CINJ OP INFUSION,33497,"Saraiya, Biren P, MD",3/25/2024,Pembrolizumab 21 Day Cycles - Kidney,Adjuvant,3/25/2024,Inactive,,
CINJ OP INFUSION,33497,"Saraiya, Biren P, MD",5/8/2024,Pembrolizumab 42 Day Cycles - Kidney,Adjuvant,5/8/2024,Active,,
CINJ OP INFUSION,68935,"Boland, Patrick M, MD",6/12/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,6/11/2024,Active,,
CINJ OP INFUSION,70616,"Leiser, Aliza, MD",4/13/2023,Trastuzumab 21 Day Cycles (Continuation) ,,4/12/2023,Inactive,,
CINJ OP INFUSION,70616,"Leiser, Aliza, MD",4/13/2023,Trastuzumab 21 Day Cycles (Continuation) - ,,4/12/2023,Inactive,,
CBMC OP INFUSION 2FL,73967,"Leitner, Stuart P, MD",11/7/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/5/2023,Inactive,,
CBMC OP INFUSION 2FL,73967,"Leitner, Stuart P, MD",12/31/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,12/30/2024,Active,,
MMC OP VP INFUSION,8790,"Cohen, Seth D, MD",3/21/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/21/2025,Active,Metastatic squamous cell carcinoma involving mediastinum with unknown primary site (CMS/HCC),
HAM OP INFUSION,83517,"Yogarajah, Meera, MD",11/4/2024,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/6/2024,Active,,
CINJ OP INFUSION,33946,"Omene, Coral Oghenerukevwe, MD",2/14/2023,Abemaciclib 28 Day Cycles - Breast ,,2/14/2023,Active,,
CINJ OP INFUSION,3761,"Omene, Coral Oghenerukevwe, MD",9/14/2023,Abemaciclib 28 Day Cycles - Breast,,9/14/2023,Inactive,,
CINJ OP INFUSION,3761,"Omene, Coral Oghenerukevwe, MD",9/25/2023,Palbociclib 28 Day Cycles - Breast,,9/25/2023,Inactive,,
CINJ OP INFUSION,3761,"Omene, Coral Oghenerukevwe, MD",10/7/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_2. Second Line,10/6/2024,Inactive,,
NBR 5N ONCOLOGY,3761,"Omene, Coral Oghenerukevwe, MD",1/7/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/6/2025,Active,,
HAM OP INFUSION,19334,"Yogarajah, Meera, MD",1/17/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/15/2024,Active,,
SOM OUTPT INFUSION,66427,"Patel, Eshan, MD",11/28/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) ,_1. First Line,11/27/2023,Inactive,,
SOM OUTPT INFUSION,66427,"Patel, Eshan, MD",12/4/2023,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/3/2023,Inactive,,
SOM OUTPT INFUSION,66427,"Patel, Eshan, MD",10/29/2024,5 FU mainiteannce Outpatient (Fluorouracil Continuous Infusion/Leucovorin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/14/2024,Active,,
CINJ OP INFUSION,35081,"Muralikrishnan, Sivraj, MD",1/7/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/30/2024,Active,,
CINJ OP INFUSION,35081,"Muralikrishnan, Sivraj, MD",1/10/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/26/2024,Inactive,"Malignant neoplasm of larynx (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)",
CINJ OP INFUSION,35081,"Muralikrishnan, Sivraj, MD",1/10/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/9/2025,Inactive,"Malignant neoplasm of larynx (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)",
CINJ OP INFUSION,35081,"Muralikrishnan, Sivraj, MD",5/13/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/13/2025,Active,Laryngeal cancer (CMS/HCC),"C32.9 - Malignant neoplasm of larynx, unspecified; C79.51 - Secondary malignant neoplasm of bone; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified"
CINJ OP INFUSION,10500,"Muralikrishnan, Sivraj",12/31/2024,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/30/2024,Active,,
MSC OP INFUSION,18803,"Pompa, Tiffany Ann, MD",4/29/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/29/2025,Active,Neoplasm of unspecified behavior of bladder,
CINJ OP INFUSION,72842,"Omene, Coral Oghenerukevwe, MD",2/3/2025,CINJ 042208 Ribociclib / Endocrine Therapy of Choice 28 Day Cycles Research- Breast Cancer,Adjuvant,2/3/2025,Inactive,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; Z90.12 - Acquired absence of left breast and nipple; N64.89 - Other specified disorders of breast; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; Z17.0 - Estrogen receptor positive status (ER+); Z09 - Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm
CINJ OP INFUSION,28727,"Stephenson, Ruth D, DO",10/14/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,10/8/2024,Active,,
HAM OP INFUSION,90370,"Patel, Malini M, MD",1/23/2025,CINJ 032201 ARM 1 Paclitaxel / CARBOplatin + Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,1/22/2025,Inactive,Mass of upper lobe of right lung,
CINJ PEDS HEMONC ,93838,"Botwinick, Marissa, DO",5/29/2025,AALL0434 - Maintenance Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,5/29/2025,Active,T-cell acute lymphoblastic leukemia in remission (CMS/HCC),
NBI OP INFUSION,3911,"Jacoby, Sari H, MD",3/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,3/18/2024,Inactive,,
NBI OP INFUSION,3911,"Jacoby, Sari H, MD",8/28/2024,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Reinduction,8/12/2024,Active,,
NBR CINJ OP INFUSION,3911,"Rhodes, Joanna Meehan, MD",9/18/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,9/17/2024,Inactive,,
NBR CINJ OP INFUSION,51443,"Mayer, Tina M, MD",12/12/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Maintenance,12/12/2023,Active,,
NBR CINJ OP INFUSION,44793,"Rhodes, Joanna Meehan, MD",11/13/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,11/12/2023,Inactive,,
CINJ OP INFUSION,131,"Boland, Patrick M, MD",1/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/13/2025,Active,,
HAM OP INFUSION,65969,"Patel, Malini M, MD",10/3/2024,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",_1. First Line,10/3/2024,Active,,
CINJ OP INFUSION,84342,"Berim, Lyudmyla, MD",1/8/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/27/2023,Inactive,,
CINJ OP INFUSION,84342,"Berim, Lyudmyla, MD",1/8/2024,CINJ 072201 Control ARM FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,12/6/2023,Inactive,,
CINJ OP INFUSION,84342,"Berim, Lyudmyla, MD",3/20/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/20/2024,Inactive,,
CINJ OP INFUSION,84342,"Berim, Lyudmyla, MD",10/14/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,10/13/2024,Active,,
CBMC OP INFUSION 2FL,84342,"Dharmapuri, Sirish, MD",2/14/2025,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/14/2025,Active,"Colorectal cancer, stage IV (CMS/HCC)","C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C19 - Malignant neoplasm of rectosigmoid junction; D63.0 - Anemia in neoplastic disease; F41.9 - Anxiety disorder, unspecified; G47.30 - Sleep apnea, unspecified; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; I48.0 - Paroxysmal atrial fibrillation; Z92.3 - Personal history of irradiation; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z90.79 - Acquired absence of other genital organ(s); Z92.21 - Personal history of antineoplastic chemotherapy; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z98.890 - Other specified postprocedural states; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z88.5 - Allergy status to narcotic agent; Z88.1 - Allergy status to other antibiotic agents; Z91.011 - Allergy to milk products; Z87.891 - Personal history of nicotine dependence; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z82.61 - Family history of arthritis; Z82.0 - Family history of epilepsy and other diseases of the nervous system; Z85.72 - Personal history of non-Hodgkin lymphomas"
MMC OP INFUSION,32276,"Lee, Patrick C, MD",11/12/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/12/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,30586,"Saraiya, Biren P, MD",6/13/2023,Cabozantinib Single agent - Kidney,Third Line,6/13/2023,Inactive,,
CINJ OP INFUSION,37797,"Gulhati, Prateek, MD PhD",5/18/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,5/17/2023,Inactive,,
CINJ OP INFUSION,37797,"Gulhati, Prateek, MD PhD",5/25/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/24/2023,Inactive,,
CINJ OP INFUSION,1526,"Boland, Patrick M, MD",3/29/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/28/2024,Inactive,,
CINJ OP INFUSION,1526,"Boland, Patrick M, MD",4/5/2024,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,3/7/2024,Inactive,,
CINJ OP INFUSION,1526,"Boland, Patrick M, MD",11/19/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Maintenance,11/18/2024,Active,,
CINJ OP INFUSION,59814,"Berim, Lyudmyla, MD",5/28/2025,CINJ 072407 Pembrolizumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Anal Carcinoma,_1. First Line,5/28/2025,Active,Anal cancer (CMS/HCC),
CINJ OP INFUSION,73264,"George, Mridula A, MD",2/15/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,2/15/2024,Active,,
CINJ OP INFUSION,73264,"George, Mridula A, MD",4/8/2025,CINJ 042209 Arm B Endocrine Therapy of Physician's Choice 5 Year Treatment Research- Breast Cancer,Adjuvant,4/8/2025,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),
JCMC CP INFUSION,54026,"Sekhri, Arunabh, MD",1/27/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,1/26/2025,Active,,
JCMC CP INFUSION,54026,"Sekhri, Arunabh, MD",2/11/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,1/26/2025,Active,Metastatic malignant neuroendocrine tumor to liver (CMS/HCC),
CINJ OP INFUSION,77397,"Salacz, Michael E, MD",5/3/2023,CINJ 142101 Lomustine 42 Day Cycles Research- Glioblastoma Multiforme,Second Line,5/2/2023,Active,,
CINJ OP INFUSION,61190,"Stephenson, Ryan D, DO",2/12/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,2/11/2025,Active,"Malignant neoplasm of urinary bladder (CMS/HCC)
Disorder of thyroid","C67.9 - Malignant neoplasm of bladder, unspecified; E07.9 - Disorder of thyroid, unspecified"
JCMC CP INFUSION,11375,"Sekhri, Arunabh, MD",3/11/2024,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,3/5/2024,Inactive,,
JCMC CP INFUSION,11375,"Sekhri, Arunabh, MD",4/30/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,4/21/2024,Inactive,,
JCMC CP INFUSION,11375,"Sekhri, Arunabh, MD",9/2/2024,Imtelstat 28 Day Cycles - MDS,_2. Second Line,9/2/2024,Inactive,,
JCMC CP INFUSION,11375,"Sekhri, Arunabh, MD",10/25/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,10/14/2024,Active,,
CINJ OP INFUSION,7438,"Leiser, Aliza, MD",3/1/2024,Albumin-bound Sirolimus 21 Day Cycles - Malignant Perivascular Epithelioid Cell Tumor (PEComa),Adjuvant,2/29/2024,Inactive,,
NBI OP INFUSION,84365,"Cheng, Yan Ho, MD",3/18/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,3/18/2024,Active,,
JCMC CP INFUSION,71734,"Cruz, Allan Louie E, MD",11/7/2024,PACLitaxel Weekly (21 Day) x 4 Cycles Followed by DOXOrubicin + Cyclophoshamide  14 Day x 4 Cycles,Neoadjuvant,10/30/2024,Inactive,,
JCMC CP INFUSION,71734,"Cruz, Allan Louie E, MD",11/7/2024,PACLitaxel-pembrolizumab weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,11/7/2024,Inactive,,
JCMC CP INFUSION,71734,"Cruz, Allan Louie E, MD",11/25/2024,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,Neoadjuvant,11/24/2024,Active,,
JCMC CP INFUSION,71734,"Cruz, Allan Louie E, MD",12/9/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,12/9/2024,Active,,
JCMC CP INFUSION,21969,"Cruz, Allan Louie E, MD",3/3/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/3/2025,Inactive,Carcinoma of right breast metastatic to axillary lymph node (CMS/HCC),C50.911 - Malignant neoplasm of unspecified site of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
NBR CINJ OP INFUSION,98337,"Shah, Mansi R, MD",9/8/2023,Carfilzomib 70 mg/m2 / Pomalyst Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,,9/7/2023,Inactive,,
NBR 4N BMTU/IMCU,98337,"Assal, Amer, MD",12/29/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,12/27/2023,Inactive,,
NBR CINJ OP INFUSION,98337,"Shah, Mansi R, MD",4/9/2024,Carfilzomib 56 mg/m2 Maintenance q 2 weeks/Pomalyst ,Maintenance,4/9/2024,Inactive,,
NBR 5N ONCOLOGY,98337,"Shah, Mansi R, MD",11/14/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,11/13/2024,Active,,
CBMC OP INFUSION 1FL,8663,"Meelheim, Brooke A, DO",10/14/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,10/6/2024,Active,,
NBR 5N ONCOLOGY,43487,"Tiger, Yun Kyoung, MD",12/2/2023,Cyclophosphamide prephase,_1. First Line,12/2/2023,Inactive,,
NBR 5N ONCOLOGY,43487,"Tiger, Yun Kyoung, MD",12/3/2023,RM-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Methotrexate / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/2/2023,Inactive,,
NBR 5N ONCOLOGY,43487,"Tiger, Yun Kyoung, MD",12/4/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/3/2023,Inactive,,
NBR 5N ONCOLOGY,43487,"Tiger, Yun Kyoung, MD",12/22/2023,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_1. First Line,12/16/2023,Inactive,,
CINJ OP INFUSION,72379,"Haigentz, Missak, MD",7/19/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/14/2024,Inactive,,
CINJ OP INFUSION,71880,"Ganesan, Shridar, MD PhD",7/10/2023,Abemaciclib 28 Day Cycles - Breast ,Third Line,7/10/2023,Inactive,,
CINJ OP INFUSION,71880,"Ganesan, Shridar, MD PhD",2/27/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_4. Fourth Line,2/27/2024,Inactive,,
CINJ OP INFUSION,71880,"Ganesan, Shridar, MD PhD",7/9/2024,Alpelisib 28 Day Cycles - Breast,_3. Third Line,7/9/2024,Inactive,,
CINJ OP INFUSION,87610,"Stephenson, Ryan D, DO",3/15/2024,Avelumab 14 Day Cycles - Bladder Cancer,Maintenance,3/14/2024,Inactive,,
CINJ OP INFUSION,87610,"Ghodoussipour, Saum Bobak, MD",7/19/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/18/2024,Inactive,,
CINJ OP INFUSION,87610,"Stephenson, Ryan D, DO",12/4/2024,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,Adjuvant,12/3/2024,Active,,
CINJ OP INFUSION,4721,"Toppmeyer, Deborah L, MD",8/24/2023,Ribociclib 28 Day Cycles - Breast,First Line,8/24/2023,Inactive,,
CINJ OP INFUSION,4721,"Toppmeyer, Deborah L, MD",8/31/2023,Palbociclib 28 Day Cycles - Breast,First Line,8/31/2023,Inactive,,
CINJ OP INFUSION,4721,"Toppmeyer, Deborah L, MD",12/26/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,12/25/2024,Active,,
CINJ OP INFUSION,10426,"Packiam, Vignesh, MD",4/24/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/23/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
NBI OP INFUSION,43019,"Schleicher, Lori, MD",8/24/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,10/31/2022,Active,,
CINJ OP INFUSION,26824,"Toppmeyer, Deborah L, MD",9/25/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,9/20/2023,Inactive,,
CINJ OP INFUSION,46148,"Hochster, Howard S, MD",1/6/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,1/5/2025,Active,,
JCMC CP INFUSION,75398,"Sekhri, Arunabh, MD",9/14/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,9/3/2023,Inactive,,
CINJ OP INFUSION,31208,"Boland, Patrick M, MD",2/6/2024,mFOLFOX6 - 14 Day Cycles,Neoadjuvant,2/5/2024,Inactive,,
CINJ OP INFUSION,31208,"Boland, Patrick M, MD",7/19/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,7/18/2024,Inactive,,
NBI OP INFUSION,6457,"Jacoby, Sari H, MD",5/3/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,5/2/2023,Active,,
NBI OP INFUSION,6457,"Jacoby, Sari H, MD",4/22/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/22/2025,Active,Carcinoma of appendix (CMS/HCC),C18.1 - Malignant neoplasm of appendix
NBR 4N BMTU/IMCU,10020,"Braunschweig, Ira, MD",7/27/2023,BMT Autologous BEAM,,7/26/2023,Inactive,,
NBR 4N BMTU/IMCU,38023,"Braunschweig, Ira, MD",11/1/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_2. Second Line,10/31/2023,Active,,
MMC OP VP INFUSION,10191,"Talwar, Sumit, MD",3/18/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/18/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,2058,"Tiger, Yun Kyoung, MD",5/24/2024,S1826 Arm 1 AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/23/2024,Inactive,,
CINJ OP INFUSION,97483,"Stephenson, Ruth D, DO",2/23/2024,Gemcitabine / CISplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/22/2024,Inactive,,
CINJ OP INFUSION,73780,"Hochster, Howard S, MD",4/11/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Maintenance,4/10/2023,Inactive,,
CINJ OP INFUSION,73780,"Hochster, Howard S, MD",1/23/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Esophageal Cancer,_1. First Line,1/22/2025,Active,,
HAM OP INFUSION,20089,"Patel, Malini M, MD",7/2/2024,Nivolumab 480 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,7/1/2024,Active,,
NBI OP INFUSION,44172,"Schleicher, Lori, MD",11/22/2023,Daratumumab 28 Day Cycles- Amyloidosis,_1. First Line,11/2/2023,Inactive,,
NBI OP INFUSION,44172,"Schleicher, Lori, MD",11/22/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Amyloidosis,Maintenance,11/21/2023,Active,,
CINJ OP INFUSION,57005,"Berim, Lyudmyla, MD",8/1/2024,mFOLFOX6 +Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/29/2024,Active,,
CINJ OP INFUSION,57727,"Berim, Lyudmyla, MD",3/12/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/12/2025,Active,Metastasis from colon cancer (CMS/HCC),"C79.9, C18.9 - Metastasis from colon cancer (CMS/HCC)"
CINJ OP INFUSION,46206,"Toppmeyer, Deborah L, MD",2/22/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,2/21/2024,Active,,
NBR CINJ OP INFUSION,81816,"Palmisiano, Neil David, MD",4/4/2024,Hydroxyurea 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,4/4/2024,Inactive,,
NBR CINJ OP INFUSION,81816,"Palmisiano, Neil David, MD",4/4/2024,Cytarabine Cytoreduction for Hyperleukocytosis,Lymphodepletion,4/4/2024,Inactive,,
TRMC TCCC OP INFUSION,51724,"Salerno, Vincent E, MD",1/14/2025,Bevacizumab 28 Day Cycles - GBM,_3. Third Line,1/14/2025,Active,,
TRMC TCCC OP INFUSION,51724,"Salerno, Vincent E, MD",2/10/2025,Bevacizumab 28 Day Cycles - GBM,_3. Third Line,2/10/2025,Inactive,Malignant neoplasm of brain (CMS/HCC),
CBMC OP INFUSION 2FL,50286,"Raptis, George, MD",9/24/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/23/2024,Active,Pancreatic cancer (CMS/HCC),
CBMC OP INFUSION 2FL,50286,"Raptis, George, MD",2/18/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/18/2025,Active,Malignant neoplasm of right breast (CMS/HCC),
CBMC OP INFUSION 2FL,97851,"Leitner, Stuart P, MD",11/14/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,11/14/2023,Inactive,,
CINJ OP INFUSION,62743,"Weiss, Sarah, MD",3/11/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,3/8/2024,Inactive,,
CMC OP INFUSION,46152,"Cohen, Seth D, MD",5/5/2025,PACLitaxel / CARBOplatin / Cemiplimab-rwlc 21 Day Cycles-- Non-Small Cell Lung Cancer,_1. First Line,5/5/2025,Active,Primary malignant neoplasm of left lower lobe of lung (CMS/HCC),
MMC OP VP INFUSION,97605,"Cohen, Seth D, MD",3/5/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/1/2024,Inactive,,
MMC OP VP INFUSION,24829,"Lee, Patrick C, MD",6/21/2024,Nivolumab (360 mg) / Ipilimumab (1 mg/kg) 21 Day Cycles,_1. First Line,6/20/2024,Inactive,,
MMC OP VP INFUSION,24829,"Lee, Patrick C, MD",6/21/2024,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_1. First Line,6/20/2024,Active,,
CBMC OP INFUSION 2FL,47944,"Dharmapuri, Sirish, MD",9/23/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,9/22/2024,Inactive,,
CBMC OP INFUSION 2FL,47944,"Dharmapuri, Sirish, MD",12/3/2024,CINJ 072108 (A021806) ARM 2 FOLFIRINOX (Fluorouracil / Leucovorin / Irinotecan / OXALiplatin) 14 Day Cycles Research- Pancreatic Adenocarcinoma,Adjuvant,11/10/2024,Active,,
CMC OP INFUSION,33174,"Meghal, Trishala, MD",3/29/2024,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,Adjuvant,3/18/2024,Inactive,,
MMC OP INFUSION,33174,"Meghal, Trishala, MD",10/10/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,10/10/2024,Active,,
CMC OP INFUSION,70649,"Meghal, Trishala, MD",11/28/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,11/20/2023,Inactive,,
CINJ OP INFUSION,98966,"Toppmeyer, Deborah L, MD",6/22/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,6/11/2023,Inactive,,
CINJ OP INFUSION,98966,"Toppmeyer, Deborah L, MD",11/6/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,11/6/2023,Active,Rectal adenocarcinoma (CMS/HCC),
NBI OP INFUSION,45518,"Schleicher, Lori, MD",8/2/2024,Bortezomib -Inpt Myeloma,_1. First Line,8/1/2024,Inactive,,
NBI OP INFUSION,45518,"Jacoby, Sari H, MD",8/26/2024,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,_1. First Line,8/25/2024,Active,,
NBI OP INFUSION,9039,"Schleicher, Lori, MD",4/23/2025,Lenalidomide (D1-D21) Maintenance 28 Day Cycles - Multiple Myeloma,Maintenance,4/23/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
SOM OUTPT INFUSION,43132,"Toomey, Kathleen C, MD",9/14/2023,PACLitaxel / Trastuzumab 21 Day Cycles - Breast,Second Line,9/5/2023,Inactive,,
SOM OUTPT INFUSION,43132,"Toomey, Kathleen C, MD",1/12/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_2. Second Line,1/11/2024,Inactive,,
CINJ OP INFUSION,20131,"Patel, Eshan, MD",5/17/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/16/2024,Inactive,,
CINJ OP INFUSION,20131,"Patel, Eshan, MD",9/20/2024,PACLitaxel / CARBOplatin / Pembrolizumab 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,9/19/2024,Inactive,,
CINJ OP INFUSION,20131,"Muralikrishnan, Sivraj",12/26/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/26/2024,Active,,
CINJ OP INFUSION,38112,"Toppmeyer, Deborah L, MD",6/15/2023,Palbociclib 28 Day Cycles - Breast,First Line,6/15/2023,Active,,
SOM OUTPT INFUSION,99665,"Yin, Faye, MD",11/28/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,11/19/2023,Inactive,,
SOM OUTPT INFUSION,99665,"Patel, Eshan, MD",10/29/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,10/28/2024,Active,,
NBR CINJ OP INFUSION,84116,"Evens, Andrew M, DO",10/2/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,10/2/2024,Inactive,,
NBR CINJ OP INFUSION,84116,"Evens, Andrew M, DO",10/2/2024,RiTUXimab 28 Day Cycle - CLL,_1. First Line,10/2/2024,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
CMMC OP INFUSION,67005,"Siu, Karleung, MD",5/19/2025,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_4. Fourth Line,5/19/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Cancer, metastatic to bone (CMS/HCC)",C79.51 - Secondary malignant neoplasm of bone; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; N13.39 - Other hydronephrosis; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z17.0 - Estrogen receptor positive status (ER+)
SOM OUTPT INFUSION,35844,"Toomey, Kathleen C, MD",5/3/2023,CISplatin 21 Day Cycles - Ovarian,Third Line,5/2/2023,Inactive,,
SOM OUTPT INFUSION,35844,"Toomey, Kathleen C, MD",5/10/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,5/9/2023,Inactive,,
SOM OUTPT INFUSION,47519,"Toomey, Kathleen C, MD",3/30/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,3/22/2023,Inactive,,
SOM OUTPT INFUSION,47519,"Toomey, Kathleen C, MD",1/18/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/17/2024,Inactive,,
SOM OUTPT INFUSION,47519,"Toomey, Kathleen C, MD",1/18/2024,PACLitaxel / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,1/17/2024,Active,,
SOM OUTPT INFUSION,7553,"Patel, Eshan, MD",9/20/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,9/6/2023,Inactive,,
CMC OP INFUSION,26962,"Tang, Horace, MD",6/30/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,6/30/2023,Inactive,,
MMC OP VP INFUSION,39402,"Cohen, Seth D, MD",3/25/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,3/24/2024,Inactive,,
MMC OP VP INFUSION,39402,"Cohen, Seth D, MD",3/25/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/22/2024,Inactive,,
MMC OP VP INFUSION,39402,"Cohen, Seth D, MD",10/21/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,10/20/2024,Active,,
CINJ OP INFUSION,49088,"Boland, Patrick M, MD",9/10/2024,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,9/9/2024,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Other acute kidney failure (CMS/HCC)",
NBR 4N ONCOLOGY,57680,"Palmisiano, Neil David, MD",5/24/2023,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,57680,"Palmisiano, Neil David, MD",7/24/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,7/24/2023,Inactive,,
NBR CINJ OP INFUSION,57680,"Palmisiano, Neil David, MD",8/28/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,8/21/2023,Inactive,,
JCMC CP INFUSION,15721,"Cruz, Allan Louie E, MD",5/8/2024,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/7/2024,Inactive,,
JCMC CP INFUSION,15721,"Cruz, Allan Louie E, MD",7/8/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,6/18/2024,Inactive,,
JCMC CP INFUSION,15721,"Cruz, Allan Louie E, MD",8/8/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,8/8/2024,Inactive,,
CBMC OP INFUSION 2FL,68722,"Raptis, George, MD",3/26/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,68722,"Raptis, George, MD",6/11/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,6/3/2024,Inactive,,
CBMC OP INFUSION 2FL,68722,"Raptis, George, MD",10/9/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/8/2024,Inactive,,
CBMC OP INFUSION 2FL,68722,"Raptis, George, MD",10/29/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,10/24/2024,Active,,
CBMC OP INFUSION 2FL,2114,"Brown, Andrew Bennett, MD",8/19/2024,PACLitaxel weekly with radiation - Angiosarcoma,Consolidation,8/18/2024,Inactive,,
TRMC TCCC OP INFUSION,72563,"Capo, Gerardo, MD",4/16/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,4/15/2024,Active,,
CBMC OP INFUSION 2FL,31605,"Wagmiller, Jennifer Ann, MD",4/25/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/16/2024,Inactive,,
NBR CINJ OP INFUSION,17609,"Shah, Mansi R, MD",7/11/2023,VKd.Carfilzomib 36mg/m2 Plus Dexamethasone and Venetoclax 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,7/10/2023,Active,Malignant neoplasm of tail of pancreas (CMS/HCC),
NBR CINJ OP INFUSION,17609,"Shah, Mansi R, MD",5/12/2025,Talquetamab 28 Day Cycles,_6. Sixth Line,5/12/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,17609,"Shah, Mansi R, MD",3/11/2025,"Bortezomib D1, D8, D15, D22 / Selinexor 100 mg / Dexamethasone 35 Day Cycles- Multiple Myeloma",_5. Fifth Line,3/11/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Encounter for screening for other viral diseases
Encounter for immunization",
SOM OUTPT INFUSION,73305,"Patel, Eshan, MD",12/27/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/21/2023,Inactive,,
CBMC OP INFUSION 2FL,61551,"Scoppetuolo, Michael, MD",4/3/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,3/31/2024,Inactive,,
MMC OP INFUSION,16366,"Cohen, Seth D, MD",7/8/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,7/7/2024,Active,"Malignant neoplasm of corpus uteri, unspecified (CMS/HCC)",
CMC OP INFUSION,34628,"Pompa, Tiffany Ann, MD",4/17/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,4/17/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,34628,"Pompa, Tiffany Ann, MD",3/20/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,3/20/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
NBR BMSCH 2 PED HEMONC,6154,"Murphy, Susan, MD",4/17/2025,PEDS LCH-III Group 3 Continuation,_1. First Line,4/17/2025,Inactive,Langerhan's cell histiocytosis (CMS/HCC),"C96.6 - Unifocal Langerhans-cell histiocytosis; D68.59 - Other primary thrombophilia; M48.04 - Spinal stenosis, thoracic region; G95.19 - Other vascular myelopathies; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; G95.20 - Unspecified cord compression; G93.0 - Cerebral cysts; G89.18 - Other acute postprocedural pain; M40.294 - Other kyphosis, thoracic region; R11.0 - Nausea; R33.9 - Retention of urine, unspecified; R63.4 - Abnormal weight loss; D64.89 - Other specified anemias; Z68.52 - Body mass index (BMI) pediatric, 5th percentile to less than 85th percentile for age; Z79.899 - Other long term (current) drug therapy; Z91.81 - History of falling; Z59.71 - Insufficient health insurance coverage"
NBR BMSCH 2 PED HEMONC,6154,"Murphy, Susan, MD",4/16/2025,"PEDS LCH-IV Stratum I Group 1 MS-LCH, Group 2 SS-LCH (IC-1) Initial Course 1  - Langerhans Cell Histiocytosis",_1. First Line,4/16/2025,Inactive,Langerhan's cell histiocytosis (CMS/HCC),"C96.6 - Unifocal Langerhans-cell histiocytosis; D68.59 - Other primary thrombophilia; M48.04 - Spinal stenosis, thoracic region; G95.19 - Other vascular myelopathies; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; G95.20 - Unspecified cord compression; G93.0 - Cerebral cysts; G89.18 - Other acute postprocedural pain; M40.294 - Other kyphosis, thoracic region; R11.0 - Nausea; R33.9 - Retention of urine, unspecified; R63.4 - Abnormal weight loss; D64.89 - Other specified anemias; Z68.52 - Body mass index (BMI) pediatric, 5th percentile to less than 85th percentile for age; Z79.899 - Other long term (current) drug therapy; Z91.81 - History of falling; Z59.71 - Insufficient health insurance coverage"
CINJ OP INFUSION,95860,"Golombos, David, MD",10/16/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,First Line,10/16/2023,Inactive,,
CINJ OP INFUSION,95860,"Golombos, David, MD",2/26/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,2/26/2024,Inactive,,
MMC OP INFUSION,81321,"Meghal, Trishala, MD",3/22/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/22/2024,Active,"Kidney cancer, primary, with metastasis from kidney to other site (CMS/HCC)",
CBMC OP INFUSION 2FL,7927,"Leitner, Stuart P, MD",5/22/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,5/22/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
HAM OP INFUSION,83818,"Yogarajah, Meera, MD",1/16/2025,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,1/8/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,73937,"Toppmeyer, Deborah L, MD",9/11/2023,Capecitabine One Week On/One Week Off Plus Tucatinib,Maintenance,9/11/2023,Active,,
CINJ OP INFUSION,70929,"Leiser, Aliza, MD",6/8/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,5/16/2023,Inactive,,
SOM OUTPT INFUSION,67899,"Patel, Eshan, MD",3/23/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,2/24/2023,Inactive,,
SOM OUTPT INFUSION,67899,"Patel, Eshan, MD",5/25/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,5/24/2023,Inactive,,
CINJ OP INFUSION,3848,"Toppmeyer, Deborah L, MD",8/31/2023,Ribociclib 28 Day Cycles - Breast,First Line,8/31/2023,Inactive,,
CINJ OP INFUSION,78813,"Leiser, Aliza, MD",9/19/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,9/19/2024,Active,,
CINJ OP INFUSION,78813,"Leiser, Aliza, MD",1/21/2025,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/21/2025,Active,,
SOM OUTPT INFUSION,15097,"Toomey, Kathleen C, MD",10/2/2024,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,9/24/2024,Active,,
CINJ OP INFUSION,24712,"Haigentz, Missak, MD",3/11/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,3/11/2024,Inactive,,
CMC OP INFUSION,37186,"Pompa, Tiffany Ann, MD",2/12/2025,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,2/10/2025,Active,Malignant melanoma of other part of trunk (CMS/HCC),
TRMC TCCC OP INFUSION,51155,"Capo, Gerardo, MD",10/8/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/2/2024,Active,,
TRMC TCCC OP INFUSION,51155,"Capo, Gerardo, MD",1/22/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/21/2025,Active,,
TRMC TCCC OP INFUSION,51155,"Capo, Gerardo, MD",5/1/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/1/2025,Active,Malignant neoplasm of overlapping sites of left bronchus and lung (CMS/HCC),
NBI D7 MED-SURG/TELE,11042,"Shah, Shailja S, MD",12/17/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,12/12/2024,Inactive,,
NBI OP INFUSION,11042,"Shah, Shailja S, MD",12/20/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,12/16/2024,Active,,
CBMC OP INFUSION 2FL,10431,"Wagmiller, Jennifer Ann, MD",10/11/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/24/2024,Active,,
CBMC OP INFUSION 2FL,10431,"Wagmiller, Jennifer Ann, MD",5/16/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,5/16/2025,Inactive,Malignant neoplasm of unspecified ovary (CMS/HCC),"C56.9 - Malignant neoplasm of ovary, unspecified laterality (CMS/HCC)"
CINJ OP INFUSION,59154,"Haigentz, Missak, MD",3/27/2023,CINJ 032013 (EA5181) ARM B PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,3/19/2023,Inactive,,
CINJ OP INFUSION,59154,"Haigentz, Missak, MD",6/2/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,Consolidation,6/2/2023,Active,,
CBMC OP INFUSION 2FL,9731,"Brown, Andrew Bennett, MD",1/8/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/7/2024,Active,,
CBMC OP INFUSION 2FL,19827,"Wagmiller, Jennifer Ann, MD",1/31/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/21/2024,Inactive,,
CINJ OP INFUSION,7825,"Stephenson, Ryan D, DO",3/10/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,First Line,3/10/2023,Inactive,,
CINJ OP INFUSION,7825,"Stephenson, Ryan D, DO",8/17/2023,Cabozantinib 28 Day Cycles- Kidney Cancers,Second Line,8/17/2023,Inactive,,
CINJ OP INFUSION,7825,"Stephenson, Ryan D, DO",12/20/2024,Everolimus / Lenvatinib 21 Day Cycles - Kidney,_3. Third Line,12/19/2024,Inactive,,
CINJ OP INFUSION,46590,"Jang, Thomas L, MD",9/10/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/8/2024,Active,,
CINJ OP INFUSION,46590,"Jang, Thomas L, MD",3/4/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,3/4/2025,Active,Malignant neoplasm of dome of urinary bladder (CMS/HCC),C67.1 - Malignant neoplasm of dome of bladder
CBMC OP INFUSION 2FL,71388,"Leitner, Stuart P, MD",6/6/2024,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,6/5/2024,Inactive,,
CBMC OP INFUSION 2FL,77321,"Scoppetuolo, Michael, MD",9/9/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_2. Second Line,8/12/2024,Active,,
CINJ OP INFUSION,35345,"Boland, Patrick M, MD",7/14/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,,7/6/2023,Inactive,,
CINJ OP INFUSION,99954,"George, Mridula A, MD",3/8/2023,CINJ 042111 (GO42784) ARM A Giredestrant 30 mg 28 Day Cycles Research- Breast Cancer,Adjuvant,3/7/2023,Active,,
NBR CINJ OP INFUSION,51663,"Matasar, Matthew J, MD",2/22/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,First Line,2/21/2023,Inactive,,
MMC BBR2 ONCOLOGY,22433,"Eltoukhy, Hussam, MD",4/8/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/8/2024,Inactive,,
NBR 4N BMTU/IMCU,22433,"Rhodes, Joanna Meehan, MD",4/10/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/10/2024,Inactive,,
MMC OP INFUSION,22433,"Eltoukhy, Hussam, MD",4/16/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,4/16/2024,Inactive,,
MMC OP VP INFUSION,39284,"Cohen, Seth D, MD",4/5/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/4/2024,Active,,
MMC OP VP INFUSION,39284,"Cohen, Seth D, MD",2/5/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_2. Second Line,2/4/2025,Active,"Bladder cancer metastasized to bone (CMS/HCC)
Hypothyroidism due to medication
End stage renal disease (CMS/HCC)",
NBR 4N ONCOLOGY,65599,"Palmisiano, Neil David, MD",3/24/2023,HyperCVAD (Cycle A) Course (Cyclophosphamide / VinCRIStine / DOXOrubicin / DexAMETHasone) + RiTUXimab 21 Day Cycle - Mantle Cell Lymphoma,,3/24/2023,Inactive,,
NBR 4N ONCOLOGY,65599,"Matasar, Matthew J, MD",4/7/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,4/7/2023,Inactive,,
JCMC CP INFUSION,60751,"Sekhri, Arunabh, MD",5/25/2023,Nivolumab 480 mg 28 Day Cycles- adjuvant esophageal cancer,Consolidation,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,7992,"Rhodes, Joanna Meehan, MD",12/14/2023,"CINJ 012315 Arm B Gemcitabine D1, D8 21 Day Cycles Research- Hodgkin Lymphoma",_4. Fourth Line,12/13/2023,Inactive,,
NBR CINJ OP INFUSION,7992,"Rhodes, Joanna Meehan, MD",3/7/2024,CINJ 012315 Arm A MK-4280A Single Agent 21 Day Cycles Research- Hodgkin Lymphoma,_5. Fifth Line,3/5/2024,Inactive,,
CINJ OP INFUSION,38216,"Berim, Lyudmyla, MD",6/17/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Cholangiocarcinoma ,_1. First Line,6/16/2024,Inactive,,
CINJ OP INFUSION,38216,"Berim, Lyudmyla, MD",11/14/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Cholangiocarcinoma ,_2. Second Line,11/10/2024,Inactive,,
CINJ OP INFUSION,38216,"Berim, Lyudmyla, MD",1/6/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Chlangiocarcinoma ,_3. Third Line,1/5/2025,Inactive,Cholangiocarcinoma (CMS/HCC),
CINJ OP INFUSION,38216,"Berim, Lyudmyla, MD",2/3/2025,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,2/3/2025,Active,Cholangiocarcinoma (CMS/HCC),
CINJ OP INFUSION,40881,"Packiam, Vignesh, MD",5/20/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/19/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
NBR 5N ONCOLOGY,8321,"Matasar, Matthew J, MD",7/10/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,7/10/2023,Inactive,,
NBR 5N ONCOLOGY,8321,"Matasar, Matthew J, MD",7/12/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,7/12/2023,Inactive,,
NBR CINJ OP INFUSION,8321,"Palmisiano, Neil David, MD",7/25/2023,CINJ 022101 ARM B Cycle 1 Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,First Line,7/25/2023,Inactive,,
NBR 4N ONCOLOGY,8321,"Palmisiano, Neil David, MD",8/18/2023,CINJ 022101 ARM B Cycle 2 Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,First Line,8/18/2023,Inactive,,
NBR CINJ OP INFUSION,8321,"Palmisiano, Neil David, MD",8/18/2023,CINJ 022101 (EA9181) Arms B / C Maintenance Methotrexate Intrathecal / Dasatinib / VinCRIStine 28 Day Cycles Research- Acute Lymphoblastic Leukemia,,8/18/2023,Inactive,,
NBR CINJ OP INFUSION,8321,"Palmisiano, Neil David, MD",9/11/2023,CINJ 022101 (EA9181)  ARM B Cycle 3 Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,,9/7/2023,Inactive,,
NBR 5N ONCOLOGY,8321,"Palmisiano, Neil David, MD",10/2/2023,CINJ 022101 (EA9181)  ARM B Cycle 4 Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,First Line,10/2/2023,Inactive,,
NBR 5N ONCOLOGY,8321,"Palmisiano, Neil David, MD",10/30/2023,CINJ 022101 (EA9181)  ARM B Cycle 5 Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,10/30/2023,Inactive,,
NBR CINJ OP INFUSION,8321,"Palmisiano, Neil David, MD",12/14/2023,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,12/13/2023,Inactive,,
NBR CINJ OP INFUSION,8321,"Palmisiano, Neil David, MD",8/27/2024,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,Consolidation,8/27/2024,Inactive,,
NBR CINJ OP INFUSION,8321,"Egini, Ogechukwu, MD",11/29/2024,BMT Allogeneic Flu (D-7) / TBI + Post Cy - Myeloablative,_3. Third Line,11/29/2024,Active,,
MMC OP VP INFUSION,23124,"Cohen, Seth D, MD",5/29/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/28/2024,Inactive,,
MMC OP VP INFUSION,23124,"Cohen, Seth D, MD",8/15/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,8/14/2024,Inactive,,
MMC OP VP INFUSION,23124,"Cohen, Seth D, MD",11/6/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_4. Fourth Line,11/5/2024,Active,,
CINJ OP INFUSION,82709,"Saraiya, Biren P, MD",6/13/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,6/13/2023,Inactive,,
CBMC OP INFUSION 2FL,20407,"Leitner, Stuart P, MD",4/3/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,4/3/2025,Active,"Cancer of right lung (CMS/HCC)
Pleural effusion, malignant
Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes (CMS/HCC)",
NBI OP INFUSION,62307,"Cohen, Alice, MD",1/10/2024,Everolimus / Exemestane 28 Day Cycles - Breast,_2. Second Line,12/13/2023,Inactive,,
NBI D7 MED-SURG/TELE,62307,"Cohen, Alice, MD",6/17/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_3. Third Line,6/4/2024,Inactive,,
NBI OP INFUSION,62307,"Cohen, Alice, MD",6/24/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_4. Fourth Line,6/23/2024,Inactive,,
NBI OP INFUSION,62307,"Cohen, Alice, MD",12/4/2024,Gemcitabine / CARBOplatin 28 Day Cycles - Breast,_4. Fourth Line,12/3/2024,Inactive,,
NBI OP INFUSION,62307,"Cohen, Alice, MD",12/4/2024,Gemcitabine 28 Day Cycles - Breast,_4. Fourth Line,12/3/2024,Active,,
NBI OP INFUSION,62307,"Cohen, Alice, MD",2/19/2025,Sacituzumab Govitecan 21 Day Cycles - Breast ,_5. Fifth Line,2/11/2025,Active,"Breast cancer metastasized to lung, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,65476,"Brown, Andrew Bennett, MD",1/31/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/31/2024,Inactive,,
CINJ OP INFUSION,24840,"Berim, Lyudmyla, MD",6/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/2/2023,Active,,
CINJ OP INFUSION,55315,"Omene, Coral Oghenerukevwe, MD",1/13/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,1/13/2025,Active,,
CINJ OP INFUSION,93788,"Stephenson, Ryan D, DO",10/4/2024,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,10/4/2024,Inactive,,
CINJ OP INFUSION,93788,"Stephenson, Ryan D, DO",10/28/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/27/2024,Active,,
CBMC OP INFUSION 2FL,42868,"Grossman, I Robert, MD",10/3/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/3/2023,Inactive,,
NBR CINJ OP INFUSION,623,"Evens, Andrew M, DO",1/11/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,1/10/2023,Active,Malignant neoplasm of hilus of left lung (CMS/HCC),
CINJ OP INFUSION,55075,"George, Mridula A, MD",5/17/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,5/16/2023,Active,,
MMC OP VP INFUSION,83872,"Cohen, Seth D, MD",1/31/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/30/2024,Active,,
CBMC OP INFUSION 2FL,41353,"Radovich, Delia, MD",9/26/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/25/2023,Inactive,,
CBMC OP INFUSION 2FL,41353,"Radovich, Delia, MD",12/28/2023,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,12/28/2023,Inactive,,
CINJ OP INFUSION,12667,"Berim, Lyudmyla, MD",2/6/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,1/29/2023,Inactive,,
CINJ OP INFUSION,12667,"Berim, Lyudmyla, MD",2/6/2023,CINJ 071702 (MK-3475-535) Pembrolizumab 21 Day Cycles Pre-Operative Research- Gastric Cancer,,1/8/2023,Inactive,,
CINJ OP INFUSION,12667,"Berim, Lyudmyla, MD",10/3/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/2/2024,Active,,
CINJ OP INFUSION,54461,"George, Mridula A, MD",6/15/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,6/13/2023,Inactive,,
CINJ OP INFUSION,54461,"George, Mridula A, MD",6/21/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,5/24/2023,Active,,
CINJ OP INFUSION,54461,"George, Mridula A, MD",9/27/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,9/26/2023,Active,Breast cancer (CMS/HCC),
CBMC OP INFUSION 2FL,63568,"Phillips, Adrienne A, MD",12/11/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,12/11/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
CBMC 2W ONCOLOGY,63568,"Phillips, Adrienne A, MD",1/13/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,1/12/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CBMC OP INFUSION 2FL,75809,"Phillips, Adrienne A, MD",3/12/2025,RiTUXimab Rapid Infusion Single Day (Outpatient),_1. First Line,3/12/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission
NBR CINJ OP INFUSION,80188,"Egini, Ogechukwu, MD",4/26/2025,BMT Allogeneic TBF + Post Cy,_3. Third Line,4/25/2025,Active,"CML (chronic myelocytic leukemia) (CMS/HCC)
Pre-transplant evaluation for stem cell transplant
Splenomegaly","C92.10 - Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; Z01.818 - Encounter for other preprocedural examination; R16.1 - Splenomegaly, not elsewhere classified"
NBR CINJ OP INFUSION,2787,"Palmisiano, Neil David, MD",4/22/2025,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,4/22/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
NBR CINJ OP INFUSION,2787,"Palmisiano, Neil David, MD",3/18/2025,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,3/18/2025,Inactive,MDS (myelodysplastic syndrome) (CMS/HCC),
CBMC OP INFUSION 2FL,68096,"Siu, Karleung, MD",4/9/2025,Obinutuzumab Maintenance q 6 months CLL with AIHA mtn.,_2. Second Line,4/9/2025,Active,"Autoimmune hemolytic anemia (CMS/HCC)
CLL (chronic lymphocytic leukemia) (CMS/HCC)",
CINJ OP INFUSION,93480,"Groisberg, Roman, MD",3/6/2023,CINJ 092102 Phase 2 Liposomal Annamycin 21 Day Cycles Research- Soft Tissue Sarcoma,Third Line,2/5/2023,Inactive,,
CINJ OP INFUSION,93480,"Groisberg, Roman, MD",4/4/2023,CINJ 092102 Phase 2 Liposomal Annamycin 21 Day Cycles Research- Soft Tissue Sarcoma,Third Line,3/6/2023,Inactive,,
CINJ OP INFUSION,93480,"Groisberg, Roman, MD",4/19/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,,4/18/2023,Inactive,,
CBMC OP INFUSION 2FL,24957,"Brown, Andrew Bennett, MD",9/6/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,9/5/2023,Inactive,,
CBMC OP INFUSION 2FL,24957,"Brown, Andrew Bennett, MD",5/21/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/21/2024,Inactive,,
CBMC OP INFUSION 2FL,24957,"Brown, Andrew Bennett, MD",6/11/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,6/11/2024,Active,,
SOM OUTPT INFUSION,3016,"Toomey, Kathleen C, MD",9/12/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,9/1/2024,Inactive,,
SOM OUTPT INFUSION,3016,"Toomey, Kathleen C, MD",12/4/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,12/3/2024,Active,Malignant neoplasm of bronchus of right upper lobe (CMS/HCC),
NBR 5N ONCOLOGY,19502,"Palmisiano, Neil David, MD",4/5/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,4/4/2023,Inactive,,
HAM OP INFUSION,17468,"Patel, Malini M, MD",5/8/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,5/7/2023,Inactive,,
HAM OP INFUSION,17468,"Patel, Malini M, MD",8/17/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,8/16/2023,Inactive,,
HAM OP INFUSION,17468,"Patel, Malini M, MD",10/12/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,10/11/2023,Inactive,,
CBMC OP INFUSION 2FL,33324,"Brown, Andrew Bennett, MD",4/4/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/2/2024,Inactive,Malignant neoplasm of upper lobe of left lung (CMS/HCC),
CBMC OP INFUSION 2FL,33324,"Brown, Andrew Bennett, MD",1/9/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,1/8/2025,Active,,
MMC OP INFUSION,83075,"Meghal, Trishala, MD",9/20/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/12/2024,Active,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",3/14/2023,"Nivolumab (D1, D15) 28 Day Cycles - Hodgkin Lymphoma",,3/13/2023,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",4/11/2023,Pembrolizumab + Gemcitabine 21 Day Cycles - Hodgkin Lymphoma,Third Line,4/10/2023,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",8/29/2023,CMOPP(cyclophosphamide/matulane/vincristineD1&8/prednisone,,8/14/2023,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",1/17/2024,"Vinblastine weekly, Relapsed Hodgkins Lymphoma",_6. Sixth Line,1/16/2024,Inactive,,
NBR 5N ONCOLOGY,95293,"Matasar, Matthew J, MD",4/2/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Hodgkin Lymphoma (Inpatient Regimen),_8. Eighth Line,4/2/2024,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",4/2/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Hodgkin Lymphoma,_8. Eighth Line,4/1/2024,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",4/2/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Hodgkin Lymphoma,_8. Eighth Line,4/1/2024,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",7/16/2024,Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,_8. Eighth Line,7/15/2024,Inactive,,
NBR CINJ OP INFUSION,95293,"Matasar, Matthew J, MD",9/4/2024,"Temsirolimus weekly and lenalidomide days 1-21, 28 Day Cycles - Hodgkins lymphoma",_2. Second Line,9/2/2024,Inactive,,
NBR CINJ OP INFUSION,95293,"Egini, Ogechukwu, MD",11/9/2024,BMT Allogeneic Flu / Cy / TBI + Post Cy,10. Tenth Line,11/8/2024,Active,,
NBR CINJ OP INFUSION,95293,"Egini, Ogechukwu, MD",1/15/2025,RiTUXimab 375 mg/m2 Weekly x 4 doses - EBV(+),_1. First Line,1/8/2025,Active,Bullous pemphigoid,
NBR 4N ONCOLOGY,9178,"Patel, Vimal D, MD",2/18/2025,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,2/18/2025,Inactive,HLH (hemophagocytic lymphohistiocytosis) (CMS/HCC),"A41.9 - Sepsis, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; B20 - Human immunodeficiency virus (HIV) disease; Z66 - Do not resuscitate; K76.7 - Hepatorenal syndrome; D76.1 - Hemophagocytic lymphohistiocytosis; E87.4 - Mixed disorder of acid-base balance; D47.Z1 - Post-transplant lymphoproliferative disorder (PTLD); A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; G93.41 - Metabolic encephalopathy; R65.20 - Severe sepsis without septic shock; Z94.81 - Bone marrow transplant status; Z94.84 - Stem cells transplant status; D70.9 - Neutropenia, unspecified; I27.20 - Pulmonary hypertension, unspecified; I11.0 - Hypertensive heart disease with heart failure; E03.9 - Hypothyroidism, unspecified; D64.9 - Anemia, unspecified; D69.6 - Thrombocytopenia, unspecified; I50.32 - Chronic diastolic (congestive) heart failure; F05 - Delirium due to known physiological condition; N17.9 - Acute kidney failure, unspecified; G96.00 - Cerebrospinal fluid leak, unspecified; I47.19 - Other supraventricular tachycardia; E87.0 - Hyperosmolality and hypernatremia; G95.20 - Unspecified cord compression; K76.82 - Hepatic encephalopathy; J15.9 - Unspecified bacterial pneumonia; Z56.0 - Unemployment, unspecified; B27.00 - Gammaherpesviral mononucleosis without complication; K76.1 - Chronic passive congestion of liver; E86.0 - Dehydration; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; R73.03 - Prediabetes;..."
CINJ OP INFUSION,97327,"Weiss, Sarah, MD",5/24/2023,CINJ 092204 Fianlimab / Cemiplimab or Pembrolizumab 21 Day Cycles Research- Melanoma,Adjuvant,5/23/2023,Inactive,,
CINJ OP INFUSION,97327,"Weiss, Sarah, MD",5/31/2023,CINJ 092204 Fianlimab (1600mg=arm A or 400mg=arm B) + Cemiplimab 350mg ] or [pembrolizumab= arm C ]  21 Day Cycles Research- Melanoma,Adjuvant,5/30/2023,Active,,
CINJ OP INFUSION,97327,"Weiss, Sarah, MD",5/31/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,5/23/2023,Inactive,,
HAM OP INFUSION,80744,"Yogarajah, Meera, MD",7/11/2024,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,_1. First Line,7/10/2024,Active,,
HAM OP INFUSION,80744,"Yogarajah, Meera, MD",10/10/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/10/2024,Active,,
MMC OP VP INFUSION,34510,"Cohen, Seth D, MD",7/17/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,7/10/2024,Inactive,,
MSC OP INFUSION,10234,"Cohen, Seth D, MD",5/4/2023,RiTUXimab Initial Infusion Single Day (Outpatient),First Line,5/4/2023,Inactive,,
MMC OP VP INFUSION,65562,"Cohen, Seth D, MD",5/4/2023,RiTUXimab Initial Infusion Single Day (Outpatient),First Line,5/4/2023,Active,"Breast cancer metastasized to liver, left (CMS/HCC)",
SOM OUTPT INFUSION,73366,"Patel, Eshan, MD",3/20/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,3/17/2023,Inactive,,
JCMC CP INFUSION,52436,"Cruz, Allan Louie E, MD",11/9/2023,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,11/7/2023,Inactive,,
JCMC CP INFUSION,22780,"Sekhri, Arunabh, MD",12/18/2023,"Pembrolizumab 21 Day Cycles - Gallbladder cancer , high TMB",_1. First Line,12/17/2023,Inactive,,
NBR 5N ONCOLOGY,57632,"Shah, Mansi R, MD",3/22/2024,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,3/22/2024,Inactive,,
NBR CINJ OP INFUSION,57632,"Zayac, Adam, MD",5/31/2024,CINJ 022301 Iadademstat / Gilteritinib 28 Day Cycles Research- Acute Myeloid Leukemia,_2. Second Line,5/21/2024,Inactive,,
NBR CINJ OP INFUSION,57632,"Zayac, Adam, MD",9/18/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_3. Third Line,9/11/2024,Inactive,,
CINJ OP INFUSION,16221,"Muralikrishnan, Sivraj, MD",3/17/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,3/17/2025,Active,Laryngeal cancer (CMS/HCC),"C32.9 - Malignant neoplasm of larynx, unspecified"
CINJ OP INFUSION,92914,"Stephenson, Ryan D, DO",4/19/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,4/18/2023,Inactive,,
CINJ OP INFUSION,92914,"Stephenson, Ryan D, DO",7/12/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,7/12/2023,Inactive,,
HAM OP INFUSION,3457,"Yogarajah, Meera, MD",4/24/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,4/23/2023,Inactive,,
CINJ OP INFUSION,38247,"Mayer, Tina M, MD",1/2/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,12/19/2024,Active,,
SOM OUTPT INFUSION,44819,"Patel, Eshan, MD",2/6/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,1/22/2023,Inactive,,
CINJ OP INFUSION,14159,"Leiser, Aliza, MD",12/15/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,12/14/2023,Inactive,,
CINJ OP INFUSION,14159,"Leiser, Aliza, MD",5/22/2024,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,5/21/2024,Active,,
CINJ OP INFUSION,77064,"Leiser, Aliza, MD",10/15/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,10/14/2024,Inactive,,
CINJ OP INFUSION,77064,"Leiser, Aliza, MD",11/8/2024,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_2. Second Line,11/7/2024,Inactive,,
CINJ OP INFUSION,77064,"Leiser, Aliza, MD",11/11/2024,PACLitaxel / CISplatin/ Pembrolizumab -21 Day Cycles - Cervical,_2. Second Line,11/8/2024,Active,,
CINJ OP INFUSION,77064,"Leiser, Aliza, MD",5/29/2025,Pembrolizumab 42 Day Cycles - Cervical,Maintenance,5/29/2025,Active,Recurrent cervical cancer (CMS/HCC),
NBI OP INFUSION,78728,"Anderson, Patrick S, MD",10/24/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,10/16/2024,Active,,
CINJ OP INFUSION,91507,"Weiss, Sarah, MD",6/11/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,6/9/2024,Active,,
JCMC CP INFUSION,67474,"Sekhri, Arunabh, MD",7/15/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,7/15/2024,Active,"Chronic lymphocytic leukemia (CLL), B-cell (CMS/HCC)",
MMC OP VP INFUSION,62278,"Cohen, Seth D, MD",9/27/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",First Line,9/19/2023,Inactive,,
MMC OP VP INFUSION,62278,"Cohen, Seth D, MD",12/20/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/19/2023,Active,,
CINJ OP INFUSION,98572,"Toppmeyer, Deborah L, MD",1/19/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/18/2024,Active,,
CINJ OP INFUSION,37174,"Stephenson, Ryan D, DO",7/21/2023,DOCEtaxel 21 Day Cycles - Prostate,Third Line,7/20/2023,Inactive,,
MMC OP VP INFUSION,67431,"Cohen, Seth D, MD",8/16/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,8/6/2023,Inactive,,
SOM OUTPT INFUSION,92958,"Patel, Eshan, MD",1/14/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/6/2025,Active,,
SOM OUTPT INFUSION,33528,"Patel, Eshan, MD",3/11/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/11/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; R91.1 - Solitary pulmonary nodule; J98.4 - Other disorders of lung; N62 - Hypertrophy of breast; K86.9 - Disease of pancreas, unspecified; K86.89 - Other specified diseases of pancreas; N28.1 - Cyst of kidney, acquired; N28.9 - Disorder of kidney and ureter, unspecified"
CINJ PEDS HEMONC ,41456,"Moerdler, Scott, MD",3/22/2024,PEDS AEWS1031 Regimen A Induction & Consolidation,_1. First Line,3/20/2024,Inactive,,
NBR CINJ OP INFUSION,45876,"Braunschweig, Ira, MD",11/29/2023,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,67029,"Shah, Mansi R, MD",11/13/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,10/30/2024,Active,,
CBMC OP INFUSION 2FL,84964,"Wagmiller, Jennifer Ann, MD",10/23/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,10/22/2023,Inactive,,
CBMC OP INFUSION 2FL,84964,"Wagmiller, Jennifer Ann, MD",12/4/2023,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,12/3/2023,Inactive,,
CBMC OP INFUSION 2FL,84964,"Wagmiller, Jennifer Ann, MD",4/8/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/31/2024,Inactive,,
CBMC OP INFUSION 2FL,84964,"Wagmiller, Jennifer Ann, MD",5/23/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,5/22/2024,Active,,
CBMC OP INFUSION 2FL,84964,"Wagmiller, Jennifer Ann, MD",5/9/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/9/2025,Active,"Encounter for immunization
Endometrial cancer (CMS/HCC)
On antineoplastic chemotherapy
Malignant neoplasm metastatic to brain (CMS/HCC)",C54.1 - Malignant neoplasm of endometrium; Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants
CINJ OP INFUSION,53767,"Saraiya, Biren P, MD",8/19/2024,CINJ 082401 Arm 3 Cohort B Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,Adjuvant,8/19/2024,Inactive,,
CINJ OP INFUSION,53767,"Saraiya, Biren P, MD",12/16/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/15/2024,Inactive,,
NBR CINJ OP INFUSION,39468,"Schaar, Dale, MD PhD",2/9/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Third Line,2/9/2023,Inactive,,
NBR 5N ONCOLOGY,50847,"Palmisiano, Neil David, MD",6/3/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,6/2/2023,Inactive,,
CMC OP INFUSION,36315,"Pompa, Tiffany Ann, MD",9/6/2024,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,9/6/2024,Active,EBV (Epstein-Barr virus) viremia,
CMC OP INFUSION,36315,"Pompa, Tiffany Ann, MD",11/7/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/7/2024,Active,,
NBR CINJ OP INFUSION,97636,"Shah, Mansi R, MD",8/15/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,8/14/2023,Active,,
NBR CINJ OP INFUSION,97636,"Shah, Mansi R, MD",5/20/2025,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_3. Third Line,5/20/2025,Active,Multiple myeloma without remission (CMS/HCC),
CINJ OP INFUSION,30216,"Saraiya, Biren P, MD",6/10/2024,Enzalutamide 30 Day Cycles - Prostate,_1. First Line,6/10/2024,Active,,
CINJ OP INFUSION,85797,"Mayer, Tina M, MD",4/26/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,4/26/2023,Active,,
NBR 5N MED-SURG OVRF,84547,"Alexander, Henry Richard, MD",12/16/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,12/16/2024,Inactive,,
MMC OP VP INFUSION,99521,"Cohen, Seth D, MD",11/27/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,11/26/2023,Inactive,,
MMC OP VP INFUSION,23480,"Lee, Patrick C, MD",11/7/2023,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,11/6/2023,Inactive,,
MMC OP INFUSION,23480,"Eltoukhy, Hussam, MD",12/8/2023,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_6. Sixth Line,12/8/2023,Inactive,,
MMC OP INFUSION,23480,"Eltoukhy, Hussam, MD",3/21/2024,Pomalidomide 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,3/21/2024,Inactive,,
MMC BBR2 ONCOLOGY,23480,"Eltoukhy, Hussam, MD",6/14/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,10. Tenth Line,6/6/2024,Inactive,,
NBI OP INFUSION,29391,"Shah, Shailja S, MD",7/7/2023,"Bortezomib D1, D15 Q21 Day Cycles- Multiple Myeloma",Maintenance,7/6/2023,Inactive,,
NBR CINJ OP INFUSION,29391,"Shah, Mansi R, MD",10/3/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Adjuvant,9/19/2024,Inactive,,
NBI OP INFUSION,29391,"Shah, Shailja S, MD",11/29/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/29/2024,Active,,
MSC OP INFUSION,66676,"Cohen, Seth D, MD",4/18/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",,4/10/2023,Inactive,,
NBR CINJ OP INFUSION,15617,"Braunschweig, Ira, MD",1/10/2024,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,1/9/2024,Inactive,,
NBR CINJ OP INFUSION,633,"Braunschweig, Ira, MD",3/2/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,3/1/2023,Inactive,,
NBR CINJ OP INFUSION,87072,"Evens, Andrew M, DO",4/17/2024,RiTUXimab 28 Day Cycle ITP ,Maintenance,4/16/2024,Inactive,,
CBMC OP INFUSION 2FL,28586,"Wagmiller, Jennifer Ann, MD",8/23/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/22/2023,Inactive,,
CBMC OP INFUSION 2FL,28586,"Wagmiller, Jennifer Ann, MD",3/5/2024,PEMEtrexed 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,2/26/2024,Inactive,,
CINJ OP INFUSION,45161,"Weiss, Sarah, MD",9/16/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_2. Second Line,9/16/2024,Inactive,,
CINJ OP INFUSION,45161,"Weiss, Sarah, MD",1/6/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_3. Third Line,1/5/2025,Active,,
CINJ OP INFUSION,45161,"Weiss, Sarah, MD",5/21/2025,CINJ 052408 Part 2.1B Escalation Step Up AB248 / Pembrolizumab 200 mg 21 Day Cycles Research- Solid Tumors,_4. Fourth Line,5/21/2025,Active,Metastatic melanoma (CMS/HCC),"C43.9 - Malignant melanoma of skin, unspecified; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C79.51 - Secondary malignant neoplasm of bone; E83.52 - Hypercalcemia"
JCMC CP INFUSION,45779,"Sekhri, Arunabh, MD",11/29/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/12/2023,Inactive,,
JCMC CP INFUSION,45779,"Sekhri, Arunabh, MD",2/28/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles - locally advanced gastric adenocarcinoma,_1. First Line,2/18/2024,Inactive,,
CINJ OP INFUSION,84639,"George, Mridula A, MD",6/5/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/4/2024,Inactive,Malignant neoplasm of lower-outer quadrant of right female breast (CMS/HCC),
CINJ OP INFUSION,84639,"George, Mridula A, MD",6/5/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,5/8/2024,Inactive,Malignant neoplasm of lower-outer quadrant of right female breast (CMS/HCC),
CINJ OP INFUSION,84639,"George, Mridula A, MD",1/8/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/2/2025,Active,,
CINJ OP INFUSION,70075,"Omene, Coral Oghenerukevwe, MD",3/14/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,3/14/2023,Inactive,,
CINJ OP INFUSION,70075,"Omene, Coral Oghenerukevwe, MD",6/29/2023,A011801 / CINJ 042106 Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,_1. First Line,6/25/2023,Inactive,,
CINJ OP INFUSION,70075,"Omene, Coral Oghenerukevwe, MD",6/29/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,6/28/2023,Inactive,,
CINJ OP INFUSION,70075,"Omene, Coral Oghenerukevwe, MD",10/31/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/30/2023,Inactive,,
CINJ OP INFUSION,75942,"Gulhati, Prateek, MD PhD",10/7/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/2/2024,Active,,
NBR 5N MED-SURG OVRF,75942,"Alexander, Henry Richard, MD",2/25/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,2/25/2025,Active,"Metastatic adenocarcinoma involving small intestine with unknown primary site (CMS/HCC)
Malignant neoplasm of appendix (CMS/HCC)",
HAM OP INFUSION,51712,"Gendy, Mina, DO",5/28/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles + RiTUXimab 84 Day Cycles - Follicular Lymphoma,_2. Second Line,5/28/2025,Inactive,Marginal zone lymphoma (CMS/HCC),"C85.80 - Other specified types of non-hodgkin lymphoma, unspecified site; K21.9 - Gastro-esophageal reflux disease without esophagitis; E03.9 - Hypothyroidism, unspecified; Z85.118 - Personal history of other malignant neoplasm of bronchus and lung; Z88.1 - Allergy status to other antibiotic agents; Z79.52 - Long term (current) use of systemic steroids; Z79.624 - Long term (current) use of inhibitors of nucleotide synthesis; Z79.890 - Hormone replacement therapy; Z79.899 - Other long term (current) drug therapy"
HAM OP INFUSION,51712,"Gendy, Mina, DO",5/14/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,5/14/2025,Inactive,Marginal zone lymphoma (CMS/HCC),"C85.80 - Other specified types of non-hodgkin lymphoma, unspecified site; C78.00 - Secondary malignant neoplasm of unspecified lung; I10 - Essential (primary) hypertension; E03.9 - Hypothyroidism, unspecified; E07.9 - Disorder of thyroid, unspecified; L75.0 - Bromhidrosis; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z79.890 - Hormone replacement therapy; Z79.899 - Other long term (current) drug therapy"
NBI OP INFUSION,9329,"Anderson, Patrick S, MD",4/12/2024,Bevacizumab (MVasi)21 Day Cycles - cervical cancer,_2. Second Line,4/12/2024,Active,,
NBI OP INFUSION,9329,"Anderson, Patrick S, MD",4/12/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,4/11/2024,Inactive,,
NBI OP INFUSION,9329,"Anderson, Patrick S, MD",4/12/2024,Bevacizumab 21 Day Cycles - Cervical Cancer,_2. Second Line,4/11/2024,Inactive,,
CINJ OP INFUSION,97158,"Goel, Sanjay, MD",7/10/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,7/7/2023,Inactive,,
CINJ OP INFUSION,479,"George, Mridula A, MD",1/3/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,1/3/2024,Inactive,,
SOM OUTPT INFUSION,29309,"Patel, Eshan, MD",12/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/1/2024,Active,,
NBR CINJ OP INFUSION,26418,"Braunschweig, Ira, MD",12/27/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,12/27/2023,Inactive,,
JCMC CP INFUSION,89670,"Cruz, Allan Louie E, MD",4/4/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,4/3/2023,Inactive,,
JCMC CP INFUSION,89670,"Cruz, Allan Louie E, MD",12/19/2023,CINJ 072213 Nivolumab 28 Day Cycles Research- Hepatocellular Carcinoma,_2. Second Line,11/23/2023,Inactive,,
HAM OP INFUSION,16531,"Gendy, Mina, DO",1/3/2025,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,1/3/2025,Active,,
CINJ OP INFUSION,9928,"Hochster, Howard S, MD",2/22/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin)  14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/21/2024,Active,,
CINJ OP INFUSION,9928,"Hochster, Howard S, MD",3/12/2025,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/12/2025,Active,Gastric cancer (CMS/HCC),
NBR BMSCH 2 PED HEMONC,54842,"Moerdler, Scott, MD",8/7/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,First Line,8/7/2023,Inactive,,
CINJ PEDS HEMONC ,54842,"Botwinick, Marissa, DO",10/13/2023,AALL1731 Non-DS SR (Fav or Avg) B-ALL - Maintenance,First Line,10/5/2023,Active,,
CINJ OP INFUSION,99003,"Haigentz, Missak, MD",1/23/2024,CINJ 052011 Cohort 9 Enfortumab Vedotin / Pembrolizumab Phase 2 21 Day Cycles Research- Solid Malignancies,_1. First Line,1/22/2024,Inactive,,
CBMC OP INFUSION 2FL,75911,"Leitner, Stuart P, MD",4/3/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/3/2025,Active,"Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)
Primary cancer of left lower lobe of lung (CMS/HCC)
Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes (CMS/HCC)
Thyroiditis, autoimmune","C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; C79.51 - Secondary malignant neoplasm of bone; C79.52 - Secondary malignant neoplasm of bone marrow; R74.8 - Abnormal levels of other serum enzymes; C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; E06.3 - Autoimmune thyroiditis; R79.89 - Other specified abnormal findings of blood chemistry; D63.0 - Anemia in neoplastic disease"
JCMC CP INFUSION,45915,"Cruz, Allan Louie E, MD",6/19/2024,CINJ 042315 Arm 1 DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Hormone Receptor (+) Breast Cancer,Neoadjuvant,6/14/2024,Active,,
CBMC OP INFUSION 2FL,75218,"McKenna, Marshall, MD",4/10/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,3/31/2025,Inactive,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
CBMC OP INFUSION 2FL,75218,"McKenna, Marshall, MD",4/10/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/10/2025,Active,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
CBMC OP INFUSION 2FL,75218,"McKenna, Marshall, MD",4/1/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/1/2025,Inactive,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; D62 - Acute posthemorrhagic anemia; M84.452A - Pathological fracture, left femur, initial encounter for fracture; E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; E11.9 - Type 2 diabetes mellitus without complications; E04.2 - Nontoxic multinodular goiter; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; Z95.2 - Presence of prosthetic heart valve; E78.5 - Hyperlipidemia, unspecified; E21.0 - Primary hyperparathyroidism; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; K59.00 - Constipation, unspecified; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z86.0100 - Personal history of colon polyps, unspecified; Z86.16 - Personal history of COVID-19; Z85.528 - Personal history of other malignant neoplasm of kidney; Z90.5 - Acquired absence of kidney; Z96.641 - Presence of right artificial hip joint; Z98.51 - Tubal ligation status; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z91.048 - Other nonmedicinal substance allergy status; G25.0 - Essential tremor"
NBR CINJ OP INFUSION,66329,"Eltoukhy, Hussam, MD",2/9/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/8/2024,Inactive,,
NBR CINJ OP INFUSION,66329,"Tiger, Yun Kyoung, MD",8/3/2024,Daratumumab 28 Day Cycles- Multiple Myeloma,_3. Third Line,8/2/2024,Inactive,,
NBR CINJ OP INFUSION,66329,"Tiger, Yun Kyoung, MD",8/3/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,8/2/2024,Inactive,,
NBR CINJ OP INFUSION,66329,"Tiger, Yun Kyoung, MD",1/3/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,1/2/2025,Active,,
CINJ OP INFUSION,67877,"Boland, Patrick M, MD",10/13/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,10/12/2023,Inactive,,
CINJ OP INFUSION,93561,"Aikins, James K, MD",3/16/2023,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,3/1/2023,Inactive,,
CINJ OP INFUSION,93561,"Aikins, James K, MD",11/17/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,11/15/2023,Active,,
MMC OP INFUSION,2837,"Eltoukhy, Hussam, MD",1/18/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,1/17/2024,Active,"Malignant neoplasm of tonsil (CMS/HCC)
Malignant neoplasm of anterior two-thirds of tongue, part unspecified (CMS/HCC)",
CBMC OP INFUSION 2FL,89807,"Radovich, Delia, MD",11/28/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Adjuvant,11/27/2023,Inactive,,
NBR 5N ONCOLOGY,17111,"Tiger, Yun Kyoung, MD",1/4/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,1/3/2025,Inactive,Acute leukemia of ambiguous lineage (CMS/HCC),
CBMC OP INFUSION 2FL,35583,"Raptis, George, MD",7/10/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,6/27/2024,Inactive,,
CBMC OP INFUSION 2FL,35583,"Raptis, George, MD",12/4/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,10/2/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
CBMC OP INFUSION 2FL,35583,"Raptis, George, MD",2/19/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,10/2/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)","C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z51.11 - Encounter for antineoplastic chemotherapy; G62.0 - Drug-induced polyneuropathy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC OP INFUSION 2FL,70398,"Raptis, George, MD",4/2/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/2/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
HAM OP INFUSION,55295,"Yogarajah, Meera, MD",4/16/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,4/14/2024,Inactive,,
HAM OP INFUSION,55295,"Yogarajah, Meera, MD",11/12/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,11/5/2024,Inactive,,
CINJ OP INFUSION,40976,"Berim, Lyudmyla, MD",3/18/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,3/18/2023,Inactive,,
CINJ OP INFUSION,40976,"Berim, Lyudmyla, MD",10/9/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Adjuvant,10/8/2023,Inactive,,
CINJ OP INFUSION,40976,"Berim, Lyudmyla, MD",10/23/2023,Capecitabine 625 mg/m2 D1-D5 with Concurrent Radiation GastricCancer,Adjuvant,10/23/2023,Inactive,,
CINJ OP INFUSION,40976,"Berim, Lyudmyla, MD",1/29/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/28/2024,Active,,
CINJ OP INFUSION,24356,"Berim, Lyudmyla, MD",2/12/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles - Gastric Cancer,_1. First Line,2/11/2025,Active,Gastric adenocarcinoma (CMS/HCC),
NBI VALERIE FND HEMONC,99871,"Batra, Surabhi, MD",1/30/2023,ARST2031 Regimen B (VINO-AC + VINO-C Maintenance),_1. First Line,1/29/2023,Active,,
CINJ PEDS HEMONC ,99871,"Moerdler, Scott, MD",1/30/2023,ARST2031 Regimen B (VINO-AC + VINO-C Maintenance),,1/30/2023,Inactive,,
CINJ PEDS HEMONC ,99871,"Moerdler, Scott, MD",4/26/2023,ARST2031 Regimen B (VINO-AC + VINO-C Maintenance),First Line,4/17/2023,Inactive,,
NBI VALERIE FND HEMONC,99871,"Batra, Surabhi, MD",3/5/2025,Individualized Treatment VI plus Temozolomide for relapsed rhabdomyosarcoma,_2. Second Line,3/3/2025,Active,Rhabdomyosarcoma of bladder (CMS/HCC),
MMC OP VP INFUSION,73866,"Cohen, Seth D, MD",2/5/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/28/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
JCMC CP INFUSION,78268,"Zarubin, Vadim, MD",3/29/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/28/2023,Inactive,,
SOM OUTPT INFUSION,48564,"Patel, Eshan, MD",9/19/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,,9/18/2023,Inactive,,
SOM OUTPT INFUSION,48564,"Patel, Eshan, MD",9/25/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,,9/17/2023,Inactive,,
CBMC OP INFUSION 2FL,35469,"Brown, Andrew Bennett, MD",10/2/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/1/2023,Inactive,,
CBMC OP INFUSION 2FL,35469,"Brown, Andrew Bennett, MD",10/23/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Induction,10/22/2023,Inactive,,
CBMC OP INFUSION 2FL,35469,"Brown, Andrew Bennett, MD",11/13/2023,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,Neoadjuvant,11/12/2023,Active,,
CBMC OP INFUSION 2FL,35469,"Brown, Andrew Bennett, MD",3/4/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,2/26/2024,Active,,
CINJ OP INFUSION,90798,"Aikins, James K, MD",7/17/2024,CISplatin WEEKLY and Pembrolizumab q 21 days  With Concurrent Radiation - Cervical (ENGOT-cx11/GOG-3047/KEYNOTE-A18 study),_1. First Line,7/16/2024,Inactive,,
CINJ OP INFUSION,90798,"Aikins, James K, MD",10/17/2024,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,10/16/2024,Active,,
CINJ OP INFUSION,63936,"Girda, Eugenia, MD",10/14/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,10/6/2024,Active,,
NBR 5N ONCOLOGY,29285,"Matasar, Matthew J, MD",10/13/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,10/13/2023,Inactive,,
NBR 4N ONCOLOGY,29285,"Rhodes, Joanna Meehan, MD",11/10/2023,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,11/9/2023,Inactive,,
HAM OP INFUSION,30233,"Patel, Malini M, MD",10/21/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,10/14/2024,Active,,
MSC OP INFUSION,84008,"Meghal, Trishala, MD",3/22/2023,Abemaciclib 28 Day Cycles - Breast,,3/22/2023,Active,,
HAM OP INFUSION,47099,"Yogarajah, Meera, MD",6/30/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,First Line,6/19/2023,Inactive,,
HAM OP INFUSION,47099,"Yogarajah, Meera, MD",5/30/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_2. Second Line,5/20/2024,Active,,
HAM OP INFUSION,47099,"Yogarajah, Meera, MD",1/28/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/27/2025,Active,,
HAM OP INFUSION,47099,"Yogarajah, Meera, MD",2/13/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/27/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)
Encounter for antineoplastic chemotherapy",
CINJ OP INFUSION,81259,"Saraiya, Biren P, MD",1/13/2025,Enzalutamide  - Prostate,_1. First Line,1/13/2025,Active,,
CINJ OP INFUSION,95091,"Stephenson, Ruth D, DO",10/31/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Vaginal SCC,_1. First Line,10/29/2023,Inactive,,
CINJ PEDS HEMONC ,18893,"Cole, Peter David, MD",2/6/2023,AALL1731 All SR-Avg B-ALL - Consolidation,,2/3/2023,Inactive,,
CINJ PEDS HEMONC ,18893,"Cole, Peter David, MD",3/6/2023,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,,3/6/2023,Inactive,,
CINJ PEDS HEMONC ,18893,"Cole, Peter David, MD",5/3/2023,"AALL1731 SR-Fav B-ALL, SR-Avg Arm A & B B-ALL, and B-LLy (including DS patients) Delayed Intensification",,5/3/2023,Inactive,,
CINJ PEDS HEMONC ,18893,"Cole, Peter David, MD",7/20/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,,7/20/2023,Inactive,,
CINJ PEDS HEMONC ,18893,"Cole, Peter David, MD",9/19/2023,AALL1731 Non-DS SR (Fav or Avg) B-ALL - Maintenance,_1. First Line,9/17/2023,Active,,
CMC OP INFUSION,16784,"Pompa, Tiffany Ann, MD",4/25/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/24/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC 2W ONCOLOGY,66008,"Derosa, William T, DO",3/19/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_2. Second Line,3/18/2025,Inactive,"DLBCL (diffuse large B cell lymphoma) (CMS/HCC)
High grade B-cell lymphoma (CMS/HCC)","C83.30 - Diffuse large B-cell lymphoma, unspecified site; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
HAM OP INFUSION,32468,"Gendy, Mina, DO",10/15/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Induction,10/14/2024,Active,,
HAM OP INFUSION,32468,"Gendy, Mina, DO",5/2/2025,GDP (Gemcitabine / Dexamethasone / CISplatin) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/2/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; R59.1 - Generalized enlarged lymph nodes; K21.9 - Gastro-esophageal reflux disease without esophagitis; E78.5 - Hyperlipidemia, unspecified; Z96.653 - Presence of artificial knee joint, bilateral; Z79.899 - Other long term (current) drug therapy"
NBR CINJ OP INFUSION,27546,"Evens, Andrew M, DO",8/9/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,27546,"Evens, Andrew M, DO",8/9/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,8/9/2023,Inactive,,
NBR CINJ OP INFUSION,27546,"Evens, Andrew M, DO",8/9/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,27546,"Evens, Andrew M, DO",8/10/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,8/9/2023,Inactive,,
NBR CINJ OP INFUSION,27546,"Evens, Andrew M, DO",8/10/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,8/10/2023,Inactive,,
NBR CINJ OP INFUSION,27546,"Evens, Andrew M, DO",8/11/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,8/11/2023,Inactive,,
SOM OUTPT INFUSION,6797,"Patel, Eshan, MD",9/21/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,First Line,9/20/2023,Inactive,,
SOM OUTPT INFUSION,6797,"Patel, Eshan, MD",10/3/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,First Line,10/1/2023,Inactive,,
NBR 5N ONCOLOGY,6797,"Saraiya, Biren P, MD",8/23/2024,TI-CE (PACLitaxel / Ifosfamide) 14 Day Cycles - Germ Cell Tumors,_2. Second Line,8/23/2024,Inactive,,
CINJ OP INFUSION,78160,"Groisberg, Roman, MD",2/10/2025,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_1. First Line,2/5/2025,Inactive,Desmoplastic small round cell tumor (CMS/HCC),C49.9 - Desmoplastic small round cell tumor (CMS/HCC)
HAM OP INFUSION,96300,"Patel, Malini M, MD",4/8/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/8/2025,Active,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),
HAM OP INFUSION,96300,"Patel, Malini M, MD",3/18/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/18/2025,Inactive,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),"C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; D62 - Acute posthemorrhagic anemia; Z66 - Do not resuscitate; J91.0 - Malignant pleural effusion; K56.7 - Ileus, unspecified; E87.1 - Hypo-osmolality and hyponatremia; M48.54XA - Collapsed vertebra, not elsewhere classified, thoracic region, initial encounter for fracture; M48.04 - Spinal stenosis, thoracic region; G83.4 - Cauda equina syndrome; F10.20 - Alcohol dependence, uncomplicated; I71.21 - Aneurysm of the ascending aorta, without rupture; I10 - Essential (primary) hypertension; K76.0 - Fatty (change of) liver, not elsewhere classified; M48.56XA - Collapsed vertebra, not elsewhere classified, lumbar region, initial encounter for fracture; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; E86.0 - Dehydration; E86.1 - Hypovolemia; Z87.891 - Personal history of nicotine dependence; Z75.1 - Person awaiting admission to adequate facility elsewhere; D72.829 - Elevated white blood cell count, unspecified; Z78.1 - Physical restraint status; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,84145,"Boland, Patrick M, MD",1/30/2023,Pembrolizumab - HCC,,1/29/2023,Inactive,,
CBMC OP INFUSION 2FL,95854,"Brown, Andrew Bennett, MD",10/7/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,10/7/2024,Active,,
CBMC OP INFUSION 2FL,18538,"Brown, Andrew Bennett, MD",3/31/2025,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,_1. First Line,3/31/2025,Inactive,Malignant neoplasm of overlapping sites of tongue (CMS/HCC),"E83.52 - Hypercalcemia; Z66 - Do not resuscitate; C78.00 - Secondary malignant neoplasm of unspecified lung; D73.89 - Other diseases of spleen; E27.8 - Other specified disorders of adrenal gland; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; J90 - Pleural effusion, not elsewhere classified; C02.8 - Malignant neoplasm of overlapping sites of tongue; D50.9 - Iron deficiency anemia, unspecified; E03.9 - Hypothyroidism, unspecified; M87.9 - Osteonecrosis, unspecified; Z93.1 - Gastrostomy status; E83.39 - Other disorders of phosphorus metabolism; T45.AX5A - Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter; Z92.3 - Personal history of irradiation; Z92.21 - Personal history of antineoplastic chemotherapy; Z91.013 - Allergy to seafood; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z90.49 - Acquired absence of other specified parts of digestive tract; Z88.6 - Allergy status to analgesic agent; Z87.891 - Personal history of nicotine dependence; Z59.41 - Food insecurity; Z98.890 - Other specified postprocedural states"
CINJ OP INFUSION,7504,"Boland, Patrick M, MD",5/9/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/16/2023,Inactive,,
CINJ OP INFUSION,7504,"Boland, Patrick M, MD",3/15/2024,TAS-Ox; D1-5 & D15-19 / 28 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/8/2024,Inactive,,
CINJ OP INFUSION,59631,"George, Mridula A, MD",3/12/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/12/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; C50.912 - Malignant neoplasm of unspecified site of left female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.0 - Estrogen receptor positive status (ER+)
MMC OP VP INFUSION,48661,"Lee, Patrick C, MD",2/16/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,First Line,2/15/2023,Inactive,,
MMC OP VP INFUSION,48661,"Lee, Patrick C, MD",11/9/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,10/25/2023,Inactive,,
MMC OP INFUSION,48661,"Lee, Patrick C, MD",1/23/2024,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,_3. Third Line,1/23/2024,Inactive,,
CINJ OP INFUSION,48661,"Goel, Sanjay, MD",5/15/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_4. Fourth Line,4/23/2024,Inactive,,
TRMC TCCC OP INFUSION,40491,"Capo, Gerardo, MD",7/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/28/2024,Active,,
TRMC TCCC OP INFUSION,1179,"Capo, Gerardo, MD",4/23/2025,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/23/2025,Inactive,"Malignant neoplasm of colon (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
TRMC TCCC OP INFUSION,1179,"Capo, Gerardo, MD",3/25/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/25/2025,Inactive,"Malignant neoplasm of colon (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)","C18.4 - Malignant neoplasm of transverse colon; K63.3 - Ulcer of intestine; C16.2 - Malignant neoplasm of body of stomach; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K29.50 - Unspecified chronic gastritis without bleeding; K25.9 - Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation; Z90.49 - Acquired absence of other specified parts of digestive tract; Z98.0 - Intestinal bypass and anastomosis status; Z98.890 - Other specified postprocedural states; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; Z85.05 - Personal history of malignant neoplasm of liver; Z92.21 - Personal history of antineoplastic chemotherapy; Z91.018 - Allergy to other foods; Z79.52 - Long term (current) use of systemic steroids; Z79.899 - Other long term (current) drug therapy"
NBI OP INFUSION,12251,"Shah, Shailja S, MD",11/7/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/6/2023,Active,"Primary malignant neoplasm of overlapping sites of vulva (CMS/HCC)
Vulvar cancer (CMS/HCC)",
NBR CINJ OP INFUSION,88499,"Shah, Mansi R, MD",7/10/2023,"Venetoclax and Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma, per Bellini trial ",,7/9/2023,Inactive,,
NBR CINJ OP INFUSION,88499,"Shah, Mansi R, MD",1/18/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_6. Sixth Line,1/16/2024,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
NBR CINJ OP INFUSION,88499,"Patel, Vimal D, MD",3/18/2024,"Bortezomib D1, D8, D15, D22 Maintenance 35 Day Cycles- Multiple Myeloma",,3/17/2024,Inactive,,
NBR CINJ OP INFUSION,88499,"Shah, Mansi R, MD",5/8/2025,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_7. Seventh Line,5/8/2025,Active,Multiple myeloma in relapse (CMS/HCC),"C90.00 - Multiple myeloma, remission status unspecified (CMS/HCC); Z11.59 - Encounter for screening for other viral diseases; Z94.84 - Stem cells transplant status (CMS/HCC)"
CINJ OP INFUSION,95466,"Jang, Thomas L, MD",11/28/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,11/28/2023,Inactive,,
MMC OP INFUSION,65334,"Lee, Patrick C, MD",5/21/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/20/2024,Active,,
CINJ OP INFUSION,4354,"Berim, Lyudmyla, MD",5/24/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,5/12/2024,Inactive,,
CINJ OP INFUSION,4354,"Berim, Lyudmyla, MD",5/24/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/22/2024,Inactive,,
CBMC OP INFUSION 2FL,90932,"Litvak, Anna M, MD",2/13/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,2/12/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,57448,"Haigentz, Missak, MD",6/2/2023,BTCRC-LUN19-396 / CINJ 032007 CISplatin / PEMEtrexed / Atezolizumab 21 Day Cycles Research- Non-Squamous NSCLC,Adjuvant,6/1/2023,Active,,
MMC BBR2 ONCOLOGY,60558,"Lee, Patrick C, MD",7/11/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,7/10/2023,Inactive,,
MMC OP VP INFUSION,31850,"Cohen, Seth D, MD",7/31/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,7/30/2023,Inactive,,
MMC BBR2 ONCOLOGY,31850,"Cohen, Seth D, MD",7/31/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/25/2024,Active,,
MMC OP VP INFUSION,31850,"Cohen, Seth D, MD",7/31/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/28/2024,Active,,
CBMC OP INFUSION 2FL,59371,"Wagmiller, Jennifer Ann, MD",10/31/2023,Bortezomib / Dexamethasone 28 Day Cycles - Multiple Myeloma,,10/23/2023,Inactive,,
CBMC OP INFUSION 2FL,59371,"Wagmiller, Jennifer Ann, MD",11/7/2023,"Bortezomib D1, D8, D15, D22 Maintenance 35 Day Cycles- Multiple Myeloma",Maintenance,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,59371,"Wagmiller, Jennifer Ann, MD",7/2/2024,"Bendamustine D1, D8 / Bortezomib + Dexamethasone D1, D8, D15, D22 28 Day Cycles - Multiple Myeloma",_3. Third Line,7/1/2024,Inactive,,
CBMC OP INFUSION 2FL,59371,"Wagmiller, Jennifer Ann, MD",7/2/2024,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_4. Fourth Line,7/2/2024,Active,,
JCMC CP INFUSION,86861,"Sekhri, Arunabh, MD",7/17/2024,RiTUXimab 28 Day Cycle --- T-cell large granular lymphocyte leukemia,_2. Second Line,6/30/2024,Inactive,,
NBR 4N ONCOLOGY,86861,"Shah, Mansi R, MD",9/25/2024,Fractionated Cyclophosphamide - Lymphoma,_2. Second Line,9/24/2024,Inactive,,
CINJ OP INFUSION,27914,"Weiss, Sarah, MD",12/27/2023,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_2. Second Line,12/21/2023,Inactive,,
NBR CINJ OP INFUSION,17080,"Shah, Mansi R, MD",8/6/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,8/6/2024,Inactive,,
NBR CINJ OP INFUSION,17080,"Shah, Mansi R, MD",9/5/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,9/5/2024,Active,,
CINJ OP INFUSION,93403,"Gulhati, Prateek, MD PhD",6/15/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,6/15/2023,Inactive,,
NBR 4N ONCOLOGY,51209,"Berim, Lyudmyla, MD",7/17/2024,DOXOrubicin 21 Day Cycles - Sarcoma,_2. Second Line,7/16/2024,Inactive,,
CINJ OP INFUSION,51209,"Groisberg, Roman, MD",7/19/2024,Pembrolizumab 21 Day Cycles - Melanoma,Neoadjuvant,7/11/2024,Inactive,,
CINJ OP INFUSION,51209,"Groisberg, Roman, MD",11/22/2024,"DOCEtaxel D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_2. Second Line,11/21/2024,Inactive,,
NBI OP INFUSION,77166,"Jacoby, Sari H, MD",7/24/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,7/23/2024,Active,,
CINJ OP INFUSION,14203,"Dasgeb, Bahar, MD",1/14/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,1/13/2025,Active,,
CINJ OP INFUSION,6144,"Girda, Eugenia, MD",2/9/2023,CINJ 102101 (19-0380) Niraparib 28 Day Cycles Research- Uterine Cancer,,12/13/2022,Inactive,,
CINJ OP INFUSION,6144,"Girda, Eugenia, MD",1/15/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/15/2024,Active,,
CINJ OP INFUSION,59197,"Leiser, Aliza, MD",3/1/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/28/2024,Inactive,,
CINJ OP INFUSION,59197,"Leiser, Aliza, MD",3/1/2024,Letrozole 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/1/2024,Active,,
CINJ OP INFUSION,59197,"Leiser, Aliza, MD",3/26/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/8/2024,Inactive,,
MMC OP VP INFUSION,4639,"Lee, Patrick C, MD",1/18/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,9/20/2023,Inactive,,
MMC OP VP INFUSION,4639,"Lee, Patrick C, MD",1/25/2024,Pembrolizumab 42 Day Cycles - Melanoma,Adjuvant,1/17/2024,Inactive,,
NBR CINJ OP INFUSION,89684,"Evens, Andrew M, DO",9/27/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,9/27/2023,Inactive,,
NBR CINJ OP INFUSION,89684,"Evens, Andrew M, DO",11/29/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,11/28/2023,Inactive,,
NBI OP INFUSION,59701,"Anderson, Patrick S, MD",11/2/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/1/2023,Inactive,,
NBI OP INFUSION,25341,"Anderson, Patrick S, MD",11/2/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/1/2023,Inactive,,
NBI OP INFUSION,25341,"Anderson, Patrick S, MD",2/1/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,1/31/2024,Inactive,,
CBMC OP INFUSION 2FL,99607,"Wagmiller, Jennifer Ann, MD",5/26/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/25/2023,Inactive,,
CBMC OP INFUSION 2FL,99607,"Wagmiller, Jennifer Ann, MD",1/31/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,1/30/2024,Inactive,,
CBMC OP INFUSION 2FL,99607,"Wagmiller, Jennifer Ann, MD",3/28/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,3/27/2024,Inactive,,
MMC OP VP INFUSION,20300,"Lee, Patrick C, MD",10/9/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,Induction,10/1/2024,Active,,
CINJ OP INFUSION,51536,"Berim, Lyudmyla, MD",5/16/2025,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/7/2025,Active,Adenocarcinoma of esophagus (CMS/HCC),"C15.9 - Malignant neoplasm of esophagus, unspecified"
CINJ OP INFUSION,50834,"Boland, Patrick M, MD",4/24/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,,3/27/2023,Active,,
CINJ OP INFUSION,56815,"Gulhati, Prateek, MD PhD",1/14/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,1/11/2023,Inactive,,
CINJ OP INFUSION,93533,"Stephenson, Ruth D, DO",8/14/2023,CISplatin 21 Day Cycles - Cervical,First Line,8/13/2023,Inactive,,
CINJ OP INFUSION,93533,"Stephenson, Ruth D, DO",8/14/2023,CARBOplatin 28 Day Cycles - Cervical,First Line,8/13/2023,Inactive,,
CINJ OP INFUSION,93533,"Stephenson, Ruth D, DO",8/14/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,8/13/2023,Inactive,,
CINJ OP INFUSION,93533,"Stephenson, Ruth D, DO",8/14/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Cervical Cancer,First Line,8/13/2023,Inactive,,
CBMC OP INFUSION 1FL,36830,"Freeman, Benjamin B, MD",5/5/2025,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,5/2/2025,Inactive,Pemphigoid,"L12.0 - Bullous pemphigoid; G93.41 - Metabolic encephalopathy; F02.B11 - Dementia in other diseases classified elsewhere, moderate, with agitation; D53.9 - Nutritional anemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; F91.9 - Conduct disorder, unspecified; G20.A1 - Parkinson's disease without dyskinesia, without mention of fluctuations; J44.9 - Chronic obstructive pulmonary disease, unspecified; I48.0 - Paroxysmal atrial fibrillation; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; N31.9 - Neuromuscular dysfunction of bladder, unspecified; I95.9 - Hypotension, unspecified; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z63.9 - Problem related to primary support group, unspecified; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z87.440 - Personal history of urinary (tract) infections; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
HAM OP INFUSION,23193,"Yogarajah, Meera, MD",5/16/2023,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Second Line,5/15/2023,Inactive,,
HAM OP INFUSION,23193,"Yogarajah, Meera, MD",8/8/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,First Line,8/7/2023,Inactive,,
SOM OUTPT INFUSION,70806,"Yin, Faye, MD",4/3/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/2/2023,Inactive,,
SOM OUTPT INFUSION,70806,"Yin, Faye, MD",8/14/2023,Pembrolizumab 21 Day Cycles - Cervical,First Line,8/3/2023,Inactive,,
CINJ OP INFUSION,74958,"Haigentz, Missak, MD",11/21/2024,PACLitaxel/CARBOplatin PLUS Pembrtolizumab (starting in C2) - 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,_1. First Line,11/20/2024,Active,,
CINJ OP INFUSION,74958,"Haigentz, Missak, MD",2/17/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/16/2025,Active,"Malignant pericardial effusion
Malignant neoplasm of upper lobe of left lung (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; I31.31 - Malignant pericardial effusion in diseases classified elsewhere"
NBR 4N ONCOLOGY,9343,"Berim, Lyudmyla, MD",1/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/4/2024,Inactive,,
NBR 4N ONCOLOGY,9343,"Berim, Lyudmyla, MD",1/16/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,1/15/2024,Inactive,,
NBR 4N ONCOLOGY,27063,"Evens, Andrew M, DO",5/24/2023,Pentostatin every 2 weeks for 6 months T-Cell Lymphoma,,5/23/2023,Inactive,,
NBR CINJ OP INFUSION,27063,"Evens, Andrew M, DO",8/9/2023,RomiDEPsin 28 Day Cycles - Cutaneous T-Cell Lymphoma,,8/1/2023,Inactive,,
NBR CINJ OP INFUSION,73225,"Tiger, Yun Kyoung, MD",1/24/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/16/2025,Active,,
CMC OP INFUSION,47069,"Cohen, Seth D, MD",11/7/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/6/2024,Active,,
CBMC OP INFUSION 2FL,59551,"Leitner, Stuart P, MD",3/13/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,3/6/2024,Active,,
CBMC OP INFUSION 2FL,36945,"Litvak, Anna M, MD",1/10/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_5. Fifth Line,1/10/2024,Inactive,,
CBMC OP INFUSION 2FL,36945,"Litvak, Anna M, MD",9/24/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,9/17/2024,Active,,
CBMC OP INFUSION 2FL,83338,"Litvak, Anna M, MD",2/4/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_1. First Line,1/27/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC)
Secondary malignant neoplasm of liver and intrahepatic bile duct (CMS/HCC)",
CINJ OP INFUSION,83338,"Girda, Eugenia, MD",2/18/2025,CINJ 052404 Dose Escalation XL309 / Olaparib 28 Day Cycles Research- Advanced Solid Tumors,_7. Seventh Line,2/18/2025,Active,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),
CBMC OP INFUSION 2FL,23414,"Litvak, Anna M, MD",5/13/2025,Bevacizumab / PACLitaxel 28 Day Cycles - Breast,_4. Fourth Line,5/13/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC)
Secondary malignant neoplasm of liver and intrahepatic bile duct (CMS/HCC)",C79.51 - Secondary malignant neoplasm of bone; C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z17.0 - Estrogen receptor positive status (ER+)
TRMC TCCC OP INFUSION,23267,"Salerno, Vincent E, MD",7/22/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,7/22/2024,Active,,
SOM OUTPT INFUSION,68916,"Patel, Eshan, MD",5/31/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,5/21/2023,Inactive,,
CBMC OP INFUSION 2FL,72344,"Leitner, Stuart P, MD",6/10/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/9/2024,Inactive,,
NBR CINJ OP INFUSION,14323,"Assal, Amer, MD",3/2/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,2/29/2024,Inactive,,
CINJ OP INFUSION,67299,"George, Mridula A, MD",2/21/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,2/21/2024,Active,,
CINJ OP INFUSION,75718,"Haigentz, Missak, MD",2/13/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,First Line,2/12/2023,Inactive,,
CINJ OP INFUSION,75718,"Haigentz, Missak, MD",6/8/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Second Line,6/8/2023,Inactive,,
SOM OUTPT INFUSION,53233,"Toomey, Kathleen C, MD",3/26/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/26/2025,Active,Malignant neoplasm of lower lobe of right lung (CMS/HCC),"C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z51.89 - Encounter for other specified aftercare"
CINJ OP INFUSION,38989,"Goel, Sanjay, MD",11/4/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,11/4/2024,Active,,
CMC OP INFUSION,94477,"Easaw, Sarah, MD",5/5/2023,Daratumumab/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,Third Line,5/3/2023,Inactive,,
CMC OP INFUSION,94477,"Easaw, Sarah, MD",11/10/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/8/2023,Inactive,,
CMC OP INFUSION,94477,"Easaw, Sarah, MD",11/10/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/9/2023,Inactive,,
CMC OP INFUSION,94477,"Easaw, Sarah, MD",11/10/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,11/9/2023,Inactive,,
CMC OP INFUSION,94477,"Eltoukhy, Hussam, MD",2/12/2024,Ixazomib/Cyclophosphamide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,2/12/2024,Inactive,,
CMC OP INFUSION,94477,"Eltoukhy, Hussam, MD",7/16/2024,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,7/15/2024,Inactive,,
CMC OP INFUSION,94477,"Eltoukhy, Hussam, MD",8/9/2024,Talquetamab 28 Day Cycles,_6. Sixth Line,8/9/2024,Inactive,,
CMC OP INFUSION,94477,"Eltoukhy, Hussam, MD",8/21/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,8/20/2024,Inactive,,
CMC OP INFUSION,94477,"Eltoukhy, Hussam, MD",9/11/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,9/10/2024,Inactive,,
NBR 4N BMTU/IMCU,94477,"Tiger, Yun Kyoung, MD",9/11/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,9/11/2024,Active,,
CINJ OP INFUSION,69049,"Saraiya, Biren P, MD",5/30/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,5/30/2024,Inactive,,
CINJ OP INFUSION,69049,"Saraiya, Biren P, MD",10/22/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,10/7/2024,Inactive,,
CINJ OP INFUSION,69049,"Saraiya, Biren P, MD",10/29/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,10/27/2024,Active,,
CINJ OP INFUSION,69049,"Saraiya, Biren P, MD",2/28/2025,"PACLitaxel 80 mg/m2 D1, D8, D15 28 Day Cycles- Small Cell Lung Cancer",_3. Third Line,2/23/2025,Active,Malignant small cell cancer (CMS/HCC),"C7A.1 - Malignant poorly differentiated neuroendocrine tumors; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; E87.1 - Hypo-osmolality and hyponatremia; C61 - Malignant neoplasm of prostate; D64.9 - Anemia, unspecified; M25.50 - Pain in unspecified joint; I82.402 - Acute embolism and thrombosis of unspecified deep veins of left lower extremity; C80.1 - Malignant (primary) neoplasm, unspecified"
NBI OP INFUSION,36809,"Cheng, Yan Ho, MD",1/20/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,1/20/2025,Active,,
NBI OP INFUSION,5089,"Shah, Shailja S, MD",10/10/2023,DOCEtaxel / Trastuzumab 21 Day Cycles - Breast,Adjuvant,9/28/2023,Inactive,,
NBI OP INFUSION,5089,"Shah, Shailja S, MD",10/10/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/28/2023,Inactive,,
NBI OP INFUSION,5089,"Shah, Shailja S, MD",9/16/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,9/16/2024,Active,,
SOM OUTPT INFUSION,10308,"Toomey, Kathleen C, MD",12/12/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,12/11/2024,Active,,
NBI VALERIE FND HEMONC,17759,"Batra, Surabhi, MD",2/24/2025,AALL1732 Consolidation,_1. First Line,2/21/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
NBI VALERIE FND HEMONC,17759,"Batra, Surabhi, MD",4/29/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,4/29/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
NBI VALERIE FND HEMONC,17759,"Batra, Surabhi, MD",3/14/2025,PEDS Asparaginase Erwinia (Rylaze),_1. First Line,3/14/2025,Active,ALL (acute lymphoid leukemia) in remission (CMS/HCC),
NBI A5 PEDIATRICS,60075,"Narang, Shalu, MD",1/17/2025,AALL1732 Induction,_1. First Line,1/16/2025,Active,,
CBMC OP INFUSION 2FL,95213,"Radovich, Delia, MD",11/1/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,10/31/2023,Inactive,,
CBMC OP INFUSION 2FL,95213,"Radovich, Delia, MD",11/1/2023,Gemzar for gallbladder,_1. First Line,10/31/2023,Inactive,,
CBMC OP INFUSION 2FL,95213,"Radovich, Delia, MD",11/13/2023,Gemcitabine / OXALIplatin 28 Day Cycles - Prostate,_2. Second Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,95213,"Radovich, Delia, MD",11/13/2023,Gemcitabine / OXALIplatin / Durvalumab for gallbladder cancer,_2. Second Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,95213,"Radovich, Delia, MD",11/22/2023,"Durvalumab, Gemzar, oxaliplatin every 2 weeks",_1. First Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,95213,"Radovich, Delia, MD",10/2/2024,Gemcitabine / OXALIplatin 28 Day Cycles - Prostate,_1. First Line,10/1/2024,Inactive,,
CBMC OP INFUSION 2FL,95213,"Dharmapuri, Sirish, MD",10/22/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - BTC,_2. Second Line,10/13/2024,Active,,
CBMC OP INFUSION 2FL,4843,"Dharmapuri, Sirish, MD",9/3/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,9/2/2024,Active,,
CBMC OP INFUSION 2FL,4843,"Dharmapuri, Sirish, MD",4/25/2025,Dostarlimab-gxly  42 Day Cycles- ANAL Cancer,_3. Third Line,4/25/2025,Active,Anal squamous cell carcinoma (CMS/HCC),C21.0 - Anal squamous cell carcinoma (CMS/HCC)
CBMC OP INFUSION 2FL,4843,"Dharmapuri, Sirish, MD",3/10/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",_2. Second Line,3/10/2025,Inactive,Anal squamous cell carcinoma (CMS/HCC),
NBR BMSCH 2 PED HEMONC,31462,"Sharma, Archana, DO",5/15/2025,as per AALL1731 Non-DS SR B-ALL Induction (Not on Study),_1. First Line,5/15/2025,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.818 - Other pancytopenia; F41.9 - Anxiety disorder, unspecified; I10 - Essential (primary) hypertension; K59.00 - Constipation, unspecified; Z80.0 - Family history of malignant neoplasm of digestive organs; Z83.3 - Family history of diabetes mellitus; Z91.89 - Other specified personal risk factors, not elsewhere classified; B97.89 - Other viral agents as the cause of diseases classified elsewhere; B97.10 - Unspecified enterovirus as the cause of diseases classified elsewhere; R73.9 - Hyperglycemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; E55.9 - Vitamin D deficiency, unspecified; R74.01 - Elevation of levels of liver transaminase levels"
CINJ OP INFUSION,16806,"Gulhati, Prateek, MD PhD",2/13/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,1/15/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),
CINJ OP INFUSION,84558,"Stephenson, Ruth D, DO",1/11/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Second Line,1/10/2023,Inactive,,
MMC OP INFUSION,388,"Lee, Patrick C, MD",3/31/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,3/31/2025,Inactive,"Myelodysplasia, high grade (CMS/HCC)",
CBMC OP INFUSION 2FL,20060,"Kulkarni, Aditya A, MD",12/6/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,12/6/2024,Active,,
NBR CINJ OP INFUSION,16459,"Tiger, Yun Kyoung, MD",3/27/2024,Mosunetuzumab-axgb 21 Day Cycles - Follicular Lymphoma,_1. First Line,3/21/2024,Active,,
CINJ OP INFUSION,47822,"Mayer, Tina M, MD",5/12/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,5/12/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone
CINJ OP INFUSION,3009,"Stephenson, Ruth D, DO",10/25/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,10/22/2024,Active,,
CINJ OP INFUSION,46359,"Leiser, Aliza, MD",6/20/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,6/19/2023,Inactive,,
CINJ OP INFUSION,46359,"Leiser, Aliza, MD",1/29/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/28/2024,Inactive,,
CINJ OP INFUSION,46359,"Leiser, Aliza, MD",6/18/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,6/17/2024,Inactive,,
CINJ OP INFUSION,46359,"Leiser, Aliza, MD",12/6/2024,CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,11/28/2024,Active,,
NBI A5 PEDIATRICS,89713,"Rao, Harini, MD",12/31/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,12/31/2024,Active,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,80027,"Gulhati, Prateek, MD PhD",6/1/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/31/2023,Inactive,,
MMC OP VP INFUSION,74683,"Meghal, Trishala, MD",11/4/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/28/2024,Active,,
HAM OP INFUSION,97323,"Patel, Malini M, MD",8/17/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,8/16/2023,Inactive,,
CMC OP INFUSION,63730,"Tang, Horace, MD",6/27/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,6/26/2023,Inactive,,
CMC OP INFUSION,63730,"Talwar, Sumit, MD",11/16/2023,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,11/16/2023,Active,,
CBMC OP INFUSION 2FL,2947,"Brown, Andrew Bennett, MD",12/2/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,12/1/2024,Active,,
CBMC OP INFUSION 2FL,86402,"Wagmiller, Jennifer Ann, MD",11/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,86402,"Wagmiller, Jennifer Ann, MD",8/20/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_5. Fifth Line,8/19/2024,Active,,
CBMC 2W ONCOLOGY,86402,"Wagmiller, Jennifer Ann, MD",2/28/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_5. Fifth Line,2/27/2025,Active,Secondary malignant neoplasm of liver and intrahepatic bile duct (CMS/HCC),"R33.9 - Urinary retention; N17.9 - AKI (acute kidney injury) (CMS/HCC); R31.9 - Hematuria, unspecified type"
CBMC OP INFUSION 2FL,38711,"Wagmiller, Jennifer Ann, MD",4/29/2025,VinORELBine 21 Day Cycles - Breast,_4. Fourth Line,4/29/2025,Inactive,"Secondary malignant neoplasm of liver and intrahepatic bile duct (CMS/HCC)
Breast cancer metastasized to multiple sites (CMS/HCC)",
JCMC CP INFUSION,14699,"Sekhri, Arunabh, MD",3/21/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,3/12/2024,Inactive,,
CINJ PEDS HEMONC ,41600,"Botwinick, Marissa, DO",7/18/2023,PEDS ANHL1131 Group B ,Induction,7/18/2023,Inactive,,
NBR 5N MED-SURG OVRF,9725,"Alexander, Henry Richard, MD",8/5/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,8/5/2024,Active,,
MMC OP VP INFUSION,90722,"Meghal, Trishala, MD",9/18/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,9/18/2024,Active,,
MMC OP VP INFUSION,90722,"Meghal, Trishala, MD",10/18/2024,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,10/18/2024,Active,,
CINJ OP INFUSION,24566,"Toppmeyer, Deborah L, MD",4/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Third Line,3/30/2023,Inactive,,
MSC OP INFUSION,55227,"Eltoukhy, Hussam, MD",6/17/2024,RiTUXimab 28 Day Cycle,Non-Oncology Research,6/13/2024,Active,Malignant neoplasm of nasal cavity (CMS/HCC),
CINJ OP INFUSION,24231,"Patankar, Sonali, MD",5/21/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/19/2024,Active,,
CINJ OP INFUSION,24231,"Patankar, Sonali, MD",3/28/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_2. Second Line,3/28/2025,Inactive,Carcinosarcoma of uterus (CMS/HCC),"C55 - Malignant neoplasm of uterus, part unspecified; R92.8 - Other abnormal and inconclusive findings on diagnostic imaging of breast; N60.02 - Solitary cyst of left breast; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; G62.9 - Polyneuropathy, unspecified"
HAM OP INFUSION,31681,"Yogarajah, Meera, MD",6/22/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,6/7/2023,Inactive,,
CBMC OP INFUSION 2FL,41459,"Brown, Andrew Bennett, MD",9/25/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,9/24/2023,Inactive,,
CBMC OP INFUSION 2FL,41459,"Brown, Andrew Bennett, MD",1/8/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/8/2024,Inactive,,
NBR CINJ OP INFUSION,46061,"Evens, Andrew M, DO",5/7/2025,(DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/7/2025,Inactive,Mixed cellularity Hodgkin lymphoma (CMS/HCC),"C81.20 - Mixed cellularity Hodgkin lymphoma, unspecified site; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; Z86.79 - Personal history of other diseases of the circulatory system"
NBR CINJ OP INFUSION,46061,"Evens, Andrew M, DO",5/7/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/7/2025,Inactive,Mixed cellularity Hodgkin lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,46061,"Evens, Andrew M, DO",5/7/2025,Nivo- AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/24/2025,Active,"Mixed cellularity Hodgkin lymphoma (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)",
CBMC OP INFUSION 2FL,69892,"Dharmapuri, Sirish, MD",12/17/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/1/2024,Active,,
CBMC OP INFUSION 2FL,52772,"Wagmiller, Jennifer Ann, MD",6/8/2023,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,Adjuvant,6/8/2023,Inactive,,
CBMC OP INFUSION 2FL,52772,"Wagmiller, Jennifer Ann, MD",11/20/2023,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,Adjuvant,11/19/2023,Inactive,,
CBMC OP INFUSION 2FL,52772,"Wagmiller, Jennifer Ann, MD",11/20/2023,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,11/19/2023,Active,,
JCMC CP INFUSION,1670,"Sekhri, Arunabh, MD",5/14/2025,Marginal zone B-cell lymphoma - Rituxan and Bendeka 28-day cycle for 6 cycles,_1. First Line,5/13/2025,Active,Marginal zone B-cell lymphoma (CMS/HCC),"C85.80 - Other specified types of non-hodgkin lymphoma, unspecified site; E78.5 - Hyperlipidemia, unspecified; I10 - Essential (primary) hypertension; R45.89 - Other symptoms and signs involving emotional state"
JCMC CP INFUSION,1670,"Sekhri, Arunabh, MD",4/23/2025,RiTUXimab 28 Day Cycle -continues on lymphoma,_1. First Line,4/23/2025,Inactive,Marginal zone B-cell lymphoma (CMS/HCC),"Z00.00 - Encounter for general adult medical examination without abnormal findings; E78.2 - Mixed hyperlipidemia; I10 - Essential (primary) hypertension; H40.9 - Unspecified glaucoma; C85.80 - Other specified types of non-hodgkin lymphoma, unspecified site; D12.6 - Benign neoplasm of colon, unspecified; E78.5 - Hyperlipidemia, unspecified; Z13.1 - Encounter for screening for diabetes mellitus; Z23 - Encounter for immunization"
CBMC OP INFUSION 2FL,98932,"Raptis, George, MD",4/2/2024,Pertuzumab / Trastuzumab / Eribulin 21 Day Cycles - Breast,_1. First Line,4/1/2024,Inactive,,
CBMC OP INFUSION 2FL,98932,"Raptis, George, MD",4/2/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,4/1/2024,Inactive,,
CBMC OP INFUSION 2FL,98932,"Raptis, George, MD",4/2/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,Adjuvant,4/1/2024,Inactive,,
CBMC OP INFUSION 2FL,98932,"Raptis, George, MD",4/25/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/16/2024,Inactive,,
CBMC OP INFUSION 2FL,98932,"Raptis, George, MD",8/6/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,8/6/2024,Inactive,,
CINJ OP INFUSION,98932,"George, Mridula A, MD",1/31/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,1/28/2025,Active,,
CINJ OP INFUSION,92690,"George, Mridula A, MD",3/3/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,3/3/2025,Active,"Breast cancer, stage 4, left (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
TRMC TCCC OP INFUSION,4910,"Salerno, Vincent E, MD",9/5/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Thoracic Cancers",_2. Second Line,9/4/2024,Active,,
NBR CINJ OP INFUSION,48895,"Zayac, Adam, MD",6/10/2024,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),_1. First Line,6/6/2024,Inactive,,
NBR CINJ OP INFUSION,48895,"Zayac, Adam, MD",7/22/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,7/22/2024,Inactive,,
NBR CINJ OP INFUSION,48895,"Zayac, Adam, MD",7/29/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,7/29/2024,Inactive,,
CBMC OP INFUSION 1FL,30245,"Meelheim, Brooke A, DO",2/24/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,2/23/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
CBMC OP INFUSION 1FL,32725,"Meelheim, Brooke A, DO",3/24/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,2/24/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
CINJ OP INFUSION,74283,"Groisberg, Roman, MD",8/26/2024,Pexidartinib 28 Day Cycles - Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor,_1. First Line,8/26/2024,Active,,
CINJ OP INFUSION,79706,"Weiss, Sarah, MD",5/13/2024,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,5/13/2024,Inactive,,
CMC OP INFUSION,87713,"Tang, Horace, MD",8/21/2023,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,,8/20/2023,Inactive,,
JCMC CP INFUSION,83894,"Sekhri, Arunabh, MD",1/6/2025,Pembrolizumab / Axitinib 21 Day Cycles - alveolar part sarcoma,_1. First Line,1/5/2025,Active,,
JCMC CP INFUSION,83894,"Sekhri, Arunabh, MD",3/7/2025,Pembrolizumab / Axitinib 21 Day Cycles - alveolar part sarcoma,_1. First Line,1/6/2025,Inactive,Alveolar soft part sarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; E78.2 - Mixed hyperlipidemia; B20 - Human immunodeficiency virus (HIV) disease; G44.229 - Chronic tension-type headache, not intractable; M79.89 - Other specified soft tissue disorders; Z92.21 - Personal history of antineoplastic chemotherapy; Z72.0 - Tobacco use"
CINJ OP INFUSION,1908,"Boland, Patrick M, MD",6/4/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,5/31/2024,Inactive,,
CINJ OP INFUSION,1908,"Boland, Patrick M, MD",12/31/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,12/30/2024,Active,,
CMC OP INFUSION,93853,"Talwar, Sumit, MD",10/4/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,10/2/2023,Inactive,,
CINJ OP INFUSION,57834,"Ghodoussipour, Saum Bobak, MD",10/3/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,10/3/2023,Active,,
HAM OP INFUSION,91886,"Patel, Malini M, MD",5/7/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_2. Second Line,5/7/2025,Active,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C64.1 - Malignant neoplasm of right kidney, except renal pelvis; C79.71 - Secondary malignant neoplasm of right adrenal gland; I10 - Essential (primary) hypertension; F41.9 - Anxiety disorder, unspecified; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z90.5 - Acquired absence of kidney; Z88.6 - Allergy status to analgesic agent; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z88.0 - Allergy status to penicillin; Z79.02 - Long term (current) use of antithrombotics/antiplatelets; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,46673,"Brown, Andrew Bennett, MD",1/16/2024,PACLitaxel / CARBOplatin/ Pembrolizumab 21 Day Cycles - Thymic Carcinoma,_1. First Line,1/15/2024,Active,,
CBMC OP INFUSION 2FL,89246,"Brown, Andrew Bennett, MD",7/12/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,7/11/2023,Inactive,,
CBMC OP INFUSION 2FL,89246,"Brown, Andrew Bennett, MD",11/17/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/16/2023,Active,,
SOM OUTPT INFUSION,73332,"George, Roshini, DO",5/5/2025,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",_1. First Line,5/5/2025,Inactive,Adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,6914,"Wagmiller, Jennifer Ann, MD",2/5/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/8/2025,Active,"Ovarian cancer, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,31390,"Raptis, George, MD",4/11/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,4/11/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,12592,"Sekhri, Arunabh, MD",5/30/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,5/21/2023,Inactive,,
MMC OP VP INFUSION,18652,"Cohen, Seth D, MD",10/28/2024,Dabrafenib/Trametinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/28/2024,Active,,
MMC OP INFUSION,55760,"Lee, Patrick C, MD",4/16/2024,EriBULin 21 Day Cycles - Breast,_2. Second Line,4/15/2024,Inactive,,
MMC OP INFUSION,55760,"Lee, Patrick C, MD",7/9/2024,VinORELBine 21 Day Cycles - Breast,_1. First Line,4/29/2024,Active,"Low grade B-cell lymphoma (CMS/HCC)
Need for hepatitis B screening test",
HAM OP INFUSION,16642,"Yogarajah, Meera, MD",4/28/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/28/2025,Active,Metastasis from pancreatic cancer (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C78.4 - Secondary malignant neoplasm of small intestine; N28.89 - Other specified disorders of kidney and ureter; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; E78.5 - Hyperlipidemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; F41.9 - Anxiety disorder, unspecified; F32.A - Depression, unspecified; M19.90 - Unspecified osteoarthritis, unspecified site; Z87.891 - Personal history of nicotine dependence; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,73940,"Weiss, Sarah, MD",11/29/2023,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,11/28/2023,Inactive,,
CINJ OP INFUSION,73940,"Weiss, Sarah, MD",3/25/2024,CINJ 092302 Cohort 1 Propranolol + Nivolumab (1 mg/kg) / Ipilumumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research- Melanoma,_2. Second Line,3/22/2024,Active,,
CINJ OP INFUSION,9835,"Hochster, Howard S, MD",5/25/2023,Capecitabine/Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,First Line,5/25/2023,Inactive,,
CINJ OP INFUSION,9835,"Hochster, Howard S, MD",8/15/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,8/14/2024,Inactive,,
CINJ OP INFUSION,9835,"Hochster, Howard S, MD",10/30/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,10/29/2024,Active,,
MMC OP VP INFUSION,52325,"Lee, Patrick C, MD",2/27/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,First Line,2/26/2023,Inactive,,
MMC BBR2 ONCOLOGY,52325,"Lee, Patrick C, MD",11/14/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,11/5/2023,Active,Laryngeal squamous cell carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,53988,"Wagmiller, Jennifer Ann, MD",1/4/2024,DOXOrubicin 21 Day Cycles - Uterine Sarcoma,_1. First Line,12/13/2023,Inactive,,
CBMC OP INFUSION 2FL,53988,"Wagmiller, Jennifer Ann, MD",9/19/2024,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_1. First Line,9/15/2024,Inactive,,
CBMC OP INFUSION 2FL,53988,"Wagmiller, Jennifer Ann, MD",9/20/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_1. First Line,9/19/2024,Inactive,,
NBI OP INFUSION,86769,"Jacoby, Sari H, MD",3/12/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/12/2025,Active,Lung cancer (CMS/HCC),Z72.0 - Tobacco abuse; C34.31 - Malignant neoplasm of lower lobe of right lung (CMS/HCC)
NBI OP INFUSION,60668,"Jacoby, Sari H, MD",8/21/2023,Obinutuzumab 28 Day Cycles/Acalabrutinib - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,8/20/2023,Active,,
NBI OP INFUSION,34908,"Schleicher, Lori, MD",10/19/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/18/2023,Active,,
SOM OUTPT INFUSION,75206,"Patel, Eshan, MD",1/31/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,1/22/2023,Inactive,,
CINJ OP INFUSION,96091,"Haigentz, Missak, MD",6/5/2023,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,Second Line,6/4/2023,Inactive,,
CINJ OP INFUSION,96091,"Haigentz, Missak, MD",6/5/2023,"Paclitaxel D1, D8, D15 with Cetuximab weekly, 28 Day Cycles- Head and Neck Cancers",Second Line,6/5/2023,Inactive,,
CINJ OP INFUSION,96091,"Haigentz, Missak, MD",11/27/2023,Cetuximab Maintenance 14 Day Cycles- Head and Neck Cancers,_2. Second Line,11/27/2023,Inactive,,
CINJ OP INFUSION,92842,"Weiss, Sarah, MD",4/21/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,4/21/2025,Inactive,Squamous cell carcinoma of preauricular region,"C44.329 - Squamous cell carcinoma of skin of other parts of face; C44.99 - Other specified malignant neoplasm of skin, unspecified"
CINJ OP INFUSION,92842,"Weiss, Sarah, MD",4/21/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,4/21/2025,Inactive,Squamous cell carcinoma of preauricular region,
CINJ OP INFUSION,92842,"Weiss, Sarah, MD",4/21/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,4/21/2025,Active,Squamous cell carcinoma of preauricular region,
NBR 4N BMTU/IMCU,58717,"Assal, Amer, MD",12/22/2023,BMT Autologous BEAM,_2. Second Line,12/21/2023,Inactive,,
HAM OP INFUSION,63451,"Yogarajah, Meera, MD",6/10/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,6/10/2024,Inactive,,
HAM OP INFUSION,63451,"Yogarajah, Meera, MD",8/15/2024,Temozolomide 28 Day Cycles - CNS,_1. First Line,8/15/2024,Active,"Gallbladder cancer (CMS/HCC)
Hypothyroidism, unspecified type
Malignant neoplasm of head of pancreas (CMS/HCC)
End stage renal disease (CMS/HCC)",
CBMC OP INFUSION 2FL,51711,"Scoppetuolo, Michael, MD",2/22/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/21/2023,Active,,
MMC OP VP INFUSION,55949,"Cohen, Seth D, MD",6/17/2024,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/17/2024,Active,,
CBMC OP INFUSION 2FL,55514,"Grossman, I Robert, MD",2/25/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,2/16/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,35379,"Scoppetuolo, Michael, MD",12/15/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/14/2023,Inactive,,
HAM OP INFUSION,72671,"Yogarajah, Meera, MD",5/20/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/3/2024,Active,,
HAM OP INFUSION,72671,"Yogarajah, Meera, MD",5/20/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/19/2024,Inactive,,
MMC OP VP INFUSION,27835,"Cohen, Seth D, MD",10/18/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,10/10/2023,Inactive,,
MMC OP VP INFUSION,27835,"Cohen, Seth D, MD",1/31/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/30/2024,Inactive,,
CINJ OP INFUSION,17082,"Patel, Eshan, MD",6/10/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_2. Second Line,6/9/2024,Active,,
NBI OP INFUSION,71917,"Shah, Maya M, MD",1/31/2024,Ibrutinib 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,1/31/2024,Inactive,,
NBI OP INFUSION,71917,"Shah, Maya M, MD",1/31/2024,Ibrutinib 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,1/31/2024,Active,,
MMC OP VP INFUSION,52342,"Cohen, Seth D, MD",7/2/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,6/17/2024,Active,"Infiltrating ductal carcinoma (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,53228,"Litvak, Anna M, MD",4/1/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,4/1/2025,Active,Breast cancer metastasized to bone (CMS/HCC),
MMC OP INFUSION,30376,"Lee, Patrick C, MD",5/9/2023,Enzalutamide 28 Day Cycles - Prostate,,5/9/2023,Inactive,,
MMC OP INFUSION,30376,"Lee, Patrick C, MD",8/29/2023,DOCEtaxel 21 Day Cycles - Prostate,Maintenance,8/28/2023,Inactive,,
MMC OP INFUSION,30376,"Lee, Patrick C, MD",8/29/2023,Enzalutamide 28 Day Cycles - Prostate,,8/29/2023,Active,,
MMC OP INFUSION,33215,"Lee, Patrick C, MD",2/11/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_4. Fourth Line,2/11/2025,Active,Carcinoma of prostate (CMS/HCC),
HAM OP INFUSION,13614,"Yogarajah, Meera, MD",5/1/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/29/2025,Active,Malignant neoplasm of right ovary (CMS/HCC),
SOM OUTPT INFUSION,397,"Patel, Eshan, MD",4/9/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/7/2024,Inactive,,
CINJ OP INFUSION,29953,"Boland, Patrick M, MD",4/2/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,3/29/2024,Inactive,,
CINJ OP INFUSION,29953,"Boland, Patrick M, MD",8/20/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,8/12/2024,Inactive,,
CINJ OP INFUSION,29953,"Boland, Patrick M, MD",8/20/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,8/19/2024,Inactive,,
CINJ OP INFUSION,29953,"Boland, Patrick M, MD",8/20/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,8/19/2024,Active,,
NBR CINJ OP INFUSION,32146,"Berim, Lyudmyla, MD",2/1/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/31/2024,Inactive,,
NBR CINJ OP INFUSION,22817,"Rhodes, Joanna Meehan, MD",5/22/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/22/2025,Inactive,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),
NBR CINJ OP INFUSION,22817,"Rhodes, Joanna Meehan, MD",5/22/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/22/2025,Active,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),C83.398 - Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC)
NBR CINJ OP INFUSION,22817,"Rhodes, Joanna Meehan, MD",5/14/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,5/14/2025,Inactive,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),
CINJ OP INFUSION,3346,"Boland, Patrick M, MD",7/7/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,,7/6/2023,Active,,
CINJ OP INFUSION,27070,"Haigentz, Missak, MD",5/15/2024,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/15/2024,Inactive,,
HAM OP INFUSION,47829,"Yogarajah, Meera, MD",4/6/2023,Albumin-Bound PACLitaxel/CARBOplatin 21 Day Cycles- uterine carcinosarcoma,First Line,4/5/2023,Inactive,,
CMC OP INFUSION,27692,"Talwar, Sumit, MD",12/18/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,Adjuvant,12/17/2024,Active,,
CMC OP INFUSION,27692,"Talwar, Sumit, MD",1/8/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,Adjuvant,12/17/2024,Active,,
CMC OP INFUSION,68339,"Talwar, Sumit, MD",4/23/2025,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,Consolidation,4/23/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
CBMC 2W ONCOLOGY,46864,"McKenna, Marshall, MD",1/10/2025,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_1. First Line,1/9/2025,Inactive,CNS lymphoma,
CBMC 2W ONCOLOGY,46864,"McKenna, Marshall, MD",1/14/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,1/14/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),
CBMC 2W ONCOLOGY,46864,"McKenna, Marshall, MD",1/24/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,1/23/2025,Active,,
CBMC 2W ONCOLOGY,46864,"McKenna, Marshall, MD",2/3/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,2/2/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C83.390 - Primary central nervous system lymphoma; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; D47.2 - Monoclonal gammopathy; K21.9 - Gastro-esophageal reflux disease without esophagitis; F43.12 - Post-traumatic stress disorder, chronic; J45.20 - Mild intermittent asthma, uncomplicated; I10 - Essential (primary) hypertension; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; Z79.899 - Other long term (current) drug therapy; Z90.89 - Acquired absence of other organs; Z98.890 - Other specified postprocedural states; Z85.46 - Personal history of malignant neoplasm of prostate; Z85.828 - Personal history of other malignant neoplasm of skin; Z85.59 - Personal history of malignant neoplasm of other urinary tract organ; Z86.16 - Personal history of COVID-19"
CBMC OP INFUSION 2FL,46864,"McKenna, Marshall, MD",4/8/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,4/4/2025,Inactive,Diffuse large B-cell lymphoma of central nervous system (CMS/HCC),C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; D47.2 - Monoclonal gammopathy; C83.390 - Primary central nervous system lymphoma
CBMC OP INFUSION 1FL,84085,"Meelheim, Brooke A, DO",12/6/2024,Pembrolizumab / PACLitaxel 135 mg/m2/ CARBOplatin AUC5 q 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/12/2024,Inactive,,
SOM OUTPT INFUSION,23766,"Toomey, Kathleen C, MD",10/14/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/14/2024,Active,,
CINJ OP INFUSION,72111,"Saraiya, Biren P, MD",3/31/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Induction,3/30/2023,Inactive,,
CMC OP INFUSION,72111,"Taff, Jessica, MD",2/5/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,2/5/2024,Active,,
HAM OP INFUSION,80100,"Gendy, Mina, DO",1/9/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,1/8/2025,Active,,
CMC OP INFUSION,11608,"Taff, Jessica, MD",3/11/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,3/3/2024,Inactive,,
CMC 4B ONCOLOGY,11608,"Taff, Jessica, MD",4/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/3/2024,Inactive,,
NBR 5N ONCOLOGY,48832,"Rhodes, Joanna Meehan, MD",12/15/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,12/15/2023,Inactive,,
NBR CINJ OP INFUSION,48832,"Rhodes, Joanna Meehan, MD",7/22/2024,RiTUXimab 168 Day Cycles - Indolent Lymphoma Maintenance,_1. First Line,7/21/2024,Inactive,,
NBR CINJ OP INFUSION,48832,"Rhodes, Joanna Meehan, MD",7/22/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,7/21/2024,Active,Malignant neoplasm of left ovary (CMS/HCC),
CINJ OP INFUSION,48517,"Leiser, Aliza, MD",4/17/2023,CISplatin 21 Day Cycles - Uterine,,4/13/2023,Inactive,,
CINJ OP INFUSION,48517,"Leiser, Aliza, MD",6/28/2023,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Third Line,6/26/2023,Inactive,,
CINJ OP INFUSION,48517,"Leiser, Aliza, MD",7/22/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,7/21/2024,Active,,
CMC OP INFUSION,91862,"Pompa, Tiffany Ann, MD",10/23/2024,Pemetrexed / CARBOplatin (AUC 6) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/15/2024,Inactive,,
CMC OP INFUSION,91862,"Pompa, Tiffany Ann, MD",10/23/2024,Pemetrexed / CARBOplatin (AUC 6) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/15/2024,Inactive,,
CMC OP INFUSION,91862,"Pompa, Tiffany Ann, MD",5/20/2025,Pemetrexed / CARBOplatin (AUC 5) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,5/20/2025,Active,"Malignant neoplasm of unspecified part of unspecified bronchus or lung (CMS/HCC)
Squamous cell carcinoma of lung, stage IV (CMS/HCC)",
MMC OP VP INFUSION,16608,"Lee, Patrick C, MD",3/23/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,3/22/2023,Inactive,,
CMC OP INFUSION,64796,"Pompa, Tiffany Ann, MD",4/15/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,Neoadjuvant,4/15/2025,Active,Cervical cancer (CMS/HCC),
CINJ OP INFUSION,64796,"Stephenson, Ruth D, DO",3/26/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/26/2025,Inactive,Cervical cancer (CMS/HCC),"C53.9 - Malignant neoplasm of cervix uteri, unspecified; C71.3 - Malignant neoplasm of parietal lobe"
NBR 5N ONCOLOGY,57269,"Rhodes, Joanna Meehan, MD",8/28/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,8/28/2024,Inactive,,
NBR 5N ONCOLOGY,57269,"Zayac, Adam, MD",9/3/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/2/2024,Inactive,,
CMC OP INFUSION,57269,"Eltoukhy, Hussam, MD",9/20/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/19/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR 5N ONCOLOGY,57269,"Palmisiano, Neil David, MD",9/20/2024,CINJ 022305 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,Induction,9/19/2024,Inactive,,
CINJ OP INFUSION,57718,"Boland, Patrick M, MD",3/28/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,3/28/2025,Active,Adenocarcinoma of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas; K86.89 - Other specified diseases of pancreas
MMC OP VP INFUSION,64259,"Meghal, Trishala, MD",3/27/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/26/2024,Inactive,,
MMC OP VP INFUSION,64259,"Meghal, Trishala, MD",7/10/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Neoadjuvant,7/9/2024,Active,"Mesothelioma, malignant (CMS/HCC)",
MSC OP INFUSION,6054,"Cohen, Seth D, MD",7/25/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/19/2023,Inactive,,
MSC OP INFUSION,6054,"Cohen, Seth D, MD",12/18/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/18/2023,Inactive,,
CINJ OP INFUSION,74204,"Saraiya, Biren P, MD",8/5/2024,Enzalutamide 30 Day Cycles - Prostate,_1. First Line,8/5/2024,Inactive,,
MSC OP INFUSION,27151,"Eltoukhy, Hussam, MD",8/10/2023,RiTUXimab 1g q6 months MS,,8/10/2023,Inactive,,
MMC OP INFUSION,45673,"Cohen, Seth D, MD",8/26/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,8/25/2024,Active,,
MMC OP VP INFUSION,45673,"Cohen, Seth D, MD",3/12/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,3/12/2025,Active,"Other specified types of non-hodgkin lymphoma, unspecified site (CMS/HCC)",
MMC OP VP INFUSION,73654,"Lee, Patrick C, MD",12/15/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/12/2023,Inactive,,
CINJ OP INFUSION,94882,"Haigentz, Missak, MD",3/24/2023,PEMEtrexed/CARBOplatin (AUC 6) plus NIVOLUMAB 21 Day Cycles- Non-Small Cell Lung Cancer ,Neoadjuvant,3/23/2023,Inactive,,
CINJ OP INFUSION,94882,"Haigentz, Missak, MD",10/13/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,Adjuvant,10/12/2023,Inactive,,
MMC OP VP INFUSION,26287,"Cohen, Seth D, MD",10/11/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,10/10/2023,Active,,
CINJ OP INFUSION,12044,"Saraiya, Biren P, MD",9/11/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,First Line,9/11/2023,Active,,
CINJ OP INFUSION,12044,"Saraiya, Biren P, MD",2/4/2025,Cabozantinib 28 Day Cycles - Kidney,_2. Second Line,2/4/2025,Active,Malignant neoplasm of kidney metastatic to bone (CMS/HCC),"C64.9, C79.51 - Malignant neoplasm of kidney metastatic to bone (CMS/HCC); E07.9 - Disorder of thyroid; Z11.59 - Encounter for screening for other viral diseases; Z11.59 - Need for hepatitis B screening test"
CBMC 2W ONCOLOGY,47271,"McKenna, Marshall, MD",3/22/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/22/2025,Active,"Leukemia, acute myeloid (CMS/HCC)","C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; J21.0 - Acute bronchiolitis due to respiratory syncytial virus; R17 - Unspecified jaundice; I10 - Essential (primary) hypertension; E66.9 - Obesity, unspecified; K59.00 - Constipation, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E87.70 - Fluid overload, unspecified; Z20.822 - Contact with and (suspected) exposure to covid-19; L40.9 - Psoriasis, unspecified; R04.0 - Epistaxis; Z11.52 - Encounter for screening for COVID-19; Z68.30 - Body mass index (BMI) 30.0-30.9, adult; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z87.891 - Personal history of nicotine dependence"
CBMC 2W ONCOLOGY,47271,"McKenna, Marshall, MD",3/21/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/21/2025,Inactive,"Leukemia, acute myeloid (CMS/HCC)","C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; J21.0 - Acute bronchiolitis due to respiratory syncytial virus; R17 - Unspecified jaundice; I10 - Essential (primary) hypertension; E66.9 - Obesity, unspecified; K59.00 - Constipation, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E87.70 - Fluid overload, unspecified; Z20.822 - Contact with and (suspected) exposure to covid-19; L40.9 - Psoriasis, unspecified; R04.0 - Epistaxis; Z11.52 - Encounter for screening for COVID-19; Z68.30 - Body mass index (BMI) 30.0-30.9, adult; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z87.891 - Personal history of nicotine dependence"
CBMC 2W ONCOLOGY,47271,"McKenna, Marshall, MD",3/21/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/21/2025,Inactive,"Leukemia, acute myeloid (CMS/HCC)","C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; J21.0 - Acute bronchiolitis due to respiratory syncytial virus; R17 - Unspecified jaundice; I10 - Essential (primary) hypertension; E66.9 - Obesity, unspecified; K59.00 - Constipation, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E87.70 - Fluid overload, unspecified; Z20.822 - Contact with and (suspected) exposure to covid-19; L40.9 - Psoriasis, unspecified; R04.0 - Epistaxis; Z11.52 - Encounter for screening for COVID-19; Z68.30 - Body mass index (BMI) 30.0-30.9, adult; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z87.891 - Personal history of nicotine dependence"
NBR CINJ OP INFUSION,41345,"Egini, Ogechukwu, MD",4/17/2025,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,_4. Fourth Line,4/17/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
JCMC CP INFUSION,91625,"Cruz, Allan Louie E, MD",5/24/2023,Daratumumab Lenalidomide / Dexamethasone Maintenance 28 Day Cycles - Multiple Myeloma,,5/24/2023,Active,,
CINJ OP INFUSION,53251,"Weiss, Sarah, MD",1/9/2023,Nivolumab 28 Day Cycles - Melanoma,,1/8/2023,Inactive,,
CINJ OP INFUSION,53251,"Weiss, Sarah, MD",3/6/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,3/3/2023,Inactive,,
CINJ OP INFUSION,53251,"Weiss, Sarah, MD",4/17/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Third Line,4/17/2023,Inactive,,
NBR CINJ OP INFUSION,15466,"Rhodes, Joanna Meehan, MD",9/9/2024,P-GemOX (Gemcitabine / OXALIplatin / Pegaspargase) 14 Day Cycles - T-Cell Lymphoma,_1. First Line,9/8/2024,Active,,
CBMC OP INFUSION 2FL,33064,"Scoppetuolo, Michael, MD",10/31/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,10/30/2023,Inactive,,
CBMC OP INFUSION 2FL,74475,"Brown, Andrew Bennett, MD",6/3/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/28/2024,Inactive,,
CBMC OP INFUSION 2FL,36953,"Leitner, Stuart P, MD",10/12/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,36953,"Leitner, Stuart P, MD",4/16/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,4/14/2024,Active,,
CINJ OP INFUSION,12272,"Goel, Sanjay, MD",11/18/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_3. Third Line,10/26/2024,Active,,
CINJ OP INFUSION,12272,"Goel, Sanjay, MD",11/18/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_3. Third Line,9/29/2024,Inactive,,
CINJ OP INFUSION,55491,"Haigentz, Missak, MD",7/12/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,7/11/2023,Inactive,,
CINJ OP INFUSION,55491,"Haigentz, Missak, MD",7/12/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/12/2023,Inactive,,
CINJ OP INFUSION,55491,"Haigentz, Missak, MD",10/2/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/2/2023,Inactive,,
CINJ OP INFUSION,55491,"Haigentz, Missak, MD",10/24/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_2. Second Line,10/24/2023,Inactive,,
NBI VALERIE FND HEMONC,73249,"Batra, Surabhi, MD",12/15/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,12/15/2024,Active,,
JCMC CP INFUSION,69706,"Cruz, Allan Louie E, MD",1/15/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/8/2025,Active,"Malignant neoplasm of prostate metastatic to bone (CMS/HCC)
Encounter for screening for other viral diseases",
NBR CINJ OP INFUSION,39853,"Shah, Mansi R, MD",5/2/2025,Carfilzomib 56 mg/m2 Weekly /Pomalyst  Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,4/29/2025,Active,"Multiple myeloma (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",
HAM OP INFUSION,13853,"Patel, Malini M, MD",12/12/2024,Rituximab - ITP,_3. Third Line,12/5/2024,Inactive,,
SOM OUTPT INFUSION,34697,"Yin, Faye, MD",2/28/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,2/26/2023,Inactive,,
CINJ OP INFUSION,41503,"Stephenson, Ruth D, DO",9/18/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Consolidation,9/11/2023,Inactive,,
CINJ OP INFUSION,91414,"Omene, Coral Oghenerukevwe, MD",4/11/2023,Olaparib 30 Day Cycles - Breast,Second Line,4/11/2023,Inactive,,
CINJ OP INFUSION,91414,"Omene, Coral Oghenerukevwe, MD",3/18/2024,Elacestrant 28 Day Cycles - Breast,_3. Third Line,3/18/2024,Inactive,,
CINJ OP INFUSION,91414,"Omene, Coral Oghenerukevwe, MD",9/3/2024,Abemaciclib 28 Day Cycles - Breast,_4. Fourth Line,9/3/2024,Inactive,,
NBR 5N ONCOLOGY,91414,"Omene, Coral Oghenerukevwe, MD",10/10/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_5. Fifth Line,10/9/2024,Inactive,,
SOM OUTPT INFUSION,26151,"Patel, Eshan, MD",7/24/2023,Pembrolizumab 42 Day Cycles - sarcoma,,7/23/2023,Active,,
CINJ OP INFUSION,33108,"Stephenson, Ryan D, DO",8/9/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,8/9/2024,Active,,
CINJ OP INFUSION,33108,"Stephenson, Ryan D, DO",10/4/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,10/1/2024,Active,,
HAM OP INFUSION,27830,"Patel, Malini M, MD",4/13/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,Second Line,4/12/2023,Inactive,,
HAM OP INFUSION,27830,"Patel, Malini M, MD",4/13/2023,Gemcitabine 21 Day Cycles - Bladder,Second Line,4/12/2023,Inactive,,
NBR 4N BMTU/IMCU,20518,"Schaar, Dale, MD PhD",11/29/2023,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,11/27/2023,Inactive,,
NBR 4N BMTU/IMCU,20518,"Egini, Ogechukwu, MD",2/14/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,2/12/2024,Inactive,,
SOM OUTPT INFUSION,30958,"Toomey, Kathleen C, MD",3/20/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,3/20/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",
NBR BMSCH 2 PED HEMONC,57749,"Cole, Peter David, MD",4/14/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Induction,4/14/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57749,"Cole, Peter David, MD",4/15/2023,AALL1732 Induction,,4/15/2023,Inactive,,
CINJ PEDS HEMONC ,57749,"Sharma, Archana, DO",5/23/2023,AALL1732 Consolidation,,5/23/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57749,"Drachtman, Richard, MD",7/6/2023,AALL1732 (Consolidation) Rylaze Substitution for Calaspargase ,Consolidation,7/6/2023,Inactive,,
CINJ PEDS HEMONC ,57749,"Sharma, Archana, DO",8/1/2023,"AALL1732, HR B-ALL, Arm A -  Interim Maintenance I (IM I) with HDMTX",First Line,7/28/2023,Inactive,,
CINJ PEDS HEMONC ,57749,"Sharma, Archana, DO",10/26/2023,AALL1732 Delayed Intensification,_1. First Line,10/26/2023,Inactive,,
CINJ PEDS HEMONC ,57749,"Sharma, Archana, DO",1/19/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,1/19/2024,Inactive,,
CINJ PEDS HEMONC ,57749,"Sharma, Archana, DO",4/11/2024,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,4/11/2024,Active,,
CINJ PEDS HEMONC ,57749,"Sharma, Archana, DO",10/30/2024,PEDS Blinatumomab,_1. First Line,10/7/2024,Inactive,,
CBMC OP INFUSION 2FL,44469,"Wagmiller, Jennifer Ann, MD",9/19/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/18/2023,Inactive,,
CBMC OP INFUSION 2FL,44469,"Wagmiller, Jennifer Ann, MD",10/24/2023,CISplatin 21 Day Cycles - Vulvar Cancer,_1. First Line,10/23/2023,Inactive,,
CBMC OP INFUSION 2FL,44469,"Wagmiller, Jennifer Ann, MD",3/19/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,3/19/2024,Inactive,,
TRMC TCCC OP INFUSION,23436,"Salerno, Vincent E, MD",10/20/2023,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_3. Third Line,10/19/2023,Inactive,,
TRMC TCCC OP INFUSION,23436,"Salerno, Vincent E, MD",10/20/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_3. Third Line,10/19/2023,Inactive,,
TRMC TCCC OP INFUSION,23436,"Salerno, Vincent E, MD",12/24/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,12/16/2024,Active,,
JCMC CP INFUSION,10803,"Sekhri, Arunabh, MD",5/29/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- adjuvant lymph nde positive cholangio ",Adjuvant,4/28/2024,Inactive,,
JCMC CP INFUSION,10803,"Sekhri, Arunabh, MD",11/1/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/6/2024,Inactive,,
JCMC CP INFUSION,10803,"Sekhri, Arunabh, MD",1/8/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/5/2025,Active,,
JCMC CP INFUSION,10803,"Sekhri, Arunabh, MD",4/16/2025,nal-IRI / 5FU 14 Day Cycles - metastatic biliary tract cancer,_3. Third Line,4/16/2025,Active,Cholangiocarcinoma (CMS/HCC),C22.1 - Intrahepatic bile duct carcinoma
CINJ OP INFUSION,60455,"George, Mridula A, MD",6/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/11/2024,Active,Malignant neoplasm of descended left testis (CMS/HCC),
NBR 5N ONCOLOGY,16870,"Palmisiano, Neil David, MD",4/1/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,3/31/2023,Inactive,,
NBR 5N ONCOLOGY,79458,"Boland, Patrick M, MD",12/8/2023,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/7/2023,Inactive,,
CINJ OP INFUSION,48687,"Stephenson, Ryan D, DO",2/26/2025,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Adjuvant,2/9/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),C67.8 - Malignant neoplasm of overlapping sites of bladder
SOM OUTPT INFUSION,30394,"Yin, Faye, MD",3/1/2023,Pomalidomide 28 Day Cycles- Multiple Myeloma,Maintenance,3/1/2023,Inactive,,
SOM OUTPT INFUSION,30394,"Patel, Eshan, MD",12/10/2024,"Bortezomib D1, D15 Maintenance 28 Day Cycles- Multiple Myeloma",Maintenance,12/1/2024,Active,,
SOM OUTPT INFUSION,26735,"Toomey, Kathleen C, MD",1/5/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Mixed Mullerian tumor of testicle,_1. First Line,1/3/2024,Inactive,,
NBR CINJ OP INFUSION,28846,"Rhodes, Joanna Meehan, MD",12/19/2024,Pembro+GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,12/18/2024,Inactive,,
NBR CINJ OP INFUSION,28846,"Rhodes, Joanna Meehan, MD",12/30/2024,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,12/29/2024,Active,,
NBR CINJ OP INFUSION,53817,"Rhodes, Joanna Meehan, MD",1/30/2025,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,12/29/2024,Active,,
NBR CINJ OP INFUSION,53817,"Rhodes, Joanna Meehan, MD",4/18/2025,BMT Autologous BEAM,_3. Third Line,4/18/2025,Active,"Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck (CMS/HCC)",
NBR CINJ OP INFUSION,53817,"Rhodes, Joanna Meehan, MD",4/17/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,4/17/2025,Inactive,"Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck (CMS/HCC)",
CINJ OP INFUSION,20800,"Saraiya, Biren P, MD",9/11/2023,Enzalutamide 30 Day Cycles - Prostate,_1. First Line,9/11/2023,Inactive,,
NBI OP INFUSION,70529,"Schleicher, Lori, MD",9/25/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,9/24/2024,Inactive,,
NBI OP INFUSION,70529,"Schleicher, Lori, MD",9/25/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/24/2024,Inactive,,
NBI OP INFUSION,70529,"Schleicher, Lori, MD",10/8/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,10/1/2024,Active,,
CBMC OP INFUSION 2FL,11710,"Litvak, Anna M, MD",4/3/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,4/3/2023,Inactive,,
MMC OP VP INFUSION,92306,"Lee, Patrick C, MD",8/10/2023,"PACLitaxel weekly / CARBOplatin weekly D1, D8, D15 q21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",,8/6/2023,Active,,
CINJ OP INFUSION,6456,"Omene, Coral Oghenerukevwe, MD",3/4/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/4/2025,Inactive,Breast cancer of upper-outer quadrant of left female breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
HAM OP INFUSION,29445,"Patel, Malini M, MD",4/15/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/15/2025,Active,"Metastatic adenocarcinoma (CMS/HCC)
Non-small cell lung cancer (CMS/HCC)","C34.90 - Non-small cell lung cancer, unspecified laterality (CMS/HCC)"
CBMC OP INFUSION 2FL,68724,"Dharmapuri, Sirish, MD",12/26/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,12/15/2024,Active,,
SOM OUTPT INFUSION,17388,"Toomey, Kathleen C, MD",3/26/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/26/2025,Active,"Endometrial cancer (CMS/HCC)
Abdominal wall mass","C54.1 - Malignant neoplasm of endometrium; R22.2 - Localized swelling, mass and lump, trunk"
NBR CINJ OP INFUSION,56437,"Shah, Mansi R, MD",11/10/2023,IVIG Gamunex monthly via Qualitas,Maintenance,11/10/2023,Inactive,,
SOM OUTPT INFUSION,83959,"Yin, Faye, MD",4/14/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/13/2023,Inactive,,
CINJ OP INFUSION,50325,"Aikins, James K, MD",1/25/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/24/2024,Inactive,,
NBI D7 MED-SURG/TELE,58070,"Anderson, Patrick S, MD",9/6/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/5/2024,Inactive,,
NBI D7 MED-SURG/TELE,58070,"Anderson, Patrick S, MD",9/13/2024,CARBOplatin Weekly  with Concurrent Radiation 49 Day Cycle - Cervical,_1. First Line,9/5/2024,Active,,
HAM OP INFUSION,48357,"Yogarajah, Meera, MD",8/8/2023,"PACLitaxel D1, D8 21 Day Cycles - Breast",,8/7/2023,Inactive,,
HAM OP INFUSION,48357,"Yogarajah, Meera, MD",11/20/2023,Palbociclib 28 Day Cycles - Breast,_1. First Line,11/20/2023,Active,,
HAM OP INFUSION,48357,"Yogarajah, Meera, MD",2/24/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,2/24/2025,Active,"Breast cancer metastasized to liver, unspecified laterality (CMS/HCC)
Hypercholesteremia",
CBMC OP INFUSION 2FL,95875,"Litvak, Anna M, MD",9/6/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,9/5/2023,Inactive,,
CBMC OP INFUSION 2FL,95875,"Litvak, Anna M, MD",1/17/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,1/17/2024,Inactive,,
CBMC OP INFUSION 2FL,95875,"Ligresti, Louise G, MD",2/14/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,2/12/2024,Active,,
CINJ OP INFUSION,23230,"Muralikrishnan, Sivraj, MD",5/19/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/19/2025,Active,Squamous cell carcinoma of tonsillar pillar (CMS/HCC),C05.1 - Malignant neoplasm of soft palate
CBMC OP INFUSION 2FL,13066,"Litvak, Anna M, MD",11/17/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,13066,"Litvak, Anna M, MD",11/17/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,11/16/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,92028,"Moerdler, Scott, MD",2/3/2023,per  AHEP1531 Group F (HCC Unresectable) Arm PLADO,,1/29/2023,Inactive,,
CBMC OP INFUSION 2FL,85716,"Leitner, Stuart P, MD",3/8/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/7/2023,Inactive,,
CBMC OP INFUSION 2FL,85716,"Leitner, Stuart P, MD",11/15/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/14/2023,Inactive,,
CBMC OP INFUSION 2FL,85716,"Leitner, Stuart P, MD",11/18/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,11/17/2024,Inactive,,
CBMC OP INFUSION 2FL,85716,"Leitner, Stuart P, MD",11/21/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,11/21/2024,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),
CINJ OP INFUSION,68977,"Goel, Sanjay, MD",4/10/2023,CINJ 052214 Single Agent Part 1B XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,4/9/2023,Inactive,,
CINJ OP INFUSION,68977,"Goel, Sanjay, MD",4/10/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,4/10/2023,Inactive,,
CINJ OP INFUSION,44088,"Leiser, Aliza, MD",12/4/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,11/19/2023,Inactive,,
CINJ OP INFUSION,48307,"Mayer, Tina M, MD",3/24/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,,3/23/2023,Inactive,,
CINJ OP INFUSION,48307,"Mayer, Tina M, MD",4/26/2023,Pembrolizumab 21 Day Cycles - Bladder ,,4/26/2023,Inactive,,
NBR CINJ OP INFUSION,86871,"Palmisiano, Neil David, MD",4/21/2025,Tagraxofusp 21 day Cycles - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),_1. First Line,4/21/2025,Active,Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (CMS/HCC),
CBMC OP INFUSION 2FL,72111,"Grossman, I Robert, MD",5/22/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/21/2023,Inactive,,
SOM OUTPT INFUSION,44059,"Toomey, Kathleen C, MD",5/8/2025,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Neoadjuvant,5/8/2025,Active,Bladder cancer (CMS/HCC),
NBI OP INFUSION,58086,"Schleicher, Lori, MD",5/29/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,5/29/2024,Active,,
NBI OP INFUSION,57176,"Schleicher, Lori, MD",3/24/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,3/24/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)
Encounter for screening for other viral diseases
Other problems related to lifestyle
End stage renal disease (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; N18.6 - End stage renal disease; Z11.59 - Encounter for screening for other viral diseases; Z72.89 - Other problems related to lifestyle; Z17.0 - Estrogen receptor positive status (ER+)
MSC OP INFUSION,30878,"Easaw, Sarah, MD",5/3/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,4/23/2023,Inactive,,
MSC OP INFUSION,30878,"Cohen, Seth D, MD",7/26/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,7/20/2023,Active,,
NBR 4N ONCOLOGY,25556,"Zayac, Adam, MD",12/5/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/3/2024,Active,,
NBR CINJ OP INFUSION,44817,"Evens, Andrew M, DO",2/6/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,2/6/2023,Inactive,,
NBR CINJ OP INFUSION,63892,"Zayac, Adam, MD",6/10/2024,"Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia Day 1 & 5 at ET, Days 2, 3, 4, 6, 7 at home",_1. First Line,6/7/2024,Inactive,,
NBR CINJ OP INFUSION,63892,"Zayac, Adam, MD",11/7/2024,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_1. First Line,11/7/2024,Active,Malignant neoplasm of trigone of bladder (CMS/HCC),
NBR CINJ OP INFUSION,1092,"Shah, Mansi R, MD",7/31/2024,BMT Autologous Melphalan Day -1 140MG/M2,Consolidation,7/29/2024,Inactive,,
NBR CINJ OP INFUSION,76656,"Zayac, Adam, MD",4/1/2025,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,_1. First Line,4/1/2025,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),C91.00 - Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC)
NBR CINJ OP INFUSION,76656,"Zayac, Adam, MD",3/3/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,2/27/2025,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; I95.1 - Orthostatic hypotension; R55 - Syncope and collapse
NBR CINJ OP INFUSION,76656,"Zayac, Adam, MD",3/3/2025,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,3/3/2025,Inactive,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),
NBI OP INFUSION,92609,"Jacoby, Sari H, MD",1/5/2024,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_1. First Line,1/5/2024,Inactive,,
NBI OP INFUSION,92609,"Jacoby, Sari H, MD",11/25/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,11/24/2024,Inactive,,
MMC OP VP INFUSION,17794,"Talwar, Sumit, MD",7/23/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/5/2024,Active,,
CMMC OP INFUSION,15036,"Freeman, Benjamin B, MD",4/22/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,4/22/2025,Inactive,Malignant neoplasm of prostate (CMS/HCC),
CMMC OP INFUSION,15036,"Freeman, Benjamin B, MD",4/11/2025,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/11/2025,Inactive,Malignant neoplasm of prostate (CMS/HCC),
CINJ OP INFUSION,93616,"Weiss, Sarah, MD",4/3/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Second Line,4/3/2023,Inactive,,
CINJ OP INFUSION,93616,"Weiss, Sarah, MD",12/28/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_3. Third Line,12/21/2023,Inactive,,
HAM OP INFUSION,520,"Yogarajah, Meera, MD",5/12/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/12/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
NBI VALERIE FND HEMONC,94569,"Bhatla, Teena, MD",3/4/2025,PEDS AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,3/4/2025,Active,Classical Hodgkin lymphoma (CMS/HCC),Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm
CMC 4B ONCOLOGY,36025,"Talwar, Sumit, MD",1/10/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/9/2025,Active,Breast cancer (CMS/HCC),
JCMC CP INFUSION,75215,"Sekhri, Arunabh, MD",12/19/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/13/2023,Inactive,,
JCMC CP INFUSION,75215,"Sekhri, Arunabh, MD",8/14/2024,CINJ 042106 (A011801)  Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,Adjuvant,7/28/2024,Active,,
NBI OP INFUSION,683,"Shah, Maya M, MD",11/17/2023,DOCEtaxel / Trastuzumab 21 Day Cycles - Breast,_1. First Line,11/16/2023,Inactive,,
NBI OP INFUSION,683,"Shah, Maya M, MD",11/17/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,11/14/2023,Inactive,,
NBI OP INFUSION,683,"Shah, Maya M, MD",10/3/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/16/2024,Active,,
CMC OP INFUSION,35031,"Tang, Horace, MD",9/4/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,9/4/2023,Inactive,,
CINJ OP INFUSION,77266,"Stephenson, Ryan D, DO",1/6/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Third Line,1/5/2023,Inactive,,
SOM OUTPT INFUSION,19443,"Toomey, Kathleen C, MD",4/4/2024,Pembrolizumab 42 Day Cycles-non-small cell lung cancer,_1. First Line,4/3/2024,Active,,
MMC OP VP INFUSION,35825,"Cohen, Seth D, MD",5/31/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,5/23/2023,Inactive,,
MMC OP VP INFUSION,35825,"Cohen, Seth D, MD",1/31/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/30/2024,Inactive,,
MMC OP VP INFUSION,35825,"Cohen, Seth D, MD",1/15/2025,Pemetrexed / CARBOplatin (AUC 5) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/5/2025,Active,,
MMC OP VP INFUSION,35825,"Cohen, Seth D, MD",4/9/2025,Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,4/9/2025,Active,"Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Hypothyroidism, unspecified type
End stage renal disease (CMS/HCC)",
CINJ OP INFUSION,69355,"Boland, Patrick M, MD",8/22/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,8/15/2023,Active,,
CINJ OP INFUSION,13377,"Girda, Eugenia, MD",11/21/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/20/2024,Active,,
CINJ OP INFUSION,48681,"Girda, Eugenia, MD",5/16/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,5/16/2025,Active,Malignant neoplasm of unspecified fallopian tube (CMS/HCC),C57.00 - Malignant neoplasm of unspecified fallopian tube
CINJ OP INFUSION,80298,"Boland, Patrick M, MD",1/3/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,1/3/2023,Inactive,,
CINJ OP INFUSION,80298,"Boland, Patrick M, MD",3/21/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,2/13/2023,Inactive,,
NBI OP INFUSION,55206,"Cheng, Yan Ho, MD",1/17/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,1/16/2024,Inactive,,
NBI OP INFUSION,55206,"Shah, Maya M, MD",1/17/2024,RiTUXimab 28 Day Cycle - refractory ITP,_3. Third Line,1/16/2024,Active,Bladder mass,
CBMC OP INFUSION 2FL,11307,"Wagmiller, Jennifer Ann, MD",12/22/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,12/21/2023,Active,,
SOM OUTPT INFUSION,55856,"Patel, Eshan, MD",5/23/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/21/2024,Active,,
SOM OUTPT INFUSION,58857,"Patel, Eshan, MD",2/15/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,2/7/2024,Active,,
CINJ OP INFUSION,8024,"Hochster, Howard S, MD",4/10/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,4/9/2024,Inactive,,
CINJ OP INFUSION,8024,"Hochster, Howard S, MD",9/16/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,9/16/2024,Inactive,,
MSC OP INFUSION,27551,"Meghal, Trishala, MD",4/25/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Maintenance,4/24/2023,Inactive,,
MMC OP INFUSION,80090,"Samuel, David, MD",3/5/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,3/5/2025,Active,Primary high grade serous adenocarcinoma of ovary (CMS/HCC),
SOM OUTPT INFUSION,21884,"Patel, Eshan, MD",7/29/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,7/26/2024,Inactive,,
SOM OUTPT INFUSION,21884,"Patel, Eshan, MD",11/15/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/12/2024,Active,,
CINJ OP INFUSION,45478,"Weiss, Sarah, MD",5/2/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,4/30/2024,Inactive,,
CINJ OP INFUSION,45478,"Weiss, Sarah, MD",6/7/2024,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_2. Second Line,6/7/2024,Active,,
CINJ OP INFUSION,5330,"Weiss, Sarah, MD",2/22/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,Third Line,2/21/2023,Inactive,,
CINJ OP INFUSION,5330,"Weiss, Sarah, MD",5/15/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Third Line,5/15/2023,Inactive,,
CINJ OP INFUSION,5330,"Weiss, Sarah, MD",1/8/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_5. Fifth Line,1/7/2024,Inactive,,
CINJ OP INFUSION,58437,"Stephenson, Ruth D, DO",10/9/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - GERM CELL,_1. First Line,10/8/2023,Inactive,,
CINJ OP INFUSION,58437,"Stephenson, Ruth D, DO",10/10/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,10/9/2023,Inactive,,
NBR 5N ONCOLOGY,58437,"Stephenson, Ruth D, DO",12/1/2023,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/30/2023,Active,,
CINJ OP INFUSION,84702,"Stephenson, Ryan D, DO",9/6/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,9/5/2023,Inactive,,
CINJ OP INFUSION,84702,"Stephenson, Ryan D, DO",9/26/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,9/24/2024,Active,,
HAM OP INFUSION,49415,"Patel, Malini M, MD",7/17/2023,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,First Line,7/16/2023,Inactive,,
HAM OP INFUSION,49415,"Patel, Malini M, MD",8/14/2023,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,First Line,8/6/2023,Inactive,,
HAM OP INFUSION,49415,"Patel, Malini M, MD",8/14/2023,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,First Line,8/13/2023,Inactive,,
SOM OUTPT INFUSION,47814,"Patel, Eshan, MD",7/27/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/25/2023,Inactive,,
SOM OUTPT INFUSION,89438,"Patel, Eshan, MD",2/27/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,2/26/2024,Active,,
NBR 4N ONCOLOGY,28126,"Shah, Mansi R, MD",12/24/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,12/23/2024,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,13431,"Boland, Patrick M, MD",1/24/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/23/2023,Inactive,,
CINJ OP INFUSION,9088,"Ghodoussipour, Saum Bobak, MD",2/23/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/23/2024,Inactive,,
SOM OUTPT INFUSION,92357,"Patel, Eshan, MD",1/21/2025,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,1/17/2025,Active,,
CINJ OP INFUSION,93498,"Mayer, Tina M, MD",10/23/2023,Darolutamide 28 Day Cycles - Prostate,_1. First Line,10/23/2023,Active,,
MMC OP VP INFUSION,65729,"Lee, Patrick C, MD",5/2/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,5/1/2023,Inactive,,
MMC OP INFUSION,65729,"Lee, Patrick C, MD",9/12/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,,9/11/2023,Inactive,,
MMC OP VP INFUSION,46684,"Cohen, Seth D, MD",9/23/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,9/22/2024,Active,,
NBR CINJ OP INFUSION,89994,"Palmisiano, Neil David, MD",4/17/2025,CINJ 022204 Cohort 3 Combination Agents Part 2 of 2 Azacitadine 28 Day Cycles Research- Myleodysplastic syndromes,_2. Second Line,4/9/2025,Inactive,"MDS (myelodysplastic syndrome) (CMS/HCC)
Hypothyroidism, unspecified type","D46.9 - Myelodysplastic syndrome, unspecified; E63.9 - Nutritional deficiency, unspecified; D53.9 - Nutritional anemia, unspecified"
NBR CINJ OP INFUSION,89994,"Palmisiano, Neil David, MD",4/17/2025,"CINJ 022204 Cohort 3 Combination Agents Part 2 of 2 Decitabine 28 Day Cycles Research - Myleodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)",_2. Second Line,4/14/2025,Active,"MDS (myelodysplastic syndrome) (CMS/HCC)
Hypothyroidism, unspecified type",
NBR CINJ OP INFUSION,89994,"Palmisiano, Neil David, MD",4/17/2025,"CINJ 022204 Cohort 3 Combination Agents Part 1 of 2 LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_2. Second Line,4/17/2025,Active,"MDS (myelodysplastic syndrome) (CMS/HCC)
Other specified hypothyroidism",
NBR CINJ OP INFUSION,89994,"Palmisiano, Neil David, MD",4/10/2025,CINJ 022204 Cohort 3 Combination Agents Part 2 of 2 Azacitadine 28 Day Cycles Research- Myleodysplastic syndromes,_2. Second Line,4/10/2025,Inactive,"MDS (myelodysplastic syndrome) (CMS/HCC)
Hypothyroidism, unspecified type","D46.9 - Myelodysplastic syndrome, unspecified; E63.9 - Nutritional deficiency, unspecified; D53.9 - Nutritional anemia, unspecified"
CBMC OP INFUSION 2FL,64913,"Brown, Andrew Bennett, MD",11/8/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Head and Neck Cancers",_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,64913,"Brown, Andrew Bennett, MD",11/22/2023,Nivolumab 28 Day Cycles - Melanoma,Maintenance,11/21/2023,Inactive,,
CBMC OP INFUSION 2FL,64913,"Brown, Andrew Bennett, MD",11/22/2023,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",Maintenance,11/21/2023,Active,,
CINJ OP INFUSION,75998,"Omene, Coral Oghenerukevwe, MD",8/8/2023,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,,8/7/2023,Inactive,,
CBMC OP INFUSION 2FL,75998,"Litvak, Anna M, MD",10/3/2023,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,_2. Second Line,10/2/2023,Inactive,,
CBMC OP INFUSION 2FL,75998,"Litvak, Anna M, MD",12/28/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,12/28/2023,Active,,
CINJ OP INFUSION,28653,"Berim, Lyudmyla, MD",1/8/2024,Imatinib 30 Day Cycles - Sarcoma,_1. First Line,1/8/2024,Active,,
CBMC OP INFUSION 2FL,40385,"Leitner, Stuart P, MD",1/26/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,1/25/2024,Inactive,,
CBMC OP INFUSION 2FL,40385,"Leitner, Stuart P, MD",4/26/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,4/25/2024,Active,,
CBMC OP INFUSION 2FL,40385,"Leitner, Stuart P, MD",4/26/2024,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,4/25/2024,Inactive,,
CBMC OP INFUSION 2FL,40385,"Leitner, Stuart P, MD",4/26/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,4/26/2024,Active,,
MMC OP VP INFUSION,24866,"Cohen, Seth D, MD",12/4/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/3/2024,Active,,
NBI OP INFUSION,42193,"Schleicher, Lori, MD",12/21/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,12/21/2023,Active,,
HAM OP INFUSION,31411,"Yogarajah, Meera, MD",3/21/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,3/19/2023,Inactive,,
HAM OP INFUSION,31411,"Yogarajah, Meera, MD",6/13/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,First Line,6/12/2023,Active,,
SOM OUTPT INFUSION,24226,"George, Roshini, DO",3/24/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,3/24/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; D51.3 - Other dietary vitamin B12 deficiency anemia; D64.9 - Anemia, unspecified; C79.51 - Secondary malignant neoplasm of bone"
CINJ OP INFUSION,43362,"Boland, Patrick M, MD",1/9/2024,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,_1. First Line,12/11/2023,Inactive,,
HAM OP INFUSION,43362,"Yogarajah, Meera, MD",6/24/2024,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,6/24/2024,Inactive,,
HAM OP INFUSION,43362,"Yogarajah, Meera, MD",12/20/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_3. Third Line,12/9/2024,Active,,
CINJ OP INFUSION,80826,"Boland, Patrick M, MD",3/31/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/26/2023,Inactive,,
CINJ OP INFUSION,60947,"Stephenson, Ruth D, DO",8/5/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,7/14/2024,Inactive,,
CBMC OP INFUSION 2FL,76722,"Scoppetuolo, Michael, MD",4/19/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,3/27/2024,Active,,
NBR CINJ OP INFUSION,63405,"Palmisiano, Neil David, MD",2/13/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,2/13/2023,Inactive,,
NBR CINJ OP INFUSION,63405,"Palmisiano, Neil David, MD",3/21/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,3/20/2023,Inactive,,
NBR 4N BMTU/IMCU,63405,"Schaar, Dale, MD PhD",4/30/2023,BMT Allogeneic TBF + Post Cy ,,4/29/2023,Inactive,,
CINJ OP INFUSION,58480,"Leiser, Aliza, MD",9/30/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,9/29/2024,Active,,
MMC OP VP INFUSION,20020,"Lee, Patrick C, MD",1/20/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/19/2023,Inactive,,
NBR 5N ONCOLOGY,46521,"Palmisiano, Neil David, MD",11/21/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,11/20/2024,Inactive,,
NBR CINJ OP INFUSION,46521,"Zayac, Adam, MD",1/13/2025,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,1/2/2025,Active,Richter's syndrome (CMS/HCC),
CINJ OP INFUSION,93302,"Toppmeyer, Deborah L, MD",4/25/2024,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,Neoadjuvant,4/18/2024,Inactive,,
CINJ OP INFUSION,93302,"Toppmeyer, Deborah L, MD",5/2/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Neoadjuvant,5/1/2024,Active,,
CINJ OP INFUSION,93302,"Toppmeyer, Deborah L, MD",4/15/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,4/15/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,19308,"Leitner, Stuart P, MD",2/1/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/31/2024,Inactive,,
CBMC OP INFUSION 2FL,19308,"Leitner, Stuart P, MD",6/27/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,6/24/2024,Active,,
CBMC OP INFUSION 2FL,10794,"Grossman, I Robert, MD",7/22/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,7/21/2024,Active,,
NBR CINJ OP INFUSION,16313,"Rhodes, Joanna Meehan, MD",8/5/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,7/31/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Metastasis to lymph nodes (CMS/HCC)",
SOM OUTPT INFUSION,50855,"Patel, Eshan, MD",5/14/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_1. First Line,5/13/2024,Active,,
CINJ OP INFUSION,43568,"Boland, Patrick M, MD",12/15/2023,Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 480 mg D1 28 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/12/2023,Active,,
CINJ OP INFUSION,21332,"Mayer, Tina M, MD",1/30/2023,weekly  CARBOplatin 28 Day Cycles - Prostate,,1/22/2023,Inactive,,
CINJ OP INFUSION,21332,"Mayer, Tina M, MD",2/27/2023,CABAZItaxel (weekly) / PredniSONE 35 Day Cycles - Prostate,,2/27/2023,Inactive,,
CINJ OP INFUSION,21332,"Mayer, Tina M, MD",8/28/2023,CABAZItaxel / PredniSONE 35 Day Cycles - Prostate,,8/20/2023,Inactive,,
CINJ OP INFUSION,21332,"Mayer, Tina M, MD",9/6/2024,Pembrolizumab 21 Day Cycles - High TMB prostate cancer,_5. Fifth Line,9/3/2024,Active,,
CINJ OP INFUSION,69857,"Aikins, James K, MD",3/23/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,3/22/2023,Inactive,,
CINJ OP INFUSION,69857,"Aikins, James K, MD",9/22/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,9/21/2023,Active,,
CINJ OP INFUSION,97164,"Leiser, Aliza, MD",4/20/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,3/29/2023,Active,,
MMC OP VP INFUSION,54188,"Meghal, Trishala, MD",11/27/2023,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",Maintenance,11/27/2023,Inactive,,
HAM OP INFUSION,55795,"Gendy, Mina, DO",12/13/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,12/8/2024,Active,,
HAM OP INFUSION,55795,"Gendy, Mina, DO",5/13/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/8/2025,Active,Bladder cancer (CMS/HCC),"C67.9 - Malignant neoplasm of urinary bladder, unspecified site (CMS/HCC)"
HAM OP INFUSION,55795,"Gendy, Mina, DO",5/8/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/7/2025,Inactive,Bladder cancer (CMS/HCC),"T83.593A - Infection and inflammatory reaction due to other urinary stents, initial encounter; A41.9 - Sepsis, unspecified organism; E43 - Unspecified severe protein-calorie malnutrition; C78.01 - Secondary malignant neoplasm of right lung; N13.6 - Pyonephrosis; N17.9 - Acute kidney failure, unspecified; R62.7 - Adult failure to thrive; C67.9 - Malignant neoplasm of bladder, unspecified; Z68.1 - Body mass index (BMI) 19.9 or less, adult; B96.1 - Klebsiella pneumoniae (k. pneumoniae) as the cause of diseases classified elsewhere; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; Z85.51 - Personal history of malignant neoplasm of bladder; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z87.440 - Personal history of urinary (tract) infections; Z86.19 - Personal history of other infectious and parasitic diseases; Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons"
JCMC CP INFUSION,68310,"Cruz, Allan Louie E, MD",9/6/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,,9/5/2023,Inactive,,
CINJ OP INFUSION,46396,"Saraiya, Biren P, MD",8/21/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,8/21/2024,Inactive,,
NBR 5N ONCOLOGY,46396,"Saraiya, Biren P, MD",9/23/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Prostate,_1. First Line,9/20/2024,Inactive,,
CBMC OP INFUSION 2FL,69088,"Dharmapuri, Sirish, MD",3/7/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/7/2025,Active,Cancer of appendix (CMS/HCC),C18.1 - Malignant neoplasm of appendix
SOM OUTPT INFUSION,3059,"Toomey, Kathleen C, MD",10/4/2024,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,10/2/2024,Active,,
NBR CINJ OP INFUSION,98767,"Schaar, Dale, MD PhD",3/11/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,3/7/2024,Active,Plasma cell neoplasm,
NBR CINJ OP INFUSION,17428,"Egini, Ogechukwu, MD",3/14/2025,BMT Autologous BEAM,_4. Fourth Line,3/13/2025,Active,Diffuse large B-cell lymphoma of intrapelvic lymph nodes (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; I07.1 - Rheumatic tricuspid insufficiency; I37.1 - Nonrheumatic pulmonary valve insufficiency; Z94.84 - Stem cells transplant status"
CINJ OP INFUSION,8837,"Ghodoussipour, Saum Bobak, MD",11/6/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,11/5/2023,Inactive,,
CINJ OP INFUSION,8837,"Ghodoussipour, Saum Bobak, MD",2/6/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,2/4/2024,Active,,
CINJ OP INFUSION,80250,"Kennedy, Timothy, MD",4/12/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,4/12/2024,Active,,
CINJ OP INFUSION,13837,"Berim, Lyudmyla, MD",1/16/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,1/1/2025,Active,,
CINJ OP INFUSION,12039,"Girda, Eugenia, MD",8/7/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Second Line,8/6/2023,Inactive,,
CBMC OP INFUSION 2FL,15190,"Ligresti, Louise G, MD",4/10/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,4/10/2024,Inactive,,
MMC OP VP INFUSION,25615,"Cohen, Seth D, MD",9/10/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,9/2/2024,Active,,
MMC OP VP INFUSION,24380,"Cohen, Seth D, MD",1/2/2024,Lenalidomide 28 Day Cycles - MDS/MPN Overlap Neoplasm,_1. First Line,1/2/2024,Inactive,,
MMC OP INFUSION,24380,"Cohen, Seth D, MD",5/20/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,5/19/2024,Active,,
JCMC CP INFUSION,21681,"Sekhri, Arunabh, MD",8/8/2024,CISplatin with Concurrent Radiation 49 Day Cycle- submandibular gland carcinoma,_1. First Line,6/17/2024,Inactive,,
CINJ OP INFUSION,54752,"Weiss, Sarah, MD",10/25/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,10/25/2023,Active,,
CBMC OP INFUSION 2FL,19356,"Radovich, Delia, MD",11/29/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,19356,"Radovich, Delia, MD",11/29/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,79779,"Litvak, Anna M, MD",12/6/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,11/18/2024,Active,,
CINJ OP INFUSION,9609,"Mayer, Tina M, MD",3/21/2023,Enzalutamide 28 Day Cycles - Prostate,,3/21/2023,Inactive,,
CINJ OP INFUSION,9609,"Mayer, Tina M, MD",4/26/2023,Enzalutamide 28 Day Cycles - Prostate,,4/26/2023,Active,,
CBMC OP INFUSION 2FL,54688,"Radovich, Delia, MD",11/28/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,11/27/2023,Inactive,,
CBMC OP INFUSION 2FL,54688,"Wagmiller, Jennifer Ann, MD",9/10/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,8/18/2024,Active,,
SOM 1PAV ONCOLOGY,37066,"Patel, Eshan, MD",11/4/2024,R-CEOP (Rituximab Hycela  / Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/3/2024,Active,,
CBMC OP INFUSION 2FL,28371,"Wagmiller, Jennifer Ann, MD",5/6/2025,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,5/6/2025,Active,Malignant pleural effusion,
CBMC 2W ONCOLOGY,28371,"Wagmiller, Jennifer Ann, MD",4/14/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,4/14/2025,Active,Cancer involving organ by non-direct metastasis from endometrium (CMS/HCC),"C78.01 - Secondary malignant neoplasm of right lung; J91.0 - Malignant pleural effusion; C54.1 - Malignant neoplasm of endometrium; E04.1 - Nontoxic single thyroid nodule; E11.649 - Type 2 diabetes mellitus with hypoglycemia without coma; D63.0 - Anemia in neoplastic disease; E66.9 - Obesity, unspecified; I10 - Essential (primary) hypertension; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; J98.11 - Atelectasis; Z79.4 - Long term (current) use of insulin; G47.33 - Obstructive sleep apnea (adult) (pediatric); E87.5 - Hyperkalemia; R19.03 - Right lower quadrant abdominal swelling, mass and lump; E78.00 - Pure hypercholesterolemia, unspecified; Z11.52 - Encounter for screening for COVID-19; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z85.42 - Personal history of malignant neoplasm of other parts of uterus; Z79.899 - Other long term (current) drug therapy; Z79.82 - Long term (current) use of aspirin; Z90.710 - Acquired absence of both cervix and uterus; Z90.49 - Acquired absence of other specified parts of digestive tract; Z63.4 - Disappearance and death of family member; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.3 - Family history of malignant neoplasm of breast; Z17.32 - Human epidermal growth factor receptor 2 negative status; Z80.49 - Family history of malignant neoplasm of other genital organs"
CMC OP INFUSION,53266,"Cohen, Seth D, MD",5/29/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/21/2024,Inactive,,
CBMC OP INFUSION 2FL,84070,"Dharmapuri, Sirish, MD",4/21/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/21/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,84070,"Dharmapuri, Sirish, MD",4/21/2025,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,4/21/2025,Active,Gastric adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,21748,"Stephenson, Ruth D, DO",3/15/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_2. Second Line,3/14/2024,Inactive,,
CINJ OP INFUSION,21748,"Stephenson, Ruth D, DO",6/28/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Maintenance,6/27/2024,Inactive,,
CINJ OP INFUSION,21748,"Stephenson, Ruth D, DO",6/28/2024,Pembrolizumab 21 Day Cycles - Uterine,Maintenance,6/27/2024,Active,,
CINJ OP INFUSION,91834,"Boland, Patrick M, MD",9/19/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,9/18/2023,Inactive,,
CINJ OP INFUSION,91834,"Boland, Patrick M, MD",9/24/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,9/23/2024,Inactive,,
CMC OP INFUSION,11605,"Talwar, Sumit, MD",8/5/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,,8/3/2023,Inactive,,
CMC OP INFUSION,11605,"Talwar, Sumit, MD",12/18/2024,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,12/18/2024,Active,,
MSC OP INFUSION,84866,"Cohen, Seth D, MD",5/28/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/21/2024,Inactive,,
MMC OP VP INFUSION,84866,"Cohen, Seth D, MD",1/7/2025,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_5. Fifth Line,1/3/2025,Active,,
MMC OP VP INFUSION,84866,"Cohen, Seth D, MD",5/1/2025,Gemcitabine / CARBOplatin 28 Day Cycles - Breast,_5. Fifth Line,5/1/2025,Inactive,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
MMC OP VP INFUSION,84866,"Cohen, Seth D, MD",5/1/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_5. Fifth Line,5/1/2025,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
CINJ OP INFUSION,70932,"Mayer, Tina M, MD",11/13/2023,CINJ 082211 Dose Escalation HB-302 / HB-301 Alternating 2-Vector Therapy 42 Day Cycles Research- Prostate Cancer,_3. Third Line,11/13/2023,Inactive,,
NBR CINJ OP INFUSION,70932,"Mayer, Tina M, MD",1/13/2025,Pembrolizumab 21 Day Cycles - Prostate cancer with high TMB,_4. Fourth Line,1/6/2025,Active,,
MSC OP INFUSION,36337,"Talwar, Sumit, MD",12/11/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,6/18/2024,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP INFUSION,31377,"Lee, Patrick C, MD",7/2/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,7/1/2024,Inactive,,
CINJ OP INFUSION,71447,"Leiser, Aliza, MD",5/5/2025,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - germ cell ovarian tumor,Adjuvant,5/5/2025,Active,Germ cell tumor (CMS/HCC),
CINJ OP INFUSION,3602,"Stephenson, Ryan D, DO",6/8/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,First Line,6/8/2023,Active,,
CINJ OP INFUSION,42405,"Boland, Patrick M, MD",8/31/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,8/31/2023,Inactive,,
CINJ OP INFUSION,10115,"Hochster, Howard S, MD",2/22/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,2/20/2023,Inactive,,
CINJ OP INFUSION,10115,"Hochster, Howard S, MD",1/11/2024,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,_3. Third Line,1/11/2024,Inactive,,
CINJ OP INFUSION,10115,"Boland, Patrick M, MD",6/6/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_4. Fourth Line,5/29/2024,Inactive,,
CINJ OP INFUSION,10115,"Hochster, Howard S, MD",6/27/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,6/27/2024,Inactive,,
HAM OP INFUSION,60425,"Patel, Malini M, MD",4/5/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,First Line,4/4/2023,Active,,
SOM OUTPT INFUSION,40017,"Toomey, Kathleen C, MD",2/27/2025,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_7. Seventh Line,2/26/2025,Active,Multiple myeloma in relapse (CMS/HCC),
SOM OUTPT INFUSION,51251,"Toomey, Kathleen C, MD",3/7/2025,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_7. Seventh Line,3/7/2025,Active,Multiple myeloma in relapse (CMS/HCC),
NBR 4N BMTU/IMCU,16961,"Braunschweig, Ira, MD",1/13/2023,D-PACE (Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,,1/13/2023,Inactive,,
NBR CINJ OP INFUSION,16961,"Braunschweig, Ira, MD",2/8/2023,Lymphodepletion Abecma 6 Day Cycle - Multiple Myeloma,,2/7/2023,Inactive,,
CINJ OP INFUSION,97796,"Boland, Patrick M, MD",3/14/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,2/27/2023,Inactive,,
TRMC TCCC OP INFUSION,98204,"Salerno, Vincent E, MD",7/9/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,7/8/2024,Active,,
NBI OP INFUSION,77153,"Shah, Shailja S, MD",7/25/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,First Line,7/24/2023,Inactive,,
NBI OP INFUSION,77153,"Shah, Shailja S, MD",4/9/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,2/19/2024,Active,"Cancer of ampulla of Vater (CMS/HCC)
Malignant ascites",
NBR BMSCH 2 PED HEMONC,39641,"Botwinick, Marissa, DO",5/5/2023,PEDS ANHL1131 Arm B ,Induction,5/5/2023,Inactive,,
CINJ PEDS HEMONC ,39641,"Botwinick, Marissa, DO",6/20/2023,PEDS ANHL1131 Group B ,First Line,6/20/2023,Inactive,,
CINJ PEDS HEMONC ,39641,"Botwinick, Marissa, DO",6/20/2023,PEDS ANHL1131 Group B ,First Line,6/20/2023,Inactive,,
CINJ OP INFUSION,39979,"Haigentz, Missak, MD",10/14/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,10/6/2024,Inactive,,
CINJ OP INFUSION,39979,"Haigentz, Missak, MD",12/23/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,12/23/2024,Active,,
CINJ OP INFUSION,51561,"Mayer, Tina M, MD",2/10/2023,Enzalutamide 30 Day Cycles - Prostate,,2/10/2023,Active,,
CBMC OP INFUSION 2FL,12338,"Leitner, Stuart P, MD",6/19/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",Adjuvant,6/17/2024,Active,,
CINJ OP INFUSION,84306,"Groisberg, Roman, MD",4/28/2025,Pembrolizumab 21 Day Cycles - Melanoma,Neoadjuvant,4/28/2025,Inactive,Undifferentiated pleomorphic sarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified"
MMC OP VP INFUSION,98062,"Cohen, Seth D, MD",4/26/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,First Line,4/25/2023,Inactive,,
NBI OP INFUSION,30433,"Jacoby, Sari H, MD",5/1/2024,Lenalidomide (D1-D21) Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,5/1/2024,Active,,
NBR CINJ OP INFUSION,12809,"Shah, Mansi R, MD",6/1/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,6/1/2023,Inactive,,
CINJ OP INFUSION,47419,"Hochster, Howard S, MD",2/9/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Second Line,2/8/2023,Inactive,,
SOM OUTPT INFUSION,66177,"Khalid, Aysha, MD",2/16/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,First Line,2/16/2023,Inactive,,
JCMC CP INFUSION,95135,"Cruz, Allan Louie E, MD",1/3/2023,Pembrolizumab 21 Day Cycles - Melanoma,,1/2/2023,Inactive,,
MMC OP INFUSION,86039,"Meghal, Trishala, MD",11/26/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,10/23/2024,Active,Bladder cancer (CMS/HCC),
CMC OP INFUSION,32273,"Taff, Jessica, MD",3/27/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,3/19/2024,Active,,
CBMC OP INFUSION 2FL,37447,"Grossman, I Robert, MD",10/31/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,10/31/2023,Active,Malignant neoplasm of central portion of left female breast (CMS/HCC),
TRMC TCCC OP INFUSION,31957,"Capo, Gerardo, MD",4/9/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,4/8/2024,Inactive,,
TRMC TCCC OP INFUSION,31957,"Capo, Gerardo, MD",4/9/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,4/8/2024,Inactive,,
TRMC TCCC OP INFUSION,31957,"Capo, Gerardo, MD",1/15/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,1/13/2025,Active,,
NBI OP INFUSION,10594,"Jacoby, Sari H, MD",1/24/2024,SUNItinib 28 Day Cycles - Sarcoma,_2. Second Line,1/24/2024,Inactive,,
NBI OP INFUSION,40664,"Jacoby, Sari H, MD",10/14/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/6/2024,Active,,
CINJ OP INFUSION,27719,"Mayer, Tina M, MD",3/14/2023,Pembrolizumab 21 Day Cycles - Prostate high TMB,,3/14/2023,Inactive,,
SOM OUTPT INFUSION,19304,"Patel, Eshan, MD",7/22/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,7/19/2024,Inactive,,
SOM OUTPT INFUSION,19304,"Patel, Eshan, MD",8/26/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,8/25/2024,Active,,
TRMC TCCC OP INFUSION,3087,"Capo, Gerardo, MD",1/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/13/2025,Active,,
CBMC OP INFUSION 2FL,62459,"Wagmiller, Jennifer Ann, MD",5/1/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,5/1/2025,Active,"Ovarian cancer, unspecified laterality (CMS/HCC)","C56.9 - Ovarian cancer, unspecified laterality (CMS/HCC)"
CBMC OP INFUSION 2FL,38453,"Brown, Andrew Bennett, MD",10/27/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/23/2023,Active,,
CBMC OP INFUSION 2FL,96307,"Leitner, Stuart P, MD",11/16/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,11/16/2023,Active,,
CBMC OP INFUSION 2FL,96307,"Leitner, Stuart P, MD",5/27/2025,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,5/22/2025,Active,"Metastatic renal cell carcinoma (CMS/HCC)
Secondary malignant neoplasm of pancreas (CMS/HCC)
Thyroiditis, autoimmune",
NBR 5N ONCOLOGY,36754,"Haigentz, Missak, MD",7/14/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",First Line,7/13/2023,Inactive,,
NBR 5N ONCOLOGY,36754,"Haigentz, Missak, MD",7/20/2023,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,First Line,7/20/2023,Inactive,,
TRMC TCCC OP INFUSION,9552,"Salerno, Vincent E, MD",5/5/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/5/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),"C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung"
CINJ OP INFUSION,45708,"Weiss, Sarah, MD",7/10/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,6/3/2024,Inactive,,
JCMC CP INFUSION,63937,"Sekhri, Arunabh, MD",3/6/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Second Line,3/6/2023,Inactive,,
NBI OP INFUSION,80728,"Jacoby, Sari H, MD",2/17/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/16/2025,Active,Rectal cancer (CMS/HCC),C20 - Malignant neoplasm of rectum; R73.03 - Prediabetes; Z95.828 - Presence of other vascular implants and grafts; Z89.411 - Acquired absence of right great toe; Z91.030 - Bee allergy status
NBI OP INFUSION,71129,"Jacoby, Sari H, MD",5/1/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,4/30/2023,Inactive,,
NBI OP INFUSION,71129,"Jacoby, Sari H, MD",10/2/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,9/28/2023,Inactive,,
NBI OP INFUSION,71129,"Jacoby, Sari H, MD",11/13/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,11/12/2023,Inactive,,
NBI OP INFUSION,71129,"Jacoby, Sari H, MD",4/1/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,3/31/2024,Inactive,,
NBI OP INFUSION,71129,"Jacoby, Sari H, MD",4/29/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/21/2024,Active,,
CINJ OP INFUSION,16441,"Dasgeb, Bahar, MD",9/3/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,7/22/2024,Active,,
NBR CINJ OP INFUSION,87706,"Braunschweig, Ira, MD",2/15/2023,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,2/14/2023,Inactive,,
NBR CINJ OP INFUSION,87706,"Shah, Mansi R, MD",6/7/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,6/6/2023,Inactive,,
NBR 4N ONCOLOGY,87706,"Shah, Mansi R, MD",9/4/2024,Pomalidomide 28 Day Cycles- Multiple Myeloma,_3. Third Line,8/19/2024,Inactive,,
NBR CINJ OP INFUSION,87706,"Shah, Mansi R, MD",9/19/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,9/11/2024,Inactive,,
NBR CINJ OP INFUSION,87706,"Shah, Mansi R, MD",10/31/2024,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,10/30/2024,Active,,
NBI D7 MED-SURG/TELE,24174,"Anderson, Patrick S, MD",11/1/2023,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_2. Second Line,10/31/2023,Inactive,,
NBI D7 MED-SURG/TELE,24174,"Anderson, Patrick S, MD",11/1/2023,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_2. Second Line,10/31/2023,Inactive,,
NBI OP INFUSION,24174,"Anderson, Patrick S, MD",11/1/2023,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_2. Second Line,10/31/2023,Inactive,,
CMC OP INFUSION,80763,"Eltoukhy, Hussam, MD",1/9/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/8/2024,Inactive,,
CINJ OP INFUSION,11070,"Mayer, Tina M, MD",10/5/2023,Enzalutamide 28 Day Cycles - Prostate,Maintenance,10/5/2023,Active,,
SOM OUTPT INFUSION,29604,"Yin, Faye, MD",12/28/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,12/21/2023,Inactive,,
SOM OUTPT INFUSION,29604,"Toomey, Kathleen C, MD",3/29/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,3/28/2024,Active,Breast cancer metastasized to multiple sites (CMS/HCC),
CINJ OP INFUSION,44454,"Goel, Sanjay, MD",12/16/2024,CINJ 052404 Dose Escalation XL309 / Olaparib 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,12/13/2024,Active,,
CINJ OP INFUSION,44454,"Goel, Sanjay, MD",12/16/2024,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,12/16/2024,Inactive,,
CINJ OP INFUSION,32205,"Girda, Eugenia, MD",6/6/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,6/6/2023,Active,,
CINJ OP INFUSION,76762,"Berim, Lyudmyla, MD",2/10/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,2/10/2025,Active,Malignant neoplasm of rectum (CMS/HCC),C20 - Malignant neoplasm of rectum (CMS/HCC)
CINJ OP INFUSION,78206,"Dasgeb, Bahar, MD",9/26/2023,RiTUXimab 168 Day Cycles - Pemphigus,Maintenance,9/7/2023,Active,Hepatocellular carcinoma (CMS/HCC),
CINJ OP INFUSION,10976,"Mayer, Tina M, MD",10/24/2023,Enfortumab Vedotin + pembrolizumab 21 Day Cycles - Bladder,_1. First Line,10/21/2023,Inactive,,
CBMC OP INFUSION 2FL,13039,"Dharmapuri, Sirish, MD",5/21/2025,CINJ 072402 Quemliclustat or Placebo / Nab-PACLitaxel / Gemcitabine 28 Day Cycles Research- Pancreatic Adenocarcinoma,_1. First Line,5/21/2025,Active,"Adenocarcinoma of pancreas, stage 4 (CMS/HCC)","C25.9 - Malignant neoplasm of pancreas, unspecified; Z00.6 - Encounter for examination for normal comparison and control in clinical research program"
CINJ OP INFUSION,65380,"Boland, Patrick M, MD",1/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/27/2025,Active,,
CBMC OP INFUSION 2FL,9839,"Leitner, Stuart P, MD",9/27/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_1. First Line,9/26/2023,Inactive,,
CINJ OP INFUSION,42714,"Stephenson, Ryan D, DO",2/24/2025,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,2/23/2025,Active,Bladder cancer (CMS/HCC),
CINJ OP INFUSION,718,"Hochster, Howard S, MD",4/16/2025,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,4/15/2025,Active,Carcinoma in situ of anus,
CMC OP INFUSION,96938,"Cohen, Seth D, MD",5/15/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,5/14/2024,Active,,
CINJ OP INFUSION,96938,"Stephenson, Ryan D, DO",5/17/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,5/16/2024,Inactive,,
CINJ OP INFUSION,27449,"Haigentz, Missak, MD",4/8/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,4/8/2024,Inactive,,
CINJ OP INFUSION,88425,"Saraiya, Biren P, MD",3/27/2023,Enzalutamide 28 Day Cycles - Prostate,First Line,3/27/2023,Inactive,,
CINJ OP INFUSION,88425,"Mayer, Tina M, MD",5/4/2023,DOCEtaxel 21 Day Cycles - Prostate,,5/2/2023,Inactive,,
CINJ OP INFUSION,88425,"Mayer, Tina M, MD",10/17/2023,Darolutamide 28 Day Cycles - Prostate,_1. First Line,10/17/2023,Inactive,,
CINJ OP INFUSION,88425,"Mayer, Tina M, MD",8/12/2024,CINJ 082304 Cohort 2 ONC-392 / Lutetium Lu 177 Vipivotide Tetraxetan 42 Day Cycles Research- Prostate Cancer,_4. Fourth Line,8/11/2024,Active,,
CINJ OP INFUSION,88425,"Saraiya, Biren P, MD",8/12/2024,CINJ 082304 ONC-392 / Lutetium Lu 177 Vipivotide Tetraxetan 28 Day Cycles Research- Prostate Cancer,_4. Fourth Line,8/11/2024,Inactive,,
NBI OP INFUSION,11116,"Anderson, Patrick S, MD",4/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Locally Advanced Serrous Endometrial adenocarcinoma,Neoadjuvant,4/17/2024,Inactive,,
NBR CINJ OP INFUSION,21365,"Rhodes, Joanna Meehan, MD",3/25/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,3/24/2024,Inactive,,
NBR CINJ OP INFUSION,21365,"Rhodes, Joanna Meehan, MD",4/22/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,4/21/2024,Active,Neuroendocrine tumor,
NBR CINJ OP INFUSION,21365,"Rhodes, Joanna Meehan, MD",4/29/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,4/28/2024,Inactive,,
NBR CINJ OP INFUSION,21365,"Rhodes, Joanna Meehan, MD",9/20/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,9/19/2024,Inactive,,
NBR CINJ OP INFUSION,21365,"Rhodes, Joanna Meehan, MD",9/20/2024,Venetoclax 42 Day Cycles - Mantle Cell Lymphoma,_1. First Line,9/20/2024,Inactive,,
NBR CINJ OP INFUSION,49043,"Shah, Mansi R, MD",11/3/2023,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,11/3/2023,Inactive,,
NBR 4N BMTU/IMCU,49043,"Schaar, Dale, MD PhD",11/21/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,11/20/2023,Inactive,,
SOM OUTPT INFUSION,19352,"Yin, Faye, MD",5/13/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - cholangiocarcinoma",_1. First Line,5/13/2024,Inactive,,
SOM OUTPT INFUSION,19352,"Yin, Faye, MD",6/5/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,6/4/2024,Inactive,,
SOM OUTPT INFUSION,19352,"Yin, Faye, MD",6/12/2024,Pembrolizumab 21 Day Cycles - cholangiocarcinoma,_1. First Line,6/12/2024,Inactive,,
CINJ OP INFUSION,56773,"Saraiya, Biren P, MD",12/18/2023,Relugolix 30 day Cycles - Prostate,_1. First Line,12/18/2023,Active,Adenocarcinoma of pancreas (CMS/HCC),
CINJ OP INFUSION,28403,"Berim, Lyudmyla, MD",2/26/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/25/2025,Active,Gastric cancer (CMS/HCC),
CBMC OP INFUSION 2FL,74423,"Scoppetuolo, Michael, MD",11/20/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,11/19/2023,Inactive,,
CBMC OP INFUSION 2FL,8121,"Dharmapuri, Sirish, MD",4/1/2025,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/1/2025,Inactive,Colon cancer (CMS/HCC),
CBMC OP INFUSION 2FL,1733,"Dave, Manish, MD",11/14/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/13/2023,Inactive,,
MMC OP VP INFUSION,53872,"Cohen, Seth D, MD",9/25/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,9/24/2024,Active,,
CMC OP INFUSION,83561,"Pompa, Tiffany Ann, MD",4/28/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,Induction,4/28/2025,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",2/10/2023,D-PACE (Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,,2/10/2023,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",6/8/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,6/8/2023,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",9/18/2023,Elotuzumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,,9/17/2023,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",10/10/2023,Carfilzomib 70 mg/m2 / Cyclophosphamide Oral Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,,10/9/2023,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",10/10/2023,Carfilzomib 70 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,,10/9/2023,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",10/16/2023,"Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles - Multiple Myeloma",10. Tenth Line,10/16/2023,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",2/29/2024,Carfilzomib 70 mg/m2 / Cyclophosphamide weekly/ Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_8. Eighth Line,2/28/2024,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",3/16/2024,Carfilzomib 70 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_9. Ninth Line,3/15/2024,Inactive,,
NBR 5N ONCOLOGY,79246,"Shah, Mansi R, MD",7/31/2024,Teclistamab Weekly 28 Day Cycles,10. Tenth Line,7/21/2024,Inactive,,
NBR CINJ OP INFUSION,79246,"Shah, Mansi R, MD",7/31/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,10. Tenth Line,7/29/2024,Inactive,,
NBR 5N ONCOLOGY,79246,"Shah, Mansi R, MD",8/23/2024,"Bortezomib/Dexamethasone D1, D4, D8, D11 21 Day Cycles- Multiple Myeloma",10. Tenth Line,8/22/2024,Inactive,,
HAM OP INFUSION,85266,"Yogarajah, Meera, MD",8/10/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,First Line,8/2/2023,Inactive,,
CINJ OP INFUSION,10216,"Haigentz, Missak, MD",7/5/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,7/4/2023,Inactive,,
JCMC CP INFUSION,20939,"Cruz, Allan Louie E, MD",1/8/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,12/25/2023,Inactive,,
CINJ OP INFUSION,56743,"Hochster, Howard S, MD",9/4/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,7/24/2024,Inactive,,
CINJ OP INFUSION,56743,"Hochster, Howard S, MD",11/13/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,10/16/2024,Active,,
CINJ OP INFUSION,3730,"Haigentz, Missak, MD",12/12/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,12/11/2023,Inactive,,
CINJ OP INFUSION,17269,"Weiss, Sarah, MD",4/7/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,1/31/2023,Inactive,,
CBMC OP INFUSION 2FL,90181,"Dharmapuri, Sirish, MD",12/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/8/2024,Inactive,,
CINJ OP INFUSION,68388,"George, Mridula A, MD",11/2/2023,Palbociclib 28 Day Cycles - Breast,_1. First Line,11/2/2023,Active,,
CINJ OP INFUSION,42886,"Stephenson, Ryan D, DO",2/3/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,2/3/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; E03.9 - Hypothyroidism, unspecified; I51.9 - Heart disease, unspecified; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels"
MMC OP VP INFUSION,80622,"Cohen, Seth D, MD",5/20/2024,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,_3. Third Line,5/20/2024,Inactive,,
TRMC TCCC OP INFUSION,8811,"Capo, Gerardo, MD",10/10/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,10/9/2023,Active,,
CBMC OP INFUSION 2FL,92404,"Wagmiller, Jennifer Ann, MD",12/4/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_3. Third Line,12/3/2023,Inactive,,
CBMC OP INFUSION 2FL,92404,"Wagmiller, Jennifer Ann, MD",4/2/2024,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,_3. Third Line,4/1/2024,Inactive,,
CBMC OP INFUSION 2FL,92404,"Wagmiller, Jennifer Ann, MD",7/15/2024,EriBULin 21 Day Cycles - Breast,_5. Fifth Line,7/8/2024,Inactive,,
CBMC OP INFUSION 2FL,47826,"Leitner, Stuart P, MD",10/6/2023,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,Adjuvant,10/5/2023,Inactive,,
CBMC OP INFUSION 2FL,33366,"Grossman, I Robert, MD",8/11/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,8/10/2023,Active,,
CINJ OP INFUSION,94203,"Stephenson, Ryan D, DO",6/5/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,5/30/2023,Inactive,,
CINJ OP INFUSION,94203,"Stephenson, Ryan D, DO",6/27/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,6/20/2023,Inactive,,
CINJ OP INFUSION,94203,"Stephenson, Ryan D, DO",11/28/2023,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,Adjuvant,11/27/2023,Inactive,,
CINJ OP INFUSION,94203,"Stephenson, Ryan D, DO",7/30/2024,Pembrolizumab 21 Day Cycles - Bladder,_2. Second Line,7/29/2024,Inactive,,
NBR CINJ OP INFUSION,81512,"Shah, Mansi R, MD",2/9/2023,Daratumumab / venetoclax / dexamethasone ,,2/8/2023,Inactive,,
NBR CINJ OP INFUSION,81512,"Shah, Mansi R, MD",2/9/2023,Daratumumab and Hyaluronidase-fihj / Venetoclax/ Dexamethasone 28Day Cycles- Multiple Myeloma,,2/8/2023,Inactive,,
NBR 4N ONCOLOGY,81512,"Shah, Mansi R, MD",2/25/2023,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),,2/25/2023,Inactive,,
NBR 4N ONCOLOGY,81512,"Shah, Mansi R, MD",3/25/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,3/24/2023,Inactive,,
MMC OP INFUSION,16163,"Eltoukhy, Hussam, MD",6/19/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,6/15/2023,Inactive,,
CINJ OP INFUSION,61815,"Weiss, Sarah, MD",11/27/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,11/26/2023,Active,,
CINJ OP INFUSION,61815,"Weiss, Sarah, MD",11/27/2023,CINJ 102310 Cohort A Neoadjuvant  MK-4280A or Pembrolizumab 21 Day Cycles Research- Solid Tumors,Neoadjuvant,11/26/2023,Inactive,,
NBR 5N ONCOLOGY,81379,"Hochster, Howard S, MD",9/2/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,First Line,8/31/2023,Inactive,,
CBMC OP INFUSION 2FL,7791,"Scoppetuolo, Michael, MD",11/2/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),_2. Second Line,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,10987,"Wagmiller, Jennifer Ann, MD",11/15/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/14/2023,Active,,
CINJ OP INFUSION,63856,"Girda, Eugenia, MD",7/25/2023,CINJ 102006 (GOG-3039) Abemaciclib + Letrozole 28 Day Cycles Research- Endometrial Cancer,Third Line,7/25/2023,Inactive,,
CINJ OP INFUSION,77384,"Haigentz, Missak, MD",4/21/2023,PEMEtrexed/CARBOplatin (AUC 5) PLUS Pembrolizumab - 21 Day Cycles- Non-Small Cell Lung Cancer ,First Line,4/13/2023,Inactive,,
CINJ OP INFUSION,77384,"Haigentz, Missak, MD",8/16/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,8/16/2023,Inactive,,
MMC OP VP INFUSION,3298,"Talwar, Sumit, MD",1/2/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,1/1/2024,Inactive,,
MMC OP INFUSION,66250,"Meghal, Trishala, MD",6/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/5/2024,Inactive,,
MMC OP INFUSION,66250,"Meghal, Trishala, MD",10/25/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,10/25/2024,Active,Primary cancer of left upper lobe of lung (CMS/HCC),
SOM OUTPT INFUSION,73701,"Toomey, Kathleen C, MD",4/12/2023,Palbociclib 28 Day Cycles - Breast,Second Line,4/12/2023,Inactive,,
SOM OUTPT INFUSION,73701,"Toomey, Kathleen C, MD",7/17/2023,Palbociclib 28 Day Cycles - Breast,Second Line,7/17/2023,Active,,
CINJ OP INFUSION,71711,"Haigentz, Missak, MD",7/26/2024,"PEMEtrexed/CISplatin PLUS Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Neoadjuvant,7/18/2024,Active,,
CINJ OP INFUSION,71711,"Haigentz, Missak, MD",12/18/2024,Pembrolizumab 42 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,12/17/2024,Active,,
CINJ OP INFUSION,25050,"Saraiya, Biren P, MD",2/15/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,2/14/2024,Inactive,,
NBR 5N ONCOLOGY,25050,"Saraiya, Biren P, MD",2/16/2024,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Penile Cancer (Neoadjuvant or Adjuvant),Neoadjuvant,2/16/2024,Inactive,,
CINJ OP INFUSION,25050,"Saraiya, Biren P, MD",4/25/2024,CISplatin with Concurrent Radiation Bladder Cancer,Consolidation,4/23/2024,Inactive,,
SOM OUTPT INFUSION,74437,"Patel, Eshan, MD",2/27/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly  Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,2/26/2025,Active,"Non-small cell lung cancer, left (CMS/HCC)",
CINJ OP INFUSION,25755,"Hochster, Howard S, MD",12/28/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,Maintenance,12/27/2023,Inactive,,
NBR 4N BMTU/IMCU,676,"Palmisiano, Neil David, MD",1/7/2025,CINJ 022305 Part 1 of 2 Non_Intensive (C1 Day 1-7 Inpatient)) Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,1/5/2025,Active,,
NBR 5N ONCOLOGY,676,"Tiger, Yun Kyoung, MD",1/7/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,1/6/2025,Inactive,Acute leukemia not having achieved remission (CMS/HCC),
CINJ OP INFUSION,82410,"Weiss, Sarah, MD",3/6/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,3/5/2023,Inactive,,
CINJ OP INFUSION,82410,"Weiss, Sarah, MD",9/23/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,9/22/2024,Active,,
MMC OP VP INFUSION,50059,"Cohen, Seth D, MD",10/18/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,10/17/2023,Inactive,,
CINJ OP INFUSION,14059,"Toppmeyer, Deborah L, MD",1/19/2023,Capecitabine,Third Line,1/19/2023,Active,,
CINJ OP INFUSION,14059,"Toppmeyer, Deborah L, MD",1/19/2023,Trastuzumab/Pertuzumab Q 21 days (Continuation) - Breast,Third Line,1/19/2023,Active,Multiple myeloma not having achieved remission (CMS/HCC),
MSC OP INFUSION,82272,"Tang, Horace, MD",5/12/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,5/12/2023,Inactive,,
TRMC TCCC OP INFUSION,3672,"Salerno, Vincent E, MD",2/27/2024,PEMEtrexed+ Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/19/2024,Active,,
TRMC TCCC OP INFUSION,3672,"Salerno, Vincent E, MD",10/15/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,10/14/2024,Inactive,,
TRMC TCCC OP INFUSION,3672,"Salerno, Vincent E, MD",10/15/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/7/2024,Inactive,,
TRMC TCCC OP INFUSION,3672,"Salerno, Vincent E, MD",1/23/2025,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,1/22/2025,Active,,
CINJ OP INFUSION,12065,"Ghodoussipour, Saum Bobak, MD",3/7/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,3/6/2023,Inactive,,
CINJ OP INFUSION,12065,"Ghodoussipour, Saum Bobak, MD",6/6/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,6/5/2023,Active,,
CBMC OP INFUSION 2FL,57455,"Raptis, George, MD",7/30/2024,CINJ 042102 Block A Zanidatamab 14 Day Cycles Research- Breast Cancer,Neoadjuvant,7/23/2024,Inactive,,
CBMC OP INFUSION 2FL,57455,"Raptis, George, MD",10/22/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,10/21/2024,Inactive,,
CBMC OP INFUSION 2FL,57455,"Raptis, George, MD",10/22/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,10/21/2024,Inactive,,
CBMC OP INFUSION 2FL,57455,"Raptis, George, MD",11/6/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,11/6/2024,Active,,
CBMC OP INFUSION 2FL,57455,"Raptis, George, MD",11/6/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,11/5/2024,Inactive,,
CBMC OP INFUSION 2FL,80309,"Raptis, George, MD",2/14/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,2/13/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,42114,"Shah, Shailja S, MD",3/12/2024,Carfilzomib 56 mg/m2 D1 & 15 / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,Maintenance,3/11/2024,Active,,
NBI OP INFUSION,42114,"Shah, Shailja S, MD",3/12/2024,Carfilzomib 36 mg/m2 Post-Transplant Maintenance - Multiple Myeloma,Maintenance,3/11/2024,Inactive,,
NBI OP INFUSION,42114,"Shah, Shailja S, MD",3/12/2024,Carfilzomib 36 mg/m2 Post-Transplant Maintenance - Multiple Myeloma,Maintenance,3/11/2024,Inactive,,
NBI OP INFUSION,42114,"Shah, Shailja S, MD",3/12/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,Maintenance,3/11/2024,Inactive,,
NBR CINJ OP INFUSION,42114,"Shah, Mansi R, MD",9/6/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,8/23/2024,Active,,
MMC OP VP INFUSION,76876,"Lee, Patrick C, MD",6/7/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,5/22/2024,Active,,
NBR CINJ OP INFUSION,41335,"Rhodes, Joanna Meehan, MD",8/8/2024,pola-r-mini chop (Cyclophosphamide / DOXOrubicin / polatuzumab vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/8/2024,Active,,
CMC OP INFUSION,23617,"Eltoukhy, Hussam, MD",3/19/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_5. Fifth Line,3/19/2025,Active,"Small cell b-cell lymphoma, lymph nodes of head, face, and neck (CMS/HCC)",
NBR CINJ OP INFUSION,42474,"Evens, Andrew M, DO",1/25/2023,Brentuximab Vedotin / Nivolumab 21 Day Cycles - Hodgkin Lymphoma,,1/24/2023,Inactive,,
MSC OP INFUSION,44507,"Talwar, Sumit, MD",5/1/2024,RiTUXimab 28 Day Cycle - Hemolytic anemia ,_1. First Line,4/30/2024,Inactive,,
MSC OP INFUSION,44507,"Talwar, Sumit, MD",1/10/2025,RiTUXimab 168 Day Cycles - RA,Maintenance,1/9/2025,Active,"Invasive ductal carcinoma of breast, female, left (CMS/HCC)",
MSC OP INFUSION,44507,"Talwar, Sumit, MD",4/28/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,4/28/2025,Active,"T-cell large granular lymphocytic leukemia (CMS/HCC)
Rheumatoid arthritis (CMS/HCC)
Other acquired hemolytic anemias (CMS/HCC)",
CBMC OP INFUSION 2FL,87022,"Litvak, Anna M, MD",11/28/2023,CINJ 042102 Block A Zanidatamab 14 Day Cycles Research- Breast Cancer,_1. First Line,11/27/2023,Inactive,,
CBMC OP INFUSION 2FL,87022,"Wagmiller, Jennifer Ann, MD",2/20/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,2/19/2024,Inactive,,
CBMC OP INFUSION 2FL,87022,"Wagmiller, Jennifer Ann, MD",5/14/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,5/13/2024,Inactive,,
CBMC OP INFUSION 2FL,87022,"Wagmiller, Jennifer Ann, MD",7/1/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,6/24/2024,Inactive,,
CBMC OP INFUSION 2FL,87022,"Raptis, George, MD",12/11/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,12/10/2024,Active,,
SOM OUTPT INFUSION,57296,"Toomey, Kathleen C, MD",5/14/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/7/2024,Inactive,,
MMC OP VP INFUSION,69242,"Lee, Patrick C, MD",7/20/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,,7/19/2023,Inactive,,
CBMC OP INFUSION 2FL,31030,"Litvak, Anna M, MD",10/13/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,31030,"Litvak, Anna M, MD",11/24/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,11/23/2023,Inactive,,
CINJ OP INFUSION,6370,"Haigentz, Missak, MD",5/1/2025,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,_1. First Line,5/1/2025,Active,"Malignant neoplasm of oropharynx, unspecified (CMS/HCC)
Acquired hypothyroidism",
NBR BMSCH 2 PED HEMONC,25954,"Botwinick, Marissa, DO",11/9/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,11/9/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,25954,"Botwinick, Marissa, DO",11/10/2023,AALL1732 Induction,Induction,11/9/2023,Inactive,,
CINJ PEDS HEMONC ,25954,"Botwinick, Marissa, DO",12/14/2023,AALL1732 Consolidation,_1. First Line,12/14/2023,Inactive,,
CINJ PEDS HEMONC ,25954,"Botwinick, Marissa, DO",3/29/2024,as per AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,3/14/2024,Inactive,,
CINJ PEDS HEMONC ,25954,"Botwinick, Marissa, DO",7/5/2024,"AALL1732, HR B-ALL Arm A: Delayed Intensification",_1. First Line,7/5/2024,Inactive,,
CINJ PEDS HEMONC ,25954,"Botwinick, Marissa, DO",9/27/2024,PEDS Blinatumomab,_1. First Line,9/12/2024,Active,,
CINJ PEDS HEMONC ,25954,"Botwinick, Marissa, DO",10/31/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,10/31/2024,Active,,
CINJ PEDS HEMONC ,25954,"Botwinick, Marissa, DO",2/7/2025,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",Maintenance,2/6/2025,Active,Acute lymphocytic leukemia in remission (CMS/HCC),
SOM OUTPT INFUSION,95177,"Patel, Eshan, MD",7/19/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),,7/18/2023,Inactive,,
SOM OUTPT INFUSION,95177,"Patel, Eshan, MD",7/25/2023,Paclitaxel weekly Trastuzumab 21 Day Cycles (Initiation) - Breast,,7/25/2023,Inactive,,
SOM OUTPT INFUSION,95177,"Patel, Eshan, MD",10/17/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,10/16/2023,Active,Rectal cancer metastasized to liver (CMS/HCC),
HAM OP INFUSION,90039,"Yogarajah, Meera, MD",3/25/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,3/24/2024,Inactive,,
CBMC OP INFUSION 2FL,91286,"Brown, Andrew Bennett, MD",4/19/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,4/15/2024,Active,,
NBI OP INFUSION,13483,"Snyder, Rose, MD",1/14/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,1/14/2025,Active,Primary malignant neoplasm of kidney with metastasis from kidney to other site (CMS/HCC),
NBI OP INFUSION,13483,"Snyder, Rose, MD",1/29/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,1/29/2025,Future,Autoimmune hemolytic anemia (CMS/HCC),
CINJ OP INFUSION,12759,"Salacz, Michael E, MD",1/9/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,First Line,1/9/2023,Inactive,,
CINJ OP INFUSION,12759,"Salacz, Michael E, MD",4/26/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,4/26/2023,Active,Malignant neoplasm of lower-inner quadrant of right female breast (CMS/HCC),
SOM OUTPT INFUSION,51082,"Patel, Eshan, MD",12/5/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,12/4/2024,Active,,
CMC OP INFUSION,74701,"Taff, Jessica, MD",3/24/2025,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,3/24/2025,Active,Malignant neoplasm of descended left testis (CMS/HCC),
CINJ OP INFUSION,42283,"Sharma, Archana, DO",1/26/2023,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,1/25/2023,Inactive,,
CINJ OP INFUSION,42283,"Aikins, James K, MD",6/23/2023,Gemcitabine / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,6/21/2023,Inactive,,
CINJ OP INFUSION,42283,"Aikins, James K, MD",2/22/2024,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_3. Third Line,2/21/2024,Inactive,,
CINJ OP INFUSION,42283,"Aikins, James K, MD",12/11/2024,Pembrolizumab 21 Day Cycles - Cervical,_3. Third Line,12/10/2024,Active,,
NBI OP INFUSION,49506,"Anderson, Patrick S, MD",8/8/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,7/29/2024,Active,,
NBI D7 MED-SURG/TELE,88226,"Anderson, Patrick S, MD",3/4/2025,Bevacizumab 21 Day Cycles -Endometrial cancer,_3. Third Line,3/3/2025,Inactive,Endometrial cancer (CMS/HCC),
CMC OP INFUSION,20854,"Talwar, Sumit, MD",4/24/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,4/23/2024,Inactive,,
SOM OUTPT INFUSION,44439,"Patel, Eshan, MD",2/28/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/24/2025,Active,"Pancreatic cancer metastasized to liver (CMS/HCC)
Pancreatic cancer (CMS/HCC)",
SOM OUTPT INFUSION,76547,"Patel, Eshan, MD",3/3/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/3/2025,Inactive,"Pancreatic cancer metastasized to liver (CMS/HCC)
Pancreatic cancer (CMS/HCC)",
SOM OUTPT INFUSION,19078,"Toomey, Kathleen C, MD",6/28/2023,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Third Line,6/27/2023,Inactive,,
SOM OUTPT INFUSION,19078,"Toomey, Kathleen C, MD",10/26/2023,Weekly Fluorouracil IV Push / Leucovorin IV Push 7 Day Cycles- Colon Cancer,_2. Second Line,10/25/2023,Inactive,,
SOM OUTPT INFUSION,19078,"Toomey, Kathleen C, MD",12/11/2023,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/11/2023,Inactive,,
NBI OP INFUSION,3450,"Snyder, Rose, MD",3/19/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/19/2025,Active,Malignant neoplasm of prostate (CMS/HCC),C61 - Malignant neoplasm of prostate
CINJ OP INFUSION,72566,"Stephenson, Ryan D, DO",5/15/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,4/28/2024,Inactive,,
CINJ OP INFUSION,72566,"Stephenson, Ryan D, DO",7/31/2024,Larotrectinib 28 Day Cycles- Prostate,_4. Fourth Line,7/31/2024,Inactive,,
CINJ OP INFUSION,41964,"Leiser, Aliza, MD",8/8/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/7/2024,Active,,
CINJ OP INFUSION,41964,"Leiser, Aliza, MD",1/24/2025,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,1/24/2025,Active,,
CINJ OP INFUSION,41964,"Leiser, Aliza, MD",1/24/2025,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,1/24/2025,Inactive,Primary malignant neoplasm of fallopian tube (CMS/HCC),
SOM OUTPT INFUSION,14584,"Toomey, Kathleen C, MD",10/17/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Induction,10/16/2023,Inactive,,
SOM OUTPT INFUSION,14584,"Toomey, Kathleen C, MD",3/20/2024,"Albumin-Bound PACLitaxel D1, D8, D15/ CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,3/19/2024,Inactive,,
SOM OUTPT INFUSION,14584,"Toomey, Kathleen C, MD",5/30/2024,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,_2. Second Line,5/30/2024,Inactive,,
SOM OUTPT INFUSION,14584,"Toomey, Kathleen C, MD",11/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/31/2024,Active,,
SOM OUTPT INFUSION,14584,"Toomey, Kathleen C, MD",1/29/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,1/28/2025,Active,,
CINJ OP INFUSION,65203,"Stephenson, Ryan D, DO",11/8/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,10/25/2023,Active,,
SOM OUTPT INFUSION,83443,"Toomey, Kathleen C, MD",4/15/2025,CISplatin 75 mg/m2 / Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Cancers,_1. First Line,4/15/2025,Inactive,"Small cell carcinoma of prostate (CMS/HCC)
Metastasis to bone (CMS/HCC)",
SOM OUTPT INFUSION,83443,"Toomey, Kathleen C, MD",4/14/2025,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_2. Second Line,4/14/2025,Active,Small cell carcinoma of prostate (CMS/HCC),
NBR 5N ONCOLOGY,78110,"Shah, Mansi R, MD",7/18/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,7/17/2024,Inactive,,
SOM OUTPT INFUSION,9772,"Toomey, Kathleen C, MD",1/19/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/18/2023,Inactive,,
SOM OUTPT INFUSION,9772,"Toomey, Kathleen C, MD",7/8/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,7/8/2024,Active,,
NBR CINJ OP INFUSION,71997,"Rhodes, Joanna Meehan, MD",9/1/2023,PEDS ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) - Hodgkin Lymphoma,First Line,8/30/2023,Inactive,,
NBR CINJ OP INFUSION,71997,"Rhodes, Joanna Meehan, MD",9/1/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,First Line,8/31/2023,Inactive,,
NBR CINJ OP INFUSION,71997,"Rhodes, Joanna Meehan, MD",11/3/2023,CINJ 112305 AVD Arm E (Doxorubicin / Vinblastine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,11/2/2023,Active,,
CBMC OP INFUSION 2FL,50811,"Litvak, Anna M, MD",9/24/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,9/24/2024,Active,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,85078,"Leiser, Aliza, MD",9/26/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,,9/25/2023,Inactive,,
CINJ OP INFUSION,85078,"Leiser, Aliza, MD",11/27/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,11/26/2023,Inactive,,
NBR 4N ONCOLOGY,85078,"Leiser, Aliza, MD",2/9/2024,PACLitaxel weekly 28 Day Cycles - Cervcial (Metastatic),_1. First Line,2/7/2024,Active,,
NBI OP INFUSION,65414,"Jacoby, Sari H, MD",11/12/2024,Weekly Fluorouracil IV Push / Leucovorin IV Push 7 Day Cycles- Colon Cancer,Adjuvant,11/11/2024,Inactive,,
NBI OP INFUSION,65414,"Jacoby, Sari H, MD",11/12/2024,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,Adjuvant,11/11/2024,Active,Hepatocellular carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,2181,"Litvak, Anna M, MD",1/24/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,1/7/2025,Active,,
JCMC CP INFUSION,17532,"Cruz, Allan Louie E, MD",4/24/2023,Simplified BiWeekly Infusional Fluorouracil/Leucovorin 14 Day Cycles- Gastrointestinal Cancers,Maintenance,4/23/2023,Inactive,,
CINJ OP INFUSION,72667,"Stephenson, Ryan D, DO",12/29/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,12/29/2023,Inactive,,
CINJ OP INFUSION,72667,"Stephenson, Ryan D, DO",4/26/2024,Cabozantinib 28 Day Cycles- Kidney Cancer,_2. Second Line,4/26/2024,Active,,
CINJ OP INFUSION,72667,"Stephenson, Ryan D, DO",2/21/2025,Lenvatinib/Everolimus 28 Day Cycles- Renal Cell Carcinoma,_3. Third Line,2/21/2025,Active,Metastatic renal cell carcinoma (CMS/HCC),"C64.2 - Malignant neoplasm of left kidney, except renal pelvis; C79.51 - Secondary malignant neoplasm of bone; G89.3 - Neoplasm related pain (acute) (chronic); I10 - Essential (primary) hypertension; Z87.2 - Personal history of diseases of the skin and subcutaneous tissue; Z86.39 - Personal history of other endocrine, nutritional and metabolic disease"
CBMC OP INFUSION 2FL,23565,"Brown, Andrew Bennett, MD",6/4/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,6/4/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
MSC OP INFUSION,48399,"Cohen, Seth D, MD",2/16/2023,Xeloda/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,2/15/2023,Inactive,,
MMC OP VP INFUSION,99896,"Lee, Patrick C, MD",4/6/2023,Atezolizumab 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/5/2023,Active,,
MMC OP INFUSION,40598,"Meghal, Trishala, MD",2/8/2023,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,Second Line,2/7/2023,Inactive,,
MMC OP INFUSION,40598,"Meghal, Trishala, MD",7/26/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Second Line,7/20/2023,Inactive,,
MMC OP INFUSION,40598,"Meghal, Trishala, MD",7/26/2023,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,,7/25/2023,Inactive,,
MMC OP INFUSION,40598,"Meghal, Trishala, MD",8/2/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Second Line,8/1/2023,Active,,
CBMC 2W ONCOLOGY,20652,"Grossman, I Robert, MD",3/1/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,2/29/2024,Inactive,,
CINJ OP INFUSION,74276,"Salacz, Michael E, MD",1/1/2023,Bevacizumab 28 Day Cycles - CNS,First Line,12/31/2022,Inactive,,
CINJ OP INFUSION,74276,"Salacz, Michael E, MD",1/19/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,First Line,1/19/2023,Inactive,,
CMC OP INFUSION,74276,"Tang, Horace, MD",5/5/2023,Bevacizumab every 14 days,Maintenance,5/5/2023,Inactive,,
CMC OP INFUSION,95450,"Talwar, Sumit, MD",6/21/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/19/2024,Inactive,,
MMC OP VP INFUSION,75178,"Cohen, Seth D, MD",1/15/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/14/2024,Inactive,,
MMC OP VP INFUSION,75178,"Cohen, Seth D, MD",1/15/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,1/14/2024,Inactive,,
MMC OP VP INFUSION,75178,"Cohen, Seth D, MD",5/21/2024,Pembrolizumab 21 Day Cycles - Uterine,Maintenance,5/21/2024,Inactive,,
SOM OUTPT INFUSION,93624,"Yin, Faye, MD",2/26/2023,Ribociclib 28 Day Cycles - Breast,First Line,2/26/2023,Inactive,,
SOM OUTPT INFUSION,93624,"Toomey, Kathleen C, MD",9/25/2023,Ribociclib 28 Day Cycles - Breast,,9/25/2023,Active,"Tonsillar cancer (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,50011,"Muralikrishnan, Sivraj, MD",3/21/2025,Entrectinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/21/2025,Active,NSCLC metastatic to brain (CMS/HCC),"C34.90, C79.31 - NSCLC metastatic to brain (CMS/HCC)"
NBR 5N ONCOLOGY,18777,"Rhodes, Joanna Meehan, MD",5/9/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,5/9/2025,Inactive,Plasmablastic lymphoma (CMS/HCC),"B20 - Human immunodeficiency virus (HIV) disease; E88.3 - Tumor lysis syndrome; A41.9 - Sepsis, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; R65.21 - Severe sepsis with septic shock; E44.0 - Moderate protein-calorie malnutrition; G93.41 - Metabolic encephalopathy; K68.3 - Retroperitoneal hematoma; R34 - Anuria and oliguria; B78.9 - Strongyloidiasis, unspecified; Z66 - Do not resuscitate; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; B25.9 - Cytomegaloviral disease, unspecified; R56.9 - Unspecified convulsions; D62 - Acute posthemorrhagic anemia; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; D69.6 - Thrombocytopenia, unspecified; Z79.899 - Other long term (current) drug therapy; Z55.6 - Problems related to health literacy; Z59.71 - Insufficient health insurance coverage; Z91.148 - Patient's other noncompliance with medication regimen for other reason; K52.9 - Noninfective gastroenteritis and colitis, unspecified; K62.9 - Disease of anus and rectum, unspecified; R59.1 - Generalized enlarged lymph nodes; I95.89 - Other hypotension; Z78.1 - Physical restraint status; A60.02 - Herpesviral infection of other male genital organs; B27.00 - Gammaherpesviral mononucleosis without complication; E83.42 - Hypomagnesemia; E87.5 - Hyperkalemia; Z68.25 - Body mass index (BMI) 25.0-25.9, adult"
NBR 5N ONCOLOGY,18777,"Rhodes, Joanna Meehan, MD",5/8/2025,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - T-Cell Lymphoma,_1. First Line,5/8/2025,Inactive,"AKI (acute kidney injury) (CMS/HCC)
Plasmablastic lymphoma (CMS/HCC)","B20 - Human immunodeficiency virus (HIV) disease; E88.3 - Tumor lysis syndrome; A41.9 - Sepsis, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; R65.21 - Severe sepsis with septic shock; E44.0 - Moderate protein-calorie malnutrition; G93.41 - Metabolic encephalopathy; K68.3 - Retroperitoneal hematoma; R34 - Anuria and oliguria; B78.9 - Strongyloidiasis, unspecified; Z66 - Do not resuscitate; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; B25.9 - Cytomegaloviral disease, unspecified; R56.9 - Unspecified convulsions; D62 - Acute posthemorrhagic anemia; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; D69.6 - Thrombocytopenia, unspecified; Z79.899 - Other long term (current) drug therapy; Z55.6 - Problems related to health literacy; Z59.71 - Insufficient health insurance coverage; Z91.148 - Patient's other noncompliance with medication regimen for other reason; K52.9 - Noninfective gastroenteritis and colitis, unspecified; K62.9 - Disease of anus and rectum, unspecified; R59.1 - Generalized enlarged lymph nodes; I95.89 - Other hypotension; Z78.1 - Physical restraint status; A60.02 - Herpesviral infection of other male genital organs; B27.00 - Gammaherpesviral mononucleosis without complication; E83.42 - Hypomagnesemia; E87.5 - Hyperkalemia; Z68.25 - Body mass index (BMI) 25.0-25.9, adult"
TRMC TCCC OP INFUSION,42545,"Capo, Gerardo, MD",4/9/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/9/2025,Inactive,Malignant neoplasm of cardia of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; C16.0 - Malignant neoplasm of cardia"
TRMC TCCC OP INFUSION,42545,"Capo, Gerardo, MD",4/8/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/8/2025,Active,Malignant neoplasm of cardia of stomach (CMS/HCC),
NBI OP INFUSION,55821,"Anderson, Patrick S, MD",11/17/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/10/2023,Inactive,,
NBI OP INFUSION,55821,"Anderson, Patrick S, MD",10/21/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_3. Third Line,10/20/2024,Active,,
CINJ OP INFUSION,92691,"George, Mridula A, MD",3/5/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,3/5/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,32279,"Sekhri, Arunabh, MD",2/9/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/7/2024,Inactive,,
JCMC CP INFUSION,32279,"Zhou, Nancy, MD",6/3/2024,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/3/2024,Inactive,,
JCMC CP INFUSION,32279,"Sekhri, Arunabh, MD",7/11/2024,Bevacizumab 21 Day Cycles - history of ovarian cancer,_1. First Line,7/7/2024,Active,,
NBR 5N ONCOLOGY,5649,"Rhodes, Joanna Meehan, MD",4/11/2025,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,4/11/2025,Inactive,HLH (hemophagocytic lymphohistiocytosis) (CMS/HCC),"A41.81 - Sepsis due to Enterococcus; D65 - Disseminated intravascular coagulation (defibrination syndrome); Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; I81 - Portal vein thrombosis; J80 - Acute respiratory distress syndrome; K72.00 - Acute and subacute hepatic failure without coma; E43 - Unspecified severe protein-calorie malnutrition; G93.41 - Metabolic encephalopathy; R65.21 - Severe sepsis with septic shock; Z11.52 - Encounter for screening for COVID-19; R57.8 - Other shock; K85.80 - Other acute pancreatitis without necrosis or infection; K68.3 - Retroperitoneal hematoma; K66.1 - Hemoperitoneum; K25.4 - Chronic or unspecified gastric ulcer with hemorrhage; I62.00 - Nontraumatic subdural hemorrhage, unspecified; R57.1 - Hypovolemic shock; J18.9 - Pneumonia, unspecified organism; D76.1 - Hemophagocytic lymphohistiocytosis; G72.81 - Critical illness myopathy; R18.8 - Other ascites; D61.818 - Other pancytopenia; D84.9 - Immunodeficiency, unspecified; Z99.2 - Dependence on renal dialysis; D70.9 - Neutropenia, unspecified; K76.82 - Hepatic encephalopathy; I11.0 - Hypertensive heart disease with heart failure; E03.9 - Hypothyroidism, unspecified; Z68.37 - Body mass index (BMI) 37.0-37.9, adult; I77.6 - Arteritis, unspecified; Z99.11 - Dependence on respirator (ventilator) status; I50.22 - Chronic systolic (congestive) heart failure; E87.20 - Acidosis, unspecified; K80.00 - Calculus of gallbladder with acute cholecystitis without obstruction; B19.9 - Unspec..."
NBR CINJ OP INFUSION,89550,"Shah, Mansi R, MD",9/17/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,9/16/2024,Active,,
NBR CINJ OP INFUSION,54839,"Assal, Amer, MD",12/6/2023,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Consolidation,12/5/2023,Inactive,,
CBMC OP INFUSION 2FL,14622,"Radovich, Delia, MD",11/2/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,14622,"Brown, Andrew Bennett, MD",2/15/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,2/14/2024,Inactive,,
NBI OP INFUSION,17837,"Shah, Shailja S, MD",2/11/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,2/11/2025,Active,Prostate cancer (CMS/HCC),
JCMC CP INFUSION,25701,"Sekhri, Arunabh, MD",4/2/2025,PACLitaxel 175 mg/m2 14 Day Cycles --- Hormone positive breast cancer,Neoadjuvant,4/2/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; E28.2 - Polycystic ovarian syndrome; Z92.21 - Personal history of antineoplastic chemotherapy; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,32302,"Berim, Lyudmyla, MD",5/3/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",,4/2/2023,Active,,
JCMC CP INFUSION,20085,"Sekhri, Arunabh, MD",1/20/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/19/2025,Active,"Acute renal transplant rejection
Oropharyngeal cancer (CMS/HCC)",
JCMC CP INFUSION,20085,"Sekhri, Arunabh, MD",2/6/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/19/2025,Active,Malignant neoplasm of left female breast (CMS/HCC),C50.312 - Malignant neoplasm of lower-inner quadrant of left female breast; R06.02 - Shortness of breath; C50.912 - Malignant neoplasm of unspecified site of left female breast; R05.3 - Chronic cough; R45.89 - Other symptoms and signs involving emotional state; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,40906,"Toppmeyer, Deborah L, MD",2/3/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,2/3/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,28976,"Weiss, Sarah, MD",10/25/2024,CINJ 092302 Cohort 2 Propranolol / Naltrexone 4.5 mg + Nivolumab (1 mg/kg) / Ipilimumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research Melanoma,_1. First Line,10/15/2024,Active,,
HAM OP INFUSION,21816,"Yogarajah, Meera, MD",2/5/2024,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,1/21/2024,Inactive,,
SOM OUTPT INFUSION,48989,"Patel, Eshan, MD",4/24/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,,4/3/2023,Active,,
TRMC TCCC OP INFUSION,58120,"Salerno, Vincent E, MD",9/20/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,9/19/2024,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)
Encounter for antineoplastic chemotherapy",
TRMC TCCC OP INFUSION,58120,"Salerno, Vincent E, MD",3/14/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,3/14/2025,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,17414,"Girda, Eugenia, MD",1/30/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,,1/29/2023,Inactive,,
CINJ OP INFUSION,17414,"Girda, Eugenia, MD",1/30/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,1/29/2023,Inactive,,
CBMC OP INFUSION 2FL,88345,"Wagmiller, Jennifer Ann, MD",10/1/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/24/2024,Active,,
TRMC TCCC OP INFUSION,80001,"Capo, Gerardo, MD",9/16/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_1. First Line,9/13/2024,Active,,
CINJ OP INFUSION,45597,"Omene, Coral Oghenerukevwe, MD",3/5/2024,CINJ 042102 (I-SPY 2 105139) Block A ARX788 21 Day Cycles Research- Breast Cancer,Neoadjuvant,3/4/2024,Inactive,,
CINJ OP INFUSION,45597,"Omene, Coral Oghenerukevwe, MD",5/28/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,5/24/2024,Inactive,,
CINJ OP INFUSION,45597,"Omene, Coral Oghenerukevwe, MD",6/18/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,5/21/2024,Inactive,,
CINJ OP INFUSION,45597,"Omene, Coral Oghenerukevwe, MD",9/12/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,9/11/2024,Inactive,,
CINJ OP INFUSION,45597,"Omene, Coral Oghenerukevwe, MD",4/1/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,4/1/2025,Active,Breast cancer of upper-outer quadrant of left female breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; H57.89 - Other specified disorders of eye and adnexa; R92.8 - Other abnormal and inconclusive findings on diagnostic imaging of breast; Z90.12 - Acquired absence of left breast and nipple; Z13.820 - Encounter for screening for osteoporosis; Z17.0 - Estrogen receptor positive status (ER+)
CMC OP INFUSION,25232,"Tang, Horace, MD",7/11/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,6/25/2023,Inactive,,
CMC OP INFUSION,25232,"Talwar, Sumit, MD",6/6/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/14/2024,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor negative (CMS/HCC)
Metastasis from malignant neoplasm of breast (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,31121,"Boland, Patrick M, MD",9/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/19/2024,Inactive,,
CMC OP INFUSION,24458,"Taff, Jessica, MD",8/30/2023,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,Neoadjuvant,8/29/2023,Inactive,,
CMC OP INFUSION,24458,"Taff, Jessica, MD",9/5/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,8/14/2023,Active,,
CMC OP INFUSION,24458,"Taff, Jessica, MD",11/2/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,10/17/2023,Active,,
CMC OP INFUSION,8752,"Taff, Jessica, MD",5/15/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/15/2025,Active,"Rectal bleeding
Malignant neoplasm of sigmoid colon (CMS/HCC)",
NBR CINJ OP INFUSION,61155,"Evens, Andrew M, DO",10/11/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,10/3/2023,Inactive,,
NBR CINJ OP INFUSION,61155,"Evens, Andrew M, DO",11/8/2023,CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,11/7/2023,Inactive,,
NBR CINJ OP INFUSION,61155,"Evens, Andrew M, DO",2/21/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,2/20/2024,Inactive,,
CINJ OP INFUSION,72502,"Toppmeyer, Deborah L, MD",5/30/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/15/2024,Active,"Squamous cell carcinoma of skin of other parts of face
Squamous cell carcinoma of skin of other part of trunk",
NBR 4N ONCOLOGY,32224,"Braunschweig, Ira, MD",6/3/2023,BMT Autologous Busulfan / Melphalan (Busulfan PK levels measured) ,,6/1/2023,Inactive,,
NBR 4N ONCOLOGY,32224,"Braunschweig, Ira, MD",6/7/2023,BMT Autologous Busulfan / Melphalan (Busulfan PK levels measured) ,,6/7/2023,Inactive,,
NBR 4N ONCOLOGY,32224,"Braunschweig, Ira, MD",6/7/2023,BMT Autologous Busulfan / Melphalan (Busulfan PK levels measured) ,,6/7/2023,Inactive,,
NBR CINJ OP INFUSION,32224,"Palmisiano, Neil David, MD",9/21/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,9/21/2023,Inactive,,
CINJ OP INFUSION,81353,"Boland, Patrick M, MD",7/26/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,7/25/2024,Inactive,,
CMC OP INFUSION,63280,"Pompa, Tiffany Ann, MD",8/6/2024,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,8/6/2024,Inactive,,
CMC OP INFUSION,63280,"Pompa, Tiffany Ann, MD",8/9/2024,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_1. First Line,7/25/2024,Active,,
NBR CINJ OP INFUSION,49370,"Braunschweig, Ira, MD",6/12/2023,Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles - Multiple Myeloma,,6/11/2023,Inactive,,
NBR CINJ OP INFUSION,49370,"Braunschweig, Ira, MD",6/12/2023,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,6/11/2023,Inactive,,
NBR CINJ OP INFUSION,49370,"Chowaniec, Wayne B, NP",8/14/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,8/13/2023,Inactive,,
NBR CINJ OP INFUSION,49370,"Chowaniec, Wayne B, NP",8/14/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,8/13/2023,Inactive,,
NBR CINJ OP INFUSION,49370,"Tiger, Yun Kyoung, MD",5/10/2024,Carfilzomib 56 mg/m2 Weekly / Pomalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,5/9/2024,Active,,
NBR CINJ OP INFUSION,49370,"Tiger, Yun Kyoung, MD",2/22/2025,Carfilzomib 56 mg/m2 Weekly / Pomalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,2/21/2025,Active,Multiple myeloma (CMS/HCC),
SOM OUTPT INFUSION,43563,"Patel, Eshan, MD",2/24/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,2/12/2025,Active,Triple negative malignant neoplasm of breast (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; N64.4 - Mastodynia; I10 - Essential (primary) hypertension; Z17.1 - Estrogen receptor negative status (ER-); Z79.899 - Other long term (current) drug therapy
CINJ OP INFUSION,78244,"George, Mridula A, MD",2/17/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,First Line,2/16/2023,Inactive,,
NBI OP INFUSION,50347,"Jacoby, Sari H, MD",5/1/2024,Roswell Park Leucovorin/Fluorouracil/MVASI 56 Day Cycles- Colon Cancer,_2. Second Line,4/30/2024,Inactive,,
NBI OP INFUSION,50347,"Jacoby, Sari H, MD",10/16/2024,"Irinotecan D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/15/2024,Active,,
MMC OP INFUSION,31099,"Meghal, Trishala, MD",8/9/2023,Capecitabine 21 Day Cycles - Breast,,8/9/2023,Inactive,,
MMC OP INFUSION,31099,"Meghal, Trishala, MD",12/20/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,12/19/2023,Inactive,,
MMC OP INFUSION,31099,"Meghal, Trishala, MD",12/21/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_2. Second Line,12/19/2023,Inactive,,
MMC OP VP INFUSION,31099,"Meghal, Trishala, MD",6/6/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_4. Fourth Line,6/4/2024,Inactive,,
MMC OP VP INFUSION,31099,"Meghal, Trishala, MD",7/10/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,7/8/2024,Inactive,,
MMC OP VP INFUSION,31099,"Meghal, Trishala, MD",7/18/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_4. Fourth Line,7/14/2024,Inactive,,
MMC OP VP INFUSION,31099,"Meghal, Trishala, MD",12/6/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/21/2024,Active,,
MMC OP INFUSION,31099,"Talwar, Sumit, MD",3/21/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,3/21/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,52616,"Lee, Patrick C, MD",11/16/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,Neoadjuvant,11/15/2023,Inactive,,
CINJ OP INFUSION,38584,"Haigentz, Missak, MD",10/24/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,10/24/2023,Inactive,,
CINJ OP INFUSION,70263,"Patankar, Sonali, MD",12/5/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/24/2024,Active,,
CINJ OP INFUSION,70263,"Patankar, Sonali, MD",1/6/2025,Pembrolizumab 42 Day Cycles - Cervical,_1. First Line,1/5/2025,Active,,
CINJ OP INFUSION,70263,"Patankar, Sonali, MD",2/10/2025,Pembrolizumab 42 Day Cycles - Cervical,_1. First Line,1/5/2025,Active,Squamous cell carcinoma of cervix (CMS/HCC),"C53.9 - Malignant neoplasm of cervix uteri, unspecified"
CINJ OP INFUSION,7840,"Hochster, Howard S, MD",9/13/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/11/2024,Inactive,,
CINJ OP INFUSION,7840,"Hochster, Howard S, MD",12/19/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/18/2024,Inactive,,
CINJ OP INFUSION,7840,"Hochster, Howard S, MD",1/6/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,1/6/2025,Inactive,"Primary malignant neoplasm of esophagogastric junction (CMS/HCC)
Abnormal results of thyroid function studies",
MMC OP VP INFUSION,66078,"Meghal, Trishala, MD",1/9/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/8/2023,Inactive,,
MMC OP INFUSION,66078,"Meghal, Trishala, MD",8/7/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,8/7/2023,Active,,
CINJ OP INFUSION,61631,"Boland, Patrick M, MD",3/16/2023,CINJ 072104 PCS6422 / Capecitabine Cohort 2D 14 Day Cycles Research- Colon Cancer,,3/8/2023,Inactive,,
CINJ OP INFUSION,61631,"Boland, Patrick M, MD",3/16/2023,CINJ 072104 Cohort 3 PCS6422 / Capecitabine 14 Day Cycles Research- Colon Cancer,,3/8/2023,Inactive,,
MSC OP INFUSION,86230,"Cohen, Seth D, MD",3/21/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,,3/20/2023,Inactive,,
MSC OP INFUSION,86230,"Cohen, Seth D, MD",7/5/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,,6/27/2023,Inactive,,
MMC OP VP INFUSION,86230,"Cohen, Seth D, MD",8/29/2023,Pembrolizumab 21 Day Cycles -  Breast,Adjuvant,8/29/2023,Inactive,,
MMC OP VP INFUSION,86230,"Cohen, Seth D, MD",10/17/2023,Capecitabine 21 Day Cycles - Breast,_2. Second Line,10/17/2023,Active,,
CINJ OP INFUSION,19526,"Leiser, Aliza, MD",1/10/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/25/2024,Active,,
CINJ OP INFUSION,11681,"Haigentz, Missak, MD",7/30/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,7/22/2024,Active,,
NBR CINJ OP INFUSION,805,"Rhodes, Joanna Meehan, MD",7/25/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,7/24/2024,Inactive,,
NBR CINJ OP INFUSION,805,"Rhodes, Joanna Meehan, MD",8/15/2024,DHAX (Dexamethasone / Oxaliplatin / Cytarabine) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/15/2024,Inactive,,
NBR CINJ OP INFUSION,805,"Rhodes, Joanna Meehan, MD",1/9/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,1/8/2025,Active,Gastric adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,18648,"Berim, Lyudmyla, MD",5/22/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/19/2023,Inactive,,
CINJ OP INFUSION,18648,"Berim, Lyudmyla, MD",5/22/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/21/2023,Inactive,,
CINJ OP INFUSION,18648,"Berim, Lyudmyla, MD",1/3/2024,Erdafitinib 28 Day Cycles - Gastric cancer,_2. Second Line,1/3/2024,Inactive,,
CINJ OP INFUSION,18648,"Berim, Lyudmyla, MD",2/12/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/10/2024,Inactive,,
CINJ OP INFUSION,18648,"Berim, Lyudmyla, MD",4/1/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/28/2024,Inactive,,
CBMC OP INFUSION 2FL,6534,"Litvak, Anna M, MD",4/2/2025,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,4/2/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,51186,"Shah, Mansi R, MD",2/23/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,2/9/2023,Inactive,,
NBR CINJ OP INFUSION,51186,"Shah, Mansi R, MD",1/22/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,1/8/2025,Active,,
NBR CINJ OP INFUSION,31711,"Evens, Andrew M, DO",3/28/2024,AVD + Nivo (DOXOrubicin /  / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,3/27/2024,Active,,
NBR CINJ OP INFUSION,31711,"Evens, Andrew M, DO",3/28/2024,S1826 Arm 1 AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,3/28/2024,Inactive,,
CBMC OP INFUSION 2FL,52417,"Dharmapuri, Sirish, MD",4/30/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/30/2025,Active,Colon adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,13353,"Dharmapuri, Sirish, MD",12/2/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/1/2024,Active,,
MMC OP VP INFUSION,39813,"Eltoukhy, Hussam, MD",9/3/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,8/28/2024,Active,"Acute monocytic leukemia not having achieved remission (CMS/HCC)
Encounter for screening for other viral diseases",
NBR 5N ONCOLOGY,59448,"Braunschweig, Ira, MD",11/9/2023,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/9/2023,Inactive,,
NBR 4N BMTU/IMCU,59448,"Schaar, Dale, MD PhD",1/18/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,1/16/2024,Inactive,,
NBR 5N ONCOLOGY,59448,"Shah, Mansi R, MD",3/15/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_4. Fourth Line,3/15/2024,Inactive,,
NBR CINJ OP INFUSION,59448,"Assal, Amer, MD",3/16/2024,VD-PACE (Bortezomib / Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,3/16/2024,Inactive,,
NBR CINJ OP INFUSION,59448,"Shah, Mansi R, MD",3/20/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,3/19/2024,Inactive,,
NBR CINJ OP INFUSION,59448,"Shah, Mansi R, MD",4/4/2024,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,4/3/2024,Inactive,,
SOM OUTPT INFUSION,20045,"Toomey, Kathleen C, MD",3/6/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,3/5/2024,Inactive,,
MMC OP INFUSION,20654,"Meghal, Trishala, MD",5/17/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,5/16/2023,Inactive,,
MMC OP VP INFUSION,20654,"Meghal, Trishala, MD",8/9/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,60173,"Braunschweig, Ira, MD",3/20/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,3/6/2023,Active,,
NBR 5N ONCOLOGY,12824,"Palmisiano, Neil David, MD",4/25/2025,CINJ 022405 Part 1 Tagraxofusp 12 mcg/kg / Venetoclax / Azacitadine (Days 1-7) 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,4/25/2025,Active,Acute leukemia not having achieved remission (CMS/HCC),"C93.00 - Acute monoblastic/monocytic leukemia, not having achieved remission; A41.9 - Sepsis, unspecified organism; E88.3 - Tumor lysis syndrome; E44.0 - Moderate protein-calorie malnutrition; D61.818 - Other pancytopenia; N17.9 - Acute kidney failure, unspecified; D84.9 - Immunodeficiency, unspecified; J43.8 - Other emphysema; F10.10 - Alcohol abuse, uncomplicated; L02.212 - Cutaneous abscess of back (any part, except buttock); L81.6 - Other disorders of diminished melanin formation; F12.90 - Cannabis use, unspecified, uncomplicated; L29.9 - Pruritus, unspecified; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; E83.42 - Hypomagnesemia; R73.9 - Hyperglycemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; B95.61 - Methicillin susceptible Staphylococcus aureus infection as the cause of diseases classified elsewhere; R63.4 - Abnormal weight loss; F17.210 - Nicotine dependence, cigarettes, uncomplicated; R63.0 - Anorexia; Z68.24 - Body mass index (BMI) 24.0-24.9, adult; Z63.4 - Disappearance and death of family member; Z80.41 - Family history of malignant neoplasm of ovary"
JCMC CP INFUSION,74611,"Sekhri, Arunabh, MD",8/14/2023,Pembrolizumab 21 Day Cycles - Uterine,First Line,8/13/2023,Inactive,,
CBMC OP INFUSION 2FL,66739,"Litvak, Anna M, MD",5/23/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/23/2025,Active,Invasive ductal carcinoma of breast (CMS/HCC),C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; E53.8 - Deficiency of other specified B group vitamins; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,66739,"Litvak, Anna M, MD",3/28/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/28/2025,Inactive,Invasive ductal carcinoma of breast (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast
CINJ OP INFUSION,53151,"Aikins, James K, MD",6/26/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,6/23/2023,Inactive,,
CINJ OP INFUSION,53151,"Aikins, James K, MD",6/29/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,6/28/2023,Inactive,,
CINJ OP INFUSION,83519,"Omene, Coral Oghenerukevwe, MD",1/23/2024,CINJ 042102 EOP A ARV-471 28 Day Cycles Research- Breast Cancer,Neoadjuvant,1/22/2024,Inactive,,
CINJ OP INFUSION,83519,"Omene, Coral Oghenerukevwe, MD",11/18/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,11/18/2024,Active,,
TRMC TCCC OP INFUSION,21095,"Salerno, Vincent E, MD",12/20/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,12/16/2024,Inactive,,
CINJ OP INFUSION,60260,"Stephenson, Ryan D, DO",5/9/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,5/9/2025,Inactive,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; C77.8 - Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions; C79.51 - Secondary malignant neoplasm of bone; E78.5 - Hyperlipidemia, unspecified; I10 - Essential (primary) hypertension; E03.9 - Hypothyroidism, unspecified; E66.812 - Obesity, class 2; Z19.1 - Hormone sensitive malignancy status; E66.09 - Other obesity due to excess calories; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels"
CINJ OP INFUSION,60260,"Stephenson, Ryan D, DO",5/2/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/2/2025,Active,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; C77.8 - Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E66.9 - Obesity, unspecified; E03.9 - Hypothyroidism, unspecified; Z19.1 - Hormone sensitive malignancy status; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels; Z68.35 - Body mass index (BMI) 35.0-35.9, adult"
CINJ OP INFUSION,70637,"Saraiya, Biren P, MD",6/27/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,6/11/2024,Inactive,,
MMC OP INFUSION,82590,"Eltoukhy, Hussam, MD",11/30/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/29/2023,Inactive,,
NBR CINJ OP INFUSION,12888,"Zayac, Adam, MD",9/16/2024,MEC (MitoXANTRONE / Etoposide / High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,12888,"Zayac, Adam, MD",12/16/2024,FLAG-GO (Fludarabine / Cytarabine / Filgrastim / Gemtuzumab Ozogamicin) - Acute Myeloid Leukemia (Age 60 Years Or Less),_4. Fourth Line,12/10/2024,Active,,
CBMC OP INFUSION 2FL,37925,"Grossman, I Robert, MD",8/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/18/2024,Inactive,,
CBMC OP INFUSION 2FL,37925,"Grossman, I Robert, MD",8/22/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/18/2024,Active,Aplastic anemia (CMS/HCC),
NBR CINJ OP INFUSION,33298,"Matasar, Matthew J, MD",5/15/2025,BMT Autologous BEAM,_2. Second Line,5/15/2025,Active,T-cell/histiocyte-rich large B-cell lymphoma (CMS/HCC),
CBMC OP INFUSION 2FL,33298,"Grossman, I Robert, MD",3/13/2025,R-ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,3/13/2025,Inactive,T-cell/histiocyte-rich large B-cell lymphoma (CMS/HCC),
CINJ OP INFUSION,28648,"Stephenson, Ruth D, DO",9/18/2023,CISplatin 21 Day Cycles - Vulvar Cancer,First Line,9/17/2023,Inactive,,
CINJ OP INFUSION,28648,"Stephenson, Ruth D, DO",9/18/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar,First Line,9/17/2023,Inactive,,
CINJ OP INFUSION,96852,"Jang, Thomas L, MD",11/15/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,11/14/2024,Active,,
CINJ OP INFUSION,96852,"Jang, Thomas L, MD",2/7/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,2/6/2025,Active,Urothelial carcinoma (CMS/HCC),"C67.4 - Malignant neoplasm of posterior wall of bladder; Z98.890 - Other specified postprocedural states; I10 - Essential (primary) hypertension; K21.9 - Gastro-esophageal reflux disease without esophagitis; E78.5 - Hyperlipidemia, unspecified; Z87.891 - Personal history of nicotine dependence; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,80618,"Omene, Coral Oghenerukevwe, MD",1/18/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/15/2024,Inactive,,
CINJ OP INFUSION,80618,"Omene, Coral Oghenerukevwe, MD",3/5/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,2/15/2024,Inactive,,
CINJ OP INFUSION,80618,"Omene, Coral Oghenerukevwe, MD",8/21/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,8/20/2024,Inactive,,
CBMC OP INFUSION 2FL,96370,"Wagmiller, Jennifer Ann, MD",1/9/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,1/8/2024,Inactive,,
CINJ OP INFUSION,94289,"Boland, Patrick M, MD",9/22/2023,CARBOplatin / Gemcitabine/Durvalumab  21 Day Cycles - Gallbladder,Neoadjuvant,9/21/2023,Inactive,,
CINJ OP INFUSION,94289,"Boland, Patrick M, MD",4/18/2024,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_2. Second Line,4/17/2024,Inactive,,
CBMC OP INFUSION 2FL,37871,"Brown, Andrew Bennett, MD",2/7/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/5/2024,Inactive,,
SOM OUTPT INFUSION,34859,"Yin, Faye, MD",11/27/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/21/2023,Inactive,,
SOM OUTPT INFUSION,34859,"Yin, Faye, MD",1/8/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2024,Inactive,,
SOM OUTPT INFUSION,34859,"Patel, Eshan, MD",10/28/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/9/2024,Inactive,,
NBI OP INFUSION,66385,"Cheng, Yan Ho, MD",6/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/27/2024,Inactive,,
NBI OP INFUSION,21558,"Cheng, Yan Ho, MD",3/3/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/3/2025,Active,Duodenal adenocarcinoma (CMS/HCC),C17.0 - Duodenal adenocarcinoma (CMS/HCC)
HAM OP INFUSION,79555,"Patel, Malini M, MD",6/10/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,6/10/2024,Active,,
MMC OP VP INFUSION,66148,"Lee, Patrick C, MD",9/13/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),Induction,9/13/2024,Active,"Peritoneal carcinomatosis (CMS/HCC)
Elevated cancer antigen 125 (CA 125)
Encounter for antineoplastic chemotherapy
Malignant neoplasm of ovary (CMS/HCC)",
CINJ OP INFUSION,9719,"Berim, Lyudmyla, MD",11/20/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/9/2023,Inactive,,
CINJ OP INFUSION,29019,"Omene, Coral Oghenerukevwe, MD",2/13/2023,CINJ 042102 (I-SPY 2 105139) Datopotamab Deruxtecan / Durvalumab Appendix AH 21 Day Cycles - Breast Cancer,Neoadjuvant,2/12/2023,Inactive,,
CINJ OP INFUSION,29019,"Omene, Coral Oghenerukevwe, MD",5/9/2023,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,,5/8/2023,Inactive,,
CINJ OP INFUSION,29019,"Omene, Coral Oghenerukevwe, MD",10/17/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Maintenance,10/14/2023,Inactive,,
CBMC OP INFUSION 2FL,58711,"Litvak, Anna M, MD",11/24/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_1. First Line,11/23/2023,Inactive,,
CBMC OP INFUSION 2FL,58711,"Ligresti, Louise G, MD",2/1/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,1/31/2024,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CBMC OP INFUSION 2FL,58711,"Litvak, Anna M, MD",11/15/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,11/14/2024,Active,Malignant neoplasm of tail of pancreas (CMS/HCC),
CMC OP INFUSION,17513,"Pompa, Tiffany Ann, MD",4/11/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/11/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),C54.1 - Endometrial cancer (CMS/HCC); C56.1 - Malignant neoplasm of right ovary (CMS/HCC)
NBI OP INFUSION,96117,"Cheng, Yan Ho, MD",8/2/2023,RiTUXimab Q 56 Day Cycles - Mantle Cell Lymphoma (Maintenance),Maintenance,8/1/2023,Inactive,,
CBMC OP INFUSION 2FL,61470,"Leitner, Stuart P, MD",6/20/2024,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,Neoadjuvant,6/13/2024,Inactive,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,61470,"Leitner, Stuart P, MD",9/27/2024,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,9/26/2024,Inactive,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,61470,"Leitner, Stuart P, MD",1/10/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,1/9/2025,Active,,
SOM OUTPT INFUSION,73303,"Toomey, Kathleen C, MD",12/11/2023,CISplatin/Etoposide with Concurrent Radiation 28 Day Cycles - Non-Small Cell Lung Cancer,Neoadjuvant,12/10/2023,Inactive,,
SOM OUTPT INFUSION,73303,"Toomey, Kathleen C, MD",2/8/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,2/1/2024,Inactive,,
SOM OUTPT INFUSION,73303,"Toomey, Kathleen C, MD",10/23/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,10/17/2024,Active,,
MSC OP INFUSION,18908,"Cohen, Seth D, MD",8/26/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,8/25/2024,Active,,
NBR 4N ONCOLOGY,91646,"Palmisiano, Neil David, MD",12/23/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,12/22/2023,Inactive,,
SOM OUTPT INFUSION,67334,"Patel, Eshan, MD",2/18/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,2/12/2025,Active,Metastatic melanoma (CMS/HCC),
NBR CINJ OP INFUSION,77497,"Tiger, Yun Kyoung, MD",10/13/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/12/2023,Inactive,,
NBR CINJ OP INFUSION,77497,"Tiger, Yun Kyoung, MD",10/13/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,10/13/2023,Inactive,,
NBR 4N ONCOLOGY,77497,"Tiger, Yun Kyoung, MD",11/3/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/3/2023,Inactive,,
NBR 4N ONCOLOGY,77497,"Tiger, Yun Kyoung, MD",11/3/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/3/2023,Inactive,,
NBR CINJ OP INFUSION,77497,"Tiger, Yun Kyoung, MD",11/3/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/2/2023,Inactive,,
NBR CINJ OP INFUSION,77497,"Tiger, Yun Kyoung, MD",3/22/2024,Brentuximab Vedotin / Nivolumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,3/21/2024,Inactive,,
SOM OUTPT INFUSION,62337,"Toomey, Kathleen C, MD",10/2/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/24/2024,Active,Metastasis from pancreatic cancer (CMS/HCC),
SOM OUTPT INFUSION,62337,"Toomey, Kathleen C, MD",2/5/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,2/4/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)
Metastasis to lymph nodes (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C50.111 - Malignant neoplasm of central portion of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,24662,"Boland, Patrick M, MD",5/30/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/25/2023,Inactive,,
NBI OP INFUSION,71094,"Cheng, Yan Ho, MD",2/27/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,2/27/2025,Inactive,Malignant neoplasm of prostate (CMS/HCC),C61 - Malignant neoplasm of prostate; Z85.46 - Personal history of malignant neoplasm of prostate; Z85.528 - Personal history of other malignant neoplasm of kidney
HAM OP INFUSION,29231,"Yogarajah, Meera, MD",1/3/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,First Line,1/2/2023,Inactive,,
CINJ OP INFUSION,98844,"Jang, Thomas L, MD",8/13/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,8/11/2024,Inactive,"Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC)
Urothelial cancer (CMS/HCC)",
CINJ OP INFUSION,98844,"Jang, Thomas L, MD",1/14/2025,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,1/13/2025,Active,,
MSC OP INFUSION,427,"Eltoukhy, Hussam, MD",5/29/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,5/29/2025,Active,Follicular lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,427,"Tiger, Yun Kyoung, MD",5/5/2025,CINJ 012503 Arm 1 Rituximab 56 Day Cycles Research - Follicular Lymphoma,_1. First Line,5/5/2025,Inactive,Follicular lymphoma (CMS/HCC),
CINJ OP INFUSION,37286,"Stephenson, Ryan D, DO",9/23/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,9/22/2024,Inactive,,
NBI OP INFUSION,45060,"Jacoby, Sari H, MD",4/23/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2025,Active,Metastatic colon cancer to liver (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K62.5 - Hemorrhage of anus and rectum; I10 - Essential (primary) hypertension; R14.0 - Abdominal distension (gaseous); E78.00 - Pure hypercholesterolemia, unspecified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z95.828 - Presence of other vascular implants and grafts; Z72.0 - Tobacco use; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,195,"Lee, Patrick C, MD",8/3/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,7/31/2023,Inactive,,
CINJ OP INFUSION,8594,"Toppmeyer, Deborah L, MD",3/9/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,First Line,3/8/2023,Inactive,,
CBMC OP INFUSION 2FL,96170,"Brown, Andrew Bennett, MD",3/25/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,3/20/2024,Inactive,,
CBMC OP INFUSION 2FL,96170,"Niranjan, Usha, MD",4/1/2024,Albumin-Bound PACLitaxel/CARBOplatin with Concurrent Radiation Therapy 7 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/31/2024,Inactive,,
CBMC OP INFUSION 2FL,96170,"Brown, Andrew Bennett, MD",6/6/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,6/5/2024,Active,,
NBR 5N ONCOLOGY,55511,"Sridharan, Ashwin, MD",10/10/2024,Cytarabine (200 mg/m2) / DAUNOrubicin (60 mg/m2) / Quizartinib (7 + 3) - Acute Myeloid Leukemia (Induction),Induction,10/10/2024,Inactive,,
NBR CINJ OP INFUSION,55511,"Zayac, Adam, MD",12/11/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,12/11/2024,Active,,
NBR CINJ OP INFUSION,55511,"Egini, Ogechukwu, MD",12/15/2024,BMT Allogeneic TBF + Post Cy,_2. Second Line,12/14/2024,Inactive,,
NBR CINJ OP INFUSION,55511,"Egini, Ogechukwu, MD",12/15/2024,BMT Allogeneic TBF + Post Cy,_2. Second Line,12/14/2024,Inactive,,
NBR CINJ OP INFUSION,55511,"Zayac, Adam, MD",12/18/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_2. Second Line,12/18/2024,Active,,
MMC OP INFUSION,57351,"Eltoukhy, Hussam, MD",8/3/2023,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,8/2/2023,Active,,
MMC OP INFUSION,57351,"Lee, Patrick C, MD",10/22/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/22/2024,Active,,
NBR CINJ OP INFUSION,99442,"Evens, Andrew M, DO",5/14/2025,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,5/14/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),"C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; C83.00 - Small cell B-cell lymphoma, unspecified site; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E83.39 - Other disorders of phosphorus metabolism; R53.83 - Other fatigue"
CINJ OP INFUSION,58317,"Stephenson, Ryan D, DO",5/17/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,First Line,5/1/2023,Inactive,,
NBR 4N ONCOLOGY,58317,"Berim, Lyudmyla, MD",6/4/2023,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),,6/4/2023,Inactive,,
NBR 4N ONCOLOGY,58317,"Berim, Lyudmyla, MD",6/4/2023,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),,6/4/2023,Inactive,,
CMC OP INFUSION,53624,"Tang, Horace, MD",2/23/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,2/23/2023,Inactive,,
CMC OP INFUSION,60021,"Eltoukhy, Hussam, MD",1/9/2024,Obinutuzumab /  Lenalidomide 28 Day Cycles + Obinutuzumab 56 Day Cycles - Follicular Lymphoma,_2. Second Line,12/21/2023,Inactive,,
MMC OP VP INFUSION,54883,"Cohen, Seth D, MD",8/20/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,8/14/2024,Inactive,,
MSC OP INFUSION,54883,"Cohen, Seth D, MD",12/25/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,12/23/2024,Active,,
CINJ OP INFUSION,10167,"Ganesan, Shridar, MD PhD",1/13/2023,Palbociclib 28 Day Cycles - Breast,Second Line,1/13/2023,Inactive,,
CINJ OP INFUSION,10167,"Ganesan, Shridar, MD PhD",8/8/2023,Abemaciclib 28 Day Cycles - Breast ,Third Line,8/8/2023,Active,,
MSC OP INFUSION,98728,"Cohen, Seth D, MD",1/30/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,1/29/2025,Inactive,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,98728,"Cohen, Seth D, MD",3/10/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/10/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,61847,"Dharmapuri, Sirish, MD",3/17/2025,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,3/17/2025,Inactive,HCC (hepatocellular carcinoma) (CMS/HCC),
CBMC 2W ONCOLOGY,40543,"McKenna, Marshall, MD",10/24/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,10/23/2024,Inactive,,
SOM OUTPT INFUSION,33163,"Toomey, Kathleen C, MD",10/10/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/24/2024,Inactive,,
NBR CINJ OP INFUSION,96081,"Rhodes, Joanna Meehan, MD",5/8/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/8/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; C83.30 - Diffuse large B-cell lymphoma, unspecified site"
NBR CINJ OP INFUSION,96081,"Rhodes, Joanna Meehan, MD",4/24/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,4/24/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
CMC OP INFUSION,24121,"Cohen, Seth D, MD",9/9/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/1/2024,Inactive,,
CMC OP INFUSION,24121,"Cohen, Seth D, MD",12/30/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/29/2024,Active,,
CMC OP INFUSION,21709,"Talwar, Sumit, MD",4/7/2025,CISplatin 75 mg/m2 / Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Cancers,Induction,4/7/2025,Active,Primary malignant neoplasm of right lower lobe of lung (CMS/HCC),
NBR CINJ OP INFUSION,13945,"Shah, Mansi R, MD",3/8/2024,Carfilzomib 70 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,3/8/2024,Inactive,,
NBR CINJ OP INFUSION,13945,"Shah, Mansi R, MD",4/8/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_5. Fifth Line,4/8/2024,Inactive,,
NBR CINJ OP INFUSION,13945,"Shah, Mansi R, MD",4/9/2024,Carfilzomib 70 mg/m2 / POM/ Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,4/8/2024,Active,,
NBR CINJ OP INFUSION,56269,"Shah, Mansi R, MD",4/10/2025,Talquetamab 28 Day Cycles,_5. Fifth Line,4/10/2025,Active,"Multiple myeloma in remission (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
CBMC OP INFUSION 2FL,57811,"Brown, Andrew Bennett, MD",9/7/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,9/6/2023,Inactive,,
CBMC OP INFUSION 2FL,57811,"Brown, Andrew Bennett, MD",11/2/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,57811,"Brown, Andrew Bennett, MD",11/30/2023,Pembrolizumab / Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/29/2023,Active,,
CBMC OP INFUSION 2FL,26965,"Brown, Andrew Bennett, MD",4/24/2025,Gemcitabine/VinORELBine 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/24/2025,Active,Primary malignant neoplasm of left upper lobe of lung (CMS/HCC),"C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung"
NBR CINJ OP INFUSION,28409,"Shah, Mansi R, MD",8/17/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,8/3/2023,Inactive,,
NBR 4N BMTU/IMCU,28409,"Braunschweig, Ira, MD",9/7/2023,BMT Autologous Melphalan Day -1 140MG/M2,,9/5/2023,Inactive,,
NBR 5N ONCOLOGY,40786,"Packiam, Vignesh, MD",2/5/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/5/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
MMC OP VP INFUSION,97745,"Lee, Patrick C, MD",11/20/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,11/15/2023,Active,,
HAM OP INFUSION,27811,"Yogarajah, Meera, MD",3/17/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/17/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",C50.811 - Malignant neoplasm of overlapping sites of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.0 - Estrogen receptor positive status (ER+); I10 - Essential (primary) hypertension; I08.1 - Rheumatic disorders of both mitral and tricuspid valves; E10.9 - Type 1 diabetes mellitus without complications; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy
NBI OP INFUSION,32140,"Schleicher, Lori, MD",11/20/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,11/14/2024,Active,,
NBI OP INFUSION,32140,"Schleicher, Lori, MD",12/10/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/10/2024,Inactive,,
CINJ OP INFUSION,40355,"Aikins, James K, MD",8/28/2023,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Third Line,8/27/2023,Inactive,,
CINJ OP INFUSION,40355,"Aikins, James K, MD",10/12/2023,"CINJ 102302 ARM 2 PHASE 1B ACR-368 + ULDG DOSE LEVEL 1 - OVARIAN, ENDOMETRIAL, UROTHELIAL CANCER",_3. Third Line,10/12/2023,Inactive,,
CINJ OP INFUSION,40355,"Aikins, James K, MD",1/18/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,1/18/2024,Inactive,,
CINJ OP INFUSION,40355,"Aikins, James K, MD",4/4/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Uterine Carcinosarcoma,_3. Third Line,4/3/2024,Inactive,,
CINJ OP INFUSION,98811,"Boland, Patrick M, MD",5/16/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/16/2025,Inactive,Adenocarcinoma of sigmoid colon (CMS/HCC),
NBR 5N ONCOLOGY,98811,"Haigentz, Missak, MD",5/1/2025,"mFOLFOX6 Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/1/2025,Inactive,Adenocarcinoma of sigmoid colon (CMS/HCC),"C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; E43 - Unspecified severe protein-calorie malnutrition; G93.41 - Metabolic encephalopathy; I85.11 - Secondary esophageal varices with bleeding; E87.20 - Acidosis, unspecified; R18.0 - Malignant ascites; K76.6 - Portal hypertension; D62 - Acute posthemorrhagic anemia; K22.10 - Ulcer of esophagus without bleeding; C18.7 - Malignant neoplasm of sigmoid colon; I10 - Essential (primary) hypertension; N17.9 - Acute kidney failure, unspecified; K74.60 - Unspecified cirrhosis of liver; E86.1 - Hypovolemia; Z74.09 - Other reduced mobility; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R79.1 - Abnormal coagulation profile; R54 - Age-related physical debility; K44.9 - Diaphragmatic hernia without obstruction or gangrene; K31.89 - Other diseases of stomach and duodenum; K21.9 - Gastro-esophageal reflux disease without esophagitis; I86.4 - Gastric varices; G62.9 - Polyneuropathy, unspecified; F40.240 - Claustrophobia; I95.9 - Hypotension, unspecified; R91.8 - Other nonspecific abnormal finding of lung field; E53.8 - Deficiency of other specified B group vitamins; Z68.27 - Body mass index (BMI) 27.0-27.9, adult; Z90.49 - Acquired absence of other specified parts of digestive tract; Z87.891 - Personal history of nicotine dependence; Z87.19 - Personal history of other diseases of the digestive system; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of..."
TRMC TCCC OP INFUSION,52406,"Capo, Gerardo, MD",2/8/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone plus Pomelyst 28 Day Cycles- Multiple Myeloma,_1. First Line,2/7/2024,Active,,
NBI OP INFUSION,18856,"Jacoby, Sari H, MD",12/11/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,12/11/2023,Active,Metastatic melanoma (CMS/HCC),
CMC OP INFUSION,56451,"Tang, Horace, MD",4/5/2023,"Albumin-Bound PACLitaxel D1,  21 Day Cycles- Non-Small Cell Lung Cancer",Second Line,4/5/2023,Inactive,,
CMC OP INFUSION,16639,"Talwar, Sumit, MD",5/20/2025,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/20/2025,Active,"Lung cancer (CMS/HCC)
Presence of permanent central venous catheter
Malignant neoplasm of left lung (CMS/HCC)
Endometrial cancer (CMS/HCC)",
NBI OP INFUSION,64951,"Anderson, Patrick S, MD",8/24/2023,Bevacizumab treatment- Endometrial Adenocarcinoma,Second Line,8/23/2023,Inactive,,
TRMC TCCC OP INFUSION,47409,"Salerno, Vincent E, MD",11/5/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/4/2024,Inactive,,
JCMC CP INFUSION,84799,"Sekhri, Arunabh, MD",5/26/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,5/26/2023,Inactive,,
SOM OUTPT INFUSION,77641,"Patel, Eshan, MD",1/6/2025,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,1/5/2025,Inactive,Rectal cancer (CMS/HCC),
SOM OUTPT INFUSION,77641,"Patel, Eshan, MD",1/6/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2025,Inactive,Rectal cancer (CMS/HCC),
SOM OUTPT INFUSION,77641,"Patel, Eshan, MD",1/7/2025,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,1/5/2025,Active,,
SOM OUTPT INFUSION,77641,"Patel, Eshan, MD",2/18/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/17/2025,Active,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,30406,"Leiser, Aliza, MD",8/14/2023,CARBOplatin 21 Day Cycles - Endometrial cancer ,,8/13/2023,Inactive,,
CINJ OP INFUSION,30406,"Leiser, Aliza, MD",1/29/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,1/21/2024,Active,,
CBMC OP INFUSION 2FL,79410,"Raptis, George, MD",5/10/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,5/9/2024,Active,,
CBMC OP INFUSION 2FL,79410,"Raptis, George, MD",5/10/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,5/9/2024,Inactive,,
SOM OUTPT INFUSION,88222,"Patel, Eshan, MD",12/6/2024,weekly Carbo/taxol- GYn,_1. First Line,11/24/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
MMC OP VP INFUSION,29354,"Lee, Patrick C, MD",10/20/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,10/11/2023,Inactive,,
SOM OUTPT INFUSION,90389,"Patel, Eshan, MD",12/24/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/16/2024,Active,,
NBI D7 MED-SURG/TELE,26245,"Snyder, Rose, MD",4/2/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/2/2025,Inactive,Lung mass,"A41.9 - Sepsis, unspecified organism; E43 - Unspecified severe protein-calorie malnutrition; J18.9 - Pneumonia, unspecified organism; C34.2 - Malignant neoplasm of middle lobe, bronchus or lung; E83.51 - Hypocalcemia; J43.9 - Emphysema, unspecified; E83.52 - Hypercalcemia; Z87.891 - Personal history of nicotine dependence; Z85.118 - Personal history of other malignant neoplasm of bronchus and lung; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z68.22 - Body mass index (BMI) 22.0-22.9, adult; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy"
NBI OP INFUSION,26245,"Snyder, Rose, MD",4/2/2025,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,_1. First Line,4/2/2025,Inactive,Lung mass,R91.8 - Other nonspecific abnormal finding of lung field; E83.52 - Hypercalcemia; C34.81 - Malignant neoplasm of overlapping sites of right bronchus and lung
CINJ OP INFUSION,74360,"Goel, Sanjay, MD",3/8/2023,CINJ 052101 (TT420X1103) ARM A TT-00420 12 mg 28 Day Cycles Research- Solid Tumors,Third Line,3/7/2023,Inactive,,
NBR 5N ONCOLOGY,74360,"Goel, Sanjay, MD",4/17/2023,R7075-ONC-2009 / CINJ 052008 Dose Level 9* REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,Third Line,3/3/2023,Inactive,,
CINJ OP INFUSION,74360,"Goel, Sanjay, MD",6/19/2023,CINJ 052212 Phase 1b RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,Third Line,6/19/2023,Inactive,,
CINJ OP INFUSION,74360,"Goel, Sanjay, MD",6/21/2023,CINJ 052212 Phase 1b RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,Third Line,6/19/2023,Inactive,,
HAM OP INFUSION,60808,"Patel, Malini M, MD",8/31/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,First Line,8/30/2023,Inactive,,
CINJ OP INFUSION,24391,"Mayer, Tina M, MD",7/25/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,7/25/2023,Inactive,,
CINJ OP INFUSION,37263,"Groisberg, Roman, MD",1/17/2025,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,1/16/2025,Active,,
CMC OP INFUSION,96518,"Pompa, Tiffany Ann, MD",3/20/2025,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,3/20/2025,Active,"Chondrosarcoma (CMS/HCC)
Secondary malignant neoplasm of unspecified site (CODE) (CMS/HCC)",
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",1/17/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/13/2023,Inactive,,
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",3/2/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/28/2023,Inactive,,
NBR 5N MED-SURG OVRF,63054,"In, Haejin, MD",9/21/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,9/21/2023,Inactive,,
NBR 5N ONCOLOGY,63054,"In, Haejin, MD",10/9/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,10/9/2023,Inactive,,
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",2/19/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/18/2024,Inactive,,
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",2/19/2024,FOLFOX,_2. Second Line,2/18/2024,Inactive,,
NBR CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",5/6/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/2/2024,Inactive,,
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",5/20/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/18/2024,Inactive,,
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",6/3/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/2/2024,Inactive,,
CINJ OP INFUSION,63054,"Berim, Lyudmyla, MD",7/1/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/28/2024,Inactive,,
CINJ OP INFUSION,63054,"Goel, Sanjay, MD",12/23/2024,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,12/20/2024,Active,,
CINJ OP INFUSION,63054,"Goel, Sanjay, MD",2/17/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,2/17/2025,Active,Adenocarcinoma of small bowel (CMS/HCC),
CINJ OP INFUSION,63054,"Goel, Sanjay, MD",4/28/2025,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,4/28/2025,Inactive,Adenocarcinoma of small bowel (CMS/HCC),
CINJ OP INFUSION,63054,"Goel, Sanjay, MD",4/28/2025,CINJ 052404 Dose Escalation XL309 / Olaparib 28 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,4/28/2025,Active,Adenocarcinoma of small bowel (CMS/HCC),
CBMC OP INFUSION 2FL,32506,"Dave, Manish, MD",5/8/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/7/2023,Active,,
CINJ OP INFUSION,75109,"Weiss, Sarah, MD",12/4/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,11/28/2023,Active,,
NBR 4N ONCOLOGY,4206,"Matasar, Matthew J, MD",8/22/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,8/21/2023,Inactive,,
MSC OP INFUSION,33472,"Tang, Horace, MD",8/25/2023,RiTUXimab weekly,,8/24/2023,Inactive,,
MSC OP INFUSION,33472,"Eltoukhy, Hussam, MD",12/2/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_2. Second Line,12/1/2024,Active,"Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC)
Urothelial cancer (CMS/HCC)",
MMC OP VP INFUSION,55340,"Cohen, Seth D, MD",2/21/2023,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,2/20/2023,Inactive,,
MMC OP VP INFUSION,63542,"Lee, Patrick C, MD",2/2/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Third Line,2/1/2023,Inactive,,
SOM OUTPT INFUSION,60500,"Toomey, Kathleen C, MD",6/13/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,Induction,5/29/2024,Active,,
CINJ OP INFUSION,7957,"Mayer, Tina M, MD",7/28/2023,Enzalutamide 28 Day Cycles - Prostate,,7/28/2023,Active,,
CINJ OP INFUSION,67837,"Jang, Thomas L, MD",4/12/2023,Gemcitabine Intravesical Weekly 42 Day Cycle - Bladder,Induction,4/11/2023,Inactive,,
HAM OP INFUSION,68570,"Yogarajah, Meera, MD",10/8/2024,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/7/2024,Active,,
MMC OP INFUSION,90207,"Lee, Patrick C, MD",5/13/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,5/13/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
NBR 5N ONCOLOGY,496,"Doraiswamy, Anupama, MD",2/11/2023,Single Dose Cyclophosphamide 1 Gram,,2/10/2023,Inactive,,
NBR CINJ OP INFUSION,496,"Evens, Andrew M, DO",3/3/2023,Brentuximab Vedotin / Bendamustine 21 Day Cycles - Hodgkin Lymphoma,Second Line,3/3/2023,Inactive,,
NBR CINJ OP INFUSION,58322,"Rhodes, Joanna Meehan, MD",4/15/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/15/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; C79.51 - Secondary malignant neoplasm of bone; I82.C12 - Acute embolism and thrombosis of left internal jugular vein; D70.1 - Agranulocytosis secondary to cancer chemotherapy; K57.20 - Diverticulitis of large intestine with perforation and abscess without bleeding; B95.2 - Enterococcus as the cause of diseases classified elsewhere; B96.5 - Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere; D84.9 - Immunodeficiency, unspecified; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; D50.9 - Iron deficiency anemia, unspecified; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; Z16.21 - Resistance to vancomycin; Z68.27 - Body mass index (BMI) 27.0-27.9, adult; B96.89 - Other specified bacterial agents as the cause of diseases classified elsewhere; F41.9 - Anxiety disorder, unspecified; Z74.09 - Other reduced mobility; E78.5 - Hyperlipidemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R29.6 - Repeated falls; D63.8 - Anemia in other chronic diseases classified elsewhere; D69.59 - Other secondary thrombocytopenia; E66.3 - Overweight; E83.52 - Hypercalcemi..."
CINJ OP INFUSION,41112,"Toppmeyer, Deborah L, MD",12/21/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,12/20/2023,Active,,
CINJ OP INFUSION,71168,"Hochster, Howard S, MD",12/12/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,12/11/2024,Active,,
JCMC CP INFUSION,48391,"Sekhri, Arunabh, MD",7/6/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/25/2023,Inactive,,
JCMC CP INFUSION,48391,"Sekhri, Arunabh, MD",9/13/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,9/6/2023,Inactive,,
CINJ OP INFUSION,83776,"Berim, Lyudmyla, MD",6/14/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/14/2023,Inactive,,
HAM OP INFUSION,69225,"Patel, Malini M, MD",3/31/2025,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_1. First Line,3/31/2025,Active,"Mesothelioma (pleural) (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C34.91 - Sarcomatoid carcinoma of lung, right (CMS/HCC); C34.11 - Malignant neoplasm of right upper lobe of lung (CMS/HCC)"
HAM OP INFUSION,72997,"Yogarajah, Meera, MD",8/29/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,First Line,8/3/2023,Inactive,,
CINJ OP INFUSION,24278,"Stephenson, Ryan D, DO",9/29/2023,Enzalutamide 28 Day Cycles - Prostate,Second Line,9/29/2023,Inactive,,
JCMC CP INFUSION,21658,"Cruz, Allan Louie E, MD",3/29/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Second Line,3/28/2023,Inactive,,
JCMC CP INFUSION,21658,"Cruz, Allan Louie E, MD",9/6/2023,"Gemcitabine (D1, D8) 21 Day Cycles ",,9/5/2023,Active,,
NBR CINJ OP INFUSION,24358,"Shah, Mansi R, MD",7/22/2024,CINJ 012310 Induction Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,_1. First Line,7/22/2024,Inactive,,
NBR CINJ OP INFUSION,24358,"Shah, Mansi R, MD",9/17/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,24358,"Shah, Mansi R, MD",9/17/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,24358,"Shah, Mansi R, MD",12/3/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,11/19/2024,Inactive,,
SOM OUTPT INFUSION,45127,"Toomey, Kathleen C, MD",12/7/2023,Pembrolizumab 42 Day Cycles -bladder,_1. First Line,12/6/2023,Inactive,,
SOM OUTPT INFUSION,670,"Patel, Eshan, MD",7/1/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,6/28/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,90110,"Sekhri, Arunabh, MD",9/29/2023,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,9/22/2023,Inactive,,
CBMC OP INFUSION 2FL,79898,"Radovich, Delia, MD",6/23/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,6/23/2023,Active,,
CINJ OP INFUSION,35674,"Aikins, James K, MD",5/18/2023,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,5/18/2023,Inactive,,
CINJ OP INFUSION,35674,"Aikins, James K, MD",10/19/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,10/18/2023,Inactive,,
CINJ OP INFUSION,35674,"Aikins, James K, MD",2/16/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/15/2024,Inactive,,
CINJ OP INFUSION,35674,"Girda, Eugenia, MD",4/18/2024,CINJ 102104 ZN-c3 400 mg 21 Day Cycles Research- Uterine Carcinoma,_4. Fourth Line,4/8/2024,Inactive,,
CINJ OP INFUSION,35674,"Aikins, James K, MD",7/19/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,7/18/2024,Inactive,,
NBR CINJ OP INFUSION,50822,"Shah, Mansi R, MD",11/1/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,10/30/2024,Inactive,,
NBR CINJ OP INFUSION,50822,"Shah, Mansi R, MD",11/11/2024,CINJ 012310 Induction Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,_1. First Line,11/11/2024,Inactive,,
NBR CINJ OP INFUSION,50822,"Shah, Mansi R, MD",11/18/2024,CINJ 012310 Induction Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,_1. First Line,11/18/2024,Active,,
NBR CINJ OP INFUSION,39486,"Chen, Xiaoyi",5/14/2025,CINJ 012310 Outpatient Consolidation Linvolsetamab Post ASCT 28 Day Cycles Research- Multiple Myeloma,_1. First Line,5/14/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),"C90.01 - Multiple myeloma in remission; L60.9 - Nail disorder, unspecified; D47.2 - Monoclonal gammopathy; C90.00 - Multiple myeloma not having achieved remission"
NBR CINJ OP INFUSION,39486,"Chen, Xiaoyi",5/14/2025,CINJ 012310 Transplant Ineligible Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,_1. First Line,5/14/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
CINJ OP INFUSION,82028,"Mayer, Tina M, MD",5/1/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,5/1/2023,Active,,
MMC OP INFUSION,53018,"Eltoukhy, Hussam, MD",10/20/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,10/19/2023,Inactive,,
MMC OP INFUSION,53018,"Eltoukhy, Hussam, MD",8/20/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,8/19/2024,Inactive,,
MMC BBR2 ONCOLOGY,53018,"Eltoukhy, Hussam, MD",10/9/2024,Ivosidenib 30 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,10/9/2024,Active,,
MMC OP INFUSION,53018,"Eltoukhy, Hussam, MD",2/13/2025,AzaCITIDine 28 Day Cycles,_4. Fourth Line,2/2/2025,Active,AML (acute myeloid leukemia) in relapse (CMS/HCC),
NBR 5N ONCOLOGY,81104,"Tiger, Yun Kyoung, MD",5/11/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/11/2024,Inactive,,
NBR 5N ONCOLOGY,81104,"Evens, Andrew M, DO",5/21/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,5/21/2024,Inactive,,
NBR CINJ OP INFUSION,81104,"Evens, Andrew M, DO",7/3/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,7/2/2024,Inactive,,
NBR CINJ OP INFUSION,81104,"Evens, Andrew M, DO",11/6/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_3. Third Line,10/1/2024,Active,Malignant neoplasm of upper third of esophagus (CMS/HCC),
TRMC TCCC OP INFUSION,20209,"Capo, Gerardo, MD",5/15/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/6/2025,Active,Malignant neoplasm of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; C16.2 - Malignant neoplasm of body of stomach"
CBMC 2W ONCOLOGY,97042,"Grossman, I Robert, MD",7/6/2024,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,7/5/2024,Active,,
CBMC 2W ONCOLOGY,97042,"Grossman, I Robert, MD",7/6/2024,"Nivolumab (D1, D15) 28 Day Cycles - Hodgkin Lymphoma",_1. First Line,7/5/2024,Active,,
MMC OP INFUSION,48822,"Meghal, Trishala, MD",10/30/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,10/25/2024,Active,,
SOM OUTPT INFUSION,10150,"Yin, Faye, MD",9/11/2024,Capmatinib 28 Day Cycles,_2. Second Line,9/11/2024,Inactive,,
SOM OUTPT INFUSION,10150,"Patel, Eshan, MD",12/23/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,12/18/2024,Active,,
SOM OUTPT INFUSION,10150,"Patel, Eshan, MD",1/6/2025,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/3/2025,Active,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",2/29/2024,Carfilzomib 56 mg/m2 Weekly / Pomalyst Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,2/29/2024,Inactive,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",5/21/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,5/18/2024,Inactive,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",6/11/2024,VCD (Bortezomib/Cyclophosphamide Oral/Dexamethasone) 21/35 Day Cycles- Multiple Myeloma,_4. Fourth Line,6/10/2024,Inactive,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",6/18/2024,"Bortezomib D1, D8, D15, D22 / Selinexor 100 mg / Dexamethasone 35 Day Cycles- Multiple Myeloma",_4. Fourth Line,6/17/2024,Inactive,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",7/17/2024,Talquetamab 28 Day Cycles,_5. Fifth Line,7/17/2024,Inactive,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",7/30/2024,Carfilzomib 70 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,7/29/2024,Inactive,,
NBR CINJ OP INFUSION,44694,"Shah, Mansi R, MD",9/11/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_7. Seventh Line,9/10/2024,Inactive,,
CBMC OP INFUSION 2FL,48044,"Dharmapuri, Sirish, MD",8/21/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/20/2024,Inactive,Gastric cancer (CMS/HCC),
CBMC OP INFUSION 2FL,48044,"Dharmapuri, Sirish, MD",1/28/2025,"PACLitaxel D1, D8, D15 28 Day Cycles- Gastric Cancers",_3. Third Line,1/27/2025,Active,,
CBMC OP INFUSION 2FL,48044,"Dharmapuri, Sirish, MD",5/20/2025,5FU/LV Outpatient (Fluorouracil Continuous Infusion/Leucovorin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,5/20/2025,Active,Gastric cancer (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified"
CBMC 2W ONCOLOGY,64279,"Grossman, I Robert, MD",11/3/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,11/2/2023,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC 2W ONCOLOGY,64279,"Grossman, I Robert, MD",11/7/2023,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_1. First Line,11/6/2023,Inactive,,
SOM OUTPT INFUSION,89985,"Yin, Faye, MD",7/25/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,First Line,7/20/2023,Inactive,,
SOM OUTPT INFUSION,89985,"Yin, Faye, MD",9/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,8/21/2023,Inactive,,
NBR 5N ONCOLOGY,16324,"Palmisiano, Neil David, MD",1/24/2025,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_4. Fourth Line,1/24/2025,Inactive,Multiple myeloma (CMS/HCC),
NBR 5N ONCOLOGY,16324,"Palmisiano, Neil David, MD",1/29/2025,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,1/29/2025,Active,,
SOM OUTPT INFUSION,50414,"Patel, Eshan, MD",7/11/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,,2/6/2023,Inactive,,
NBR 4N ONCOLOGY,56435,"Patel, Vimal D, MD",3/20/2023,DAUNOrubicin Liposomal - Cytarabine (VYXEOS) - Induction 14 Day Cycle - Acute Myeloid Leukemia,Induction,3/20/2023,Inactive,,
NBR 4N ONCOLOGY,56435,"Patel, Vimal D, MD",4/20/2023,FLAG (Fludarabine / Cytarabine / Filgrastim) - Acute Myeloid Leukemia,Third Line,4/19/2023,Inactive,,
MMC OP VP INFUSION,98271,"Lee, Patrick C, MD",11/3/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/2/2023,Inactive,,
MMC OP VP INFUSION,98271,"Lee, Patrick C, MD",11/3/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/2/2023,Inactive,,
CINJ OP INFUSION,44427,"Boland, Patrick M, MD",5/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/13/2024,Inactive,Colon cancer (CMS/HCC),
CINJ OP INFUSION,44427,"Boland, Patrick M, MD",1/20/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/9/2025,Active,,
CINJ OP INFUSION,44427,"Boland, Patrick M, MD",2/4/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/9/2025,Active,Colon cancer (CMS/HCC),"C18.7 - Malignant neoplasm of sigmoid colon; C18.9 - Malignant neoplasm of colon, unspecified"
CMC OP INFUSION,53397,"Taff, Jessica, MD",5/1/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/30/2023,Inactive,,
CMC OP INFUSION,53397,"Taff, Jessica, MD",10/2/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/17/2023,Active,,
TRMC TCCC OP INFUSION,22049,"Capo, Gerardo, MD",12/4/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,12/3/2024,Active,,
CMC 4B ONCOLOGY,35452,"Cohen, Seth D, MD",12/18/2023,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Adjuvant,12/17/2023,Inactive,,
CMC OP INFUSION,35452,"Cohen, Seth D, MD",9/20/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_2. Second Line,9/18/2024,Active,,
CMMC OP INFUSION,66770,"Freeman, Benjamin B, MD",4/21/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/21/2025,Active,Gastric adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,60478,"Stephenson, Ryan D, DO",1/22/2025,CINJ 082104 (EA8191) ARM A Short Term Androgen Deprivation GnRH Therapy 84 Cycles Research- Prostate Cancer,Adjuvant,12/25/2024,Active,,
NBR CINJ OP INFUSION,87039,"Eltoukhy, Hussam, MD",3/16/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,,3/15/2023,Inactive,,
NBR CINJ OP INFUSION,87039,"Eltoukhy, Hussam, MD",3/16/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,3/15/2023,Inactive,,
JCMC CP INFUSION,4609,"Cruz, Allan Louie E, MD",12/23/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,11/20/2024,Active,,
JCMC CP INFUSION,4609,"Cruz, Allan Louie E, MD",12/23/2024,TH+P (DOCEtaxel / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/15/2024,Active,"Metastatic malignant neoplasm, unspecified site (CMS/HCC)
End stage renal disease (CMS/HCC)",
CINJ OP INFUSION,56357,"Saraiya, Biren P, MD",1/30/2024,Lenvatinib + Everolimus 30  Day Cycles- RCC,_3. Third Line,1/30/2024,Active,,
CBMC OP INFUSION 2FL,81658,"Wagmiller, Jennifer Ann, MD",2/4/2025,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_4. Fourth Line,2/3/2025,Active,Malignant neoplasm of ovary (CMS/HCC),
CBMC OP INFUSION 2FL,62738,"Wagmiller, Jennifer Ann, MD",4/1/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,4/1/2025,Inactive,"Malignant neoplasm of ovary (CMS/HCC)
Ovary cancer, right (CMS/HCC)","C56.1 - Malignant neoplasm of right ovary; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; E44.0 - Moderate protein-calorie malnutrition; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; D68.9 - Coagulation defect, unspecified; E87.1 - Hypo-osmolality and hyponatremia; K94.02 - Colostomy infection; D84.9 - Immunodeficiency, unspecified; R62.7 - Adult failure to thrive; J91.0 - Malignant pleural effusion; I10 - Essential (primary) hypertension; F32.A - Depression, unspecified; J45.909 - Unspecified asthma, uncomplicated; L02.211 - Cutaneous abscess of abdominal wall; I48.0 - Paroxysmal atrial fibrillation; D64.81 - Anemia due to antineoplastic chemotherapy; Z90.710 - Acquired absence of both cervix and uterus; F41.9 - Anxiety disorder, unspecified; R09.02 - Hypoxemia; R73.03 - Prediabetes; R53.0 - Neoplastic (malignant) related fatigue; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E78.5 - Hyperlipidemia, unspecified; G47.33 - Obstructive sleep apnea (adult) (pediatric); Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z11.52 - Encounter for screening for COVID-19; Z79.01 - Long term (current) use of anticoagulants; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.3 - Family history of malignant neoplasm of breast; Z80.41 - Family history of malignant neoplasm of ovary; Z82.49 - Family history of ischemic heart disease and other di..."
CBMC OP INFUSION 2FL,39303,"Wagmiller, Jennifer Ann, MD",11/14/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,11/13/2023,Inactive,,
CBMC OP INFUSION 2FL,39303,"Wagmiller, Jennifer Ann, MD",2/28/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/14/2024,Inactive,,
CBMC OP INFUSION 2FL,39303,"Wagmiller, Jennifer Ann, MD",12/16/2024,Everolimus / Letrozole 28 Day Cycles - Uterine,_1. First Line,12/16/2024,Inactive,,
CINJ OP INFUSION,30721,"Saraiya, Biren P, MD",10/18/2023,CINJ 082107 (CURLU177PSM001) Abiraterone / Prednisone 28 Day Cycles Research- Prostate Cancer,_2. Second Line,9/11/2023,Inactive,,
MMC OP VP INFUSION,30721,"Cohen, Seth D, MD",1/12/2024,DOCEtaxel 21 Day Cycles - Prostate,_2. Second Line,1/11/2024,Inactive,,
NBR 4N ONCOLOGY,34422,"Hochster, Howard S, MD",4/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/1/2024,Inactive,,
CINJ OP INFUSION,14749,"Groisberg, Roman, MD",5/23/2025,ARST2032 Regimen VA,Adjuvant,5/1/2025,Inactive,Rhabdomyosarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; C54.9 - Malignant neoplasm of corpus uteri, unspecified"
CINJ OP INFUSION,14749,"Groisberg, Roman, MD",5/23/2025,ARST2032 Regimen VAC/VA,Adjuvant,5/23/2025,Active,Rhabdomyosarcoma (CMS/HCC),
CINJ OP INFUSION,91730,"Jang, Thomas L, MD",5/30/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/30/2025,Active,Urothelial cancer (CMS/HCC),
CINJ OP INFUSION,32954,"Stephenson, Ryan D, DO",5/21/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,5/21/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels
CBMC 2W ONCOLOGY,37928,"Grossman, I Robert, MD",10/31/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,10/30/2023,Inactive,,
CBMC 2W ONCOLOGY,37928,"Grossman, I Robert, MD",11/1/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,10/31/2023,Inactive,,
NBR CINJ OP INFUSION,82997,"Shah, Mansi R, MD",2/13/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,1/8/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Abnormal coagulation profile
Other reduced mobility","C90.00 - Multiple myeloma not having achieved remission; D70.9 - Neutropenia, unspecified; D80.1 - Nonfamilial hypogammaglobulinemia; Z94.84 - Stem cells transplant status"
NBR CINJ OP INFUSION,82997,"Shah, Mansi R, MD",3/13/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,2/13/2025,Inactive,"Multiple myeloma not having achieved remission (CMS/HCC)
Abnormal coagulation profile
Other reduced mobility","C90.00 - Multiple myeloma not having achieved remission; D70.9 - Neutropenia, unspecified; D80.1 - Nonfamilial hypogammaglobulinemia; Z94.84 - Stem cells transplant status"
HAM OP INFUSION,25015,"Patel, Malini M, MD",7/13/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Head and Neck Cancers",Third Line,7/12/2023,Inactive,,
CMC OP INFUSION,83176,"Lee, Patrick C, MD",6/19/2023,Topotecan 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,6/18/2023,Inactive,,
HAM OP INFUSION,87721,"Yogarajah, Meera, MD",8/16/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,8/13/2023,Inactive,,
HAM OP INFUSION,87721,"Yogarajah, Meera, MD",2/5/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/28/2024,Inactive,,
CINJ OP INFUSION,28790,"George, Mridula A, MD",1/16/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/15/2025,Active,"Chronic lymphocytic leukemia of B-cell type not having achieved remission (CMS/HCC)
Autoimmune hemolytic anemia (CMS/HCC)",
CINJ OP INFUSION,49155,"Berim, Lyudmyla, MD",6/7/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/4/2024,Active,,
CBMC 2W ONCOLOGY,31875,"Brown, Andrew Bennett, MD",2/15/2024,Bevacizumab 28 Day Cycles - GBM,_2. Second Line,2/15/2024,Inactive,,
MMC OP VP INFUSION,13179,"Lee, Patrick C, MD",2/4/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,2/4/2025,Active,Rectal cancer (CMS/HCC),
MMC OP VP INFUSION,13179,"Lee, Patrick C, MD",4/24/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/24/2025,Active,Rectal cancer (CMS/HCC),
HAM OP INFUSION,65433,"Yogarajah, Meera, MD",4/29/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/28/2024,Inactive,,
CINJ OP INFUSION,15743,"Haigentz, Missak, MD",4/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,4/22/2024,Inactive,,
CINJ OP INFUSION,53819,"George, Mridula A, MD",8/5/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,8/4/2024,Active,"Metastasis from breast cancer (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)",
CBMC OP INFUSION 2FL,32159,"Brown, Andrew Bennett, MD",11/13/2023,PACLitaxel / CARBOplatin Post Concurrent Radiation Consolidation 21 Day Cycles - Non-Small Cell Lung Cancer,_2. Second Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,32159,"Brown, Andrew Bennett, MD",11/13/2023,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,_1. First Line,11/12/2023,Inactive,,
NBI OP INFUSION,93482,"Cohen, Alice, MD",2/6/2025,Capecitabine / Lapatinib 21 Day Cycles - Breast,_3. Third Line,2/6/2025,Active,Breast cancer (CMS/HCC),
CINJ OP INFUSION,76578,"Mayer, Tina M, MD",5/1/2024,Apalutamide 30 Day Cycles - Prostate,_2. Second Line,5/1/2024,Active,,
NBR CINJ OP INFUSION,76578,"Mayer, Tina M, MD",1/21/2025,DOCEtaxel with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,1/20/2025,Active,,
MMC OP VP INFUSION,83852,"Talwar, Sumit, MD",10/1/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,9/30/2024,Active,,
CBMC OP INFUSION 2FL,1194,"Litvak, Anna M, MD",11/10/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_3. Third Line,11/9/2023,Inactive,,
SOM OUTPT INFUSION,1651,"Yin, Faye, MD",3/1/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,2/18/2024,Inactive,,
NBR 4N BMTU/IMCU,3818,"Braunschweig, Ira, MD",3/24/2023,BMT Allogeneic TBF + Post Cy ,,3/23/2023,Inactive,,
NBR CINJ OP INFUSION,39473,"Evens, Andrew M, DO",5/22/2024,Maintenance RiTUXimab / Lenalidomide 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/21/2024,Active,,
CINJ OP INFUSION,86595,"Mayer, Tina M, MD",7/27/2023,Enzalutamide 28 Day Cycles - Prostate,,7/27/2023,Active,,
MMC OP VP INFUSION,79008,"Cohen, Seth D, MD",3/7/2023,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,3/6/2023,Inactive,,
MMC OP VP INFUSION,79008,"Cohen, Seth D, MD",9/18/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,First Line,9/17/2023,Inactive,,
NBR CINJ OP INFUSION,79008,"Cohen, Seth D, MD",2/24/2025,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_4. Fourth Line,2/24/2025,Active,"Myelodysplastic syndrome (CMS/HCC)
Encounter for antineoplastic chemotherapy
End stage renal disease (CMS/HCC)
Pancytopenia (CMS/HCC)",
MMC OP INFUSION,79008,"Cohen, Seth D, MD",4/8/2025,Chlorambucil / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,Reinduction,4/7/2025,Active,"Myelodysplastic syndrome (CMS/HCC)
Encounter for antineoplastic chemotherapy
End stage renal disease (CMS/HCC)
Pancytopenia (CMS/HCC)",
NBR CINJ OP INFUSION,43981,"Shah, Mansi R, MD",4/30/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,4/18/2024,Inactive,,
NBR 4N BMTU/IMCU,43981,"Assal, Amer, MD",5/22/2024,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,5/21/2024,Inactive,,
NBR 4N ONCOLOGY,48338,"Hinrichs, Christian, MD",5/12/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,5/12/2025,Active,"Malignant neuroendocrine neoplasm of pancreas (CMS/HCC)
Small cell lung cancer (CMS/HCC)","C7A.1 - Malignant poorly differentiated neuroendocrine tumors; E44.0 - Moderate protein-calorie malnutrition; C7B.8 - Other secondary neuroendocrine tumors; I87.1 - Compression of vein; N17.9 - Acute kidney failure, unspecified; C50.111 - Malignant neoplasm of central portion of right female breast; R13.10 - Dysphagia, unspecified; E86.0 - Dehydration; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; B96.81 - Helicobacter pylori (H. pylori) as the cause of diseases classified elsewhere; E87.6 - Hypokalemia; K29.50 - Unspecified chronic gastritis without bleeding; F41.9 - Anxiety disorder, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); Z87.891 - Personal history of nicotine dependence; K59.00 - Constipation, unspecified; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z68.25 - Body mass index (BMI) 25.0-25.9, adult; Z80.3 - Family history of malignant neoplasm of breast; Z56.0 - Unemployment, unspecified; Z92.3 - Personal history of irradiation; Z92.21 - Personal history of antineoplastic chemotherapy; Z17.0 - Estrogen receptor positive status (ER+); Z17.21 - Progesterone receptor positive status; Z17.32 - Human epidermal growth factor receptor 2 negative status"
JCMC CP INFUSION,55847,"Cruz, Allan Louie E, MD",5/18/2023,Pembrolizumab 42 Day Cycles -adjuvant breast (cycles 10-17),Adjuvant,5/18/2023,Inactive,,
JCMC CP INFUSION,55847,"Cruz, Allan Louie E, MD",6/5/2023,Pembrolizumab 42 Day Cycles - Breast. (maintenance 4 cycles left),Maintenance,6/5/2023,Inactive,,
NBR 4N ONCOLOGY,47359,"Tiger, Yun Kyoung, MD",10/24/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/24/2024,Active,Multiple myeloma (CMS/HCC),
NBR 4N ONCOLOGY,47359,"Zayac, Adam, MD",10/25/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,10/25/2024,Active,,
NBR 4N ONCOLOGY,47359,"Tiger, Yun Kyoung, MD",3/26/2025,High-Dose Methotrexate - CNS prophylaxis,_2. Second Line,3/26/2025,Active,Marginal zone B-cell lymphoma (CMS/HCC),
CMC OP INFUSION,13340,"Taff, Jessica, MD",10/27/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/22/2023,Active,,
CMC OP INFUSION,36001,"Taff, Jessica, MD",3/7/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Avastin 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/7/2025,Active,"Adenocarcinoma, colon (CMS/HCC)",
CINJ OP INFUSION,60717,"Packiam, Vignesh, MD",2/28/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,2/27/2024,Inactive,,
CINJ OP INFUSION,94555,"Gulhati, Prateek, MD PhD",3/9/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,3/8/2023,Inactive,,
CINJ OP INFUSION,82600,"Stephenson, Ryan D, DO",10/2/2024,CINJ 082003 (NRG-GU008) ARM 2  GnRH Agonist or Antagonist Therapy / Apalutamide 84 Day Cycles Research- Prostate Cancer,Adjuvant,10/1/2024,Active,,
HAM OP INFUSION,36752,"Yogarajah, Meera, MD",12/26/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/16/2024,Active,,
CINJ OP INFUSION,64873,"Berim, Lyudmyla, MD",4/28/2023,Imatinib 30 Day Cycles - Sarcoma,,4/28/2023,Inactive,,
CINJ OP INFUSION,64873,"Berim, Lyudmyla, MD",8/26/2024,Ripretinib 28 Day Cycles - Sarcoma,_2. Second Line,8/26/2024,Inactive,,
CINJ OP INFUSION,64873,"Berim, Lyudmyla, MD",9/4/2024,SUNItinib 28 Day Cycles - Sarcoma,_2. Second Line,9/4/2024,Inactive,,
CINJ OP INFUSION,32931,"Goel, Sanjay, MD",2/14/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 9W REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,_3. Third Line,1/24/2024,Inactive,,
CMC OP INFUSION,60066,"Tang, Horace, MD",12/1/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,11/30/2023,Inactive,,
CMC OP INFUSION,60695,"Pompa, Tiffany Ann, MD",3/21/2025,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,Neoadjuvant,3/20/2025,Active,Primary Merkel cell carcinoma of cheek (CMS/HCC),
CINJ OP INFUSION,31531,"Boland, Patrick M, MD",5/12/2023,"Gemcitabine D1, D8/OXALIplatin D1 21 Day Cycles- Gastrointestinal Cancers",,5/4/2023,Inactive,,
CINJ OP INFUSION,31531,"Boland, Patrick M, MD",8/25/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,,8/24/2023,Inactive,,
NBR CINJ OP INFUSION,39101,"Tiger, Yun Kyoung, MD",5/13/2024,CINJ 012320 Group 1 CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) / Belinostat 21 Day Cycles Research- Peripheral T-Cell Lymphoma,_1. First Line,5/12/2024,Inactive,,
NBR CINJ OP INFUSION,39101,"Tiger, Yun Kyoung, MD",5/13/2024,CINJ 012320 Group 1 CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) / Belinostat 21 Day Cycles Research- Peripheral T-Cell Lymphoma,_1. First Line,5/12/2024,Inactive,,
NBR CINJ OP INFUSION,39101,"Egini, Ogechukwu, MD",12/12/2024,BMT Autologous BEAM,_2. Second Line,12/11/2024,Active,,
CMC OP INFUSION,56058,"Taff, Jessica, MD",8/1/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,,7/31/2023,Inactive,,
CMC OP INFUSION,5247,"Talwar, Sumit, MD",7/20/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/19/2024,Inactive,,
NBR CINJ OP INFUSION,63790,"Evens, Andrew M, DO",3/1/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,2/28/2023,Active,Cancer of sigmoid colon (CMS/HCC),
CMC OP INFUSION,15819,"Cohen, Seth D, MD",4/13/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,4/13/2023,Active,,
CBMC OP INFUSION 2FL,59431,"Brown, Andrew Bennett, MD",1/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/10/2024,Inactive,,
CBMC OP INFUSION 2FL,59431,"Brown, Andrew Bennett, MD",5/16/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/16/2025,Active,"Malignant neoplasm of sigmoid colon (CMS/HCC)
Metastatic colon cancer to liver (CMS/HCC)",C18.7 - Malignant neoplasm of sigmoid colon
CBMC OP INFUSION 2FL,59431,"Brown, Andrew Bennett, MD",5/2/2025,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/2/2025,Active,"Malignant neoplasm of sigmoid colon (CMS/HCC)
Colon cancer (CMS/HCC)",
CINJ OP INFUSION,99330,"Girda, Eugenia, MD",5/1/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,4/18/2023,Inactive,,
CBMC OP INFUSION 2FL,24242,"Litvak, Anna M, MD",10/25/2024,Capivasertib 28 Day Cycles - Breast,_2. Second Line,10/25/2024,Active,,
NBI OP INFUSION,11577,"Shah, Maya M, MD",7/24/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,5/14/2024,Active,,
NBI OP INFUSION,11577,"Shah, Maya M, MD",1/29/2025,Adjuvant Ribociclib 28 Day Cycles for 3 years - Breast,Adjuvant,1/29/2025,Active,,
CINJ OP INFUSION,55962,"Ghodoussipour, Saum Bobak, MD",11/28/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,11/28/2023,Inactive,,
SOM OUTPT INFUSION,68650,"Toomey, Kathleen C, MD",2/14/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,1/21/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),"C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung"
MMC OP VP INFUSION,70894,"Eltoukhy, Hussam, MD",7/15/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,7/14/2024,Inactive,,
CINJ OP INFUSION,31907,"Hochster, Howard S, MD",1/5/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/4/2023,Inactive,,
CINJ OP INFUSION,31907,"Hochster, Howard S, MD",6/21/2023,FOLFIRI Outpatient + Nivo (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,6/20/2023,Inactive,,
CINJ OP INFUSION,55588,"Packiam, Vignesh, MD",1/19/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,1/18/2024,Inactive,,
CINJ OP INFUSION,55588,"Packiam, Vignesh, MD",4/5/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Maintenance,4/4/2024,Inactive,,
CINJ OP INFUSION,55588,"Packiam, Vignesh, MD",4/5/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,4/4/2024,Active,,
SOM OUTPT INFUSION,4051,"Yin, Faye, MD",6/14/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/13/2023,Inactive,,
SOM OUTPT INFUSION,4051,"Yin, Faye, MD",6/14/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/6/2023,Inactive,,
SOM OUTPT INFUSION,4051,"Yin, Faye, MD",9/6/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,9/5/2023,Inactive,,
SOM OUTPT INFUSION,4051,"Yin, Faye, MD",9/6/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/5/2023,Inactive,,
NBR CINJ OP INFUSION,45694,"Rhodes, Joanna Meehan, MD",4/3/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/3/2025,Active,"Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC)
Abnormal coagulation profile",C83.398 - Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC)
NBR CINJ OP INFUSION,45694,"Rhodes, Joanna Meehan, MD",3/13/2025,Pola-Mini-R-CHP (Polatuzumab-Cyclophosphamide / DOXOrubicin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/13/2025,Active,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),
NBR CINJ OP INFUSION,45694,"Rhodes, Joanna Meehan, MD",3/13/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Maintenance,3/13/2025,Inactive,"Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC)
Abnormal coagulation profile",C83.398 - Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC)
CMMC OP INFUSION,88160,"Siu, Karleung, MD",4/22/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,4/22/2025,Active,Small cell carcinoma of upper lobe of right lung (CMS/HCC),"C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung; E05.00 - Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm; E03.9 - Hypothyroidism, unspecified; R53.81 - Other malaise; J43.1 - Panlobular emphysema"
TRMC TCCC OP INFUSION,79678,"Capo, Gerardo, MD",4/11/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,4/11/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,1334,"Schaar, Dale, MD PhD",1/30/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,1/27/2023,Active,,
NBR 4N ONCOLOGY,3193,"Palmisiano, Neil David, MD",1/24/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,1/22/2024,Inactive,,
NBR 4N ONCOLOGY,3193,"Palmisiano, Neil David, MD",6/25/2024,Olutasidenib 30 Day Cycles - Acute Myeloid Leukemia,Maintenance,6/25/2024,Active,,
NBR 5N ONCOLOGY,80184,"Schaar, Dale, MD PhD",1/19/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,,1/18/2023,Inactive,,
NBR CINJ OP INFUSION,80184,"Schaar, Dale, MD PhD",1/19/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,Second Line,1/18/2023,Inactive,,
NBR CINJ OP INFUSION,80184,"Schaar, Dale, MD PhD",1/21/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,1/21/2023,Inactive,,
CBMC OP INFUSION 2FL,88228,"Brown, Andrew Bennett, MD",3/6/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,3/6/2025,Inactive,Esophageal adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,88228,"Brown, Andrew Bennett, MD",3/5/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,3/5/2025,Inactive,Esophageal adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,34882,"Haigentz, Missak, MD",5/30/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/30/2024,Active,,
CINJ OP INFUSION,34882,"Haigentz, Missak, MD",6/7/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/30/2024,Inactive,,
CINJ OP INFUSION,34882,"Haigentz, Missak, MD",8/9/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,8/1/2024,Active,,
CINJ OP INFUSION,79134,"Saraiya, Biren P, MD",2/6/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,2/6/2023,Active,,
CBMC OP INFUSION 2FL,97485,"Brown, Andrew Bennett, MD",7/23/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/23/2024,Inactive,,
CMC OP INFUSION,38800,"Taff, Jessica, MD",6/9/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,5/30/2023,Inactive,,
TRMC TCCC OP INFUSION,27043,"Capo, Gerardo, MD",11/4/2024,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,11/3/2024,Active,,
SOM OUTPT INFUSION,93693,"Yin, Faye, MD",7/25/2023,Paclitaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/18/2023,Inactive,,
NBI OP INFUSION,59887,"Anderson, Patrick S, MD",5/23/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - carcinosarcoma of the endometrium,_1. First Line,5/22/2024,Active,,
CMC OP INFUSION,91783,"Talwar, Sumit, MD",9/27/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,Third Line,9/19/2023,Inactive,,
NBI OP INFUSION,3172,"Jacoby, Sari H, MD",12/8/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,12/7/2023,Inactive,,
NBI OP INFUSION,3172,"Jacoby, Sari H, MD",12/8/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,12/7/2023,Inactive,,
MSC OP INFUSION,35227,"Eltoukhy, Hussam, MD",10/31/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),Non-Oncology Research,10/31/2023,Inactive,,
MSC OP INFUSION,35227,"Eltoukhy, Hussam, MD",10/31/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),Non-Oncology Research,10/31/2023,Inactive,,
MMC OP VP INFUSION,78056,"Cohen, Seth D, MD",5/17/2023,Elotuzumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma (started January 2018),Maintenance,5/16/2023,Inactive,,
MMC OP VP INFUSION,78056,"Cohen, Seth D, MD",10/13/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,10/12/2023,Active,,
CMC OP INFUSION,7951,"Cohen, Seth D, MD",12/7/2023,Nivolumab/Ipilimumab + PEMEtrexed/CISplatin 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/29/2023,Inactive,,
CMC OP INFUSION,7951,"Cohen, Seth D, MD",4/16/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_2. Second Line,4/15/2024,Inactive,,
CMC OP INFUSION,7951,"Cohen, Seth D, MD",10/31/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/31/2024,Active,,
SOM OUTPT INFUSION,28640,"Yin, Faye, MD",1/25/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,First Line,1/24/2023,Inactive,,
SOM OUTPT INFUSION,28640,"Yin, Faye, MD",3/2/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/5/2023,Inactive,,
SOM OUTPT INFUSION,28640,"Yin, Faye, MD",6/15/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,6/14/2023,Inactive,,
SOM OUTPT INFUSION,28640,"Yin, Faye, MD",8/17/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,8/16/2023,Inactive,,
MMC OP VP INFUSION,87084,"Cohen, Seth D, MD",9/19/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,9/18/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,71769,"Moerdler, Scott, MD",3/28/2023,PEDS AEWS1031 Regimen A Induction & Consolidation,,3/22/2023,Active,,
JCMC CP INFUSION,94283,"Sekhri, Arunabh, MD",8/7/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,First Line,8/7/2023,Inactive,,
CINJ OP INFUSION,76924,"Leiser, Aliza, MD",2/18/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,2/5/2023,Inactive,,
CINJ OP INFUSION,76924,"Leiser, Aliza, MD",11/8/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,54947,"Grossman, I Robert, MD",5/5/2025,AVD (DOXORUBICIN / VINBLASTINE / DACARBAZINE) + NIVOLUMAB 28 DAY CYCLES,_1. First Line,5/5/2025,Active,Nodular sclerosis Hodgkin lymphoma of intrathoracic lymph nodes (CMS/HCC),"C81.12 - Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes; I30.9 - Acute pericarditis, unspecified; I31.4 - Cardiac tamponade; I82.621 - Acute embolism and thrombosis of deep veins of right upper extremity; J90 - Pleural effusion, not elsewhere classified; I80.8 - Phlebitis and thrombophlebitis of other sites; D50.9 - Iron deficiency anemia, unspecified; F12.90 - Cannabis use, unspecified, uncomplicated; F32.A - Depression, unspecified; R63.4 - Abnormal weight loss; Z68.1 - Body mass index (BMI) 19.9 or less, adult; D72.829 - Elevated white blood cell count, unspecified; F41.9 - Anxiety disorder, unspecified; F17.290 - Nicotine dependence, other tobacco product, uncomplicated; F91.9 - Conduct disorder, unspecified; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; M26.69 - Other specified disorders of temporomandibular joint; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; D75.839 - Thrombocytosis, unspecified; E53.8 - Deficiency of other specified B group vitamins; I80.9 - Phlebitis and thrombophlebitis of unspecified site; K59.00 - Constipation, unspecified; Z74.09 - Other reduced mobility; H92.02 - Otalgia, left ear; H57.12 - Ocular pain, left eye; G89.3 - Neoplasm related pain (acute) (chronic); Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z81.8 - Family history of other mental and beha..."
HAM OP INFUSION,28572,"Yogarajah, Meera, MD",8/16/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/12/2024,Active,,
SOM OUTPT INFUSION,82281,"George, Roshini, DO",2/26/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/25/2025,Active,Metastatic cancer to liver (CMS/HCC),C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
CINJ OP INFUSION,47626,"Berim, Lyudmyla, MD",4/17/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/1/2024,Inactive,,
CINJ OP INFUSION,47626,"Goel, Sanjay, MD",7/1/2024,CINJ 052308 Cohort D Dose Escalation DCC3116 / Sotorasib 28 Day Cycles Research- Malignant Solid Tumors,_3. Third Line,7/1/2024,Inactive,,
CBMC OP INFUSION 1FL,38047,"Siu, Karleung, MD",1/8/2025,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",_2. Second Line,12/10/2024,Active,,
NBR 5N ONCOLOGY,17644,"Doraiswamy, Anupama, MD",2/12/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,2/12/2023,Inactive,,
NBR CINJ OP INFUSION,17644,"Matasar, Matthew J, MD",2/16/2023,Modified Magrath CODOX-M + IVAC (Cyclophosphamide / DOXOrubicin / VinCRIStine / High Dose Methotrexate/Etoposide / Ifosfamide / Cytarabine / Intrathecal M) + RiTUXimab 28 Day Cycle - Burkitt Lymphoma,First Line,2/16/2023,Inactive,,
CMC OP INFUSION,66971,"Talwar, Sumit, MD",11/4/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/22/2024,Active,,
CMC OP INFUSION,66971,"Talwar, Sumit, MD",2/12/2025,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/6/2025,Active,Malignant neoplasm of upper lobe of left lung (CMS/HCC),
SOM OUTPT INFUSION,60736,"Patel, Eshan, MD",4/29/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/26/2024,Inactive,,
SOM OUTPT INFUSION,60736,"Patel, Eshan, MD",8/5/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,8/4/2024,Active,Metastatic non-small cell lung cancer (CMS/HCC),
CBMC OP INFUSION 2FL,12328,"Grossman, I Robert, MD",5/2/2025,AVD (DOXORUBICIN / VINBLASTINE / DACARBAZINE) + NIVOLUMAB 28 DAY CYCLES,_1. First Line,5/2/2025,Active,Nodular sclerosis Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),"C81.18 - Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites; D68.9 - Coagulation defect, unspecified; E87.20 - Acidosis, unspecified; I47.10 - Supraventricular tachycardia, unspecified; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; D63.8 - Anemia in other chronic diseases classified elsewhere; E83.39 - Other disorders of phosphorus metabolism; I48.91 - Unspecified atrial fibrillation; E87.6 - Hypokalemia; M54.50 - Low back pain, unspecified; Z59.71 - Insufficient health insurance coverage; Z91.013 - Allergy to seafood; Z87.892 - Personal history of anaphylaxis; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z82.5 - Family history of asthma and other chronic lower respiratory diseases; Z83.3 - Family history of diabetes mellitus"
NBI OP INFUSION,5706,"Anderson, Patrick S, MD",7/20/2023,Albumin-Bound PACLitaxel 21 Day Cycles -  Recurrent endometrial cancer ,_4. Fourth Line,7/19/2023,Active,,
CMC OP INFUSION,78679,"Meghal, Trishala, MD",1/24/2023,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Adjuvant,1/23/2023,Inactive,,
HAM OP INFUSION,57626,"Gendy, Mina, DO",11/20/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/19/2024,Inactive,,
HAM OP INFUSION,57626,"Gendy, Mina, DO",11/20/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,11/19/2024,Active,,
NBR CINJ OP INFUSION,52272,"Egini, Ogechukwu, MD",1/30/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_2. Second Line,1/15/2025,Active,,
CINJ OP INFUSION,36255,"Mayer, Tina M, MD",12/10/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,12/10/2024,Active,,
CINJ OP INFUSION,53977,"George, Mridula A, MD",11/27/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,11/19/2023,Inactive,,
CINJ OP INFUSION,53977,"George, Mridula A, MD",7/24/2024,CINJ 042312 Arm B Camizestrant +/- Abemaciclib +/- LHRH Agonist 90 / 180 Day Cycles Research- Breast Cancer,Adjuvant,7/24/2024,Active,,
CINJ OP INFUSION,85801,"George, Mridula A, MD",9/13/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,9/12/2023,Inactive,"Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC)
Pleural effusion, left",
CINJ OP INFUSION,85801,"George, Mridula A, MD",12/13/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,12/12/2023,Inactive,"Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC)
Pleural effusion, left",
CINJ OP INFUSION,85801,"George, Mridula A, MD",7/24/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,7/24/2024,Inactive,"Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC)
Pleural effusion, left",
CINJ OP INFUSION,85801,"George, Mridula A, MD",8/1/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,8/1/2024,Inactive,"Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC)
Pleural effusion, left",
CINJ OP INFUSION,85801,"George, Mridula A, MD",1/13/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,_1. First Line,1/12/2025,Active,Renal cell carcinoma of right kidney (CMS/HCC),
CINJ OP INFUSION,75199,"Stephenson, Ruth D, DO",5/10/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,5/9/2023,Inactive,,
CINJ OP INFUSION,75199,"Stephenson, Ruth D, DO",10/17/2024,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/17/2024,Active,,
SOM OUTPT INFUSION,13518,"Patel, Eshan, MD",8/21/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,,8/18/2023,Active,,
MMC OP INFUSION,17281,"Meghal, Trishala, MD",4/19/2024,Alpelisib 28 Day Cycles - Breast,_2. Second Line,4/19/2024,Inactive,,
MMC OP INFUSION,17281,"Meghal, Trishala, MD",4/19/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/18/2024,Inactive,,
CINJ OP INFUSION,19895,"Berim, Lyudmyla, MD",5/22/2023,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,,5/15/2023,Inactive,,
CINJ OP INFUSION,92902,"Salacz, Michael E, MD",4/24/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Second Line,4/24/2023,Inactive,,
HAM OP INFUSION,72540,"Patel, Malini M, MD",11/7/2023,Cetuximab / PACLitaxel 100 mg/m2 / CARBOplatin AUC 2.5 21 Day Cycles- Head and Neck Cancers,_4. Fourth Line,10/30/2023,Inactive,,
SOM OUTPT INFUSION,47689,"Yin, Faye, MD",4/4/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,First Line,3/30/2023,Inactive,,
SOM OUTPT INFUSION,32495,"Patel, Eshan, MD",6/14/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Second Line,6/13/2023,Inactive,,
CBMC OP INFUSION 2FL,67613,"Ligresti, Louise G, MD",7/15/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,7/15/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Breast cancer metastasized to bone (CMS/HCC)",
CINJ OP INFUSION,30773,"Toppmeyer, Deborah L, MD",7/31/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,First Line,7/24/2023,Inactive,,
CINJ OP INFUSION,30773,"Toppmeyer, Deborah L, MD",2/24/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,2/23/2024,Inactive,,
CINJ OP INFUSION,30773,"Toppmeyer, Deborah L, MD",5/16/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_2. Second Line,5/16/2024,Inactive,,
JCMC CP INFUSION,10773,"Sekhri, Arunabh, MD",10/23/2023,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,10/23/2023,Inactive,,
NBI OP INFUSION,6769,"Shah, Shailja S, MD",3/4/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,3/4/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.1 - Estrogen receptor negative status (ER-)
MMC OP INFUSION,21055,"Lee, Patrick C, MD",6/4/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,5/20/2024,Inactive,,
MMC OP INFUSION,21055,"Lee, Patrick C, MD",7/1/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,6/30/2024,Active,,
CINJ OP INFUSION,662,"Boland, Patrick M, MD",10/6/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,10/5/2023,Inactive,,
CINJ OP INFUSION,66681,"Omene, Coral Oghenerukevwe, MD",6/24/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,6/23/2024,Active,,
CBMC OP INFUSION 2FL,62622,"Brown, Andrew Bennett, MD",9/23/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,9/22/2024,Active,,
CBMC OP INFUSION 2FL,62622,"Brown, Andrew Bennett, MD",9/23/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Neoadjuvant,9/15/2024,Active,,
CINJ OP INFUSION,37123,"Muralikrishnan, Sivraj, MD",1/3/2025,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,1/3/2025,Active,,
JCMC CP INFUSION,26444,"Sekhri, Arunabh, MD",1/3/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/2/2024,Inactive,,
CMC OP INFUSION,62157,"Taff, Jessica, MD",5/18/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,5/17/2023,Inactive,,
CMC OP INFUSION,62157,"Taff, Jessica, MD",7/31/2023,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",First Line,7/26/2023,Inactive,,
NBR CINJ OP INFUSION,22134,"Shah, Mansi R, MD",5/31/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,5/16/2024,Active,,
NBI OP INFUSION,946,"Shah, Maya M, MD",11/1/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/31/2023,Inactive,,
CINJ OP INFUSION,49650,"Stephenson, Ryan D, DO",2/17/2025,Apalutamide 30 Day Cycles - Prostate,_1. First Line,2/17/2025,Active,Prostate cancer metastatic to bone (CMS/HCC),C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; E03.2 - Hypothyroidism due to medicaments and other exogenous substances
MSC OP INFUSION,58462,"Taff, Jessica, MD",6/7/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,74016,"Litvak, Anna M, MD",4/8/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,4/8/2025,Active,Malignant neoplasm of right female breast (CMS/HCC),C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,74016,"Litvak, Anna M, MD",3/11/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,3/11/2025,Inactive,Malignant neoplasm of right female breast (CMS/HCC),
CBMC OP INFUSION 2FL,74016,"Litvak, Anna M, MD",3/11/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,3/11/2025,Inactive,Malignant neoplasm of right female breast (CMS/HCC),
NBI OP INFUSION,64391,"Cheng, Yan Ho, MD",2/19/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,2/19/2024,Inactive,,
NBI OP INFUSION,64391,"Cheng, Yan Ho, MD",4/17/2024,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,4/16/2024,Inactive,,
NBI OP INFUSION,64391,"Cheng, Yan Ho, MD",4/17/2024,RiTUXimab 28 Day Cycle - ITP,_2. Second Line,4/16/2024,Inactive,,
NBI OP INFUSION,64391,"Cheng, Yan Ho, MD",4/23/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_2. Second Line,4/23/2024,Inactive,,
CBMC OP INFUSION 2FL,72530,"Wagmiller, Jennifer Ann, MD",3/21/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Adjuvant,3/3/2024,Inactive,,
CBMC OP INFUSION 2FL,72530,"Wagmiller, Jennifer Ann, MD",6/13/2024,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,6/13/2024,Active,,
CBMC OP INFUSION 2FL,72530,"Wagmiller, Jennifer Ann, MD",6/20/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/19/2024,Inactive,,
CBMC OP INFUSION 2FL,72530,"Wagmiller, Jennifer Ann, MD",6/20/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/19/2024,Inactive,,
CMC OP INFUSION,22881,"Samuel, David, MD",12/11/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,12/10/2024,Active,,
NBR 5N ONCOLOGY,69976,"Saraiya, Biren P, MD",6/10/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,First Line,6/9/2023,Inactive,,
CBMC OP INFUSION 2FL,37279,"Brown, Andrew Bennett, MD",12/27/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,12/26/2024,Active,,
TRMC TCCC OP INFUSION,35735,"Salerno, Vincent E, MD",11/11/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/4/2024,Active,,
CINJ OP INFUSION,85753,"Stephenson, Ryan D, DO",9/13/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,9/12/2023,Inactive,,
CINJ OP INFUSION,65886,"Haigentz, Missak, MD",5/14/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,5/14/2024,Inactive,,
SOM OUTPT INFUSION,74939,"Patel, Eshan, MD",7/24/2023,Pembrolizumab/Trastuzumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,7/21/2023,Inactive,,
CINJ OP INFUSION,74267,"Goel, Sanjay, MD",7/3/2023,CINJ 052205 ICP-192 Dose Expansion 21 Cycles Research- Advanced Solid Tumors,,5/30/2023,Inactive,,
NBI OP INFUSION,65072,"Anderson, Patrick S, MD",4/10/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,4/10/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),
CINJ OP INFUSION,26171,"Ghodoussipour, Saum Bobak, MD",1/4/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,1/3/2023,Inactive,,
CINJ OP INFUSION,26171,"Ghodoussipour, Saum Bobak, MD",4/12/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,4/11/2023,Active,,
NBI OP INFUSION,24020,"Schleicher, Lori, MD",4/12/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,4/2/2024,Active,,
CBMC OP INFUSION 2FL,36289,"Phillips, Adrienne A, MD",9/25/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/10/2024,Active,,
CINJ OP INFUSION,4486,"George, Mridula A, MD",5/24/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/23/2024,Inactive,,
CINJ OP INFUSION,4486,"George, Mridula A, MD",1/8/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,1/8/2025,Active,Malignant neoplasm of prostate (CMS/HCC),
CINJ OP INFUSION,4486,"George, Mridula A, MD",4/4/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,4/4/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)","C50.112 - Malignant neoplasm of central portion of left female breast; N93.9 - Abnormal uterine and vaginal bleeding, unspecified; Z17.0 - Estrogen receptor positive status (ER+); Z15.01 - Genetic susceptibility to malignant neoplasm of breast; Z15.02 - Genetic susceptibility to malignant neoplasm of ovary; Z15.09 - Genetic susceptibility to other malignant neoplasm"
SOM OUTPT INFUSION,91887,"Patel, Eshan, MD",8/2/2024,Imatinib 30 Day Cycles - Sarcoma (GIST),_1. First Line,8/2/2024,Active,,
MSC OP INFUSION,54380,"Cohen, Seth D, MD",5/24/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/23/2024,Active,,
CINJ OP INFUSION,1801,"Jang, Thomas L, MD",3/17/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,3/17/2023,Inactive,,
CINJ OP INFUSION,1801,"Jang, Thomas L, MD",10/20/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,10/20/2023,Inactive,,
CINJ OP INFUSION,1801,"Packiam, Vignesh, MD",1/19/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,1/11/2024,Inactive,,
CINJ OP INFUSION,1801,"Packiam, Vignesh, MD",12/31/2024,CINJ 082403 PHASE 2 (4 INSTILLATION REGIMEN) EG-70,Adjuvant,12/31/2024,Active,,
CINJ OP INFUSION,7470,"Leiser, Aliza, MD",10/26/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,10/24/2023,Inactive,,
CINJ OP INFUSION,7470,"Leiser, Aliza, MD",2/14/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,2/13/2025,Active,"Endometrial cancer (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",C54.1 - Malignant neoplasm of endometrium
NBI OP INFUSION,62359,"Jacoby, Sari H, MD",3/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/24/2024,Inactive,,
CINJ OP INFUSION,3349,"Saraiya, Biren P, MD",9/10/2024,Darolutamide 30 Day Cycles - Prostate,_1. First Line,9/10/2024,Active,,
NBR CINJ OP INFUSION,67367,"Egini, Ogechukwu, MD",1/16/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_2. Second Line,1/2/2025,Active,,
NBR 5N ONCOLOGY,66810,"Palmisiano, Neil David, MD",1/27/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,1/26/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
NBR 5N ONCOLOGY,66810,"Chen, Xiaoyi",2/13/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,2/12/2025,Active,Acute leukemia not having achieved remission (CMS/HCC),; D61.818 - Pancytopenia (CMS/HCC)
CBMC 2W ONCOLOGY,68639,"Grossman, I Robert, MD",4/13/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,4/13/2024,Inactive,,
CBMC OP INFUSION 2FL,68639,"Grossman, I Robert, MD",4/22/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,4/22/2024,Inactive,,
NBI OP INFUSION,19889,"Schleicher, Lori, MD",3/19/2024,Pembrolizumab + Abraxane + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,3/18/2024,Inactive,,
CINJ OP INFUSION,19207,"Boland, Patrick M, MD",4/5/2024,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,2/26/2024,Inactive,,
CBMC OP INFUSION 2FL,19207,"Brown, Andrew Bennett, MD",7/2/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/2/2024,Active,,
CBMC OP INFUSION 2FL,19207,"Brown, Andrew Bennett, MD",8/13/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/12/2024,Inactive,,
CINJ OP INFUSION,19207,"Goel, Sanjay, MD",12/30/2024,CINJ 052401 Pre-Treatment Assments Research GIM-122 - Solid Malignancies,_3. Third Line,12/30/2024,Active,,
CINJ OP INFUSION,51491,"Goel, Sanjay, MD",1/15/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,1/15/2025,Active,,
CINJ OP INFUSION,51491,"Goel, Sanjay, MD",2/26/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,2/26/2025,Active,Cancer of ascending colon (CMS/HCC),
NBI OP INFUSION,14480,"Cohen, Alice, MD",11/15/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,10/10/2024,Active,,
NBR 4N ONCOLOGY,86528,"Palmisiano, Neil David, MD",1/14/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Second Line,1/13/2023,Inactive,,
NBR CINJ OP INFUSION,86528,"Palmisiano, Neil David, MD",2/20/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,2/19/2023,Inactive,,
NBR CINJ OP INFUSION,86528,"Palmisiano, Neil David, MD",8/7/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,8/6/2023,Inactive,,
NBI OP INFUSION,18172,"Shah, Maya M, MD",5/7/2025,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles + Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,5/7/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
NBI OP INFUSION,18172,"Shah, Maya M, MD",5/7/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,5/7/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
NBI OP INFUSION,18172,"Shah, Maya M, MD",5/7/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/7/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
CBMC OP INFUSION 2FL,49576,"Grossman, I Robert, MD",5/12/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/12/2025,Active,"CLL (chronic lymphocytic leukemia) (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)","C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E88.3 - Tumor lysis syndrome; E46 - Unspecified protein-calorie malnutrition; D73.5 - Infarction of spleen; E87.1 - Hypo-osmolality and hyponatremia; E87.0 - Hyperosmolality and hypernatremia; E83.39 - Other disorders of phosphorus metabolism; E83.51 - Hypocalcemia; I27.22 - Pulmonary hypertension due to left heart disease; K76.1 - Chronic passive congestion of liver; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; Z11.52 - Encounter for screening for COVID-19; D69.59 - Other secondary thrombocytopenia; E66.01 - Morbid (severe) obesity due to excess calories; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; D63.0 - Anemia in neoplastic disease; Z68.34 - Body mass index (BMI) 34.0-34.9, adult; E04.1 - Nontoxic single thyroid nodule; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; T82.838A - Hemorrhage due to vascular prosthetic devices, implants and grafts, initial encounter; I48.0 - Paroxysmal atrial fibrillation; R62.7 - Adult failure to thrive; K82.9 - Disease of gallbladder, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecif..."
CBMC 2W ONCOLOGY,49576,"Scoppetuolo, Michael, MD",4/17/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/17/2025,Inactive,"CLL (chronic lymphocytic leukemia) (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)","C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E88.3 - Tumor lysis syndrome; E46 - Unspecified protein-calorie malnutrition; D73.5 - Infarction of spleen; E87.1 - Hypo-osmolality and hyponatremia; E87.0 - Hyperosmolality and hypernatremia; E83.39 - Other disorders of phosphorus metabolism; E83.51 - Hypocalcemia; I27.22 - Pulmonary hypertension due to left heart disease; K76.1 - Chronic passive congestion of liver; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; Z11.52 - Encounter for screening for COVID-19; D69.59 - Other secondary thrombocytopenia; E66.01 - Morbid (severe) obesity due to excess calories; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; D63.0 - Anemia in neoplastic disease; Z68.34 - Body mass index (BMI) 34.0-34.9, adult; E04.1 - Nontoxic single thyroid nodule; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; T82.838A - Hemorrhage due to vascular prosthetic devices, implants and grafts, initial encounter; I48.0 - Paroxysmal atrial fibrillation; R62.7 - Adult failure to thrive; K82.9 - Disease of gallbladder, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecif..."
CBMC 2W ONCOLOGY,49576,"Grossman, I Robert, MD",4/17/2025,Dose-Adjusted R-EPOCH (For AIDS-Related) (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/17/2025,Inactive,"CLL (chronic lymphocytic leukemia) (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)","C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E88.3 - Tumor lysis syndrome; E46 - Unspecified protein-calorie malnutrition; D73.5 - Infarction of spleen; E87.1 - Hypo-osmolality and hyponatremia; E87.0 - Hyperosmolality and hypernatremia; E83.39 - Other disorders of phosphorus metabolism; E83.51 - Hypocalcemia; I27.22 - Pulmonary hypertension due to left heart disease; K76.1 - Chronic passive congestion of liver; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; Z11.52 - Encounter for screening for COVID-19; D69.59 - Other secondary thrombocytopenia; E66.01 - Morbid (severe) obesity due to excess calories; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; D63.0 - Anemia in neoplastic disease; Z68.34 - Body mass index (BMI) 34.0-34.9, adult; E04.1 - Nontoxic single thyroid nodule; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; T82.838A - Hemorrhage due to vascular prosthetic devices, implants and grafts, initial encounter; I48.0 - Paroxysmal atrial fibrillation; R62.7 - Adult failure to thrive; K82.9 - Disease of gallbladder, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecif..."
CINJ OP INFUSION,43749,"Gulhati, Prateek, MD PhD",12/26/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,11/27/2024,Active,,
CINJ OP INFUSION,84596,"Stephenson, Ryan D, DO",2/17/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,2/17/2023,Active,,
NBI OP INFUSION,75262,"Shah, Shailja S, MD",10/17/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,10/16/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Botwinick, Marissa, DO",1/9/2023,(MRD+) Acute Lymphoblastic Leukemia (Consolidation) per AALL1731,,1/9/2023,Inactive,,
CINJ PEDS HEMONC ,57572,"Cole, Peter David, MD",2/20/2023,AALL1732 Consolidation,,2/20/2023,Inactive,,
CINJ PEDS HEMONC ,57572,"Cole, Peter David, MD",5/8/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,,5/8/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Cole, Peter David, MD",6/6/2023,per AALL1731 Blinatumomab,,6/5/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Cole, Peter David, MD",6/30/2023,per AALL1731 Blinatumomab ,,6/8/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Cole, Peter David, MD",8/4/2023,per AALL1732 Delayed Intensification,,8/3/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Cole, Peter David, MD",11/9/2023,Dosing per AALL1731 Blinatumomab,Adjuvant,11/9/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Cole, Peter David, MD",11/14/2023,Dosing per AALL1731 Blinatumomab (substitution for Interim Maintenance II),_2. Second Line,11/8/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,57572,"Cole, Peter David, MD",1/29/2024,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,Maintenance,1/26/2024,Active,,
CINJ PEDS HEMONC ,57572,"Botwinick, Marissa, DO",2/13/2025,Palliative therapy: Methotrexate Intrathecal 12 mg IT and Vincristine  (dosing per AAALL1732),_2. Second Line,2/13/2025,Active,B-cell acute lymphoblastic leukemia (ALL) in relapse (CMS/HCC),"K94.23 - Gastrostomy malfunction; D61.810 - Antineoplastic chemotherapy induced pancytopenia; T80.212A - Local infection due to central venous catheter, initial encounter; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; C91.02 - Acute lymphoblastic leukemia, in relapse; D80.1 - Nonfamilial hypogammaglobulinemia; Z94.82 - Intestine transplant status; D84.821 - Immunodeficiency due to drugs; Z94.4 - Liver transplant status; I42.2 - Other hypertrophic cardiomyopathy; E27.40 - Unspecified adrenocortical insufficiency; K92.2 - Gastrointestinal hemorrhage, unspecified; Z16.11 - Resistance to penicillins; Z23 - Encounter for immunization; I27.20 - Pulmonary hypertension, unspecified; Z11.52 - Encounter for screening for COVID-19; B96.1 - Klebsiella pneumoniae (k. pneumoniae) as the cause of diseases classified elsewhere; B96.20 - Unspecified Escherichia coli (E. coli) as the cause of diseases classified elsewhere; D75.A - Glucose-6-phosphate dehydrogenase (G6PD) deficiency without anemia; D89.832 - Cytokine release syndrome, grade 2; E83.39 - Other disorders of phosphorus metabolism; E87.5 - Hyperkalemia; E87.6 - Hypokalemia; E87.70 - Fluid overload, unspecified; F41.9 - Anxiety disorder, unspecified; F88 - Other disorders of psychological development; G62.0 - Drug-induced polyneuropathy; I10 - Essential (primary) hypertension; J45.909 - Unspecified asthma, uncomplicated; J98.4 - Other disorders of lung; K21.9 - Gastro-esophageal reflux disease without esophagiti..."
CINJ OP INFUSION,59719,"George, Mridula A, MD",5/20/2024,CINJ 042209 Arm A Imlunestrant 5 Year Treatment Research- Breast Cancer,Adjuvant,5/20/2024,Active,,
NBI OP INFUSION,2034,"Schleicher, Lori, MD",10/14/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,10/14/2024,Active,,
CBMC OP INFUSION 2FL,9471,"Raptis, George, MD",2/21/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,2/17/2025,Active,"Breast cancer, left (CMS/HCC)",
SOM OUTPT INFUSION,27091,"Yin, Faye, MD",6/14/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/21/2023,Inactive,,
SOM OUTPT INFUSION,27091,"Yin, Faye, MD",10/25/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,10/19/2023,Inactive,,
SOM OUTPT INFUSION,27091,"Yin, Faye, MD",12/6/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,12/5/2023,Inactive,,
SOM OUTPT INFUSION,27091,"Toomey, Kathleen C, MD",6/3/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/31/2024,Inactive,,
HAM OP INFUSION,51685,"Gendy, Mina, DO",1/28/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/27/2025,Active,,
HAM OP INFUSION,51685,"Gendy, Mina, DO",2/26/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/27/2025,Active,Pancreatic cancer (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; I10 - Essential (primary) hypertension; E03.9 - Hypothyroidism, unspecified; E78.5 - Hyperlipidemia, unspecified; Z87.891 - Personal history of nicotine dependence; Z79.890 - Hormone replacement therapy; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,64350,"Berim, Lyudmyla, MD",12/24/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/18/2024,Active,,
CINJ OP INFUSION,6625,"Berim, Lyudmyla, MD",2/24/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/13/2025,Active,Malignant neoplasm of tail of pancreas (CMS/HCC),
NBR 5N MED-SURG OVRF,843,"Alexander, Henry Richard, MD",10/31/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_3. Third Line,10/31/2024,Active,,
CMC OP INFUSION,79256,"Cohen, Seth D, MD",12/28/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/18/2023,Inactive,,
CBMC OP INFUSION 2FL,36987,"Leitner, Stuart P, MD",12/17/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,12/16/2024,Active,,
CINJ OP INFUSION,45303,"Leiser, Aliza, MD",11/30/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,11/17/2023,Inactive,,
CINJ OP INFUSION,45303,"Leiser, Aliza, MD",4/19/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/16/2024,Active,,
CINJ OP INFUSION,66262,"Gulhati, Prateek, MD PhD",3/2/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,3/1/2023,Inactive,,
CINJ OP INFUSION,52962,"Haigentz, Missak, MD",9/18/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,First Line,9/18/2023,Inactive,,
CINJ OP INFUSION,52962,"Haigentz, Missak, MD",11/22/2023,Cetuximab / PACLitaxel 80 mg/m2 - 28 Day Cycles- Head and Neck Cancers,_2. Second Line,11/22/2023,Inactive,,
CINJ OP INFUSION,93037,"Omene, Coral Oghenerukevwe, MD",5/12/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/12/2025,Active,Stage IV breast cancer in female (CMS/HCC),C50.912 - Malignant neoplasm of unspecified site of left female breast
CINJ OP INFUSION,52010,"Boland, Patrick M, MD",11/21/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",Neoadjuvant,11/20/2024,Inactive,,
CINJ OP INFUSION,52010,"Boland, Patrick M, MD",11/26/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,11/20/2024,Active,,
CINJ OP INFUSION,97912,"Saraiya, Biren P, MD",5/31/2023,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Bladder Cancer,Third Line,5/21/2023,Inactive,,
CINJ OP INFUSION,97912,"Saraiya, Biren P, MD",6/8/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles ,Third Line,6/7/2023,Inactive,,
CINJ OP INFUSION,46780,"Boland, Patrick M, MD",2/4/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/4/2025,Active,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
MMC OP VP INFUSION,98562,"Meghal, Trishala, MD",1/21/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,1/21/2025,Inactive,Malignant neoplasm of lower lobe of left lung (CMS/HCC),
MMC OP VP INFUSION,32579,"Talwar, Sumit, MD",2/4/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,2/3/2025,Active,Malignant neoplasm of lower lobe of left lung (CMS/HCC),
MMC OP VP INFUSION,32579,"Talwar, Sumit, MD",3/21/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/21/2025,Inactive,"Malignant neoplasm of lower lobe of left lung (CMS/HCC)
Disorder of thyroid, unspecified",
CBMC OP INFUSION 2FL,98574,"Leitner, Stuart P, MD",1/17/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,1/16/2024,Inactive,,
JCMC CP INFUSION,81022,"Cruz, Allan Louie E, MD",4/25/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,4/24/2023,Inactive,,
JCMC CP INFUSION,81022,"Cruz, Allan Louie E, MD",4/25/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,4/24/2023,Inactive,,
JCMC CP INFUSION,81022,"Cruz, Allan Louie E, MD",8/14/2023,Nivolumab 480 mg 28 Day Cycles- recurrent and metastatic head and neck cancer,Second Line,8/14/2023,Inactive,,
JCMC CP INFUSION,81022,"Cruz, Allan Louie E, MD",11/29/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/20/2023,Inactive,,
JCMC CP INFUSION,81022,"Cruz, Allan Louie E, MD",11/29/2023,Nivolumab 480 mg D1 28 Day Cycles- recurrent and metastatic oropharyngeal carcinoma,_1. First Line,11/20/2023,Inactive,,
CINJ OP INFUSION,81022,"Haigentz, Missak, MD",1/14/2025,CINJ 032405 Cohort 4 Amivantamab Monotherapy (Pt. Weight < 80 kg) 21 Day Cycles Research- Head and Neck Cancers,_3. Third Line,1/14/2025,Active,,
CINJ OP INFUSION,69191,"Boland, Patrick M, MD",9/14/2023,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,First Line,9/13/2023,Inactive,,
CINJ OP INFUSION,69191,"Boland, Patrick M, MD",3/7/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/6/2024,Inactive,,
CINJ OP INFUSION,69191,"Boland, Patrick M, MD",12/17/2024,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,Maintenance,12/16/2024,Active,,
HAM OP INFUSION,84393,"Yogarajah, Meera, MD",5/22/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,5/21/2023,Inactive,,
HAM OP INFUSION,84393,"Yogarajah, Meera, MD",8/14/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,8/13/2023,Inactive,,
SOM OUTPT INFUSION,40881,"Yin, Faye, MD",2/6/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,2/5/2024,Inactive,,
SOM OUTPT INFUSION,62499,"Toomey, Kathleen C, MD",7/24/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,7/23/2024,Active,,
CBMC OP INFUSION 2FL,42893,"Scoppetuolo, Michael, MD",2/6/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,1/18/2024,Active,,
CBMC 2W ONCOLOGY,95807,"McKenna, Marshall, MD",11/18/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,11/17/2024,Inactive,,
CINJ OP INFUSION,800,"Boland, Patrick M, MD",6/26/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,6/24/2024,Inactive,,
CINJ OP INFUSION,800,"Boland, Patrick M, MD",8/13/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,8/12/2024,Inactive,,
NBR CINJ OP INFUSION,4175,"Matasar, Matthew J, MD",6/28/2023,MATRiX (High-Dose Methotrexate / Cytarabine / Thiotepa / RiTUXimab) - CNS Lymphoma,,6/27/2023,Inactive,,
NBR 4N BMTU/IMCU,4175,"Braunschweig, Ira, MD",10/18/2023,BMT Autologous Thio / Bu / Cy,_2. Second Line,10/16/2023,Inactive,,
NBR 4N BMTU/IMCU,4175,"Braunschweig, Ira, MD",11/1/2023,BMT Autologous Thio / Bu / Cy,_3. Third Line,10/30/2023,Inactive,,
CBMC OP INFUSION 2FL,72941,"Wagmiller, Jennifer Ann, MD",8/16/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/7/2024,Active,,
CBMC OP INFUSION 2FL,10845,"Scoppetuolo, Michael, MD",6/18/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,4/21/2024,Active,,
NBR 4N ONCOLOGY,85486,"Sridharan, Ashwin, MD",4/8/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,4/7/2024,Inactive,,
CMC OP INFUSION,79064,"Pompa, Tiffany Ann, MD",8/22/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,8/21/2024,Inactive,,
CMC OP INFUSION,79064,"Pompa, Tiffany Ann, MD",8/29/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,8/28/2024,Inactive,,
CMC OP INFUSION,79064,"Pompa, Tiffany Ann, MD",11/7/2024,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/5/2024,Active,,
CMC OP INFUSION,79064,"Pompa, Tiffany Ann, MD",11/7/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Cervical ,_2. Second Line,11/5/2024,Active,,
CINJ OP INFUSION,56939,"Saraiya, Biren P, MD",10/2/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,10/2/2023,Inactive,,
CINJ OP INFUSION,56939,"Saraiya, Biren P, MD",7/1/2024,Enzalutamide 30 Day Cycles - Prostate,_2. Second Line,7/1/2024,Active,,
NBR 5N ONCOLOGY,56939,"Saraiya, Biren P, MD",12/23/2024,Relugolix 30 day Cycles - Prostate,_1. First Line,12/23/2024,Active,"Malignant neoplasm of ascending colon (CMS/HCC)
Secondary malignant neoplasm of unspecified lung (CMS/HCC)",
CINJ OP INFUSION,41972,"Saraiya, Biren P, MD",2/18/2025,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,1/27/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; K75.9 - Inflammatory liver disease, unspecified; Z11.59 - Encounter for screening for other viral diseases"
CINJ OP INFUSION,41972,"Saraiya, Biren P, MD",5/28/2025,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,5/28/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; K75.9 - Inflammatory liver disease, unspecified; Z11.59 - Encounter for screening for other viral diseases"
NBI OP INFUSION,60621,"Cheng, Yan Ho, MD",12/19/2023,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,12/19/2023,Active,,
CINJ OP INFUSION,60816,"Berim, Lyudmyla, MD",4/17/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,4/13/2023,Inactive,,
CINJ OP INFUSION,60816,"Berim, Lyudmyla, MD",12/18/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,Maintenance,12/17/2023,Inactive,,
CINJ OP INFUSION,60816,"Berim, Lyudmyla, MD",12/18/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Maintenance,12/17/2023,Inactive,,
CINJ OP INFUSION,14443,"Hochster, Howard S, MD",11/16/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/8/2023,Inactive,,
HAM OP INFUSION,27105,"Yogarajah, Meera, MD",5/3/2024,Acalabrutinib 30 Day Cycles - CLL,_1. First Line,5/3/2024,Inactive,,
HAM OP INFUSION,27105,"Yogarajah, Meera, MD",11/4/2024,CLL,_1. First Line,11/4/2024,Active,,
CINJ OP INFUSION,39145,"Goel, Sanjay, MD",4/14/2025,CINJ 052006 Arm 9 FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) / TTX-080 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,4/14/2025,Inactive,"Cancer of ascending colon (CMS/HCC)
Cancer, metastatic to liver (CMS/HCC)
Metastatic malignant neoplasm, unspecified site (CMS/HCC)",
TRMC TCCC OP INFUSION,15169,"Capo, Gerardo, MD",10/8/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,10/7/2024,Inactive,,
TRMC TCCC OP INFUSION,15169,"Capo, Gerardo, MD",10/29/2024,PACLitaxel / Topotecan / Bevacizumab 21 Day Cycles - Cervical,_2. Second Line,10/28/2024,Inactive,,
TRMC TCCC OP INFUSION,15169,"Capo, Gerardo, MD",11/19/2024,Topotecan / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/18/2024,Active,Grade 3b follicular lymphoma of lymph nodes of multiple regions (CMS/HCC),
TRMC TCCC OP INFUSION,15169,"Capo, Gerardo, MD",11/21/2024,Topotecan / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/20/2024,Inactive,,
SOM OUTPT INFUSION,1774,"Yin, Faye, MD",1/25/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles plus Pembrolizumab - Breast,Neoadjuvant,1/23/2023,Inactive,,
SOM OUTPT INFUSION,1774,"Yin, Faye, MD",5/31/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,First Line,3/29/2023,Inactive,,
MMC OP VP INFUSION,96866,"Cohen, Seth D, MD",9/18/2023,Atezolizumab/Bevacizumab/PACLitaxel/CARBOplatin 21 Day Cycles - Non-Small Cell Lung Cancer,,9/17/2023,Inactive,,
MMC OP VP INFUSION,96866,"Cohen, Seth D, MD",9/18/2023,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,,9/17/2023,Inactive,,
MMC OP VP INFUSION,96866,"Cohen, Seth D, MD",9/18/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,First Line,9/17/2023,Inactive,,
NBR CINJ OP INFUSION,77739,"Evens, Andrew M, DO",6/9/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,First Line,6/8/2023,Inactive,,
NBR CINJ OP INFUSION,77739,"Evens, Andrew M, DO",6/14/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,First Line,5/30/2023,Inactive,,
NBR CINJ OP INFUSION,77739,"Evens, Andrew M, DO",8/9/2023,"CINJ 112305 Arms B,D,F,H (Brentuximab Vendotin + Nivolumab) 21 Day Cycles - Hodgkin Lymphoma",First Line,8/8/2023,Active,,
NBI OP INFUSION,89630,"Jacoby, Sari H, MD",1/22/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/22/2025,Active,,
NBR CINJ OP INFUSION,73144,"Evens, Andrew M, DO",2/8/2023,Mogamulizumab-kpkc 28 Day Cycle - Mycosis Fungoides / Sezary Syndrome ,,2/7/2023,Inactive,,
CINJ OP INFUSION,3159,"Haigentz, Missak, MD",11/25/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,11/25/2024,Active,,
CBMC OP INFUSION 2FL,77785,"Grossman, I Robert, MD",1/14/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/12/2025,Active,,
NBI VALERIE FND HEMONC,14962,"Rao, Harini, MD",11/14/2023,PEDS AEWS1031 Regimen A Induction & Consolidation,_2. Second Line,11/13/2023,Inactive,,
NBI VALERIE FND HEMONC,14962,"Rao, Harini, MD",11/20/2023,PEDS IE - Osteosarcoma,_2. Second Line,11/13/2023,Inactive,,
HAM OP INFUSION,94041,"Yogarajah, Meera, MD",2/20/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,2/19/2024,Active,,
HAM OP INFUSION,94041,"Yogarajah, Meera, MD",4/1/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,4/1/2025,Active,"Squamous cell carcinoma of lateral tongue (CMS/HCC)
Encounter for screening for other viral diseases
Encounter for screening for viral disease
Abnormal thyroid function test",
CINJ OP INFUSION,95213,"Hochster, Howard S, MD",3/30/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,3/28/2023,Inactive,,
CINJ OP INFUSION,95213,"Hochster, Howard S, MD",10/18/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/13/2023,Inactive,,
CINJ OP INFUSION,95213,"Hochster, Howard S, MD",10/25/2023,CINJ 072110 Capecitabine / Bevacizumab 21 Day Cycles Research- Colon Cancer,_1. First Line,10/25/2023,Inactive,,
CINJ OP INFUSION,95213,"Hochster, Howard S, MD",1/17/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/16/2024,Inactive,,
CMC OP INFUSION,76850,"Talwar, Sumit, MD",11/17/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,11/17/2023,Inactive,,
CINJ OP INFUSION,7685,"Goel, Sanjay, MD",3/5/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,3/3/2025,Active,Malignant neoplasm of pylorus of stomach (CMS/HCC),
HAM OP INFUSION,65580,"Yogarajah, Meera, MD",9/17/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,_1. First Line,8/20/2024,Active,,
HAM OP INFUSION,65580,"Yogarajah, Meera, MD",9/17/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/16/2024,Inactive,,
HAM OP INFUSION,65580,"Yogarajah, Meera, MD",9/17/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/16/2024,Inactive,,
HAM OP INFUSION,65580,"Yogarajah, Meera, MD",12/16/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,11/26/2024,Active,Primary squamous cell carcinoma of bronchus of left upper lobe (CMS/HCC),
NBI OP INFUSION,44964,"Jacoby, Sari H, MD",4/8/2024,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,_1. First Line,4/7/2024,Inactive,,
CINJ OP INFUSION,66906,"Saraiya, Biren P, MD",6/6/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,6/6/2023,Active,,
CINJ OP INFUSION,12500,"Haigentz, Missak, MD",5/22/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/22/2023,Inactive,,
MMC OP INFUSION,61093,"Lee, Patrick C, MD",10/3/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,9/16/2024,Active,,
CINJ OP INFUSION,3192,"Boland, Patrick M, MD",12/12/2024,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/11/2024,Active,,
CINJ OP INFUSION,25245,"Boland, Patrick M, MD",10/23/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/22/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC BBR2 ONCOLOGY,82903,"Meghal, Trishala, MD",5/5/2024,R-MPV (High-Dose Methotrexate / VinCRIStine / Procarbazine / RiTUXimab) 14 Day Cycles - CNS Lymphoma,Induction,5/4/2024,Inactive,,
MSC OP INFUSION,82903,"Eltoukhy, Hussam, MD",5/6/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,5/5/2024,Inactive,,
CINJ OP INFUSION,57564,"Haigentz, Missak, MD",8/21/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,8/21/2023,Inactive,,
NBR 4N ONCOLOGY,2308,"Braunschweig, Ira, MD",12/4/2023,CINJ 012208 Lymphodepletion UCART20x22 T-Cells 84 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_5. Fifth Line,12/4/2023,Active,,
NBR 5N ONCOLOGY,83699,"Omene, Coral Oghenerukevwe, MD",3/4/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,3/4/2025,Inactive,Stage IV breast cancer in female (CMS/HCC),"A41.51 - Sepsis due to Escherichia coli (e. coli); I21.A1 - Myocardial infarction type 2; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; J96.01 - Acute respiratory failure with hypoxia; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C78.02 - Secondary malignant neoplasm of left lung; C78.01 - Secondary malignant neoplasm of right lung; I96 - Gangrene, not elsewhere classified; J91.0 - Malignant pleural effusion; I27.20 - Pulmonary hypertension, unspecified; C79.51 - Secondary malignant neoplasm of bone; D72.819 - Decreased white blood cell count, unspecified; C50.911 - Malignant neoplasm of unspecified site of right female breast; D69.6 - Thrombocytopenia, unspecified; I10 - Essential (primary) hypertension; D63.0 - Anemia in neoplastic disease; M84.452A - Pathological fracture, left femur, initial encounter for fracture; M84.48XA - Pathological fracture, other site, initial encounter for fracture; E87.1 - Hypo-osmolality and hyponatremia; J93.9 - Pneumothorax, unspecified; E87.70 - Fluid overload, unspecified; E87.6 - Hypokalemia; T50.2X5A - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter; Z17.31 - Human epidermal growth factor receptor 2 positive status; R54 - Age-related physical debility; Z17.0 - Estrogen receptor positive status (ER+); Z17.21 - Progesterone receptor positive status; I95.9 - Hypotension, unspecified; R60.0 - Localized edema; I80.8 - Phlebitis and thro..."
CBMC OP INFUSION 2FL,22110,"Radovich, Delia, MD",11/29/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,11/28/2023,Inactive,,
CINJ OP INFUSION,47216,"George, Mridula A, MD",3/10/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,3/9/2023,Inactive,,
CINJ OP INFUSION,47216,"George, Mridula A, MD",11/8/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,11/8/2023,Active,,
CINJ OP INFUSION,47216,"George, Mridula A, MD",11/10/2023,CINJ 042211 Arm A Sacituzumab govitecan / Pembrolizumab 21 Day Cycles Research- Breast Cancer,Adjuvant,11/2/2023,Inactive,,
NBI VALERIE FND HEMONC,18905,"de Benedictis, Marianna, MD",1/26/2024,PEDS R-CHOP - B-Cell Lymphoma,_1. First Line,1/25/2024,Inactive,,
TRMC TCCC OP INFUSION,55772,"Salerno, Vincent E, MD",4/15/2025,Pembrolizumab 21 Day Cycles - Hepatocellular cancer,_1. First Line,4/15/2025,Active,"Malignant neoplasm of liver, not specified as primary or secondary (CMS/HCC)
Other abnormal tumor markers
Nonspecific hepatocellular changes",
CINJ OP INFUSION,99785,"Hochster, Howard S, MD",1/26/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,1/18/2023,Inactive,,
CINJ OP INFUSION,99785,"Hochster, Howard S, MD",9/13/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,9/13/2023,Inactive,,
NBR CINJ OP INFUSION,50745,"Matasar, Matthew J, MD",2/15/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,1/30/2023,Inactive,,
NBR 5N ONCOLOGY,82931,"Matasar, Matthew J, MD",2/6/2025,DHAX (Dexamethasone / Cytarabine / OXALIplatin) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,2/6/2025,Active,"Diffuse large B-cell lymphoma, unspecified site (CMS/HCC)",J90 - Pleural effusion
NBR CINJ OP INFUSION,82931,"Matasar, Matthew J, MD",4/2/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,4/1/2025,Active,"Diffuse large B-cell lymphoma, unspecified site (CMS/HCC)
Abnormal coagulation profile",
NBR 5N ONCOLOGY,82931,"Matasar, Matthew J, MD",3/7/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_2. Second Line,3/7/2025,Active,"Diffuse large B-cell lymphoma, unspecified site (CMS/HCC)","C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; J96.01 - Acute respiratory failure with hypoxia; J91.0 - Malignant pleural effusion; Z59.00 - Homelessness unspecified; B19.10 - Unspecified viral hepatitis B without hepatic coma; F11.20 - Opioid dependence, uncomplicated; D50.9 - Iron deficiency anemia, unspecified; D75.839 - Thrombocytosis, unspecified; E87.5 - Hyperkalemia; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; J98.11 - Atelectasis; Z11.52 - Encounter for screening for COVID-19; F40.240 - Claustrophobia; R59.0 - Localized enlarged lymph nodes; R19.7 - Diarrhea, unspecified; M16.11 - Unilateral primary osteoarthritis, right hip; F41.1 - Generalized anxiety disorder; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; G89.3 - Neoplasm related pain (acute) (chronic); M54.31 - Sciatica, right side; H01.005 - Unspecified blepharitis left lower eyelid; K59.00 - Constipation, unspecified; Z90.49 - Acquired absence of other specified parts of digestive tract; Z98.891 - History of uterine scar from previous surgery; Z91.81 - History of falling; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z86.711 - Personal history of pulmonary embolism; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence"
CINJ OP INFUSION,37427,"Berim, Lyudmyla, MD",1/5/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,1/3/2023,Inactive,,
NBI OP INFUSION,44317,"Cheng, Yan Ho, MD",1/26/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- breast cancer with spinal mets,_1. First Line,1/26/2024,Inactive,,
MMC OP VP INFUSION,50051,"Meghal, Trishala, MD",9/23/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,9/23/2024,Active,,
NBI OP INFUSION,58412,"Anderson, Patrick S, MD",5/16/2024,Bevacizumab 21 Day Cycles - Endometrial Adenocarcinoma,_2. Second Line,5/15/2024,Active,,
NBI OP INFUSION,58412,"Anderson, Patrick S, MD",5/16/2024,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/15/2024,Inactive,,
NBI OP INFUSION,43099,"Shah, Shailja S, MD",11/3/2023,Daratumumab 28 Day Cycles- Multiple Myeloma,Maintenance,10/12/2023,Inactive,,
NBI OP INFUSION,43099,"Shah, Shailja S, MD",9/13/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,9/13/2024,Active,,
NBI OP INFUSION,43099,"Snyder, Rose, MD",2/28/2025,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_3. Third Line,2/27/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; C88.90 - Malignant immunoproliferative disease, unspecified not having achieved remission"
NBR CINJ OP INFUSION,27186,"Shah, Mansi R, MD",5/29/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,5/29/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,27186,"Shah, Mansi R, MD",5/2/2025,Talquetamab 28 Day Cycles,_5. Fifth Line,5/2/2025,Inactive,"Multiple myeloma not having achieved remission (CMS/HCC)
Multiple myeloma and immunoproliferative neoplasms (CMS/HCC)",
NBI A5 PEDIATRICS,36583,"Narang, Shalu, MD",4/24/2025,AGCT1531 Arm PEb (CISplatin / Etoposide / Bleomycin),_1. First Line,4/23/2025,Inactive,Mixed germ cell tumor (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; R18.8 - Other ascites; C56.1 - Malignant neoplasm of right ovary; N83.9 - Noninflammatory disorder of ovary, fallopian tube and broad ligament, unspecified; R77.2 - Abnormality of alphafetoprotein; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z90.721 - Acquired absence of ovaries, unilateral; Z98.890 - Other specified postprocedural states"
NBI A5 PEDIATRICS,36583,"Narang, Shalu, MD",4/23/2025,AGCT1532 Arm A (Standard BEP),_1. First Line,4/23/2025,Active,Mixed germ cell tumor (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; R18.8 - Other ascites; C56.1 - Malignant neoplasm of right ovary; N83.9 - Noninflammatory disorder of ovary, fallopian tube and broad ligament, unspecified; R77.2 - Abnormality of alphafetoprotein; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z90.721 - Acquired absence of ovaries, unilateral; Z98.890 - Other specified postprocedural states"
NBI OP INFUSION,16359,"Anderson, Patrick S, MD",7/11/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,6/26/2024,Active,,
CBMC OP INFUSION 2FL,99546,"Grossman, I Robert, MD",5/7/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,5/7/2025,Active,"Multiple myeloma, remission status unspecified (CMS/HCC)
Multiple myeloma not having achieved remission (CMS/HCC)",
CBMC OP INFUSION 2FL,99546,"Grossman, I Robert, MD",4/3/2025,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,4/3/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,99546,"Grossman, I Robert, MD",3/23/2025,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,3/23/2025,Inactive,"Multiple myeloma, remission status unspecified (CMS/HCC)
Multiple myeloma not having achieved remission (CMS/HCC)",
NBR CINJ OP INFUSION,13991,"Shah, Mansi R, MD",6/8/2023,"Bortezomib (3 weeks on, 1 week off)/Selinexor/Dexamethasone  28 Day Cycles- Multiple Myeloma",,6/7/2023,Inactive,,
NBR CINJ OP INFUSION,13991,"Shah, Mansi R, MD",1/10/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,1/2/2024,Inactive,,
NBR CINJ OP INFUSION,13991,"Shah, Mansi R, MD",3/12/2024,Carfilzomib 56 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,10. Tenth Line,3/11/2024,Inactive,,
NBR CINJ OP INFUSION,13991,"Shah, Mansi R, MD",5/14/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,10. Tenth Line,5/13/2024,Inactive,,
NBR CINJ OP INFUSION,13991,"Shah, Mansi R, MD",6/17/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_8. Eighth Line,6/17/2024,Active,Acute lymphocytic leukemia not having achieved remission (CMS/HCC),
MMC OP INFUSION,19868,"Meghal, Trishala, MD",11/15/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,11/14/2023,Inactive,,
MMC OP INFUSION,19868,"Meghal, Trishala, MD",2/7/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,2/6/2024,Inactive,,
MMC OP INFUSION,19868,"Meghal, Trishala, MD",2/7/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,2/7/2024,Inactive,,
MMC OP VP INFUSION,19868,"Meghal, Trishala, MD",8/23/2024,CINJ 042211 Arm B Capecitabine / Pembrolizumab 21 Day Cycles Research- Breast Cancer,Adjuvant,8/21/2024,Active,,
MMC OP VP INFUSION,19868,"Meghal, Trishala, MD",8/23/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/23/2024,Inactive,,
CBMC OP INFUSION 2FL,8483,"Wagmiller, Jennifer Ann, MD",8/13/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,8/11/2024,Active,,
CBMC OP INFUSION 2FL,14749,"Brown, Andrew Bennett, MD",2/1/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,1/31/2024,Inactive,,
CBMC OP INFUSION 2FL,14749,"Brown, Andrew Bennett, MD",8/15/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,8/14/2024,Active,,
CBMC OP INFUSION 2FL,10409,"Litvak, Anna M, MD",3/6/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,3/5/2023,Inactive,,
CBMC OP INFUSION 2FL,95524,"Brown, Andrew Bennett, MD",5/21/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/5/2024,Active,,
CBMC OP INFUSION 2FL,71579,"Brown, Andrew Bennett, MD",4/21/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,4/21/2025,Inactive,Malignant neoplasm of body of stomach (CMS/HCC),
CBMC OP INFUSION 2FL,40059,"Wagmiller, Jennifer Ann, MD",3/18/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/18/2025,Inactive,Endometrial adenocarcinoma (CMS/HCC),
NBR BMSCH 2 PED HEMONC,13256,"Moerdler, Scott, MD",4/20/2023,per ANHL1131 Pre-Phase Group B COP-  B-Cell Lymphoma,,4/20/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,13256,"Moerdler, Scott, MD",4/21/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,4/21/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,13256,"Moerdler, Scott, MD",4/27/2023,per ANHL1131 Group B Induction 1 (R-COPADM) 21 Day Cycles - Burkitt Lymphoma,,4/27/2023,Inactive,,
CBMC OP INFUSION 2FL,77197,"Litvak, Anna M, MD",10/31/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/30/2023,Active,,
CBMC OP INFUSION 2FL,50583,"Raptis, George, MD",4/2/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,4/2/2024,Inactive,,
CBMC OP INFUSION 2FL,50583,"Raptis, George, MD",4/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,50583,"Raptis, George, MD",6/1/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,6/1/2024,Inactive,,
CBMC OP INFUSION 2FL,50583,"Raptis, George, MD",6/4/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,50583,"Raptis, George, MD",12/3/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,12/1/2024,Active,,
TRMC TCCC OP INFUSION,79891,"Salerno, Vincent E, MD",11/22/2024,Pembrolizumab 21 Day Cycles - Prostate CA MSI High,_3. Third Line,11/13/2024,Active,,
HAM OP INFUSION,11788,"Patel, Malini M, MD",2/2/2023,DOCEtaxel 21 Day Cycles - Prostate,Second Line,2/1/2023,Inactive,,
HAM OP INFUSION,11788,"Patel, Malini M, MD",4/6/2023,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,Third Line,4/5/2023,Inactive,,
HAM OP INFUSION,11788,"Patel, Malini M, MD",4/6/2023,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,Third Line,4/5/2023,Inactive,,
NBI D7 MED-SURG/TELE,6320,"Anderson, Patrick S, MD",5/16/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,3/24/2024,Active,,
NBI OP INFUSION,6320,"Anderson, Patrick S, MD",1/22/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,1/22/2025,Active,,
NBI OP INFUSION,73963,"Anderson, Patrick S, MD",5/29/2025,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,5/29/2025,Active,"Cancer of ovary (CMS/HCC)
Malignant neoplasm of both ovaries (CMS/HCC)","C79.60 - Secondary adenocarcinoma of ovary, unspecified laterality (CMS/HCC)"
CBMC OP INFUSION 2FL,55899,"Brown, Andrew Bennett, MD",8/14/2024,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,_1. First Line,8/13/2024,Active,,
NBR 4N ONCOLOGY,91904,"Schaar, Dale, MD PhD",11/29/2023,BMT Autologous Carmustine / Thiotepa,_2. Second Line,11/28/2023,Inactive,,
MMC OP VP INFUSION,63431,"Meghal, Trishala, MD",7/10/2023,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,,7/9/2023,Inactive,,
MMC OP VP INFUSION,63431,"Meghal, Trishala, MD",9/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Third Line,9/18/2023,Inactive,,
NBI OP INFUSION,47792,"Shah, Shailja S, MD",4/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/15/2024,Active,,
SOM OUTPT INFUSION,23267,"Toomey, Kathleen C, MD",12/5/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,12/4/2024,Active,,
NBR CINJ OP INFUSION,16747,"Patel, Vimal D, MD",6/29/2023,IVIGx 4 days (total 2gm/kg),,6/29/2023,Inactive,,
MSC OP INFUSION,59494,"Cohen, Seth D, MD",10/10/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/9/2023,Inactive,,
MSC OP INFUSION,59494,"Cohen, Seth D, MD",10/31/2023,Albumin-Bound PACLitaxel/CARBOplatin with Concurrent Radiation Therapy 7 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/30/2023,Inactive,,
MSC OP INFUSION,59494,"Cohen, Seth D, MD",12/12/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,12/11/2023,Inactive,,
JCMC CP INFUSION,14087,"Sekhri, Arunabh, MD",5/2/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,Third Line,5/1/2023,Inactive,,
JCMC CP INFUSION,14087,"Sekhri, Arunabh, MD",6/26/2024,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_4. Fourth Line,6/16/2024,Inactive,,
JCMC CP INFUSION,14087,"Sekhri, Arunabh, MD",10/17/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_4. Fourth Line,10/16/2024,Active,,
SOM OUTPT INFUSION,88419,"Toomey, Kathleen C, MD",8/23/2023,Pembrolizumab 42 Day Cycles- Bladder Cancer,First Line,8/22/2023,Inactive,,
NBR CINJ OP INFUSION,70268,"Chen, Xiaoyi",4/10/2025,CINJ 022101 (EA9181)  ARM B Cycle 2 Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,4/10/2025,Inactive,Acute leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,70268,"Chen, Xiaoyi",4/10/2025,CINJ 022101 (EA9181) ARM C Induction Ponatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,_1. First Line,4/10/2025,Active,Acute leukemia not having achieved remission (CMS/HCC),
NBR 4N BMTU/IMCU,70268,"Chen, Xiaoyi",4/3/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,4/3/2025,Active,Acute leukemia not having achieved remission (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; D59.4 - Other nonautoimmune hemolytic anemias; I69.351 - Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side; D50.9 - Iron deficiency anemia, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; D63.0 - Anemia in neoplastic disease; E66.01 - Morbid (severe) obesity due to excess calories; F20.9 - Schizophrenia, unspecified; I10 - Essential (primary) hypertension; Z68.42 - Body mass index (BMI) 45.0-49.9, adult; F84.0 - Autistic disorder; Z79.4 - Long term (current) use of insulin; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z80.8 - Family history of malignant neoplasm of other organs or systems; Z80.6 - Family history of leukemia; Z80.0 - Family history of malignant neoplasm of digestive organs; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z11.52 - Encounter for screening for COVID-19"
NBR 5N ONCOLOGY,70268,"Chen, Xiaoyi",3/18/2025,CINJ 022101 (EA9181) ARM A Dasatinib / Prednisone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,3/18/2025,Inactive,Acute leukemia not having achieved remission (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; D59.4 - Other nonautoimmune hemolytic anemias; I69.351 - Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side; D50.9 - Iron deficiency anemia, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; D63.0 - Anemia in neoplastic disease; E66.01 - Morbid (severe) obesity due to excess calories; F20.9 - Schizophrenia, unspecified; I10 - Essential (primary) hypertension; Z68.42 - Body mass index (BMI) 45.0-49.9, adult; F84.0 - Autistic disorder; Z79.4 - Long term (current) use of insulin; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z80.8 - Family history of malignant neoplasm of other organs or systems; Z80.6 - Family history of leukemia; Z80.0 - Family history of malignant neoplasm of digestive organs; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z11.52 - Encounter for screening for COVID-19"
CBMC OP INFUSION 2FL,8129,"Derosa, William T, DO",10/29/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,10/27/2024,Active,,
JCMC CP INFUSION,44586,"Sekhri, Arunabh, MD",1/15/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,1/1/2025,Active,,
CINJ OP INFUSION,76115,"Mayer, Tina M, MD",10/17/2023,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,10/17/2023,Active,,
NBR 5N ONCOLOGY,16112,"Patel, Vimal D, MD",4/13/2023,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,4/12/2023,Inactive,,
NBR CINJ OP INFUSION,38325,"Matasar, Matthew J, MD",2/1/2023,Zanubrutinib (160 mg) 30 Day Cycles - CLL,First Line,2/1/2023,Inactive,,
NBR CINJ OP INFUSION,38325,"Matasar, Matthew J, MD",9/13/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,9/12/2023,Inactive,,
SOM OUTPT INFUSION,42448,"Toomey, Kathleen C, MD",4/3/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,3/28/2024,Active,,
NBI OP INFUSION,99825,"Shah, Maya M, MD",1/29/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/28/2025,Active,,
NBI OP INFUSION,99825,"Shah, Maya M, MD",2/5/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/5/2025,Active,"Malignant neoplasm of overlapping sites of right lung (CMS/HCC)
Metastasis from malignant neoplasm of lung (CMS/HCC)
Secondary malignant neoplasm of brain and spinal cord (CMS/HCC)
Encounter for screening for other viral diseases",C34.81 - Malignant neoplasm of overlapping sites of right bronchus and lung; C79.9 - Secondary malignant neoplasm of unspecified site; C79.31 - Secondary malignant neoplasm of brain; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C79.49 - Secondary malignant neoplasm of other parts of nervous system; Z11.59 - Encounter for screening for other viral diseases
CINJ OP INFUSION,39545,"Haigentz, Missak, MD",4/25/2024,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,_1. First Line,4/25/2024,Active,,
NBI VALERIE FND HEMONC,37413,"Rao, Harini, MD",4/9/2025,PEDS ANHL1131 Group B ,_1. First Line,4/9/2025,Active,Non-Hodgkin lymphoma (CMS/HCC),"C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site; C85.10 - Unspecified B-cell lymphoma, unspecified site; R83.6 - Abnormal cytological findings in cerebrospinal fluid"
NBR 4N ONCOLOGY,81048,"Palmisiano, Neil David, MD",5/6/2025,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,Induction,5/6/2025,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.818 - Other pancytopenia; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; E83.39 - Other disorders of phosphorus metabolism; D62 - Acute posthemorrhagic anemia; K59.00 - Constipation, unspecified; B97.10 - Unspecified enterovirus as the cause of diseases classified elsewhere; Z11.52 - Encounter for screening for COVID-19; N92.6 - Irregular menstruation, unspecified; R74.01 - Elevation of levels of liver transaminase levels; R31.9 - Hematuria, unspecified; N93.9 - Abnormal uterine and vaginal bleeding, unspecified; B97.89 - Other viral agents as the cause of diseases classified elsewhere; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z59.71 - Insufficient health insurance coverage"
CINJ OP INFUSION,49864,"Patankar, Sonali, MD",12/4/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/21/2024,Active,,
CINJ OP INFUSION,49864,"Patankar, Sonali, MD",1/24/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/21/2024,Active,,
CINJ OP INFUSION,80605,"George, Mridula A, MD",12/6/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,12/6/2023,Active,,
CINJ OP INFUSION,46567,"Boland, Patrick M, MD",3/21/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/21/2025,Active,Cancer of appendix (CMS/HCC),C18.1 - Malignant neoplasm of appendix
CINJ OP INFUSION,4382,"George, Mridula A, MD",10/11/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,9/13/2024,Active,,
CINJ OP INFUSION,4382,"George, Mridula A, MD",10/11/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/8/2024,Active,Overlapping malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,4382,"George, Mridula A, MD",3/14/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/14/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)
Chemotherapy-induced neutropenia (CMS/HCC)","C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; I10 - Essential (primary) hypertension; D70.1 - Agranulocytosis secondary to cancer chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.0 - Estrogen receptor positive status (ER+)"
HAM OP INFUSION,17899,"Yogarajah, Meera, MD",4/3/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/2/2025,Inactive,Adenocarcinoma of colon metastatic to liver (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; A41.9 - Sepsis, unspecified organism; Z51.5 - Encounter for palliative care; K75.0 - Abscess of liver; I31.4 - Cardiac tamponade; I31.39 - Other pericardial effusion (noninflammatory); E44.0 - Moderate protein-calorie malnutrition; R18.0 - Malignant ascites; K56.609 - Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction; I31.9 - Disease of pericardium, unspecified; B37.0 - Candidal stomatitis; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I10 - Essential (primary) hypertension; D50.9 - Iron deficiency anemia, unspecified; K25.9 - Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation; K50.90 - Crohn's disease, unspecified, without complications; K56.7 - Ileus, unspecified; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; N17.9 - Acute kidney failure, unspecified; I48.0 - Paroxysmal atrial fibrillation; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; E86.9 - Volume depletion, unspecified; E87.70 - Fluid overload, unspecified; E87.5 - Hyperkalemia; K21.9 - Gastro-esophageal reflux disease without esophagitis; M81.0 - Age-related osteoporosis without current pathological fracture; R91.8 - Other nonspecific abnormal finding of lung field; K29.70 - Gastritis, unspecified, without bleeding; D63.0 - Anemia in neoplastic disease; F41.9 - Anxiety disorder, unspecified; R63.4 - Abnormal..."
JCMC CP INFUSION,26180,"Cruz, Allan Louie E, MD",8/29/2023,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,8/27/2023,Inactive,,
JCMC CP INFUSION,26180,"Cruz, Allan Louie E, MD",1/14/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,1/14/2025,Active,,
JCMC CP INFUSION,78966,"Sekhri, Arunabh, MD",10/18/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,10/6/2024,Inactive,,
JCMC CP INFUSION,78966,"Sekhri, Arunabh, MD",11/6/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/4/2024,Active,,
JCMC CP INFUSION,78966,"Sekhri, Arunabh, MD",2/10/2025,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,2/9/2025,Active,Cancer of oropharynx (CMS/HCC),
JCMC CP INFUSION,78966,"Sekhri, Arunabh, MD",3/7/2025,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,2/10/2025,Inactive,Primary squamous cell carcinoma of oropharynx (CMS/HCC),
NBR CINJ OP INFUSION,16601,"Evens, Andrew M, DO",8/14/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_1. First Line,8/14/2023,Inactive,,
NBR CINJ OP INFUSION,16601,"Evens, Andrew M, DO",11/6/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/6/2023,Inactive,,
NBR CINJ OP INFUSION,16601,"Evens, Andrew M, DO",11/6/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/6/2023,Inactive,,
NBR 4N ONCOLOGY,16601,"Braunschweig, Ira, MD",12/2/2023,BMT Autologous BEAM,_3. Third Line,12/1/2023,Inactive,,
NBR 5N ONCOLOGY,16601,"Evens, Andrew M, DO",9/19/2024,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_3. Third Line,9/19/2024,Inactive,,
NBR CINJ OP INFUSION,16601,"Evens, Andrew M, DO",10/9/2024,PRALAtrexate 49 Day Cycle - Peripheral T-Cell Lymphoma,_4. Fourth Line,10/8/2024,Inactive,,
CINJ OP INFUSION,32315,"Stephenson, Ryan D, DO",3/27/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Neoadjuvant,3/27/2023,Active,,
CINJ OP INFUSION,12824,"Toppmeyer, Deborah L, MD",6/13/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,6/12/2024,Active,,
CINJ OP INFUSION,32518,"Toppmeyer, Deborah L, MD",1/12/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",Neoadjuvant,1/11/2023,Active,,
CINJ OP INFUSION,32518,"Toppmeyer, Deborah L, MD",4/4/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,4/3/2023,Inactive,,
CINJ OP INFUSION,63892,"Berim, Lyudmyla, MD",5/22/2025,Dostarlimab-gxly  42 Day Cycles- Colon Cancer,_1. First Line,5/22/2025,Active,Rectal adenocarcinoma (CMS/HCC),C20 - Malignant neoplasm of rectum
CINJ OP INFUSION,25223,"Omene, Coral Oghenerukevwe, MD",1/31/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,1/30/2023,Inactive,,
CINJ OP INFUSION,25223,"Omene, Coral Oghenerukevwe, MD",11/13/2023,Olaparib 30 Day Cycles - Breast,Adjuvant,11/13/2023,Inactive,,
CINJ OP INFUSION,25223,"Berim, Lyudmyla, MD",1/13/2025,Imatinib 30 Day Cycles - Sarcoma,Adjuvant,1/13/2025,Active,,
CINJ OP INFUSION,66548,"Saraiya, Biren P, MD",9/11/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/11/2023,Inactive,,
CINJ OP INFUSION,66548,"Haigentz, Missak, MD",9/18/2023,Erlotinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/18/2023,Active,,
CBMC OP INFUSION 2FL,17538,"Scoppetuolo, Michael, MD",11/1/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,10/31/2023,Inactive,,
NBR CINJ OP INFUSION,13884,"Matasar, Matthew J, MD",2/8/2023,Bendamustine / RiTUXimab 28 Day Cycles - FL,First Line,1/31/2023,Inactive,,
CBMC OP INFUSION 2FL,30185,"Radovich, Delia, MD",11/10/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,11/9/2023,Inactive,,
CBMC OP INFUSION 2FL,30185,"Radovich, Delia, MD",11/10/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,11/9/2023,Inactive,,
NBR CINJ OP INFUSION,100000,"Palmisiano, Neil David, MD",2/9/2023,Nilotinib (Newly Diagnosed) 28 Day Cycles - Chronic Myeloid Leukemia,,2/9/2023,Inactive,,
NBR CINJ OP INFUSION,83280,"Shah, Mansi R, MD",1/3/2023,Teclistamab Weekly 28 Day Cycles- Multiple Myeloma,,1/1/2023,Inactive,,
NBR CINJ OP INFUSION,83280,"Shah, Mansi R, MD",1/3/2023,Teclistamab Weekly 28 Day Cycles- Multiple Myeloma,,1/2/2023,Inactive,,
NBR CINJ OP INFUSION,83280,"Shah, Mansi R, MD",3/14/2023,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,,3/6/2023,Inactive,,
NBR CINJ OP INFUSION,83280,"Shah, Mansi R, MD",12/18/2023,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_7. Seventh Line,12/18/2023,Inactive,,
NBR CINJ OP INFUSION,83280,"Shah, Mansi R, MD",1/21/2025,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,1/20/2025,Active,,
CINJ OP INFUSION,80800,"Omene, Coral Oghenerukevwe, MD",4/14/2025,CINJ 042102 Block B TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles Research Breast Cancer,Neoadjuvant,4/14/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)","C50.411, Z17.0 - Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)"
CINJ OP INFUSION,80800,"Omene, Coral Oghenerukevwe, MD",4/14/2025,CINJ 042102 Block C Pac-CHP (PACLitaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles Research- HER2 Breast Cancer,Neoadjuvant,4/14/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)","C50.411, Z17.0 - Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)"
CINJ OP INFUSION,80800,"Omene, Coral Oghenerukevwe, MD",3/24/2025,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,3/24/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,98435,"Schleicher, Lori, MD",4/12/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/11/2023,Inactive,,
NBI OP INFUSION,98435,"Schleicher, Lori, MD",4/18/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/17/2023,Inactive,,
CINJ OP INFUSION,2620,"Haigentz, Missak, MD",5/15/2023,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,First Line,5/15/2023,Active,,
TRMC TCCC OP INFUSION,72916,"Capo, Gerardo, MD",6/13/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/12/2024,Inactive,,
CINJ OP INFUSION,86207,"Stephenson, Ryan D, DO",5/17/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,5/16/2023,Inactive,,
CINJ OP INFUSION,90926,"Haigentz, Missak, MD",10/29/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/29/2024,Active,,
CBMC OP INFUSION 2FL,96598,"Scoppetuolo, Michael, MD",7/29/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/28/2024,Inactive,,
CBMC OP INFUSION 2FL,96598,"Scoppetuolo, Michael, MD",8/1/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/24/2024,Active,,
CBMC OP INFUSION 2FL,96598,"Scoppetuolo, Michael, MD",5/29/2025,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_2. Second Line,5/22/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas
CBMC OP INFUSION 2FL,96598,"Scoppetuolo, Michael, MD",5/27/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/27/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),
CMC 4B ONCOLOGY,89330,"Pompa, Tiffany Ann, MD",8/6/2024,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_1. First Line,8/5/2024,Active,,
CINJ OP INFUSION,32142,"Dasgeb, Bahar, MD",4/29/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,4/7/2024,Active,,
CBMC OP INFUSION 2FL,92323,"Scoppetuolo, Michael, MD",1/8/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,1/7/2024,Inactive,,
CBMC OP INFUSION 2FL,60139,"Litvak, Anna M, MD",1/28/2025,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_1. First Line,1/28/2025,Active,,
CBMC OP INFUSION 2FL,45747,"Litvak, Anna M, MD",4/30/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_2. Second Line,4/30/2025,Active,"Invasive ductal carcinoma of breast, female, left (CMS/HCC)",
HAM OP INFUSION,98504,"Gendy, Mina, DO",2/4/2025,"Encorafenib + Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,2/3/2025,Inactive,Primary adenocarcinoma of rectosigmoid junction (CMS/HCC),
CINJ OP INFUSION,93511,"Saraiya, Biren P, MD",4/10/2023,"PACLitaxel D1, D8, D15 28 Day Cycles- Small Cell Lung Cancer",Third Line,4/9/2023,Inactive,,
CINJ OP INFUSION,93511,"Saraiya, Biren P, MD",10/16/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_5. Fifth Line,10/9/2023,Inactive,,
CINJ OP INFUSION,42066,"Mayer, Tina M, MD",11/14/2023,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,11/14/2023,Inactive,,
CINJ OP INFUSION,42066,"Mayer, Tina M, MD",7/25/2024,CINJ 082307 Arm 2 Abiraterone + Prednisone 28 Day Cycles Research- Prostate Cancer,_3. Third Line,7/25/2024,Active,,
MMC OP INFUSION,27211,"Eltoukhy, Hussam, MD",6/3/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/24/2024,Inactive,,
MMC OP INFUSION,27211,"Eltoukhy, Hussam, MD",6/3/2024,CINJ 022105 (Part 2 of 2) Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,6/2/2024,Inactive,,
MMC OP VP INFUSION,27211,"Eltoukhy, Hussam, MD",6/3/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/29/2024,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,42778,"Wagmiller, Jennifer Ann, MD",10/15/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,10/13/2024,Active,,
CMC OP INFUSION,58407,"Easaw, Sarah, MD",9/6/2023,PCbTP (Paclitaxel / Carboplatin / Trastuzumab / Pertuzumab) 21 Day Cycle - HER2 Breast Cancer,Neoadjuvant,9/6/2023,Inactive,,
MSC OP INFUSION,58407,"Easaw, Sarah, MD",9/6/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/2/2023,Inactive,,
MSC OP INFUSION,58407,"Easaw, Sarah, MD",9/7/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,9/2/2023,Inactive,,
MMC OP INFUSION,58407,"Meghal, Trishala, MD",1/24/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,1/23/2024,Active,,
CMC OP INFUSION,1415,"Talwar, Sumit, MD",6/5/2024,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,6/4/2024,Active,,
CMC OP INFUSION,1415,"Pompa, Tiffany Ann, MD",1/30/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,1/29/2025,Active,,
HAM OP INFUSION,65986,"Yogarajah, Meera, MD",9/28/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,9/27/2023,Inactive,,
NBR 5N ONCOLOGY,83984,"Sridharan, Ashwin, MD",4/3/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,4/3/2024,Inactive,,
NBI OP INFUSION,65710,"Jacoby, Sari H, MD",5/15/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/14/2023,Inactive,,
NBI OP INFUSION,65710,"Jacoby, Sari H, MD",2/26/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/25/2024,Active,,
NBI OP INFUSION,34324,"Schleicher, Lori, MD",9/27/2024,Pembrolizumab with weekly Paclitaxel,Neoadjuvant,9/26/2024,Inactive,,
NBI OP INFUSION,34324,"Schleicher, Lori, MD",9/27/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/26/2024,Active,,
NBI VALERIE FND HEMONC,4308,"Ford, Maegan C, MD",12/27/2023,AGCT1531 Arm PEb (CISplatin / Etoposide / Bleomycin),Induction,12/27/2023,Inactive,,
JCMC CP INFUSION,96819,"Cruz, Allan Louie E, MD",10/5/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,10/1/2023,Inactive,,
CINJ OP INFUSION,33294,"Girda, Eugenia, MD",3/10/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,2/22/2023,Inactive,,
CINJ OP INFUSION,33294,"Girda, Eugenia, MD",8/15/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,7/26/2023,Inactive,,
CINJ OP INFUSION,33294,"Girda, Eugenia, MD",4/2/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/1/2024,Inactive,,
CINJ OP INFUSION,33294,"Girda, Eugenia, MD",10/11/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/9/2024,Active,,
NBR 5N ONCOLOGY,23596,"Zayac, Adam, MD",6/14/2024,Cytarabine / DAUNOrubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,6/14/2024,Inactive,,
NBR CINJ OP INFUSION,23596,"Zayac, Adam, MD",8/6/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_2. Second Line,8/5/2024,Inactive,,
NBR CINJ OP INFUSION,23596,"Egini, Ogechukwu, MD",12/11/2024,BMT UCB Omidubicel / Fludarabine / Thiotepa / TBI  ,_2. Second Line,12/7/2024,Active,,
CINJ OP INFUSION,71259,"Hochster, Howard S, MD",5/11/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,First Line,5/10/2023,Inactive,,
CINJ OP INFUSION,80813,"Boland, Patrick M, MD",2/25/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,2/24/2025,Active,Gastric adenocarcinoma (CMS/HCC),C16.9 - Gastric adenocarcinoma (CMS/HCC)
CBMC OP INFUSION 2FL,17462,"Wagmiller, Jennifer Ann, MD",2/3/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/2/2025,Active,"Ovary cancer, left (CMS/HCC)",
CBMC OP INFUSION 2FL,37139,"Wagmiller, Jennifer Ann, MD",4/14/2025,PACLitaxel / CISplatin 21 Day Cycles - Cervical,Adjuvant,4/14/2025,Active,Ovarian cancer (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C56.2 - Malignant neoplasm of left ovary
NBR CINJ OP INFUSION,96240,"Shah, Mansi R, MD",4/27/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,4/13/2023,Inactive,,
JCMC CP INFUSION,96240,"Sekhri, Arunabh, MD",5/5/2023,Daratumumab 28 Day Cycles- Multiple Myeloma,First Line,5/4/2023,Inactive,,
JCMC CP INFUSION,96240,"Sekhri, Arunabh, MD",5/12/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/11/2023,Inactive,,
NBR CINJ OP INFUSION,96240,"Shah, Mansi R, MD",9/28/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,9/28/2023,Inactive,,
TRMC TCCC OP INFUSION,9147,"Salerno, Vincent E, MD",11/7/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,11/6/2024,Active,Sarcoma (CMS/HCC),
SOM OUTPT INFUSION,20736,"Toomey, Kathleen C, MD",1/13/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,1/12/2023,Inactive,,
NBI OP INFUSION,48424,"Schleicher, Lori, MD",8/2/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,8/2/2024,Inactive,,
NBI OP INFUSION,5624,"Cheng, Yan Ho, MD",3/12/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,3/11/2024,Inactive,,
NBI OP INFUSION,5624,"Cheng, Yan Ho, MD",3/12/2024,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,3/4/2024,Active,"Multiple myeloma in remission (CMS/HCC)
Nonfamilial hypogammaglobulinemia (CMS/HCC)",
CINJ OP INFUSION,49542,"Omene, Coral Oghenerukevwe, MD",3/25/2025,Capecitabine 21 Day Cycles - Breast,_2. Second Line,3/25/2025,Active,Stage IV breast cancer in female (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C79.51 - Secondary malignant neoplasm of bone; R92.8 - Other abnormal and inconclusive findings on diagnostic imaging of breast
NBI OP INFUSION,80805,"Cheng, Yan Ho, MD",4/19/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Metastatic Rectal Cancer,_2. Second Line,4/18/2024,Inactive,,
NBI OP INFUSION,94044,"Schleicher, Lori, MD",3/21/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Neoadjuvant,3/21/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,89983,"Cruz, Allan Louie E, MD",7/11/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,7/10/2024,Inactive,,
JCMC CP INFUSION,89983,"Cruz, Allan Louie E, MD",7/16/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,7/10/2024,Inactive,,
JCMC CP INFUSION,89983,"Cruz, Allan Louie E, MD",9/25/2024,Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,9/24/2024,Inactive,,
JCMC CP INFUSION,89983,"Cruz, Allan Louie E, MD",9/25/2024,PACLitaxel / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,9/25/2024,Active,,
CINJ OP INFUSION,96991,"Groisberg, Roman, MD",6/2/2023,SORAfenib 30 Day Cycles - Kidney,First Line,6/2/2023,Inactive,,
HAM OP INFUSION,25663,"Yogarajah, Meera, MD",5/30/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,First Line,5/29/2023,Inactive,,
HAM OP INFUSION,25663,"Yogarajah, Meera, MD",6/1/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,First Line,5/31/2023,Active,,
CMC OP INFUSION,5443,"Talwar, Sumit, MD",4/28/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,4/27/2023,Inactive,,
CINJ OP INFUSION,15862,"Stephenson, Ryan D, DO",8/16/2024,Relugolix 30 day Cycles - Prostate,Neoadjuvant,8/16/2024,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,52345,"Sekhri, Arunabh, MD",1/22/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,1/22/2024,Inactive,,
HAM OP INFUSION,57331,"Yogarajah, Meera, MD",8/2/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,8/2/2024,Active,"Malignant (primary) neoplasm, unspecified (CMS/HCC)
Malignant neoplasm of bilateral ovaries (CMS/HCC)
Encounter for screening for other viral diseases",
HAM OP INFUSION,57331,"Gendy, Mina, DO",2/7/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,2/7/2025,Inactive,Carcinoma of right breast metastatic to intrathoracic lymph node (CMS/HCC),"C50.811 - Malignant neoplasm of overlapping sites of right female breast; C50.911 - Malignant neoplasm of unspecified site of right female breast; C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; F41.9 - Anxiety disorder, unspecified; F32.A - Depression, unspecified; E03.9 - Hypothyroidism, unspecified; Z79.899 - Other long term (current) drug therapy; Z79.01 - Long term (current) use of anticoagulants; Z88.6 - Allergy status to analgesic agent; Z91.040 - Latex allergy status; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z85.41 - Personal history of malignant neoplasm of cervix uteri; Z17.0 - Estrogen receptor positive status (ER+)"
CINJ OP INFUSION,31059,"Boland, Patrick M, MD",9/9/2024,Imatinib 30 Day Cycles - Sarcoma,Maintenance,9/9/2024,Active,,
NBI OP INFUSION,42156,"Cheng, Yan Ho, MD",5/23/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,5/22/2023,Inactive,,
CINJ OP INFUSION,79006,"Boland, Patrick M, MD",7/14/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,7/12/2023,Inactive,,
CINJ OP INFUSION,79006,"Boland, Patrick M, MD",7/14/2023,CINJ 072201 Control ARM FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,,6/16/2023,Inactive,,
CINJ OP INFUSION,79006,"Boland, Patrick M, MD",1/19/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,1/19/2024,Inactive,,
CINJ OP INFUSION,79006,"Boland, Patrick M, MD",1/30/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_1. First Line,1/22/2024,Inactive,,
NBI OP INFUSION,4205,"Jacoby, Sari H, MD",8/20/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,8/18/2024,Active,,
NBI OP INFUSION,4205,"Jacoby, Sari H, MD",2/11/2025,Pembrolizumab 21 Day Cycles - Adjuvant Bladder,Adjuvant,2/11/2025,Active,Urothelial carcinoma (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified; N39.0 - Urinary tract infection, site not specified; M17.30 - Unilateral post-traumatic osteoarthritis, unspecified knee; A49.9 - Bacterial infection, unspecified"
NBI OP INFUSION,4205,"Jacoby, Sari H, MD",5/20/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/20/2025,Active,Urothelial carcinoma (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified"
SOM OUTPT INFUSION,9864,"Toomey, Kathleen C, MD",8/7/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,8/6/2024,Inactive,,
SOM OUTPT INFUSION,9864,"Toomey, Kathleen C, MD",11/14/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,11/12/2024,Active,,
NBR 5N ONCOLOGY,30556,"Boland, Patrick M, MD",4/3/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/2/2024,Inactive,,
NBR 5N ONCOLOGY,30556,"Boland, Patrick M, MD",4/3/2024,CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/2/2024,Inactive,,
CINJ OP INFUSION,30556,"Haigentz, Missak, MD",5/1/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/1/2024,Inactive,,
CINJ OP INFUSION,30556,"Haigentz, Missak, MD",7/23/2024,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/23/2024,Active,,
NBR 5N ONCOLOGY,30556,"Haigentz, Missak, MD",2/5/2025,CARBOplatin / Etoposide 21 Day Cycles - Small Cell Lung Cancer,_2. Second Line,2/5/2025,Active,"Small cell lung cancer in adult (CMS/HCC)
Lung cancer metastatic to brain (CMS/HCC)","C79.31 - Secondary malignant neoplasm of brain; R18.8 - Other ascites; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; H49.01 - Third (oculomotor) nerve palsy, right eye; E87.1 - Hypo-osmolality and hyponatremia; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; I50.22 - Chronic systolic (congestive) heart failure; J98.4 - Other disorders of lung; Z92.21 - Personal history of antineoplastic chemotherapy; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z80.0 - Family history of malignant neoplasm of digestive organs; H02.401 - Unspecified ptosis of right eyelid; Z87.891 - Personal history of nicotine dependence; Z98.890 - Other specified postprocedural states; Z11.52 - Encounter for screening for COVID-19"
CINJ OP INFUSION,13538,"Haigentz, Missak, MD",5/27/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,5/27/2025,Active,"Small cell lung cancer (CMS/HCC)
Malignant neoplasm of lung (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)","C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; C79.31 - Secondary malignant neoplasm of brain; C79.51 - Secondary malignant neoplasm of bone; C79.52 - Secondary malignant neoplasm of bone marrow; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; E03.9 - Hypothyroidism, unspecified; D61.818 - Other pancytopenia; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; D81.818 - Other biotin-dependent carboxylase deficiency; S32.020D - Wedge compression fracture of second lumbar vertebra, subsequent encounter for fracture with routine healing; E83.39 - Other disorders of phosphorus metabolism; Z87.891 - Personal history of nicotine dependence"
NBR BMSCH 2 PED HEMONC,14248,"Moerdler, Scott, MD",3/28/2023,PEDS AEWS1031 Regimen A Induction & Consolidation,First Line,3/26/2023,Inactive,,
CMC OP INFUSION,73989,"Talwar, Sumit, MD",11/13/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/12/2024,Active,,
CINJ OP INFUSION,12030,"Weiss, Sarah, MD",6/28/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,6/25/2024,Inactive,,
CINJ OP INFUSION,44921,"Goel, Sanjay, MD",3/18/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_3. Third Line,2/28/2024,Inactive,,
CINJ OP INFUSION,44921,"Goel, Sanjay, MD",8/12/2024,CINJ 052212 Phase 1b RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,_4. Fourth Line,8/12/2024,Active,,
CBMC OP INFUSION 2FL,85219,"Litvak, Anna M, MD",11/22/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,11/22/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,13125,"Boland, Patrick M, MD",2/9/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,2/9/2023,Inactive,,
CINJ OP INFUSION,13125,"Boland, Patrick M, MD",1/9/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/4/2024,Inactive,,
MMC OP VP INFUSION,65421,"Talwar, Sumit, MD",3/1/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,2/28/2023,Inactive,,
MMC OP VP INFUSION,65421,"Talwar, Sumit, MD",2/19/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,2/18/2024,Inactive,,
NBI OP INFUSION,32387,"Schleicher, Lori, MD",8/31/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/30/2023,Inactive,,
NBI OP INFUSION,32387,"Schleicher, Lori, MD",8/31/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/30/2023,Active,,
NBR CINJ OP INFUSION,73288,"Patel, Eshan, MD",11/3/2023, Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles ,_1. First Line,10/13/2023,Active,,
CINJ OP INFUSION,73288,"Patel, Eshan, MD",12/18/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/10/2023,Inactive,,
CINJ OP INFUSION,73288,"Patel, Eshan, MD",4/26/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,4/25/2024,Inactive,,
CINJ OP INFUSION,60871,"Leiser, Aliza, MD",2/6/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,Adjuvant,1/4/2023,Inactive,,
CINJ OP INFUSION,60871,"Leiser, Aliza, MD",10/31/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,10/23/2023,Inactive,,
CINJ OP INFUSION,60871,"Leiser, Aliza, MD",8/12/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,8/12/2024,Active,,
CINJ OP INFUSION,60871,"Leiser, Aliza, MD",5/2/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_4. Fourth Line,5/2/2025,Active,"Secondary malignant neoplasm of unspecified digestive organ (CMS/HCC)
Malignant neoplasm of unspecified ovary (CMS/HCC)",
CBMC OP INFUSION 2FL,74325,"Brown, Andrew Bennett, MD",9/28/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,9/26/2023,Inactive,,
CMC 4B ONCOLOGY,29376,"Eltoukhy, Hussam, MD",1/3/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/3/2024,Inactive,,
CINJ OP INFUSION,23851,"Stephenson, Ruth D, DO",3/1/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/15/2024,Active,,
CINJ OP INFUSION,17072,"Leiser, Aliza, MD",3/4/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/4/2025,Inactive,Malignant neoplasm of ovary (CMS/HCC),
CBMC OP INFUSION 2FL,96877,"Wagmiller, Jennifer Ann, MD",4/6/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,4/6/2025,Inactive,"Metastatic disease (CMS/HCC)
Endometrial cancer (CMS/HCC)
Long term use of drug",C78.00 - Secondary malignant neoplasm of unspecified lung; C54.1 - Malignant neoplasm of endometrium
NBR 5N ONCOLOGY,9799,"Shah, Mansi R, MD",7/28/2023,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),,7/28/2023,Inactive,,
CBMC OP INFUSION 2FL,36402,"Dharmapuri, Sirish, MD",11/9/2023,Gemcitabine / CARBOplatin / durvalumab -- hepatobiliary ,_1. First Line,11/9/2023,Active,,
CBMC OP INFUSION 2FL,136,"Litvak, Anna M, MD",3/28/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,3/27/2025,Active,"Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor negative (CMS/HCC)","C50.311, Z17.1 - Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor negative (CMS/HCC)"
CBMC OP INFUSION 2FL,42075,"Scoppetuolo, Michael, MD",10/14/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/13/2024,Inactive,,
CBMC OP INFUSION 2FL,42075,"Scoppetuolo, Michael, MD",11/12/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/3/2024,Active,,
CBMC OP INFUSION 2FL,22131,"Scoppetuolo, Michael, MD",2/24/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/23/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),C25.1 - Malignant neoplasm of body of pancreas
NBI OP INFUSION,35731,"Shah, Shailja S, MD",12/5/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,12/4/2023,Inactive,,
NBI OP INFUSION,35731,"Shah, Shailja S, MD",12/5/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,12/4/2023,Inactive,,
CMC OP INFUSION,82214,"Taff, Jessica, MD",3/7/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/7/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),
NBR 4N ONCOLOGY,40116,"Tiger, Yun Kyoung, MD",1/3/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_3. Third Line,1/3/2024,Inactive,,
NBR 4N ONCOLOGY,40116,"Tiger, Yun Kyoung, MD",1/3/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_3. Third Line,1/3/2024,Inactive,,
NBR 4N ONCOLOGY,40116,"Palmisiano, Neil David, MD",1/6/2024,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,_2. Second Line,1/5/2024,Inactive,,
NBR 5N ONCOLOGY,40116,"Palmisiano, Neil David, MD",1/15/2024,HyperCVD Mini + Venetoclax (High-Dose Methotrexate / Cytarabine / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,1/15/2024,Inactive,,
CMC OP INFUSION,4429,"Talwar, Sumit, MD",12/17/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/10/2024,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC 2W ONCOLOGY,17340,"McKenna, Marshall, MD",1/10/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,1/9/2025,Active,,
CBMC OP INFUSION 2FL,17340,"McKenna, Marshall, MD",2/7/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,2/6/2025,Active,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
SOM OUTPT INFUSION,79162,"Yin, Faye, MD",5/21/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,5/21/2024,Inactive,,
SOM OUTPT INFUSION,79162,"Yin, Faye, MD",6/14/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,6/14/2024,Inactive,,
CINJ OP INFUSION,55044,"George, Mridula A, MD",1/20/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,First Line,1/17/2023,Inactive,,
SOM OUTPT INFUSION,12000,"Patel, Eshan, MD",8/20/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,8/19/2024,Active,,
HAM OP INFUSION,9368,"Yogarajah, Meera, MD",12/12/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/10/2023,Inactive,,
CINJ OP INFUSION,44128,"Aikins, James K, MD",7/12/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,7/11/2023,Inactive,,
CINJ OP INFUSION,20384,"George, Mridula A, MD",4/28/2023,Palbociclib 28 Day Cycles - Breast,First Line,4/28/2023,Active,,
JCMC CP INFUSION,53427,"Cruz, Allan Louie E, MD",5/14/2024,Darzalex Faspro 28 Day Cycles- Multiple Myeloma,_1. First Line,5/14/2024,Active,,
JCMC CP INFUSION,53427,"Cruz, Allan Louie E, MD",5/16/2024,Daratumumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_1. First Line,5/15/2024,Inactive,,
MMC OP VP INFUSION,15442,"Cohen, Seth D, MD",2/15/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,2/7/2024,Active,,
CBMC OP INFUSION 2FL,85352,"Leitner, Stuart P, MD",8/7/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,8/6/2023,Inactive,,
NBI OP INFUSION,84333,"Schleicher, Lori, MD",11/17/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,11/16/2023,Inactive,,
NBI OP INFUSION,84333,"Schleicher, Lori, MD",11/17/2023,Pembrolizumab + Abraxane + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,11/16/2023,Active,,
NBI OP INFUSION,48543,"Schleicher, Lori, MD",11/27/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,11/26/2023,Inactive,,
JCMC CP INFUSION,17578,"Cruz, Allan Louie E, MD",4/12/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,4/12/2023,Inactive,,
JCMC CP INFUSION,17578,"Cruz, Allan Louie E, MD",8/14/2023,Pembrolizumab 42 Day Cycles- Non-Squamous Non-Small Cell Lung Cancer,First Line,8/14/2023,Active,,
MMC OP VP INFUSION,38922,"Cohen, Seth D, MD",7/23/2024,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_1. First Line,7/18/2024,Active,,
MMC OP VP INFUSION,29050,"Lee, Patrick C, MD",6/27/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),Reinduction,6/27/2024,Active,Urothelial cancer (CMS/HCC),
MMC OP VP INFUSION,67276,"Lee, Patrick C, MD",3/24/2023,FOLFIRINOX and avastin (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,First Line,3/23/2023,Inactive,,
NBR CINJ OP INFUSION,61640,"Rhodes, Joanna Meehan, MD",4/16/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,4/15/2024,Inactive,,
NBR CINJ OP INFUSION,61640,"Matasar, Matthew J, MD",5/13/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,5/8/2024,Active,,
CMC OP INFUSION,44084,"Tang, Horace, MD",5/1/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/30/2023,Inactive,,
CMC OP INFUSION,44084,"Tang, Horace, MD",5/18/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,5/18/2023,Inactive,,
CMC OP INFUSION,47157,"Tang, Horace, MD",6/30/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,6/30/2023,Inactive,,
CMC OP INFUSION,43082,"Talwar, Sumit, MD",10/7/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,10/6/2024,Inactive,,
CMC 4B ONCOLOGY,43082,"Talwar, Sumit, MD",10/15/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,10/3/2024,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Immunization due",
CINJ OP INFUSION,34261,"Haigentz, Missak, MD",8/28/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,8/27/2024,Inactive,,
CINJ OP INFUSION,34261,"Haigentz, Missak, MD",10/9/2024,Pembrolizumab/CARBOplatin (5FU refused) -  21 Day Cycles- Head and Neck Cancers,_2. Second Line,10/9/2024,Active,,
CINJ OP INFUSION,34796,"Haigentz, Missak, MD",2/11/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,2/10/2025,Active,"Secondary malignant neoplasm of right lung (CMS/HCC)
Malignant neoplasm of base of tongue (CMS/HCC)",
CINJ OP INFUSION,34796,"Haigentz, Missak, MD",5/13/2025,"Cetuximab/CARBOplatin (without 5FU, patient request) - 21 Day Cycles- Head and Neck Cancers",_2. Second Line,5/13/2025,Active,"Asymptomatic HIV infection (CMS/HCC)
Secondary malignant neoplasm of right lung (CMS/HCC)
Malignant neoplasm of base of tongue (CMS/HCC)
Hepatitis B, chronic (CMS/HCC)",
CBMC OP INFUSION 2FL,65268,"Brown, Andrew Bennett, MD",4/30/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,4/30/2025,Active,Malignant neoplasm of glottis (CMS/HCC),
CBMC OP INFUSION 2FL,22393,"Wagmiller, Jennifer Ann, MD",6/21/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,6/20/2023,Inactive,,
CBMC OP INFUSION 2FL,22393,"Wagmiller, Jennifer Ann, MD",11/20/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,11/19/2023,Inactive,,
CBMC 2W ONCOLOGY,22393,"Wagmiller, Jennifer Ann, MD",1/20/2024,PCbTP (Paclitaxel / Carboplatin / Trastuzumab / Pertuzumab) 21 Day Cycle - HER2 Breast Cancer,_2. Second Line,1/20/2024,Inactive,,
SOM OUTPT INFUSION,48750,"Toomey, Kathleen C, MD",11/20/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/19/2024,Active,Malignant neoplasm of overlapping sites of lung (CMS/HCC),
CMC OP INFUSION,81520,"Pompa, Tiffany Ann, MD",3/27/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Unknown Primary,_1. First Line,3/27/2025,Active,"Mediastinal lymphadenopathy
Other soft tissue disorders related to use, overuse and pressure, right upper arm
Adenocarcinoma of unknown primary (CMS/HCC)",R91.1 - Lung nodule seen on imaging study
CBMC OP INFUSION 2FL,44634,"Dharmapuri, Sirish, MD",4/21/2025,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/21/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),"D49.0 - Neoplasm of unspecified behavior of digestive system; C25.9 - Malignant neoplasm of pancreas, unspecified"
NBI D7 MED-SURG/TELE,53236,"Anderson, Patrick S, MD",10/26/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine- cervical Cancer,_1. First Line,10/24/2024,Active,,
CBMC OP INFUSION 2FL,30449,"Wagmiller, Jennifer Ann, MD",4/14/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/4/2025,Active,"Secondary malignant neoplasm of bone (CMS/HCC)
Metastasis from breast cancer (CMS/HCC)
Antineoplastic chemotherapy induced anemia","C79.51 - Secondary malignant neoplasm of bone; D64.81 - Anemia due to antineoplastic chemotherapy; D53.9 - Nutritional anemia, unspecified; C50.912 - Malignant neoplasm of unspecified site of left female breast; E55.9 - Vitamin D deficiency, unspecified; C79.52 - Secondary malignant neoplasm of bone marrow; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
CINJ OP INFUSION,25753,"Berim, Lyudmyla, MD",7/12/2024,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,7/11/2024,Active,,
CBMC OP INFUSION 2FL,4652,"Brown, Andrew Bennett, MD",8/8/2024,Ramucirumab 14 Day Cycles- Lung Cancer,_2. Second Line,7/31/2024,Inactive,,
CBMC OP INFUSION 2FL,4652,"Brown, Andrew Bennett, MD",12/19/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/9/2024,Active,,
CBMC OP INFUSION 2FL,97970,"Grossman, I Robert, MD",1/12/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,1/7/2024,Inactive,,
CINJ OP INFUSION,26250,"Leiser, Aliza, MD",4/19/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,_1. First Line,4/18/2024,Inactive,,
CINJ OP INFUSION,26250,"Leiser, Aliza, MD",4/19/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,4/18/2024,Inactive,,
CINJ OP INFUSION,26250,"Leiser, Aliza, MD",6/20/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,6/19/2024,Active,,
CBMC OP INFUSION 2FL,26208,"Radovich, Delia, MD",10/30/2023,FOLFOXIRI + Panitumumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,26208,"Radovich, Delia, MD",10/30/2023,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/29/2023,Active,,
NBI OP INFUSION,60963,"Shah, Shailja S, MD",10/24/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/23/2023,Inactive,,
NBI OP INFUSION,60963,"Shah, Shailja S, MD",10/29/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/28/2024,Active,,
NBR 4N ONCOLOGY,93036,"Girda, Eugenia, MD",2/2/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/26/2024,Inactive,,
NBR 5N ONCOLOGY,93036,"Girda, Eugenia, MD",4/15/2024,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Consolidation,4/15/2024,Inactive,,
CINJ OP INFUSION,93036,"Girda, Eugenia, MD",7/31/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,7/30/2024,Active,,
CINJ OP INFUSION,93036,"Girda, Eugenia, MD",4/11/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/11/2025,Active,"Carcinomatosis (CMS/HCC)
Fallopian tube carcinoma (CMS/HCC)",
CINJ OP INFUSION,93036,"Girda, Eugenia, MD",3/21/2025,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,3/21/2025,Inactive,"Carcinomatosis (CMS/HCC)
Fallopian tube carcinoma (CMS/HCC)","C80.0 - Disseminated malignant neoplasm, unspecified; C57.00 - Malignant neoplasm of unspecified fallopian tube; J90 - Pleural effusion, not elsewhere classified; R97.1 - Elevated cancer antigen 125 (CA 125)"
CBMC OP INFUSION 2FL,73446,"Scoppetuolo, Michael, MD",11/19/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,11/18/2024,Active,Multiple myeloma (CMS/HCC),
CBMC 2W ONCOLOGY,11970,"Grossman, I Robert, MD",6/29/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,6/27/2024,Active,,
CBMC OP INFUSION 2FL,10498,"Raptis, George, MD",5/17/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,5/16/2024,Inactive,,
CBMC OP INFUSION 2FL,10498,"Raptis, George, MD",9/23/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,9/19/2024,Active,Adenocarcinoma of head of pancreas (CMS/HCC),
CINJ OP INFUSION,99133,"Girda, Eugenia, MD",1/17/2023,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",,1/17/2023,Inactive,,
CINJ OP INFUSION,99133,"Girda, Eugenia, MD",1/25/2023,CINJ 052101 (TT420X1103) ARM A TT-00420 12 mg 28 Day Cycles Research- Solid Tumors,,1/23/2023,Inactive,,
NBR CINJ OP INFUSION,99133,"Girda, Eugenia, MD",4/4/2023,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",,4/4/2023,Inactive,,
SOM OUTPT INFUSION,68744,"Toomey, Kathleen C, MD",7/12/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,7/11/2023,Inactive,,
SOM OUTPT INFUSION,68744,"Toomey, Kathleen C, MD",11/22/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,11/14/2023,Inactive,,
CINJ OP INFUSION,18984,"Stephenson, Ryan D, DO",2/28/2024,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_1. First Line,2/19/2024,Inactive,,
CINJ OP INFUSION,18984,"Stephenson, Ryan D, DO",5/20/2024,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,5/20/2024,Inactive,,
CINJ OP INFUSION,18984,"Stephenson, Ryan D, DO",6/17/2024,CINJ 082401 Arm 3 Cohort B Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,Adjuvant,6/17/2024,Active,,
MMC OP INFUSION,54768,"Eltoukhy, Hussam, MD",5/31/2023,RiTUXimab Subsequent Infusion Single Day (Outpatient),,5/31/2023,Inactive,,
MMC OP INFUSION,54768,"Eltoukhy, Hussam, MD",8/18/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,8/14/2023,Inactive,,
MMC OP VP INFUSION,54768,"Eltoukhy, Hussam, MD",9/11/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,9/10/2024,Inactive,,
MMC OP VP INFUSION,54768,"Eltoukhy, Hussam, MD",9/25/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,9/24/2024,Inactive,,
CINJ OP INFUSION,95390,"Haigentz, Missak, MD",10/28/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,10/27/2024,Active,,
CINJ OP INFUSION,2375,"George, Mridula A, MD",2/24/2023,CINJ 042111 (GO42784) ARM B Endocrine Therapy 28 Day Cycles Research- Breast Cancer,Adjuvant,2/23/2023,Active,,
NBR 4N ONCOLOGY,10264,"Doraiswamy, Anupama, MD",4/19/2023,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),,4/19/2023,Inactive,,
NBR 4N ONCOLOGY,10264,"Matasar, Matthew J, MD",5/17/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,5/11/2023,Inactive,,
NBR 4N BMTU/IMCU,10264,"Doraiswamy, Anupama, MD",5/30/2023,HiDAC-123 + Midostaurin (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,5/30/2023,Inactive,,
NBR 4N BMTU/IMCU,10264,"Assal, Amer, MD",7/13/2023,BMT Allogeneic TBF + Post Cy ,,7/13/2023,Inactive,,
NBR CINJ OP INFUSION,10264,"Schaar, Dale, MD PhD",11/6/2023,Decitabine (Maintenance Phase) 56 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,11/5/2023,Active,,
CINJ OP INFUSION,4843,"George, Mridula A, MD",9/8/2023,Palbociclib 28 Day Cycles - Breast,First Line,9/8/2023,Active,,
CBMC OP INFUSION 2FL,13710,"Kulkarni, Aditya A, MD",3/14/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/5/2025,Active,"Adenocarcinoma of lung, stage 4 (CMS/HCC)",
CBMC OP INFUSION 2FL,13710,"Kulkarni, Aditya A, MD",3/5/2025,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/5/2025,Active,"Adenocarcinoma of lung, stage 4 (CMS/HCC)",
CINJ OP INFUSION,84710,"Groisberg, Roman, MD",4/24/2024,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,4/24/2024,Inactive,,
CINJ OP INFUSION,84710,"Groisberg, Roman, MD",7/22/2024,Ifosfamide / Mesna 21 Day Cycles - Sarcoma,Neoadjuvant,7/18/2024,Inactive,,
NBI OP INFUSION,84313,"Schleicher, Lori, MD",11/24/2023,Pembrolizumab / PACLitaxel weekly 21 Day Cycles - Breast,_1. First Line,11/23/2023,Inactive,,
NBI OP INFUSION,84313,"Schleicher, Lori, MD",1/3/2025,Olaparib 30 Day Cycles - Breast,_2. Second Line,1/3/2025,Active,,
CINJ OP INFUSION,29740,"Salacz, Michael E, MD",6/5/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Adjuvant,6/5/2023,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
NBR 5N ONCOLOGY,29740,"Rhodes, Joanna Meehan, MD",7/21/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/19/2024,Inactive,,
CBMC OP INFUSION 2FL,9348,"Scoppetuolo, Michael, MD",12/19/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_4. Fourth Line,12/18/2024,Active,Endometrial cancer (CMS/HCC),
NBR CINJ OP INFUSION,3012,"Palmisiano, Neil David, MD",2/6/2023,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,2/1/2023,Inactive,,
NBI OP INFUSION,9444,"Cheng, Yan Ho, MD",10/28/2024,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,10/27/2024,Inactive,,
CBMC OP INFUSION 2FL,89139,"Wagmiller, Jennifer Ann, MD",7/30/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/10/2024,Inactive,Malignant neoplasm of endometrium (CMS/HCC),
CBMC OP INFUSION 2FL,89139,"Wagmiller, Jennifer Ann, MD",11/7/2024,PACLitaxel / CISplatin 21 Day Cycles - Cervical,_1. First Line,11/7/2024,Active,,
CBMC OP INFUSION 2FL,46158,"Raptis, George, MD",4/26/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,4/25/2024,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,46158,"Raptis, George, MD",1/23/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,1/21/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,94739,"Litvak, Anna M, MD",10/11/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_2. Second Line,10/10/2023,Active,"Malignant neoplasm of uterus (CMS/HCC)
Ovarian carcinoma (CMS/HCC)",
NBR CINJ OP INFUSION,35753,"Evens, Andrew M, DO",4/16/2025,mini Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/16/2025,Active,B-cell lymphoma of solid organ excluding spleen (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; N17.9 - Acute kidney failure, unspecified; M79.606 - Pain in leg, unspecified; R60.9 - Edema, unspecified; R53.1 - Weakness; E83.52 - Hypercalcemia; B18.2 - Chronic viral hepatitis C; C85.19 - Unspecified b-cell lymphoma, extranodal and solid organ sites; R79.1 - Abnormal coagulation profile; D53.8 - Other specified nutritional anemias; E41 - Nutritional marasmus"
CINJ OP INFUSION,51135,"George, Mridula A, MD",1/25/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/16/2023,Inactive,,
CINJ OP INFUSION,62159,"Berim, Lyudmyla, MD",7/8/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/3/2024,Active,,
CINJ OP INFUSION,83983,"Berim, Lyudmyla, MD",3/18/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/9/2024,Inactive,,
CMC OP INFUSION,69593,"Cohen, Seth D, MD",4/1/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,4/1/2024,Inactive,,
CINJ OP INFUSION,1593,"Dasgeb, Bahar, MD",4/2/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,4/1/2024,Active,,
CBMC OP INFUSION 2FL,36311,"Brown, Andrew Bennett, MD",11/9/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,36311,"Brown, Andrew Bennett, MD",12/12/2023,Pembrolizumab / Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/11/2023,Inactive,,
CBMC OP INFUSION 2FL,36311,"Brown, Andrew Bennett, MD",1/11/2024,Pembrolizumab / Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/10/2024,Inactive,,
CBMC OP INFUSION 2FL,22587,"Brown, Andrew Bennett, MD",3/25/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,3/25/2025,Active,Cancer of tonsillar fossa (CMS/HCC),
MMC OP VP INFUSION,23832,"Cohen, Seth D, MD",11/12/2024,"PACLitaxel D1, D15 28 Day Cycles - Breast",_1. First Line,11/11/2024,Inactive,,
MSC OP INFUSION,23832,"Cohen, Seth D, MD",11/12/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,11/11/2024,Active,,
CINJ OP INFUSION,73546,"Leiser, Aliza, MD",4/14/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,4/14/2025,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,53436,"Saraiya, Biren P, MD",6/26/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,6/26/2024,Active,,
CINJ OP INFUSION,14701,"Berim, Lyudmyla, MD",4/20/2023,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,,3/26/2023,Inactive,,
CINJ OP INFUSION,14701,"Berim, Lyudmyla, MD",8/28/2024,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,8/28/2024,Active,,
NBR BMSCH 2 PED HEMONC,38010,"Moerdler, Scott, MD",10/18/2023,ARST2031 Regimen B (VINO-AC + VINO-C Maintenance),_1. First Line,10/18/2023,Inactive,,
CBMC OP INFUSION 2FL,14782,"Litvak, Anna M, MD",6/1/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/31/2023,Inactive,,
MMC OP VP INFUSION,46477,"Cohen, Seth D, MD",9/23/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/22/2024,Inactive,,
MMC OP VP INFUSION,46477,"Cohen, Seth D, MD",10/7/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/6/2024,Active,,
CINJ OP INFUSION,58927,"Stephenson, Ryan D, DO",7/4/2024,Relugolix 30 day Cycles - Prostate,Adjuvant,7/4/2024,Inactive,,
SOM OUTPT INFUSION,61659,"Yin, Faye, MD",6/12/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/4/2023,Inactive,,
NBI OP INFUSION,47486,"Cheng, Yan Ho, MD",11/14/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,11/13/2023,Inactive,,
CBMC OP INFUSION 1FL,99624,"Meelheim, Brooke A, DO",1/20/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/20/2025,Active,,
CBMC OP INFUSION 1FL,922,"Meelheim, Brooke A, DO",12/9/2024,PACLitaxel / CARBOplatin Weekly x 6 Cycles - Cervical,Induction,11/28/2024,Active,,
CINJ OP INFUSION,49996,"Leiser, Aliza, MD",8/16/2023,Pembrolizumab 21 Day Cycles - Uterine,,8/15/2023,Inactive,,
CINJ OP INFUSION,49996,"Leiser, Aliza, MD",8/16/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,8/15/2023,Inactive,,
CINJ OP INFUSION,49996,"Leiser, Aliza, MD",9/6/2023,Pembrolizumab 21 Day Cycles - Uterine,,9/5/2023,Inactive,,
CINJ OP INFUSION,49996,"Leiser, Aliza, MD",11/7/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/23/2023,Inactive,,
CINJ OP INFUSION,49996,"Leiser, Aliza, MD",8/2/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,8/1/2024,Active,,
CBMC OP INFUSION 2FL,4756,"Litvak, Anna M, MD",6/22/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,6/21/2023,Inactive,,
CBMC OP INFUSION 2FL,12433,"Grossman, I Robert, MD",8/31/2023,Bortezomib /Dexamethasone 21 Day Cycles - Multiple Myeloma,_1. First Line,8/30/2023,Inactive,,
CBMC OP INFUSION 2FL,12433,"Grossman, I Robert, MD",8/31/2023,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,8/30/2023,Inactive,,
CBMC OP INFUSION 2FL,12433,"Grossman, I Robert, MD",1/4/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_2. Second Line,1/3/2024,Inactive,,
CBMC OP INFUSION 2FL,12433,"Grossman, I Robert, MD",1/18/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,1/17/2024,Active,,
HAM OP INFUSION,8377,"Yogarajah, Meera, MD",12/12/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,12/8/2024,Active,"Colorectal cancer, stage IV (CMS/HCC)",
CINJ OP INFUSION,92698,"Dasgeb, Bahar, MD",10/3/2023,RiTUXimab 168 Day Cycles - Pemphigus,Maintenance,10/2/2023,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,78405,"Dasgeb, Bahar, MD",9/13/2023,Talimogene Laherparepvec 21 Day Cycle + Talimogene Laherparepvec 14 Day Cycles - Melanoma,,9/12/2023,Inactive,,
CBMC OP INFUSION 2FL,6165,"Grossman, I Robert, MD",3/5/2025,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,3/5/2025,Active,Malignant neoplasm of supraglottis (CMS/HCC),
CINJ OP INFUSION,13854,"Stephenson, Ryan D, DO",8/16/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,8/16/2024,Active,,
CINJ OP INFUSION,82854,"Goel, Sanjay, MD",11/6/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_4. Fourth Line,9/17/2024,Inactive,,
CINJ OP INFUSION,82854,"Goel, Sanjay, MD",11/19/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_3. Third Line,10/15/2024,Active,,
CBMC OP INFUSION 1FL,2770,"Gallinson, David Herschel, DO",2/13/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,2/11/2025,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,66719,"Boland, Patrick M, MD",2/21/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/17/2023,Inactive,,
CINJ OP INFUSION,66719,"Berim, Lyudmyla, MD",9/4/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Gastric Cancer,,9/4/2023,Inactive,,
NBI OP INFUSION,91572,"Anderson, Patrick S, MD",11/2/2023,CISplatin With Concurrent Radiation 7 Day Cycles -  Vulvar,_1. First Line,11/1/2023,Inactive,,
NBI OP INFUSION,91572,"Anderson, Patrick S, MD",11/24/2023,CISplatin 21 Day Cycles - Vulvar Cancer,_1. First Line,11/23/2023,Inactive,,
NBI OP INFUSION,91572,"Anderson, Patrick S, MD",11/24/2023,CISplatin With Concurrent Radiation 7 Day Cycles - vulvar,_1. First Line,11/24/2023,Inactive,,
NBI OP INFUSION,91572,"Anderson, Patrick S, MD",5/16/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Vulvar Cancer,_2. Second Line,5/14/2024,Inactive,,
NBI OP INFUSION,91572,"Anderson, Patrick S, MD",1/9/2025,Nivolumab 480 mg 28 Day Cycles- Vulvar Cancer,_3. Third Line,1/8/2025,Active,,
NBI OP INFUSION,91572,"Anderson, Patrick S, MD",3/6/2025,Nivolumab 480 mg 28 Day Cycles- Vulvar Cancer,_3. Third Line,3/6/2025,Active,"Vulvar cancer, carcinoma (CMS/HCC)
Malignant neoplasm of overlapping sites of vulva (CMS/HCC)","L59.8 - Other specified disorders of the skin and subcutaneous tissue related to radiation; Z16.24 - Resistance to multiple antibiotics; B96.4 - Proteus (mirabilis) (morganii) as the cause of diseases classified elsewhere; C51.9 - Malignant neoplasm of vulva, unspecified; I10 - Essential (primary) hypertension; Z87.891 - Personal history of nicotine dependence; Z88.0 - Allergy status to penicillin; Z88.5 - Allergy status to narcotic agent; Z80.0 - Family history of malignant neoplasm of digestive organs; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z86.718 - Personal history of other venous thrombosis and embolism; Z98.890 - Other specified postprocedural states; Z92.3 - Personal history of irradiation"
CINJ OP INFUSION,64843,"Saraiya, Biren P, MD",1/22/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,1/16/2024,Inactive,,
CBMC OP INFUSION 2FL,24198,"Brown, Andrew Bennett, MD",11/13/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Induction,11/13/2023,Inactive,,
CINJ OP INFUSION,67891,"Stephenson, Ruth D, DO",5/19/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,5/18/2023,Inactive,,
CINJ OP INFUSION,94762,"Mayer, Tina M, MD",6/20/2023,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",,6/20/2023,Inactive,,
CINJ OP INFUSION,40004,"Haigentz, Missak, MD",12/2/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,12/1/2024,Inactive,,
CINJ OP INFUSION,40004,"Haigentz, Missak, MD",12/10/2024,"PEMEtrexed/CISplatin PLUS Pembrolizumab -  21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Neoadjuvant,12/1/2024,Active,,
CINJ OP INFUSION,91168,"Haigentz, Missak, MD",4/24/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/24/2025,Active,"Malignant neoplasm of lower lobe of right lung (CMS/HCC)
Chronic fatigue
Thyroid disorder screen","Z51.89 - Encounter for other specified aftercare; C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; E78.00 - Pure hypercholesterolemia, unspecified; I10 - Essential (primary) hypertension; Z98.890 - Other specified postprocedural states; Z98.41 - Cataract extraction status, right eye; Z98.42 - Cataract extraction status, left eye; Z90.2 - Acquired absence of lung (part of); Z96.652 - Presence of left artificial knee joint; Z79.899 - Other long term (current) drug therapy"
NBR CINJ OP INFUSION,54373,"Shah, Mansi R, MD",4/22/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Consolidation,4/22/2025,Inactive,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; I10 - Essential (primary) hypertension; Z01.818 - Encounter for other preprocedural examination; M89.8X9 - Other specified disorders of bone, unspecified site; D64.9 - Anemia, unspecified; F41.9 - Anxiety disorder, unspecified; R09.89 - Other specified symptoms and signs involving the circulatory and respiratory systems"
CBMC 2W ONCOLOGY,21276,"Grossman, I Robert, MD",3/6/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/5/2024,Inactive,,
CBMC 2W ONCOLOGY,21276,"Grossman, I Robert, MD",3/25/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/24/2024,Inactive,,
CINJ OP INFUSION,70743,"Gulhati, Prateek, MD PhD",12/5/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/4/2024,Active,,
HAM OP INFUSION,6764,"Gendy, Mina, DO",5/27/2025,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,5/26/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
NBR BMSCH 2 PED HEMONC,98672,"Moerdler, Scott, MD",1/12/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,1/12/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,98672,"Moerdler, Scott, MD",1/12/2024,AALL1731 Non-DS SR B-ALL Induction,Induction,1/12/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Moerdler, Scott, MD",2/15/2024,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,2/15/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",4/1/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,3/14/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",4/1/2024,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,4/1/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",5/30/2024,AALL1731 SR-Avg B-ALL Arm A,_1. First Line,5/30/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",5/30/2024,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,5/30/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",8/13/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,7/30/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",9/19/2024,AALL1731 All Arms - Interim Maintenance II EscMTX,_1. First Line,9/19/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",11/15/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,11/13/2024,Inactive,,
CINJ PEDS HEMONC ,98672,"Drachtman, Richard, MD",12/19/2024,"AALL1731 SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-Lly (including DS patients) - Maintenance",_1. First Line,12/19/2024,Active,,
CINJ OP INFUSION,36865,"Ghodoussipour, Saum Bobak, MD",5/3/2024,Gemcitabine Intravesical Weekly 42 Day Cycle - Bladder,Induction,5/2/2024,Inactive,,
CINJ OP INFUSION,59651,"Leiser, Aliza, MD",6/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,5/30/2023,Inactive,,
CINJ OP INFUSION,59651,"Leiser, Aliza, MD",10/24/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_9. Ninth Line,5/28/2024,Inactive,,
NBI OP INFUSION,12377,"Schleicher, Lori, MD",9/18/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,9/17/2023,Inactive,,
CINJ OP INFUSION,11132,"Saraiya, Biren P, MD",4/18/2023,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,First Line,4/4/2023,Inactive,,
NBR CINJ OP INFUSION,98704,"Zayac, Adam, MD",5/13/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/6/2024,Inactive,,
CINJ OP INFUSION,40370,"Leiser, Aliza, MD",12/14/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/26/2023,Inactive,,
CINJ OP INFUSION,40370,"Leiser, Aliza, MD",12/14/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,12/13/2023,Inactive,,
CINJ OP INFUSION,40370,"Leiser, Aliza, MD",12/14/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,12/13/2023,Active,,
CINJ OP INFUSION,40370,"Leiser, Aliza, MD",1/11/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/10/2024,Inactive,,
CINJ OP INFUSION,40370,"Leiser, Aliza, MD",1/12/2024,PACLitaxel weekly 28 Day Cycles - Bladder,_3. Third Line,1/11/2024,Inactive,,
CINJ OP INFUSION,40370,"Leiser, Aliza, MD",1/12/2024,PACLitaxel weekly 28 Day Cycles Endometrial Cancer,_3. Third Line,1/11/2024,Inactive,,
CINJ OP INFUSION,36294,"Toppmeyer, Deborah L, MD",9/5/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_1. First Line,9/5/2024,Active,,
SOM OUTPT INFUSION,69646,"Patel, Eshan, MD",3/22/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,First Line,3/20/2023,Inactive,,
SOM OUTPT INFUSION,69646,"Patel, Eshan, MD",5/3/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",,5/3/2023,Inactive,,
SOM OUTPT INFUSION,69646,"Patel, Eshan, MD",5/10/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,5/2/2023,Inactive,,
SOM OUTPT INFUSION,69646,"Patel, Eshan, MD",2/27/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,2/27/2024,Active,,
MSC OP INFUSION,80919,"Talwar, Sumit, MD",9/27/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/26/2023,Inactive,,
MSC OP INFUSION,80919,"Talwar, Sumit, MD",8/7/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,8/3/2024,Inactive,,
MSC OP INFUSION,80919,"Talwar, Sumit, MD",10/30/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,10/30/2024,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
SOM OUTPT INFUSION,87668,"Stephenson, Ruth D, DO",3/14/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,3/13/2023,Active,,
CINJ OP INFUSION,57505,"Patankar, Sonali, MD",1/17/2025,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,1/12/2025,Active,,
NBR 4N BMTU/IMCU,40648,"Palmisiano, Neil David, MD",5/23/2023,HyperCVAD (Cycle A) Course (Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,First Line,5/22/2023,Inactive,,
NBR CINJ OP INFUSION,40648,"Palmisiano, Neil David, MD",6/20/2023,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,,6/8/2023,Inactive,,
NBR CINJ OP INFUSION,40648,"Palmisiano, Neil David, MD",1/2/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,1/2/2024,Inactive,,
NBR 4N ONCOLOGY,40648,"Palmisiano, Neil David, MD",1/4/2024,Methotrexate / Cytarabine / Hydrocortisone Intrathecal 1 Day Cycle- Hematological Malignancies,Adjuvant,1/4/2024,Inactive,,
NBR CINJ OP INFUSION,40648,"Palmisiano, Neil David, MD",1/16/2024,HyperCVD Mini + Venetoclax (Venetoclax / High-Dose Methotrexate / Cytarabine / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,1/11/2024,Inactive,,
NBR 5N ONCOLOGY,40648,"Palmisiano, Neil David, MD",5/10/2024,"Daratumumab T-ALL/LBL relepased disease/MRD eradication (no bortezomib, no revlamide to be given)",Consolidation,5/9/2024,Inactive,,
NBR CINJ OP INFUSION,40648,"Chowaniec, Wayne B, NP",5/23/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,5/23/2024,Active,,
CINJ OP INFUSION,88978,"Berim, Lyudmyla, MD",11/11/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/3/2024,Active,,
CINJ OP INFUSION,72768,"Toppmeyer, Deborah L, MD",2/13/2023,Palbociclib 28 Day Cycles - Breast,First Line,2/13/2023,Inactive,,
CINJ OP INFUSION,72768,"Toppmeyer, Deborah L, MD",3/18/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_2. Second Line,3/17/2024,Inactive,,
CINJ OP INFUSION,72768,"Toppmeyer, Deborah L, MD",3/18/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,3/18/2024,Inactive,,
CINJ OP INFUSION,72768,"Toppmeyer, Deborah L, MD",7/8/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_3. Third Line,6/27/2024,Inactive,,
CINJ OP INFUSION,72768,"Toppmeyer, Deborah L, MD",10/29/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_1. First Line,10/29/2024,Active,,
NBR 5N ONCOLOGY,72768,"Gulhati, Prateek, MD PhD",2/8/2025,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_4. Fourth Line,2/7/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)","C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z51.5 - Encounter for palliative care; C79.31 - Secondary malignant neoplasm of brain; E44.0 - Moderate protein-calorie malnutrition; J93.9 - Pneumothorax, unspecified; J94.8 - Other specified pleural conditions; R62.7 - Adult failure to thrive; D63.0 - Anemia in neoplastic disease; E11.9 - Type 2 diabetes mellitus without complications; E04.2 - Nontoxic multinodular goiter; I10 - Essential (primary) hypertension; E66.9 - Obesity, unspecified; E83.52 - Hypercalcemia; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; G89.3 - Neoplasm related pain (acute) (chronic); K08.89 - Other specified disorders of teeth and supporting structures; K59.00 - Constipation, unspecified; Z88.4 - Allergy status to anesthetic agent; Z90.49 - Acquired absence of other specified parts of digestive tract; Z92.21 - Personal history of antineoplastic chemotherapy; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z85.3 - Personal history of malignant neoplasm of breast; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z68.32 - Body mass index (BMI) 32.0-32.9, adult"
SOM OUTPT INFUSION,9755,"Yin, Faye, MD",10/28/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/28/2024,Inactive,,
CINJ OP INFUSION,71785,"Saraiya, Biren P, MD",9/6/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/6/2024,Active,,
NBR 4N ONCOLOGY,69604,"Rhodes, Joanna Meehan, MD",4/15/2025,RiTUXimab Initial Infusion Single Day,_1. First Line,4/15/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),"D69.3 - Immune thrombocytopenic purpura; B37.0 - Candidal stomatitis; C85.99 - Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites; L03.115 - Cellulitis of right lower limb; D61.818 - Other pancytopenia; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; I10 - Essential (primary) hypertension; K76.0 - Fatty (change of) liver, not elsewhere classified; L03.116 - Cellulitis of left lower limb; D62 - Acute posthemorrhagic anemia; K92.2 - Gastrointestinal hemorrhage, unspecified; E66.813 - Obesity, class 3; G89.29 - Other chronic pain; G47.33 - Obstructive sleep apnea (adult) (pediatric); E87.6 - Hypokalemia; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecified; Z59.71 - Insufficient health insurance coverage; Z86.711 - Personal history of pulmonary embolism; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence; Z91.041 - Radiographic dye allergy status; Z95.0 - Presence of cardiac pacemaker; Z86.16 - Personal history of COVID-19; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.9 - Family history of malignant neoplasm, unspecified; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states"
SOM OUTPT INFUSION,57272,"Yin, Faye, MD",9/20/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/29/2023,Inactive,,
SOM OUTPT INFUSION,57272,"Yin, Faye, MD",1/24/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,1/23/2024,Inactive,,
NBI OP INFUSION,41596,"Jacoby, Sari H, MD",1/19/2024,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,1/19/2024,Inactive,,
CINJ OP INFUSION,11767,"Toppmeyer, Deborah L, MD",7/29/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,7/28/2024,Inactive,,
CINJ OP INFUSION,11767,"Toppmeyer, Deborah L, MD",11/18/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,11/17/2024,Active,,
CINJ OP INFUSION,11767,"Toppmeyer, Deborah L, MD",2/10/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,2/9/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor negative (CMS/HCC)
Diarrhea due to drug",
HAM OP INFUSION,86671,"Yogarajah, Meera, MD",1/30/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,1/28/2024,Active,,
HAM OP INFUSION,86671,"Yogarajah, Meera, MD",1/23/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,1/23/2025,Active,,
CINJ OP INFUSION,80542,"Haigentz, Missak, MD",4/3/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,4/3/2023,Inactive,,
MMC OP VP INFUSION,72371,"Meghal, Trishala, MD",12/3/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,12/3/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Hypercalcemia of malignancy
Cancer related pain
Malignant neoplasm metastatic to bone (CMS/HCC)
Malignant neoplasm metastatic to liver (CMS/HCC)
Hypercalcemia of malignancy",
CBMC OP INFUSION 2FL,33099,"Dave, Manish, MD",5/9/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/8/2023,Inactive,,
CBMC OP INFUSION 2FL,33099,"Niranjan, Usha, MD",3/5/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,3/5/2024,Active,,
CBMC OP INFUSION 2FL,67935,"Litvak, Anna M, MD",11/9/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,76287,"Litvak, Anna M, MD",3/27/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,3/27/2025,Active,Malignant neoplasm of unspecified site of left female breast (CMS/HCC),
NBR CINJ OP INFUSION,56958,"Evens, Andrew M, DO",4/5/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,4/5/2023,Inactive,,
NBR CINJ OP INFUSION,56958,"Evens, Andrew M, DO",10/4/2023,RiTUXimab / Lenalidomide 56 Day Cycles - Mantle Cell Lymphoma (Maintenance),,10/3/2023,Inactive,,
NBR CINJ OP INFUSION,56958,"Evens, Andrew M, DO",10/4/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,10/3/2023,Active,"Adenocarcinoma of gastroesophageal junction (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",
NBR CINJ OP INFUSION,12856,"Matasar, Matthew J, MD",5/2/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,5/1/2023,Inactive,,
CMC OP INFUSION,89235,"Cohen, Seth D, MD",12/18/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/17/2023,Active,,
CMC OP INFUSION,18455,"Cohen, Seth D, MD",4/18/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,4/15/2024,Inactive,,
CMC OP INFUSION,18455,"Cohen, Seth D, MD",7/26/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,7/25/2024,Active,Chondroblastic osteosarcoma (CMS/HCC),
CINJ OP INFUSION,75264,"Haigentz, Missak, MD",2/6/2025,Lenvatinib 28 Day Cycles- Papillary Carcinoma,_1. First Line,2/6/2025,Active,Papillary thyroid carcinoma (CMS/HCC),C73 - Malignant neoplasm of thyroid gland
SOM OUTPT INFUSION,19632,"Yin, Faye, MD",8/21/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,8/20/2023,Inactive,,
CINJ OP INFUSION,19632,"George, Mridula A, MD",9/15/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,9/12/2023,Inactive,,
CINJ OP INFUSION,76565,"George, Mridula A, MD",3/21/2025,Abemaciclib 28 Day Cycles - Breast,Adjuvant,3/21/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)","C50.911 - Malignant neoplasm of unspecified site of right female breast; H53.131 - Sudden visual loss, right eye; I82.C19 - Acute embolism and thrombosis of unspecified internal jugular vein; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z79.811 - Long term (current) use of aromatase inhibitors; Z17.0 - Estrogen receptor positive status (ER+)"
CMC OP INFUSION,86162,"Talwar, Sumit, MD",1/31/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,1/31/2024,Active,,
CINJ OP INFUSION,5930,"Leiser, Aliza, MD",1/26/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/25/2024,Inactive,,
CINJ OP INFUSION,5930,"Leiser, Aliza, MD",3/19/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles -High Grade Carcinoma of Mullerian Origin,_2. Second Line,3/18/2024,Inactive,,
CINJ PEDS HEMONC ,81921,"Cole, Peter David, MD",8/28/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,First Line,8/21/2023,Inactive,,
CINJ PEDS HEMONC ,81921,"Cole, Peter David, MD",1/2/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,1/2/2024,Inactive,,
CINJ PEDS HEMONC ,81921,"Cole, Peter David, MD",3/28/2024,AALL1732 HR-Fav B-ALL Maintenance,_1. First Line,3/28/2024,Active,,
NBR 5N ONCOLOGY,5824,"Zayac, Adam, MD",1/24/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/23/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
NBR 5N ONCOLOGY,5824,"Matasar, Matthew J, MD",1/25/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/25/2025,Active,,
NBR CINJ OP INFUSION,5824,"Matasar, Matthew J, MD",2/24/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/24/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
MMC OP VP INFUSION,35197,"Lee, Patrick C, MD",5/30/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,5/29/2023,Inactive,,
MMC OP VP INFUSION,29293,"Cohen, Seth D, MD",6/28/2023,Pembrolizumab 21 Day Cycles - Melanoma,,6/13/2023,Inactive,,
MMC OP VP INFUSION,29293,"Cohen, Seth D, MD",10/11/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,10/10/2023,Inactive,,
MMC OP VP INFUSION,29293,"Cohen, Seth D, MD",10/11/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/10/2023,Inactive,,
CINJ OP INFUSION,55398,"Girda, Eugenia, MD",7/31/2023,CINJ 102203 ARM 3 Nemvaleukin 21 Day Cycles Research- Ovarian Cancer,,7/29/2023,Inactive,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,55398,"Girda, Eugenia, MD",10/2/2023,CINJ 102303 ARM A Relacorilant / Nab-PACLitaxel 28 Day Cycles Research- Ovarian Cancer ,_4. Fourth Line,10/1/2023,Inactive,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,55398,"Girda, Eugenia, MD",6/11/2024,CINJ 102302 ARM 2 PHASE 2 ACR-368 + ULDG DOSE LEVEL 1 - OVARIAN,_4. Fourth Line,6/11/2024,Inactive,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,55398,"Girda, Eugenia, MD",8/19/2024,Olaparib 30 Day Cycles - Ovarian Cancer,_5. Fifth Line,8/19/2024,Inactive,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,55398,"Girda, Eugenia, MD",1/7/2025,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,_5. Fifth Line,1/7/2025,Active,,
CINJ OP INFUSION,21506,"Girda, Eugenia, MD",2/28/2025,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,2/18/2025,Active,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,21506,"Girda, Eugenia, MD",5/6/2025,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,5/6/2025,Active,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,21506,"Girda, Eugenia, MD",3/7/2025,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,2/26/2025,Inactive,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,21506,"Girda, Eugenia, MD",3/7/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,3/7/2025,Inactive,"Malignant neoplasm metastatic to peritoneum with unknown primary site (CMS/HCC)
Malignant neoplasm of ovary, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,25895,"Toppmeyer, Deborah L, MD",9/26/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,_1. First Line,9/25/2024,Active,,
NBR CINJ OP INFUSION,90448,"Assal, Amer, MD",11/8/2023,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,_6. Sixth Line,11/7/2023,Inactive,,
CBMC 2W ONCOLOGY,51247,"Grossman, I Robert, MD",5/9/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,5/8/2024,Inactive,,
CINJ OP INFUSION,1968,"Boland, Patrick M, MD",1/16/2025,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_1. First Line,1/15/2025,Active,,
SOM OUTPT INFUSION,41847,"Toomey, Kathleen C, MD",4/28/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,4/25/2023,Inactive,,
SOM OUTPT INFUSION,41847,"Toomey, Kathleen C, MD",8/11/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,8/10/2023,Inactive,,
CINJ OP INFUSION,13412,"Ghodoussipour, Saum Bobak, MD",12/4/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Induction - Bladder Cancer,Induction,12/3/2024,Active,,
CINJ OP INFUSION,24839,"Stephenson, Ryan D, DO",4/9/2025,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,4/9/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; D69.9 - Hemorrhagic condition, unspecified; C68.9 - Malignant neoplasm of urinary organ, unspecified; R79.1 - Abnormal coagulation profile; Z90.79 - Acquired absence of other genital organ(s)"
HAM OP INFUSION,95234,"Yogarajah, Meera, MD",8/12/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,8/12/2024,Inactive,,
HAM OP INFUSION,95234,"Yogarajah, Meera, MD",10/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/20/2024,Inactive,,
HAM OP INFUSION,95234,"Yogarajah, Meera, MD",11/1/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/21/2024,Active,,
CINJ OP INFUSION,72978,"Hochster, Howard S, MD",2/26/2025,mFOLFOX6 + Cetuximab + Encorafenib Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/11/2025,Active,"Malignant neoplasm of colon, unspecified (CMS/HCC)",
CINJ OP INFUSION,64026,"Stephenson, Ryan D, DO",11/18/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,11/10/2024,Active,,
NBR CINJ OP INFUSION,25911,"Palmisiano, Neil David, MD",3/22/2024,Tagraxofusp 21 day Cycles - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),Induction,3/22/2024,Inactive,,
NBR CINJ OP INFUSION,25911,"Zayac, Adam, MD",4/8/2024,Tagraxofusp 21 day Cycles - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),_1. First Line,4/8/2024,Inactive,,
NBR CINJ OP INFUSION,25911,"Zayac, Adam, MD",4/9/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/9/2024,Inactive,,
CMC OP INFUSION,86482,"Cohen, Seth D, MD",7/15/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,7/2/2024,Active,,
NBR CINJ OP INFUSION,88210,"Shah, Mansi R, MD",2/20/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/19/2024,Inactive,,
CMC OP INFUSION,80113,"Taff, Jessica, MD",7/18/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,First Line,6/20/2023,Inactive,,
CINJ OP INFUSION,8618,"Boland, Patrick M, MD",8/3/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,7/31/2023,Inactive,,
CINJ OP INFUSION,87324,"Patel, Eshan, MD",6/3/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,6/2/2024,Inactive,,
CINJ OP INFUSION,87324,"Patel, Eshan, MD",6/10/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,6/3/2024,Inactive,,
CINJ OP INFUSION,87324,"George, Mridula A, MD",7/15/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,6/30/2024,Inactive,,
CINJ OP INFUSION,87324,"George, Mridula A, MD",11/22/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,11/21/2024,Active,Adenocarcinoma of appendix (CMS/HCC),
CINJ OP INFUSION,92379,"Haigentz, Missak, MD",10/4/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/3/2024,Active,,
CINJ OP INFUSION,23618,"Patankar, Sonali, MD",12/2/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,11/11/2024,Active,,
NBI OP INFUSION,2433,"Anderson, Patrick S, MD",6/22/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/21/2023,Inactive,,
NBI OP INFUSION,2433,"Anderson, Patrick S, MD",6/22/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/21/2023,Inactive,,
NBI OP INFUSION,2433,"Anderson, Patrick S, MD",4/29/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/29/2024,Active,,
NBI OP INFUSION,2433,"Anderson, Patrick S, MD",5/15/2025,Liposomal DOXOrubicin / CARBOplatin / bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,5/15/2025,Active,Cancer of ovary (CMS/HCC),"Z08, Z85.43 - Encounter for follow-up surveillance of ovarian cancer"
CINJ OP INFUSION,3072,"George, Mridula A, MD",4/28/2025,Talazoparib 28 Day Cycles ,Neoadjuvant,4/28/2025,Active,Malignant neoplasm of female breast (CMS/HCC),"C50.912 - Malignant neoplasm of unspecified site of left female breast; I10 - Essential (primary) hypertension; F41.9 - Anxiety disorder, unspecified; L03.114 - Cellulitis of left upper limb; R12 - Heartburn; Z90.12 - Acquired absence of left breast and nipple; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast"
CINJ OP INFUSION,35672,"Patankar, Sonali, MD",10/9/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_3. Third Line,10/8/2024,Inactive,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,35672,"Patankar, Sonali, MD",1/29/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Uterine Cancer,_4. Fourth Line,1/28/2025,Active,,
SOM OUTPT INFUSION,93970,"Toomey, Kathleen C, MD",11/7/2024,Elacestrant 28 Day Cycles - Breast,_2. Second Line,11/7/2024,Inactive,,
SOM OUTPT INFUSION,93970,"Toomey, Kathleen C, MD",11/20/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,11/19/2024,Inactive,,
CINJ OP INFUSION,59206,"Stephenson, Ryan D, DO",2/21/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/20/2024,Active,,
SOM OUTPT INFUSION,63698,"Toomey, Kathleen C, MD",3/22/2023,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,First Line,3/14/2023,Inactive,,
SOM OUTPT INFUSION,63698,"Toomey, Kathleen C, MD",4/19/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",First Line,4/18/2023,Inactive,,
NBR 5N MED-SURG OVRF,80346,"Alexander, Henry Richard, MD",6/20/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,First Line,6/20/2023,Active,,
CBMC OP INFUSION 2FL,76645,"Dave, Manish, MD",11/7/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/7/2023,Inactive,,
NBR 4N ONCOLOGY,45480,"Jang, Thomas L, MD",1/14/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,1/14/2025,Active,,
CINJ OP INFUSION,36067,"Mayer, Tina M, MD",4/3/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,4/3/2025,Active,Renal cell carcinoma of right kidney (CMS/HCC),"C64.1 - Malignant neoplasm of right kidney, except renal pelvis; E07.9 - Disorder of thyroid, unspecified"
CBMC OP INFUSION 2FL,96689,"Wagmiller, Jennifer Ann, MD",6/4/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,50057,"Scoppetuolo, Michael, MD",5/3/2024,GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,4/28/2024,Inactive,,
CBMC OP INFUSION 2FL,50057,"Scoppetuolo, Michael, MD",5/3/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,4/28/2024,Active,,
NBR 4N BMTU/IMCU,50057,"Phillips, Adrienne A, MD",6/28/2024,BMT Autologous BEAM,_3. Third Line,6/27/2024,Inactive,,
CMC OP INFUSION,48703,"Cohen, Seth D, MD",12/30/2024,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,12/29/2024,Active,,
CMC OP INFUSION,48703,"Cohen, Seth D, MD",1/3/2025,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,12/29/2024,Active,,
CINJ OP INFUSION,96675,"Mayer, Tina M, MD",8/17/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,8/1/2023,Inactive,,
CINJ OP INFUSION,96675,"Mayer, Tina M, MD",8/17/2023,Pembrolizumab and Enfortumab Vedotin 21 Day Cycles - Bladder,_1. First Line,8/16/2023,Inactive,,
CINJ OP INFUSION,96675,"Mayer, Tina M, MD",8/17/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,,8/17/2023,Inactive,,
CBMC OP INFUSION 2FL,71135,"Wagmiller, Jennifer Ann, MD",11/27/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,11/27/2023,Active,,
JCMC CP INFUSION,5278,"Sekhri, Arunabh, MD",8/19/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,8/18/2024,Inactive,,
SOM OUTPT INFUSION,49894,"Patel, Eshan, MD",9/4/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,8/11/2024,Active,,
MSC OP INFUSION,31083,"Cohen, Seth D, MD",2/6/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,2/6/2024,Active,,
CINJ OP INFUSION,49720,"Mayer, Tina M, MD",1/11/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,1/5/2024,Active,,
HAM OP INFUSION,65182,"Yogarajah, Meera, MD",1/15/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/15/2024,Inactive,,
CINJ OP INFUSION,63490,"Boland, Patrick M, MD",2/7/2023,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,,2/6/2023,Inactive,,
CINJ OP INFUSION,63490,"Boland, Patrick M, MD",1/23/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/22/2024,Inactive,,
CINJ OP INFUSION,63490,"Boland, Patrick M, MD",2/28/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,2/27/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),C15.5 - Malignant neoplasm of lower third of esophagus
NBR 4N BMTU/IMCU,98348,"Braunschweig, Ira, MD",9/13/2023,BMT Autologous Melphalan Day -1  200mg/m2,,9/11/2023,Inactive,,
NBR CINJ OP INFUSION,98348,"Shah, Mansi R, MD",12/4/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,11/12/2024,Inactive,,
MMC BBR2 ONCOLOGY,6838,"Eltoukhy, Hussam, MD",11/12/2023,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,11/11/2023,Inactive,,
MMC OP INFUSION,6838,"Eltoukhy, Hussam, MD",11/27/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Maintenance,11/27/2023,Inactive,,
MMC OP INFUSION,6838,"Eltoukhy, Hussam, MD",4/8/2024,ECOG - ACRIN E1910 (Step 4) Maintenance (VinCRIStine / Prednisone / Mercaptopurine / Methotrexate Oral / Methotrexate IT) - Acute Lymphoblastic Leukemia,Maintenance,4/2/2024,Inactive,,
MMC BBR2 ONCOLOGY,6838,"Eltoukhy, Hussam, MD",5/1/2024,VINCRISTINE T-ALL/LBL,_2. Second Line,5/1/2024,Inactive,,
CINJ OP INFUSION,84752,"Stephenson, Ryan D, DO",5/15/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,5/15/2025,Active,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),C61 - Malignant neoplasm of prostate; Z19.1 - Hormone sensitive malignancy status
MMC OP INFUSION,48071,"Lee, Patrick C, MD",9/12/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,,9/11/2023,Active,,
CINJ OP INFUSION,90873,"Stephenson, Ryan D, DO",10/27/2023,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,10/27/2023,Inactive,,
CINJ OP INFUSION,90873,"Stephenson, Ryan D, DO",10/30/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,10/29/2023,Inactive,,
CINJ OP INFUSION,90873,"Stephenson, Ryan D, DO",11/17/2023,DOCEtaxel 21 Day Cycles - Prostate,_2. Second Line,11/16/2023,Inactive,,
CINJ OP INFUSION,90873,"Stephenson, Ryan D, DO",2/23/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_3. Third Line,2/23/2024,Active,,
CINJ OP INFUSION,94253,"Saraiya, Biren P, MD",3/13/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,Second Line,3/13/2023,Inactive,,
MMC OP VP INFUSION,29518,"Meghal, Trishala, MD",11/9/2023,Palbociclib 28 Day Cycles - Breast,_2. Second Line,11/9/2023,Inactive,,
MMC OP VP INFUSION,29518,"Meghal, Trishala, MD",10/7/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,10/7/2024,Active,,
MMC OP VP INFUSION,238,"Talwar, Sumit, MD",7/25/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,7/24/2023,Inactive,,
CBMC OP INFUSION 2FL,62683,"Leitner, Stuart P, MD",10/27/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/26/2023,Active,,
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",1/8/2024,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,1/7/2024,Inactive,,
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",6/11/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,6/3/2024,Inactive,,
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",6/11/2024,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,6/10/2024,Inactive,,
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",7/11/2024,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,7/10/2024,Inactive,,
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",8/8/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,8/7/2024,Active,,
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",4/18/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,4/18/2025,Inactive,Multiple myeloma (CMS/HCC),
NBR CINJ OP INFUSION,82488,"Shah, Mansi R, MD",4/18/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,4/18/2025,Active,Multiple myeloma (CMS/HCC),
CBMC OP INFUSION 2FL,15367,"Brown, Andrew Bennett, MD",11/15/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/31/2023,Inactive,,
MMC OP VP INFUSION,53076,"Lee, Patrick C, MD",5/19/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/19/2025,Active,Rectal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,35707,"Brown, Andrew Bennett, MD",1/29/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,1/28/2024,Inactive,,
MMC OP VP INFUSION,79315,"Meghal, Trishala, MD",3/19/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,3/19/2024,Inactive,,
MMC OP VP INFUSION,61679,"Cohen, Seth D, MD",2/28/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/27/2024,Inactive,,
SOM OUTPT INFUSION,30897,"Patel, Eshan, MD",1/21/2025,mFOLFOX6 Inpatient (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/20/2025,Inactive,Adenocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,30897,"Patel, Eshan, MD",2/3/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/20/2025,Active,Adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,81521,"Leitner, Stuart P, MD",9/25/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/24/2023,Inactive,,
CBMC OP INFUSION 2FL,81521,"Leitner, Stuart P, MD",12/27/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,12/26/2023,Active,Malignant neoplasm of ascending colon (CMS/HCC),
CBMC OP INFUSION 2FL,41802,"Litvak, Anna M, MD",4/30/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,4/30/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,3185,"Girda, Eugenia, MD",7/10/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,6/14/2023,Inactive,,
CINJ OP INFUSION,3185,"Girda, Eugenia, MD",2/13/2024,CINJ 102101 (19-0380) Niraparib 28 Day Cycles Research- Uterine Cancer,Maintenance,1/16/2024,Inactive,,
CINJ OP INFUSION,3185,"Girda, Eugenia, MD",6/11/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,6/11/2024,Inactive,,
CINJ OP INFUSION,3185,"Girda, Eugenia, MD",9/4/2024,CINJ 102310 Cohort B MK-4280A or Pembrolizumab / Lenvatinib 21 Day Cycles Research Solid Tumors,_2. Second Line,9/4/2024,Inactive,,
CINJ OP INFUSION,3185,"Girda, Eugenia, MD",12/30/2024,CINJ 102104 (Azenosertib) ZN-c3 400 mg 21 Day Cycles Research- Uterine Carcinoma,_3. Third Line,12/29/2024,Active,,
CINJ OP INFUSION,3185,"Girda, Eugenia, MD",12/30/2024,CINJ 102104 ZN-c3 400 mg 21 Day Cycles Research- Uterine Carcinoma,_3. Third Line,12/29/2024,Inactive,,
CINJ OP INFUSION,63838,"Girda, Eugenia, MD",5/13/2025,CINJ 172401 (Combo Match E5) Cohort 1 Sotorasib/Panitumumab 28 Day Cycles Research- Advanced Solid Tumors,_5. Fifth Line,5/13/2025,Active,"Endometrial cancer (CMS/HCC)
Abnormal coagulation profile
Abnormal findings on diagnostic imaging of other specified body structures",
CINJ OP INFUSION,63838,"Girda, Eugenia, MD",3/11/2025,CINJ 102404 Sacituzumab 21 Day Cycles Research- Endometrial Cancer,_4. Fourth Line,3/11/2025,Inactive,"Endometrial cancer (CMS/HCC)
Abnormal coagulation profile
Abnormal findings on diagnostic imaging of other specified body structures",R79.1 - Abnormal coagulation profile; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; C54.1 - Endometrial cancer (CMS/HCC)
CBMC 2W ONCOLOGY,70533,"Leitner, Stuart P, MD",12/14/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,12/14/2023,Inactive,,
CMC OP INFUSION,5937,"Cohen, Seth D, MD",1/11/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,1/10/2024,Inactive,,
MMC OP VP INFUSION,89377,"Cohen, Seth D, MD",9/20/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/19/2023,Inactive,,
SOM OUTPT INFUSION,93176,"Toomey, Kathleen C, MD",11/7/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,11/6/2024,Active,,
HAM OP INFUSION,80681,"Patel, Malini M, MD",12/5/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,12/4/2023,Active,,
CINJ OP INFUSION,5727,"Stephenson, Ryan D, DO",6/5/2024,Relugolix 30 day Cycles - Prostate,Adjuvant,6/5/2024,Inactive,,
TRMC TCCC OP INFUSION,6593,"Capo, Gerardo, MD",5/20/2025,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,5/20/2025,Active,Malignant neoplasm metastatic to lung (CMS/HCC),"C79.31 - Secondary malignant neoplasm of brain; G93.41 - Metabolic encephalopathy; G93.6 - Cerebral edema; C78.01 - Secondary malignant neoplasm of right lung; F20.0 - Paranoid schizophrenia; R47.01 - Aphasia; C64.2 - Malignant neoplasm of left kidney, except renal pelvis; C78.02 - Secondary malignant neoplasm of left lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C79.51 - Secondary malignant neoplasm of bone; J44.9 - Chronic obstructive pulmonary disease, unspecified; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; E66.9 - Obesity, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; N39.0 - Urinary tract infection, site not specified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; G47.33 - Obstructive sleep apnea (adult) (pediatric); E78.00 - Pure hypercholesterolemia, unspecified; F10.90 - Alcohol use, unspecified, uncomplicated; F17.210 - Nicotine dependence, cigarettes, uncomplicated; E87.6 - Hypokalemia; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z88.8 - Allergy status to other drugs, medicaments and biolo..."
CINJ OP INFUSION,38175,"Weiss, Sarah, MD",3/17/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,3/17/2025,Active,"Squamous cell carcinoma of chin
Other fatigue",C44.329 - Squamous cell carcinoma of skin of other parts of face
CMC OP INFUSION,13790,"Tang, Horace, MD",9/1/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,9/1/2023,Inactive,,
CMC OP INFUSION,13790,"Talwar, Sumit, MD",2/2/2024,EriBULin / Trastuzumab 21 Day Cycles - Breast,_4. Fourth Line,2/2/2024,Inactive,,
CINJ OP INFUSION,20661,"Leiser, Aliza, MD",8/2/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/2/2023,Active,,
CINJ OP INFUSION,36050,"Stephenson, Ryan D, DO",1/22/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,1/1/2025,Active,,
CINJ OP INFUSION,26968,"Mayer, Tina M, MD",4/12/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,4/12/2024,Active,,
CMC OP INFUSION,20127,"Cohen, Seth D, MD",11/30/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/29/2023,Inactive,,
CMC OP INFUSION,20127,"Cohen, Seth D, MD",11/30/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/22/2023,Inactive,,
CMC OP INFUSION,20127,"Cohen, Seth D, MD",11/30/2023,Dabrafenib/Trametinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/30/2023,Inactive,,
CMC OP INFUSION,20127,"Cohen, Seth D, MD",11/30/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/22/2023,Inactive,,
MMC OP VP INFUSION,88545,"Meghal, Trishala, MD",10/22/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,10/22/2024,Active,,
CINJ OP INFUSION,44658,"Stephenson, Ryan D, DO",1/10/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,1/7/2025,Active,,
MMC OP INFUSION,70626,"Meghal, Trishala, MD",9/8/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,9/8/2023,Inactive,,
NBI VALERIE FND HEMONC,88037,"Batra, Surabhi, MD",11/17/2023,PEDS IE - Osteosarcoma,_2. Second Line,11/15/2023,Inactive,,
CINJ OP INFUSION,50286,"Weiss, Sarah, MD",2/10/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_4. Fourth Line,2/9/2025,Active,Malignant melanoma of right lower extremity including hip (CMS/HCC),C43.71 - Malignant melanoma of right lower extremity including hip (CMS/HCC)
SOM OUTPT INFUSION,34871,"Patel, Eshan, MD",7/31/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/30/2024,Active,,
CINJ OP INFUSION,26572,"Toppmeyer, Deborah L, MD",5/20/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,5/16/2024,Active,,
CINJ OP INFUSION,121,"Saraiya, Biren P, MD",1/28/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,1/27/2025,Active,,
MMC OP VP INFUSION,121,"Cohen, Seth D, MD",3/6/2025,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,3/6/2025,Active,Renal cell carcinoma (CMS/HCC),
CINJ OP INFUSION,95056,"Stephenson, Ryan D, DO",2/8/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,2/8/2023,Active,,
CBMC OP INFUSION 2FL,1814,"Phillips, Adrienne A, MD",9/28/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,9/27/2023,Inactive,,
NBR 4N ONCOLOGY,1814,"Egini, Ogechukwu, MD",2/16/2024,BMT Autologous BEAM,_3. Third Line,2/15/2024,Inactive,,
NBR 4N ONCOLOGY,1814,"Egini, Ogechukwu, MD",2/16/2024,BMT Autologous BEAM,_2. Second Line,2/15/2024,Inactive,,
CBMC OP INFUSION 2FL,46872,"Leitner, Stuart P, MD",5/2/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/2/2024,Active,,
CBMC OP INFUSION 2FL,46872,"Leitner, Stuart P, MD",1/9/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/7/2025,Active,,
CINJ OP INFUSION,60878,"Hochster, Howard S, MD",9/27/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,9/27/2023,Inactive,,
CINJ OP INFUSION,60878,"Hochster, Howard S, MD",11/20/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,11/19/2023,Inactive,,
CINJ OP INFUSION,60878,"Hochster, Howard S, MD",12/18/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,12/18/2023,Inactive,,
CINJ OP INFUSION,60878,"Hochster, Howard S, MD",3/6/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,3/5/2024,Active,,
CINJ OP INFUSION,60878,"Hochster, Howard S, MD",3/10/2025,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,3/10/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),"G89.3 - Neoplasm related pain (acute) (chronic); G89.29 - Other chronic pain; F32.A - Depression, unspecified; F41.9 - Anxiety disorder, unspecified; R53.81 - Other malaise; C18.7 - Malignant neoplasm of sigmoid colon; D64.9 - Anemia, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I10 - Essential (primary) hypertension; E03.9 - Hypothyroidism, unspecified; N18.9 - Chronic kidney disease, unspecified; C18.9 - Malignant neoplasm of colon, unspecified"
SOM OUTPT INFUSION,44736,"Toomey, Kathleen C, MD",7/11/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,6/23/2024,Active,,
SOM OUTPT INFUSION,44736,"Toomey, Kathleen C, MD",2/10/2025,Capecitabine 21 Day Cycles - Breast,Adjuvant,2/10/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,15706,"Grossman, I Robert, MD",3/16/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,3/15/2023,Active,,
MMC OP INFUSION,28210,"Meghal, Trishala, MD",4/21/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,,4/20/2023,Inactive,,
NBR 5N ONCOLOGY,7990,"Palmisiano, Neil David, MD",7/14/2023,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),,7/14/2023,Inactive,,
NBR CINJ OP INFUSION,7990,"Palmisiano, Neil David, MD",9/12/2023,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,9/12/2023,Inactive,,
NBR 4N BMTU/IMCU,7990,"Palmisiano, Neil David, MD",6/28/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_2. Second Line,6/28/2024,Inactive,,
NBR 5N ONCOLOGY,7990,"Rhodes, Joanna Meehan, MD",6/28/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_2. Second Line,6/28/2024,Inactive,,
NBR CINJ OP INFUSION,7990,"Palmisiano, Neil David, MD",9/27/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,9/26/2024,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
CINJ OP INFUSION,81785,"Boland, Patrick M, MD",11/27/2023,Rucaparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,11/27/2023,Inactive,,
CINJ OP INFUSION,34099,"Leiser, Aliza, MD",9/27/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,9/13/2023,Inactive,,
CBMC OP INFUSION 2FL,72718,"Grossman, I Robert, MD",11/8/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/7/2023,Active,,
MMC OP VP INFUSION,49908,"Cohen, Seth D, MD",11/8/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/7/2024,Active,,
CINJ OP INFUSION,16707,"Toppmeyer, Deborah L, MD",1/30/2023,Palbociclib 28 Day Cycles - Breast,First Line,1/30/2023,Inactive,,
CINJ OP INFUSION,16707,"Toppmeyer, Deborah L, MD",3/3/2023,Ribociclib 28 Day Cycles - Breast,Second Line,3/3/2023,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,25902,"Tang, Horace, MD",1/2/2024,RiTUXimab 28 Day Cycles - B-Cell Lymphoma,_1. First Line,1/1/2024,Inactive,,
CMC OP INFUSION,25902,"Tang, Horace, MD",1/2/2024,RiTUXimab / Lenalidomide 28 Day Cycles - Follicular Lymphoma,_1. First Line,1/1/2024,Inactive,,
CMC OP INFUSION,25902,"Tang, Horace, MD",1/2/2024,RiTUXimab 28 Day Cycles - Marginal Zone Lymphoma,_1. First Line,1/2/2024,Inactive,,
CMC OP INFUSION,25902,"Eltoukhy, Hussam, MD",1/3/2024,RiTUXimab 28 Day Cycle - Marginal Zone Lymphoma ,_1. First Line,1/2/2024,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)
Carcinoma of breast metastatic to bone (CMS/HCC)",
CBMC OP INFUSION 2FL,13478,"Dharmapuri, Sirish, MD",10/24/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/20/2024,Active,,
CBMC OP INFUSION 2FL,13478,"Dharmapuri, Sirish, MD",2/26/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/17/2025,Active,Pancreatic cancer (CMS/HCC),
SOM OUTPT INFUSION,85427,"Patel, Eshan, MD",12/20/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/19/2023,Inactive,,
SOM OUTPT INFUSION,18705,"Patel, Eshan, MD",3/17/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,3/17/2025,Active,Malignant neoplasm of esophagus (CMS/HCC),
CBMC OP INFUSION 2FL,45163,"Derosa, William T, DO",1/10/2025,DOXOrubicin Liposomal 28 Day Cycles - Breast,_1. First Line,1/9/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Hypercalcemia of malignancy
Cancer related pain
Malignant neoplasm metastatic to bone (CMS/HCC)
Malignant neoplasm metastatic to liver (CMS/HCC)
Hypercalcemia of malignancy",
CBMC OP INFUSION 2FL,45163,"Derosa, William T, DO",1/13/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/7/2025,Active,,
CMC OP INFUSION,53025,"Cohen, Seth D, MD",11/21/2023,Everolimus / Exemestane 28 Day Cycles - Breast,_3. Third Line,11/21/2023,Inactive,,
CMC OP INFUSION,53025,"Cohen, Seth D, MD",6/21/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_2. Second Line,6/13/2024,Inactive,,
CMC OP INFUSION,53025,"Cohen, Seth D, MD",10/28/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,10/17/2024,Active,,
CBMC OP INFUSION 2FL,24753,"Leitner, Stuart P, MD",11/6/2023,Pembrolizumab 42 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/5/2023,Active,,
CINJ OP INFUSION,17568,"Berim, Lyudmyla, MD",7/8/2024,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,7/8/2024,Inactive,,
CINJ OP INFUSION,17568,"Berim, Lyudmyla, MD",7/8/2024,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,7/8/2024,Inactive,,
CINJ OP INFUSION,17568,"Berim, Lyudmyla, MD",9/6/2024,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,_1. First Line,8/27/2024,Inactive,,
CBMC OP INFUSION 2FL,5223,"Phillips, Adrienne A, MD",11/15/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_2. Second Line,11/15/2023,Inactive,,
CBMC OP INFUSION 2FL,5223,"Phillips, Adrienne A, MD",4/17/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,4/17/2024,Active,Desmoid fibromatosis,
CINJ OP INFUSION,84884,"Saraiya, Biren P, MD",1/18/2023,CINJ 081908 (NCI/CTEP 10096) Phase 2 ARM A Radium-223 / Olaparib 28 Day Cycles Research- Prostate Cancer,Third Line,12/21/2022,Inactive,,
CINJ OP INFUSION,84884,"Saraiya, Biren P, MD",9/26/2023,DOCEtaxel 21 Day Cycles - Prostate,Third Line,9/17/2023,Inactive,,
CINJ OP INFUSION,84884,"Saraiya, Biren P, MD",10/12/2023,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_3. Third Line,10/12/2023,Inactive,,
MMC OP VP INFUSION,99060,"Talwar, Sumit, MD",1/28/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,1/27/2025,Active,,
MMC OP INFUSION,50692,"Meghal, Trishala, MD",4/26/2023,Letrozole 30 Day Cycles - Breast,,4/26/2023,Inactive,,
MSC OP INFUSION,97850,"Easaw, Sarah, MD",5/9/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,5/8/2023,Inactive,,
MSC OP INFUSION,97850,"Easaw, Sarah, MD",5/10/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,4/23/2023,Inactive,,
MSC OP INFUSION,97850,"Easaw, Sarah, MD",5/10/2023,Trastuzumab 14  Day Cycles- Gastrointestinal Cancers,Maintenance,5/9/2023,Inactive,,
MSC OP INFUSION,97850,"Easaw, Sarah, MD",5/10/2023,Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,Maintenance,4/23/2023,Inactive,,
MSC OP INFUSION,97850,"Cohen, Seth D, MD",10/11/2023,Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/4/2023,Inactive,,
MSC OP INFUSION,97850,"Cohen, Seth D, MD",10/25/2023,5Flurouracil/Leucovorin as Outpatient (Fluorouracil Continuous Infusion/Leucovorin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/23/2023,Inactive,,
MSC OP INFUSION,97850,"Cohen, Seth D, MD",2/29/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,2/22/2024,Inactive,,
CMC OP INFUSION,37465,"Taff, Jessica, MD",11/12/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,10/29/2024,Active,,
NBI OP INFUSION,42452,"Anderson, Patrick S, MD",4/1/2024,Cyclophosphamide Oral / Bevacizumab/ pembrolizumab  21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,3/31/2024,Active,,
NBI OP INFUSION,42452,"Anderson, Patrick S, MD",4/1/2024,Cyclophosphamide Oral / Bevacizumab/Pembrolizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,3/31/2024,Inactive,,
CINJ OP INFUSION,38862,"Berim, Lyudmyla, MD",8/10/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,8/10/2023,Inactive,,
CINJ OP INFUSION,38862,"Berim, Lyudmyla, MD",10/9/2023,Durvalumab 1500 mg 28 Day Cycles- Cholangiocarcinoma Maintenance,,10/1/2023,Inactive,,
NBR CINJ OP INFUSION,38862,"Berim, Lyudmyla, MD",1/22/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,1/19/2024,Inactive,,
CINJ OP INFUSION,38862,"Berim, Lyudmyla, MD",8/8/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/6/2024,Active,,
CINJ OP INFUSION,38862,"Berim, Lyudmyla, MD",9/16/2024,Ivosidenib 30 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,9/16/2024,Active,,
CINJ OP INFUSION,87859,"Berim, Lyudmyla, MD",6/29/2023,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,,6/29/2023,Inactive,,
CINJ OP INFUSION,87859,"Berim, Lyudmyla, MD",9/27/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,,9/26/2023,Inactive,,
CINJ OP INFUSION,87859,"Berim, Lyudmyla, MD",11/21/2023,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,Maintenance,11/21/2023,Inactive,,
CINJ OP INFUSION,87859,"Berim, Lyudmyla, MD",1/22/2024,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/15/2024,Inactive,,
SOM OUTPT INFUSION,89519,"Yin, Faye, MD",4/8/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/7/2024,Inactive,,
SOM OUTPT INFUSION,89519,"George, Mridula A, MD",4/16/2024,Phesgo (Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/14/2024,Active,,
CINJ OP INFUSION,9466,"Boland, Patrick M, MD",11/4/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,10/2/2024,Inactive,Rectal adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,9466,"Boland, Patrick M, MD",1/10/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Rectal Cancer,Neoadjuvant,1/9/2025,Active,,
NBR CINJ OP INFUSION,48076,"Sridharan, Ashwin, MD",10/8/2024,AALL0434 - Induction (All Arms) 35 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,10/8/2024,Inactive,,
NBR CINJ OP INFUSION,48076,"Zayac, Adam, MD",10/8/2024,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,_1. First Line,10/7/2024,Active,,
NBR 5N ONCOLOGY,92446,"Palmisiano, Neil David, MD",11/8/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/8/2023,Inactive,,
JCMC CP INFUSION,92446,"Sekhri, Arunabh, MD",11/9/2023,Methotrexate Intrathecal 12 mg IT 7 Day Cycle- Hematological Malignancies,_1. First Line,11/9/2023,Inactive,,
NBR CINJ OP INFUSION,92446,"Matasar, Matthew J, MD",11/15/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,11/15/2023,Inactive,,
CINJ OP INFUSION,56539,"Packiam, Vignesh, MD",3/29/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,_6. Sixth Line,3/28/2024,Inactive,,
CINJ OP INFUSION,56539,"Packiam, Vignesh, MD",4/4/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,4/3/2024,Inactive,,
CINJ OP INFUSION,56539,"Packiam, Vignesh, MD",7/25/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,7/17/2024,Active,,
MMC OP INFUSION,41089,"Lee, Patrick C, MD",5/9/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,5/9/2023,Inactive,,
MMC OP INFUSION,41089,"Lee, Patrick C, MD",5/16/2023,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,,5/15/2023,Inactive,,
NBI OP INFUSION,77912,"Cheng, Yan Ho, MD",3/7/2024,PACLitaxel/CARBOplatin 21 Day Cycles- Metastatic Anal Carcinoma,_1. First Line,3/6/2024,Inactive,,
CBMC OP INFUSION 2FL,77912,"Brown, Andrew Bennett, MD",4/18/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Anal Cancer,_1. First Line,4/15/2024,Inactive,,
CBMC OP INFUSION 2FL,77912,"Brown, Andrew Bennett, MD",9/3/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/2/2024,Inactive,,
CBMC OP INFUSION 2FL,77912,"Brown, Andrew Bennett, MD",9/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/3/2024,Active,,
NBR CINJ OP INFUSION,12387,"Braunschweig, Ira, MD",12/28/2023,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,_4. Fourth Line,12/27/2023,Inactive,,
NBI OP INFUSION,12387,"Shah, Maya M, MD",3/6/2024,Carfilzomib 56 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,2/27/2024,Inactive,,
NBR CINJ OP INFUSION,12387,"Shah, Mansi R, MD",6/25/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_5. Fifth Line,6/25/2024,Inactive,,
NBR CINJ OP INFUSION,12387,"Shah, Mansi R, MD",8/26/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,8/25/2024,Active,,
CINJ OP INFUSION,27452,"Hochster, Howard S, MD",3/8/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,3/7/2023,Inactive,,
CINJ OP INFUSION,27452,"Hochster, Howard S, MD",8/23/2023,CINJ 072110 Capecitabine / Bevacizumab 21 Day Cycles Research- Colon Cancer,First Line,8/22/2023,Inactive,,
CINJ OP INFUSION,27452,"Hochster, Howard S, MD",2/28/2024,CINJ 072110 Simplified Biweekly Infusional Fluorouracil / Leucovorin + Bevacizumab 14 Day Cycles- Colon Cancer,Maintenance,2/27/2024,Inactive,,
CINJ OP INFUSION,27452,"Hochster, Howard S, MD",7/3/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/1/2024,Active,,
CINJ OP INFUSION,62451,"Saraiya, Biren P, MD",4/8/2025,Relugolix 30 day Cycles - Prostate,_1. First Line,4/8/2025,Active,Primary prostate adenocarcinoma (CMS/HCC),C61 - Malignant neoplasm of prostate
MMC OP INFUSION,36137,"Meghal, Trishala, MD",3/6/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,2/29/2024,Inactive,,
CINJ OP INFUSION,49328,"Goel, Sanjay, MD",2/19/2024,CINJ 052302 (DF9001) Monotherapy - Solid Tumor,_2. Second Line,2/19/2024,Inactive,,
NBR CINJ OP INFUSION,79984,"Tiger, Yun Kyoung, MD",9/30/2024,MT-R (High-Dose Methotrexate / Temozolomide EVEN Cycles / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,9/29/2024,Active,,
NBR 4N BMTU/IMCU,22371,"Rabinovich, Emma, MD",3/6/2025,BMT Autologous Carmustine / Thiotepa,_1. First Line,3/5/2025,Active,Primary CNS lymphoma (CMS/HCC),"C83.390 - Primary central nervous system lymphoma; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; D61.810 - Antineoplastic chemotherapy induced pancytopenia; Z66 - Do not resuscitate; D70.1 - Agranulocytosis secondary to cancer chemotherapy; I10 - Essential (primary) hypertension; K52.1 - Toxic gastroenteritis and colitis; F41.9 - Anxiety disorder, unspecified; K04.7 - Periapical abscess without sinus; R73.03 - Prediabetes; R73.9 - Hyperglycemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; I95.9 - Hypotension, unspecified; R50.81 - Fever presenting with conditions classified elsewhere; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z90.710 - Acquired absence of both cervix and uterus; Z83.3 - Family history of diabetes mellitus; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,20361,"Leitner, Stuart P, MD",11/7/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/31/2023,Inactive,,
CBMC OP INFUSION 2FL,20361,"Leitner, Stuart P, MD",5/29/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,20361,"Leitner, Stuart P, MD",8/7/2024,"Cetuximab D1, D15 28 Day Cycles- Colon Cancer",_3. Third Line,8/6/2024,Inactive,,
CBMC OP INFUSION 2FL,20361,"Leitner, Stuart P, MD",8/21/2024,Cetuximab Weekly 28 Day Cycles- Colon Cancer,_3. Third Line,8/6/2024,Active,,
CMC OP INFUSION,64849,"Tang, Horace, MD",9/15/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,9/14/2023,Active,,
NBI OP INFUSION,95604,"Shah, Maya M, MD",8/29/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,8/29/2024,Inactive,,
CINJ OP INFUSION,80634,"Mayer, Tina M, MD",4/17/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,4/17/2025,Active,Malignant neoplasm of prostate (CMS/HCC),
CBMC OP INFUSION 2FL,59142,"Wagmiller, Jennifer Ann, MD",11/6/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,11/21/2021,Inactive,,
CBMC OP INFUSION 2FL,59142,"Wagmiller, Jennifer Ann, MD",11/12/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,11/11/2024,Inactive,,
CBMC OP INFUSION 2FL,59142,"Wagmiller, Jennifer Ann, MD",1/20/2025,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,1/1/2025,Active,,
CINJ OP INFUSION,56667,"Stephenson, Ruth D, DO",8/30/2023,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,8/29/2023,Inactive,,
CINJ OP INFUSION,71571,"Gulhati, Prateek, MD PhD",9/25/2024,Ivosidenib 30 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/25/2024,Active,,
CINJ OP INFUSION,22531,"Berim, Lyudmyla, MD",3/14/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/12/2024,Active,,
CINJ OP INFUSION,94266,"Hochster, Howard S, MD",2/1/2024,mFOLFOX6 Outpatient + NIVO 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/31/2024,Active,,
CINJ OP INFUSION,54343,"Hochster, Howard S, MD",10/12/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,10/11/2023,Inactive,,
MMC OP VP INFUSION,92430,"Lee, Patrick C, MD",3/5/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/4/2024,Inactive,,
MMC OP VP INFUSION,92430,"Lee, Patrick C, MD",3/5/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Unknown Primary ,_1. First Line,3/4/2024,Inactive,,
CMC OP INFUSION,45250,"Taff, Jessica, MD",4/4/2023,Albumin-Bound PACLitaxel/CARBOplatin with Concurrent Radiation Therapy 7 Day Cycles- Non-Small Cell Lung Cancer,First Line,4/3/2023,Inactive,,
CMC OP INFUSION,45250,"Taff, Jessica, MD",5/2/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,4/3/2023,Inactive,,
CMC OP INFUSION,45250,"Taff, Jessica, MD",7/1/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,6/30/2023,Inactive,,
CMC OP INFUSION,45250,"Taff, Jessica, MD",7/12/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/11/2023,Inactive,,
SOM OUTPT INFUSION,37350,"Yin, Faye, MD",7/17/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/9/2023,Inactive,,
CINJ OP INFUSION,13197,"Gulhati, Prateek, MD PhD",1/5/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2024,Inactive,,
CINJ OP INFUSION,33613,"Omene, Coral Oghenerukevwe, MD",1/24/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,1/24/2023,Inactive,,
CBMC OP INFUSION 2FL,12515,"Dharmapuri, Sirish, MD",2/21/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,1/21/2025,Active,"Adenocarcinoma of pancreas, stage 4 (CMS/HCC)",
CBMC OP INFUSION 2FL,61105,"Dharmapuri, Sirish, MD",3/4/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,2/19/2025,Inactive,"Adenocarcinoma of pancreas, stage 4 (CMS/HCC)",
NBI OP INFUSION,74168,"Shah, Shailja S, MD",7/24/2024,Lenvatinib 28 Day Cycles- Papillary Carcinoma,_1. First Line,7/24/2024,Active,,
NBI OP INFUSION,72504,"Cheng, Yan Ho, MD",11/5/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,10/28/2024,Active,Breast cancer of upper-inner quadrant of right female breast (CMS/HCC),
CBMC OP INFUSION 2FL,21622,"Litvak, Anna M, MD",10/30/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,_1. First Line,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,21622,"Litvak, Anna M, MD",1/29/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,1/29/2024,Inactive,,
HAM OP INFUSION,7728,"Yogarajah, Meera, MD",3/21/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/21/2025,Active,Gastroesophageal cancer (CMS/HCC),
MMC OP VP INFUSION,26863,"Lee, Patrick C, MD",5/16/2024,PEMEtrexed/CARBOplatin 21 Day Cycles- Malignant Pleural Mesothelioma,_1. First Line,5/2/2024,Inactive,,
MMC OP VP INFUSION,26863,"Lee, Patrick C, MD",5/17/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/9/2024,Inactive,,
MMC OP VP INFUSION,26863,"Lee, Patrick C, MD",5/17/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/9/2024,Active,,
CBMC OP INFUSION 2FL,26779,"Gurubhagavatula, Sarada, MD",1/2/2025,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/25/2024,Active,,
CINJ OP INFUSION,51652,"Haigentz, Missak, MD",10/23/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Small Cell Lung Cancer",_5. Fifth Line,10/23/2023,Inactive,,
CINJ OP INFUSION,51652,"Haigentz, Missak, MD",2/8/2024,Cabozantinib 28 Day Cycles- Neuroendocrine Cancer,_7. Seventh Line,2/8/2024,Inactive,,
MMC OP VP INFUSION,69293,"Meghal, Trishala, MD",9/20/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),,9/15/2023,Inactive,,
MMC OP INFUSION,69293,"Meghal, Trishala, MD",1/3/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,12/10/2023,Inactive,,
MMC OP INFUSION,69293,"Meghal, Trishala, MD",1/3/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,1/2/2024,Inactive,,
MMC OP VP INFUSION,69293,"Meghal, Trishala, MD",7/15/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,7/15/2024,Inactive,,
MMC OP VP INFUSION,69293,"Meghal, Trishala, MD",7/23/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,7/23/2024,Inactive,,
MSC OP INFUSION,86422,"Taff, Jessica, MD",5/31/2023,AzaCITIDine (Post Transplant) 28 Day Cycle - Acute Myeloid Leukemia / MDS,First Line,5/30/2023,Inactive,,
NBR 5N ONCOLOGY,45536,"Zayac, Adam, MD",1/17/2024,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,1/16/2024,Inactive,,
NBR CINJ OP INFUSION,45536,"Zayac, Adam, MD",2/6/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,2/6/2024,Inactive,,
NBR CINJ OP INFUSION,45536,"Zayac, Adam, MD",4/22/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,4/21/2024,Inactive,,
NBR CINJ OP INFUSION,45536,"Zayac, Adam, MD",5/20/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,5/20/2024,Inactive,,
NBR CINJ OP INFUSION,45536,"Egini, Ogechukwu, MD",8/23/2024,BMT Allogeneic Flu (D-7) / TBI + Post Cy - Myeloablative,_1. First Line,8/23/2024,Active,,
NBR CINJ OP INFUSION,81905,"Evens, Andrew M, DO",5/24/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,,5/23/2023,Inactive,,
SOM OUTPT INFUSION,23662,"Toomey, Kathleen C, MD",3/20/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,3/12/2024,Inactive,,
SOM OUTPT INFUSION,23662,"Toomey, Kathleen C, MD",6/12/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,6/11/2024,Active,"Vulvar cancer, carcinoma (CMS/HCC)
Malignant neoplasm of overlapping sites of vulva (CMS/HCC)",
SOM OUTPT INFUSION,23662,"Toomey, Kathleen C, MD",2/19/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,2/18/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)
Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,45341,"Berim, Lyudmyla, MD",7/11/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Pancreatobiliary Cancer,_1. First Line,7/9/2024,Inactive,,
CINJ OP INFUSION,45341,"Berim, Lyudmyla, MD",1/30/2025,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,Maintenance,1/30/2025,Active,,
CINJ OP INFUSION,45341,"Berim, Lyudmyla, MD",4/30/2025,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,Maintenance,1/30/2025,Active,Adenocarcinoma of bile duct (CMS/HCC),"C24.0 - Malignant neoplasm of extrahepatic bile duct; C22.1 - Intrahepatic bile duct carcinoma; T81.72XA - Complication of vein following a procedure, not elsewhere classified, initial encounter"
MSC OP INFUSION,45093,"Cohen, Seth D, MD",11/7/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,10/30/2023,Inactive,,
MSC OP INFUSION,32247,"Cohen, Seth D, MD",5/4/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib q2w/Dexamethasone 28 Day Cycles- Multiple Myeloma,,5/1/2023,Active,,
NBR CINJ OP INFUSION,34649,"Schaar, Dale, MD PhD",12/27/2023,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,12/26/2023,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
MMC OP VP INFUSION,90969,"Cohen, Seth D, MD",11/19/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/15/2024,Active,,
CINJ OP INFUSION,5071,"Toppmeyer, Deborah L, MD",2/23/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,First Line,1/25/2023,Inactive,,
CINJ OP INFUSION,5071,"Toppmeyer, Deborah L, MD",2/23/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,2/22/2023,Inactive,,
CINJ OP INFUSION,5071,"Stephenson, Ruth D, DO",1/18/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/17/2024,Inactive,,
CINJ OP INFUSION,5071,"Stephenson, Ruth D, DO",5/30/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,5/30/2024,Active,,
HAM OP INFUSION,94329,"Yogarajah, Meera, MD",11/4/2024,Everolimus,_2. Second Line,11/4/2024,Active,,
HAM OP INFUSION,94329,"Yogarajah, Meera, MD",5/16/2025,Capecitabine 21 Day Cycles - Breast,_3. Third Line,5/16/2025,Active,"Breast cancer metastasized to bone, left (CMS/HCC)","C50.912 - Malignant neoplasm of unspecified site of left female breast; C79.51 - Secondary malignant neoplasm of bone; M19.90 - Unspecified osteoarthritis, unspecified site; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; G47.33 - Obstructive sleep apnea (adult) (pediatric); R79.1 - Abnormal coagulation profile; J44.9 - Chronic obstructive pulmonary disease, unspecified; F51.04 - Psychophysiologic insomnia; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z79.899 - Other long term (current) drug therapy; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.4 - Long term (current) use of insulin; Z79.82 - Long term (current) use of aspirin; Z79.891 - Long term (current) use of opiate analgesic; Z88.0 - Allergy status to penicillin; Z17.410 - Hormone receptor positive with human epidermal growth factor receptor 2 positive status; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
CBMC OP INFUSION 2FL,58628,"Litvak, Anna M, MD",10/10/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,10/10/2023,Inactive,,
CBMC OP INFUSION 2FL,58628,"Raptis, George, MD",10/29/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,10/29/2024,Active,,
HAM OP INFUSION,37391,"Yogarajah, Meera, MD",2/16/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,2/8/2023,Inactive,,
MMC OP VP INFUSION,80731,"Cohen, Seth D, MD",1/10/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_2. Second Line,1/9/2024,Active,"Chronic lymphocytic leukemia of B-cell type (CMS/HCC)
Prolymphocytic leukemia of B-cell type not having achieved remission (CMS/HCC)",
MMC OP VP INFUSION,74859,"Cohen, Seth D, MD",12/5/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,12/4/2024,Active,,
MMC OP VP INFUSION,74859,"Cohen, Seth D, MD",2/27/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,2/26/2025,Active,Malignant melanoma of torso excluding breast (CMS/HCC),
CMC OP INFUSION,61799,"Talwar, Sumit, MD",6/26/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,6/26/2024,Inactive,,
CMC OP INFUSION,55263,"Cohen, Seth D, MD",11/2/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/1/2023,Inactive,,
CMC OP INFUSION,55263,"Cohen, Seth D, MD",2/15/2024,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,2/14/2024,Inactive,,
CMC OP INFUSION,55263,"Cohen, Seth D, MD",11/15/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,11/11/2024,Active,,
CBMC 2W ONCOLOGY,25388,"Grossman, I Robert, MD",4/29/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,4/29/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"T83.518A - Infection and inflammatory reaction due to other urinary catheter, initial encounter; G93.41 - Metabolic encephalopathy; Z66 - Do not resuscitate; U07.1 - COVID-19; C90.00 - Multiple myeloma not having achieved remission; L89.152 - Pressure ulcer of sacral region, stage 2; E87.20 - Acidosis, unspecified; E87.0 - Hyperosmolality and hypernatremia; D69.6 - Thrombocytopenia, unspecified; E83.39 - Other disorders of phosphorus metabolism; B95.62 - Methicillin resistant Staphylococcus aureus infection as the cause of diseases classified elsewhere; C73 - Malignant neoplasm of thyroid gland; F03.918 - Unspecified dementia, unspecified severity, with other behavioral disturbance; I27.20 - Pulmonary hypertension, unspecified; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; E66.811 - Obesity, class 1; D53.9 - Nutritional anemia, unspecified; E05.90 - Thyrotoxicosis, unspecified without thyrotoxic crisis or storm; F32.A - Depression, unspecified; F03.93 - Unspecified dementia, unspecified severity, with mood disturbance; N17.9 - Acute kidney failure, unspecified; R45.851 - Suicidal ideations; N30.01 - Acute cystitis with hematuria; E87.1 - Hypo-osmolality and hyponatremia; N13.9 - Obstructive and reflux uropathy, unspecified; E83.52 - Hypercalcemia; D89.2 - Hypergammaglobulinemia, unspecified; E87.5 - Hyperkalemia; E87.6 - Hypokalemia; R74.01 - Elevation of levels of liver transaminase levels; E07.9 - Disorder of thyroid, unspecified; E86.0 - D..."
CINJ OP INFUSION,79722,"Boland, Patrick M, MD",2/6/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,2/5/2024,Active,,
CINJ OP INFUSION,69227,"Omene, Coral Oghenerukevwe, MD",3/21/2023,CINJ 042102 EOP A Lasofoxifene 28 Day Cycles Research- Breast Cancer,Neoadjuvant,3/20/2023,Inactive,,
JCMC CP INFUSION,48879,"Cruz, Allan Louie E, MD",7/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/30/2024,Inactive,,
CBMC OP INFUSION 2FL,60909,"Freeman, Benjamin B, MD",2/7/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/5/2025,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,56451,"Hochster, Howard S, MD",12/23/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,12/23/2024,Active,,
CINJ OP INFUSION,56451,"Hochster, Howard S, MD",2/12/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/12/2025,Active,Malignant neoplasm of rectum (CMS/HCC),"C20 - Malignant neoplasm of rectum; C61 - Malignant neoplasm of prostate; I10 - Essential (primary) hypertension; R79.1 - Abnormal coagulation profile; R94.5 - Abnormal results of liver function studies; Z86.718 - Personal history of other venous thrombosis and embolism; Z90.49 - Acquired absence of other specified parts of digestive tract; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; G89.3 - Neoplasm related pain (acute) (chronic); G89.29 - Other chronic pain; R19.7 - Diarrhea, unspecified; R53.81 - Other malaise; Z51.5 - Encounter for palliative care; K52.9 - Noninfective gastroenteritis and colitis, unspecified; R97.20 - Elevated prostate specific antigen (PSA); Z79.891 - Long term (current) use of opiate analgesic"
CINJ OP INFUSION,17618,"Gulhati, Prateek, MD PhD",7/11/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,7/10/2024,Inactive,,
CINJ OP INFUSION,17618,"Gulhati, Prateek, MD PhD",8/30/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,8/29/2024,Active,,
CINJ OP INFUSION,78992,"Haigentz, Missak, MD",10/6/2023,CINJ 032203 (D967SC00001) ARM 2 Pemetrexed / CARBOplatin + Pembrolizumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,10/5/2023,Active,,
NBI OP INFUSION,31786,"Jacoby, Sari H, MD",9/24/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,9/23/2024,Active,,
NBI OP INFUSION,31786,"Jacoby, Sari H, MD",12/26/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,12/25/2024,Active,,
NBI OP INFUSION,31786,"Jacoby, Sari H, MD",2/12/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,2/11/2025,Active,Malignant neoplasm of hilus of right lung (CMS/HCC),"C80.1 - Malignant (primary) neoplasm, unspecified (CMS/HCC)"
CMC OP INFUSION,71770,"Talwar, Sumit, MD",1/18/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,1/17/2024,Inactive,,
CMC OP INFUSION,85634,"Eltoukhy, Hussam, MD",4/16/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,4/16/2025,Active,Follicular lymphoma (CMS/HCC),
CINJ OP INFUSION,40702,"Muralikrishnan, Sivraj, MD",5/9/2025,PACLitaxel / CARBOplatin / Cemiplimab-rwlc 21 Day Cycles-- Non-Small Cell Lung Cancer,_1. First Line,5/9/2025,Active,Lung cancer metastatic to bone (CMS/HCC),
CINJ OP INFUSION,40702,"Muralikrishnan, Sivraj, MD",5/1/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/1/2025,Inactive,Lung cancer metastatic to bone (CMS/HCC),C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C79.51 - Secondary malignant neoplasm of bone; E83.52 - Hypercalcemia
CBMC OP INFUSION 2FL,4977,"Scoppetuolo, Michael, MD",2/14/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,1/29/2024,Inactive,,
CBMC OP INFUSION 2FL,4977,"Scoppetuolo, Michael, MD",5/9/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/1/2024,Inactive,,
CBMC OP INFUSION 2FL,4977,"Scoppetuolo, Michael, MD",7/1/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,6/24/2024,Active,,
CBMC OP INFUSION 2FL,4977,"Scoppetuolo, Michael, MD",2/18/2025,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,2/17/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),"C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung"
CINJ OP INFUSION,34016,"Weiss, Sarah, MD",8/10/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,8/6/2023,Inactive,,
NBR 5N ONCOLOGY,34016,"Berim, Lyudmyla, MD",10/11/2023,RiTUXimab for Myasthenia Gravis,Non-Oncology Research,10/10/2023,Inactive,,
NBR 5N ONCOLOGY,34016,"Berim, Lyudmyla, MD",10/12/2023,RiTUXimab Initial Infusion Single Day for Myasthenia Gravis,_1. First Line,10/12/2023,Inactive,,
CINJ OP INFUSION,34016,"Stephenson, Ryan D, DO",10/12/2023,RiTUXimab 28 Day Cycle - Myasthenia Gravis,_1. First Line,10/11/2023,Inactive,,
CINJ OP INFUSION,54512,"Boland, Patrick M, MD",1/24/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/13/2025,Active,,
CBMC OP INFUSION 2FL,76321,"Wagmiller, Jennifer Ann, MD",12/19/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,12/19/2023,Inactive,,
CBMC OP INFUSION 2FL,76321,"Wagmiller, Jennifer Ann, MD",1/9/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,1/8/2024,Inactive,,
CBMC OP INFUSION 2FL,76321,"Wagmiller, Jennifer Ann, MD",1/16/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,1/16/2024,Inactive,,
CBMC OP INFUSION 2FL,38077,"Leitner, Stuart P, MD",12/4/2023,Ribociclib 28 Day Cycles - Breast,_1. First Line,12/4/2023,Inactive,,
MMC OP VP INFUSION,77711,"Cohen, Seth D, MD",10/25/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,_1. First Line,10/24/2023,Inactive,,
MMC OP VP INFUSION,77711,"Cohen, Seth D, MD",5/12/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_2. Second Line,5/12/2025,Active,"Malignant neoplasm of urinary bladder (CMS/HCC)
End stage renal disease (CMS/HCC)
Hypothyroid coma (CMS/HCC)",
CBMC OP INFUSION 2FL,68174,"Brown, Andrew Bennett, MD",6/30/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,6/29/2023,Active,Malignant neoplasm of ascending colon (CMS/HCC),
TRMC TCCC OP INFUSION,61140,"Salerno, Vincent E, MD",6/21/2024,Trastuzumab + pembrlizumab 21 Day Cycles (Initiation) - Breast,Maintenance,6/20/2024,Active,Adenocarcinoma of small bowel (CMS/HCC),
CINJ OP INFUSION,60316,"Hochster, Howard S, MD",10/12/2023,mFOLFOX6 + Trastuzumab + Nivo 14 Day Cycles- Gastrointestinal Cancers,First Line,10/10/2023,Inactive,,
CINJ OP INFUSION,39833,"Weiss, Sarah, MD",4/17/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,4/16/2024,Inactive,,
CMC 4B ONCOLOGY,44807,"Talwar, Sumit, MD",2/21/2025,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_1. First Line,2/20/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; G93.41 - Metabolic encephalopathy; E87.20 - Acidosis, unspecified; I69.351 - Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side; R47.01 - Aphasia; D69.6 - Thrombocytopenia, unspecified; D47.2 - Monoclonal gammopathy; G20.C - Parkinsonism, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; F02.80 - Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety; D63.0 - Anemia in neoplastic disease; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; N30.01 - Acute cystitis with hematuria; N17.9 - Acute kidney failure, unspecified; T83.83XA - Hemorrhage due to genitourinary prosthetic devices, implants and grafts, initial encounter; Z79.4 - Long term (current) use of insulin; E78.5 - Hyperlipidemia, unspecified; R33.8 - Other retention of urine; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; M15.9 - Polyosteoarthritis, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; E87.5 - Hyperkalemia; E53.8 - Deficiency of other specified B group vitamins; E86.1 - Hypovolemia; E83.52 - Hypercalcemia; Z79.890 - Hormone replacement therapy; Z80.9 - Family history of malignant neoplasm, unspecified; Z79.82 - Long term (current) use of aspirin; Z87.891 - Personal history of nicotine dependenc..."
CMC OP INFUSION,44807,"Talwar, Sumit, MD",4/3/2025,Isatuximab-irfc/VRd- 42 Day Cycles- Multiple Myeloma,_1. First Line,4/3/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CMC OP INFUSION,44807,"Talwar, Sumit, MD",4/3/2025,Bortezomib / Lenalidomide / Dexamethasone/ with Isatuximab 28 Day Cycles - Multiple Myeloma,_1. First Line,4/3/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
HAM OP INFUSION,62625,"Yogarajah, Meera, MD",3/25/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,3/24/2024,Inactive,,
NBR CINJ OP INFUSION,46643,"Eltoukhy, Hussam, MD",6/2/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,First Line,5/26/2023,Inactive,,
NBR 4N BMTU/IMCU,46643,"Assal, Amer, MD",11/2/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,11/1/2023,Inactive,,
NBR 5N ONCOLOGY,46643,"Rhodes, Joanna Meehan, MD",3/9/2024,CD  (Cyclophosphamide / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,3/9/2024,Inactive,,
NBR CINJ OP INFUSION,46643,"Shah, Mansi R, MD",3/28/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,3/27/2024,Inactive,,
NBR CINJ OP INFUSION,46643,"Shah, Mansi R, MD",10/22/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,10/21/2024,Inactive,,
NBR CINJ OP INFUSION,46643,"Shah, Mansi R, MD",12/8/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,12/5/2024,Active,,
NBR 5N ONCOLOGY,46643,"Zayac, Adam, MD",12/11/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,12/11/2024,Inactive,,
CINJ OP INFUSION,43714,"Ghodoussipour, Saum Bobak, MD",8/13/2024,BCG Induction (TICE) 42 Day Cycle,Induction,8/11/2024,Inactive,,
CINJ OP INFUSION,43714,"Ghodoussipour, Saum Bobak, MD",11/19/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,11/12/2024,Active,,
NBR CINJ OP INFUSION,15697,"Tiger, Yun Kyoung, MD",12/20/2024,Polatuzumab / Obinutuzumab / Gemcitabine / Oxaliplatin - 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_2. Second Line,12/18/2024,Active,,
NBR CINJ OP INFUSION,15697,"Tiger, Yun Kyoung, MD",12/30/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,12/29/2024,Inactive,,
NBR CINJ OP INFUSION,15697,"Tiger, Yun Kyoung, MD",1/30/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,1/27/2025,Active,,
CINJ OP INFUSION,66708,"Patel, Eshan, MD",6/24/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/6/2024,Active,,
CINJ OP INFUSION,66708,"Patel, Eshan, MD",9/30/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/29/2024,Active,,
CINJ OP INFUSION,66708,"Muralikrishnan, Sivraj, MD",4/22/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,Reinduction,4/22/2025,Active,"Small cell lung carcinoma, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,85600,"Groisberg, Roman, MD",8/7/2023,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,8/7/2023,Inactive,,
CINJ OP INFUSION,85600,"Groisberg, Roman, MD",11/15/2023,DOXOrubicin Liposomal / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,11/7/2023,Inactive,,
HAM OP INFUSION,86169,"Yogarajah, Meera, MD",3/3/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/3/2025,Active,"Rectosigmoid cancer (CMS/HCC)
Screening for viral disease",
HAM OP INFUSION,86169,"Yogarajah, Meera, MD",3/3/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/3/2025,Inactive,"Rectosigmoid cancer (CMS/HCC)
Screening for viral disease","C19 - Malignant neoplasm of rectosigmoid junction; I10 - Essential (primary) hypertension; R79.1 - Abnormal coagulation profile; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.2 - Mixed hyperlipidemia; I34.0 - Nonrheumatic mitral (valve) insufficiency; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z95.2 - Presence of prosthetic heart valve; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,11129,"Saraiya, Biren P, MD",5/15/2024,Darolutamide 30 Day Cycles - Prostate,_2. Second Line,5/15/2024,Active,,
MMC OP INFUSION,64341,"Meghal, Trishala, MD",6/5/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/30/2024,Inactive,,
MMC OP VP INFUSION,64341,"Meghal, Trishala, MD",6/26/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,5/29/2024,Active,,
MMC OP INFUSION,64341,"Meghal, Trishala, MD",10/9/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,10/8/2024,Active,,
CINJ OP INFUSION,10163,"Ghodoussipour, Saum Bobak, MD",8/23/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,8/15/2024,Active,,
SOM OUTPT INFUSION,92054,"Toomey, Kathleen C, MD",2/27/2023,"NAB-PACLitaxel / CARBOplatin Day 1,8,15 q 28 day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",First Line,2/22/2023,Inactive,,
CINJ OP INFUSION,72783,"Haigentz, Missak, MD",12/4/2024,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Adjuvant,12/4/2024,Active,,
CINJ OP INFUSION,72783,"Muralikrishnan, Sivraj, MD",1/15/2025,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,1/14/2025,Active,,
CINJ OP INFUSION,72783,"Muralikrishnan, Sivraj, MD",1/15/2025,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,1/14/2025,Inactive,"Adenosquamous carcinoma (CMS/HCC)
Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)
Other fatigue",
CINJ OP INFUSION,69784,"Packiam, Vignesh, MD",11/12/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,11/11/2024,Active,,
CINJ OP INFUSION,69784,"Packiam, Vignesh, MD",1/29/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,1/28/2025,Active,,
CINJ OP INFUSION,78236,"Mayer, Tina M, MD",3/19/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,3/13/2024,Inactive,,
NBR 5N ONCOLOGY,17155,"Tiger, Yun Kyoung, MD",11/28/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,74250,"Brown, Andrew Bennett, MD",4/19/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,4/11/2024,Inactive,,
CBMC OP INFUSION 2FL,74250,"Brown, Andrew Bennett, MD",9/6/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,9/5/2024,Active,,
CINJ OP INFUSION,13142,"Boland, Patrick M, MD",4/15/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,4/15/2025,Active,"Malignant neoplasm of colon, unspecified (CMS/HCC)
Malignant neoplasm of colon (CMS/HCC)
Encounter for adjustment and management of vascular access device","C18.9 - Malignant neoplasm of colon, unspecified part of colon (CMS/HCC); C18.2 - Malignant neoplasm of ascending colon (CMS/HCC); Z45.2 - Encounter for adjustment and management of vascular access device"
MMC OP VP INFUSION,74429,"Lee, Patrick C, MD",3/30/2023,CINJ 011912 (54767414MMY3021) ARM A Daratumumab and Hyaluronidase-fihj / Lenalidomide 28 Day Cycles Research- Multiple Myeloma,Maintenance,3/29/2023,Inactive,,
MMC OP VP INFUSION,74429,"Lee, Patrick C, MD",6/8/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,6/7/2023,Active,,
CINJ OP INFUSION,21975,"Hochster, Howard S, MD",2/16/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,2/15/2023,Inactive,,
CINJ OP INFUSION,21975,"Hochster, Howard S, MD",7/26/2023,CINJ 072214 PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,Second Line,7/25/2023,Inactive,,
CINJ OP INFUSION,21975,"Hochster, Howard S, MD",9/27/2023,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,Third Line,9/26/2023,Inactive,,
CINJ OP INFUSION,21975,"Hochster, Howard S, MD",11/1/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/31/2023,Inactive,,
CINJ OP INFUSION,21975,"Hochster, Howard S, MD",11/1/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/31/2023,Inactive,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",10/18/2024,Cyclophosphamide Oral,_4. Fourth Line,10/17/2024,Active,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",10/18/2024,cytoxan / Bevacizumab / Pembrolizumab 21 Day Cycles - ovarian,_4. Fourth Line,10/17/2024,Active,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",10/18/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/17/2024,Inactive,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",10/18/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/17/2024,Inactive,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",10/18/2024,Pembrolizumab / avastin / Cyclophosphamide 21 Day Cycles - Ovarian,_4. Fourth Line,10/17/2024,Inactive,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",10/18/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,10/17/2024,Inactive,,
CINJ OP INFUSION,27417,"Stephenson, Ruth D, DO",2/14/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - HER 2+ Ovarian,_6. Sixth Line,2/11/2025,Active,"Malignant neoplasm of overlapping sites of female genital organs (CMS/HCC)
Other abnormal findings on diagnostic imaging of central nervous system",C57.8 - Malignant neoplasm of overlapping sites of female genital organs; R90.89 - Other abnormal findings on diagnostic imaging of central nervous system
CINJ OP INFUSION,10613,"Stephenson, Ryan D, DO",4/2/2024,Cabozantinib 28 Day Cycles- Kidney,_2. Second Line,4/2/2024,Inactive,,
CINJ OP INFUSION,10613,"Stephenson, Ryan D, DO",8/2/2024,Belzutifan 28 Day Cycles,_1. First Line,8/2/2024,Inactive,,
HAM OP INFUSION,16203,"Yogarajah, Meera, MD",10/19/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,10/18/2023,Inactive,,
MSC OP INFUSION,38634,"Talwar, Sumit, MD",5/14/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,5/8/2025,Active,Non-small cell cancer of right lung (CMS/HCC),
MMC OP VP INFUSION,16468,"Cohen, Seth D, MD",6/14/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/6/2024,Inactive,,
MMC OP VP INFUSION,16468,"Cohen, Seth D, MD",6/26/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/25/2024,Inactive,,
CINJ PEDS HEMONC ,19617,"Botwinick, Marissa, DO",8/9/2024,PEDS ANHL12P1 Arm BV ,_1. First Line,8/9/2024,Inactive,,
CINJ PEDS HEMONC ,19617,"Botwinick, Marissa, DO",8/21/2024,PEDS ANHL12P1 Arm BV ,_1. First Line,8/8/2024,Active,,
CINJ OP INFUSION,28533,"George, Mridula A, MD",1/10/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,1/9/2024,Inactive,,
CINJ OP INFUSION,28533,"George, Mridula A, MD",4/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/25/2024,Active,,
NBR CINJ OP INFUSION,4002,"Matasar, Matthew J, MD",5/6/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_4. Fourth Line,5/6/2025,Active,Chronic lymphocytic leukemia of B-cell type in relapse (CMS/HCC),"C83.08 - Small cell b-cell lymphoma, lymph nodes of multiple sites; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; D72.0 - Genetic anomalies of leukocytes; C91.12 - Chronic lymphocytic leukemia of B-cell type in relapse"
NBR CINJ OP INFUSION,93046,"Evens, Andrew M, DO",6/7/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,Second Line,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,93046,"Evens, Andrew M, DO",11/15/2023,Obinutuzumab 28 Day Cycles - Low Grade Indolent Lymphoma ,_3. Third Line,11/14/2023,Inactive,,
NBR CINJ OP INFUSION,93046,"Evens, Andrew M, DO",11/15/2023,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_3. Third Line,11/15/2023,Active,,
CBMC OP INFUSION 2FL,97448,"Brown, Andrew Bennett, MD",2/28/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/20/2024,Inactive,,
JCMC CP INFUSION,97448,"Brown, Andrew Bennett, MD",7/17/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,7/17/2024,Inactive,,
JCMC CP INFUSION,97448,"Sekhri, Arunabh, MD",7/22/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,7/21/2024,Inactive,,
CINJ OP INFUSION,83811,"Hochster, Howard S, MD",11/6/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/3/2024,Active,,
CINJ OP INFUSION,78363,"Hochster, Howard S, MD",5/1/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,5/1/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),"C18.7 - Malignant neoplasm of sigmoid colon; R73.9 - Hyperglycemia, unspecified; E83.42 - Hypomagnesemia; Z90.49 - Acquired absence of other specified parts of digestive tract"
CINJ OP INFUSION,10898,"Weiss, Sarah, MD",7/1/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,6/30/2024,Active,,
CINJ OP INFUSION,20666,"Weiss, Sarah, MD",1/13/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,12/8/2024,Active,,
MSC OP INFUSION,39872,"Cohen, Seth D, MD",5/28/2025,CISplatin 75 mg/m2 / Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Cancers,_1. First Line,5/28/2025,Active,Malignant neoplasm of lower lobe of right lung (CMS/HCC),
CINJ OP INFUSION,10609,"Haigentz, Missak, MD",8/16/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,8/8/2023,Inactive,,
CINJ OP INFUSION,10609,"Haigentz, Missak, MD",11/8/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/31/2023,Inactive,,
CINJ OP INFUSION,10609,"Haigentz, Missak, MD",2/19/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer (Postoperative),Adjuvant,2/18/2024,Inactive,,
SOM OUTPT INFUSION,29541,"Toomey, Kathleen C, MD",2/9/2023,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,2/1/2023,Inactive,,
SOM OUTPT INFUSION,29541,"Toomey, Kathleen C, MD",10/5/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/4/2023,Inactive,,
SOM OUTPT INFUSION,29541,"Toomey, Kathleen C, MD",10/5/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/4/2023,Inactive,,
SOM OUTPT INFUSION,29541,"Toomey, Kathleen C, MD",2/9/2024,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,2/7/2024,Inactive,,
CINJ OP INFUSION,93299,"Aikins, James K, MD",9/14/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,9/13/2023,Inactive,,
CINJ PEDS HEMONC ,4409,"Moerdler, Scott, MD",4/15/2024,Selumetinib (Koselugo),_2. Second Line,4/14/2024,Active,Primary malignant neoplasm of right kidney with metastasis from kidney to other site (CMS/HCC),
CBMC 2W ONCOLOGY,10686,"Brown, Andrew Bennett, MD",5/1/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Breast,_1. First Line,5/1/2024,Inactive,"Breast cancer metastasized to central nervous system, right (CMS/HCC)",
CBMC OP INFUSION 2FL,10686,"Litvak, Anna M, MD",1/15/2025,Sacituzumab Govitecan 21 Day Cycles - Breast ,_2. Second Line,1/8/2025,Active,Malignant neoplasm metastatic to both lungs (CMS/HCC),
CBMC OP INFUSION 2FL,45086,"Litvak, Anna M, MD",4/22/2025,Olaparib 30 Day Cycles - Breast,_1. First Line,4/22/2025,Inactive,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,50836,"Gulhati, Prateek, MD PhD",4/20/2023,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,,4/19/2023,Inactive,,
CINJ OP INFUSION,50836,"Gulhati, Prateek, MD PhD",11/16/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_5. Fifth Line,11/16/2023,Inactive,,
NBR 5N ONCOLOGY,6194,"Mayer, Tina M, MD",3/6/2025,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,3/6/2025,Active,High grade neuroendocrine carcinoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C7A.1 - Malignant poorly differentiated neuroendocrine tumors; C7B.8 - Other secondary neuroendocrine tumors; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; Z53.20 - Procedure and treatment not carried out because of patient's decision for unspecified reasons; K21.9 - Gastro-esophageal reflux disease without esophagitis; G89.29 - Other chronic pain; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z92.21 - Personal history of antineoplastic chemotherapy; Z88.5 - Allergy status to narcotic agent"
CINJ OP INFUSION,69111,"Mayer, Tina M, MD",9/18/2023,Enzalutamide 28 Day Cycles - Prostate,,9/18/2023,Active,,
NBR CINJ OP INFUSION,47262,"Girda, Eugenia, MD",5/2/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,5/2/2023,Active,,
CINJ OP INFUSION,91227,"Toppmeyer, Deborah L, MD",4/11/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",Adjuvant,4/10/2023,Inactive,,
NBR CINJ OP INFUSION,90474,"Palmisiano, Neil David, MD",8/22/2023,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,,8/20/2023,Inactive,,
NBR CINJ OP INFUSION,90474,"Palmisiano, Neil David, MD",2/7/2024,Alemtuzumab 28 Day Cycle - refractory aplastic anemia,_2. Second Line,2/5/2024,Active,,
CMMC OP INFUSION,16352,"Freeman, Benjamin B, MD",5/20/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/20/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of inguinal region (CMS/HCC),"C83.35 - Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb; D70.4 - Cyclic neutropenia"
CINJ OP INFUSION,1711,"Toppmeyer, Deborah L, MD",1/12/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Second Line,1/12/2023,Inactive,,
NBR CINJ OP INFUSION,26085,"Evens, Andrew M, DO",1/24/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,1/24/2024,Inactive,,
NBR CINJ OP INFUSION,26085,"Evens, Andrew M, DO",4/10/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,4/9/2024,Active,Primary angiosarcoma of heart (CMS/HCC),
CINJ OP INFUSION,31944,"Packiam, Vignesh, MD",12/3/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,12/2/2024,Active,,
CINJ OP INFUSION,89941,"Packiam, Vignesh, MD",4/22/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,4/22/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
MMC OP VP INFUSION,13490,"Cohen, Seth D, MD",11/6/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/6/2024,Active,,
MMC OP VP INFUSION,13490,"Cohen, Seth D, MD",11/18/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/10/2024,Active,,
SOM OUTPT INFUSION,85269,"Patel, Eshan, MD",11/5/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/29/2024,Active,,
CINJ OP INFUSION,7930,"Gulhati, Prateek, MD PhD",10/17/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/16/2024,Active,,
CINJ OP INFUSION,7930,"Gulhati, Prateek, MD PhD",3/6/2025,"Encorafenib + Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/6/2025,Inactive,Malignant neoplasm of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CMC OP INFUSION,1432,"Taff, Jessica, MD",12/4/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/1/2023,Inactive,,
HAM OP INFUSION,13493,"Yogarajah, Meera, MD",8/15/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,First Line,8/14/2023,Inactive,,
HAM OP INFUSION,13493,"Yogarajah, Meera, MD",8/21/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,First Line,8/16/2023,Inactive,,
CMC OP INFUSION,33264,"Talwar, Sumit, MD",3/21/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/13/2024,Active,,
CINJ OP INFUSION,97938,"Aikins, James K, MD",3/22/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/19/2024,Inactive,,
CINJ OP INFUSION,97938,"Aikins, James K, MD",6/18/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,6/17/2024,Active,,
NBR 5N ONCOLOGY,97938,"Girda, Eugenia, MD",7/9/2024,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/9/2024,Inactive,,
CINJ OP INFUSION,97938,"Aikins, James K, MD",2/20/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,2/19/2025,Active,"Malignant neoplasm of female genital organ (CMS/HCC)
Malignant ascites","C57.9 - Malignant neoplasm of female genital organ, unspecified; D69.6 - Thrombocytopenia, unspecified; R11.0 - Nausea; G60.9 - Hereditary and idiopathic neuropathy, unspecified; Z51.12 - Encounter for antineoplastic immunotherapy; R30.0 - Dysuria; C56.2 - Malignant neoplasm of left ovary; R18.0 - Malignant ascites"
CINJ OP INFUSION,97938,"Aikins, James K, MD",5/29/2025,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,5/10/2025,Active,"Malignant neoplasm of female genital organ (CMS/HCC)
Malignant ascites","C57.7 - Malignant neoplasm of other specified female genital organs; Z00.00 - Encounter for general adult medical examination without abnormal findings; C56.2 - Malignant neoplasm of left ovary; C57.9 - Malignant neoplasm of female genital organ, unspecified; R18.0 - Malignant ascites"
CINJ OP INFUSION,97938,"Aikins, James K, MD",4/24/2025,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/24/2025,Inactive,"Malignant neoplasm of female genital organ (CMS/HCC)
Malignant ascites","C57.7 - Malignant neoplasm of other specified female genital organs; Z00.00 - Encounter for general adult medical examination without abnormal findings; C56.2 - Malignant neoplasm of left ovary; C57.9 - Malignant neoplasm of female genital organ, unspecified; R18.0 - Malignant ascites"
NBR CINJ OP INFUSION,40939,"Evens, Andrew M, DO",3/15/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,,3/14/2023,Inactive,,
CINJ OP INFUSION,94495,"Stephenson, Ruth D, DO",12/6/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,12/3/2024,Active,,
CINJ OP INFUSION,25725,"Hochster, Howard S, MD",9/20/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Maintenance,9/19/2024,Active,,
CINJ OP INFUSION,6796,"Boland, Patrick M, MD",12/9/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,12/2/2024,Active,,
CINJ OP INFUSION,12832,"Girda, Eugenia, MD",3/14/2023,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Third Line,2/13/2023,Inactive,,
CINJ OP INFUSION,12832,"Girda, Eugenia, MD",8/4/2023,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",Third Line,8/2/2023,Inactive,,
NBR CINJ OP INFUSION,70865,"Tiger, Yun Kyoung, MD",1/26/2024,CINJ 012203 Lead-In Treatment for Fit and Non-Fit Treatments Cycle 42 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,1/22/2024,Inactive,,
NBR CINJ OP INFUSION,85499,"Tiger, Yun Kyoung, MD",4/9/2025,Nivo miniAVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_2. Second Line,4/9/2025,Active,"Nodular sclerosing Hodgkin's lymphoma (CMS/HCC)
Acquired hypothyroidism",
NBR CINJ OP INFUSION,79174,"Palmisiano, Neil David, MD",1/10/2023,Midostaurin 28 Day Cycles - AML maintenance,,1/10/2023,Inactive,,
SOM OUTPT INFUSION,81397,"Yin, Faye, MD",4/27/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,4/19/2023,Inactive,,
NBR 4N BMTU/IMCU,83543,"Schaar, Dale, MD PhD",6/15/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/15/2023,Inactive,,
NBR CINJ OP INFUSION,83543,"Schaar, Dale, MD PhD",1/9/2024,Decitabine (5 day) 56 Day Cycles - Post transplant,_1. First Line,11/30/2023,Active,,
CMC OP INFUSION,80181,"Cohen, Seth D, MD",7/26/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,First Line,7/26/2023,Inactive,,
MMC OP VP INFUSION,80181,"Cohen, Seth D, MD",7/26/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,,7/26/2023,Active,"Carcinoma of breast, ER+ and PR+, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,67987,"Gulhati, Prateek, MD PhD",2/22/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,2/20/2024,Inactive,,
CINJ OP INFUSION,67987,"Gulhati, Prateek, MD PhD",9/9/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Induction,9/9/2024,Inactive,,
CINJ OP INFUSION,67987,"Gulhati, Prateek, MD PhD",9/14/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/13/2024,Inactive,,
CINJ OP INFUSION,60408,"Toppmeyer, Deborah L, MD",1/4/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/2/2024,Inactive,,
CINJ OP INFUSION,60408,"Toppmeyer, Deborah L, MD",5/23/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/22/2024,Active,,
CINJ OP INFUSION,16932,"Boland, Patrick M, MD",9/29/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,9/28/2023,Inactive,,
MMC OP VP INFUSION,61523,"Cohen, Seth D, MD",1/30/2024,Olaparib 30 Day Cycles - Breast,_1. First Line,1/30/2024,Inactive,,
MMC OP VP INFUSION,61523,"Cohen, Seth D, MD",4/18/2024,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,4/18/2024,Inactive,,
MMC OP VP INFUSION,61523,"Cohen, Seth D, MD",9/5/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,9/4/2024,Active,,
NBR 5N MED-SURG OVRF,87877,"Alexander, Henry Richard, MD",12/2/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,12/2/2024,Active,,
CINJ OP INFUSION,38650,"Jang, Thomas L, MD",2/22/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) - Bladder Cancer,_1. First Line,2/13/2024,Inactive,,
CINJ OP INFUSION,38650,"Jang, Thomas L, MD",5/31/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,5/22/2024,Active,,
CBMC OP INFUSION 2FL,10762,"Derosa, William T, DO",10/30/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,10/18/2024,Active,,
MMC OP VP INFUSION,28850,"Cohen, Seth D, MD",6/12/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,6/6/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Metastasis to lymph nodes (CMS/HCC)",
CBMC OP INFUSION 2FL,31098,"Raptis, George, MD",1/3/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/2/2025,Active,"Malignant neoplasm of upper gum (CMS/HCC)
Other diseases of tongue
Encounter for screening for other viral diseases",
SOM OUTPT INFUSION,88438,"Patel, Eshan, MD",1/13/2025,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,1/12/2025,Active,,
SOM OUTPT INFUSION,88438,"Patel, Eshan, MD",2/18/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,2/17/2025,Active,Malignant neoplasm of trigone of bladder (CMS/HCC),
SOM OUTPT INFUSION,88438,"Patel, Eshan, MD",3/6/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,2/18/2025,Active,Malignant neoplasm of trigone of bladder (CMS/HCC),C67.0 - Malignant neoplasm of trigone of bladder
SOM OUTPT INFUSION,48158,"Patel, Eshan, MD",7/2/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,7/1/2024,Inactive,,
SOM OUTPT INFUSION,48158,"Patel, Eshan, MD",11/21/2024,Nivolumab 28 Day Cycles - Kidney or Bladder,Maintenance,11/19/2024,Active,,
CMC OP INFUSION,14599,"Eltoukhy, Hussam, MD",4/24/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,First Line,4/24/2023,Active,,
CINJ OP INFUSION,41078,"Mayer, Tina M, MD",6/7/2023,Apalutamide 30 Day Cycles - Prostate,,6/7/2023,Inactive,,
CINJ OP INFUSION,24040,"Packiam, Vignesh, MD",9/23/2024,BCG Induction (TICE) 42 Day Cycle,Adjuvant,9/22/2024,Inactive,,
CINJ OP INFUSION,72857,"Packiam, Vignesh, MD",3/10/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,3/10/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CBMC OP INFUSION 2FL,65775,"Leitner, Stuart P, MD",11/22/2023,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,11/22/2023,Active,,
NBR CINJ OP INFUSION,94788,"Matasar, Matthew J, MD",11/26/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,11/25/2024,Active,,
MMC OP VP INFUSION,98271,"Lee, Patrick C, MD",7/1/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,6/30/2024,Active,,
CBMC OP INFUSION 2FL,32433,"Brown, Andrew Bennett, MD",4/22/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/7/2024,Active,,
CBMC OP INFUSION 2FL,32433,"Brown, Andrew Bennett, MD",11/11/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/3/2024,Inactive,,
CBMC OP INFUSION 2FL,32433,"Brown, Andrew Bennett, MD",11/11/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/3/2024,Active,,
CBMC OP INFUSION 2FL,32433,"Brown, Andrew Bennett, MD",4/10/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,4/10/2025,Active,"Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Drug-induced thyroiditis
Seizure-like activity (CMS/HCC)","C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; E06.4 - Drug-induced thyroiditis; M04.9 - Autoinflammatory syndrome, unspecified; R56.9 - Unspecified convulsions; Z72.89 - Other problems related to lifestyle"
MMC OP VP INFUSION,78209,"Cohen, Seth D, MD",6/28/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Second Line,6/27/2023,Inactive,,
SOM OUTPT INFUSION,20719,"Patel, Eshan, MD",5/20/2024,Pembrolizumab/Gemcitabine / CISplatin (1000/35) 21 Day Cycles,Neoadjuvant,4/28/2024,Inactive,,
SOM OUTPT INFUSION,20719,"Patel, Eshan, MD",11/29/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/17/2024,Active,,
HAM OP INFUSION,25054,"Yogarajah, Meera, MD",5/16/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/15/2024,Active,,
CBMC OP INFUSION 2FL,37523,"Brown, Andrew Bennett, MD",11/13/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Induction,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,37523,"Brown, Andrew Bennett, MD",11/15/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Induction,11/12/2023,Inactive,,
CMC OP INFUSION,64263,"Talwar, Sumit, MD",6/1/2023,Pembrolizumab 21 Day Cycles - Uterine,Second Line,5/19/2023,Inactive,,
CINJ OP INFUSION,85652,"George, Mridula A, MD",4/5/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,4/5/2024,Inactive,,
NBR 5N ONCOLOGY,48426,"Palmisiano, Neil David, MD",4/18/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,4/17/2024,Inactive,,
CINJ OP INFUSION,49847,"Saraiya, Biren P, MD",1/10/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,,1/9/2023,Inactive,,
CBMC OP INFUSION 2FL,6414,"Niranjan, Usha, MD",9/23/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,9/9/2024,Inactive,,
CBMC OP INFUSION 2FL,6414,"McKenna, Marshall, MD",11/18/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/17/2024,Active,,
CBMC OP INFUSION 2FL,56621,"Derosa, William T, DO",5/21/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,5/21/2025,Active,"Melanoma metastatic to lymph node (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)",
NBR CINJ OP INFUSION,86466,"Shah, Mansi R, MD",1/9/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,12/30/2024,Active,,
NBR CINJ OP INFUSION,86466,"Shah, Mansi R, MD",4/24/2025,"Bortezomib D1, D15 Maintenance 28 Day Cycles- Multiple Myeloma",_1. First Line,4/3/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
CINJ OP INFUSION,33238,"Ghodoussipour, Saum Bobak, MD",7/21/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,7/21/2023,Inactive,,
NBR CINJ OP INFUSION,21035,"Rhodes, Joanna Meehan, MD",12/23/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_2. Second Line,12/22/2024,Active,Gastroesophageal cancer (CMS/HCC),
MMC OP VP INFUSION,74749,"Cohen, Seth D, MD",9/30/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,9/29/2024,Active,,
MMC OP VP INFUSION,42705,"Lee, Patrick C, MD",10/24/2024,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,10/16/2024,Inactive,,
MMC OP VP INFUSION,42705,"Lee, Patrick C, MD",12/12/2024,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,12/11/2024,Inactive,,
CINJ OP INFUSION,3544,"Boland, Patrick M, MD",3/7/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",,2/6/2023,Inactive,,
CINJ OP INFUSION,8407,"Goel, Sanjay, MD",8/6/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 A Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_4. Fourth Line,7/15/2024,Active,,
CINJ OP INFUSION,53027,"Stephenson, Ruth D, DO",11/20/2023,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,_1. First Line,11/20/2023,Inactive,,
CINJ OP INFUSION,53027,"Stephenson, Ruth D, DO",5/2/2024,Trastuzumab 21 Day Cycles (Continuation) Endometrial Cancer HER2,Maintenance,4/30/2024,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),
CINJ OP INFUSION,79641,"Saraiya, Biren P, MD",9/25/2024,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_1. First Line,8/29/2024,Active,,
CINJ OP INFUSION,92200,"Haigentz, Missak, MD",3/10/2023,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,Second Line,3/10/2023,Inactive,,
CINJ OP INFUSION,92200,"Haigentz, Missak, MD",12/13/2024,Lorlatinib 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/13/2024,Active,,
CINJ OP INFUSION,7353,"Haigentz, Missak, MD",4/8/2025,"PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles, C1 with Radiotherapy, C2 without RT - Non-Small Cell Lung Cancer",Induction,4/8/2025,Active,"Malignant neoplasm of lower lobe, left bronchus or lung (CMS/HCC)","C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; R05.9 - Cough, unspecified; E89.0 - Postprocedural hypothyroidism; R50.9 - Fever, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z20.822 - Contact with and (suspected) exposure to covid-19; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z79.891 - Long term (current) use of opiate analgesic; Z79.52 - Long term (current) use of systemic steroids; Z79.890 - Hormone replacement therapy"
SOM OUTPT INFUSION,67835,"Patel, Eshan, MD",11/21/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,11/20/2023,Inactive,,
JCMC CP INFUSION,93403,"Cruz, Allan Louie E, MD",6/19/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,6/18/2024,Inactive,,
CINJ OP INFUSION,6707,"Goel, Sanjay, MD",10/11/2023,CINJ 052304 Cohort A Dose Escalation ABM-168 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,10/10/2023,Inactive,,
SOM OUTPT INFUSION,32859,"Patel, Eshan, MD",6/28/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Maintenance,6/21/2023,Inactive,,
SOM OUTPT INFUSION,32859,"Patel, Eshan, MD",3/6/2024,"5 fu, irinotecan  + Bevacizumab (Fluorouracil Continuous Infusion/Irinotecan) 21 Day Cycles- Gastrointestinal Cancers",_3. Third Line,3/5/2024,Active,,
HAM OP INFUSION,86030,"Yogarajah, Meera, MD",6/17/2024,"DOCETAXEL / DAROLUTAMIDE, 21 DAY CYCLES - PROSTATE CANCER",_1. First Line,5/31/2024,Active,,
MMC OP INFUSION,61378,"Meghal, Trishala, MD",11/15/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,11/7/2024,Active,"Clear cell renal cell carcinoma, left (CMS/HCC)
Other fatigue
Disorder of thyroid",
MMC OP INFUSION,61378,"Meghal, Trishala, MD",2/21/2025,"PACLitaxel D1, D8 21 Day Cycles - Breast",_5. Fifth Line,2/19/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,33002,"Dasgeb, Bahar, MD",6/2/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,5/29/2023,Active,,
EMH HEM ONC,69921,"Toomey, Kathleen C, MD",11/7/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/5/2024,Active,,
SOM OUTPT INFUSION,81473,"Patel, Eshan, MD",2/10/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,_1. First Line,2/7/2025,Active,Breast cancer (CMS/HCC),C50.111 - Malignant neoplasm of central portion of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
SOM OUTPT INFUSION,81473,"Patel, Eshan, MD",4/7/2025,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,4/7/2025,Active,Breast cancer (CMS/HCC),
CINJ PEDS HEMONC ,85281,"Moerdler, Scott, MD",4/1/2025,as per ARST2031 Regimen A (VAC + VINO-C Maintenance),_1. First Line,3/31/2025,Active,Rhabdomyosarcoma (CMS/HCC),
CBMC OP INFUSION 2FL,9285,"Chowaniec, Wayne B, NP",8/28/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,8/27/2023,Inactive,,
CBMC OP INFUSION 2FL,9285,"Grossman, I Robert, MD",10/30/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,9285,"Grossman, I Robert, MD",10/31/2023,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,10/29/2023,Inactive,,
CBMC 2W ONCOLOGY,9285,"Grossman, I Robert, MD",11/6/2023,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_2. Second Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,9285,"Grossman, I Robert, MD",5/23/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,Consolidation,5/21/2024,Inactive,,
CBMC 2W ONCOLOGY,9285,"Grossman, I Robert, MD",8/15/2024,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,8/15/2024,Inactive,,
CINJ OP INFUSION,37560,"George, Mridula A, MD",3/24/2023,Palbociclib 28 Day Cycles - Breast,First Line,3/24/2023,Inactive,,
CINJ OP INFUSION,37560,"George, Mridula A, MD",12/20/2024,Elacestrant 28 Day Cycles - Breast,_2. Second Line,12/20/2024,Active,,
CINJ OP INFUSION,37560,"George, Mridula A, MD",5/28/2025,Capivasertib 28 Day Cycles - Breast,_3. Third Line,5/28/2025,Active,Malignant neoplasm metastatic to bone (CMS/HCC),
HAM OP INFUSION,80331,"Yogarajah, Meera, MD",8/19/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,_5. Fifth Line,8/11/2024,Active,,
SOM OUTPT INFUSION,17352,"Patel, Eshan, MD",4/2/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/2/2025,Inactive,Pancreatic adenocarcinoma (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified"
SOM OUTPT INFUSION,92950,"Toomey, Kathleen C, MD",7/28/2023,Pembrolizumab 21 Day Cycles - Uterine,First Line,7/27/2023,Inactive,,
CINJ OP INFUSION,92950,"Stephenson, Ruth D, DO",5/17/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles with dostalamab for recurrent dMMR endometrial cancer,Adjuvant,5/16/2024,Inactive,,
SOM OUTPT INFUSION,92950,"Toomey, Kathleen C, MD",5/17/2024,PACLitaxel / CARBOplatin 21 Day Cycles -  weekly Carboplatin AUC2/Taxol 60 mg (MITO 7 protocol),Maintenance,4/11/2024,Inactive,,
MMC OP VP INFUSION,84724,"Cohen, Seth D, MD",10/11/2023,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/11/2023,Active,,
HAM OP INFUSION,84578,"Patel, Malini M, MD",5/21/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/21/2025,Inactive,"Esophageal cancer, stage IV (CMS/HCC)",
CINJ OP INFUSION,77850,"Toppmeyer, Deborah L, MD",3/23/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,First Line,3/22/2023,Inactive,,
HAM OP INFUSION,72449,"Gendy, Mina, DO",5/1/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/1/2025,Active,"Malignant neoplasm of lateral wall of bladder (CMS/HCC)
Bladder cancer (CMS/HCC)","C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; C79.11 - Secondary malignant neoplasm of bladder; I10 - Essential (primary) hypertension; E03.9 - Hypothyroidism, unspecified; Z90.5 - Acquired absence of kidney; Z79.890 - Hormone replacement therapy; Z79.899 - Other long term (current) drug therapy"
HAM OP INFUSION,72449,"Gendy, Mina, DO",3/20/2025,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",Adjuvant,3/11/2025,Inactive,"Malignant neoplasm of lateral wall of bladder (CMS/HCC)
Bladder cancer (CMS/HCC)","C64.9 - Malignant neoplasm of kidney, unspecified laterality (CMS/HCC); C67.9 - Malignant neoplasm of urinary bladder, unspecified site (CMS/HCC)"
CMC OP INFUSION,33647,"Talwar, Sumit, MD",3/31/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/31/2025,Active,Metastatic colon cancer to liver (CMS/HCC),
CINJ OP INFUSION,82766,"Saraiya, Biren P, MD",2/13/2023,Relugolix 30 day Cycles - Prostate,First Line,2/13/2023,Inactive,,
CINJ OP INFUSION,53651,"Berim, Lyudmyla, MD",3/25/2024,Nivolumab 360mg and Capecitabine,_1. First Line,3/21/2024,Inactive,,
CINJ OP INFUSION,53651,"Berim, Lyudmyla, MD",9/23/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/23/2024,Inactive,,
CINJ OP INFUSION,53651,"Berim, Lyudmyla, MD",10/16/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/15/2024,Active,,
CINJ OP INFUSION,44221,"Berim, Lyudmyla, MD",3/31/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,3/31/2025,Active,Esophageal adenocarcinoma (CMS/HCC),C15.9 - Esophageal adenocarcinoma (CMS/HCC)
CINJ OP INFUSION,48408,"Stephenson, Ryan D, DO",4/29/2024,CINJ 082003 (NRG-GU008) ARM 1 GNRH Agonist or Antagonist Therapy 84 Day Cycles Research- Prostate Cancer,Adjuvant,4/28/2024,Active,,
CINJ OP INFUSION,6431,"Haigentz, Missak, MD",7/26/2023,Tucatinib / Trastuzumab 21 Day Cycles- HER2 amp cancer,,7/26/2023,Inactive,,
CINJ OP INFUSION,6431,"Haigentz, Missak, MD",8/16/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - HER2 amp Salivary Ductal Carcinoma,_3. Third Line,8/15/2023,Active,,
CINJ OP INFUSION,84179,"Patankar, Sonali, MD",5/2/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/2/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),Z48.817 - Encounter for surgical aftercare following surgery on the skin and subcutaneous tissue; C56.3 - Malignant neoplasm of bilateral ovaries
CINJ OP INFUSION,16026,"Omene, Coral Oghenerukevwe, MD",5/5/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,5/1/2023,Inactive,,
CINJ OP INFUSION,7148,"George, Mridula A, MD",9/29/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,9/29/2023,Inactive,,
CINJ PEDS HEMONC ,58145,"Botwinick, Marissa, DO",4/12/2024,"PEDS AALL1331 Blocks 1,2,3",_2. Second Line,4/12/2024,Inactive,,
CINJ PEDS HEMONC ,58145,"Botwinick, Marissa, DO",7/2/2024,PEDS AALL1331 Blinatumomab,_2. Second Line,6/27/2024,Inactive,,
CINJ PEDS HEMONC ,58145,"Botwinick, Marissa, DO",8/5/2024,PEDS AALL1331 Continuation ,_1. First Line,8/5/2024,Inactive,,
CINJ PEDS HEMONC ,58145,"Botwinick, Marissa, DO",10/22/2024,PEDS AALL1331 Blinatumomab   CYCLE 2,_2. Second Line,9/30/2024,Inactive,,
CINJ PEDS HEMONC ,58145,"Botwinick, Marissa, DO",12/2/2024,PEDS AALL1331 Continuation ,_2. Second Line,12/2/2024,Active,,
CINJ PEDS HEMONC ,58145,"Botwinick, Marissa, DO",2/18/2025,PEDS AALL1331 Blinatumomab,_2. Second Line,2/10/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),"C91.01 - Acute lymphoblastic leukemia, in remission"
CINJ PEDS HEMONC ,77906,"Botwinick, Marissa, DO",3/25/2025,AALL1331 Arm D  LR Maintenance,_2. Second Line,3/24/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),
CBMC OP INFUSION 2FL,26441,"Leitner, Stuart P, MD",6/4/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,5/15/2024,Active,,
HAM OP INFUSION,11149,"Yogarajah, Meera, MD",6/9/2024,VIP- germ cell tumor,_1. First Line,6/9/2024,Active,Multiple myeloma (CMS/HCC),
EMH HEM ONC,45782,"Yin, Faye, MD",1/4/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,1/3/2023,Inactive,,
SOM OUTPT INFUSION,45782,"Yin, Faye, MD",1/4/2023,RiTUXimab Initial Infusion Single dose,First Line,1/4/2023,Inactive,,
CBMC OP INFUSION 2FL,81624,"Scoppetuolo, Michael, MD",2/19/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,2/4/2024,Inactive,,
CINJ OP INFUSION,71143,"Patankar, Sonali, MD",12/5/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,11/20/2024,Active,,
CINJ OP INFUSION,71143,"Patankar, Sonali, MD",2/25/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/23/2025,Active,Carcinosarcoma of uterus (CMS/HCC),"C55 - Malignant neoplasm of uterus, part unspecified; G62.9 - Polyneuropathy, unspecified; M79.2 - Neuralgia and neuritis, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); N89.8 - Other specified noninflammatory disorders of vagina; R53.81 - Other malaise; Z51.5 - Encounter for palliative care; Z71.89 - Other specified counseling"
CINJ OP INFUSION,1216,"Saraiya, Biren P, MD",1/22/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Adjuvant,1/13/2024,Inactive,,
CINJ OP INFUSION,1081,"Haigentz, Missak, MD",6/8/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,6/6/2023,Inactive,,
CINJ OP INFUSION,1081,"Haigentz, Missak, MD",9/12/2023,CINJ 032209 PART 8 Dose 5.1 Maintenance Tarlatamab Q2W Plus Durvalumab,Maintenance,9/12/2023,Active,,
CINJ OP INFUSION,53422,"Stephenson, Ryan D, DO",3/1/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,2/28/2023,Inactive,,
JCMC CP INFUSION,73552,"Cruz, Allan Louie E, MD",11/13/2023,CINJ 032111 (EA3161) ARMS A and B CISplatin with Concurrent Radiation 7 Day Cycles Research- Oropharyngeal Carcinoma,_1. First Line,11/7/2023,Inactive,,
JCMC CP INFUSION,73552,"Cruz, Allan Louie E, MD",2/6/2024,CINJ 032111 (EA3161) ARM A Maintenance Nivolumab 480 mg 28 Day Cycles Research- Oropharyngeal Carcinoma,Adjuvant,1/22/2024,Active,,
MMC OP VP INFUSION,87488,"Lee, Patrick C, MD",3/2/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,3/1/2023,Inactive,,
MMC OP VP INFUSION,87488,"Lee, Patrick C, MD",6/22/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,6/21/2023,Inactive,,
CBMC OP INFUSION 2FL,82040,"Brown, Andrew Bennett, MD",12/20/2023,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Induction,12/17/2023,Inactive,,
CBMC OP INFUSION 2FL,82040,"Brown, Andrew Bennett, MD",3/11/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,3/10/2024,Inactive,,
NBR 5N ONCOLOGY,53339,"Stephenson, Ryan D, DO",11/8/2023,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_3. Third Line,11/6/2023,Inactive,,
MMC OP VP INFUSION,45620,"Cohen, Seth D, MD",6/15/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,6/14/2023,Inactive,,
MMC OP VP INFUSION,45620,"Cohen, Seth D, MD",9/11/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,8/20/2024,Active,,
CINJ OP INFUSION,13094,"Stephenson, Ruth D, DO",8/17/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/17/2023,Inactive,,
CINJ OP INFUSION,13094,"Stephenson, Ruth D, DO",10/16/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,10/15/2024,Inactive,,
CINJ OP INFUSION,13094,"Stephenson, Ruth D, DO",10/17/2024,Liposomal DOXOrubicin/carboplatin/Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/15/2024,Active,,
CINJ OP INFUSION,18542,"Haigentz, Missak, MD",12/8/2023,CISplatin/DOCEtaxel 21 Day Cycles- Head and Neck Cancers,Neoadjuvant,12/7/2023,Inactive,,
CINJ OP INFUSION,18542,"Haigentz, Missak, MD",3/11/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,3/11/2024,Inactive,,
MMC OP VP INFUSION,62739,"Lee, Patrick C, MD",4/18/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/18/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of head (CMS/HCC),
NBR CINJ OP INFUSION,14548,"Evens, Andrew M, DO",9/6/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,9/5/2023,Inactive,,
NBR CINJ OP INFUSION,14548,"Evens, Andrew M, DO",9/6/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,9/5/2023,Inactive,,
CBMC OP INFUSION 2FL,63024,"Raptis, George, MD",8/7/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/6/2024,Inactive,,
CBMC OP INFUSION 2FL,63024,"Raptis, George, MD",8/14/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/13/2024,Inactive,,
CBMC OP INFUSION 2FL,63024,"Raptis, George, MD",8/14/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/13/2024,Inactive,,
CBMC OP INFUSION 2FL,63024,"Raptis, George, MD",12/11/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,12/2/2024,Active,,
CBMC OP INFUSION 2FL,63024,"Raptis, George, MD",2/14/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,2/13/2025,Active,Breast CA (CMS/HCC),
CBMC OP INFUSION 2FL,54844,"Derosa, William T, DO",11/6/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,10/21/2024,Active,,
SOM OUTPT INFUSION,82703,"Toomey, Kathleen C, MD",4/23/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,4/23/2024,Inactive,,
SOM OUTPT INFUSION,82703,"Toomey, Kathleen C, MD",10/15/2024,Elacestrant 28 Day Cycles - Breast,_2. Second Line,10/15/2024,Inactive,,
JCMC CP INFUSION,84903,"Sekhri, Arunabh, MD",6/17/2024,Durvalumab maintenance - cholangiocarcinoma,_1. First Line,5/5/2024,Active,,
CBMC OP INFUSION 2FL,35819,"Brown, Andrew Bennett, MD",2/14/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,2/1/2024,Inactive,,
NBR CINJ OP INFUSION,76735,"Evens, Andrew M, DO",8/2/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,8/2/2023,Inactive,,
NBR CINJ OP INFUSION,76735,"Evens, Andrew M, DO",10/18/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,10/17/2023,Active,Dedifferentiated chondrosarcoma (CMS/HCC),
CMC OP INFUSION,62014,"Pompa, Tiffany Ann, MD",11/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/23/2024,Active,,
CINJ OP INFUSION,87377,"Goel, Sanjay, MD",2/6/2024,CINJ 052214 Single Agent Part 2A and 2B XTX202 21 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,2/6/2024,Inactive,,
CINJ OP INFUSION,87377,"Goel, Sanjay, MD",7/18/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,7/18/2024,Active,,
CINJ OP INFUSION,87377,"Goel, Sanjay, MD",7/18/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,7/18/2024,Inactive,,
CINJ OP INFUSION,17560,"Berim, Lyudmyla, MD",10/17/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,10/13/2024,Active,,
CBMC OP INFUSION 2FL,61418,"Raptis, George, MD",4/30/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_1. First Line,4/25/2024,Active,,
MMC OP INFUSION,90864,"Lee, Patrick C, MD",5/26/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,,5/25/2023,Inactive,,
MMC OP INFUSION,90864,"Eltoukhy, Hussam, MD",6/19/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,First Line,6/18/2023,Inactive,,
NBR 4N ONCOLOGY,90864,"Braunschweig, Ira, MD",12/6/2023,BMT Autologous Melphalan Day -1 140MG/M2,_2. Second Line,12/4/2023,Inactive,,
NBR 4N ONCOLOGY,90864,"Braunschweig, Ira, MD",12/6/2023,BMT Autologous Melphalan Day -1 140MG/M2,_2. Second Line,12/4/2023,Inactive,,
MMC OP INFUSION,90864,"Eltoukhy, Hussam, MD",2/19/2024,Lenalidomide (D1-D21) Maintenance 28 Day Cycles - Multiple Myeloma,Maintenance,2/19/2024,Active,,
CINJ OP INFUSION,17608,"Goel, Sanjay, MD",2/15/2023,CINJ 052006 (TTX-080-001) ARM 5 TTX-80 / Cetuximab Dose Expansion 21 Day Cycles Research- Colorectal Cancer,Third Line,2/15/2023,Inactive,,
CINJ OP INFUSION,17608,"Goel, Sanjay, MD",2/15/2023,CINJ 052006 (TTX-080-001) ARM 4 TTX-80 / Cetuximab Dose Expansion 21 Day Cycles Research- Colorectal Cancer,Third Line,1/14/2023,Inactive,,
CINJ OP INFUSION,17608,"Goel, Sanjay, MD",2/22/2023,CINJ 052006 (TTX-080-001) ARM 1 TTX-80 / Pembrolizumab Dose Expansion 21 Day Cycles Research- Head and Neck Cancer,Third Line,1/21/2023,Inactive,,
CINJ OP INFUSION,17608,"Goel, Sanjay, MD",3/6/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_5. Fifth Line,2/15/2024,Inactive,,
NBR CINJ OP INFUSION,98782,"Mayer, Tina M, MD",8/20/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,8/20/2024,Active,,
NBR CINJ OP INFUSION,98782,"Mayer, Tina M, MD",8/20/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,8/20/2024,Inactive,,
CINJ OP INFUSION,55854,"Berim, Lyudmyla, MD",7/10/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/8/2024,Active,,
CINJ OP INFUSION,55854,"Berim, Lyudmyla, MD",4/2/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/2/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),
CINJ OP INFUSION,55854,"Berim, Lyudmyla, MD",3/21/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/21/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas
CBMC OP INFUSION 2FL,17958,"Brown, Andrew Bennett, MD",3/31/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,3/31/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,17958,"Brown, Andrew Bennett, MD",3/10/2025,PACLitaxel / CARBOplatin - 21 Day Cycles - Non-Small Cell Lung Cancer,Adjuvant,3/10/2025,Inactive,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
MMC OP INFUSION,91008,"Eltoukhy, Hussam, MD",3/10/2025,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,3/10/2025,Inactive,"Follicular lymphoma grade i, lymph nodes of head, face, and neck (CMS/HCC)","C82.11 - Follicular lymphoma grade ii, lymph nodes of head, face, and neck; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z79.2 - Long term (current) use of antibiotics; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,51843,"Cohen, Seth D, MD",3/31/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,3/31/2025,Active,"High grade urothelial carcinoma present on urine cytology (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,51467,"Berim, Lyudmyla, MD",1/31/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,1/3/2024,Inactive,,
CINJ OP INFUSION,51467,"Berim, Lyudmyla, MD",4/10/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,4/8/2024,Active,,
CBMC OP INFUSION 2FL,24931,"Scoppetuolo, Michael, MD",1/25/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,1/11/2024,Inactive,,
CBMC OP INFUSION 2FL,24931,"Scoppetuolo, Michael, MD",5/30/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/29/2024,Inactive,,
CBMC OP INFUSION 2FL,24931,"Scoppetuolo, Michael, MD",5/31/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/30/2024,Inactive,,
CBMC OP INFUSION 2FL,24931,"Scoppetuolo, Michael, MD",8/21/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,8/20/2024,Active,,
CINJ OP INFUSION,17500,"Omene, Coral Oghenerukevwe, MD",2/7/2023,Palbociclib 28 Day Cycles - Breast,,2/7/2023,Inactive,,
CBMC OP INFUSION 2FL,70557,"Wagmiller, Jennifer Ann, MD",11/30/2023,Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/30/2023,Inactive,,
MMC OP VP INFUSION,2657,"Talwar, Sumit, MD",6/13/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,4/18/2023,Inactive,,
MMC OP INFUSION,2657,"Talwar, Sumit, MD",12/2/2024,Polatuzumab vedotin/R-ICE 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,12/1/2024,Active,,
MMC BBR2 ONCOLOGY,2657,"Talwar, Sumit, MD",12/3/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,12/3/2024,Active,,
NBR CINJ OP INFUSION,2657,"Matasar, Matthew J, MD",3/14/2025,BMT Autologous BEAM,_2. Second Line,3/5/2025,Active,Follicular lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; Z94.84 - Stem cells transplant status"
CINJ OP INFUSION,10472,"Aikins, James K, MD",3/20/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar,,2/8/2023,Inactive,,
CINJ OP INFUSION,10472,"Aikins, James K, MD",10/25/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,10/3/2024,Active,,
SOM OUTPT INFUSION,70847,"Toomey, Kathleen C, MD",1/12/2024,Nivolumab 480 mg D1 28 Day Cycles- HCC,_1. First Line,1/11/2024,Inactive,,
CBMC OP INFUSION 2FL,93370,"Ligresti, Louise G, MD",11/4/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,11/4/2024,Active,,
NBR CINJ OP INFUSION,93635,"Braunschweig, Ira, MD",12/29/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,12/26/2023,Active,,
CINJ OP INFUSION,19421,"Haigentz, Missak, MD",8/22/2024,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,_1. First Line,8/22/2024,Active,,
TRMC TCCC OP INFUSION,3938,"Capo, Gerardo, MD",10/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/12/2024,Active,,
CBMC OP INFUSION 2FL,40116,"Dharmapuri, Sirish, MD",12/24/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_3. Third Line,12/23/2024,Active,,
CBMC 2W ONCOLOGY,16759,"Dharmapuri, Sirish, MD",4/11/2025,"PACLitaxel D1, D8, D15 28 Day Cycles- Esophageal and Esophagogastric Junction Cancers",_4. Fourth Line,4/11/2025,Inactive,Stage IV adenocarcinoma of stomach (CMS/HCC),"T85.520A - Displacement of bile duct prosthesis, initial encounter; C16.9 - Malignant neoplasm of stomach, unspecified; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; R18.8 - Other ascites; E83.39 - Other disorders of phosphorus metabolism; E87.1 - Hypo-osmolality and hyponatremia; K74.60 - Unspecified cirrhosis of liver; D50.9 - Iron deficiency anemia, unspecified; I15.9 - Secondary hypertension, unspecified; R54 - Age-related physical debility; R13.10 - Dysphagia, unspecified; E87.6 - Hypokalemia; D63.0 - Anemia in neoplastic disease; G89.29 - Other chronic pain; Z96.659 - Presence of unspecified artificial knee joint; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z85.028 - Personal history of other malignant neoplasm of stomach; Z90.3 - Acquired absence of stomach (part of); Z90.411 - Acquired partial absence of pancreas; Z98.890 - Other specified postprocedural states; Z92.21 - Personal history of antineoplastic chemotherapy"
CMC OP INFUSION,98211,"Pompa, Tiffany Ann, MD",10/10/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,10/7/2024,Inactive,,
CMC OP INFUSION,98211,"Pompa, Tiffany Ann, MD",11/5/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,11/4/2024,Inactive,,
CMC OP INFUSION,98211,"Pompa, Tiffany Ann, MD",12/17/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,12/16/2024,Active,,
CINJ OP INFUSION,90365,"Haigentz, Missak, MD",4/5/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,3/28/2023,Inactive,,
CINJ OP INFUSION,90365,"Haigentz, Missak, MD",6/28/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/20/2023,Inactive,,
CMC OP INFUSION,1820,"Cohen, Seth D, MD",1/30/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/29/2024,Active,,
CBMC OP INFUSION 2FL,36065,"Wagmiller, Jennifer Ann, MD",11/12/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,11/11/2024,Active,,
CMC OP INFUSION,3084,"Cohen, Seth D, MD",3/20/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/18/2024,Inactive,,
MMC OP VP INFUSION,3084,"Cohen, Seth D, MD",5/20/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,5/19/2024,Inactive,,
MMC OP VP INFUSION,3084,"Cohen, Seth D, MD",6/17/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/16/2024,Inactive,,
CBMC OP INFUSION 2FL,66671,"Kulkarni, Aditya A, MD",2/10/2025,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,2/9/2025,Inactive,Primary squamous cell carcinoma of lower lobe of left lung (CMS/HCC),C34.92 - Malignant neoplasm of unspecified part of left bronchus or lung; E83.52 - Hypercalcemia
CINJ OP INFUSION,60645,"Haigentz, Missak, MD",6/30/2023,BTCRC-LUN19-396 / CINJ 032007 CISplatin / PEMEtrexed / Atezolizumab 21 Day Cycles Research- Non-Squamous NSCLC,Adjuvant,6/22/2023,Active,,
NBR 5N ONCOLOGY,90226,"Rhodes, Joanna Meehan, MD",4/15/2025,Cytarabine Cytoreduction for Hyperleukocytosis,Adjuvant,4/15/2025,Inactive,Leukemia consultation (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; D84.821 - Immunodeficiency due to drugs; D70.9 - Neutropenia, unspecified; D69.6 - Thrombocytopenia, unspecified; N45.1 - Epididymitis; F17.210 - Nicotine dependence, cigarettes, uncomplicated; F42.9 - Obsessive-compulsive disorder, unspecified; Z59.41 - Food insecurity; F90.9 - Attention-deficit hyperactivity disorder, unspecified type; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z88.1 - Allergy status to other antibiotic agents; L27.0 - Generalized skin eruption due to drugs and medicaments taken internally"
NBI OP INFUSION,97453,"Anderson, Patrick S, MD",1/22/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Locally advanced Endometrial,_1. First Line,1/3/2024,Inactive,,
NBI OP INFUSION,64794,"Anderson, Patrick S, MD",5/8/2025,PACLitaxel Weekly  sereous carcinoma of endometrium,_2. Second Line,5/8/2025,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,25233,"Saraiya, Biren P, MD",7/2/2024,Relugolix 30 day Cycles - Prostate,_1. First Line,7/2/2024,Active,Adenocarcinoma of head of pancreas (CMS/HCC),
MMC OP INFUSION,30981,"Cohen, Seth D, MD",7/9/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,7/8/2024,Active,Malignant neoplasm of body of stomach (CMS/HCC),
CBMC OP INFUSION 2FL,28540,"Gallinson, David Herschel, DO",1/20/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_4. Fourth Line,1/19/2025,Active,,
NBR CINJ OP INFUSION,89848,"Doraiswamy, Anupama, MD",9/6/2023,Dasatinib (Chronic Phase) 30 Day Cycles ,,10/11/2022,Inactive,,
NBR CINJ OP INFUSION,89848,"Palmisiano, Neil David, MD",10/22/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_2. Second Line,10/22/2024,Active,,
NBR CINJ OP INFUSION,89848,"Palmisiano, Neil David, MD",1/6/2025,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,_3. Third Line,1/6/2025,Active,,
NBR CINJ OP INFUSION,97205,"Palmisiano, Neil David, MD",5/19/2025,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,5/19/2025,Active,"Acute lymphoblastic leukemia, in remission (CMS/HCC)
Cerebral infarction due to embolism of bilateral cerebellar arteries (CMS/HCC)",
SOM OUTPT INFUSION,32698,"Patel, Eshan, MD",4/30/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/29/2024,Inactive,,
CMC OP INFUSION,83024,"Talwar, Sumit, MD",1/3/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/2/2024,Inactive,,
MMC OP INFUSION,18514,"Lee, Patrick C, MD",7/16/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Bladder,_1. First Line,7/15/2024,Active,,
NBI OP INFUSION,3984,"Shah, Shailja S, MD",2/2/2024,Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles - Multiple Myeloma,_1. First Line,1/22/2024,Inactive,,
NBI OP INFUSION,3984,"Shah, Shailja S, MD",4/12/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,4/11/2024,Active,,
CMC OP INFUSION,27954,"Talwar, Sumit, MD",4/24/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/23/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP INFUSION,92678,"Cohen, Seth D, MD",2/19/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/18/2024,Inactive,,
CBMC OP INFUSION 2FL,60084,"Leitner, Stuart P, MD",7/16/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/8/2024,Active,Malignant neoplasm of endometrium (CMS/HCC),
CBMC OP INFUSION 2FL,60084,"Leitner, Stuart P, MD",11/19/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,10/29/2024,Active,,
CMC OP INFUSION,92369,"Talwar, Sumit, MD",2/27/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/25/2025,Active,Malignant neoplasm of descending colon (CMS/HCC),
SOM OUTPT INFUSION,506,"Yin, Faye, MD",7/19/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,7/1/2024,Inactive,,
HAM OP INFUSION,506,"Patel, Malini M, MD",8/1/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,7/31/2024,Active,Diffuse large B-cell lymphoma (CMS/HCC),
HAM OP INFUSION,79551,"Patel, Malini M, MD",2/6/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,1/29/2025,Active,"Grade 2 follicular lymphoma of lymph nodes of multiple regions (CMS/HCC)
Encounter for screening for other viral diseases
Other problems related to lifestyle
End stage renal disease (CMS/HCC)","C82.90 - Follicular lymphoma, unspecified grade, unspecified body region (CMS/HCC); F41.9 - Anxiety; N18.31 - Stage 3a chronic kidney disease (CMS/HCC)"
CMC OP INFUSION,59305,"Taff, Jessica, MD",2/26/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,2/18/2025,Active,"Adenocarcinoma, lung, left (CMS/HCC)",
CBMC OP INFUSION 2FL,16375,"Brown, Andrew Bennett, MD",2/6/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,2/5/2024,Inactive,,
CBMC OP INFUSION 2FL,16375,"Brown, Andrew Bennett, MD",4/30/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,4/29/2024,Inactive,,
JCMC CP INFUSION,2882,"Cruz, Allan Louie E, MD",2/5/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/4/2024,Inactive,,
CBMC OP INFUSION 2FL,7466,"Wagmiller, Jennifer Ann, MD",9/2/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/1/2023,Inactive,,
CBMC OP INFUSION 2FL,7466,"Wagmiller, Jennifer Ann, MD",9/27/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,9/22/2024,Inactive,,
NBR 5N ONCOLOGY,99162,"Doraiswamy, Anupama, MD",4/17/2023,HyperCVD (Cycle A) Course (Cyclophosphamide / VinCRIStine/ Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,,4/16/2023,Inactive,,
NBR CINJ OP INFUSION,99162,"Doraiswamy, Anupama, MD",5/15/2023,HyperCVAD (Cycle B) Course (High Dose Methotrexate / Cytarabine) 21 Day Cycles - Acute Lymphoblastic Leukemia,,5/15/2023,Inactive,,
NBR CINJ OP INFUSION,99162,"Doraiswamy, Anupama, MD",6/12/2023,HyperCVAD Cycle 3 (Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,,6/12/2023,Inactive,,
NBR 4N ONCOLOGY,99162,"Palmisiano, Neil David, MD",9/26/2023,Cycle 1B (MTX) HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,,9/24/2023,Inactive,,
NBR CINJ OP INFUSION,99162,"Palmisiano, Neil David, MD",10/2/2023,Inotuzumab Ozogamicin 21 Day Cycle + Inotuzumab Ozogamicin 28 Day Cycles - Acute Lymphoblastic Leukemia,,10/1/2023,Inactive,,
NBR CINJ OP INFUSION,99162,"Palmisiano, Neil David, MD",11/9/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_3. Third Line,11/9/2023,Inactive,,
NBR CINJ OP INFUSION,99162,"Palmisiano, Neil David, MD",12/7/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_3. Third Line,12/7/2023,Inactive,,
NBR 4N BMTU/IMCU,68910,"Patel, Vimal D, MD",9/28/2023,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,9/26/2023,Inactive,,
NBR CINJ OP INFUSION,68910,"Shah, Mansi R, MD",2/22/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles - Multiple Myeloma Post transplant,Maintenance,2/12/2024,Active,,
JCMC CP INFUSION,56160,"Cruz, Allan Louie E, MD",6/15/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",Induction,6/14/2023,Inactive,,
MMC OP VP INFUSION,69242,"Cohen, Seth D, MD",1/13/2025,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/10/2025,Active,,
MMC OP VP INFUSION,69242,"Cohen, Seth D, MD",4/28/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/31/2025,Active,"Primary malignant neoplasm of left lower lobe of lung (CMS/HCC)
Hypothyroidism, unspecified type",
CBMC OP INFUSION 2FL,15544,"Brown, Andrew Bennett, MD",10/19/2023,Nivolumab/Ipilimumab 42 Day Cycles- Mesothelioma,_2. Second Line,10/18/2023,Inactive,,
CBMC OP INFUSION 2FL,15544,"Brown, Andrew Bennett, MD",8/29/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,8/29/2024,Active,,
CINJ OP INFUSION,82383,"George, Mridula A, MD",4/26/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,Third Line,4/25/2023,Inactive,,
CINJ OP INFUSION,82383,"George, Mridula A, MD",3/18/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_4. Fourth Line,3/17/2024,Inactive,,
CINJ OP INFUSION,82383,"George, Mridula A, MD",7/22/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_6. Sixth Line,7/21/2024,Inactive,,
CINJ OP INFUSION,82383,"George, Mridula A, MD",9/25/2024,EriBULin 21 Day Cycles - Breast,_7. Seventh Line,9/24/2024,Inactive,,
CINJ OP INFUSION,82383,"George, Mridula A, MD",1/15/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_6. Sixth Line,1/14/2025,Active,,
HAM OP INFUSION,58431,"Patel, Malini M, MD",8/7/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,8/2/2024,Inactive,,
NBI OP INFUSION,58002,"Schleicher, Lori, MD",1/18/2023,"PACLitaxel D1,D8, D15 28 Day Cycles - Breast",_1. First Line,1/17/2023,Active,,
JCMC CP INFUSION,98631,"Sekhri, Arunabh, MD",8/5/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Parotid gland carcinoma,Adjuvant,7/28/2024,Inactive,,
CMC OP INFUSION,32583,"Talwar, Sumit, MD",3/26/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,3/26/2025,Active,Endometrial cancer (CMS/HCC),
NBR 5N ONCOLOGY,75618,"Palmisiano, Neil David, MD",8/12/2023,cytarabine flat dose 100mg for count reduction,,8/12/2023,Inactive,,
NBR 5N ONCOLOGY,75618,"Palmisiano, Neil David, MD",8/19/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,8/19/2023,Inactive,,
NBR CINJ OP INFUSION,75618,"Palmisiano, Neil David, MD",10/26/2023,CINJ 022301 Iadademstat / Gilteritinib 28 Day Cycles Research- Acute Myeloid Leukemia,_2. Second Line,10/25/2023,Inactive,,
NBR 4N BMTU/IMCU,75618,"Assal, Amer, MD",2/29/2024,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,Consolidation,2/29/2024,Active,,
NBR CINJ OP INFUSION,75618,"Chowaniec, Wayne B, NP",8/19/2024,"Decitabine (3 day) 28 Day Cycles - Post transplant, CD33 chimerism decreased",_1. First Line,8/19/2024,Active,,
CMC OP INFUSION,77257,"Talwar, Sumit, MD",9/25/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",Adjuvant,9/25/2024,Active,,
CINJ OP INFUSION,60320,"George, Mridula A, MD",8/2/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,8/1/2023,Inactive,,
CINJ OP INFUSION,60320,"George, Mridula A, MD",3/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,3/11/2024,Inactive,,
NBR 5N ONCOLOGY,50912,"Matasar, Matthew J, MD",7/11/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,7/10/2023,Active,Follicular lymphoma of lymph nodes of multiple regions (CMS/HCC),
NBI OP INFUSION,50912,"Shah, Maya M, MD",4/21/2025,Enasidenib 30 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,4/21/2025,Active,AML (acute myelogenous leukemia) (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission"
NBI OP INFUSION,50912,"Shah, Maya M, MD",4/21/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,4/21/2025,Active,Acute leukemia (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission"
NBR CINJ OP INFUSION,92762,"Evens, Andrew M, DO",3/1/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,,2/15/2023,Inactive,,
TRMC TCCC OP INFUSION,59713,"Salerno, Vincent E, MD",8/15/2024,Pembrolizumab 21 Day Cycles - ovary mmr deficient,Maintenance,8/14/2024,Active,,
NBI OP INFUSION,49257,"Schleicher, Lori, MD",10/23/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/22/2023,Inactive,,
SOM OUTPT INFUSION,35023,"Toomey, Kathleen C, MD",3/24/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,3/1/2023,Inactive,,
SOM OUTPT INFUSION,35023,"Toomey, Kathleen C, MD",6/23/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,6/23/2023,Inactive,,
CINJ OP INFUSION,88569,"Stephenson, Ryan D, DO",3/21/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/21/2025,Active,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),
CINJ OP INFUSION,98131,"Berim, Lyudmyla, MD",9/17/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/15/2024,Active,,
CINJ OP INFUSION,54425,"Saraiya, Biren P, MD",10/10/2023,Darolutamide 30 Day Cycles - Prostate,_3. Third Line,10/10/2023,Inactive,,
CINJ OP INFUSION,26267,"Packiam, Vignesh, MD",5/2/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/2/2025,Active,Malignant neoplasm of anterior wall of bladder (CMS/HCC),C67.3 - Malignant neoplasm of anterior wall of bladder
CBMC OP INFUSION 2FL,9399,"Raptis, George, MD",2/11/2025,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,2/6/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,9399,"Raptis, George, MD",5/16/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,5/16/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,15053,"Brown, Andrew Bennett, MD",8/8/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/7/2023,Inactive,,
CBMC OP INFUSION 2FL,15053,"Brown, Andrew Bennett, MD",4/19/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/19/2024,Active,,
CBMC OP INFUSION 2FL,90612,"Brown, Andrew Bennett, MD",2/14/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/13/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
JCMC CP INFUSION,43545,"Cruz, Allan Louie E, MD",5/2/2024,Nivolumab 28 Day Cycles - Metastatic Clear Cell  Renal Cell Carcinoma,_1. First Line,5/2/2024,Active,,
CMC OP INFUSION,63803,"Taff, Jessica, MD",7/7/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,First Line,6/22/2023,Inactive,,
MMC OP VP INFUSION,54622,"Lee, Patrick C, MD",3/5/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Unknown primary ,_1. First Line,3/4/2024,Inactive,,
MSC OP INFUSION,11164,"Meghal, Trishala, MD",4/26/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,4/25/2024,Inactive,,
MMC OP VP INFUSION,99736,"Meghal, Trishala, MD",7/29/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_2. Second Line,7/25/2024,Active,Endometrial cancer (CMS/HCC),
CBMC OP INFUSION 2FL,79306,"Brown, Andrew Bennett, MD",8/12/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,8/12/2024,Active,,
CBMC OP INFUSION 2FL,79306,"Brown, Andrew Bennett, MD",1/24/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/22/2025,Active,,
CINJ OP INFUSION,96196,"Berim, Lyudmyla, MD",7/8/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/1/2024,Active,,
CINJ OP INFUSION,57623,"Berim, Lyudmyla, MD",3/10/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,Consolidation,3/10/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),C15.5 - Malignant neoplasm of lower third of esophagus
CINJ OP INFUSION,95167,"Vojnic, Morana, MD, MBA",5/15/2025,CINJ 142202 Arm 2 Lomustine / Temozolomide 42 Day Cycles Research Glioblastoma,_1. First Line,5/12/2025,Active,Glioblastoma (CMS/HCC),
HAM OP INFUSION,62737,"Yogarajah, Meera, MD",4/29/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/28/2024,Inactive,,
HAM OP INFUSION,62737,"Yogarajah, Meera, MD",6/13/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/8/2024,Active,,
TRMC TCCC OP INFUSION,15299,"Capo, Gerardo, MD",4/23/2025,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,_3. Third Line,4/23/2025,Active,Malignant neoplasm of upper-inner quadrant of right female breast (CMS/HCC),C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,60836,"Boland, Patrick M, MD",3/6/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/6/2025,Active,Malignant neoplasm of colorectal area with metastasis (CMS/HCC),C19 - Malignant neoplasm of rectosigmoid junction; C18.7 - Malignant neoplasm of sigmoid colon; Z90.49 - Acquired absence of other specified parts of digestive tract
CINJ OP INFUSION,65695,"Omene, Coral Oghenerukevwe, MD",1/20/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,1/20/2025,Active,,
CINJ OP INFUSION,16248,"Toppmeyer, Deborah L, MD",5/30/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/30/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,30536,"Sekhri, Arunabh, MD",10/26/2023,Ropeginterferon alfa-2b-njft 14 Day Cycles - Myeloproliferative Neoplasms (Not on Hydrea),First Line,10/25/2023,Inactive,,
NBI OP INFUSION,32872,"Jacoby, Sari H, MD",7/25/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,7/25/2024,Active,,
NBI D7 MED-SURG/TELE,91513,"Anderson, Patrick S, MD",5/24/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/23/2024,Inactive,,
SOM OUTPT INFUSION,76914,"George, Roshini, DO",5/23/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,5/23/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)
Metastasis to lymph nodes (CMS/HCC)",C50.511 - Malignant neoplasm of lower-outer quadrant of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.0 - Estrogen receptor positive status (ER+)
SOM OUTPT INFUSION,23048,"Patel, Eshan, MD",3/18/2025,Gemcitabine / CISplatin/durvalumab (1000/35) 21 Day Cycles - Bladder,_1. First Line,3/17/2025,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),C67.2 - Malignant neoplasm of lateral wall of bladder
SOM OUTPT INFUSION,51880,"Patel, Eshan, MD",11/4/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/13/2024,Active,,
SOM OUTPT INFUSION,51880,"Patel, Eshan, MD",2/14/2025,"DOCEtaxel D1, D8, D15  28 Day Cycles-Non-Small Cell Lung Cancer",_2. Second Line,2/10/2025,Active,Lung cancer metastatic to brain (CMS/HCC),
NBR CINJ OP INFUSION,86074,"Braunschweig, Ira, MD",11/15/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_1. First Line,11/14/2023,Inactive,,
NBR CINJ OP INFUSION,86074,"Assal, Amer, MD",12/13/2023,Bortezomib for donor specific antibodies,Induction,12/12/2023,Inactive,,
NBR CINJ OP INFUSION,86074,"Assal, Amer, MD",1/3/2024,RiTUXimab Initial Infusion Single Day (Outpatient) - DSA managment,_1. First Line,1/3/2024,Inactive,,
NBR CINJ OP INFUSION,86074,"Egini, Ogechukwu, MD",6/13/2024,Daratumumab 28 Day Cycles- Multiple Myeloma,_3. Third Line,6/11/2024,Active,,
NBR CINJ OP INFUSION,86074,"Egini, Ogechukwu, MD",11/7/2024,BMT Allogeneic Fludarabine / Cyclophosphamide / Alemtuzumab / TBI - MMUD / MUD,_2. Second Line,11/7/2024,Active,,
NBR 4N BMTU/IMCU,86074,"Egini, Ogechukwu, MD",1/17/2025,BMT Allogeneic rATG / Flu / Cy / TBI + Post Cy,_4. Fourth Line,1/15/2025,Active,,
NBR 5N ONCOLOGY,91332,"Berim, Lyudmyla, MD",3/29/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,,3/21/2023,Inactive,,
NBR 5N ONCOLOGY,91332,"Berim, Lyudmyla, MD",3/29/2023,PEMEtrexed/CARBOplatin (AUC 4) 21 Day Cycles- Non-Small Cell Lung Cancer ,,3/21/2023,Inactive,,
NBR 5N ONCOLOGY,91332,"Haigentz, Missak, MD",4/15/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,4/15/2023,Inactive,,
CINJ OP INFUSION,34136,"Stephenson, Ruth D, DO",4/18/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/9/2023,Inactive,,
CBMC OP INFUSION 2FL,43752,"Dharmapuri, Sirish, MD",12/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/1/2024,Active,"Cancer of cecum (CMS/HCC)
Metastasis to peritoneal cavity (CMS/HCC)",
CBMC OP INFUSION 2FL,35973,"Grossman, I Robert, MD",3/28/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/28/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
CBMC 2W ONCOLOGY,35973,"Grossman, I Robert, MD",3/5/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,3/5/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; J18.9 - Pneumonia, unspecified organism; Z51.5 - Encounter for palliative care; M48.52XA - Collapsed vertebra, not elsewhere classified, cervical region, initial encounter for fracture; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; D63.0 - Anemia in neoplastic disease; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; N18.9 - Chronic kidney disease, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E66.813 - Obesity, class 3; J45.909 - Unspecified asthma, uncomplicated; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; E11.43 - Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E29.1 - Testicular hypofunction; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; R09.02 - Hypoxemia; M89.58 - Osteolysis, other site; G47.33 - Obstructive sleep apnea (adult) (pediatric); K31.84 - Gastroparesis; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; K59.00 - Constipation, unspecified; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z83.3 - Family history of diabetes mellitus; Z11.52 - Encounter for screening for COVID-19; Z91.013 - Allergy to seafood; Z87.891 - Personal history of nicotine dependence; Z87.442 - Personal history of urinary ca..."
SOM OUTPT INFUSION,20814,"Toomey, Kathleen C, MD",9/15/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,First Line,9/5/2023,Inactive,,
SOM OUTPT INFUSION,20814,"Toomey, Kathleen C, MD",11/10/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,11/9/2023,Inactive,,
CMC OP INFUSION,4719,"Tang, Horace, MD",9/22/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",,9/21/2023,Inactive,,
CBMC OP INFUSION 2FL,35941,"Leitner, Stuart P, MD",12/11/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Induction,12/11/2023,Inactive,,
MMC OP VP INFUSION,5680,"Meghal, Trishala, MD",1/8/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,1/2/2024,Active,Carcinoma of right breast metastatic to lung (CMS/HCC),
CMC OP INFUSION,76790,"Taff, Jessica, MD",7/28/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,Adjuvant,7/27/2023,Inactive,,
HAM OP INFUSION,20602,"Yogarajah, Meera, MD",9/25/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,First Line,9/10/2023,Active,Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) (CMS/HCC),
HAM OP INFUSION,89946,"Yogarajah, Meera, MD",2/6/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,2/1/2023,Inactive,,
JCMC CP INFUSION,35117,"Cruz, Allan Louie E, MD",7/29/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Laryngeal Carcinoma,Induction,7/22/2024,Inactive,,
JCMC CP INFUSION,35117,"Cruz, Allan Louie E, MD",8/19/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Consolidation,8/18/2024,Inactive,,
JCMC CP INFUSION,35117,"Cruz, Allan Louie E, MD",2/14/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/14/2025,Active,Malignant neoplasm of larynx (CMS/HCC),"C32.9 - Malignant neoplasm of larynx, unspecified; B18.2 - Chronic viral hepatitis C"
MMC OP VP INFUSION,18296,"Cohen, Seth D, MD",1/31/2025,CINJ 072014 Expanded Access Ulixertinib (BVD-523) - MAPK Pathway Altered Malignancies,_4. Fourth Line,1/31/2025,Active,,
CBMC OP INFUSION 2FL,91767,"Dave, Manish, MD",5/15/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/14/2023,Active,,
HAM OP INFUSION,31821,"Yogarajah, Meera, MD",3/5/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/5/2025,Active,Adenocarcinoma of colon (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C18.4 - Malignant neoplasm of transverse colon; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; E44.1 - Mild protein-calorie malnutrition; C19 - Malignant neoplasm of rectosigmoid junction; B19.20 - Unspecified viral hepatitis C without hepatic coma; D64.9 - Anemia, unspecified; J43.9 - Emphysema, unspecified; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; I48.91 - Unspecified atrial fibrillation; E78.5 - Hyperlipidemia, unspecified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z79.01 - Long term (current) use of anticoagulants; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z88.5 - Allergy status to narcotic agent; Z90.49 - Acquired absence of other specified parts of digestive tract; Z65.1 - Imprisonment and other incarceration; L30.9 - Dermatitis, unspecified; Z68.24 - Body mass index (BMI) 24.0-24.9, adult"
NBR CINJ OP INFUSION,60194,"Shah, Mansi R, MD",10/19/2023,Carfilzomib 56 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,10/18/2023,Active,,
CINJ OP INFUSION,48140,"Hochster, Howard S, MD",6/8/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,Third Line,6/1/2023,Inactive,,
TRMC TCCC OP INFUSION,87855,"Salerno, Vincent E, MD",2/29/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,2/28/2024,Active,,
CBMC OP INFUSION 2FL,89363,"Leitner, Stuart P, MD",11/15/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,11/15/2023,Active,,
CBMC OP INFUSION 2FL,43503,"Litvak, Anna M, MD",11/18/2024,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,_1. First Line,11/14/2024,Active,,
CBMC OP INFUSION 2FL,43503,"Litvak, Anna M, MD",2/27/2025,CINJ 042102 Block C (TNBC) Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Triple Negative Breast Cancer,_1. First Line,2/26/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,43503,"Litvak, Anna M, MD",5/1/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,4/21/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,95328,"Evens, Andrew M, DO",2/16/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,Third Line,2/15/2023,Inactive,,
CBMC OP INFUSION 2FL,95328,"Grossman, I Robert, MD",4/21/2025,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_4. Fourth Line,4/21/2025,Active,"Diffuse large B cell lymphoma (CMS/HCC)
Hypercholesterolemia
Acquired coagulation factor deficiency (CMS/HCC)",
JCMC CP INFUSION,72264,"Cruz, Allan Louie E, MD",2/5/2024,Bevacizumab single agent 21 Day Cycles - serous ovarian cancer,_2. Second Line,2/4/2024,Active,,
JCMC CP INFUSION,57195,"Cruz, Allan Louie E, MD",2/26/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,2/25/2025,Active,Ovarian cancer (CMS/HCC),"C56.9 - Malignant neoplasm of ovary, unspecified laterality (CMS/HCC); C56.2 - Malignant neoplasm of left ovary (CMS/HCC)"
CBMC OP INFUSION 2FL,63599,"Radovich, Delia, MD",10/3/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,9/27/2023,Inactive,,
CBMC OP INFUSION 2FL,63599,"Radovich, Delia, MD",12/28/2023,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/28/2023,Inactive,,
SOM OUTPT INFUSION,72012,"Toomey, Kathleen C, MD",4/26/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",First Line,4/25/2023,Inactive,,
NBR 5N ONCOLOGY,77821,"Shah, Mansi R, MD",4/26/2023,Cytarabine Intrathecal IT 1 Day Cycle- Hematological Malignancies,,4/26/2023,Inactive,,
NBR 5N ONCOLOGY,77821,"Shah, Mansi R, MD",4/26/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,4/25/2023,Inactive,,
CINJ OP INFUSION,7603,"Stephenson, Ryan D, DO",10/23/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,10/23/2023,Active,,
NBI OP INFUSION,90419,"Jacoby, Sari H, MD",10/31/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/31/2023,Active,,
CINJ OP INFUSION,65931,"Saraiya, Biren P, MD",1/27/2025,Relugolix 30 day Cycles - Prostate,_1. First Line,1/27/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,60388,"Matasar, Matthew J, MD",2/1/2023,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,Adjuvant,1/31/2023,Inactive,,
MMC OP INFUSION,17424,"Meghal, Trishala, MD",7/12/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,Third Line,7/11/2023,Inactive,,
CINJ OP INFUSION,17424,"George, Mridula A, MD",10/16/2023,CINJ 042303 Part 1 Dose Escalation RLY-5836 Single Agent 28 Day Cycles Research- Breast Cancer,_4. Fourth Line,10/16/2023,Inactive,,
MMC OP VP INFUSION,17424,"Meghal, Trishala, MD",10/20/2023,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,Third Line,10/3/2023,Inactive,,
MMC BBR2 ONCOLOGY,17424,"Meghal, Trishala, MD",11/10/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Induction,11/10/2023,Inactive,,
MMC OP VP INFUSION,7429,"Meghal, Trishala, MD",4/11/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/10/2024,Inactive,,
MMC OP VP INFUSION,7429,"Meghal, Trishala, MD",7/11/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,7/11/2024,Active,Malignant neoplasm of left female breast (CMS/HCC),
SOM OUTPT INFUSION,46202,"Patel, Eshan, MD",5/16/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,,5/9/2023,Inactive,,
SOM OUTPT INFUSION,88961,"Yin, Faye, MD",7/22/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,7/9/2024,Active,,
CINJ OP INFUSION,61997,"George, Mridula A, MD",8/23/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,8/23/2024,Active,,
CINJ OP INFUSION,52650,"Boland, Patrick M, MD",11/16/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/15/2023,Inactive,,
CINJ OP INFUSION,52650,"Boland, Patrick M, MD",10/22/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/21/2024,Active,,
CINJ OP INFUSION,29001,"Stephenson, Ruth D, DO",10/26/2023,Ifosfamide / Mesna 21 Day Cycles - Uterine Sarcoma,_2. Second Line,10/18/2023,Inactive,,
SOM OUTPT INFUSION,95718,"Patel, Eshan, MD",5/20/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,5/19/2024,Active,,
MMC OP VP INFUSION,98332,"Cohen, Seth D, MD",5/5/2023,Anastrozole 30 Day Cycles - Breast,,5/5/2023,Active,,
JCMC CP INFUSION,77849,"Cruz, Allan Louie E, MD",10/7/2024,Nivolumab 480 mg D1 28 Day Cycles- Thoracic Cancers,_1. First Line,10/6/2024,Active,,
CINJ OP INFUSION,17362,"Haigentz, Missak, MD",8/6/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Salivary Gland Cancer,Adjuvant,8/5/2024,Active,,
NBI OP INFUSION,75063,"Jacoby, Sari H, MD",4/22/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/22/2025,Inactive,"Adenocarcinoma of lung, right (CMS/HCC)","C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; I24.9 - Acute ischemic heart disease, unspecified; I23.8 - Other current complications following acute myocardial infarction"
NBI OP INFUSION,75063,"Jacoby, Sari H, MD",4/22/2025,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,4/22/2025,Active,"Adenocarcinoma of lung, right (CMS/HCC)",C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; Z00.6 - Encounter for examination for normal comparison and control in clinical research program
SOM OUTPT INFUSION,77993,"Toomey, Kathleen C, MD",7/15/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/23/2024,Active,,
CBMC OP INFUSION 2FL,33369,"Wagmiller, Jennifer Ann, MD",10/25/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,10/24/2023,Inactive,,
NBR CINJ OP INFUSION,6136,"Tiger, Yun Kyoung, MD",7/29/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,7/25/2024,Inactive,,
NBR CINJ OP INFUSION,90914,"Rhodes, Joanna Meehan, MD",6/26/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,6/19/2024,Active,"Prostate cancer (CMS/HCC)
Metastasis to bone (CMS/HCC)",
CINJ OP INFUSION,75566,"Haigentz, Missak, MD",4/27/2023,CARBOplatin/Etoposide D1-D3 PLUS ATEZOlizumab 21 Day Cycles- Small-Cell Lung Cancer,First Line,4/27/2023,Inactive,,
NBI OP INFUSION,28627,"Jacoby, Sari H, MD",6/13/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/12/2023,Inactive,,
CBMC OP INFUSION 2FL,41021,"Brown, Andrew Bennett, MD",7/17/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/17/2024,Active,,
CBMC OP INFUSION 2FL,41021,"Brown, Andrew Bennett, MD",4/7/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/7/2025,Inactive,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,64446,"Boland, Patrick M, MD",5/3/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/2/2024,Inactive,,
SOM OUTPT INFUSION,65884,"Toomey, Kathleen C, MD",7/3/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/2/2024,Inactive,,
CINJ OP INFUSION,27175,"Mayer, Tina M, MD",8/15/2023,Enzalutamide 28 Day Cycles - Prostate,,8/15/2023,Active,,
CBMC OP INFUSION 2FL,89489,"Brown, Andrew Bennett, MD",7/12/2023,Bevacizumab 28 Day Cycles - CNS,Adjuvant,7/12/2023,Active,,
NBR 5N ONCOLOGY,77318,"Palmisiano, Neil David, MD",7/20/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,7/19/2023,Inactive,,
CINJ OP INFUSION,78885,"Berim, Lyudmyla, MD",6/12/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/11/2023,Inactive,,
CINJ OP INFUSION,78885,"Goel, Sanjay, MD",9/19/2023,CINJ 052008 / R7075-ONC-2009 Dose Level 10 (ad hoc from DL9W) REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,Third Line,8/14/2023,Inactive,,
NBI OP INFUSION,64203,"Schleicher, Lori, MD",1/13/2023,Daratumumab and Hyaluronidase-fihj -Maintenance Q56D- Multiple Myeloma,Maintenance,1/12/2023,Active,,
CINJ OP INFUSION,56826,"Hochster, Howard S, MD",10/19/2023,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_2. Second Line,10/18/2023,Inactive,,
CINJ OP INFUSION,90596,"Saraiya, Biren P, MD",3/21/2023,CINJ 082107 (CURLU177PSM001) Enzalutamide 28 Day Cycles Research Prostate Cancer,Second Line,2/21/2023,Inactive,,
CINJ OP INFUSION,90596,"Saraiya, Biren P, MD",4/8/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_4. Fourth Line,4/2/2024,Inactive,,
CBMC OP INFUSION 2FL,31253,"Gurubhagavatula, Sarada, MD",4/14/2025,CINJ 032409 Cohort 1 (<80kg) Amivantamab / Lazertinib 28 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,4/14/2025,Active,Adenocarcinoma of lower lobe of left lung (CMS/HCC),
CMC OP INFUSION,9275,"Tang, Horace, MD",6/1/2023,Cetuximab with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,5/31/2023,Inactive,,
NBR CINJ OP INFUSION,95625,"Rhodes, Joanna Meehan, MD",12/18/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_4. Fourth Line,10/8/2024,Active,,
MSC OP INFUSION,31415,"Cohen, Seth D, MD",2/8/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,2/7/2023,Inactive,,
MSC OP INFUSION,31415,"Cohen, Seth D, MD",12/14/2023,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,12/11/2023,Inactive,,
CINJ OP INFUSION,55837,"Haigentz, Missak, MD",3/6/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,3/6/2023,Inactive,,
CINJ OP INFUSION,55837,"Haigentz, Missak, MD",6/19/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Second Line,6/18/2023,Inactive,,
CINJ OP INFUSION,55837,"Haigentz, Missak, MD",2/26/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,2/25/2024,Active,,
MMC OP INFUSION,8400,"Lee, Patrick C, MD",9/18/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,,9/17/2023,Inactive,,
CMC OP INFUSION,71869,"Taff, Jessica, MD",5/22/2023,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Adjuvant,5/14/2023,Inactive,,
CMC OP INFUSION,71869,"Taff, Jessica, MD",9/25/2023,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,9/17/2023,Active,,
NBR CINJ OP INFUSION,61827,"Matasar, Matthew J, MD",3/19/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/19/2025,Inactive,Marginal zone lymphoma (CMS/HCC),"C85.80 - Other specified types of non-hodgkin lymphoma, unspecified site"
MSC OP INFUSION,17129,"Cohen, Seth D, MD",3/15/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_2. Second Line,3/14/2024,Inactive,,
MMC OP VP INFUSION,17129,"Cohen, Seth D, MD",5/2/2024,Selinexor 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,5/2/2024,Inactive,,
MMC OP VP INFUSION,17129,"Cohen, Seth D, MD",5/6/2024,Selinexor 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,5/6/2024,Inactive,,
MMC OP VP INFUSION,17129,"Cohen, Seth D, MD",5/6/2024,Bortezomib 21 Day Cycles - Mantle Cell Lymphoma,_3. Third Line,5/5/2024,Inactive,,
MMC OP VP INFUSION,33099,"Meghal, Trishala, MD",6/26/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,6/13/2024,Active,,
CBMC OP INFUSION 2FL,43538,"Brown, Andrew Bennett, MD",5/1/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/30/2024,Inactive,,
CINJ OP INFUSION,3343,"Saraiya, Biren P, MD",2/1/2024,Abiraterone (Low Dose) / PredniSONE 30 Day Cycles - Prostate,_3. Third Line,2/1/2024,Inactive,,
CINJ OP INFUSION,30917,"Salacz, Michael E, MD",5/2/2023,Bevacizumab 28 Day Cycles - CNS,Second Line,5/2/2023,Inactive,,
CINJ OP INFUSION,24772,"Toppmeyer, Deborah L, MD",3/14/2023,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 28 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,3/13/2023,Inactive,,
CINJ OP INFUSION,24772,"Toppmeyer, Deborah L, MD",6/21/2023,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,6/19/2023,Active,,
MMC OP VP INFUSION,24026,"Meghal, Trishala, MD",1/23/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/22/2023,Inactive,,
MMC OP INFUSION,24026,"Meghal, Trishala, MD",6/12/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,6/11/2023,Inactive,,
MMC OP INFUSION,24026,"Meghal, Trishala, MD",9/4/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,9/4/2023,Inactive,,
MMC OP VP INFUSION,24026,"Meghal, Trishala, MD",1/31/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,1/26/2024,Active,,
MMC OP VP INFUSION,24026,"Talwar, Sumit, MD",5/6/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,5/6/2025,Inactive,Malignant neoplasm of ovary (CMS/HCC),
MMC OP VP INFUSION,24026,"Talwar, Sumit, MD",5/6/2025,Bevacizumab / PACLitaxel 28 Day Cycles - Breast,_4. Fourth Line,5/6/2025,Active,Malignant neoplasm of ovary (CMS/HCC),
MMC OP VP INFUSION,70714,"Lee, Patrick C, MD",3/20/2025,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,3/20/2025,Active,"Renal cell carcinoma (CMS/HCC)
Chemotherapy-induced fatigue",
MMC OP VP INFUSION,71163,"Lee, Patrick C, MD",1/16/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,1/16/2025,Active,,
NBR CINJ OP INFUSION,62170,"Schaar, Dale, MD PhD",4/3/2023,Cladribine 5 Day Cycle - Systemic Mastocytosis,,4/2/2023,Inactive,,
CBMC OP INFUSION 2FL,62326,"Grossman, I Robert, MD",7/19/2024,RiTUXimab 168 Day Cycles - ITP,_2. Second Line,7/19/2024,Inactive,,
HAM OP INFUSION,18537,"Patel, Malini M, MD",7/24/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,First Line,7/23/2023,Active,,
HAM OP INFUSION,18537,"Yogarajah, Meera, MD",2/13/2025,Venetoclax / Cytarabine (Low Dose) 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,2/12/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
CINJ OP INFUSION,61411,"Mayer, Tina M, MD",12/11/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,_2. Second Line,12/11/2023,Inactive,,
CINJ OP INFUSION,61411,"Mayer, Tina M, MD",3/14/2024,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,3/14/2024,Inactive,,
CINJ OP INFUSION,32582,"Stephenson, Ryan D, DO",1/4/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,1/4/2024,Inactive,,
CINJ OP INFUSION,25909,"Ghodoussipour, Saum Bobak, MD",6/18/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,6/18/2024,Active,,
HAM OP INFUSION,88825,"Yogarajah, Meera, MD",6/26/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/26/2023,Inactive,,
TRMC TCCC OP INFUSION,97407,"Salerno, Vincent E, MD",2/20/2025,RiTUXimab 28 Day Cycle - ITP,_1. First Line,2/11/2025,Active,Acute ITP (CMS/HCC),D69.3 - Immune thrombocytopenic purpura; D47.2 - Monoclonal gammopathy
NBR CINJ OP INFUSION,79642,"Shah, Mansi R, MD",1/3/2025,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_1. First Line,1/1/2025,Active,,
SOM OUTPT INFUSION,69017,"Patel, Eshan, MD",2/28/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/27/2023,Inactive,,
NBI D7 MED-SURG/TELE,2032,"Schleicher, Lori, MD",12/7/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/6/2023,Inactive,,
CINJ OP INFUSION,35809,"Boland, Patrick M, MD",10/7/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,9/9/2024,Inactive,,
CINJ OP INFUSION,35809,"Boland, Patrick M, MD",12/17/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,12/3/2024,Active,,
CINJ OP INFUSION,10396,"Girda, Eugenia, MD",2/21/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,2/20/2023,Inactive,,
CMC 4B ONCOLOGY,10396,"Taff, Jessica, MD",9/15/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,8/30/2023,Inactive,,
CINJ OP INFUSION,10396,"Girda, Eugenia, MD",3/5/2024,CINJ 102303 ARM B Nab-PACLitaxel 28 Day Cycles Research- Gynecological Malignancies,_3. Third Line,3/4/2024,Inactive,,
CINJ OP INFUSION,50606,"Weiss, Sarah, MD",8/19/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,8/18/2024,Active,,
CINJ OP INFUSION,24089,"Girda, Eugenia, MD",9/27/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,9/22/2024,Active,,
CINJ OP INFUSION,7016,"Packiam, Vignesh, MD",9/11/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/10/2024,Inactive,,
CINJ OP INFUSION,7016,"Packiam, Vignesh, MD",1/17/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,1/14/2025,Active,,
HAM OP INFUSION,99727,"Yogarajah, Meera, MD",1/16/2024,Gemcitabine / DOCEtaxel 21 Day Cycles - Uterine Sarcoma,_1. First Line,1/15/2024,Inactive,,
HAM OP INFUSION,99727,"Yogarajah, Meera, MD",6/18/2024,DOXOrubicin +Pembrolizuamb- 21 Day Cycles - Uterine Sarcoma,_2. Second Line,6/16/2024,Inactive,,
HAM OP INFUSION,99727,"Yogarajah, Meera, MD",8/29/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_3. Third Line,8/28/2024,Active,Malignant neoplasm of breast metastatic to bone (CMS/HCC),
MSC OP INFUSION,46099,"Lee, Patrick C, MD",2/20/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,Second Line,2/19/2023,Inactive,,
MSC OP INFUSION,46099,"Lee, Patrick C, MD",4/25/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,Second Line,4/24/2023,Active,,
NBR CINJ OP INFUSION,95468,"Doraiswamy, Anupama, MD",2/2/2023,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,,2/2/2023,Inactive,,
NBR 5N ONCOLOGY,95468,"Doraiswamy, Anupama, MD",2/8/2023,Cytarabine Subcutaneous (Low Intensity) 28 Day Cycles - Acute Myeloid Leukemia,,2/7/2023,Inactive,,
CMC 4B ONCOLOGY,94136,"Talwar, Sumit, MD",7/30/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,7/29/2024,Inactive,,
CMC OP INFUSION,87566,"Tang, Horace, MD",4/11/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,4/10/2023,Inactive,,
CINJ PEDS HEMONC ,9247,"Goyal-Khemka, Meenakshi, MD",6/19/2023,RiTUXimab 28 Day Cycle ,Second Line,6/18/2023,Inactive,,
CINJ OP INFUSION,5992,"Goel, Sanjay, MD",2/1/2023,CINJ 052006 (TTX-080-001) ARM 4 TTX-80 / Cetuximab Dose Expansion 21 Day Cycles Research- Colorectal Cancer,Third Line,12/31/2022,Inactive,,
CINJ OP INFUSION,3673,"George, Mridula A, MD",8/11/2023,Palbociclib 28 Day Cycles - Breast,,8/11/2023,Inactive,,
CINJ OP INFUSION,3673,"George, Mridula A, MD",10/31/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,10/31/2024,Active,,
NBR 4N ONCOLOGY,29554,"Jang, Thomas L, MD",12/3/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,12/3/2024,Active,,
NBR 4N ONCOLOGY,29554,"Jang, Thomas L, MD",5/28/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,5/28/2025,Active,Urothelial carcinoma of bladder (CMS/HCC),
MMC OP INFUSION,79339,"Cohen, Seth D, MD",4/18/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,4/11/2023,Inactive,,
MMC OP INFUSION,79339,"Cohen, Seth D, MD",11/21/2023,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/17/2023,Inactive,,
MMC OP VP INFUSION,79339,"Cohen, Seth D, MD",3/4/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,2/20/2024,Inactive,,
MMC OP VP INFUSION,79339,"Cohen, Seth D, MD",9/9/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,9/9/2024,Active,Squamous cell carcinoma of anal skin,
CBMC OP INFUSION 2FL,80283,"Brown, Andrew Bennett, MD",9/16/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/3/2024,Inactive,,
CBMC OP INFUSION 2FL,68424,"Litvak, Anna M, MD",4/10/2025,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,_1. First Line,4/2/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,1036,"Litvak, Anna M, MD",1/3/2025,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,_1. First Line,12/23/2024,Active,,
HAM OP INFUSION,86844,"Palmisiano, Neil David, MD",9/15/2023,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,9/15/2023,Inactive,,
NBR CINJ OP INFUSION,86844,"Palmisiano, Neil David, MD",10/24/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,10/24/2023,Inactive,,
NBR CINJ OP INFUSION,86844,"Palmisiano, Neil David, MD",12/19/2023,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,Consolidation,12/18/2023,Inactive,,
NBR CINJ OP INFUSION,86844,"Palmisiano, Neil David, MD",1/23/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,1/23/2024,Inactive,,
NBR CINJ OP INFUSION,86844,"Palmisiano, Neil David, MD",7/23/2024,CALGB 9111 (Maintenance Therapy) 28 Day Cycles + Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,7/23/2024,Active,,
CBMC OP INFUSION 2FL,20084,"Dharmapuri, Sirish, MD",12/9/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Consolidation,12/8/2024,Active,,
CBMC OP INFUSION 2FL,86411,"Phillips, Adrienne A, MD",10/18/2023,Bendamustine / RiTUXimab 28 Day Cycles - Marginal Zone Lymphoma,_1. First Line,10/17/2023,Inactive,,
MMC OP VP INFUSION,62971,"Talwar, Sumit, MD",1/25/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_2. Second Line,1/24/2023,Active,,
CINJ OP INFUSION,66320,"Stephenson, Ryan D, DO",2/5/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,2/5/2025,Active,"Malignant neoplasm of left kidney (CMS/HCC)
Disorder of thyroid","C64.2 - Malignant neoplasm of left kidney, except renal pelvis; R80.9 - Proteinuria, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.32 - Chronic kidney disease, stage 3b; M54.50 - Low back pain, unspecified; G89.29 - Other chronic pain; E07.9 - Disorder of thyroid, unspecified"
CINJ OP INFUSION,66320,"Stephenson, Ryan D, DO",4/28/2025,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,4/28/2025,Active,"Malignant neoplasm of left kidney (CMS/HCC)
Disorder of thyroid","C64.2 - Malignant neoplasm of left kidney, except renal pelvis; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; F32.A - Depression, unspecified; N18.32 - Chronic kidney disease, stage 3b; K59.09 - Other constipation; G89.29 - Other chronic pain; E07.9 - Disorder of thyroid, unspecified"
CINJ OP INFUSION,68726,"Boland, Patrick M, MD",4/26/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/25/2024,Inactive,,
SOM OUTPT INFUSION,42251,"Yin, Faye, MD",6/27/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,6/20/2024,Active,,
SOM OUTPT INFUSION,42251,"Yin, Faye, MD",8/16/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/15/2024,Inactive,,
NBR 4N ONCOLOGY,86596,"Palmisiano, Neil David, MD",7/18/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_2. Second Line,7/17/2023,Inactive,,
NBR CINJ OP INFUSION,86596,"Assal, Amer, MD",4/8/2024,BMT Autologus Busulfan / Melphalan - Acute Promyelocytic Leukemia,Consolidation,4/8/2024,Inactive,,
NBR CINJ OP INFUSION,86596,"Palmisiano, Neil David, MD",5/6/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,5/5/2024,Active,"Multiple myeloma (CMS/HCC)
Encounter for pre-transplant evaluation for stem cell transplant",
NBR 4N ONCOLOGY,50322,"Egini, Ogechukwu, MD",3/27/2025,BMT Allogeneic Mel / Thio / Flu +abatacept/ Post Cy,_3. Third Line,3/7/2025,Active,"AML (acute myeloid leukemia) in remission (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
NBR CINJ OP INFUSION,35617,"Mayer, Tina M, MD",11/8/2024,CINJ 082003 (NRG-GU008) ARM 1 GNRH Agonist or Antagonist Therapy 84 Day Cycles Research- Prostate Cancer,_1. First Line,11/7/2024,Active,,
CBMC OP INFUSION 2FL,15503,"Brown, Andrew Bennett, MD",7/12/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,7/11/2023,Inactive,,
NBR CINJ OP INFUSION,68378,"Matasar, Matthew J, MD",6/28/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,6/26/2023,Inactive,,
MMC OP VP INFUSION,82998,"Lee, Patrick C, MD",3/27/2024,Atezolizumab 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/26/2024,Inactive,,
SOM OUTPT INFUSION,45433,"Patel, Eshan, MD",6/17/2024,mFOLFOX6 + bevacizumab Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin/bevacizumab) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/14/2024,Inactive,,
SOM OUTPT INFUSION,559,"Patel, Eshan, MD",1/13/2025,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,_2. Second Line,1/10/2025,Active,,
CINJ OP INFUSION,25297,"Hochster, Howard S, MD",5/2/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/30/2024,Inactive,,
MMC OP VP INFUSION,93064,"Lee, Patrick C, MD",4/6/2023,Pembrolizumab 42 Day Cycles- Non-Small Cell Lung Cancer,First Line,4/5/2023,Inactive,,
MMC OP VP INFUSION,93064,"Lee, Patrick C, MD",9/6/2023,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",,9/5/2023,Inactive,,
CINJ OP INFUSION,98062,"Ghodoussipour, Saum Bobak, MD",3/28/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,3/28/2023,Inactive,,
CINJ OP INFUSION,98062,"Ghodoussipour, Saum Bobak, MD",5/2/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,5/1/2023,Inactive,,
CINJ OP INFUSION,98062,"Stephenson, Ryan D, DO",11/15/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,11/15/2023,Inactive,,
CINJ OP INFUSION,94841,"Boland, Patrick M, MD",4/18/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,4/18/2025,Active,Cholangiocarcinoma (CMS/HCC),R97.0 - Elevated carcinoembryonic antigen (CEA); C22.1 - Intrahepatic bile duct carcinoma
CINJ OP INFUSION,46814,"Weiss, Sarah, MD",5/31/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,5/30/2023,Inactive,,
CINJ OP INFUSION,46814,"Weiss, Sarah, MD",11/29/2023,CINJ 092302 Cohort 1 Propranolol + Nivolumab (1 mg/kg) / Ipilumumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research- Melanoma,_2. Second Line,11/28/2023,Inactive,,
CINJ OP INFUSION,46814,"Weiss, Sarah, MD",11/30/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,11/29/2023,Inactive,,
CINJ OP INFUSION,50480,"Haigentz, Missak, MD",3/11/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,3/11/2025,Active,Oropharyngeal cancer (CMS/HCC),"C10.9 - Malignant neoplasm of oropharynx, unspecified; E85.4 - Organ-limited amyloidosis; D80.1 - Nonfamilial hypogammaglobulinemia"
MSC OP INFUSION,34885,"Cohen, Seth D, MD",5/2/2023,Bevacizumab 28 Day Cycles - CNS,First Line,5/2/2023,Inactive,,
CBMC OP INFUSION 2FL,20414,"Grossman, I Robert, MD",12/27/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,12/17/2024,Active,,
SOM OUTPT INFUSION,48703,"Patel, Eshan, MD",3/6/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,2/26/2023,Inactive,,
SOM OUTPT INFUSION,48703,"Patel, Eshan, MD",3/13/2023,Tremelimumab/Durvalumab/PEMEtrexed/CARBOplatin 21 Day Cycles- Malignant Pleural Mesothelioma,First Line,2/26/2023,Inactive,,
NBR 5N ONCOLOGY,80527,"Gulhati, Prateek, MD PhD",6/3/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Adjuvant,6/3/2024,Inactive,,
MSC OP INFUSION,18179,"Cohen, Seth D, MD",5/30/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,Third Line,5/29/2023,Inactive,,
MSC OP INFUSION,18179,"Cohen, Seth D, MD",4/25/2024,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,_4. Fourth Line,4/25/2024,Inactive,,
NBR CINJ OP INFUSION,42658,"Rhodes, Joanna Meehan, MD",11/22/2024,POLA Mini-R-CHP (Cyclophosphamide / DOXOrubicin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/20/2024,Active,,
NBR 4N ONCOLOGY,14495,"Zayac, Adam, MD",5/31/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,5/30/2024,Inactive,,
NBR CINJ OP INFUSION,14495,"Zayac, Adam, MD",8/12/2024,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,8/12/2024,Inactive,,
CBMC OP INFUSION 2FL,75728,"Dharmapuri, Sirish, MD",1/6/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/5/2025,Inactive,,
CINJ OP INFUSION,7211,"George, Mridula A, MD",12/11/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,12/10/2024,Active,,
MMC OP INFUSION,68139,"Lee, Patrick C, MD",3/18/2025,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/18/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),
NBR CINJ OP INFUSION,83988,"Matasar, Matthew J, MD",2/22/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,2/21/2023,Inactive,,
MSC OP INFUSION,28705,"Talwar, Sumit, MD",12/18/2024,Pembrolizumab 21 Day Cycles,Adjuvant,12/17/2024,Active,,
MSC OP INFUSION,43893,"Talwar, Sumit, MD",2/13/2025,Pembrolizumab 21 Day Cycles,Adjuvant,12/17/2024,Active,Astrocytoma (CMS/HCC),
CMC OP INFUSION,39448,"Talwar, Sumit, MD",12/30/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/25/2024,Inactive,,
CMC OP INFUSION,39448,"Talwar, Sumit, MD",1/3/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,1/2/2025,Inactive,Metastatic melanoma (CMS/HCC),
CINJ OP INFUSION,80355,"Boland, Patrick M, MD",4/8/2023,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,,4/7/2023,Inactive,,
CINJ OP INFUSION,80355,"Gulhati, Prateek, MD PhD",6/14/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,6/14/2024,Active,,
CMC OP INFUSION,84516,"Talwar, Sumit, MD",2/5/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,2/5/2024,Active,,
CBMC 2W ONCOLOGY,63488,"Grossman, I Robert, MD",7/12/2024,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,7/11/2024,Active,,
NBR 5N ONCOLOGY,89311,"Groisberg, Roman, MD",5/26/2023,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,5/26/2023,Inactive,,
CINJ OP INFUSION,98392,"Ghodoussipour, Saum Bobak, MD",3/11/2025,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,3/11/2025,Active,Urothelial carcinoma (CMS/HCC),
CINJ OP INFUSION,81624,"Berim, Lyudmyla, MD",12/9/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,12/8/2024,Active,,
CBMC OP INFUSION 2FL,86353,"Kulkarni, Aditya A, MD",2/5/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/4/2025,Active,Gastric adenocarcinoma (CMS/HCC),
NBI OP INFUSION,33201,"Anderson, Patrick S, MD",5/6/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,4/28/2025,Active,"Endometrial cancer determined by uterine biopsy (CMS/HCC)
Endometrial cancer (CMS/HCC)",
CMC OP INFUSION,12148,"Taff, Jessica, MD",8/8/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,First Line,8/6/2023,Inactive,,
CMC OP INFUSION,12148,"Taff, Jessica, MD",2/18/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_3. Third Line,2/6/2025,Active,"Secondary malignant neoplasm of liver (CMS/HCC)
Malignant neoplasm of female breast (CMS/HCC)",
TRMC TCCC OP INFUSION,83752,"Salerno, Vincent E, MD",9/9/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,9/8/2024,Active,,
NBI OP INFUSION,56645,"Shah, Maya M, MD",6/5/2024,Pembrolizumab 21 Day Cycles - Pancreatic adenocarcinoma with high TMB,_1. First Line,6/4/2024,Inactive,,
TRMC TCCC OP INFUSION,39819,"Salerno, Vincent E, MD",9/30/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,9/6/2024,Active,,
NBR 5N ONCOLOGY,92219,"Boland, Patrick M, MD",10/9/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/8/2024,Inactive,,
CINJ OP INFUSION,92219,"Boland, Patrick M, MD",12/17/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/16/2024,Active,,
NBR CINJ OP INFUSION,5236,"Tiger, Yun Kyoung, MD",4/26/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,4/23/2024,Inactive,,
TRMC TCCC OP INFUSION,38100,"Capo, Gerardo, MD",4/4/2025,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,4/4/2025,Active,"Primary prostate cancer with metastasis from prostate to other site (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)",
CINJ OP INFUSION,55463,"Berim, Lyudmyla, MD",9/15/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/14/2023,Inactive,,
CINJ OP INFUSION,55463,"Berim, Lyudmyla, MD",10/24/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/23/2024,Active,,
CINJ OP INFUSION,88372,"Saraiya, Biren P, MD",8/23/2023,CINJ 082107 (CURLU177PSM001) Abiraterone / Prednisone 28 Day Cycles Research- Prostate Cancer,Second Line,7/26/2023,Inactive,,
HAM OP INFUSION,95025,"Patel, Malini M, MD",2/2/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/1/2023,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
TRMC TCCC OP INFUSION,56019,"Capo, Gerardo, MD",8/21/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,8/20/2024,Inactive,,
TRMC TCCC OP INFUSION,56019,"Capo, Gerardo, MD",10/2/2024,Ramucirumab 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,10/1/2024,Inactive,,
CINJ OP INFUSION,66697,"Hochster, Howard S, MD",10/19/2023,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,_1. First Line,9/20/2023,Inactive,,
CINJ OP INFUSION,66697,"Hochster, Howard S, MD",3/27/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,Maintenance,3/26/2025,Active,"Hepatocellular carcinoma (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C22.0 - Liver cell carcinoma; B37.9 - Candidiasis, unspecified; D64.9 - Anemia, unspecified; J45.909 - Unspecified asthma, uncomplicated; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures"
NBR CINJ OP INFUSION,55558,"Shah, Mansi R, MD",2/7/2023,Carfilzomib/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,Third Line,2/7/2023,Inactive,,
NBR CINJ OP INFUSION,55558,"Shah, Mansi R, MD",4/9/2024,Carfilzomib 56 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,4/8/2024,Inactive,,
NBR CINJ OP INFUSION,55558,"Shah, Mansi R, MD",5/27/2024,Elranatamab-bcmm Cycle 1 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,5/19/2024,Inactive,,
NBR CINJ OP INFUSION,55558,"Shah, Mansi R, MD",10/8/2024,Elotuzumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_4. Fourth Line,8/26/2024,Active,,
NBR CINJ OP INFUSION,55558,"Shah, Mansi R, MD",5/6/2025,Isatuximab-irfc/Selinexor /Dexamethasone 28 Day Cycles- Multiple Myeloma,_8. Eighth Line,5/6/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CINJ OP INFUSION,21616,"Saraiya, Biren P, MD",7/11/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,7/11/2023,Active,,
CBMC OP INFUSION 2FL,47960,"Brown, Andrew Bennett, MD",9/12/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/10/2024,Active,,
CINJ OP INFUSION,87865,"Toppmeyer, Deborah L, MD",3/3/2023,DOCEtaxel / Trastuzumab 21 Day Cycles - Breast,Adjuvant,3/2/2023,Inactive,,
CBMC OP INFUSION 2FL,9466,"Dharmapuri, Sirish, MD",2/18/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/3/2025,Active,Cancer of sigmoid (CMS/HCC),
CINJ OP INFUSION,51039,"Ghodoussipour, Saum Bobak, MD",4/21/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/21/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)","C67.7 - Malignant neoplasm of urachus; R82.6 - Abnormal urine levels of substances chiefly nonmedicinal as to source; C68.9 - Malignant neoplasm of urinary organ, unspecified; C67.8 - Malignant neoplasm of overlapping sites of bladder"
CBMC OP INFUSION 2FL,32257,"Leitner, Stuart P, MD",8/18/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,8/17/2023,Inactive,,
CBMC OP INFUSION 2FL,32257,"Leitner, Stuart P, MD",7/19/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/18/2024,Active,,
CINJ OP INFUSION,50478,"Leiser, Aliza, MD",1/8/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/4/2024,Inactive,,
NBR CINJ OP INFUSION,44848,"Evens, Andrew M, DO",9/27/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,9/26/2023,Inactive,,
CINJ OP INFUSION,79068,"Weiss, Sarah, MD",3/13/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,3/13/2023,Active,,
SOM OUTPT INFUSION,40421,"Toomey, Kathleen C, MD",1/26/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,1/24/2024,Inactive,,
SOM OUTPT INFUSION,40421,"Toomey, Kathleen C, MD",7/15/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,7/15/2024,Active,,
MMC OP VP INFUSION,11508,"Cohen, Seth D, MD",8/15/2024,Afatinib 28 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,8/15/2024,Inactive,,
CINJ OP INFUSION,95859,"Stephenson, Ryan D, DO",9/11/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,9/11/2023,Inactive,,
CINJ OP INFUSION,3846,"Weiss, Sarah, MD",1/8/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,1/7/2025,Active,,
CBMC OP INFUSION 2FL,32528,"Leitner, Stuart P, MD",9/21/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,9/20/2023,Inactive,,
CINJ OP INFUSION,50228,"Saraiya, Biren P, MD",11/19/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_5. Fifth Line,11/11/2024,Active,,
NBR 5N MED-SURG OVRF,86837,"Alexander, Henry Richard, MD",4/28/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,4/28/2025,Active,"Malignant neoplasm of sigmoid colon (CMS/HCC)
Pseudomyxoma peritonei (CMS/HCC)",
HAM OP INFUSION,47503,"Yogarajah, Meera, MD",6/3/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/20/2024,Active,,
NBR 5N ONCOLOGY,280,"Haigentz, Missak, MD",11/6/2024,Dabrafenib/Trametinib 28 Day Cycles- Anaplastic Thyroid Cancer,_2. Second Line,11/6/2024,Inactive,,
NBR 5N ONCOLOGY,280,"Haigentz, Missak, MD",11/7/2024,"PACLitaxel D1, D8, D15, D22, D29, D36 56 Day Cycles- Head and Neck Cancers",_1. First Line,11/7/2024,Inactive,,
CINJ OP INFUSION,98924,"Omene, Coral Oghenerukevwe, MD",6/13/2023,Palbociclib 28 Day Cycles - Breast,,6/13/2023,Inactive,,
CINJ OP INFUSION,12164,"Stephenson, Ryan D, DO",8/2/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,8/2/2024,Active,,
JCMC CP INFUSION,49646,"Sekhri, Arunabh, MD",3/24/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,Second Line,3/23/2023,Inactive,,
JCMC CP INFUSION,49646,"Sekhri, Arunabh, MD",7/14/2023,Abemaciclib+Fulvestrant  28 Day Cycles - Breast ,Second Line,7/14/2023,Inactive,,
JCMC CP INFUSION,91000,"Sekhri, Arunabh, MD",1/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/8/2023,Inactive,,
CINJ OP INFUSION,39845,"Boland, Patrick M, MD",12/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/4/2023,Inactive,,
CINJ OP INFUSION,74719,"Boland, Patrick M, MD",2/27/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/25/2025,Active,Rectal cancer (CMS/HCC),C20 - Malignant neoplasm of rectum; K62.5 - Hemorrhage of anus and rectum
CMC OP INFUSION,51550,"Tang, Horace, MD",5/18/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/16/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,58291,"Masterson, Margaret, MD",2/17/2023,AALL1732 B-ALL Induction,,2/17/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,58291,"Masterson, Margaret, MD",2/18/2023,per AALL1732 B-ALL Induction+ Dasatinib,,2/18/2023,Inactive,,
CINJ PEDS HEMONC ,58291,"Masterson, Margaret, MD",4/4/2023,AALL1732 Consolidation,Consolidation,3/24/2023,Inactive,,
CINJ PEDS HEMONC ,29802,"Parikh, Nehal S, MD",2/21/2025,PEDS ACNS0332 - Other than Average Risk Medulloblastoma / PNET ,_1. First Line,2/14/2025,Active,Medulloblastoma (CMS/HCC),
SOM 1PAV ONCOLOGY,21076,"Patel, Eshan, MD",11/21/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/21/2023,Inactive,,
CMC OP INFUSION,80581,"Taff, Jessica, MD",5/1/2023,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,Third Line,5/1/2023,Inactive,,
CINJ OP INFUSION,84940,"Weiss, Sarah, MD",4/8/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,3/22/2024,Active,,
CMC OP INFUSION,53241,"Cohen, Seth D, MD",8/8/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,8/7/2024,Active,,
CBMC OP INFUSION 2FL,95486,"Brown, Andrew Bennett, MD",7/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,7/21/2024,Active,,
CINJ OP INFUSION,51444,"Berim, Lyudmyla, MD",1/30/2025,Atezolizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,1/29/2025,Active,,
CINJ OP INFUSION,77470,"Haigentz, Missak, MD",3/25/2025,PACLitaxel 200 mg/m2 /CARBOplatin PLUS Ramucirumab 21 Day Cycles Neoadjuvant/Adjuvant- Thymic Carcinoma,Neoadjuvant,3/25/2025,Inactive,"Thymic carcinoma (CMS/HCC)
Secondary malignant neoplasm of pleura (CMS/HCC)",D49.89 - Neoplasm of unspecified behavior of other specified sites; C37 - Malignant neoplasm of thymus; C78.2 - Secondary malignant neoplasm of pleura
NBR CINJ OP INFUSION,47461,"Chen, Xiaoyi",3/25/2025,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,3/25/2025,Active,"Myelodysplastic syndrome, high grade (CMS/HCC)",D46.Z - Other myelodysplastic syndromes
CINJ OP INFUSION,68233,"Girda, Eugenia, MD",6/2/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,6/1/2023,Inactive,,
CINJ OP INFUSION,68233,"Girda, Eugenia, MD",10/30/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,10/18/2023,Active,,
CINJ OP INFUSION,65083,"Stephenson, Ryan D, DO",4/18/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,4/18/2025,Active,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)","C64.1 - Malignant neoplasm of right kidney, except renal pelvis; I82.403 - Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral"
CINJ OP INFUSION,65083,"Stephenson, Ryan D, DO",3/28/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,3/28/2025,Inactive,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)","C64.1 - Malignant neoplasm of right kidney, except renal pelvis; I82.403 - Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral"
CBMC OP INFUSION 2FL,94528,"Litvak, Anna M, MD",11/2/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,_2. Second Line,11/2/2023,Inactive,,
MMC OP VP INFUSION,76790,"Cohen, Seth D, MD",5/2/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,5/1/2024,Inactive,,
NBR 4N ONCOLOGY,21000,"Leiser, Aliza, MD",1/5/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,1/4/2023,Inactive,,
CINJ OP INFUSION,21000,"Leiser, Aliza, MD",1/23/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,12/18/2022,Inactive,,
NBR 5N ONCOLOGY,3257,"Tiger, Yun Kyoung, MD",9/10/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_2. Second Line,9/10/2024,Inactive,,
NBR 5N ONCOLOGY,25876,"Tiger, Yun Kyoung, MD",12/25/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,12/25/2024,Active,,
NBR CINJ OP INFUSION,25876,"Tiger, Yun Kyoung, MD",2/5/2025,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_2. Second Line,1/30/2025,Inactive,High grade B-cell lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,8027,"Tiger, Yun Kyoung, MD",5/29/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_4. Fourth Line,5/29/2025,Active,"Retroperitoneal mass
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)",
NBR CINJ OP INFUSION,8027,"Tiger, Yun Kyoung, MD",5/14/2025,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,5/14/2025,Inactive,"Retroperitoneal mass
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)",
NBR 5N ONCOLOGY,8027,"Tiger, Yun Kyoung, MD",5/9/2025,Pola-R ICE 21 Day Cycles - B-Cell Lymphoma (Inpatient Regimen),_3. Third Line,5/9/2025,Active,"Retroperitoneal mass
High grade B-cell lymphoma (CMS/HCC)","C85.10 - Unspecified B-cell lymphoma, unspecified site; E88.3 - Tumor lysis syndrome; N13.6 - Pyonephrosis; N17.9 - Acute kidney failure, unspecified; E83.39 - Other disorders of phosphorus metabolism; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; D64.81 - Anemia due to antineoplastic chemotherapy; C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site; Z99.2 - Dependence on renal dialysis; E03.9 - Hypothyroidism, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E66.9 - Obesity, unspecified; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy; I48.0 - Paroxysmal atrial fibrillation; N18.30 - Chronic kidney disease, stage 3 unspecified; Z79.4 - Long term (current) use of insulin; K59.00 - Constipation, unspecified; H26.9 - Unspecified cataract; Z74.09 - Other reduced mobility; E78.5 - Hyperlipidemia, unspecified; H91.90 - Unspecified hearing loss, unspecified ear; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; E87.5 - Hyperkalemia; E87.70 - Fluid overload, unspecified; R33.8 - Other retention of urine; R31.9 - Hematuria, unspecified; Z90.49 - Acquired absence of other specified parts of digestive tract; Z88.5 - Allergy status to narcotic agent; Z88.1 - Alle..."
CINJ OP INFUSION,8027,"Tiger, Yun Kyoung, MD",3/21/2025,Rituximab,_1. First Line,3/19/2025,Inactive,"Retroperitoneal mass
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)",
NBR CINJ OP INFUSION,8027,"Tiger, Yun Kyoung, MD",3/21/2025,Pola-R-GemOx (Polatuzumab Vedotin / RiTUXimab / Gemcitabine / OXALIplatin) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/21/2025,Inactive,High grade B-cell lymphoma (CMS/HCC),"C85.10 - Unspecified B-cell lymphoma, unspecified site; I48.91 - Unspecified atrial fibrillation; N17.9 - Acute kidney failure, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I10 - Essential (primary) hypertension; K59.00 - Constipation, unspecified; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; E03.9 - Hypothyroidism, unspecified; K12.30 - Oral mucositis (ulcerative), unspecified; E83.42 - Hypomagnesemia; E44.1 - Mild protein-calorie malnutrition; F41.9 - Anxiety disorder, unspecified; R19.00 - Intra-abdominal and pelvic swelling, mass and lump, unspecified site; Z79.4 - Long term (current) use of insulin; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
NBR CINJ OP INFUSION,8027,"Tiger, Yun Kyoung, MD",3/21/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/21/2025,Inactive,"Retroperitoneal mass
High grade B-cell lymphoma (CMS/HCC)",
JCMC CP INFUSION,84656,"Cruz, Allan Louie E, MD",5/2/2025,Cetuximab with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,4/29/2025,Active,Malignant neoplasm of tongue (CMS/HCC),"C02.9 - Malignant neoplasm of tongue, unspecified"
NBI OP INFUSION,76240,"Anderson, Patrick S, MD",9/1/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_7. Seventh Line,8/31/2023,Inactive,,
NBI OP INFUSION,76240,"Anderson, Patrick S, MD",11/30/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Granulosa cell tumor of the Ovary recurrent,Adjuvant,11/29/2023,Inactive,,
NBI OP INFUSION,76240,"Anderson, Patrick S, MD",5/30/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer ( granulosa cell tumor of the ovary),_3. Third Line,5/29/2024,Active,,
CBMC OP INFUSION 2FL,17994,"Brown, Andrew Bennett, MD",11/14/2023,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,11/14/2023,Active,,
CINJ OP INFUSION,48935,"Boland, Patrick M, MD",6/22/2023,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,,6/22/2023,Inactive,,
CBMC OP INFUSION 2FL,94039,"Brown, Andrew Bennett, MD",11/13/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,11/12/2023,Inactive,,
MMC OP INFUSION,71942,"Lee, Patrick C, MD",6/25/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Adjuvant,6/25/2024,Inactive,,
MMC OP INFUSION,71942,"Lee, Patrick C, MD",11/12/2024,Bevacizumab 28 Day Cycles - CNS,_1. First Line,11/12/2024,Active,,
MMC OP INFUSION,71942,"Lee, Patrick C, MD",11/19/2024,Temozolomide 28 Day Cycles - CNS,_1. First Line,11/19/2024,Active,Anal carcinoma (CMS/HCC),
NBR CINJ OP INFUSION,29805,"Evens, Andrew M, DO",9/27/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,9/27/2023,Inactive,,
NBR CINJ OP INFUSION,29805,"Evens, Andrew M, DO",12/13/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,12/12/2023,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
SOM OUTPT INFUSION,51552,"Yin, Faye, MD",7/19/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/19/2023,Inactive,,
SOM OUTPT INFUSION,11396,"Yin, Faye, MD",10/14/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/13/2024,Inactive,,
NBR CINJ OP INFUSION,90824,"Doraiswamy, Anupama, MD",1/23/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,First Line,1/22/2023,Inactive,,
CINJ OP INFUSION,98697,"Stephenson, Ryan D, DO",2/19/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,2/19/2024,Inactive,,
CINJ OP INFUSION,98697,"Stephenson, Ryan D, DO",3/6/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,3/6/2024,Inactive,,
NBR CINJ OP INFUSION,574,"Evens, Andrew M, DO",3/3/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,3/1/2023,Inactive,,
NBR 5N ONCOLOGY,574,"Evens, Andrew M, DO",3/6/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,3/5/2023,Inactive,,
NBR 4N ONCOLOGY,574,"Evens, Andrew M, DO",12/7/2023,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 14 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,12/6/2023,Inactive,,
NBR 4N ONCOLOGY,574,"Tiger, Yun Kyoung, MD",1/3/2024,DHAX (Dexamethasone / Cytarabine / OXALIplatin) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,1/3/2024,Inactive,,
NBR 4N ONCOLOGY,574,"Matasar, Matthew J, MD",1/4/2024,Cytarabine,_3. Third Line,1/4/2024,Inactive,,
NBR 4N ONCOLOGY,574,"Evens, Andrew M, DO",1/11/2024,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,Lymphodepletion,1/11/2024,Inactive,,
NBR CINJ OP INFUSION,574,"Evens, Andrew M, DO",2/14/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_3. Third Line,2/13/2024,Inactive,,
NBR CINJ OP INFUSION,574,"Evens, Andrew M, DO",6/12/2024,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,6/11/2024,Inactive,,
NBR CINJ OP INFUSION,574,"Evens, Andrew M, DO",7/10/2024,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,7/9/2024,Inactive,,
CBMC 2W ONCOLOGY,85677,"Grossman, I Robert, MD",5/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/16/2024,Inactive,,
NBR 5N ONCOLOGY,9066,"Zayac, Adam, MD",3/26/2024,Cytarabine (100 mg/m2) / DAUNOrubicin (90 mg/m2) (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,3/26/2024,Inactive,,
NBR CINJ OP INFUSION,9066,"Zayac, Adam, MD",5/6/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),_1. First Line,5/6/2024,Inactive,,
NBR CINJ OP INFUSION,9066,"Zayac, Adam, MD",11/22/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_2. Second Line,11/20/2024,Active,,
NBR 4N ONCOLOGY,9066,"Tiger, Yun Kyoung, MD",12/6/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_2. Second Line,12/6/2024,Inactive,,
NBR CINJ OP INFUSION,9066,"Zayac, Adam, MD",1/16/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Maintenance,1/15/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,9066,"Zayac, Adam, MD",1/27/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,1/26/2025,Inactive,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Pancytopenia due to chemotherapy (CMS/HCC)",
CBMC OP INFUSION 2FL,34248,"Brown, Andrew Bennett, MD",5/21/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/13/2024,Inactive,,
CBMC OP INFUSION 2FL,34248,"Brown, Andrew Bennett, MD",9/17/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,9/16/2024,Active,,
NBI OP INFUSION,86791,"Schleicher, Lori, MD",8/29/2024,Ibrutinib 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,8/29/2024,Active,,
CBMC OP INFUSION 2FL,81673,"Raptis, George, MD",12/5/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/3/2024,Active,"Cancer with unknown primary site (CMS/HCC)
Squamous cell carcinoma metastatic to lymph nodes of head and neck (CMS/HCC)",
CBMC OP INFUSION 2FL,81673,"Raptis, George, MD",4/9/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,4/9/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,83918,"Grossman, I Robert, MD",10/29/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_4. Fourth Line,10/27/2024,Active,,
SOM 1PAV ONCOLOGY,8359,"Patel, Eshan, MD",8/14/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,8/13/2023,Inactive,,
TRMC TCCC OP INFUSION,4787,"Capo, Gerardo, MD",4/15/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,4/15/2025,Active,Malignant neoplasm of overlapping sites of body of uterus (CMS/HCC),
TRMC TCCC OP INFUSION,4787,"Capo, Gerardo, MD",4/15/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,4/15/2025,Inactive,Malignant neoplasm of overlapping sites of body of uterus (CMS/HCC),"C78.89 - Secondary malignant neoplasm of other digestive organs; C48.2 - Malignant neoplasm of peritoneum, unspecified; R19.04 - Left lower quadrant abdominal swelling, mass and lump; N95.0 - Postmenopausal bleeding; R97.8 - Other abnormal tumor markers; R41.9 - Unspecified symptoms and signs involving cognitive functions and awareness; E43 - Unspecified severe protein-calorie malnutrition"
CBMC 2W ONCOLOGY,36827,"Wagmiller, Jennifer Ann, MD",11/14/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,36827,"Wagmiller, Jennifer Ann, MD",5/20/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/19/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,11963,"Masterson, Margaret, MD",6/6/2023,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,Induction,6/6/2023,Active,,
CMC OP INFUSION,46128,"Pompa, Tiffany Ann, MD",8/13/2024,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,8/7/2024,Inactive,,
CMC OP INFUSION,46128,"Pompa, Tiffany Ann, MD",1/9/2025,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,1/7/2025,Active,,
CMC OP INFUSION,80952,"Pompa, Tiffany Ann, MD",4/23/2025,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_2. Second Line,4/23/2025,Inactive,"Sarcoma of left lower extremity (CMS/HCC)
Malignant neoplasm of connective and soft tissue of left lower limb, including hip (CMS/HCC)",
CBMC 2W ONCOLOGY,77006,"Grossman, I Robert, MD",1/13/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,1/12/2024,Active,,
CINJ OP INFUSION,14851,"Omene, Coral Oghenerukevwe, MD",11/26/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,11/25/2024,Active,,
JCMC CP INFUSION,6472,"Sekhri, Arunabh, MD",11/11/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/3/2024,Inactive,,
JCMC CP INFUSION,6472,"Sekhri, Arunabh, MD",11/11/2024,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,11/3/2024,Active,,
CINJ OP INFUSION,84458,"Haigentz, Missak, MD",1/30/2023,CISplatin 75 mg/m2/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,Adjuvant,1/29/2023,Inactive,,
SOM OUTPT INFUSION,7304,"Patel, Eshan, MD",8/12/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,8/9/2024,Active,,
SOM OUTPT INFUSION,7711,"Patel, Eshan, MD",5/30/2023,"Bortezomib D1, D15 Q28 Day Cycles- Multiple Myeloma",Maintenance,5/29/2023,Inactive,,
NBR CINJ OP INFUSION,22825,"Evens, Andrew M, DO",2/17/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),Second Line,2/17/2023,Inactive,,
NBR CINJ OP INFUSION,22825,"Evens, Andrew M, DO",3/8/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,3/8/2023,Inactive,,
NBR 4N ONCOLOGY,22825,"Braunschweig, Ira, MD",5/5/2023,BMT Autologous BEAM,,5/5/2023,Inactive,,
CINJ OP INFUSION,68471,"George, Mridula A, MD",4/28/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,4/28/2023,Active,,
CINJ OP INFUSION,8602,"Ghodoussipour, Saum Bobak, MD",2/27/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,2/26/2024,Inactive,,
CINJ OP INFUSION,8602,"Ghodoussipour, Saum Bobak, MD",5/21/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Maintenance,5/20/2024,Active,,
NBI OP INFUSION,13276,"Anderson, Patrick S, MD",7/30/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Squamous Cell Cancer of the Cervix,_1. First Line,7/29/2024,Active,,
HAM OP INFUSION,89447,"Gendy, Mina, DO",3/27/2025,Mogamulizumab-kpkc 28 Day Cycle - Mycosis Fungoides / Sezary Syndrome ,_2. Second Line,3/27/2025,Active,Cutaneous T-cell lymphoma (CMS/HCC),"C84.A0 - Cutaneous T-cell lymphoma, unspecified, unspecified site; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.30 - Chronic kidney disease, stage 3 unspecified; E11.51 - Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I08.0 - Rheumatic disorders of both mitral and aortic valves; I65.29 - Occlusion and stenosis of unspecified carotid artery; E78.2 - Mixed hyperlipidemia; E66.9 - Obesity, unspecified; M19.90 - Unspecified osteoarthritis, unspecified site; Z87.442 - Personal history of urinary calculi; Z95.1 - Presence of aortocoronary bypass graft; Z96.659 - Presence of unspecified artificial knee joint; Z88.0 - Allergy status to penicillin; Z91.041 - Radiographic dye allergy status; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
MMC OP INFUSION,73939,"Meghal, Trishala, MD",6/14/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,6/14/2024,Active,,
MMC OP INFUSION,73939,"Meghal, Trishala, MD",11/27/2024,Relugolix 30 day Cycles - Prostate,_1. First Line,11/27/2024,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,99308,"Palmisiano, Neil David, MD",4/14/2023,HyperCVAD (Cycle A) Course (Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,Induction,4/13/2023,Inactive,,
NBR CINJ OP INFUSION,99308,"Palmisiano, Neil David, MD",5/8/2023,HyperCVAD (Cycle B) Course (High Dose Methotrexate / Cytarabine) 21 Day Cycles - Acute Lymphoblastic Leukemia,,5/4/2023,Inactive,,
NBR CINJ OP INFUSION,99308,"Palmisiano, Neil David, MD",6/20/2023,HyperCVD (Cyclophosphamide / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,,6/19/2023,Inactive,,
NBR CINJ OP INFUSION,99308,"Palmisiano, Neil David, MD",11/3/2023,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,10/22/2023,Active,,
NBR CINJ OP INFUSION,99308,"Palmisiano, Neil David, MD",12/14/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,12/14/2023,Active,,
CBMC OP INFUSION 2FL,57492,"Leitner, Stuart P, MD",9/17/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/16/2024,Active,Malignant melanoma of left thigh (CMS/HCC),
CINJ OP INFUSION,56983,"Stephenson, Ryan D, DO",9/18/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,9/18/2024,Active,,
CINJ OP INFUSION,47983,"Toppmeyer, Deborah L, MD",5/8/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,5/8/2025,Active,On antineoplastic chemotherapy,"C50.911 - Malignant neoplasm of unspecified site of right female breast; C50.912 - Malignant neoplasm of unspecified site of left female breast; Z17.0 - Estrogen receptor positive status (ER+); Z17.22 - Progesterone receptor negative status; Z17.32 - Human epidermal growth factor receptor 2 negative status; C79.81 - Secondary malignant neoplasm of breast; C79.31 - Secondary malignant neoplasm of brain; C79.51 - Secondary malignant neoplasm of bone; R59.0 - Localized enlarged lymph nodes; M43.16 - Spondylolisthesis, lumbar region; M51.369 - Other intervertebral disc degeneration, lumbar region without mention of lumbar back pain or lower extremity pain; M48.061 - Spinal stenosis, lumbar region without neurogenic claudication; M48.54XD - Collapsed vertebra, not elsewhere classified, thoracic region, subsequent encounter for fracture with routine healing; M47.814 - Spondylosis without myelopathy or radiculopathy, thoracic region; M51.34 - Other intervertebral disc degeneration, thoracic region; J90 - Pleural effusion, not elsewhere classified; M50.31 - Other cervical disc degeneration, high cervical region; M48.02 - Spinal stenosis, cervical region; M47.812 - Spondylosis without myelopathy or radiculopathy, cervical region; M25.78 - Osteophyte, vertebrae; J32.8 - Other chronic sinusitis; I67.82 - Cerebral ischemia; Z79.811 - Long term (current) use of aromatase inhibitors; Z88.2 - Allergy status to sulfonamides; Z88.8 - Allergy status to other drugs, medicaments and biologica..."
NBI OP INFUSION,50622,"Cohen, Alice, MD",10/19/2023,"PACLitaxel D1, D15 28 Day Cycles - Breast",_2. Second Line,10/18/2023,Inactive,,
NBI OP INFUSION,50622,"Cohen, Alice, MD",12/27/2023,Everolimus / Exemestane 28 Day Cycles - Breast,_3. Third Line,12/27/2023,Inactive,,
NBI OP INFUSION,50622,"Cohen, Alice, MD",6/20/2024,Gemcitabine 28 Day Cycles - Breast,_4. Fourth Line,6/19/2024,Inactive,,
NBI OP INFUSION,50622,"Cohen, Alice, MD",9/12/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_4. Fourth Line,9/11/2024,Inactive,,
NBI OP INFUSION,50622,"Cohen, Alice, MD",11/7/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,11/7/2024,Active,,
NBI OP INFUSION,46506,"Cohen, Alice, MD",5/15/2025,Alpelisib 28 Day Cycles - Breast,_6. Sixth Line,5/15/2025,Active,"Breast cancer metastasized to liver, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,25291,"Patankar, Sonali, MD",11/7/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Neoadjuvant,11/6/2024,Inactive,,
CBMC 2W ONCOLOGY,88634,"Grossman, I Robert, MD",1/21/2024,RiTUXimab Initial ++ Infusion Single Day (Outpatient),_1. First Line,1/21/2024,Inactive,,
MMC OP VP INFUSION,48362,"Cohen, Seth D, MD",7/3/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/25/2023,Inactive,,
NBR CINJ OP INFUSION,228,"Shah, Mansi R, MD",6/27/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,6/19/2024,Inactive,,
NBR CINJ OP INFUSION,228,"Shah, Mansi R, MD",10/24/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,10/23/2024,Active,,
NBR CINJ OP INFUSION,76890,"Shah, Mansi R, MD",2/13/2025,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_3. Third Line,2/12/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
NBR CINJ OP INFUSION,76890,"Shah, Mansi R, MD",3/6/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,3/6/2025,Active,Metastatic multiple myeloma to bone (CMS/HCC),"Z94.84 - Stem cells transplant status; C90.00 - Multiple myeloma not having achieved remission; S12.000B - Unspecified displaced fracture of first cervical vertebra, initial encounter for open fracture; I10 - Essential (primary) hypertension; I82.622 - Acute embolism and thrombosis of deep veins of left upper extremity; R73.03 - Prediabetes; E66.01 - Morbid (severe) obesity due to excess calories; Z78.0 - Asymptomatic menopausal state; Z88.0 - Allergy status to penicillin; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z92.3 - Personal history of irradiation; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,80218,"Cohen, Seth D, MD",2/21/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/12/2024,Inactive,,
CMC OP INFUSION,69966,"Taff, Jessica, MD",9/26/2023,mFOLFOX6  4 Day Cycles- Gastrointestinal Cancers - Desensitization on C4 + Panitumumab (on C8),Third Line,9/13/2023,Inactive,,
CMC OP INFUSION,32174,"Tang, Horace, MD",3/6/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,3/5/2023,Inactive,,
CMC OP INFUSION,32174,"Tang, Horace, MD",7/17/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/16/2023,Inactive,,
CINJ OP INFUSION,67974,"Goel, Sanjay, MD",10/23/2024,CINJ 052401 Part B GIM-122 ,_3. Third Line,10/22/2024,Active,,
CINJ OP INFUSION,67974,"Goel, Sanjay, MD",2/19/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,2/19/2025,Active,Mucinous adenocarcinoma of appendix (CMS/HCC),
CMC OP INFUSION,71801,"Taff, Jessica, MD",5/3/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/2/2023,Inactive,,
CMC OP INFUSION,71801,"Taff, Jessica, MD",1/10/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/6/2024,Inactive,,
CBMC 2W ONCOLOGY,37115,"Wagmiller, Jennifer Ann, MD",12/10/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_4. Fourth Line,12/10/2024,Inactive,,
CBMC OP INFUSION 2FL,37115,"Wagmiller, Jennifer Ann, MD",12/25/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_4. Fourth Line,12/24/2024,Active,,
CBMC 2W ONCOLOGY,43695,"Wagmiller, Jennifer Ann, MD",5/29/2025,PACLitaxel 21 Day Cycles - Breast,_4. Fourth Line,5/29/2025,Active,"Stage IV breast cancer in female (CMS/HCC)
Antineoplastic chemotherapy induced anemia
Bone disease
Chemotherapy-induced fatigue",R10.32 - LLQ abdominal pain; R11.2 - Nausea & vomiting; R52 - Intractable pain
CINJ OP INFUSION,34611,"Golombos, David, MD",8/28/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,8/28/2023,Inactive,,
CINJ OP INFUSION,34611,"Golombos, David, MD",1/2/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/2/2024,Active,,
MMC OP VP INFUSION,72523,"Meghal, Trishala, MD",12/31/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/16/2024,Active,Primary endometrioid carcinoma of left ovary (CMS/HCC),
CMC OP INFUSION,78853,"Taff, Jessica, MD",5/15/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,5/9/2024,Active,,
CBMC OP INFUSION 2FL,95815,"Dave, Manish, MD",5/10/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/9/2023,Active,,
SOM OUTPT INFUSION,74866,"Patel, Eshan, MD",1/18/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,1/17/2024,Active,,
MMC OP INFUSION,8142,"Meghal, Trishala, MD",4/28/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,4/27/2023,Inactive,,
MMC OP VP INFUSION,8142,"Meghal, Trishala, MD",2/23/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,2/15/2024,Active,,
CBMC OP INFUSION 2FL,11934,"Grossman, I Robert, MD",8/29/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,8/28/2023,Inactive,,
CBMC OP INFUSION 2FL,11934,"Litvak, Anna M, MD",8/29/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/28/2023,Inactive,,
CBMC 2W ONCOLOGY,11934,"Grossman, I Robert, MD",11/4/2023,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,11/4/2023,Inactive,,
CBMC OP INFUSION 2FL,11934,"Grossman, I Robert, MD",3/12/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,2/19/2024,Inactive,,
CBMC OP INFUSION 2FL,11934,"Raptis, George, MD",8/14/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,8/14/2024,Inactive,,
CBMC OP INFUSION 2FL,76699,"Grossman, I Robert, MD",4/5/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,76699,"Grossman, I Robert, MD",1/20/2025,Venetoclax / AzaCITIDine 42 Day Cycles - Acute Myeloid Leukemia,_1. First Line,1/20/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
CBMC OP INFUSION 2FL,76699,"Grossman, I Robert, MD",3/10/2025,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,3/3/2025,Active,AML (acute myeloid leukemia) in remission (CMS/HCC),
CMC OP INFUSION,45660,"Packiam, Vignesh, MD",5/13/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,5/13/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"N30.90 - Cystitis, unspecified without hematuria; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CMC OP INFUSION,45660,"Packiam, Vignesh, MD",3/6/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/5/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C67.8 - Malignant neoplasm of overlapping sites of bladder; C67.9 - Malignant neoplasm of bladder, unspecified; R82.90 - Unspecified abnormal findings in urine; R30.0 - Dysuria; R39.9 - Unspecified symptoms and signs involving the genitourinary system"
MMC OP VP INFUSION,18753,"Talwar, Sumit, MD",5/20/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,5/20/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,4780,"Rhodes, Joanna Meehan, MD",1/25/2024,Pembrolizumab 21 Day Cycles ,_3. Third Line,1/24/2024,Inactive,,
NBR CINJ OP INFUSION,4780,"Rhodes, Joanna Meehan, MD",2/26/2024,Pola+R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_5. Fifth Line,2/25/2024,Inactive,,
NBR CINJ OP INFUSION,4780,"Rhodes, Joanna Meehan, MD",4/29/2024,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE ) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_6. Sixth Line,4/29/2024,Inactive,,
NBR 4N ONCOLOGY,4780,"Rhodes, Joanna Meehan, MD",6/7/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_7. Seventh Line,6/7/2024,Inactive,,
NBR 4N ONCOLOGY,4780,"Rhodes, Joanna Meehan, MD",6/11/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Lymphoma ,_8. Eighth Line,6/11/2024,Inactive,,
JCMC CP INFUSION,47433,"Cruz, Allan Louie E, MD",6/6/2024,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,6/3/2024,Inactive,,
JCMC CP INFUSION,47433,"Cruz, Allan Louie E, MD",8/16/2024,"CINJ 112305 Arms B,D,F,H (Brentuximab Vendotin + Nivolumab) 21 Day Cycles - Hodgkin Lymphoma",Consolidation,8/14/2024,Inactive,,
JCMC CP INFUSION,47433,"Cruz, Allan Louie E, MD",9/5/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine)  28 Day Cycles - Hodgkin Lymphoma,Induction,9/4/2024,Inactive,,
MMC OP VP INFUSION,63664,"Cohen, Seth D, MD",12/11/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,12/3/2024,Active,,
CINJ OP INFUSION,80552,"Berim, Lyudmyla, MD",8/3/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/1/2023,Inactive,,
CINJ OP INFUSION,80552,"Berim, Lyudmyla, MD",4/18/2024,CINJ 072201 Control ARM FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,3/16/2024,Inactive,,
CINJ OP INFUSION,17515,"Dasgeb, Bahar, MD",9/19/2023,RiTUXimab 168 Day Cycles - Pemphigus,Maintenance,9/7/2023,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,16854,"Lee, Patrick C, MD",1/23/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,,1/22/2023,Inactive,,
NBI A5 PEDIATRICS,65328,"Narang, Shalu, MD",1/17/2025,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,1/16/2025,Active,,
NBI VALERIE FND HEMONC,65328,"de Benedictis, Marianna, MD",2/24/2025,AALL1731 SR-High B-ALL and DS-High B-ALL Consolidation,_1. First Line,2/24/2025,Active,Leukemia not having achieved remission (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission
NBI VALERIE FND HEMONC,65328,"de Benedictis, Marianna, MD",4/29/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,4/21/2025,Inactive,Leukemia not having achieved remission (CMS/HCC),
SOM OUTPT INFUSION,62826,"Yin, Faye, MD",10/11/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,10/11/2023,Inactive,,
MMC OP INFUSION,11152,"Meghal, Trishala, MD",7/18/2023,Ribociclib 28 Day Cycles - Breast,First Line,6/21/2023,Active,"Malignant neoplasm of rectum (CMS/HCC)
Secondary malignant neoplasm of left lung (CMS/HCC)
Metastasis to liver (CMS/HCC)",
CINJ OP INFUSION,69627,"Boland, Patrick M, MD",1/3/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,,1/2/2023,Inactive,,
CINJ OP INFUSION,69627,"Boland, Patrick M, MD",3/14/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,3/13/2023,Inactive,,
CINJ OP INFUSION,69627,"Boland, Patrick M, MD",7/7/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg q 6 wk) 21 Day Cycles - ESCC,,7/5/2023,Inactive,,
CINJ OP INFUSION,69627,"Boland, Patrick M, MD",11/17/2023,PACLitaxel/CARBOplatin 21 Day Cycles- Esophageal and Esophagogastric Junction Cancers,_3. Third Line,11/16/2023,Inactive,,
NBR CINJ OP INFUSION,89202,"Eltoukhy, Hussam, MD",4/7/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,4/6/2023,Inactive,,
NBR CINJ OP INFUSION,98660,"Tiger, Yun Kyoung, MD",9/11/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,9/10/2024,Inactive,,
NBR CINJ OP INFUSION,98660,"Tiger, Yun Kyoung, MD",9/20/2024,Daratumumab and Hyaluronidase-fihj / Carfilzomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/19/2024,Active,,
NBR CINJ OP INFUSION,98660,"Tiger, Yun Kyoung, MD",10/4/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,10/3/2024,Inactive,,
CINJ OP INFUSION,57576,"Berim, Lyudmyla, MD",2/28/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,2/27/2024,Inactive,,
CINJ OP INFUSION,57576,"Berim, Lyudmyla, MD",7/9/2024,Capecitabine / Lapatinib 21 Day Cycles - Breast,_3. Third Line,7/9/2024,Inactive,,
CBMC OP INFUSION 2FL,97914,"Grossman, I Robert, MD",2/27/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,2/25/2025,Active,Heavy chain deposition disease,
CBMC 2W ONCOLOGY,97914,"Grossman, I Robert, MD",5/8/2025,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_2. Second Line,5/8/2025,Active,Heavy chain deposition disease (CMS/HCC),"D47.9 - Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified; K50.90 - Crohn's disease, unspecified, without complications; N17.9 - Acute kidney failure, unspecified; D69.6 - Thrombocytopenia, unspecified; D63.1 - Anemia in chronic kidney disease; D47.2 - Monoclonal gammopathy; N18.4 - Chronic kidney disease, stage 4 (severe); I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; J45.909 - Unspecified asthma, uncomplicated; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; E87.6 - Hypokalemia; R91.1 - Solitary pulmonary nodule; R59.1 - Generalized enlarged lymph nodes; R31.29 - Other microscopic hematuria; Z91.09 - Other allergy status, other than to drugs and biological substances; Z79.01 - Long term (current) use of anticoagulants; E87.70 - Fluid overload, unspecified; Z85.46 - Personal history of malignant neoplasm of prostate; Z87.891 - Personal history of nicotine dependence; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z63.4 - Disappearance and death of family member; Z79.899 - Other long term (current) drug therapy; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.41 - Family history of malignant neoplasm of ovary; Z80.7 - Family history of other malignant neoplasms of lymphoid, hematopoietic and related tissues; Z82.49 - Family history of ischemic heart disease and other diseases of the..."
SOM OUTPT INFUSION,81489,"Toomey, Kathleen C, MD",9/13/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/1/2024,Inactive,,
NBR 5N ONCOLOGY,64494,"Rhodes, Joanna Meehan, MD",4/30/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/30/2024,Inactive,,
NBR CINJ OP INFUSION,64494,"Rhodes, Joanna Meehan, MD",6/10/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,6/5/2024,Inactive,,
NBR CINJ OP INFUSION,64494,"Rhodes, Joanna Meehan, MD",11/4/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_3. Third Line,10/27/2024,Active,"CML (chronic myelocytic leukemia) (CMS/HCC)
AMML (acute myelomonocytic leukemia) (CMS/HCC)",
NBR CINJ OP INFUSION,90565,"Rhodes, Joanna Meehan, MD",5/1/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,5/1/2025,Active,"Lymphoma (CMS/HCC)
Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC)","C82.90 - Follicular lymphoma, unspecified, unspecified site; G62.9 - Polyneuropathy, unspecified; F32.A - Depression, unspecified; C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site"
NBI OP INFUSION,96767,"Shah, Shailja S, MD",6/18/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/10/2024,Inactive,,
NBI OP INFUSION,96767,"Shah, Shailja S, MD",10/8/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/8/2024,Inactive,,
NBI OP INFUSION,96767,"Shah, Shailja S, MD",10/29/2024,"DOCEtaxel D1, D8, D15  28 Day Cycles-Non-Small Cell Lung Cancer",_2. Second Line,10/29/2024,Active,,
NBR 5N ONCOLOGY,43156,"Palmisiano, Neil David, MD",3/25/2025,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,3/24/2025,Active,Acute undifferentiated leukemia (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.818 - Other pancytopenia; I82.621 - Acute embolism and thrombosis of deep veins of right upper extremity; D69.59 - Other secondary thrombocytopenia; K76.0 - Fatty (change of) liver, not elsewhere classified; N30.00 - Acute cystitis without hematuria; Z11.52 - Encounter for screening for COVID-19; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; Z88.8 - Allergy status to other drugs, medicaments and biological substances; G43.109 - Migraine with aura, not intractable, without status migrainosus; K59.00 - Constipation, unspecified; H66.92 - Otitis media, unspecified, left ear; Z90.710 - Acquired absence of both cervix and uterus; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; G97.1 - Other reaction to spinal and lumbar puncture"
CBMC OP INFUSION 2FL,62630,"Leitner, Stuart P, MD",11/8/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,11/8/2023,Inactive,,
TRMC TCCC OP INFUSION,16783,"Salerno, Vincent E, MD",1/13/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/5/2023,Active,,
TRMC TCCC OP INFUSION,16783,"Salerno, Vincent E, MD",1/31/2025,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,1/30/2025,Active,,
NBR BMSCH 2 PED HEMONC,87431,"Murphy, Susan, MD",5/23/2025,as per AAML1831 Arm A Induction 2 (NOT on study),Induction,5/17/2025,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.818 - Other pancytopenia; C91.00 - Acute lymphoblastic leukemia not having achieved remission; D84.9 - Immunodeficiency, unspecified; R23.3 - Spontaneous ecchymoses; K06.8 - Other specified disorders of gingiva and edentulous alveolar ridge; Z80.6 - Family history of leukemia; Z59.71 - Insufficient health insurance coverage; K59.00 - Constipation, unspecified; H10.213 - Acute toxic conjunctivitis, bilateral; R04.0 - Epistaxis; Z11.52 - Encounter for screening for COVID-19"
CINJ PEDS HEMONC ,87431,"Murphy, Susan, MD",4/17/2025,as per AAML1831 Arm A Induction 1 (NOT on study),Induction,4/17/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.818 - Other pancytopenia; C91.00 - Acute lymphoblastic leukemia not having achieved remission; D84.9 - Immunodeficiency, unspecified; R23.3 - Spontaneous ecchymoses; K06.8 - Other specified disorders of gingiva and edentulous alveolar ridge; Z80.6 - Family history of leukemia; Z59.71 - Insufficient health insurance coverage; K59.00 - Constipation, unspecified; H10.213 - Acute toxic conjunctivitis, bilateral; R04.0 - Epistaxis; Z11.52 - Encounter for screening for COVID-19"
NBR BMSCH 2 PED HEMONC,87431,"Murphy, Susan, MD",4/16/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,4/16/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.818 - Other pancytopenia; C91.00 - Acute lymphoblastic leukemia not having achieved remission; D84.9 - Immunodeficiency, unspecified; R23.3 - Spontaneous ecchymoses; K06.8 - Other specified disorders of gingiva and edentulous alveolar ridge; Z80.6 - Family history of leukemia; Z59.71 - Insufficient health insurance coverage; K59.00 - Constipation, unspecified; H10.213 - Acute toxic conjunctivitis, bilateral; R04.0 - Epistaxis; Z11.52 - Encounter for screening for COVID-19"
NBR BMSCH 2 PED HEMONC,87671,"Moerdler, Scott, MD",5/21/2025,as per AALL1732 Induction (NOT on study),_1. First Line,5/21/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),D72.829 - Leukocytosis
NBR CINJ OP INFUSION,32553,"Palmisiano, Neil David, MD",8/4/2023,CALGB 10403 (Course I) Remission Induction - Acute Lymphocytic Leukemia,,8/4/2023,Inactive,,
NBR CINJ OP INFUSION,32553,"Palmisiano, Neil David, MD",10/9/2023,CALGB 10403 (Course II) Remission Consolidation - Acute Lymphoblastic Leukemia,,9/1/2023,Inactive,,
NBR CINJ OP INFUSION,32553,"Palmisiano, Neil David, MD",6/3/2024,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,Consolidation,6/3/2024,Active,,
NBR CINJ OP INFUSION,32553,"Palmisiano, Neil David, MD",6/3/2024,CALGB 9111 (Maintenance Therapy) 28 Day Cycles + Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia,Consolidation,6/2/2024,Inactive,,
TRMC TCCC OP INFUSION,36355,"Capo, Gerardo, MD",2/26/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles-Cervical Cancer Stage 4",_2. Second Line,2/25/2024,Active,,
CINJ OP INFUSION,80020,"Patel, Eshan, MD",5/3/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,4/30/2024,Inactive,,
CINJ OP INFUSION,80020,"Haigentz, Missak, MD",11/19/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,11/18/2024,Active,,
HAM OP INFUSION,74680,"Yogarajah, Meera, MD",1/27/2023,Avelumab 14 Day Cycles - Merkel Cell Carcinoma,First Line,1/25/2023,Inactive,,
HAM OP INFUSION,74680,"Yogarajah, Meera, MD",4/20/2023,Nivolumab/Ipilimumab 42 Day Cycles- merkel cell carcinoma recurrent,Second Line,4/18/2023,Inactive,,
MMC OP INFUSION,86754,"Lee, Patrick C, MD",1/2/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,12/20/2023,Active,Rectal cancer (CMS/HCC),
SOM OUTPT INFUSION,83880,"Yin, Faye, MD",2/14/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,2/13/2023,Inactive,,
SOM OUTPT INFUSION,83880,"Yin, Faye, MD",8/1/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/26/2023,Inactive,,
SOM OUTPT INFUSION,83880,"Yin, Faye, MD",10/16/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/12/2023,Inactive,,
SOM OUTPT INFUSION,83880,"Yin, Faye, MD",12/26/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/19/2023,Inactive,,
SOM OUTPT INFUSION,83880,"Yin, Faye, MD",1/22/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/21/2024,Inactive,,
CINJ OP INFUSION,76683,"Aikins, James K, MD",2/3/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Recurrent Uterine,Second Line,2/1/2023,Inactive,,
CINJ OP INFUSION,76683,"Aikins, James K, MD",8/25/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/23/2023,Inactive,,
CINJ OP INFUSION,76683,"Aikins, James K, MD",9/21/2023,PACLitaxel 28 Day Cycles - Uterine,,9/19/2023,Inactive,,
MMC OP VP INFUSION,66155,"Lee, Patrick C, MD",6/7/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,5/21/2023,Inactive,,
NBR 4N ONCOLOGY,24033,"Doraiswamy, Anupama, MD",6/14/2023,MATRiX (High-Dose Methotrexate / Cytarabine / Thiotepa / RiTUXimab) - CNS Lymphoma,,6/14/2023,Inactive,,
JCMC CP INFUSION,41367,"Sekhri, Arunabh, MD",5/12/2023,Bevacizumab Maintenance 14 Day Cycles- Gastrointestinal Cancers,Third Line,5/11/2023,Inactive,,
CBMC OP INFUSION 2FL,861,"Dharmapuri, Sirish, MD",3/12/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,3/4/2025,Inactive,Malignant neoplasm of anal canal (CMS/HCC),
NBR CINJ OP INFUSION,91664,"Matasar, Matthew J, MD",4/4/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,4/3/2023,Inactive,,
MMC OP VP INFUSION,16250,"Talwar, Sumit, MD",1/2/2024,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,57041,"Kulkarni, Aditya A, MD",5/8/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,5/8/2025,Active,"Metastatic renal cell carcinoma, right (CMS/HCC)",
CINJ OP INFUSION,38705,"Toppmeyer, Deborah L, MD",2/6/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/5/2023,Inactive,,
CMC OP INFUSION,63924,"Cohen, Seth D, MD",1/2/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/27/2023,Inactive,,
CBMC OP INFUSION 2FL,18936,"Brown, Andrew Bennett, MD",1/8/2024,Bev + Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/7/2024,Inactive,,
CBMC OP INFUSION 2FL,18936,"Brown, Andrew Bennett, MD",6/6/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,Maintenance,6/6/2024,Inactive,,
CBMC OP INFUSION 2FL,70251,"Wagmiller, Jennifer Ann, MD",12/9/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/10/2024,Active,,
CINJ OP INFUSION,34954,"Muralikrishnan, Sivraj, MD",3/14/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/14/2025,Inactive,"Metastatic lung carcinoma, unspecified laterality (CMS/HCC)
Other fatigue",C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; I48.91 - Unspecified atrial fibrillation; Z51.89 - Encounter for other specified aftercare; R91.8 - Other nonspecific abnormal finding of lung field; C78.00 - Secondary malignant neoplasm of unspecified lung; R53.83 - Other fatigue; Z87.891 - Personal history of nicotine dependence
HAM OP INFUSION,49339,"Yogarajah, Meera, MD",9/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/11/2024,Active,,
CINJ OP INFUSION,2580,"Saraiya, Biren P, MD",9/11/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,9/11/2023,Active,,
CBMC OP INFUSION 2FL,17805,"Ligresti, Louise G, MD",5/30/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_2. Second Line,5/30/2024,Inactive,,
CBMC OP INFUSION 2FL,17805,"Ligresti, Louise G, MD",11/25/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,11/24/2024,Active,Malignant neoplasm of descending colon (CMS/HCC),
NBI OP INFUSION,96981,"Schleicher, Lori, MD",9/6/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,9/6/2023,Inactive,,
NBI OP INFUSION,96981,"Schleicher, Lori, MD",5/15/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,5/14/2024,Inactive,,
NBI OP INFUSION,96981,"Schleicher, Lori, MD",8/14/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,8/13/2024,Active,"Malignant neoplasm of lateral wall of bladder (CMS/HCC)
Disorder of thyroid",
NBI OP INFUSION,96981,"Schleicher, Lori, MD",1/31/2025,Capecitabine 21 Day Cycles - Breast,_7. Seventh Line,1/31/2025,Active,,
CINJ OP INFUSION,60072,"Stephenson, Ryan D, DO",7/7/2023,Apalutamide 30 Day Cycles - Prostate,First Line,7/7/2023,Inactive,,
NBR 5N ONCOLOGY,36636,"Stein, Stacey",5/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/28/2025,Active,Gastric cancer (CMS/HCC),"C78.89 - Secondary malignant neoplasm of other digestive organs; E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; E44.0 - Moderate protein-calorie malnutrition; E87.20 - Acidosis, unspecified; R18.8 - Other ascites; C80.1 - Malignant (primary) neoplasm, unspecified; D72.828 - Other elevated white blood cell count; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; J42 - Unspecified chronic bronchitis; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); F10.10 - Alcohol abuse, uncomplicated; J43.9 - Emphysema, unspecified; R59.1 - Generalized enlarged lymph nodes; D75.839 - Thrombocytosis, unspecified; K59.00 - Constipation, unspecified; E66.3 - Overweight; E16.2 - Hypoglycemia, unspecified; F17.200 - Nicotine dependence, unspecified, uncomplicated; M25.511 - Pain in right shoulder; Z79.899 - Other long term (current) drug therapy; Z68.26 - Body mass index (BMI) 26.0-26.9, adult"
NBI OP INFUSION,2531,"Anderson, Patrick S, MD",5/23/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Endometrial Cancer,_1. First Line,5/22/2024,Active,,
NBR 5N ONCOLOGY,29968,"Chen, Xiaoyi",9/25/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,9/24/2024,Active,"Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC)
Plasma cell neoplasm",
NBR CINJ OP INFUSION,91188,"Egini, Ogechukwu, MD",2/9/2025,BMT Allogeneic TBF + Post Cy,_2. Second Line,2/8/2025,Active,Acute myeloid leukemia (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; Z01.818 - Encounter for other preprocedural examination"
CBMC OP INFUSION 2FL,9790,"Ligresti, Louise G, MD",3/18/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,3/18/2025,Inactive,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,84586,"Groisberg, Roman, MD",3/3/2023,DOXOrubicin Liposomal 28 Day Cycles - Sarcoma,First Line,3/2/2023,Inactive,,
CINJ OP INFUSION,11610,"Berim, Lyudmyla, MD",11/6/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,11/4/2023,Inactive,,
CINJ OP INFUSION,11610,"Berim, Lyudmyla, MD",2/7/2024,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,2/7/2024,Inactive,,
CINJ OP INFUSION,11610,"Berim, Lyudmyla, MD",6/10/2024,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,_3. Third Line,6/10/2024,Active,,
CINJ OP INFUSION,18428,"Hochster, Howard S, MD",3/22/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,3/14/2023,Inactive,,
CBMC OP INFUSION 2FL,17968,"Leitner, Stuart P, MD",10/11/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,10/10/2023,Active,,
NBR 4N ONCOLOGY,11694,"Tiger, Yun Kyoung, MD",3/27/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,3/21/2024,Inactive,,
NBR CINJ OP INFUSION,11694,"Tiger, Yun Kyoung, MD",3/27/2024,Daratumumab and Hyaluronidase-fihj / Venetoclax/Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,3/26/2024,Inactive,,
NBR 4N ONCOLOGY,11694,"Tiger, Yun Kyoung, MD",6/5/2024,D-PACE (Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,_2. Second Line,6/5/2024,Inactive,,
NBR CINJ OP INFUSION,11694,"Tiger, Yun Kyoung, MD",6/12/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,6/11/2024,Inactive,,
NBR CINJ OP INFUSION,11694,"Tiger, Yun Kyoung, MD",9/11/2024,RiTUXimab 28 Day Cycle - CIDP,_1. First Line,9/10/2024,Inactive,,
CINJ OP INFUSION,78661,"George, Mridula A, MD",5/16/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,5/14/2024,Inactive,,
CINJ OP INFUSION,78661,"George, Mridula A, MD",12/20/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,12/19/2024,Active,"Malignant neoplasm of bronchus of right lower lobe (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",
CINJ OP INFUSION,74892,"Leiser, Aliza, MD",1/5/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,1/4/2023,Inactive,,
CBMC OP INFUSION 2FL,93116,"Brown, Andrew Bennett, MD",5/21/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_2. Second Line,5/21/2025,Active,"Malignant neoplasm of lung (CMS/HCC)
Primary malignant neuroendocrine tumor of lung (CMS/HCC)","C7A.8 - Other malignant neuroendocrine tumors; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; C7B.8 - Other secondary neuroendocrine tumors; J91.0 - Malignant pleural effusion; I50.22 - Chronic systolic (congestive) heart failure; N18.4 - Chronic kidney disease, stage 4 (severe); E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; Z21 - Asymptomatic human immunodeficiency virus (hiv) infection status; Z79.4 - Long term (current) use of insulin; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; E78.5 - Hyperlipidemia, unspecified; F11.90 - Opioid use, unspecified, uncomplicated; G89.3 - Neoplasm related pain (acute) (chronic); I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; Z74.09 - Other reduced mobility; Z96.41 - Presence of insulin pump (external) (internal); Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.3 - Family history of diabetes mellitus; Z85.118 - Personal history of other malignant neoplasm of bronchus and lung; Z87.891 - Personal history of nicotine dependence; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.710 - ..."
CBMC OP INFUSION 2FL,86844,"Grossman, I Robert, MD",10/22/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/20/2024,Inactive,,
CBMC OP INFUSION 1FL,15701,"Kulkarni, Aditya A, MD",2/24/2025,Gemcitabine Intravesical Single Dose - Bladder,_2. Second Line,2/24/2025,Active,Malignant neoplasm of anterior wall of bladder (CMS/HCC),"D70.9 - Neutropenia, unspecified; E78.5 - Hyperlipidemia, unspecified; I10 - Essential (primary) hypertension; Z79.899 - Other long term (current) drug therapy; Z85.51 - Personal history of malignant neoplasm of bladder; Z90.710 - Acquired absence of both cervix and uterus; Z91.014 - Allergy to mammalian meats"
NBR CINJ OP INFUSION,86705,"Mayer, Tina M, MD",1/10/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,1/10/2025,Active,,
MMC OP VP INFUSION,41582,"Cohen, Seth D, MD",5/15/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/14/2023,Inactive,,
CINJ OP INFUSION,96176,"Omene, Coral Oghenerukevwe, MD",4/4/2023,Abemaciclib 28 Day Cycles - Breast ,,4/4/2023,Active,,
CMC OP INFUSION,5887,"Taff, Jessica, MD",8/31/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Adjuvant,8/27/2023,Inactive,,
CINJ OP INFUSION,5887,"Weiss, Sarah, MD",7/2/2024,Talimogene Laherparepvec 21 Day Cycle + Talimogene Laherparepvec 14 Day Cycles - Melanoma,_4. Fourth Line,7/1/2024,Inactive,,
CMC OP INFUSION,5887,"Taff, Jessica, MD",12/16/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Melanoma,_4. Fourth Line,12/15/2024,Active,,
CMC OP INFUSION,5887,"Taff, Jessica, MD",1/17/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Melanoma,_4. Fourth Line,12/15/2024,Inactive,"Malignant melanoma of skin, unspecified (CMS/HCC)",
CMC OP INFUSION,5887,"Taff, Jessica, MD",2/19/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_5. Fifth Line,2/18/2025,Active,"Malignant melanoma of skin, unspecified (CMS/HCC)",
CINJ OP INFUSION,43457,"Ghodoussipour, Saum Bobak, MD",9/20/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/18/2024,Active,,
SOM OUTPT INFUSION,68986,"Toomey, Kathleen C, MD",8/23/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,First Line,8/22/2023,Inactive,,
MMC OP INFUSION,38331,"Meghal, Trishala, MD",9/8/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,9/8/2023,Inactive,,
MMC OP INFUSION,38331,"Meghal, Trishala, MD",1/27/2024,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,1/27/2024,Inactive,,
CINJ OP INFUSION,72594,"Saraiya, Biren P, MD",3/5/2024,CINJ 082002 Pre-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,_1. First Line,3/4/2024,Inactive,,
CINJ OP INFUSION,72594,"Saraiya, Biren P, MD",7/8/2024,CINJ 082002 Post-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,_1. First Line,5/12/2024,Inactive,,
CINJ OP INFUSION,72594,"Saraiya, Biren P, MD",1/20/2025,Belzutifan 28 Day Cycles,_2. Second Line,1/20/2025,Active,,
CBMC OP INFUSION 2FL,47744,"Siu, Karleung, MD",4/23/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/16/2025,Inactive,Breast cancer metastasized to lung (CMS/HCC),C79.31 - Secondary malignant neoplasm of brain; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C78.01 - Secondary malignant neoplasm of right lung; Z92.3 - Personal history of irradiation; Z92.21 - Personal history of antineoplastic chemotherapy; Z98.890 - Other specified postprocedural states; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy
CBMC OP INFUSION 1FL,78,"Meelheim, Brooke A, DO",9/16/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/15/2024,Inactive,,
CBMC OP INFUSION 1FL,78,"Meelheim, Brooke A, DO",10/4/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/22/2024,Active,,
CINJ OP INFUSION,5111,"Patel, Eshan, MD",10/14/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/4/2024,Inactive,Malignant neoplasm of lung (CMS/HCC),
CINJ OP INFUSION,5111,"Patel, Eshan, MD",1/11/2025,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,1/3/2025,Future,Malignant neoplasm of lung (CMS/HCC),
CBMC OP INFUSION 2FL,91995,"Leitner, Stuart P, MD",11/21/2023,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,11/20/2023,Inactive,,
CBMC OP INFUSION 2FL,52308,"Kovtun, Jeanette Muniz, MD",7/12/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_2. Second Line,7/11/2024,Active,,
MMC BBR2 ONCOLOGY,99177,"Lee, Patrick C, MD",12/18/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/16/2024,Active,,
CINJ OP INFUSION,82516,"Groisberg, Roman, MD",1/10/2025,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,1/9/2025,Active,,
CINJ OP INFUSION,75612,"Goel, Sanjay, MD",3/25/2024,CINJ 052208 Part 1K AMG-193 28 Day Cycles Research  - Solid Tumors,_3. Third Line,3/25/2024,Inactive,,
CBMC OP INFUSION 2FL,15817,"Brown, Andrew Bennett, MD",2/2/2024,Pembrolizumab 21 Day Cycles - Breast,Maintenance,2/2/2024,Active,,
CMC OP INFUSION,36816,"Taff, Jessica, MD",5/16/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,5/15/2023,Active,,
CMC OP INFUSION,85176,"Cohen, Seth D, MD",4/21/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/20/2023,Inactive,,
CBMC OP INFUSION 2FL,41226,"Litvak, Anna M, MD",10/5/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,10/4/2023,Inactive,,
CINJ OP INFUSION,36692,"Berim, Lyudmyla, MD",6/20/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/18/2024,Active,,
CINJ OP INFUSION,36692,"Berim, Lyudmyla, MD",5/23/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/23/2025,Active,Cancer of antrum of stomach (CMS/HCC),C16.3 - Cancer of antrum of stomach (CMS/HCC)
CINJ OP INFUSION,36692,"Berim, Lyudmyla, MD",4/8/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/8/2025,Inactive,Cancer of antrum of stomach (CMS/HCC),
NBR 5N ONCOLOGY,74662,"Haigentz, Missak, MD",2/27/2024,Dabrafenib/Trametinib 28 Day Cycles- Anaplastic Thyroid Cancer,_1. First Line,2/27/2024,Active,,
CINJ PEDS HEMONC ,20020,"Moerdler, Scott, MD",7/22/2023,Dabrafenib / Trametinib 30 Day Cycles - BRAF V600E Mutation-Positive Low-Grade Glioma,First Line,7/22/2023,Active,,
CMC OP INFUSION,46828,"Taff, Jessica, MD",10/5/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,10/4/2023,Inactive,,
CMC OP INFUSION,46828,"Taff, Jessica, MD",3/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/14/2024,Inactive,,
CMC OP INFUSION,46828,"Taff, Jessica, MD",10/18/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/11/2024,Active,,
CINJ OP INFUSION,16107,"Goel, Sanjay, MD",3/11/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,3/11/2025,Inactive,"Adenocarcinoma of lower esophagus (CMS/HCC)
Liver cell damage",
MSC OP INFUSION,51562,"Cohen, Seth D, MD",4/16/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,4/15/2024,Active,,
NBR CINJ OP INFUSION,80311,"Rhodes, Joanna Meehan, MD",2/22/2024,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_3. Third Line,2/13/2024,Active,,
NBR 5N ONCOLOGY,28283,"Shah, Mansi R, MD",12/25/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,12/24/2024,Active,Breast cancer of upper-inner quadrant of right female breast (CMS/HCC),
CINJ OP INFUSION,10686,"Weiss, Sarah, MD",12/7/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,12/6/2023,Inactive,,
HAM OP INFUSION,64543,"Patel, Malini M, MD",11/18/2024,Temozolomide 28 Day Cycles - CNS,_2. Second Line,11/18/2024,Active,"Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Hypothyroidism, unspecified type
End stage renal disease (CMS/HCC)",
CINJ OP INFUSION,5949,"Berim, Lyudmyla, MD",1/22/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,1/12/2024,Inactive,,
CINJ OP INFUSION,5949,"Berim, Lyudmyla, MD",5/20/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Adjuvant,5/14/2024,Active,,
CBMC OP INFUSION 2FL,50561,"Leitner, Stuart P, MD",11/6/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,_1. First Line,11/6/2023,Active,,
CBMC OP INFUSION 2FL,51278,"Litvak, Anna M, MD",10/30/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,10/30/2023,Active,,
TRMC TCCC OP INFUSION,83215,"Salerno, Vincent E, MD",11/26/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_3. Third Line,11/25/2024,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,50066,"George, Mridula A, MD",10/16/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/15/2023,Active,,
CINJ OP INFUSION,56112,"George, Mridula A, MD",1/25/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,1/24/2023,Inactive,,
CINJ OP INFUSION,56112,"George, Mridula A, MD",4/27/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,4/18/2023,Inactive,,
CINJ OP INFUSION,56112,"George, Mridula A, MD",9/1/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,9/1/2023,Inactive,,
NBI VALERIE FND HEMONC,70979,"Ford, Maegan C, MD",10/27/2023,AALL1732 Induction,Induction,10/26/2023,Inactive,,
NBI VALERIE FND HEMONC,70979,"de Benedictis, Marianna, MD",12/4/2023,AALL1732 Consolidation,Consolidation,12/4/2023,Inactive,,
NBI VALERIE FND HEMONC,70979,"de Benedictis, Marianna, MD",2/6/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,2/5/2024,Inactive,,
NBI VALERIE FND HEMONC,70979,"de Benedictis, Marianna, MD",4/16/2024,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy: Delayed Intensification",_1. First Line,4/16/2024,Inactive,,
NBI VALERIE FND HEMONC,70979,"de Benedictis, Marianna, MD",6/25/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,6/25/2024,Inactive,,
NBI A5 PEDIATRICS,70979,"de Benedictis, Marianna, MD",6/26/2024,PEDS Asparaginase Erwinia (Rylaze),_2. Second Line,6/26/2024,Inactive,,
CBMC OP INFUSION 2FL,7965,"Wagmiller, Jennifer Ann, MD",8/8/2023,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Neoadjuvant,8/7/2023,Inactive,,
CBMC OP INFUSION 2FL,7965,"Wagmiller, Jennifer Ann, MD",10/31/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Neoadjuvant,10/30/2023,Inactive,,
CBMC OP INFUSION 2FL,7965,"Wagmiller, Jennifer Ann, MD",4/24/2024,Dostarlimab-gxly 42 Day Cycles- Gynecologic Cancers,Adjuvant,4/23/2024,Active,,
CMC OP INFUSION,168,"Cohen, Seth D, MD",5/19/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/19/2025,Active,Diffuse follicle center lymphoma of intrathoracic lymph nodes (CMS/HCC),
CBMC OP INFUSION 2FL,90753,"Wagmiller, Jennifer Ann, MD",6/13/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/3/2024,Inactive,,
CBMC OP INFUSION 2FL,90753,"Wagmiller, Jennifer Ann, MD",10/31/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,10/28/2024,Active,,
CBMC OP INFUSION 2FL,70851,"Leitner, Stuart P, MD",9/14/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/13/2023,Inactive,,
JCMC CP INFUSION,92409,"Sekhri, Arunabh, MD",11/27/2023,Atezolizumab 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/19/2023,Inactive,,
JCMC CP INFUSION,92409,"Sekhri, Arunabh, MD",12/11/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_2. Second Line,12/6/2024,Active,,
JCMC CP INFUSION,92409,"Sekhri, Arunabh, MD",2/3/2025,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_3. Third Line,2/2/2025,Inactive,"Small cell lung cancer (CMS/HCC)
Anxiety disorder due to known physiological condition","A41.9 - Sepsis, unspecified organism; J18.9 - Pneumonia, unspecified organism; R65.21 - Severe sepsis with septic shock; J96.21 - Acute and chronic respiratory failure with hypoxia; E87.20 - Acidosis, unspecified; J90 - Pleural effusion, not elsewhere classified; Z11.52 - Encounter for screening for COVID-19; D61.818 - Other pancytopenia; B37.0 - Candidal stomatitis; C34.2 - Malignant neoplasm of middle lobe, bronchus or lung; I10 - Essential (primary) hypertension; I07.1 - Rheumatic tricuspid insufficiency; N17.9 - Acute kidney failure, unspecified; I48.91 - Unspecified atrial fibrillation; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; F17.210 - Nicotine dependence, cigarettes, uncomplicated; E78.5 - Hyperlipidemia, unspecified; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z90.49 - Acquired absence of other specified parts of digestive tract; Z98.41 - Cataract extraction status, right eye; Z98.42 - Cataract extraction status, left eye; Z88.2 - Allergy status to sulfonamides; Z99.81 - Dependence on supplemental oxygen"
CINJ OP INFUSION,64950,"Haigentz, Missak, MD",12/24/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_6. Sixth Line,12/24/2024,Active,,
NBR CINJ OP INFUSION,88604,"Shah, Mansi R, MD",7/25/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,7/25/2023,Inactive,,
NBR 4N ONCOLOGY,88604,"Schaar, Dale, MD PhD",12/1/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,11/29/2023,Inactive,,
MMC BBR2 ONCOLOGY,82621,"Meghal, Trishala, MD",11/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/18/2024,Active,Cervical neoplasm,
NBR CINJ OP INFUSION,87281,"Leiser, Aliza, MD",2/5/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,2/4/2024,Inactive,,
MMC OP INFUSION,24044,"Meghal, Trishala, MD",4/26/2023,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,4/25/2023,Inactive,,
MMC OP VP INFUSION,24044,"Meghal, Trishala, MD",6/12/2024,Gemcitabine 28 Day Cycles - Breast,_2. Second Line,6/6/2024,Active,,
NBI OP INFUSION,73181,"Anderson, Patrick S, MD",7/10/2024,Gemcitabine / DOCEtaxel 21 Day Cycles - Uterine Sarcoma,_1. First Line,7/2/2024,Active,,
CINJ OP INFUSION,37695,"Stephenson, Ruth D, DO",5/30/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/30/2025,Active,Malignant neoplasm of ovary (CMS/HCC),Z48.817 - Encounter for surgical aftercare following surgery on the skin and subcutaneous tissue; C56.9 - Malignant neoplasm of unspecified ovary; R30.0 - Dysuria; C56.1 - Malignant neoplasm of right ovary
JCMC CP INFUSION,72387,"Cruz, Allan Louie E, MD",6/6/2024,Elotuzumab/Bortezomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/26/2024,Inactive,,
JCMC CP INFUSION,72387,"Cruz, Allan Louie E, MD",11/13/2024,Carfilzomib 27 mg/m2  Weekly Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,11/13/2024,Active,,
CINJ OP INFUSION,67758,"Toppmeyer, Deborah L, MD",1/10/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,1/8/2023,Inactive,,
NBI OP INFUSION,80180,"Jacoby, Sari H, MD",3/11/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,3/3/2024,Active,"Primary malignant neoplasm of lung metastatic to other site, unspecified laterality (CMS/HCC)
Metastatic cancer to brain (CMS/HCC)",
NBI OP INFUSION,80180,"Jacoby, Sari H, MD",11/18/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/17/2024,Active,,
NBR 5N ONCOLOGY,11743,"Tiger, Yun Kyoung, MD",2/20/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,2/20/2024,Inactive,,
NBR CINJ OP INFUSION,11743,"Zayac, Adam, MD",2/21/2024,CINJ 022101 (EA9181) ARM A Dasatinib / Prednisone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,2/20/2024,Inactive,,
NBR CINJ OP INFUSION,11743,"Zayac, Adam, MD",3/11/2024,CINJ 022101 (EA9181) ARM C Dasatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,_1. First Line,3/10/2024,Inactive,,
NBR 5N ONCOLOGY,11743,"Zayac, Adam, MD",7/8/2024,CINJ 022101 (EA9181) Arm C Consolidation Dasatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,_1. First Line,7/7/2024,Active,,
NBR CINJ OP INFUSION,11743,"Zayac, Adam, MD",7/8/2024,CINJ 022101 (EA9181) ARM C Dasatinib / Blinatumomab 42 Day Cycles Research- Acute Lymphoblastic Leukemia,Consolidation,7/7/2024,Inactive,,
JCMC CP INFUSION,26442,"Sekhri, Arunabh, MD",8/21/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Lower uterine segment carcinosarcoma,Adjuvant,8/18/2024,Inactive,,
CINJ OP INFUSION,42145,"Stephenson, Ryan D, DO",1/6/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,1/5/2023,Inactive,,
CINJ OP INFUSION,70527,"Stephenson, Ryan D, DO",3/31/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_3. Third Line,3/31/2025,Active,"Malignant melanoma of other part of trunk (CMS/HCC)
Hypothyroidism
Encounter for antineoplastic immunotherapy",
NBR BMSCH 2 PED HEMONC,77939,"Goyal-Khemka, Meenakshi, MD",2/2/2023,per AAML1831 Arm A Induction 1,,2/2/2023,Inactive,,
CINJ PEDS HEMONC ,77939,"Goyal-Khemka, Meenakshi, MD",3/10/2023,Dosing per AAML0531  Arm B Induction 2(ADE-8)+ GO,,3/9/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,77939,"Masterson, Margaret, MD",4/6/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,4/6/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,77939,"Goyal-Khemka, Meenakshi, MD",4/7/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,4/7/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,77939,"Goyal-Khemka, Meenakshi, MD",4/21/2023,"per AAML1831 Arm A & B: High Risk, Intensification I",,4/21/2023,Inactive,,
CINJ PEDS HEMONC ,77939,"Goyal-Khemka, Meenakshi, MD",6/5/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,5/30/2023,Inactive,,
CINJ OP INFUSION,90049,"Mayer, Tina M, MD",11/27/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,11/27/2024,Active,,
CBMC OP INFUSION 2FL,31543,"Brown, Andrew Bennett, MD",12/10/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,Induction,12/9/2024,Active,,
CBMC OP INFUSION 2FL,56341,"Brown, Andrew Bennett, MD",3/19/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,Induction,3/19/2025,Inactive,"Skin cancer
SCCA (squamous cell carcinoma) of skin",
CINJ OP INFUSION,18609,"Haigentz, Missak, MD",1/30/2023,PEMEtrexed/CARBOplatin 21 Day Cycles- Malignant Pleural Mesothelioma,Second Line,1/15/2023,Inactive,,
CINJ OP INFUSION,18609,"Haigentz, Missak, MD",6/8/2023,Nivolumab/Ipilimumab - Malignant Pleural Mesothelioma,Second Line,6/8/2023,Inactive,,
SOM OUTPT INFUSION,7352,"Toomey, Kathleen C, MD",2/23/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,2/22/2023,Inactive,,
MMC OP VP INFUSION,30985,"Lee, Patrick C, MD",4/14/2025,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,4/14/2025,Active,Malignant neoplasm of tail of pancreas (CMS/HCC),
MMC OP VP INFUSION,30985,"Lee, Patrick C, MD",4/10/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/10/2025,Inactive,Malignant neoplasm of tail of pancreas (CMS/HCC),
MMC OP VP INFUSION,30985,"Lee, Patrick C, MD",3/14/2025,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",Adjuvant,3/14/2025,Inactive,Malignant neoplasm of tail of pancreas (CMS/HCC),
CINJ OP INFUSION,45643,"Weiss, Sarah, MD",7/12/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,First Line,7/11/2023,Inactive,,
SOM OUTPT INFUSION,87701,"Toomey, Kathleen C, MD",3/19/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/19/2025,Active,"Metastatic cancer (CMS/HCC)
Breast cancer, stage 4, right (CMS/HCC)",C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; R97.8 - Other abnormal tumor markers; C50.911 - Malignant neoplasm of unspecified site of right female breast; C78.00 - Secondary malignant neoplasm of unspecified lung
SOM OUTPT INFUSION,50841,"Patel, Eshan, MD",3/13/2023,Daratumumab-fihj / Dexamethasone 28 Day Cycles- Multiple Myeloma,First Line,3/7/2023,Inactive,,
NBR 5N ONCOLOGY,21854,"Shah, Mansi R, MD",4/11/2025,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_3. Third Line,4/11/2025,Inactive,"Multiple myeloma (CMS/HCC)
Stem cells transplant status (CMS/HCC)
Immunocompromised state (CMS/HCC)
Multiple myeloma not having achieved remission (CMS/HCC)",
MMC OP VP INFUSION,31211,"Cohen, Seth D, MD",3/10/2025,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/10/2025,Inactive,Esophageal mass,
MMC OP VP INFUSION,51920,"Cohen, Seth D, MD",8/1/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/31/2023,Inactive,,
MMC OP VP INFUSION,51920,"Cohen, Seth D, MD",1/6/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/3/2025,Active,,
MMC OP VP INFUSION,32565,"Cohen, Seth D, MD",4/30/2025,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,4/30/2025,Active,Malignant neoplasm metastatic to liver (CMS/HCC),
MMC OP VP INFUSION,42823,"Lee, Patrick C, MD",9/25/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,First Line,9/21/2023,Inactive,,
MMC OP VP INFUSION,42823,"Lee, Patrick C, MD",2/19/2024,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,_1. First Line,2/19/2024,Active,,
MMC OP INFUSION,95533,"Cohen, Seth D, MD",2/8/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Second Line,2/7/2023,Inactive,,
JCMC CP INFUSION,48234,"Cruz, Allan Louie E, MD",4/29/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Metastatic/recurrent endometrial adenocarcinoma,_1. First Line,4/29/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium
HAM OP INFUSION,87949,"Yogarajah, Meera, MD",6/19/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/18/2023,Inactive,,
HAM OP INFUSION,87949,"Yogarajah, Meera, MD",6/26/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/18/2023,Inactive,,
CINJ OP INFUSION,74061,"Toppmeyer, Deborah L, MD",2/13/2023,Olaparib 30 Day Cycles - Breast,Neoadjuvant,2/13/2023,Active,,
CINJ OP INFUSION,98229,"Weiss, Sarah, MD",8/19/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,8/18/2024,Active,,
CINJ OP INFUSION,98229,"Weiss, Sarah, MD",2/24/2025,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_2. Second Line,2/24/2025,Active,Metastatic melanoma (CMS/HCC),C43.9 - Metastatic melanoma (CMS/HCC)
NBR 5N ONCOLOGY,89184,"Berim, Lyudmyla, MD",11/4/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,11/4/2023,Inactive,,
CMC OP INFUSION,96635,"Talwar, Sumit, MD",9/12/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,First Line,8/31/2023,Inactive,,
CMC OP INFUSION,96635,"Talwar, Sumit, MD",3/12/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,_1. First Line,3/11/2024,Inactive,,
CMC OP INFUSION,96635,"Talwar, Sumit, MD",4/26/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/16/2024,Inactive,,
CMC OP INFUSION,96635,"Talwar, Sumit, MD",9/11/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,8/27/2024,Active,,
CBMC OP INFUSION 2FL,26689,"Raptis, George, MD",4/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,26689,"Raptis, George, MD",5/31/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Adjuvant,5/30/2024,Active,,
SOM OUTPT INFUSION,16969,"Patel, Eshan, MD",1/17/2025,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/9/2025,Inactive,Primary malignant neoplasm of lung metastatic to other site (CMS/HCC),
SOM OUTPT INFUSION,16969,"Patel, Eshan, MD",2/4/2025,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,2/3/2025,Active,Primary malignant neoplasm of lung metastatic to other site (CMS/HCC),C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung
SOM OUTPT INFUSION,16969,"Patel, Eshan, MD",2/4/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,2/3/2025,Active,Primary malignant neoplasm of lung metastatic to other site (CMS/HCC),C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung
MMC OP VP INFUSION,19943,"Cohen, Seth D, MD",7/17/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,,7/6/2023,Inactive,,
MMC OP VP INFUSION,19943,"Cohen, Seth D, MD",12/27/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/18/2023,Inactive,,
MMC OP VP INFUSION,19943,"Cohen, Seth D, MD",8/21/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,8/14/2024,Active,Endometrial cancer (CMS/HCC),
MMC OP VP INFUSION,72919,"Meghal, Trishala, MD",4/8/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,4/8/2024,Inactive,,
HAM OP INFUSION,55204,"Yogarajah, Meera, MD",6/4/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/3/2024,Active,,
SOM OUTPT INFUSION,64742,"Toomey, Kathleen C, MD",5/25/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/24/2023,Inactive,,
SOM OUTPT INFUSION,64742,"Toomey, Kathleen C, MD",2/1/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/30/2024,Inactive,,
CBMC 2W ONCOLOGY,51973,"Grossman, I Robert, MD",5/17/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_6. Sixth Line,5/17/2024,Inactive,,
CINJ OP INFUSION,61284,"Toppmeyer, Deborah L, MD",2/17/2025,CINJ 042102 EOP F Endoxifen / Abemaciclib 28 Day Cycles Research,Neoadjuvant,2/16/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,42806,"Mayer, Tina M, MD",4/6/2023,Enzalutamide 28 Day Cycles - Prostate,,4/6/2023,Inactive,,
CINJ OP INFUSION,42806,"Mayer, Tina M, MD",3/27/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,3/27/2024,Active,,
CINJ OP INFUSION,92463,"Dasgeb, Bahar, MD",7/29/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,7/29/2024,Active,,
CINJ OP INFUSION,42304,"Patel, Eshan, MD",7/25/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,7/25/2023,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
HAM OP INFUSION,94146,"Patel, Malini M, MD",11/3/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,_1. First Line,11/3/2023,Inactive,,
HAM OP INFUSION,94146,"Patel, Malini M, MD",6/14/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,_1. First Line,6/7/2024,Inactive,,
SOM OUTPT INFUSION,11605,"Patel, Eshan, MD",11/25/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/23/2024,Active,,
SOM OUTPT INFUSION,91500,"Patel, Eshan, MD",1/13/2025,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/12/2025,Inactive,Malignant neoplasm metastatic to intra-abdominal lymph node (CMS/HCC),
CINJ OP INFUSION,67348,"Salacz, Michael E, MD",2/3/2023,Bevacizumab 28 Day Cycles - CNS,First Line,2/2/2023,Inactive,,
NBI OP INFUSION,68675,"Anderson, Patrick S, MD",3/13/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/13/2025,Active,Malignant neoplasm of cervix (CMS/HCC),"C53.9 - Malignant neoplasm of cervix uteri, unspecified"
CBMC OP INFUSION 2FL,59103,"Scoppetuolo, Michael, MD",10/20/2023,Daratumumab and Hyaluronidase-fihj Monthly / Bortezomib Bi-Weekly 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,10/20/2023,Inactive,,
CBMC OP INFUSION 2FL,55897,"Scoppetuolo, Michael, MD",5/22/2025,Carfilzomib 56 mg/m2 Weekly / Pomalidomide 21/28 days Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,5/22/2025,Active,Multiple myeloma in relapse (CMS/HCC),
CBMC 2W ONCOLOGY,55897,"Grossman, I Robert, MD",3/16/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,3/16/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),"C90.02 - Multiple myeloma in relapse; A41.9 - Sepsis, unspecified organism; Z51.5 - Encounter for palliative care; G93.41 - Metabolic encephalopathy; J96.01 - Acute respiratory failure with hypoxia; R53.2 - Functional quadriplegia; C78.00 - Secondary malignant neoplasm of unspecified lung; I82.C12 - Acute embolism and thrombosis of left internal jugular vein; I82.611 - Acute embolism and thrombosis of superficial veins of right upper extremity; D61.818 - Other pancytopenia; Z94.84 - Stem cells transplant status; Z68.43 - Body mass index (BMI) 50.0-59.9, adult; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; J45.909 - Unspecified asthma, uncomplicated; I10 - Essential (primary) hypertension; D63.0 - Anemia in neoplastic disease; M48.56XA - Collapsed vertebra, not elsewhere classified, lumbar region, initial encounter for fracture; E66.2 - Morbid (severe) obesity with alveolar hypoventilation; E87.20 - Acidosis, unspecified; E87.0 - Hyperosmolality and hypernatremia; Z59.811 - Housing instability, housed, with risk of homelessness; B37.0 - Candidal stomatitis; N17.9 - Acute kidney failure, unspecified; Z79.4 - Long term (current) use of insulin; E83.52 - Hypercalcemia; E83.51 - Hypocalcemia; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; G89.4 - Chronic pain syndrome; Z86.718 - Personal histor..."
CBMC 2W ONCOLOGY,55897,"Grossman, I Robert, MD",3/12/2025,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,3/12/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),"C90.02 - Multiple myeloma in relapse; A41.9 - Sepsis, unspecified organism; Z51.5 - Encounter for palliative care; G93.41 - Metabolic encephalopathy; J96.01 - Acute respiratory failure with hypoxia; R53.2 - Functional quadriplegia; C78.00 - Secondary malignant neoplasm of unspecified lung; I82.C12 - Acute embolism and thrombosis of left internal jugular vein; I82.611 - Acute embolism and thrombosis of superficial veins of right upper extremity; D61.818 - Other pancytopenia; Z94.84 - Stem cells transplant status; Z68.43 - Body mass index (BMI) 50.0-59.9, adult; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; J45.909 - Unspecified asthma, uncomplicated; I10 - Essential (primary) hypertension; D63.0 - Anemia in neoplastic disease; M48.56XA - Collapsed vertebra, not elsewhere classified, lumbar region, initial encounter for fracture; E66.2 - Morbid (severe) obesity with alveolar hypoventilation; E87.20 - Acidosis, unspecified; E87.0 - Hyperosmolality and hypernatremia; Z59.811 - Housing instability, housed, with risk of homelessness; B37.0 - Candidal stomatitis; N17.9 - Acute kidney failure, unspecified; Z79.4 - Long term (current) use of insulin; E83.52 - Hypercalcemia; E83.51 - Hypocalcemia; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; G89.4 - Chronic pain syndrome; Z86.718 - Personal histor..."
MMC OP INFUSION,1428,"Meghal, Trishala, MD",9/22/2023,Abemaciclib 28 Day Cycles - Breast ,,8/4/2023,Active,,
MMC OP VP INFUSION,39753,"Cohen, Seth D, MD",8/21/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,First Line,8/20/2023,Inactive,,
MMC OP VP INFUSION,39753,"Cohen, Seth D, MD",2/28/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,2/27/2024,Active,,
MMC OP VP INFUSION,39753,"Cohen, Seth D, MD",2/5/2025,CISplatin/Cetuximab 28 Day Cycles- Head and Neck Cancers,_2. Second Line,2/4/2025,Active,Malignant neoplasm of supraglottis (CMS/HCC),
NBR CINJ OP INFUSION,74253,"Evens, Andrew M, DO",3/29/2023,Mosunetuzumab-axgb 21 Day Cycles - Follicular Lymphoma,,3/28/2023,Inactive,,
NBR CINJ OP INFUSION,74253,"Evens, Andrew M, DO",5/10/2023,Lymphodepletion Kymriah 6 Day Cycle - Diffuse Large B-Cell Lymphoma,Third Line,5/9/2023,Inactive,,
NBR CINJ OP INFUSION,74253,"Evens, Andrew M, DO",12/11/2024,Mosunetuzumab-axgb 21 Day Cycles - Follicular Lymphoma,_3. Third Line,12/3/2024,Active,,
NBR CINJ OP INFUSION,69084,"Egini, Ogechukwu, MD",4/11/2025,BMT Allogeneic Flu / Cy / TBI + Post Cy,_9. Ninth Line,4/11/2025,Active,"Follicular lymphoma grade ii, intra-abdominal lymph nodes (CMS/HCC)",
CBMC OP INFUSION 2FL,31091,"Wagmiller, Jennifer Ann, MD",5/9/2025,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,5/5/2025,Active,"Malignant neoplasm of vulva, unspecified (CMS/HCC)
Malignant melanoma of overlapping sites (CMS/HCC)",
SOM OUTPT INFUSION,76412,"Toomey, Kathleen C, MD",8/16/2023,Ribociclib 28 Day Cycles - Breast,First Line,8/16/2023,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CINJ OP INFUSION,47281,"Ghodoussipour, Saum Bobak, MD",1/16/2025,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/16/2025,Active,,
CINJ OP INFUSION,41783,"Toppmeyer, Deborah L, MD",3/21/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/21/2024,Active,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,89275,"Toppmeyer, Deborah L, MD",3/20/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,3/18/2025,Inactive,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,60583,"Goel, Sanjay, MD",4/29/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10 REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_3. Third Line,4/7/2024,Inactive,,
CINJ OP INFUSION,66500,"George, Mridula A, MD",4/28/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/27/2023,Inactive,,
CINJ OP INFUSION,66500,"George, Mridula A, MD",8/10/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,7/20/2023,Inactive,,
CINJ OP INFUSION,92638,"Packiam, Vignesh, MD",11/13/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,11/12/2024,Active,,
CINJ OP INFUSION,94782,"Packiam, Vignesh, MD",3/28/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/28/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
SOM OUTPT INFUSION,68753,"Patel, Eshan, MD",3/20/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,,3/20/2023,Active,,
CBMC OP INFUSION 2FL,7104,"Litvak, Anna M, MD",5/13/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,5/13/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,7104,"Litvak, Anna M, MD",5/13/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,5/13/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,22673,"Cohen, Seth D, MD",6/26/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,6/20/2024,Active,,
NBR CINJ OP INFUSION,96347,"Palmisiano, Neil David, MD",3/13/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,3/12/2023,Inactive,,
NBR CINJ OP INFUSION,96347,"Palmisiano, Neil David, MD",3/17/2023,CINJ 022105 Magrolimab or Placebo 28 Day Cycles Research- Acute Myeloid Leukemia,First Line,3/16/2023,Inactive,,
CMC OP INFUSION,96347,"Eltoukhy, Hussam, MD",10/3/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,10/2/2023,Active,Primary squamous cell carcinoma of lingual tonsil (CMS/HCC),
NBR CINJ OP INFUSION,44200,"Evens, Andrew M, DO",1/19/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,,1/18/2023,Inactive,,
CINJ OP INFUSION,99971,"Boland, Patrick M, MD",8/25/2023,"PACLitaxel D1, D8, D15 28 Day Cycles- Esophageal and Esophagogastric Junction Cancers",,8/24/2023,Inactive,,
CINJ OP INFUSION,67161,"Leiser, Aliza, MD",3/20/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar,,2/21/2023,Inactive,,
HAM OP INFUSION,65816,"Yogarajah, Meera, MD",5/30/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,5/22/2024,Active,,
CINJ OP INFUSION,42361,"Salacz, Michael E, MD",2/3/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Second Line,2/3/2023,Inactive,,
MMC OP VP INFUSION,42361,"Cohen, Seth D, MD",5/8/2023,Bevacizumab 28 Day Cycles - CNS,,5/8/2023,Inactive,,
CINJ OP INFUSION,18348,"Mayer, Tina M, MD",3/9/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,3/9/2023,Active,,
MMC OP VP INFUSION,71673,"Cohen, Seth D, MD",10/16/2023,CINJ 051706 (REGN-ONC-1613) Cohort 16 REGN3767 / Cemiplimab 21 Day Cycles Research- Melanoma,_1. First Line,10/15/2023,Inactive,,
MMC OP VP INFUSION,71673,"Cohen, Seth D, MD",10/16/2023,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,_1. First Line,10/13/2023,Inactive,,
MMC OP VP INFUSION,71673,"Cohen, Seth D, MD",12/4/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,12/3/2023,Inactive,,
MMC OP VP INFUSION,71673,"Cohen, Seth D, MD",2/29/2024,Pembrolizumab 21 Day Cycles - Melanoma,_2. Second Line,2/22/2024,Inactive,,
MMC OP VP INFUSION,71673,"Cohen, Seth D, MD",7/3/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_3. Third Line,7/2/2024,Inactive,,
NBR CINJ OP INFUSION,53695,"Braunschweig, Ira, MD",2/16/2023,D-PACE (Dexamethasone / DOXOrubicin / CISplatin / Cyclophosphamide / Etoposide) 28 Day Cycles - Multiple Myeloma,,2/16/2023,Inactive,,
NBR CINJ OP INFUSION,53695,"Braunschweig, Ira, MD",4/27/2023,Carfilzomib 56 mg/m2 Weekly / Pomalidomide  Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,,4/26/2023,Inactive,,
NBR 5N ONCOLOGY,53695,"Braunschweig, Ira, MD",6/8/2023,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,6/7/2023,Inactive,,
NBR CINJ OP INFUSION,53695,"Braunschweig, Ira, MD",7/13/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,7/12/2023,Inactive,,
NBR CINJ OP INFUSION,53695,"Shah, Mansi R, MD",2/13/2024,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,_6. Sixth Line,2/9/2024,Inactive,,
NBR 5N ONCOLOGY,53695,"Sridharan, Ashwin, MD",3/31/2024,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),Reinduction,3/31/2024,Inactive,,
NBR CINJ OP INFUSION,53695,"Shah, Mansi R, MD",4/18/2024,Bortezomib/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,4/18/2024,Active,,
NBR CINJ OP INFUSION,53695,"Shah, Mansi R, MD",2/11/2025,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,1/27/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Multiple myeloma with failed remission (CMS/HCC)
Multiple myeloma and immunoproliferative neoplasms (CMS/HCC)",
NBR CINJ OP INFUSION,86651,"Shah, Mansi R, MD",5/2/2025,Talquetamab 28 Day Cycles,_6. Sixth Line,5/2/2025,Active,Multiple myeloma in relapse (CMS/HCC),
CMC OP INFUSION,68270,"Eltoukhy, Hussam, MD",9/5/2024,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_1. First Line,9/3/2024,Inactive,,
CMC OP INFUSION,68270,"Eltoukhy, Hussam, MD",12/19/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,12/18/2024,Active,,
HAM OP INFUSION,66067,"Yogarajah, Meera, MD",12/18/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,12/18/2023,Inactive,,
CBMC OP INFUSION 2FL,83555,"Wagmiller, Jennifer Ann, MD",1/7/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,1/7/2025,Active,,
CBMC OP INFUSION 2FL,4705,"Brown, Andrew Bennett, MD",6/13/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,6/13/2024,Active,,
CBMC OP INFUSION 2FL,88592,"Leitner, Stuart P, MD",4/22/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_2. Second Line,4/9/2024,Inactive,,
CBMC 2W ONCOLOGY,88592,"Leitner, Stuart P, MD",8/6/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/5/2024,Inactive,,
CMC OP INFUSION,62766,"Tang, Horace, MD",8/8/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,8/8/2023,Inactive,,
NBI OP INFUSION,37904,"Anderson, Patrick S, MD",11/9/2023,PACLitaxe175mg/m2l / CARBOplatin (AUC 6) 21 Day Cycles - high Grade Endometrial adenocarcinoma advanced,_2. Second Line,11/8/2023,Active,,
CINJ OP INFUSION,77033,"George, Mridula A, MD",5/5/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/27/2023,Inactive,,
CINJ OP INFUSION,77033,"George, Mridula A, MD",8/4/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,8/3/2023,Inactive,,
CINJ OP INFUSION,77033,"George, Mridula A, MD",2/7/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,2/7/2024,Active,,
MMC BBR2 ONCOLOGY,30543,"Lee, Patrick C, MD",12/20/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles + RiTUXimab 84 Day Cycles - Follicular Lymphoma,Induction,12/18/2023,Inactive,,
CINJ OP INFUSION,80384,"Mayer, Tina M, MD",2/3/2025,Pembrolizumab 21 Day Cycles - Kidney,_1. First Line,2/3/2025,Active,"Renal cancer, right (CMS/HCC)","C64.1 - Malignant neoplasm of right kidney, except renal pelvis"
NBR CINJ OP INFUSION,99814,"Matasar, Matthew J, MD",4/15/2024,Cladribine 5 Day Cycle - Hairy Cell Leukemia,_1. First Line,4/14/2024,Inactive,,
CBMC OP INFUSION 2FL,62699,"Radovich, Delia, MD",11/9/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,11/8/2023,Active,,
CBMC OP INFUSION 2FL,95291,"Wagmiller, Jennifer Ann, MD",5/9/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_2. Second Line,4/28/2024,Active,,
CBMC OP INFUSION 2FL,65454,"Wagmiller, Jennifer Ann, MD",5/9/2025,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_3. Third Line,5/9/2025,Active,Malignant neoplasm of labium majus (CMS/HCC),"C51.0 - Malignant neoplasm of labium majus; Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants; Z79.899 - Other long term (current) drug therapy; S31.829A - Unspecified open wound of left buttock, initial encounter; S31.819A - Unspecified open wound of right buttock, initial encounter; C44.590 - Other specified malignant neoplasm of anal skin; Z85.44 - Personal history of malignant neoplasm of other female genital organs"
CMC OP INFUSION,48985,"Tang, Horace, MD",1/11/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/11/2024,Inactive,,
CMC OP INFUSION,48985,"Eltoukhy, Hussam, MD",4/3/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,4/2/2024,Inactive,,
NBR BLOOD SERVICES,48985,"Tiger, Yun Kyoung, MD",7/1/2024,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_3. Third Line,4/17/2024,Active,,
CBMC 2W ONCOLOGY,94316,"Dharmapuri, Sirish, MD",10/7/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,10/3/2024,Inactive,,
CBMC OP INFUSION 2FL,94316,"Dharmapuri, Sirish, MD",10/22/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/21/2024,Active,,
CINJ OP INFUSION,42956,"Omene, Coral Oghenerukevwe, MD",6/19/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,,6/17/2023,Inactive,,
CINJ OP INFUSION,42956,"Omene, Coral Oghenerukevwe, MD",5/20/2024,CINJ 042103 (BRE 354) Part A/B U3-1402 21 Day Cycles Research- Metastatic Breast Cancer,_6. Sixth Line,5/12/2024,Inactive,,
NBI OP INFUSION,33744,"Schleicher, Lori, MD",2/6/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/5/2023,Inactive,,
NBI OP INFUSION,33744,"Schleicher, Lori, MD",6/12/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,6/11/2023,Inactive,,
CINJ OP INFUSION,64015,"Boland, Patrick M, MD",5/16/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/16/2025,Active,"Cancer, hepatocellular (CMS/HCC)","C22.0 - Liver cell carcinoma; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; I10 - Essential (primary) hypertension"
CMC OP INFUSION,18851,"Pompa, Tiffany Ann, MD",4/28/2025,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,4/28/2025,Active,Metastatic melanoma to head and neck (CMS/HCC),
NBR 4N ONCOLOGY,85054,"Rhodes, Joanna Meehan, MD",12/17/2024,MT-R (High-Dose Methotrexate / Temozolomide EVEN Cycles / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,12/16/2024,Active,,
CINJ OP INFUSION,61637,"George, Mridula A, MD",9/6/2023,Palbociclib 28 Day Cycles - Breast,,9/6/2023,Active,,
CINJ OP INFUSION,61637,"George, Mridula A, MD",2/5/2025,CINJ 042305 Phase 1B Cohort 2  Elacestrant / Capivasertib 28 Day Cycles Research- Breast Cancer,_2. Second Line,2/5/2025,Active,"Breast cancer metastasized to bone, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,68467,"Dharmapuri, Sirish, MD",2/18/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/17/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C25.9 - Malignant neoplasm of pancreas, unspecified"
SOM OUTPT INFUSION,90113,"Toomey, Kathleen C, MD",9/6/2023,Trastuzumab 21 Day Cycles - Breast,First Line,9/5/2023,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,90113,"Toomey, Kathleen C, MD",2/12/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,2/11/2025,Active,"Breast cancer metastasized to axillary lymph node, right (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
HAM OP INFUSION,56829,"Patel, Malini M, MD",3/19/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/19/2025,Inactive,"Small cell carcinoma of overlapping sites of right lung (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",
TRMC TCCC OP INFUSION,27994,"Capo, Gerardo, MD",12/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,12/4/2024,Inactive,,
TRMC TCCC OP INFUSION,27994,"Capo, Gerardo, MD",12/5/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,12/4/2024,Active,,
CINJ OP INFUSION,35917,"Stephenson, Ruth D, DO",10/24/2024,DOCEtaxel / avastin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/16/2024,Active,,
HAM OP INFUSION,76867,"Patel, Malini M, MD",6/10/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,6/9/2024,Active,,
CMC OP INFUSION,56052,"Taff, Jessica, MD",5/5/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,4/30/2023,Active,,
CBMC OP INFUSION 2FL,53401,"Derosa, William T, DO",5/7/2025,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,_3. Third Line,5/7/2025,Inactive,"Malignant neoplasm of colon (CMS/HCC)
H/O resection of liver","C18.5 - Malignant neoplasm of splenic flexure; C18.9 - Malignant neoplasm of colon, unspecified; Z90.49 - Acquired absence of other specified parts of digestive tract"
CBMC OP INFUSION 2FL,53401,"Derosa, William T, DO",5/6/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/6/2025,Inactive,"Malignant neoplasm of colon (CMS/HCC)
H/O resection of liver",
CINJ OP INFUSION,36160,"Berim, Lyudmyla, MD",11/29/2023,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/27/2023,Inactive,,
CINJ OP INFUSION,36160,"Berim, Lyudmyla, MD",3/7/2024,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,3/6/2024,Inactive,,
CINJ OP INFUSION,36160,"Berim, Lyudmyla, MD",4/22/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/18/2024,Inactive,,
CINJ OP INFUSION,36160,"Berim, Lyudmyla, MD",7/29/2024,Capecitabine 675 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Pancreatic Cancer,Adjuvant,7/29/2024,Inactive,,
CINJ OP INFUSION,20453,"Haigentz, Missak, MD",6/28/2024,Albumin-Bound PACLitaxel/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,6/27/2024,Inactive,,
CINJ OP INFUSION,20453,"Haigentz, Missak, MD",7/29/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,7/28/2024,Inactive,,
CINJ OP INFUSION,20453,"Haigentz, Missak, MD",1/13/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,1/12/2025,Active,,
CBMC OP INFUSION 2FL,2023,"Dharmapuri, Sirish, MD",2/10/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/9/2025,Active,Adenocarcinoma of gastroesophageal junction (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C16.0 - Malignant neoplasm of cardia
CINJ OP INFUSION,58218,"George, Mridula A, MD",7/10/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/9/2024,Inactive,,
CINJ OP INFUSION,18349,"Mayer, Tina M, MD",1/18/2024,Doxorubicin / CISplatin / Etoposide D1-D3 Day Cycles for ACC,_1. First Line,1/14/2024,Inactive,,
CINJ OP INFUSION,18349,"Mayer, Tina M, MD",3/14/2024,Pembrolizumab 21 Day Cycles - Adrenocortical cancer ,_2. Second Line,3/14/2024,Inactive,,
SOM OUTPT INFUSION,17556,"Patel, Eshan, MD",3/14/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,3/14/2023,Inactive,,
SOM OUTPT INFUSION,17556,"Patel, Eshan, MD",7/18/2023,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,,7/16/2023,Inactive,,
CINJ OP INFUSION,20604,"Mayer, Tina M, MD",2/2/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,2/2/2023,Active,,
NBI OP INFUSION,13784,"Cheng, Yan Ho, MD",10/21/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,10/20/2024,Inactive,"Breast cancer metastasized to liver, left (CMS/HCC)",
CINJ OP INFUSION,13784,"George, Mridula A, MD",1/24/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,1/19/2025,Active,,
NBR CINJ OP INFUSION,84407,"Evens, Andrew M, DO",3/6/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,3/6/2024,Inactive,,
NBR CINJ OP INFUSION,84407,"Evens, Andrew M, DO",5/22/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,5/21/2024,Active,Colon cancer (CMS/HCC),
MMC OP VP INFUSION,78560,"Lee, Patrick C, MD",5/20/2025,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,5/20/2025,Active,Malignant neoplasm of overlapping sites of brain (CMS/HCC),
CBMC OP INFUSION 2FL,49046,"Brown, Andrew Bennett, MD",8/7/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,8/6/2024,Active,,
HAM OP INFUSION,26507,"Patel, Malini M, MD",3/9/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/8/2023,Inactive,,
CINJ OP INFUSION,31197,"Stephenson, Ruth D, DO",12/4/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,12/3/2024,Active,,
MMC BBR2 ONCOLOGY,79927,"Talwar, Sumit, MD",5/24/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/24/2025,Active,Small cell carcinoma of lung (CMS/HCC),"R06.02 - Shortness of breath; J44.9 - Chronic obstructive pulmonary disease, unspecified COPD type (CMS/HCC)"
NBR CINJ OP INFUSION,65141,"Evens, Andrew M, DO",8/2/2023,CINJ 012203 Lead-In Treatment for Fit and Non-Fit Treatments Cycle 42 Day Cycle Research- Hodgkin Lymphoma,First Line,8/1/2023,Inactive,,
CBMC OP INFUSION 2FL,56156,"Litvak, Anna M, MD",5/6/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,5/6/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
NBR 4N BMTU/IMCU,95701,"Rhodes, Joanna Meehan, MD",4/4/2025,R-CEP (Cyclophosphamide / Etoposide / PredniSONE / RiTUXimab) 21 Day Cycles -Castleman's (TAFRO),_1. First Line,4/4/2025,Inactive,"Castleman disease (CMS/HCC)
Thrombocytopenia (CMS/HCC)","D47.Z2 - Castleman disease; E88.3 - Tumor lysis syndrome; D65 - Disseminated intravascular coagulation (defibrination syndrome); J96.01 - Acute respiratory failure with hypoxia; A41.52 - Sepsis due to Pseudomonas; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; N18.6 - End stage renal disease; K63.1 - Perforation of intestine (nontraumatic); B25.8 - Other cytomegaloviral diseases; D61.818 - Other pancytopenia; M72.6 - Necrotizing fasciitis; D62 - Acute posthemorrhagic anemia; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; D70.2 - Other drug-induced agranulocytosis; Z99.2 - Dependence on renal dialysis; D75.81 - Myelofibrosis; D84.9 - Immunodeficiency, unspecified; J90 - Pleural effusion, not elsewhere classified; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; G93.41 - Metabolic encephalopathy; E66.9 - Obesity, unspecified; K76.1 - Chronic passive congestion of liver; D63.1 - Anemia in chronic kidney disease; E03.9 - Hypothyroidism, unspecified; I77.6 - Arteritis, unspecified; R57.8 - Other shock; K25.5 - Chronic or unspecified gastric ulcer with perforation; Z79.4 - Long term (current) use of insulin; R56.9 - Unspecified convulsions; I63.89 - Other cerebral infarction; E11.649 - Type 2 diabetes mellitus with hypoglycemia without coma; E11.65 - Type 2 diabetes mellitus with hyperglycemia; K94.19 - Other complications of enterostomy; I96 - Gangrene, not elsewhere classified..."
NBR 4N BMTU/IMCU,95701,"Shah, Mansi R, MD",3/26/2025,RiTUXimab Initial Infusion - TAFRO,_2. Second Line,3/26/2025,Inactive,"Castleman disease (CMS/HCC)
Thrombocytopenia (CMS/HCC)","D47.Z2 - Castleman disease; E88.3 - Tumor lysis syndrome; D65 - Disseminated intravascular coagulation (defibrination syndrome); J96.01 - Acute respiratory failure with hypoxia; A41.52 - Sepsis due to Pseudomonas; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; N18.6 - End stage renal disease; K63.1 - Perforation of intestine (nontraumatic); B25.8 - Other cytomegaloviral diseases; D61.818 - Other pancytopenia; M72.6 - Necrotizing fasciitis; D62 - Acute posthemorrhagic anemia; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; D70.2 - Other drug-induced agranulocytosis; Z99.2 - Dependence on renal dialysis; D75.81 - Myelofibrosis; D84.9 - Immunodeficiency, unspecified; J90 - Pleural effusion, not elsewhere classified; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; G93.41 - Metabolic encephalopathy; E66.9 - Obesity, unspecified; K76.1 - Chronic passive congestion of liver; D63.1 - Anemia in chronic kidney disease; E03.9 - Hypothyroidism, unspecified; I77.6 - Arteritis, unspecified; R57.8 - Other shock; K25.5 - Chronic or unspecified gastric ulcer with perforation; Z79.4 - Long term (current) use of insulin; R56.9 - Unspecified convulsions; I63.89 - Other cerebral infarction; E11.649 - Type 2 diabetes mellitus with hypoglycemia without coma; E11.65 - Type 2 diabetes mellitus with hyperglycemia; K94.19 - Other complications of enterostomy; I96 - Gangrene, not elsewhere classified..."
SOM OUTPT INFUSION,19436,"Toomey, Kathleen C, MD",12/5/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,11/5/2024,Active,,
CMC OP INFUSION,93157,"Easaw, Sarah, MD",4/19/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,4/18/2023,Inactive,,
CMC OP INFUSION,93157,"Talwar, Sumit, MD",11/21/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,11/21/2023,Active,,
MMC OP VP INFUSION,15840,"Cohen, Seth D, MD",8/2/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,Third Line,7/25/2023,Active,,
CMC OP INFUSION,428,"Pompa, Tiffany Ann, MD",5/29/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/29/2025,Active,"Carcinoma of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Carcinoma of lower-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,2568,"Cohen, Seth D, MD",4/3/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_2. Second Line,4/2/2024,Inactive,,
MMC OP VP INFUSION,2568,"Cohen, Seth D, MD",5/14/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/14/2025,Active,"Lobular carcinoma in situ (LCIS) of right breast
Breast cancer (CMS/HCC)",
NBR CINJ OP INFUSION,33038,"Zayac, Adam, MD",3/14/2025,CINJ 022405 Part 1 Tagraxofusp 12 mcg/kg / Venetoclax / Azacitadine (Days 1-7) 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,3/14/2025,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Other specified hypothyroidism
Abnormal bleeding time",
MMC OP VP INFUSION,36825,"Meghal, Trishala, MD",11/7/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,11/7/2024,Active,,
CBMC OP INFUSION 2FL,90731,"Radovich, Delia, MD",11/17/2023,Nivolumab 480 mg 21 Day Cycles- Colon Cancer,_2. Second Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,90731,"Brown, Andrew Bennett, MD",4/12/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Maintenance,4/11/2024,Active,,
CMC OP INFUSION,14970,"Meghal, Trishala, MD",4/4/2023,Alpelisib 28 Day Cycles - Breast,,4/4/2023,Inactive,,
MMC OP VP INFUSION,14970,"Meghal, Trishala, MD",7/31/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,7/14/2024,Inactive,,
MMC OP VP INFUSION,14970,"Meghal, Trishala, MD",8/21/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,8/20/2024,Inactive,,
MMC OP VP INFUSION,14970,"Meghal, Trishala, MD",1/29/2025,Elacestrant 28 Day Cycles - Breast,_3. Third Line,1/29/2025,Active,,
CBMC OP INFUSION 2FL,12189,"Leitner, Stuart P, MD",2/15/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/16/2023,Inactive,,
CBMC 2W ONCOLOGY,31207,"Gallinson, David Herschel, DO",4/1/2025,"mFOLFOX6 Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/1/2025,Inactive,Small bowel cancer (CMS/HCC),"C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I26.99 - Other pulmonary embolism without acute cor pulmonale; K56.609 - Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C18.9 - Malignant neoplasm of colon, unspecified; D50.9 - Iron deficiency anemia, unspecified; C53.9 - Malignant neoplasm of cervix uteri, unspecified; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; I10 - Essential (primary) hypertension; I82.451 - Acute embolism and thrombosis of right peroneal vein; E66.813 - Obesity, class 3; R62.7 - Adult failure to thrive; D63.8 - Anemia in other chronic diseases classified elsewhere; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z96.651 - Presence of right artificial knee joint; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; K42.9 - Umbilical hernia without obstruction or gangrene; F40.240 - Claustrophobia; E53.8 - Deficiency of other specified B group vitamins; D25.2 - Subserosal leiomyoma of uterus; Z56.0 - Unemployment, unspecified; Z79.899 - Other long term (current) drug therapy; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.3 - Family history of malignant neoplasm of breast; Z83.2 - F..."
CBMC OP INFUSION 2FL,69640,"Scoppetuolo, Michael, MD",11/8/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/7/2023,Active,,
NBR CINJ OP INFUSION,49690,"Assal, Amer, MD",5/15/2024,BMT Autologous Melphalan Day -1  200mg/m2,_1. First Line,5/13/2024,Active,,
JCMC CP INFUSION,50481,"Cruz, Allan Louie E, MD",4/25/2023,"Gemcitabine 1000 mg/m2 D1, D8,  21 Day Cycles- Non-Small Cell Lung Cancer",Second Line,4/25/2023,Inactive,,
NBR 5N MED-SURG OVRF,49391,"Alexander, Henry Richard, MD",3/11/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,3/11/2024,Active,,
CMC OP INFUSION,98304,"Eltoukhy, Hussam, MD",5/21/2025,CINJ 012407 Golcadomide or Placebo + R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles Research- Non-Hodkin's Lymphoma,_1. First Line,5/21/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,51226,"Palmisiano, Neil David, MD",1/5/2023,Gilteritinib 30 Day Cycles - Acute Myeloid Leukemia,,1/5/2023,Inactive,,
CINJ OP INFUSION,51226,"Omene, Coral Oghenerukevwe, MD",3/24/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,,3/20/2023,Inactive,,
CINJ OP INFUSION,51226,"Omene, Coral Oghenerukevwe, MD",7/31/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,7/31/2023,Inactive,,
CINJ OP INFUSION,51226,"Omene, Coral Oghenerukevwe, MD",8/21/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,,8/20/2023,Inactive,,
MMC OP VP INFUSION,26834,"Cohen, Seth D, MD",5/14/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/14/2025,Inactive, N/A,
MMC OP VP INFUSION,63662,"Cohen, Seth D, MD",5/14/2025,Daratumumab 28 Day Cycles- Multiple Myeloma,_1. First Line,5/14/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
MMC OP VP INFUSION,63662,"Cohen, Seth D, MD",5/14/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/14/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CMC OP INFUSION,16429,"Easaw, Sarah, MD",9/8/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,8/29/2023,Inactive,,
MSC OP INFUSION,16429,"Talwar, Sumit, MD",1/12/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,1/11/2024,Inactive,,
MSC OP INFUSION,16429,"Cohen, Seth D, MD",3/29/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,3/28/2024,Inactive,,
CMC OP INFUSION,16429,"Cohen, Seth D, MD",7/19/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,7/18/2024,Active,,
CINJ OP INFUSION,35792,"Mayer, Tina M, MD",10/25/2023,Apalutamide 30 Day Cycles - Prostate,_1. First Line,10/25/2023,Inactive,,
CINJ OP INFUSION,35792,"Mayer, Tina M, MD",2/2/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,2/2/2024,Active,,
CINJ OP INFUSION,45348,"Stephenson, Ryan D, DO",1/30/2023,Relugolix 30 day Cycles - Prostate,First Line,1/30/2023,Inactive,,
SOM OUTPT INFUSION,63709,"Patel, Eshan, MD",2/13/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - salivary gland tumor,_1. First Line,2/11/2025,Active,"Adenocarcinoma (CMS/HCC)
Secondary malignancy of lymph nodes of neck with unknown primary site (CMS/HCC)",
CINJ OP INFUSION,92201,"Boland, Patrick M, MD",2/25/2025,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,1/28/2025,Active,Malignant neoplasm of rectum (CMS/HCC),C20 - Malignant neoplasm of rectum
CINJ OP INFUSION,60669,"Boland, Patrick M, MD",5/6/2025,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,5/6/2025,Active,Malignant neoplasm of rectum (CMS/HCC),C20 - Malignant neoplasm of rectum (CMS/HCC)
CINJ OP INFUSION,78479,"Mayer, Tina M, MD",1/29/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,1/28/2024,Active,,
NBR 4N ONCOLOGY,79542,"Boland, Patrick M, MD",11/18/2023,Gemcitabine/CISplatin 21 Day Cycles- Hepatobiliary Cancers- Gemcitabine-CISplatin Sequencing,_1. First Line,11/16/2023,Inactive,,
CINJ OP INFUSION,81125,"Stephenson, Ryan D, DO",2/6/2023,Enzalutamide 30 Day Cycles - Prostate,First Line,2/6/2023,Inactive,,
CINJ OP INFUSION,81125,"Mayer, Tina M, MD",6/27/2024,CINJ 082307 Arm 2 Abiraterone + Prednisone 28 Day Cycles Research- Prostate Cancer,_2. Second Line,6/27/2024,Inactive,,
CINJ OP INFUSION,81125,"Stephenson, Ryan D, DO",7/12/2024,DOCEtaxel 21 Day Cycles - Prostate,_3. Third Line,7/9/2024,Inactive,,
CINJ OP INFUSION,88267,"Girda, Eugenia, MD",1/2/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,1/1/2025,Active,,
CMC OP INFUSION,7702,"Cohen, Seth D, MD",9/26/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,First Line,9/26/2023,Inactive,,
CINJ OP INFUSION,13546,"Boland, Patrick M, MD",5/20/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,5/9/2024,Active,,
CINJ OP INFUSION,42938,"Hochster, Howard S, MD",3/6/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/5/2024,Inactive,,
CINJ OP INFUSION,42938,"Hochster, Howard S, MD",10/30/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,10/30/2024,Active,,
CINJ OP INFUSION,97562,"George, Mridula A, MD",9/6/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,8/29/2024,Active,,
NBI VALERIE FND HEMONC,92930,"Rao, Harini, MD",11/3/2023,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/3/2023,Active,,
CINJ OP INFUSION,66605,"Haigentz, Missak, MD",7/10/2023,CINJ 032111 (EA3161) ARMS A and B CISplatin with Concurrent Radiation 7 Day Cycles Research- Oropharyngeal Carcinoma,First Line,7/8/2023,Inactive,,
CINJ OP INFUSION,66605,"Haigentz, Missak, MD",10/17/2023,CINJ 032111 (EA3161) ARM A Maintenance Nivolumab 480 mg 28 Day Cycles Research- Oropharyngeal Carcinoma,Consolidation,10/16/2023,Active,,
CMC OP INFUSION,14798,"Pompa, Tiffany Ann, MD",3/25/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,3/25/2025,Active,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)",
MMC OP INFUSION,81974,"Talwar, Sumit, MD",4/11/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/11/2025,Active,Malignant neoplasm of upper-inner quadrant of left female breast (CMS/HCC),
CBMC OP INFUSION 2FL,23310,"Grossman, I Robert, MD",8/8/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/1/2024,Active,,
SOM 1PAV ONCOLOGY,86476,"Patel, Eshan, MD",10/17/2024,Cyclophosphamide - vasculitis,_1. First Line,10/16/2024,Active,,
CINJ OP INFUSION,44457,"Boland, Patrick M, MD",8/2/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,8/1/2024,Inactive,,
MMC OP VP INFUSION,26390,"Cohen, Seth D, MD",1/30/2024,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,1/30/2024,Active,,
NBR CINJ OP INFUSION,70594,"Shah, Mansi R, MD",10/8/2023,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,9/29/2023,Inactive,,
CMC 4B ONCOLOGY,24178,"Talwar, Sumit, MD",7/12/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/4/2023,Inactive,,
CMC OP INFUSION,24178,"Talwar, Sumit, MD",3/13/2024,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,2/27/2024,Inactive,,
NBR CINJ OP INFUSION,50985,"Shah, Mansi R, MD",10/30/2023,Carfilzomib 70 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,Consolidation,10/29/2023,Active,,
MMC OP VP INFUSION,60439,"Cohen, Seth D, MD",8/31/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Induction,8/31/2023,Inactive,,
CINJ OP INFUSION,85001,"Hochster, Howard S, MD",8/7/2024,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,7/9/2024,Inactive,,
CINJ OP INFUSION,85001,"Hochster, Howard S, MD",8/22/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/21/2024,Active,,
CINJ OP INFUSION,85001,"Hochster, Howard S, MD",4/3/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,4/3/2025,Active,Cancer of sigmoid colon (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon; E87.6 - Hypokalemia; I10 - Essential (primary) hypertension; E27.40 - Unspecified adrenocortical insufficiency; R91.1 - Solitary pulmonary nodule; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
MSC OP INFUSION,7703,"Cohen, Seth D, MD",6/12/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,6/6/2023,Active,,
MMC OP VP INFUSION,76204,"Talwar, Sumit, MD",5/9/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,First Line,5/8/2023,Inactive,,
CINJ OP INFUSION,66426,"Haigentz, Missak, MD",6/13/2023,PACLitaxel/CARBOplatin + Pembrolizumab  X C1 followed by Pembro Single agent - 21 Day Cycles-  Non-Small Cell Lung Cancer,First Line,6/13/2023,Inactive,,
CINJ OP INFUSION,66426,"Haigentz, Missak, MD",6/18/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/18/2024,Active,,
CBMC OP INFUSION 2FL,54279,"Scoppetuolo, Michael, MD",9/16/2024,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",_1. First Line,9/3/2024,Active,,
CINJ OP INFUSION,72190,"Stephenson, Ryan D, DO",8/23/2023,Pembrolizumab 42 Day Cycles - Melanoma,Second Line,8/22/2023,Active,,
HAM OP INFUSION,29205,"Patel, Malini M, MD",4/4/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/27/2023,Inactive,,
HAM OP INFUSION,29205,"Patel, Malini M, MD",6/27/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/26/2023,Active,,
CBMC OP INFUSION 2FL,48039,"Leitner, Stuart P, MD",3/20/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/19/2024,Inactive,,
CINJ OP INFUSION,28017,"Toppmeyer, Deborah L, MD",2/16/2023,Sacituzumab Govitecan 28 Day Cycles - Breast ,Second Line,2/15/2023,Inactive,,
CINJ OP INFUSION,28017,"Toppmeyer, Deborah L, MD",6/29/2023,EriBULin 28 Day Cycles - Breast,Third Line,6/21/2023,Inactive,,
CINJ OP INFUSION,28017,"Toppmeyer, Deborah L, MD",11/6/2023,Gemcitabine / CARBOplatin 28 Day Cycles - Breast,_4. Fourth Line,11/5/2023,Inactive,,
CINJ OP INFUSION,28017,"Toppmeyer, Deborah L, MD",11/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,11/6/2023,Inactive,,
CINJ PEDS HEMONC ,28373,"Sharma, Archana, DO",5/12/2025,"AALL1731 All SR-Fav B-ALL, SR-Avg B-ALL, and B-LLy (including DS patients) Consolidation",_1. First Line,5/12/2025,Active,ALL (acute lymphoblastic leukemia) (CMS/HCC),
NBR BMSCH 2 PED HEMONC,28373,"Sharma, Archana, DO",4/8/2025,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,4/8/2025,Inactive,ALL (acute lymphoblastic leukemia) (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; J18.9 - Pneumonia, unspecified organism; D61.9 - Aplastic anemia, unspecified; J81.1 - Chronic pulmonary edema; D70.9 - Neutropenia, unspecified; I10 - Essential (primary) hypertension; N17.9 - Acute kidney failure, unspecified; B97.19 - Other enterovirus as the cause of diseases classified elsewhere; I34.0 - Nonrheumatic mitral (valve) insufficiency; I35.1 - Nonrheumatic aortic (valve) insufficiency; B97.29 - Other coronavirus as the cause of diseases classified elsewhere; D53.9 - Nutritional anemia, unspecified; D69.59 - Other secondary thrombocytopenia; D63.0 - Anemia in neoplastic disease; Z79.899 - Other long term (current) drug therapy; Z87.01 - Personal history of pneumonia (recurrent); Z11.52 - Encounter for screening for COVID-19; Z98.890 - Other specified postprocedural states; Z80.8 - Family history of malignant neoplasm of other organs or systems; Z82.0 - Family history of epilepsy and other diseases of the nervous system"
CINJ OP INFUSION,56716,"Leiser, Aliza, MD",2/27/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,2/26/2023,Inactive,,
CINJ OP INFUSION,56716,"Leiser, Aliza, MD",1/3/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,1/2/2024,Inactive,,
CINJ OP INFUSION,56716,"Girda, Eugenia, MD",3/12/2024,CINJ 052306 Part B Dose Expansion NXP800 28 Day Cycles Research- Ovarian Cancer,_4. Fourth Line,3/11/2024,Inactive,,
CINJ OP INFUSION,56716,"Leiser, Aliza, MD",7/2/2024,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_4. Fourth Line,7/1/2024,Inactive,,
CINJ OP INFUSION,56716,"Leiser, Aliza, MD",7/26/2024,Pembrolizumab 21 Day Cycles,_5. Fifth Line,7/25/2024,Inactive,,
CINJ OP INFUSION,69462,"Saraiya, Biren P, MD",10/28/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/28/2024,Active,,
CINJ OP INFUSION,69462,"Saraiya, Biren P, MD",12/13/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,11/14/2024,Active,,
MMC OP VP INFUSION,61196,"Lee, Patrick C, MD",5/25/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/24/2023,Inactive,,
CINJ OP INFUSION,33295,"Stephenson, Ryan D, DO",1/4/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Melanoma,Third Line,1/4/2023,Inactive,,
NBR 4N ONCOLOGY,25207,"Patel, Vimal D, MD",1/7/2023,BMT Autologous BEAM,,1/6/2023,Inactive,,
NBR CINJ OP INFUSION,25207,"Tiger, Yun Kyoung, MD",10/20/2023,RomiDEPsin 28 Day Cycles - Cutaneous T-Cell Lymphoma,_2. Second Line,10/18/2023,Inactive,,
NBR 4N ONCOLOGY,25207,"Tiger, Yun Kyoung, MD",10/24/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_3. Third Line,10/24/2023,Inactive,,
NBR CINJ OP INFUSION,25207,"Tiger, Yun Kyoung, MD",10/27/2023,Duvelisib 28 Day Cycles - Follicular Lymphoma,_3. Third Line,10/27/2023,Inactive,,
NBR 4N ONCOLOGY,25207,"Tiger, Yun Kyoung, MD",11/14/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,11/14/2023,Inactive,,
NBR 5N ONCOLOGY,25207,"Tiger, Yun Kyoung, MD",11/14/2023,DHAX (Dexamethasone / Cytarabine / OXALIplatin) 21 Day Cycles - T-Cell Lymphoma,_3. Third Line,11/14/2023,Inactive,,
NBR 5N ONCOLOGY,25207,"Tiger, Yun Kyoung, MD",12/5/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,12/5/2023,Inactive,,
NBR CINJ OP INFUSION,25207,"Tiger, Yun Kyoung, MD",12/26/2023,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_2. Second Line,12/25/2023,Inactive,,
NBR CINJ OP INFUSION,25207,"Tiger, Yun Kyoung, MD",12/26/2023,SMILE (Methotrexate / Ifosfamide / Mesna / Etoposide / Dexamethasone / Pegaspargase) 28 Day Cycles - (NK) / T-Cell Lymphoma,_3. Third Line,12/25/2023,Inactive,,
NBI OP INFUSION,24476,"Anderson, Patrick S, MD",5/11/2023,Bevacizumab 21 Day Cycles - Papillary serous endometrial,Maintenance,5/10/2023,Inactive,,
NBI OP INFUSION,24476,"Anderson, Patrick S, MD",7/17/2024,Liposomal DOXOrubicin 28 Day Cycles - Recurrent Endometrial cancer,_2. Second Line,7/2/2024,Active,,
MMC OP VP INFUSION,48180,"Lee, Patrick C, MD",10/26/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Adjuvant,10/25/2023,Inactive,,
CINJ OP INFUSION,2988,"Haigentz, Missak, MD",8/2/2023,"Carboplatin D1/Vinorelbine D1, D8 21 Day Cycles- Salivary Gland Cancer",First Line,8/1/2023,Inactive,,
HAM OP INFUSION,73541,"Toppmeyer, Deborah L, MD",9/30/2024,Alpelisib 28 Day Cycles - Breast,_2. Second Line,9/30/2024,Inactive,,
CINJ OP INFUSION,73541,"Toppmeyer, Deborah L, MD",10/24/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,10/24/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,97768,"Weiss, Sarah, MD",11/21/2023,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,11/19/2023,Inactive,,
CINJ OP INFUSION,97768,"Weiss, Sarah, MD",4/26/2024,Talimogene Laherparepvec 21 Day Cycle + Talimogene Laherparepvec 14 Day Cycles - Melanoma,_2. Second Line,4/12/2024,Inactive,,
NBI OP INFUSION,98455,"Snyder, Rose, MD",2/4/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,2/3/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBI OP INFUSION,74100,"Anderson, Patrick S, MD",9/26/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Endometrial cancer,_3. Third Line,8/18/2024,Inactive,,
CBMC OP INFUSION 2FL,90644,"Grossman, I Robert, MD",11/15/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/14/2024,Active,CNS lymphoma,
CINJ OP INFUSION,94363,"George, Mridula A, MD",4/29/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,4/29/2024,Active,,
CINJ OP INFUSION,28057,"Berim, Lyudmyla, MD",3/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/27/2024,Inactive,,
CINJ OP INFUSION,28057,"Berim, Lyudmyla, MD",8/15/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,8/14/2024,Active,,
CMC 4B ONCOLOGY,59138,"Ferretti, Mark J, MD",10/22/2024,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,10/22/2024,Active,,
CMC OP INFUSION,59138,"Ferretti, Mark J, MD",11/19/2024,BCG Induction (TICE) 42 Day Cycle,_1. First Line,11/18/2024,Future,,
CMC OP INFUSION,59138,"Ferretti, Mark J, MD",1/20/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,_1. First Line,1/19/2025,Active,,
MMC OP VP INFUSION,31807,"Lee, Patrick C, MD",4/25/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/25/2025,Active,"Diffuse large b-cell lymphoma, lymph nodes of multiple sites (CMS/HCC)",
HAM OP INFUSION,28271,"Patel, Malini M, MD",8/2/2023,Gemcitabine / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,8/1/2023,Inactive,,
CBMC OP INFUSION 2FL,65664,"Wagmiller, Jennifer Ann, MD",2/28/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,2/4/2024,Active,,
MMC OP VP INFUSION,68011,"Cohen, Seth D, MD",1/28/2025,"PACLitaxel d 1,8,15 X 4 Cycles Followed by DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles",_1. First Line,1/14/2025,Active,,
MMC OP VP INFUSION,32765,"Lee, Patrick C, MD",5/10/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,5/8/2024,Inactive,,
MMC OP VP INFUSION,32765,"Lee, Patrick C, MD",9/26/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,9/18/2024,Active,,
CINJ OP INFUSION,79381,"Weiss, Sarah, MD",3/7/2023,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,First Line,2/28/2023,Inactive,,
CBMC OP INFUSION 2FL,88179,"Litvak, Anna M, MD",11/6/2023,Everolimus / Exemestane 28 Day Cycles - Breast,_2. Second Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,88179,"Ligresti, Louise G, MD",1/24/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,1/24/2024,Inactive,,
CINJ OP INFUSION,59287,"Berim, Lyudmyla, MD",4/10/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,4/6/2023,Inactive,,
CINJ OP INFUSION,59287,"Berim, Lyudmyla, MD",5/8/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",,5/7/2023,Inactive,,
CINJ OP INFUSION,59287,"Berim, Lyudmyla, MD",10/11/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,9/17/2023,Active,,
CBMC OP INFUSION 2FL,40459,"Phillips, Adrienne A, MD",4/21/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,3/31/2025,Active,Small lymphocytic lymphoma (CMS/HCC),"C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes"
CBMC OP INFUSION 2FL,73719,"Scoppetuolo, Michael, MD",10/24/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/7/2024,Active,,
SOM OUTPT INFUSION,74917,"Patel, Eshan, MD",9/4/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/27/2024,Inactive,,
CMC OP INFUSION,87229,"Taff, Jessica, MD",8/30/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,8/22/2023,Active,Laryngeal cancer (CMS/HCC),
CINJ OP INFUSION,2671,"Toppmeyer, Deborah L, MD",7/29/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_1. First Line,7/25/2024,Inactive,,
CINJ OP INFUSION,2671,"Toppmeyer, Deborah L, MD",12/9/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,12/8/2024,Active,Renal cell carcinoma (CMS/HCC),
CINJ OP INFUSION,2671,"Toppmeyer, Deborah L, MD",3/24/2025,CINJ 042407 Arm A PCS6422 / Capecitabine 42 Day Cycles Research- Breast Cancer,_3. Third Line,3/24/2025,Inactive,"Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)
Breast cancer metastasized to axillary lymph node, left (CMS/HCC)",
CMC OP INFUSION,30188,"Cohen, Seth D, MD",11/28/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/27/2023,Active,Malignant neoplasm of cerebral meninges (CMS/HCC),
NBR CINJ OP INFUSION,37126,"Matasar, Matthew J, MD",7/18/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,,7/17/2023,Inactive,,
NBR CINJ OP INFUSION,40007,"Matasar, Matthew J, MD",4/30/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_3. Third Line,4/30/2025,Active,"Non-Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC)
Marginal zone lymphoma (CMS/HCC)",
CMC OP INFUSION,60520,"Taff, Jessica, MD",7/7/2023,Daratumumab 28 Day Cycles- Multiple Myeloma,Consolidation,7/4/2023,Active,,
CINJ OP INFUSION,83947,"Saraiya, Biren P, MD",2/28/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,2/28/2024,Active,,
CBMC 2W ONCOLOGY,65017,"Leitner, Stuart P, MD",6/10/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,6/9/2024,Active,,
NBR CINJ OP INFUSION,3332,"Palmisiano, Neil David, MD",3/27/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,3/22/2023,Inactive,,
CMC OP INFUSION,58865,"Tang, Horace, MD",2/17/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,2/16/2023,Inactive,,
CMC OP INFUSION,58865,"Tang, Horace, MD",5/19/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,5/19/2023,Inactive,,
CMC OP INFUSION,58865,"Tang, Horace, MD",8/18/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,8/18/2023,Inactive,,
NBR 4N ONCOLOGY,77859,"Rhodes, Joanna Meehan, MD",12/14/2023,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,Adjuvant,12/14/2023,Inactive,,
NBR 4N ONCOLOGY,77859,"Rhodes, Joanna Meehan, MD",12/14/2023,Tretinoin (ATRA) / Arsenic / Gemtuzumab 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),Induction,12/14/2023,Inactive,,
NBR CINJ OP INFUSION,77859,"Zayac, Adam, MD",1/22/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,_1. First Line,1/19/2024,Inactive,,
MSC OP INFUSION,58367,"Talwar, Sumit, MD",1/8/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,12/25/2024,Inactive,Hepatocellular carcinoma (CMS/HCC),
SOM OUTPT INFUSION,53963,"George, Roshini, DO",2/17/2025,"Ramucirumab D1, D15/Abraxane  D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,2/16/2025,Active,Malignant neoplasm of overlapping sites of stomach (CMS/HCC),
MMC OP INFUSION,80838,"Meghal, Trishala, MD",6/21/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/8/2024,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
CBMC OP INFUSION 2FL,11719,"Leitner, Stuart P, MD",10/2/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/2/2023,Inactive,,
CBMC OP INFUSION 2FL,11719,"Leitner, Stuart P, MD",10/2/2023,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,10/2/2023,Inactive,,
CBMC OP INFUSION 2FL,3542,"Wagmiller, Jennifer Ann, MD",11/8/2023,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,3542,"Wagmiller, Jennifer Ann, MD",2/2/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,1/31/2024,Inactive,,
CBMC OP INFUSION 2FL,3542,"Wagmiller, Jennifer Ann, MD",5/21/2024,Topotecan 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,3542,"Wagmiller, Jennifer Ann, MD",8/20/2024,PACLitaxel 28 Day Cycles -  Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,8/19/2024,Active,,
CINJ OP INFUSION,62766,"Packiam, Vignesh, MD",4/17/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,4/16/2024,Inactive,,
CBMC OP INFUSION 2FL,57868,"Brown, Andrew Bennett, MD",2/21/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/11/2024,Active,,
CINJ OP INFUSION,23365,"Boland, Patrick M, MD",11/10/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,11/9/2023,Inactive,,
CINJ OP INFUSION,23365,"Boland, Patrick M, MD",12/8/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,11/13/2023,Inactive,,
CINJ OP INFUSION,23365,"Boland, Patrick M, MD",3/1/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,2/29/2024,Inactive,,
CBMC OP INFUSION 2FL,36099,"Brown, Andrew Bennett, MD",10/27/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,10/26/2023,Inactive,,
CBMC OP INFUSION 2FL,36099,"Brown, Andrew Bennett, MD",6/7/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,6/6/2024,Inactive,,
CMC OP INFUSION,42535,"Taff, Jessica, MD",4/3/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/2/2023,Inactive,,
CMC OP INFUSION,9254,"Cohen, Seth D, MD",3/6/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/6/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
MSC OP INFUSION,95681,"Talwar, Sumit, MD",12/19/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,10/30/2024,Active,"Malignant neoplasm of endometrium (CMS/HCC)
Malignant neoplasm of ovary, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,3457,"Gulhati, Prateek, MD PhD",7/6/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,7/5/2023,Inactive,,
CINJ OP INFUSION,3457,"Gulhati, Prateek, MD PhD",10/12/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,10/12/2023,Inactive,,
CINJ OP INFUSION,3457,"Stephenson, Ryan D, DO",8/30/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,8/29/2024,Inactive,,
MMC OP VP INFUSION,87242,"Cohen, Seth D, MD",5/29/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,5/13/2024,Inactive,,
CMC OP INFUSION,41562,"Talwar, Sumit, MD",6/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,6/4/2024,Inactive,,
MSC OP INFUSION,41562,"Talwar, Sumit, MD",7/31/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,7/29/2024,Inactive,,
CINJ OP INFUSION,53677,"Omene, Coral Oghenerukevwe, MD",4/22/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/22/2025,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,74665,"Matasar, Matthew J, MD",7/5/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,7/4/2023,Inactive,,
NBR CINJ OP INFUSION,74665,"Matasar, Matthew J, MD",7/5/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,7/4/2023,Inactive,,
NBR CINJ OP INFUSION,74665,"Matasar, Matthew J, MD",7/12/2023,CINJ 012103 ARM 1 CC-486 + MINI-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / RiTUXimab) 21 Day Cycles Research- Non-Hodgkin Lymphoma,,6/28/2023,Active,,
CINJ OP INFUSION,74665,"Weiss, Sarah, MD",7/3/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,7/2/2024,Active,,
MMC OP VP INFUSION,57709,"Meghal, Trishala, MD",6/10/2024,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,Maintenance,6/10/2024,Active,,
NBI OP INFUSION,80332,"Jacoby, Sari H, MD",9/22/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/21/2023,Active,,
NBR 4N ONCOLOGY,35912,"Shah, Mansi R, MD",3/25/2024,Cytarabine / IDArubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,3/25/2024,Inactive,,
NBR CINJ OP INFUSION,35912,"Zayac, Adam, MD",5/13/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),_1. First Line,4/9/2024,Inactive,,
NBR 4N BMTU/IMCU,35912,"Egini, Ogechukwu, MD",7/14/2024,BMT Allogeneic TBF + Post Cy ,Consolidation,7/13/2024,Active,,
NBR 4N BMTU/IMCU,35912,"Rabinovich, Emma",2/20/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_3. Third Line,2/20/2025,Active,Acute myeloid leukemia (CMS/HCC),"C92.01 - Acute myeloid leukemia in remission (CMS/HCC); R06.02 - Shortness of breath; I31.39 - Pericardial effusion; Z94.81 - S/P allogeneic bone marrow transplant (CMS/HCC); R07.9 - Chest pain, unspecified type"
NBR 4N BMTU/IMCU,35912,"Rabinovich, Emma",2/21/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_4. Fourth Line,2/20/2025,Active,Acute myeloid leukemia (CMS/HCC),"C92.01 - Acute myeloid leukemia in remission (CMS/HCC); R06.02 - Shortness of breath; I31.39 - Pericardial effusion; Z94.81 - S/P allogeneic bone marrow transplant (CMS/HCC); R07.9 - Chest pain, unspecified type"
CINJ OP INFUSION,33231,"Gulhati, Prateek, MD PhD",8/23/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/14/2024,Inactive,,
CINJ OP INFUSION,33231,"Gulhati, Prateek, MD PhD",11/1/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/17/2024,Inactive,,
NBR CINJ OP INFUSION,88398,"Matasar, Matthew J, MD",3/27/2024,Venetoclax 42 Day Cycles - Mantle Cell Lymphoma,_2. Second Line,3/27/2024,Inactive,,
NBR CINJ OP INFUSION,88398,"Matasar, Matthew J, MD",8/21/2024,Venetoclax / Rituximab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,8/21/2024,Active,"Malignant neoplasm of middle third of esophagus (CMS/HCC)
Drug-induced thyroiditis
Encounter for screening for other viral diseases",
CMC OP INFUSION,53234,"Taff, Jessica, MD",5/4/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/3/2023,Inactive,,
NBR 5N ONCOLOGY,51954,"Tiger, Yun Kyoung, MD",2/5/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Neoadjuvant,2/5/2024,Inactive,,
NBR CINJ OP INFUSION,51954,"Matasar, Matthew J, MD",2/20/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/19/2024,Inactive,,
NBR CINJ OP INFUSION,51954,"Matasar, Matthew J, MD",7/17/2024,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,6/10/2024,Active,,
CMC OP INFUSION,49325,"Samuel, David, MD",2/27/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,2/24/2025,Active,Endometrial cancer (CMS/HCC),
MMC OP INFUSION,65251,"Meghal, Trishala, MD",2/8/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,2/7/2023,Inactive,,
MMC OP INFUSION,65251,"Meghal, Trishala, MD",6/21/2023,Pembrolizumab 21 Day Cycles - Uterine,Maintenance,6/20/2023,Inactive,,
MMC OP INFUSION,65251,"Meghal, Trishala, MD",2/7/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/6/2024,Active,,
CINJ OP INFUSION,87440,"Saraiya, Biren P, MD",5/23/2023,Enzalutamide 28 Day Cycles - Prostate,Second Line,5/23/2023,Inactive,,
CINJ OP INFUSION,52253,"Haigentz, Missak, MD",11/28/2024,"PEMEtrexed/CISplatin PLUS Pembrolizumab -21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,11/26/2024,Inactive,,
CINJ OP INFUSION,99104,"Goel, Sanjay, MD",10/16/2024,CINJ 052401 Part A Enrichment GIM-122,_4. Fourth Line,10/16/2024,Inactive,,
MMC OP VP INFUSION,30594,"Talwar, Sumit, MD",11/7/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,11/6/2023,Inactive,,
NBR 5N ONCOLOGY,42902,"Palmisiano, Neil David, MD",12/17/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,12/16/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
HAM OP INFUSION,18262,"Yogarajah, Meera, MD",2/29/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/11/2024,Inactive,,
TRMC TCCC OP INFUSION,55780,"Capo, Gerardo, MD",11/1/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,10/31/2024,Active,Urothelial carcinoma of right distal ureter (CMS/HCC),
CMC OP INFUSION,82850,"Cohen, Seth D, MD",12/5/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/4/2023,Inactive,,
CINJ OP INFUSION,26930,"Saraiya, Biren P, MD",8/26/2024,Enzalutamide 30 Day Cycles - Prostate,_2. Second Line,8/26/2024,Inactive,,
CINJ OP INFUSION,29113,"Girda, Eugenia, MD",11/16/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,11/15/2023,Inactive,,
CINJ OP INFUSION,29113,"Girda, Eugenia, MD",11/16/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/15/2023,Inactive,,
CINJ OP INFUSION,29113,"Girda, Eugenia, MD",9/10/2024,CINJ 102310 Cohort B MK-4280A or Pembrolizumab / Lenvatinib 21 Day Cycles Research Solid Tumors,_2. Second Line,8/27/2024,Active,,
CINJ OP INFUSION,29113,"Girda, Eugenia, MD",2/13/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,2/6/2025,Active,Endometrial carcinoma (CMS/HCC),"K44.9 - Diaphragmatic hernia without obstruction or gangrene; K43.9 - Ventral hernia without obstruction or gangrene; R14.0 - Abdominal distension (gaseous); R18.0 - Malignant ascites; J90 - Pleural effusion, not elsewhere classified; R93.1 - Abnormal findings on diagnostic imaging of heart and coronary circulation; E66.9 - Obesity, unspecified; R73.03 - Prediabetes; E03.9 - Hypothyroidism, unspecified; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.722 - Acquired absence of ovaries, bilateral; Z90.710 - Acquired absence of both cervix and uterus; Z90.89 - Acquired absence of other organs; Z98.890 - Other specified postprocedural states; Z78.0 - Asymptomatic menopausal state; Z88.1 - Allergy status to other antibiotic agents; Z85.42 - Personal history of malignant neoplasm of other parts of uterus; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,71547,"Scoppetuolo, Michael, MD",5/8/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/7/2023,Active,,
HAM OP INFUSION,11721,"Patel, Malini M, MD",1/8/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,57936,"Scoppetuolo, Michael, MD",2/26/2024,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,_1. First Line,2/25/2024,Inactive,,
CBMC OP INFUSION 2FL,57936,"Scoppetuolo, Michael, MD",7/16/2024,CINJ 042102 Block B Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles- Breast Cancer,_2. Second Line,7/15/2024,Inactive,,
CBMC OP INFUSION 2FL,57936,"Scoppetuolo, Michael, MD",11/12/2024,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,_1. First Line,11/11/2024,Active,,
CMC OP INFUSION,66978,"Cohen, Seth D, MD",1/29/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,1/20/2025,Active,,
CMC OP INFUSION,55589,"Cohen, Seth D, MD",1/9/2024,Atezolizumab/Bevacizumab/PACLitaxel/CARBOplatin 21 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,1/3/2024,Inactive,,
CMC OP INFUSION,55589,"Cohen, Seth D, MD",5/9/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/9/2024,Active,,
CMC OP INFUSION,55589,"Cohen, Seth D, MD",5/15/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/14/2024,Inactive,,
NBR BLOOD SERVICES,54492,"Tiger, Yun Kyoung, MD",6/11/2024,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_3. Third Line,4/24/2024,Active,,
NBR 4N ONCOLOGY,54492,"Tiger, Yun Kyoung, MD",4/16/2025,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_4. Fourth Line,4/16/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"E83.52 - Hypercalcemia; E88.3 - Tumor lysis syndrome; C83.37 - Diffuse large b-cell lymphoma, spleen; L76.32 - Postprocedural hematoma of skin and subcutaneous tissue following other procedure; I10 - Essential (primary) hypertension; D53.9 - Nutritional anemia, unspecified; I82.453 - Acute embolism and thrombosis of peroneal vein, bilateral; N17.9 - Acute kidney failure, unspecified; D62 - Acute posthemorrhagic anemia; I82.463 - Acute embolism and thrombosis of calf muscular vein, bilateral; Z96.653 - Presence of artificial knee joint, bilateral; R15.9 - Full incontinence of feces; K59.00 - Constipation, unspecified; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; E83.42 - Hypomagnesemia; K64.9 - Unspecified hemorrhoids; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R26.2 - Difficulty in walking, not elsewhere classified; G62.9 - Polyneuropathy, unspecified; R32 - Unspecified urinary incontinence; Z79.52 - Long term (current) use of systemic steroids; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z90.81 - Acquired absence of spleen; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.850 - Personal history of chimeric antigen receptor t-cell therapy"
NBR 4N ONCOLOGY,54492,"Tiger, Yun Kyoung, MD",4/15/2025,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,4/14/2025,Inactive,Diffuse large B-cell lymphoma (CMS/HCC),"E83.52 - Hypercalcemia; E88.3 - Tumor lysis syndrome; C83.37 - Diffuse large b-cell lymphoma, spleen; L76.32 - Postprocedural hematoma of skin and subcutaneous tissue following other procedure; I10 - Essential (primary) hypertension; D53.9 - Nutritional anemia, unspecified; I82.453 - Acute embolism and thrombosis of peroneal vein, bilateral; N17.9 - Acute kidney failure, unspecified; D62 - Acute posthemorrhagic anemia; I82.463 - Acute embolism and thrombosis of calf muscular vein, bilateral; Z96.653 - Presence of artificial knee joint, bilateral; R15.9 - Full incontinence of feces; K59.00 - Constipation, unspecified; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; E83.42 - Hypomagnesemia; K64.9 - Unspecified hemorrhoids; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R26.2 - Difficulty in walking, not elsewhere classified; G62.9 - Polyneuropathy, unspecified; R32 - Unspecified urinary incontinence; Z79.52 - Long term (current) use of systemic steroids; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z90.81 - Acquired absence of spleen; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.850 - Personal history of chimeric antigen receptor t-cell therapy"
CINJ OP INFUSION,62062,"Stephenson, Ryan D, DO",4/1/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,4/1/2024,Active,,
CMC OP INFUSION,83076,"Pompa, Tiffany Ann, MD",3/6/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/6/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",
NBR 5N ONCOLOGY,27341,"Patel, Vimal D, MD",1/9/2023,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,,1/8/2023,Inactive,,
CMC OP INFUSION,34213,"Taff, Jessica, MD",4/20/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/19/2023,Active,Primary prostate cancer with metastasis from prostate to other site (CMS/HCC),
CINJ OP INFUSION,56634,"Haigentz, Missak, MD",3/18/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles with Radiotherapy - Non-Small Cell Lung Cancer,Induction,3/18/2025,Inactive,"Malignant neoplasm metastatic to lymph nodes of multiple sites (CMS/HCC)
Malignant neoplasm of hilus of left lung (CMS/HCC)
Chronic fatigue","C34.02 - Malignant neoplasm of left main bronchus; J44.9 - Chronic obstructive pulmonary disease, unspecified; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z86.711 - Personal history of pulmonary embolism; Z78.0 - Asymptomatic menopausal state; Z79.01 - Long term (current) use of anticoagulants; Z79.82 - Long term (current) use of aspirin; Z79.51 - Long term (current) use of inhaled steroids; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; F17.200 - Nicotine dependence, unspecified, uncomplicated; Z88.5 - Allergy status to narcotic agent"
CINJ OP INFUSION,41605,"Leiser, Aliza, MD",4/22/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,4/21/2024,Inactive,,
CINJ OP INFUSION,47656,"Muralikrishnan, Sivraj, MD",1/7/2025,Cetuximab Maintenance 14 Day Cycles- Head and Neck Cancers,_2. Second Line,1/6/2025,Active,,
CINJ OP INFUSION,24844,"Goel, Sanjay, MD",5/5/2025,CINJ 052404 Dose Escalation XL309 / Olaparib 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,5/5/2025,Active,Laryngeal squamous cell carcinoma (CMS/HCC),
CINJ OP INFUSION,96714,"Berim, Lyudmyla, MD",4/26/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,,4/25/2023,Inactive,,
CINJ OP INFUSION,96714,"Berim, Lyudmyla, MD",5/9/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,5/4/2023,Inactive,,
CINJ OP INFUSION,96714,"Berim, Lyudmyla, MD",7/3/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,6/30/2023,Inactive,,
HAM OP INFUSION,66472,"Yogarajah, Meera, MD",1/12/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,First Line,1/4/2023,Inactive,,
CINJ OP INFUSION,76728,"Haigentz, Missak, MD",11/16/2023,CISplatin / Etoposide (75/100) 21 Day Cycles - Sinonasal Teratocarcinosarcoma,Neoadjuvant,11/16/2023,Inactive,,
CINJ OP INFUSION,76728,"Haigentz, Missak, MD",4/9/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,4/9/2024,Inactive,,
CINJ OP INFUSION,76728,"Haigentz, Missak, MD",1/15/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,1/15/2025,Active,,
CINJ OP INFUSION,7650,"Leiser, Aliza, MD",2/13/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,2/12/2024,Active,,
NBR CINJ OP INFUSION,28141,"Palmisiano, Neil David, MD",6/6/2024,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_1. First Line,6/4/2024,Active,,
HAM OP INFUSION,99693,"Patel, Malini M, MD",10/16/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,10/14/2024,Inactive,,
HAM OP INFUSION,99693,"Patel, Malini M, MD",10/16/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,10/14/2024,Inactive,,
JCMC CP INFUSION,27655,"Cruz, Allan Louie E, MD",2/7/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,2/6/2023,Inactive,,
JCMC CP INFUSION,27655,"Maggi, Jason C, MD",7/27/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Induction,7/27/2023,Inactive,,
JCMC CP INFUSION,27655,"Cruz, Allan Louie E, MD",12/5/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/4/2023,Inactive,,
CINJ OP INFUSION,37418,"Berim, Lyudmyla, MD",10/4/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,10/3/2024,Active,,
NBR CINJ OP INFUSION,31980,"Rhodes, Joanna Meehan, MD",12/4/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/3/2024,Active,,
NBR CINJ OP INFUSION,31980,"Rhodes, Joanna Meehan, MD",2/6/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,2/6/2025,Inactive,High grade B-cell lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,31980,"Rhodes, Joanna Meehan, MD",5/12/2025,CYVE (High-Dose Cytarabine / Etoposide) - CNS Lymphoma (Age 60 Years Or More),_2. Second Line,5/12/2025,Active,"B-cell lymphoma (CMS/HCC)
CNS lymphoma (CMS/HCC)",
NBR 5N ONCOLOGY,31980,"Tiger, Yun Kyoung, MD",3/31/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_2. Second Line,3/31/2025,Inactive,"B-cell lymphoma (CMS/HCC)
Diffuse large B-cell lymphoma of central nervous system (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C79.32 - Secondary malignant neoplasm of cerebral meninges; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; N17.9 - Acute kidney failure, unspecified; E87.1 - Hypo-osmolality and hyponatremia; D64.9 - Anemia, unspecified; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; R25.9 - Unspecified abnormal involuntary movements; K21.9 - Gastro-esophageal reflux disease without esophagitis; M51.27 - Other intervertebral disc displacement, lumbosacral region; M48.07 - Spinal stenosis, lumbosacral region; R07.81 - Pleurodynia; E87.70 - Fluid overload, unspecified; I95.9 - Hypotension, unspecified; G62.0 - Drug-induced polyneuropathy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; F41.9 - Anxiety disorder, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); N14.11 - Contrast-induced nephropathy; K59.00 - Constipation, unspecified; R11.0 - Nausea; R47.02 - Dysphasia; T50.8X5A - Adverse effect of diagnostic agents, initial encounter; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence; Z86.711 - Personal history of pulmonary e..."
NBR 5N ONCOLOGY,31980,"Rhodes, Joanna Meehan, MD",3/25/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_2. Second Line,3/25/2025,Inactive,"B-cell lymphoma (CMS/HCC)
CNS lymphoma (CMS/HCC)",C85.10 - High grade B-cell lymphoma (CMS/HCC)
NBR 5N ONCOLOGY,31980,"Shah, Mansi R, MD",3/25/2025,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/25/2025,Inactive,"B-cell lymphoma (CMS/HCC)
CNS lymphoma (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C79.32 - Secondary malignant neoplasm of cerebral meninges; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; N17.9 - Acute kidney failure, unspecified; E87.1 - Hypo-osmolality and hyponatremia; D64.9 - Anemia, unspecified; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; R25.9 - Unspecified abnormal involuntary movements; K21.9 - Gastro-esophageal reflux disease without esophagitis; M51.27 - Other intervertebral disc displacement, lumbosacral region; M48.07 - Spinal stenosis, lumbosacral region; R07.81 - Pleurodynia; E87.70 - Fluid overload, unspecified; I95.9 - Hypotension, unspecified; G62.0 - Drug-induced polyneuropathy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; F41.9 - Anxiety disorder, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); N14.11 - Contrast-induced nephropathy; K59.00 - Constipation, unspecified; R11.0 - Nausea; R47.02 - Dysphasia; T50.8X5A - Adverse effect of diagnostic agents, initial encounter; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence; Z86.711 - Personal history of pulmonary e..."
NBR CINJ OP INFUSION,31980,"Rhodes, Joanna Meehan, MD",3/24/2025,IT chemo - MTX alternating with ARA-C,Adjuvant,3/24/2025,Active,B-cell lymphoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C79.32 - Secondary malignant neoplasm of cerebral meninges; C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; N17.9 - Acute kidney failure, unspecified; E87.1 - Hypo-osmolality and hyponatremia; D64.9 - Anemia, unspecified; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; R25.9 - Unspecified abnormal involuntary movements; K21.9 - Gastro-esophageal reflux disease without esophagitis; M51.27 - Other intervertebral disc displacement, lumbosacral region; M48.07 - Spinal stenosis, lumbosacral region; R07.81 - Pleurodynia; E87.70 - Fluid overload, unspecified; I95.9 - Hypotension, unspecified; G62.0 - Drug-induced polyneuropathy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; F41.9 - Anxiety disorder, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); N14.11 - Contrast-induced nephropathy; K59.00 - Constipation, unspecified; R11.0 - Nausea; R47.02 - Dysphasia; T50.8X5A - Adverse effect of diagnostic agents, initial encounter; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z86.718 - Personal history of other venous thrombosis and embolism; Z87.891 - Personal history of nicotine dependence; Z86.711 - Personal history of pulmonary e..."
NBI OP INFUSION,58115,"Anderson, Patrick S, MD",3/21/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles -Endometrial cancer,_1. First Line,3/20/2024,Active,,
NBR CINJ OP INFUSION,21890,"Schaar, Dale, MD PhD",4/10/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,4/10/2023,Inactive,,
NBR CINJ OP INFUSION,21890,"Schaar, Dale, MD PhD",4/11/2023,Decitabine (Maintenance Phase) 56 Day Cycles- Post Transplant ,,4/9/2023,Inactive,,
JCMC CP INFUSION,65948,"Cruz, Allan Louie E, MD",9/29/2023,RiTUXimab 28 Day Cycle - Thrombotic thrombocytopenic purpura,Induction,9/29/2023,Inactive,,
JCMC CP INFUSION,27369,"Sekhri, Arunabh, MD",3/23/2023,Pembrolizumab 21 Day Cycles - Uterine,Second Line,3/22/2023,Active,,
CINJ OP INFUSION,16080,"Stephenson, Ryan D, DO",7/9/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,7/9/2024,Active,,
NBI OP INFUSION,47809,"Jacoby, Sari H, MD",3/25/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,3/25/2024,Inactive,,
CBMC 2W ONCOLOGY,88277,"Brown, Andrew Bennett, MD",5/16/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,5/15/2025,Inactive,Malignant endobronchial neoplasm of left lung (CMS/HCC),"A41.9 - Sepsis, unspecified organism; J15.69 - Pneumonia due to other gram-negative bacteria; J96.01 - Acute respiratory failure with hypoxia; J90 - Pleural effusion, not elsewhere classified; I27.20 - Pulmonary hypertension, unspecified; C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; D63.0 - Anemia in neoplastic disease; R65.20 - Severe sepsis without septic shock; E66.811 - Obesity, class 1; I34.0 - Nonrheumatic mitral (valve) insufficiency; I48.19 - Other persistent atrial fibrillation; J98.11 - Atelectasis; Z79.4 - Long term (current) use of insulin; I36.1 - Nonrheumatic tricuspid (valve) insufficiency; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; Z98.891 - History of uterine scar from previous surgery; Z90.710 - Acquired absence of both cervix and uterus; Z90.722 - Acquired absence of ovaries, bilateral; Z90.49 - Acquired absence of other specified parts of digestive tract; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z79.01 - Long term (current) use of anticoagulants; Z68.32 - Body mass index (BMI) 32.0-32.9, adult; Z85.42 - Personal history of malignant neoplasm of other parts of uterus; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.3 - Personal history of irradiation"
CBMC 2W ONCOLOGY,88277,"Brown, Andrew Bennett, MD",5/15/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,5/15/2025,Inactive,Malignant endobronchial neoplasm of left lung (CMS/HCC),"A41.9 - Sepsis, unspecified organism; J15.69 - Pneumonia due to other gram-negative bacteria; J96.01 - Acute respiratory failure with hypoxia; J90 - Pleural effusion, not elsewhere classified; I27.20 - Pulmonary hypertension, unspecified; C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; D63.0 - Anemia in neoplastic disease; R65.20 - Severe sepsis without septic shock; E66.811 - Obesity, class 1; I34.0 - Nonrheumatic mitral (valve) insufficiency; I48.19 - Other persistent atrial fibrillation; J98.11 - Atelectasis; Z79.4 - Long term (current) use of insulin; I36.1 - Nonrheumatic tricuspid (valve) insufficiency; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; Z98.891 - History of uterine scar from previous surgery; Z90.710 - Acquired absence of both cervix and uterus; Z90.722 - Acquired absence of ovaries, bilateral; Z90.49 - Acquired absence of other specified parts of digestive tract; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z79.01 - Long term (current) use of anticoagulants; Z68.32 - Body mass index (BMI) 32.0-32.9, adult; Z85.42 - Personal history of malignant neoplasm of other parts of uterus; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.3 - Personal history of irradiation"
NBR CINJ OP INFUSION,24051,"Evens, Andrew M, DO",1/15/2025,Nivolumab +AVD (DOXOrubicin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/14/2025,Active,,
SOM OUTPT INFUSION,77967,"Toomey, Kathleen C, MD",5/24/2024,Pembrolizumab  -  Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_1. First Line,5/21/2024,Inactive,,
SOM OUTPT INFUSION,77967,"Toomey, Kathleen C, MD",1/17/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,1/16/2025,Active,Anal cancer (CMS/HCC),
SOM OUTPT INFUSION,1462,"Toomey, Kathleen C, MD",5/5/2025,Capecitabine 21 Day Cycles - Breast,_3. Third Line,5/5/2025,Active,"Breast cancer metastasized to bone, unspecified laterality (CMS/HCC)",
NBR 4N ONCOLOGY,96411,"Matasar, Matthew J, MD",1/16/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,1/16/2023,Inactive,,
NBR CINJ OP INFUSION,96411,"Matasar, Matthew J, MD",2/7/2023, Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,2/6/2023,Inactive,,
NBR CINJ OP INFUSION,96411,"Braunschweig, Ira, MD",3/29/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,,3/28/2023,Inactive,,
NBR 4N ONCOLOGY,96411,"Braunschweig, Ira, MD",4/6/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,,4/4/2023,Inactive,,
NBR 4N BMTU/IMCU,7810,"Evens, Andrew M, DO",9/11/2024,BMT Autologous BEAM,_3. Third Line,9/10/2024,Active,,
NBI OP INFUSION,70336,"Cheng, Yan Ho, MD",11/21/2024,CISplatin with Concurrent Radiation 42 Day Cycle- Head and Neck Cancers,_1. First Line,11/3/2024,Active,,
CINJ OP INFUSION,6065,"Haigentz, Missak, MD",2/16/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,Second Line,2/15/2023,Inactive,,
CINJ OP INFUSION,6065,"Haigentz, Missak, MD",4/18/2023,PACLitaxel / CARBOplatin plus Pembrolizumab 21 Day Cycles - -Small Cell Lung Cancer,Third Line,4/18/2023,Inactive,,
CINJ OP INFUSION,6065,"Haigentz, Missak, MD",6/27/2023,Pembrolizumab 21 Day Cycles- Small Cell Lung Cancer,,6/27/2023,Inactive,,
CBMC OP INFUSION 2FL,8339,"Brown, Andrew Bennett, MD",10/17/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/16/2023,Inactive,,
NBI OP INFUSION,21974,"Schleicher, Lori, MD",8/4/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,8/3/2023,Active,,
CBMC 2W ONCOLOGY,16742,"Grossman, I Robert, MD",10/24/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/23/2023,Inactive,,
NBR CINJ OP INFUSION,60181,"Tiger, Yun Kyoung, MD",7/29/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/28/2024,Active,,
TRMC TCCC OP INFUSION,43271,"Capo, Gerardo, MD",12/4/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,12/3/2024,Active,,
TRMC TCCC OP INFUSION,43271,"Capo, Gerardo, MD",4/30/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,4/30/2025,Active,Adenocarcinoma of upper lobe of right lung (CMS/HCC),
CINJ OP INFUSION,2843,"Stephenson, Ruth D, DO",5/22/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,5/21/2023,Inactive,,
CINJ OP INFUSION,2843,"Stephenson, Ruth D, DO",12/26/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_2. Second Line,12/22/2024,Active,,
CINJ OP INFUSION,46579,"Boland, Patrick M, MD",5/2/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,5/1/2023,Inactive,,
CBMC OP INFUSION 2FL,27759,"Brown, Andrew Bennett, MD",9/26/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,9/23/2024,Inactive,,
CBMC OP INFUSION 2FL,27759,"Brown, Andrew Bennett, MD",10/15/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,10/14/2024,Active,,
CINJ OP INFUSION,80629,"Leiser, Aliza, MD",3/10/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,,3/7/2023,Inactive,,
CINJ OP INFUSION,58599,"Packiam, Vignesh, MD",5/5/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,5/5/2025,Active,Bladder cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C67.8 - Malignant neoplasm of overlapping sites of bladder"
JCMC CP INFUSION,5230,"Sekhri, Arunabh, MD",7/8/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Pembrolizumab 21 Day Cycles - Metastatic serous carcinoma from GYN tract favor endometrial primary,Neoadjuvant,7/7/2024,Inactive,,
JCMC CP INFUSION,5230,"Sekhri, Arunabh, MD",8/16/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - serous endometrial carcinoma HER2(+),_1. First Line,8/8/2024,Active,,
CINJ PEDS HEMONC ,76195,"Moerdler, Scott, MD",5/22/2023,PEDS AREN0321 VinCRIStine / Irinotecan - Renal,Third Line,5/19/2023,Inactive,,
NBR CINJ OP INFUSION,33828,"Evens, Andrew M, DO",4/9/2025,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,Lymphodepletion,4/9/2025,Active,Hodgkin lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,32496,"Tiger, Yun Kyoung, MD",10/24/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,10/24/2024,Active,,
HAM OP INFUSION,11623,"Gendy, Mina, DO",5/15/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/15/2025,Inactive,"Malignant neoplasm metastatic to lung (CMS/HCC)
Squamous cell carcinoma of unknown origin
Abnormal findings on diagnostic imaging of other specified body structures",C44.92 - Squamous cell carcinoma of unknown origin
HAM OP INFUSION,11623,"Gendy, Mina, DO",5/15/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,5/9/2025,Active,"Malignant neoplasm metastatic to lung (CMS/HCC)
Squamous cell carcinoma of unknown origin
Abnormal findings on diagnostic imaging of other specified body structures",
CMC OP INFUSION,30888,"Cohen, Seth D, MD",2/27/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,2/26/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,59376,"Cohen, Seth D, MD",3/6/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,3/6/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,47031,"Brown, Andrew Bennett, MD",11/21/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/13/2024,Active,,
CBMC OP INFUSION 2FL,23994,"Brown, Andrew Bennett, MD",12/1/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/28/2023,Active,,
TRMC TCCC OP INFUSION,67499,"Capo, Gerardo, MD",10/25/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,10/25/2024,Active,,
NBI OP INFUSION,42183,"Anderson, Patrick S, MD",5/13/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,5/2/2024,Inactive,,
NBI OP INFUSION,42183,"Anderson, Patrick S, MD",8/20/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,8/19/2024,Active,,
SOM OUTPT INFUSION,77891,"Toomey, Kathleen C, MD",7/26/2024,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,7/18/2024,Inactive,,
SOM OUTPT INFUSION,77891,"Toomey, Kathleen C, MD",8/16/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,8/15/2024,Inactive,,
CINJ OP INFUSION,17284,"Hochster, Howard S, MD",12/27/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/21/2023,Inactive,,
CINJ OP INFUSION,53154,"Boland, Patrick M, MD",4/11/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/11/2025,Inactive,Anal cancer (CMS/HCC),"C21.0 - Malignant neoplasm of anus, unspecified; C20 - Malignant neoplasm of rectum"
CINJ OP INFUSION,99324,"Boland, Patrick M, MD",1/13/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,1/11/2023,Inactive,,
CINJ OP INFUSION,99324,"Boland, Patrick M, MD",3/24/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,,3/23/2023,Inactive,,
NBR 5N ONCOLOGY,99324,"Boland, Patrick M, MD",4/12/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,4/12/2023,Inactive,,
CBMC OP INFUSION 2FL,79184,"Wagmiller, Jennifer Ann, MD",2/25/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/18/2025,Active,"Cancer of head, face, or neck lymph nodes, secondary (CMS/HCC)","R19.03 - Right lower quadrant abdominal swelling, mass and lump; C77.0 - Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck"
CBMC OP INFUSION 2FL,32689,"Wagmiller, Jennifer Ann, MD",4/8/2025,Dostarlimab-gxly  42 Day Cycles- Colon Cancer,_1. First Line,4/8/2025,Active,Endometrial cancer (CMS/HCC),
MMC OP VP INFUSION,15716,"Lee, Patrick C, MD",1/15/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,1/4/2024,Inactive,,
CBMC OP INFUSION 2FL,43116,"Dharmapuri, Sirish, MD",10/22/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Gastric,Neoadjuvant,10/22/2024,Active,,
MMC OP INFUSION,65872,"Meghal, Trishala, MD",3/1/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,2/28/2023,Inactive,,
CMC OP INFUSION,57619,"Taff, Jessica, MD",4/13/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Consolidation,4/12/2023,Active,Malignant melanoma of right upper extremity including shoulder (CMS/HCC),
CMC OP INFUSION,94831,"Cohen, Seth D, MD",8/5/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/14/2024,Active,,
CINJ OP INFUSION,25641,"Haigentz, Missak, MD",3/22/2023,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,Second Line,3/22/2023,Active,,
NBR CINJ OP INFUSION,20121,"Matasar, Matthew J, MD",7/25/2023,R-CHOP+Bortezomib (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,7/24/2023,Inactive,,
NBR CINJ OP INFUSION,20121,"Matasar, Matthew J, MD",1/8/2024,CINJ 012316 Outpatient Lymphodepletion / JNJ-90014496 21 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,_2. Second Line,12/18/2023,Active,,
CINJ OP INFUSION,46385,"Stephenson, Ryan D, DO",3/3/2025,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/3/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C67.8 - Malignant neoplasm of overlapping sites of bladder; R22.2 - Localized swelling, mass and lump, trunk"
SOM OUTPT INFUSION,15753,"Patel, Eshan, MD",12/18/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- cervical Cancers,_1. First Line,12/17/2023,Inactive,,
NBI OP INFUSION,29907,"Shah, Maya M, MD",2/14/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,2/13/2024,Inactive,,
NBI OP INFUSION,29907,"Shah, Maya M, MD",5/8/2024,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,Neoadjuvant,5/7/2024,Active,,
CINJ OP INFUSION,92161,"Stephenson, Ryan D, DO",9/8/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,9/7/2023,Inactive,,
SOM OUTPT INFUSION,37355,"Toomey, Kathleen C, MD",12/9/2024,Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,11/21/2024,Active,,
CBMC OP INFUSION 2FL,99997,"Leitner, Stuart P, MD",7/15/2024,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,Neoadjuvant,7/9/2024,Inactive,,
CBMC OP INFUSION 2FL,99997,"Leitner, Stuart P, MD",10/16/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,10/15/2024,Active,,
HAM OP INFUSION,75411,"Patel, Malini M, MD",4/10/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,Third Line,4/9/2023,Inactive,,
CINJ OP INFUSION,84890,"Berim, Lyudmyla, MD",3/20/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/16/2023,Inactive,,
SOM OUTPT INFUSION,2488,"Toomey, Kathleen C, MD",5/9/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,5/9/2024,Inactive,,
CBMC OP INFUSION 2FL,81617,"Brown, Andrew Bennett, MD",10/20/2023,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,10/20/2023,Inactive,,
CBMC OP INFUSION 2FL,29294,"Leitner, Stuart P, MD",10/2/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/1/2023,Active,,
CBMC OP INFUSION 2FL,29294,"Leitner, Stuart P, MD",5/28/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/28/2025,Active,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of lower lobe, right bronchus or lung (CMS/HCC)
Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes (CMS/HCC)
Malignant neoplasm metastatic to both lungs (CMS/HCC)","C78.01 - Secondary malignant neoplasm of right lung; C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; E06.3 - Autoimmune thyroiditis; C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; C79.51 - Secondary malignant neoplasm of bone; C78.02 - Secondary malignant neoplasm of left lung"
CINJ OP INFUSION,21551,"Saraiya, Biren P, MD",8/7/2024,CINJ 082301 TAR-200 Kit (225 mg of Gemcitabine) / Cetrelimab 21 Day Cycles Research- Urothelial Carcinoma of the Bladder,Neoadjuvant,8/6/2024,Inactive,,
CMC OP INFUSION,21551,"Cohen, Seth D, MD",12/10/2024,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_2. Second Line,12/8/2024,Active,,
CMC OP INFUSION,4207,"Talwar, Sumit, MD",4/1/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,3/19/2024,Inactive,,
CMC OP INFUSION,4207,"Talwar, Sumit, MD",7/18/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,6/26/2024,Inactive,,
CMC OP INFUSION,4207,"Talwar, Sumit, MD",8/14/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/13/2024,Active,Myelofibrosis (CMS/HCC),
CINJ OP INFUSION,92922,"Patel, Eshan, MD",5/26/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,5/25/2023,Inactive,,
CINJ OP INFUSION,76366,"Stephenson, Ryan D, DO",11/8/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,11/8/2023,Active,,
CMC OP INFUSION,23324,"Pompa, Tiffany Ann, MD",10/29/2024,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",Adjuvant,10/28/2024,Active,,
CINJ OP INFUSION,70295,"Aikins, James K, MD",4/20/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,4/20/2023,Active,,
NBR 5N ONCOLOGY,22763,"Sridharan, Ashwin, MD",9/21/2023,Venetoclax / Cytarabine (Low Dose) 28 Day Cycles - Acute Myeloid Leukemia,First Line,9/20/2023,Inactive,,
CINJ OP INFUSION,6560,"Stephenson, Ryan D, DO",5/1/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Renal Collecting Duct Carcinoma,_1. First Line,5/1/2025,Inactive,Collecting duct carcinoma of kidney (CMS/HCC),"C64.2 - Malignant neoplasm of left kidney, except renal pelvis; E04.1 - Nontoxic single thyroid nodule; R05.9 - Cough, unspecified; Z51.11 - Encounter for antineoplastic chemotherapy; C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; Z90.5 - Acquired absence of kidney"
CINJ OP INFUSION,6560,"Stephenson, Ryan D, DO",5/1/2025,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Renal Collecting Duct Carcinoma,_1. First Line,5/1/2025,Active,Collecting duct carcinoma of kidney (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis"
CINJ OP INFUSION,75481,"Toppmeyer, Deborah L, MD",2/9/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,2/8/2023,Inactive,,
CINJ OP INFUSION,81193,"Haigentz, Missak, MD",10/2/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,10/2/2023,Inactive,,
CINJ OP INFUSION,81193,"Omene, Coral Oghenerukevwe, MD",12/15/2023,Palbociclib 28 Day Cycles - Breast,Maintenance,12/15/2023,Inactive,,
MMC OP VP INFUSION,2122,"Cohen, Seth D, MD",8/8/2023,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,,7/31/2023,Inactive,,
CMC OP INFUSION,59986,"Pompa, Tiffany Ann, MD",4/1/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/1/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),C54.1 - Endometrial cancer (CMS/HCC)
CBMC OP INFUSION 2FL,3141,"Grossman, I Robert, MD",10/12/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/11/2023,Inactive,,
CINJ OP INFUSION,76860,"Goel, Sanjay, MD",1/11/2023,CINJ 052311: Expanded Use of ICP-192 in patients with advanced solid,Third Line,12/14/2022,Inactive,,
CINJ OP INFUSION,76860,"Berim, Lyudmyla, MD",5/20/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_4. Fourth Line,5/12/2024,Inactive,,
CINJ OP INFUSION,76860,"Goel, Sanjay, MD",6/17/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,6/17/2024,Inactive,,
CINJ OP INFUSION,79933,"Berim, Lyudmyla, MD",5/14/2025,Durvalumab + Gemcitabine / CARBOplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CARBOplatin Sequencing,_4. Fourth Line,5/14/2025,Active,Cholangiocarcinoma (CMS/HCC),C22.1 - Intrahepatic bile duct carcinoma
SOM OUTPT INFUSION,75238,"Patel, Eshan, MD",3/18/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,3/12/2024,Active,,
NBI OP INFUSION,89846,"Jacoby, Sari H, MD",10/2/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,10/1/2023,Active,,
CINJ OP INFUSION,49281,"Patel, Eshan, MD",3/10/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,3/9/2023,Inactive,,
CMC OP INFUSION,47780,"Taff, Jessica, MD",5/12/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/12/2023,Inactive,,
CINJ OP INFUSION,83692,"Boland, Patrick M, MD",4/8/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/8/2025,Inactive,"Malignant neoplasm of pancreas, unspecified (CMS/HCC)","C25.0 - Malignant neoplasm of head of pancreas; M85.80 - Other specified disorders of bone density and structure, unspecified site; R68.83 - Chills (without fever); I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms"
CINJ OP INFUSION,18571,"Boland, Patrick M, MD",12/19/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,12/18/2023,Inactive,,
CINJ OP INFUSION,18571,"Boland, Patrick M, MD",11/5/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,11/4/2024,Active,,
CINJ OP INFUSION,76310,"Boland, Patrick M, MD",3/24/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,3/16/2023,Inactive,,
CINJ OP INFUSION,76310,"Boland, Patrick M, MD",12/12/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,12/11/2023,Inactive,,
HAM OP INFUSION,71356,"Patel, Malini M, MD",8/12/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/31/2024,Active,,
HAM OP INFUSION,68115,"Patel, Malini M, MD",4/28/2025,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,4/28/2025,Active,"Diffuse large B-cell lymphoma (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C83.30 - Diffuse large B-cell lymphoma, unspecified site; N13.30 - Unspecified hydronephrosis"
CINJ OP INFUSION,34569,"Haigentz, Missak, MD",3/26/2025,Nivolumab / Ipilimumab 42 Day Cycles - Malignant Pleural Mesothelioma,_1. First Line,3/26/2025,Inactive,"Mesothelioma (CMS/HCC)
Chronic fatigue","R31.9 - Hematuria, unspecified; C83.19 - Mantle cell lymphoma, extranodal and solid organ sites; D68.32 - Hemorrhagic disorder due to extrinsic circulating anticoagulants; C45.0 - Mesothelioma of pleura; C61 - Malignant neoplasm of prostate; F31.81 - Bipolar II disorder; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); I10 - Essential (primary) hypertension; I48.21 - Permanent atrial fibrillation; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; E27.8 - Other specified disorders of adrenal gland; F42.9 - Obsessive-compulsive disorder, unspecified; H91.92 - Unspecified hearing loss, left ear; I49.3 - Ventricular premature depolarization; K59.00 - Constipation, unspecified; R53.82 - Chronic fatigue, unspecified; Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z85.118 - Personal history of other malignant neoplasm of bronchus and lung; M77.9 - Enthesopathy, unspecified; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z87.442 - Personal history of urinary calculi; Z87.891 - Personal history of nicotine dependence; Z95.0 - Presence of cardiac pacemaker; F41.9 - Anxiety disorder, unspecified; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z98.890 - Other specified postprocedural states"
CINJ OP INFUSION,34569,"Haigentz, Missak, MD",3/26/2025,Nivolumab (360mg)/Ipilimumab 42 Day Cycles- Malignant Pleural Mesothelioma,_1. First Line,3/26/2025,Inactive,"Mesothelioma (CMS/HCC)
Chronic fatigue","R31.9 - Hematuria, unspecified; C83.19 - Mantle cell lymphoma, extranodal and solid organ sites; D68.32 - Hemorrhagic disorder due to extrinsic circulating anticoagulants; C45.0 - Mesothelioma of pleura; C61 - Malignant neoplasm of prostate; F31.81 - Bipolar II disorder; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); I10 - Essential (primary) hypertension; I48.21 - Permanent atrial fibrillation; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; E27.8 - Other specified disorders of adrenal gland; F42.9 - Obsessive-compulsive disorder, unspecified; H91.92 - Unspecified hearing loss, left ear; I49.3 - Ventricular premature depolarization; K59.00 - Constipation, unspecified; R53.82 - Chronic fatigue, unspecified; Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z85.118 - Personal history of other malignant neoplasm of bronchus and lung; M77.9 - Enthesopathy, unspecified; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z87.442 - Personal history of urinary calculi; Z87.891 - Personal history of nicotine dependence; Z95.0 - Presence of cardiac pacemaker; F41.9 - Anxiety disorder, unspecified; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z98.890 - Other specified postprocedural states"
JCMC CP INFUSION,97266,"Cruz, Allan Louie E, MD",9/17/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,9/12/2024,Inactive,,
CINJ PEDS HEMONC ,43948,"Moerdler, Scott, MD",9/3/2024,PEDS AOST0331 MAP Arm (DOXOrubicin / CISplatin / Methotrexate),_1. First Line,9/2/2024,Inactive,,
CINJ PEDS HEMONC ,43948,"Moerdler, Scott, MD",9/4/2024,PEDS AOST0331 MAP Arm (DOXOrubicin / CISplatin / Methotrexate),_1. First Line,9/4/2024,Active,,
CINJ OP INFUSION,3259,"Hochster, Howard S, MD",11/15/2023,CINJ 072304 Cohort 1 ME-344 + Bevacizumab - Colorectal Cancer,_3. Third Line,11/15/2023,Inactive,,
CINJ OP INFUSION,3259,"Hochster, Howard S, MD",1/10/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab and Irinotecan D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,1/10/2024,Inactive,,
CINJ OP INFUSION,3259,"Hochster, Howard S, MD",7/10/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_6. Sixth Line,7/10/2024,Inactive,,
CINJ OP INFUSION,40616,"Stephenson, Ryan D, DO",4/3/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,4/2/2024,Inactive,,
CMC OP INFUSION,41613,"Pompa, Tiffany Ann, MD",5/20/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,5/20/2025,Active,Neuroendocrine carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,7453,"Scoppetuolo, Michael, MD",2/26/2024,"PACLitaxel D1, D15/CISplatin D1, D15 28 Day Cycles- Esophageal and Esophagogastric Junction Cancers",_1. First Line,2/25/2024,Inactive,,
CBMC OP INFUSION 2FL,7453,"Scoppetuolo, Michael, MD",3/20/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/19/2024,Inactive,,
CMC OP INFUSION,61742,"Easaw, Sarah, MD",11/13/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/24/2023,Inactive,,
CMC OP INFUSION,61742,"Talwar, Sumit, MD",2/12/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/11/2024,Active,,
CMC OP INFUSION,61742,"Talwar, Sumit, MD",2/12/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/11/2024,Inactive,,
CMC OP INFUSION,61742,"Talwar, Sumit, MD",2/3/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,2/3/2025,Active,Rectal cancer (CMS/HCC),
HAM OP INFUSION,22406,"Patel, Malini M, MD",11/20/2023,Capecitabine 21 Day Cycles - Breast,_4. Fourth Line,11/20/2023,Inactive,,
HAM OP INFUSION,51169,"Patel, Malini M, MD",1/9/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_5. Fifth Line,1/9/2025,Active,,
NBI OP INFUSION,13531,"Schleicher, Lori, MD",2/5/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,2/4/2025,Active,Malignant neoplasm of right female breast (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+); Z17.1 - Estrogen receptor negative status (ER-)
NBR 4N ONCOLOGY,28955,"Rhodes, Joanna Meehan, MD",11/6/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/6/2024,Inactive,,
NBR CINJ OP INFUSION,28955,"Rhodes, Joanna Meehan, MD",11/29/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/27/2024,Active,,
MMC OP VP INFUSION,82293,"Eltoukhy, Hussam, MD",5/2/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,5/1/2024,Inactive,,
NBR CINJ OP INFUSION,68650,"Rhodes, Joanna Meehan, MD",9/7/2023,GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,Second Line,9/6/2023,Inactive,,
NBR 4N ONCOLOGY,68650,"Schaar, Dale, MD PhD",11/29/2023,BMT Autologous BEAM,_3. Third Line,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,68650,"Rhodes, Joanna Meehan, MD",2/7/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,Maintenance,2/6/2024,Inactive,,
CINJ OP INFUSION,23611,"Hochster, Howard S, MD",10/23/2024,CINJ 072310 Triapine / Lutetium Lu 177 Dotatate 56 Day Cycles Research- Neuroendocrine Tumors,_2. Second Line,10/23/2024,Inactive,,
CMC OP INFUSION,41977,"Tang, Horace, MD",6/27/2023,"CapeOX (Capecitabine 625 mg/m2 BID/OXALIplatin 85mg/m2 Days 1, 15, 29) GE junction ESO28",Neoadjuvant,6/27/2023,Inactive,,
CMC OP INFUSION,41977,"Talwar, Sumit, MD",12/1/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Adjuvant,11/30/2023,Inactive,,
CMC OP INFUSION,41977,"Talwar, Sumit, MD",4/17/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/14/2024,Inactive,,
CMC OP INFUSION,41977,"Talwar, Sumit, MD",7/31/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,7/30/2024,Active,,
CMC OP INFUSION,41977,"Talwar, Sumit, MD",1/29/2025,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/21/2025,Active,,
CMC OP INFUSION,41977,"Talwar, Sumit, MD",4/2/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,4/2/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),
TRMC TCCC OP INFUSION,61163,"Capo, Gerardo, MD",8/16/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,8/15/2024,Active,,
NBR 4N BMTU/IMCU,20313,"Schaar, Dale, MD PhD",4/20/2023,BMT Autologous BEAM,,4/13/2023,Inactive,,
MSC OP INFUSION,34193,"Cohen, Seth D, MD",7/9/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_2. Second Line,7/8/2024,Active,,
CMC OP INFUSION,501,"Talwar, Sumit, MD",12/26/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,12/21/2023,Inactive,,
CINJ OP INFUSION,21733,"Toppmeyer, Deborah L, MD",5/11/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,5/10/2023,Inactive,,
CINJ OP INFUSION,21733,"Toppmeyer, Deborah L, MD",1/17/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,1/17/2024,Active,"Malignant neoplasm of thyroid gland (CMS/HCC)
Malignant neoplasm of prostate (CMS/HCC)
Malignant neoplasm of overlapping sites of bladder (CMS/HCC)
Encounter for screening for other viral diseases
Iron deficiency anemia secondary to blood loss (chronic)
Chronic kidney disease, stage 4 (severe) (CMS/HCC)",
NBR 4N BMTU/IMCU,74464,"Girda, Eugenia, MD",8/21/2024,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_4. Fourth Line,8/19/2024,Inactive,,
SOM OUTPT INFUSION,69903,"Yin, Faye, MD",9/11/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,9/5/2023,Inactive,,
SOM OUTPT INFUSION,69903,"Yin, Faye, MD",4/22/2024,Trastuzumab 21 Day Cycles- Uterine Cancers,_1. First Line,4/19/2024,Inactive,,
SOM OUTPT INFUSION,69903,"Yin, Faye, MD",5/6/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_2. Second Line,5/5/2024,Inactive,,
SOM OUTPT INFUSION,69903,"Yin, Faye, MD",9/30/2024,Trastuzumab 21 Day Cycles (Continuation) - uterine cancer,_2. Second Line,9/27/2024,Inactive,,
SOM OUTPT INFUSION,69903,"Patel, Eshan, MD",10/7/2024,Pembrolizumab/Trastuzumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,9/29/2024,Active,,
CINJ OP INFUSION,65,"Boland, Patrick M, MD",12/13/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/12/2024,Active,,
MMC OP VP INFUSION,6178,"Talwar, Sumit, MD",3/28/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,3/27/2023,Inactive,,
MMC OP VP INFUSION,6178,"Talwar, Sumit, MD",1/6/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,1/5/2025,Active,,
MMC BBR2 ONCOLOGY,6178,"Talwar, Sumit, MD",1/7/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_2. Second Line,1/5/2025,Inactive,"Endometrial carcinoma (CMS/HCC)
Disorder of thyroid, unspecified",
CBMC OP INFUSION 1FL,20682,"Wagmiller, Jennifer Ann, MD",9/21/2023,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/20/2023,Inactive,,
CBMC OP INFUSION 2FL,20682,"Wagmiller, Jennifer Ann, MD",12/18/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/17/2024,Active,,
CINJ OP INFUSION,80209,"Leiser, Aliza, MD",3/28/2025,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/28/2025,Active,Malignant neoplasm of right fallopian tube (CMS/HCC),
CINJ OP INFUSION,80209,"Leiser, Aliza, MD",3/7/2025,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles/Bevacizumab 10mg/kg Q 2 weeks - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/7/2025,Inactive,Malignant neoplasm of right fallopian tube (CMS/HCC),
CINJ OP INFUSION,26296,"Haigentz, Missak, MD",10/1/2024,CINJ 032201 ARM 1 Paclitaxel / CARBOplatin + Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,9/30/2024,Active,,
CINJ OP INFUSION,26296,"Haigentz, Missak, MD",4/1/2025,CINJ 032201 Pembrolizumab Maintenance 21 Day Cycles Research- Non-Small Cell Lung Cancer,Maintenance,4/1/2025,Active,"Primary cancer of right middle lobe of lung (CMS/HCC)
Malignant neoplasm metastatic to left lung (CMS/HCC)
Chronic fatigue",
NBR BMSCH 2 PED HEMONC,63239,"Parikh, Nehal S, MD",4/8/2025,as per ARST2031 Regimen A (VAC + VINO-C Maintenance) (NOT on STUDY),_1. First Line,4/8/2025,Active,Rhabdomyosarcoma (CMS/HCC),"C79.52 - Secondary malignant neoplasm of bone marrow; C78.2 - Secondary malignant neoplasm of pleura; C79.89 - Secondary malignant neoplasm of other specified sites; C61 - Malignant neoplasm of prostate; I86.1 - Scrotal varices; R59.9 - Enlarged lymph nodes, unspecified; Z88.1 - Allergy status to other antibiotic agents; Z91.048 - Other nonmedicinal substance allergy status; Z80.9 - Family history of malignant neoplasm, unspecified; Z11.52 - Encounter for screening for COVID-19"
CINJ OP INFUSION,56523,"Berim, Lyudmyla, MD",7/25/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/24/2024,Active,,
CBMC OP INFUSION 2FL,67514,"Wagmiller, Jennifer Ann, MD",8/8/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,7/21/2024,Active,,
CINJ OP INFUSION,26238,"Omene, Coral Oghenerukevwe, MD",5/6/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_4. Fourth Line,5/5/2024,Inactive,,
CINJ OP INFUSION,26238,"Omene, Coral Oghenerukevwe, MD",9/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,9/11/2024,Active,,
CINJ OP INFUSION,93451,"Packiam, Vignesh, MD",2/7/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) - Bladder Cancer,_1. First Line,2/5/2024,Inactive,,
CINJ OP INFUSION,93451,"Packiam, Vignesh, MD",5/8/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Adjuvant,5/7/2024,Inactive,,
CINJ OP INFUSION,93451,"Packiam, Vignesh, MD",7/16/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,7/9/2024,Inactive,,
CINJ OP INFUSION,93451,"Packiam, Vignesh, MD",11/19/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,11/19/2024,Active,,
CBMC OP INFUSION 2FL,92742,"Raptis, George, MD",4/23/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/22/2024,Inactive,,
CBMC OP INFUSION 2FL,92742,"Raptis, George, MD",9/24/2024,Pertuzumab / Trastuzumab / Eribulin 21 Day Cycles - Breast,Neoadjuvant,9/23/2024,Inactive,,
CBMC OP INFUSION 2FL,92742,"Raptis, George, MD",10/16/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,9/25/2024,Inactive,,
CBMC OP INFUSION 2FL,49674,"Dave, Manish, MD",5/9/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/8/2023,Inactive,,
MMC OP VP INFUSION,61158,"Cohen, Seth D, MD",10/12/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,10/11/2023,Inactive,,
MMC OP VP INFUSION,61158,"Cohen, Seth D, MD",6/20/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,6/20/2024,Active,,
SOM OUTPT INFUSION,15140,"Toomey, Kathleen C, MD",4/2/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/2/2025,Active,Diffuse large B cell lymphoma (CMS/HCC),"C83.31 - Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck"
JCMC CP INFUSION,63045,"Cruz, Allan Louie E, MD",1/25/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/16/2024,Inactive,,
JCMC CP INFUSION,63045,"Sekhri, Arunabh, MD",7/22/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,7/21/2024,Inactive,,
CINJ OP INFUSION,84108,"Hochster, Howard S, MD",7/6/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,First Line,6/28/2023,Inactive,,
JCMC CP INFUSION,25715,"Sekhri, Arunabh, MD",3/18/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/13/2024,Inactive,,
CMC OP INFUSION,78527,"Tang, Horace, MD",4/24/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,First Line,4/23/2023,Inactive,,
MSC OP INFUSION,78527,"Cohen, Seth D, MD",8/29/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,Second Line,8/29/2023,Active,,
CINJ OP INFUSION,28660,"Jang, Thomas L, MD",1/5/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,1/5/2023,Inactive,,
CINJ OP INFUSION,13644,"Mayer, Tina M, MD",7/27/2023,CINJ 082107 (CURLU177PSM001) Abiraterone / Prednisone 28 Day Cycles Research- Prostate Cancer,_2. Second Line,7/27/2023,Active,,
NBR 5N ONCOLOGY,45116,"Rhodes, Joanna Meehan, MD",4/12/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/11/2024,Inactive,,
NBR 5N ONCOLOGY,45116,"Palmisiano, Neil David, MD",4/13/2024,Fractionated cytarabine ,Induction,4/13/2024,Inactive,,
NBR 5N ONCOLOGY,45116,"Rhodes, Joanna Meehan, MD",4/16/2024,Fractionated Cyclophosphamide/etoposide/doxorubicin,_1. First Line,4/16/2024,Inactive,,
NBR 5N ONCOLOGY,45116,"Rhodes, Joanna Meehan, MD",5/8/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,5/8/2024,Inactive,,
NBR CINJ OP INFUSION,45116,"Rhodes, Joanna Meehan, MD",9/26/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,9/25/2024,Active,Carcinomatosis (CMS/HCC),
CINJ OP INFUSION,70578,"Stephenson, Ryan D, DO",8/30/2023,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,First Line,8/29/2023,Inactive,,
CMC OP INFUSION,99943,"Cohen, Seth D, MD",11/7/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,11/5/2024,Active,,
CINJ OP INFUSION,81972,"Boland, Patrick M, MD",2/10/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/9/2023,Inactive,,
CINJ OP INFUSION,81972,"Boland, Patrick M, MD",4/30/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/29/2024,Inactive,,
JCMC CP INFUSION,55808,"Sekhri, Arunabh, MD",9/11/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,9/3/2023,Inactive,,
JCMC CP INFUSION,55808,"Sekhri, Arunabh, MD",12/11/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,12/3/2023,Active,,
JCMC CP INFUSION,59793,"Sekhri, Arunabh, MD",8/12/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,8/11/2024,Inactive,,
JCMC CP INFUSION,59793,"Sekhri, Arunabh, MD",8/23/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,_1. First Line,8/11/2024,Inactive,,
JCMC CP INFUSION,59793,"Sekhri, Arunabh, MD",10/25/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,10/24/2024,Active,,
NBR 4N ONCOLOGY,48311,"Hochster, Howard S, MD",5/20/2024,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_3. Third Line,5/20/2024,Inactive,,
CINJ OP INFUSION,48311,"Hochster, Howard S, MD",6/26/2024,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,Neoadjuvant,5/28/2024,Inactive,,
CINJ OP INFUSION,27677,"Haigentz, Missak, MD",9/27/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,First Line,9/26/2023,Active,,
SOM OUTPT INFUSION,56871,"Toomey, Kathleen C, MD",11/3/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/1/2023,Inactive,,
JCMC CP INFUSION,98428,"Sekhri, Arunabh, MD",9/22/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,8/15/2023,Inactive,,
JCMC CP INFUSION,98428,"Sekhri, Arunabh, MD",10/25/2023,Enfortumab Vedotin + pembrolizumab - Bladder,_2. Second Line,10/24/2023,Active,,
CMC OP INFUSION,90836,"Cohen, Seth D, MD",5/14/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/13/2024,Inactive,,
HAM OP INFUSION,75752,"Gendy, Mina, DO",11/6/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,11/5/2024,Active,,
CINJ OP INFUSION,84572,"Mayer, Tina M, MD",12/2/2023,DOCEtaxel 21 Day Cycles - Prostate,_4. Fourth Line,11/26/2023,Inactive,,
CINJ OP INFUSION,60594,"Weiss, Sarah, MD",3/11/2025,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,3/11/2025,Active,Merkel cell carcinoma of right lower extremity (CMS/HCC),"C4A.71 - Merkel cell carcinoma of right lower limb, including hip; I50.9 - Heart failure, unspecified; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified; B20 - Human immunodeficiency virus (HIV) disease"
CINJ OP INFUSION,4625,"Stephenson, Ryan D, DO",12/11/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,12/11/2023,Active,,
MMC OP VP INFUSION,45217,"Cohen, Seth D, MD",3/13/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,3/12/2023,Inactive,,
MMC OP VP INFUSION,45217,"Cohen, Seth D, MD",6/3/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,5/24/2024,Active,,
NBR 4N BMTU/IMCU,90959,"Assal, Amer, MD",1/30/2024,BMT Autologous Busulfan / Melphalan (Busulfan PK levels measured) ,_3. Third Line,1/29/2024,Inactive,,
MMC OP INFUSION,82207,"Meghal, Trishala, MD",7/26/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,7/26/2024,Active,,
MMC OP INFUSION,11106,"Meghal, Trishala, MD",1/24/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,1/24/2025,Active,,
MMC OP VP INFUSION,13476,"Cohen, Seth D, MD",9/14/2023,DOCEtaxel 21 Day Cycles - Prostate,First Line,9/5/2023,Inactive,,
CINJ OP INFUSION,24308,"Omene, Coral Oghenerukevwe, MD",5/6/2025,Capecitabine 21 Day Cycles - Breast,_1. First Line,5/6/2025,Active,"Malignant neoplasm of right female breast (CMS/HCC)
Stage IV breast cancer in female (CMS/HCC)","C50.911 - Malignant neoplasm of unspecified site of right female breast; C78.00 - Secondary malignant neoplasm of unspecified lung; G62.9 - Polyneuropathy, unspecified; Z90.11 - Acquired absence of right breast and nipple; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.1 - Estrogen receptor negative status (ER-)"
CINJ OP INFUSION,24308,"Omene, Coral Oghenerukevwe, MD",4/17/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles,_1. First Line,4/17/2025,Inactive,"Malignant neoplasm of right female breast (CMS/HCC)
Stage IV breast cancer in female (CMS/HCC)","C50.011 - Malignant neoplasm of nipple and areola, right female breast; C78.00 - Secondary malignant neoplasm of unspecified lung; Z17.1 - Estrogen receptor negative status (ER-); Z17.22 - Progesterone receptor negative status; Z17.32 - Human epidermal growth factor receptor 2 negative status; R91.8 - Other nonspecific abnormal finding of lung field; J98.4 - Other disorders of lung; K82.0 - Obstruction of gallbladder; D73.89 - Other diseases of spleen; I70.0 - Atherosclerosis of aorta; I70.8 - Atherosclerosis of other arteries; K57.90 - Diverticulosis of intestine, part unspecified, without perforation or abscess without bleeding; G62.9 - Polyneuropathy, unspecified; Z92.3 - Personal history of irradiation; Z92.21 - Personal history of antineoplastic chemotherapy; Z98.890 - Other specified postprocedural states"
CINJ OP INFUSION,24308,"Omene, Coral Oghenerukevwe, MD",4/17/2025,Pembrolizumab and NAB-Paclitaxel 21 Day Cycles - Breast,_1. First Line,4/17/2025,Inactive,"Malignant neoplasm of right female breast (CMS/HCC)
Stage IV breast cancer in female (CMS/HCC)",
NBR CINJ OP INFUSION,56073,"Evens, Andrew M, DO",5/24/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,5/23/2023,Inactive,,
NBR CINJ OP INFUSION,56073,"Evens, Andrew M, DO",12/20/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,12/19/2023,Active,Rectal adenocarcinoma (CMS/HCC),
NBR BMSCH 2 PED HEMONC,35459,"Goyal-Khemka, Meenakshi, MD",3/17/2023,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),,3/17/2023,Inactive,,
CBMC OP INFUSION 2FL,94235,"Litvak, Anna M, MD",9/12/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,9/11/2023,Inactive,,
CBMC OP INFUSION 2FL,94235,"Litvak, Anna M, MD",4/9/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,4/8/2024,Inactive,,
MMC OP VP INFUSION,59959,"Cohen, Seth D, MD",5/2/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,First Line,5/1/2023,Inactive,,
MMC OP VP INFUSION,59959,"Cohen, Seth D, MD",5/10/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,5/9/2023,Inactive,,
MMC OP VP INFUSION,59959,"Cohen, Seth D, MD",5/31/2023,DHAP (Dexamethasone / CISplatin / Cytarabine) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,5/31/2023,Inactive,,
MMC OP VP INFUSION,59959,"Cohen, Seth D, MD",6/22/2023,Maxi-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) Alternating With High-Dose Cytarabine / RiTUXimab 21 Day Cycles - Mantle Cell Lymphoma (Nordic Trial Regimen),First Line,6/20/2023,Inactive,,
MMC BBR2 ONCOLOGY,59959,"Cohen, Seth D, MD",7/12/2023,DHAP (Dexamethasone / CISplatin / Cytarabine) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/12/2023,Inactive,,
MMC OP VP INFUSION,59959,"Cohen, Seth D, MD",8/2/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,8/1/2023,Inactive,,
MMC BBR2 ONCOLOGY,59959,"Cohen, Seth D, MD",8/23/2023,DHAP (Dexamethasone / CISplatin / Cytarabine) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,8/23/2023,Inactive,,
MMC OP VP INFUSION,59959,"Cohen, Seth D, MD",2/12/2024,RiTUXimab / Ibrutinib 56 Day Cycles - Mantle Cell Lymphoma (Maintenance),_1. First Line,2/11/2024,Active,Malignant neoplasm of endometrium (CMS/HCC),
CMC 4B ONCOLOGY,78689,"Eltoukhy, Hussam, MD",6/17/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,6/17/2024,Inactive,,
MMC BBR2 ONCOLOGY,89270,"Eltoukhy, Hussam, MD",2/29/2024,RiTUXimab,Non-Oncology Research,2/28/2024,Inactive,,
CINJ OP INFUSION,63735,"Gulhati, Prateek, MD PhD",1/5/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,1/4/2023,Inactive,,
NBR 5N ONCOLOGY,63735,"Berim, Lyudmyla, MD",3/20/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,3/19/2023,Inactive,,
CINJ OP INFUSION,63735,"Gulhati, Prateek, MD PhD",3/20/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,3/20/2023,Inactive,,
CMC OP INFUSION,9486,"Pompa, Tiffany Ann, MD",12/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/25/2024,Active,Alveolar soft part sarcoma (CMS/HCC),
CMC OP INFUSION,9486,"Pompa, Tiffany Ann, MD",1/17/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/25/2024,Active,"Malignant neoplasm of hypopharynx, unspecified (CMS/HCC)",
CINJ OP INFUSION,12259,"Shah, Mansi R, MD",12/6/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,11/28/2024,Active,,
SOM OUTPT INFUSION,11831,"Toomey, Kathleen C, MD",5/16/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/16/2025,Active,Mesothelioma (pleural) (CMS/HCC),
CBMC OP INFUSION 2FL,85557,"Grossman, I Robert, MD",1/31/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,1/19/2025,Active,,
SOM OUTPT INFUSION,19492,"Toomey, Kathleen C, MD",10/24/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/22/2024,Active,Cholangiocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,61718,"Toomey, Kathleen C, MD",4/25/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,4/25/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",C50.111 - Malignant neoplasm of central portion of right female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,22449,"Hochster, Howard S, MD",4/17/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/13/2024,Active,,
CINJ OP INFUSION,22449,"Kennedy, Timothy, MD",8/14/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,8/14/2024,Active,,
CINJ OP INFUSION,93782,"Dasgeb, Bahar, MD",1/13/2025,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,1/12/2025,Active,Secondary malignant neoplasm of bone (CMS/HCC),
NBI OP INFUSION,51013,"Cheng, Yan Ho, MD",11/25/2024,Darolutamide 28 Day Cycles - Prostate,_3. Third Line,11/25/2024,Inactive,,
NBI OP INFUSION,51013,"Cheng, Yan Ho, MD",12/19/2024,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,12/19/2024,Active,,
CINJ OP INFUSION,13657,"Weiss, Sarah, MD",5/31/2024,Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,45082,"Wagmiller, Jennifer Ann, MD",11/27/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,11/27/2023,Inactive,,
CINJ OP INFUSION,45515,"Stephenson, Ryan D, DO",2/1/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,1/6/2023,Inactive,,
CINJ OP INFUSION,45515,"Stephenson, Ryan D, DO",12/26/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Maintenance,12/26/2024,Active,,
CBMC OP INFUSION 2FL,63237,"Brown, Andrew Bennett, MD",6/27/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,6/25/2024,Active,,
JCMC CP INFUSION,54579,"Cruz, Allan Louie E, MD",3/14/2025,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_2. Second Line,3/14/2025,Active,"Multiple myeloma in remission (CMS/HCC)
Multiple myeloma in relapse (CMS/HCC)",C90.01 - Multiple myeloma in remission; Z00.00 - Encounter for general adult medical examination without abnormal findings; C90.02 - Multiple myeloma in relapse
CINJ OP INFUSION,60333,"Weiss, Sarah, MD",9/11/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,9/10/2024,Active,,
CBMC OP INFUSION 2FL,34612,"Raptis, George, MD",5/27/2025,EriBULin 21 Day Cycles - Breast,_3. Third Line,5/27/2025,Inactive,"Stage 4 carcinoma of breast, ER+, unspecified laterality (CMS/HCC)",
CMC OP INFUSION,21580,"Pompa, Tiffany Ann, MD",8/30/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/28/2024,Inactive,,
CMC OP INFUSION,21580,"Pompa, Tiffany Ann, MD",9/11/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,9/10/2024,Inactive,,
CMC OP INFUSION,21580,"Pompa, Tiffany Ann, MD",10/29/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,9/25/2024,Active,,
CBMC OP INFUSION 2FL,34586,"Raptis, George, MD",9/4/2024,EriBULin 21 Day Cycles - Breast,_3. Third Line,9/3/2024,Active,,
CINJ OP INFUSION,56591,"Ghodoussipour, Saum Bobak, MD",8/29/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,8/28/2023,Inactive,,
CINJ OP INFUSION,56591,"Ghodoussipour, Saum Bobak, MD",2/1/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/1/2024,Inactive,,
CINJ OP INFUSION,56591,"Ghodoussipour, Saum Bobak, MD",5/7/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,5/7/2024,Inactive,,
CINJ OP INFUSION,56591,"Ghodoussipour, Saum Bobak, MD",10/9/2024,BCG Induction (TICE) 42 Day Cycle,Induction,10/1/2024,Active,,
CINJ OP INFUSION,56591,"Ghodoussipour, Saum Bobak, MD",2/4/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,2/3/2025,Active,Urothelial carcinoma (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; N32.3 - Diverticulum of bladder; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; M19.90 - Unspecified osteoarthritis, unspecified site; Z92.21 - Personal history of antineoplastic chemotherapy; Z86.718 - Personal history of other venous thrombosis and embolism; Z85.828 - Personal history of other malignant neoplasm of skin; Z85.46 - Personal history of malignant neoplasm of prostate; Z87.891 - Personal history of nicotine dependence; Z79.01 - Long term (current) use of anticoagulants; Z79.4 - Long term (current) use of insulin; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,22827,"Haigentz, Missak, MD",5/24/2023,Lenvatinib 28 Day Cycles- Thyroid Cancer,Third Line,5/24/2023,Active,,
CINJ OP INFUSION,62385,"Boland, Patrick M, MD",4/4/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_4. Fourth Line,4/2/2024,Inactive,,
CINJ OP INFUSION,62385,"Boland, Patrick M, MD",7/5/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_4. Fourth Line,6/26/2024,Inactive,,
CINJ OP INFUSION,62385,"Boland, Patrick M, MD",8/30/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_5. Fifth Line,8/30/2024,Inactive,,
CINJ OP INFUSION,52129,"Dasgeb, Bahar, MD",5/27/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,5/27/2025,Active,"Basal cell carcinoma (BCC) of multiple sites
Basal cell carcinoma of skin of other parts of face
Squamous cell carcinoma of skin of other parts of face",
MMC OP INFUSION,86129,"Meghal, Trishala, MD",11/8/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,10/30/2024,Active,,
CINJ OP INFUSION,67733,"Hochster, Howard S, MD",3/27/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Induction,2/27/2023,Inactive,,
CINJ OP INFUSION,67733,"Hochster, Howard S, MD",5/25/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,First Line,5/10/2023,Inactive,,
CINJ OP INFUSION,96095,"Weiss, Sarah, MD",12/17/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/12/2024,Active,,
CINJ OP INFUSION,3279,"Boland, Patrick M, MD",10/22/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,10/14/2024,Inactive,,
MMC BBR2 ONCOLOGY,21027,"Talwar, Sumit, MD",5/4/2023,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_5. Fifth Line,5/2/2023,Active,"Multiple myeloma, remission status unspecified (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,99696,"Girda, Eugenia, MD",2/13/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,2/12/2024,Inactive,,
CINJ OP INFUSION,99696,"Girda, Eugenia, MD",8/29/2024,Abemaciclib 28 Day Cycles - Uterine,_3. Third Line,8/29/2024,Active,,
CINJ OP INFUSION,99696,"Girda, Eugenia, MD",5/20/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_4. Fourth Line,5/15/2025,Inactive,Recurrent carcinoma of endometrium (CMS/HCC),
CINJ OP INFUSION,99696,"Girda, Eugenia, MD",5/20/2025,Albumin-Bound PACLitaxel 21 Day Cycles- Uterine,_4. Fourth Line,5/20/2025,Active,Recurrent carcinoma of endometrium (CMS/HCC),
CINJ OP INFUSION,87224,"Boland, Patrick M, MD",9/29/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,9/14/2023,Inactive,,
HAM OP INFUSION,87224,"Yogarajah, Meera, MD",4/19/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/11/2024,Active,,
NBR 4N BMTU/IMCU,77685,"Schaar, Dale, MD PhD",4/17/2025,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,_2. Second Line,4/17/2025,Active,Chronic myelomonocytic leukemia not having achieved remission (CMS/HCC),"D46.9 - Myelodysplastic syndrome, unspecified; D61.810 - Antineoplastic chemotherapy induced pancytopenia; I31.39 - Other pericardial effusion (noninflammatory); E87.0 - Hyperosmolality and hypernatremia; R18.8 - Other ascites; E87.20 - Acidosis, unspecified; H35.60 - Retinal hemorrhage, unspecified eye; D84.9 - Immunodeficiency, unspecified; Z11.52 - Encounter for screening for COVID-19; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.31 - Chronic kidney disease, stage 3a; E04.1 - Nontoxic single thyroid nodule; I50.32 - Chronic diastolic (congestive) heart failure; E78.00 - Pure hypercholesterolemia, unspecified; R79.1 - Abnormal coagulation profile; K82.8 - Other specified diseases of gallbladder; E83.42 - Hypomagnesemia; G89.29 - Other chronic pain; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K59.00 - Constipation, unspecified; K64.4 - Residual hemorrhoidal skin tags; E87.6 - Hypokalemia; E83.39 - Other disorders of phosphorus metabolism; R19.7 - Diarrhea, unspecified; R11.0 - Nausea; R25.1 - Tremor, unspecified; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specifi..."
HAM OP INFUSION,64717,"Patel, Malini M, MD",3/21/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,3/20/2023,Inactive,,
HAM OP INFUSION,64717,"Taha, Hesham, MD",1/30/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,1/15/2024,Active,,
SOM OUTPT INFUSION,10622,"Patel, Eshan, MD",1/4/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,,1/3/2023,Inactive,,
CINJ OP INFUSION,68708,"Toppmeyer, Deborah L, MD",6/19/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),Third Line,6/18/2023,Inactive,,
CINJ OP INFUSION,3258,"Stephenson, Ryan D, DO",8/21/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,First Line,8/13/2023,Inactive,,
CINJ OP INFUSION,3258,"Stephenson, Ryan D, DO",2/26/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,Adjuvant,2/25/2024,Inactive,,
CINJ OP INFUSION,898,"Packiam, Vignesh, MD",6/24/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,6/23/2024,Active,,
CINJ OP INFUSION,898,"Packiam, Vignesh, MD",4/16/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/8/2025,Inactive,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
CBMC OP INFUSION 2FL,19192,"Litvak, Anna M, MD",11/14/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/14/2023,Inactive,,
CINJ PEDS HEMONC ,5321,"Moerdler, Scott, MD",8/19/2024,PEDS ANBL1221 Regimen B,_6. Sixth Line,8/18/2024,Inactive,,
CINJ PEDS HEMONC ,5321,"Moerdler, Scott, MD",8/19/2024,PEDS ANBL1221 Regimen B,_6. Sixth Line,8/18/2024,Active,,
CBMC OP INFUSION 2FL,29098,"Grossman, I Robert, MD",4/1/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/1/2025,Active,"Non-Hodgkin's lymphoma, unspecified body region, unspecified non-Hodgkin lymphoma type (CMS/HCC)
Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC)",
CBMC 2W ONCOLOGY,29098,"Grossman, I Robert, MD",3/11/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,3/11/2025,Inactive,"Non-Hodgkin's lymphoma, unspecified body region, unspecified non-Hodgkin lymphoma type (CMS/HCC)
Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC)","C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E87.0 - Hyperosmolality and hypernatremia; E83.39 - Other disorders of phosphorus metabolism; D64.81 - Anemia due to antineoplastic chemotherapy; D69.59 - Other secondary thrombocytopenia; C50.511 - Malignant neoplasm of lower-outer quadrant of right female breast; C81.04 - Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of axilla and upper limb; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; F10.90 - Alcohol use, unspecified, uncomplicated; R59.9 - Enlarged lymph nodes, unspecified; R91.1 - Solitary pulmonary nodule; R10.10 - Upper abdominal pain, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K59.00 - Constipation, unspecified; E87.6 - Hypokalemia; D72.829 - Elevated white blood cell count, unspecified; T45.8X5A - Adverse effect of other primarily systemic and hematological agents, initial encounter; Z92.3 - Personal history of irradiation; Z90.12 - Acquired absence of left breast and nipple; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z88.6 - Allergy status to analgesic agent; Z85.828 - Personal history of other malignant neoplasm of skin; Z80.3 - Family history of malignant neoplasm of breast"
CMC OP INFUSION,7814,"Pompa, Tiffany Ann, MD",11/11/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/10/2024,Active,,
CMC OP INFUSION,7814,"Pompa, Tiffany Ann, MD",5/12/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/12/2025,Active,Pancreatic cancer (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C25.0 - Malignant neoplasm of head of pancreas"
CINJ OP INFUSION,64036,"Weiss, Sarah, MD",10/9/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,10/6/2024,Active,,
CINJ OP INFUSION,88181,"Stephenson, Ryan D, DO",1/29/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,1/28/2024,Inactive,,
CINJ OP INFUSION,88181,"Stephenson, Ryan D, DO",5/22/2024,Nivolumab 28 Day Cycles - Bladder,Adjuvant,5/22/2024,Active,,
CINJ OP INFUSION,63678,"Aikins, James K, MD",1/11/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/11/2024,Inactive,,
CINJ OP INFUSION,63678,"Aikins, James K, MD",7/11/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,7/11/2024,Active,,
CINJ OP INFUSION,63678,"Aikins, James K, MD",7/18/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,7/17/2024,Active,,
CBMC OP INFUSION 2FL,62684,"Leitner, Stuart P, MD",1/11/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,1/10/2024,Inactive,,
CBMC 2W ONCOLOGY,62684,"Leitner, Stuart P, MD",5/31/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/30/2024,Inactive,,
MMC OP INFUSION,92364,"Lee, Patrick C, MD",8/13/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,8/13/2024,Inactive,,
MMC OP VP INFUSION,92364,"Cohen, Seth D, MD",1/15/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/14/2025,Active,,
NBR CINJ OP INFUSION,34725,"Schaar, Dale, MD PhD",12/1/2024,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,_2. Second Line,12/1/2024,Active,,
NBR CINJ OP INFUSION,88603,"Chowaniec, Wayne B, NP",3/17/2025,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,Maintenance,3/17/2025,Active,"MDS (myelodysplastic syndrome) (CMS/HCC)
H/O allogeneic bone marrow transplant (CMS/HCC)",Z94.81 - H/O allogeneic bone marrow transplant (CMS/HCC); D46.9 - MDS (myelodysplastic syndrome) (CMS/HCC)
SOM OUTPT INFUSION,47520,"Patel, Eshan, MD",1/30/2025,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/29/2025,Active,,
SOM OUTPT INFUSION,67700,"Patel, Eshan, MD",2/11/2025,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/29/2025,Inactive,Jejunal adenocarcinoma (CMS/HCC),C17.1 - Malignant neoplasm of jejunum
CBMC OP INFUSION 2FL,1913,"Brown, Andrew Bennett, MD",1/4/2024,Bevacizumab 28 Day Cycles - CNS,Maintenance,1/4/2024,Active,,
NBI OP INFUSION,45323,"Snyder, Rose, MD",4/23/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,4/23/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),"Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm; Z85.79 - Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues"
CINJ OP INFUSION,59650,"Berim, Lyudmyla, MD",2/26/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/21/2024,Active,,
CBMC OP INFUSION 1FL,40214,"Wagmiller, Jennifer Ann, MD",11/9/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,11/8/2023,Active,,
NBI OP INFUSION,99975,"Anderson, Patrick S, MD",12/27/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,12/26/2024,Active,,
NBI OP INFUSION,64692,"Jacoby, Sari H, MD",8/3/2023,Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles - Multiple Myeloma,_1. First Line,8/2/2023,Inactive,,
NBI OP INFUSION,64692,"Jacoby, Sari H, MD",9/9/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,9/6/2024,Active,,
NBI OP INFUSION,46084,"Anderson, Patrick S, MD",12/21/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_5. Fifth Line,12/20/2023,Inactive,,
NBI OP INFUSION,46084,"Anderson, Patrick S, MD",5/30/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_4. Fourth Line,5/29/2024,Inactive,,
CBMC OP INFUSION 2FL,40019,"Wagmiller, Jennifer Ann, MD",2/6/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,1/12/2025,Active,"Endometrial cancer, FIGO stage IIIC2 (CMS/HCC)","C54.1 - Malignant neoplasm of endometrium; D53.9 - Nutritional anemia, unspecified; E55.9 - Vitamin D deficiency, unspecified; R97.0 - Elevated carcinoembryonic antigen (CEA)"
CBMC OP INFUSION 2FL,7306,"Wagmiller, Jennifer Ann, MD",9/26/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,9/26/2024,Inactive,,
CINJ OP INFUSION,85253,"Leiser, Aliza, MD",10/26/2023,Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,10/25/2023,Inactive,,
CINJ OP INFUSION,19453,"Gulhati, Prateek, MD PhD",1/26/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,,1/25/2023,Inactive,,
CINJ OP INFUSION,19453,"Gulhati, Prateek, MD PhD",8/3/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,,8/2/2023,Inactive,,
CBMC OP INFUSION 2FL,93131,"Wagmiller, Jennifer Ann, MD",10/27/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,10/26/2023,Inactive,,
CBMC 2W ONCOLOGY,93131,"Wagmiller, Jennifer Ann, MD",2/3/2024,Topotecan 28 Day Cycles - Cervical,_3. Third Line,2/2/2024,Inactive,,
CBMC OP INFUSION 2FL,29194,"Scoppetuolo, Michael, MD",1/17/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/8/2025,Active,,
SOM OUTPT INFUSION,7171,"Toomey, Kathleen C, MD",10/25/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/24/2024,Inactive,,
MSC OP INFUSION,24105,"Cohen, Seth D, MD",9/7/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,8/23/2023,Inactive,,
MSC OP INFUSION,24105,"Cohen, Seth D, MD",5/21/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,5/21/2024,Inactive,,
NBR 5N ONCOLOGY,35016,"Shah, Mansi R, MD",6/29/2023,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),,6/29/2023,Inactive,,
NBR CINJ OP INFUSION,35016,"Palmisiano, Neil David, MD",8/24/2023,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,8/24/2023,Inactive,,
MSC OP INFUSION,13809,"Taff, Jessica, MD",4/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/3/2024,Active,,
MSC OP INFUSION,86085,"Taff, Jessica, MD",4/10/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/10/2025,Active,Adenocarcinoma of colon metastatic to liver (CMS/HCC),
CBMC OP INFUSION 2FL,38252,"McKenna, Marshall, MD",3/27/2025,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,3/27/2025,Active,Chronic lymphocytic leuk of B-cell type not achieve remis (CMS/HCC),
CBMC OP INFUSION 2FL,38252,"McKenna, Marshall, MD",3/27/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,3/27/2025,Inactive,Chronic lymphocytic leuk of B-cell type not achieve remis (CMS/HCC),
CBMC OP INFUSION 2FL,38252,"McKenna, Marshall, MD",3/13/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,3/13/2025,Inactive,Chronic lymphocytic leuk of B-cell type not achieve remis (CMS/HCC),C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission
CINJ OP INFUSION,29809,"Stephenson, Ryan D, DO",2/6/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,First Line,2/5/2023,Active,,
CINJ OP INFUSION,87991,"Salacz, Michael E, MD",2/13/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,2/13/2023,Active,"Primary malignant neoplasm of left lower lobe of lung (CMS/HCC)
End stage renal disease (CMS/HCC)",
CBMC OP INFUSION 2FL,8108,"Scoppetuolo, Michael, MD",9/18/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/17/2023,Active,,
CBMC OP INFUSION 2FL,8108,"Scoppetuolo, Michael, MD",4/22/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/21/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,87376,"Ghodoussipour, Saum Bobak, MD",7/6/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,7/4/2023,Inactive,,
CINJ OP INFUSION,87376,"Ghodoussipour, Saum Bobak, MD",10/4/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,,9/26/2023,Active,,
MSC OP INFUSION,156,"Cohen, Seth D, MD",3/21/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,3/21/2025,Active,Urothelial cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C68.9 - Malignant neoplasm of urinary organ, unspecified; N28.89 - Other specified disorders of kidney and ureter"
MMC OP VP INFUSION,18245,"Cohen, Seth D, MD",11/7/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/29/2024,Active,,
MMC OP INFUSION,63971,"Lee, Patrick C, MD",8/22/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,8/21/2023,Active,Right renal mass,
MMC OP INFUSION,52782,"Meghal, Trishala, MD",7/17/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,7/17/2023,Inactive,,
JCMC CP INFUSION,64823,"Sekhri, Arunabh, MD",12/2/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/17/2024,Active,,
CINJ OP INFUSION,14551,"Saraiya, Biren P, MD",9/5/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/5/2024,Active,,
CINJ OP INFUSION,74046,"Hinrichs, Christian, MD",10/4/2023,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,Third Line,10/2/2023,Active,,
CINJ OP INFUSION,96097,"Haigentz, Missak, MD",1/17/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer/ Head and Neck cancer,First Line,1/16/2023,Inactive,,
CINJ OP INFUSION,96097,"Haigentz, Missak, MD",3/21/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,3/20/2023,Inactive,,
CINJ OP INFUSION,10846,"Gulhati, Prateek, MD PhD",5/9/2025,Imatinib 30 Day Cycles - Sarcoma,Adjuvant,5/9/2025,Active,Malignant gastrointestinal stromal tumor (GIST) of stomach (CMS/HCC),C49.A2 - Gastrointestinal stromal tumor of stomach
JCMC CP INFUSION,6389,"Sekhri, Arunabh, MD",1/13/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,First Line,1/12/2023,Inactive,,
CINJ OP INFUSION,23797,"Haigentz, Missak, MD",7/18/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,7/17/2023,Inactive,,
CINJ OP INFUSION,23797,"Haigentz, Missak, MD",10/30/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,10/27/2023,Inactive,,
SOM OUTPT INFUSION,31753,"Patel, Eshan, MD",1/18/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,1/17/2023,Inactive,,
SOM OUTPT INFUSION,40360,"Patel, Eshan, MD",11/20/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/12/2023,Inactive,,
SOM OUTPT INFUSION,69164,"Patel, Eshan, MD",4/22/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,4/22/2025,Active,Malignant neoplasm of female breast (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; R45.89 - Other symptoms and signs involving emotional state
CINJ OP INFUSION,22256,"Hinrichs, Christian, MD",2/13/2024,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_1. First Line,2/12/2024,Inactive,,
CINJ OP INFUSION,22256,"Haigentz, Missak, MD",6/18/2024,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_2. Second Line,6/17/2024,Active,,
CINJ OP INFUSION,22256,"Haigentz, Missak, MD",12/12/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,12/12/2024,Active,,
CINJ OP INFUSION,22256,"Haigentz, Missak, MD",2/3/2025,CINJ 032405 Cohort 4 Amivantamab Monotherapy (Pt weight >/=80 kg) 21 Day cycles Research- Head and Neck Cancers,_3. Third Line,2/2/2025,Active,Oropharyngeal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,55650,"Leitner, Stuart P, MD",2/26/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,2/25/2024,Active,,
NBR CINJ OP INFUSION,87355,"Tiger, Yun Kyoung, MD",7/17/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,7/16/2024,Inactive,,
TRMC TCCC OP INFUSION,39291,"Capo, Gerardo, MD",8/20/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/19/2024,Active,,
MMC OP INFUSION,65538,"Meghal, Trishala, MD",9/6/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,,9/5/2023,Inactive,,
MMC OP INFUSION,65538,"Meghal, Trishala, MD",1/31/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/23/2024,Inactive,,
MMC OP INFUSION,65538,"Meghal, Trishala, MD",4/3/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/2/2024,Active,,
CINJ OP INFUSION,95978,"Berim, Lyudmyla, MD",1/8/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,12/10/2024,Active,,
CINJ OP INFUSION,31128,"Berim, Lyudmyla, MD",4/7/2025,"Gemcitabine D1, D15 -  28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/27/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K68.9 - Other disorders of retroperitoneum; E87.6 - Hypokalemia; C25.0 - Malignant neoplasm of head of pancreas"
CINJ OP INFUSION,56811,"Stephenson, Ruth D, DO",4/6/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,4/4/2023,Inactive,,
CINJ OP INFUSION,56811,"Stephenson, Ruth D, DO",9/13/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,9/12/2023,Inactive,,
CINJ OP INFUSION,56811,"Stephenson, Ruth D, DO",7/24/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,7/23/2024,Active,,
CINJ OP INFUSION,56811,"Stephenson, Ruth D, DO",4/25/2025,Liposomal DOXOrubicin / Carboplatin/Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,4/23/2025,Active,"Metastatic adenocarcinoma of ovary, unspecified laterality (CMS/HCC)",
NBR CINJ OP INFUSION,10388,"Shah, Mansi R, MD",1/30/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,1/29/2025,Active,,
CMC OP INFUSION,50144,"Easaw, Sarah, MD",9/18/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/29/2023,Inactive,,
NBR CINJ OP INFUSION,41484,"Evens, Andrew M, DO",5/7/2025,CINJ 012503 Arm 2 Mosunetuzumab 21 Day Cycles Research - Follicular Lymphoma,_1. First Line,5/7/2025,Inactive,Follicular lymphoma of lymph nodes of multiple regions (CMS/HCC),
NBR CINJ OP INFUSION,41484,"Evens, Andrew M, DO",5/7/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,5/7/2025,Inactive,Follicular lymphoma of lymph nodes of multiple regions (CMS/HCC),
NBR CINJ OP INFUSION,41484,"Evens, Andrew M, DO",5/7/2025,CINJ 012503 Arm 2 Mosunetuzumab 21 Day Cycles Research - Follicular Lymphoma,_1. First Line,5/7/2025,Active,Follicular lymphoma of lymph nodes of multiple regions (CMS/HCC),"C82.98 - Follicular lymphoma of lymph nodes of multiple regions, unspecified grade (CMS/HCC)"
TRMC TCCC OP INFUSION,15970,"Salerno, Vincent E, MD",10/15/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,10/14/2024,Active,,
MMC OP VP INFUSION,157,"Meghal, Trishala, MD",7/7/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/2/2023,Inactive,,
CBMC OP INFUSION 2FL,76790,"Dharmapuri, Sirish, MD",4/22/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,4/21/2025,Active,HCC (hepatocellular carcinoma) (CMS/HCC),C22.0 - Liver cell carcinoma
NBI OP INFUSION,77399,"Schleicher, Lori, MD",5/24/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/24/2024,Inactive,,
MSC OP INFUSION,61176,"Cohen, Seth D, MD",3/9/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,3/8/2023,Inactive,,
MSC OP INFUSION,61176,"Cohen, Seth D, MD",9/8/2023,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,Maintenance,9/6/2023,Inactive,,
MMC OP VP INFUSION,61176,"Cohen, Seth D, MD",12/7/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,12/1/2023,Inactive,,
CMC OP INFUSION,61176,"Cohen, Seth D, MD",11/12/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,11/12/2024,Active,Malignant neoplasm of right ovary (CMS/HCC),
HAM OP INFUSION,96976,"Patel, Malini M, MD",5/2/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Third Line,5/1/2023,Inactive,,
MSC OP INFUSION,11031,"Tang, Horace, MD",8/2/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/1/2023,Inactive,,
CBMC OP INFUSION 2FL,14933,"Brown, Andrew Bennett, MD",2/1/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,1/31/2024,Inactive,,
CINJ OP INFUSION,54914,"Berim, Lyudmyla, MD",2/12/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_3. Third Line,2/12/2024,Inactive,,
CINJ OP INFUSION,54914,"Berim, Lyudmyla, MD",4/11/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,4/3/2024,Inactive,,
CBMC OP INFUSION 2FL,37348,"Grossman, I Robert, MD",1/25/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/24/2024,Active,,
TRMC TCCC OP INFUSION,66414,"Capo, Gerardo, MD",10/8/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/7/2024,Active,,
NBR CINJ OP INFUSION,93015,"Evens, Andrew M, DO",4/12/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,3/28/2023,Inactive,,
MMC OP VP INFUSION,92647,"Lee, Patrick C, MD",1/18/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,Induction,1/17/2023,Active,,
CMC OP INFUSION,92194,"Tang, Horace, MD",9/25/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab Uterine cancer,,9/25/2023,Inactive,,
CMC OP INFUSION,92194,"Cohen, Seth D, MD",2/19/2024,Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/19/2024,Inactive,,
CMC OP INFUSION,92194,"Cohen, Seth D, MD",4/3/2024,Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,4/2/2024,Active,,
CINJ OP INFUSION,97321,"Weiss, Sarah, MD",10/14/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,10/1/2024,Active,,
CINJ OP INFUSION,36245,"Jang, Thomas L, MD",3/23/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,3/23/2023,Inactive,,
NBR 5N ONCOLOGY,37435,"Berim, Lyudmyla, MD",2/8/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/6/2023,Inactive,,
CINJ OP INFUSION,37435,"Berim, Lyudmyla, MD",7/13/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,7/12/2023,Active,,
SOM OUTPT INFUSION,12893,"Patel, Eshan, MD",2/17/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Cancer",_1. First Line,2/14/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),
NBI OP INFUSION,51402,"Cheng, Yan Ho, MD",2/20/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,2/19/2023,Inactive,,
NBI OP INFUSION,51402,"Cheng, Yan Ho, MD",5/16/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,5/15/2023,Inactive,,
CINJ OP INFUSION,77807,"Haigentz, Missak, MD",3/25/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles with Radiotherapy- Non-Small Cell Lung Cancer,Consolidation,3/25/2025,Active,"Primary lung adenocarcinoma, unspecified laterality (CMS/HCC)
Warfarin anticoagulation","C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; I10 - Essential (primary) hypertension; I48.91 - Unspecified atrial fibrillation; J44.9 - Chronic obstructive pulmonary disease, unspecified; Z86.711 - Personal history of pulmonary embolism; Z79.01 - Long term (current) use of anticoagulants; Z79.51 - Long term (current) use of inhaled steroids; Z79.899 - Other long term (current) drug therapy; Z90.710 - Acquired absence of both cervix and uterus"
SOM OUTPT INFUSION,87081,"George, Roshini, DO",1/31/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/30/2025,Active,,
HAM OP INFUSION,91468,"Patel, Malini M, MD",7/29/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_3. Third Line,7/28/2024,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,51844,"Cohen, Seth D, MD",5/3/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Unknown Primary,_2. Second Line,5/2/2024,Inactive,,
MMC OP VP INFUSION,51844,"Cohen, Seth D, MD",5/3/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/2/2024,Inactive,,
HAM OP INFUSION,32150,"Patel, Malini M, MD",5/19/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,5/19/2025,Active,Head and neck cancer (CMS/HCC),C05.1 - Malignant tumor of soft palate (CMS/HCC)
NBR 4N ONCOLOGY,98660,"Rhodes, Joanna Meehan, MD",1/19/2024,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/19/2024,Inactive,,
NBR CINJ OP INFUSION,98660,"Rhodes, Joanna Meehan, MD",2/15/2024,BV-CHEP (Brentuximab + Cyclophosphamide / DOXOrubicin/ Prednisone / Etoposide) 21 Day Cycles - Non-Hodgkin's Lymphoma,_1. First Line,2/8/2024,Inactive,,
NBR CINJ OP INFUSION,98660,"Egini, Ogechukwu, MD",7/17/2024,BMT Autologous BEAM,Adjuvant,7/16/2024,Inactive,,
MMC OP INFUSION,84484,"Meghal, Trishala, MD",8/18/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,8/17/2023,Inactive,,
MMC OP INFUSION,84484,"Meghal, Trishala, MD",8/23/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,First Line,7/26/2023,Active,,
MMC OP VP INFUSION,84484,"Meghal, Trishala, MD",12/29/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,12/28/2023,Inactive,,
MMC OP INFUSION,84484,"Meghal, Trishala, MD",1/19/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/18/2024,Inactive,,
MMC OP VP INFUSION,84484,"Meghal, Trishala, MD",1/26/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/25/2024,Inactive,,
MMC OP VP INFUSION,84484,"Meghal, Trishala, MD",3/27/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,3/26/2024,Inactive,,
MMC OP INFUSION,84484,"Meghal, Trishala, MD",4/19/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/26/2024,Active,,
MMC OP INFUSION,84484,"Meghal, Trishala, MD",1/24/2025,Neratinib 28 Day Cycles - Breast,Adjuvant,1/24/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,84484,"Meghal, Trishala, MD",1/25/2025,Neratinib 28 Day Cycles - Breast,Adjuvant,1/25/2025,Active,,
MMC OP INFUSION,84484,"Meghal, Trishala, MD",1/25/2025,Neratinib 28 Day Cycles - Breast,Adjuvant,1/25/2025,Inactive,"Mass of upper outer quadrant of right breast
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,91857,"Talwar, Sumit, MD",5/10/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,4/27/2023,Inactive,,
CMC OP INFUSION,91857,"Cohen, Seth D, MD",10/19/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/19/2023,Active,,
CBMC OP INFUSION 2FL,65919,"Wagmiller, Jennifer Ann, MD",5/22/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/21/2023,Inactive,,
CBMC OP INFUSION 2FL,65919,"Wagmiller, Jennifer Ann, MD",7/10/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,6/25/2024,Inactive,,
CBMC OP INFUSION 2FL,65919,"Wagmiller, Jennifer Ann, MD",10/15/2024,DOXOrubicin weekly MBC,_5. Fifth Line,10/15/2024,Inactive,,
CBMC OP INFUSION 2FL,65919,"Wagmiller, Jennifer Ann, MD",1/16/2025,EriBULin 21 Day Cycles - Breast,_5. Fifth Line,12/25/2024,Active,,
CBMC OP INFUSION 2FL,65919,"Wagmiller, Jennifer Ann, MD",4/15/2025,Gemcitabine 28 Day Cycles - Breast,10. Tenth Line,4/15/2025,Inactive,"Malignant neoplasm of nipple and areola, left female breast (CMS/HCC)
On antineoplastic chemotherapy
Coagulation defect (CMS/HCC)","C50.012 - Malignant neoplasm of nipple and areola, left female breast; Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants"
CMC OP INFUSION,67980,"Taff, Jessica, MD",11/13/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,11/12/2024,Inactive,,
MSC OP INFUSION,67980,"Taff, Jessica, MD",12/30/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,12/29/2024,Active,,
SOM OUTPT INFUSION,75452,"Yin, Faye, MD",5/7/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/28/2024,Inactive,,
SOM OUTPT INFUSION,75452,"Toomey, Kathleen C, MD",9/10/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,9/10/2024,Active,,
CBMC OP INFUSION 2FL,20804,"Grossman, I Robert, MD",6/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/2/2024,Active,,
NBR CINJ OP INFUSION,14298,"Evens, Andrew M, DO",12/18/2024,Rituximab for RA,_2. Second Line,12/17/2024,Active,Renal cell carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,7363,"Brown, Andrew Bennett, MD",10/11/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,10/10/2023,Inactive,,
CINJ OP INFUSION,44713,"Berim, Lyudmyla, MD",1/15/2025,folfox,_1. First Line,1/14/2025,Active,,
CINJ OP INFUSION,20557,"Berim, Lyudmyla, MD",4/10/2025,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/9/2025,Active,Malignant neoplasm of rectum (CMS/HCC),C20 - Malignant neoplasm of rectum (CMS/HCC)
NBI OP INFUSION,34377,"Anderson, Patrick S, MD",2/8/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/24/2024,Active,,
TRMC TCCC OP INFUSION,49022,"Capo, Gerardo, MD",9/28/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,_2. Second Line,9/28/2023,Active,,
NBI VALERIE FND HEMONC,59980,"Bhatla, Teena, MD",6/23/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,Maintenance,6/23/2023,Active,,
CINJ OP INFUSION,80710,"Boland, Patrick M, MD",8/25/2023,mFOLFOX6 + Irino- 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/24/2023,Active,,
NBR 4N ONCOLOGY,4888,"Stephenson, Ruth D, DO",12/20/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,12/19/2024,Active,,
CINJ OP INFUSION,38436,"Stephenson, Ruth D, DO",5/1/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/1/2025,Active,"Carcinomatosis (CMS/HCC)
Ascites
Malignant neoplasm of both ovaries (CMS/HCC)","C56.3 - Malignant neoplasm of bilateral ovaries; C80.0 - Disseminated malignant neoplasm, unspecified; R18.0 - Malignant ascites"
NBR 4N ONCOLOGY,38436,"Stephenson, Ruth D, DO",3/27/2025,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/27/2025,Inactive,"Carcinomatosis (CMS/HCC)
Ascites
Malignant neoplasm of both ovaries (CMS/HCC)","C56.3 - Malignant neoplasm of bilateral ovaries; K56.600 - Partial intestinal obstruction, unspecified as to cause; R18.0 - Malignant ascites; C57.01 - Malignant neoplasm of right fallopian tube; K56.7 - Ileus, unspecified; C57.02 - Malignant neoplasm of left fallopian tube; C57.7 - Malignant neoplasm of other specified female genital organs; K91.89 - Other postprocedural complications and disorders of digestive system; N73.6 - Female pelvic peritoneal adhesions (postinfective)"
NBI OP INFUSION,98948,"Anderson, Patrick S, MD",7/8/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles -Recurrent Endometrial Cancer,_2. Second Line,7/2/2024,Active,,
CINJ OP INFUSION,13653,"Saraiya, Biren P, MD",6/4/2024,CISplatin with Concurrent Radiation 42 Day Cycle- Bladder,_1. First Line,6/3/2024,Inactive,,
JCMC CP INFUSION,90562,"Sekhri, Arunabh, MD",8/7/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/14/2024,Inactive,,
CBMC 2W ONCOLOGY,56042,"McKenna, Marshall, MD",2/14/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,2/10/2025,Active,Large B-cell lymphoma (CMS/HCC),"C83.37 - Diffuse large b-cell lymphoma, spleen; D61.818 - Other pancytopenia; E83.39 - Other disorders of phosphorus metabolism; D63.1 - Anemia in chronic kidney disease; I47.19 - Other supraventricular tachycardia; E86.9 - Volume depletion, unspecified; D70.9 - Neutropenia, unspecified; I48.0 - Paroxysmal atrial fibrillation; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.32 - Chronic kidney disease, stage 3b; Z95.3 - Presence of xenogenic heart valve; F32.A - Depression, unspecified; I73.9 - Peripheral vascular disease, unspecified; E66.9 - Obesity, unspecified; Q61.2 - Polycystic kidney, adult type; I48.20 - Chronic atrial fibrillation, unspecified; I50.32 - Chronic diastolic (congestive) heart failure; E87.1 - Hypo-osmolality and hyponatremia; H40.213 - Acute angle-closure glaucoma, bilateral; K92.1 - Melena; N17.9 - Acute kidney failure, unspecified; Z11.52 - Encounter for screening for COVID-19; E83.52 - Hypercalcemia; Z80.0 - Family history of malignant neoplasm of digestive organs; I49.3 - Ventricular premature depolarization; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; F41.1 - Generalized anxiety disorder; Z85.46 - Personal history of malignant neoplasm of prostate; Z87.891 - Personal history of nicotine d..."
NBR CINJ OP INFUSION,24736,"Rhodes, Joanna Meehan, MD",8/29/2024,CINJ 022401 Arm B Venetoclax / Obinutuzumab 28 Day Cycles Research- Chronic Lymphocytic Leukemia,_1. First Line,8/27/2024,Active,,
CINJ OP INFUSION,16441,"Weiss, Sarah, MD",7/22/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,7/21/2024,Active,,
CINJ OP INFUSION,59409,"Girda, Eugenia, MD",1/21/2025,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,10. Tenth Line,1/21/2025,Inactive,Ovarian cancer (CMS/HCC),
CINJ OP INFUSION,59409,"Girda, Eugenia, MD",1/22/2025,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,10. Tenth Line,1/22/2025,Active,,
NBR CINJ OP INFUSION,96154,"Braunschweig, Ira, MD",7/26/2023,Lymphodepletion Yescarta with Fludarabine/Cyclophosphamide 6 Day Cycle - Refractory Large B-Cell Lymphoma,,7/12/2023,Inactive,,
CBMC OP INFUSION 2FL,89600,"Scoppetuolo, Michael, MD",7/23/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/21/2024,Active,,
NBR 4N ONCOLOGY,16380,"Zayac, Adam, MD",12/31/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,12/29/2023,Inactive,,
NBR CINJ OP INFUSION,16380,"Zayac, Adam, MD",12/9/2024,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_2. Second Line,12/2/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,54659,"Berim, Lyudmyla, MD",9/26/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,9/14/2024,Inactive,,
CINJ OP INFUSION,54659,"Berim, Lyudmyla, MD",11/25/2024,"Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel D1, D8 21 Day Cycles - Breast",_3. Third Line,11/24/2024,Active,,
CBMC 2W ONCOLOGY,68510,"Grossman, I Robert, MD",1/22/2025,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,1/21/2025,Active,,
TRMC TCCC OP INFUSION,88039,"Capo, Gerardo, MD",2/5/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,2/4/2025,Active,"Invasive ductal carcinoma of breast, female, right (CMS/HCC)",
CINJ PEDS HEMONC ,75592,"Masterson, Margaret, MD",1/24/2023,AALL1731 SR-High B-ALL Consolidation,Consolidation,1/24/2023,Inactive,,
CINJ PEDS HEMONC ,75592,"Masterson, Margaret, MD",4/14/2023,AALL1731 SR-High B-ALL Arm C Interim Maintenance I HDMTX,First Line,3/29/2023,Inactive,,
CINJ PEDS HEMONC ,75592,"Masterson, Margaret, MD",7/6/2023,AALL1731 SR-High B-ALL Arms C & D Delayed Intensification,,7/5/2023,Inactive,,
CINJ PEDS HEMONC ,75592,"Masterson, Margaret, MD",9/27/2023,AALL1731 SR-High B-ALL Arms C & D - Interim Maintenance II CMTX,First Line,9/27/2023,Inactive,,
CINJ PEDS HEMONC ,75592,"Masterson, Margaret, MD",11/29/2023,AALL1731 SR-High B-ALL Arm C - Maintenance,_1. First Line,11/29/2023,Active,,
CINJ OP INFUSION,69537,"Berim, Lyudmyla, MD",1/27/2025,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/20/2025,Active,,
CMC OP INFUSION,5305,"Cohen, Seth D, MD",11/2/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/30/2023,Inactive,,
CINJ OP INFUSION,80591,"Haigentz, Missak, MD",8/14/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,8/13/2023,Inactive,,
TRMC TCCC OP INFUSION,17692,"Salerno, Vincent E, MD",4/29/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,4/28/2024,Active,,
TRMC TCCC OP INFUSION,17692,"Salerno, Vincent E, MD",7/1/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,6/30/2024,Inactive,,
NBI VALERIE FND HEMONC,76870,"Narang, Shalu, MD",8/1/2024,AALL1732 Induction,_1. First Line,8/1/2024,Inactive,,
NBI VALERIE FND HEMONC,76870,"Ford, Maegan C, MD",9/6/2024,AALL1732 Consolidation,_1. First Line,9/5/2024,Inactive,,
NBI VALERIE FND HEMONC,76870,"Ford, Maegan C, MD",9/20/2024,PEDS Asparaginase Erwinia (Rylaze),Consolidation,9/20/2024,Active,,
NBI VALERIE FND HEMONC,76870,"Ford, Maegan C, MD",11/7/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,Consolidation,11/7/2024,Inactive,,
NBI VALERIE FND HEMONC,76870,"Ford, Maegan C, MD",1/10/2025,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy Delayed Intensification",_1. First Line,1/10/2025,Active,,
NBI VALERIE FND HEMONC,76870,"de Benedictis, Marianna, MD",5/9/2025,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",_1. First Line,5/8/2025,Active,"Mixed phenotype acute leukemia, B-myeloid (CMS/HCC)",C95.00 - Acute leukemia of unspecified cell type not having achieved remission
NBI VALERIE FND HEMONC,76870,"Ford, Maegan C, MD",3/14/2025,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,3/14/2025,Inactive,"Mixed phenotype acute leukemia, B-myeloid (CMS/HCC)",C95.00 - Acute leukemia of unspecified cell type not having achieved remission
NBI VALERIE FND HEMONC,76870,"Ford, Maegan C, MD",3/14/2025,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,3/14/2025,Inactive,"Mixed phenotype acute leukemia, B-myeloid (CMS/HCC)",C95.00 - Acute leukemia of unspecified cell type not having achieved remission
SOM OUTPT INFUSION,94640,"Toomey, Kathleen C, MD",10/24/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/22/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,94640,"Toomey, Kathleen C, MD",2/26/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,2/25/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,94640,"Toomey, Kathleen C, MD",5/29/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,5/29/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",C50.811 - Malignant neoplasm of overlapping sites of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
SOM OUTPT INFUSION,94640,"Toomey, Kathleen C, MD",4/17/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,4/17/2025,Inactive,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,83368,"George, Roshini, DO",3/24/2025,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,3/24/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",
MMC BBR2 ONCOLOGY,64011,"Lee, Patrick C, MD",6/30/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,First Line,6/29/2023,Inactive,,
CINJ OP INFUSION,87347,"Toppmeyer, Deborah L, MD",12/31/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,12/31/2024,Active,IgA myeloma (CMS/HCC),
CINJ OP INFUSION,87347,"Toppmeyer, Deborah L, MD",2/17/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,2/17/2025,Active,Carcinoma of left breast metastatic to axillary lymph node (CMS/HCC),Z79.811 - Long term (current) use of aromatase inhibitors
CINJ OP INFUSION,22454,"Boland, Patrick M, MD",3/28/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/28/2025,Inactive,Malignant neoplasm of descending colon (CMS/HCC),C18.6 - Malignant neoplasm of descending colon
CINJ OP INFUSION,22454,"Boland, Patrick M, MD",3/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/28/2025,Active,Malignant neoplasm of descending colon (CMS/HCC),C18.6 - Malignant neoplasm of descending colon; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z90.49 - Acquired absence of other specified parts of digestive tract
NBR CINJ OP INFUSION,71710,"Shah, Mansi R, MD",1/30/2023,Bendamustine / RiTUXimab 28 Day Cycles - Waldenstorm's ,,1/29/2023,Inactive,,
NBR CINJ OP INFUSION,71710,"Shah, Mansi R, MD",10/15/2024,Bendamustine / RiTUXimab 28 Day Cycles - Waldenstroms,_1. First Line,10/13/2024,Active,,
CMC OP INFUSION,41858,"Pompa, Tiffany Ann, MD",1/7/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,1/6/2025,Active,,
HAM OP INFUSION,48119,"Yogarajah, Meera, MD",8/28/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,8/27/2024,Active,,
CINJ OP INFUSION,48231,"Berim, Lyudmyla, MD",1/23/2023,"Gemcitabine D1, D8, D15, 28 Day Cycles- Pancreatic Adenocarcinoma",,1/22/2023,Inactive,,
CMC OP INFUSION,52251,"Talwar, Sumit, MD",2/10/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/6/2025,Active,Malignant neoplasm of transverse colon (CMS/HCC),
CINJ OP INFUSION,82731,"Stephenson, Ryan D, DO",1/29/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,1/29/2024,Active,,
CMMC OP INFUSION,18347,"Freeman, Benjamin B, MD",3/27/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/27/2025,Inactive,"Adenocarcinoma, metastatic (CMS/HCC)
Carcinomatosis (CMS/HCC)","C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C18.9 - Malignant neoplasm of colon, unspecified; D68.9 - Coagulation defect, unspecified; C80.0 - Disseminated malignant neoplasm, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct"
CINJ OP INFUSION,60352,"Boland, Patrick M, MD",8/18/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,8/17/2023,Active,,
NBR CINJ OP INFUSION,17063,"Matasar, Matthew J, MD",3/19/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,3/19/2025,Inactive,Chronic lymphocytic leukemia of B-cell type in remission (CMS/HCC),
NBI D7 MED-SURG/TELE,80255,"Jacoby, Sari H, MD",7/31/2023,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,7/31/2023,Inactive,,
NBI D7 MED-SURG/TELE,80255,"Jacoby, Sari H, MD",11/6/2023,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,11/5/2023,Inactive,,
NBI OP INFUSION,80255,"Jacoby, Sari H, MD",12/19/2023,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_2. Second Line,12/19/2023,Inactive,,
NBI OP INFUSION,80255,"Jacoby, Sari H, MD",3/4/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,3/3/2024,Inactive,,
NBI OP INFUSION,80255,"Jacoby, Sari H, MD",4/22/2024,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_3. Third Line,4/22/2024,Active,,
HAM OP INFUSION,6745,"Gendy, Mina, DO",11/20/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,11/12/2024,Active,,
HAM OP INFUSION,6745,"Gendy, Mina, DO",2/26/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,2/25/2025,Active,"Bladder cancer (CMS/HCC)
Abnormal results of thyroid function studies",
HAM OP INFUSION,94782,"Gendy, Mina, DO",3/13/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,3/13/2025,Inactive,"Bladder cancer (CMS/HCC)
Abnormal results of thyroid function studies",
CINJ OP INFUSION,45666,"Jang, Thomas L, MD",12/24/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,12/17/2024,Active,,
CINJ OP INFUSION,55273,"Jang, Thomas L, MD",3/18/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,3/18/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),"N30.01 - Acute cystitis with hematuria; Z85.51 - Personal history of malignant neoplasm of bladder; E11.9 - Type 2 diabetes mellitus without complications; E78.5 - Hyperlipidemia, unspecified; I10 - Essential (primary) hypertension; E55.9 - Vitamin D deficiency, unspecified; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.82 - Long term (current) use of aspirin; Z79.51 - Long term (current) use of inhaled steroids; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs; Z79.890 - Hormone replacement therapy; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,99697,"Aikins, James K, MD",3/10/2023,Gemcitabine / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,3/8/2023,Inactive,,
CINJ OP INFUSION,1816,"Haigentz, Missak, MD",9/1/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,9/1/2023,Inactive,,
CINJ OP INFUSION,1816,"Haigentz, Missak, MD",1/5/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/5/2024,Inactive,,
CINJ OP INFUSION,24197,"Kennedy, Timothy, MD",3/29/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,3/29/2024,Inactive,,
CBMC OP INFUSION 2FL,64682,"Wagmiller, Jennifer Ann, MD",12/20/2023,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,12/19/2023,Inactive,,
CBMC 2W ONCOLOGY,42988,"Grossman, I Robert, MD",7/8/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_2. Second Line,7/8/2024,Inactive,,
CBMC 2W ONCOLOGY,42988,"Grossman, I Robert, MD",9/20/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,9/20/2024,Inactive,,
CBMC 2W ONCOLOGY,42988,"Grossman, I Robert, MD",11/3/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_3. Third Line,11/2/2024,Inactive,,
CBMC 2W ONCOLOGY,42988,"Grossman, I Robert, MD",12/9/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_5. Fifth Line,12/9/2024,Inactive,,
MMC OP VP INFUSION,13787,"Cohen, Seth D, MD",7/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/4/2023,Inactive,,
MMC OP VP INFUSION,13787,"Cohen, Seth D, MD",6/24/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/23/2024,Active,,
CINJ OP INFUSION,34915,"Mayer, Tina M, MD",4/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,4/18/2023,Active,,
CINJ OP INFUSION,70429,"Ganesan, Shridar, MD PhD",8/27/2024,Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Trastuzumab 21 Day Cycles - Breast,_1. First Line,8/19/2024,Active,Malignant neoplasm of overlapping sites of left lung (CMS/HCC),
MMC OP VP INFUSION,4129,"Meghal, Trishala, MD",12/16/2024,Olaparib 30 Day Cycles - Breast,_3. Third Line,12/16/2024,Active,,
MMC OP VP INFUSION,58094,"Meghal, Trishala, MD",1/31/2025,Olaparib 30 Day Cycles - Breast,_3. Third Line,1/31/2025,Active,,
CBMC OP INFUSION 2FL,54711,"Wagmiller, Jennifer Ann, MD",2/24/2025,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,2/23/2025,Active,Malignant neoplasm of fundus of stomach (CMS/HCC),
CMC OP INFUSION,77172,"Pompa, Tiffany Ann, MD",1/29/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/28/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),
CBMC OP INFUSION 2FL,62498,"Grossman, I Robert, MD",11/1/2023,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,96307,"Leitner, Stuart P, MD",5/15/2025,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,Adjuvant,5/15/2025,Inactive,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,96307,"Leitner, Stuart P, MD",5/9/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/29/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP INFUSION,16410,"Meghal, Trishala, MD",4/9/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/8/2024,Inactive,,
MMC OP VP INFUSION,16410,"Meghal, Trishala, MD",10/7/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,10/7/2024,Active,Malignant neoplasm of upper lobe of left lung (CMS/HCC),
CBMC OP INFUSION 2FL,38766,"Leitner, Stuart P, MD",7/29/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,7/28/2024,Active,,
NBR BMSCH 2 PED HEMONC,66388,"Drachtman, Richard, MD",11/3/2023,AALL1732 Induction,Induction,11/2/2023,Inactive,,
CINJ PEDS HEMONC ,66388,"Masterson, Margaret, MD",12/13/2023,AALL1732 Consolidation,_1. First Line,12/13/2023,Inactive,,
CINJ PEDS HEMONC ,66388,"Masterson, Margaret, MD",3/5/2024,AALL1732 HR B-ALL Arm C- INOtuzumab ozogamicin Block 1 IT,_1. First Line,3/5/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Masterson, Margaret, MD",3/11/2024,AALL1732 HR B-ALL Arm C Inotuzumab ozogamicin Block 1,_1. First Line,3/6/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Masterson, Margaret, MD",4/12/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,4/10/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Botwinick, Marissa, DO",7/12/2024,AALL1732 HR B-ALL Arm C Delayed Intensification,_1. First Line,7/10/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Botwinick, Marissa, DO",8/16/2024,PEDS Blinatumomab,_1. First Line,8/15/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Botwinick, Marissa, DO",8/29/2024,per AALL1732 HR B-ALL Arm C Inotuzumab ozogamicin Block 2,_1. First Line,8/29/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Botwinick, Marissa, DO",10/9/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,10/9/2024,Inactive,,
CINJ PEDS HEMONC ,66388,"Botwinick, Marissa, DO",12/20/2024,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",_1. First Line,12/19/2024,Active,,
NBR CINJ OP INFUSION,36126,"Tiger, Yun Kyoung, MD",6/19/2024,RiTUXimab 28 Day Cycle,_1. First Line,6/18/2024,Inactive,,
NBR CINJ OP INFUSION,36126,"Tiger, Yun Kyoung, MD",8/23/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_2. Second Line,8/22/2024,Active,,
NBI VALERIE FND HEMONC,55457,"Batra, Surabhi, MD",4/23/2024,PEDS ARST0121 Regimen A - Relapsed Rhabdomyosarcoma,_2. Second Line,4/23/2024,Active,,
NBI VALERIE FND HEMONC,55457,"Batra, Surabhi, MD",6/18/2024,ARST0121 Regimen 3 (orders according to PEDS AEWS1031 Regimen A Induction & Consolidation),_1. First Line,6/17/2024,Active,,
CINJ OP INFUSION,42768,"Stephenson, Ryan D, DO",12/9/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,12/9/2024,Active,,
CINJ OP INFUSION,10868,"Weiss, Sarah, MD",3/1/2023,CARBOplatin / Etoposide 21 Day Cycles - Merkel Cell Carcinoma Metastatic,Third Line,2/14/2023,Inactive,,
CINJ OP INFUSION,10868,"Weiss, Sarah, MD",3/25/2024,Topotecan 21 Day Cycles- Small Cell Lung Cancer,_5. Fifth Line,3/22/2024,Inactive,,
JCMC CP INFUSION,34912,"Cruz, Allan Louie E, MD",11/22/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,Induction,11/13/2023,Inactive,,
JCMC CP INFUSION,34912,"Cruz, Allan Louie E, MD",12/5/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/5/2023,Inactive,,
NBR CINJ OP INFUSION,62271,"Palmisiano, Neil David, MD",3/13/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia ,,3/12/2023,Inactive,,
NBR 4N BMTU/IMCU,62271,"Assal, Amer, MD",7/4/2023,BMT Autologous Busulfan / Melphalan (Busulfan PK levels measured) ,,7/4/2023,Inactive,,
NBR 4N ONCOLOGY,62271,"Palmisiano, Neil David, MD",4/22/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,4/22/2024,Inactive,,
HAM OP INFUSION,6055,"Yogarajah, Meera, MD",5/3/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/1/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33357,"Goyal-Khemka, Meenakshi, MD",3/17/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,3/17/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,33357,"Goyal-Khemka, Meenakshi, MD",3/19/2023,AALL1732 Induction,,3/18/2023,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",4/25/2023,AALL1732 Consolidation,First Line,4/25/2023,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",7/18/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,First Line,6/29/2023,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",11/2/2023,AALL1732 Delayed Intensification,_1. First Line,11/2/2023,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",1/8/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,1/8/2024,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",1/31/2024,Dosing per PEDS AALL1731 Blinatumomab,Adjuvant,1/31/2024,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",3/28/2024,Dosing per AALL1731 ALL Blinatumomab Block 2,_1. First Line,3/13/2024,Inactive,,
CINJ PEDS HEMONC ,33357,"Drachtman, Richard, MD",4/25/2024, as per AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,4/25/2024,Active,,
NBR 4N ONCOLOGY,98667,"Berim, Lyudmyla, MD",2/7/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/5/2023,Inactive,,
NBR 5N ONCOLOGY,98667,"Berim, Lyudmyla, MD",6/23/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/23/2023,Inactive,,
CBMC OP INFUSION 2FL,28484,"Brown, Andrew Bennett, MD",12/16/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/15/2024,Active,,
CBMC OP INFUSION 2FL,34129,"Brown, Andrew Bennett, MD",11/17/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,34129,"Brown, Andrew Bennett, MD",9/19/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,9/18/2024,Active,,
CBMC OP INFUSION 2FL,37123,"Brown, Andrew Bennett, MD",2/13/2025,Gemcitabine/VinORELBine 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/12/2025,Active,"Malignant neoplasm of lower lobe, left bronchus or lung (CMS/HCC)",
CINJ OP INFUSION,89340,"Leiser, Aliza, MD",1/31/2023,Everolimus - Uterine,,1/31/2023,Inactive,,
CBMC OP INFUSION 2FL,32811,"Wagmiller, Jennifer Ann, MD",9/26/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/15/2024,Active,,
NBR CINJ OP INFUSION,75490,"Zayac, Adam, MD",1/14/2025,Cytarabine / DAUNOrubicin / Midostaurin (7 + 3) - Acute Myeloid Leukemia (Induction),_2. Second Line,1/14/2025,Active,,
CINJ OP INFUSION,66348,"Haigentz, Missak, MD",4/12/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/12/2024,Inactive,,
CINJ OP INFUSION,66348,"Haigentz, Missak, MD",7/2/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/2/2024,Active,,
CINJ OP INFUSION,84572,"Leiser, Aliza, MD",5/8/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,5/8/2025,Active,Carcinosarcoma of endometrium (CMS/HCC),
JCMC CP INFUSION,50996,"Sekhri, Arunabh, MD",1/31/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,1/30/2025,Active,,
JCMC CP INFUSION,50996,"Sekhri, Arunabh, MD",2/13/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,1/30/2025,Active,Cholangiocarcinoma (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C80.1 - Malignant (primary) neoplasm, unspecified; C22.1 - Intrahepatic bile duct carcinoma; K83.1 - Obstruction of bile duct; K86.89 - Other specified diseases of pancreas; R45.89 - Other symptoms and signs involving emotional state; D64.9 - Anemia, unspecified"
NBI OP INFUSION,97072,"Cheng, Yan Ho, MD",4/7/2025,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,_1. First Line,4/7/2025,Inactive,"Extramedullary plasmacytoma not having achieved remission (CMS/HCC)
AL amyloidosis (CMS/HCC)",
CINJ OP INFUSION,23200,"Stephenson, Ryan D, DO",8/18/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,First Line,8/18/2023,Inactive,,
CINJ OP INFUSION,23200,"Stephenson, Ryan D, DO",9/13/2024,Cabozantinib 28 Day Cycles- Renal Cell Carcinoma,_2. Second Line,9/13/2024,Active,,
NBR CINJ OP INFUSION,86668,"Shah, Mansi R, MD",12/4/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,12/3/2024,Active,,
NBI OP INFUSION,44932,"Schleicher, Lori, MD",9/5/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,9/4/2024,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),
JCMC CP INFUSION,75819,"Sekhri, Arunabh, MD",9/9/2024,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,9/8/2024,Inactive,,
JCMC CP INFUSION,75819,"Sekhri, Arunabh, MD",9/27/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - ovarian,_2. Second Line,9/26/2024,Inactive,,
JCMC CP INFUSION,75819,"Sekhri, Arunabh, MD",9/27/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,9/26/2024,Inactive,,
JCMC CP INFUSION,75819,"Sekhri, Arunabh, MD",9/27/2024,"Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles ,avastin 15 days - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_2. Second Line,9/26/2024,Inactive,,
JCMC CP INFUSION,75819,"Sekhri, Arunabh, MD",10/11/2024,Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/10/2024,Active,,
TRMC TCCC OP INFUSION,37881,"Capo, Gerardo, MD",10/17/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,10/16/2024,Active,,
CINJ OP INFUSION,91971,"Gulhati, Prateek, MD PhD",2/27/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,2/26/2023,Inactive,,
TRMC TCCC OP INFUSION,5835,"Capo, Gerardo, MD",3/26/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/26/2025,Active,"Metastatic colon cancer to liver (CMS/HCC)
Malignant neoplasm of sigmoid colon (CMS/HCC)","C19 - Malignant neoplasm of rectosigmoid junction; A41.9 - Sepsis, unspecified organism; K56.601 - Complete intestinal obstruction, unspecified as to cause; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; N13.6 - Pyonephrosis; C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes; D63.8 - Anemia in other chronic diseases classified elsewhere; I10 - Essential (primary) hypertension; J45.909 - Unspecified asthma, uncomplicated; E66.9 - Obesity, unspecified; R18.8 - Other ascites; N13.30 - Unspecified hydronephrosis; D63.0 - Anemia in neoplastic disease; D25.9 - Leiomyoma of uterus, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I45.10 - Unspecified right bundle-branch block; K59.00 - Constipation, unspecified; D50.9 - Iron deficiency anemia, unspecified; E78.2 - Mixed hyperlipidemia; Z60.3 - Acculturation difficulty; Z80.9 - Family history of malignant neoplasm, unspecified; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z85.048 - Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus; Z86.711 - Personal history of pulmonary embolism; Z87.891 - Personal history of nicotine dependence; Z88.0 - Allergy status to penicillin; Z68.34 - Body mass index (BMI) 34.0-34.9, adult; Z79.899 - Other long term (current) drug the..."
JCMC CP INFUSION,3107,"Sekhri, Arunabh, MD",9/18/2023,Abemaciclib 28 Day Cycles - Breast ,First Line,9/18/2023,Inactive,,
CINJ OP INFUSION,3107,"George, Mridula A, MD",7/1/2024,CINJ 042402 Parts 1 and 2 RLY-2608 / Ribociclib 400 mg / Fulvestrant 28 Day Cycles- Breast Cancer,_2. Second Line,7/1/2024,Inactive,,
JCMC CP INFUSION,3107,"Sekhri, Arunabh, MD",9/25/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_3. Third Line,9/15/2024,Inactive,,
JCMC 7W MED-SURG 2,3107,"Sekhri, Arunabh, MD",11/4/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,11/3/2024,Inactive,,
NBR CINJ OP INFUSION,61797,"Schaar, Dale, MD PhD",1/30/2023,Decitabine (5 day) 56 Day Cycles - Post transplant maintenance,,1/30/2023,Inactive,,
CINJ OP INFUSION,9383,"Groisberg, Roman, MD",8/27/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_2. Second Line,8/22/2024,Active,"Malignant neoplasm of nipple and areola, left female breast (CMS/HCC)
Encounter for screening for other viral diseases",
CMC OP INFUSION,1983,"Cohen, Seth D, MD",6/11/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/11/2024,Inactive,,
CMC OP INFUSION,1983,"Cohen, Seth D, MD",10/8/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/7/2024,Active,,
CMC OP INFUSION,70452,"Taff, Jessica, MD",5/9/2023,Cervical Ca - Bevacizumab,First Line,5/9/2023,Active,,
CINJ OP INFUSION,43038,"Stephenson, Ruth D, DO",2/5/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,2/2/2025,Active,"Malignant neoplasm of overlapping sites of cervix (CMS/HCC)
Weight loss, unintentional",
NBI OP INFUSION,68630,"Jacoby, Sari H, MD",3/18/2024,Atezolizumab / Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,3/17/2024,Inactive,,
NBI OP INFUSION,68630,"Jacoby, Sari H, MD",9/16/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_2. Second Line,9/15/2024,Active,Peritoneal mesothelioma (CMS/HCC),
NBR 4N BMTU/IMCU,41659,"Schaar, Dale, MD PhD",8/17/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,8/16/2023,Inactive,,
NBR CINJ OP INFUSION,41659,"Braunschweig, Ira, MD",12/11/2023,"Daratumumab and Hyaluronidase-fihj., Mismatched ABO incompatibility ",Consolidation,12/10/2023,Inactive,,
SOM OUTPT INFUSION,22608,"Yin, Faye, MD",2/9/2023,Zanubrutinib (160 mg) 30 Day Cycles - Marginal zone Lymphoma,Second Line,2/9/2023,Inactive,,
CINJ OP INFUSION,18692,"Toppmeyer, Deborah L, MD",7/5/2023,Ribociclib 28 Day Cycles - Breast,Second Line,7/5/2023,Active,"Malignant neoplasm of nipple and areola, left female breast (CMS/HCC)",
CINJ OP INFUSION,18692,"Toppmeyer, Deborah L, MD",3/17/2025,CINJ 042407 Arm A PCS6422 / Capecitabine 42 Day Cycles Research- Breast Cancer,_3. Third Line,3/16/2025,Active,"Malignant neoplasm of axillary tail of left breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,24879,"Taff, Jessica, MD",5/9/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/8/2023,Inactive,,
CMC OP INFUSION,24879,"Taff, Jessica, MD",12/4/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/1/2023,Inactive,,
CMC OP INFUSION,24879,"Taff, Jessica, MD",9/6/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,8/7/2024,Inactive,,
CINJ OP INFUSION,18272,"Ghodoussipour, Saum Bobak, MD",6/23/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,,6/22/2023,Inactive,,
CBMC OP INFUSION 2FL,71623,"Wagmiller, Jennifer Ann, MD",8/4/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,8/3/2023,Active,,
CINJ OP INFUSION,58729,"Haigentz, Missak, MD",12/13/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/7/2023,Inactive,,
CINJ OP INFUSION,58729,"Haigentz, Missak, MD",2/27/2024,"DOCEtaxel D1, D8, D15 /Ramucirumab 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,2/27/2024,Inactive,,
CBMC OP INFUSION 2FL,44810,"Brown, Andrew Bennett, MD",4/11/2025,Bevacizumab Maintenance 21 Day Cycles- CNS,_1. First Line,4/11/2025,Active,Glioblastoma (CMS/HCC),"C71.9 - Malignant neoplasm of brain, unspecified; R80.9 - Proteinuria, unspecified; R31.9 - Hematuria, unspecified"
NBR 4N ONCOLOGY,47439,"Gulhati, Prateek, MD PhD",6/10/2024,Bleomycin Conventional TACE,_4. Fourth Line,6/10/2024,Inactive,,
CINJ OP INFUSION,47439,"Gulhati, Prateek, MD PhD",5/8/2025,Bleomycin Conventional TACE - Hepatic Hemangiomas,_1. First Line,5/8/2025,Active,Hepatic hemangioma,
CINJ OP INFUSION,39133,"Leiser, Aliza, MD",10/30/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,10/25/2023,Inactive,,
CINJ OP INFUSION,39133,"Leiser, Aliza, MD",3/27/2024,CARBOplatin Weekly / Trastuzumab with Concurrent Radiation 49 Day Cycle - Breast,_3. Third Line,3/26/2024,Inactive,,
CINJ OP INFUSION,39133,"Leiser, Aliza, MD",5/31/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,5/30/2024,Inactive,,
CINJ OP INFUSION,57944,"Hochster, Howard S, MD",9/4/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/2/2024,Active,,
NBR CINJ OP INFUSION,60008,"Schaar, Dale, MD PhD",10/30/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,10/29/2023,Inactive,,
NBR 4N BMTU/IMCU,60008,"Assal, Amer, MD",12/22/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,_3. Third Line,12/22/2023,Inactive,,
NBR 4N BMTU/IMCU,60008,"Schaar, Dale, MD PhD",2/9/2024,BMT Allogeneic Flu / Cy / TBI + Post Cy ,Consolidation,2/8/2024,Inactive,,
SOM OUTPT INFUSION,98757,"Toomey, Kathleen C, MD",5/30/2025,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,5/30/2025,Active,Chordoma (CMS/HCC),C41.2 - Malignant neoplasm of vertebral column
CBMC OP INFUSION 2FL,61603,"Brown, Andrew Bennett, MD",12/1/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,11/30/2023,Inactive,,
CINJ OP INFUSION,15303,"Haigentz, Missak, MD",4/2/2025,CINJ 032203 (D967SC00001) ARM 1 Trastuzumab Deruxtecan 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,4/2/2025,Active,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Adenocarcinoma of right lung, stage 4 (CMS/HCC)",
CINJ OP INFUSION,17496,"Jang, Thomas L, MD",9/22/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,First Line,9/21/2023,Inactive,,
CMC OP INFUSION,19451,"Talwar, Sumit, MD",5/16/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Third Line,5/15/2023,Active,,
CMC OP INFUSION,19451,"Brodskiy, Nolan, PA",1/29/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,1/29/2024,Inactive,,
CINJ OP INFUSION,19451,"Packiam, Vignesh, MD",2/26/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,2/22/2024,Inactive,,
MMC OP VP INFUSION,56547,"Lee, Patrick C, MD",10/18/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,10/16/2024,Active,,
CMC OP INFUSION,53485,"Pompa, Tiffany Ann, MD",7/23/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,7/22/2024,Active,,
CINJ OP INFUSION,35942,"Haigentz, Missak, MD",9/17/2024,CINJ 032403 Arm 4 CISplatin / Atezolizumab w / Concurrent Radiation Therapy 148 Day Cycle Research- Head and Neck Cancers,_1. First Line,9/15/2024,Active,,
JCMC CP INFUSION,40558,"Cruz, Allan Louie E, MD",2/26/2024,Sacituzumab Govitecan 21 Day Cycles - Breast,_1. First Line,2/26/2024,Inactive,,
NBI OP INFUSION,40558,"Schleicher, Lori, MD",10/28/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,10/28/2024,Active,,
NBI OP INFUSION,40558,"Schleicher, Lori, MD",1/22/2025,EriBULin 21 Day Cycles - Breast,_4. Fourth Line,1/21/2025,Active,,
CINJ OP INFUSION,57763,"Hochster, Howard S, MD",6/8/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,6/8/2023,Inactive,,
CINJ OP INFUSION,57763,"Hochster, Howard S, MD",12/21/2023,CINJ 072214 PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_2. Second Line,12/19/2023,Inactive,,
CINJ OP INFUSION,57763,"Hochster, Howard S, MD",1/31/2024,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_2. Second Line,1/31/2024,Inactive,,
CINJ OP INFUSION,57763,"Hochster, Howard S, MD",4/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/2/2024,Inactive,,
CINJ OP INFUSION,14980,"Stephenson, Ruth D, DO",4/7/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,4/4/2023,Active,,
CINJ OP INFUSION,14980,"Stephenson, Ruth D, DO",10/4/2023,CINJ 102101 (19-0380) Niraparib 28 Day Cycles Research- Uterine Cancer,Maintenance,9/6/2023,Active,,
NBR 5N ONCOLOGY,12560,"Saraiya, Biren P, MD",8/24/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/23/2024,Inactive,,
MMC OP INFUSION,54135,"Eltoukhy, Hussam, MD",7/18/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/15/2024,Active,,
CINJ OP INFUSION,96687,"Mayer, Tina M, MD",6/5/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,,6/4/2023,Inactive,,
CINJ OP INFUSION,65421,"Berim, Lyudmyla, MD",3/13/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,3/13/2023,Inactive,,
CINJ OP INFUSION,65421,"Berim, Lyudmyla, MD",5/15/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) ,,5/10/2023,Inactive,,
CINJ OP INFUSION,99135,"Aikins, James K, MD",5/25/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,5/24/2023,Inactive,,
CINJ OP INFUSION,55587,"George, Mridula A, MD",5/23/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/23/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)","C50.911 - Malignant neoplasm of unspecified site of right female breast; E78.5 - Hyperlipidemia, unspecified; C43.10 - Malignant melanoma of unspecified eyelid, including canthus; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC OP INFUSION 2FL,99787,"Wagmiller, Jennifer Ann, MD",10/10/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_3. Third Line,10/10/2023,Inactive,,
CBMC OP INFUSION 2FL,99787,"Wagmiller, Jennifer Ann, MD",10/24/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_3. Third Line,10/23/2023,Inactive,,
CINJ OP INFUSION,14539,"Gulhati, Prateek, MD PhD",8/3/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,8/2/2023,Inactive,,
CINJ OP INFUSION,14539,"Gulhati, Prateek, MD PhD",2/15/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/15/2024,Inactive,,
NBR CINJ OP INFUSION,60373,"Matasar, Matthew J, MD",7/12/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/11/2023,Inactive,,
CINJ OP INFUSION,22333,"Leiser, Aliza, MD",1/14/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/19/2024,Active,,
CBMC OP INFUSION 2FL,98603,"Brown, Andrew Bennett, MD",1/17/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,1/15/2024,Inactive,,
CINJ OP INFUSION,2827,"Packiam, Vignesh, MD",5/23/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,5/19/2024,Inactive,,
CINJ OP INFUSION,2827,"Packiam, Vignesh, MD",8/26/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,8/25/2024,Inactive,,
CINJ OP INFUSION,2827,"Packiam, Vignesh, MD",10/3/2024,BCG Induction (TICE) 42 Day Cycle,Adjuvant,9/30/2024,Active,,
CINJ OP INFUSION,2827,"Packiam, Vignesh, MD",2/17/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,2/16/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),C67.8 - Malignant neoplasm of overlapping sites of bladder
SOM OUTPT INFUSION,41215,"Toomey, Kathleen C, MD",5/28/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,5/27/2024,Inactive,,
SOM OUTPT INFUSION,41215,"Toomey, Kathleen C, MD",11/20/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,11/20/2024,Active,,
SOM OUTPT INFUSION,41215,"Toomey, Kathleen C, MD",12/4/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,12/4/2024,Active,,
NBI OP INFUSION,14021,"Shah, Shailja S, MD",11/15/2024,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,11/15/2024,Active,,
CINJ OP INFUSION,39714,"Leiser, Aliza, MD",1/21/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,1/19/2025,Active,,
CBMC OP INFUSION 2FL,98938,"Grossman, I Robert, MD",10/13/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,10/12/2023,Active,,
NBR CINJ OP INFUSION,98938,"Egini, Ogechukwu, MD",5/8/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,4/24/2024,Inactive,,
NBR CINJ OP INFUSION,98938,"Egini, Ogechukwu, MD",6/11/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,6/10/2024,Inactive,,
CINJ OP INFUSION,54741,"Patel, Eshan, MD",11/15/2023,CINJ 032013 (EA5181) ARM B PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,11/7/2023,Inactive,,
CINJ OP INFUSION,54741,"Patel, Eshan, MD",12/29/2023,CARBOplatin Weekly  Concurrent Radiation - lung,_1. First Line,12/21/2023,Inactive,,
CINJ OP INFUSION,54741,"Patel, Eshan, MD",2/2/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,2/1/2024,Active,,
CINJ OP INFUSION,68129,"Ghodoussipour, Saum Bobak, MD",10/16/2024,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,10/15/2024,Active,,
CMC OP INFUSION,51333,"Taff, Jessica, MD",3/31/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,First Line,3/30/2023,Inactive,,
CMC OP INFUSION,51333,"Taff, Jessica, MD",12/29/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,12/28/2023,Active,,
JCMC CP INFUSION,23150,"Sekhri, Arunabh, MD",4/25/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,4/25/2025,Active,Malignant neoplasm of upper lobe of left lung (CMS/HCC),
NBR CINJ OP INFUSION,5231,"Egini, Ogechukwu, MD",2/5/2025,BMT Autologous Carmustine / Thiotepa,_2. Second Line,2/4/2025,Active,CNS lymphoma,"C83.390 - Primary central nervous system lymphoma; C91.41 - Hairy cell leukemia, in remission; I10 - Essential (primary) hypertension; G47.33 - Obstructive sleep apnea (adult) (pediatric); I42.9 - Cardiomyopathy, unspecified; Z01.818 - Encounter for other preprocedural examination"
CINJ OP INFUSION,47203,"Berim, Lyudmyla, MD",1/23/2023,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",,1/20/2023,Inactive,,
CINJ OP INFUSION,47203,"Goel, Sanjay, MD",2/20/2023,CINJ 052103 (TJ033721STM101) Dose Escalation TJ033721 12 mg/kg 28 Day Cycle Research- Advanced / Metastatic Solid Tumors,Third Line,1/23/2023,Inactive,,
NBI OP INFUSION,23281,"Jacoby, Sari H, MD",10/10/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/9/2023,Inactive,,
NBI OP INFUSION,23281,"Jacoby, Sari H, MD",2/28/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/20/2024,Inactive,,
NBI OP INFUSION,23281,"Jacoby, Sari H, MD",2/28/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/20/2024,Active,,
CINJ OP INFUSION,53474,"George, Mridula A, MD",1/12/2024,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,1/12/2024,Active,,
CINJ OP INFUSION,23848,"Haigentz, Missak, MD",1/9/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/8/2024,Inactive,,
CINJ OP INFUSION,23848,"Haigentz, Missak, MD",5/29/2024,"Pembrolizumab monotherapy, Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,5/29/2024,Inactive,,
CINJ OP INFUSION,90683,"Aikins, James K, MD",3/17/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/16/2023,Inactive,,
CINJ OP INFUSION,90683,"Aikins, James K, MD",1/18/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_3. Third Line,1/17/2024,Inactive,,
CINJ OP INFUSION,6167,"Aikins, James K, MD",8/21/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,8/20/2024,Active,,
NBR CINJ OP INFUSION,8159,"Palmisiano, Neil David, MD",1/20/2023,HyperCVD Mini + Ponatinib (Cycle 1) (RiTUXimab / Cyclophosphamide / VinCRIStine / Dexamethasone) 28 Day Cycles - Acute Lymphoblastic Leukemia (Induction),,1/20/2023,Inactive,,
NBR 5N ONCOLOGY,8159,"Palmisiano, Neil David, MD",3/3/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,First Line,3/3/2023,Inactive,,
NBR CINJ OP INFUSION,8159,"Palmisiano, Neil David, MD",4/13/2023,Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,4/13/2023,Inactive,,
NBR 5N ONCOLOGY,79842,"Chen, Xiaoyi",2/13/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,2/13/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),"C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes; I81 - Portal vein thrombosis; K55.059 - Acute (reversible) ischemia of intestine, part and extent unspecified; I82.890 - Acute embolism and thrombosis of other specified veins; E87.1 - Hypo-osmolality and hyponatremia; R18.8 - Other ascites; I10 - Essential (primary) hypertension; F32.9 - Major depressive disorder, single episode, unspecified; D64.9 - Anemia, unspecified; I35.8 - Other nonrheumatic aortic valve disorders; Z68.26 - Body mass index (BMI) 26.0-26.9, adult; R63.0 - Anorexia; R35.1 - Nocturia; R59.0 - Localized enlarged lymph nodes; E78.00 - Pure hypercholesterolemia, unspecified; E87.5 - Hyperkalemia; G47.00 - Insomnia, unspecified; I87.8 - Other specified disorders of veins; K59.00 - Constipation, unspecified; N32.81 - Overactive bladder; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; Z90.710 - Acquired absence of both cervix and uterus; Z98.891 - History of uterine scar from previous surgery; Z87.891 - Personal history of nicotine dependence; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system"
NBR CINJ OP INFUSION,79842,"Matasar, Matthew J, MD",3/5/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/4/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
CBMC 2W ONCOLOGY,29183,"Grossman, I Robert, MD",11/22/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/22/2023,Inactive,,
CBMC OP INFUSION 2FL,88941,"Scoppetuolo, Michael, MD",11/7/2023,Elotuzumab / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,11/6/2023,Active,,
JCMC CP INFUSION,8060,"Sekhri, Arunabh, MD",5/22/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,First Line,5/21/2023,Inactive,,
JCMC CP INFUSION,8060,"Sekhri, Arunabh, MD",5/22/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,5/21/2023,Inactive,,
JCMC CP INFUSION,8060,"Sekhri, Arunabh, MD",5/22/2023,mFOLFOX6 + Keytruda(Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/21/2023,Inactive,,
JCMC CP INFUSION,8060,"Sekhri, Arunabh, MD",6/21/2023,Pembrolizumab 42 Day Cycles-MSI high colon cancer,First Line,6/13/2023,Inactive,,
CMC OP INFUSION,39229,"Taff, Jessica, MD",3/18/2024,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,Adjuvant,3/17/2024,Active,,
CINJ OP INFUSION,63253,"Berim, Lyudmyla, MD",3/10/2025,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/10/2025,Active,Malignant neoplasm of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; C16.3 - Malignant neoplasm of pyloric antrum"
MMC OP VP INFUSION,91436,"Talwar, Sumit, MD",5/19/2023,Nivolumab 28 Day Cycles - Melanoma,,5/5/2023,Inactive,,
CINJ OP INFUSION,36897,"Stephenson, Ruth D, DO",12/27/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,_1. First Line,12/26/2024,Active,,
CINJ OP INFUSION,80692,"Stephenson, Ruth D, DO",1/24/2025,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/22/2025,Active,,
CINJ OP INFUSION,80692,"Stephenson, Ruth D, DO",1/24/2025,PACLitaxel Weekly / CARBOplatin 21 Day Cycles,_1. First Line,1/23/2025,Inactive,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,80692,"Stephenson, Ruth D, DO",5/23/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/23/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; I82.401 - Acute embolism and thrombosis of unspecified deep veins of right lower extremity; I26.99 - Other pulmonary embolism without acute cor pulmonale; Z51.11 - Encounter for antineoplastic chemotherapy
CINJ OP INFUSION,80692,"Stephenson, Ruth D, DO",5/2/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/2/2025,Inactive,Endometrial cancer (CMS/HCC),"C54.1 - Malignant neoplasm of endometrium; N13.9 - Obstructive and reflux uropathy, unspecified; N89.8 - Other specified noninflammatory disorders of vagina; I61.8 - Other nontraumatic intracerebral hemorrhage; E78.5 - Hyperlipidemia, unspecified; R33.9 - Retention of urine, unspecified; Z51.11 - Encounter for antineoplastic chemotherapy; Z51.12 - Encounter for antineoplastic immunotherapy"
NBR CINJ OP INFUSION,23771,"Matasar, Matthew J, MD",5/2/2023,CINJ 012207 Arm I Dose Level 1 Tazemetostat + Rituximab + Bendamustine 28 Day Cycle Research - Follicular Lymphoma,First Line,4/3/2023,Active,,
CINJ OP INFUSION,7127,"Dasgeb, Bahar, MD",5/6/2025,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,5/6/2025,Active,Pemphigus,
CBMC OP INFUSION 2FL,57945,"Derosa, William T, DO",12/6/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,12/5/2024,Active,,
MMC OP VP INFUSION,65636,"Talwar, Sumit, MD",4/22/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/22/2025,Active,Esophageal cancer (CMS/HCC),
JCMC CP INFUSION,2713,"Sekhri, Arunabh, MD",12/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,11/25/2024,Active,,
JCMC CP INFUSION,2713,"Sekhri, Arunabh, MD",2/26/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,1/24/2025,Active,Malignant neoplasm of upper lobe of left lung (CMS/HCC),"C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; R19.7 - Diarrhea, unspecified; R11.2 - Nausea with vomiting, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
JCMC CP INFUSION,2713,"Sekhri, Arunabh, MD",3/13/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,3/13/2025,Active,Malignant neoplasm of upper lobe of left lung (CMS/HCC),"C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; R19.7 - Diarrhea, unspecified; R11.2 - Nausea with vomiting, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter"
NBR CINJ OP INFUSION,82299,"Evens, Andrew M, DO",3/22/2023,CINJ 011813 (EA4151) ARM A RiTUXimab Maintenance 56 Day Cycles Research- Mantle Cell Lymphoma,,3/21/2023,Active,,
MMC OP VP INFUSION,2008,"Cohen, Seth D, MD",1/21/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,1/8/2025,Active,,
CBMC OP INFUSION 2FL,87834,"Grossman, I Robert, MD",6/20/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,6/4/2024,Active,,
NBR CINJ OP INFUSION,3652,"Evens, Andrew M, DO",7/3/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,6/25/2024,Inactive,,
NBR CINJ OP INFUSION,3652,"Evens, Andrew M, DO",7/10/2024,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,7/8/2024,Inactive,,
NBI OP INFUSION,60216,"Cheng, Yan Ho, MD",12/12/2023,Capecitabine 825 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/12/2023,Active,,
CINJ OP INFUSION,11287,"Groisberg, Roman, MD",8/11/2023,Pembrolizumab 42 Day Cycles - Melanoma,First Line,8/10/2023,Inactive,,
NBR 5N ONCOLOGY,86955,"Palmisiano, Neil David, MD",1/22/2023,Cytarabine for count reduction flat dose  - Acute Myeloid Leukemia,First Line,1/22/2023,Inactive,,
NBR 5N ONCOLOGY,86955,"Palmisiano, Neil David, MD",1/23/2023,Cytarabine / IDArubicin / Midostaurin (7 + 3) - Acute Myeloid Leukemia FLT3+ (Induction),Induction,1/23/2023,Inactive,,
NBR CINJ OP INFUSION,86955,"Palmisiano, Neil David, MD",3/28/2023,Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,3/28/2023,Inactive,,
NBR 4N BMTU/IMCU,86955,"Assal, Amer, MD",8/17/2023,BMT Allogeneic TBF + Post Cy ,,8/16/2023,Inactive,,
NBR 4N BMTU/IMCU,86955,"Schaar, Dale, MD PhD",8/18/2023,BMT Allogeneic TBF + Post Cy ,,8/11/2023,Inactive,,
MMC OP VP INFUSION,89079,"Cohen, Seth D, MD",3/20/2023,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,First Line,3/19/2023,Inactive,,
MMC OP VP INFUSION,89079,"Cohen, Seth D, MD",9/18/2023,Daratumumab and Hyaluronidase-fihj Monthly / Bortezomib Bi-Weekly 28 Day Cycles- Multiple Myeloma,Maintenance,9/8/2023,Active,,
NBR 4N ONCOLOGY,3935,"Palmisiano, Neil David, MD",11/18/2023,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,11/18/2023,Inactive,,
NBR CINJ OP INFUSION,3935,"Palmisiano, Neil David, MD",3/11/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,Consolidation,3/10/2024,Inactive,,
NBR CINJ OP INFUSION,3935,"Palmisiano, Neil David, MD",4/22/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,4/22/2024,Inactive,,
NBR CINJ OP INFUSION,3935,"Palmisiano, Neil David, MD",7/9/2024,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,Consolidation,7/8/2024,Inactive,,
NBR CINJ OP INFUSION,3935,"Palmisiano, Neil David, MD",10/22/2024,GRAALL Maintenance - Acute Lymphocytic Leukemia,Maintenance,9/30/2024,Inactive,,
CINJ OP INFUSION,19262,"Ghodoussipour, Saum Bobak, MD",8/18/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,8/17/2023,Inactive,,
CINJ OP INFUSION,19262,"Ghodoussipour, Saum Bobak, MD",1/5/2024,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Ureter Catheter,Maintenance,1/4/2024,Inactive,,
CBMC OP INFUSION 2FL,12815,"Wagmiller, Jennifer Ann, MD",5/5/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/4/2023,Inactive,,
HAM OP INFUSION,88614,"Patel, Malini M, MD",10/24/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Adjuvant,10/18/2023,Inactive,,
SOM OUTPT INFUSION,57115,"Yin, Faye, MD",11/29/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,20918,"Brown, Andrew Bennett, MD",1/29/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,1/29/2025,Active,,
CINJ OP INFUSION,6586,"Hochster, Howard S, MD",4/8/2025,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/8/2025,Active,"Malignant carcinoid tumor of the cecum (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures","C7A.021 - Malignant carcinoid tumor of the cecum; I48.91 - Unspecified atrial fibrillation; M14.671 - Charcot's joint, right ankle and foot; D50.9 - Iron deficiency anemia, unspecified; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; Z90.49 - Acquired absence of other specified parts of digestive tract"
CBMC OP INFUSION 2FL,5060,"Kulkarni, Aditya A, MD",3/5/2025,Everolimus 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,3/5/2025,Inactive,"Tuberous sclerosis (CMS/HCC)
Bilateral renal masses",
CINJ OP INFUSION,61537,"Stephenson, Ruth D, DO",9/27/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,9/25/2023,Active,,
NBR 4N ONCOLOGY,69401,"Hinrichs, Christian, MD",7/14/2023,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,Second Line,7/13/2023,Inactive,,
CINJ OP INFUSION,69401,"Haigentz, Missak, MD",2/16/2024,Pembrolizumab/CARBOplatin/Fluorouracil ---> Maintenance Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,2/16/2024,Inactive,,
CINJ OP INFUSION,69401,"Haigentz, Missak, MD",9/23/2024,Cetuximab / PACLitaxel 28 Day Cycles - Head and Neck Cancers,_3. Third Line,9/22/2024,Inactive,,
CMC OP INFUSION,57637,"Talwar, Sumit, MD",7/17/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/9/2024,Active,,
CMC OP INFUSION,28407,"Cohen, Seth D, MD",1/4/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,1/4/2024,Inactive,,
MMC OP INFUSION,87543,"Lee, Patrick C, MD",11/19/2024,RiTUXimab Initial Infusion Single Day (Outpatient),Lymphodepletion,11/19/2024,Active,"Malignant tumor of fallopian tube, right (CMS/HCC)
Malignant neoplasm of overlapping sites of right breast, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,29954,"Goel, Sanjay, MD",9/19/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,9/18/2024,Inactive,,
CMC OP INFUSION,71520,"Taff, Jessica, MD",10/16/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,First Line,10/1/2023,Inactive,,
NBR 4N ONCOLOGY,56676,"Braunschweig, Ira, MD",11/3/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,10/31/2023,Inactive,,
CINJ OP INFUSION,8654,"Saraiya, Biren P, MD",5/23/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,Maintenance,5/23/2024,Active,,
CINJ OP INFUSION,17974,"Mayer, Tina M, MD",10/2/2023,CINJ 081603 ARM 2 Apalutamide / Abiraterone / Prednisone / GnRH Agonist 90 Day Cycle Research- Prostate Cancer,,9/20/2023,Active,,
CINJ OP INFUSION,25028,"Boland, Patrick M, MD",4/25/2023,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,,4/25/2023,Inactive,,
CINJ OP INFUSION,25028,"Boland, Patrick M, MD",2/23/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,2/22/2024,Inactive,,
JCMC CP INFUSION,37003,"Cruz, Allan Louie E, MD",6/19/2024,CISplatin with Concurrent Radiation 49 Day Cycle- bilateral base of tongue and supraglottic carcinoma,_1. First Line,6/2/2024,Inactive,,
JCMC CP INFUSION,37003,"Cruz, Allan Louie E, MD",12/31/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/30/2024,Active,,
JCMC CP INFUSION,37003,"Cruz, Allan Louie E, MD",2/27/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/31/2024,Active,Malignant neoplasm of base of tongue (CMS/HCC),C01 - Malignant neoplasm of base of tongue
CMC OP INFUSION,62842,"Taff, Jessica, MD",11/27/2023,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,Neoadjuvant,11/17/2023,Inactive,,
CMC OP INFUSION,62842,"Taff, Jessica, MD",3/8/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Non-Small Cell Lung Cancer",Neoadjuvant,2/26/2024,Inactive,,
MMC OP VP INFUSION,38861,"Eltoukhy, Hussam, MD",11/11/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,11/7/2024,Inactive,,
MMC OP VP INFUSION,38861,"Eltoukhy, Hussam, MD",2/20/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,2/16/2025,Active,"Lymphoma (CMS/HCC)
Encounter for screening for other viral diseases","C82.98 - Follicular lymphoma, unspecified, lymph nodes of multiple sites; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E11.9 - Type 2 diabetes mellitus without complications; K21.9 - Gastro-esophageal reflux disease without esophagitis; K58.9 - Irritable bowel syndrome, unspecified; M35.00 - Sjogren syndrome, unspecified; M85.80 - Other specified disorders of bone density and structure, unspecified site; Z79.624 - Long term (current) use of inhibitors of nucleotide synthesis; Z79.02 - Long term (current) use of antithrombotics/antiplatelets; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,49955,"Lee, Patrick C, MD",2/15/2024,Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 480 mg D1 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/14/2024,Inactive,,
MSC OP INFUSION,67174,"Eltoukhy, Hussam, MD",2/4/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/28/2025,Active,"Lymphoma (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,88920,"Weiss, Sarah, MD",4/30/2025,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,4/21/2025,Active,Melanoma metastatic to lymph node (CMS/HCC),"C43.9 - Malignant melanoma of skin, unspecified; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; R91.1 - Solitary pulmonary nodule"
CBMC OP INFUSION 2FL,64864,"Leitner, Stuart P, MD",12/13/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/12/2023,Inactive,,
CBMC OP INFUSION 2FL,64864,"Leitner, Stuart P, MD",10/7/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/6/2024,Active,,
CINJ OP INFUSION,92858,"Boland, Patrick M, MD",5/3/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,4/24/2024,Inactive,,
CINJ OP INFUSION,13860,"Saraiya, Biren P, MD",6/12/2023,CINJ 082105 (R4336-ONC-20104) Module 1 Weekly REGN4336 DL3-INT1 Dose Escalation 63 Day Cycles Research- Prostate Cancer,Third Line,6/9/2023,Inactive,,
CINJ OP INFUSION,13860,"Saraiya, Biren P, MD",2/5/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_6. Sixth Line,2/4/2024,Inactive,,
MSC OP INFUSION,61451,"Cohen, Seth D, MD",10/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,10/21/2024,Active,,
CMC OP INFUSION,69403,"Cohen, Seth D, MD",4/14/2025,Nivolumab/Ipilimumab + PEMEtrexed/CISplatin 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/14/2025,Inactive,Primary non-small cell carcinoma of lower lobe of right lung (CMS/HCC),
CMC OP INFUSION,69403,"Cohen, Seth D, MD",4/14/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/11/2025,Active,Primary non-small cell carcinoma of lower lobe of right lung (CMS/HCC),
TRMC TCCC OP INFUSION,74308,"Salerno, Vincent E, MD",6/17/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,6/16/2024,Active,,
TRMC TCCC OP INFUSION,74308,"Capo, Gerardo, MD",8/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/4/2024,Inactive,,
CINJ OP INFUSION,15834,"Haigentz, Missak, MD",12/22/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/22/2023,Active,,
CINJ OP INFUSION,15834,"Haigentz, Missak, MD",1/12/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,1/1/2024,Inactive,,
CINJ OP INFUSION,94991,"Goel, Sanjay, MD",4/29/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 10W Schedule A Escalation Weekly REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research,_5. Fifth Line,4/9/2024,Inactive,,
CBMC OP INFUSION 2FL,66192,"Brown, Andrew Bennett, MD",4/21/2025,Bevacizumab 21 Day Cycles - CNS,_1. First Line,4/21/2025,Active,GBM (glioblastoma multiforme) (CMS/HCC),
NBR 4N ONCOLOGY,77102,"Berim, Lyudmyla, MD",2/28/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/27/2023,Inactive,,
CINJ OP INFUSION,18937,"Boland, Patrick M, MD",11/4/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,10/27/2024,Active,,
TRMC TCCC OP INFUSION,53121,"Capo, Gerardo, MD",5/16/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/15/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,71435,"Toomey, Kathleen C, MD",5/26/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/23/2023,Inactive,,
MMC OP VP INFUSION,938,"Meghal, Trishala, MD",1/9/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/9/2023,Inactive,,
MMC OP VP INFUSION,938,"Meghal, Trishala, MD",3/26/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/24/2024,Active,,
CBMC OP INFUSION 2FL,91931,"Dharmapuri, Sirish, MD",2/21/2025,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/21/2025,Active,Colorectal cancer (CMS/HCC),
CBMC OP INFUSION 2FL,91931,"Dharmapuri, Sirish, MD",3/19/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/19/2025,Active,Rectal adenocarcinoma metastatic to liver (CMS/HCC),C20 - Malignant neoplasm of rectum; C19 - Malignant neoplasm of rectosigmoid junction; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
TRMC TCCC OP INFUSION,35945,"Salerno, Vincent E, MD",8/27/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/26/2024,Active,Endometrial cancer (CMS/HCC),
TRMC TCCC OP INFUSION,84092,"Salerno, Vincent E, MD",5/20/2025,Pola-R-GemOx (Polatuzumab Vedotin / RiTUXimab / Gemcitabine / OXALIplatin) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,5/20/2025,Active,Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC),
CINJ OP INFUSION,64245,"Stephenson, Ryan D, DO",3/31/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Adjuvant,3/30/2023,Inactive,,
CINJ OP INFUSION,64245,"Stephenson, Ryan D, DO",12/29/2023,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/28/2023,Inactive,,
CINJ OP INFUSION,64245,"Stephenson, Ryan D, DO",7/25/2024,Erdafitinib 28 Day Cycles - Bladder,_2. Second Line,7/25/2024,Inactive,,
CINJ OP INFUSION,64245,"Stephenson, Ryan D, DO",12/6/2024,Sacituzumab Govitecan 21 Day Cycles - Bladder,_3. Third Line,11/24/2024,Inactive,,
CINJ OP INFUSION,64245,"Stephenson, Ryan D, DO",12/18/2024,"CINJ 102302 ARM 2 PHASE 2 ACR-368 + ULDG DOSE LEVEL 1 - OVARIAN, ENDOMETRIAL, UROTHELIAL CANCER",_5. Fifth Line,12/18/2024,Active,,
CINJ OP INFUSION,64245,"Stephenson, Ryan D, DO",12/18/2024,"CINJ 102302 ARM 2 PHASE 1B ACR-368 + ULDG DOSE LEVEL 1 - OVARIAN, ENDOMETRIAL, UROTHELIAL CANCER",_5. Fifth Line,12/18/2024,Inactive,,
NBR CINJ OP INFUSION,35171,"Shah, Mansi R, MD",4/20/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,,4/19/2023,Active,,
CINJ OP INFUSION,2657,"Leiser, Aliza, MD",7/11/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Second Line,7/10/2023,Inactive,,
CINJ OP INFUSION,95686,"Ghodoussipour, Saum Bobak, MD",5/14/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,5/6/2024,Inactive,,
CINJ OP INFUSION,95686,"Ghodoussipour, Saum Bobak, MD",10/16/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,10/15/2024,Inactive,,
CINJ OP INFUSION,95686,"Ghodoussipour, Saum Bobak, MD",1/23/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,1/21/2025,Active,,
CINJ OP INFUSION,91589,"Berim, Lyudmyla, MD",7/7/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,7/5/2023,Inactive,,
CINJ OP INFUSION,91589,"Berim, Lyudmyla, MD",8/14/2023,Capecitabine675 mg/m2 D1-D5 with Concurrent Radiation Weekly -Gastric Cancer,,8/14/2023,Inactive,,
CINJ OP INFUSION,91589,"Berim, Lyudmyla, MD",8/21/2023,Fluorouracil with Concurrent Radiation - Gastric Cancer,,8/20/2023,Inactive,,
CINJ OP INFUSION,64012,"Berim, Lyudmyla, MD",5/22/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,5/22/2025,Active,"Malignant neoplasm of stomach, unspecified location (CMS/HCC)",
CINJ PEDS HEMONC ,87893,"Drachtman, Richard, MD",5/1/2023,DFCI 16-001 Continuation,Maintenance,4/27/2023,Active,,
NBI OP INFUSION,55672,"Shah, Shailja S, MD",1/7/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,1/6/2025,Active,,
CINJ OP INFUSION,9346,"Berim, Lyudmyla, MD",5/12/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,5/11/2023,Inactive,,
CINJ OP INFUSION,9346,"Berim, Lyudmyla, MD",12/13/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/10/2023,Inactive,,
CINJ OP INFUSION,75896,"Stephenson, Ruth D, DO",1/10/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,1/9/2024,Active,,
CINJ OP INFUSION,94084,"Stephenson, Ruth D, DO",5/14/2025,Pembrolizumab + Bevacizumab 21 Day Cycles - Uterine,_1. First Line,5/14/2025,Active,"Malignant neoplasm of overlapping sites of vulva (CMS/HCC)
Other problems related to lifestyle
Secondary malignant neoplasm of other specified sites (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C51.8 - Malignant neoplasm of overlapping sites of vulva; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; T82.9XXA - Unspecified complication of cardiac and vascular prosthetic device, implant and graft, initial encounter; C51.9 - Malignant neoplasm of vulva, unspecified; M19.90 - Unspecified osteoarthritis, unspecified site; J45.909 - Unspecified asthma, uncomplicated; E78.5 - Hyperlipidemia, unspecified; I10 - Essential (primary) hypertension; E83.42 - Hypomagnesemia; Z29.89 - Encounter for other specified prophylactic measures; Z51.12 - Encounter for antineoplastic immunotherapy; Z11.59 - Encounter for screening for other viral diseases; Z72.89 - Other problems related to lifestyle; Z91.89 - Other specified personal risk factors, not elsewhere classified; Z92.3 - Personal history of irradiation; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm; F17.200 - Nicotine dependence, unspecified, uncomplicated; C79.89 - Secondary malignant neoplasm of other specified sites"
CBMC OP INFUSION 2FL,96806,"Leitner, Stuart P, MD",4/21/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,4/21/2023,Active,,
CBMC OP INFUSION 2FL,96806,"Leitner, Stuart P, MD",7/17/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,7/17/2023,Inactive,,
HAM OP INFUSION,88624,"Patel, Malini M, MD",10/3/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,10/1/2023,Inactive,,
NBR CINJ OP INFUSION,79791,"Shah, Mansi R, MD",2/27/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/26/2024,Active,,
SOM OUTPT INFUSION,6596,"Yin, Faye, MD",7/13/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,First Line,6/9/2023,Inactive,,
SOM OUTPT INFUSION,6596,"Yin, Faye, MD",5/7/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/6/2024,Inactive,,
SOM OUTPT INFUSION,6596,"Yin, Faye, MD",6/3/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/31/2024,Inactive,,
SOM OUTPT INFUSION,6596,"Yin, Faye, MD",6/3/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/27/2024,Inactive,,
SOM OUTPT INFUSION,6596,"Toomey, Kathleen C, MD",10/25/2024,DOCEtaxel 21 Day Cycles- Esophageal/Esophagogastric Junction Cancers,_4. Fourth Line,10/24/2024,Inactive,,
HAM OP INFUSION,6943,"Patel, Malini M, MD",5/24/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Second Line,5/23/2023,Inactive,,
HAM OP INFUSION,6943,"Patel, Malini M, MD",8/30/2023,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",Third Line,8/29/2023,Active,,
MMC OP VP INFUSION,1709,"Cohen, Seth D, MD",10/1/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,9/26/2024,Inactive,,
MSC OP INFUSION,1709,"Cohen, Seth D, MD",12/17/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/16/2024,Active,,
CINJ OP INFUSION,45612,"Toomey, Kathleen C, MD",4/27/2023,PACLitaxel / CARBOplatin (AUC 2) 7 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,4/25/2023,Inactive,,
CINJ OP INFUSION,45612,"Stephenson, Ruth D, DO",7/24/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,7/24/2023,Inactive,,
SOM OUTPT INFUSION,45612,"Toomey, Kathleen C, MD",8/24/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,8/23/2023,Inactive,,
SOM OUTPT INFUSION,45612,"Toomey, Kathleen C, MD",10/5/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,9/27/2023,Inactive,,
SOM OUTPT INFUSION,45612,"Toomey, Kathleen C, MD",6/28/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,6/27/2024,Active,,
SOM OUTPT INFUSION,54833,"Toomey, Kathleen C, MD",5/15/2025,Desensitization CARBOplatin 7 Day Cycles- Ovarian Cancer,Maintenance,5/15/2025,Active,"Malignant neoplasm of ovary (CMS/HCC)
Encounter for screening for other viral diseases
Ovarian cancer (CMS/HCC)",
CINJ OP INFUSION,97196,"Boland, Patrick M, MD",6/10/2024,Imatinib 30 Day Cycles - Sarcoma,_1. First Line,6/10/2024,Active,,
NBI OP INFUSION,19450,"Shah, Maya M, MD",7/26/2023,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,6/27/2023,Inactive,,
NBI OP INFUSION,19450,"Shah, Maya M, MD",10/30/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/29/2024,Active,,
NBI OP INFUSION,94880,"Shah, Shailja S, MD",5/17/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_2. Second Line,5/16/2024,Active,,
CBMC OP INFUSION 2FL,84828,"Scoppetuolo, Michael, MD",9/21/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/21/2023,Active,Colon cancer metastasized to liver (CMS/HCC),
NBI OP INFUSION,40061,"Schleicher, Lori, MD",8/11/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,8/10/2023,Inactive,,
CBMC OP INFUSION 2FL,87173,"Litvak, Anna M, MD",4/7/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,4/7/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,87173,"Litvak, Anna M, MD",4/3/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,4/3/2025,Inactive,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,87173,"Litvak, Anna M, MD",4/1/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,4/1/2025,Inactive,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,94302,"Aikins, James K, MD",1/31/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/15/2025,Active,,
NBI VALERIE FND HEMONC,38926,"Batra, Surabhi, MD",3/5/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,3/5/2025,Active,Chronic idiopathic thrombocytopenic purpura (CMS/HCC),
NBR CINJ OP INFUSION,37638,"Evens, Andrew M, DO",5/17/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,5/16/2023,Inactive,,
NBR CINJ OP INFUSION,37638,"Evens, Andrew M, DO",9/20/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,9/19/2023,Inactive,,
NBR CINJ OP INFUSION,37638,"Braunschweig, Ira, MD",10/2/2023,CINJ 012208 Lymphodepletion UCART20x22 T-Cells 84 Day Cycle Research- B-Cell Non-Hodgkin's Lymphoma,,10/2/2023,Inactive,,
NBR 4N ONCOLOGY,37638,"Palmisiano, Neil David, MD",11/27/2023,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,_8. Eighth Line,11/27/2023,Inactive,,
NBR 4N BMTU/IMCU,54271,"Palmisiano, Neil David, MD",4/28/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,4/28/2025,Active,Acute myeloid leukemia (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; D61.810 - Antineoplastic chemotherapy induced pancytopenia; B48.8 - Other specified mycoses; D46.C - Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality; D63.1 - Anemia in chronic kidney disease; J01.90 - Acute sinusitis, unspecified; D84.9 - Immunodeficiency, unspecified; F11.20 - Opioid dependence, uncomplicated; E11.9 - Type 2 diabetes mellitus without complications; F31.9 - Bipolar disorder, unspecified; E66.01 - Morbid (severe) obesity due to excess calories; I10 - Essential (primary) hypertension; K92.1 - Melena; Z96.652 - Presence of left artificial knee joint; K21.9 - Gastro-esophageal reflux disease without esophagitis; G47.33 - Obstructive sleep apnea (adult) (pediatric); G47.00 - Insomnia, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K58.9 - Irritable bowel syndrome, unspecified; K64.9 - Unspecified hemorrhoids; F90.9 - Attention-deficit hyperactivity disorder, unspecified type; F41.9 - Anxiety disorder, unspecified; E78.5 - Hyperlipidemia, unspecified; Z87.442 - Personal history of urinary calculi; Z86.711 - Personal history of pulmonary embolism; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.89 - Acquired absence of other organs; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; Z83.3 - Family history of diabetes mellitus; Z82.49 - Family history of ischemic heart disease and other diseases of the circul..."
SOM OUTPT INFUSION,96845,"Patel, Eshan, MD",11/27/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,11/26/2023,Active,,
NBR CINJ OP INFUSION,29394,"Evens, Andrew M, DO",6/21/2023,Pembrolizumab/GVD 21 Day Cycles - Hodgkin Lymphoma,,6/21/2023,Inactive,,
NBR 4N ONCOLOGY,29394,"Schaar, Dale, MD PhD",8/16/2023,BMT Autologous BEAM,,8/15/2023,Inactive,,
NBR CINJ OP INFUSION,29394,"Evens, Andrew M, DO",11/15/2023,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,11/14/2023,Inactive,,
CMC OP INFUSION,77942,"Taff, Jessica, MD",10/6/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,First Line,10/3/2023,Active,,
MMC OP VP INFUSION,66725,"Talwar, Sumit, MD",10/24/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/23/2023,Inactive,,
MMC OP VP INFUSION,66725,"Talwar, Sumit, MD",2/27/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/26/2024,Inactive,,
MMC OP VP INFUSION,66725,"Talwar, Sumit, MD",8/27/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/26/2024,Active,,
CBMC OP INFUSION 2FL,4503,"Ligresti, Louise G, MD",8/5/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,8/5/2024,Active,,
NBR 5N ONCOLOGY,94008,"Zayac, Adam, MD",5/2/2024,HyperCVD Mini + Venetoclax (High-Dose Methotrexate / Cytarabine / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,5/2/2024,Inactive,,
NBR CINJ OP INFUSION,94008,"Zayac, Adam, MD",11/18/2024,Blinatumomab Consolidation (R/R ALL),_2. Second Line,11/18/2024,Inactive,,
MSC OP INFUSION,94008,"Zayac, Adam, MD",12/2/2024,HyperCVD Mini ( High-Dose Methotrexate / Cytarabine / / Cyclophosphamide / VinCRIStine / DexAMETHasone) + Venetoclax 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,12/2/2024,Inactive,,
NBR CINJ OP INFUSION,94008,"Zayac, Adam, MD",1/13/2025,Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia Consolidation with reaction at faster ramp-up,_2. Second Line,1/13/2025,Active,,
NBR CINJ OP INFUSION,94008,"Zayac, Adam, MD",4/14/2025,CALGB 9111 (Maintenance Therapy) 28 Day Cycles + Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,4/14/2025,Inactive,ALL (acute lymphoid leukemia) in relapse (CMS/HCC),
CINJ OP INFUSION,78325,"Berim, Lyudmyla, MD",2/5/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/4/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),C18.2 - Malignant neoplasm of ascending colon; C7A.8 - Other malignant neuroendocrine tumors
CINJ OP INFUSION,81289,"Berim, Lyudmyla, MD",3/10/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/10/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),"C18.2 - Malignant neoplasm of ascending colon; E83.39 - Other disorders of phosphorus metabolism; K59.00 - Constipation, unspecified"
CINJ OP INFUSION,81289,"Berim, Lyudmyla, MD",3/7/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,3/7/2025,Inactive,Malignant neoplasm of ascending colon (CMS/HCC),"C18.2 - Malignant neoplasm of ascending colon; E83.39 - Other disorders of phosphorus metabolism; K59.00 - Constipation, unspecified"
CINJ OP INFUSION,42984,"Aikins, James K, MD",3/16/2023,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,3/15/2023,Inactive,,
CINJ OP INFUSION,31531,"Aikins, James K, MD",3/17/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,3/15/2023,Inactive,,
CINJ OP INFUSION,31531,"Aikins, James K, MD",7/12/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,7/4/2024,Active,,
CINJ OP INFUSION,88910,"Aikins, James K, MD",2/27/2025,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/26/2025,Inactive,"Ascites, malignant
Ovarian cancer (CMS/HCC)
Malignant neoplasm of ovary (CMS/HCC)","C56.9 - Malignant neoplasm of ovary, unspecified laterality (CMS/HCC)"
CINJ OP INFUSION,88910,"Aikins, James K, MD",3/21/2025,Liposomal DOXOrubicin / CISPLATIN 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/18/2025,Active,"Ascites, malignant
Ovarian cancer (CMS/HCC)
Malignant neoplasm of ovary (CMS/HCC)",C56.9 - Malignant neoplasm of unspecified ovary; I10 - Essential (primary) hypertension; Z51.12 - Encounter for antineoplastic immunotherapy; R18.0 - Malignant ascites
CBMC OP INFUSION 2FL,85137,"Litvak, Anna M, MD",11/13/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/12/2023,Active,,
CINJ OP INFUSION,64150,"George, Mridula A, MD",11/8/2023,CINJ 042303 Part 1 Dose Escalation RLY-5836 / Fulvestrant 28 Day Cycles Research- Breast Cancer,_3. Third Line,11/8/2023,Inactive,,
CINJ OP INFUSION,64150,"George, Mridula A, MD",1/26/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_4. Fourth Line,1/22/2024,Active,,
CINJ OP INFUSION,64150,"George, Mridula A, MD",2/3/2025,CINJ 042402 Part 1 RLY-2608 / PF-07220060 / Fulvestrant 28 Day Cycles- Breast Cancer,_5. Fifth Line,2/3/2025,Active,"Primary malignant neoplasm of breast with metastasis (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)",
CBMC OP INFUSION 2FL,30615,"Litvak, Anna M, MD",10/31/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,10/30/2023,Inactive,,
CBMC OP INFUSION 2FL,30615,"Ligresti, Louise G, MD",7/11/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_3. Third Line,7/10/2024,Inactive,,
CBMC OP INFUSION 2FL,30615,"Ligresti, Louise G, MD",10/23/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_5. Fifth Line,10/9/2024,Active,,
CBMC 2W ONCOLOGY,88793,"Litvak, Anna M, MD",4/30/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_4. Fourth Line,4/28/2025,Inactive,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of central portion of female breast (CMS/HCC)","A41.9 - Sepsis, unspecified organism; J18.9 - Pneumonia, unspecified organism; Z66 - Do not resuscitate; J96.01 - Acute respiratory failure with hypoxia; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C79.51 - Secondary malignant neoplasm of bone; K72.90 - Hepatic failure, unspecified without coma; E44.0 - Moderate protein-calorie malnutrition; D63.0 - Anemia in neoplastic disease; E03.9 - Hypothyroidism, unspecified; R18.8 - Other ascites; N39.0 - Urinary tract infection, site not specified; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z79.890 - Hormone replacement therapy; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z82.3 - Family history of stroke; Z88.0 - Allergy status to penicillin; Z88.1 - Allergy status to other antibiotic agents; Z91.018 - Allergy to other foods; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.710 - Acquired absence of both cervix and uterus; Z92.3 - Personal history of irradiation; G47.9 - Sleep disorder, unspecified; Z86.711 - Personal history of pulmonary embolism; Z87.01 - Personal history of pneumonia (recurrent); Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons; F41.0 - Panic disorder (episodic paroxysmal anxiety); Z85.3 - Personal history of malignant neoplasm of breast; Z68.27 - Body mass index (BMI) 27.0-27.9, adult; Z17.21 - Progesterone receptor positive status; Z17.0 - Estrogen receptor ..."
CBMC OP INFUSION 2FL,88793,"Litvak, Anna M, MD",4/17/2025,Datopotamab deruxtecan-dlnk 21 Day Cycles- Breast Cancer,_1. First Line,4/17/2025,Inactive,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of central portion of female breast (CMS/HCC)",
CINJ OP INFUSION,55635,"Groisberg, Roman, MD",1/27/2025,DOXOrubicin 21 Day Cycles - Sarcoma,_1. First Line,1/23/2025,Active,,
CINJ OP INFUSION,66687,"Groisberg, Roman, MD",3/28/2025,Pembrolizumab 21 Day Cycles - Melanoma,_2. Second Line,3/28/2025,Inactive,Dedifferentiated liposarcoma (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified"
NBR 5N ONCOLOGY,34185,"Groisberg, Roman, MD",1/13/2023,DOXOrubicin 21 Day Cycles - Sarcoma,,1/12/2023,Inactive,,
CINJ OP INFUSION,34185,"Groisberg, Roman, MD",2/24/2023,Pembrolizumab 42 Day Cycles - Melanoma,Third Line,2/23/2023,Inactive,,
CMC OP INFUSION,62710,"Talwar, Sumit, MD",1/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/15/2024,Inactive,,
CMC OP INFUSION,62710,"Talwar, Sumit, MD",1/31/2024,PCbTP (Paclitaxel / Carboplatin / Trastuzumab / Pertuzumab) 21 Day Cycle - HER2 Breast Cancer,Neoadjuvant,1/31/2024,Inactive,,
CMC OP INFUSION,62710,"Talwar, Sumit, MD",2/5/2024,Albumin-Bound PACLitaxel/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/4/2024,Inactive,,
CMC OP INFUSION,62710,"Talwar, Sumit, MD",2/19/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,2/15/2024,Inactive,,
CMC OP INFUSION,62710,"Talwar, Sumit, MD",7/31/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,7/30/2024,Active,,
MMC OP VP INFUSION,41987,"Meghal, Trishala, MD",3/20/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,3/14/2024,Inactive,,
MMC OP VP INFUSION,41987,"Meghal, Trishala, MD",6/21/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,6/20/2024,Inactive,,
MMC OP INFUSION,41987,"Meghal, Trishala, MD",12/13/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,12/13/2024,Active,,
CINJ OP INFUSION,2270,"George, Mridula A, MD",9/15/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/12/2023,Active,,
NBR CINJ OP INFUSION,34255,"Rhodes, Joanna Meehan, MD",10/17/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,10/16/2024,Active,Malignant neoplasm of left ovary (CMS/HCC),
NBR MEDICAL SAME DAY,4985,"Golombos, David, MD",1/30/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,1/30/2025,Active,,
CINJ OP INFUSION,24591,"Golombos, David, MD",2/24/2025,Gemcitabine Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,2/23/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
SOM OUTPT INFUSION,60379,"Patel, Eshan, MD",6/4/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,6/3/2024,Inactive,,
SOM OUTPT INFUSION,60379,"Patel, Eshan, MD",8/20/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,8/19/2024,Active,Autoimmune hemolytic anemia (CMS/HCC),
CINJ OP INFUSION,21291,"Jang, Thomas L, MD",2/24/2023,MitoMYcin Intravesical Weekly 42 Day Cycle - Bladder,Induction,2/23/2023,Inactive,,
CINJ OP INFUSION,21291,"Jang, Thomas L, MD",2/24/2023,Gemcitabine Intravesical Weekly 42 Day Cycle - Bladder,Induction,2/23/2023,Inactive,,
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",5/19/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Lenalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,5/19/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",5/12/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/12/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",5/12/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/6/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",5/12/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/6/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",5/6/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/6/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",4/21/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,4/21/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
NBI OP INFUSION,67029,"Cheng, Yan Ho, MD",3/26/2025,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,_1. First Line,3/26/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
JCMC CP INFUSION,25630,"Sekhri, Arunabh, MD",5/19/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,5/10/2023,Inactive,,
JCMC CP INFUSION,25630,"Sekhri, Arunabh, MD",3/7/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,2/28/2024,Inactive,,
JCMC CP INFUSION,25630,"Sekhri, Arunabh, MD",6/7/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/23/2024,Inactive,,
CINJ OP INFUSION,43486,"Ghodoussipour, Saum Bobak, MD",7/7/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/7/2023,Inactive,,
NBI OP INFUSION,85777,"Jacoby, Sari H, MD",2/26/2024,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,1/28/2024,Active,,
NBI OP INFUSION,85777,"Jacoby, Sari H, MD",3/13/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,3/12/2024,Inactive,,
NBI OP INFUSION,85777,"Jacoby, Sari H, MD",4/14/2025,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/14/2025,Active,Malignant neoplasm of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; C16.0 - Malignant neoplasm of cardia"
NBR 4N BMTU/IMCU,25641,"Schaar, Dale, MD PhD",3/1/2023,BMT Autologous Carmustine / Thiotepa,,3/1/2023,Inactive,,
CINJ OP INFUSION,5473,"Saraiya, Biren P, MD",1/11/2023,CINJ 082005 (011-03) Control ARM Cabozantinib 28 Day Cycles Research- Renal Cell Carcinoma,Second Line,1/1/2023,Inactive,,
CINJ OP INFUSION,5473,"Saraiya, Biren P, MD",5/8/2024,Lenvatinib + Everolimus for RCC,_3. Third Line,5/8/2024,Inactive,,
MSC OP INFUSION,84981,"Easaw, Sarah, MD",5/4/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/28/2023,Inactive,,
MSC OP INFUSION,84981,"Cohen, Seth D, MD",8/10/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,,8/3/2023,Inactive,,
CINJ OP INFUSION,55039,"Mayer, Tina M, MD",2/25/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,2/25/2025,Active,Prostate cancer (CMS/HCC),C61 - Prostate cancer (CMS/HCC)
NBR CINJ OP INFUSION,53527,"Tiger, Yun Kyoung, MD",1/22/2025,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,1/21/2025,Active,,
CINJ OP INFUSION,43475,"Patel, Eshan, MD",7/19/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,7/18/2024,Active,,
CINJ OP INFUSION,523,"Haigentz, Missak, MD",3/13/2023,CINJ 032111 (EA3161) ARMS A and B CISplatin with Concurrent Radiation 7 Day Cycles Research- Oropharyngeal Carcinoma,,3/11/2023,Active,,
CINJ OP INFUSION,97031,"Weiss, Sarah, MD",2/22/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/7/2023,Inactive,,
NBR 5N ONCOLOGY,61070,"Patel, Eshan, MD",2/17/2023,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,First Line,2/17/2023,Inactive,,
CINJ OP INFUSION,61070,"Patel, Eshan, MD",3/10/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,3/2/2023,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",10/24/2023,PEDS AALL15P1 Consolidation,_1. First Line,10/23/2023,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",1/12/2024,PEDS AALL15P1 Interim Maintenance,_1. First Line,1/5/2024,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",4/5/2024,PEDS AALL15P1 Delayed Intensification Part 1,_1. First Line,4/5/2024,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",4/23/2024,PEDS AALL1331 Blinatumomab,Adjuvant,4/22/2024,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",4/25/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",Adjuvant,4/23/2024,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",9/2/2024,PEDS AALL15P1 Delayed Intensification Part 2,_1. First Line,9/2/2024,Inactive,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",10/7/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,10/4/2024,Active,,
NBI VALERIE FND HEMONC,58404,"Rao, Harini, MD",11/15/2024,PEDS AALL15P1 Maintenance,_1. First Line,11/15/2024,Active,,
CINJ OP INFUSION,59382,"Stephenson, Ryan D, DO",3/30/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,3/28/2023,Inactive,,
CINJ OP INFUSION,59382,"Stephenson, Ryan D, DO",9/27/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,9/27/2023,Inactive,,
CMC OP INFUSION,43271,"Tang, Horace, MD",10/30/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/30/2023,Inactive,,
CMC OP INFUSION,43271,"Tang, Horace, MD",12/26/2023,Abraxane/CISplatin 80 mg/m2 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/26/2023,Inactive,,
CINJ OP INFUSION,8933,"Boland, Patrick M, MD",5/23/2023,CINJ 072205 Stage 1 (Run In Cycle) ALX148 (evorpacept) / Cetuximab / Pembrolizumab 21 Day Cycle Research- Colorectal Cancer,,4/24/2023,Inactive,,
CINJ OP INFUSION,8933,"Boland, Patrick M, MD",5/30/2023,CINJ 072205 ALX148 (evorpacept) / Cetuximab / Pembrolizumab 21 Day Cycles Research- Colorectal Cancer,,5/1/2023,Inactive,,
CINJ OP INFUSION,69150,"Toppmeyer, Deborah L, MD",4/11/2023,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,Third Line,4/7/2023,Inactive,,
CINJ OP INFUSION,990,"Stephenson, Ryan D, DO",12/16/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,12/15/2024,Active,,
SOM OUTPT INFUSION,70638,"George, Roshini, DO",2/26/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,2/25/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
SOM OUTPT INFUSION,70638,"George, Roshini, DO",3/5/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,2/26/2025,Active,Malignant neoplasm of female breast (CMS/HCC),
CINJ OP INFUSION,89466,"Haigentz, Missak, MD",8/14/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers (High TMB positive),_1. First Line,8/13/2024,Active,,
CBMC OP INFUSION 2FL,75426,"Grossman, I Robert, MD",12/18/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,12/17/2023,Active,,
NBR 4N ONCOLOGY,84094,"Zayac, Adam, MD",6/11/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,6/11/2024,Inactive,,
NBR CINJ OP INFUSION,84094,"Zayac, Adam, MD",10/2/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,9/19/2024,Inactive,,
NBR CINJ OP INFUSION,84094,"Zayac, Adam, MD",10/29/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,10/29/2024,Inactive,,
NBR CINJ OP INFUSION,84094,"Zayac, Adam, MD",11/14/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,11/14/2024,Active,,
NBR 4N BMTU/IMCU,84094,"Zayac, Adam, MD",11/18/2024,Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia (Consolidation 2 cycles in E1910 with slow ramp up due to reaction with fast ramp up),_1. First Line,11/18/2024,Active,,
NBR CINJ OP INFUSION,84094,"Zayac, Adam, MD",2/17/2025,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,2/17/2025,Active,Acute lymphoblastic leukemia not having achieved remission (CMS/HCC),C91.00 - Acute lymphoblastic leukemia not having achieved remission; L23.1 - Allergic contact dermatitis due to adhesives
JCMC CP INFUSION,25884,"Sekhri, Arunabh, MD",6/24/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/23/2024,Inactive,,
JCMC CP INFUSION,25884,"Sekhri, Arunabh, MD",7/2/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,6/27/2024,Inactive,,
CINJ OP INFUSION,38082,"Haigentz, Missak, MD",3/19/2024,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/19/2024,Inactive,,
CINJ OP INFUSION,16721,"Boland, Patrick M, MD",5/12/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,5/11/2023,Inactive,,
CINJ OP INFUSION,18013,"Saraiya, Biren P, MD",8/8/2023,Cabozantinib  - Kidney,Second Line,8/8/2023,Inactive,,
CBMC OP INFUSION 2FL,8477,"Grossman, I Robert, MD",5/30/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_2. Second Line,5/30/2025,Active,Idiopathic hypertrophic pachymeningitis,
CBMC 2W ONCOLOGY,8477,"Grossman, I Robert, MD",5/9/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,5/9/2025,Inactive,Peripheral polyneuropathy,"G03.8 - Meningitis due to other specified causes; A41.9 - Sepsis, unspecified organism; G93.41 - Metabolic encephalopathy; I67.83 - Posterior reversible encephalopathy syndrome; G93.6 - Cerebral edema; K71.9 - Toxic liver disease, unspecified; E87.20 - Acidosis, unspecified; G91.0 - Communicating hydrocephalus; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; Z68.1 - Body mass index (BMI) 19.9 or less, adult; G93.89 - Other specified disorders of brain; S09.90XA - Unspecified injury of head, initial encounter; Z74.09 - Other reduced mobility; Z53.8 - Procedure and treatment not carried out for other reasons; H54.3 - Unqualified visual loss, both eyes; G62.9 - Polyneuropathy, unspecified; R63.6 - Underweight; T50.905A - Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter; Z78.1 - Physical restraint status; Z98.2 - Presence of cerebrospinal fluid drainage device; Z79.899 - Other long term (current) drug therapy; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z86.61 - Personal history of infections of the central nervous system"
SOM OUTPT INFUSION,73924,"Yin, Faye, MD",9/28/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Adjuvant,9/28/2023,Inactive,,
SOM OUTPT INFUSION,73924,"Yin, Faye, MD",2/29/2024,Temozolomide 28 Day Cycles - CNS,Adjuvant,12/19/2023,Inactive,,
SOM OUTPT INFUSION,73924,"Yin, Faye, MD",6/5/2024,PCV (Procarbazine / Lomustine / VinCRIStine) 42 Day Cycles - CNS,_2. Second Line,4/25/2024,Inactive,,
CINJ OP INFUSION,73924,"Vojnic, Morana, MD, MBA",5/22/2025,Bevacizumab 28 Day Cycles - CNS,_1. First Line,5/22/2025,Active,Glioma (CMS/HCC),"C71.9 - Malignant neoplasm of brain, unspecified; I67.89 - Other cerebrovascular disease"
JCMC CP INFUSION,21501,"Cruz, Allan Louie E, MD",6/2/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,5/31/2023,Inactive,,
JCMC CP INFUSION,21501,"Cruz, Allan Louie E, MD",11/8/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,11/8/2023,Inactive,,
CINJ OP INFUSION,12068,"Saraiya, Biren P, MD",6/27/2023,Enzalutamide 28 Day Cycles - Prostate,First Line,6/27/2023,Inactive,,
CINJ OP INFUSION,12068,"Saraiya, Biren P, MD",8/29/2023,CINJ 082107 (CURLU177PSM001) Abiraterone / Prednisone 28 Day Cycles Research- Prostate Cancer,Second Line,8/1/2023,Inactive,,
NBR CINJ OP INFUSION,46887,"Shah, Mansi R, MD",3/23/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,3/9/2023,Inactive,,
CBMC OP INFUSION 2FL,2404,"Raptis, George, MD",11/27/2024,CINJ 042102 EOP E ARV-471 and Abemaciclib 28 Day Cycles Research,Neoadjuvant,11/26/2024,Active,,
CINJ OP INFUSION,81445,"Stephenson, Ryan D, DO",3/13/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,3/12/2024,Active,,
NBR CINJ OP INFUSION,95984,"Palmisiano, Neil David, MD",1/9/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Second Line,1/4/2023,Inactive,,
NBR CINJ OP INFUSION,95984,"Palmisiano, Neil David, MD",1/9/2023,Gilteritinib 30 Day Cycles - Acute Myeloid Leukemia,,1/9/2023,Inactive,,
NBR 4N ONCOLOGY,95984,"Schaar, Dale, MD PhD",7/28/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Abatacept,,7/28/2023,Inactive,,
SOM OUTPT INFUSION,1877,"Patel, Eshan, MD",2/6/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed byFollowed By Pembrolizumab Maintance Q21 Days,_1. First Line,2/5/2024,Inactive,,
CBMC OP INFUSION 2FL,73730,"Wagmiller, Jennifer Ann, MD",10/23/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,10/22/2023,Inactive,,
CBMC OP INFUSION 2FL,73730,"Wagmiller, Jennifer Ann, MD",5/13/2024,Pembrolizumab 42 Day Cycles - Cervical,Adjuvant,5/12/2024,Inactive,,
CBMC OP INFUSION 2FL,3766,"Dharmapuri, Sirish, MD",2/26/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/24/2025,Active,Rectal cancer metastasized to liver (CMS/HCC),"C20, C78.7 - Rectal cancer metastasized to liver (CMS/HCC)"
NBR BMSCH 2 PED HEMONC,73020,"Drachtman, Richard, MD",1/2/2023,AALL1731 Non-DS SR B-ALL Patients - Induction,,1/2/2023,Inactive,,
TRMC TCCC OP INFUSION,75889,"Salerno, Vincent E, MD",4/15/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/7/2024,Active,,
MMC OP VP INFUSION,53979,"Talwar, Sumit, MD",6/4/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/29/2024,Active,,
MMC OP VP INFUSION,49454,"Talwar, Sumit, MD",3/4/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,Maintenance,3/4/2025,Inactive,Malignant neoplasm of overlapping sites of stomach (CMS/HCC),
TRMC TCCC OP INFUSION,52820,"Capo, Gerardo, MD",12/28/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,12/27/2023,Active,,
TRMC TCCC OP INFUSION,22299,"Capo, Gerardo, MD",10/14/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,10/13/2024,Active,,
CMC OP INFUSION,26512,"Pompa, Tiffany Ann, MD",4/8/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/8/2025,Active,"Endometrial adenocarcinoma (CMS/HCC)
Primary ovarian adenocarcinoma, left (CMS/HCC)",C56.3 - Malignant neoplasm of both ovaries (CMS/HCC); C54.1 - Endometrial cancer (CMS/HCC)
HAM OP INFUSION,9899,"Patel, Malini M, MD",11/13/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,11/5/2023,Inactive,,
NBI OP INFUSION,46340,"Cheng, Yan Ho, MD",2/19/2024,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,2/19/2024,Active,,
CMC OP INFUSION,48406,"Pompa, Tiffany Ann, MD",3/28/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/27/2025,Active,Rectal adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,79388,"Girda, Eugenia, MD",2/29/2024,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,2/27/2024,Active,,
CBMC 2W ONCOLOGY,29032,"Brown, Andrew Bennett, MD",1/30/2025,PACLitaxel weekly 28 Day Cycles - Head and Neck Cancer,_2. Second Line,1/29/2025,Active,,
JCMC CP INFUSION,72879,"Cruz, Allan Louie E, MD",5/17/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",,5/9/2023,Inactive,,
NBR CINJ OP INFUSION,4009,"Shah, Mansi R, MD",11/13/2023,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_1. First Line,11/12/2023,Inactive,,
NBR CINJ OP INFUSION,4009,"Shah, Mansi R, MD",4/23/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/23/2024,Inactive,,
NBI OP INFUSION,11555,"Anderson, Patrick S, MD",12/21/2023,Gemcitabine / DOCEtaxel 21 Day Cycles - Uterine Sarcoma,_1. First Line,12/20/2023,Inactive,,
NBI OP INFUSION,11555,"Anderson, Patrick S, MD",2/19/2024,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_2. Second Line,2/18/2024,Inactive,,
NBI OP INFUSION,923,"Snyder, Rose, MD",5/16/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/16/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
MMC OP VP INFUSION,34020,"Meghal, Trishala, MD",3/31/2023,PACLitaxel / CARBOplatin/Trastuzumab 21 Day Cycles - Uterine,,3/30/2023,Inactive,,
MMC OP INFUSION,34020,"Meghal, Trishala, MD",8/4/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/3/2023,Active,Malignant neoplasm of labium majus (CMS/HCC),
MMC OP INFUSION,98302,"Meghal, Trishala, MD",9/4/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,8/28/2024,Active,,
JCMC CP INFUSION,47082,"Cruz, Allan Louie E, MD",6/20/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/19/2023,Inactive,,
CBMC OP INFUSION 2FL,39833,"Wagmiller, Jennifer Ann, MD",11/16/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/15/2023,Inactive,,
CBMC OP INFUSION 2FL,39833,"Wagmiller, Jennifer Ann, MD",2/21/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,_2. Second Line,2/18/2024,Inactive,,
CBMC OP INFUSION 2FL,39833,"Wagmiller, Jennifer Ann, MD",5/1/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,4/30/2024,Inactive,,
CBMC 2W ONCOLOGY,39833,"Wagmiller, Jennifer Ann, MD",8/2/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,7/21/2024,Active,,
NBR CINJ OP INFUSION,25574,"Matasar, Matthew J, MD",12/5/2023,CINJ 012312 Tazemetostat / Belinostat 21 Day Cycles Research- Lymphoma,_4. Fourth Line,12/4/2023,Inactive,,
NBR CINJ OP INFUSION,25574,"Matasar, Matthew J, MD",1/16/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_4. Fourth Line,1/15/2024,Inactive,,
NBR 4N BMTU/IMCU,25574,"Matasar, Matthew J, MD",8/6/2024,RiTUXimab / Brentuximab /Lenalidomide 21 Day Cycles - DLBCL Per Echelon-3,_1. First Line,8/4/2024,Inactive,,
MMC OP VP INFUSION,59749,"Cohen, Seth D, MD",12/11/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/8/2024,Active,,
NBR 4N BMTU/IMCU,13125,"Schaar, Dale, MD PhD",1/20/2023,BMT Autologous Carmustine / Thiotepa,,1/19/2023,Inactive,,
NBI VALERIE FND HEMONC,1467,"Rao, Harini, MD",11/11/2023,ANBL1232 Group B and C,_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,46383,"Scoppetuolo, Michael, MD",9/28/2023,"VinORELBine D1, D8, D15, D22  28 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,9/27/2023,Inactive,,
CINJ OP INFUSION,1606,"Omene, Coral Oghenerukevwe, MD",1/16/2024,Enhertu (Fam-trastuzumab Deruxtecan) 21 Day Cycles - Breast,_3. Third Line,1/15/2024,Inactive,,
NBI OP INFUSION,1619,"Anderson, Patrick S, MD",1/30/2025,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/29/2025,Inactive,Primary mucinous adenocarcinoma of ovary (CMS/HCC),
NBI OP INFUSION,53617,"Anderson, Patrick S, MD",2/6/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/5/2025,Active,Primary mucinous adenocarcinoma of ovary (CMS/HCC),
NBR CINJ OP INFUSION,95079,"Evens, Andrew M, DO",10/2/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,10/1/2024,Inactive,,
MMC BBR2 ONCOLOGY,5839,"Cohen, Seth D, MD",4/11/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,4/11/2025,Inactive,Prostate cancer (CMS/HCC),"N13.9 - Obstructive and reflux uropathy, unspecified; R65.11 - Systemic inflammatory response syndrome (sirs) of non-infectious origin with acute organ dysfunction; E87.0 - Hyperosmolality and hypernatremia; N17.9 - Acute kidney failure, unspecified; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; C61 - Malignant neoplasm of prostate; D32.9 - Benign neoplasm of meninges, unspecified; N18.31 - Chronic kidney disease, stage 3a; G31.84 - Mild cognitive impairment of uncertain or unknown etiology; D72.829 - Elevated white blood cell count, unspecified; R31.0 - Gross hematuria; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; R73.9 - Hyperglycemia, unspecified; Z79.899 - Other long term (current) drug therapy"
JCMC CP INFUSION,59069,"Sekhri, Arunabh, MD",7/31/2024,Daratumumab/Weekly Bortezomib/Revlimid/ Dexamethasone 21 Day Cycles- Multiple Myeloma,Induction,7/28/2024,Active,,
NBR CINJ OP INFUSION,59069,"Egini, Ogechukwu, MD",12/20/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_2. Second Line,12/18/2024,Active,,
SOM OUTPT INFUSION,98681,"Patel, Eshan, MD",3/5/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/5/2024,Inactive,,
CINJ OP INFUSION,66160,"Boland, Patrick M, MD",4/23/2024,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,4/22/2024,Inactive,,
CINJ OP INFUSION,22088,"Aikins, James K, MD",1/23/2023,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/23/2023,Inactive,,
CINJ OP INFUSION,22088,"Aikins, James K, MD",5/9/2024,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,4/28/2024,Inactive,,
CINJ OP INFUSION,65541,"Berim, Lyudmyla, MD",1/22/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/18/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,20828,"Botwinick, Marissa, DO",2/7/2024,AALL1732 Induction,Induction,2/6/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",3/14/2024,AALL1732 Consolidation,_1. First Line,3/14/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",6/6/2024,AALL1732 HR B-ALL Arm C Inotuzumab ozogamicin Block 1,_1. First Line,6/3/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",7/5/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,7/2/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",9/6/2024,AALL1732 HR B-ALL Arm C Delayed Intensification,_1. First Line,9/5/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",10/1/2024,AALL1732 HR B-ALL Arm C Delayed Intensification,_1. First Line,9/30/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",11/7/2024,AALL1732 HR B-ALL Arm C Inotuzumab ozogamicin Block 2,_1. First Line,11/7/2024,Inactive,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",12/5/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,12/5/2024,Active,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",1/2/2025,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,12/5/2024,Active,,
CINJ PEDS HEMONC ,20828,"Botwinick, Marissa, DO",2/28/2025,AALL1732 HR B-ALL Arm C Maintenance,Maintenance,2/27/2025,Active,ALL (acute lymphoid leukemia) in remission (CMS/HCC),C91.01 - ALL (acute lymphoid leukemia) in remission (CMS/HCC)
CINJ PEDS HEMONC ,44320,"Cole, Peter David, MD",7/24/2023,AALL1731 DS-High B-ALL Delayed Intensification,Maintenance,7/24/2023,Inactive,,
CINJ PEDS HEMONC ,44320,"Cole, Peter David, MD",7/25/2023,per AALL1731 DS SR-Avg B-ALL - Maintenance,Maintenance,7/24/2023,Active,,
CINJ PEDS HEMONC ,44320,"Cole, Peter David, MD",10/17/2023,AALL1731 DS SR-Fav B-ALL - Maintenance,Maintenance,10/17/2023,Inactive,,
CINJ OP INFUSION,25739,"Girda, Eugenia, MD",6/13/2023,CINJ 052202 Dose Expansion Cohort 1 RGX104 / Ipilimumab 28 Day Cycles Research- Solid Tumor Malignancies,,5/21/2023,Inactive,,
CINJ OP INFUSION,25739,"Girda, Eugenia, MD",10/27/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,10/3/2023,Inactive,,
CINJ OP INFUSION,25739,"Girda, Eugenia, MD",9/24/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,9/4/2024,Inactive,,
CINJ OP INFUSION,25739,"Girda, Eugenia, MD",12/12/2024,Abemaciclib 28 Day Cycles - Breast,_4. Fourth Line,12/12/2024,Active,,
JCMC CP INFUSION,13038,"Cruz, Allan Louie E, MD",2/16/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,2/15/2023,Inactive,,
SOM OUTPT INFUSION,72715,"Toomey, Kathleen C, MD",8/5/2024,Pembrolizumab + Albumin-Bound PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/4/2024,Inactive,,
CBMC OP INFUSION 2FL,57701,"Leitner, Stuart P, MD",12/2/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,12/1/2024,Active,,
NBR BMSCH 2 PED HEMONC,34680,"Cole, Peter David, MD",9/8/2023,PEDS AALL02P2,Second Line,9/8/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,34680,"Cole, Peter David, MD",11/21/2023,PEDS AALL02P2 Intensification I (Weeks 11-22 or 13-24),_1. First Line,11/17/2023,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",2/9/2024,Blinatumomab,_3. Third Line,2/8/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",3/18/2024,PEDS AALL02P2 Reinduction (Weeks 23-26 or 25-28),Reinduction,3/18/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",3/25/2024,PEDS AALL02P2 Reinduction (Weeks 23-26 or 25-28),Reinduction,3/25/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",4/30/2024,PEDS AALL02P2 Intensification II (Weeks 27-50 or 29-52),_2. Second Line,4/22/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",9/20/2024,IT Cytarabine and Hydrocortisone,Reinduction,9/20/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",9/25/2024,"Dosing taken from combo of JCO Vol 40, issue 14 ""POMP"" + re-induction ( weekly VCR) + IO CxT",_3. Third Line,9/25/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",11/4/2024,"PEDS AALL1331 Blocks 1,2,3",Reinduction,10/21/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Cole, Peter David, MD",12/9/2024,AALL1731 - Maintenance (Bridge Chemo),Non-Oncology Research,12/9/2024,Inactive,,
CINJ PEDS HEMONC ,34680,"Shah, Niketa, MD",1/10/2025,PEDS BMT Allogeneic TBI / Cy ,_4. Fourth Line,1/3/2025,Active,,
CINJ OP INFUSION,75376,"Girda, Eugenia, MD",9/21/2023,CINJ 051709 BRCA1 / BRCA2 Mutations Pembrolizumab 200 mg IV D1 21 Day Cycles Research- Basket Trial for Advanced Solid Tumors,,9/21/2023,Inactive,,
HAM OP INFUSION,65482,"Yogarajah, Meera, MD",6/15/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,6/12/2023,Inactive,,
MMC OP VP INFUSION,97715,"Lee, Patrick C, MD",5/27/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,,5/25/2023,Inactive,,
MMC OP INFUSION,97715,"Lee, Patrick C, MD",12/5/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,12/4/2023,Inactive,,
MMC OP INFUSION,97715,"Lee, Patrick C, MD",3/28/2024,Atezolizumab/CARBOplatin 21 Day Cycles- Small Cell Lung Cancer,Maintenance,3/25/2024,Active,,
MMC OP INFUSION,97715,"Lee, Patrick C, MD",8/13/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,8/12/2024,Active,,
CINJ OP INFUSION,9142,"Hochster, Howard S, MD",8/8/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,7/31/2024,Active,,
NBR CINJ OP INFUSION,8642,"Shah, Mansi R, MD",3/8/2023,Lymphodepletion Abecma 6 Day Cycle - Multiple Myeloma,,3/8/2023,Inactive,,
JCMC CP INFUSION,70156,"Sekhri, Arunabh, MD",1/6/2025,Decitabine (5 day) 28 Day Cycles - cmml,_1. First Line,1/5/2025,Inactive,Chronic myelomonocytic leukemia not having achieved remission (CMS/HCC),
CINJ OP INFUSION,63496,"Saraiya, Biren P, MD",9/17/2024,CINJ 082104 (EA8191) ARM D Short Term Androgen Deprivation GnRH Therapy / Apalutamide 84 Day Cycles Research- Prostate Cancer,_1. First Line,8/20/2024,Active,,
CMC OP INFUSION,58146,"Taff, Jessica, MD",4/4/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,4/4/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CMC OP INFUSION,58359,"Talwar, Sumit, MD",9/16/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_2. Second Line,9/15/2024,Inactive,,
CMC OP INFUSION,58359,"Talwar, Sumit, MD",9/20/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Breast,_1. First Line,9/17/2024,Active,,
CBMC OP INFUSION 2FL,15293,"Brown, Andrew Bennett, MD",4/2/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,4/2/2025,Active,Malignant neoplasm of overlapping sites of oropharynx (CMS/HCC),
JCMC CP INFUSION,89376,"Cruz, Allan Louie E, MD",4/1/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,Adjuvant,3/17/2024,Inactive,,
CINJ OP INFUSION,16638,"Haigentz, Missak, MD",7/18/2023,CINJ 032201 ARM 1 Paclitaxel / CARBOplatin + Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,7/18/2023,Inactive,,
CINJ OP INFUSION,21394,"Girda, Eugenia, MD",6/18/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/18/2024,Active,,
CINJ OP INFUSION,21394,"Girda, Eugenia, MD",10/17/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,10/16/2024,Inactive,,
CINJ OP INFUSION,77775,"Saraiya, Biren P, MD",6/27/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,6/27/2023,Inactive,,
CINJ OP INFUSION,10445,"Leiser, Aliza, MD",2/28/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,2/22/2024,Inactive,,
CINJ OP INFUSION,10445,"Leiser, Aliza, MD",7/12/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/11/2024,Active,,
CINJ OP INFUSION,2585,"Berim, Lyudmyla, MD",5/20/2024,Gemcitabine 300mg/m2 weekly with Radiation-Pancreatic Adenocarcinoma,_2. Second Line,5/19/2024,Active,,
CINJ OP INFUSION,2585,"Berim, Lyudmyla, MD",1/27/2025,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,1/26/2025,Active,,
CINJ OP INFUSION,2585,"Berim, Lyudmyla, MD",1/27/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/21/2025,Inactive,Pancreatic adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,6720,"Leiser, Aliza, MD",10/21/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/29/2024,Active,,
CINJ OP INFUSION,73308,"Hochster, Howard S, MD",1/5/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/4/2023,Inactive,,
CINJ OP INFUSION,73308,"Hochster, Howard S, MD",5/18/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,First Line,5/18/2023,Inactive,,
CBMC 2W ONCOLOGY,21922,"Scoppetuolo, Michael, MD",7/3/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,7/2/2024,Active,,
TRMC TCCC OP INFUSION,79271,"Capo, Gerardo, MD",2/21/2025,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/20/2025,Active,Adenocarcinoma of gastroesophageal junction (CMS/HCC),
CBMC OP INFUSION 2FL,11495,"Radovich, Delia, MD",10/31/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Pancreatic Cancer,_1. First Line,10/30/2023,Inactive,Malignant neoplasm of body of pancreas (CMS/HCC),
CBMC OP INFUSION 2FL,11495,"Scoppetuolo, Michael, MD",1/27/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Cancer",_2. Second Line,1/26/2025,Active,,
CBMC OP INFUSION 2FL,11495,"Scoppetuolo, Michael, MD",3/31/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/31/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),C25.1 - Malignant neoplasm of body of pancreas
CINJ OP INFUSION,52047,"Ghodoussipour, Saum Bobak, MD",1/27/2023,Mitomycin for Pyelocalyceal Instillation (Ureteral Gel) - Urothelial ,Induction,1/26/2023,Inactive,,
CINJ OP INFUSION,52047,"Ghodoussipour, Saum Bobak, MD",9/28/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,9/27/2023,Inactive,,
CINJ OP INFUSION,52047,"Ghodoussipour, Saum Bobak, MD",9/29/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,9/29/2023,Inactive,,
CINJ OP INFUSION,52047,"Ghodoussipour, Saum Bobak, MD",12/14/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,12/13/2023,Inactive,,
NBI OP INFUSION,87095,"Schleicher, Lori, MD",5/9/2025,Zanubrutinib (320 mg) 30 Day Cycles - Chronic Lymphocytic Leukemia,_1. First Line,5/9/2025,Inactive,CLL (chronic lymphocytic leukemia) (CMS/HCC),D72.820 - Lymphocytosis (symptomatic); C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission
NBI OP INFUSION,87095,"Schleicher, Lori, MD",5/9/2025,Acalabrutinib 100 mg 30 days - Chronic Lymphocytic Leukemia,_1. First Line,5/9/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
CMC OP INFUSION,34443,"Taff, Jessica, MD",11/29/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/28/2023,Active,,
NBR CINJ OP INFUSION,89264,"Evens, Andrew M, DO",7/10/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/9/2024,Active,,
CINJ OP INFUSION,41965,"Berim, Lyudmyla, MD",7/31/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,,7/27/2023,Inactive,,
CINJ OP INFUSION,41965,"Berim, Lyudmyla, MD",11/13/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/9/2023,Inactive,,
CINJ OP INFUSION,41965,"Berim, Lyudmyla, MD",11/27/2023,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/16/2023,Inactive,,
CINJ OP INFUSION,41965,"Berim, Lyudmyla, MD",2/9/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,2/8/2024,Inactive,,
CINJ OP INFUSION,41965,"Berim, Lyudmyla, MD",4/19/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,4/19/2024,Inactive,,
CBMC 2W ONCOLOGY,19797,"Grossman, I Robert, MD",6/7/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,6/7/2024,Active,,
NBR CINJ OP INFUSION,27,"Evens, Andrew M, DO",6/12/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,6/12/2024,Inactive,,
NBR CINJ OP INFUSION,47912,"Evens, Andrew M, DO",2/12/2025,Bendamustine / RiTUXimab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphatic Lymphoma,_2. Second Line,2/11/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
NBR CINJ OP INFUSION,99073,"Evens, Andrew M, DO",9/13/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,9/13/2023,Inactive,,
NBR 4N ONCOLOGY,99073,"Evens, Andrew M, DO",10/4/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/3/2023,Inactive,,
CINJ OP INFUSION,32430,"Haigentz, Missak, MD",7/30/2023,Lorlatinib 28 Day Cycles- Non-Small Cell Lung Cancer,,7/30/2023,Inactive,,
NBR CINJ OP INFUSION,60525,"Rhodes, Joanna Meehan, MD",4/28/2025,Triangle Regimen R-I-CHOP / R-DHAX  (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Ibrutinib) / (Dexamethasone / Cytarabine / OXALIplatin) RiTUXimab Every 21 Days - Mantle Cell Lymphoma,_1. First Line,4/28/2025,Active,Mantle cell lymphoma (CMS/HCC),
CINJ OP INFUSION,78709,"Saraiya, Biren P, MD",4/28/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,First Line,4/27/2023,Inactive,,
NBI OP INFUSION,40358,"Jacoby, Sari H, MD",5/20/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/19/2024,Inactive,,
CMC OP INFUSION,77959,"Cohen, Seth D, MD",7/2/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/1/2024,Active,,
CBMC OP INFUSION 2FL,57267,"Ligresti, Louise G, MD",1/26/2024,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,1/26/2024,Inactive,,
CBMC OP INFUSION 2FL,87249,"Wagmiller, Jennifer Ann, MD",9/11/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,9/10/2023,Inactive,,
CBMC OP INFUSION 2FL,87249,"Wagmiller, Jennifer Ann, MD",4/15/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,4/14/2024,Inactive,,
CBMC 2W ONCOLOGY,87249,"Wagmiller, Jennifer Ann, MD",12/26/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_5. Fifth Line,12/25/2024,Active,,
CINJ OP INFUSION,85658,"Stephenson, Ruth D, DO",8/29/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/28/2024,Inactive,,
CINJ OP INFUSION,85658,"Stephenson, Ruth D, DO",1/15/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,1/14/2025,Active,,
CMC OP INFUSION,17055,"Packiam, Vignesh, MD",1/24/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,1/23/2025,Inactive,Bladder cancer (CMS/HCC),
CMC OP INFUSION,17055,"Packiam, Vignesh, MD",2/5/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,1/23/2025,Active,Bladder cancer (CMS/HCC),
CBMC OP INFUSION 2FL,82693,"Litvak, Anna M, MD",1/27/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/8/2025,Active,,
CBMC OP INFUSION 2FL,82693,"Litvak, Anna M, MD",2/12/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/8/2025,Active,"Malignant neoplasm of nipple and areola, left female breast (CMS/HCC)",
NBR 4N BMTU/IMCU,84051,"Shah, Mansi R, MD",8/4/2024,Tretinoin (ATRA) / IDArubicin (Induction) - Acute Promyelocytic Leukemia,_1. First Line,8/3/2024,Inactive,,
NBR CINJ OP INFUSION,84051,"Zayac, Adam, MD",9/27/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,9/26/2024,Active,"Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck (CMS/HCC)",
MMC OP VP INFUSION,29473,"Cohen, Seth D, MD",9/11/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,First Line,9/10/2023,Inactive,,
CMC OP INFUSION,9616,"Tang, Horace, MD",11/22/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,11/22/2023,Inactive,,
CMC OP INFUSION,9616,"Talwar, Sumit, MD",6/21/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,6/20/2024,Inactive,,
CINJ OP INFUSION,51365,"Gulhati, Prateek, MD PhD",7/2/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",Adjuvant,6/14/2024,Active,,
CBMC OP INFUSION 2FL,99850,"Grossman, I Robert, MD",10/4/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,10/3/2023,Inactive,,
CBMC OP INFUSION 2FL,99850,"Grossman, I Robert, MD",4/12/2024,Daratumumab and Hyaluronidase-fihj Monthly / Bortezomib Bi-Weekly 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/9/2024,Inactive,,
NBR 5N ONCOLOGY,70796,"Chen, Xiaoyi",12/5/2024,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/5/2024,Active,,
NBR CINJ OP INFUSION,53429,"Chen, Xiaoyi",4/14/2025,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,_1. First Line,4/14/2025,Active,Philadelphia chromosome-negative pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
NBR 5N ONCOLOGY,53429,"Chen, Xiaoyi",3/17/2025,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,3/14/2025,Inactive,Philadelphia chromosome-negative pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),"R10.9 - Unspecified abdominal pain; C91.00 - Acute lymphoblastic leukemia not having achieved remission; E87.3 - Alkalosis; E83.39 - Other disorders of phosphorus metabolism; K29.80 - Duodenitis without bleeding; E83.51 - Hypocalcemia; F32.9 - Major depressive disorder, single episode, unspecified; E66.9 - Obesity, unspecified; K76.0 - Fatty (change of) liver, not elsewhere classified; H47.10 - Unspecified papilledema; N17.9 - Acute kidney failure, unspecified; R18.8 - Other ascites; Z68.35 - Body mass index (BMI) 35.0-35.9, adult; E87.6 - Hypokalemia; F41.1 - Generalized anxiety disorder; F43.10 - Post-traumatic stress disorder, unspecified; M54.9 - Dorsalgia, unspecified; Z28.21 - Immunization not carried out because of patient refusal; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; G47.33 - Obstructive sleep apnea (adult) (pediatric); G93.2 - Benign intracranial hypertension; G89.29 - Other chronic pain; G58.9 - Mononeuropathy, unspecified; I73.00 - Raynaud's syndrome without gangrene; K21.9 - Gastro-esophageal reflux disease without esophagitis; K29.70 - Gastritis, unspecified, without bleeding; E53.8 - Deficiency of other specified B group vitamins; M94.0 - Chondrocostal junction syndrome (tietze); K58.2 - Mixed irritable bowel syndrome; M79.7 - Fibromyalgia; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; Z79.899 - Other long term (current) drug therapy; Z80.7 - Family history of other malignant neoplasms of ..."
NBR 5N ONCOLOGY,53429,"Chen, Xiaoyi",3/13/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,3/13/2025,Active,Philadelphia chromosome-negative pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),"R10.9 - Unspecified abdominal pain; C91.00 - Acute lymphoblastic leukemia not having achieved remission; E87.3 - Alkalosis; E83.39 - Other disorders of phosphorus metabolism; K29.80 - Duodenitis without bleeding; E83.51 - Hypocalcemia; F32.9 - Major depressive disorder, single episode, unspecified; E66.9 - Obesity, unspecified; K76.0 - Fatty (change of) liver, not elsewhere classified; H47.10 - Unspecified papilledema; N17.9 - Acute kidney failure, unspecified; R18.8 - Other ascites; Z68.35 - Body mass index (BMI) 35.0-35.9, adult; E87.6 - Hypokalemia; F41.1 - Generalized anxiety disorder; F43.10 - Post-traumatic stress disorder, unspecified; M54.9 - Dorsalgia, unspecified; Z28.21 - Immunization not carried out because of patient refusal; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; G47.33 - Obstructive sleep apnea (adult) (pediatric); G93.2 - Benign intracranial hypertension; G89.29 - Other chronic pain; G58.9 - Mononeuropathy, unspecified; I73.00 - Raynaud's syndrome without gangrene; K21.9 - Gastro-esophageal reflux disease without esophagitis; K29.70 - Gastritis, unspecified, without bleeding; E53.8 - Deficiency of other specified B group vitamins; M94.0 - Chondrocostal junction syndrome (tietze); K58.2 - Mixed irritable bowel syndrome; M79.7 - Fibromyalgia; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; Z79.899 - Other long term (current) drug therapy; Z80.7 - Family history of other malignant neoplasms of ..."
JCMC CP INFUSION,51325,"Sekhri, Arunabh, MD",4/19/2024,Pembrolizumab 42 Day Cycles - Endometrial cancer Stage IVB,_1. First Line,4/14/2024,Active,,
CBMC OP INFUSION 2FL,27575,"Dharmapuri, Sirish, MD",10/15/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,9/20/2024,Active,,
NBR 5N ONCOLOGY,70120,"Shah, Mansi R, MD",4/24/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - (Inpatient Regimen),,4/24/2023,Inactive,,
CINJ OP INFUSION,10486,"Berim, Lyudmyla, MD",12/21/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,12/20/2023,Inactive,,
CINJ OP INFUSION,10486,"Berim, Lyudmyla, MD",5/6/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,5/6/2024,Active,,
NBR CINJ OP INFUSION,76960,"Shah, Mansi R, MD",1/25/2023,Lymphodepletion Abecma 6 Day Cycle - Multiple Myeloma,,1/25/2023,Inactive,,
CMC OP INFUSION,45272,"Talwar, Sumit, MD",1/30/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,1/28/2024,Inactive,,
CBMC OP INFUSION 2FL,97637,"Grossman, I Robert, MD",10/5/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,10/5/2023,Inactive,,
CBMC OP INFUSION 2FL,97637,"Grossman, I Robert, MD",10/10/2023,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,Consolidation,10/9/2023,Inactive,,
CINJ OP INFUSION,64429,"Stephenson, Ryan D, DO",10/21/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/18/2024,Inactive,,
CINJ OP INFUSION,93975,"Saraiya, Biren P, MD",2/14/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,2/14/2023,Inactive,,
NBR CINJ OP INFUSION,4138,"Tiger, Yun Kyoung, MD",4/24/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,4/24/2025,Active,Primary CNS lymphoma (CMS/HCC),C83.390 - Primary central nervous system lymphoma
HAM OP INFUSION,37706,"Gendy, Mina, DO",8/28/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,8/27/2024,Inactive,,
CBMC OP INFUSION 2FL,89727,"Brown, Andrew Bennett, MD",4/5/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/2/2024,Active,,
CBMC OP INFUSION 2FL,89727,"Brown, Andrew Bennett, MD",7/29/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,Consolidation,7/29/2024,Active,,
HAM OP INFUSION,1127,"Yogarajah, Meera, MD",5/7/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/5/2024,Active,,
CBMC OP INFUSION 2FL,89255,"Brown, Andrew Bennett, MD",10/29/2024,DOCEtaxel/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,10/28/2024,Active,,
CBMC OP INFUSION 2FL,89255,"Brown, Andrew Bennett, MD",2/14/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,2/13/2025,Active,"Primary malignant neoplasm of left upper lobe of lung (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)","C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; M04.9 - Autoinflammatory syndrome, unspecified"
MSC OP INFUSION,56282,"Cohen, Seth D, MD",12/28/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/20/2023,Inactive,,
MSC OP INFUSION,56282,"Cohen, Seth D, MD",5/21/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/20/2024,Inactive,,
MMC OP INFUSION,34857,"Lee, Patrick C, MD",9/26/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,,9/25/2023,Inactive,,
MMC OP INFUSION,34857,"Lee, Patrick C, MD",10/3/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,10/2/2024,Active,,
SOM OUTPT INFUSION,98259,"Yin, Faye, MD",2/1/2023,Bendamustine / RiTUXimab 28 Day Cycles - Marginal Zone Lymphoma,First Line,1/30/2023,Inactive,,
CINJ OP INFUSION,65047,"Leiser, Aliza, MD",5/15/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,5/14/2023,Inactive,,
CINJ OP INFUSION,65047,"Leiser, Aliza, MD",10/27/2023,Trastuzumab 21 Day Cycles (Continuation) ,Maintenance,10/27/2023,Active,"T-cell large granular lymphocytic leukemia (CMS/HCC)
Rheumatoid arthritis (CMS/HCC)
Other acquired hemolytic anemias (CMS/HCC)",
TRMC TCCC OP INFUSION,93440,"Salerno, Vincent E, MD",6/13/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,6/12/2024,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
NBI OP INFUSION,51060,"Anderson, Patrick S, MD",4/28/2025,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_1. First Line,4/28/2025,Active,"Leiomyosarcoma (CMS/HCC)
Uterine sarcoma (CMS/HCC)",
MMC OP VP INFUSION,69242,"Cohen, Seth D, MD",3/7/2025,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,3/7/2025,Active,"Sarcoma (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,65781,"Aikins, James K, MD",9/5/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,9/4/2024,Active,,
JCMC CP INFUSION,69313,"Cruz, Allan Louie E, MD",1/15/2025,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,1/12/2025,Inactive,Malignant neoplasm of tail of pancreas (CMS/HCC),
TRMC TCCC OP INFUSION,6028,"Capo, Gerardo, MD",3/14/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,3/14/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
JCMC CP INFUSION,92081,"Sekhri, Arunabh, MD",5/15/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,5/14/2023,Inactive,,
NBR CINJ OP INFUSION,80527,"Palmisiano, Neil David, MD",3/20/2023,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,,3/19/2023,Inactive,,
NBR 5N ONCOLOGY,80527,"Palmisiano, Neil David, MD",6/21/2023,Blinatumomab 84 Day Cycles - Acute Lymphoblastic Leukemia (Continued Therapy),Maintenance,6/21/2023,Inactive,,
NBR 4N BMTU/IMCU,80527,"Assal, Amer, MD",11/15/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_4. Fourth Line,11/15/2023,Inactive,,
NBR CINJ OP INFUSION,80527,"Assal, Amer, MD",2/22/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Maintenance,2/22/2024,Inactive,,
TRMC TCCC OP INFUSION,95873,"Capo, Gerardo, MD",6/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/20/2024,Active,,
CBMC 2W ONCOLOGY,53071,"McKenna, Marshall, MD",12/31/2024,Tretinoin (ATRA) / IDArubicin / Arsenic 36 Day Cycle (Induction) - Acute Promyelocytic Leukemia,_1. First Line,12/31/2024,Inactive,,
NBR 4N ONCOLOGY,53071,"Chen, Xiaoyi",1/1/2025,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,1/1/2025,Inactive,APL (acute promyelocytic leukemia) (CMS/HCC),
NBR CINJ OP INFUSION,53071,"Chen, Xiaoyi",2/3/2025,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,2/2/2025,Active,APL (acute promyelocytic leukemia) (CMS/HCC),
CINJ OP INFUSION,81545,"Groisberg, Roman, MD",5/2/2023,MAP (High-Dose Methotrexate / DOXOrubicin / CISplatin) - Bone Cancer,Neoadjuvant,5/2/2023,Inactive,,
CINJ OP INFUSION,81545,"Groisberg, Roman, MD",8/7/2023,DOXOrubicin 21 Day Cycles - Sarcoma,,8/3/2023,Inactive,,
NBR CINJ OP INFUSION,83016,"Egini, Ogechukwu, MD",1/30/2025,BMT Allogeneic TBF + Post Cy,_2. Second Line,1/16/2025,Active,,
NBR CINJ OP INFUSION,83016,"Egini, Ogechukwu, MD",2/6/2025,BMT Allogeneic TBF + Post Cy,_2. Second Line,1/16/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),"D46.9 - Myelodysplastic syndrome, unspecified; R71.8 - Other abnormality of red blood cells; R91.1 - Solitary pulmonary nodule; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; I10 - Essential (primary) hypertension; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E11.9 - Type 2 diabetes mellitus without complications; E78.5 - Hyperlipidemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; G25.81 - Restless legs syndrome; F41.9 - Anxiety disorder, unspecified; F32.A - Depression, unspecified; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,87221,"Dasgeb, Bahar, MD",9/19/2023,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,First Line,9/18/2023,Inactive,,
JCMC CP INFUSION,39234,"Cruz, Allan Louie E, MD",10/2/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/17/2023,Inactive,,
NBR CINJ OP INFUSION,2758,"Evens, Andrew M, DO",6/28/2023,Pembrolizumab + GVD - 21 Day Cycles - Hodgkin Lymphoma,,6/22/2023,Inactive,,
NBR 4N ONCOLOGY,2758,"Assal, Amer, MD",8/24/2023,BMT Autologous BEAM,,8/23/2023,Inactive,,
NBR CINJ OP INFUSION,2758,"Evens, Andrew M, DO",11/29/2023,Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,2758,"Evens, Andrew M, DO",1/3/2024,"Nivolumab (D1, D15) 28 Day Cycles - Hodgkin Lymphoma",_3. Third Line,1/2/2024,Inactive,,
NBR CINJ OP INFUSION,2758,"Evens, Andrew M, DO",10/23/2024,Brentuximab Vedotin / Bendamustine 21 Day Cycles - Hodgkin Lymphoma,_4. Fourth Line,10/22/2024,Active,,
NBR CINJ OP INFUSION,92671,"Rhodes, Joanna Meehan, MD",9/5/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,8/28/2024,Active,Malignant neoplasm of endometrium (CMS/HCC),
NBR 4N BMTU/IMCU,95220,"Schaar, Dale, MD PhD",10/8/2023,BMT Autologous Melphalan Day -1  200mg/m2,_3. Third Line,10/5/2023,Inactive,,
NBR CINJ OP INFUSION,95220,"Shah, Mansi R, MD",1/9/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,12/12/2024,Active,,
NBR CINJ OP INFUSION,29630,"Patel, Vimal D, MD",2/18/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,2/10/2023,Inactive,,
CINJ OP INFUSION,80509,"Haigentz, Missak, MD",3/27/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,3/27/2023,Inactive,,
NBI OP INFUSION,8319,"Shah, Shailja S, MD",7/9/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,7/8/2024,Inactive,,
NBI OP INFUSION,60933,"Jacoby, Sari H, MD",4/4/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,4/3/2023,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,60933,"Jacoby, Sari H, MD",7/9/2024,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,7/2/2024,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,60933,"Jacoby, Sari H, MD",10/8/2024,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,10/7/2024,Inactive,,
NBR CINJ OP INFUSION,60933,"Shah, Mansi R, MD",11/25/2024,Talquetamab 28 Day Cycles,_5. Fifth Line,11/25/2024,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,60933,"Phillips, Adrienne A, MD",1/1/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_6. Sixth Line,12/31/2024,Active,,
CBMC 2W ONCOLOGY,45637,"Grossman, I Robert, MD",8/29/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_3. Third Line,8/29/2024,Inactive,,
NBI OP INFUSION,27238,"Shah, Maya M, MD",11/15/2023,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/7/2023,Inactive,,
NBI OP INFUSION,27238,"Shah, Maya M, MD",6/5/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/28/2024,Active,,
NBR 4N ONCOLOGY,35321,"Evens, Andrew M, DO",3/11/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,3/9/2023,Inactive,,
NBR CINJ OP INFUSION,35321,"Evens, Andrew M, DO",3/28/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,3/22/2023,Inactive,,
NBR CINJ OP INFUSION,35321,"Evens, Andrew M, DO",3/20/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/19/2024,Inactive,,
NBR CINJ OP INFUSION,35321,"Evens, Andrew M, DO",4/17/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,4/16/2024,Inactive,,
MMC OP VP INFUSION,83121,"Meghal, Trishala, MD",7/24/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,7/7/2024,Inactive,,
MMC OP VP INFUSION,83121,"Meghal, Trishala, MD",9/25/2024,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Adjuvant,8/29/2024,Inactive,,
MMC OP INFUSION,83121,"Meghal, Trishala, MD",10/30/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,10/29/2024,Active,,
CINJ OP INFUSION,46351,"Girda, Eugenia, MD",6/6/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/21/2024,Active,,
MMC OP INFUSION,72429,"Meghal, Trishala, MD",12/27/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/26/2023,Inactive,,
CINJ OP INFUSION,30576,"Boland, Patrick M, MD",9/8/2023,TAS-Ox,,9/7/2023,Inactive,,
NBR CINJ OP INFUSION,54849,"Evens, Andrew M, DO",11/27/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/27/2024,Active,Malignant neoplasm of pancreas (CMS/HCC),
CBMC 2W ONCOLOGY,70613,"Grossman, I Robert, MD",11/7/2023,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/6/2023,Active,Cholangiocarcinoma (CMS/HCC),
CINJ OP INFUSION,68813,"Weiss, Sarah, MD",10/1/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,9/8/2024,Inactive,,
CINJ OP INFUSION,88824,"George, Mridula A, MD",4/26/2023,EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / DOCEtaxel 21 Day Cycles Research- Breast Cancer,Neoadjuvant,4/20/2023,Inactive,,
CINJ OP INFUSION,88824,"George, Mridula A, MD",7/19/2023,EA1181 / CINJ 042004 Post-Operative Trastuzumab / Pertuzumab 21 Day Cycles Research ARM A- Breast Cancer,Adjuvant,7/18/2023,Inactive,,
CINJ OP INFUSION,88824,"George, Mridula A, MD",9/8/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,9/5/2023,Active,,
CMC OP INFUSION,16803,"Tang, Horace, MD",4/24/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,Third Line,4/23/2023,Inactive,,
MMC OP VP INFUSION,90427,"Meghal, Trishala, MD",9/25/2023,Alpelisib 28 Day Cycles - Breast,,9/25/2023,Inactive,,
MMC OP VP INFUSION,90427,"Meghal, Trishala, MD",10/30/2023,Alpelisib 28 Day Cycles - Breast,_3. Third Line,10/30/2023,Inactive,,
MMC OP VP INFUSION,90427,"Meghal, Trishala, MD",11/27/2023,Alpelisib 28 Day Cycles - Breast,_2. Second Line,11/27/2023,Active,,
CBMC OP INFUSION 2FL,57980,"Dharmapuri, Sirish, MD",4/9/2025,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/9/2025,Active,Adenocarcinoma of colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CINJ OP INFUSION,74625,"Leitner, Stuart P, MD",4/19/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Second Line,4/19/2023,Inactive,,
NBI D7 MED-SURG/TELE,51096,"Shah, Shailja S, MD",11/3/2023,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_2. Second Line,11/2/2023,Inactive,,
SOM OUTPT INFUSION,93312,"Yin, Faye, MD",5/19/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/18/2023,Inactive,,
CBMC OP INFUSION 2FL,125,"Wagmiller, Jennifer Ann, MD",12/27/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,12/25/2023,Inactive,,
CBMC OP INFUSION 2FL,125,"Wagmiller, Jennifer Ann, MD",3/27/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/27/2024,Inactive,,
CBMC OP INFUSION 2FL,125,"Wagmiller, Jennifer Ann, MD",5/6/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,Neoadjuvant,5/6/2024,Inactive,,
NBR CINJ OP INFUSION,40395,"Zayac, Adam, MD",5/20/2024,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_1. First Line,5/13/2024,Active,,
NBR CINJ OP INFUSION,1215,"Schaar, Dale, MD PhD",1/20/2024,BMT Allogeneic TBF + Post Cy ,_3. Third Line,1/13/2024,Inactive,,
CMC OP INFUSION,25301,"Talwar, Sumit, MD",12/16/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/16/2024,Active,,
CMC OP INFUSION,23637,"Talwar, Sumit, MD",7/2/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,7/1/2024,Active,,
HAM OP INFUSION,23605,"Yogarajah, Meera, MD",4/29/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/29/2025,Active,Rectal cancer (CMS/HCC),"C20 - Malignant neoplasm of rectum; I48.91 - Unspecified atrial fibrillation; E78.5 - Hyperlipidemia, unspecified; M19.90 - Unspecified osteoarthritis, unspecified site; R79.1 - Abnormal coagulation profile; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.3 - Personal history of irradiation; Z85.038 - Personal history of other malignant neoplasm of large intestine; Z86.16 - Personal history of COVID-19; Z95.0 - Presence of cardiac pacemaker; Z79.82 - Long term (current) use of aspirin; Z79.1 - Long term (current) use of non-steroidal anti-inflammatories (nsaid); Z79.899 - Other long term (current) drug therapy"
NBR CINJ OP INFUSION,4684,"Rhodes, Joanna Meehan, MD",1/8/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/21/2023,Inactive,,
NBR CINJ OP INFUSION,4684,"Rhodes, Joanna Meehan, MD",1/8/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/8/2024,Inactive,,
NBR CINJ OP INFUSION,4684,"Rhodes, Joanna Meehan, MD",5/13/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,Adjuvant,5/12/2024,Inactive,,
CBMC OP INFUSION 2FL,39089,"Wagmiller, Jennifer Ann, MD",9/19/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,9/2/2024,Inactive,,
CBMC OP INFUSION 2FL,39089,"Wagmiller, Jennifer Ann, MD",11/14/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),Adjuvant,11/13/2024,Active,,
CMC OP INFUSION,2860,"Taff, Jessica, MD",7/5/2023,DOXOrubicin Conventional TACE - Hepatocellular Cancer,First Line,7/5/2023,Inactive,,
CINJ OP INFUSION,74235,"Berim, Lyudmyla, MD",7/24/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/23/2023,Inactive,,
CINJ OP INFUSION,74235,"Berim, Lyudmyla, MD",1/15/2024,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,1/15/2024,Inactive,,
CINJ OP INFUSION,74235,"Berim, Lyudmyla, MD",2/5/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/4/2024,Inactive,,
CINJ OP INFUSION,74235,"Berim, Lyudmyla, MD",2/7/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/6/2024,Inactive,,
CMC OP INFUSION,82307,"Tang, Horace, MD",7/10/2023,Pembrolizumab 21 Day Cycles - Breast,,7/10/2023,Inactive,,
NBR CINJ OP INFUSION,28838,"Matasar, Matthew J, MD",10/11/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/10/2023,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,55642,"Berim, Lyudmyla, MD",5/12/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/30/2025,Active,Rectal cancer (CMS/HCC),C20 - Malignant neoplasm of rectum
CINJ OP INFUSION,73970,"George, Mridula A, MD",5/1/2024,Palbociclib 28 Day Cycles - Breast,_2. Second Line,5/1/2024,Active,,
NBR CINJ OP INFUSION,76492,"Rhodes, Joanna Meehan, MD",12/5/2024,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,12/1/2024,Active,,
CINJ OP INFUSION,64743,"Boland, Patrick M, MD",7/7/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,First Line,7/6/2023,Inactive,,
CMC 4B ONCOLOGY,67454,"Meghal, Trishala, MD",1/6/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,12/17/2024,Active,,
MMC OP VP INFUSION,89578,"Lee, Patrick C, MD",4/18/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,4/17/2023,Inactive,,
NBR CINJ OP INFUSION,32517,"Egini, Ogechukwu, MD",10/23/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,10/22/2024,Active,,
CINJ OP INFUSION,53784,"Stephenson, Ryan D, DO",11/1/2023,CINJ 082002 Pre-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,_1. First Line,10/31/2023,Inactive,,
CINJ OP INFUSION,53784,"Stephenson, Ryan D, DO",3/6/2024,CINJ 082002 Post-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,_1. First Line,1/10/2024,Inactive,,
CINJ OP INFUSION,10621,"Groisberg, Roman, MD",7/18/2024,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_1. First Line,7/12/2024,Inactive,,
CINJ OP INFUSION,10621,"Groisberg, Roman, MD",9/24/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_2. Second Line,9/23/2024,Active,"Endometrial carcinoma (CMS/HCC)
Disorder of thyroid, unspecified",
CINJ OP INFUSION,48305,"Berim, Lyudmyla, MD",12/29/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,Maintenance,12/28/2023,Inactive,,
CINJ OP INFUSION,93413,"Haigentz, Missak, MD",5/7/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,5/7/2024,Inactive,,
CINJ OP INFUSION,93413,"Haigentz, Missak, MD",7/22/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/21/2024,Inactive,,
NBR CINJ OP INFUSION,65349,"Shah, Mansi R, MD",4/12/2023,Lymphodepletion Abecma 6 Day Cycle - Multiple Myeloma,,4/11/2023,Inactive,,
HAM OP INFUSION,98308,"Yogarajah, Meera, MD",5/20/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/20/2025,Active,"Squamous cell carcinoma of bronchus of right lung (CMS/HCC)
Abnormal results of thyroid function studies",C34.31 - Primary cancer of right lower lobe of lung (CMS/HCC)
HAM OP INFUSION,98308,"Yogarajah, Meera, MD",3/6/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/3/2025,Inactive,"Squamous cell carcinoma of bronchus of right lung (CMS/HCC)
Abnormal results of thyroid function studies","Z51.89 - Encounter for other specified aftercare; C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; J86.9 - Pyothorax without fistula; J91.8 - Pleural effusion in other conditions classified elsewhere; D52.9 - Folate deficiency anemia, unspecified; J44.9 - Chronic obstructive pulmonary disease, unspecified; G90.50 - Complex regional pain syndrome I, unspecified; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.631 - Long term (current) use of antimetabolite agent; Z79.899 - Other long term (current) drug therapy"
SOM OUTPT INFUSION,53277,"Yin, Faye, MD",9/18/2023,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,,9/18/2023,Inactive,,
SOM OUTPT INFUSION,53277,"Yin, Faye, MD",10/11/2023,Dasatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,10/11/2023,Active,,
CBMC OP INFUSION 2FL,881,"Brown, Andrew Bennett, MD",11/22/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/21/2023,Inactive,,
NBI D7 MED-SURG/TELE,83783,"Shah, Shailja S, MD",10/22/2024,RiTUXimab Initial ++ Infusion Single Day (Outpatient),_1. First Line,10/22/2024,Inactive,,
CMC OP INFUSION,33035,"Talwar, Sumit, MD",1/15/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/14/2025,Inactive,"Malignant neoplasm of right renal pelvis (CMS/HCC)
Malignant neoplasm of urinary bladder (CMS/HCC)
Disorder of thyroid, unspecified",
CMC OP INFUSION,33035,"Talwar, Sumit, MD",1/15/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/13/2025,Inactive,"Malignant neoplasm of right renal pelvis (CMS/HCC)
Malignant neoplasm of urinary bladder (CMS/HCC)
Disorder of thyroid, unspecified",
HAM OP INFUSION,73594,"Yogarajah, Meera, MD",11/13/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,11/13/2023,Inactive,,
HAM OP INFUSION,73594,"Yogarajah, Meera, MD",1/19/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/17/2024,Active,,
HAM OP INFUSION,73594,"Yogarajah, Meera, MD",2/4/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/3/2025,Active,Rectosigmoid cancer (CMS/HCC),C19 - Rectosigmoid cancer (CMS/HCC)
CBMC OP INFUSION 2FL,9026,"Wagmiller, Jennifer Ann, MD",2/12/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/11/2024,Active,,
SOM OUTPT INFUSION,10372,"Packiam, Vignesh, MD",8/5/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Induction - Bladder Cancer,Adjuvant,8/4/2024,Inactive,,
SOM OUTPT INFUSION,10372,"Packiam, Vignesh, MD",11/7/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,11/3/2024,Active,,
NBR 5N ONCOLOGY,66015,"Matasar, Matthew J, MD",5/8/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),First Line,5/8/2023,Inactive,,
SOM OUTPT INFUSION,96611,"Toomey, Kathleen C, MD",2/12/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,2/12/2024,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CINJ OP INFUSION,52374,"Haigentz, Missak, MD",2/13/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/12/2024,Inactive,,
CINJ OP INFUSION,97379,"Aikins, James K, MD",1/19/2023,PEMEtrexed 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,1/11/2023,Inactive,,
CINJ OP INFUSION,97379,"Girda, Eugenia, MD",2/8/2023,CINJ 052101 (TT420X1103) ARM A TT-00420 (tinengotinib) 12 mg 28 Day Cycles Research- Solid Tumors: ID: 02-377,,2/7/2023,Inactive,,
CINJ OP INFUSION,97379,"Aikins, James K, MD",8/31/2023,PEMEtrexed 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/23/2023,Inactive,,
CINJ OP INFUSION,49256,"Gulhati, Prateek, MD PhD",11/16/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,10/18/2023,Active,,
CINJ PEDS HEMONC ,53225,"Botwinick, Marissa, DO",10/11/2024,"Nivolumab (D1, D15) 28 Day Cycles - Hodgkin Lymphoma",_1. First Line,10/10/2024,Active,,
MMC OP VP INFUSION,14546,"Meghal, Trishala, MD",11/12/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,10/22/2024,Active,,
TRMC TCCC OP INFUSION,45883,"Capo, Gerardo, MD",8/14/2024,PCbTP (Paclitaxel / Carboplatin / Trastuzumab / Pertuzumab) 21 Day Cycle - HER2 Breast Cancer,_1. First Line,8/14/2024,Active,,
TRMC TCCC OP INFUSION,45883,"Capo, Gerardo, MD",1/30/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,1/29/2025,Future,Malignant neoplasm of upper-outer quadrant of left female breast (CMS/HCC),
TRMC TCCC OP INFUSION,45883,"Capo, Gerardo, MD",2/27/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,2/26/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)","C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.0 - Estrogen receptor positive status (ER+)"
MMC OP VP INFUSION,61244,"Cohen, Seth D, MD",4/26/2023,Anastrozole 30 Day Cycles - Breast,Adjuvant,4/26/2023,Inactive,,
SOM OUTPT INFUSION,65277,"Toomey, Kathleen C, MD",11/1/2023,Trastuzumab Q21 Day Cycles- Breast,Adjuvant,10/26/2023,Inactive,,
NBR CINJ OP INFUSION,37470,"Shah, Mansi R, MD",9/13/2023,Lymphodepletion CARVIKTY with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,9/12/2023,Inactive,,
NBI OP INFUSION,82322,"Schleicher, Lori, MD",5/30/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,5/30/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)","C50.811, Z17.1 - Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)"
SOM OUTPT INFUSION,30205,"Patel, Eshan, MD",7/10/2023,CINJ 032013 (EA5181) ARM A Durvalumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,,7/2/2023,Inactive,,
SOM OUTPT INFUSION,30205,"Patel, Eshan, MD",8/29/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,,8/28/2023,Active,,
CMC OP INFUSION,67949,"Talwar, Sumit, MD",8/19/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,7/22/2024,Inactive,,
CMC OP INFUSION,67949,"Talwar, Sumit, MD",10/24/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,10/8/2024,Active,,
CINJ OP INFUSION,96527,"Golombos, David, MD",12/12/2024,BCG Induction (TICE) 42 Day Cycle,Induction,12/2/2024,Active,,
NBR CINJ OP INFUSION,87182,"Palmisiano, Neil David, MD",1/23/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,1/21/2023,Inactive,,
NBR CINJ OP INFUSION,87182,"Palmisiano, Neil David, MD",5/8/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,5/7/2023,Inactive,,
NBR 4N BMTU/IMCU,87182,"Patel, Vimal D, MD",6/7/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/7/2023,Inactive,,
NBR 4N ONCOLOGY,87182,"Braunschweig, Ira, MD",12/5/2023,Meningococcal 2nd doses of series for Complement inhibitor,_1. First Line,12/5/2023,Inactive,,
JCMC CP INFUSION,84346,"Sekhri, Arunabh, MD",6/17/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,6/16/2024,Inactive,,
HAM OP INFUSION,65739,"Patel, Malini M, MD",5/3/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,5/2/2023,Inactive,,
HAM OP INFUSION,65739,"Patel, Malini M, MD",12/11/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,12/10/2023,Inactive,,
CBMC OP INFUSION 2FL,76422,"Leitner, Stuart P, MD",1/9/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/11/2024,Active,Warm autoimmune hemolytic anemia (CMS/HCC),
CBMC OP INFUSION 2FL,82421,"Radovich, Delia, MD",11/30/2023,palbo faslodex xgeva 28 day cycle,,11/2/2023,Inactive,,
NBR 4N BMTU/IMCU,12297,"Schaar, Dale, MD PhD",1/19/2024,BMT Allogeneic TBF + Post Cy ,Consolidation,1/18/2024,Active,,
CMC OP INFUSION,52971,"Eltoukhy, Hussam, MD",4/4/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/3/2024,Active,,
NBR 5N ONCOLOGY,29567,"Tiger, Yun Kyoung, MD",12/7/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/4/2024,Active,,
CBMC OP INFUSION 2FL,60942,"Grossman, I Robert, MD",5/3/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,5/2/2024,Active,,
CMC OP INFUSION,28932,"Cohen, Seth D, MD",4/28/2025,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/28/2025,Active,Malignant neoplasm of right lung (CMS/HCC),
CINJ OP INFUSION,64131,"Saraiya, Biren P, MD",5/15/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/15/2024,Active,,
CINJ OP INFUSION,61678,"Saraiya, Biren P, MD",3/12/2025,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,3/12/2025,Active,Metastatic malignant neoplasm to prostate (CMS/HCC),C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; C79.11 - Secondary malignant neoplasm of bladder
CBMC 2W ONCOLOGY,86793,"Dave, Manish, MD",11/20/2023,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/20/2023,Inactive,,
CBMC 2W ONCOLOGY,86793,"Dave, Manish, MD",11/21/2023,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_1. First Line,11/21/2023,Inactive,,
CBMC 2W ONCOLOGY,86793,"Grossman, I Robert, MD",3/25/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,3/25/2024,Inactive,,
NBR CINJ OP INFUSION,86793,"Egini, Ogechukwu, MD",9/13/2024,BMT Allogeneic Flu (D-7) / TBI + Post Cy - Myeloablative,_1. First Line,9/13/2024,Active,,
NBI OP INFUSION,18698,"Shah, Maya M, MD",12/11/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/10/2024,Active,,
CBMC OP INFUSION 2FL,44016,"Radovich, Delia, MD",11/2/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,11/1/2023,Inactive,,
MMC OP INFUSION,47369,"Cohen, Seth D, MD",5/2/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,First Line,4/30/2023,Inactive,,
JCMC CP INFUSION,86986,"Cruz, Allan Louie E, MD",5/16/2023,Pembrolizumab 21 Day Cycles --- Squamous Cell Carcinoma;  Non-Small Cell Lung Cancer,Maintenance,5/16/2023,Active,,
SOM OUTPT INFUSION,26668,"Patel, Eshan, MD",4/6/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,4/5/2023,Active,,
NBR CINJ OP INFUSION,76842,"Rhodes, Joanna Meehan, MD",9/23/2024,Cladribine 5 Day Cycle - Hairy Cell Leukemia,_1. First Line,9/22/2024,Active,,
CINJ OP INFUSION,87529,"Stephenson, Ryan D, DO",12/11/2023,Enfortumab Vedotin / Pembrolizumab 21 Day Cycles - Bladder,_1. First Line,12/10/2023,Inactive,,
CINJ OP INFUSION,75989,"Salacz, Michael E, MD",1/5/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Second Line,1/5/2023,Inactive,,
CINJ OP INFUSION,19020,"Haigentz, Missak, MD",11/8/2023,CINJ 032003 PACLitaxel / CARBOplatin 21 Day Cycle CYCLE 1 Group C Research- Non-Small Cell Lung Cancer,Induction,11/7/2023,Inactive,,
CINJ OP INFUSION,19020,"Haigentz, Missak, MD",2/5/2024,CINJ 032003 Durvalumab 14 Day Cycles Group C Post-RT Research- Non-Small Cell Lung Cancer,Consolidation,2/4/2024,Active,,
CINJ OP INFUSION,19020,"Haigentz, Missak, MD",2/13/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/13/2025,Active,"Malignant neoplasm of right upper lobe of lung (CMS/HCC)
Metastasis to pleura (CMS/HCC)",C34.11 - Malignant neoplasm of right upper lobe of lung (CMS/HCC)
CINJ OP INFUSION,19020,"Haigentz, Missak, MD",4/28/2025,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/28/2025,Active,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Metastasis to pleura (CMS/HCC)
Secondary cancer of bone (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; I87.8 - Other specified disorders of veins; Z98.890 - Other specified postprocedural states; Z90.710 - Acquired absence of both cervix and uterus; Z90.722 - Acquired absence of ovaries, bilateral; Z90.89 - Acquired absence of other organs; Z87.19 - Personal history of other diseases of the digestive system; Z79.899 - Other long term (current) drug therapy; Z88.0 - Allergy status to penicillin"
NBR CINJ OP INFUSION,1325,"Zayac, Adam, MD",3/25/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,3/20/2024,Inactive,,
CINJ OP INFUSION,22538,"Leiser, Aliza, MD",7/2/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,7/1/2024,Active,,
NBR 5N ONCOLOGY,32030,"Rhodes, Joanna Meehan, MD",4/8/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_1. First Line,4/7/2024,Inactive,,
NBR CINJ OP INFUSION,32030,"Tiger, Yun Kyoung, MD",4/23/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,4/21/2024,Inactive,,
NBR CINJ OP INFUSION,32030,"Tiger, Yun Kyoung, MD",7/29/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,7/28/2024,Inactive,,
NBR CINJ OP INFUSION,32030,"Tiger, Yun Kyoung, MD",8/23/2024,EA (Etoposide / High-Dose Cytarabine) 28 Day Cycle - CNS Lymphoma,_1. First Line,8/23/2024,Inactive,,
CBMC OP INFUSION 2FL,75567,"Kulkarni, Aditya A, MD",12/11/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/10/2024,Active,,
CBMC OP INFUSION 2FL,64613,"Leitner, Stuart P, MD",4/3/2025,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,4/3/2025,Active,"Metastatic malignant neoplasm to prostate (CMS/HCC)
Secondary and malignant neoplasm of lymph nodes of multiple sites (CMS/HCC)",
MMC OP INFUSION,26656,"Lee, Patrick C, MD",9/22/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,9/21/2023,Inactive,,
SOM OUTPT INFUSION,70412,"Patel, Eshan, MD",5/10/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,,4/30/2023,Inactive,,
SOM OUTPT INFUSION,70412,"Patel, Eshan, MD",5/10/2023,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,,5/10/2023,Inactive,,
SOM OUTPT INFUSION,70412,"Patel, Eshan, MD",6/4/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/27/2024,Inactive,,
SOM OUTPT INFUSION,70412,"Patel, Eshan, MD",9/10/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,9/2/2024,Active,,
NBR CINJ OP INFUSION,97425,"Braunschweig, Ira, MD",1/24/2024,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,1/23/2024,Inactive,,
NBR 4N ONCOLOGY,97425,"Matasar, Matthew J, MD",3/5/2024,CINJ 012302 Part 1 Cohort 6D AZD0486 (TNB-486) 28 Day Cycles Research- High Grade B Cell Lymphoma,_3. Third Line,3/5/2024,Active,,
NBR CINJ OP INFUSION,97425,"Matasar, Matthew J, MD",3/5/2024,CINJ 012302 Part I AZD0486 (TNB-486) - High Grade B Cell Lymphoma,_3. Third Line,3/5/2024,Inactive,,
SOM OUTPT INFUSION,50195,"Patel, Eshan, MD",2/17/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/10/2025,Active,Small cell carcinoma of hilum of lung (CMS/HCC),
SOM OUTPT INFUSION,95734,"Patel, Eshan, MD",5/12/2025,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,Maintenance,5/12/2025,Inactive,Small cell carcinoma of hilum of lung (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C34.00 - Malignant neoplasm of unspecified main bronchus; R94.6 - Abnormal results of thyroid function studies; Z94.1 - Heart transplant status
CINJ OP INFUSION,86257,"Muralikrishnan, Sivraj, MD",4/29/2025,Atezolizumab/Bevacizumab/PACLitaxel/CARBOplatin 21 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/29/2025,Inactive,"Mediastinal cancer (CMS/HCC)
High grade neuroendocrine carcinoma (CMS/HCC)",
NBR 4N ONCOLOGY,86257,"Haigentz, Missak, MD",4/26/2025,CISplatin / Etoposide (75/100) 21 Day Cycles - High Grade Neuroendocrine,Neoadjuvant,4/26/2025,Active,"Mediastinal cancer (CMS/HCC)
High grade neuroendocrine carcinoma (CMS/HCC)","C7A.1 - Malignant poorly differentiated neuroendocrine tumors; E88.3 - Tumor lysis syndrome; I82.290 - Acute embolism and thrombosis of other thoracic veins; I31.39 - Other pericardial effusion (noninflammatory); I82.C12 - Acute embolism and thrombosis of left internal jugular vein; C38.3 - Malignant neoplasm of mediastinum, part unspecified; D75.9 - Disease of blood and blood-forming organs, unspecified; N18.30 - Chronic kidney disease, stage 3 unspecified; E03.9 - Hypothyroidism, unspecified; E04.2 - Nontoxic multinodular goiter; E66.9 - Obesity, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E87.20 - Acidosis, unspecified; H54.7 - Unspecified visual loss; H91.90 - Unspecified hearing loss, unspecified ear; K21.9 - Gastro-esophageal reflux disease without esophagitis; G43.909 - Migraine, unspecified, not intractable, without status migrainosus; H93.19 - Tinnitus, unspecified ear; K59.00 - Constipation, unspecified; R73.03 - Prediabetes; R74.01 - Elevation of levels of liver transaminase levels; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z79.01 - Long term (current) use of anticoagulants; Z68.36 - Body mass index (BMI) 36.0-36.9, adult; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.890 - Hormone replacement therapy; Z80.42 - Family history of malignant neoplasm..."
SOM OUTPT INFUSION,50009,"Patel, Eshan, MD",5/11/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,First Line,5/8/2023,Inactive,,
NBR CINJ OP INFUSION,50009,"Shah, Mansi R, MD",8/17/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,8/3/2023,Inactive,,
NBR 4N ONCOLOGY,50009,"Braunschweig, Ira, MD",9/7/2023,BMT Autologous Melphalan Day -1  200mg/m2,,9/5/2023,Inactive,,
HAM OP INFUSION,92365,"Yogarajah, Meera, MD",2/14/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,1/29/2025,Active,Metastasis from pancreatic cancer (CMS/HCC),
CBMC OP INFUSION 2FL,17409,"Brown, Andrew Bennett, MD",8/26/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/19/2024,Active,"Malignant melanoma of other part of trunk (CMS/HCC)
Disorder of thyroid, unspecified",
CINJ OP INFUSION,21493,"Muralikrishnan, Sivraj, MD",1/24/2025,PACLitaxel/CARBOplatin 21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer,_1. First Line,1/23/2025,Active,,
MMC OP VP INFUSION,37525,"Cohen, Seth D, MD",8/14/2024,Zanubrutinib (160 mg) 30 Day Cycles - Mantle Cell Lymphoma,_2. Second Line,8/14/2024,Active,Nodular sclerosis Hodgkin lymphoma of intra-abdominal lymph nodes (CMS/HCC),
JCMC CP INFUSION,52929,"Cruz, Allan Louie E, MD",5/12/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/12/2025,Active,Primary malignant neoplasm of left lower lobe of lung (CMS/HCC),"C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung"
CINJ OP INFUSION,26300,"Haigentz, Missak, MD",1/7/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/6/2025,Active,,
CINJ OP INFUSION,90130,"Haigentz, Missak, MD",4/1/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,4/1/2025,Inactive,"Squamous cell lung cancer (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Chronic fatigue
Secondary malignant neoplasm of brain (CMS/HCC)
Thyroid disorder screen",
JCMC CP INFUSION,71917,"Cruz, Allan Louie E, MD",8/13/2024,"CINJ 042315 Arm 2 Durvalumab / PACLitaxel D1, D8 14 Day Cycles followed by Durvalumab / DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer",Neoadjuvant,8/5/2024,Inactive,,
JCMC CP INFUSION,71917,"Cruz, Allan Louie E, MD",11/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,11/5/2024,Active,,
CBMC OP INFUSION 2FL,51593,"Scoppetuolo, Michael, MD",12/21/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,12/7/2023,Active,,
CMC OP INFUSION,64872,"Easaw, Sarah, MD",5/19/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Second Line,5/18/2023,Inactive,,
CMC OP INFUSION,64872,"Meghal, Trishala, MD",12/12/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,12/12/2023,Inactive,,
CMC OP INFUSION,64872,"Meghal, Trishala, MD",2/13/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,2/8/2024,Inactive,,
SOM OUTPT INFUSION,41536,"Toomey, Kathleen C, MD",4/20/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,4/19/2023,Inactive,,
SOM OUTPT INFUSION,41536,"Toomey, Kathleen C, MD",1/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/11/2024,Inactive,,
SOM OUTPT INFUSION,41536,"Toomey, Kathleen C, MD",6/28/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,6/27/2024,Inactive,,
NBR 5N ONCOLOGY,46725,"Rhodes, Joanna Meehan, MD",5/19/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/19/2025,Active,Follicular lymphoma (CMS/HCC),"C82.90 - Follicular lymphoma, unspecified, unspecified site; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified"
CBMC OP INFUSION 2FL,16220,"Scoppetuolo, Michael, MD",2/17/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_2. Second Line,2/9/2025,Active,Follicular lymphoma grade II of lymph nodes of multiple sites (CMS/HCC),"C82.18 - Follicular lymphoma grade ii, lymph nodes of multiple sites"
CBMC OP INFUSION 2FL,57511,"Scoppetuolo, Michael, MD",12/12/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,12/5/2023,Inactive,,
CBMC OP INFUSION 2FL,57511,"Scoppetuolo, Michael, MD",3/27/2024,Bendamustine / Obinutuzumab 28 Day Cycles + Obinutuzumab 56 Day Cycles - Follicular Lymphoma ,_2. Second Line,3/26/2024,Inactive,,
CINJ OP INFUSION,76359,"Hochster, Howard S, MD",2/8/2023,"TASIRI-Bev: Trifluridine and Tipiracil D1-5; D15-19 /Iriotecan/ Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Third Line,2/8/2023,Inactive,,
HAM OP INFUSION,1998,"Yogarajah, Meera, MD",3/23/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",First Line,3/22/2023,Inactive,,
NBR CINJ OP INFUSION,5780,"Rhodes, Joanna Meehan, MD",4/22/2024,AHOD2131 All Arms ABVD,_1. First Line,4/21/2024,Inactive,,
NBR CINJ OP INFUSION,5780,"Rhodes, Joanna Meehan, MD",4/23/2024,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/22/2024,Inactive,,
NBR CINJ OP INFUSION,5780,"Rhodes, Joanna Meehan, MD",4/23/2024,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,4/22/2024,Inactive,,
NBR CINJ OP INFUSION,5780,"Rhodes, Joanna Meehan, MD",6/27/2024,"CINJ 112305 Arms B,D,F,H (Brentuximab Vendotin + Nivolumab) 21 Day Cycles - Hodgkin Lymphoma",_1. First Line,6/26/2024,Active,,
CINJ OP INFUSION,13262,"Toppmeyer, Deborah L, MD",7/20/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,7/18/2023,Inactive,,
CINJ OP INFUSION,13262,"Toppmeyer, Deborah L, MD",9/30/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,9/30/2024,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
JCMC CP INFUSION,61600,"Sekhri, Arunabh, MD",10/28/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles + Xgeva (hypercalcemia)- metastatic Esophageal squamous cell carcinoma,_1. First Line,10/7/2024,Inactive,,
JCMC CP INFUSION,61600,"Sekhri, Arunabh, MD",12/23/2024,DOCEtaxel 21 Day Cycles- Esophageal/Esophagogastric Junction Cancers,_2. Second Line,12/22/2024,Active,,
MMC OP VP INFUSION,70861,"Cohen, Seth D, MD",2/6/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/5/2024,Inactive,,
SOM OUTPT INFUSION,33339,"Patel, Eshan, MD",8/7/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,8/6/2024,Active,,
CINJ OP INFUSION,81178,"Toppmeyer, Deborah L, MD",9/7/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/5/2023,Inactive,,
CINJ OP INFUSION,81178,"Toppmeyer, Deborah L, MD",4/22/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,4/22/2024,Active,,
CMC OP INFUSION,11352,"Ferretti, Mark J, MD",5/9/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,5/9/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
SOM OUTPT INFUSION,13231,"Patel, Eshan, MD",8/1/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/24/2024,Inactive,,
SOM OUTPT INFUSION,13231,"Patel, Eshan, MD",10/24/2024,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/23/2024,Active,,
SOM OUTPT INFUSION,13231,"Patel, Eshan, MD",11/14/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/13/2024,Inactive,,
CINJ OP INFUSION,83873,"Girda, Eugenia, MD",12/24/2024,Methotrexate 7 Day Cycles - Gestational Trophoblastic Neoplasia,_1. First Line,12/23/2024,Active,,
CMC OP INFUSION,71690,"Easaw, Sarah, MD",6/12/2023,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",Third Line,6/1/2023,Inactive,,
CINJ OP INFUSION,96653,"George, Mridula A, MD",7/28/2023,Ribociclib 28 Day Cycles - Breast,First Line,7/28/2023,Inactive,,
CINJ OP INFUSION,24726,"George, Mridula A, MD",1/22/2025,CINJ 042402 Part 1 RLY-2608 / Fulvestrant 28 Day Cycles Research- Breast Cancer,_2. Second Line,1/22/2025,Active,,
CINJ OP INFUSION,10188,"Girda, Eugenia, MD",4/27/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,4/27/2023,Inactive,,
CINJ OP INFUSION,10188,"Girda, Eugenia, MD",8/18/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/15/2023,Inactive,,
NBR 4N ONCOLOGY,10188,"Girda, Eugenia, MD",10/20/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,10/19/2023,Inactive,,
CINJ OP INFUSION,10188,"Girda, Eugenia, MD",4/11/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_4. Fourth Line,4/7/2024,Inactive,,
CBMC OP INFUSION 2FL,31522,"Wagmiller, Jennifer Ann, MD",11/13/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,31522,"Wagmiller, Jennifer Ann, MD",12/27/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,12/26/2023,Inactive,,
CBMC OP INFUSION 2FL,31522,"Wagmiller, Jennifer Ann, MD",10/21/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/20/2024,Active,,
CINJ OP INFUSION,23397,"Weiss, Sarah, MD",1/17/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,1/16/2024,Inactive,,
NBI OP INFUSION,59336,"Anderson, Patrick S, MD",3/28/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,3/27/2024,Inactive,,
NBI OP INFUSION,59336,"Anderson, Patrick S, MD",10/3/2024,Gemcitabine D1 & 8  / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/2/2024,Active,,
CMC OP INFUSION,63202,"Cohen, Seth D, MD",12/27/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/27/2023,Inactive,,
CMC OP INFUSION,79473,"Talwar, Sumit, MD",6/24/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Induction,6/17/2024,Active,,
CINJ OP INFUSION,10289,"Haigentz, Missak, MD",4/25/2025,Lenvatinib 28 Day Cycles- Papillary Carcinoma,_1. First Line,4/25/2025,Active,"Malignant neoplasm of thyroid gland (CMS/HCC)
Protein C deficiency (CMS/HCC)
History of DVT (deep vein thrombosis)
Malignant neoplasm metastatic to lung (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)
Encounter for monitoring Coumadin therapy",C73 - Malignant neoplasm of thyroid gland; C78.00 - Secondary malignant neoplasm of unspecified lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; Z51.81 - Encounter for therapeutic drug level monitoring; Z79.01 - Long term (current) use of anticoagulants
CBMC OP INFUSION 2FL,62346,"Litvak, Anna M, MD",8/24/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,8/23/2023,Inactive,,
CBMC OP INFUSION 2FL,62346,"Ligresti, Louise G, MD",2/20/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,2/12/2024,Active,,
MMC OP VP INFUSION,51451,"Lee, Patrick C, MD",1/4/2024,CAP (Cyclophosphamide / DOXOrubicin / CISplatin) 21 Day Cycles - Thymoma,_1. First Line,11/15/2023,Active,,
CBMC OP INFUSION 2FL,38623,"Wagmiller, Jennifer Ann, MD",3/21/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/17/2024,Active,,
NBR CINJ OP INFUSION,97457,"Rhodes, Joanna Meehan, MD",4/17/2025,N-AVD (NIVOlumab/DOXOrubicin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/17/2025,Active,"HIV (human immunodeficiency virus infection) (CMS/HCC)
Nodular sclerosis Hodgkin lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC)","C81.10 - Nodular sclerosis Hodgkin lymphoma, unspecified site; Z21 - Asymptomatic human immunodeficiency virus (hiv) infection status; R59.1 - Generalized enlarged lymph nodes; C81.19 - Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites"
CINJ OP INFUSION,81377,"Saraiya, Biren P, MD",6/4/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_1. First Line,6/4/2024,Active,,
NBR CINJ OP INFUSION,17746,"Tiger, Yun Kyoung, MD",10/30/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_1. First Line,10/24/2024,Active,,
NBR CINJ OP INFUSION,31393,"Doraiswamy, Anupama, MD",3/16/2023,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,,3/14/2023,Inactive,,
NBR CINJ OP INFUSION,31393,"Doraiswamy, Anupama, MD",3/21/2023,CINJ 021808 Vincristine and Venetoclax Arm D 28 Day Cycles - Acute Lymphoblastic Leukemia,,3/16/2023,Inactive,,
CINJ OP INFUSION,50518,"Stephenson, Ruth D, DO",5/18/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,5/16/2023,Inactive,,
CINJ OP INFUSION,50518,"Stephenson, Ruth D, DO",11/10/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,11/9/2023,Inactive,,
CINJ OP INFUSION,50518,"Stephenson, Ruth D, DO",5/3/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,4/25/2024,Inactive,,
CINJ OP INFUSION,50518,"Stephenson, Ruth D, DO",10/24/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,10/22/2024,Active,,
TRMC TCCC OP INFUSION,60536,"Capo, Gerardo, MD",7/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/9/2024,Active,,
TRMC TCCC OP INFUSION,60536,"Capo, Gerardo, MD",3/5/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/28/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
CINJ OP INFUSION,11157,"Omene, Coral Oghenerukevwe, MD",6/13/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,6/13/2023,Inactive,,
MMC OP VP INFUSION,75319,"Talwar, Sumit, MD",8/18/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,8/16/2023,Inactive,,
CINJ OP INFUSION,35509,"George, Mridula A, MD",9/22/2023,Pembrolizumab / DOCetaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,9/21/2023,Inactive,,
NBR CINJ OP INFUSION,35509,"Palmisiano, Neil David, MD",10/22/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,10/21/2024,Active,Multiple myeloma (CMS/HCC),
CBMC OP INFUSION 2FL,73498,"Scoppetuolo, Michael, MD",6/16/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,6/16/2023,Inactive,,
CBMC OP INFUSION 2FL,73498,"Scoppetuolo, Michael, MD",1/18/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,1/9/2024,Inactive,,
CBMC OP INFUSION 2FL,73498,"Scoppetuolo, Michael, MD",4/24/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,4/23/2024,Active,,
CBMC OP INFUSION 2FL,66376,"Leitner, Stuart P, MD",12/13/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,_3. Third Line,12/12/2023,Active,Acute lymphoblastic leukemia (ALL) in child (CMS/HCC),
CINJ OP INFUSION,8744,"Weiss, Sarah, MD",8/12/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,8/11/2024,Inactive,,
NBI C5 PEDS ICU,46842,"Batra, Surabhi, MD",12/24/2024,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,12/23/2024,Active,,
CINJ OP INFUSION,77750,"Aikins, James K, MD",7/25/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/24/2024,Inactive,,
CINJ OP INFUSION,77750,"Aikins, James K, MD",11/22/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/21/2024,Active,,
CINJ OP INFUSION,77750,"Aikins, James K, MD",2/6/2025,Cyclophosphamide Oral / Bevacizumab/pembrolizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,2/5/2025,Inactive,Peritoneal carcinomatosis (CMS/HCC),"C56.9 - Malignant neoplasm of unspecified ovary; Z51.11 - Encounter for antineoplastic chemotherapy; R97.1 - Elevated cancer antigen 125 (CA 125); T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R11.2 - Nausea with vomiting, unspecified; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum"
JCMC CP INFUSION,53018,"Sekhri, Arunabh, MD",1/27/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,First Line,1/27/2023,Inactive,,
JCMC CP INFUSION,53018,"Sekhri, Arunabh, MD",4/28/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,4/14/2023,Inactive,,
NBR 4N ONCOLOGY,47596,"Groisberg, Roman, MD",6/28/2024,AD (DOXOrubicin / Dacarbazine) 21 Day Cycles - Sarcoma,_1. First Line,6/27/2024,Inactive,,
NBI OP INFUSION,72259,"Schleicher, Lori, MD",2/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/15/2024,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),
JCMC CP INFUSION,77835,"Sekhri, Arunabh, MD",3/10/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/10/2025,Active,"Ductal carcinoma of breast, stage 4, right (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; R45.89 - Other symptoms and signs involving emotional state; M81.0 - Age-related osteoporosis without current pathological fracture; Z92.21 - Personal history of antineoplastic chemotherapy
MSC OP INFUSION,18767,"Talwar, Sumit, MD",6/26/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,6/25/2024,Active,,
CBMC OP INFUSION 2FL,24549,"Litvak, Anna M, MD",11/3/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,24549,"Ligresti, Louise G, MD",5/30/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_3. Third Line,5/29/2024,Active,,
SOM OUTPT INFUSION,64124,"Patel, Eshan, MD",9/5/2023,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,,8/28/2023,Active,,
SOM OUTPT INFUSION,64124,"Patel, Eshan, MD",2/13/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,2/3/2025,Active,Primary small cell carcinoma of lower lobe of right lung (CMS/HCC),
SOM OUTPT INFUSION,64124,"Patel, Eshan, MD",2/13/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_2. Second Line,2/3/2025,Active,"Squamous cell carcinoma lung, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,51500,"Ghodoussipour, Saum Bobak, MD",6/28/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,6/28/2024,Inactive,,
CINJ OP INFUSION,51500,"Stephenson, Ryan D, DO",8/14/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Adjuvant,8/13/2024,Inactive,,
NBR CINJ OP INFUSION,69294,"Shah, Mansi R, MD",12/15/2023,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,12/14/2023,Inactive,,
NBR CINJ OP INFUSION,69294,"Shah, Mansi R, MD",12/15/2023,Carfilzomib 70 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,12/10/2023,Inactive,,
NBR CINJ OP INFUSION,69294,"Shah, Mansi R, MD",3/21/2024,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,2/7/2024,Inactive,,
NBI OP INFUSION,73503,"Shah, Maya M, MD",12/27/2023,Pembrolizumab / PACLitaxel  21 Day Cycles - Breast,_1. First Line,12/26/2023,Inactive,,
NBI OP INFUSION,73503,"Cheng, Yan Ho, MD",5/8/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/7/2024,Inactive,,
CMC OP INFUSION,2050,"Talwar, Sumit, MD",1/8/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/7/2025,Active,,
HAM OP INFUSION,48015,"Yogarajah, Meera, MD",10/17/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,10/4/2023,Inactive,,
CMC OP INFUSION,69632,"Tang, Horace, MD",2/20/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,2/19/2023,Inactive,,
CMC OP INFUSION,69632,"Tang, Horace, MD",8/18/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,8/18/2023,Inactive,,
NBR CINJ OP INFUSION,69632,"Braunschweig, Ira, MD",10/11/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,10/10/2023,Inactive,,
NBR CINJ OP INFUSION,69632,"Braunschweig, Ira, MD",10/16/2023,Epcoritamab-bysp 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,10/15/2023,Inactive,,
NBR 4N BMTU/IMCU,69632,"Braunschweig, Ira, MD",2/7/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,2/6/2024,Inactive,,
CBMC OP INFUSION 2FL,88177,"Wagmiller, Jennifer Ann, MD",1/14/2025,"Albumin-Bound PACLitaxel D1, D8, D15/ CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,1/5/2025,Active,Gastric adenocarcinoma (CMS/HCC),
MMC OP VP INFUSION,42765,"Meghal, Trishala, MD",11/21/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,11/4/2024,Inactive,,
CBMC OP INFUSION 2FL,90448,"Wagmiller, Jennifer Ann, MD",9/18/2023,Pembrolizumab 21 Day Cycles - Uterine,,9/17/2023,Active,,
SOM OUTPT INFUSION,56530,"Toomey, Kathleen C, MD",8/15/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,8/14/2024,Inactive,,
NBI VALERIE FND HEMONC,42329,"Rao, Harini, MD",1/27/2025,AALL1732 Consolidation,_1. First Line,1/27/2025,Active,,
SOM 1PAV ONCOLOGY,44807,"Patel, Eshan, MD",7/31/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,,7/27/2023,Inactive,,
CINJ OP INFUSION,96556,"Mayer, Tina M, MD",1/26/2023,CINJ 082002 Pre-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,First Line,1/25/2023,Inactive,,
CINJ OP INFUSION,96556,"Mayer, Tina M, MD",4/27/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,,4/27/2023,Inactive,,
CINJ OP INFUSION,97995,"Weiss, Sarah, MD",2/12/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,2/11/2024,Inactive,,
SOM OUTPT INFUSION,724,"Toomey, Kathleen C, MD",10/10/2023,RiTUXimab 375mg/m2 weekly x 4,Reinduction,10/5/2023,Active,"Malignant neoplasm of ovary (CMS/HCC)
Malignant neoplasm of uterus, part unspecified (CMS/HCC)",
CMC OP INFUSION,57701,"Taff, Jessica, MD",10/13/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,10/8/2023,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,36861,"Leitner, Stuart P, MD",9/15/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,9/14/2023,Inactive,,
CBMC OP INFUSION 2FL,36861,"Leitner, Stuart P, MD",1/15/2024,PACLitaxel/CISplatin 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/14/2024,Inactive,,
CBMC OP INFUSION 2FL,36861,"Leitner, Stuart P, MD",1/16/2024,CISplatin 21 Day Cycles - Breast,Neoadjuvant,1/15/2024,Inactive,,
NBR CINJ OP INFUSION,32162,"Evens, Andrew M, DO",2/16/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,2/15/2023,Inactive,,
HAM OP INFUSION,82635,"Yogarajah, Meera, MD",8/15/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,8/8/2023,Active,,
TRMC TCCC OP INFUSION,52464,"Salerno, Vincent E, MD",8/2/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,8/1/2024,Active,,
CINJ OP INFUSION,66742,"Weiss, Sarah, MD",3/7/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,3/7/2023,Inactive,,
CINJ OP INFUSION,66742,"Weiss, Sarah, MD",3/24/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,3/19/2023,Inactive,,
CMC OP INFUSION,20819,"Cohen, Seth D, MD",2/8/2024,Dostarlimab-gxly  42 Day Cycles- Colon Cancer,_1. First Line,2/7/2024,Active,,
JCMC CP INFUSION,57317,"Ghuman, Damanjit, MD",5/26/2023,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,5/22/2023,Inactive,,
JCMC CP INFUSION,42220,"Sekhri, Arunabh, MD",1/17/2023,mFU + Bevacizumab (Fluorouracil Continuous Infusion) 14 Day Cycles- Gastrointestinal Cancers,First Line,1/16/2023,Inactive,,
JCMC CP INFUSION,42220,"Sekhri, Arunabh, MD",10/16/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/24/2024,Active,,
CBMC OP INFUSION 2FL,95681,"Scoppetuolo, Michael, MD",4/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/21/2024,Inactive,,
CMC OP INFUSION,10013,"Taff, Jessica, MD",10/25/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/22/2024,Active,,
CMC OP INFUSION,10013,"Taff, Jessica, MD",5/16/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/16/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
NBR CINJ OP INFUSION,68627,"Shah, Mansi R, MD",5/22/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,5/22/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Abnormal coagulation profile","C90.00 - Multiple myeloma not having achieved remission; D80.1 - Nonfamilial hypogammaglobulinemia; Z86.16 - Personal history of COVID-19; Z94.84 - Stem cells transplant status; D47.2 - Monoclonal gammopathy; C90.01 - Multiple myeloma in remission; G62.9 - Polyneuropathy, unspecified; G62.0 - Drug-induced polyneuropathy; T45.1X5S - Adverse effect of antineoplastic and immunosuppressive drugs, sequela; R79.1 - Abnormal coagulation profile; Z71.89 - Other specified counseling"
NBR CINJ OP INFUSION,27104,"Evens, Andrew M, DO",10/11/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,First Line,10/10/2023,Inactive,,
CINJ OP INFUSION,35275,"Weiss, Sarah, MD",2/12/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/11/2025,Active,Malignant melanoma of scalp (CMS/HCC),"C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; C43.39 - Malignant melanoma of other parts of face; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified; C44.90 - Unspecified malignant neoplasm of skin, unspecified; C43.4 - Malignant melanoma of scalp and neck; C43.9 - Malignant melanoma of skin, unspecified"
TRMC TCCC OP INFUSION,27366,"Capo, Gerardo, MD",10/25/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,10/24/2024,Active,,
CINJ OP INFUSION,87341,"Stephenson, Ryan D, DO",2/14/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,2/14/2024,Active,,
CINJ OP INFUSION,87341,"Stephenson, Ryan D, DO",2/3/2025,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,2/3/2025,Active,"Primary malignant neoplasm of right kidney with metastasis from kidney to other site (CMS/HCC)
Hypothyroidism due to medication","C64.1 - Malignant neoplasm of right kidney, except renal pelvis; C79.51 - Secondary malignant neoplasm of bone; C79.52 - Secondary malignant neoplasm of bone marrow; E03.2 - Hypothyroidism due to medicaments and other exogenous substances"
MMC OP VP INFUSION,60573,"Talwar, Sumit, MD",9/19/2023,Ruxolitinib 30 Day Cycles - Myelofibrosis,,9/19/2023,Active,"Invasive ductal carcinoma of breast, female, left (CMS/HCC)",
NBR 5N ONCOLOGY,49070,"Berim, Lyudmyla, MD",5/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/2/2024,Inactive,,
CBMC OP INFUSION 2FL,50472,"Leitner, Stuart P, MD",4/10/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/10/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,84161,"Brown, Andrew Bennett, MD",1/29/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/22/2024,Active,,
CINJ OP INFUSION,62574,"Salacz, Michael E, MD",1/3/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,First Line,1/3/2023,Inactive,,
HAM OP INFUSION,52629,"Yogarajah, Meera, MD",4/25/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,4/19/2023,Inactive,,
CINJ OP INFUSION,9632,"Boland, Patrick M, MD",7/15/2024,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,7/15/2024,Active,,
CMC OP INFUSION,9632,"Taff, Jessica, MD",9/5/2024,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,_1. First Line,8/7/2024,Inactive,,
MSC OP INFUSION,25902,"Cohen, Seth D, MD",1/12/2023,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,,1/11/2023,Inactive,,
MMC OP VP INFUSION,25902,"Cohen, Seth D, MD",7/18/2024,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,7/17/2024,Inactive,,
MSC OP INFUSION,25902,"Cohen, Seth D, MD",8/28/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_3. Third Line,8/20/2024,Inactive,,
CBMC OP INFUSION 2FL,49873,"Leitner, Stuart P, MD",3/11/2025,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Induction,3/11/2025,Active,Malignant neoplasm of dome of urinary bladder (CMS/HCC),
NBI OP INFUSION,25639,"Shah, Maya M, MD",1/4/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,1/3/2023,Inactive,,
NBR 4N BMTU/IMCU,9117,"Patel, Vimal D, MD",6/7/2023,BMT Autologous Carmustine / Thiotepa,,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,9117,"Braunschweig, Ira, MD",7/12/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,7/11/2023,Inactive,,
NBR 4N ONCOLOGY,8344,"Stephenson, Ryan D, DO",9/19/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,,9/18/2023,Inactive,,
NBR CINJ OP INFUSION,70226,"Rhodes, Joanna Meehan, MD",2/5/2024,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/14/2024,Inactive,,
NBR 5N MED-SURG OVRF,82031,"Alexander, Henry Richard, MD",12/8/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,12/8/2023,Inactive,,
SOM OUTPT INFUSION,69888,"Patel, Eshan, MD",4/27/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,First Line,4/23/2023,Inactive,,
SOM OUTPT INFUSION,69888,"Patel, Eshan, MD",5/23/2023,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,,5/23/2023,Inactive,,
CINJ OP INFUSION,82252,"Haigentz, Missak, MD",7/4/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/4/2023,Active,,
SOM OUTPT INFUSION,46766,"Patel, Eshan, MD",3/27/2024,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,3/19/2024,Active,ALL (acute lymphoid leukemia) in relapse (CMS/HCC),
CINJ PEDS HEMONC ,58420,"Moerdler, Scott, MD",6/27/2023,PEDS ACNS0232 Regimen B,First Line,6/1/2023,Inactive,,
NBR 5N ONCOLOGY,81613,"Rhodes, Joanna Meehan, MD",9/2/2023,CVP (Cyclophosphamide / VinCRIStine / PredniSONE) 21 Day Cycles - Indolent Lymphoma,Second Line,9/1/2023,Inactive,,
NBR CINJ OP INFUSION,55702,"Rhodes, Joanna Meehan, MD",8/15/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,First Line,8/15/2023,Inactive,,
NBR CINJ OP INFUSION,55702,"Rhodes, Joanna Meehan, MD",9/8/2023,CINJ 012103 ARM 1 CC-486 + MINI-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / RiTUXimab) 21 Day Cycles Research- Non-Hodgkin Lymphoma,,8/25/2023,Inactive,,
NBR CINJ OP INFUSION,55702,"Rhodes, Joanna Meehan, MD",9/19/2024,Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,9/18/2024,Active,,
CBMC OP INFUSION 2FL,77970,"Litvak, Anna M, MD",4/10/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,4/10/2025,Active,"Malignant neoplasm of overlapping sites of both breasts in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,47992,"Toomey, Kathleen C, MD",9/18/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,9/17/2024,Active,,
MMC OP INFUSION,30323,"Lee, Patrick C, MD",3/5/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),Neoadjuvant,3/5/2024,Inactive,,
CBMC OP INFUSION 2FL,41158,"Wagmiller, Jennifer Ann, MD",5/21/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,41158,"Wagmiller, Jennifer Ann, MD",5/21/2024,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,_1. First Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,41158,"Wagmiller, Jennifer Ann, MD",6/5/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Neoadjuvant,6/2/2024,Inactive,,
CBMC 2W ONCOLOGY,41158,"Wagmiller, Jennifer Ann, MD",12/5/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/2/2024,Inactive,,
NBI A5 PEDIATRICS,81138,"Batra, Surabhi, MD",5/18/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_3. Third Line,5/18/2024,Active,"Malignant neoplasm of middle third of esophagus (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures
Brachial plexopathy due to malignant neoplasm (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,10240,"Girda, Eugenia, MD",1/24/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,1/23/2025,Active,,
NBR CINJ OP INFUSION,33326,"Tiger, Yun Kyoung, MD",6/18/2024,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_3. Third Line,6/17/2024,Active,,
CMC OP INFUSION,25130,"Taff, Jessica, MD",4/29/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/28/2025,Active,Hodgkin lymphoma (CMS/HCC),
CMC OP INFUSION,25130,"Taff, Jessica, MD",4/22/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/22/2025,Inactive,Hodgkin lymphoma (CMS/HCC),
NBR 4N BMTU/IMCU,91999,"Braunschweig, Ira, MD",6/19/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/19/2023,Inactive,,
NBR CINJ OP INFUSION,91999,"Zayac, Adam, MD",11/20/2024,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,11/20/2024,Inactive,,
CMC OP INFUSION,73646,"Pompa, Tiffany Ann, MD",5/8/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/8/2025,Active,Malignant neoplasm of right female breast (CMS/HCC),
MSC OP INFUSION,77543,"Talwar, Sumit, MD",7/3/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Second Line,7/2/2023,Inactive,,
JCMC CP INFUSION,26557,"Cruz, Allan Louie E, MD",10/9/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,10/9/2024,Inactive,,
CINJ OP INFUSION,26557,"Weiss, Sarah, MD",2/19/2025,"CINJ 052408 Part 2.2A, B, C, and D Expansion AB248 / Pembrolizumab 200 mg 21 Day Cycles Research- Solid Tumors",_2. Second Line,2/19/2025,Active,"Malignant melanoma of skin, unspecified (CMS/HCC)","Z00.6 - Encounter for examination for normal comparison and control in clinical research program; D64.9 - Anemia, unspecified; C30.0 - Malignant neoplasm of nasal cavity; D35.2 - Benign neoplasm of pituitary gland; G62.9 - Polyneuropathy, unspecified; C79.89 - Secondary malignant neoplasm of other specified sites; Z85.05 - Personal history of malignant neoplasm of liver; Z85.028 - Personal history of other malignant neoplasm of stomach; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; Z90.721 - Acquired absence of ovaries, unilateral; Z90.710 - Acquired absence of both cervix and uterus; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; Z78.0 - Asymptomatic menopausal state; Z80.0 - Family history of malignant neoplasm of digestive organs"
JCMC CP INFUSION,26557,"Cruz, Allan Louie E, MD",5/22/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_3. Third Line,5/22/2025,Active,"Malignant melanoma of scalp and neck (CMS/HCC)
Secondary malignant neoplasm of skin (CMS/HCC)",C43.4 - Malignant melanoma of scalp and neck; C79.2 - Secondary malignant neoplasm of skin
MMC OP VP INFUSION,6865,"Cohen, Seth D, MD",6/20/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,6/19/2023,Inactive,,
NBI OP INFUSION,10496,"Anderson, Patrick S, MD",2/6/2025,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles -Vulvar cancer,_2. Second Line,2/5/2025,Active,"Vulvar cancer (CMS/HCC)
Vulvar carcinoma (CMS/HCC)",
NBI OP INFUSION,10496,"Anderson, Patrick S, MD",3/19/2025,PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles -Vulvar cancer,_2. Second Line,2/6/2025,Active,"Vulvar cancer (CMS/HCC)
Vulvar carcinoma (CMS/HCC)",
CBMC OP INFUSION 2FL,62309,"Kulkarni, Aditya A, MD",1/13/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,1/13/2025,Active,,
CINJ OP INFUSION,48258,"Berim, Lyudmyla, MD",1/12/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,,1/8/2023,Inactive,,
CINJ OP INFUSION,48258,"Berim, Lyudmyla, MD",5/13/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/8/2024,Active,,
CINJ OP INFUSION,48258,"Berim, Lyudmyla, MD",2/19/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,2/18/2025,Active,"Malignant neoplasm of transverse colon (CMS/HCC)
Secondary malignant neoplasm of liver and intrahepatic bile duct (CMS/HCC)",C18.4 - Malignant neoplasm of transverse colon; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
CBMC OP INFUSION 2FL,8334,"Brown, Andrew Bennett, MD",10/25/2023,Pembrolizumab 21 Day Cycles- Renal Cell Carcinoma,_1. First Line,10/24/2023,Active,,
CINJ OP INFUSION,82010,"Stephenson, Ryan D, DO",6/9/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,First Line,6/9/2023,Inactive,,
CINJ OP INFUSION,82010,"Stephenson, Ryan D, DO",12/26/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_2. Second Line,11/28/2023,Inactive,,
CINJ OP INFUSION,32977,"Toppmeyer, Deborah L, MD",2/26/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,2/26/2024,Active,,
MMC OP INFUSION,51000,"Meghal, Trishala, MD",2/8/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,2/7/2023,Inactive,,
TRMC TCCC OP INFUSION,14040,"Capo, Gerardo, MD",10/23/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,10/14/2024,Active,,
TRMC TCCC OP INFUSION,14040,"Capo, Gerardo, MD",11/13/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,11/12/2024,Inactive,,
TRMC TCCC OP INFUSION,14040,"Capo, Gerardo, MD",1/22/2025,DOCEtaxel21 Day Cycles - Breast,_1. First Line,1/20/2025,Active,,
SOM OUTPT INFUSION,42545,"Toomey, Kathleen C, MD",6/17/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/9/2024,Active,,
TRMC TCCC OP INFUSION,68712,"Capo, Gerardo, MD",11/8/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/8/2024,Active,,
TRMC TCCC OP INFUSION,15399,"Capo, Gerardo, MD",3/27/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/27/2025,Inactive,"Malignant neoplasm of lung, unspecified laterality, unspecified part of lung (CMS/HCC)","I82.A12 - Acute embolism and thrombosis of left axillary vein; I82.629 - Acute embolism and thrombosis of deep veins of unspecified upper extremity; E83.42 - Hypomagnesemia; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C79.51 - Secondary malignant neoplasm of bone"
TRMC TCCC OP INFUSION,15399,"Capo, Gerardo, MD",3/21/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/21/2025,Inactive,"Malignant neoplasm of lung, unspecified laterality, unspecified part of lung (CMS/HCC)",
TRMC TCCC OP INFUSION,15399,"Capo, Gerardo, MD",3/19/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/19/2025,Inactive,"Malignant neoplasm of lung, unspecified laterality, unspecified part of lung (CMS/HCC)","I82.A12 - Acute embolism and thrombosis of left axillary vein; I82.629 - Acute embolism and thrombosis of deep veins of unspecified upper extremity; E83.42 - Hypomagnesemia; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C79.51 - Secondary malignant neoplasm of bone"
CINJ OP INFUSION,3865,"Mayer, Tina M, MD",2/4/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,1/8/2025,Active,Renal cell carcinoma (CMS/HCC),"C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; D47.3 - Essential (hemorrhagic) thrombocythemia; R19.7 - Diarrhea, unspecified"
CINJ OP INFUSION,48930,"Berim, Lyudmyla, MD",12/5/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,12/5/2023,Active,,
NBR 4N BMTU/IMCU,2464,"Sridharan, Ashwin, MD",4/11/2024,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,4/10/2024,Inactive,,
NBR 4N ONCOLOGY,2464,"Rhodes, Joanna Meehan, MD",4/16/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/16/2024,Inactive,,
CINJ OP INFUSION,47635,"Leiser, Aliza, MD",9/18/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,8/31/2023,Inactive,,
MMC OP VP INFUSION,17472,"Cohen, Seth D, MD",1/27/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/19/2025,Active,,
CMC OP INFUSION,45780,"Taff, Jessica, MD",4/18/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/18/2025,Inactive,Adenocarcinoma of middle lobe of right lung (CMS/HCC),
CMC OP INFUSION,45780,"Taff, Jessica, MD",4/11/2025,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,4/11/2025,Active,Adenocarcinoma of middle lobe of right lung (CMS/HCC),
CINJ OP INFUSION,75935,"Packiam, Vignesh, MD",2/24/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,2/23/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),C67.8 - Malignant neoplasm of overlapping sites of bladder
CINJ OP INFUSION,75935,"Ghodoussipour, Saum Bobak, MD",5/20/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,5/6/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C67.8 - Malignant neoplasm of overlapping sites of bladder; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; N20.0 - Calculus of kidney; N39.0 - Urinary tract infection, site not specified; Z85.46 - Personal history of malignant neoplasm of prostate; I10 - Essential (primary) hypertension; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,40844,"Toppmeyer, Deborah L, MD",2/21/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",First Line,2/20/2023,Active,,
CINJ OP INFUSION,40844,"Toppmeyer, Deborah L, MD",3/14/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,2/14/2023,Active,,
CINJ OP INFUSION,40844,"Toppmeyer, Deborah L, MD",5/23/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/22/2023,Inactive,,
CBMC OP INFUSION 2FL,646,"Litvak, Anna M, MD",10/20/2023,CINJ 042301 Capecitabine 21 Day Cycles Research- Breast Cancer,_3. Third Line,10/20/2023,Inactive,,
CBMC OP INFUSION 2FL,646,"Raptis, George, MD",7/17/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_2. Second Line,7/16/2024,Inactive,,
CBMC OP INFUSION 2FL,646,"Raptis, George, MD",7/17/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_2. Second Line,7/16/2024,Active,Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC),
CMC OP INFUSION,39373,"Talwar, Sumit, MD",5/3/2023,Pembrolizumab 42 Day Cycles - Uterine,,4/26/2023,Inactive,,
CMC OP INFUSION,39373,"Talwar, Sumit, MD",11/29/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,11/28/2023,Active,,
CMC OP INFUSION,39373,"Talwar, Sumit, MD",11/29/2023,Trastuzumab 21 Day Cycles (with chemotherapy) ,_3. Third Line,11/28/2023,Active,Peripheral T cell lymphoma of inguinal region (CMS/HCC),
CINJ OP INFUSION,5568,"Boland, Patrick M, MD",8/9/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,8/5/2024,Inactive,,
MMC OP INFUSION,29670,"Meghal, Trishala, MD",3/29/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,3/26/2024,Active,,
NBR 4N BMTU/IMCU,21560,"Braunschweig, Ira, MD",1/3/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,12/28/2022,Inactive,,
NBR CINJ OP INFUSION,21560,"Chowaniec, Wayne B, NP",8/10/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,8/10/2023,Inactive,,
NBR CINJ OP INFUSION,21560,"Chowaniec, Wayne B, NP",10/5/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,10/5/2023,Inactive,,
NBR CINJ OP INFUSION,21560,"Chowaniec, Wayne B, NP",9/24/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,9/24/2024,Active,,
CINJ OP INFUSION,34809,"Jang, Thomas L, MD",11/10/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,11/10/2023,Inactive,,
CINJ OP INFUSION,34809,"Jang, Thomas L, MD",3/15/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,3/15/2024,Active,,
CBMC OP INFUSION 2FL,99847,"Raptis, George, MD",3/26/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,3/25/2024,Active,,
CINJ OP INFUSION,67035,"Saraiya, Biren P, MD",4/11/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,4/9/2024,Inactive,,
MMC OP VP INFUSION,86690,"Cohen, Seth D, MD",9/16/2024,DOCEtaxel 21 Day Cycles - Prostate,_2. Second Line,9/15/2024,Inactive,,
SOM OUTPT INFUSION,17462,"Patel, Eshan, MD",3/20/2025,PEMEtrexed/CARBOplatin + Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/20/2025,Active,"Non-small cell lung cancer with metastasis (CMS/HCC)
Other fatigue",
HAM OP INFUSION,41242,"Yogarajah, Meera, MD",3/20/2025,RiTUXimab 28 Day Cycle - Hairy Cell Leukemia,_3. Third Line,3/20/2025,Active,Hairy cell leukemia not having achieved remission (CMS/HCC),
HAM OP INFUSION,41242,"Yogarajah, Meera, MD",3/6/2025,Vemurafenib 28 Day Cycles - Hairy Cell Leukemia,_3. Third Line,3/6/2025,Active,Hairy cell leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,88818,"Shah, Mansi R, MD",4/13/2023,Ven/Velcade/Dex (Bortezomib/Venetoclax Oral/Dexamethasone) 21/35 Day Cycles- Multiple Myeloma,,4/12/2023,Inactive,,
NBR CINJ OP INFUSION,88818,"Shah, Mansi R, MD",4/20/2023,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",,4/12/2023,Inactive,,
NBR CINJ OP INFUSION,88818,"Shah, Mansi R, MD",11/7/2024,Isatuximab-irfc/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,11/4/2024,Active,,
HAM OP INFUSION,30022,"Patel, Malini M, MD",3/26/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,3/26/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified location of malignancy (CMS/HCC); E11.69 - Type 2 diabetes mellitus with other specified complication, unspecified whether long term insulin use (CMS/HCC); Z86.718 - History of DVT (deep vein thrombosis)"
NBR CINJ OP INFUSION,31712,"Palmisiano, Neil David, MD",4/18/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,4/16/2023,Inactive,,
CINJ OP INFUSION,66586,"Stephenson, Ryan D, DO",1/29/2024,Relugolix 30 day Cycles - Prostate,_1. First Line,1/29/2024,Active,Uterine cancer (CMS/HCC),
CINJ OP INFUSION,66586,"Stephenson, Ryan D, DO",7/8/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,7/8/2024,Active,,
JCMC CP INFUSION,50572,"Cruz, Allan Louie E, MD",8/1/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Thymic cancer,Maintenance,7/31/2023,Inactive,,
JCMC CP INFUSION,50572,"Cruz, Allan Louie E, MD",11/16/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/15/2023,Inactive,,
CBMC OP INFUSION 2FL,34570,"McKenna, Marshall, MD",3/11/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,3/11/2025,Active,Splenic marginal zone b-cell lymphoma (CMS/HCC),
MSC OP INFUSION,75740,"Pompa, Tiffany Ann, MD",4/21/2025,RiTUXimab Initial Infusion weekly x 4,_1. First Line,4/18/2025,Active,"Monoclonal gammopathy
Rapidly progressive glomerulonephritis","N17.9 - Acute kidney failure, unspecified; J18.9 - Pneumonia, unspecified organism; E44.0 - Moderate protein-calorie malnutrition; E87.20 - Acidosis, unspecified; D63.1 - Anemia in chronic kidney disease; E83.39 - Other disorders of phosphorus metabolism; C61 - Malignant neoplasm of prostate; I77.82 - Antineutrophilic cytoplasmic antibody (ANCA) vasculitis; N18.9 - Chronic kidney disease, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; D47.2 - Monoclonal gammopathy; E07.9 - Disorder of thyroid, unspecified; H10.33 - Unspecified acute conjunctivitis, bilateral; H53.2 - Diplopia; I95.2 - Hypotension due to drugs; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z92.3 - Personal history of irradiation; Z87.440 - Personal history of urinary (tract) infections; Z80.7 - Family history of other malignant neoplasms of lymphoid, hematopoietic and related tissues; Z79.82 - Long term (current) use of aspirin; Z63.4 - Disappearance and death of family member; Z79.899 - Other long term (current) drug therapy; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.89 - Acquired absence of other organs; Z98.890 - Other specified postprocedural states"
NBI OP INFUSION,70541,"Schleicher, Lori, MD",12/20/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/22/2023,Inactive,,
NBI OP INFUSION,44860,"Schleicher, Lori, MD",1/5/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_3. Third Line,12/14/2023,Inactive,,
NBI OP INFUSION,44860,"Schleicher, Lori, MD",5/3/2024,Ribociclib 28 Day Cycles - Breast,_3. Third Line,5/3/2024,Inactive,,
NBI OP INFUSION,44860,"Schleicher, Lori, MD",6/28/2024,Palbociclib 28 Day Cycles - Breast,_3. Third Line,6/28/2024,Inactive,,
NBI OP INFUSION,44860,"Schleicher, Lori, MD",11/8/2024,Elacestrant 28 Day Cycles - Breast,_4. Fourth Line,11/8/2024,Inactive,,
NBI OP INFUSION,44860,"Schleicher, Lori, MD",11/29/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,11/28/2024,Active,,
CBMC OP INFUSION 2FL,74743,"Brown, Andrew Bennett, MD",4/10/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,4/9/2024,Inactive,,
CBMC OP INFUSION 2FL,74743,"Brown, Andrew Bennett, MD",6/21/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,6/21/2024,Active,,
CINJ OP INFUSION,52118,"Patankar, Sonali, MD",10/17/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,10/15/2024,Active,,
NBR BMSCH 2 PED HEMONC,70557,"Moerdler, Scott, MD",1/17/2023,PEDS AEWS1221 Regimen A Induction & Consolidation,,1/17/2023,Inactive,,
CINJ OP INFUSION,99144,"Goel, Sanjay, MD",3/31/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,3/31/2025,Active,Cancer of cecum (CMS/HCC),
NBR 5N MED-SURG OVRF,94970,"Alexander, Henry Richard, MD",11/21/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,11/21/2024,Active,,
CBMC OP INFUSION 2FL,6418,"Scoppetuolo, Michael, MD",10/23/2023,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,10/22/2023,Active,,
CBMC 2W ONCOLOGY,56625,"Grossman, I Robert, MD",1/8/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,1/8/2024,Inactive,,
CBMC OP INFUSION 2FL,3702,"Brown, Andrew Bennett, MD",12/18/2023,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/14/2023,Active,,
CBMC OP INFUSION 2FL,53559,"Brown, Andrew Bennett, MD",3/18/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",Adjuvant,3/18/2025,Active,"Malignant neoplasm of head of pancreas (CMS/HCC)
Encounter for screening for other viral diseases
Need for hepatitis C screening test",C25.0 - Malignant neoplasm of head of pancreas; Z11.59 - Encounter for screening for other viral diseases
CMC OP INFUSION,45066,"Taff, Jessica, MD",7/13/2023,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",First Line,7/12/2023,Active,,
TRMC TCCC OP INFUSION,39032,"Capo, Gerardo, MD",12/18/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,12/17/2024,Active,,
TRMC TCCC OP INFUSION,39032,"Capo, Gerardo, MD",12/18/2024,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 80 mg/m2 D1 21 Day Cycles- Head and Neck Cancers",_1. First Line,12/17/2024,Inactive,,
TRMC TCCC OP INFUSION,39032,"Capo, Gerardo, MD",2/26/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,2/25/2025,Active,Nasopharynx cancer (CMS/HCC),C11.9 - Nasopharynx cancer (CMS/HCC)
TRMC TCCC OP INFUSION,39032,"Capo, Gerardo, MD",3/19/2025,"Gemcitabine D1,8 /CARBOplatin D1,8,15  Q21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant; Adjuvant)",_1. First Line,3/19/2025,Active,Nasopharynx cancer (CMS/HCC),
MMC OP VP INFUSION,82573,"Talwar, Sumit, MD",1/31/2023,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,,1/30/2023,Inactive,,
CINJ OP INFUSION,5934,"Berim, Lyudmyla, MD",1/27/2025,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,1/15/2025,Active,,
NBI OP INFUSION,70743,"Anderson, Patrick S, MD",1/30/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day CyclesEndometrial cancer,_2. Second Line,1/29/2025,Active,,
HAM OP INFUSION,30353,"Yogarajah, Meera, MD",3/18/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,3/3/2024,Inactive,,
CMC OP INFUSION,68034,"Tang, Horace, MD",3/30/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,3/29/2023,Inactive,,
HAM OP INFUSION,22512,"Patel, Malini M, MD",7/15/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,7/12/2024,Active,,
SOM OUTPT INFUSION,48632,"Yin, Faye, MD",5/22/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/14/2024,Inactive,,
SOM OUTPT INFUSION,48632,"Yin, Faye, MD",9/25/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,9/25/2024,Active,,
CINJ OP INFUSION,93073,"Omene, Coral Oghenerukevwe, MD",2/25/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,2/25/2025,Active,Stage IV breast cancer in female (CMS/HCC),"C50.919 - Malignant neoplasm of female breast, unspecified estrogen receptor status, unspecified laterality, unspecified site of breast (CMS/HCC)"
CMC OP INFUSION,25513,"Taff, Jessica, MD",2/12/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/10/2025,Active,"Malignant neoplasm of esophagus (CMS/HCC)
Malignant neoplasm metastatic to left lung (CMS/HCC)",
TRMC TCCC OP INFUSION,73328,"Capo, Gerardo, MD",10/30/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/29/2024,Active,,
HAM OP INFUSION,25899,"Yogarajah, Meera, MD",1/31/2023,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,Third Line,1/31/2023,Inactive,,
HAM OP INFUSION,25899,"Yogarajah, Meera, MD",5/16/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Third Line,5/16/2023,Inactive,,
HAM OP INFUSION,25899,"Yogarajah, Meera, MD",9/12/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,,9/6/2023,Inactive,,
CINJ OP INFUSION,75631,"Hochster, Howard S, MD",9/28/2023,Imatinib 30 Day Cycles - Sarcoma,Adjuvant,9/28/2023,Active,,
CBMC OP INFUSION 2FL,44207,"Leitner, Stuart P, MD",10/7/2024,Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 480 mg D1 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/3/2024,Inactive,"Cancer of cecum (CMS/HCC)
Metastasis to peritoneal cavity (CMS/HCC)",
CBMC OP INFUSION 2FL,44207,"Leitner, Stuart P, MD",12/18/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/16/2024,Inactive,,
CBMC OP INFUSION 2FL,44207,"Leitner, Stuart P, MD",1/3/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/2/2025,Active,,
NBI A5 PEDIATRICS,88581,"Ford, Maegan C, MD",12/6/2023,PEDS DD-4A - Renal,Neoadjuvant,12/6/2023,Active,,
CINJ OP INFUSION,44677,"Haigentz, Missak, MD",10/16/2023,"DOCEtaxel D1, D8, D15 21 Day Cycles- Head and Neck Cancers",First Line,10/15/2023,Active,,
JCMC CP INFUSION,23393,"Sekhri, Arunabh, MD",6/20/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,6/13/2024,Inactive,,
MMC OP VP INFUSION,63777,"Talwar, Sumit, MD",1/3/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,,1/2/2023,Inactive,,
MMC OP VP INFUSION,63777,"Talwar, Sumit, MD",7/25/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,6/13/2023,Active,Primary malignant neoplasm of ascending colon (CMS/HCC),
CINJ OP INFUSION,12111,"Toppmeyer, Deborah L, MD",11/30/2023,Palbociclib 28 Day Cycles - Breast,_1. First Line,11/30/2023,Inactive,,
CBMC OP INFUSION 2FL,88868,"Dharmapuri, Sirish, MD",8/13/2024,Nalirifox x 6 --> 5FU/Nal-ipi - Pancreatic Adenocarcinoma,_2. Second Line,8/12/2024,Inactive,,
CBMC OP INFUSION 2FL,88868,"Dharmapuri, Sirish, MD",11/27/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,11/26/2024,Active,,
CBMC OP INFUSION 2FL,29767,"Dharmapuri, Sirish, MD",3/4/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/3/2025,Inactive,Malignant neoplasm of pancreas (CMS/HCC),
MMC OP VP INFUSION,91499,"Cohen, Seth D, MD",4/3/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,First Line,4/2/2023,Inactive,,
MMC OP VP INFUSION,91499,"Cohen, Seth D, MD",8/16/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,8/15/2023,Inactive,,
MMC OP VP INFUSION,91499,"Cohen, Seth D, MD",3/13/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Maintenance,3/12/2024,Active,,
CINJ OP INFUSION,70054,"Boland, Patrick M, MD",5/26/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",,5/25/2023,Inactive,,
CINJ OP INFUSION,70054,"Boland, Patrick M, MD",9/8/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,9/6/2023,Inactive,,
CMMC OP INFUSION,90318,"Siu, Karleung, MD",3/31/2025,"CISplatin D1/Vinorelbine D1, D8 21 Day Cycles- Head and Neck Cancers",_3. Third Line,3/31/2025,Inactive,"Malignant neoplasm of nasal cavity (CMS/HCC)
Secondary malignant neoplasm of brain and spinal cord (CMS/HCC)
Metastatic cancer to lung (CMS/HCC)
Adenoid cystic carcinoma of head and neck (CMS/HCC)
Metastases to the liver (CMS/HCC)
Antineoplastic chemotherapy induced anemia",
CMMC OP INFUSION,90318,"Siu, Karleung, MD",3/3/2025,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_3. Third Line,3/3/2025,Inactive,"Malignant neoplasm of nasal cavity (CMS/HCC)
Secondary malignant neoplasm of brain and spinal cord (CMS/HCC)
Metastatic cancer to lung (CMS/HCC)
Adenoid cystic carcinoma of head and neck (CMS/HCC)
Metastases to the liver (CMS/HCC)
Antineoplastic chemotherapy induced anemia","C30.0 - Malignant neoplasm of nasal cavity; C80.1 - Malignant (primary) neoplasm, unspecified"
CINJ OP INFUSION,65759,"Hochster, Howard S, MD",9/13/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/12/2023,Inactive,,
CINJ OP INFUSION,65759,"Hochster, Howard S, MD",6/17/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Adjuvant,6/17/2024,Inactive,,
CINJ OP INFUSION,65759,"Hochster, Howard S, MD",7/18/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/17/2024,Inactive,,
CINJ OP INFUSION,65759,"Hochster, Howard S, MD",7/22/2024,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,6/12/2024,Inactive,,
CINJ OP INFUSION,65759,"Hochster, Howard S, MD",9/4/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/3/2024,Active,,
NBR CINJ OP INFUSION,80818,"Matasar, Matthew J, MD",5/23/2023,CINJ 012207 Arm I Dose Level 1 Tazemetostat + Rituximab + Bendamustine 28 Day Cycle Research - Follicular Lymphoma,,5/22/2023,Active,,
CBMC OP INFUSION 2FL,84371,"Brown, Andrew Bennett, MD",10/11/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,10/10/2023,Inactive,,
CMC OP INFUSION,45099,"Easaw, Sarah, MD",10/2/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,9/19/2023,Inactive,,
CMC OP INFUSION,41232,"Taff, Jessica, MD",6/1/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/31/2023,Inactive,,
CMC OP INFUSION,41232,"Taff, Jessica, MD",12/29/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,12/17/2023,Active,,
CINJ OP INFUSION,65959,"Stephenson, Ryan D, DO",5/24/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,5/23/2023,Inactive,,
CINJ OP INFUSION,23548,"Patel, Eshan, MD",3/29/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,3/17/2024,Inactive,,
CINJ OP INFUSION,97974,"Stephenson, Ryan D, DO",1/10/2024,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,Neoadjuvant,1/9/2024,Inactive,,
JCMC CP INFUSION,81140,"Cruz, Allan Louie E, MD",5/9/2023,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,5/9/2023,Inactive,,
JCMC CP INFUSION,81140,"Cruz, Allan Louie E, MD",1/16/2024,Carfilzomib 56 mg/m2 Weekly cyclophosphamide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,1/8/2024,Inactive,,
NBR CINJ OP INFUSION,81140,"Shah, Mansi R, MD",6/28/2024,Talquetamab 28 Day Cycles,_5. Fifth Line,6/28/2024,Inactive,,
NBR 5N ONCOLOGY,81140,"Shah, Mansi R, MD",7/29/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,7/23/2024,Inactive,,
NBR CINJ OP INFUSION,81140,"Shah, Mansi R, MD",9/11/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,8/27/2024,Inactive,,
CINJ OP INFUSION,98186,"Saraiya, Biren P, MD",10/8/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/8/2024,Active,,
CINJ OP INFUSION,68477,"Girda, Eugenia, MD",7/30/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,7/29/2024,Inactive,,
NBR 5N ONCOLOGY,68477,"Girda, Eugenia, MD",8/3/2024,CISplatin 25 mg/m2 D1-D3/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,8/1/2024,Inactive,,
CINJ OP INFUSION,68477,"Groisberg, Roman, MD",12/2/2024,ARST2032 Regimen M (VAC),_2. Second Line,12/1/2024,Active,,
NBR 4N ONCOLOGY,42424,"Groisberg, Roman, MD",5/9/2025,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_3. Third Line,5/9/2025,Active,Alveolar rhabdomyosarcoma (CMS/HCC),"C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; I21.A1 - Myocardial infarction type 2; R18.0 - Malignant ascites; D63.8 - Anemia in other chronic diseases classified elsewhere; E83.39 - Other disorders of phosphorus metabolism; D69.59 - Other secondary thrombocytopenia; C57.8 - Malignant neoplasm of overlapping sites of female genital organs; D63.0 - Anemia in neoplastic disease; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; E78.5 - Hyperlipidemia, unspecified; E83.42 - Hypomagnesemia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G62.9 - Polyneuropathy, unspecified; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z83.438 - Family history of other disorder of lipoprotein metabolism and other lipidemia; Z82.5 - Family history of asthma and other chronic lower respiratory diseases; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system"
CBMC OP INFUSION 2FL,55163,"Scoppetuolo, Michael, MD",7/1/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,6/24/2024,Active,Kaposi's sarcoma (CMS/HCC),
CINJ OP INFUSION,50342,"Boland, Patrick M, MD",5/21/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/17/2024,Active,,
JCMC CP INFUSION,38114,"Sekhri, Arunabh, MD",6/19/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,6/14/2024,Inactive,,
TRMC TCCC OP INFUSION,94353,"Capo, Gerardo, MD",2/9/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/8/2023,Active,,
CINJ OP INFUSION,92396,"Ghodoussipour, Saum Bobak, MD",7/11/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/11/2023,Inactive,,
CINJ OP INFUSION,92396,"Ghodoussipour, Saum Bobak, MD",10/10/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,10/10/2023,Active,,
CINJ OP INFUSION,78150,"Aikins, James K, MD",7/25/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,7/24/2024,Active,,
NBR 5N MED-SURG OVRF,53281,"Alexander, Henry Richard, MD",7/31/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,First Line,7/31/2023,Active,,
NBR 5N MED-SURG OVRF,37717,"Alexander, Henry Richard, MD",7/31/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,First Line,7/31/2023,Active,,
CINJ OP INFUSION,25782,"Stephenson, Ryan D, DO",10/27/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,10/27/2023,Inactive,,
CINJ OP INFUSION,25782,"Stephenson, Ryan D, DO",1/22/2024,DOCEtaxel 21 Day Cycles - Prostate,_3. Third Line,1/9/2024,Inactive,,
CINJ OP INFUSION,64485,"Saraiya, Biren P, MD",3/7/2023,CINJ 082201 (NRG-GU010) ARM 4 Androgen Deprivation Therapy / Darolutamide 3 Month Cycles (90 Days) Research- Prostate Cancer,First Line,2/6/2023,Active,,
CBMC OP INFUSION 2FL,34138,"Brown, Andrew Bennett, MD",6/12/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/11/2023,Inactive,,
CBMC OP INFUSION 2FL,34138,"Brown, Andrew Bennett, MD",11/27/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/26/2023,Inactive,,
NBI OP INFUSION,38285,"Cheng, Yan Ho, MD",5/28/2024,"Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/26/2024,Inactive,,
NBI OP INFUSION,38285,"Cheng, Yan Ho, MD",6/11/2024,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,_2. Second Line,6/10/2024,Active,,
NBI OP INFUSION,28621,"Cheng, Yan Ho, MD",3/25/2025,"Roswell Park Regimen (weekly 5-FU)/Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,3/25/2025,Active,Colon cancer metastasized to bone (CMS/HCC),
NBI OP INFUSION,28621,"Cheng, Yan Ho, MD",3/11/2025,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,_3. Third Line,3/11/2025,Inactive,Colon cancer metastasized to bone (CMS/HCC),
NBI OP INFUSION,32278,"Cheng, Yan Ho, MD",10/31/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/30/2023,Inactive,,
NBI OP INFUSION,32278,"Cheng, Yan Ho, MD",11/14/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/13/2023,Inactive,,
NBI OP INFUSION,32278,"Cheng, Yan Ho, MD",1/23/2024,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,1/22/2024,Inactive,,
NBI OP INFUSION,32278,"Cheng, Yan Ho, MD",8/13/2024,FOLFIRI and Bevacizumab Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan and Bevacizumab) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/5/2024,Active,,
CINJ OP INFUSION,57329,"Mayer, Tina M, MD",12/10/2024,Darolutamide 28 Day Cycles - Prostate,_2. Second Line,12/10/2024,Active,,
NBR CINJ OP INFUSION,57329,"Mayer, Tina M, MD",12/13/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,12/13/2024,Active,,
CINJ OP INFUSION,57329,"Mayer, Tina M, MD",5/7/2025,Darolutamide 28 Day Cycles - Prostate,_3. Third Line,5/7/2025,Active,Prostate cancer (CMS/HCC),C61 - Prostate cancer (CMS/HCC)
CMC OP INFUSION,74933,"Tang, Horace, MD",1/2/2024,PEGinterferon alfa-2a 28 Day Cycle - ET,_2. Second Line,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,41142,"Siu, Karleung, MD",3/17/2025,Carfilzomib 36 mg/m2 / Lenalidomide 25 mg / Dexamethasone (Internal) 28 Day Cycles- Multiple Myeloma,_2. Second Line,3/17/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),C61 - Malignant neoplasm of prostate; C90.00 - Multiple myeloma not having achieved remission; M79.89 - Other specified soft tissue disorders
MSC OP INFUSION,56652,"Easaw, Sarah, MD",9/14/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/30/2023,Inactive,,
MMC OP VP INFUSION,36358,"Cohen, Seth D, MD",1/28/2025,"PACLitaxel D1,8,15  X 4 Cycles + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles",_2. Second Line,1/24/2025,Active,,
HAM OP INFUSION,32638,"Yogarajah, Meera, MD",4/8/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,4/8/2024,Inactive,,
HAM OP INFUSION,32638,"Yogarajah, Meera, MD",4/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/14/2024,Active,,
CBMC OP INFUSION 2FL,43960,"Brown, Andrew Bennett, MD",2/29/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/21/2024,Inactive,,
NBR CINJ OP INFUSION,99124,"Zayac, Adam, MD",3/15/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,2/2/2024,Inactive,,
NBR CINJ OP INFUSION,99124,"Zayac, Adam, MD",9/23/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/23/2024,Active,Diffuse large B-cell lymphoma (CMS/HCC),
NBI OP INFUSION,70498,"Jacoby, Sari H, MD",1/2/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/2/2025,Active,,
CMC OP INFUSION,75165,"Cohen, Seth D, MD",1/11/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/10/2024,Inactive,,
CINJ OP INFUSION,84275,"Haigentz, Missak, MD",9/23/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,9/23/2024,Active,,
CBMC OP INFUSION 2FL,24234,"Wagmiller, Jennifer Ann, MD",10/3/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,10/1/2024,Active,,
HAM OP INFUSION,38286,"Yogarajah, Meera, MD",1/5/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,12/17/2023,Active,,
NBR CINJ OP INFUSION,49275,"Evens, Andrew M, DO",1/4/2023,Bendamustine / RiTUXimab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphatic Lymphoma,,1/3/2023,Inactive,,
NBR CINJ OP INFUSION,49275,"Evens, Andrew M, DO",1/4/2023,Bendamustine / RiTUXimab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphatic Lymphoma,,1/3/2023,Inactive,,
NBR 5N ONCOLOGY,49275,"Evens, Andrew M, DO",1/17/2025,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_4. Fourth Line,1/17/2025,Active,,
CINJ OP INFUSION,39048,"Berim, Lyudmyla, MD",4/26/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,4/24/2023,Inactive,,
CINJ OP INFUSION,39048,"Berim, Lyudmyla, MD",5/2/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/30/2024,Active,,
CINJ OP INFUSION,39048,"Berim, Lyudmyla, MD",2/6/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,2/4/2025,Active,"Gastric cancer (CMS/HCC)
Adenocarcinoma of gastroesophageal junction (CMS/HCC)",
CINJ OP INFUSION,6208,"Omene, Coral Oghenerukevwe, MD",12/12/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Adjuvant,12/11/2023,Inactive,,
CMMC OP INFUSION,17494,"Siu, Karleung, MD",1/27/2025,"mFOLFOX6 Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/26/2025,Inactive,"Metastasis to mediastinum (CMS/HCC)
Colon cancer metastasized to lung (CMS/HCC)",
CINJ PEDS HEMONC ,96685,"Moerdler, Scott, MD",1/28/2025,per AGCT1532 Arm A BEP (Bleomycin / Etoposide / CISplatin),_1. First Line,1/26/2025,Active,,
JCMC CP INFUSION,82208,"Sekhri, Arunabh, MD",11/30/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/15/2023,Inactive,,
JCMC CP INFUSION,82208,"Sekhri, Arunabh, MD",2/8/2025,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,2/3/2025,Active,Myeloma (CMS/HCC),
JCMC CP INFUSION,82208,"Sekhri, Arunabh, MD",3/3/2025,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,3/3/2025,Active,Myeloma (CMS/HCC),
CINJ OP INFUSION,62397,"Haigentz, Missak, MD",2/1/2025,Everolimus 28 Day Cycles - Lung Neuroendocrine Cancer,_1. First Line,2/1/2025,Active,Neuroendocrine carcinoma of lung (CMS/HCC),"C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; C79.31 - Secondary malignant neoplasm of brain; C7A.8 - Other malignant neuroendocrine tumors; R53.82 - Chronic fatigue, unspecified; H91.93 - Unspecified hearing loss, bilateral; Z13.220 - Encounter for screening for lipoid disorders; Z13.6 - Encounter for screening for cardiovascular disorders"
CINJ OP INFUSION,62397,"Haigentz, Missak, MD",5/22/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Lung Neuroendocrine Cancer,_2. Second Line,5/22/2025,Active,"Malignant neoplasm of lower lobe of left lung (CMS/HCC)
Secondary cancer of brain (CMS/HCC)
Neuroendocrine carcinoma of lung (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)","C80.1 - Malignant (primary) neoplasm, unspecified; C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; C79.31 - Secondary malignant neoplasm of brain; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C7A.8 - Other malignant neuroendocrine tumors; H91.93 - Unspecified hearing loss, bilateral; E78.49 - Other hyperlipidemia; R53.82 - Chronic fatigue, unspecified; R53.81 - Other malaise; R63.0 - Anorexia; J91.0 - Malignant pleural effusion; C79.51 - Secondary malignant neoplasm of bone; E04.1 - Nontoxic single thyroid nodule; E87.1 - Hypo-osmolality and hyponatremia; C79.9 - Secondary malignant neoplasm of unspecified site; Z51.5 - Encounter for palliative care"
NBI OP INFUSION,15597,"Shah, Maya M, MD",1/3/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/2/2024,Inactive,,
NBI OP INFUSION,15597,"Shah, Maya M, MD",8/16/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/15/2024,Active,,
HAM OP INFUSION,64183,"Yogarajah, Meera, MD",10/21/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,10/12/2024,Active,,
CBMC OP INFUSION 2FL,65750,"Dharmapuri, Sirish, MD",2/20/2025,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,2/20/2025,Active,Malignant neoplasm of liver (CMS/HCC),
TRMC TCCC OP INFUSION,65750,"Capo, Gerardo, MD",4/3/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,3/27/2025,Active,Malignant neoplasm of liver (CMS/HCC),"C22.9 - Malignant neoplasm of liver, not specified as primary or secondary; C22.0 - Liver cell carcinoma"
HAM OP INFUSION,47324,"Patel, Malini M, MD",2/19/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,2/17/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified location of malignancy (CMS/HCC)"
CMC OP INFUSION,13209,"Easaw, Sarah, MD",6/13/2023,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",Second Line,6/6/2023,Active,,
NBR CINJ OP INFUSION,26306,"Palmisiano, Neil David, MD",1/25/2023,Mini-HyperCVD + Venetoclax Cycle 2 (High Dose Methotrexate / Cytarabine / Venetoclax) - 28 Day Cycles - Mixed Lineage Acute Lymphoblastic Leukemia ,,1/24/2023,Inactive,,
NBR CINJ OP INFUSION,79393,"Rhodes, Joanna Meehan, MD",3/20/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/20/2025,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),"C83.38 - Diffuse large b-cell lymphoma, lymph nodes of multiple sites; E11.9 - Type 2 diabetes mellitus without complications; R16.1 - Splenomegaly, not elsewhere classified; C83.30 - Diffuse large B-cell lymphoma, unspecified site; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs; Z79.4 - Long term (current) use of insulin"
CMC OP INFUSION,83419,"Cohen, Seth D, MD",3/21/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,3/20/2024,Inactive,,
CMC OP INFUSION,83419,"Cohen, Seth D, MD",6/13/2024,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,_2. Second Line,6/12/2024,Inactive,,
CMC OP INFUSION,83419,"Cohen, Seth D, MD",7/5/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles,Maintenance,7/4/2024,Active,,
MMC OP VP INFUSION,83264,"Meghal, Trishala, MD",10/28/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/21/2024,Active,,
MMC OP VP INFUSION,83264,"Talwar, Sumit, MD",3/4/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,3/4/2025,Inactive,"Malignant neoplasm of right breast in female, estrogen receptor negative (CMS/HCC)","C50.111, Z17.1 - Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)"
MMC OP VP INFUSION,35868,"Cohen, Seth D, MD",7/10/2023,Pembrolizumab 21 Day Cycles - Melanoma,,7/9/2023,Inactive,,
CBMC OP INFUSION 2FL,79550,"Wagmiller, Jennifer Ann, MD",5/15/2024,Pembrolizumab 21 Day Cycles - Melanoma,_1. First Line,4/9/2024,Active,,
CINJ OP INFUSION,31153,"George, Mridula A, MD",6/9/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/8/2023,Inactive,,
CBMC OP INFUSION 2FL,9304,"Brown, Andrew Bennett, MD",1/20/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,1/20/2025,Active,,
CBMC OP INFUSION 2FL,42049,"Wagmiller, Jennifer Ann, MD",10/30/2023,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,42049,"Wagmiller, Jennifer Ann, MD",5/21/2024,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,5/19/2024,Inactive,,
CBMC OP INFUSION 2FL,42049,"Wagmiller, Jennifer Ann, MD",9/5/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,8/25/2024,Active,,
CBMC OP INFUSION 2FL,42049,"Wagmiller, Jennifer Ann, MD",4/29/2025,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_5. Fifth Line,4/29/2025,Active,"Serous carcinoma of female pelvis (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)
Malignant neoplasm of endometrium (CMS/HCC)
On antineoplastic chemotherapy
Bone disease
Antineoplastic chemotherapy induced anemia","C76.3 - Malignant neoplasm of pelvis; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified; C53.1 - Malignant neoplasm of exocervix; C54.1 - Malignant neoplasm of endometrium; C54.9 - Malignant neoplasm of corpus uteri, unspecified; D63.0 - Anemia in neoplastic disease; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; M89.9 - Disorder of bone, unspecified; Z79.899 - Other long term (current) drug therapy; Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants"
CBMC OP INFUSION 2FL,42049,"Wagmiller, Jennifer Ann, MD",3/4/2025,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_4. Fourth Line,3/4/2025,Inactive,"Serous carcinoma of female pelvis (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)
Malignant neoplasm of endometrium (CMS/HCC)
On antineoplastic chemotherapy
Bone disease
Antineoplastic chemotherapy induced anemia","C54.1 - Malignant neoplasm of endometrium; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified; C76.3 - Malignant neoplasm of pelvis"
MMC BBR2 ONCOLOGY,52470,"Meghal, Trishala, MD",10/4/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,10/3/2024,Inactive,,
NBI OP INFUSION,30160,"Anderson, Patrick S, MD",4/27/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles - Cervical,_1. First Line,4/26/2023,Inactive,,
NBI OP INFUSION,30160,"Anderson, Patrick S, MD",8/22/2024,Gemcitabine 28 Day Cycles -  Cervical,_4. Fourth Line,8/19/2024,Inactive,,
NBI OP INFUSION,98076,"Snyder, Rose, MD",4/21/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/21/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.20 - Extramedullary plasmacytoma not having achieved remission; D53.9 - Nutritional anemia, unspecified; C90.00 - Multiple myeloma not having achieved remission"
NBI OP INFUSION,98076,"Snyder, Rose, MD",4/16/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,4/16/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),"C90.20 - Extramedullary plasmacytoma not having achieved remission; D53.9 - Nutritional anemia, unspecified; C90.00 - Multiple myeloma not having achieved remission"
CINJ OP INFUSION,10326,"Ghodoussipour, Saum Bobak, MD",3/22/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,3/22/2023,Active,,
CINJ OP INFUSION,56674,"Hochster, Howard S, MD",7/19/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,Second Line,7/18/2023,Inactive,,
JCMC CP INFUSION,70560,"Sekhri, Arunabh, MD",1/17/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/11/2023,Active,,
JCMC CP INFUSION,70560,"Maggi, Jason C, MD",7/11/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,7/11/2024,Inactive,,
CINJ OP INFUSION,53715,"Boland, Patrick M, MD",8/23/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/21/2024,Active,,
NBI OP INFUSION,23480,"Schleicher, Lori, MD",1/2/2025,Nilotinib (Newly Diagnosed) 28 Day Cycles - Chronic Myeloid Leukemia,_3. Third Line,1/2/2025,Active,,
CINJ OP INFUSION,7093,"Boland, Patrick M, MD",10/6/2023,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastric Cancer",_1. First Line,9/7/2023,Inactive,,
CINJ OP INFUSION,7093,"Boland, Patrick M, MD",6/28/2024,Nivolumab 480 mg 28 Day Cycles- Gastric Cancer,Consolidation,6/27/2024,Inactive,,
CINJ OP INFUSION,7093,"Boland, Patrick M, MD",12/26/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastric Cancer,_2. Second Line,12/24/2024,Inactive,,
CINJ OP INFUSION,7093,"Boland, Patrick M, MD",1/14/2025,FLOX (Fluorouracil/Leucovorin/OXALIplatin) 56 Day Cycles- Colon Cancer,_2. Second Line,1/13/2025,Active,,
MMC OP VP INFUSION,42985,"Lee, Patrick C, MD",4/24/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,4/23/2023,Inactive,,
MMC OP VP INFUSION,42985,"Lee, Patrick C, MD",2/14/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/7/2024,Inactive,,
CBMC OP INFUSION 2FL,39772,"Grossman, I Robert, MD",7/26/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,7/26/2023,Inactive,,
CBMC OP INFUSION 2FL,39772,"Grossman, I Robert, MD",7/1/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,6/16/2024,Inactive,,
CBMC 2W ONCOLOGY,39772,"Grossman, I Robert, MD",9/27/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_4. Fourth Line,9/26/2024,Inactive,,
HAM OP INFUSION,56164,"Patel, Malini M, MD",3/27/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,First Line,3/21/2023,Inactive,,
SOM OUTPT INFUSION,73074,"Patel, Eshan, MD",2/7/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,2/6/2023,Inactive,,
CINJ OP INFUSION,41279,"Berim, Lyudmyla, MD",1/26/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,1/23/2024,Inactive,,
CINJ OP INFUSION,80101,"Leiser, Aliza, MD",3/3/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,2/23/2023,Inactive,,
CINJ OP INFUSION,60386,"Berim, Lyudmyla, MD",3/17/2023, Nivolumab Gastric cancer,,3/3/2023,Inactive,,
CINJ PEDS HEMONC ,35469,"Moerdler, Scott, MD",4/3/2024, as per AGCT1532 Arm A (Standard BEP),_1. First Line,4/1/2024,Inactive,,
JCMC CP INFUSION,7961,"Cruz, Allan Louie E, MD",12/6/2024,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,_1. First Line,12/6/2024,Active,,
CINJ OP INFUSION,20255,"Ganesan, Shridar, MD PhD",1/16/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Third Line,2/21/2023,Inactive,,
CINJ OP INFUSION,20255,"Omene, Coral Oghenerukevwe, MD",10/21/2024,Capivasertib 28 Day Cycles - Breast,_5. Fifth Line,10/21/2024,Inactive,,
CINJ OP INFUSION,47419,"Boland, Patrick M, MD",5/12/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,,5/9/2023,Inactive,,
NBI OP INFUSION,26668,"Shah, Maya M, MD",5/31/2024,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,5/31/2024,Active,,
NBI OP INFUSION,81972,"Cheng, Yan Ho, MD",12/5/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,_1. First Line,12/4/2023,Inactive,,
NBI OP INFUSION,81972,"Cheng, Yan Ho, MD",12/19/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_1. First Line,12/4/2023,Inactive,,
NBI OP INFUSION,81972,"Cheng, Yan Ho, MD",4/2/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_2. Second Line,3/18/2024,Inactive,,
CINJ OP INFUSION,12207,"Toppmeyer, Deborah L, MD",3/23/2023,Palbociclib 28 Day Cycles - Breast,First Line,3/23/2023,Inactive,,
SOM OUTPT INFUSION,63292,"Patel, Eshan, MD",6/10/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,6/9/2024,Inactive,,
SOM OUTPT INFUSION,63292,"Patel, Eshan, MD",11/5/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,11/4/2024,Active,,
CBMC OP INFUSION 2FL,88651,"Brown, Andrew Bennett, MD",3/21/2024,DOCEtaxel / Trastuzumab 21 Day Cycles - Breast,_1. First Line,3/5/2024,Inactive,,
CINJ OP INFUSION,88063,"Weiss, Sarah, MD",3/28/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,3/28/2023,Active,,
CMC 4B ONCOLOGY,7803,"Talwar, Sumit, MD",12/23/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/15/2024,Active,,
CBMC OP INFUSION 2FL,88205,"Leitner, Stuart P, MD",3/21/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,3/20/2023,Inactive,,
CBMC OP INFUSION 2FL,88205,"Leitner, Stuart P, MD",5/15/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,5/14/2024,Inactive,,
CINJ OP INFUSION,69664,"Boland, Patrick M, MD",10/10/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,10/2/2023,Inactive,,
CINJ OP INFUSION,69664,"Boland, Patrick M, MD",1/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/15/2024,Active,,
CINJ OP INFUSION,84065,"Boland, Patrick M, MD",4/23/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,4/22/2024,Active,Breast cancer (CMS/HCC),
CINJ OP INFUSION,81306,"Dasgeb, Bahar, MD",12/3/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/2/2024,Active,,
CINJ OP INFUSION,58903,"Patel, Eshan, MD",12/29/2023,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 80 mg/m2 D1 21 Day Cycles- Head and Neck Cancers",_1. First Line,12/21/2023,Inactive,,
CINJ OP INFUSION,58903,"Patel, Eshan, MD",3/18/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,3/7/2024,Inactive,,
CINJ OP INFUSION,58903,"Patel, Eshan, MD",7/12/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,7/11/2024,Active,,
CINJ OP INFUSION,58903,"Patel, Eshan, MD",8/23/2024,"Paclitaxel D1, D8, D15 28 Day Cycles- Head and Neck Cancers",_3. Third Line,8/22/2024,Inactive,,
JCMC CP INFUSION,56781,"Cruz, Allan Louie E, MD",6/26/2023,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Second Line,6/25/2023,Inactive,,
MMC OP INFUSION,92178,"Lee, Patrick C, MD",1/8/2024,Methotrexate / Leucovorin 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_1. First Line,1/7/2024,Active,,
CINJ OP INFUSION,19885,"Hochster, Howard S, MD",11/26/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/24/2024,Active,,
CBMC OP INFUSION 2FL,72120,"Scoppetuolo, Michael, MD",9/24/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,9/8/2024,Active,Malignant neoplasm of lower lobe of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,72120,"Scoppetuolo, Michael, MD",1/31/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,1/30/2025,Active,,
CBMC OP INFUSION 2FL,72120,"Scoppetuolo, Michael, MD",4/11/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,4/11/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBI OP INFUSION,28881,"Cheng, Yan Ho, MD",1/23/2024,"Gemcitabine D1, D8/OXALIplatin D1 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/4/2023,Inactive,,
NBI OP INFUSION,28881,"Cheng, Yan Ho, MD",2/6/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,2/5/2024,Active,Malignant neoplasm of central portion of right breast (CMS/HCC),
CBMC OP INFUSION 2FL,1434,"Dharmapuri, Sirish, MD",12/16/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,12/10/2024,Active,,
NBI OP INFUSION,23178,"Cohen, Alice, MD",2/26/2024,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,2/26/2024,Active,,
NBR BLOOD SERVICES,64541,"Girda, Eugenia, MD",11/12/2024,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_3. Third Line,11/11/2024,Active,,
MMC OP INFUSION,4765,"Meghal, Trishala, MD",10/8/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/2/2024,Active,,
JCMC CP INFUSION,90932,"Sekhri, Arunabh, MD",8/3/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,8/2/2023,Inactive,,
NBR CINJ OP INFUSION,76465,"Shah, Mansi R, MD",7/11/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,7/9/2024,Inactive,,
HAM OP INFUSION,93728,"Yogarajah, Meera, MD",8/8/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,,7/11/2023,Active,,
HAM OP INFUSION,93728,"Yogarajah, Meera, MD",8/8/2023,DOCEtaxel / Trastuzumab 21 Day Cycles - Neoadjuvant Breast- Clinical trial EA1181,First Line,8/7/2023,Inactive,,
HAM OP INFUSION,93728,"Yogarajah, Meera, MD",8/8/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,8/7/2023,Active,,
MSC OP INFUSION,14432,"Tang, Horace, MD",1/24/2024,Enfortumab Vedotin 28 Day Cycles - Bladder,_2. Second Line,1/21/2024,Active,,
CMC OP INFUSION,14432,"Cohen, Seth D, MD",4/1/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_2. Second Line,4/1/2024,Active,,
NBI OP INFUSION,69088,"Jacoby, Sari H, MD",1/13/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,1/13/2025,Active,,
CBMC OP INFUSION 2FL,12572,"Brown, Andrew Bennett, MD",3/5/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,3/5/2025,Active,Malignant neoplasm of overlapping sites of larynx (CMS/HCC),
NBR CINJ OP INFUSION,84933,"Shah, Mansi R, MD",10/19/2023,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,10/19/2023,Inactive,,
NBR CINJ OP INFUSION,84933,"Shah, Mansi R, MD",11/16/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Pomalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/15/2023,Inactive,,
NBR 4N ONCOLOGY,84933,"Shah, Mansi R, MD",11/28/2023,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/27/2023,Inactive,,
NBR CINJ OP INFUSION,84933,"Shah, Mansi R, MD",2/6/2024,Daratumumab/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,2/5/2024,Inactive,,
NBR CINJ OP INFUSION,84933,"Shah, Mansi R, MD",2/6/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,2/6/2024,Inactive,,
NBR CINJ OP INFUSION,84933,"Shah, Mansi R, MD",9/12/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,9/11/2024,Inactive,,
NBR CINJ OP INFUSION,30355,"Schaar, Dale, MD PhD",12/4/2023,Decitabine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,12/3/2023,Inactive,,
CINJ OP INFUSION,75649,"Boland, Patrick M, MD",4/19/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/18/2024,Active,,
CINJ OP INFUSION,75649,"Boland, Patrick M, MD",4/19/2024,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,3/11/2024,Inactive,,
CINJ OP INFUSION,98742,"George, Mridula A, MD",3/20/2023,Talazoparib 28 Day Cycles ,Second Line,3/20/2023,Inactive,,
JCMC CP INFUSION,6568,"Sekhri, Arunabh, MD",12/23/2023,VIP (Etoposide / Ifosfamide / Mesna / CISplatin) 21 Day Cycles - Gestational Trophoblastic Neoplasia,_1. First Line,12/17/2023,Inactive,,
NBR 5N ONCOLOGY,6568,"Mayer, Tina M, MD",12/21/2024,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Testicular,_2. Second Line,12/20/2024,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,67954,"Litvak, Anna M, MD",10/24/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Breast",_2. Second Line,10/23/2023,Inactive,,
CBMC OP INFUSION 2FL,67954,"Litvak, Anna M, MD",11/21/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_3. Third Line,11/20/2023,Inactive,,
CBMC OP INFUSION 2FL,67954,"Litvak, Anna M, MD",1/23/2024,Gemcitabine 28 Day Cycles - Breast,_5. Fifth Line,1/22/2024,Inactive,,
CBMC OP INFUSION 2FL,67954,"Ligresti, Louise G, MD",3/1/2024,Sacituzumab Govitecan 21 Day Cycles - Breast,_4. Fourth Line,3/1/2024,Inactive,,
CBMC OP INFUSION 2FL,67954,"Ligresti, Louise G, MD",4/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_6. Sixth Line,4/24/2024,Active,,
CBMC OP INFUSION 2FL,67954,"Litvak, Anna M, MD",12/11/2024,Olaparib 30 Day Cycles - Breast,_4. Fourth Line,12/11/2024,Inactive,,
CBMC OP INFUSION 2FL,67954,"Litvak, Anna M, MD",3/14/2025,EriBULin 21 Day Cycles - Breast,_4. Fourth Line,3/7/2025,Active,"Malignant neoplasm of lower-inner quadrant of left female breast (CMS/HCC)
Malignant neoplasm of lower-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)","C50.812 - Malignant neoplasm of overlapping sites of left female breast; R22.1 - Localized swelling, mass and lump, neck; R22.32 - Localized swelling, mass and lump, left upper limb; C50.312 - Malignant neoplasm of lower-inner quadrant of left female breast; C50.011 - Malignant neoplasm of nipple and areola, right female breast; C79.51 - Secondary malignant neoplasm of bone; C79.31 - Secondary malignant neoplasm of brain; C77.0 - Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck; Z17.1 - Estrogen receptor negative status (ER-); F41.9 - Anxiety disorder, unspecified; Z90.13 - Acquired absence of bilateral breasts and nipples; Z80.3 - Family history of malignant neoplasm of breast; Z87.891 - Personal history of nicotine dependence; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z91.048 - Other nonmedicinal substance allergy status; Z79.899 - Other long term (current) drug therapy; Z90.722 - Acquired absence of ovaries, bilateral"
MMC OP INFUSION,40101,"Meghal, Trishala, MD",8/17/2023,Ribociclib 28 Day Cycles - Breast,,8/17/2023,Active,Cancer of central portion of right breast (CMS/HCC),
CINJ OP INFUSION,62539,"Dasgeb, Bahar, MD",3/18/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,3/18/2025,Active,Squamous cell carcinoma of multiple sites,
JCMC CP INFUSION,53580,"Sekhri, Arunabh, MD",4/1/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,3/10/2024,Inactive,,
JCMC CP INFUSION,53580,"Sekhri, Arunabh, MD",7/15/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/23/2024,Inactive,,
CBMC OP INFUSION 2FL,11435,"Scoppetuolo, Michael, MD",5/29/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_2. Second Line,5/19/2025,Active,"Malignant neoplasm of upper lobe, left bronchus or lung (CMS/HCC)","C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung"
CMC 4B ONCOLOGY,19790,"Pompa, Tiffany Ann, MD",9/14/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,9/12/2024,Active,,
NBI OP INFUSION,96354,"Anderson, Patrick S, MD",1/11/2024,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/3/2024,Inactive,,
NBI OP INFUSION,58942,"Schleicher, Lori, MD",12/1/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/23/2023,Inactive,,
NBI OP INFUSION,58942,"Schleicher, Lori, MD",3/15/2024,"DOCEtaxel D1, D8, D15 /Ramucirumab 28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,3/14/2024,Inactive,,
JCMC CP INFUSION,67758,"Cruz, Allan Louie E, MD",12/17/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_3. Third Line,12/17/2024,Inactive,,
JCMC CP INFUSION,67758,"Cruz, Allan Louie E, MD",1/14/2025,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_5. Fifth Line,1/13/2025,Active,,
CINJ OP INFUSION,54876,"Boland, Patrick M, MD",12/19/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,12/18/2023,Inactive,,
MMC OP INFUSION,91198,"Meghal, Trishala, MD",10/10/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,10/10/2024,Active,,
SOM OUTPT INFUSION,24156,"Toomey, Kathleen C, MD",7/24/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,6/9/2024,Inactive,,
SOM OUTPT INFUSION,24156,"Toomey, Kathleen C, MD",12/18/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,12/17/2024,Active,,
CMC OP INFUSION,70380,"Pompa, Tiffany Ann, MD",2/24/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,2/23/2025,Future,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)
Encounter for antineoplastic chemotherapy",
CMC OP INFUSION,70380,"Pompa, Tiffany Ann, MD",5/8/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,5/8/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)
Encounter for antineoplastic chemotherapy",
CMC OP INFUSION,6473,"Pompa, Tiffany Ann, MD",8/30/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/13/2024,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
SOM OUTPT INFUSION,32018,"Patel, Eshan, MD",8/1/2023,Pembrolizumab 21 Day Cycles - ovary,,7/31/2023,Inactive,,
SOM OUTPT INFUSION,32018,"Patel, Eshan, MD",8/1/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,7/31/2023,Inactive,,
CINJ OP INFUSION,32018,"Stephenson, Ruth D, DO",11/10/2023,Gemcitabine / CISplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,11/8/2023,Inactive,,
CINJ OP INFUSION,32018,"Stephenson, Ruth D, DO",2/23/2024,PEMEtrexed 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,2/15/2024,Inactive,,
CINJ OP INFUSION,96090,"Toppmeyer, Deborah L, MD",1/29/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,1/28/2024,Inactive,,
CINJ OP INFUSION,96090,"Toppmeyer, Deborah L, MD",7/15/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,7/10/2024,Inactive,,
CINJ OP INFUSION,96090,"Toppmeyer, Deborah L, MD",11/21/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,11/19/2024,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
CINJ OP INFUSION,15668,"Toppmeyer, Deborah L, MD",4/17/2025,Datopotamab deruxtecan-dlnk 21 Day Cycles- Breast Cancer,_5. Fifth Line,4/17/2025,Inactive,"Malignant neoplasm metastatic to bone (CMS/HCC)
Malignant neoplasm of lower-inner quadrant of left female breast (CMS/HCC)",
CINJ OP INFUSION,15668,"Toppmeyer, Deborah L, MD",4/17/2025,Ixabepilone 21 Day Cycles- Breast,_5. Fifth Line,4/17/2025,Inactive,"Malignant neoplasm metastatic to bone (CMS/HCC)
Malignant neoplasm of lower-inner quadrant of left female breast (CMS/HCC)",
JCMC CP INFUSION,82153,"Sekhri, Arunabh, MD",3/13/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,3/13/2025,Inactive,Ovarian neoplasm,"C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C56.9 - Malignant neoplasm of unspecified ovary; J90 - Pleural effusion, not elsewhere classified; R18.0 - Malignant ascites; I10 - Essential (primary) hypertension; F32.9 - Major depressive disorder, single episode, unspecified; M81.0 - Age-related osteoporosis without current pathological fracture; K58.9 - Irritable bowel syndrome, unspecified; C44.320 - Squamous cell carcinoma of skin of unspecified parts of face; F17.210 - Nicotine dependence, cigarettes, uncomplicated; E78.5 - Hyperlipidemia, unspecified; Z91.013 - Allergy to seafood; Z82.3 - Family history of stroke; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z85.828 - Personal history of other malignant neoplasm of skin; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states"
CINJ OP INFUSION,15754,"Ghodoussipour, Saum Bobak, MD",3/8/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,2/21/2023,Inactive,,
CINJ OP INFUSION,15754,"Ghodoussipour, Saum Bobak, MD",7/19/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,7/18/2023,Inactive,,
CINJ OP INFUSION,15754,"Ghodoussipour, Saum Bobak, MD",12/18/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,12/17/2024,Active,,
CBMC OP INFUSION 2FL,32466,"Dharmapuri, Sirish, MD",12/10/2024,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/1/2024,Active,,
NBI OP INFUSION,50333,"Schleicher, Lori, MD",4/21/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,4/21/2025,Active,Malignant neoplasm of breast (CMS/HCC),"C50.919, Z17.0 - Malignant neoplasm of breast in female, estrogen receptor positive, unspecified laterality, unspecified site of breast (CMS/HCC)"
CBMC OP INFUSION 2FL,67638,"Scoppetuolo, Michael, MD",11/6/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,11/5/2024,Inactive,,
NBI OP INFUSION,34015,"Schleicher, Lori, MD",10/18/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/17/2023,Inactive,,
NBI OP INFUSION,93967,"Cheng, Yan Ho, MD",2/22/2024,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,_1. First Line,2/12/2024,Inactive,,
NBI OP INFUSION,93967,"Cheng, Yan Ho, MD",6/6/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,6/5/2024,Active,,
CINJ OP INFUSION,47255,"Patankar, Sonali, MD",3/7/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Neoadjuvant,3/6/2024,Active,,
CINJ OP INFUSION,74298,"Patel, Eshan, MD",1/5/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - lung,_1. First Line,1/4/2024,Inactive,,
CINJ OP INFUSION,74298,"Patel, Eshan, MD",5/31/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,5/2/2024,Inactive,,
HAM OP INFUSION,45801,"Patel, Malini M, MD",12/4/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/1/2023,Inactive,,
HAM OP INFUSION,45801,"Patel, Malini M, MD",11/18/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/15/2024,Active,,
CBMC OP INFUSION 2FL,16096,"Scoppetuolo, Michael, MD",9/13/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,9/12/2023,Inactive,,
CINJ OP INFUSION,16096,"Weiss, Sarah, MD",6/5/2024,CINJ 092203 ARM A Tebentafusp 21 Day Cycles Research- Melanoma,_2. Second Line,6/4/2024,Inactive,,
CINJ OP INFUSION,16096,"Weiss, Sarah, MD",8/14/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,8/8/2024,Inactive,,
CINJ OP INFUSION,16096,"Weiss, Sarah, MD",11/27/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_4. Fourth Line,11/26/2024,Active,,
MMC OP INFUSION,71333,"Lee, Patrick C, MD",6/24/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,6/5/2024,Active,,
CINJ OP INFUSION,73520,"Haigentz, Missak, MD",3/29/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/28/2023,Active,,
MSC OP INFUSION,15490,"Talwar, Sumit, MD",11/14/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/12/2024,Active,,
CMC OP INFUSION,72731,"Talwar, Sumit, MD",9/30/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,9/30/2024,Inactive,,
CMC OP INFUSION,72731,"Talwar, Sumit, MD",3/6/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,3/6/2025,Active,"Malignant neoplasm of overlapping sites of both breasts in female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,36818,"Cruz, Allan Louie E, MD",3/5/2024,DOCEtaxel / Trastuzumab 21 Day Cycles - Breast,Adjuvant,3/4/2024,Inactive,,
JCMC CP INFUSION,36818,"Cruz, Allan Louie E, MD",3/6/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/5/2024,Inactive,,
CMC OP INFUSION,14577,"Talwar, Sumit, MD",6/7/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/31/2023,Inactive,,
CMC OP INFUSION,14577,"Talwar, Sumit, MD",6/28/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/30/2023,Inactive,,
CINJ OP INFUSION,30762,"Omene, Coral Oghenerukevwe, MD",4/10/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,4/10/2025,Active,Primary malignant neoplasm of breast with metastasis (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast
CBMC OP INFUSION 2FL,78893,"Scoppetuolo, Michael, MD",1/11/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,1/3/2024,Inactive,Intrahepatic bile duct carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,78893,"Scoppetuolo, Michael, MD",8/21/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/20/2024,Inactive,Intrahepatic bile duct carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,78893,"Scoppetuolo, Michael, MD",12/6/2024,Durvalumab Maintenance 28 Day Cycles- Biliary Tract Cancers,Maintenance,12/5/2024,Active,,
CINJ OP INFUSION,27722,"Patankar, Sonali, MD",5/20/2024,DOXOrubicin + Trabectedin 3hr Infusion q21 Day Cycles - Uterine Sarcoma,_1. First Line,5/19/2024,Active,,
CINJ OP INFUSION,27722,"Patankar, Sonali, MD",5/7/2025,Gemcitabine / DOCEtaxel 21 Day Cycles - Uterine Sarcoma,_2. Second Line,5/7/2025,Active,Leiomyosarcoma (CMS/HCC),"C55 - Malignant neoplasm of uterus, part unspecified; J91.0 - Malignant pleural effusion; C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; Z90.79 - Acquired absence of other genital organ(s)"
CMC OP INFUSION,81202,"Pompa, Tiffany Ann, MD",2/14/2025,mFOLFOX6 Inpatient (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/10/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CINJ OP INFUSION,92306,"Mayer, Tina M, MD",2/6/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,2/6/2024,Inactive,,
CINJ OP INFUSION,61281,"Weiss, Sarah, MD",7/12/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,7/11/2023,Inactive,,
CBMC OP INFUSION 2FL,56593,"Brown, Andrew Bennett, MD",1/9/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,1/8/2024,Inactive,,
CBMC OP INFUSION 2FL,56593,"Brown, Andrew Bennett, MD",3/5/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,2/20/2024,Inactive,,
CINJ OP INFUSION,74338,"Hochster, Howard S, MD",11/8/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,11/7/2023,Inactive,,
CINJ PEDS HEMONC ,42878,"Drachtman, Richard, MD",2/23/2023,AALL1731 - Delayed Intensification,First Line,2/23/2023,Inactive,,
CINJ PEDS HEMONC ,42878,"Drachtman, Richard, MD",4/27/2023,AALL1731 All SR-Fav B-ALL (including DS patients) - Interim Maintenance II EscMTX,First Line,4/27/2023,Inactive,,
CINJ PEDS HEMONC ,42878,"Drachtman, Richard, MD",6/29/2023,AALL1731 Non-DS SR-Avg B-ALL - Maintenance,First Line,6/29/2023,Active,,
MMC OP VP INFUSION,44309,"Cohen, Seth D, MD",10/7/2024,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/6/2024,Active,,
MSC OP INFUSION,44309,"Cohen, Seth D, MD",3/31/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/31/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CINJ OP INFUSION,14638,"Stephenson, Ryan D, DO",7/31/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,7/31/2024,Active,,
MMC OP VP INFUSION,88642,"Lee, Patrick C, MD",9/6/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,8/29/2024,Active,,
CINJ OP INFUSION,72944,"Gulhati, Prateek, MD PhD",4/25/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/25/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas
CINJ OP INFUSION,34202,"Groisberg, Roman, MD",8/25/2023,Pembrolizumab 42 Day Cycles - Melanoma,First Line,8/24/2023,Inactive,,
NBR CINJ OP INFUSION,82990,"Assal, Amer, MD",9/7/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,9/6/2023,Inactive,,
NBR CINJ OP INFUSION,82990,"Egini, Ogechukwu, MD",5/8/2024,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,5/7/2024,Inactive,,
NBR CINJ OP INFUSION,82990,"Egini, Ogechukwu, MD",5/15/2024,Venetoclax / Decitabine 56 Day Cycles - Acute Myeloid Leukemia,Maintenance,5/13/2024,Inactive,,
NBR CINJ OP INFUSION,82990,"Egini, Ogechukwu, MD",8/28/2024,CINJ 022305 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_3. Third Line,8/23/2024,Active,,
NBR CINJ OP INFUSION,82990,"Chen, Xiaoyi",5/12/2025,Venetoclax / Cytarabine (Low Dose) 28 Day Cycles - Acute Myeloid Leukemia,_6. Sixth Line,5/2/2025,Active,Stem cells transplant status (CMS/HCC),
NBR CINJ OP INFUSION,82990,"Egini, Ogechukwu, MD",5/8/2025,Venetoclax / Decitabine 56 Day Cycles - Acute Myeloid Leukemia,Maintenance,5/8/2025,Inactive,Acute myeloid leukemia in remission (CMS/HCC),"C92.01 - Acute myeloblastic leukemia, in remission; Z94.84 - Stem cells transplant status; C92.00 - Acute myeloblastic leukemia, not having achieved remission; D89.811 - Chronic graft-versus-host disease"
NBR CINJ OP INFUSION,82990,"Chen, Xiaoyi",4/28/2025,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,10. Tenth Line,4/28/2025,Inactive,Stem cells transplant status (CMS/HCC),"C92.02 - Acute myeloblastic leukemia, in relapse; Z94.84 - Stem cells transplant status"
TRMC TCCC OP INFUSION,9473,"Capo, Gerardo, MD",12/6/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/14/2024,Active,,
EMH HEM ONC,55417,"Yin, Faye, MD",9/12/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Second Line,9/11/2023,Inactive,,
CINJ OP INFUSION,93158,"Stephenson, Ryan D, DO",4/21/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,Third Line,4/20/2023,Inactive,,
CINJ OP INFUSION,93158,"Stephenson, Ryan D, DO",8/9/2023,Sacituzumab Govitecan 21 Day Cycles -  Bladder,Third Line,8/8/2023,Inactive,,
CINJ OP INFUSION,93158,"Stephenson, Ryan D, DO",10/9/2024,CINJ 102302 ARM 2 PHASE 2 ACR-368 + ULDG DOSE LEVEL 1 - UROTHELIAL CANCER,_6. Sixth Line,10/9/2024,Inactive,,
CINJ OP INFUSION,93158,"Stephenson, Ryan D, DO",12/27/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_7. Seventh Line,12/26/2024,Active,,
SOM OUTPT INFUSION,80312,"Yin, Faye, MD",1/24/2023,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/24/2023,Inactive,,
CINJ OP INFUSION,36468,"George, Mridula A, MD",5/17/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,5/16/2023,Inactive,,
CINJ OP INFUSION,36468,"George, Mridula A, MD",2/14/2024,CINJ 042211 Arm B Capecitabine / Pembrolizumab 21 Day Cycles Research- Breast Cancer,Adjuvant,2/13/2024,Inactive,,
CINJ PEDS HEMONC ,59466,"Drachtman, Richard, MD",5/26/2023,DFCI 16-001 Continuation,_1. First Line,5/26/2023,Inactive,,
JCMC CP INFUSION,66339,"Sekhri, Arunabh, MD",3/29/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,3/28/2023,Inactive,,
CINJ OP INFUSION,24824,"Hochster, Howard S, MD",6/12/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",First Line,6/7/2023,Inactive,,
MSC OP INFUSION,47652,"Easaw, Sarah, MD",5/19/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Third Line,4/23/2023,Inactive,,
MSC OP INFUSION,47652,"Talwar, Sumit, MD",9/20/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,9/19/2024,Active,,
CBMC OP INFUSION 2FL,35760,"Wagmiller, Jennifer Ann, MD",11/13/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,35760,"Wagmiller, Jennifer Ann, MD",12/1/2023,Sacituzumab Govitecan 21 Day Cycles - Breast,_2. Second Line,11/19/2023,Inactive,,
CBMC OP INFUSION 2FL,35760,"Wagmiller, Jennifer Ann, MD",5/6/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,5/2/2024,Inactive,,
CBMC OP INFUSION 2FL,35760,"Wagmiller, Jennifer Ann, MD",5/10/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,5/8/2024,Inactive,,
CBMC OP INFUSION 2FL,35760,"Wagmiller, Jennifer Ann, MD",8/20/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_5. Fifth Line,8/15/2024,Active,,
CINJ OP INFUSION,10732,"Omene, Coral Oghenerukevwe, MD",1/27/2025,Abemaciclib 28 Day Cycles - Breast,Adjuvant,1/27/2025,Active,,
CINJ OP INFUSION,24655,"Omene, Coral Oghenerukevwe, MD",3/24/2025,Pembrolizumab Plus Albumin-bound PACLitaxel - 21 Day Cycles - Bladder or Breast,_1. First Line,3/10/2025,Active,"Malignant neoplasm of left female breast (CMS/HCC)
Stage IV breast cancer in female (CMS/HCC)
Drug-induced thyroiditis",C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z90.12 - Acquired absence of left breast and nipple; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,24655,"Omene, Coral Oghenerukevwe, MD",3/24/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_1. First Line,3/24/2025,Active,Stage IV breast cancer in female (CMS/HCC),C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z90.12 - Acquired absence of left breast and nipple; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBI VALERIE FND HEMONC,5971,"Batra, Surabhi, MD",6/27/2023,AALL1731 Non-DS SR (Fav or Avg) B-ALL - Maintenance,_1. First Line,6/26/2023,Active,,
JCMC CP INFUSION,64585,"Cruz, Allan Louie E, MD",2/11/2025,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,2/11/2025,Active,"Cancer, hepatocellular (CMS/HCC)","C22.0 - Liver cell carcinoma; K08.9 - Disorder of teeth and supporting structures, unspecified; G89.29 - Other chronic pain"
NBI OP INFUSION,43921,"Anderson, Patrick S, MD",11/20/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - endometrial Cancer,_1. First Line,11/19/2023,Inactive,,
CMC OP INFUSION,40072,"Cohen, Seth D, MD",11/11/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,11/10/2024,Active,,
NBI OP INFUSION,88526,"Jacoby, Sari H, MD",6/10/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,6/9/2024,Active,,
NBI OP INFUSION,88526,"Jacoby, Sari H, MD",12/20/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,12/19/2024,Active,Malignant neoplasm of pancreas (CMS/HCC),
JCMC CP INFUSION,64227,"Sekhri, Arunabh, MD",2/16/2023,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Kaposi sarcoma in HIV positive patient",First Line,2/15/2023,Inactive,,
JCMC CP INFUSION,64227,"Sekhri, Arunabh, MD",10/5/2023,DOXOrubicin Liposomal 42 Day Cycles - Sarcoma,Second Line,9/27/2023,Active,,
JCMC CP INFUSION,70109,"Sekhri, Arunabh, MD",1/6/2025,Temozolomide with Concurrent Radiation 21 Day Cycle - CNS,_1. First Line,1/6/2025,Inactive,GBM (glioblastoma multiforme) (CMS/HCC),
JCMC CP INFUSION,70109,"Sekhri, Arunabh, MD",3/3/2025,Temozolomide 28 Day Cycles - CNS,_1. First Line,3/3/2025,Active,GBM (glioblastoma multiforme) (CMS/HCC),"C71.9 - Malignant neoplasm of brain, unspecified"
CINJ OP INFUSION,88378,"Omene, Coral Oghenerukevwe, MD",4/18/2023,Palbociclib 28 Day Cycles - Breast,First Line,4/18/2023,Inactive,,
CBMC OP INFUSION 2FL,16211,"Litvak, Anna M, MD",11/19/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,11/18/2024,Active,Malignant neoplasm of tail of pancreas (CMS/HCC),
CBMC OP INFUSION 2FL,760,"Dave, Manish, MD",5/11/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/10/2023,Inactive,,
CMC OP INFUSION,64256,"Meghal, Trishala, MD",9/6/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,9/2/2023,Inactive,,
CMC OP INFUSION,64256,"Talwar, Sumit, MD",10/17/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,9/25/2023,Inactive,,
CINJ OP INFUSION,42438,"Haigentz, Missak, MD",8/14/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,8/14/2023,Inactive,,
MMC OP VP INFUSION,4744,"Lee, Patrick C, MD",9/21/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,9/13/2023,Inactive,,
CBMC OP INFUSION 2FL,67498,"Brown, Andrew Bennett, MD",5/23/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,5/23/2024,Inactive,,
CBMC OP INFUSION 2FL,67498,"Brown, Andrew Bennett, MD",8/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/20/2024,Inactive,,
CINJ PEDS HEMONC ,31883,"Cole, Peter David, MD",11/7/2024,as per ACNS1123 Stratum I,_1. First Line,11/7/2024,Active,,
CINJ PEDS HEMONC ,31883,"Cole, Peter David, MD",11/7/2024,ACNS2021 Induction,_1. First Line,11/5/2024,Inactive,,
CINJ OP INFUSION,43145,"Boland, Patrick M, MD",7/24/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,6/26/2024,Inactive,,
CINJ OP INFUSION,43145,"Boland, Patrick M, MD",10/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/24/2024,Active,,
NBR CINJ OP INFUSION,10494,"Matasar, Matthew J, MD",3/4/2025,Obinutuzumab 28 Day Cycles - Low Grade Indolent Lymphoma ,_1. First Line,3/4/2025,Inactive,"Chronic lymphocytic leukemia of B-cell type in remission (CMS/HCC)
Acute idiopathic thrombocytopenic purpura (CMS/HCC)","C83.00 - Small cell B-cell lymphoma, unspecified site; C91.11 - Chronic lymphocytic leukemia of B-cell type in remission; D80.1 - Nonfamilial hypogammaglobulinemia; D69.6 - Thrombocytopenia, unspecified; Z00.00 - Encounter for general adult medical examination without abnormal findings; D69.3 - Immune thrombocytopenic purpura"
CINJ OP INFUSION,74405,"George, Mridula A, MD",9/27/2023,EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / DOCEtaxel 21 Day Cycles Research- Breast Cancer,Neoadjuvant,9/26/2023,Inactive,,
CINJ OP INFUSION,74405,"George, Mridula A, MD",9/29/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / Nab-PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",Neoadjuvant,9/28/2023,Inactive,,
CINJ OP INFUSION,74405,"George, Mridula A, MD",10/13/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Maintenance,9/15/2023,Active,,
CINJ OP INFUSION,74405,"George, Mridula A, MD",1/19/2024,EA1181 / CINJ 042004 Post-Operative Trastuzumab / Pertuzumab 21 Day Cycles Research ARM A- Breast Cancer,Adjuvant,1/5/2024,Inactive,,
CINJ OP INFUSION,74405,"George, Mridula A, MD",3/20/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/14/2024,Inactive,,
CINJ OP INFUSION,74405,"George, Mridula A, MD",5/8/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,4/16/2024,Active,,
NBR CINJ OP INFUSION,96854,"Palmisiano, Neil David, MD",6/13/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,6/13/2023,Inactive,,
SOM OUTPT INFUSION,12266,"Patel, Eshan, MD",10/14/2024,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,10/6/2024,Inactive,,
SOM OUTPT INFUSION,12266,"Patel, Eshan, MD",12/2/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/19/2024,Active,,
CINJ OP INFUSION,89287,"Haigentz, Missak, MD",11/26/2024,Capmatinib 28 Day Cycles,_1. First Line,11/26/2024,Active,,
CINJ OP INFUSION,1147,"Saraiya, Biren P, MD",3/4/2025,Relugolix 30 day Cycles - Prostate,Neoadjuvant,3/4/2025,Inactive,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
CINJ OP INFUSION,47689,"Mayer, Tina M, MD",1/18/2024,Pembrolizumab 21 Day Cycles - Bladder ,_2. Second Line,1/18/2024,Inactive,,
CINJ OP INFUSION,47689,"Mayer, Tina M, MD",7/25/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_2. Second Line,7/24/2024,Active,,
HAM OP INFUSION,57834,"Yogarajah, Meera, MD",11/28/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,11/26/2023,Inactive,,
CINJ OP INFUSION,55646,"Goel, Sanjay, MD",5/28/2025,CINJ 052008 Schedule G REGN7075 Q2W/Cemiplimab Q6W/Trifluridine-Tipiracil/Bevacizumab Q2W,_2. Second Line,5/28/2025,Active,Cancer of sigmoid colon (CMS/HCC),
CINJ OP INFUSION,98895,"Haigentz, Missak, MD",9/26/2023,Bevacizumab Maintenance 21 Day Cycles- Radiation Induced Optic Neuritis,,9/26/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,28107,"Moerdler, Scott, MD",1/25/2024,per ANBL1531 Induction,Induction,1/25/2024,Inactive,,
CINJ PEDS HEMONC ,28107,"Shah, Niketa, MD",6/19/2024,PEDS BMT Autologous (Per ANBL1531 Consolidation #1) Thiotepa / Cyclophosphamide,Consolidation,6/17/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,28107,"Shah, Niketa, MD",8/20/2024,PEDS BMT Autologous (Per ANBL1531 Consolidation #2) CEM Melphalan / Etoposide / Carboplatin  ,Consolidation,8/19/2024,Inactive,,
CINJ PEDS HEMONC ,28107,"Moerdler, Scott, MD",12/13/2024,ANBL1531 Post-Consolidation Therapy,_1. First Line,12/6/2024,Inactive,,
CINJ PEDS HEMONC ,28107,"Moerdler, Scott, MD",1/5/2025,PEDS ANBL1221 Regimen B,_2. Second Line,1/3/2025,Active,,
TRMC TCCC OP INFUSION,24225,"Capo, Gerardo, MD",5/22/2025,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_1. First Line,5/22/2025,Inactive,MDS (myelodysplastic syndrome) (CMS/HCC),
CBMC OP INFUSION 2FL,99349,"Brown, Andrew Bennett, MD",1/22/2025,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,_1. First Line,1/9/2025,Active,,
MMC OP VP INFUSION,31246,"Lee, Patrick C, MD",4/4/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/19/2024,Inactive,,
CBMC 2W ONCOLOGY,832,"Grossman, I Robert, MD",12/8/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/7/2023,Inactive,,
CBMC 2W ONCOLOGY,832,"Grossman, I Robert, MD",12/29/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,12/29/2023,Inactive,,
CBMC 2W ONCOLOGY,832,"Grossman, I Robert, MD",1/23/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,1/23/2024,Inactive,,
CBMC 2W ONCOLOGY,832,"Grossman, I Robert, MD",3/3/2024,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 14 Day Cycles - Mantle Cell Lymphoma,_2. Second Line,3/2/2024,Inactive,,
CBMC 2W ONCOLOGY,832,"Grossman, I Robert, MD",3/26/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_3. Third Line,3/25/2024,Inactive,,
NBR CINJ OP INFUSION,832,"Assal, Amer, MD",5/18/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_5. Fifth Line,5/16/2024,Active,,
CINJ OP INFUSION,17870,"Saraiya, Biren P, MD",6/12/2023,CINJ 082211 Dose Escalation HB-302 / HB-301 Alternating 2-Vector Therapy 42 Day Cycles Research- Prostate Cancer,Third Line,6/9/2023,Inactive,,
CBMC OP INFUSION 2FL,40937,"Litvak, Anna M, MD",5/7/2025,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,_1. First Line,5/7/2025,Inactive,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,40937,"Litvak, Anna M, MD",5/7/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,4/23/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,40937,"Litvak, Anna M, MD",4/9/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,4/9/2025,Inactive,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,40937,"Litvak, Anna M, MD",3/10/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,_1. First Line,3/10/2025,Inactive,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",
NBI OP INFUSION,65965,"Schleicher, Lori, MD",10/2/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,9/26/2024,Active,,
CINJ OP INFUSION,40663,"Saraiya, Biren P, MD",8/12/2024,Enzalutamide 30 Day Cycles - Prostate,_1. First Line,8/12/2024,Inactive,,
CINJ OP INFUSION,40663,"Saraiya, Biren P, MD",10/2/2024,Talazoparib 30 Day Cycles,_1. First Line,10/2/2024,Inactive,,
NBR CINJ OP INFUSION,75254,"Shah, Mansi R, MD",5/27/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/27/2025,Active,Multiple myeloma (CMS/HCC),
NBR 5N ONCOLOGY,75254,"Chen, Xiaoyi",5/24/2025,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,5/24/2025,Inactive,Multiple myeloma (CMS/HCC),
NBR 4N ONCOLOGY,75254,"Chen, Xiaoyi",4/25/2025,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,4/25/2025,Inactive,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; E43 - Unspecified severe protein-calorie malnutrition; Z66 - Do not resuscitate; J96.01 - Acute respiratory failure with hypoxia; J98.59 - Other diseases of mediastinum, not elsewhere classified; I16.1 - Hypertensive emergency; E87.3 - Alkalosis; J81.1 - Chronic pulmonary edema; S22.43XA - Multiple fractures of ribs, bilateral, initial encounter for closed fracture; J90 - Pleural effusion, not elsewhere classified; D53.9 - Nutritional anemia, unspecified; E03.8 - Other specified hypothyroidism; I82.493 - Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; J98.11 - Atelectasis; I10 - Essential (primary) hypertension; D63.0 - Anemia in neoplastic disease; D75.89 - Other specified diseases of blood and blood-forming organs; E78.00 - Pure hypercholesterolemia, unspecified; E87.70 - Fluid overload, unspecified; F41.9 - Anxiety disorder, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); I49.3 - Ventricular premature depolarization; K59.03 - Drug induced constipation; M40.204 - Unspecified kyphosis, thoracic region; T40.2X5A - Adverse effect of other opioids, initial encounter; Z79.83 - Long term (current) use of bisphosphonates; Z79.899 - Other long term (current) drug therapy; Z80.42 - Family history of malignant neoplasm of prostate; Z80.7 - Family history of othe..."
CINJ OP INFUSION,24961,"Patankar, Sonali, MD",3/11/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/6/2024,Inactive,,
CINJ OP INFUSION,24961,"Patankar, Sonali, MD",8/2/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,8/2/2024,Active,,
CINJ OP INFUSION,83419,"Patankar, Sonali, MD",3/3/2025,"Carboplatin, doxil, bevacizumab for recurrent platinum sensitive ovarian cancer",_2. Second Line,3/3/2025,Active,Malignant neoplasm of ovary (CMS/HCC),C56.3 - Malignant neoplasm of bilateral ovaries; C56.9 - Malignant neoplasm of unspecified ovary
MMC OP VP INFUSION,90314,"Cohen, Seth D, MD",4/14/2023,CINJ 082106 Pembrolizumab / Belzutifan or Placebo 42 Day Cycles Research- Renal Cell Carcinoma,Adjuvant,4/4/2023,Inactive,,
MMC OP VP INFUSION,90314,"Cohen, Seth D, MD",12/18/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,_1. First Line,12/18/2023,Inactive,,
CINJ OP INFUSION,43097,"George, Mridula A, MD",5/26/2023,Ribociclib 28 Day Cycles - Breast,First Line,5/26/2023,Inactive,,
CINJ OP INFUSION,43097,"George, Mridula A, MD",6/14/2023,Palbociclib 28 Day Cycles - Breast,First Line,6/14/2023,Inactive,,
NBI OP INFUSION,75558,"Schleicher, Lori, MD",8/9/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,8/8/2023,Inactive,,
NBI OP INFUSION,7158,"Schleicher, Lori, MD",5/6/2024,TH+P (DOCEtaxel  / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/5/2024,Inactive,,
NBI OP INFUSION,7158,"Schleicher, Lori, MD",10/14/2024,kadcyla,_2. Second Line,10/13/2024,Inactive,,
NBI OP INFUSION,7158,"Schleicher, Lori, MD",10/23/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_2. Second Line,10/21/2024,Inactive,,
NBI OP INFUSION,7158,"Schleicher, Lori, MD",12/24/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,12/23/2024,Active,,
HAM OP INFUSION,7330,"Yogarajah, Meera, MD",2/7/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,2/6/2023,Inactive,,
NBI OP INFUSION,36023,"Schleicher, Lori, MD",4/11/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,4/10/2023,Active,,
NBR CINJ OP INFUSION,84765,"Schaar, Dale, MD PhD",3/28/2023, Intrathecal chemotherapy (IT) 1 Day Cycle- Hematological Malignancies,,3/27/2023,Active,,
NBR CINJ OP INFUSION,84765,"Schaar, Dale, MD PhD",9/5/2023,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,,9/4/2023,Inactive,,
NBR 4N ONCOLOGY,84765,"Schaar, Dale, MD PhD",9/26/2024,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,9/25/2024,Inactive,,
MMC OP INFUSION,84765,"Schaar, Dale, MD PhD",10/7/2024,AALL1131 VHR B-ALL - Maintenance,_3. Third Line,10/7/2024,Active,,
NBI OP INFUSION,99207,"Schleicher, Lori, MD",10/25/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/17/2023,Active,,
CMC OP INFUSION,86748,"Taff, Jessica, MD",8/28/2023,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,First Line,8/21/2023,Inactive,,
MMC OP INFUSION,75569,"Cohen, Seth D, MD",6/19/2023,AzaCITIDine (Post Transplant) 28 Day Cycle - Acute Myeloid Leukemia / MDS,First Line,6/18/2023,Inactive,,
MMC OP VP INFUSION,75569,"Cohen, Seth D, MD",12/11/2023,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_2. Second Line,12/10/2023,Inactive,,
MMC OP VP INFUSION,24399,"Meghal, Trishala, MD",7/10/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Induction,7/7/2024,Active,,
MMC OP VP INFUSION,24399,"Meghal, Trishala, MD",2/7/2025,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,2/6/2025,Active,Malignant neoplasm of endocervix (CMS/HCC),
CINJ OP INFUSION,6342,"Stephenson, Ruth D, DO",5/26/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Third Line,5/22/2023,Inactive,,
CINJ OP INFUSION,40546,"Toppmeyer, Deborah L, MD",11/11/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,11/10/2024,Active,,
CBMC OP INFUSION 2FL,54629,"Brown, Andrew Bennett, MD",8/15/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/15/2024,Active,,
CINJ OP INFUSION,50238,"George, Mridula A, MD",9/7/2023,Palbociclib 28 Day Cycles - Breast,,9/7/2023,Active,,
HAM OP INFUSION,17044,"Yogarajah, Meera, MD",11/22/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,11/11/2024,Active,,
HAM OP INFUSION,23789,"Yogarajah, Meera, MD",5/22/2025,Abemaciclib 28 Day Cycles - Breast,Adjuvant,5/22/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,85073,"Talwar, Sumit, MD",11/6/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/1/2024,Active,,
CBMC OP INFUSION 2FL,83655,"Wagmiller, Jennifer Ann, MD",1/2/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,12/13/2023,Inactive,,
CBMC OP INFUSION 2FL,83655,"Wagmiller, Jennifer Ann, MD",3/13/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,3/13/2025,Active,Malignant neoplasm of unspecified site of left female breast (CMS/HCC),C79.31 - Secondary malignant neoplasm of brain; C50.912 - Malignant neoplasm of unspecified site of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,76604,"Sekhri, Arunabh, MD",8/30/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/14/2024,Active,,
CINJ OP INFUSION,9270,"Omene, Coral Oghenerukevwe, MD",8/6/2024,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,Neoadjuvant,8/5/2024,Inactive,,
CINJ OP INFUSION,9270,"Omene, Coral Oghenerukevwe, MD",10/29/2024,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,Neoadjuvant,10/28/2024,Active,,
CINJ OP INFUSION,9270,"Omene, Coral Oghenerukevwe, MD",1/28/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,1/27/2025,Active,,
CMC OP INFUSION,80773,"Pompa, Tiffany Ann, MD",5/7/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,5/7/2025,Active,"Mantle cell lymphoma (CMS/HCC)
Lymphoma (CMS/HCC)",
CMC OP INFUSION,80773,"Pompa, Tiffany Ann, MD",3/11/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,3/11/2025,Active,Mantle cell lymphoma (CMS/HCC),
NBR 4N ONCOLOGY,66216,"Patel, Vimal D, MD",2/15/2023,BMT Autologous BEAM,Consolidation,2/15/2023,Inactive,,
NBR CINJ OP INFUSION,66216,"Evens, Andrew M, DO",5/10/2023,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,,5/9/2023,Inactive,,
NBR CINJ OP INFUSION,66216,"Evens, Andrew M, DO",3/19/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,3/19/2025,Inactive,"Hodgkin disease (CMS/HCC)
Hodgkin lymphoma, unspecified, unspecified site (CMS/HCC)
Abnormal coagulation profile
Diffuse large b-cell lymphoma, intra-abdominal lymph nodes (CMS/HCC)",
NBR CINJ OP INFUSION,66216,"Evens, Andrew M, DO",3/19/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_4. Fourth Line,3/19/2025,Inactive,"Hodgkin disease (CMS/HCC)
Hodgkin lymphoma, unspecified, unspecified site (CMS/HCC)
Abnormal coagulation profile
Diffuse large b-cell lymphoma, intra-abdominal lymph nodes (CMS/HCC)",
NBR CINJ OP INFUSION,66216,"Evens, Andrew M, DO",3/19/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_4. Fourth Line,3/19/2025,Active,"Hodgkin disease (CMS/HCC)
Hodgkin lymphoma, unspecified, unspecified site (CMS/HCC)
Abnormal coagulation profile
Diffuse large b-cell lymphoma, intra-abdominal lymph nodes (CMS/HCC)",
MSC OP INFUSION,76223,"Eltoukhy, Hussam, MD",5/10/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,First Line,5/4/2023,Inactive,,
CMC OP INFUSION,55561,"Tang, Horace, MD",10/12/2023,CISplatin With Concurrent Radiation 7 Day Cycles - bladder ,Induction,10/11/2023,Inactive,,
NBR 5N ONCOLOGY,24890,"Palmisiano, Neil David, MD",9/23/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_9. Ninth Line,9/19/2024,Active,,
NBR CINJ OP INFUSION,24890,"Rhodes, Joanna Meehan, MD",9/23/2024,Mini-Pola- R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab/ PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/21/2024,Active,,
HAM OP INFUSION,12079,"Yogarajah, Meera, MD",4/8/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,4/8/2024,Active,,
CINJ OP INFUSION,82787,"Omene, Coral Oghenerukevwe, MD",3/26/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,3/26/2024,Active,,
NBI OP INFUSION,68612,"Anderson, Patrick S, MD",12/7/2023,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,12/5/2023,Inactive,,
NBI OP INFUSION,68612,"Anderson, Patrick S, MD",10/24/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/20/2024,Active,,
NBR CINJ OP INFUSION,98870,"Rabinovich, Emma, MD",3/27/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Induction,3/14/2025,Inactive,"Multiple myeloma not having achieved remission (CMS/HCC)
Encounter for lumbar puncture
Coagulopathy (CMS/HCC)",Z94.84 - Stem cells transplant status (CMS/HCC); C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
CINJ OP INFUSION,71623,"Boland, Patrick M, MD",7/19/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/18/2024,Inactive,,
CINJ OP INFUSION,71623,"Boland, Patrick M, MD",9/13/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/12/2024,Inactive,,
CINJ OP INFUSION,772,"Gulhati, Prateek, MD PhD",5/11/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,5/10/2023,Active,,
CINJ OP INFUSION,1890,"Gulhati, Prateek, MD PhD",3/6/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/6/2025,Inactive,Malignant neoplasm of pancreas (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C25.9 - Malignant neoplasm of pancreas, unspecified; K86.9 - Disease of pancreas, unspecified; C79.51 - Secondary malignant neoplasm of bone; I25.2 - Old myocardial infarction; J44.9 - Chronic obstructive pulmonary disease, unspecified; I10 - Essential (primary) hypertension; K21.9 - Gastro-esophageal reflux disease without esophagitis; E78.5 - Hyperlipidemia, unspecified; R11.2 - Nausea with vomiting, unspecified; G62.9 - Polyneuropathy, unspecified; Z95.5 - Presence of coronary angioplasty implant and graft; Z92.21 - Personal history of antineoplastic chemotherapy; Z80.0 - Family history of malignant neoplasm of digestive organs; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum"
NBR 5N ONCOLOGY,66501,"Palmisiano, Neil David, MD",4/17/2023,Bosutinib (Newly Diagnosed) 30 Day Cycles - Chronic Myeloid Leukemia,,4/17/2023,Inactive,,
NBR 4N ONCOLOGY,66501,"Palmisiano, Neil David, MD",7/2/2023,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,,7/1/2023,Inactive,,
NBR CINJ OP INFUSION,66501,"Palmisiano, Neil David, MD",8/21/2023,Inotuzumab Ozogamicin 21 Day Cycle + Inotuzumab Ozogamicin 28 Day Cycles - Acute Lymphoblastic Leukemia,,8/21/2023,Inactive,,
NBR CINJ OP INFUSION,66501,"Palmisiano, Neil David, MD",1/16/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_2. Second Line,1/10/2024,Inactive,,
NBR 5N ONCOLOGY,66501,"Palmisiano, Neil David, MD",2/6/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,2/6/2024,Inactive,,
NBR 4N ONCOLOGY,66501,"Palmisiano, Neil David, MD",2/15/2024,CINJ 021808 (EA9152) ARM D Venetoclax / Vincristine 28 Day Cycles Research- Acute Lymphoblastic Leukemia,Reinduction,2/8/2024,Inactive,,
CINJ OP INFUSION,6996,"Berim, Lyudmyla, MD",10/16/2023,"Gemcitabine 1000 mg/m2 D1, D8, D15/Capecitabine 830 mg/m2 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",,10/8/2023,Active,,
MMC OP VP INFUSION,36466,"Cohen, Seth D, MD",3/8/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Small Cell Lung Cancer",Second Line,3/7/2023,Inactive,,
MMC OP VP INFUSION,36466,"Cohen, Seth D, MD",6/28/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,,6/27/2023,Inactive,,
MMC OP VP INFUSION,36466,"Cohen, Seth D, MD",10/4/2023,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,10/3/2023,Inactive,,
CINJ OP INFUSION,51892,"Boland, Patrick M, MD",12/24/2024,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,12/23/2024,Active,,
CINJ OP INFUSION,55969,"Boland, Patrick M, MD",3/25/2025,Capecitabine 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/25/2025,Active,Pancreatic cancer (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C25.2 - Malignant neoplasm of tail of pancreas; C25.9 - Malignant neoplasm of pancreas, unspecified; E11.21 - Type 2 diabetes mellitus with diabetic nephropathy; E87.1 - Hypo-osmolality and hyponatremia; R64 - Cachexia; K59.00 - Constipation, unspecified; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C79.51 - Secondary malignant neoplasm of bone"
NBR 4N ONCOLOGY,75406,"Jang, Thomas L, MD",1/14/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,1/14/2025,Active,,
CINJ OP INFUSION,54149,"Saraiya, Biren P, MD",8/9/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,8/9/2023,Inactive,,
NBR 5N ONCOLOGY,93685,"Rhodes, Joanna Meehan, MD",7/10/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,7/10/2024,Inactive,,
NBR CINJ OP INFUSION,93685,"Rhodes, Joanna Meehan, MD",8/5/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/5/2024,Inactive,,
NBR CINJ OP INFUSION,35383,"Rhodes, Joanna Meehan, MD",4/2/2025,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,Lymphodepletion,4/2/2025,Inactive,"Mediastinal mass
SVC syndrome
Diffuse large B-cell lymphoma (CMS/HCC)","C83.30 - Diffuse large B-cell lymphoma, unspecified site; J98.59 - Other diseases of mediastinum, not elsewhere classified; I87.1 - Compression of vein"
TRMC TCCC OP INFUSION,76774,"Capo, Gerardo, MD",8/21/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,8/20/2024,Active,,
NBR 5N ONCOLOGY,27361,"Mayer, Tina M, MD",10/22/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,10/20/2023,Active,,
MMC OP VP INFUSION,25306,"Cohen, Seth D, MD",6/6/2024,Zanubrutinib (160 mg) 30 Day Cycles - Mantle Cell Lymphoma,_1. First Line,6/6/2024,Active,"Malignant neoplasm of upper lobe, right bronchus or lung (CMS/HCC)
Secondary malignant neoplasm of brain (CMS/HCC)",
CBMC OP INFUSION 2FL,89176,"Wagmiller, Jennifer Ann, MD",5/21/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,89176,"Wagmiller, Jennifer Ann, MD",6/5/2024,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,6/2/2024,Active,,
SOM OUTPT INFUSION,25407,"Patel, Eshan, MD",4/16/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/15/2024,Inactive,,
SOM OUTPT INFUSION,25407,"Patel, Eshan, MD",7/22/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/8/2024,Inactive,,
NBR 4N ONCOLOGY,76102,"Zayac, Adam, MD",3/27/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,3/27/2024,Inactive,,
NBR 4N ONCOLOGY,76102,"Zayac, Adam, MD",3/28/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,3/28/2024,Inactive,,
CMC OP INFUSION,76102,"Eltoukhy, Hussam, MD",6/3/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,5/30/2024,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,91905,"Boland, Patrick M, MD",3/25/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/25/2025,Active,Malignant neoplasm of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C78.00 - Secondary malignant neoplasm of unspecified lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C77.8 - Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions; R91.8 - Other nonspecific abnormal finding of lung field; I31.39 - Other pericardial effusion (noninflammatory); I11.9 - Hypertensive heart disease without heart failure; K44.9 - Diaphragmatic hernia without obstruction or gangrene; J90 - Pleural effusion, not elsewhere classified; N28.1 - Cyst of kidney, acquired; E78.5 - Hyperlipidemia, unspecified; M41.9 - Scoliosis, unspecified; I44.0 - Atrioventricular block, first degree; K59.00 - Constipation, unspecified; E03.9 - Hypothyroidism, unspecified; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; Z79.899 - Other long term (current) drug therapy; Z79.890 - Hormone replacement therapy; Z87.891 - Personal history of nicotine dependence; Z78.0 - Asymptomatic menopausal state; Z95.0 - Presence of cardiac pacemaker"
CINJ OP INFUSION,66258,"Saraiya, Biren P, MD",12/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,12/18/2023,Inactive,,
CINJ OP INFUSION,66258,"Saraiya, Biren P, MD",2/22/2024,Darolutamide 30 Day Cycles - Prostate M1 HSPC with Chemo ,_1. First Line,2/22/2024,Active,,
CINJ OP INFUSION,36304,"Stephenson, Ruth D, DO",2/17/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,2/11/2025,Active,Malignant neoplasm of left ovary (CMS/HCC),C53.1 - Malignant neoplasm of exocervix; Z51.89 - Encounter for other specified aftercare; C56.2 - Malignant neoplasm of left ovary
CINJ OP INFUSION,37003,"Haigentz, Missak, MD",8/29/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,8/29/2023,Inactive,,
NBR CINJ OP INFUSION,24689,"Chen, Xiaoyi",1/19/2025,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_1. First Line,1/19/2025,Active,,
CBMC 2W ONCOLOGY,24689,"Grossman, I Robert, MD",4/14/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/14/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"A41.9 - Sepsis, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; L89.154 - Pressure ulcer of sacral region, stage 4; E87.4 - Mixed disorder of acid-base balance; C90.00 - Multiple myeloma not having achieved remission; Z11.52 - Encounter for screening for COVID-19; M46.28 - Osteomyelitis of vertebra, sacral and sacrococcygeal region; I48.92 - Unspecified atrial flutter; D84.9 - Immunodeficiency, unspecified; G82.20 - Paraplegia, unspecified; D64.9 - Anemia, unspecified; E66.9 - Obesity, unspecified; I10 - Essential (primary) hypertension; Z68.41 - Body mass index (BMI) 40.0-44.9, adult; L97.418 - Non-pressure chronic ulcer of right heel and midfoot with other specified severity; L97.428 - Non-pressure chronic ulcer of left heel and midfoot with other specified severity; K94.03 - Colostomy malfunction; J93.82 - Other air leak; K59.2 - Neurogenic bowel, not elsewhere classified; N39.0 - Urinary tract infection, site not specified; T83.511A - Infection and inflammatory reaction due to indwelling urethral catheter, initial encounter; L03.311 - Cellulitis of abdominal wall; Z16.21 - Resistance to vancomycin; I48.91 - Unspecified atrial fibrillation; L98.493 - Non-pressure chronic ulcer of skin of other sites with necrosis of muscle; N31.8 - Other neuromuscular dysfunction of bladder; I87.8 - Other specified disorders of veins; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; M10.9 - Gout, unspecified; F41.1 - Generalized ..."
SOM OUTPT INFUSION,35702,"Toomey, Kathleen C, MD",12/7/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/28/2023,Inactive,,
CINJ OP INFUSION,28242,"Patel, Eshan, MD",4/21/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,2/16/2023,Inactive,,
NBI OP INFUSION,63531,"Jacoby, Sari H, MD",8/14/2023, Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_3. Third Line,8/13/2023,Inactive,,
NBI OP INFUSION,63531,"Jacoby, Sari H, MD",7/1/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,7/1/2024,Active,,
HAM OP INFUSION,87777,"Gendy, Mina, DO",2/21/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,2/6/2025,Active,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission; R17 - Unspecified jaundice
HAM OP INFUSION,87777,"Gendy, Mina, DO",5/23/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,5/23/2025,Active,Multiple myeloma (CMS/HCC),
HAM OP INFUSION,87777,"Gendy, Mina, DO",5/21/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,5/21/2025,Inactive,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,44309,"Berim, Lyudmyla, MD",1/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/19/2024,Active,,
CINJ OP INFUSION,40540,"Aikins, James K, MD",5/30/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Neoadjuvant,5/29/2023,Inactive,,
MMC OP VP INFUSION,77005,"Meghal, Trishala, MD",12/22/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,12/21/2023,Inactive,,
NBR CINJ OP INFUSION,44113,"Shah, Mansi R, MD",10/17/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,10/16/2023,Active,,
CBMC OP INFUSION 2FL,4133,"Raptis, George, MD",1/14/2025,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,Neoadjuvant,1/13/2025,Active,,
CBMC OP INFUSION 2FL,18699,"Raptis, George, MD",2/25/2025,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,2/24/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,34612,"George, Mridula A, MD",1/8/2025,CINJ 042311 Part A Letrozole / Abemaciclib 28 Day Cycles Research- Breast Cancer,Neoadjuvant,1/7/2025,Active,,
CBMC OP INFUSION 2FL,46457,"Scoppetuolo, Michael, MD",7/10/2024,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,7/8/2024,Active,,
CBMC OP INFUSION 2FL,74935,"Wagmiller, Jennifer Ann, MD",7/8/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/26/2024,Active,,
JCMC CP INFUSION,87918,"Cruz, Allan Louie E, MD",9/18/2024,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_5. Fifth Line,9/16/2024,Inactive,,
JCMC CP INFUSION,87918,"Cruz, Allan Louie E, MD",9/26/2024,Nivolumab 480 mg D1 of 28 Day Cycles- Thoracic Cancers,_5. Fifth Line,9/26/2024,Active,,
JCMC CP INFUSION,87918,"Cruz, Allan Louie E, MD",4/8/2025,"Gemcitabine D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_7. Seventh Line,4/8/2025,Active,"Malignant neoplasm of lung (CMS/HCC)
Thrombosis due to vascular prosthetic devices, implants and grafts, sequela",
CINJ OP INFUSION,97209,"Haigentz, Missak, MD",7/22/2024,"DOCEtaxel weekly with radiotherapy D1, D8, D15, D22, D29, D36, D43- Head and Neck Cancers",Induction,7/22/2024,Active,,
CBMC OP INFUSION 2FL,53249,"Dharmapuri, Sirish, MD",5/14/2025,CINJ 072401 Quemliclustat / Zimberelimab / Gemcitabine / CISplatin 42 Day Cycles Research- Advanced Biliary Tract Cancers,_1. First Line,5/7/2025,Active,Cholangiocarcinoma (CMS/HCC),C22.1 - Intrahepatic bile duct carcinoma; Z00.6 - Encounter for examination for normal comparison and control in clinical research program
SOM OUTPT INFUSION,95513,"Yin, Faye, MD",10/9/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/4/2023,Inactive,,
SOM OUTPT INFUSION,95513,"Yin, Faye, MD",2/20/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,2/16/2024,Inactive,,
SOM OUTPT INFUSION,95513,"Yin, Faye, MD",5/13/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,5/12/2024,Inactive,,
SOM OUTPT INFUSION,95513,"Toomey, Kathleen C, MD",7/1/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,6/28/2024,Active,,
CBMC OP INFUSION 2FL,49654,"Derosa, William T, DO",10/23/2024,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,10/22/2024,Inactive,,
CINJ OP INFUSION,92302,"Toppmeyer, Deborah L, MD",4/22/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,4/22/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBR CINJ OP INFUSION,69194,"Doraiswamy, Anupama, MD",3/6/2023,Asciminib 28 Day Cycles - Chronic Myeloid Leukemia (T315I mutation),,3/6/2023,Active,,
MSC OP INFUSION,75742,"Cohen, Seth D, MD",3/2/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,,3/1/2023,Inactive,,
SOM OUTPT INFUSION,26540,"Yin, Faye, MD",6/24/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,6/23/2024,Inactive,,
SOM OUTPT INFUSION,26540,"Yin, Faye, MD",7/8/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,6/23/2024,Inactive,,
SOM OUTPT INFUSION,26540,"Patel, Eshan, MD",11/4/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,10/28/2024,Active,,
MMC OP VP INFUSION,99255,"Lee, Patrick C, MD",5/6/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/22/2024,Active,,
CINJ OP INFUSION,61634,"Weiss, Sarah, MD",7/22/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,7/21/2024,Inactive,,
CINJ OP INFUSION,61634,"Weiss, Sarah, MD",12/9/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_2. Second Line,12/8/2024,Active,,
CINJ OP INFUSION,61634,"Weiss, Sarah, MD",3/17/2025,CINJ 052408 Part 2.1B Escalation Step Up AB248 / Pembrolizumab 200 mg 21 Day Cycles Research- Solid Tumors,_2. Second Line,3/17/2025,Active,Metastatic melanoma to parotid gland (CMS/HCC),Z00.6 - Clinical trial participant; C79.89 - Metastatic melanoma to parotid gland (CMS/HCC)
CINJ OP INFUSION,61634,"Weiss, Sarah, MD",3/11/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_3. Third Line,3/11/2025,Inactive,Metastatic melanoma to parotid gland (CMS/HCC),"C79.89 - Secondary malignant neoplasm of other specified sites; C43.39 - Malignant melanoma of other parts of face; J44.9 - Chronic obstructive pulmonary disease, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z87.891 - Personal history of nicotine dependence"
NBR 5N ONCOLOGY,30968,"Packiam, Vignesh, MD",3/19/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,3/19/2024,Inactive,,
CINJ OP INFUSION,30968,"Packiam, Vignesh, MD",4/12/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,4/11/2024,Inactive,,
CINJ OP INFUSION,30968,"Packiam, Vignesh, MD",8/9/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,Adjuvant,8/8/2024,Active,,
CINJ OP INFUSION,32787,"Vojnic, Morana, MD, MBA",5/23/2025,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,5/23/2025,Active,"Glioblastoma, IDH-wildtype (CMS/HCC)","C71.9 - Malignant neoplasm of brain, unspecified"
SOM OUTPT INFUSION,99119,"Patel, Eshan, MD",4/16/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/8/2024,Active,,
CINJ OP INFUSION,55874,"Haigentz, Missak, MD",2/20/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,2/19/2024,Active,,
SOM OUTPT INFUSION,49968,"Toomey, Kathleen C, MD",11/1/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,10/3/2023,Inactive,,
SOM OUTPT INFUSION,49968,"Toomey, Kathleen C, MD",11/8/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/7/2023,Inactive,,
SOM OUTPT INFUSION,49968,"Toomey, Kathleen C, MD",11/8/2023,CapeOX/Irinotecan (Capecitabine 1000 mg/m2/OXALIplatin/Irinotecan) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,65026,"Dharmapuri, Sirish, MD",8/28/2024,mFOLFIRINOX (Fluorouracil IV Push 300 mg/m2 / Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 135 mg/m2 / OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,8/25/2024,Active,,
CBMC OP INFUSION 2FL,65026,"Dharmapuri, Sirish, MD",5/5/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/5/2025,Active,"Adenocarcinoma of pancreas, stage 4 (CMS/HCC)","C25.9 - Adenocarcinoma of pancreas, stage 4 (CMS/HCC)"
NBR CINJ OP INFUSION,97879,"Matasar, Matthew J, MD",1/7/2023,Alemtuzumab 28 Day Cycles - T-Cell Prolymphocytic Leukemia (T-PLL),,1/7/2023,Inactive,,
MMC OP VP INFUSION,4845,"Talwar, Sumit, MD",10/24/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/18/2023,Inactive,,
CINJ OP INFUSION,4845,"Hochster, Howard S, MD",1/4/2024,"Irinotecan/Panitumuimab/Bev D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/2/2024,Active,,
TRMC TCCC OP INFUSION,94958,"Capo, Gerardo, MD",9/18/2024,"Bortezomib D1, D8, D15, D22 / Lenalidomide 28 Day Cycles 28 Day Cycles - Multiple Myeloma",_1. First Line,9/17/2024,Active,,
CBMC OP INFUSION 2FL,28512,"Scoppetuolo, Michael, MD",4/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/14/2024,Active,,
NBR 5N MED-SURG OVRF,76242,"Alexander, Henry Richard, MD",2/24/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,2/24/2025,Active,"Mesothelioma, malignant (CMS/HCC)",
CINJ OP INFUSION,95420,"Haigentz, Missak, MD",8/14/2023,CINJ 032013 (EA5181) ARM A Durvalumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,,8/6/2023,Inactive,,
CINJ OP INFUSION,95420,"Goel, Sanjay, MD",11/13/2023,CINJ 052212 Phase 1b RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,_3. Third Line,11/13/2023,Inactive,,
CBMC OP INFUSION 2FL,70626,"Freeman, Benjamin B, MD",2/14/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,2/13/2025,Active,"Breast cancer, stage 4, right (CMS/HCC)",C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
CBMC OP INFUSION 2FL,19376,"Ligresti, Louise G, MD",9/9/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_2. Second Line,9/8/2024,Inactive,,
CBMC OP INFUSION 2FL,19376,"Litvak, Anna M, MD",12/18/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,12/18/2024,Active,,
CBMC OP INFUSION 2FL,19376,"Litvak, Anna M, MD",2/25/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,2/24/2025,Active,"Malignant neoplasm of breast (CMS/HCC)
Malignant neoplasm of central portion of left female breast (CMS/HCC)
Malignant neoplasm of overlapping sites of left female breast (CMS/HCC)",
CINJ OP INFUSION,15382,"Ghodoussipour, Saum Bobak, MD",12/5/2024,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,12/5/2024,Active,,
CINJ OP INFUSION,8715,"Ghodoussipour, Saum Bobak, MD",2/28/2025,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,2/28/2025,Active,Urothelial carcinoma (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; I10 - Essential (primary) hypertension; R35.0 - Frequency of micturition; E11.9 - Type 2 diabetes mellitus without complications; E78.5 - Hyperlipidemia, unspecified; G47.30 - Sleep apnea, unspecified; Z96.651 - Presence of right artificial knee joint; Z98.890 - Other specified postprocedural states; Z87.891 - Personal history of nicotine dependence; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,89273,"Talwar, Sumit, MD",1/5/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,1/4/2024,Inactive,,
MMC OP VP INFUSION,89273,"Talwar, Sumit, MD",5/16/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",Neoadjuvant,5/14/2024,Inactive,,
MMC OP VP INFUSION,89273,"Talwar, Sumit, MD",1/7/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,1/6/2025,Active,,
MMC BBR2 ONCOLOGY,29661,"Talwar, Sumit, MD",3/24/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,3/24/2025,Active,Anal carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,73596,"Derosa, William T, DO",11/14/2024,Nivolumab 28 Day Cycles - Kidney or Bladder,_1. First Line,11/14/2024,Active,,
JCMC CP INFUSION,63727,"Cruz, Allan Louie E, MD",10/21/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,9/15/2024,Inactive,,
MSC OP INFUSION,59179,"Cohen, Seth D, MD",8/31/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,8/30/2023,Inactive,,
SOM OUTPT INFUSION,86744,"Yin, Faye, MD",3/29/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,3/28/2023,Inactive,,
SOM OUTPT INFUSION,86744,"Yin, Faye, MD",8/1/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,16326,"Eltoukhy, Hussam, MD",1/27/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,Third Line,1/26/2023,Inactive,,
NBR CINJ OP INFUSION,16326,"Eltoukhy, Hussam, MD",3/3/2023,RiTUXimab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphatic Lymphoma,Third Line,2/25/2023,Inactive,,
CINJ OP INFUSION,16326,"Stephenson, Ryan D, DO",8/19/2024,Relugolix 30 day Cycles - Prostate,Adjuvant,8/19/2024,Active,Malignant neoplasm of overlapping sites of lung (CMS/HCC),
NBR CINJ OP INFUSION,51043,"Rhodes, Joanna Meehan, MD",9/24/2024,Mini-Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/19/2024,Active,,
CINJ OP INFUSION,84538,"Muralikrishnan, Sivraj, MD",5/16/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,5/16/2025,Active,NSCLC of left lung (CMS/HCC),C34.92 - Malignant neoplasm of unspecified part of left bronchus or lung; R91.1 - Solitary pulmonary nodule
NBR CINJ OP INFUSION,96055,"Matasar, Matthew J, MD",7/24/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,7/23/2024,Inactive,,
CINJ OP INFUSION,70200,"Boland, Patrick M, MD",10/12/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,10/10/2023,Inactive,,
CBMC OP INFUSION 2FL,62513,"Litvak, Anna M, MD",10/20/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_2. Second Line,10/19/2023,Inactive,,
CBMC OP INFUSION 2FL,62513,"Litvak, Anna M, MD",11/10/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_2. Second Line,11/9/2023,Inactive,,
CINJ OP INFUSION,25221,"Goel, Sanjay, MD",6/19/2023,CINJ 052214 Single Agent Part 1B XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,6/19/2023,Inactive,,
CBMC OP INFUSION 2FL,18345,"Scoppetuolo, Michael, MD",12/21/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,11/27/2023,Inactive,,
NBR 4N ONCOLOGY,76903,"Tiger, Yun Kyoung, MD",3/27/2024,CINJ 012320 Group 2 COP (Cyclophosphamide / VinCRIStine / PredniSONE) + Pralatrexate 21 Day Cycles Research- Peripheral T-Cell Lymphoma,_1. First Line,3/20/2024,Inactive,,
NBR CINJ OP INFUSION,76903,"Tiger, Yun Kyoung, MD",7/24/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_2. Second Line,7/23/2024,Inactive,,
NBR CINJ OP INFUSION,44095,"Shah, Mansi R, MD",5/8/2023,CINJ 011912 (54767414MMY3021) ARM A Daratumumab and Hyaluronidase-fihj / Lenalidomide 28 Day Cycles Research- Multiple Myeloma,,5/4/2023,Inactive,,
NBR CINJ OP INFUSION,44095,"Shah, Mansi R, MD",4/23/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,4/22/2024,Inactive,,
NBR CINJ OP INFUSION,44095,"Shah, Mansi R, MD",9/18/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,9/17/2024,Inactive,,
CMC OP INFUSION,53918,"Meghal, Trishala, MD",12/5/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,12/4/2023,Inactive,,
CMC OP INFUSION,53918,"Meghal, Trishala, MD",12/14/2023,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,12/13/2023,Inactive,,
MMC OP VP INFUSION,53918,"Meghal, Trishala, MD",5/6/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/6/2024,Active,,
CINJ OP INFUSION,49312,"Omene, Coral Oghenerukevwe, MD",9/23/2024,Palbociclib 35 Day Cycles - Breast,_1. First Line,9/23/2024,Active,,
CINJ OP INFUSION,53047,"Omene, Coral Oghenerukevwe, MD",5/12/2025,Capivasertib 28 Day Cycles - Breast,_2. Second Line,5/12/2025,Active,"Malignant neoplasm of unspecified site of left female breast (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)","C50.912 - Malignant neoplasm of unspecified site of left female breast; C79.51 - Secondary malignant neoplasm of bone; G20.A1 - Parkinson's disease without dyskinesia, without mention of fluctuations; Z90.12 - Acquired absence of left breast and nipple; Z17.0 - Estrogen receptor positive status (ER+)"
NBR CINJ OP INFUSION,24715,"Matasar, Matthew J, MD",11/22/2023,CINJ 012303 Odronextamab + REGN5837 - NHL,_5. Fifth Line,11/21/2023,Inactive,,
NBR CINJ OP INFUSION,24715,"Matasar, Matthew J, MD",12/18/2023,CINJ 012303 Odronextamab + REGN5837 - NHL,_3. Third Line,12/17/2023,Active,,
CINJ OP INFUSION,72729,"Saraiya, Biren P, MD",6/10/2024,Enzalutamide 30 Day Cycles - Prostate,_1. First Line,6/10/2024,Inactive,,
CINJ OP INFUSION,72729,"Saraiya, Biren P, MD",10/30/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/30/2024,Active,,
CINJ OP INFUSION,45191,"Patel, Eshan, MD",11/3/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,_1. First Line,11/2/2023,Inactive,,
CINJ OP INFUSION,57453,"Haigentz, Missak, MD",3/15/2023,Afatinib 28 Day Cycles- Non-Small Cell Lung Cancer,,3/15/2023,Inactive,,
CINJ OP INFUSION,57453,"Haigentz, Missak, MD",5/24/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,5/24/2024,Inactive,,
SOM OUTPT INFUSION,50517,"George, Roshini, DO",3/4/2025,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,3/4/2025,Active,Glioblastoma multiforme of brain (CMS/HCC),"C71.2 - Malignant neoplasm of temporal lobe; G93.41 - Metabolic encephalopathy; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; I60.9 - Nontraumatic subarachnoid hemorrhage, unspecified; J69.0 - Pneumonitis due to inhalation of food and vomit; R65.11 - Systemic inflammatory response syndrome (sirs) of non-infectious origin with acute organ dysfunction; E44.0 - Moderate protein-calorie malnutrition; B37.0 - Candidal stomatitis; N18.31 - Chronic kidney disease, stage 3a; F31.9 - Bipolar disorder, unspecified; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E66.9 - Obesity, unspecified; I65.21 - Occlusion and stenosis of right carotid artery; Q23.81 - Bicuspid aortic valve; I48.20 - Chronic atrial fibrillation, unspecified; N17.9 - Acute kidney failure, unspecified; E87.1 - Hypo-osmolality and hyponatremia; R47.01 - Aphasia; G97.51 - Postprocedural hemorrhage of a nervous system organ or structure following a nervous system procedure; I48.0 - Paroxysmal atrial fibrillation; I16.0 - Hypertensive urgency; E86.0 - Dehydration; E86.1 - Hypovolemia; E78.2 - Mixed hyperlipidemia; G89.29 - Other chronic pain; I95.89 - Other hypotension; N20.0 - Calculus of kidney; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; D72.828 - Other elevated white blood cell count; N28..."
SOM OUTPT INFUSION,94128,"Yin, Faye, MD",4/28/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,4/28/2023,Inactive,,
HAM OP INFUSION,87811,"Yogarajah, Meera, MD",3/12/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/4/2024,Active,,
HAM OP INFUSION,87811,"Yogarajah, Meera, MD",7/24/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/24/2024,Active,,
SOM OUTPT INFUSION,13511,"Patel, Eshan, MD",6/27/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,6/17/2024,Active,,
CBMC 2W ONCOLOGY,95667,"Scoppetuolo, Michael, MD",2/24/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/23/2024,Inactive,,
NBR 5N ONCOLOGY,67482,"Gulhati, Prateek, MD PhD",2/10/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,2/10/2025,Active,Pancreatic mass,"K26.4 - Chronic or unspecified duodenal ulcer with hemorrhage; C25.0 - Malignant neoplasm of head of pancreas; K31.1 - Adult hypertrophic pyloric stenosis; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; D69.6 - Thrombocytopenia, unspecified; N18.31 - Chronic kidney disease, stage 3a; I50.42 - Chronic combined systolic (congestive) and diastolic (congestive) heart failure; D62 - Acute posthemorrhagic anemia; K20.90 - Esophagitis, unspecified without bleeding; E78.5 - Hyperlipidemia, unspecified; K44.9 - Diaphragmatic hernia without obstruction or gangrene; I95.9 - Hypotension, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; K22.70 - Barrett's esophagus without dysplasia; R74.8 - Abnormal levels of other serum enzymes; Z96.89 - Presence of other specified functional implants; I25.5 - Ischemic cardiomyopathy; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; I25.2 - Old myocardial infarction; Z95.1 - Presence of aortocoronary bypass graft; Z85.07 - Personal history of malignant neoplasm of pancreas; Z87.442 - Personal history of urinary calculi; Z87.891 - Personal history of nicotine dependence; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z79.82 - Long term (current) use of aspirin; Z87.19 - Personal history of other diseases of..."
MMC OP INFUSION,80768,"Meghal, Trishala, MD",5/31/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,,5/23/2023,Inactive,,
MMC OP INFUSION,80768,"Meghal, Trishala, MD",8/30/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,,8/27/2023,Inactive,,
MMC BBR2 ONCOLOGY,80768,"Meghal, Trishala, MD",1/10/2024,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_2. Second Line,1/4/2024,Inactive,,
MMC OP VP INFUSION,80768,"Meghal, Trishala, MD",5/22/2024,Gemcitabine / CISplatin 21 Day Cycles - Unknown Primary,_3. Third Line,5/13/2024,Inactive,,
CBMC 2W ONCOLOGY,58321,"Grossman, I Robert, MD",2/24/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,2/23/2024,Inactive,,
NBR 4N ONCOLOGY,58321,"Schaar, Dale, MD PhD",6/18/2024,BMT Autologous Carmustine / Thiotepa,_2. Second Line,6/18/2024,Inactive,,
CBMC OP INFUSION 2FL,13198,"Leitner, Stuart P, MD",4/21/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/21/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,13198,"Leitner, Stuart P, MD",4/17/2025,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/17/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,13198,"Leitner, Stuart P, MD",4/17/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,4/17/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,25631,"George, Mridula A, MD",8/23/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,8/23/2024,Active,,
NBR CINJ OP INFUSION,71714,"Shah, Mansi R, MD",4/24/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,4/18/2024,Inactive,,
NBI OP INFUSION,40670,"Cheng, Yan Ho, MD",12/17/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/18/2024,Active,,
NBI OP INFUSION,40670,"Cheng, Yan Ho, MD",2/25/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,11/18/2024,Active,Stage IV adenocarcinoma of pancreas (CMS/HCC),C25.9 - Stage IV adenocarcinoma of pancreas (CMS/HCC)
NBI OP INFUSION,40670,"Cheng, Yan Ho, MD",3/11/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/11/2025,Active,Stage IV adenocarcinoma of pancreas (CMS/HCC),C25.9 - Stage IV adenocarcinoma of pancreas (CMS/HCC)
MMC OP INFUSION,1483,"Lee, Patrick C, MD",5/2/2023,Durvalumab 1500 mg 28 Day Cycles- ,,5/1/2023,Inactive,,
MMC OP INFUSION,1483,"Lee, Patrick C, MD",6/27/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,,6/19/2023,Inactive,,
MMC OP INFUSION,1483,"Lee, Patrick C, MD",10/3/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,,9/25/2023,Inactive,,
SOM OUTPT INFUSION,35698,"Patel, Eshan, MD",12/6/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/8/2023,Inactive,,
NBR CINJ OP INFUSION,9942,"Shah, Mansi R, MD",5/16/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/15/2024,Inactive,,
NBR CINJ OP INFUSION,9942,"Shah, Mansi R, MD",8/28/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,8/14/2024,Inactive,,
NBR CINJ OP INFUSION,9942,"Shah, Mansi R, MD",10/1/2024,Daratumumab/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/30/2024,Inactive,,
NBR CINJ OP INFUSION,9942,"Shah, Mansi R, MD",2/20/2025,Carfilzomib 56 mg/m2 Weekly /Pomalyst  Plus Dexamethasone 28 Day Cycles - Maintenance,Maintenance,2/19/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,9942,"Shah, Mansi R, MD",3/20/2025,Carfilzomib 56 mg/m2 Weekly /Pomalyst  Plus Dexamethasone 28 Day Cycles - Maintenance,Maintenance,2/20/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,47379,"Jacoby, Sari H, MD",2/27/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,_1. First Line,2/19/2024,Inactive,,
HAM OP INFUSION,95021,"Patel, Malini M, MD",11/16/2023,CHOPE (Cyclophosphamide / DOXOrubicin / VinCRIStine / Prednisone / Etoposide) 21 Day Cycles - Non-Hodgkin's Lymphoma,_1. First Line,11/8/2023,Inactive,,
NBR 5N ONCOLOGY,95021,"Rhodes, Joanna Meehan, MD",6/10/2024,GemOX (Gemcitabine / OXALIplatin ) 14 Day Cycles - T-Cell Lymphoma,_2. Second Line,4/30/2024,Inactive,,
NBR 4N BMTU/IMCU,95021,"Rhodes, Joanna Meehan, MD",10/9/2024,BMT Autologous BEAM,_3. Third Line,10/8/2024,Inactive,,
CINJ OP INFUSION,41324,"Berim, Lyudmyla, MD",11/27/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,11/19/2023,Inactive,,
CINJ OP INFUSION,41324,"Berim, Lyudmyla, MD",3/18/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/14/2024,Inactive,,
CINJ OP INFUSION,41324,"Berim, Lyudmyla, MD",3/25/2024,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_2. Second Line,3/22/2024,Inactive,,
CINJ OP INFUSION,97944,"Boland, Patrick M, MD",2/24/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,2/23/2023,Inactive,,
MMC OP INFUSION,52388,"Lee, Patrick C, MD",5/8/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,,4/25/2023,Active,,
CINJ OP INFUSION,44381,"Hochster, Howard S, MD",3/7/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/5/2024,Inactive,,
NBR 5N ONCOLOGY,93320,"Palmisiano, Neil David, MD",8/13/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,8/12/2023,Inactive,,
NBR CINJ OP INFUSION,93320,"Palmisiano, Neil David, MD",12/19/2023,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,Induction,12/19/2023,Inactive,,
NBR CINJ OP INFUSION,93320,"Palmisiano, Neil David, MD",2/2/2024,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_2. Second Line,1/31/2024,Inactive,,
NBR 4N ONCOLOGY,93320,"Palmisiano, Neil David, MD",3/4/2024,CINJ 022204 LYT- 200 / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia (AML),Induction,3/4/2024,Inactive,,
NBR CINJ OP INFUSION,93320,"Palmisiano, Neil David, MD",7/30/2024,AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,7/28/2024,Inactive,,
CBMC OP INFUSION 2FL,58926,"Brown, Andrew Bennett, MD",8/30/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,8/29/2024,Inactive,,
CBMC OP INFUSION 2FL,58926,"Brown, Andrew Bennett, MD",12/13/2024,Sacituzumab Govitecan 21 Day Cycles - Breast ,_2. Second Line,12/13/2024,Active,Cholangiocarcinoma metastatic to liver (CMS/HCC),
HAM OP INFUSION,79166,"Gendy, Mina, DO",11/13/2024,Bendamustine / Obinutuzumab 28 Day Cycles + Obinutuzumab 56 Day Cycles - Follicular Lymphoma ,_1. First Line,11/5/2024,Active,,
CINJ OP INFUSION,55164,"George, Mridula A, MD",5/24/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,5/21/2024,Active,,
CMC OP INFUSION,85043,"Talwar, Sumit, MD",7/28/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,7/26/2023,Inactive,,
NBR 4N BMTU/IMCU,52635,"Girda, Eugenia, MD",8/2/2024,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,Lymphodepletion,7/29/2024,Active,,
NBR CINJ OP INFUSION,80749,"Rhodes, Joanna Meehan, MD",10/6/2023,RiTUXimab 56 Day Cycle - Follicular Lymphoma,Second Line,10/4/2023,Active,Metastatic melanoma (CMS/HCC),
MMC OP VP INFUSION,59924,"Cohen, Seth D, MD",12/30/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,12/18/2024,Active,,
MMC OP VP INFUSION,59924,"Cohen, Seth D, MD",1/6/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,12/18/2024,Active,,
CINJ OP INFUSION,48653,"Saraiya, Biren P, MD",11/19/2024,CINJ 082210 Arm A Durvalumab / ddMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles Research- Urothelial Cancer,Neoadjuvant,11/18/2024,Inactive,,
CMC OP INFUSION,63300,"Taff, Jessica, MD",2/5/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/15/2013,Active,Cancer of left renal pelvis and ureter (CMS/HCC),
CINJ OP INFUSION,72858,"Stephenson, Ruth D, DO",8/9/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/25/2024,Inactive,,
CINJ OP INFUSION,41226,"Boland, Patrick M, MD",3/14/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,3/13/2023,Active,,
CINJ OP INFUSION,34407,"Haigentz, Missak, MD",8/26/2024,Dabrafenib/Trametinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/26/2024,Active,,
CINJ OP INFUSION,26221,"Jang, Thomas L, MD",11/30/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,_1. First Line,11/1/2023,Inactive,,
CINJ OP INFUSION,26221,"Jang, Thomas L, MD",11/8/2024,BCG Induction (TICE) 42 Day Cycle,Induction,11/6/2024,Active,,
CBMC OP INFUSION 2FL,47572,"Wagmiller, Jennifer Ann, MD",4/23/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,4/23/2025,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,47572,"Wagmiller, Jennifer Ann, MD",4/14/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,4/14/2025,Inactive,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),
TRMC TCCC OP INFUSION,50410,"Capo, Gerardo, MD",5/23/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/23/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),
NBR CINJ OP INFUSION,63938,"Evens, Andrew M, DO",11/20/2024,CINJ 012203 Lead-In Treatment for Fit and Non-Fit Treatments Cycle 42 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,11/19/2024,Inactive,,
CMC OP INFUSION,68141,"Eltoukhy, Hussam, MD",10/11/2024,Bevacizumab for HHT,Non-Oncology Research,10/11/2024,Active,,
CINJ OP INFUSION,63781,"Haigentz, Missak, MD",1/9/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,1/9/2023,Inactive,,
SOM OUTPT INFUSION,83918,"Patel, Eshan, MD",3/6/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,,3/5/2023,Inactive,,
CINJ OP INFUSION,72352,"Hochster, Howard S, MD",1/25/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/23/2024,Inactive,,
NBR CINJ OP INFUSION,29068,"Assal, Amer, MD",12/12/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,12/11/2023,Inactive,,
NBR CINJ OP INFUSION,29068,"Zayac, Adam, MD",2/14/2024,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_4. Fourth Line,2/12/2024,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,29068,"Zayac, Adam, MD",1/21/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_5. Fifth Line,1/21/2025,Active,"Primary adenocarcinoma of right lung (CMS/HCC)
Malignant neoplasm metastatic to brain (CMS/HCC)",
NBR CINJ OP INFUSION,45538,"Zayac, Adam, MD",5/5/2025,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_4. Fourth Line,5/5/2025,Active,Acute myeloid leukemia in relapse (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C92.02 - Acute myeloblastic leukemia, in relapse; N18.6 - End stage renal disease; Z94.84 - Stem cells transplant status; D89.811 - Chronic graft-versus-host disease; Z72.89 - Other problems related to lifestyle; Z23 - Encounter for immunization"
NBR CINJ OP INFUSION,17992,"Mayer, Tina M, MD",1/20/2025,Pembrolizumab 21 Day Cycles - Kidney,Adjuvant,1/20/2025,Active,,
JCMC CP INFUSION,41991,"Sekhri, Arunabh, MD",2/14/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/4/2024,Inactive,,
CBMC 2W ONCOLOGY,57908,"Brown, Andrew Bennett, MD",11/9/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,11/3/2023,Inactive,,
HAM OP INFUSION,9534,"Yogarajah, Meera, MD",3/23/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,3/21/2023,Inactive,,
CINJ OP INFUSION,74392,"Ganesan, Shridar, MD PhD",5/9/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,5/7/2023,Inactive,,
CINJ OP INFUSION,32954,"Saraiya, Biren P, MD",5/19/2025,CINJ 082212 TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles Research- Penile Cancer,Neoadjuvant,5/19/2025,Active,Penile cancer (CMS/HCC),
CINJ OP INFUSION,92802,"George, Mridula A, MD",12/6/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,11/12/2024,Active,,
CINJ OP INFUSION,51433,"Packiam, Vignesh, MD",1/27/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,1/26/2025,Active,,
CINJ OP INFUSION,51433,"Packiam, Vignesh, MD",4/16/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,4/15/2025,Active,Bladder cancer (CMS/HCC),"N30.20 - Other chronic cystitis without hematuria; Z85.51 - Personal history of malignant neoplasm of bladder; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; G20.A1 - Parkinson's disease without dyskinesia, without mention of fluctuations; E78.5 - Hyperlipidemia, unspecified; D64.9 - Anemia, unspecified; Z87.440 - Personal history of urinary (tract) infections; Z79.82 - Long term (current) use of aspirin; Z79.624 - Long term (current) use of inhibitors of nucleotide synthesis; Z79.899 - Other long term (current) drug therapy"
NBR CINJ OP INFUSION,59616,"Rhodes, Joanna Meehan, MD",9/30/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,9/29/2024,Inactive,,
CINJ OP INFUSION,70065,"George, Mridula A, MD",1/27/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/17/2025,Active,,
CINJ OP INFUSION,70065,"George, Mridula A, MD",2/17/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,1/20/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,24409,"George, Mridula A, MD",5/5/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/5/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z90.11 - Acquired absence of right breast and nipple; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,69776,"Mayer, Tina M, MD",4/16/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,4/16/2024,Inactive,,
CINJ OP INFUSION,69776,"Mayer, Tina M, MD",8/20/2024,Darolutamide 28 Day Cycles - Prostate,_2. Second Line,8/20/2024,Active,,
CINJ OP INFUSION,95027,"Toppmeyer, Deborah L, MD",5/15/2025,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/15/2025,Active,"Malignant neoplasm of breast metastatic to mediastinum (CMS/HCC)
Postprocedural hypothyroidism
On antineoplastic chemotherapy",
CINJ OP INFUSION,54411,"Stephenson, Ryan D, DO",5/12/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,5/12/2025,Active,Urothelial carcinoma (CMS/HCC),"C68.9 - Malignant neoplasm of urinary organ, unspecified"
SOM OUTPT INFUSION,76862,"Patel, Eshan, MD",1/16/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,Consolidation,1/15/2024,Active,,
NBR CINJ OP INFUSION,2322,"Egini, Ogechukwu, MD",3/13/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_2. Second Line,3/13/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBI OP INFUSION,60264,"Anderson, Patrick S, MD",11/9/2023,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/8/2023,Inactive,,
NBI OP INFUSION,60264,"Anderson, Patrick S, MD",3/25/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,3/25/2024,Active,,
CINJ OP INFUSION,36696,"George, Mridula A, MD",4/23/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,4/23/2025,Active,Malignant neoplasm of central portion of left female breast (CMS/HCC),C50.112 - Malignant neoplasm of central portion of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
HAM OP INFUSION,22510,"Patel, Malini M, MD",4/7/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/7/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),D47.2 - Monoclonal gammopathy present on serum protein electrophoresis
HAM OP INFUSION,22510,"Patel, Malini M, MD",3/27/2025,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,_1. First Line,3/27/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),D47.2 - Monoclonal gammopathy present on serum protein electrophoresis
NBR 4N ONCOLOGY,82405,"Tiger, Yun Kyoung, MD",12/17/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,12/17/2024,Active,,
NBR CINJ OP INFUSION,82405,"Tiger, Yun Kyoung, MD",1/8/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/8/2025,Inactive,Diffuse large B-cell lymphoma of intrathoracic lymph nodes (CMS/HCC),
SOM OUTPT INFUSION,57595,"Patel, Eshan, MD",10/8/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/1/2024,Active,,
SOM OUTPT INFUSION,89165,"Toomey, Kathleen C, MD",1/2/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,12/26/2023,Inactive,,
CINJ OP INFUSION,72488,"Dasgeb, Bahar, MD",10/8/2024,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,10/7/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,85139,"Patel, Eshan, MD",7/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,7/14/2024,Inactive,,
SOM OUTPT INFUSION,85139,"Patel, Eshan, MD",1/13/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_2. Second Line,1/6/2025,Active,,
CINJ OP INFUSION,10901,"Muralikrishnan, Sivraj, MD",5/20/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,5/20/2025,Inactive,Squamous cell carcinoma of mandible (CMS/HCC),C41.1 - Malignant neoplasm of mandible; I10 - Essential (primary) hypertension; Z90.09 - Acquired absence of other part of head and neck; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; Z91.048 - Other nonmedicinal substance allergy status
HAM OP INFUSION,72369,"Yogarajah, Meera, MD",10/15/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,10/6/2024,Active,"Prostate cancer metastatic to intrapelvic lymph node (CMS/HCC)
Malignant neoplasm of prostate (CMS/HCC)",
HAM OP INFUSION,83107,"Yogarajah, Meera, MD",4/8/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,4/8/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,24419,"Leitner, Stuart P, MD",10/31/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,10/30/2023,Inactive,,
CINJ OP INFUSION,82411,"Stephenson, Ryan D, DO",5/8/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,First Line,5/2/2023,Inactive,,
MMC OP VP INFUSION,80385,"Lee, Patrick C, MD",4/21/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,4/14/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,33785,"Toppmeyer, Deborah L, MD",5/23/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,5/23/2025,Active,"Malignant neoplasm of lower-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z17.0 - Estrogen receptor positive status (ER+); Z17.21 - Progesterone receptor positive status; Z17.32 - Human epidermal growth factor receptor 2 negative status; Z98.890 - Other specified postprocedural states; Z98.891 - History of uterine scar from previous surgery; Z79.899 - Other long term (current) drug therapy
SOM OUTPT INFUSION,41358,"Patel, Eshan, MD",4/2/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/2/2025,Active,Non-small cell cancer of right lung (CMS/HCC),C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; R06.02 - Shortness of breath; R07.89 - Other chest pain
NBR 4N ONCOLOGY,49633,"Tiger, Yun Kyoung, MD",12/2/2024,CINJ 022305 Induction Ziftomenib / Cytarabine / Daunorubicin (7 + 3) 28 Day Cycle Research- Acute Myeloid Leukemia,_1. First Line,12/1/2024,Inactive,,
NBR CINJ OP INFUSION,24932,"Chen, Xiaoyi",5/12/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,5/12/2025,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission"
SOM OUTPT INFUSION,63573,"Patel, Eshan, MD",11/18/2024,Pembrolizumab / Cetuximab 21 Day Cycles- Head and Neck Cancers,_3. Third Line,10/31/2024,Active,,
CINJ OP INFUSION,93812,"Berim, Lyudmyla, MD",7/10/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,7/7/2023,Inactive,,
CINJ OP INFUSION,93812,"Berim, Lyudmyla, MD",9/6/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,9/5/2023,Inactive,,
CINJ OP INFUSION,87031,"Patel, Eshan, MD",7/7/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,7/6/2023,Inactive,,
NBR CINJ OP INFUSION,34658,"Matasar, Matthew J, MD",9/17/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,9/16/2024,Inactive,,
NBR CINJ OP INFUSION,34658,"Matasar, Matthew J, MD",11/6/2024,Triangle Regimen R-I-CHOP / R-DHAX  (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Ibrutinib) / (Dexamethasone / Cytarabine / OXALIplatin) RiTUXimab Every 21 Days - Mantle Cell Lymphoma,_1. First Line,11/5/2024,Active,"Acute lymphoblastic leukemia, in remission (CMS/HCC)",
NBR CINJ OP INFUSION,34658,"Matasar, Matthew J, MD",1/28/2025,DHAX (Dexamethasone / Cytarabine / OXALIplatin) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/28/2025,Inactive,Mantle cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
NBR CINJ OP INFUSION,34658,"Matasar, Matthew J, MD",4/1/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,4/1/2025,Active,Mantle cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
NBI OP INFUSION,16270,"Anderson, Patrick S, MD",5/19/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/19/2025,Inactive,Malignant neoplasm of body of uterus (CMS/HCC),
CINJ OP INFUSION,13999,"Stephenson, Ruth D, DO",3/3/2023,Bevacizumab Maintenance 21 Day Cycles,Maintenance,3/2/2023,Inactive,,
CINJ OP INFUSION,13999,"Stephenson, Ruth D, DO",8/16/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,Third Line,8/1/2023,Inactive,,
CINJ OP INFUSION,98662,"George, Mridula A, MD",2/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/18/2024,Inactive,,
CINJ OP INFUSION,98662,"George, Mridula A, MD",7/2/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,7/1/2024,Active,,
CINJ OP INFUSION,17143,"Omene, Coral Oghenerukevwe, MD",8/21/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,8/13/2023,Inactive,,
CINJ OP INFUSION,17143,"Omene, Coral Oghenerukevwe, MD",8/24/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,,7/27/2023,Inactive,,
NBR CINJ OP INFUSION,86473,"Schaar, Dale, MD PhD",10/29/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,10/28/2024,Active,Mantle cell lymphoma (CMS/HCC),
CINJ OP INFUSION,71111,"Patel, Eshan, MD",9/16/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,9/13/2024,Active,,
CINJ OP INFUSION,71111,"Muralikrishnan, Sivraj, MD",2/12/2025,Nivolumab 480 mg D1 28 Day Cycles- Head and Neck Cancers,_2. Second Line,2/11/2025,Active,"Malig neoplm of ovrlp sites of lip, oral cavity and pharynx (CMS/HCC)
Other fatigue",
CINJ OP INFUSION,9190,"Gulhati, Prateek, MD PhD",5/15/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Induction,5/15/2025,Active,Colorectal cancer (CMS/HCC),C19 - Malignant neoplasm of rectosigmoid junction; C79.51 - Secondary malignant neoplasm of bone
CINJ OP INFUSION,36563,"Stephenson, Ryan D, DO",11/13/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,11/13/2024,Active,,
CBMC 2W ONCOLOGY,35665,"Kulkarni, Aditya A, MD",3/13/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,3/13/2025,Active,Small cell neuroendocrine carcinoma of prostate (CMS/HCC),"E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; E43 - Unspecified severe protein-calorie malnutrition; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; J18.9 - Pneumonia, unspecified organism; K56.600 - Partial intestinal obstruction, unspecified as to cause; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C79.51 - Secondary malignant neoplasm of bone; B95.2 - Enterococcus as the cause of diseases classified elsewhere; D69.6 - Thrombocytopenia, unspecified; C61 - Malignant neoplasm of prostate; E11.40 - Type 2 diabetes mellitus with diabetic neuropathy, unspecified; D50.9 - Iron deficiency anemia, unspecified; I10 - Essential (primary) hypertension; K56.7 - Ileus, unspecified; Z68.1 - Body mass index (BMI) 19.9 or less, adult; E87.3 - Alkalosis; D3A.8 - Other benign neuroendocrine tumors; E11.65 - Type 2 diabetes mellitus with hyperglycemia; D72.821 - Monocytosis (symptomatic); D75.839 - Thrombocytosis, unspecified; E78.00 - Pure hypercholesterolemia, unspecified; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; E83.39 - Other disorders of phosphorus metabolism; E87.6 - Hypokalemia; E83.42 - Hypomagnesemia; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; F41.9 - Anxiety disorder, unspecified; G89.29 - Other chronic pain; K11.7 - Disturbances of salivary secretion; K21.9 - Gastro-esophageal reflux disease without esophagitis; K22.4 - Dyskinesia ..."
CINJ OP INFUSION,20778,"Stephenson, Ruth D, DO",2/9/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/8/2024,Inactive,,
CINJ OP INFUSION,7321,"Patel, Eshan, MD",2/10/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,,2/9/2023,Inactive,,
CINJ OP INFUSION,95295,"Haigentz, Missak, MD",6/2/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,First Line,6/2/2023,Active,,
SOM OUTPT INFUSION,10934,"Patel, Eshan, MD",1/8/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/1/2025,Active,Bilateral malignant neoplasm of central portion of breast in female (CMS/HCC),
SOM OUTPT INFUSION,10934,"Patel, Eshan, MD",5/14/2025,Pertuzumab and Trastuzumab  21 Day Cycles - Breast,_1. First Line,5/14/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",C50.811 - Malignant neoplasm of overlapping sites of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,81515,"Patel, Eshan, MD",3/3/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,3/2/2023,Inactive,,
CINJ OP INFUSION,81515,"Patel, Eshan, MD",7/12/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,7/4/2024,Inactive,,
SOM OUTPT INFUSION,81515,"Patel, Eshan, MD",12/6/2024,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,12/5/2024,Active,,
CBMC OP INFUSION 2FL,42778,"Derosa, William T, DO",12/6/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,12/4/2024,Active,,
CINJ OP INFUSION,96445,"Haigentz, Missak, MD",2/27/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Nasopharyngeal Cancer,Induction,2/27/2023,Inactive,,
CINJ OP INFUSION,96445,"Haigentz, Missak, MD",5/15/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,5/14/2023,Inactive,,
CINJ OP INFUSION,34336,"Haigentz, Missak, MD",10/14/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,10/13/2024,Inactive,,
CINJ OP INFUSION,34336,"Haigentz, Missak, MD",10/22/2024,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,10/21/2024,Inactive,,
CINJ OP INFUSION,34336,"Haigentz, Missak, MD",11/12/2024,Cetuximab / PACLitaxel 28 Day Cycles PLUS CARBOplatin q21days starting 12/17/2024 - Head and Neck Cancers,_2. Second Line,11/11/2024,Active,,
CINJ OP INFUSION,48173,"Haigentz, Missak, MD",4/15/2025,Methotrexate Weekly- Head and Neck Cancers,_4. Fourth Line,4/15/2025,Inactive,"Malignant neoplasm of floor of mouth (CMS/HCC)
Malignant neoplasm metastatic to lung (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)",
CINJ OP INFUSION,65739,"George, Mridula A, MD",5/1/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Third Line,4/30/2023,Inactive,,
CINJ OP INFUSION,65739,"George, Mridula A, MD",5/17/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Third Line,5/16/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,22358,"Moerdler, Scott, MD",8/8/2023,AALL1732 Induction,Induction,8/8/2023,Inactive,,
CINJ PEDS HEMONC ,22358,"Goyal-Khemka, Meenakshi, MD",9/18/2023,AALL1732 Consolidation,Consolidation,9/18/2023,Inactive,,
CINJ PEDS HEMONC ,22358,"Goyal-Khemka, Meenakshi, MD",9/18/2023,AALL1732 Consolidation,First Line,9/18/2023,Inactive,,
CINJ PEDS HEMONC ,22358,"Goyal-Khemka, Meenakshi, MD",12/5/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,11/17/2023,Inactive,,
CINJ PEDS HEMONC ,22358,"Goyal-Khemka, Meenakshi, MD",3/25/2024,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy: Delayed Intensification",_1. First Line,3/25/2024,Inactive,,
CINJ PEDS HEMONC ,22358,"Goyal-Khemka, Meenakshi, MD",6/3/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,6/3/2024,Inactive,,
CINJ PEDS HEMONC ,22358,"Botwinick, Marissa, DO",8/21/2024,Blinatumomab Block 1,_1. First Line,8/20/2024,Inactive,,
CINJ PEDS HEMONC ,22358,"Botwinick, Marissa, DO",8/29/2024,PEDS AALL1331 Blinatumomab,_1. First Line,8/28/2024,Inactive,,
CINJ PEDS HEMONC ,22358,"Botwinick, Marissa, DO",9/6/2024,PEDS Blinatumomab,_1. First Line,8/29/2024,Inactive,,
CINJ PEDS HEMONC ,22358,"Botwinick, Marissa, DO",10/25/2024,AALL1732 HR B-ALL Arm A  Maintenance,_1. First Line,10/17/2024,Active,,
CINJ PEDS HEMONC ,22358,"Botwinick, Marissa, DO",1/17/2025,PEDS Blinatumomab,_1. First Line,1/16/2025,Active,,
CINJ OP INFUSION,40794,"Saraiya, Biren P, MD",4/8/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,4/8/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
NBR CINJ OP INFUSION,47484,"Matasar, Matthew J, MD",1/19/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,1/18/2023,Inactive,,
JCMC CP INFUSION,80293,"Sekhri, Arunabh, MD",6/17/2024,PACLitaxel 7 Day Cycles x 12 weeks - Hormone Receptor (+) Breast Cancer,Neoadjuvant,6/9/2024,Inactive,,
CINJ OP INFUSION,65888,"Toppmeyer, Deborah L, MD",6/12/2023,Palbociclib 28 Day Cycles - Breast,First Line,6/12/2023,Active,,
NBR CINJ OP INFUSION,78046,"Egini, Ogechukwu, MD",3/25/2025,BMT Allogeneic Flu / Mel (140 mg/m2) + Post Cy,_3. Third Line,3/25/2025,Active,CML (chronic myelocytic leukemia) (CMS/HCC),"C92.10 - Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; A18.31 - Tuberculous peritonitis; J98.4 - Other disorders of lung; J90 - Pleural effusion, not elsewhere classified; Z01.818 - Encounter for other preprocedural examination; Z86.11 - Personal history of tuberculosis"
NBR CINJ OP INFUSION,78046,"Palmisiano, Neil David, MD",3/6/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,3/6/2025,Active,CML (chronic myelocytic leukemia) (CMS/HCC),C92.10 - CML (chronic myelocytic leukemia) (CMS/HCC)
NBR 4N BMTU/IMCU,99479,"Schaar, Dale, MD PhD",3/10/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,3/10/2023,Inactive,,
CINJ PEDS HEMONC ,95882,"Moerdler, Scott, MD",2/16/2024,AOST0331 MAP Arm (DOXOrubicin / CISplatin / Methotrexate),_1. First Line,2/15/2024,Active,,
NBR CINJ OP INFUSION,7007,"Matasar, Matthew J, MD",5/13/2025,RiTUXimab 28 Day Cycle - Hairy Cell Leukemia,_2. Second Line,4/17/2025,Active,"Hairy cell leukemia, in relapse (CMS/HCC)","C91.42 - Hairy cell leukemia, in relapse (CMS/HCC)"
NBR CINJ OP INFUSION,7007,"Matasar, Matthew J, MD",3/24/2025,Cladribine 5 Day Cycle - Hairy Cell Leukemia,_2. Second Line,3/11/2025,Active,"Hairy cell leukemia, in relapse (CMS/HCC)","C91.42 - Hairy cell leukemia, in relapse; D75.9 - Disease of blood and blood-forming organs, unspecified"
NBR CINJ OP INFUSION,63833,"Evens, Andrew M, DO",2/2/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,,1/24/2023,Inactive,,
NBR CINJ OP INFUSION,63833,"Evens, Andrew M, DO",4/29/2023,RiTUXimab Rapid Infusion Single Day (Outpatient),,4/29/2023,Inactive,,
NBR 4N ONCOLOGY,40824,"George, Mridula A, MD",4/7/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Neoadjuvant,4/5/2024,Inactive,,
CINJ OP INFUSION,40824,"George, Mridula A, MD",11/18/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/17/2024,Active,,
CINJ OP INFUSION,24942,"Saraiya, Biren P, MD",6/12/2024,CINJ 082104 (EA8191) ARM D Short Term Androgen Deprivation GnRH Therapy / Apalutamide 84 Day Cycles Research- Prostate Cancer,Consolidation,5/15/2024,Inactive,,
CINJ OP INFUSION,2479,"Boland, Patrick M, MD",8/29/2023,Imatinib 30 Day Cycles - Sarcoma,,8/29/2023,Inactive,,
CINJ OP INFUSION,43375,"Patel, Eshan, MD",5/24/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,5/23/2024,Inactive,,
CINJ OP INFUSION,3244,"Boland, Patrick M, MD",12/5/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/4/2023,Inactive,,
CINJ OP INFUSION,3244,"Boland, Patrick M, MD",7/24/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,7/24/2024,Active,,
CINJ OP INFUSION,2194,"Toppmeyer, Deborah L, MD",11/4/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,11/4/2024,Active,"Breast cancer metastasized to central nervous system, right (CMS/HCC)",
CINJ OP INFUSION,96663,"Saraiya, Biren P, MD",2/25/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,2/24/2025,Active,Malignant neoplasm of prostate (CMS/HCC),C61 - Prostate cancer (CMS/HCC)
CINJ OP INFUSION,84972,"Patel, Eshan, MD",12/29/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,12/21/2023,Inactive,,
SOM OUTPT INFUSION,8726,"Packiam, Vignesh, MD",7/9/2024,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Adjuvant,7/9/2024,Inactive,,
SOM OUTPT INFUSION,8726,"Dave, Dhiren, MD",10/11/2024,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,10/11/2024,Active,,
NBR BMSCH 2 PED HEMONC,92534,"Moerdler, Scott, MD",2/27/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,2/27/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,92534,"Moerdler, Scott, MD",2/27/2023,PEDS AALL1231 Arm A Induction,,2/27/2023,Inactive,,
CINJ PEDS HEMONC ,92534,"Drachtman, Richard, MD",4/3/2023,AALL0434 - Consolidation Arm B (CMTX+Nel) and  Arm D (HDMTX + Nel) 77 Day Cycle - Acute Lymphoblastic Leukemia,,4/2/2023,Inactive,,
CINJ PEDS HEMONC ,92534,"Drachtman, Richard, MD",4/3/2023,PEDS AALL0434 Arm B (CMTX + Nel) Consolidation,,4/3/2023,Inactive,,
CINJ PEDS HEMONC ,92534,"Drachtman, Richard, MD",5/8/2023,FOR Cal PEG ALLERGY Asparaginase Erwinia (Rylaze) ,,5/8/2023,Inactive,,
CINJ PEDS HEMONC ,92534,"Drachtman, Richard, MD",6/26/2023,AALL0434 - Interim Maintenance Arm A (CMTX) and Arm B (CMTX + Nel) 56 Day Cycle - Acute Lymphoblastic Leukemia,,6/26/2023,Inactive,,
CINJ PEDS HEMONC ,92534,"Cole, Peter David, MD",8/25/2023,"PEDS AALL1331 Blocks 1,2,3",,8/24/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,92534,"Cole, Peter David, MD",12/19/2023,Per CHOP plan (Modified induction),_5. Fifth Line,12/19/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,92534,"Cole, Peter David, MD",1/25/2024,Triple Intrathecal (ITT)- dosing per AALL1331,Adjuvant,1/25/2024,Inactive,,
HAM OP INFUSION,28067,"Yogarajah, Meera, MD",3/19/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/17/2024,Inactive,,
NBR 4N ONCOLOGY,44529,"Zayac, Adam, MD",12/10/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,12/10/2024,Inactive,,
NBR 4N ONCOLOGY,44529,"Zayac, Adam, MD",12/12/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/12/2024,Active,,
NBR CINJ OP INFUSION,44529,"Zayac, Adam, MD",4/22/2025,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,_1. First Line,4/22/2025,Inactive,"B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)
B-cell acute lymphoblastic leukemia (ALL) in relapse (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; D61.810 - Antineoplastic chemotherapy induced pancytopenia; C91.00 - Acute lymphoblastic leukemia not having achieved remission; F41.9 - Anxiety disorder, unspecified; R00.2 - Palpitations; R53.83 - Other fatigue; R19.7 - Diarrhea, unspecified; R11.0 - Nausea; E28.2 - Polycystic ovarian syndrome; G47.00 - Insomnia, unspecified; M47.892 - Other spondylosis, cervical region; G89.29 - Other chronic pain; I49.3 - Ventricular premature depolarization; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z80.3 - Family history of malignant neoplasm of breast; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.438 - Family history of other disorder of lipoprotein metabolism and other lipidemia"
NBR 4N ONCOLOGY,44529,"Zayac, Adam, MD",3/24/2025,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,3/24/2025,Inactive,"B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)
B-cell acute lymphoblastic leukemia (ALL) in relapse (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; D61.810 - Antineoplastic chemotherapy induced pancytopenia; C91.02 - Acute lymphoblastic leukemia, in relapse; R56.9 - Unspecified convulsions; E83.51 - Hypocalcemia; E28.2 - Polycystic ovarian syndrome; G47.00 - Insomnia, unspecified; F41.9 - Anxiety disorder, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R19.7 - Diarrhea, unspecified; Z86.16 - Personal history of COVID-19; Z91.09 - Other allergy status, other than to drugs and biological substances; Z79.2 - Long term (current) use of antibiotics; Z79.899 - Other long term (current) drug therapy; Z83.438 - Family history of other disorder of lipoprotein metabolism and other lipidemia; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z80.3 - Family history of malignant neoplasm of breast; Z28.21 - Immunization not carried out because of patient refusal"
CINJ OP INFUSION,25904,"Packiam, Vignesh, MD",11/21/2024,Nadofaragene Firadenovic-vncg 84 Day Cycles - Bladder,Adjuvant,11/14/2024,Active,,
CINJ OP INFUSION,59204,"Packiam, Vignesh, MD",4/18/2025,CINJ 082403 PHASE 2 (4 INSTILLATION REGIMEN) EG-70,Induction,4/18/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
NBR CINJ OP INFUSION,4760,"Assal, Amer, MD",4/18/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_3. Third Line,4/17/2024,Inactive,,
CMC OP INFUSION,47511,"Talwar, Sumit, MD",6/24/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,6/24/2024,Inactive,,
CMC OP INFUSION,47511,"Talwar, Sumit, MD",11/20/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/22/2024,Active,,
CINJ OP INFUSION,40802,"Boland, Patrick M, MD",1/6/2023,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",,12/20/2022,Inactive,,
CINJ OP INFUSION,60836,"Berim, Lyudmyla, MD",7/19/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/30/2024,Active,,
MMC OP INFUSION,17922,"Meghal, Trishala, MD",9/29/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,9/28/2023,Inactive,,
CINJ OP INFUSION,14742,"Dasgeb, Bahar, MD",6/6/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,Second Line,6/5/2023,Inactive,,
CINJ OP INFUSION,53818,"Gulhati, Prateek, MD PhD",6/22/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,6/21/2023,Inactive,,
CINJ OP INFUSION,53818,"Gulhati, Prateek, MD PhD",9/28/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,9/28/2023,Inactive,,
NBR 5N ONCOLOGY,70373,"Rhodes, Joanna Meehan, MD",3/21/2025,CINJ 022405 Part 1 Tagraxofusp 9 mcg/kg / Venetoclax / Azacitadine (Days 1-7) 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,3/21/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),"C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; I21.19 - ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall; J96.01 - Acute respiratory failure with hypoxia; R78.81 - Bacteremia; Z11.52 - Encounter for screening for COVID-19; Z28.21 - Immunization not carried out because of patient refusal; J44.0 - Chronic obstructive pulmonary disease with (acute) lower respiratory infection; E66.9 - Obesity, unspecified; K76.0 - Fatty (change of) liver, not elsewhere classified; I48.19 - Other persistent atrial fibrillation; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; J21.9 - Acute bronchiolitis, unspecified; K57.20 - Diverticulitis of large intestine with perforation and abscess without bleeding; R73.03 - Prediabetes; K59.00 - Constipation, unspecified; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E87.70 - Fluid overload, unspecified; B96.20 - Unspecified Escherichia coli (E. coli) as the cause of diseases classified elsewhere; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; G47.33 - Obstructive sleep apnea (adult) (pediatric); Z68.33 - Body mass index (BMI) 33.0-33.9, adult"
MMC OP VP INFUSION,11250,"Meghal, Trishala, MD",11/27/2023,Acalabrutinib 30 Day Cycles - Mantle Cell Lymphoma,_1. First Line,11/27/2023,Inactive,,
MMC OP VP INFUSION,11250,"Meghal, Trishala, MD",1/3/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,1/2/2024,Inactive,,
CBMC OP INFUSION 2FL,68811,"Wagmiller, Jennifer Ann, MD",9/1/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,8/31/2023,Inactive,,
CINJ OP INFUSION,83408,"Groisberg, Roman, MD",11/17/2023,PAZOPanib 30 Day Cycles - Uterine Sarcoma,_3. Third Line,11/17/2023,Inactive,,
SOM OUTPT INFUSION,72945,"Patel, Eshan, MD",10/8/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/7/2024,Inactive,,
SOM OUTPT INFUSION,72945,"Patel, Eshan, MD",3/5/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/5/2025,Inactive,Overlapping malignant neoplasm of colon (CMS/HCC),C18.8 - Malignant neoplasm of overlapping sites of colon
CINJ OP INFUSION,68140,"Haigentz, Missak, MD",1/19/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,Second Line,1/11/2023,Inactive,,
CINJ OP INFUSION,68140,"Haigentz, Missak, MD",4/20/2023,PEMEtrexed matintenence PLUS Osimetinib 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,4/20/2023,Inactive,,
NBR 5N ONCOLOGY,68140,"Saraiya, Biren P, MD",5/25/2023,"PACLitaxel 80 mg/m2 D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",Second Line,5/24/2023,Inactive,,
NBR 4N ONCOLOGY,93263,"Rhodes, Joanna Meehan, MD",9/18/2023,Modified Magrath CODOX-M + IVAC (Cyclophosphamide / DOXOrubicin / VinCRIStine / High Dose Methotrexate/Etoposide / Ifosfamide / Cytarabine / Intrathecal M) + RiTUXimab 28 Day Cycle - Burkitt Lymphoma,First Line,9/18/2023,Inactive,,
NBR 5N ONCOLOGY,93263,"Rhodes, Joanna Meehan, MD",11/21/2024,RiTUXimab 168 Day Cycles - Indolent Lymphoma Maintenance,_1. First Line,11/20/2024,Inactive,,
CINJ OP INFUSION,7286,"Weiss, Sarah, MD",2/26/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,2/22/2024,Active,,
NBI OP INFUSION,31457,"Anderson, Patrick S, MD",5/12/2025,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Granulosa Cell tumoe of the ovary,_1. First Line,5/12/2025,Active,"Abdominal pain, unspecified abdominal location
Granulosa cell tumor",
NBR CINJ OP INFUSION,54727,"Matasar, Matthew J, MD",8/28/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,8/26/2024,Active,"Chondrosarcoma (CMS/HCC)
Secondary malignant neoplasm of unspecified site (CODE) (CMS/HCC)",
JCMC CP INFUSION,58876,"Sekhri, Arunabh, MD",8/9/2024,CISplatin +keytrudaWith Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,8/4/2024,Inactive,,
JCMC CP INFUSION,58876,"Sekhri, Arunabh, MD",10/30/2024,Pembrolizumab 42 Day Cycles - Cervical,Consolidation,10/27/2024,Active,,
CINJ OP INFUSION,82959,"Haigentz, Missak, MD",3/19/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/19/2025,Active,"Small cell lung cancer, left upper lobe (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)
Chronic fatigue","C34.12 - Malignant neoplasm of upper lobe, left bronchus or lung; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; E87.1 - Hypo-osmolality and hyponatremia; I70.1 - Atherosclerosis of renal artery; R53.82 - Chronic fatigue, unspecified; Z87.891 - Personal history of nicotine dependence"
JCMC CP INFUSION,70612,"Sekhri, Arunabh, MD",8/27/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,8/22/2024,Inactive,,
JCMC CP INFUSION,70612,"Sekhri, Arunabh, MD",1/14/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles-pancreatic Cancer,_1. First Line,1/14/2025,Active,,
CBMC OP INFUSION 2FL,63364,"Leitner, Stuart P, MD",3/21/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,3/20/2024,Active,,
CBMC OP INFUSION 2FL,92732,"Brown, Andrew Bennett, MD",11/9/2023,"Paclitaxel D1, D8, D15 28 Day Cycles- Head and Neck Cancers",_2. Second Line,11/8/2023,Active,,
CINJ OP INFUSION,83631,"Weiss, Sarah, MD",5/26/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,5/25/2023,Inactive,,
CMC OP INFUSION,11852,"Pompa, Tiffany Ann, MD",5/14/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/13/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
SOM OUTPT INFUSION,69927,"Yin, Faye, MD",4/25/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,4/24/2023,Inactive,,
SOM OUTPT INFUSION,69927,"Yin, Faye, MD",9/15/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,9/4/2023,Inactive,,
SOM OUTPT INFUSION,44162,"Patel, Eshan, MD",12/17/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,12/8/2024,Active,,
SOM OUTPT INFUSION,44162,"Patel, Eshan, MD",5/13/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,5/13/2025,Active,Metastatic squamous cell carcinoma to parotid gland (CMS/HCC),C79.89 - Secondary malignant neoplasm of other specified sites
CBMC OP INFUSION 2FL,79973,"Wagmiller, Jennifer Ann, MD",11/11/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,11/10/2024,Inactive,,
CBMC OP INFUSION 2FL,2636,"Freeman, Benjamin B, MD",1/31/2025,DOXOrubicin Liposomal 28 Day Cycles - Breast,_1. First Line,1/23/2025,Active,,
CMC OP INFUSION,88474,"Easaw, Sarah, MD",5/26/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,5/24/2023,Inactive,,
JCMC CP INFUSION,40811,"Cruz, Allan Louie E, MD",2/14/2023,CINJ 042109 SGNTUC-028 Trastuzumab / Pertuzumab + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,,2/13/2023,Inactive,,
JCMC CP INFUSION,40811,"Cruz, Allan Louie E, MD",8/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,8/6/2023,Inactive,,
JCMC CP INFUSION,40811,"Cruz, Allan Louie E, MD",4/22/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/22/2024,Active,,
JCMC CP INFUSION,90183,"Cruz, Allan Louie E, MD",2/3/2025,"PACLitaxel D1, D8 21 Day Cycles - Breast",_3. Third Line,2/3/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of female breast (CMS/HCC)
Malignant neoplasm metastatic to liver (CMS/HCC)
Malignant neoplasm metastatic to bone (CMS/HCC)",
JCMC CP INFUSION,90183,"Cruz, Allan Louie E, MD",2/24/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_3. Third Line,2/24/2025,Active,"Malignant neoplasm of upper-outer quadrant of female breast (CMS/HCC)
Malignant neoplasm metastatic to liver (CMS/HCC)
Malignant neoplasm metastatic to bone (CMS/HCC)","C79.51 - Malignant neoplasm metastatic to bone (CMS/HCC); C78.7 - Malignant neoplasm metastatic to liver (CMS/HCC); C50.412, Z17.0 - Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)"
JCMC CP INFUSION,43931,"Cruz, Allan Louie E, MD",4/7/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_3. Third Line,4/7/2025,Inactive,"Malignant neoplasm of female breast (CMS/HCC)
Malignant neoplasm metastatic to liver (CMS/HCC)
Carcinoma of breast metastatic to lung (CMS/HCC)",
JCMC CP INFUSION,43931,"Cruz, Allan Louie E, MD",3/31/2025,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_4. Fourth Line,3/31/2025,Inactive,"Malignant neoplasm of female breast (CMS/HCC)
Malignant neoplasm metastatic to liver (CMS/HCC)
Carcinoma of breast metastatic to lung (CMS/HCC)",
CINJ OP INFUSION,86431,"Goel, Sanjay, MD",6/12/2024,CINJ 052008 / R7075-ONC-2009 Dose level 10A REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_2. Second Line,5/23/2024,Inactive,,
NBI OP INFUSION,47157,"Jacoby, Sari H, MD",10/17/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,10/16/2023,Inactive,,
NBI OP INFUSION,47157,"Jacoby, Sari H, MD",8/19/2024,CINJ 042211 Arm A Sacituzumab govitecan / Pembrolizumab 21 Day Cycles Research- Breast Cancer,_1. First Line,8/18/2024,Active,,
CINJ OP INFUSION,36527,"Hochster, Howard S, MD",6/22/2023,Nivolumab / Ipilimumab 21 Day Cycles - peritoneal mesothelioma,Induction,6/22/2023,Inactive,,
CINJ OP INFUSION,36527,"Hochster, Howard S, MD",12/14/2023,Nivolumab 28 Day Cycles,Maintenance,12/13/2023,Inactive,,
CINJ OP INFUSION,96156,"Haigentz, Missak, MD",12/23/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,12/22/2024,Inactive,,
CINJ OP INFUSION,24120,"Saraiya, Biren P, MD",4/16/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_3. Third Line,4/15/2024,Active,,
CINJ OP INFUSION,34576,"George, Mridula A, MD",9/25/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,9/24/2024,Active,,
CINJ OP INFUSION,37494,"Patel, Eshan, MD",10/20/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,10/19/2023,Inactive,,
CINJ OP INFUSION,37494,"Patel, Eshan, MD",12/29/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,12/28/2023,Active,,
SOM OUTPT INFUSION,36658,"Yin, Faye, MD",1/23/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,1/17/2023,Inactive,,
CBMC 2W ONCOLOGY,76647,"Grossman, I Robert, MD",12/21/2023,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_2. Second Line,12/20/2023,Inactive,,
CBMC 2W ONCOLOGY,76647,"Grossman, I Robert, MD",1/30/2024,ICE Augmented (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Hodgkin Lymphoma (Inpatient Regimen),_3. Third Line,1/30/2024,Inactive,,
NBR CINJ OP INFUSION,76647,"Matasar, Matthew J, MD",3/15/2024,BMT Autologous BEAM,Consolidation,3/15/2024,Inactive,,
CBMC 2W ONCOLOGY,76647,"Grossman, I Robert, MD",5/7/2025,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_5. Fifth Line,5/7/2025,Active,"Anaplastic large cell lymphoma, ALK-positive, unspecified site (CMS/HCC)
Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck (CMS/HCC)","C84.69 - Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites; A41.01 - Sepsis due to methicillin susceptible Staphylococcus aureus; Z51.5 - Encounter for palliative care; R65.20 - Severe sepsis without septic shock; K56.699 - Other intestinal obstruction unspecified as to partial versus complete obstruction; R64 - Cachexia; D70.9 - Neutropenia, unspecified; E83.39 - Other disorders of phosphorus metabolism; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; E83.51 - Hypocalcemia; Z94.84 - Stem cells transplant status; Z94.81 - Bone marrow transplant status; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; I07.1 - Rheumatic tricuspid insufficiency; D63.0 - Anemia in neoplastic disease; R18.8 - Other ascites; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; G89.4 - Chronic pain syndrome; Z74.09 - Other reduced mobility; F41.1 - Generalized anxiety disorder; N32.81 - Overactive bladder; F43.10 - Post-traumatic stress disorder, unspecified; E87.6 - Hypokalemia; R50.81 - Fever presenting with conditions classified elsewhere; E83.42 - Hypomagnesemia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G47.00 - Insomnia, unspecified; K52.89 - Other specified noninfective gastroenteritis and colitis; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D69.59 - Other secondary thrombocytopenia; T45.1X5A - Adverse effect of ..."
CBMC 2W ONCOLOGY,76647,"Grossman, I Robert, MD",5/7/2025,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_5. Fifth Line,5/7/2025,Active,"Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck (CMS/HCC)","C84.69 - Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites; A41.01 - Sepsis due to methicillin susceptible Staphylococcus aureus; Z51.5 - Encounter for palliative care; R65.20 - Severe sepsis without septic shock; K56.699 - Other intestinal obstruction unspecified as to partial versus complete obstruction; R64 - Cachexia; D70.9 - Neutropenia, unspecified; E83.39 - Other disorders of phosphorus metabolism; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; E83.51 - Hypocalcemia; Z94.84 - Stem cells transplant status; Z94.81 - Bone marrow transplant status; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; I07.1 - Rheumatic tricuspid insufficiency; D63.0 - Anemia in neoplastic disease; R18.8 - Other ascites; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; G89.4 - Chronic pain syndrome; Z74.09 - Other reduced mobility; F41.1 - Generalized anxiety disorder; N32.81 - Overactive bladder; F43.10 - Post-traumatic stress disorder, unspecified; E87.6 - Hypokalemia; R50.81 - Fever presenting with conditions classified elsewhere; E83.42 - Hypomagnesemia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G47.00 - Insomnia, unspecified; K52.89 - Other specified noninfective gastroenteritis and colitis; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D69.59 - Other secondary thrombocytopenia; T45.1X5A - Adverse effect of ..."
CBMC 2W ONCOLOGY,76647,"Grossman, I Robert, MD",5/1/2025,CVP (Cyclophosphamide / VinCRIStine / PredniSONE) 21 Day Cycles - Indolent Lymphoma,_5. Fifth Line,5/1/2025,Inactive,"Anaplastic large cell lymphoma, ALK-positive, unspecified site (CMS/HCC)
Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck (CMS/HCC)","C84.69 - Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites; A41.01 - Sepsis due to methicillin susceptible Staphylococcus aureus; Z51.5 - Encounter for palliative care; R65.20 - Severe sepsis without septic shock; K56.699 - Other intestinal obstruction unspecified as to partial versus complete obstruction; R64 - Cachexia; D70.9 - Neutropenia, unspecified; E83.39 - Other disorders of phosphorus metabolism; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; E83.51 - Hypocalcemia; Z94.84 - Stem cells transplant status; Z94.81 - Bone marrow transplant status; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; I07.1 - Rheumatic tricuspid insufficiency; D63.0 - Anemia in neoplastic disease; R18.8 - Other ascites; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; G89.4 - Chronic pain syndrome; Z74.09 - Other reduced mobility; F41.1 - Generalized anxiety disorder; N32.81 - Overactive bladder; F43.10 - Post-traumatic stress disorder, unspecified; E87.6 - Hypokalemia; R50.81 - Fever presenting with conditions classified elsewhere; E83.42 - Hypomagnesemia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G47.00 - Insomnia, unspecified; K52.89 - Other specified noninfective gastroenteritis and colitis; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; D69.59 - Other secondary thrombocytopenia; T45.1X5A - Adverse effect of ..."
CINJ OP INFUSION,28366,"Gulhati, Prateek, MD PhD",4/20/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,4/19/2023,Inactive,,
CINJ OP INFUSION,28366,"Gulhati, Prateek, MD PhD",7/4/2023,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,,7/4/2023,Inactive,,
CINJ OP INFUSION,28366,"Gulhati, Prateek, MD PhD",9/21/2023,Gemcitabine / CISplatin 28 Day Cycles - Days 1 and 15,,9/20/2023,Inactive,,
JCMC CP INFUSION,6408,"Cruz, Allan Louie E, MD",12/15/2023,Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,12/14/2023,Inactive,,
JCMC CP INFUSION,6408,"Cruz, Allan Louie E, MD",4/26/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,4/21/2024,Inactive,,
CBMC OP INFUSION 2FL,62625,"Leitner, Stuart P, MD",1/3/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,1/3/2024,Inactive,,
CBMC OP INFUSION 2FL,62625,"Leitner, Stuart P, MD",3/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/4/2024,Inactive,,
CINJ OP INFUSION,43279,"Berim, Lyudmyla, MD",3/24/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/24/2025,Active,"Colorectal cancer (CMS/HCC)
Malignant neoplasm of sigmoid colon (CMS/HCC)",C18.7 - Malignant neoplasm of sigmoid colon; C19 - Malignant neoplasm of rectosigmoid junction
CINJ OP INFUSION,90999,"George, Mridula A, MD",5/24/2023,Olaparib 30 Day Cycles - Breast,Adjuvant,5/24/2023,Active,,
NBR CINJ OP INFUSION,5528,"Chowaniec, Wayne B, NP",7/30/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_3. Third Line,7/30/2024,Active,Cancer of endometrium (CMS/HCC),
CBMC 2W ONCOLOGY,9508,"Grossman, I Robert, MD",4/20/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/19/2024,Inactive,,
CBMC 2W ONCOLOGY,9508,"Grossman, I Robert, MD",4/24/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/24/2024,Inactive,,
CINJ OP INFUSION,97054,"Salacz, Michael E, MD",4/4/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Adjuvant,4/4/2023,Active,"Adenocarcinoma, lung, right (CMS/HCC)
On antineoplastic chemotherapy",
MMC OP VP INFUSION,68095,"Cohen, Seth D, MD",6/28/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,First Line,6/27/2023,Inactive,,
MMC OP VP INFUSION,68095,"Cohen, Seth D, MD",2/7/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Maintenance,2/6/2024,Inactive,,
MMC OP VP INFUSION,68095,"Cohen, Seth D, MD",9/26/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,9/24/2024,Active,,
NBR 4N ONCOLOGY,28546,"Chen, Xiaoyi",5/8/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,5/8/2025,Active,"Malignant neoplasm of left ovary (CMS/HCC)
Acute myeloid leukemia not having achieved remission (CMS/HCC)","C56.2 - Malignant neoplasm of left ovary; C92.00 - Acute myeloblastic leukemia, not having achieved remission; D61.818 - Other pancytopenia; T80.219A - Unspecified infection due to central venous catheter, initial encounter; L29.9 - Pruritus, unspecified"
NBR CINJ OP INFUSION,28546,"Chen, Xiaoyi",5/5/2025,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/5/2025,Inactive,"Malignant neoplasm of left ovary (CMS/HCC)
Acute myeloid leukemia not having achieved remission (CMS/HCC)",
CBMC OP INFUSION 2FL,97159,"Grossman, I Robert, MD",8/31/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/31/2023,Inactive,,
NBR CINJ OP INFUSION,4017,"Palmisiano, Neil David, MD",5/28/2024,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,5/28/2024,Active,,
HAM OP INFUSION,15382,"Yogarajah, Meera, MD",4/1/2025,FOLFOX + Pembrolizumab,_2. Second Line,4/1/2025,Active,Metastasis from gastric cancer (CMS/HCC),C16.9 - Gastric adenocarcinoma (CMS/HCC)
SOM OUTPT INFUSION,70535,"Toomey, Kathleen C, MD",11/20/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/7/2023,Inactive,,
CMC 4B ONCOLOGY,51147,"Easaw, Sarah, MD",5/16/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/8/2023,Inactive,,
CMC OP INFUSION,51147,"Talwar, Sumit, MD",8/31/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,8/22/2023,Inactive,,
CINJ OP INFUSION,73533,"Toppmeyer, Deborah L, MD",4/2/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,4/1/2024,Active,,
NBR CINJ OP INFUSION,67378,"Matasar, Matthew J, MD",8/2/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,67378,"Matasar, Matthew J, MD",9/6/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,9/5/2023,Inactive,,
NBR CINJ OP INFUSION,67378,"Matasar, Matthew J, MD",12/22/2023,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_3. Third Line,12/21/2023,Inactive,,
NBR CINJ OP INFUSION,67378,"Egini, Ogechukwu, MD",9/21/2024,BMT Allogeneic Flu / Cy / TBI + Post Cy,_5. Fifth Line,9/20/2024,Active,,
CINJ OP INFUSION,71231,"Boland, Patrick M, MD",2/8/2024,Nivolumab 480 mg 28 Day Cycles- Colon Cancer,Adjuvant,2/7/2024,Inactive,,
NBR 4N BMTU/IMCU,1948,"Assal, Amer, MD",12/20/2023,BMT Autologous Melphalan Day -1  200mg/m2,_2. Second Line,12/18/2023,Inactive,,
CINJ OP INFUSION,46533,"Patel, Malini M, MD",5/3/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,5/3/2024,Active,,
CINJ OP INFUSION,9289,"Haigentz, Missak, MD",4/25/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,4/25/2024,Inactive,,
CBMC 2W ONCOLOGY,98867,"Grossman, I Robert, MD",4/8/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/8/2024,Inactive,,
CBMC 2W ONCOLOGY,98867,"Grossman, I Robert, MD",4/29/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/28/2024,Active,Cancer of overlapping sites of cervix uteri (CMS/HCC),
CBMC OP INFUSION 2FL,51394,"Brown, Andrew Bennett, MD",1/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/17/2023,Active,,
JCMC CP INFUSION,89615,"Sekhri, Arunabh, MD",5/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/14/2025,Active,Overlapping malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,34616,"Boland, Patrick M, MD",5/16/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,,5/16/2023,Inactive,,
CINJ OP INFUSION,86514,"Stephenson, Ryan D, DO",10/13/2023,Pembrolizumab 21 Day Cycles - Cutaneous Squamous Cell Carcinoma,_1. First Line,10/12/2023,Inactive,,
CINJ OP INFUSION,86514,"Stephenson, Ryan D, DO",12/8/2023,Cetuximab / PACLitaxel 100 mg/m2 / CARBOplatin AUC 2.5 21 Day Cycles- Head and Neck Cancers,_2. Second Line,12/3/2023,Active,,
CINJ PEDS HEMONC ,50752,"Moerdler, Scott, MD",6/19/2023,PEDS AHOD2131 ABVD All Arms,,6/18/2023,Inactive,,
CINJ OP INFUSION,12116,"Berim, Lyudmyla, MD",7/12/2024,CINJ 072108 (A021806) ARM 1 FOLFIRINOX (Fluorouracil / Leucovorin / Irinotecan / OXALiplatin) 14 Day Cycles Research- Pancreatic Adenocarcinoma,Neoadjuvant,6/27/2024,Inactive,,
CINJ OP INFUSION,12116,"Berim, Lyudmyla, MD",10/3/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/2/2024,Active,,
CINJ OP INFUSION,1640,"Goel, Sanjay, MD",3/24/2025,CINJ 052410 Arm 2 MK-0472 / Pembrolizumab 21 Day Cycles Research- Advanced / Metastatic Solid Tumors,_3. Third Line,3/24/2025,Inactive,"Malignant neoplasm of tail of pancreas (CMS/HCC)
Secondary malignant neoplasm of other specified sites (CMS/HCC)",
HAM OP INFUSION,63051,"Yogarajah, Meera, MD",8/10/2023,Dose-Adjusted R-EPOCH (For AIDS-Related) (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (AIDS-Related),First Line,8/7/2023,Inactive,,
CBMC OP INFUSION 2FL,28678,"Litvak, Anna M, MD",1/4/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,1/4/2024,Inactive,,
CINJ OP INFUSION,60360,"Stephenson, Ryan D, DO",10/9/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Adjuvant,10/8/2024,Inactive,,
CINJ OP INFUSION,47515,"Boland, Patrick M, MD",4/21/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",,4/21/2023,Inactive,,
CMC OP INFUSION,78605,"Eltoukhy, Hussam, MD",1/17/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/16/2025,Active,,
CBMC 2W ONCOLOGY,9556,"Brown, Andrew Bennett, MD",2/9/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/9/2025,Active,"Malignant neoplasm of overlapping sites of tongue (CMS/HCC)
Malignant neoplasm of head, face, and neck (CMS/HCC)","C06.9 - Malignant neoplasm of mouth, unspecified; E43 - Unspecified severe protein-calorie malnutrition; J18.9 - Pneumonia, unspecified organism; E87.3 - Alkalosis; R64 - Cachexia; E87.1 - Hypo-osmolality and hyponatremia; R62.7 - Adult failure to thrive; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; C02.8 - Malignant neoplasm of overlapping sites of tongue; R56.9 - Unspecified convulsions; E03.9 - Hypothyroidism, unspecified; D63.0 - Anemia in neoplastic disease; I10 - Essential (primary) hypertension; L03.221 - Cellulitis of neck; Z68.1 - Body mass index (BMI) 19.9 or less, adult; Z93.0 - Tracheostomy status; Z93.1 - Gastrostomy status; G25.3 - Myoclonus; Z11.52 - Encounter for screening for COVID-19; E86.0 - Dehydration; D50.9 - Iron deficiency anemia, unspecified; G89.3 - Neoplasm related pain (acute) (chronic); I95.9 - Hypotension, unspecified; R19.7 - Diarrhea, unspecified; R74.01 - Elevation of levels of liver transaminase levels; E53.8 - Deficiency of other specified B group vitamins; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; T42.6X5A - Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter; K59.09 - Other constipation; R13.10 - Dysphagia, unspecified; Z28.21 - Immunization not carried out because of patient refusal; Z92.3 - Personal history of irradiation; Z92.21 - Personal history of antineoplastic chemotherapy; Z90.49 - Acquired absence of other specified p..."
EMH HEM ONC,53267,"Yin, Faye, MD",5/9/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/2/2023,Inactive,,
CINJ OP INFUSION,45211,"Groisberg, Roman, MD",2/9/2024,DOXOrubicin 21 Day Cycles - Sarcoma,_1. First Line,2/8/2024,Inactive,,
CINJ OP INFUSION,45211,"Groisberg, Roman, MD",3/1/2024,AD (DOXOrubicin / Dacarbazine) 21 Day Cycles - Sarcoma,_1. First Line,2/29/2024,Inactive,,
CINJ OP INFUSION,45211,"Groisberg, Roman, MD",8/9/2024,"DOCEtaxel D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_2. Second Line,8/8/2024,Active,,
CINJ PEDS HEMONC ,99007,"Drachtman, Richard, MD",5/2/2023,PEDS Bendamustine / Gemcitabine / VinORELBine (Q21D) - Hodgkin Lymphoma,Third Line,4/28/2023,Inactive,,
CINJ PEDS HEMONC ,99007,"Drachtman, Richard, MD",9/28/2023,Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,Maintenance,9/21/2023,Inactive,,
JCMC CP INFUSION,68383,"Sekhri, Arunabh, MD",3/8/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,First Line,3/7/2023,Inactive,,
JCMC CP INFUSION,68383,"Sekhri, Arunabh, MD",5/3/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/22/2024,Inactive,,
CBMC OP INFUSION 2FL,9222,"Leitner, Stuart P, MD",3/1/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_1. First Line,2/26/2024,Inactive,,
CINJ OP INFUSION,21181,"Jang, Thomas L, MD",1/25/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,_1. First Line,1/25/2024,Inactive,,
MMC OP VP INFUSION,472,"Cohen, Seth D, MD",5/30/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/21/2024,Inactive,,
CBMC OP INFUSION 2FL,30771,"Wagmiller, Jennifer Ann, MD",3/31/2025,CISplatin 21 Day Cycles - Uterine,_1. First Line,3/31/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C54.1 - Malignant neoplasm of endometrium; C56.9 - Malignant neoplasm of unspecified ovary; Z79.899 - Other long term (current) drug therapy
CBMC OP INFUSION 2FL,63235,"Wagmiller, Jennifer Ann, MD",1/28/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,1/26/2025,Active,Chronic myeloid leukemia (CMS/HCC),
NBR CINJ OP INFUSION,9499,"Rhodes, Joanna Meehan, MD",2/19/2024,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,2/18/2024,Inactive,,
NBR CINJ OP INFUSION,9499,"Rhodes, Joanna Meehan, MD",4/22/2024,"CINJ 112305 Arms B,D,F,H (Brentuximab Vendotin + Nivolumab) 21 Day Cycles - Hodgkin Lymphoma",_1. First Line,4/21/2024,Active,,
NBR CINJ OP INFUSION,9499,"Rhodes, Joanna Meehan, MD",4/22/2024,"AHOD2131 Arms B,D,F and H Brentuximab + Nivolumab",_1. First Line,4/22/2024,Inactive,,
NBI OP INFUSION,97612,"Schleicher, Lori, MD",9/19/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/18/2024,Inactive,,
NBI OP INFUSION,97612,"Schleicher, Lori, MD",11/29/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/28/2024,Active,,
NBI OP INFUSION,97612,"Schleicher, Lori, MD",3/24/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,3/24/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,59177,"Omene, Coral Oghenerukevwe, MD",4/7/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,4/3/2023,Active,,
CBMC OP INFUSION 2FL,50298,"Gallinson, David Herschel, DO",5/8/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,5/8/2025,Inactive,Lymphoma (CMS/HCC),"I26.99 - Other pulmonary embolism without acute cor pulmonale; C85.1A - Unspecified b-cell lymphoma, in remission"
NBR CINJ OP INFUSION,6608,"Zayac, Adam, MD",12/12/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,12/11/2024,Active,,
NBR CINJ OP INFUSION,6608,"Rhodes, Joanna Meehan, MD",12/13/2024,Mini-R-pola-CHP (Cyclophosphamide / DOXOrubicin / polatuzumab vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/11/2024,Active,,
NBI OP INFUSION,79413,"Cheng, Yan Ho, MD",10/7/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,10/7/2024,Active,,
NBI OP INFUSION,79413,"Cheng, Yan Ho, MD",1/23/2025,Apalutamide 30 Day Cycles - Prostate,_2. Second Line,1/23/2025,Inactive,Prostate cancer metastatic to bone (CMS/HCC),
NBI OP INFUSION,79413,"Cheng, Yan Ho, MD",2/18/2025,Darolutamide 28 Day Cycles - Prostate,_2. Second Line,2/18/2025,Active,Prostate cancer metastatic to bone (CMS/HCC),
NBI OP INFUSION,52633,"Shah, Shailja S, MD",8/27/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/27/2024,Inactive,,
NBI OP INFUSION,52633,"Shah, Shailja S, MD",12/3/2024,Erdafitinib 28 Day Cycles - Bladder,_2. Second Line,12/3/2024,Active,,
NBR 4N ONCOLOGY,38638,"Haigentz, Missak, MD",8/15/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,8/7/2024,Active,,
CINJ OP INFUSION,38638,"Haigentz, Missak, MD",11/20/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,11/20/2024,Active,,
MMC OP VP INFUSION,89423,"Lee, Patrick C, MD",5/4/2023,Gemcitabine 1000 mg/m2/ CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,5/3/2023,Inactive,,
MMC OP VP INFUSION,89423,"Lee, Patrick C, MD",5/9/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Neoadjuvant,5/8/2023,Inactive,,
MMC OP VP INFUSION,89423,"Lee, Patrick C, MD",10/5/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,10/4/2023,Inactive,,
MMC OP VP INFUSION,89423,"Lee, Patrick C, MD",1/25/2024,Nivolumab/Ipilimumab + PACLitaxel/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/17/2024,Inactive,,
MMC OP VP INFUSION,89423,"Lee, Patrick C, MD",1/25/2024,Gemcitabine 1000 mg/m2/ CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/24/2024,Inactive,,
NBI OP INFUSION,67328,"Schleicher, Lori, MD",11/1/2023,Pertuzumab / Trastuzumab-ANNS / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab-ANNS 21 Day Cycles - Breast,_1. First Line,10/29/2023,Active,,
CINJ OP INFUSION,36715,"Patankar, Sonali, MD",1/10/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/8/2025,Active,,
CINJ OP INFUSION,29491,"Mayer, Tina M, MD",11/13/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,11/12/2023,Inactive,,
MMC OP INFUSION,64464,"Meghal, Trishala, MD",9/21/2023,Abemaciclib 28 Day Cycles - Breast,,9/21/2023,Inactive,,
NBI OP INFUSION,32326,"Schleicher, Lori, MD",4/23/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,4/23/2025,Active,Prostate CA (CMS/HCC),C61 - Malignant neoplasm of prostate
NBR 4N BMTU/IMCU,59356,"Schaar, Dale, MD PhD",3/29/2024,BMT Autologous BEAM,Consolidation,3/28/2024,Active,,
CINJ OP INFUSION,77783,"Groisberg, Roman, MD",1/3/2025,DOXOrubicin Liposomal 21 Day Cycles - Sarcoma,_1. First Line,1/2/2025,Active,,
JCMC CP INFUSION,30758,"Cruz, Allan Louie E, MD",10/3/2023,DOCEtaxel 21 Day Cycles - Prostate,First Line,10/3/2023,Inactive,,
JCMC CP INFUSION,30758,"Cruz, Allan Louie E, MD",2/13/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,2/13/2024,Inactive,,
CBMC OP INFUSION 2FL,31591,"Brown, Andrew Bennett, MD",1/29/2024,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,Neoadjuvant,1/28/2024,Inactive,,
CBMC OP INFUSION 2FL,31591,"Brown, Andrew Bennett, MD",3/13/2024,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,3/12/2024,Inactive,,
CBMC OP INFUSION 2FL,31591,"Brown, Andrew Bennett, MD",6/13/2024,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,6/12/2024,Active,,
NBI OP INFUSION,17851,"Anderson, Patrick S, MD",4/11/2023,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_4. Fourth Line,4/10/2023,Inactive,,
NBI OP INFUSION,17851,"Anderson, Patrick S, MD",11/7/2023,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_4. Fourth Line,11/6/2023,Inactive,,
NBI OP INFUSION,17851,"Anderson, Patrick S, MD",3/5/2024,Dostarlimab-gxly 42 Day Cycles- Gynecologic Cancers,_5. Fifth Line,3/4/2024,Inactive,,
NBI OP INFUSION,17851,"Anderson, Patrick S, MD",8/20/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_5. Fifth Line,8/19/2024,Active,,
NBI OP INFUSION,17851,"Anderson, Patrick S, MD",2/25/2025,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_4. Fourth Line,2/25/2025,Active,"Endometrial cancer (CMS/HCC)
Lung nodule, multiple",
NBI OP INFUSION,90653,"Anderson, Patrick S, MD",5/27/2025,Nivolumab 28 Day Cycles - Endometrial Cancer,_5. Fifth Line,5/27/2025,Active,Endometrial cancer (CMS/HCC),"M54.16 - Radiculopathy, lumbar region; M54.17 - Radiculopathy, lumbosacral region; C54.1 - Malignant neoplasm of endometrium"
NBI OP INFUSION,90653,"Anderson, Patrick S, MD",5/15/2025,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,5/15/2025,Inactive,Endometrial cancer (CMS/HCC),"M54.16 - Radiculopathy, lumbar region; M54.17 - Radiculopathy, lumbosacral region; C54.1 - Malignant neoplasm of endometrium"
NBI OP INFUSION,90653,"Anderson, Patrick S, MD",3/25/2025,Pembrolizumab / Gemcitabine / CISplatin 21 Day Cycles- Gemcitabine-CISplatin Sequencing- Endometrial cancer,_4. Fourth Line,3/25/2025,Inactive,Endometrial cancer (CMS/HCC),
NBI OP INFUSION,90653,"Anderson, Patrick S, MD",3/20/2025,Pembrolizumab / Gemcitabine / CISplatin 21 Day Cycles- Gemcitabine-CISplatin Sequencing- Gastrointestinal Cancers,_4. Fourth Line,3/20/2025,Inactive,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,86221,"Goel, Sanjay, MD",11/20/2024,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,11/20/2024,Active,,
JCMC CP INFUSION,35384,"Cruz, Allan Louie E, MD",6/10/2024,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- sigmoid adenocarcinoma,_1. First Line,6/7/2024,Inactive,,
CBMC 2W ONCOLOGY,35384,"Maggi, Jason C, MD",11/6/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,11/6/2024,Active,,
JCMC CP INFUSION,64781,"Cruz, Allan Louie E, MD",3/17/2025,"mFOLFOX6 Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers",Adjuvant,3/17/2025,Inactive,"Malignant neoplasm of sigmoid colon (CMS/HCC)
Carcinomatosis (CMS/HCC)","C18.7 - Malignant neoplasm of sigmoid colon; C80.0 - Disseminated malignant neoplasm, unspecified"
CMC OP INFUSION,47983,"Easaw, Sarah, MD",8/18/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,8/6/2023,Inactive,,
CMC OP INFUSION,47983,"Easaw, Sarah, MD",9/8/2023,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,Adjuvant,9/7/2023,Inactive,,
CMC OP INFUSION,47983,"Talwar, Sumit, MD",9/29/2023,Albumin-Bound PACLitaxel / Trastuzumab 21 Day Cycles - Breast,Adjuvant,9/28/2023,Inactive,,
CMC OP INFUSION,47983,"Talwar, Sumit, MD",2/9/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/8/2024,Inactive,,
NBR 5N MED-SURG OVRF,56510,"Alexander, Henry Richard, MD",5/20/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,5/20/2024,Inactive,,
NBI A5 PEDIATRICS,10658,"Rao, Harini, MD",6/28/2024,ARAR2221,_1. First Line,6/27/2024,Active,,
NBI VALERIE FND HEMONC,10658,"Rao, Harini, MD",6/28/2024,ARAR2221 - Gemcitabine / CISplatin / Nivolumab Induction Chemoimmunotherapy for Nasopharyngeal Carcinoma,_1. First Line,6/27/2024,Inactive,,
CINJ PEDS HEMONC ,91239,"Drachtman, Richard, MD",1/24/2023,per AALL1732 Consolidation,First Line,1/24/2023,Inactive,,
CINJ PEDS HEMONC ,91239,"Drachtman, Richard, MD",4/26/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,First Line,4/20/2023,Inactive,,
CINJ PEDS HEMONC ,91239,"Drachtman, Richard, MD",7/20/2023,AALL1732 Delayed Intensification,First Line,7/20/2023,Inactive,,
CINJ PEDS HEMONC ,91239,"Drachtman, Richard, MD",9/25/2023,AALL1732 Interim Maintenance II (IM II) with CMTX,First Line,9/25/2023,Inactive,,
CINJ PEDS HEMONC ,91239,"Drachtman, Richard, MD",11/30/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,_1. First Line,11/30/2023,Active,,
CINJ OP INFUSION,79361,"George, Mridula A, MD",8/26/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/25/2024,Active,,
SOM OUTPT INFUSION,71064,"George, Roshini, DO",2/5/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,2/4/2025,Active,Malignant neoplasm of overlapping sites of cervix (CMS/HCC),"N88.8 - Other specified noninflammatory disorders of cervix uteri; C53.8 - Malignant neoplasm of overlapping sites of cervix uteri; N93.9 - Abnormal uterine and vaginal bleeding, unspecified"
JCMC CP INFUSION,3360,"Sekhri, Arunabh, MD",4/3/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/2/2023,Inactive,,
CINJ OP INFUSION,41490,"Mayer, Tina M, MD",12/2/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,11/29/2024,Active,,
CINJ PEDS HEMONC ,79531,"Goyal-Khemka, Meenakshi, MD",4/25/2023,DFCI 16-001 Continuation,Maintenance,4/20/2023,Inactive,,
CBMC OP INFUSION 2FL,21900,"Brown, Andrew Bennett, MD",10/30/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,21900,"Brown, Andrew Bennett, MD",6/3/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/2/2024,Inactive,,
CBMC OP INFUSION 2FL,58532,"Litvak, Anna M, MD",4/14/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,_1. First Line,4/14/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ PEDS HEMONC ,48727,"Botwinick, Marissa, DO",2/27/2025,ANHL1931 Arm C and Arm E R-CHOP,_1. First Line,2/24/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified body region (CMS/HCC); C83.32 - Diffuse large B-cell lymphoma of intrathoracic lymph nodes (CMS/HCC)"
TRMC TCCC OP INFUSION,79113,"Salerno, Vincent E, MD",12/19/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,12/18/2024,Inactive,,
CINJ PEDS HEMONC ,92880,"Drachtman, Richard, MD",5/13/2025,PEDS AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/13/2025,Active,Hodgkin lymphoma (CMS/HCC),
NBR 5N ONCOLOGY,1307,"Rhodes, Joanna Meehan, MD",10/30/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_4. Fourth Line,10/30/2024,Active,,
CINJ OP INFUSION,49832,"Boland, Patrick M, MD",9/26/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,9/25/2024,Active,,
CBMC OP INFUSION 2FL,94739,"Grossman, I Robert, MD",5/14/2024,RiTUXimab Initial ++ Infusion Single Day (Outpatient),_1. First Line,5/14/2024,Inactive,,
CMC OP INFUSION,90387,"Pompa, Tiffany Ann, MD",4/28/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/28/2025,Active,"Invasive ductal carcinoma of breast, female, left (CMS/HCC)",
MMC OP INFUSION,72183,"Lee, Patrick C, MD",5/30/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,,5/30/2023,Inactive,,
MMC OP INFUSION,72183,"Lee, Patrick C, MD",6/20/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,6/19/2023,Inactive,,
MMC OP INFUSION,72183,"Lee, Patrick C, MD",8/1/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,7/16/2023,Inactive,,
MMC OP INFUSION,72183,"Lee, Patrick C, MD",8/8/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,7/24/2023,Inactive,,
CINJ PEDS HEMONC ,86348,"Cole, Peter David, MD",5/25/2023,DFCI 16-001 Continuation,Maintenance,5/24/2023,Inactive,,
MMC OP VP INFUSION,15298,"Cohen, Seth D, MD",1/27/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/26/2025,Active,,
CINJ OP INFUSION,30604,"Boland, Patrick M, MD",8/7/2023,CINJ 072104 Cohort 4 PCS6422 / Capecitabine 14 Day Cycles Research- Colon Cancer,,8/6/2023,Inactive,,
CINJ OP INFUSION,10709,"Mayer, Tina M, MD",1/31/2023,Nivolumab 28 Day Cycles - Kidney or Bladder,First Line,1/31/2023,Inactive,,
CINJ OP INFUSION,10709,"Mayer, Tina M, MD",1/4/2024,Cabozantinib  - Kidney,_2. Second Line,1/4/2024,Inactive,,
CINJ OP INFUSION,85227,"Berim, Lyudmyla, MD",11/6/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Adjuvant,11/5/2024,Active,,
CINJ OP INFUSION,91650,"Berim, Lyudmyla, MD",5/12/2025,Gemcitabine with Concurrent Radiation Preceding Adjuvant Chemotherapy Weekly- Pancreatic Adenocarcinoma,Adjuvant,5/12/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas (CMS/HCC)
CINJ OP INFUSION,72183,"Stephenson, Ryan D, DO",10/21/2024,Pembrolizumab 42 Day Cycles - Kidney Cancer,Adjuvant,10/21/2024,Active,,
TRMC TCCC OP INFUSION,64100,"Capo, Gerardo, MD",6/7/2024,PCV (Procarbazine / Lomustine / VinCRIStine) 42 Day Cycles - CNS,_1. First Line,6/6/2024,Active,,
CINJ OP INFUSION,4338,"Ganesan, Shridar, MD PhD",2/14/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,2/13/2023,Inactive,,
NBR CINJ OP INFUSION,37194,"Zayac, Adam, MD",8/19/2024,HyperCVD Mini + Venetoclax (High-Dose Methotrexate / Cytarabine / Venetoclax / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_1. First Line,8/12/2024,Active,,
NBR CINJ OP INFUSION,62269,"Zayac, Adam, MD",4/21/2025,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,4/21/2025,Active,"Adult T-cell leukemia/lymphoma, not in remission (CMS/HCC)
T-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)",C91.00 - Acute lymphoblastic leukemia not having achieved remission; D61.818 - Other pancytopenia; I10 - Essential (primary) hypertension; B20 - Human immunodeficiency virus (HIV) disease; B19.10 - Unspecified viral hepatitis B without hepatic coma; C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
CINJ OP INFUSION,80466,"Saraiya, Biren P, MD",4/16/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,4/16/2024,Active,,
CMC OP INFUSION,42055,"Taff, Jessica, MD",5/1/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,First Line,4/30/2023,Inactive,,
CBMC OP INFUSION 2FL,47436,"Litvak, Anna M, MD",11/9/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,47436,"Litvak, Anna M, MD",2/1/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/16/2024,Active,,
CBMC OP INFUSION 2FL,47436,"Litvak, Anna M, MD",5/22/2025,Capivasertib 28 Day Cycles - Breast,_1. First Line,5/22/2025,Active,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of unspecified site of right female breast (CMS/HCC)",
CBMC OP INFUSION 2FL,47436,"Ligresti, Louise G, MD",5/19/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,_4. Fourth Line,5/16/2025,Inactive,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of unspecified site of right female breast (CMS/HCC)",C79.51 - Secondary malignant neoplasm of bone; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,47436,"Ligresti, Louise G, MD",5/19/2025,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_4. Fourth Line,5/19/2025,Inactive,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of unspecified site of right female breast (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; C79.51 - Secondary malignant neoplasm of bone; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,47436,"Ligresti, Louise G, MD",3/11/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_3. Third Line,3/11/2025,Inactive,"Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of unspecified site of right female breast (CMS/HCC)",C79.51 - Secondary malignant neoplasm of bone; C50.911 - Malignant neoplasm of unspecified site of right female breast; K52.1 - Toxic gastroenteritis and colitis; R97.8 - Other abnormal tumor markers; R97.0 - Elevated carcinoembryonic antigen (CEA); C50.819 - Malignant neoplasm of overlapping sites of unspecified female breast; E87.1 - Hypo-osmolality and hyponatremia; Z17.0 - Estrogen receptor positive status (ER+)
CINJ PEDS HEMONC ,1052,"Moerdler, Scott, MD",9/3/2024,as per AGCT1531 Arm BEP (Bleomycin / Etoposide / CISplatin),_1. First Line,9/2/2024,Active,,
CINJ PEDS HEMONC ,1052,"Moerdler, Scott, MD",9/4/2024,AGCT1531 Arm BEP (Bleomycin / Etoposide / CISplatin),_1. First Line,9/2/2024,Inactive,,
MMC OP VP INFUSION,9422,"Cohen, Seth D, MD",7/5/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,6/19/2023,Inactive,,
MMC OP VP INFUSION,9422,"Cohen, Seth D, MD",6/20/2024,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/18/2024,Active,,
CBMC OP INFUSION 2FL,59949,"Siu, Karleung, MD",3/5/2025,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,3/5/2025,Active,Malignant neoplasm of middle lobe of right lung (CMS/HCC),
CINJ OP INFUSION,69924,"Girda, Eugenia, MD",4/20/2023,PACLitaxel / CARBOplatin/Pembrolizumab 21 Day Cycles - Uterine,Adjuvant,4/19/2023,Inactive,,
CINJ OP INFUSION,69924,"Girda, Eugenia, MD",8/23/2023,Pembrolizumab 21 Day Cycles - Uterine,,8/22/2023,Active,,
NBR 4N BMTU/IMCU,83715,"Schaar, Dale, MD PhD",2/21/2024,BMT Allogeneic TBF + Post Cy ,Consolidation,2/21/2024,Inactive,,
MMC OP VP INFUSION,33414,"Talwar, Sumit, MD",8/22/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",,8/14/2023,Inactive,,
CBMC 2W ONCOLOGY,80937,"Grossman, I Robert, MD",8/27/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,8/27/2024,Inactive,,
CBMC 2W ONCOLOGY,80937,"Grossman, I Robert, MD",9/20/2024,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 14 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,9/19/2024,Inactive,,
CBMC 2W ONCOLOGY,80937,"Grossman, I Robert, MD",9/20/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,9/19/2024,Inactive,,
CBMC 2W ONCOLOGY,80937,"Grossman, I Robert, MD",10/11/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_3. Third Line,10/10/2024,Inactive,,
CINJ OP INFUSION,87337,"Girda, Eugenia, MD",5/27/2025,Methotrexate / Leucovorin 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_1. First Line,5/27/2025,Active,Gestational trophoblastic neoplasm,
JCMC CP INFUSION,74462,"Cruz, Allan Louie E, MD",7/10/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,7/9/2023,Inactive,,
CINJ OP INFUSION,31350,"Ghodoussipour, Saum Bobak, MD",1/19/2024,CINJ 082303 Arm B BCG - Bladder Cancer,Induction,1/18/2024,Inactive,,
CINJ OP INFUSION,31350,"Ghodoussipour, Saum Bobak, MD",4/26/2024,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,4/26/2024,Active,,
CMC OP INFUSION,34950,"Tang, Horace, MD",10/16/2023,AzaCITIDine Oral 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,10/16/2023,Inactive,,
CMC OP INFUSION,34950,"Tang, Horace, MD",12/4/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,12/4/2023,Inactive,,
NBR 4N ONCOLOGY,26966,"Gulhati, Prateek, MD PhD",5/30/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Induction,5/28/2024,Inactive,,
MSC OP INFUSION,13667,"Eltoukhy, Hussam, MD",6/17/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,6/13/2024,Inactive,,
SOM OUTPT INFUSION,7240,"Yin, Faye, MD",10/9/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,10/9/2023,Inactive,,
MMC OP INFUSION,19391,"Lee, Patrick C, MD",4/18/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,,4/10/2023,Inactive,,
CINJ OP INFUSION,29867,"Patel, Eshan, MD",2/17/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,2/15/2024,Inactive,,
CINJ OP INFUSION,29867,"Patel, Eshan, MD",2/26/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/15/2024,Inactive,,
CINJ OP INFUSION,29867,"Haigentz, Missak, MD",6/7/2024,pemetrexed / pembrolizumab maintenance,Maintenance,5/23/2024,Active,,
MMC OP VP INFUSION,83489,"Lee, Patrick C, MD",2/16/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,Induction,2/15/2023,Inactive,,
NBR CINJ OP INFUSION,83489,"Shah, Mansi R, MD",6/8/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,5/28/2023,Inactive,,
MMC OP VP INFUSION,83489,"Lee, Patrick C, MD",11/2/2023,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,Maintenance,11/2/2023,Inactive,,
MMC BBR2 ONCOLOGY,83489,"Lee, Patrick C, MD",11/7/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/5/2024,Inactive,,
MMC OP VP INFUSION,18406,"Lee, Patrick C, MD",5/28/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,5/28/2025,Active,Chronic lymphocytic leukemia (CMS/HCC),
NBI OP INFUSION,13919,"Shah, Maya M, MD",7/3/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,7/3/2024,Inactive,,
CINJ OP INFUSION,50552,"Goel, Sanjay, MD",4/15/2024,CINJ 052008 / R7075-ONC-2009 Dose level 10A REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_3. Third Line,3/26/2024,Inactive,,
JCMC CP INFUSION,69129,"Sekhri, Arunabh, MD",10/9/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,9/24/2024,Inactive,,
JCMC CP INFUSION,69129,"Sekhri, Arunabh, MD",1/23/2025,Nivolumab 28 Day Cycles -bladder,Adjuvant,1/22/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,69129,"Saraiya, Biren P, MD",3/4/2025,CINJ 082401 Arm 3 Cohort B Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,Adjuvant,3/4/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,97891,"Weiss, Sarah, MD",5/22/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,5/22/2023,Active,,
CINJ OP INFUSION,7480,"Omene, Coral Oghenerukevwe, MD",2/10/2025,CINJ 042102 Block A Rilvestomig / T-Dxd Appendix AJ 21 Day Cycles Research,Neoadjuvant,2/9/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,7480,"Omene, Coral Oghenerukevwe, MD",5/6/2025,CINJ 042102 Block B (TNBC) Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles Research- Triple Negative Breast Cancer,Neoadjuvant,5/6/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,46398,"Tiger, Yun Kyoung, MD",1/5/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,1/4/2024,Inactive,,
CBMC OP INFUSION 2FL,16998,"Leitner, Stuart P, MD",11/14/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,11/14/2023,Inactive,,
CINJ OP INFUSION,26661,"Boland, Patrick M, MD",1/10/2023,Pemigatinib 21 Day Cycles- Hepatobiliary Cancers,,1/10/2023,Inactive,,
CBMC 2W ONCOLOGY,40857,"Brown, Andrew Bennett, MD",12/29/2023,"Weekly DOXOrubicin D1, D8, D15 q21 Day Cycles - Breast Cancer",_2. Second Line,12/29/2023,Inactive,,
HAM OP INFUSION,48770,"Yogarajah, Meera, MD",5/30/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,5/19/2024,Active,,
CINJ OP INFUSION,63466,"Omene, Coral Oghenerukevwe, MD",9/25/2023,Abemaciclib 28 Day Cycles - Breast,,9/25/2023,Inactive,,
MMC OP VP INFUSION,29825,"Cohen, Seth D, MD",9/20/2023,Ipilimumab 21 Day Cycles - Melanoma,,9/19/2023,Inactive,,
CINJ OP INFUSION,54297,"Leiser, Aliza, MD",5/22/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,5/22/2023,Inactive,,
CINJ OP INFUSION,54297,"Leiser, Aliza, MD",12/18/2023,Liposomal DOXOrubicin / CARBOplatin/ Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,12/17/2023,Active,,
CINJ OP INFUSION,21901,"Leiser, Aliza, MD",5/27/2025,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_3. Third Line,5/27/2025,Active,"Metastatic adenocarcinoma of ovary, unspecified laterality (CMS/HCC)
Malignant neoplasm of overlapping sites of female genital organs (CMS/HCC)",
CINJ OP INFUSION,21901,"Leiser, Aliza, MD",3/18/2025,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/18/2025,Inactive,"Metastatic adenocarcinoma of ovary, unspecified laterality (CMS/HCC)
Malignant neoplasm of overlapping sites of female genital organs (CMS/HCC)",
CMC OP INFUSION,1504,"Tang, Horace, MD",6/21/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,6/20/2023,Inactive,,
CMC OP INFUSION,1504,"Tang, Horace, MD",9/20/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,9/20/2023,Inactive,,
CMC OP INFUSION,1504,"Talwar, Sumit, MD",12/29/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Adjuvant,12/29/2023,Inactive,,
CINJ OP INFUSION,46119,"Stephenson, Ruth D, DO",2/7/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,2/4/2025,Active,Malignant neoplasm of uterus (CMS/HCC),"C55 - Malignant neoplasm of uterus, part unspecified"
CINJ OP INFUSION,15111,"Boland, Patrick M, MD",8/14/2024,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,7/17/2024,Active,,
CINJ OP INFUSION,10742,"Boland, Patrick M, MD",4/8/2025,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,4/8/2025,Inactive,Gastroesophageal cancer (CMS/HCC),"C16.0 - Malignant neoplasm of cardia; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; K21.9 - Gastro-esophageal reflux disease without esophagitis; D50.9 - Iron deficiency anemia, unspecified; R63.4 - Abnormal weight loss"
CINJ OP INFUSION,40203,"Stephenson, Ryan D, DO",4/3/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,4/3/2025,Active,Metastatic castration-resistant adenocarcinoma of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; C77.5 - Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes; G30.9 - Alzheimer's disease, unspecified; C79.51 - Secondary malignant neoplasm of bone; Z19.2 - Hormone resistant malignancy status"
CMC OP INFUSION,23484,"Samuel, David, MD",4/1/2025,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/1/2025,Active,Endometrial cancer (CMS/HCC),
MSC OP INFUSION,90485,"Cohen, Seth D, MD",10/11/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,9/27/2023,Active,,
CMC OP INFUSION,45206,"Taff, Jessica, MD",3/29/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,3/20/2024,Inactive,,
NBR CINJ OP INFUSION,73754,"Shah, Mansi R, MD",1/16/2025,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,1/15/2025,Active,,
NBR 4N ONCOLOGY,73754,"Shah, Mansi R, MD",4/8/2025,Pomalidomide 28 Day Cycles- Multiple Myeloma,Maintenance,4/8/2025,Inactive,Multiple myeloma (CMS/HCC),"C90.01 - Multiple myeloma in remission; Z79.899 - Other long term (current) drug therapy; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z88.2 - Allergy status to sulfonamides; Z11.59 - Encounter for screening for other viral diseases; G89.3 - Neoplasm related pain (acute) (chronic); G89.29 - Other chronic pain; R53.81 - Other malaise; K59.03 - Drug induced constipation; C90.00 - Multiple myeloma not having achieved remission; M48.00 - Spinal stenosis, site unspecified; E04.9 - Nontoxic goiter, unspecified; M80.08XA - Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture; H53.142 - Visual discomfort, left eye; K21.9 - Gastro-esophageal reflux disease without esophagitis; D64.9 - Anemia, unspecified; G47.00 - Insomnia, unspecified; R22.43 - Localized swelling, mass and lump, lower limb, bilateral; M79.18 - Myalgia, other site"
NBR 4N ONCOLOGY,73754,"Shah, Mansi R, MD",4/8/2025,Pomalidomide 28 Day Cycles- Multiple Myeloma,Maintenance,4/8/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,34722,"Wagmiller, Jennifer Ann, MD",6/12/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,6/11/2023,Inactive,,
CBMC OP INFUSION 2FL,34722,"Wagmiller, Jennifer Ann, MD",8/20/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,8/19/2024,Inactive,,
CINJ OP INFUSION,42236,"Boland, Patrick M, MD",2/24/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,2/16/2023,Inactive,,
CINJ OP INFUSION,42236,"Boland, Patrick M, MD",7/7/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,7/7/2023,Inactive,,
CBMC OP INFUSION 1FL,5960,"Meelheim, Brooke A, DO",4/28/2025,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/28/2025,Active,"Ovarian cancer (CMS/HCC)
Granulosa cell carcinoma of left ovary (CMS/HCC)",
CBMC OP INFUSION 1FL,83691,"Meelheim, Brooke A, DO",9/11/2024,PACLitaxel / CARBOplatin (AUC 5) / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/10/2024,Active,,
CBMC OP INFUSION 2FL,57125,"Brown, Andrew Bennett, MD",11/10/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/9/2023,Active,,
NBI OP INFUSION,75438,"Shah, Shailja S, MD",3/5/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,3/4/2024,Inactive,,
NBI OP INFUSION,75438,"Shah, Shailja S, MD",10/1/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/1/2024,Active,,
CBMC OP INFUSION 2FL,24610,"Leitner, Stuart P, MD",8/1/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,8/1/2023,Inactive,,
CBMC OP INFUSION 2FL,79509,"Brown, Andrew Bennett, MD",10/30/2023,"Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/29/2023,Inactive,,
SOM OUTPT INFUSION,28310,"Toomey, Kathleen C, MD",4/18/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/18/2025,Inactive,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",C50.811 - Malignant neoplasm of overlapping sites of right female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; Z51.89 - Encounter for other specified aftercare; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,41291,"Weiss, Sarah, MD",1/24/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,1/23/2024,Inactive,,
CINJ OP INFUSION,41291,"Weiss, Sarah, MD",4/8/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,4/5/2024,Active,,
CMC OP INFUSION,87856,"Cohen, Seth D, MD",5/3/2023,Bevacizumab 28 Day Cycles - CNS,,5/3/2023,Inactive,,
CINJ OP INFUSION,27764,"Boland, Patrick M, MD",10/25/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/23/2024,Active,,
CINJ OP INFUSION,27764,"Boland, Patrick M, MD",2/28/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,2/28/2025,Active,Malignant neoplasm of rectum (CMS/HCC),"C20 - Malignant neoplasm of rectum; D50.9 - Iron deficiency anemia, unspecified"
JCMC CP INFUSION,60907,"Sekhri, Arunabh, MD",4/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/31/2024,Inactive,,
JCMC CP INFUSION,60907,"Sekhri, Arunabh, MD",11/13/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/3/2024,Active,,
NBR CINJ OP INFUSION,51857,"Shah, Mansi R, MD",3/4/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/4/2025,Active,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma, remission status unspecified (CMS/HCC)"
JCMC CP INFUSION,26515,"Sekhri, Arunabh, MD",1/22/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,1/21/2024,Inactive,,
NBR CINJ OP INFUSION,21236,"Zayac, Adam, MD",7/11/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,7/8/2024,Inactive,,
MSC OP INFUSION,11441,"Pompa, Tiffany Ann, MD",9/19/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,9/18/2024,Active,,
CBMC OP INFUSION 2FL,2505,"Scoppetuolo, Michael, MD",3/26/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/25/2024,Inactive,,
CBMC OP INFUSION 2FL,2505,"Scoppetuolo, Michael, MD",3/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,3/25/2024,Inactive,,
CBMC OP INFUSION 2FL,2505,"Wagmiller, Jennifer Ann, MD",6/3/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Neoadjuvant,5/29/2024,Active,,
CINJ OP INFUSION,291,"Boland, Patrick M, MD",5/6/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/6/2025,Active,Primary pancreatic adenocarcinoma (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; Z90.410 - Acquired total absence of pancreas"
MMC OP VP INFUSION,87103,"Cohen, Seth D, MD",1/25/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Third Line,1/24/2023,Inactive,,
MMC OP VP INFUSION,87103,"Cohen, Seth D, MD",8/21/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,8/18/2024,Active,,
CBMC OP INFUSION 2FL,18063,"Brown, Andrew Bennett, MD",11/6/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/30/2023,Inactive,,
CBMC OP INFUSION 2FL,18063,"Brown, Andrew Bennett, MD",5/2/2025,Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel weekly 21 Day Cycles - Breast,Neoadjuvant,5/2/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,12240,"Scoppetuolo, Michael, MD",3/4/2024,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,_1. First Line,3/3/2024,Inactive,,
CBMC OP INFUSION 2FL,12240,"Scoppetuolo, Michael, MD",4/9/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_2. Second Line,4/8/2024,Active,,
CBMC OP INFUSION 2FL,12240,"Scoppetuolo, Michael, MD",7/10/2024,CINJ 042102 Block C Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer,_1. First Line,7/9/2024,Active,,
CBMC OP INFUSION 2FL,12240,"Scoppetuolo, Michael, MD",8/13/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,8/13/2024,Active,,
HAM OP INFUSION,99492,"Yogarajah, Meera, MD",9/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/8/2024,Active,,
NBI OP INFUSION,47745,"Jacoby, Sari H, MD",3/19/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,10782,"Wagmiller, Jennifer Ann, MD",11/1/2023,Dostarlimab-gxly 42 Day Cycles- Gynecologic Cancers,Neoadjuvant,10/31/2023,Active,,
NBI OP INFUSION,37949,"Shah, Maya M, MD",1/12/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,1/11/2024,Active,,
MMC OP INFUSION,59625,"Lee, Patrick C, MD",11/8/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/19/2023,Inactive,,
MMC OP VP INFUSION,59625,"Lee, Patrick C, MD",10/10/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/10/2024,Active,,
NBR CINJ OP INFUSION,80511,"Eltoukhy, Hussam, MD",10/6/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,First Line,10/5/2023,Inactive,,
CBMC OP INFUSION 2FL,25041,"Wagmiller, Jennifer Ann, MD",2/24/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,2/2/2025,Active,Cervical cancer (CMS/HCC),
NBR CINJ OP INFUSION,73487,"Evens, Andrew M, DO",8/30/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,8/30/2023,Inactive,,
NBR 5N ONCOLOGY,73487,"Evens, Andrew M, DO",8/31/2023,Dose-Adjusted R-POCH (DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,8/31/2023,Inactive,,
CINJ OP INFUSION,65078,"Groisberg, Roman, MD",3/3/2023,Gemcitabine 21 Day Cycles - Sarcoma,,3/2/2023,Inactive,,
CINJ OP INFUSION,81320,"Patel, Eshan, MD",1/20/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,1/19/2023,Inactive,,
CINJ OP INFUSION,81320,"Patel, Eshan, MD",4/14/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,4/13/2023,Inactive,,
CINJ OP INFUSION,47440,"George, Mridula A, MD",6/21/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,5/24/2023,Active,,
CINJ OP INFUSION,47440,"George, Mridula A, MD",6/21/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,,6/14/2023,Inactive,,
CINJ OP INFUSION,47440,"George, Mridula A, MD",9/29/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,9/19/2023,Inactive,,
MSC OP INFUSION,68846,"Cohen, Seth D, MD",3/8/2023,Pertuzumab / Trastuzumab / Abraxane weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,,3/7/2023,Inactive,,
MSC OP INFUSION,68846,"Cohen, Seth D, MD",5/30/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,First Line,5/29/2023,Inactive,,
MMC OP VP INFUSION,68846,"Cohen, Seth D, MD",7/6/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,,7/5/2023,Active,Colon adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,37830,"Toppmeyer, Deborah L, MD",4/6/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,4/5/2023,Inactive,,
CINJ OP INFUSION,37830,"Toppmeyer, Deborah L, MD",8/31/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,8/30/2023,Active,,
CINJ OP INFUSION,49349,"Stephenson, Ruth D, DO",2/27/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,Second Line,2/21/2023,Inactive,,
CINJ OP INFUSION,49349,"Berim, Lyudmyla, MD",7/19/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,7/18/2024,Inactive,,
CINJ OP INFUSION,49349,"Stephenson, Ruth D, DO",9/13/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,9/12/2024,Active,,
NBR 4N ONCOLOGY,65326,"Palmisiano, Neil David, MD",12/5/2023,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),Induction,12/4/2023,Inactive,,
NBR CINJ OP INFUSION,65326,"Palmisiano, Neil David, MD",1/22/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,1/17/2024,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Light chain nephropathy due to multiple myeloma (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
NBR 4N ONCOLOGY,82816,"Braunschweig, Ira, MD",6/22/2023,BMT Autologous Carmustine / Thiotepa,,6/22/2023,Inactive,,
MMC OP VP INFUSION,78782,"Meghal, Trishala, MD",12/20/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,12/12/2023,Inactive,,
MMC OP INFUSION,78782,"Meghal, Trishala, MD",3/20/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/19/2024,Inactive,,
SOM OUTPT INFUSION,20766,"Toomey, Kathleen C, MD",5/10/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,5/5/2024,Active,,
CINJ OP INFUSION,57062,"Saraiya, Biren P, MD",6/6/2023,Relugolix 30 day Cycles - Prostate,Maintenance,6/6/2023,Active,Diffuse large B-cell lymphoma of lymph nodes of head (CMS/HCC),
CINJ OP INFUSION,57062,"Saraiya, Biren P, MD",6/27/2023,Abiraterone (Low Dose) / PredniSONE  90 Day Cycles - Prostate,First Line,6/27/2023,Active,,
NBI OP INFUSION,83166,"Shah, Maya M, MD",6/1/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,6/1/2023,Active,,
NBI OP INFUSION,83166,"Shah, Maya M, MD",6/1/2023,Tamoxifen (Daily) 28 Day Cycles - Breast,Adjuvant,6/1/2023,Active,Langerhan's cell histiocytosis (CMS/HCC),
NBI OP INFUSION,10964,"Cheng, Yan Ho, MD",2/15/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,2/13/2024,Inactive,,
CBMC OP INFUSION 2FL,70497,"Scoppetuolo, Michael, MD",11/10/2023,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Adjuvant",_3. Third Line,11/9/2023,Inactive,,
CBMC OP INFUSION 2FL,70497,"Scoppetuolo, Michael, MD",8/2/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,8/1/2024,Inactive,,
CBMC OP INFUSION 2FL,70497,"Scoppetuolo, Michael, MD",10/25/2024,"VinORELBine D1, D8, D15, D22  28 Day Cycles- Non-Small Cell Lung Cancer",_4. Fourth Line,9/26/2024,Inactive,,
CBMC OP INFUSION 2FL,87848,"Brown, Andrew Bennett, MD",12/12/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Consolidation,12/10/2023,Inactive,,
JCMC CP INFUSION,8843,"Sekhri, Arunabh, MD",5/17/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,4/30/2023,Inactive,,
JCMC CP INFUSION,8843,"Sekhri, Arunabh, MD",9/15/2023,Dabrafenib/Trametinib 28 Day Cycles- Non-Small Cell Lung Cancer,Second Line,9/15/2023,Inactive,,
JCMC CP INFUSION,8843,"Sekhri, Arunabh, MD",7/22/2024,Gemcitabine/CARBOplatin 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,7/21/2024,Inactive,,
CBMC 2W ONCOLOGY,14226,"Grossman, I Robert, MD",11/5/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/4/2024,Active,"Cancer of skin, squamous cell
Regional lymph node metastasis present (CMS/HCC)",
CBMC 2W ONCOLOGY,82589,"Grossman, I Robert, MD",12/4/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_1. First Line,12/3/2024,Active,,
CBMC OP INFUSION 2FL,82589,"Grossman, I Robert, MD",1/6/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Supportive Care,12/30/2024,Active,,
NBR CINJ OP INFUSION,82589,"Egini, Ogechukwu, MD",4/12/2025,BMT Allogeneic TBF + Post Cy,_2. Second Line,4/11/2025,Active,Adult T-cell lymphoma (CMS/HCC),C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission; Z01.818 - Encounter for other preprocedural examination
CBMC OP INFUSION 2FL,3148,"Brown, Andrew Bennett, MD",11/2/2023,"Gemcitabine D1, D8  21 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,3148,"Brown, Andrew Bennett, MD",11/16/2023,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Pancreas Cancer",_2. Second Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,27719,"McKenna, Marshall, MD",1/6/2025,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,1/1/2025,Active,,
CBMC OP INFUSION 2FL,27719,"McKenna, Marshall, MD",5/28/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,5/28/2025,Inactive,Multiple myeloma (CMS/HCC),
NBR CINJ OP INFUSION,27719,"Shah, Mansi R, MD",5/28/2025,Infusion of Carvykti Multiple Myeloma,_5. Fifth Line,5/12/2025,Active,Multiple myeloma (CMS/HCC),
CBMC OP INFUSION 2FL,27719,"McKenna, Marshall, MD",5/12/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_3. Third Line,5/12/2025,Inactive,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,34302,"Goel, Sanjay, MD",12/11/2024,CINJ 052310 Pharmacodynamic Cohort AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,12/11/2024,Active,,
NBR CINJ OP INFUSION,16254,"Evens, Andrew M, DO",2/1/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,1/31/2023,Inactive,,
CINJ OP INFUSION,22620,"Girda, Eugenia, MD",8/15/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,,8/14/2023,Inactive,,
NBI OP INFUSION,43092,"Cheng, Yan Ho, MD",11/25/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,11/25/2024,Active,,
NBR CINJ OP INFUSION,92422,"Shah, Mansi R, MD",8/22/2023,CINJ 012301 Inpatient Arm C Daratumumab / DC talquetamab due to toxicity 28 Day Cycles Research- Multiple Myeloma,_2. Second Line,8/21/2023,Active,,
NBR CINJ OP INFUSION,92422,"Shah, Mansi R, MD",10/19/2023,Home Infusion IVIG thru Qualitas,Maintenance,10/19/2023,Inactive,,
CBMC OP INFUSION 2FL,3754,"Dave, Manish, MD",5/15/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/15/2023,Inactive,,
CBMC OP INFUSION 2FL,3754,"McKenna, Marshall, MD",11/19/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,11/18/2024,Active,,
NBI VALERIE FND HEMONC,82773,"Rao, Harini, MD",3/5/2025,PEDS AEWS1031 Regimen A Induction & Consolidation,_2. Second Line,3/5/2025,Active,Osteosarcoma in relapse (CMS/HCC),
NBI VALERIE FND HEMONC,5391,"Bhatla, Teena, MD",10/5/2023,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,Maintenance,10/5/2023,Active,,
NBI VALERIE FND HEMONC,5391,"Bhatla, Teena, MD",10/5/2023,AALL1731 Non-DS SR (Fav or Avg) B-ALL - Maintenance,Maintenance,10/4/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,51707,"Moerdler, Scott, MD",1/28/2023,per AAML1331 Std Risk; Tretinoin (ATRA) / Arsenic- Acute Promyelocytic Leukemia (Induction),,1/27/2023,Inactive,,
CINJ PEDS HEMONC ,51707,"Moerdler, Scott, MD",3/13/2023,per AAML1331 STD Risk Tretinoin Consolidation - Acute Promyelocytic Leukemia,,3/12/2023,Inactive,,
CINJ PEDS HEMONC ,51707,"Moerdler, Scott, MD",3/20/2023,PEDS AAML1331 Standard Risk APL Consolidation ,First Line,3/20/2023,Active,,
CINJ PEDS HEMONC ,51707,"Moerdler, Scott, MD",9/4/2023,PEDS AAML1331 Standard Risk APL Consolidation ,,9/4/2023,Inactive,,
CINJ PEDS HEMONC ,51707,"Moerdler, Scott, MD",10/30/2023,PEDS AAML1331 Standard Risk APL Consolidation ,First Line,10/30/2023,Inactive,,
SOM OUTPT INFUSION,60919,"Yin, Faye, MD",3/6/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Vaginal,First Line,3/3/2023,Inactive,,
CBMC OP INFUSION 2FL,14299,"Wagmiller, Jennifer Ann, MD",4/22/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,4/14/2024,Inactive,,
CINJ OP INFUSION,86208,"Packiam, Vignesh, MD",4/12/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,4/11/2024,Inactive,,
CINJ OP INFUSION,86208,"Packiam, Vignesh, MD",8/6/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,8/4/2024,Inactive,,
CINJ OP INFUSION,31263,"Omene, Coral Oghenerukevwe, MD",10/15/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,10/14/2024,Inactive,,
CINJ OP INFUSION,31263,"Omene, Coral Oghenerukevwe, MD",11/26/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,11/11/2024,Inactive,,
CINJ OP INFUSION,31263,"Omene, Coral Oghenerukevwe, MD",12/16/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,Adjuvant,12/15/2024,Active,,
NBI OP INFUSION,39859,"Anderson, Patrick S, MD",1/16/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Carcino sarcoma of the endometrium,_1. First Line,1/15/2025,Active,,
HAM OP INFUSION,92424,"Yogarajah, Meera, MD",12/9/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/9/2024,Active,,
CBMC OP INFUSION 2FL,46732,"Dave, Manish, MD",9/21/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,9/21/2023,Inactive,,
MMC OP VP INFUSION,35998,"Cohen, Seth D, MD",4/15/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/7/2024,Inactive,,
MMC OP VP INFUSION,35998,"Cohen, Seth D, MD",7/10/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/9/2024,Active,,
CINJ OP INFUSION,7446,"Berim, Lyudmyla, MD",1/13/2023,mFOLFOX6 + Nivolumab 14 Day Cycles- Gastric Cancer,,1/11/2023,Inactive,,
CINJ OP INFUSION,7446,"Berim, Lyudmyla, MD",2/23/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/21/2023,Inactive,,
CINJ OP INFUSION,7446,"Berim, Lyudmyla, MD",3/28/2023,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",,3/23/2023,Inactive,,
CINJ OP INFUSION,7446,"Berim, Lyudmyla, MD",5/24/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,,5/22/2023,Inactive,,
CBMC OP INFUSION 2FL,63912,"Wagmiller, Jennifer Ann, MD",10/5/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,10/4/2023,Inactive,,
CBMC 2W ONCOLOGY,63912,"Wagmiller, Jennifer Ann, MD",1/19/2024,Albumin-Bound PACLitaxel / CARBOplatin 28 Day Cycles - Melanoma,_3. Third Line,1/17/2024,Inactive,,
CBMC OP INFUSION 2FL,63912,"Wagmiller, Jennifer Ann, MD",2/27/2024,Abraxane d1 8 15 cisplatin d 1,_3. Third Line,2/27/2024,Inactive,,
CBMC OP INFUSION 2FL,63912,"Wagmiller, Jennifer Ann, MD",5/20/2024,Topotecan 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,5/19/2024,Inactive,,
CBMC OP INFUSION 2FL,53102,"Wagmiller, Jennifer Ann, MD",11/17/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,53102,"Wagmiller, Jennifer Ann, MD",3/28/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_3. Third Line,3/27/2024,Active,,
CBMC OP INFUSION 2FL,53102,"Wagmiller, Jennifer Ann, MD",7/12/2024,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_3. Third Line,7/11/2024,Inactive,,
CBMC OP INFUSION 2FL,62557,"Scoppetuolo, Michael, MD",4/22/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/25/2024,Inactive,,
SOM OUTPT INFUSION,11871,"Toomey, Kathleen C, MD",3/16/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",Neoadjuvant,3/13/2023,Inactive,,
SOM OUTPT INFUSION,11871,"Toomey, Kathleen C, MD",6/8/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,6/7/2023,Inactive,,
CINJ OP INFUSION,91986,"Toppmeyer, Deborah L, MD",5/30/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,5/30/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+); Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants
CINJ OP INFUSION,20866,"Saraiya, Biren P, MD",4/11/2024,CINJ 082101 (NRG-GU009) ARM 1 Androgen Deprivation Therapy 3 Month Cycles (84 Days) Research- Prostate Cancer,Adjuvant,4/1/2024,Active,,
MMC OP VP INFUSION,86732,"Cohen, Seth D, MD",5/15/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma started Griffin DRVd 1/18/22,First Line,5/7/2023,Active,,
MMC OP INFUSION,95557,"Cohen, Seth D, MD",4/30/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_2. Second Line,4/30/2025,Active,"Multiple myeloma (CMS/HCC)
Smoldering multiple myeloma",
CMC OP INFUSION,45598,"Pompa, Tiffany Ann, MD",8/15/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,8/14/2024,Active,,
CINJ OP INFUSION,37616,"Stephenson, Ryan D, DO",4/25/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,4/25/2025,Active,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),"C61, Z19.1 - Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC)"
CBMC 2W ONCOLOGY,94003,"Dharmapuri, Sirish, MD",10/2/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,9/30/2024,Inactive,,
CINJ OP INFUSION,31068,"Haigentz, Missak, MD",11/8/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_4. Fourth Line,11/8/2024,Active,,
CMC OP INFUSION,93161,"Taff, Jessica, MD",5/28/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,5/28/2025,Active,Adenocarcinoma of left lung (CMS/HCC),
CMC OP INFUSION,2700,"Talwar, Sumit, MD",9/8/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,8/31/2023,Inactive,,
CMC OP INFUSION,2700,"Talwar, Sumit, MD",1/12/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,1/12/2024,Active,,
CMC OP INFUSION,57708,"Tang, Horace, MD",11/1/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,11/1/2023,Inactive,,
CINJ OP INFUSION,56819,"Saraiya, Biren P, MD",3/21/2023,CINJ 081910 (A031704) Induction Therapy Nivolumab / Ipilimumab 21 Day Cycles Research- Renal Cell Carcinoma,First Line,3/20/2023,Inactive,,
CINJ OP INFUSION,56819,"Saraiya, Biren P, MD",6/20/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,6/20/2023,Inactive,,
CINJ OP INFUSION,56819,"Saraiya, Biren P, MD",6/20/2023,CINJ 081910 (A031704) ARM B Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Carcinoma,Maintenance,6/19/2023,Inactive,,
CINJ OP INFUSION,56819,"Saraiya, Biren P, MD",8/13/2024,Everolimus / Lenvatinib 30 Day Cycles - Kidney,_2. Second Line,8/12/2024,Active,,
CINJ OP INFUSION,56819,"Saraiya, Biren P, MD",1/24/2025,Belzutifan 28 Day Cycles,_3. Third Line,1/24/2025,Active,,
CINJ OP INFUSION,56819,"Goel, Sanjay, MD",2/12/2025,CINJ 052401 Part A Enrichment GIM-122,_3. Third Line,2/12/2025,Active,Primary malignant neoplasm of right kidney with metastasis from kidney to other site (CMS/HCC),
CMC OP INFUSION,50020,"Pompa, Tiffany Ann, MD",10/24/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,10/22/2024,Active,,
TRMC TCCC OP INFUSION,86302,"Salerno, Vincent E, MD",5/20/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/14/2025,Active,Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC),"C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes"
NBI OP INFUSION,99006,"Cheng, Yan Ho, MD",8/27/2024,R-Pola-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,8/26/2024,Inactive,,
NBR 5N ONCOLOGY,99006,"Tiger, Yun Kyoung, MD",2/8/2025,Pola-R-ICE (Polatuzumab/Rituximab/Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,2/6/2025,Active,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs,"B19.10 - Unspecified viral hepatitis B without hepatic coma; C83.37 - Diffuse large b-cell lymphoma, spleen; D69.6 - Thrombocytopenia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; D63.0 - Anemia in neoplastic disease; E78.00 - Pure hypercholesterolemia, unspecified; I10 - Essential (primary) hypertension; F32.9 - Major depressive disorder, single episode, unspecified; F41.9 - Anxiety disorder, unspecified; M10.9 - Gout, unspecified; Z80.42 - Family history of malignant neoplasm of prostate; Z82.41 - Family history of sudden cardiac death; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states"
NBR 5N MED-SURG OVRF,30590,"Alexander, Henry Richard, MD",6/15/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Second Line,6/15/2023,Inactive,,
HAM OP INFUSION,6786,"Gendy, Mina, DO",2/12/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/10/2025,Active,Uterine malignancy (CMS/HCC),
SOM OUTPT INFUSION,82794,"Toomey, Kathleen C, MD",2/14/2024,PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles,Neoadjuvant,1/30/2024,Inactive,,
SOM OUTPT INFUSION,82794,"Toomey, Kathleen C, MD",12/27/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,12/27/2024,Active,,
CMC OP INFUSION,55276,"Tang, Horace, MD",4/4/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,4/4/2023,Inactive,,
CMC OP INFUSION,55276,"Tang, Horace, MD",4/24/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Second Line,4/24/2023,Inactive,,
CINJ PEDS HEMONC ,68597,"Botwinick, Marissa, DO",12/5/2024,PEDS AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,11/25/2024,Active,,
CMC OP INFUSION,3850,"Tang, Horace, MD",9/11/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,,9/11/2023,Inactive,,
CINJ OP INFUSION,30380,"Omene, Coral Oghenerukevwe, MD",8/31/2023,Palbociclib 35 Day Cycles - Breast,,8/31/2023,Inactive,,
MMC OP VP INFUSION,22076,"Cohen, Seth D, MD",11/8/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,11/1/2024,Active,,
NBR 4N ONCOLOGY,15746,"Evens, Andrew M, DO",6/14/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,6/14/2023,Inactive,,
NBR CINJ OP INFUSION,15746,"Evens, Andrew M, DO",8/9/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,15746,"Evens, Andrew M, DO",9/6/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,8/22/2023,Inactive,,
CMC OP INFUSION,62563,"Taff, Jessica, MD",12/19/2024,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,12/18/2024,Active,,
CMC OP INFUSION,62563,"Taff, Jessica, MD",4/23/2025,Atezolizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/23/2025,Active,"Non-small cell carcinoma of left lung (CMS/HCC)
Hypothyroidism, unspecified type",
CMC OP INFUSION,8942,"Pompa, Tiffany Ann, MD",9/26/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,9/25/2024,Active,,
CMC OP INFUSION,8942,"Pompa, Tiffany Ann, MD",4/9/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,4/9/2025,Active,"Carcinoma of right ureter (CMS/HCC)
Malignant neoplasm of right ureter (CMS/HCC)",
CMC OP INFUSION,86178,"Pompa, Tiffany Ann, MD",11/26/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,11/25/2024,Active,,
CMC OP INFUSION,81375,"Pompa, Tiffany Ann, MD",3/11/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,Maintenance,3/11/2025,Inactive,Cancer of right breast (CMS/HCC),
CMC OP INFUSION,81375,"Pompa, Tiffany Ann, MD",3/11/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,3/11/2025,Active,Cancer of right breast (CMS/HCC),
CMC OP INFUSION,81375,"Pompa, Tiffany Ann, MD",3/4/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Neoadjuvant,3/4/2025,Future,Cancer of right breast (CMS/HCC),
CINJ OP INFUSION,48409,"Muralikrishnan, Sivraj, MD",1/17/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/16/2025,Inactive,Metastatic squamous cell carcinoma to head and neck (CMS/HCC),
CINJ OP INFUSION,40691,"Mayer, Tina M, MD",7/18/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,7/14/2024,Inactive,,
CINJ OP INFUSION,55833,"Toppmeyer, Deborah L, MD",7/1/2024,FAC in Pregnancy  (Fluorouracil / Doxorubicin / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,6/30/2024,Inactive,,
CINJ OP INFUSION,55833,"Toppmeyer, Deborah L, MD",11/4/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,11/3/2024,Active,,
CINJ OP INFUSION,81819,"Weiss, Sarah, MD",1/26/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,1/25/2023,Inactive,,
CINJ OP INFUSION,79383,"Weiss, Sarah, MD",2/13/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,2/5/2023,Inactive,,
NBR CINJ OP INFUSION,74244,"Tiger, Yun Kyoung, MD",10/24/2023,MT-R (High-Dose Methotrexate / Temozolomide EVEN CYCLES / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,10/23/2023,Inactive,,
NBR 5N ONCOLOGY,74244,"Tiger, Yun Kyoung, MD",12/20/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_2. Second Line,12/20/2023,Inactive,,
NBR 5N ONCOLOGY,74244,"Tiger, Yun Kyoung, MD",12/22/2023,RiTUXimab / Ibrutinib 28 Day Cycles -PCNSL,_2. Second Line,12/21/2023,Inactive,,
HAM OP INFUSION,36527,"Yogarajah, Meera, MD",2/7/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,1/22/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,69240,"Radovich, Delia, MD",11/7/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/6/2023,Active,,
CINJ OP INFUSION,17767,"Saraiya, Biren P, MD",2/6/2024,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Penile Cancer (Neoadjuvant or Adjuvant),Adjuvant,2/6/2024,Inactive,,
CINJ OP INFUSION,17767,"Saraiya, Biren P, MD",9/24/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Urethral Squamous,Adjuvant,9/8/2024,Inactive,,
CINJ OP INFUSION,17767,"Saraiya, Biren P, MD",10/8/2024,Pembrolizumab 42 Day Cycles - Urethral Squamous Cell Cancer,_2. Second Line,10/1/2024,Inactive,,
CINJ OP INFUSION,68689,"Mayer, Tina M, MD",6/6/2023,Enzalutamide 28 Day Cycles - Prostate,,6/6/2023,Inactive,,
NBI VALERIE FND HEMONC,54250,"Rao, Harini, MD",3/18/2024,Bevacizumab( Zirabev) & Nivolumab Q21 Day Cycles - CNS,_1. First Line,3/18/2024,Active,,
NBI OP INFUSION,68078,"Anderson, Patrick S, MD",11/3/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles Followed by 4 cycles of 21day cycles of taxol and carboplatin - Non-Small Cell Lung Cancer,_1. First Line,11/2/2023,Inactive,,
NBI OP INFUSION,68078,"Anderson, Patrick S, MD",3/28/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,3/13/2024,Inactive,,
NBI OP INFUSION,68078,"Anderson, Patrick S, MD",5/30/2024,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Advanced Endometrial  Cancer,_2. Second Line,5/22/2024,Active,,
CINJ OP INFUSION,23328,"Omene, Coral Oghenerukevwe, MD",4/17/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,4/17/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,23328,"George, Mridula A, MD",3/26/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/26/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor negative (CMS/HCC)",C50.911 - Malignant neoplasm of unspecified site of right female breast; D05.11 - Intraductal carcinoma in situ of right breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,56997,"Jang, Thomas L, MD",2/11/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,2/10/2025,Active,Urothelial cancer (CMS/HCC),"Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm; Z85.51 - Personal history of malignant neoplasm of bladder; Z98.890 - Other specified postprocedural states; F41.9 - Anxiety disorder, unspecified; I10 - Essential (primary) hypertension; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,24493,"Mayer, Tina M, MD",3/28/2024,CINJ 082201 (NRG-GU010) ARM 3 Androgen Deprivation Therapy 6 Months Cycle (180 Days) Research- Prostate Cancer,_1. First Line,2/25/2024,Active,,
MMC OP VP INFUSION,36729,"Cohen, Seth D, MD",6/14/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,6/13/2024,Active,,
MMC OP VP INFUSION,11739,"Cohen, Seth D, MD",5/21/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/21/2025,Active,"Pancreatic cancer metastasized to intra-abdominal lymph node (CMS/HCC)
End stage renal disease (CMS/HCC)",
CINJ OP INFUSION,37034,"Saraiya, Biren P, MD",3/24/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,3/24/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
NBR 4N ONCOLOGY,18010,"Palmisiano, Neil David, MD",1/23/2023,Cytarabine / IDArubicin / Midostaurin (7 + 3) - Acute Myeloid Leukemia (Induction),,1/23/2023,Inactive,,
NBR CINJ OP INFUSION,18010,"Palmisiano, Neil David, MD",3/29/2023,HiDAC-123 + Midostaurin (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,3/29/2023,Inactive,,
NBR 4N BMTU/IMCU,18010,"Assal, Amer, MD",6/7/2023,BMT Allogeneic TBF + Post Cy ,,6/7/2023,Inactive,,
NBR CINJ OP INFUSION,18010,"Assal, Amer, MD",10/23/2023,Cytarabine alternating with Methotrexate Intrathecal (IT) Monthly,Adjuvant,2/1/2024,Active,,
NBR CINJ OP INFUSION,18010,"Assal, Amer, MD",11/6/2023,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,11/5/2023,Inactive,,
NBR CINJ OP INFUSION,18010,"Assal, Amer, MD",11/6/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,11/3/2023,Inactive,,
NBR CINJ OP INFUSION,18010,"Palmisiano, Neil David, MD",2/17/2025,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,Consolidation,2/17/2025,Active,Acute myeloid leukemia in remission (CMS/HCC),
CMC OP INFUSION,74578,"Eltoukhy, Hussam, MD",5/8/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/7/2023,Active,,
CINJ OP INFUSION,36215,"Hochster, Howard S, MD",1/25/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,1/24/2023,Inactive,,
CINJ OP INFUSION,36215,"Hochster, Howard S, MD",8/2/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,7/28/2023,Inactive,,
CINJ OP INFUSION,36215,"Hochster, Howard S, MD",4/10/2024,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,3/13/2024,Inactive,,
CINJ OP INFUSION,36215,"Hochster, Howard S, MD",6/19/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/18/2024,Active,,
CINJ OP INFUSION,9611,"Boland, Patrick M, MD",3/15/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/14/2024,Inactive,,
JCMC CP INFUSION,26222,"Cruz, Allan Louie E, MD",5/23/2023,PACLitaxel / CARBOplatin / Pembrolizumab 21 Day Cycles - Uterine,First Line,5/23/2023,Inactive,,
JCMC CP INFUSION,26222,"Cruz, Allan Louie E, MD",8/9/2023,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,,8/8/2023,Inactive,,
JCMC CP INFUSION,26222,"Cruz, Allan Louie E, MD",8/9/2023,Topotecan 28 Day Cycles - Uterine,Second Line,8/9/2023,Inactive,,
CINJ OP INFUSION,19403,"Weiss, Sarah, MD",4/12/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,4/9/2023,Inactive,,
CINJ OP INFUSION,19403,"Weiss, Sarah, MD",8/2/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,Second Line,7/28/2023,Inactive,,
CINJ OP INFUSION,19403,"Weiss, Sarah, MD",12/11/2023,CINJ 092205 Lymphodepleting Chemotherapy / LYL845 Cell Treatment Research- Melanoma and Selected Solid Tumors,_3. Third Line,12/11/2023,Inactive,,
CINJ OP INFUSION,19403,"Weiss, Sarah, MD",6/28/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_5. Fifth Line,6/27/2024,Inactive,,
MMC OP VP INFUSION,36899,"Lee, Patrick C, MD",2/28/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,2/20/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,36899,"Lee, Patrick C, MD",3/30/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,3/30/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,55029,"Jang, Thomas L, MD",10/24/2024,BCG Induction (TICE) 42 Day Cycle,Adjuvant,10/23/2024,Inactive,,
CINJ OP INFUSION,55029,"Jang, Thomas L, MD",2/20/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,2/19/2025,Active,Bladder cancer (CMS/HCC),"N30.90 - Cystitis, unspecified without hematuria; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z85.51 - Personal history of malignant neoplasm of bladder; Z87.442 - Personal history of urinary calculi; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I25.2 - Old myocardial infarction; E78.5 - Hyperlipidemia, unspecified; E03.9 - Hypothyroidism, unspecified; M10.9 - Gout, unspecified; M19.012 - Primary osteoarthritis, left shoulder; Z95.5 - Presence of coronary angioplasty implant and graft; Z98.890 - Other specified postprocedural states; Z88.1 - Allergy status to other antibiotic agents; Z88.0 - Allergy status to penicillin; Z88.5 - Allergy status to narcotic agent; Z91.048 - Other nonmedicinal substance allergy status; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,22774,"Aikins, James K, MD",8/16/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,8/8/2024,Inactive,,
NBR CINJ OP INFUSION,11182,"Shah, Mansi R, MD",4/4/2023,CINJ 011910 Loratidine / Placebo 15 Day Cycle Research- Multiple Myeloma,,3/21/2023,Inactive,,
CMC OP INFUSION,19292,"Tang, Horace, MD",7/21/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,7/21/2023,Inactive,,
CMC OP INFUSION,19292,"Cohen, Seth D, MD",8/9/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/8/2023,Inactive,,
CMC OP INFUSION,19292,"Cohen, Seth D, MD",6/27/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin 14 Day Cycles- Gastrointestinal Cancers,Maintenance,6/27/2024,Inactive,,
CMC OP INFUSION,19292,"Cohen, Seth D, MD",8/7/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/6/2024,Inactive,,
TRMC TCCC OP INFUSION,81279,"Capo, Gerardo, MD",10/3/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/2/2024,Active,,
TRMC TCCC OP INFUSION,81279,"Capo, Gerardo, MD",10/7/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,10/2/2024,Inactive,,
TRMC TCCC OP INFUSION,81279,"Capo, Gerardo, MD",10/30/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/29/2024,Inactive,,
MMC OP INFUSION,98511,"Meghal, Trishala, MD",8/4/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,First Line,8/1/2023,Inactive,,
MMC OP INFUSION,98511,"Meghal, Trishala, MD",12/1/2023,EriBULin 21 Day Cycles - Breast,_2. Second Line,11/30/2023,Inactive,,
MMC OP VP INFUSION,98511,"Meghal, Trishala, MD",1/19/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/18/2024,Inactive,,
MMC OP VP INFUSION,7240,"Cohen, Seth D, MD",1/30/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,1/28/2025,Active,"Squamous cell carcinoma of skin of left upper limb, including shoulder",
NBR 5N ONCOLOGY,42122,"Berim, Lyudmyla, MD",4/5/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,4/4/2025,Inactive,"Mesenteric mass
High grade neuroendocrine carcinoma (CMS/HCC)","C7A.8 - Other malignant neuroendocrine tumors; A41.9 - Sepsis, unspecified organism; E43 - Unspecified severe protein-calorie malnutrition; K56.690 - Other partial intestinal obstruction; D70.9 - Neutropenia, unspecified; D50.9 - Iron deficiency anemia, unspecified; F10.10 - Alcohol abuse, uncomplicated; B95.4 - Other streptococcus as the cause of diseases classified elsewhere; I10 - Essential (primary) hypertension; Z68.30 - Body mass index (BMI) 30.0-30.9, adult; B96.89 - Other specified bacterial agents as the cause of diseases classified elsewhere; F17.290 - Nicotine dependence, other tobacco product, uncomplicated; R59.9 - Enlarged lymph nodes, unspecified; E78.5 - Hyperlipidemia, unspecified; R19.00 - Intra-abdominal and pelvic swelling, mass and lump, unspecified site; K82.8 - Other specified diseases of gallbladder; K52.9 - Noninfective gastroenteritis and colitis, unspecified; Z59.71 - Insufficient health insurance coverage"
MSC OP INFUSION,89180,"Taff, Jessica, MD",12/3/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/14/2024,Active,,
NBR CINJ OP INFUSION,9844,"Matasar, Matthew J, MD",2/23/2024,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,2/20/2024,Inactive,,
NBR 4N ONCOLOGY,9844,"Matasar, Matthew J, MD",12/27/2024,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles -  Lymphoma,_2. Second Line,12/27/2024,Inactive,,
NBR CINJ OP INFUSION,9844,"Matasar, Matthew J, MD",1/15/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_2. Second Line,1/14/2025,Active,Malignant neoplasm of female breast (CMS/HCC),
MMC OP VP INFUSION,33674,"Cohen, Seth D, MD",12/2/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/26/2024,Inactive,,
CINJ OP INFUSION,85804,"Haigentz, Missak, MD",9/11/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,First Line,9/10/2023,Inactive,,
NBR 4N ONCOLOGY,85804,"Haigentz, Missak, MD",10/2/2023,Cetuximab/CARBOplatin/Fluorouracil Continuous Infusion 21 Day Cycles- Head and Neck Cancers,Second Line,10/1/2023,Inactive,,
CINJ OP INFUSION,85804,"Haigentz, Missak, MD",3/1/2024,Cetuximab Maintenance 14 Day Cycles- Head and Neck Cancers,Maintenance,2/29/2024,Inactive,,
NBR 4N ONCOLOGY,85804,"Haigentz, Missak, MD",5/5/2024,"Paclitaxel D1, D8, D15, with Cetuximab weekly, 28 Day Cycles- Head and Neck Cancers",_3. Third Line,5/5/2024,Inactive,,
CBMC OP INFUSION 1FL,15833,"Meelheim, Brooke A, DO",12/3/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/1/2024,Active,,
CBMC OP INFUSION 1FL,15833,"Meelheim, Brooke A, DO",5/2/2025,Bevacizumab Maintenance 21 Day Cycles- Ovarian cancer,Maintenance,5/2/2025,Active,Malignant neoplasm of right ovary (CMS/HCC),
CINJ OP INFUSION,76809,"Haigentz, Missak, MD",3/15/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,3/14/2023,Inactive,,
CINJ OP INFUSION,76809,"Haigentz, Missak, MD",4/16/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/16/2024,Inactive,,
HAM OP INFUSION,74949,"Gendy, Mina, DO",10/1/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/1/2024,Inactive,,
HAM OP INFUSION,74949,"Gendy, Mina, DO",10/11/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,10/1/2024,Active,,
HAM OP INFUSION,74949,"Gendy, Mina, DO",5/8/2025,Nivolumab 28 Day Cycles - Kidney or Bladder,_1. First Line,5/8/2025,Active,"Renal cell carcinoma of right kidney (CMS/HCC)
Metastasis from malignant tumor of kidney, right (CMS/HCC)","C64.1 - Renal cell carcinoma of right kidney (CMS/HCC); C79.9, C64.1 - Metastasis from malignant tumor of kidney, right (CMS/HCC)"
CINJ OP INFUSION,63874,"Mayer, Tina M, MD",5/19/2023,Enzalutamide 28 Day Cycles - Prostate,,5/19/2023,Active,,
HAM OP INFUSION,62161,"Patel, Malini M, MD",10/1/2024,CINJ 032201 ARM 1 Paclitaxel / CARBOplatin + Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,9/30/2024,Active,,
NBI OP INFUSION,32468,"Cheng, Yan Ho, MD",1/21/2025,Ruxolitinib 30 Day Cycles - Myelofibrosis,_1. First Line,1/21/2025,Active,"Cholangiocarcinoma (CMS/HCC)
Other specified hypothyroidism
Malignant carcinoid tumor of the appendix (CMS/HCC)",
NBI OP INFUSION,32468,"Cheng, Yan Ho, MD",3/12/2025,Ruxolitinib 30 Day Cycles - Myelofibrosis,_1. First Line,3/12/2025,Active,Myelofibrosis (CMS/HCC),"I50.43 - Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure; E88.3 - Tumor lysis syndrome; J96.01 - Acute respiratory failure with hypoxia; N17.9 - Acute kidney failure, unspecified; R16.2 - Hepatomegaly with splenomegaly, not elsewhere classified; B35.1 - Tinea unguium; D47.1 - Chronic myeloproliferative disease; F11.10 - Opioid abuse, uncomplicated; J43.2 - Centrilobular emphysema; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); N18.9 - Chronic kidney disease, unspecified; I42.8 - Other cardiomyopathies; F14.10 - Cocaine abuse, uncomplicated; E87.6 - Hypokalemia; K42.9 - Umbilical hernia without obstruction or gangrene; E55.9 - Vitamin D deficiency, unspecified; D75.839 - Thrombocytosis, unspecified; Z23 - Encounter for immunization; E87.5 - Hyperkalemia; K43.9 - Ventral hernia without obstruction or gangrene; K52.9 - Noninfective gastroenteritis and colitis, unspecified; K80.20 - Calculus of gallbladder without cholecystitis without obstruction; L85.3 - Xerosis cutis; I87.2 - Venous insufficiency (chronic) (peripheral); T40.3X5A - Adverse effect of methadone, initial encounter; I99.8 - Other disorder of circulatory system; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; Z11.52 - Encounter for screening for COVID-19; Z87.891 - Personal history of nicotine dependence; Z86.19 - Personal history of other infectious and parasitic diseases; Z83.3 - Family history of diabetes mell..."
NBI OP INFUSION,24262,"Shah, Maya M, MD",2/14/2024,Brentuximab Vedotin / Bendamustine 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,2/13/2024,Inactive,,
NBR 4N BMTU/IMCU,24262,"Assal, Amer, MD",7/12/2024,BMT Autologous Benda-EAM (Bendamustine / Etoposide / Cytarabine / Melphalan),_2. Second Line,7/12/2024,Active,,
NBI OP INFUSION,24262,"Shah, Maya M, MD",11/6/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,11/5/2024,Active,,
TRMC TCCC OP INFUSION,88119,"Capo, Gerardo, MD",9/3/2024,Bevacizumab 28 Day Cycles - HHT,_1. First Line,9/3/2024,Active,,
CBMC OP INFUSION 2FL,9823,"Brown, Andrew Bennett, MD",11/20/2023,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,11/17/2023,Inactive,,
CINJ OP INFUSION,39631,"Weiss, Sarah, MD",2/28/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,2/27/2024,Inactive,,
NBR 4N ONCOLOGY,39631,"Haigentz, Missak, MD",5/19/2024,RiTUXimab Initial ++ Infusion Single Day (Inpatient),Maintenance,5/19/2024,Inactive,,
NBR 5N ONCOLOGY,59218,"Shah, Mansi R, MD",2/1/2025,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,1/31/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; E11.9 - Type 2 diabetes mellitus without complications; M27.2 - Inflammatory conditions of jaws; D80.1 - Nonfamilial hypogammaglobulinemia; D72.819 - Decreased white blood cell count, unspecified; D84.9 - Immunodeficiency, unspecified; D64.9 - Anemia, unspecified; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; Z01.818 - Encounter for other preprocedural examination; Z94.84 - Stem cells transplant status; Z71.89 - Other specified counseling"
CMC OP INFUSION,85256,"Tang, Horace, MD",10/23/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/22/2023,Inactive,,
CMC OP INFUSION,85256,"Cohen, Seth D, MD",2/22/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/22/2024,Inactive,,
CMC OP INFUSION,85256,"Cohen, Seth D, MD",3/20/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/19/2024,Inactive,,
CMC OP INFUSION,85256,"Cohen, Seth D, MD",9/24/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,9/24/2024,Active,Acute lymphoblastic leukemia (ALL) in adult (CMS/HCC),
HAM OP INFUSION,32851,"Patel, Malini M, MD",3/30/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,Second Line,3/22/2023,Inactive,,
CBMC OP INFUSION 2FL,14133,"Phillips, Adrienne A, MD",4/9/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,4/2/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
CBMC OP INFUSION 2FL,14133,"Phillips, Adrienne A, MD",3/31/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,3/31/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),
HAM OP INFUSION,60017,"Yogarajah, Meera, MD",6/28/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,6/26/2023,Inactive,,
CMC OP INFUSION,82995,"Taff, Jessica, MD",1/29/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Neoadjuvant,1/21/2024,Active,,
CMC OP INFUSION,82995,"Taff, Jessica, MD",2/5/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Neoadjuvant,1/21/2024,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
MMC OP VP INFUSION,18809,"Cohen, Seth D, MD",12/27/2023,Methotrexate 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_1. First Line,12/25/2023,Inactive,,
NBR 4N ONCOLOGY,90612,"Rhodes, Joanna Meehan, MD",7/16/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,7/16/2024,Inactive,,
NBR 4N ONCOLOGY,90612,"Rhodes, Joanna Meehan, MD",7/19/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 14 Day Cycles - B-Cell Lymphoma,_1. First Line,7/18/2024,Inactive,,
NBR CINJ OP INFUSION,90612,"Rhodes, Joanna Meehan, MD",9/20/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,9/18/2024,Active,,
CINJ OP INFUSION,7708,"Girda, Eugenia, MD",4/23/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/23/2025,Active,Endometrial carcinoma (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; Z51.89 - Encounter for other specified aftercare
HAM OP INFUSION,30427,"Patel, Malini M, MD",7/24/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,7/22/2024,Active,,
CINJ OP INFUSION,81081,"Leiser, Aliza, MD",3/26/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/25/2024,Inactive,,
CINJ OP INFUSION,81081,"Leiser, Aliza, MD",8/6/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,8/6/2024,Active,,
JCMC CP INFUSION,98460,"Cruz, Allan Louie E, MD",7/9/2024,"PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles --- Squamous cell carcinoma, high grade; Non-Small Cell Lung Cancer",Induction,7/7/2024,Inactive,,
JCMC CP INFUSION,98460,"Cruz, Allan Louie E, MD",10/7/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,10/6/2024,Active,,
NBI OP INFUSION,54239,"Anderson, Patrick S, MD",2/15/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Cervical cancer,_1. First Line,2/14/2024,Inactive,,
NBR CINJ OP INFUSION,52973,"Dasgeb, Bahar, MD",2/20/2023,Methotrexate q4w,,2/20/2023,Inactive,,
CINJ OP INFUSION,52973,"Haigentz, Missak, MD",5/11/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,,5/11/2023,Inactive,,
NBI OP INFUSION,64224,"Anderson, Patrick S, MD",5/2/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,5/1/2024,Active,,
CBMC OP INFUSION 2FL,57035,"Grossman, I Robert, MD",5/21/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_2. Second Line,5/21/2025,Active,Thrombocytopenia (CMS/HCC),
CINJ OP INFUSION,5694,"Toppmeyer, Deborah L, MD",5/11/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,First Line,5/10/2023,Inactive,,
CINJ OP INFUSION,5694,"Toppmeyer, Deborah L, MD",5/25/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Neoadjuvant,5/24/2023,Inactive,,
CINJ OP INFUSION,5694,"Toppmeyer, Deborah L, MD",1/2/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,12/25/2023,Inactive,,
CBMC OP INFUSION 2FL,2578,"Leitner, Stuart P, MD",11/16/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,11/15/2023,Active,,
CINJ OP INFUSION,25152,"Gulhati, Prateek, MD PhD",7/25/2024,CINJ 071702 (MK-3475-535) Pembrolizumab 21 Day Cycles Pre-Operative Research- Gastric Cancer,Neoadjuvant,6/26/2024,Inactive,,
CINJ OP INFUSION,53191,"Patel, Eshan, MD",8/15/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,8/15/2023,Inactive,,
CINJ OP INFUSION,53191,"Weiss, Sarah, MD",11/27/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,11/25/2023,Inactive,,
NBR CINJ OP INFUSION,46567,"Tiger, Yun Kyoung, MD",11/27/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/26/2024,Active,,
CMC OP INFUSION,36658,"Tang, Horace, MD",5/8/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,4/24/2023,Inactive,,
SOM OUTPT INFUSION,13176,"Patel, Eshan, MD",2/7/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,2/6/2023,Active,,
CINJ OP INFUSION,8771,"George, Mridula A, MD",8/21/2023,Palbociclib 28 Day Cycles - Breast,,8/21/2023,Active,,
CMC OP INFUSION,64276,"Tang, Horace, MD",8/8/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,,8/7/2023,Active,,
CINJ OP INFUSION,90424,"Packiam, Vignesh, MD",11/29/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Adjuvant,11/28/2023,Inactive,,
SOM OUTPT INFUSION,45417,"Toomey, Kathleen C, MD",3/17/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,3/17/2025,Active,Rectal cancer (CMS/HCC),C20 - Malignant neoplasm of rectum
CBMC OP INFUSION 2FL,69100,"McKenna, Marshall, MD",10/28/2024,S1826 Arm 1 AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,10/27/2024,Inactive,,
NBI OP INFUSION,16966,"Jacoby, Sari H, MD",11/8/2023,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),Induction,11/8/2023,Inactive,,
NBR CINJ OP INFUSION,73830,"Evens, Andrew M, DO",1/15/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/14/2025,Active,HCC (hepatocellular carcinoma) (CMS/HCC),
CMC OP INFUSION,54936,"Anton, Danielle Alexus, NP",2/6/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/6/2024,Inactive,,
MMC OP INFUSION,67478,"Eltoukhy, Hussam, MD",7/28/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,7/27/2023,Active,"AML (acute myeloid leukemia) in remission (CMS/HCC)
H/O allogeneic bone marrow transplant (CMS/HCC)",
MMC OP INFUSION,67478,"Eltoukhy, Hussam, MD",8/10/2023,RiTUXimab 28 Day Cycle - Marginal zone lymphoma,Maintenance,8/9/2023,Inactive,,
CINJ OP INFUSION,85793,"Weiss, Sarah, MD",2/25/2025,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,2/25/2025,Active,Malignant melanoma of other part of trunk (CMS/HCC),C43.59 - Malignant melanoma of other part of trunk (CMS/HCC)
JCMC CP INFUSION,53738,"Cruz, Allan Louie E, MD",6/12/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,First Line,6/11/2023,Inactive,,
CINJ OP INFUSION,45092,"Jang, Thomas L, MD",11/7/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,11/6/2024,Active,,
CINJ OP INFUSION,65322,"Jang, Thomas L, MD",1/22/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,1/21/2025,Active,,
MMC OP INFUSION,46757,"Cohen, Seth D, MD",8/29/2023,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,,8/28/2023,Inactive,,
MMC BBR2 ONCOLOGY,46757,"Lee, Patrick C, MD",10/13/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,10/12/2023,Inactive,,
SOM OUTPT INFUSION,44868,"Toomey, Kathleen C, MD",1/11/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,1/3/2023,Inactive,,
NBI OP INFUSION,69237,"Anderson, Patrick S, MD",7/6/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/5/2023,Inactive,,
NBI OP INFUSION,69237,"Anderson, Patrick S, MD",11/16/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/15/2023,Inactive,,
NBI OP INFUSION,69237,"Anderson, Patrick S, MD",3/20/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,3/20/2024,Active,,
SOM OUTPT INFUSION,72133,"Patel, Eshan, MD",10/1/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,9/17/2024,Inactive,,
CINJ OP INFUSION,89442,"Weiss, Sarah, MD",10/23/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,10/22/2024,Active,,
CINJ OP INFUSION,89442,"Weiss, Sarah, MD",1/29/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,1/28/2025,Active,,
CINJ OP INFUSION,89442,"Weiss, Sarah, MD",1/29/2025,CINJ 092302 Cohort 2 Propranolol / Naltrexone 4.5 mg + Nivolumab (1 mg/kg) / Ipilimumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research Melanoma,_2. Second Line,1/28/2025,Inactive,Metastatic melanoma (CMS/HCC),
CINJ OP INFUSION,46823,"Aikins, James K, MD",7/15/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,7/2/2024,Inactive,,
CINJ OP INFUSION,46823,"Aikins, James K, MD",12/5/2024,Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,12/4/2024,Active,,
CBMC 2W ONCOLOGY,52066,"Grossman, I Robert, MD",8/5/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,8/4/2024,Active,,
SOM OUTPT INFUSION,57846,"Patel, Eshan, MD",6/26/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,6/25/2023,Inactive,,
SOM OUTPT INFUSION,57846,"Patel, Eshan, MD",6/29/2023,PEMEtrexed 21 Days / carboplatin AUC 1.5 weekly - 21 day  Cycles- Non-Small Cell Lung Cancer,,6/18/2023,Inactive,,
SOM OUTPT INFUSION,57846,"Patel, Eshan, MD",8/10/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,,8/2/2023,Inactive,,
SOM OUTPT INFUSION,57846,"Patel, Eshan, MD",5/13/2024,"Albumin-Bound PACLitaxel D1, D8, D15/ CARBOplatin D1, D8, D15 , keytruda 21 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,5/10/2024,Inactive,,
SOM OUTPT INFUSION,57846,"Toomey, Kathleen C, MD",6/11/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_3. Third Line,6/10/2024,Inactive,,
MMC OP VP INFUSION,99516,"Cohen, Seth D, MD",7/3/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,7/2/2023,Inactive,,
MMC OP VP INFUSION,99516,"Cohen, Seth D, MD",9/18/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",,9/17/2023,Inactive,,
MMC OP VP INFUSION,99516,"Cohen, Seth D, MD",11/27/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/26/2023,Inactive,,
CBMC OP INFUSION 2FL,49861,"Leitner, Stuart P, MD",12/28/2023,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,12/25/2023,Inactive,,
CBMC OP INFUSION 2FL,49861,"Leitner, Stuart P, MD",10/31/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/30/2024,Active,,
CBMC 2W ONCOLOGY,4308,"Grossman, I Robert, MD",11/9/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/8/2023,Active,,
CMC OP INFUSION,59299,"Taff, Jessica, MD",4/13/2023,CINJ 071801 TAS-102 + OXALiplatin 14 Day Cycles Research- Colorectal Cancer,Third Line,3/29/2023,Active,,
NBI OP INFUSION,11754,"Anderson, Patrick S, MD",7/1/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles -high grade Endometrial Cancer,_1. First Line,6/29/2024,Inactive,,
NBI OP INFUSION,11754,"Anderson, Patrick S, MD",9/16/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,9/16/2024,Active,,
NBR 5N ONCOLOGY,70853,"Berim, Lyudmyla, MD",6/3/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,,6/3/2023,Inactive,,
NBR 4N BMTU/IMCU,81800,"Schaar, Dale, MD PhD",10/13/2023,BMT Autologous BEAM,_3. Third Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,72447,"Grossman, I Robert, MD",3/6/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,2/28/2024,Active,Colon cancer (CMS/HCC),
CBMC 2W ONCOLOGY,7980,"Grossman, I Robert, MD",6/5/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,6/4/2024,Inactive,,
CINJ OP INFUSION,78026,"Weiss, Sarah, MD",6/14/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,6/6/2023,Inactive,,
MMC OP VP INFUSION,76600,"Cohen, Seth D, MD",2/8/2023,CINJ 071801 TAS-102 + OXALiplatin 14 Day Cycles Research- Colorectal Cancer,Second Line,1/24/2023,Inactive,,
MMC OP VP INFUSION,76600,"Cohen, Seth D, MD",3/27/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,3/27/2024,Inactive,,
MMC OP VP INFUSION,76600,"Cohen, Seth D, MD",2/3/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,2/2/2025,Active,Adenocarcinoma of colon (CMS/HCC),
MMC OP VP INFUSION,76600,"Cohen, Seth D, MD",5/12/2025,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,5/12/2025,Active,Adenocarcinoma of colon (CMS/HCC),
SOM OUTPT INFUSION,14858,"Yin, Faye, MD",3/29/2023,DOCEtaxel / Trastuzumab 21 Day Cycles - Breast,Adjuvant,3/28/2023,Inactive,,
SOM OUTPT INFUSION,14858,"Yin, Faye, MD",4/5/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/27/2023,Inactive,,
SOM OUTPT INFUSION,14858,"Yin, Faye, MD",9/22/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,9/18/2023,Active,,
NBR 4N ONCOLOGY,87017,"Stephenson, Ryan D, DO",2/17/2025,CINJ 082105 (R4336-ONC-20104) MODULE 1 WEEKLY IV REGN4336,_3. Third Line,2/14/2025,Active,Malignant neoplasm of prostate metastatic to bone (CMS/HCC),"Z51.12 - Encounter for antineoplastic immunotherapy; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C79.51 - Secondary malignant neoplasm of bone; E87.20 - Acidosis, unspecified; N17.9 - Acute kidney failure, unspecified; E83.51 - Hypocalcemia; D89.831 - Cytokine release syndrome, grade 1; C61 - Malignant neoplasm of prostate; N18.30 - Chronic kidney disease, stage 3 unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; Z59.811 - Housing instability, housed, with risk of homelessness; K59.00 - Constipation, unspecified; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; R32 - Unspecified urinary incontinence; T80.82XA - Complication of immune effector cellular therapy, initial encounter; N32.0 - Bladder-neck obstruction; F10.90 - Alcohol use, unspecified, uncomplicated; Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung; Z87.442 - Personal history of urinary calculi; Z80.3 - Family history of malignant neoplasm of breast; Z80.42 - Family history of malignant neoplasm of prostate; Z82.3 - Family history of stroke; Z86.16 - Personal history of COVID-19; Z90.79 - Acquired absence of other genital organ(s); Z92.3 - Personal history of irradiation; Z87.440 - Personal history of urinary (tract) infections; Z98.890 - Other specified postprocedural states; Z88.0 - Allergy status to penicillin;..."
CMC OP INFUSION,47602,"Talwar, Sumit, MD",3/18/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,3/18/2025,Active,Multiple myeloma (CMS/HCC),
HAM OP INFUSION,14822,"Yogarajah, Meera, MD",7/9/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_1. First Line,6/23/2024,Active,,
CINJ OP INFUSION,32528,"Weiss, Sarah, MD",9/30/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,8/18/2024,Active,,
JCMC CP INFUSION,92638,"Ghuman, Damanjit, MD",8/3/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,Second Line,7/11/2023,Inactive,,
CINJ OP INFUSION,37273,"Hochster, Howard S, MD",3/19/2025,CINJ 072404 Stage 1 ABBV-400 2 mg/kg 21 Day Cycles Research- Colorectal Cancer,_4. Fourth Line,3/19/2025,Active,"Malignant neoplasm of sigmoid colon (CMS/HCC)
Abnormal findings on diagnostic imaging of other parts of digestive tract
Abnormal coagulation profile",C18.7 - Malignant neoplasm of sigmoid colon (CMS/HCC); R93.3 - Abnormal findings on diagnostic imaging of other parts of digestive tract; R79.1 - Abnormal coagulation profile
EMH HEM ONC,45532,"Patel, Eshan, MD",8/14/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,8/13/2024,Active,Peripheral T cell lymphoma of lymph nodes of multiple sites (CMS/HCC),
NBR CINJ OP INFUSION,45532,"Palmisiano, Neil David, MD",4/29/2025,"CINJ 022204 Cohort 3 Combination Agents Part 2 of 2 Decitabine 28 Day Cycles Research - Myleodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)",_2. Second Line,4/29/2025,Active,"Acute leukemia not having achieved remission (CMS/HCC)
Other fatigue
Hemorrhagic condition (CMS/HCC)",
NBR CINJ OP INFUSION,45532,"Palmisiano, Neil David, MD",4/29/2025,"CINJ 022204 Cohort 3 Combination Agents Part 1 of 2 LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_2. Second Line,4/29/2025,Active,"Acute leukemia not having achieved remission (CMS/HCC)
Abnormal coagulation profile
Anemia, unspecified type",
MSC OP INFUSION,59283,"Easaw, Sarah, MD",7/28/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/20/2023,Inactive,,
NBI OP INFUSION,93285,"Schleicher, Lori, MD",3/15/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,3/14/2024,Active,,
CINJ OP INFUSION,31533,"Hochster, Howard S, MD",5/16/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/14/2024,Inactive,,
CINJ OP INFUSION,31533,"Hochster, Howard S, MD",12/5/2024,mFOLFOX6  (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/4/2024,Active,,
CBMC 2W ONCOLOGY,56153,"Leitner, Stuart P, MD",6/20/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,6/19/2024,Active,,
CINJ OP INFUSION,10807,"Toppmeyer, Deborah L, MD",3/24/2025,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,_1. First Line,3/24/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z90.12 - Acquired absence of left breast and nipple; Z17.1 - Estrogen receptor negative status (ER-)
MMC OP INFUSION,4604,"Meghal, Trishala, MD",3/17/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/16/2023,Inactive,,
MMC OP INFUSION,4604,"Meghal, Trishala, MD",5/12/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,5/11/2023,Inactive,,
MMC BBR2 ONCOLOGY,58216,"Cohen, Seth D, MD",9/10/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,9/6/2024,Active,"Multiple myeloma in remission (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,10423,"Hochster, Howard S, MD",1/5/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,1/4/2023,Inactive,,
CINJ OP INFUSION,10423,"Hochster, Howard S, MD",5/25/2023,CINJ 072201 Control ARM FOLFIRI (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,Second Line,4/26/2023,Inactive,,
CINJ OP INFUSION,10423,"Hochster, Howard S, MD",7/27/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,7/27/2023,Inactive,,
CINJ OP INFUSION,10423,"Hochster, Howard S, MD",5/16/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,5/13/2024,Active,,
MSC OP INFUSION,26349,"Cohen, Seth D, MD",8/3/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,8/2/2023,Inactive,,
MMC OP VP INFUSION,26349,"Cohen, Seth D, MD",8/24/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,,8/21/2023,Inactive,,
CINJ OP INFUSION,10582,"Berim, Lyudmyla, MD",4/10/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/10/2025,Active,"Duodenal mass
Metastatic adenocarcinoma (CMS/HCC)","C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C79.9 - Secondary malignant neoplasm of unspecified site; K31.89 - Other diseases of stomach and duodenum; R97.8 - Other abnormal tumor markers; C80.1 - Malignant (primary) neoplasm, unspecified"
CINJ OP INFUSION,91338,"Haigentz, Missak, MD",4/24/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,4/23/2023,Inactive,,
CINJ OP INFUSION,91338,"Haigentz, Missak, MD",4/24/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,4/23/2023,Inactive,,
CINJ OP INFUSION,91338,"Haigentz, Missak, MD",6/5/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,,6/4/2023,Inactive,,
CINJ OP INFUSION,91338,"Haigentz, Missak, MD",8/28/2023,PEMEtrexed 21 Day Cycles Maintenance- Non-Small Cell Lung Cancer,Maintenance,8/20/2023,Inactive,,
CINJ OP INFUSION,88492,"Mayer, Tina M, MD",8/13/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,7/31/2024,Active,,
CINJ OP INFUSION,88492,"Mayer, Tina M, MD",1/27/2025,Nivolumab 28 Day Cycles - Bladder,Adjuvant,1/21/2025,Active,,
CMC OP INFUSION,17103,"Talwar, Sumit, MD",5/31/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,5/28/2024,Inactive,,
SOM OUTPT INFUSION,38611,"Yin, Faye, MD",9/7/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/29/2023,Inactive,,
SOM OUTPT INFUSION,38611,"Yin, Faye, MD",11/2/2023,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,10/24/2023,Inactive,,
SOM OUTPT INFUSION,38611,"Yin, Faye, MD",3/11/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,3/11/2024,Active,,
CINJ OP INFUSION,68858,"Haigentz, Missak, MD",8/7/2024,CINJ 032213 Group E Pembrolizumab / HB-201 and HB-202 Alternating Therapy 42 Day Cycles 1 and 2 / 84 Days Cycles 3 and Beyond Research- HPV 16+ Head and Neck Cancers,_1. First Line,8/6/2024,Active,,
CINJ OP INFUSION,68858,"Haigentz, Missak, MD",12/11/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,12/10/2024,Inactive,,
NBR CINJ OP INFUSION,85806,"Zayac, Adam, MD",3/10/2025,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,3/10/2025,Active,"MDS (myelodysplastic syndrome), high grade (CMS/HCC)","D46.9 - Myelodysplastic syndrome, unspecified; D61.818 - Other pancytopenia; D46.Z - Other myelodysplastic syndromes"
CINJ OP INFUSION,55554,"Boland, Patrick M, MD",3/28/2023,FOLFIRI + ramucirumab,Second Line,3/27/2023,Inactive,,
CMC 4B ONCOLOGY,54921,"Lee, Patrick C, MD",3/17/2024,Cyclophosphamide,_1. First Line,3/17/2024,Inactive,,
CMC OP INFUSION,54921,"Lee, Patrick C, MD",3/18/2024,Cyotxan,_1. First Line,3/17/2024,Inactive,,
NBI OP INFUSION,23307,"Jacoby, Sari H, MD",11/20/2023,DOXOrubicin Liposomal Day 1&15 Q 28 Day Cycles - Adenoid Cystic Carcinoma,_5. Fifth Line,11/19/2023,Inactive,,
CINJ OP INFUSION,20516,"Mayer, Tina M, MD",3/29/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,3/29/2023,Active,,
CINJ OP INFUSION,7879,"Stephenson, Ryan D, DO",4/21/2025,Everolimus 28 Day Cycles - Angiomyolipoma,_1. First Line,4/21/2025,Active,"Angiomyolipoma of both kidneys
Hyperlipidemia, unspecified hyperlipidemia type","D17.71 - Benign lipomatous neoplasm of kidney; E78.5 - Hyperlipidemia, unspecified"
NBR CINJ OP INFUSION,36123,"Egini, Ogechukwu, MD",8/14/2024,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,_3. Third Line,8/13/2024,Inactive,,
CMMC OP INFUSION,27756,"Siu, Karleung, MD",3/7/2025,Tremelimumab / Durvalumab / Pemetrexed / CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/7/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),"C79.51 - Secondary malignant neoplasm of bone; A41.9 - Sepsis, unspecified organism; J94.8 - Other specified pleural conditions; C77.1 - Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes; G99.2 - Myelopathy in diseases classified elsewhere; J18.9 - Pneumonia, unspecified organism; J90 - Pleural effusion, not elsewhere classified; M48.04 - Spinal stenosis, thoracic region; Z51.5 - Encounter for palliative care; C34.11 - Malignant neoplasm of upper lobe, right bronchus or lung; F32.A - Depression, unspecified; D63.8 - Anemia in other chronic diseases classified elsewhere; K76.89 - Other specified diseases of liver; G95.29 - Other cord compression; J98.11 - Atelectasis; M84.58XD - Pathological fracture in neoplastic disease, other specified site, subsequent encounter for fracture with routine healing; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; D18.03 - Hemangioma of intra-abdominal structures; K59.00 - Constipation, unspecified; N39.498 - Other specified urinary incontinence; Z59.71 - Insufficient health insurance coverage; D50.9 - Iron deficiency anemia, unspecified; Z92.3 - Personal history of irradiation; K20.80 - Other esophagitis without bleeding; F17.210 - Nicotine dependence, cigarettes, uncomplicated; B95.62 - Methicillin resistant Staphylococcus aureus infection as the cause of diseases classified elsewhere; G43.919 - Migraine, unspecified, intractable, without status migrainosus; H92.22 ..."
CINJ OP INFUSION,96335,"Haigentz, Missak, MD",2/13/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/13/2024,Active,,
CINJ OP INFUSION,88266,"Boland, Patrick M, MD",3/31/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,3/30/2023,Inactive,,
CINJ OP INFUSION,88266,"Boland, Patrick M, MD",9/15/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,,9/15/2023,Inactive,,
CINJ OP INFUSION,88266,"Goel, Sanjay, MD",10/9/2023,CINJ 052215 Dose Expansion Single Agent XB002 21 Day Cycles Research- Solid Tumors,_3. Third Line,10/8/2023,Inactive,,
CINJ OP INFUSION,88266,"Boland, Patrick M, MD",11/29/2023,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_3. Third Line,11/28/2023,Inactive,,
CINJ OP INFUSION,88266,"Boland, Patrick M, MD",11/29/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_3. Third Line,11/28/2023,Inactive,,
CINJ OP INFUSION,69217,"Stephenson, Ryan D, DO",1/31/2023,Enzalutamide 30 Day Cycles - Prostate,First Line,1/31/2023,Active,,
MMC OP VP INFUSION,15469,"Talwar, Sumit, MD",12/3/2024,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,12/2/2024,Active,,
CINJ OP INFUSION,81734,"Stephenson, Ryan D, DO",10/14/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/9/2024,Active,,
NBR 4N ONCOLOGY,13063,"Palmisiano, Neil David, MD",12/14/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,12/14/2023,Inactive,,
NBR CINJ OP INFUSION,13063,"Palmisiano, Neil David, MD",7/16/2024,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,7/16/2024,Active,,
CMC OP INFUSION,42947,"Pompa, Tiffany Ann, MD",2/25/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,2/24/2025,Active,Waldenstrom's disease,
CINJ OP INFUSION,86607,"Ghodoussipour, Saum Bobak, MD",12/20/2023,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,12/19/2023,Inactive,,
NBI OP INFUSION,73824,"Schleicher, Lori, MD",11/13/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/4/2024,Active,,
CBMC OP INFUSION 2FL,39827,"Wagmiller, Jennifer Ann, MD",5/7/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,5/7/2025,Active,Malignant neoplasm of left ovary (CMS/HCC),C56.2 - Malignant neoplasm of left ovary (CMS/HCC)
CMC OP INFUSION,75691,"Pompa, Tiffany Ann, MD",10/24/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Adjuvant,10/16/2024,Active,,
NBI OP INFUSION,94187,"Snyder, Rose, MD",2/4/2025,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,2/3/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; M34.9 - Systemic sclerosis, unspecified"
CBMC OP INFUSION 2FL,44390,"Wagmiller, Jennifer Ann, MD",4/4/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/4/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),
NBR CINJ OP INFUSION,18596,"Shah, Mansi R, MD",12/5/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,12/4/2023,Inactive,,
NBR CINJ OP INFUSION,18596,"Shah, Mansi R, MD",1/9/2024,CINJ 012310 Induction Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,_1. First Line,1/8/2024,Inactive,,
NBR 4N BMTU/IMCU,18596,"Shah, Mansi R, MD",6/5/2024,BMT Autologous Melphalan Day -1 140MG/M2,_1. First Line,6/3/2024,Inactive,,
NBR CINJ OP INFUSION,18596,"Shah, Mansi R, MD",11/4/2024,CINJ 012310 Inpatient Consolidation Linvolsetamab Post ASCT 28 Day Cycles Research- Multiple Myeloma,Consolidation,11/4/2024,Inactive,,
NBR CINJ OP INFUSION,62691,"Shah, Mansi R, MD",2/13/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,2/5/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Encounter for screening for other viral diseases",C90.00 - Multiple myeloma not having achieved remission; D84.821 - Immunodeficiency due to drugs; D80.1 - Nonfamilial hypogammaglobulinemia; R05.3 - Chronic cough; E61.1 - Iron deficiency; Z94.84 - Stem cells transplant status; Z79.899 - Other long term (current) drug therapy
NBI OP INFUSION,61604,"Anderson, Patrick S, MD",1/16/2025,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,1/15/2025,Active,,
NBI OP INFUSION,61604,"Anderson, Patrick S, MD",2/28/2025,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,1/15/2025,Active,"Malignant neoplasm of uterus (CMS/HCC)
Ovarian carcinoma (CMS/HCC)","C55 - Malignant neoplasm of uterus, unspecified site (CMS/HCC)"
MMC OP VP INFUSION,15300,"Cohen, Seth D, MD",7/24/2024,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,7/23/2024,Active,,
MMC OP VP INFUSION,15300,"Cohen, Seth D, MD",7/24/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,7/23/2024,Active,,
MMC OP VP INFUSION,15969,"Cohen, Seth D, MD",4/23/2025,Pembrolizumab 42 Day Cycles - Uterine,Maintenance,4/23/2025,Active,"Ovarian cancer (CMS/HCC)
End stage renal disease (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C56.2 - Malignant neoplasm of left ovary; N18.6 - End stage renal disease
CBMC OP INFUSION 2FL,44399,"Litvak, Anna M, MD",8/14/2023,CINJ 042208 Ribociclib / Endocrine Therapy of Choice 28 Day Cycles Research- Breast Cancer,_1. First Line,8/14/2023,Active,,
CINJ OP INFUSION,37836,"Haigentz, Missak, MD",4/21/2025,Crizotinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/21/2025,Active,"Malignant neoplasm of lower lobe of right lung (CMS/HCC)
Malignant pleural effusion","C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; J91.0 - Malignant pleural effusion; R60.0 - Localized edema; C79.70 - Secondary malignant neoplasm of unspecified adrenal gland"
CBMC OP INFUSION 2FL,2341,"Wagmiller, Jennifer Ann, MD",1/31/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,1/30/2025,Active,AML (acute myeloid leukemia) in relapse (CMS/HCC),
NBR CINJ OP INFUSION,2842,"Evens, Andrew M, DO",2/1/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,,1/24/2023,Inactive,,
NBR CINJ OP INFUSION,2842,"Evens, Andrew M, DO",6/28/2023,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,,6/27/2023,Inactive,,
NBR CINJ OP INFUSION,2842,"Evens, Andrew M, DO",7/31/2024,Pembrolizumab 21 Day Cycles - Mycosis Fungoides / Sezary Syndrome ,_4. Fourth Line,7/30/2024,Inactive,,
NBR CINJ OP INFUSION,2842,"Evens, Andrew M, DO",11/13/2024,GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - T- Cell Lymphoma Lymphoma,_4. Fourth Line,11/12/2024,Active,,
NBI OP INFUSION,56530,"Cheng, Yan Ho, MD",1/27/2025,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_2. Second Line,1/26/2025,Active,,
NBI OP INFUSION,56530,"Cheng, Yan Ho, MD",2/25/2025,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_2. Second Line,1/26/2025,Active,Aplastic anemia (CMS/HCC),
NBI OP INFUSION,56530,"Cheng, Yan Ho, MD",4/21/2025,Ibrutinib 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_3. Third Line,4/21/2025,Active,"Stage IV low grade lymphoma (CMS/HCC)
Low grade B-cell lymphoma (CMS/HCC)",
NBI OP INFUSION,56530,"Cheng, Yan Ho, MD",4/11/2025,RiTUXimab 28 Day Cycle - B cell lymphoma,_2. Second Line,4/11/2025,Active,History of B-cell lymphoma,
CINJ OP INFUSION,39676,"Omene, Coral Oghenerukevwe, MD",12/6/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,12/5/2024,Active,,
NBR 5N ONCOLOGY,35149,"Saraiya, Biren P, MD",3/28/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,3/28/2023,Inactive,,
CINJ OP INFUSION,44852,"Packiam, Vignesh, MD",3/14/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,3/12/2024,Inactive,,
CINJ OP INFUSION,44852,"Gulhati, Prateek, MD PhD",6/25/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,_1. First Line,6/24/2024,Inactive,,
CMC OP INFUSION,70521,"Taff, Jessica, MD",4/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - SqCC skin  x 6 weeks,Adjuvant,4/16/2024,Active,,
CBMC OP INFUSION 2FL,5068,"Wagmiller, Jennifer Ann, MD",6/5/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,6/4/2024,Inactive,,
CBMC OP INFUSION 2FL,5068,"Wagmiller, Jennifer Ann, MD",8/23/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,7/7/2024,Active,,
CINJ OP INFUSION,84094,"Boland, Patrick M, MD",3/4/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,3/4/2024,Inactive,,
CINJ OP INFUSION,84094,"Boland, Patrick M, MD",5/28/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/27/2024,Inactive,,
SOM OUTPT INFUSION,34871,"Toomey, Kathleen C, MD",4/10/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,3/21/2023,Inactive,,
SOM OUTPT INFUSION,34871,"Toomey, Kathleen C, MD",12/9/2024,Decitabine (5 day) 28 Day Cycles - AML,_1. First Line,12/6/2024,Active,,
CINJ OP INFUSION,83496,"George, Mridula A, MD",1/24/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/22/2025,Active,Malignant neoplasm of overlapping sites of right female breast (CMS/HCC),
CBMC OP INFUSION 2FL,96594,"Litvak, Anna M, MD",10/19/2023,Gemcitabine / CARBOplatin 14 Day Cycles - Breast,_2. Second Line,10/19/2023,Inactive,,
CBMC OP INFUSION 2FL,96594,"Leitner, Stuart P, MD",1/2/2024,CISplatin + Gemcitabine 28 Day Cycles - Pancreatic Adenocarcinoma,_2. Second Line,1/2/2024,Inactive,Malignant neoplasm of breast ,
CBMC OP INFUSION 2FL,96594,"Litvak, Anna M, MD",1/3/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,1/2/2025,Active,,
CBMC OP INFUSION 2FL,96594,"Leitner, Stuart P, MD",2/25/2025,EriBULin 21 Day Cycles - Breast,_3. Third Line,2/24/2025,Active,"Secondary malignant neoplasm of liver (CMS/HCC)
Malignant neoplasm of central portion of left female breast (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes (CMS/HCC)",
CBMC OP INFUSION 2FL,3172,"Litvak, Anna M, MD",4/9/2025,DOXOrubicin Liposomal 28 Day Cycles - Breast,_1. First Line,4/9/2025,Inactive,"Secondary malignant neoplasm of liver (CMS/HCC)
Breast cancer metastasized to multiple sites (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Antineoplastic drugs causing adverse effect, subsequent encounter
Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes (CMS/HCC)",
CINJ OP INFUSION,19291,"Omene, Coral Oghenerukevwe, MD",3/21/2023,CINJ 042102 EOP B (Z)-Endoxifen 28 Day Cycles Research- Breast Cancer,Neoadjuvant,3/20/2023,Inactive,,
CINJ OP INFUSION,19291,"Omene, Coral Oghenerukevwe, MD",1/2/2024,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,1/2/2024,Inactive,,
CINJ OP INFUSION,19291,"Omene, Coral Oghenerukevwe, MD",7/2/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,7/2/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,95264,"Aikins, James K, MD",6/12/2023,DOXOrubicin 21 Day Cycles - Uterine Sarcoma,Third Line,6/11/2023,Inactive,,
JCMC CP INFUSION,68638,"Cruz, Allan Louie E, MD",11/29/2023,Pembrolizumab 42 Day Cycles (starting cycle 11),_2. Second Line,11/29/2023,Active,,
CINJ OP INFUSION,19961,"Boland, Patrick M, MD",9/8/2023,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,,9/8/2023,Inactive,,
JCMC CP INFUSION,11482,"Sekhri, Arunabh, MD",1/2/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_3. Third Line,1/1/2024,Inactive,,
JCMC CP INFUSION,11482,"Cruz, Allan Louie E, MD",1/3/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_3. Third Line,1/2/2024,Inactive,,
SOM OUTPT INFUSION,91456,"Yin, Faye, MD",7/1/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,6/30/2024,Active,,
MMC OP VP INFUSION,24653,"Meghal, Trishala, MD",4/9/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/9/2024,Inactive,,
MMC OP INFUSION,39875,"Meghal, Trishala, MD",3/8/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,3/7/2023,Inactive,,
CBMC OP INFUSION 2FL,60503,"Grossman, I Robert, MD",12/26/2024,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_2. Second Line,12/25/2024,Active,Squamous cell carcinoma of mandible (CMS/HCC),
EMH HEM ONC,6465,"Patel, Eshan, MD",7/30/2024,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_1. First Line,7/30/2024,Active,,
NBI OP INFUSION,70577,"Jacoby, Sari H, MD",8/20/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,8/4/2024,Inactive,,
CINJ OP INFUSION,16132,"Saraiya, Biren P, MD",1/13/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,1/13/2023,Active,,
CBMC OP INFUSION 2FL,90628,"Grossman, I Robert, MD",4/7/2025,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,3/29/2025,Active,Malignant neoplasm of hepatic flexure (CMS/HCC),C18.3 - Malignant neoplasm of hepatic flexure (CMS/HCC); C77.5 - Secondary malignant neoplasm of iliac lymph node (CMS/HCC)
MMC OP VP INFUSION,38235,"Cohen, Seth D, MD",9/30/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,9/27/2024,Active,,
CMC OP INFUSION,38235,"Cohen, Seth D, MD",4/29/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/29/2025,Active,"Urothelial carcinoma (CMS/HCC)
Hypothyroidism, unspecified type",
CINJ OP INFUSION,68887,"Stephenson, Ruth D, DO",2/3/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/2/2023,Inactive,,
NBR 4N BMTU/IMCU,65962,"Assal, Amer, MD",12/21/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,_3. Third Line,12/21/2023,Inactive,,
CINJ OP INFUSION,1207,"Stephenson, Ryan D, DO",1/27/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/26/2025,Active,,
CINJ OP INFUSION,7241,"Haigentz, Missak, MD",3/27/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/26/2024,Inactive,,
CINJ OP INFUSION,7241,"Haigentz, Missak, MD",6/26/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/18/2024,Inactive,,
CINJ OP INFUSION,7241,"Haigentz, Missak, MD",10/31/2024,Sotorasib 28 Day Cycles - Non-Small Cell Lung Cancer,_2. Second Line,10/31/2024,Active,Adenocarcinoma of unknown primary (CMS/HCC),
MMC OP INFUSION,38204,"Lee, Patrick C, MD",9/5/2023,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,9/4/2023,Inactive,,
JCMC CP INFUSION,58924,"Sekhri, Arunabh, MD",11/29/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,10/8/2023,Inactive,,
JCMC CP INFUSION,58924,"Sekhri, Arunabh, MD",8/14/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,8/7/2024,Inactive,,
MMC OP VP INFUSION,75460,"Lee, Patrick C, MD",3/23/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,3/15/2023,Inactive,,
NBI VALERIE FND HEMONC,51324,"de Benedictis, Marianna, MD",3/6/2024,AHOD2131 All Arms ABVD,Induction,3/5/2024,Inactive,,
NBR 4N ONCOLOGY,18163,"Goel, Sanjay, MD",4/3/2023,R7075-ONC-2009 / CINJ 052008 Dose Level 9* REGN7075 / Cemiplimab 350 mg 21 Day Cycles Combination Research- Solid Tumors,Third Line,2/20/2023,Inactive,,
NBR CINJ OP INFUSION,16223,"Schaar, Dale, MD PhD",12/10/2024,"CINJ 022204 Cohort 5 Single Agent LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_3. Third Line,12/10/2024,Active,,
CINJ OP INFUSION,73592,"Berim, Lyudmyla, MD",2/26/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,2/25/2025,Active,Hepatocellular carcinoma (CMS/HCC),C22.0 - Liver cell carcinoma; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
CBMC OP INFUSION 2FL,22598,"Raptis, George, MD",4/9/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,4/9/2025,Active,Breast cancer (CMS/HCC),
CINJ OP INFUSION,9964,"Girda, Eugenia, MD",3/21/2023,CINJ 052202 Dose Expansion Cohort 1 RGX104 / DOCEtaxel 28 Day Cycles Research- Solid Malignancies,,2/12/2023,Inactive,,
NBR CINJ OP INFUSION,52673,"Braunschweig, Ira, MD",8/2/2023,Lymphodepletion Yescarta with Fludarabine/Cyclophosphamide 6 Day Cycle - Refractory Large B-Cell Lymphoma,,8/1/2023,Inactive,,
CINJ OP INFUSION,94155,"Haigentz, Missak, MD",8/7/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/7/2024,Inactive,,
CINJ OP INFUSION,30076,"Omene, Coral Oghenerukevwe, MD",5/6/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,5/5/2024,Active,,
NBR CINJ OP INFUSION,89112,"Shah, Mansi R, MD",5/25/2023,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,5/23/2023,Active,,
SOM OUTPT INFUSION,18712,"Toomey, Kathleen C, MD",2/10/2023,Pembrolizumab 42 Day Cycles - Bladder ,First Line,2/9/2023,Inactive,,
NBR CINJ OP INFUSION,20756,"Palmisiano, Neil David, MD",11/30/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,20756,"Assal, Amer, MD",4/2/2024,BMT Allogeneic TBF + Post Cy ,Consolidation,4/1/2024,Active,,
MMC OP VP INFUSION,74731,"Cohen, Seth D, MD",9/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/30/2024,Active,Intrahepatic bile duct carcinoma (CMS/HCC),
MMC OP VP INFUSION,4704,"Lee, Patrick C, MD",3/29/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/13/2024,Inactive,,
MMC OP VP INFUSION,4704,"Lee, Patrick C, MD",11/6/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/28/2024,Active,,
SOM OUTPT INFUSION,45719,"Patel, Eshan, MD",7/19/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/11/2024,Active,,
CINJ OP INFUSION,947,"Boland, Patrick M, MD",3/14/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,3/13/2023,Inactive,,
CINJ OP INFUSION,17359,"George, Mridula A, MD",10/4/2023,CINJ 042001 / I-0012-196-08 INCMGA00012 + Pelareorep 28 Day Cycles Research- Breast Cancer,Second Line,10/3/2023,Inactive,,
CINJ OP INFUSION,17359,"George, Mridula A, MD",11/6/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,11/5/2023,Inactive,,
CINJ OP INFUSION,17359,"George, Mridula A, MD",4/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,4/16/2024,Inactive,,
CINJ OP INFUSION,17359,"George, Mridula A, MD",9/6/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,_3. Third Line,8/27/2024,Inactive,,
CINJ OP INFUSION,17359,"George, Mridula A, MD",12/20/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_5. Fifth Line,12/19/2024,Inactive,,
CINJ OP INFUSION,15235,"Ganesan, Shridar, MD PhD",5/14/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,5/14/2024,Inactive,,
CINJ OP INFUSION,16076,"Girda, Eugenia, MD",1/27/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,1/26/2023,Inactive,,
CINJ OP INFUSION,16076,"Girda, Eugenia, MD",12/22/2023,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,12/19/2023,Inactive,,
CINJ OP INFUSION,16076,"Girda, Eugenia, MD",4/16/2024,"CINJ 102302 ARM 1 Phase 2 ACR-368 - Ovarian, Endometrial, Urothelial Cancer",_4. Fourth Line,4/16/2024,Active,,
CINJ OP INFUSION,33606,"Omene, Coral Oghenerukevwe, MD",8/30/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,8/29/2024,Active,,
CINJ OP INFUSION,33606,"Omene, Coral Oghenerukevwe, MD",1/28/2025,Capecitabine 21 Day Cycles - Breast,_2. Second Line,1/28/2025,Active,,
NBR 5N ONCOLOGY,33606,"Omene, Coral Oghenerukevwe, MD",2/15/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_2. Second Line,2/14/2025,Active,"Carcinoma of breast metastatic to multiple sites (CMS/HCC)
Metastases to the liver (CMS/HCC)","E87.5 - Hyperkalemia; C78.7 - Metastases to the liver (CMS/HCC); N17.9 - Acute kidney injury (CMS/HCC); C50.919 - Carcinoma of breast metastatic to multiple sites, unspecified laterality (CMS/HCC)"
NBR CINJ OP INFUSION,50992,"Assal, Amer, MD",10/10/2023,"Bortezomib D1, D4, D8, D11 21 Day Cycles- Multiple Myeloma",Induction,10/9/2023,Inactive,,
NBR 4N BMTU/IMCU,50992,"Assal, Amer, MD",11/10/2023,BMT UCB Flu / Cy / Thio / TBI,_2. Second Line,11/9/2023,Inactive,,
JCMC CP INFUSION,62444,"Cruz, Allan Louie E, MD",5/4/2023,PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,,5/4/2023,Inactive,,
JCMC CP INFUSION,62444,"Cruz, Allan Louie E, MD",5/30/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,5/29/2023,Inactive,,
JCMC CP INFUSION,62444,"Cruz, Allan Louie E, MD",10/16/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,_1. First Line,10/15/2023,Inactive,,
JCMC CP INFUSION,62444,"Cruz, Allan Louie E, MD",12/21/2023,Cetuximab Maintenance 14 Day Cycles- Head and Neck Cancers,_2. Second Line,12/20/2023,Inactive,,
JCMC CP INFUSION,62444,"Cruz, Allan Louie E, MD",3/18/2024,"Gemcitabine D1, D8 Cycles- Head and Neck Cancers 21 day cycle",_4. Fourth Line,3/18/2024,Inactive,,
NBI VALERIE FND HEMONC,14213,"Rao, Harini, MD",8/14/2024,PEDS AHOD1331 Bv-AVE-PC,_1. First Line,8/7/2024,Active,,
CINJ OP INFUSION,37191,"Patankar, Sonali, MD",7/29/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,7/10/2024,Active,,
SOM OUTPT INFUSION,64539,"George, Roshini, DO",2/10/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,2/7/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
SOM OUTPT INFUSION,64539,"George, Roshini, DO",2/10/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,2/10/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
SOM OUTPT INFUSION,64539,"George, Roshini, DO",4/21/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,4/21/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; E06.3 - Autoimmune thyroiditis; I10 - Essential (primary) hypertension; Z17.1 - Estrogen receptor negative status (ER-)
TRMC TCCC OP INFUSION,83685,"Capo, Gerardo, MD",2/19/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,2/19/2025,Active,Renal cell carcinoma (CMS/HCC),"C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis"
TRMC TCCC OP INFUSION,83685,"Capo, Gerardo, MD",3/7/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,2/19/2025,Active,Malignant neoplasm of right kidney (CMS/HCC),"C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis"
CINJ OP INFUSION,21667,"Berim, Lyudmyla, MD",1/25/2023,CINJ 071903 (EA2174) ARM C Nivolumab 240 mg 14 Day Cycles Research- Esophageal and Esophagogastric Junction Cancers,,1/23/2023,Inactive,,
JCMC CP INFUSION,73342,"Cruz, Allan Louie E, MD",3/24/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/24/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)","D50.0 - Iron deficiency anemia secondary to blood loss (chronic); D50.8 - Other iron deficiency anemias; C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; C80.1 - Malignant (primary) neoplasm, unspecified; Z17.0 - Estrogen receptor positive status (ER+)"
SOM OUTPT INFUSION,15373,"Toomey, Kathleen C, MD",4/5/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",Neoadjuvant,4/4/2023,Inactive,,
CINJ OP INFUSION,90126,"Omene, Coral Oghenerukevwe, MD",6/2/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,5/29/2023,Inactive,,
CINJ OP INFUSION,90126,"Omene, Coral Oghenerukevwe, MD",8/31/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,8/30/2023,Inactive,,
CBMC OP INFUSION 2FL,36725,"Wagmiller, Jennifer Ann, MD",8/19/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,8/18/2024,Inactive,,
JCMC CP INFUSION,20684,"Sekhri, Arunabh, MD",4/22/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/7/2024,Inactive,,
CINJ OP INFUSION,62290,"Boland, Patrick M, MD",3/13/2025,PACLitaxel/CARBOplatin 21 Day Cycles- Esophageal and Esophagogastric Junction Cancers,_1. First Line,3/13/2025,Active,Cancer of anal canal (CMS/HCC),"C21.0 - Malignant neoplasm of anus, unspecified"
NBI OP INFUSION,71476,"Anderson, Patrick S, MD",9/12/2024,Cisplatin / Topotecan / Bevacizumab 21 Day Cycles - Cervical,_3. Third Line,9/11/2024,Active,,
NBR CINJ OP INFUSION,55542,"Shah, Mansi R, MD",12/6/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,12/2/2024,Active,,
NBR CINJ OP INFUSION,91000,"Matasar, Matthew J, MD",5/19/2025,ICE Augmented (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - Hodgkin Lymphoma (Inpatient Regimen),_2. Second Line,5/19/2025,Active,Hodgkin lymphoma (CMS/HCC),"C81.90 - Hodgkin lymphoma, unspecified, unspecified site"
NBR BMSCH 2 PED HEMONC,91995,"Botwinick, Marissa, DO",11/13/2023,AALL1731 Non-DS SR B-ALL Patients- Induction,Induction,11/13/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,91995,"Botwinick, Marissa, DO",11/14/2023,AALL1731 Non-DS B-LLy - Induction,Induction,11/12/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,91995,"Botwinick, Marissa, DO",11/14/2023,AALL1731 Non-DS SR B-ALL Induction,Induction,11/13/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,91995,"Botwinick, Marissa, DO",11/14/2023,AALL1731 Non-DS SR B-ALL Induction,Induction,11/14/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,91995,"Goyal-Khemka, Meenakshi, MD",12/26/2023,AALL1731 SR-High B-ALL and DS-High B-ALL Consolidation,Consolidation,12/26/2023,Inactive,,
CINJ PEDS HEMONC ,91995,"Goyal-Khemka, Meenakshi, MD",3/12/2024,AALL1731 SR-High B-ALL Arms C & D Interim Maintenance I HDMTX,_1. First Line,3/11/2024,Inactive,,
CINJ PEDS HEMONC ,91995,"Goyal-Khemka, Meenakshi, MD",3/19/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,3/18/2024,Inactive,,
CINJ PEDS HEMONC ,91995,"Goyal-Khemka, Meenakshi, MD",4/23/2024,AALL1731 SR-High B-ALL Arms C & D Interim Maintenance I HDMTX,_1. First Line,4/18/2024,Inactive,,
CINJ PEDS HEMONC ,91995,"Goyal-Khemka, Meenakshi, MD",7/23/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 2",_1. First Line,7/15/2024,Inactive,,
CINJ PEDS HEMONC ,91995,"Botwinick, Marissa, DO",9/4/2024,AALL1731 SR-High B-ALL Arms C & D Delayed Intensification,_1. First Line,9/3/2024,Inactive,,
CINJ PEDS HEMONC ,91995,"Botwinick, Marissa, DO",12/12/2024,AALL1731 SR-High B-ALL Arms C & D - Interim Maintenance II CMTX,_1. First Line,12/12/2024,Active,,
CINJ OP INFUSION,19698,"Hochster, Howard S, MD",1/25/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Induction,1/23/2024,Inactive,,
CINJ OP INFUSION,19698,"Hochster, Howard S, MD",5/31/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,5/30/2024,Inactive,,
SOM OUTPT INFUSION,79201,"Patel, Eshan, MD",4/7/2025,Bevacizumab 28 Day Cycles - CNS,_1. First Line,4/7/2025,Active,Necrosis of brain due to radiation therapy,I67.89 - Other cerebrovascular disease
CBMC OP INFUSION 2FL,69603,"Dharmapuri, Sirish, MD",10/15/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/29/2024,Active,,
NBI A5 PEDIATRICS,64387,"Rao, Harini, MD",6/28/2024,Bevacizumab/Nivolumab Q 21 Day Cycles - CNS,_1. First Line,6/28/2024,Active,,
NBR CINJ OP INFUSION,91168,"Rhodes, Joanna Meehan, MD",8/24/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,8/23/2023,Inactive,,
CBMC OP INFUSION 2FL,68480,"Dharmapuri, Sirish, MD",5/23/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/12/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified"
JCMC CP INFUSION,71299,"Cruz, Allan Louie E, MD",9/4/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/3/2024,Inactive,,
JCMC CP INFUSION,71299,"Sekhri, Arunabh, MD",11/18/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/17/2024,Active,,
CBMC OP INFUSION 2FL,15789,"Dharmapuri, Sirish, MD",3/20/2025,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/20/2025,Active,Cancer of sigmoid (CMS/HCC),"C19 - Malignant neoplasm of rectosigmoid junction; K66.1 - Hemoperitoneum; K68.3 - Retroperitoneal hematoma; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; R71.0 - Precipitous drop in hematocrit; D69.59 - Other secondary thrombocytopenia; K81.1 - Chronic cholecystitis; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; K91.870 - Postprocedural hematoma of a digestive system organ or structure following a digestive system procedure; R19.7 - Diarrhea, unspecified; R55 - Syncope and collapse; Z53.8 - Procedure and treatment not carried out for other reasons; Z92.21 - Personal history of antineoplastic chemotherapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z98.890 - Other specified postprocedural states"
JCMC CP INFUSION,61375,"Cruz, Allan Louie E, MD",2/4/2025,mFOLFOX6  (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/3/2025,Active,Cancer of transverse colon (CMS/HCC),C18.4 - Malignant neoplasm of transverse colon
CBMC OP INFUSION 2FL,29245,"Scoppetuolo, Michael, MD",8/28/2023,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",_1. First Line,8/27/2023,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",2/1/2023,mFOLFOX6 Nivolumab Gastric cancer ,,1/30/2023,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",2/1/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,1/30/2023,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",5/18/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,5/3/2023,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",6/19/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,6/19/2023,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",3/22/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/21/2024,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",11/6/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/3/2024,Inactive,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",12/19/2024,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,12/11/2024,Active,,
CINJ OP INFUSION,69136,"Berim, Lyudmyla, MD",1/6/2025,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,12/11/2024,Active,,
CBMC OP INFUSION 2FL,91437,"Litvak, Anna M, MD",10/12/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,10/11/2023,Inactive,,
CBMC OP INFUSION 2FL,91437,"Scoppetuolo, Michael, MD",1/15/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_1. First Line,1/14/2024,Inactive,,
CMC OP INFUSION,28474,"Pompa, Tiffany Ann, MD",4/30/2025,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,4/30/2025,Active,"Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes (CMS/HCC)
Primary squamous cell carcinoma of cervix (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)",C77.5 - Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes (CMS/HCC); C53.9 - Primary squamous cell carcinoma of cervix (CMS/HCC)
CMC OP INFUSION,28474,"Pompa, Tiffany Ann, MD",4/30/2025,Atezolizumab 21 Day Cycles - Bladder,Maintenance,4/30/2025,Active,Primary squamous cell carcinoma of cervix (CMS/HCC),C77.5 - Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes (CMS/HCC); C53.9 - Primary squamous cell carcinoma of cervix (CMS/HCC)
NBR 5N ONCOLOGY,13373,"Tiger, Yun Kyoung, MD",10/2/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,10/1/2023,Inactive,,
CINJ OP INFUSION,720,"Mayer, Tina M, MD",8/31/2023,Enzalutamide 28 Day Cycles - Prostate,,8/31/2023,Inactive,,
CINJ OP INFUSION,720,"Mayer, Tina M, MD",10/8/2024,CINJ 082307 Arm 1 MK-5684 / Hormone Replacement Therapy 28 Day Cycles- Prostate Cancer,_2. Second Line,10/8/2024,Inactive,,
CINJ OP INFUSION,720,"Mayer, Tina M, MD",12/12/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,12/9/2024,Active,,
CINJ OP INFUSION,24437,"Mayer, Tina M, MD",5/12/2025,CINJ 082304 Phase 1 Cohort 2 and Phase 2 Arm 2 ONC-392 / Lutetium Lu 177 Vipivotide Tetraxetan 42 Day Cycles Research- Prostate Cancer,_3. Third Line,5/12/2025,Active,Malignant neoplasm of prostate (CMS/HCC),
CBMC OP INFUSION 2FL,8696,"Brown, Andrew Bennett, MD",4/22/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/21/2024,Inactive,,
JCMC CP INFUSION,53517,"Cruz, Allan Louie E, MD",7/18/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles --- Her2 (+)  Breast cancer,Neoadjuvant,7/17/2024,Inactive,,
JCMC CP INFUSION,53517,"Cruz, Allan Louie E, MD",8/20/2024,Perjeta / Trastuzumab 21 Day Cycles (Continuation) - Breast,Neoadjuvant,8/20/2024,Inactive,,
JCMC CP INFUSION,53517,"Cruz, Allan Louie E, MD",12/3/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,12/2/2024,Active,,
JCMC CP INFUSION,53517,"Cruz, Allan Louie E, MD",5/15/2025,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_3. Third Line,5/15/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,66162,"Berim, Lyudmyla, MD",10/20/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/19/2023,Inactive,,
CINJ OP INFUSION,66162,"Berim, Lyudmyla, MD",10/23/2023,CINJ 071702 (MK-3475-535) Pembrolizumab 21 Day Cycles Pre-Operative Research- Gastric Cancer,Neoadjuvant,9/24/2023,Inactive,,
NBI D7 MED-SURG/TELE,93479,"Jacoby, Sari H, MD",1/6/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,1/6/2025,Active,,
NBI OP INFUSION,93479,"Jacoby, Sari H, MD",2/26/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,2/25/2025,Active,Diffuse large B cell lymphoma (CMS/HCC),"C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes; C83.30 - Diffuse large B-cell lymphoma, unspecified site"
CBMC OP INFUSION 2FL,77960,"Gallinson, David Herschel, DO",3/31/2025,RiTUXimab 168 Day Cycles - Pemphigus (also MS/NMO),_1. First Line,3/31/2025,Inactive,Neuromyelitis optica (CMS/HCC),G36.0 - Neuromyelitis optica (devic); D72.820 - Lymphocytosis (symptomatic)
CBMC OP INFUSION 2FL,77960,"Gallinson, David Herschel, DO",3/31/2025,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,3/31/2025,Active,Neuromyelitis optica (CMS/HCC),
MMC OP INFUSION,89056,"Meghal, Trishala, MD",4/6/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,3/28/2024,Inactive,,
MMC OP INFUSION,89056,"Meghal, Trishala, MD",6/14/2024,CISplatin + Gemcitabine 28 Day Cycles - Pancreatic Adenocarcinoma,_1. First Line,6/14/2024,Inactive,,
MMC OP INFUSION,89056,"Meghal, Trishala, MD",9/11/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/9/2024,Active,,
CINJ OP INFUSION,73232,"Girda, Eugenia, MD",2/15/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,1/26/2023,Inactive,,
CINJ OP INFUSION,56118,"Toppmeyer, Deborah L, MD",7/11/2023,Palbociclib 28 Day Cycles - Breast,First Line,7/11/2023,Active,,
CINJ OP INFUSION,68067,"Aikins, James K, MD",9/22/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,9/21/2023,Inactive,,
CINJ OP INFUSION,68067,"Aikins, James K, MD",7/10/2024,Trastuzumab 21 Day Cycles (Continuation) -Uterine,Maintenance,7/9/2024,Inactive,,
CINJ OP INFUSION,68067,"Aikins, James K, MD",7/18/2024,CINJ 102310 Cohort B MK-4280A or Pembrolizumab / Lenvatinib 21 Day Cycles Research Solid Tumors,_2. Second Line,7/17/2024,Inactive,,
CINJ OP INFUSION,68067,"Aikins, James K, MD",9/13/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,9/12/2024,Active,,
CINJ OP INFUSION,32364,"Shah, Mansi R, MD",10/9/2023,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,10/8/2023,Inactive,,
NBR CINJ OP INFUSION,32364,"Shah, Mansi R, MD",2/9/2024,MAINTENANCE Carfilzomib 56 mg/m2 Weekly / Lenalidomide 5mg x 21 D Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,Maintenance,2/1/2024,Active,,
CBMC OP INFUSION 2FL,86396,"Grossman, I Robert, MD",3/14/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/19/2024,Active,Hepatocellular carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,43988,"Scoppetuolo, Michael, MD",3/29/2023,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",_1. First Line,3/28/2023,Inactive,,
CINJ OP INFUSION,40141,"Aikins, James K, MD",9/22/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,9/21/2023,Active,,
CINJ OP INFUSION,29219,"Saraiya, Biren P, MD",9/18/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,First Line,9/18/2023,Inactive,,
CINJ OP INFUSION,4204,"Boland, Patrick M, MD",8/10/2023,CINJ 072304 Cohort 1 ME-344 + Bevacizumab - Colorectal Cancer,,8/10/2023,Active,,
CINJ OP INFUSION,45035,"Toppmeyer, Deborah L, MD",9/7/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,9/6/2023,Inactive,,
CINJ OP INFUSION,45035,"Toppmeyer, Deborah L, MD",2/29/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/29/2024,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",
NBI OP INFUSION,8292,"Jacoby, Sari H, MD",10/15/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/7/2024,Active,,
NBR CINJ OP INFUSION,75609,"Rhodes, Joanna Meehan, MD",12/28/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/27/2023,Inactive,,
NBR CINJ OP INFUSION,75609,"Rhodes, Joanna Meehan, MD",1/25/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/17/2024,Inactive,,
CBMC OP INFUSION 2FL,21414,"Brown, Andrew Bennett, MD",9/19/2024,PACLitaxel / CARBOplatin Post Concurrent Radiation Consolidation 21 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,9/18/2024,Inactive,,
CBMC OP INFUSION 2FL,21414,"Brown, Andrew Bennett, MD",12/9/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,12/8/2024,Active,,
CBMC OP INFUSION 2FL,65233,"Brown, Andrew Bennett, MD",3/3/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/3/2025,Active,"Primary malignant neoplasm of right lower lobe of lung (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)","C34.31 - Malignant neoplasm of lower lobe, right bronchus or lung; M04.9 - Autoinflammatory syndrome, unspecified; Z11.59 - Encounter for screening for other viral diseases"
SOM OUTPT INFUSION,59570,"Toomey, Kathleen C, MD",12/7/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,12/6/2023,Inactive,,
CMC OP INFUSION,77852,"Eltoukhy, Hussam, MD",12/4/2024,RiTUXimab 28 Day Cycle - Marginal Zone Lymphoma,_1. First Line,12/3/2024,Inactive,,
CMC OP INFUSION,77852,"Eltoukhy, Hussam, MD",2/19/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,2/18/2025,Active,"Marginal zone lymphoma (CMS/HCC)
Encounter for screening for other viral diseases",
MSC OP INFUSION,77852,"Eltoukhy, Hussam, MD",3/7/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,3/7/2025,Active,"Marginal zone lymphoma (CMS/HCC)
Encounter for screening for other viral diseases",
CBMC OP INFUSION 2FL,50187,"Brown, Andrew Bennett, MD",4/16/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,3/31/2024,Inactive,,
CMC OP INFUSION,36006,"Taff, Jessica, MD",5/10/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/9/2023,Inactive,,
CBMC OP INFUSION 2FL,5747,"Radovich, Delia, MD",11/10/2023,ZIRABEV Maintenance 21 Day Cycles- Gastrointestinal Cancers (ZIRABEV PREFERRED BY INSURANCE),_2. Second Line,11/9/2023,Active,Sarcoidosis,
NBR CINJ OP INFUSION,39691,"Leiser, Aliza, MD",4/8/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,4/8/2025,Active,Endometrial cancer (CMS/HCC),
HAM OP INFUSION,53933,"Patel, Malini M, MD",6/19/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/16/2023,Inactive,,
CBMC OP INFUSION 2FL,42280,"Dharmapuri, Sirish, MD",9/18/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,9/8/2024,Active,,
CINJ OP INFUSION,39940,"Omene, Coral Oghenerukevwe, MD",4/11/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/11/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.22 - Progesterone receptor negative status; Z17.32 - Human epidermal growth factor receptor 2 negative status; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; N60.32 - Fibrosclerosis of left breast; Z17.1 - Estrogen receptor negative status (ER-)
HAM OP INFUSION,22262,"Yogarajah, Meera, MD",3/14/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/6/2024,Active,,
NBR 5N ONCOLOGY,38882,"Zayac, Adam, MD",10/16/2024,HyperCVAD + RiTUXimab (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate / RiTUXimab) - Lymphoma,_1. First Line,10/16/2024,Inactive,,
NBR CINJ OP INFUSION,38882,"Zayac, Adam, MD",10/31/2024,Twice Weekly-->NOW WEEKLY x 4 Intrathecal (IT) Chemotherapy for Lymphomatous Meningitis- Hematological Malignancies,_1. First Line,10/31/2024,Active,Multiple myeloma (CMS/HCC),
NBR CINJ OP INFUSION,38882,"Zayac, Adam, MD",12/2/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/2/2024,Active,,
NBR 5N ONCOLOGY,38882,"Zayac, Adam, MD",1/27/2025,Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia (Relapsed and Refractory),_2. Second Line,1/27/2025,Active,,
NBR 5N ONCOLOGY,55995,"Zayac, Adam, MD",5/14/2025,FLAG-IDA (Fludarabine / Cytarabine / IDArubicin / Filgrastim) - Acute Lymphoblastic Leukemia (Induction),_4. Fourth Line,5/14/2025,Inactive,"B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)
Lymphomatous meningitis (CMS/HCC)
Disorder of central nervous system concurrent with and due to acute lymphoblastic leukemia (ALL) (CMS/HCC)
Refractory acute lymphoblastic leukemia (ALL) (CMS/HCC)
Brain mass
Secondary malignancy of brain treated with chemotherapy (CMS/HCC)
Cancer related pain","C91.02 - Acute lymphoblastic leukemia, in relapse; A41.9 - Sepsis, unspecified organism; T80.211A - Bloodstream infection due to central venous catheter, initial encounter; Z66 - Do not resuscitate; D61.810 - Antineoplastic chemotherapy induced pancytopenia; G93.41 - Metabolic encephalopathy; J18.9 - Pneumonia, unspecified organism; J96.01 - Acute respiratory failure with hypoxia; R65.20 - Severe sepsis without septic shock; M62.82 - Rhabdomyolysis; C85.99 - Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites; D84.9 - Immunodeficiency, unspecified; J90 - Pleural effusion, not elsewhere classified; M48.54XA - Collapsed vertebra, not elsewhere classified, thoracic region, initial encounter for fracture; E87.20 - Acidosis, unspecified; Z11.52 - Encounter for screening for COVID-19; E83.39 - Other disorders of phosphorus metabolism; D64.81 - Anemia due to antineoplastic chemotherapy; F41.9 - Anxiety disorder, unspecified; Z74.09 - Other reduced mobility; G89.3 - Neoplasm related pain (acute) (chronic); E78.5 - Hyperlipidemia, unspecified; K59.03 - Drug induced constipation; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; D35.01 - Benign neoplasm of right adrenal gland; F17.290 - Nicotine dependence, other tobacco product, uncomplicated; G25.3 - Myoclonus; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.3 - Family history of diabetes mellitus; Z83.438 - Family history..."
NBR CINJ OP INFUSION,55995,"Zayac, Adam, MD",4/18/2025,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_3. Third Line,4/18/2025,Inactive,"B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)
Lymphomatous meningitis (CMS/HCC)
Disorder of central nervous system concurrent with and due to acute lymphoblastic leukemia (ALL) (CMS/HCC)
Refractory acute lymphoblastic leukemia (ALL) (CMS/HCC)
Brain mass
Secondary malignancy of brain treated with chemotherapy (CMS/HCC)
Cancer related pain",
CINJ OP INFUSION,91513,"Berim, Lyudmyla, MD",8/31/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/30/2023,Inactive,,
CINJ OP INFUSION,91513,"Berim, Lyudmyla, MD",12/19/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/18/2024,Active,,
CINJ OP INFUSION,70772,"Ghodoussipour, Saum Bobak, MD",12/5/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,12/5/2023,Inactive,,
MMC OP INFUSION,64545,"Meghal, Trishala, MD",2/7/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,2/6/2025,Inactive,Breast cancer metastasized to multiple sites (CMS/HCC),"C50.111 - Malignant neoplasm of central portion of right female breast; E43 - Unspecified severe protein-calorie malnutrition; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; I26.93 - Single subsegmental thrombotic pulmonary embolism without acute cor pulmonale; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C78.00 - Secondary malignant neoplasm of unspecified lung; K56.690 - Other partial intestinal obstruction; K56.699 - Other intestinal obstruction unspecified as to partial versus complete obstruction; R18.8 - Other ascites; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; D64.9 - Anemia, unspecified; N18.9 - Chronic kidney disease, unspecified; I50.32 - Chronic diastolic (congestive) heart failure; G62.9 - Polyneuropathy, unspecified; N17.9 - Acute kidney failure, unspecified; N13.39 - Other hydronephrosis; Z79.4 - Long term (current) use of insulin; Z17.0 - Estrogen receptor positive status (ER+); Z68.22 - Body mass index (BMI) 22.0-22.9, adult; Z17.21 - Progesterone receptor positive status; Z90.710 - Acquired absence of both cervix and uterus; Z90.12 - Acquired absence of left breast and nipple; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z79.84 - Long term (current) use of oral hypoglyc..."
CINJ OP INFUSION,12117,"Berim, Lyudmyla, MD",2/17/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,2/17/2025,Active,Colorectal cancer (CMS/HCC),N95.0 - Postmenopausal bleeding; C19 - Malignant neoplasm of rectosigmoid junction
HAM OP INFUSION,660,"Yogarajah, Meera, MD",5/25/2023,"PACLitaxel D1, D8 21 Day Cycles - Breast",First Line,5/24/2023,Inactive,,
NBR 4N ONCOLOGY,27229,"Matasar, Matthew J, MD",7/26/2023,G-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Obinuyuzumab) 21 Day Cycles - B-Cell Lymphoma,,7/25/2023,Inactive,,
NBR CINJ OP INFUSION,27229,"Matasar, Matthew J, MD",8/17/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Obinituzumab) 21 Day Cycles - B-Cell Lymphoma,First Line,7/25/2023,Inactive,,
NBR CINJ OP INFUSION,27229,"Matasar, Matthew J, MD",1/24/2024,Obinutuzumab Maintenance 56 Day Cycles - Follicular Lymphoma ,Maintenance,1/23/2024,Active,,
SOM OUTPT INFUSION,36805,"Patel, Eshan, MD",2/5/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/4/2024,Inactive,,
CINJ OP INFUSION,79967,"Saraiya, Biren P, MD",4/4/2023,Enzalutamide 30 Day Cycles - Prostate,First Line,4/4/2023,Inactive,,
CINJ OP INFUSION,95348,"Weiss, Sarah, MD",4/10/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,4/9/2024,Active,,
MMC BBR2 ONCOLOGY,60268,"Cohen, Seth D, MD",9/10/2024,"Bortezomib/Dexamethasone D1, D4, D8, D11 21 Day Cycles- Multiple Myeloma",_1. First Line,9/9/2024,Inactive,,
MMC OP VP INFUSION,60268,"Cohen, Seth D, MD",9/25/2024,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,9/13/2024,Inactive,,
MMC OP VP INFUSION,60268,"Cohen, Seth D, MD",10/17/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,10/13/2024,Active,,
CINJ OP INFUSION,99371,"Salacz, Michael E, MD",5/16/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Adjuvant,5/16/2023,Active,Malignant neoplasm of ascending colon (CMS/HCC),
CINJ OP INFUSION,2217,"Toppmeyer, Deborah L, MD",5/9/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/1/2024,Inactive,,
CINJ OP INFUSION,2217,"Toppmeyer, Deborah L, MD",8/29/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/28/2024,Active,Cecum mass,
CBMC OP INFUSION 2FL,51412,"Dave, Manish, MD",11/20/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/19/2023,Inactive,,
CINJ OP INFUSION,75325,"Stephenson, Ruth D, DO",5/19/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,5/16/2023,Active,,
SOM OUTPT INFUSION,74845,"Yin, Faye, MD",10/9/2023,PACLitaxel weekly / Trastuzumab Q21 Days Cycles - Breast,Adjuvant,10/6/2023,Inactive,,
SOM OUTPT INFUSION,74845,"Yin, Faye, MD",1/2/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,12/31/2023,Active,"Malignant neoplasm of overlapping sites of right lung (CMS/HCC)
Metastasis from malignant neoplasm of lung (CMS/HCC)
Secondary malignant neoplasm of brain and spinal cord (CMS/HCC)
Encounter for screening for other viral diseases",
CMC OP INFUSION,45587,"Talwar, Sumit, MD",12/4/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,12/4/2023,Inactive,,
CINJ OP INFUSION,24938,"Stephenson, Ryan D, DO",7/10/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,7/10/2024,Active,,
CINJ OP INFUSION,10164,"Gulhati, Prateek, MD PhD",5/25/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,5/25/2023,Inactive,,
CINJ OP INFUSION,10164,"Gulhati, Prateek, MD PhD",12/21/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/20/2023,Inactive,,
CINJ OP INFUSION,10164,"Gulhati, Prateek, MD PhD",10/3/2024,Amivantamab-vmjw Patients < 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,10/2/2024,Active,,
CMC OP INFUSION,27726,"Pompa, Tiffany Ann, MD",2/25/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/24/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CMC OP INFUSION,27726,"Pompa, Tiffany Ann, MD",3/6/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/6/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,64253,"Haigentz, Missak, MD",6/21/2023,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,Second Line,6/21/2023,Inactive,,
CINJ OP INFUSION,796,"Dasgeb, Bahar, MD",1/29/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,1/8/2024,Inactive,,
HAM OP INFUSION,58916,"Yogarajah, Meera, MD",6/24/2024,Gemcitabine 1000 mg/m2/ CISplatin 75 mg/m2 + pembrolizumb 200mg 21 Day Cycles- NeoadjuvantNon-Small Cell Lung Cancer,Neoadjuvant,6/23/2024,Active,,
CINJ OP INFUSION,97944,"Berim, Lyudmyla, MD",7/12/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/11/2024,Inactive,,
CINJ OP INFUSION,97944,"Berim, Lyudmyla, MD",9/11/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/10/2024,Inactive,,
NBI OP INFUSION,16819,"Shah, Shailja S, MD",8/15/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/14/2023,Active,,
NBI D7 MED-SURG/TELE,16819,"Shah, Shailja S, MD",12/19/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,12/19/2024,Active,,
SOM OUTPT INFUSION,72933,"Yin, Faye, MD",5/14/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,5/7/2024,Inactive,,
SOM OUTPT INFUSION,72933,"Patel, Eshan, MD",11/1/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/1/2024,Active,,
SOM OUTPT INFUSION,11286,"Patel, Eshan, MD",2/5/2025,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,1/28/2025,Active,"Malignant neoplasm of both ovaries (CMS/HCC)
Gynecologic cancer (CMS/HCC)","C57.9 - Malignant neoplasm of female genital organ, unspecified; C56.3 - Malignant neoplasm of bilateral ovaries"
NBR CINJ OP INFUSION,60003,"Matasar, Matthew J, MD",7/17/2024,Gamunex IVIG every 2 months,Maintenance,7/17/2024,Active,,
JCMC CP INFUSION,68954,"Cruz, Allan Louie E, MD",12/29/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Endometrial adenocarcinoma,Neoadjuvant,12/20/2023,Active,,
CBMC OP INFUSION 2FL,62004,"Wagmiller, Jennifer Ann, MD",5/9/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,5/9/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C50.112 - Malignant neoplasm of central portion of left female breast; Z17.1 - Estrogen receptor negative status (ER-); Z79.899 - Other long term (current) drug therapy
CBMC 2W ONCOLOGY,62004,"Wagmiller, Jennifer Ann, MD",4/18/2025,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_1. First Line,4/18/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)
Long term use of drug","A41.9 - Sepsis, unspecified organism; J18.9 - Pneumonia, unspecified organism; J91.0 - Malignant pleural effusion; C78.2 - Secondary malignant neoplasm of pleura; Z11.52 - Encounter for screening for COVID-19; J94.8 - Other specified pleural conditions; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; C50.112 - Malignant neoplasm of central portion of left female breast; B19.20 - Unspecified viral hepatitis C without hepatic coma; J45.909 - Unspecified asthma, uncomplicated; E87.1 - Hypo-osmolality and hyponatremia; J98.11 - Atelectasis; R06.03 - Acute respiratory distress; K76.0 - Fatty (change of) liver, not elsewhere classified; E87.70 - Fluid overload, unspecified; Z17.1 - Estrogen receptor negative status (ER-); Z17.22 - Progesterone receptor negative status; Z17.32 - Human epidermal growth factor receptor 2 negative status; Z85.3 - Personal history of malignant neoplasm of breast; Z87.892 - Personal history of anaphylaxis; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.899 - Other long term (current) drug therapy; Z91.048 - Other nonmedicinal substance allergy status"
CBMC 2W ONCOLOGY,62004,"Wagmiller, Jennifer Ann, MD",4/17/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,4/17/2025,Inactive,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)
Long term use of drug","A41.9 - Sepsis, unspecified organism; J18.9 - Pneumonia, unspecified organism; J91.0 - Malignant pleural effusion; C78.2 - Secondary malignant neoplasm of pleura; Z11.52 - Encounter for screening for COVID-19; J94.8 - Other specified pleural conditions; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; C50.112 - Malignant neoplasm of central portion of left female breast; B19.20 - Unspecified viral hepatitis C without hepatic coma; J45.909 - Unspecified asthma, uncomplicated; E87.1 - Hypo-osmolality and hyponatremia; J98.11 - Atelectasis; R06.03 - Acute respiratory distress; K76.0 - Fatty (change of) liver, not elsewhere classified; E87.70 - Fluid overload, unspecified; Z17.1 - Estrogen receptor negative status (ER-); Z17.22 - Progesterone receptor negative status; Z17.32 - Human epidermal growth factor receptor 2 negative status; Z85.3 - Personal history of malignant neoplasm of breast; Z87.892 - Personal history of anaphylaxis; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.899 - Other long term (current) drug therapy; Z91.048 - Other nonmedicinal substance allergy status"
CBMC OP INFUSION 2FL,61675,"Litvak, Anna M, MD",4/29/2025,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,_1. First Line,4/29/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
MSC OP INFUSION,47553,"Talwar, Sumit, MD",4/12/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Second Line,4/11/2023,Inactive,,
CINJ OP INFUSION,72652,"Stephenson, Ryan D, DO",12/11/2023,Relugolix 30 day Cycles - Prostate,Neoadjuvant,12/11/2023,Inactive,,
SOM OUTPT INFUSION,24791,"Patel, Eshan, MD",12/30/2024,pembrolizumab 200 m g q21days-lung,_1. First Line,12/30/2024,Active,,
CINJ OP INFUSION,94311,"Boland, Patrick M, MD",3/17/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,3/16/2023,Inactive,,
CMC OP INFUSION,35307,"Easaw, Sarah, MD",6/1/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/24/2023,Inactive,,
CINJ OP INFUSION,65655,"Mayer, Tina M, MD",1/9/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,1/7/2024,Inactive,,
CINJ OP INFUSION,65655,"Mayer, Tina M, MD",7/16/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_4. Fourth Line,7/15/2024,Inactive,,
CINJ OP INFUSION,65655,"Mayer, Tina M, MD",10/8/2024,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_4. Fourth Line,10/7/2024,Inactive,,
CINJ OP INFUSION,13293,"Girda, Eugenia, MD",5/2/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,5/1/2024,Inactive,,
CINJ OP INFUSION,13293,"Girda, Eugenia, MD",12/5/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,12/5/2024,Active,,
SOM OUTPT INFUSION,38835,"Patel, Eshan, MD",10/14/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,10/14/2024,Active,"Oral cavity carcinoma (CMS/HCC)
End stage renal disease (CMS/HCC)",
HAM OP INFUSION,57705,"Yogarajah, Meera, MD",3/28/2024,"Bortezomib/Dexamethasone D1, D4, D8, D11 21 Day Cycles- Multiple Myeloma",_1. First Line,3/25/2024,Inactive,,
HAM OP INFUSION,57705,"Yogarajah, Meera, MD",4/22/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,4/14/2024,Active,,
NBR BMSCH 2 PED HEMONC,5686,"Cole, Peter David, MD",2/19/2025,PEDS ANHL1131 steroid prephase,_1. First Line,2/19/2025,Inactive,Diffuse large B-cell lymphoma of intrathoracic lymph nodes (CMS/HCC),"C83.32 - Diffuse large b-cell lymphoma, intrathoracic lymph nodes; F41.9 - Anxiety disorder, unspecified; L29.9 - Pruritus, unspecified; I86.1 - Scrotal varices; Z11.52 - Encounter for screening for COVID-19; Z83.2 - Family history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism; Z23 - Encounter for immunization"
CBMC OP INFUSION 2FL,20543,"Raptis, George, MD",6/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/3/2024,Inactive,,
CBMC OP INFUSION 2FL,20543,"Raptis, George, MD",7/30/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,7/29/2024,Active,,
NBR CINJ OP INFUSION,45151,"Shah, Mansi R, MD",7/16/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,7/2/2024,Inactive,,
NBR CINJ OP INFUSION,40327,"Matasar, Matthew J, MD",7/14/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/11/2023,Inactive,,
CINJ OP INFUSION,94249,"George, Mridula A, MD",2/21/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/20/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,33266,"Boland, Patrick M, MD",4/16/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,_1. First Line,3/18/2024,Inactive,,
CINJ OP INFUSION,33266,"Boland, Patrick M, MD",6/25/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,_1. First Line,6/10/2024,Active,,
CINJ OP INFUSION,73613,"Stephenson, Ryan D, DO",5/21/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,5/21/2025,Active,Malignant neoplasm of prostate (CMS/HCC),C61 - Malignant neoplasm of prostate; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels
CBMC 2W ONCOLOGY,54555,"Grossman, I Robert, MD",9/5/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,9/5/2023,Inactive,,
CBMC 2W ONCOLOGY,54555,"Grossman, I Robert, MD",11/20/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,11/20/2023,Inactive,,
CINJ OP INFUSION,17132,"Haigentz, Missak, MD",11/11/2024,DOCEtaxel with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,11/10/2024,Active,,
CINJ OP INFUSION,49898,"Girda, Eugenia, MD",5/11/2023,CINJ 102203 ARM 1 Nemvaleukin / Pembrolizumab 21 Day Cycles Research- Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,5/4/2023,Inactive,,
CINJ OP INFUSION,30375,"Berim, Lyudmyla, MD",8/3/2023,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI +/- Bevacizumab (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,,7/5/2023,Inactive,,
CINJ OP INFUSION,30375,"Berim, Lyudmyla, MD",10/4/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,10/3/2023,Inactive,,
CINJ OP INFUSION,30375,"Berim, Lyudmyla, MD",2/7/2024,"Encorafenib + Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,1/31/2024,Inactive,,
CINJ OP INFUSION,30375,"Berim, Lyudmyla, MD",9/5/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_3. Third Line,9/5/2024,Inactive,,
CINJ OP INFUSION,19022,"Hochster, Howard S, MD",7/27/2023,"Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Third Line,7/26/2023,Inactive,,
MMC OP VP INFUSION,77244,"Lee, Patrick C, MD",2/15/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/5/2024,Inactive,,
NBR 5N ONCOLOGY,15691,"Palmisiano, Neil David, MD",4/6/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),First Line,4/5/2023,Inactive,,
CMC 4B ONCOLOGY,13533,"Ferretti, Mark J, MD",9/15/2024,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,9/15/2024,Active,,
CMC OP INFUSION,13533,"Ferretti, Mark J, MD",10/4/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,_1. First Line,10/3/2024,Active,,
CMC OP INFUSION,13533,"Ferretti, Mark J, MD",12/9/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,_1. First Line,12/8/2024,Active,,
CINJ OP INFUSION,11987,"Stephenson, Ryan D, DO",3/1/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,3/1/2023,Inactive,,
CINJ OP INFUSION,11987,"Stephenson, Ryan D, DO",7/29/2024,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,7/29/2024,Active,,
CINJ OP INFUSION,11987,"Stephenson, Ryan D, DO",7/29/2024,Talazoparib 28 Day Cycles ,_2. Second Line,7/29/2024,Active,On antineoplastic chemotherapy,
MMC OP VP INFUSION,4972,"Lee, Patrick C, MD",9/12/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 42 Day Cycles- Mesothelioma,_2. Second Line,9/11/2024,Active,,
CINJ OP INFUSION,14291,"Gulhati, Prateek, MD PhD",4/21/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,4/21/2023,Inactive,,
CINJ OP INFUSION,14291,"Gulhati, Prateek, MD PhD",9/22/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,9/6/2023,Inactive,,
CBMC OP INFUSION 2FL,982,"Wagmiller, Jennifer Ann, MD",1/15/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/15/2024,Inactive,,
NBR CINJ OP INFUSION,98232,"Evens, Andrew M, DO",4/19/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,,4/18/2023,Inactive,,
CBMC OP INFUSION 2FL,89291,"Wagmiller, Jennifer Ann, MD",4/28/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/28/2025,Active,"Ovary cancer, left (CMS/HCC)
Anemia associated with nutritional deficiency",
NBR 5N ONCOLOGY,46088,"Haigentz, Missak, MD",11/2/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,11/2/2023,Inactive,,
SOM OUTPT INFUSION,29410,"Patel, Eshan, MD",9/27/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/24/2024,Inactive,,
CBMC OP INFUSION 2FL,27099,"Litvak, Anna M, MD",1/30/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,_1. First Line,1/21/2025,Active,,
CBMC OP INFUSION 2FL,27099,"Litvak, Anna M, MD",4/24/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,4/24/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",C50.111 - Malignant neoplasm of central portion of right female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,92658,"Boland, Patrick M, MD",8/25/2023,CINJ 072201 Control ARM Cetuximab + Irinotecan 14 Day Cycles Research- Colorectal Cancer,,7/23/2023,Inactive,,
CINJ OP INFUSION,92658,"Boland, Patrick M, MD",10/27/2023,"Irinotecan/Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/26/2023,Inactive,,
CINJ OP INFUSION,92658,"Boland, Patrick M, MD",3/8/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,3/8/2024,Inactive,,
CINJ OP INFUSION,31280,"Saraiya, Biren P, MD",1/30/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,First Line,1/29/2023,Inactive,,
NBR CINJ OP INFUSION,39996,"Matasar, Matthew J, MD",1/8/2023,rabbit Anti-Thymocyte Globulin / CycloSPORINE / Eltrombopag - Aplastic Anemia,,1/8/2023,Inactive,,
JCMC CP INFUSION,61008,"Sekhri, Arunabh, MD",2/13/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,2/12/2023,Inactive,,
JCMC CP INFUSION,61008,"Sekhri, Arunabh, MD",6/7/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Maintenance,6/7/2023,Inactive,,
JCMC CP INFUSION,61008,"Sekhri, Arunabh, MD",10/2/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,10/1/2023,Inactive,,
JCMC CP INFUSION,61008,"Sekhri, Arunabh, MD",3/27/2024,Enfortumab Vedotin 28 Day Cycles - Bladder,_2. Second Line,3/19/2024,Inactive,,
JCMC CP INFUSION,61008,"Sekhri, Arunabh, MD",8/22/2024,Sacituzumab Govitecan 21 Day Cycles - Stage IV Urothelial carcinoma,_3. Third Line,8/4/2024,Inactive,,
JCMC CP INFUSION,61008,"Sekhri, Arunabh, MD",12/23/2024,DOCEtaxel 21 Day Cycles - bladder,_5. Fifth Line,12/22/2024,Active,,
JCMC CP INFUSION,52675,"Cruz, Allan Louie E, MD",1/16/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,12/19/2023,Active,,
JCMC CP INFUSION,52675,"Cruz, Allan Louie E, MD",1/16/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/15/2024,Inactive,,
JCMC CP INFUSION,52675,"Cruz, Allan Louie E, MD",7/9/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Maintenance,7/8/2024,Active,,
SOM OUTPT INFUSION,4638,"Toomey, Kathleen C, MD",5/17/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,Third Line,5/15/2023,Inactive,,
SOM OUTPT INFUSION,4638,"Toomey, Kathleen C, MD",10/15/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,10/15/2024,Active,,
SOM OUTPT INFUSION,4638,"Toomey, Kathleen C, MD",10/15/2024,Neratinib 28 Day Cycles - Breast,_3. Third Line,10/15/2024,Active,,
SOM OUTPT INFUSION,4638,"Toomey, Kathleen C, MD",5/30/2025,Capecitabine / Lapatinib 21 Day Cycles - Breast,_3. Third Line,5/30/2025,Active,"Stage IV breast cancer in female (CMS/HCC)
Metastasis to bone (CMS/HCC)",
NBR CINJ OP INFUSION,99207,"Chowaniec, Wayne B, NP",6/9/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,Maintenance,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,99207,"Braunschweig, Ira, MD",9/27/2023,Isatuximab-irfc/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,,9/26/2023,Inactive,,
NBR CINJ OP INFUSION,99207,"Braunschweig, Ira, MD",11/13/2023,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,11/12/2023,Inactive,,
NBR CINJ OP INFUSION,99207,"Braunschweig, Ira, MD",11/8/2024,Isatuximab-irfc/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,,11/6/2024,Inactive,,
NBR 4N ONCOLOGY,48681,"Tiger, Yun Kyoung, MD",3/8/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/7/2024,Inactive,,
NBR 4N ONCOLOGY,48681,"Zayac, Adam, MD",3/9/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/7/2024,Inactive,,
NBR CINJ OP INFUSION,48681,"Zayac, Adam, MD",5/28/2024,Venetoclax / Decitabine 28 Day Cycles - Myeloid Blast Crisis of Chronic Myeloid Leukemia,_1. First Line,5/27/2024,Inactive,,
CMC OP INFUSION,16135,"Cohen, Seth D, MD",1/19/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,1/18/2024,Inactive,,
CINJ OP INFUSION,33420,"Stephenson, Ryan D, DO",4/28/2025,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,4/28/2025,Active,Primary nonseminomatous germ cell tumor of descended left testicle (CMS/HCC),C62.12 - Malignant neoplasm of descended left testis
CINJ OP INFUSION,14408,"Stephenson, Ryan D, DO",1/16/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,1/16/2025,Active,,
CINJ OP INFUSION,99328,"Berim, Lyudmyla, MD",12/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/4/2023,Active,,
CINJ OP INFUSION,26568,"Mayer, Tina M, MD",12/12/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_2. Second Line,11/6/2024,Active,,
NBR CINJ OP INFUSION,40011,"Rhodes, Joanna Meehan, MD",5/28/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,5/22/2024,Active,,
NBR CINJ OP INFUSION,40011,"Rhodes, Joanna Meehan, MD",6/28/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_2. Second Line,6/27/2024,Inactive,,
SOM OUTPT INFUSION,65194,"Patel, Eshan, MD",12/3/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,12/2/2024,Active,,
SOM OUTPT INFUSION,65194,"Patel, Eshan, MD",2/5/2025,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,12/2/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
CBMC OP INFUSION 2FL,25248,"Brown, Andrew Bennett, MD",4/24/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Colon Cancer,_1. First Line,4/24/2024,Active,,
CBMC OP INFUSION 2FL,25248,"Brown, Andrew Bennett, MD",5/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Colon Cancer,Consolidation,5/21/2024,Inactive,Colon cancer metastasized to liver (CMS/HCC),
CBMC OP INFUSION 2FL,25248,"Brown, Andrew Bennett, MD",1/29/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Colon Cancer,_1. First Line,1/28/2025,Active,,
CBMC OP INFUSION 2FL,25248,"Brown, Andrew Bennett, MD",5/13/2025,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,5/13/2025,Active,Adenocarcinoma of colon metastatic to liver (CMS/HCC),
CBMC OP INFUSION 2FL,82685,"Dharmapuri, Sirish, MD",1/17/2025,CINJ 072207 (NRG-GI008) Cohort B ARM 4 MFOLFIRINOX (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Ressearch- Colorectal Cancer,Adjuvant,1/5/2025,Active,,
NBI OP INFUSION,29036,"Jacoby, Sari H, MD",12/16/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,12/16/2024,Active,,
NBI OP INFUSION,27860,"Schleicher, Lori, MD",1/27/2025,Nivo AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/26/2025,Active,,
MSC OP INFUSION,18491,"Cohen, Seth D, MD",8/10/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,First Line,8/9/2023,Inactive,,
NBR CINJ OP INFUSION,52058,"Eltoukhy, Hussam, MD",9/8/2023,CINJ 012207 Arm 1 Dose Level 2 Tazemetostat / Rituximab / Bendamustine 28 Day Cycles Research- Follicular Lymphoma,First Line,9/4/2023,Active,,
CINJ OP INFUSION,19171,"Mayer, Tina M, MD",9/12/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,9/12/2024,Active,,
CINJ OP INFUSION,19171,"Mayer, Tina M, MD",10/3/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - urothelial cancer,Adjuvant,10/2/2024,Inactive,,
CBMC OP INFUSION 2FL,40029,"Dharmapuri, Sirish, MD",2/19/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/18/2025,Active,Carcinoma of unknown primary (CMS/HCC),"C80.1 - Malignant (primary) neoplasm, unspecified"
CBMC OP INFUSION 2FL,40029,"Dharmapuri, Sirish, MD",3/4/2025,FOLFOX - B,_1. First Line,2/19/2025,Active,Carcinoma of unknown primary (CMS/HCC),"C80.1 - Malignant (primary) neoplasm, unspecified"
NBR CINJ OP INFUSION,94200,"Evens, Andrew M, DO",1/4/2024,Lymphodepletion Tecartus with Fludarabine / Cyclophosphamide - Mantle Cell Lymphoma,Lymphodepletion,1/3/2024,Active,,
SOM OUTPT INFUSION,23344,"Patel, Eshan, MD",3/18/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/14/2024,Active,,
SOM OUTPT INFUSION,23344,"Patel, Eshan, MD",5/13/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/13/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; E06.4 - Drug-induced thyroiditis; E53.8 - Deficiency of other specified B group vitamins"
CMC OP INFUSION,67828,"Easaw, Sarah, MD",6/19/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,6/15/2023,Inactive,,
CMC OP INFUSION,67828,"Talwar, Sumit, MD",6/19/2023,Pembrolizumab 21 Day Cycles - Uterine,First Line,6/15/2023,Active,,
CMC OP INFUSION,75122,"Easaw, Sarah, MD",3/27/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles + RiTUXimab 84 Day Cycles - Follicular Lymphoma,First Line,3/26/2023,Inactive,,
CMC OP INFUSION,54137,"Talwar, Sumit, MD",7/17/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/16/2024,Inactive,,
CBMC OP INFUSION 2FL,21948,"Litvak, Anna M, MD",3/28/2025,CINJ 042102 EOP F Endoxifen / Abemaciclib 28 Day Cycles Research,Neoadjuvant,3/28/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,12692,"Anderson, Patrick S, MD",11/30/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles -Endometrial cancer,_1. First Line,11/29/2023,Active,,
NBR CINJ OP INFUSION,63182,"Evens, Andrew M, DO",5/31/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,,5/30/2023,Inactive,,
CINJ OP INFUSION,30559,"Girda, Eugenia, MD",9/1/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Uterine cancer,,8/30/2023,Inactive,,
TRMC TCCC OP INFUSION,93256,"Salerno, Vincent E, MD",5/7/2025,Pembrolizumab 21 Day Cycles - Hepatocellular ca,_1. First Line,5/7/2025,Active,"Hepatocellular carcinoma (CMS/HCC)
Encntr for follow-up exam after trtmt for malignant neoplasm",C22.0 - Liver cell carcinoma; Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm
CINJ OP INFUSION,98808,"Aikins, James K, MD",8/8/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/7/2024,Active,,
CINJ PEDS HEMONC ,23860,"Drachtman, Richard, MD",10/24/2023,112304 GBT440-041 Voxelotor (Cohorts B & C),_1. First Line,10/24/2023,Inactive,,
CINJ PEDS HEMONC ,23860,"Drachtman, Richard, MD",4/30/2024,112304 GBT440-041 Voxelotor (Cohorts B & C),_1. First Line,4/30/2024,Inactive,,
CINJ PEDS HEMONC ,23860,"Drachtman, Richard, MD",7/25/2024,112304 GBT440-041 Voxelotor (Cohorts B & C),_1. First Line,7/25/2024,Inactive,,
CBMC OP INFUSION 2FL,37821,"Brown, Andrew Bennett, MD",10/4/2023,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,10/4/2023,Inactive,,
CBMC OP INFUSION 2FL,37821,"Brown, Andrew Bennett, MD",11/2/2023,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,11/2/2023,Inactive,,
NBR CINJ OP INFUSION,65728,"Matasar, Matthew J, MD",7/8/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,,7/7/2023,Inactive,,
NBR CINJ OP INFUSION,65728,"Matasar, Matthew J, MD",3/5/2024,GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,3/4/2024,Inactive,,
NBR 4N ONCOLOGY,65728,"Schaar, Dale, MD PhD",9/17/2024,BMT Autologous BEAM,_4. Fourth Line,9/17/2024,Active,,
CINJ OP INFUSION,32345,"Haigentz, Missak, MD",1/3/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,1/3/2023,Inactive,,
CINJ OP INFUSION,32345,"Haigentz, Missak, MD",3/28/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/27/2023,Inactive,,
CINJ OP INFUSION,32345,"Girda, Eugenia, MD",10/10/2023,CINJ 052202 Dose Expansion Cohort 1 RGX104 / DOCEtaxel 28 mg/m2 28 Day Cycles Research- Solid Malignancies,_3. Third Line,9/17/2023,Inactive,,
NBR 4N BMTU/IMCU,47809,"Braunschweig, Ira, MD",2/8/2023,BMT Autologous BEAM,,2/7/2023,Inactive,,
CINJ OP INFUSION,67646,"Boland, Patrick M, MD",9/20/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/19/2024,Active,,
CINJ OP INFUSION,67646,"Boland, Patrick M, MD",4/8/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Maintenance,4/8/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum
JCMC CP INFUSION,65118,"Sekhri, Arunabh, MD",7/18/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/7/2024,Active,,
SOM OUTPT INFUSION,30906,"Yin, Faye, MD",10/13/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,9/25/2023,Inactive,,
JCMC CP INFUSION,89042,"Sekhri, Arunabh, MD",5/3/2023,NALIRIFOX (Fluorouracil Continuous Infusion/nanoliposomal Irinotecan/OXALIplatin) 21 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,5/1/2023,Inactive,,
JCMC CP INFUSION,89042,"Sekhri, Arunabh, MD",3/20/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,3/19/2024,Active,,
CINJ OP INFUSION,94412,"Stephenson, Ruth D, DO",3/1/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/21/2023,Inactive,,
CINJ OP INFUSION,94412,"Stephenson, Ruth D, DO",7/12/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,First Line,7/11/2023,Inactive,,
CINJ OP INFUSION,94412,"Stephenson, Ruth D, DO",6/7/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,6/6/2024,Active,,
CINJ PEDS HEMONC ,80649,"Masterson, Margaret, MD",2/3/2023,PEDS Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia,Third Line,2/1/2023,Inactive,,
CINJ OP INFUSION,76519,"Stephenson, Ryan D, DO",10/3/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Adjuvant,10/1/2024,Active,,
TRMC TCCC OP INFUSION,2377,"Salerno, Vincent E, MD",3/15/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/14/2023,Active,,
NBR 5N ONCOLOGY,89390,"Palmisiano, Neil David, MD",5/10/2024,Cytarabine Cytoreduction for Hyperleukocytosis,Induction,5/10/2024,Inactive,,
NBR 5N ONCOLOGY,89390,"Palmisiano, Neil David, MD",5/14/2024,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,_2. Second Line,5/13/2024,Active,,
NBR CINJ OP INFUSION,89390,"Palmisiano, Neil David, MD",2/6/2025,CALGB 9111 (Maintenance Therapy) 28 Day Cycles + Blinatumomab 42 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,2/4/2025,Active,ALL (acute lymphocytic leukemia) (CMS/HCC),
NBR CINJ OP INFUSION,90678,"Palmisiano, Neil David, MD",4/29/2025,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,4/28/2025,Inactive,ALL (acute lymphocytic leukemia) (CMS/HCC),
NBR CINJ OP INFUSION,90678,"Palmisiano, Neil David, MD",4/28/2025,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_2. Second Line,4/28/2025,Inactive,ALL (acute lymphocytic leukemia) (CMS/HCC),
CINJ OP INFUSION,49730,"Boland, Patrick M, MD",11/5/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/28/2024,Active,,
JCMC CP INFUSION,24638,"Sekhri, Arunabh, MD",2/24/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,2/23/2025,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),"C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; R06.02 - Shortness of breath; C50.911 - Malignant neoplasm of unspecified site of right female breast; D64.9 - Anemia, unspecified; N18.31 - Chronic kidney disease, stage 3a; Z17.1 - Estrogen receptor negative status (ER-)"
JCMC CP INFUSION,24638,"Sekhri, Arunabh, MD",3/3/2025,Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,2/24/2025,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),"C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; R06.02 - Shortness of breath; C50.911 - Malignant neoplasm of unspecified site of right female breast; D64.9 - Anemia, unspecified; N18.31 - Chronic kidney disease, stage 3a; Z17.1 - Estrogen receptor negative status (ER-)"
CINJ OP INFUSION,4485,"Saraiya, Biren P, MD",7/5/2023,Abiraterone (Low Dose) / PredniSONE- Prostate,,7/5/2023,Inactive,,
CINJ OP INFUSION,4485,"Saraiya, Biren P, MD",12/5/2023,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,11/14/2023,Inactive,,
CINJ OP INFUSION,92239,"Hochster, Howard S, MD",11/1/2023,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,_3. Third Line,11/1/2023,Inactive,,
CINJ OP INFUSION,92239,"Hochster, Howard S, MD",5/23/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,5/22/2024,Inactive,,
HAM OP INFUSION,14593,"Yogarajah, Meera, MD",2/26/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/21/2024,Inactive,,
CMC OP INFUSION,81535,"Samuel, David, MD",5/8/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,5/8/2025,Active,Uterine carcinosarcoma (CMS/HCC),
CINJ OP INFUSION,74311,"Boland, Patrick M, MD",9/6/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/16/2024,Inactive,,
NBR CINJ OP INFUSION,78307,"Shah, Mansi R, MD",1/19/2023,Bortezomib/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,,1/18/2023,Inactive,,
NBR CINJ OP INFUSION,78307,"Shah, Mansi R, MD",6/22/2023,Isatuximab-irfc/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,,6/21/2023,Inactive,,
NBR CINJ OP INFUSION,78307,"Shah, Mansi R, MD",10/27/2023,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_7. Seventh Line,10/26/2023,Active,Pre B-cell acute lymphoblastic leukemia in remission (CMS/HCC),
CMC OP INFUSION,92905,"Cohen, Seth D, MD",4/22/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,4/21/2024,Inactive,,
CMC OP INFUSION,92905,"Cohen, Seth D, MD",9/11/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,8/28/2024,Active,,
NBR CINJ OP INFUSION,60737,"Evens, Andrew M, DO",7/17/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,7/17/2024,Inactive,,
NBR CINJ OP INFUSION,60737,"Evens, Andrew M, DO",8/28/2024,RiTUXimab and holding bendamustine 28 Day Cycles - Follicular Lymphoma,_2. Second Line,8/27/2024,Active,"Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Chronic fatigue
A-fib (CMS/HCC)
Recurrent lung adenocarcinoma, left (CMS/HCC)",
CINJ OP INFUSION,63528,"Boland, Patrick M, MD",9/12/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,9/11/2023,Inactive,,
JCMC CP INFUSION,19618,"Cruz, Allan Louie E, MD",8/9/2023,Maintenance Bevacizumab 21 Day Cycles - Ovarian Cancer,_1. First Line,8/7/2023,Active,,
JCMC CP INFUSION,19618,"Zhou, Nancy, MD",11/27/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/27/2023,Inactive,,
MSC OP INFUSION,93046,"Easaw, Sarah, MD",5/10/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,5/9/2023,Inactive,,
MSC OP INFUSION,93046,"Talwar, Sumit, MD",3/6/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/4/2024,Inactive,,
CINJ OP INFUSION,7896,"Boland, Patrick M, MD",1/9/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,1/8/2023,Inactive,,
CINJ OP INFUSION,7896,"Boland, Patrick M, MD",4/25/2023,Lonsurf + Oxaliplatin desensitization (+ Bevacizumab),,4/23/2023,Inactive,,
CINJ OP INFUSION,7896,"Boland, Patrick M, MD",10/2/2023,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",,9/21/2023,Inactive,,
SOM OUTPT INFUSION,99442,"Yin, Faye, MD",12/22/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/12/2023,Inactive,,
SOM OUTPT INFUSION,99442,"Toomey, Kathleen C, MD",4/27/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,4/26/2024,Inactive,,
SOM OUTPT INFUSION,99442,"Yin, Faye, MD",6/7/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,6/6/2024,Inactive,,
SOM OUTPT INFUSION,99442,"Toomey, Kathleen C, MD",7/19/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,6/30/2024,Active,,
CINJ OP INFUSION,88344,"Hochster, Howard S, MD",7/6/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,Neoadjuvant,7/5/2023,Inactive,,
JCMC CP INFUSION,72001,"Sekhri, Arunabh, MD",10/21/2024,Methotrexate 14 Day Cycles - Gestational Trophoblastic Neoplasia ,_1. First Line,10/20/2024,Active,,
NBR CINJ OP INFUSION,68607,"Zayac, Adam, MD",10/7/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,10/3/2024,Inactive,,
CINJ OP INFUSION,84764,"Weiss, Sarah, MD",6/6/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,5/30/2023,Inactive,,
CINJ OP INFUSION,84764,"Weiss, Sarah, MD",7/5/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,7/4/2023,Inactive,,
NBR 5N ONCOLOGY,30342,"Haigentz, Missak, MD",3/28/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Lung (advanced poorly differentiated carcinoma),_1. First Line,3/28/2024,Inactive,,
CINJ OP INFUSION,59703,"Patel, Eshan, MD",1/29/2024,CINJ 032111 (EA3161) ARMS A and B CISplatin with Concurrent Radiation 7 Day Cycles Research- Oropharyngeal Carcinoma,_1. First Line,1/27/2024,Active,,
CINJ OP INFUSION,4189,"Ghodoussipour, Saum Bobak, MD",4/7/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,4/6/2023,Inactive,,
CMC OP INFUSION,4189,"Taff, Jessica, MD",9/1/2023,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,Second Line,8/27/2023,Inactive,,
CINJ OP INFUSION,18444,"Saraiya, Biren P, MD",12/9/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,12/9/2024,Active,,
CINJ OP INFUSION,21273,"Mayer, Tina M, MD",4/18/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,4/18/2023,Inactive,,
HAM OP INFUSION,78422,"Patel, Malini M, MD",5/10/2023,"PACLitaxel D1, D8 21 Day Cycles - Breast",Third Line,5/8/2023,Inactive,,
CINJ OP INFUSION,32174,"Hochster, Howard S, MD",3/14/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/12/2024,Inactive,,
CINJ OP INFUSION,32174,"Hochster, Howard S, MD",11/7/2024,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,11/7/2024,Active,,
CINJ OP INFUSION,76357,"Hochster, Howard S, MD",10/30/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,10/2/2024,Active,,
CBMC OP INFUSION 2FL,41986,"Leitner, Stuart P, MD",1/22/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,1/21/2024,Inactive,,
CBMC OP INFUSION 2FL,41986,"Leitner, Stuart P, MD",3/18/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,3/17/2024,Active,,
CBMC OP INFUSION 2FL,67052,"Wagmiller, Jennifer Ann, MD",11/15/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,10/24/2024,Active,,
HAM OP INFUSION,64757,"Patel, Malini M, MD",12/1/2023,Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles - Multiple Myeloma,_2. Second Line,11/28/2023,Inactive,,
CINJ OP INFUSION,51776,"George, Mridula A, MD",12/16/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,12/15/2024,Active,,
CINJ OP INFUSION,73942,"George, Mridula A, MD",2/12/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,2/11/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.21 - Progesterone receptor positive status; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+); Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,54568,"Litvak, Anna M, MD",10/13/2023,CINJ 042102 Block A Zanidatamab 14 Day Cycles Research- Breast Cancer,_1. First Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,54568,"Brown, Andrew Bennett, MD",2/7/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,2/7/2024,Inactive,,
CBMC OP INFUSION 2FL,54568,"Brown, Andrew Bennett, MD",6/3/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,6/3/2024,Active,,
NBR 4N BMTU/IMCU,22996,"Schaar, Dale, MD PhD",2/16/2024,BMT Allogeneic Mel / Thio / Flu + Post Cy,Consolidation,2/16/2024,Inactive,,
NBI OP INFUSION,55891,"Anderson, Patrick S, MD",5/21/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/21/2025,Active,Endometrial adenocarcinoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; R18.8 - Other ascites; C54.1 - Malignant neoplasm of endometrium; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; N89.8 - Other specified noninflammatory disorders of vagina; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
SOM OUTPT INFUSION,623,"Patel, Eshan, MD",3/16/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,3/14/2023,Inactive,,
SOM OUTPT INFUSION,623,"Patel, Eshan, MD",7/10/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,6/4/2023,Inactive,,
CBMC OP INFUSION 2FL,77854,"Grossman, I Robert, MD",5/24/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,5/24/2024,Inactive,,
NBR CINJ OP INFUSION,77854,"Palmisiano, Neil David, MD",5/30/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,5/30/2024,Inactive,,
NBR CINJ OP INFUSION,77854,"Palmisiano, Neil David, MD",9/5/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,Consolidation,8/22/2024,Inactive,,
NBR CINJ OP INFUSION,77854,"Palmisiano, Neil David, MD",10/8/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,10/8/2024,Inactive,,
NBR CINJ OP INFUSION,77854,"Palmisiano, Neil David, MD",1/6/2025,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,1/6/2025,Active,,
CBMC OP INFUSION 2FL,96919,"Brown, Andrew Bennett, MD",7/22/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/21/2024,Active,,
NBR 4N ONCOLOGY,97283,"Sridharan, Ashwin, MD",3/5/2023,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),,3/5/2023,Inactive,,
NBR 5N ONCOLOGY,97283,"Braunschweig, Ira, MD",5/7/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,5/7/2023,Inactive,,
NBR CINJ OP INFUSION,97283,"Braunschweig, Ira, MD",11/15/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/7/2023,Inactive,,
CINJ OP INFUSION,56670,"Saraiya, Biren P, MD",4/19/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,4/19/2023,Active,,
NBR CINJ OP INFUSION,47446,"Chen, Xiaoyi",1/3/2025,FLAG-IDA (Fludarabine / Cytarabine / IDArubicin / Filgrastim) - Acute Myeloid Leukemia (Induction),_1. First Line,1/3/2025,Inactive,"Myeloid sarcoma, not having achieved remission (CMS/HCC)",
NBR CINJ OP INFUSION,47446,"Chen, Xiaoyi",1/14/2025,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia,_1. First Line,1/14/2025,Active,,
CMC OP INFUSION,23957,"Easaw, Sarah, MD",3/15/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,First Line,3/14/2023,Inactive,,
CMC OP INFUSION,23957,"Talwar, Sumit, MD",2/28/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/6/2024,Inactive,,
CMC OP INFUSION,23957,"Talwar, Sumit, MD",7/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/8/2024,Inactive,,
CMC OP INFUSION,23957,"Talwar, Sumit, MD",10/9/2024,FOLFIRI  (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,10/8/2024,Active,,
CINJ OP INFUSION,60501,"Weiss, Sarah, MD",4/28/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,4/24/2023,Inactive,,
NBR CINJ OP INFUSION,83514,"Egini, Ogechukwu, MD",12/15/2024,BMT Allogeneic TBF + Post Cy,_3. Third Line,12/14/2024,Active,,
NBR CINJ OP INFUSION,83514,"Egini, Ogechukwu, MD",1/25/2025,BMT Allogeneic TBF + Post Cy,_3. Third Line,12/14/2024,Active,,
NBR CINJ OP INFUSION,83514,"Egini, Ogechukwu, MD",2/1/2025,BMT Allogeneic TBF + Post Cy,_3. Third Line,12/14/2024,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Stem cells transplant status (CMS/HCC)","Z94.84 - Stem cells transplant status; Z01.818 - Encounter for other preprocedural examination; C92.00 - Acute myeloblastic leukemia, not having achieved remission"
CMC OP INFUSION,1475,"Taff, Jessica, MD",8/28/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,8/17/2023,Inactive,,
CINJ OP INFUSION,87146,"Mayer, Tina M, MD",5/15/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,,5/15/2023,Inactive,,
CINJ OP INFUSION,80407,"Toppmeyer, Deborah L, MD",3/23/2023,Palbociclib 28 Day Cycles - Breast,First Line,3/23/2023,Active,,
CBMC OP INFUSION 2FL,66811,"Gallinson, David Herschel, DO",4/8/2025,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,Maintenance,4/8/2025,Active,Cancer of sigmoid colon (CMS/HCC),
CBMC OP INFUSION 2FL,66811,"Gallinson, David Herschel, DO",3/17/2025,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,Maintenance,3/17/2025,Inactive,Cancer of sigmoid colon (CMS/HCC),
MMC OP INFUSION,90600,"Meghal, Trishala, MD",5/2/2023,"Bortezomib D1, D15 Maintenance 28 Day Cycles- Multiple Myeloma",Maintenance,4/30/2023,Inactive,,
MMC OP VP INFUSION,90600,"Meghal, Trishala, MD",9/26/2024,Pomalidomide 28 Day Cycles- Multiple Myeloma,Maintenance,9/26/2024,Active,,
NBR CINJ OP INFUSION,54274,"Shah, Mansi R, MD",5/22/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_3. Third Line,5/22/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; R60.0 - Localized edema; G62.9 - Polyneuropathy, unspecified; E05.00 - Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm; M25.551 - Pain in right hip; Z94.84 - Stem cells transplant status; R93.1 - Abnormal findings on diagnostic imaging of heart and coronary circulation; R25.1 - Tremor, unspecified; G40.209 - Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus; J06.9 - Acute upper respiratory infection, unspecified; D80.1 - Nonfamilial hypogammaglobulinemia; Z92.25 - Personal history of immunosuppression therapy; Z92.21 - Personal history of antineoplastic chemotherapy"
SOM OUTPT INFUSION,46412,"Toomey, Kathleen C, MD",10/3/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,10/2/2024,Active,"Malignant neoplasm of areola of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,15522,"Toomey, Kathleen C, MD",2/26/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,2/25/2025,Active,Breast cancer of upper-outer quadrant of right female breast (CMS/HCC),
MMC OP VP INFUSION,51791,"Meghal, Trishala, MD",11/12/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,11/12/2024,Active,,
CBMC OP INFUSION 2FL,74505,"Wagmiller, Jennifer Ann, MD",9/28/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,9/27/2023,Inactive,,
CBMC OP INFUSION 2FL,74505,"Wagmiller, Jennifer Ann, MD",9/28/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,9/28/2023,Inactive,,
MMC OP INFUSION,88166,"Lee, Patrick C, MD",4/30/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,Induction,4/21/2024,Inactive,,
CINJ OP INFUSION,44254,"Stephenson, Ruth D, DO",1/19/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,First Line,1/5/2023,Inactive,,
CINJ OP INFUSION,44254,"Stephenson, Ruth D, DO",2/15/2023,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Consolidation,2/14/2023,Inactive,,
CINJ OP INFUSION,15622,"Dasgeb, Bahar, MD",3/4/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers Scalp Squamous Cell,_1. First Line,2/13/2025,Active,"Squamous cell carcinoma of multiple sites
History of squamous cell carcinoma in situ",
CINJ OP INFUSION,47013,"Berim, Lyudmyla, MD",8/9/2023,CINJ 072201 Treatment ARM NBT-NM108 14 Day Cycles Research- Colorectal Cancer,,7/12/2023,Active,,
CINJ OP INFUSION,47013,"Berim, Lyudmyla, MD",11/9/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/8/2023,Active,,
CINJ OP INFUSION,47013,"Berim, Lyudmyla, MD",2/24/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,2/23/2025,Active,Colon cancer metastasized to multiple sites (CMS/HCC),
MSC OP INFUSION,84945,"Cohen, Seth D, MD",10/10/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,10/9/2024,Active,,
CMC OP INFUSION,84945,"Cohen, Seth D, MD",1/14/2025,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_2. Second Line,1/14/2025,Active,,
NBI VALERIE FND HEMONC,95347,"Bhatla, Teena, MD",11/19/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,11/17/2024,Active,,
NBR CINJ OP INFUSION,70074,"Shah, Mansi R, MD",11/29/2023,Carfilzomib 56 mg/m2 Weekly / Pomalyst Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,11/29/2023,Inactive,,
MSC OP INFUSION,48530,"Eltoukhy, Hussam, MD",2/27/2024,HyperCVD Mini (RiTUXimab / Cytarabine / Cyclophosphamide / VinCRIStine / DexAMETHasone) + Venetoclax 28 Day Cycles - Acute Lymphoblastic Leukemia,_1. First Line,2/25/2024,Inactive,,
NBR CINJ OP INFUSION,48530,"Zayac, Adam, MD",3/27/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,3/27/2024,Inactive,,
NBR CINJ OP INFUSION,48530,"Zayac, Adam, MD",4/10/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/10/2024,Inactive,,
NBR CINJ OP INFUSION,68540,"Shah, Mansi R, MD",10/23/2023,"CINJ 012309 Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles Research- Multiple Myeloma",10. Tenth Line,10/23/2023,Inactive,,
NBR CINJ OP INFUSION,68540,"Shah, Mansi R, MD",10/23/2023,"Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles- Multiple Myeloma",10. Tenth Line,10/23/2023,Inactive,,
NBR CINJ OP INFUSION,68540,"Shah, Mansi R, MD",1/23/2024,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_7. Seventh Line,1/22/2024,Inactive,,
NBR CINJ OP INFUSION,68540,"Shah, Mansi R, MD",2/13/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_8. Eighth Line,2/12/2024,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",10/4/2023,AALL1732 Induction,_1. First Line,10/3/2023,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",11/2/2023,AALL1732 Induction,_1. First Line,11/1/2023,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",11/8/2023,AALL1732 Consolidation,_1. First Line,11/8/2023,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",11/9/2023,AALL1732 Consolidation,_1. First Line,11/8/2023,Inactive,,
NBI VALERIE FND HEMONC,8794,"Ford, Maegan C, MD",12/29/2023,Asparaginase Erwinia (Rylaze) 14 Day Cycles,Consolidation,12/29/2023,Inactive,,
NBI VALERIE FND HEMONC,8794,"Ford, Maegan C, MD",1/9/2024,Asparaginase Erwinia (Rylaze) 14 Day Cycles,Consolidation,1/9/2024,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",1/19/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,1/10/2024,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",4/5/2024,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy: Delayed Intensification",_1. First Line,4/4/2024,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",6/17/2024,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,6/17/2024,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",8/14/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,8/13/2024,Inactive,,
NBI VALERIE FND HEMONC,8794,"Rao, Harini, MD",9/20/2024,"AALL1732 HR B-ALL Arm A & C, MPAL, B-LLy Maintenance",_1. First Line,9/20/2024,Active,,
CBMC OP INFUSION 2FL,72316,"Grossman, I Robert, MD",1/3/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,1/3/2024,Active,,
CBMC OP INFUSION 2FL,26101,"Brown, Andrew Bennett, MD",5/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/28/2024,Active,,
CBMC OP INFUSION 2FL,94312,"Leitner, Stuart P, MD",2/24/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,2/16/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,94312,"Leitner, Stuart P, MD",5/19/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/19/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,82952,"Jang, Thomas L, MD",10/24/2024,BCG Induction (TICE) 42 Day Cycle,Induction,10/22/2024,Active,,
NBI OP INFUSION,55277,"Anderson, Patrick S, MD",12/14/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_4. Fourth Line,12/13/2023,Inactive,,
NBI OP INFUSION,99418,"Anderson, Patrick S, MD",4/14/2025,Dostarlimab-gxly 42 Day Cycles- Gynecologic Cancers,_3. Third Line,4/14/2025,Active,"Malignant neoplasm of endocardium (CMS/HCC)
Endometrial cancer (CMS/HCC)",
HAM OP INFUSION,67801,"Yogarajah, Meera, MD",6/21/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,6/16/2024,Active,Malignant neoplasm of bronchus of left lower lobe (CMS/HCC),
CINJ OP INFUSION,1413,"Girda, Eugenia, MD",12/6/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,12/5/2023,Active,,
CINJ OP INFUSION,25362,"Hochster, Howard S, MD",9/14/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/12/2023,Inactive,,
CINJ OP INFUSION,25362,"Hochster, Howard S, MD",1/8/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,1/8/2024,Active,,
CBMC OP INFUSION 2FL,42474,"Scoppetuolo, Michael, MD",11/14/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_1. First Line,11/13/2023,Inactive,,
CINJ OP INFUSION,82464,"Patel, Eshan, MD",3/19/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,3/10/2024,Inactive,,
CINJ OP INFUSION,82464,"Patel, Eshan, MD",6/28/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/20/2024,Inactive,,
CINJ OP INFUSION,82464,"Patel, Eshan, MD",7/30/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles,_1. First Line,7/29/2024,Inactive,,
CINJ OP INFUSION,55722,"Toppmeyer, Deborah L, MD",6/24/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,6/23/2024,Inactive,,
CINJ OP INFUSION,55722,"Toppmeyer, Deborah L, MD",10/28/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/6/2024,Inactive,,
CINJ OP INFUSION,55722,"Toppmeyer, Deborah L, MD",11/18/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,11/15/2024,Active,,
CINJ OP INFUSION,12741,"Gulhati, Prateek, MD PhD",2/22/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/21/2024,Inactive,,
NBR CINJ OP INFUSION,61048,"Egini, Ogechukwu, MD",9/25/2024,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,_4. Fourth Line,9/24/2024,Active,,
NBI OP PED SEDATION,17302,"de Benedictis, Marianna, MD",9/27/2023,AALL1731 All SR-Avg B-ALL (including DS patients) - Interim Maintenance I EscMTX,_1. First Line,9/27/2023,Inactive,,
NBI VALERIE FND HEMONC,17302,"de Benedictis, Marianna, MD",11/28/2023,"AALL1731 ALL SR-Fav B-ALL, SR-Avg B-ALL Arms A & B, and B-LLy (including DS patients) Delayed Intensification",_1. First Line,11/28/2023,Inactive,,
CMC 4B ONCOLOGY,84915,"Talwar, Sumit, MD",12/7/2024,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_3. Third Line,12/6/2024,Active,,
HAM OP INFUSION,35191,"Patel, Malini M, MD",7/17/2023,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,7/16/2023,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
Encounter for screening for other viral diseases",
CBMC OP INFUSION 2FL,66554,"Wagmiller, Jennifer Ann, MD",9/11/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_3. Third Line,9/10/2023,Inactive,,
NBR CINJ OP INFUSION,45802,"Dasgeb, Bahar, MD",8/13/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,7/29/2024,Active,"Invasive ductal carcinoma of breast, female, right (CMS/HCC)",
CMC OP INFUSION,64932,"Taff, Jessica, MD",4/21/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/21/2025,Active,Malignant neoplasm of other parts of pancreas (CMS/HCC),
CINJ OP INFUSION,85953,"Mayer, Tina M, MD",1/9/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,1/9/2024,Inactive,,
CINJ OP INFUSION,85953,"Mayer, Tina M, MD",3/18/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,3/15/2024,Inactive,,
CINJ OP INFUSION,85953,"Mayer, Tina M, MD",5/24/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,5/24/2024,Active,,
SOM OUTPT INFUSION,79216,"Patel, Eshan, MD",6/24/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Bladder,_2. Second Line,5/26/2024,Active,,
JCMC CP INFUSION,47219,"Cruz, Allan Louie E, MD",3/18/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,3/3/2024,Inactive,,
SOM OUTPT INFUSION,82174,"Toomey, Kathleen C, MD",7/9/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/8/2024,Active,,
SOM OUTPT INFUSION,63597,"Toomey, Kathleen C, MD",4/4/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,4/4/2025,Active,"Malignant neoplasm of ovary (CMS/HCC)
Ovarian cancer (CMS/HCC)",
CINJ OP INFUSION,8345,"Mayer, Tina M, MD",3/10/2023,Pembrolizumab 21 Day Cycles - high TMB,,3/10/2023,Inactive,,
CINJ OP INFUSION,42041,"Groisberg, Roman, MD",3/6/2025,Pembrolizumab 21 Day Cycles - Melanoma,Neoadjuvant,3/6/2025,Active,"Angiosarcoma of skin
Hypothyroidism due to medication","C49.0 - Malignant neoplasm of connective and soft tissue of head, face and neck; C44.99 - Other specified malignant neoplasm of skin, unspecified"
CINJ PEDS HEMONC ,69106,"Cole, Peter David, MD",11/6/2023,Selumetinib (Koselugo),_1. First Line,11/5/2023,Active,Primary malignant neoplasm of fallopian tube (CMS/HCC),
SOM OUTPT INFUSION,89506,"Patel, Eshan, MD",1/7/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/6/2025,Active,,
CINJ OP INFUSION,45429,"Aikins, James K, MD",3/14/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,2/14/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),"C54.9 - Malignant neoplasm of corpus uteri, unspecified; Z48.816 - Encounter for surgical aftercare following surgery on the genitourinary system"
NBR CINJ OP INFUSION,26921,"Evens, Andrew M, DO",8/16/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,,8/15/2023,Inactive,,
CINJ OP INFUSION,19929,"Berim, Lyudmyla, MD",11/16/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/15/2023,Inactive,,
NBR CINJ OP INFUSION,4563,"Shah, Mansi R, MD",7/11/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,Third Line,7/10/2023,Active,,
CBMC OP INFUSION 2FL,76689,"Brown, Andrew Bennett, MD",3/21/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_2. Second Line,3/20/2024,Inactive,,
NBI OP INFUSION,27974,"Cheng, Yan Ho, MD",12/12/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,11/27/2023,Inactive,,
NBI OP INFUSION,27974,"Cheng, Yan Ho, MD",3/5/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_2. Second Line,3/4/2024,Inactive,,
CINJ OP INFUSION,28576,"Saraiya, Biren P, MD",3/26/2024,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,3/26/2024,Active,,
CINJ OP INFUSION,23975,"Boland, Patrick M, MD",3/21/2025,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/21/2025,Active,"Metastatic adenocarcinoma (CMS/HCC)
Other abnormal tumor markers","C80.1 - Malignant (primary) neoplasm, unspecified; C79.9 - Secondary malignant neoplasm of unspecified site; D50.9 - Iron deficiency anemia, unspecified"
CBMC OP INFUSION 2FL,34757,"Scoppetuolo, Michael, MD",11/4/2024,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,11/3/2024,Active,,
CBMC OP INFUSION 2FL,7571,"Scoppetuolo, Michael, MD",4/14/2025,Durvalumab Maintenance 28 Day Cycles- Biliary Tract Cancers,_1. First Line,4/14/2025,Active,"Metastatic cancer to liver (CMS/HCC)
Carcinoma of hepatobiliary system (CMS/HCC)","C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C24.9 - Malignant neoplasm of biliary tract, unspecified"
CBMC OP INFUSION 2FL,68688,"Wagmiller, Jennifer Ann, MD",11/7/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,11/7/2023,Inactive,,
CBMC OP INFUSION 2FL,68688,"Wagmiller, Jennifer Ann, MD",2/7/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,1/31/2024,Inactive,,
CBMC OP INFUSION 2FL,68688,"Wagmiller, Jennifer Ann, MD",1/20/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/17/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),
CINJ OP INFUSION,63447,"Berim, Lyudmyla, MD",10/28/2024,Everolimus 28 Day Cycles - NET,_2. Second Line,10/28/2024,Active,,
CINJ OP INFUSION,68737,"Aikins, James K, MD",2/3/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,2/2/2023,Active,,
CINJ OP INFUSION,41586,"Aikins, James K, MD",4/25/2025,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,4/25/2025,Active,Peritoneal carcinomatosis (CMS/HCC),C56.9 - Malignant neoplasm of unspecified ovary; Z51.11 - Encounter for antineoplastic chemotherapy; I10 - Essential (primary) hypertension; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum
NBR CINJ OP INFUSION,59965,"Schaar, Dale, MD PhD",3/13/2023,Gemcitabine 28 Day Cycles - Cutaneous T-Cell Lymphoma,,3/12/2023,Inactive,,
CBMC OP INFUSION 2FL,46033,"Wagmiller, Jennifer Ann, MD",7/21/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,7/20/2023,Inactive,,
CBMC OP INFUSION 2FL,46033,"Wagmiller, Jennifer Ann, MD",3/4/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/3/2024,Inactive,,
CBMC OP INFUSION 2FL,46033,"Wagmiller, Jennifer Ann, MD",3/25/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,3/24/2024,Active,,
CBMC OP INFUSION 2FL,82949,"Gallinson, David Herschel, DO",4/10/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,4/3/2025,Active,"Malignant neoplasm of axillary tail of right breast in male, estrogen receptor negative (CMS/HCC)","C50.621, Z17.1 - Malignant neoplasm of axillary tail of right breast in male, estrogen receptor negative (CMS/HCC)"
CBMC OP INFUSION 2FL,89970,"Dharmapuri, Sirish, MD",4/21/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,4/14/2025,Active,Anal cancer (CMS/HCC),"C21.0 - Malignant neoplasm of anus, unspecified"
CINJ OP INFUSION,28295,"Toppmeyer, Deborah L, MD",3/25/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/22/2024,Inactive,,
CINJ OP INFUSION,28295,"Toppmeyer, Deborah L, MD",7/30/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,7/28/2024,Inactive,,
CINJ OP INFUSION,28295,"Toppmeyer, Deborah L, MD",10/3/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,9/29/2024,Active,,
CINJ OP INFUSION,92661,"Packiam, Vignesh, MD",4/28/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/28/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),C67.8 - Malignant neoplasm of overlapping sites of bladder; Z85.46 - Personal history of malignant neoplasm of prostate
CBMC OP INFUSION 2FL,65189,"Dharmapuri, Sirish, MD",11/2/2023,FOLFIRI + B --> CAPIRI - B,_2. Second Line,11/1/2023,Inactive,"Malignant neoplasm of rectum (CMS/HCC)
Secondary malignant neoplasm of left lung (CMS/HCC)
Metastasis to liver (CMS/HCC)",
CBMC OP INFUSION 2FL,65189,"Dharmapuri, Sirish, MD",1/16/2025,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/15/2025,Active,,
CBMC OP INFUSION 2FL,32995,"Scoppetuolo, Michael, MD",11/22/2023,Palbociclib 28 Day Cycles - Breast,_2. Second Line,11/22/2023,Active,,
CINJ OP INFUSION,79757,"Mayer, Tina M, MD",12/14/2023,Pembrolizumab 21 Day Cycles - Kidney,Adjuvant,12/14/2023,Inactive,,
CINJ OP INFUSION,79757,"Mayer, Tina M, MD",4/25/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,4/25/2024,Active,,
NBR CINJ OP INFUSION,44261,"Shah, Mansi R, MD",3/7/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,2/21/2024,Inactive,,
NBR CINJ OP INFUSION,44261,"Shah, Mansi R, MD",7/19/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Maintenance,7/11/2024,Inactive,,
NBR CINJ OP INFUSION,44261,"Shah, Mansi R, MD",11/19/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,11/18/2024,Active,,
JCMC CP INFUSION,38407,"Ghuman, Damanjit, MD",8/17/2023,Daratumumab 28 Day Cycles- Multiple Myeloma,Third Line,7/11/2023,Inactive,,
CINJ OP INFUSION,54011,"Haigentz, Missak, MD",3/14/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,First Line,3/14/2023,Inactive,,
CINJ OP INFUSION,54011,"Haigentz, Missak, MD",10/31/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,10/30/2023,Inactive,,
CINJ OP INFUSION,54011,"Haigentz, Missak, MD",2/1/2024,Cetuximab / PACLitaxel 80 mg/m2 - 28 Day Cycles- Head and Neck Cancers,_2. Second Line,1/31/2024,Inactive,,
CINJ OP INFUSION,54011,"Goel, Sanjay, MD",7/31/2024,CINJ 052212 Phase 1b RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,_4. Fourth Line,7/31/2024,Inactive,,
CBMC OP INFUSION 2FL,27244,"Brown, Andrew Bennett, MD",3/29/2023,Daratumumab 28 Day Cycles- Multiple Myeloma,Maintenance,3/28/2023,Active,,
HAM OP INFUSION,47637,"Patel, Malini M, MD",10/14/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_3. Third Line,10/13/2024,Active,,
MMC OP INFUSION,42321,"Lee, Patrick C, MD",8/13/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/12/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
MMC OP INFUSION,42321,"Lee, Patrick C, MD",1/28/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/27/2025,Active,,
MMC OP INFUSION,42321,"Lee, Patrick C, MD",1/28/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,1/27/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
NBR 5N ONCOLOGY,94875,"Palmisiano, Neil David, MD",5/23/2023,ECOG - ACRIN E1910 (Step 1) Induction - Acute Lymphoblastic Leukemia,,5/23/2023,Inactive,,
NBR CINJ OP INFUSION,94875,"Palmisiano, Neil David, MD",8/9/2023,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,94875,"Palmisiano, Neil David, MD",9/12/2023,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,,9/10/2023,Inactive,,
NBR CINJ OP INFUSION,94875,"Palmisiano, Neil David, MD",10/12/2023,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,10/12/2023,Inactive,,
NBR CINJ OP INFUSION,94875,"Palmisiano, Neil David, MD",11/7/2023,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,11/7/2023,Inactive,,
NBR CINJ OP INFUSION,94875,"Palmisiano, Neil David, MD",12/19/2023,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,_1. First Line,12/19/2023,Inactive,,
NBR CINJ OP INFUSION,94875,"Assal, Amer, MD",2/20/2024,BMT Allogeneic TBF + Post Cy (Reduced Intensity),Consolidation,2/20/2024,Inactive,,
NBR CINJ OP INFUSION,94875,"Assal, Amer, MD",7/23/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Adjuvant,7/23/2024,Active,,
CINJ OP INFUSION,71055,"Leiser, Aliza, MD",2/5/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/2/2025,Active,Endometrial cancer (CMS/HCC),
CMC OP INFUSION,78280,"Talwar, Sumit, MD",4/10/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/9/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),
NBI OP INFUSION,58758,"Shah, Shailja S, MD",5/28/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,5/20/2024,Inactive,,
NBI OP INFUSION,58758,"Shah, Shailja S, MD",12/31/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,12/31/2024,Active,,
TRMC TCCC OP INFUSION,57969,"Capo, Gerardo, MD",7/10/2024,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,7/9/2024,Inactive,,
TRMC TCCC OP INFUSION,57969,"Capo, Gerardo, MD",5/29/2025,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,5/29/2025,Active,Multiple myeloma (CMS/HCC),
SOM OUTPT INFUSION,31993,"Yin, Faye, MD",7/31/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,7/31/2023,Active,,
CINJ OP INFUSION,54628,"Berim, Lyudmyla, MD",3/29/2024,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,3/28/2024,Inactive,,
CINJ OP INFUSION,54628,"Berim, Lyudmyla, MD",4/4/2024,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,4/3/2024,Active,,
CINJ OP INFUSION,78917,"Mayer, Tina M, MD",5/19/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,,5/3/2023,Inactive,,
MMC OP VP INFUSION,73638,"Lee, Patrick C, MD",12/8/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/7/2023,Inactive,,
MMC OP VP INFUSION,73638,"Lee, Patrick C, MD",3/7/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,3/6/2024,Inactive,,
CBMC OP INFUSION 2FL,84467,"Dharmapuri, Sirish, MD",1/20/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,1/12/2025,Active,,
CINJ OP INFUSION,60980,"Saraiya, Biren P, MD",6/11/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,6/11/2024,Active,,
SOM OUTPT INFUSION,8317,"Patel, Eshan, MD",6/21/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,6/19/2023,Inactive,,
SOM OUTPT INFUSION,8317,"Patel, Eshan, MD",7/19/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,7/18/2023,Inactive,,
SOM OUTPT INFUSION,8317,"Patel, Eshan, MD",10/18/2023,FOLFIRI +Durvalumab + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,10/10/2023,Inactive,,
SOM OUTPT INFUSION,8317,"Patel, Eshan, MD",11/29/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,11/28/2023,Inactive,,
SOM OUTPT INFUSION,8317,"Patel, Eshan, MD",1/3/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/2/2024,Inactive,,
SOM OUTPT INFUSION,8317,"Patel, Eshan, MD",2/27/2024,Pembrolizumab 21 Day Cycles- Cholangiocarcinoma,Maintenance,2/26/2024,Inactive,,
CBMC OP INFUSION 2FL,53948,"Brown, Andrew Bennett, MD",2/11/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Induction,2/11/2025,Active,Colon cancer (CMS/HCC),
NBI OP INFUSION,45979,"Jacoby, Sari H, MD",12/23/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/22/2024,Active,,
SOM OUTPT INFUSION,43496,"Patel, Eshan, MD",11/7/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,10/8/2024,Active,,
NBR CINJ OP INFUSION,43496,"Egini, Ogechukwu, MD",3/4/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_1. First Line,3/4/2025,Active,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; R19.7 - Diarrhea, unspecified; Z01.818 - Encounter for other preprocedural examination; D47.2 - Monoclonal gammopathy; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C90.01 - Multiple myeloma in remission; Z85.038 - Personal history of other malignant neoplasm of large intestine"
CBMC OP INFUSION 2FL,95179,"Brown, Andrew Bennett, MD",10/2/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,10/1/2023,Inactive,,
MMC OP VP INFUSION,50914,"Lee, Patrick C, MD",11/5/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,10/30/2024,Active,,
NBR CINJ OP INFUSION,48177,"Palmisiano, Neil David, MD",1/5/2024,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,1/5/2024,Inactive,,
NBR CINJ OP INFUSION,48177,"Palmisiano, Neil David, MD",2/12/2024,HAM-VEN (High-Dose Cytarabine / Mitoxantrone / Venetoclax) Per Ruhnke et al 2023.,Reinduction,2/12/2024,Inactive,,
NBR CINJ OP INFUSION,48177,"Palmisiano, Neil David, MD",4/18/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,4/18/2024,Inactive,,
NBR CINJ OP INFUSION,48177,"Egini, Ogechukwu, MD",6/26/2024,DSA Desensitization with: Daratumumab/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,_1. First Line,6/25/2024,Inactive,,
NBR CINJ OP INFUSION,48177,"Egini, Ogechukwu, MD",8/15/2024,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_3. Third Line,8/14/2024,Active,,
CBMC OP INFUSION 2FL,14618,"Litvak, Anna M, MD",10/30/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,2103,"Brown, Andrew Bennett, MD",4/30/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,4/30/2025,Active,"Malignant neoplasm of larynx, unspecified (CMS/HCC)",
NBI OP INFUSION,98203,"Jacoby, Sari H, MD",1/21/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,1/21/2025,Inactive,"Breast cancer, stage 4 (CMS/HCC)",
NBI OP INFUSION,98203,"Schleicher, Lori, MD",1/23/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,1/23/2025,Active,,
NBI OP INFUSION,51482,"Anderson, Patrick S, MD",7/28/2023,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_4. Fourth Line,7/27/2023,Inactive,,
CINJ OP INFUSION,82670,"Leiser, Aliza, MD",4/14/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,3/27/2023,Inactive,,
CINJ OP INFUSION,82670,"Leiser, Aliza, MD",11/27/2023,CINJ 102006 (GOG-3039) Abemaciclib + Letrozole 28 Day Cycles Research- Endometrial Cancer,_3. Third Line,11/27/2023,Inactive,,
CINJ OP INFUSION,82670,"Leiser, Aliza, MD",10/18/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,9/29/2024,Inactive,,
CBMC OP INFUSION 2FL,69093,"Grossman, I Robert, MD",10/11/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,10/10/2023,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),
CINJ OP INFUSION,22663,"George, Mridula A, MD",12/16/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,Neoadjuvant,12/3/2024,Active,,
HAM OP INFUSION,72875,"Patel, Malini M, MD",1/31/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,1/30/2023,Inactive,,
CMC OP INFUSION,50015,"Easaw, Sarah, MD",9/11/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/1/2023,Inactive,,
CMC OP INFUSION,50015,"Cohen, Seth D, MD",10/9/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,9/28/2023,Inactive,,
CBMC OP INFUSION 2FL,29649,"Brown, Andrew Bennett, MD",6/11/2024,Pembrolizumab 21 Day Cycles- Oral Cavity Cancer,Induction,6/11/2024,Active,,
NBI OP INFUSION,90664,"Schleicher, Lori, MD",2/22/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,2/21/2024,Inactive,,
NBI OP INFUSION,90664,"Schleicher, Lori, MD",3/7/2024,"Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel D1, D8 21 Day Cycles - Breast",_4. Fourth Line,3/6/2024,Inactive,,
NBI OP INFUSION,90664,"Schleicher, Lori, MD",6/27/2024,Sacituzumab Govitecan 21 Day Cycles - Breast,_6. Sixth Line,6/26/2024,Inactive,,
NBR CINJ OP INFUSION,15411,"Braunschweig, Ira, MD",6/30/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,,6/29/2023,Inactive,,
CINJ OP INFUSION,62207,"Weiss, Sarah, MD",12/18/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,12/15/2024,Active,,
CINJ OP INFUSION,62207,"Weiss, Sarah, MD",2/17/2025,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,2/17/2025,Active,Malignant melanoma of right upper extremity including shoulder (CMS/HCC),
CINJ OP INFUSION,50753,"Weiss, Sarah, MD",5/12/2025,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,5/12/2025,Active,Malignant melanoma of right upper extremity including shoulder (CMS/HCC),
CBMC OP INFUSION 2FL,48688,"Wagmiller, Jennifer Ann, MD",9/12/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,9/11/2023,Inactive,,
CBMC OP INFUSION 2FL,27261,"Leitner, Stuart P, MD",9/20/2024,CINJ 042102 Amendment 36 Block A DAN-222 / Niraparib 7 Day Cycles Research- Breast Cancer,Neoadjuvant,9/19/2024,Inactive,,
CBMC OP INFUSION 2FL,27261,"Raptis, George, MD",11/13/2024,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,11/7/2024,Inactive,,
CBMC OP INFUSION 2FL,27261,"Raptis, George, MD",1/3/2025,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,1/2/2025,Active,,
CBMC OP INFUSION 2FL,27261,"Raptis, George, MD",1/10/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,1/9/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,27261,"Raptis, George, MD",2/21/2025,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 14 Day Cycles Research- Breast Cancer HER2 Negative Tumors ,Neoadjuvant,2/21/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
NBR 4N ONCOLOGY,3858,"Patel, Vimal D, MD",6/21/2023,"Intrathecal Triples Methotrexate 12 mg, hydrocortisone 15mg, Arac 30 mg IT 1 Day ",,6/21/2023,Inactive,,
NBR CINJ OP INFUSION,3858,"Patel, Vimal D, MD",6/28/2023,Daratumumab / Pomalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,6/20/2023,Inactive,,
NBR 4N ONCOLOGY,3858,"Assal, Amer, MD",7/7/2023,BPD (Bendamustine / Pomalidomide / Dexamethasone) 28 Day Cycles - Multiple Myeloma,,7/6/2023,Inactive,,
NBR CINJ OP INFUSION,3858,"Assal, Amer, MD",10/6/2023,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,,10/6/2023,Inactive,,
NBR CINJ OP INFUSION,3858,"Assal, Amer, MD",12/7/2023,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,_6. Sixth Line,12/4/2023,Inactive,,
NBR CINJ OP INFUSION,3858,"Shah, Mansi R, MD",9/21/2024,Bortezomib / Dexamethasone Twice Weekly 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_7. Seventh Line,9/21/2024,Inactive,,
NBR CINJ OP INFUSION,3858,"Shah, Mansi R, MD",10/1/2024,Elotuzumab/Bortezomib/Dexamethasone - Multiple Myeloma,_7. Seventh Line,10/1/2024,Inactive,,
NBR 5N ONCOLOGY,3858,"Shah, Mansi R, MD",11/12/2024,Talquetamab 28 Day Cycles,_5. Fifth Line,11/12/2024,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBR CINJ OP INFUSION,3858,"Shah, Mansi R, MD",11/26/2024,Cytarabine / Methotrexate / Hydrocortisone Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Adjuvant,11/26/2024,Active,,
CINJ OP INFUSION,86519,"Patel, Eshan, MD",7/12/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,7/2/2024,Inactive,,
CINJ OP INFUSION,86519,"Patel, Eshan, MD",10/4/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,10/3/2024,Active,,
CBMC OP INFUSION 2FL,97889,"Wagmiller, Jennifer Ann, MD",1/9/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,1/4/2024,Inactive,,
CBMC OP INFUSION 2FL,97889,"Wagmiller, Jennifer Ann, MD",1/12/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,Neoadjuvant,1/8/2024,Inactive,,
CBMC OP INFUSION 2FL,97889,"Wagmiller, Jennifer Ann, MD",3/15/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/14/2024,Inactive,Malignant neoplasm of right ovary (CMS/HCC),
CINJ OP INFUSION,74172,"Weiss, Sarah, MD",12/27/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_3. Third Line,12/27/2023,Active,,
CINJ OP INFUSION,89990,"Weiss, Sarah, MD",3/18/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_4. Fourth Line,3/18/2025,Active,Malignant melanoma of scalp and neck (CMS/HCC),"D50.9 - Iron deficiency anemia, unspecified"
HAM OP INFUSION,70982,"Gendy, Mina, DO",9/4/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,9/3/2024,Inactive,,
HAM OP INFUSION,70982,"Gendy, Mina, DO",12/4/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/4/2024,Active,,
HAM OP INFUSION,70982,"Gendy, Mina, DO",2/27/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/26/2025,Active,Small cell lung cancer (CMS/HCC),
HAM OP INFUSION,46514,"Gendy, Mina, DO",3/27/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,3/27/2025,Inactive,"Small cell lung cancer (CMS/HCC)
Abnormal results of thyroid function studies","Z51.11 - Encounter for antineoplastic chemotherapy; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; E05.90 - Thyrotoxicosis, unspecified without thyrotoxic crisis or storm"
HAM OP INFUSION,46514,"Gendy, Mina, DO",3/25/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,3/19/2025,Active,"Small cell lung cancer (CMS/HCC)
Abnormal results of thyroid function studies",
CINJ OP INFUSION,54037,"Stephenson, Ryan D, DO",2/10/2025,Relugolix 30 day Cycles - Prostate,Adjuvant,2/10/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
CINJ OP INFUSION,91565,"Omene, Coral Oghenerukevwe, MD",2/6/2024,Abemaciclib 28 Day Cycles - Breast ,_1. First Line,2/6/2024,Inactive,,
CINJ OP INFUSION,92845,"Stein, Stacey",5/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/28/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),C19 - Malignant neoplasm of rectosigmoid junction; Z48.816 - Encounter for surgical aftercare following surgery on the genitourinary system; C18.7 - Malignant neoplasm of sigmoid colon
MMC OP VP INFUSION,8558,"Talwar, Sumit, MD",3/11/2025,CINJ 072207 (NRG-GI008) Cohort A  ARM 1 CAPEOX (Capecitabine / OXALiplatin) 21 Day Cycles Research- Colon Cancer,Adjuvant,3/11/2025,Active,Colon cancer (CMS/HCC),
CBMC OP INFUSION 2FL,11881,"Raptis, George, MD",5/21/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,5/20/2024,Inactive,,
JCMC 7W MED-SURG 2,16724,"Cruz, Allan Louie E, MD",11/1/2024,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,10/31/2024,Inactive,,
NBI D7 MED-SURG/TELE,90477,"Jacoby, Sari H, MD",1/19/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Head and Neck,_1. First Line,1/19/2024,Inactive,,
CBMC OP INFUSION 2FL,46271,"Wagmiller, Jennifer Ann, MD",12/21/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,12/13/2023,Inactive,,
CBMC OP INFUSION 2FL,46271,"Wagmiller, Jennifer Ann, MD",4/25/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,4/24/2024,Active,,
CBMC OP INFUSION 2FL,46271,"Wagmiller, Jennifer Ann, MD",1/14/2025,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_2. Second Line,1/14/2025,Active,Malignant neoplasm of pyloric antrum (CMS/HCC),
NBR 5N ONCOLOGY,26202,"George, Mridula A, MD",3/9/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,3/8/2024,Inactive,,
NBR 5N ONCOLOGY,26202,"Haigentz, Missak, MD",3/16/2024,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/16/2024,Inactive,,
NBR 4N ONCOLOGY,12429,"Boland, Patrick M, MD",1/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/9/2024,Active,,
CINJ OP INFUSION,64930,"Boland, Patrick M, MD",12/22/2023,Imatinib 30 Day Cycles - Sarcoma,_1. First Line,12/22/2023,Active,,
CINJ OP INFUSION,6346,"Patel, Eshan, MD",1/20/2023,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,,1/18/2023,Inactive,,
CINJ OP INFUSION,6346,"Patel, Eshan, MD",4/21/2023,"Gemcitabine D1, D8  21 Day Cycles- mesothelioma ",,4/20/2023,Inactive,,
CINJ OP INFUSION,6346,"Patel, Eshan, MD",9/1/2023,"VinORELBine D1, D8 21 Day Cycles- Malignant Pleural Mesothelioma",,8/31/2023,Inactive,,
CMC OP INFUSION,31287,"Talwar, Sumit, MD",6/12/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,6/4/2024,Inactive,,
CMC OP INFUSION,31287,"Talwar, Sumit, MD",8/12/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/11/2024,Inactive,,
CINJ OP INFUSION,44452,"Boland, Patrick M, MD",1/3/2023,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,,1/3/2023,Inactive,,
SOM OUTPT INFUSION,52206,"Yin, Faye, MD",3/15/2023,Letrozole 30 Day Cycles - Breast,First Line,3/15/2023,Inactive,,
SOM OUTPT INFUSION,52206,"Yin, Faye, MD",3/22/2023,Ribociclib 28 Day Cycles - Breast,First Line,3/22/2023,Inactive,,
NBR 4N BMTU/IMCU,31433,"Schaar, Dale, MD PhD",3/9/2023,BMT Autologous BEAM,,3/8/2023,Inactive,,
NBR CINJ OP INFUSION,31433,"Rhodes, Joanna Meehan, MD",5/24/2023,Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,Maintenance,5/23/2023,Inactive,,
CINJ OP INFUSION,23602,"Stephenson, Ryan D, DO",11/17/2023,CINJ 082107 (CURLU177PSM001) Enzalutamide 28 Day Cycles Research Prostate Cancer,_2. Second Line,11/16/2023,Inactive,,
NBR CINJ OP INFUSION,81921,"Patel, Vimal D, MD",5/18/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,5/17/2023,Inactive,,
HAM OP INFUSION,58337,"Yogarajah, Meera, MD",3/21/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/20/2025,Active,Metastasis from rectal cancer (CMS/HCC),"C19 - Malignant neoplasm of rectosigmoid junction; C78.02 - Secondary malignant neoplasm of left lung; D50.9 - Iron deficiency anemia, unspecified; J45.909 - Unspecified asthma, uncomplicated; F17.210 - Nicotine dependence, cigarettes, uncomplicated; I10 - Essential (primary) hypertension; Z86.19 - Personal history of other infectious and parasitic diseases; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.891 - Long term (current) use of opiate analgesic; Z79.2 - Long term (current) use of antibiotics; Z79.899 - Other long term (current) drug therapy; Z93.3 - Colostomy status; Z90.49 - Acquired absence of other specified parts of digestive tract"
SOM 1PAV ONCOLOGY,97932,"Toomey, Kathleen C, MD",9/25/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,9/24/2024,Active,,
NBR CINJ OP INFUSION,6146,"Evens, Andrew M, DO",4/9/2025,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,4/9/2025,Active,Nodular sclerosis Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),C81.18 - Nodular sclerosis Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC)
NBR CINJ OP INFUSION,6146,"Evens, Andrew M, DO",4/9/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/9/2025,Inactive,Nodular sclerosis Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),"C81.18 - Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites"
NBI VALERIE FND HEMONC,49857,"Bhatla, Teena, MD",1/30/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,1/30/2025,Active,Bladder cancer (CMS/HCC),
NBR CINJ OP INFUSION,31256,"Tiger, Yun Kyoung, MD",2/5/2024,Zanubrutinib (160 mg) 30 Day Cycles - Mantle Cell Lymphoma,_2. Second Line,2/5/2024,Inactive,,
NBR CINJ OP INFUSION,31256,"Tiger, Yun Kyoung, MD",2/14/2024,RiTUXimab weekly x4 then maintenance every 2 months - Follicular Lymphoma,_2. Second Line,2/13/2024,Active,"Drug-induced polyneuropathy (CMS/HCC)
Malignant ascites
Malignant neoplasm of unspecified ovary (CMS/HCC)",
CINJ OP INFUSION,55101,"Stephenson, Ryan D, DO",3/27/2023,Relugolix 30 day Cycles - Prostate,First Line,3/27/2023,Inactive,,
NBR 5N ONCOLOGY,35083,"Saraiya, Biren P, MD",9/25/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,First Line,9/24/2023,Inactive,,
CINJ OP INFUSION,35083,"Saraiya, Biren P, MD",1/24/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_1. First Line,1/16/2024,Inactive,,
CINJ OP INFUSION,34083,"Saraiya, Biren P, MD",3/20/2025,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_1. First Line,3/17/2025,Active,Malignant neoplasm of trigone of urinary bladder (CMS/HCC),
NBR CINJ OP INFUSION,51175,"Rhodes, Joanna Meehan, MD",8/19/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,8/18/2024,Inactive,,
SOM OUTPT INFUSION,56040,"Patel, Eshan, MD",8/13/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,7/28/2024,Inactive,,
SOM OUTPT INFUSION,56040,"Patel, Eshan, MD",12/5/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,11/3/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,24312,"Lee, Patrick C, MD",7/18/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,Second Line,7/17/2023,Active,,
MMC OP INFUSION,24312,"Lee, Patrick C, MD",11/27/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/27/2023,Active,,
CINJ OP INFUSION,13487,"Omene, Coral Oghenerukevwe, MD",8/7/2023,Everolimus / Exemestane 28 Day Cycles - Breast,,8/7/2023,Inactive,,
CINJ OP INFUSION,13487,"Omene, Coral Oghenerukevwe, MD",1/11/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_4. Fourth Line,1/10/2024,Inactive,,
CINJ OP INFUSION,13487,"Omene, Coral Oghenerukevwe, MD",6/4/2024,Capecitabine 21 Day Cycles - Breast,_5. Fifth Line,6/4/2024,Inactive,,
CBMC OP INFUSION 2FL,58871,"Litvak, Anna M, MD",12/4/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,_1. First Line,12/3/2024,Active,,
NBR CINJ OP INFUSION,12548,"Tiger, Yun Kyoung, MD",7/2/2024,R-MPV (High-Dose Methotrexate / VinCRIStine / Procarbazine / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,7/1/2024,Active,Prostate cancer (CMS/HCC),
CINJ OP INFUSION,55823,"Girda, Eugenia, MD",12/31/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,12/8/2024,Active,,
CBMC OP INFUSION 2FL,90639,"Dave, Manish, MD",5/28/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/28/2023,Active,,
CINJ OP INFUSION,55311,"Boland, Patrick M, MD",4/1/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,4/1/2025,Inactive,Malignant neoplasm of pancreas (CMS/HCC),
TRMC TCCC OP INFUSION,96338,"Salerno, Vincent E, MD",5/13/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,5/13/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CINJ OP INFUSION,66290,"Goel, Sanjay, MD",12/2/2024,CINJ 052310 Dose Escalation / Pharmacodynamic AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,12/2/2024,Inactive,,
MMC OP INFUSION,69052,"Lee, Patrick C, MD",10/17/2023,RiTUXimab Initial Infusion Single Day (Outpatient),First Line,10/17/2023,Inactive,,
CINJ OP INFUSION,19504,"Omene, Coral Oghenerukevwe, MD",4/18/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,4/17/2023,Inactive,,
JCMC CP INFUSION,2814,"Sekhri, Arunabh, MD",6/19/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,6/18/2023,Inactive,,
CINJ OP INFUSION,32215,"Ghodoussipour, Saum Bobak, MD",6/6/2024,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,6/6/2024,Inactive,,
CINJ OP INFUSION,32215,"Ghodoussipour, Saum Bobak, MD",6/19/2024,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,6/19/2024,Inactive,,
CINJ OP INFUSION,32215,"Ghodoussipour, Saum Bobak, MD",10/3/2024,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Adjuvant,10/3/2024,Active,,
CINJ OP INFUSION,95777,"Boland, Patrick M, MD",2/23/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/21/2024,Inactive,,
CINJ OP INFUSION,44371,"Berim, Lyudmyla, MD",10/30/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,10/26/2023,Active,,
CINJ OP INFUSION,54544,"Berim, Lyudmyla, MD",1/19/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/4/2023,Inactive,,
CINJ OP INFUSION,54544,"Berim, Lyudmyla, MD",5/9/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/2/2024,Active,,
JCMC CP INFUSION,98616,"Sekhri, Arunabh, MD",7/24/2024,mFOLFOX6(Fluorouracil Continuous Infusion/OXALIplatin) 14 Day Cycles- Stage IV appendiceal cancer,Adjuvant,7/21/2024,Inactive,,
JCMC CP INFUSION,98616,"Sekhri, Arunabh, MD",4/30/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/30/2025,Active,Cancer of appendix (CMS/HCC),C18.1 - Malignant neoplasm of appendix; G62.0 - Drug-induced polyneuropathy; E53.8 - Deficiency of other specified B group vitamins; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); R10.9 - Unspecified abdominal pain; R45.89 - Other symptoms and signs involving emotional state
JCMC CP INFUSION,38175,"Cruz, Allan Louie E, MD",6/1/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,,5/21/2023,Inactive,,
JCMC CP INFUSION,38175,"Cruz, Allan Louie E, MD",12/4/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_6. Sixth Line,12/4/2023,Inactive,,
JCMC CP INFUSION,38175,"Cruz, Allan Louie E, MD",11/12/2024,"Carboplatin PACLitaxel D1, D8 21 Day Cycles - Breast",_6. Sixth Line,11/4/2024,Inactive,,
JCMC CP INFUSION,26795,"Cruz, Allan Louie E, MD",1/14/2025,Gemcitabine 21 Day Cycles - Breast,_7. Seventh Line,1/13/2025,Active,,
JCMC CP INFUSION,26795,"Cruz, Allan Louie E, MD",2/25/2025,Datopotamab deruxtecan-dlnk 21 Day Cycles- Breast Cancer,_8. Eighth Line,2/20/2025,Active,Malignant neoplasm of lower-outer quadrant of female breast (CMS/HCC),
NBI OP INFUSION,47991,"Schleicher, Lori, MD",8/30/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,8/29/2023,Active,Chronic ITP (idiopathic thrombocytopenia) (CMS/HCC),
TRMC TCCC OP INFUSION,42759,"Capo, Gerardo, MD",2/11/2025,"PACLitaxel D1, D8, D15/CARBOplatin D1 28 Day Cycles- Anal Carcinoma",_1. First Line,2/10/2025,Active,Anal cancer (CMS/HCC),
TRMC TCCC OP INFUSION,78496,"Capo, Gerardo, MD",5/13/2025,"Albumin-Bound PACLitaxel D1, D8, D15/ CARBOplatin D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,5/13/2025,Active,Anal cancer (CMS/HCC),"C21.0 - Malignant neoplasm of anus, unspecified"
CINJ OP INFUSION,64576,"George, Mridula A, MD",3/8/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,3/8/2024,Active,,
CINJ OP INFUSION,86852,"Patel, Eshan, MD",1/19/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,1/18/2023,Inactive,,
SOM OUTPT INFUSION,86852,"Patel, Eshan, MD",9/13/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - lung,_2. Second Line,8/29/2024,Inactive,,
SOM OUTPT INFUSION,86852,"Patel, Eshan, MD",12/13/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/13/2024,Active,,
SOM OUTPT INFUSION,86852,"Patel, Eshan, MD",1/30/2025,Cetuximab with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_3. Third Line,1/29/2025,Active,,
SOM OUTPT INFUSION,9390,"Patel, Eshan, MD",5/22/2025,"DOCEtaxel D1, D15 --  21 Day Cycles- Head and Neck Cancers",_3. Third Line,5/22/2025,Active,Primary cancer of oropharynx (CMS/HCC),"C10.9 - Malignant neoplasm of oropharynx, unspecified"
TRMC TCCC OP INFUSION,20054,"Capo, Gerardo, MD",12/26/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/19/2024,Inactive,,
CINJ OP INFUSION,95468,"Muralikrishnan, Sivraj, MD",5/19/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,5/19/2025,Active,Cancer of temporal bone (CMS/HCC),"C44.229 - Squamous cell carcinoma of skin of left ear and external auricular canal; C07 - Malignant neoplasm of parotid gland; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; R91.1 - Solitary pulmonary nodule; C76.0 - Malignant neoplasm of head, face and neck; C41.0 - Malignant neoplasm of bones of skull and face; Z90.89 - Acquired absence of other organs"
MMC OP VP INFUSION,13579,"Cohen, Seth D, MD",5/9/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,5/9/2024,Inactive,,
CMC OP INFUSION,13579,"Cohen, Seth D, MD",6/3/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,6/2/2024,Active,,
CMC OP INFUSION,10825,"Cohen, Seth D, MD",3/14/2025,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/14/2025,Active,"Secondary malignant neoplasm of pelvis (CMS/HCC)
Malignant neoplasm of rectum (CMS/HCC)
End stage renal disease (CMS/HCC)
Ovarian cancer (CMS/HCC)",
SOM OUTPT INFUSION,18303,"Patel, Eshan, MD",7/3/2023,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,,6/27/2023,Inactive,,
CINJ PEDS HEMONC ,14597,"Moerdler, Scott, MD",11/5/2024,as per AGCT1532 Arm A (Standard BEP),_2. Second Line,11/2/2024,Active,,
CINJ OP INFUSION,81809,"Mayer, Tina M, MD",1/27/2023,DOCEtaxel 21 Day Cycles - Prostate,,1/9/2023,Inactive,,
CINJ OP INFUSION,81809,"Mayer, Tina M, MD",2/28/2023,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,,2/28/2023,Inactive,,
CINJ OP INFUSION,89174,"Groisberg, Roman, MD",1/3/2025,SORAfenib 30 Day Cycles - Kidney,_2. Second Line,1/3/2025,Active,Gastric carcinoma (CMS/HCC),
TRMC TCCC OP INFUSION,74217,"Capo, Gerardo, MD",6/28/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,6/27/2024,Active,,
CINJ OP INFUSION,90008,"Omene, Coral Oghenerukevwe, MD",5/12/2025,CINJ 042403 Tirzepatide Weekly 28 Day Cycles Research- Breast Cancer,Adjuvant,5/12/2025,Active,Malignant neoplasm of overlapping sites of left female breast (CMS/HCC),"Z13.820 - Encounter for screening for osteoporosis; C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.0 - Estrogen receptor positive status (ER+); M85.88 - Other specified disorders of bone density and structure, other site; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z98.890 - Other specified postprocedural states; Z79.82 - Long term (current) use of aspirin; Z79.811 - Long term (current) use of aromatase inhibitors; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy"
TRMC TCCC OP INFUSION,37329,"Capo, Gerardo, MD",8/13/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/12/2024,Inactive,,
TRMC TCCC OP INFUSION,37329,"Capo, Gerardo, MD",12/23/2024,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,12/22/2024,Active,,
TRMC TCCC OP INFUSION,37329,"Capo, Gerardo, MD",1/9/2025,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,12/22/2024,Active,,
NBR 4N BMTU/IMCU,74874,"Patel, Vimal D, MD",9/21/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),Consolidation,9/20/2023,Inactive,,
CINJ OP INFUSION,86662,"Berim, Lyudmyla, MD",8/18/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,86662,"Berim, Lyudmyla, MD",1/22/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/21/2024,Inactive,,
CINJ OP INFUSION,86662,"Berim, Lyudmyla, MD",8/30/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_5. Fifth Line,8/28/2024,Active,,
NBR CINJ OP INFUSION,81636,"Rhodes, Joanna Meehan, MD",2/3/2025,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,1/22/2025,Active,CLL (chronic lymphocytic leukemia) (CMS/HCC),"C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; C95.90 - Leukemia, unspecified not having achieved remission"
JCMC CP INFUSION,62288,"Sekhri, Arunabh, MD",6/29/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,6/28/2023,Inactive,,
NBI OP INFUSION,7781,"Jacoby, Sari H, MD",4/22/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,3/27/2024,Inactive,,
MMC OP VP INFUSION,14268,"Talwar, Sumit, MD",3/14/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,3/13/2023,Inactive,,
MMC OP VP INFUSION,14268,"Talwar, Sumit, MD",7/11/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Third Line,7/11/2023,Inactive,,
CBMC OP INFUSION 2FL,84083,"Scoppetuolo, Michael, MD",2/8/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,2/7/2024,Inactive,,
NBR CINJ OP INFUSION,89800,"Rhodes, Joanna Meehan, MD",2/1/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/31/2024,Inactive,,
MMC OP VP INFUSION,93477,"Cohen, Seth D, MD",8/21/2023,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,First Line,8/20/2023,Inactive,,
CBMC OP INFUSION 2FL,50961,"Scoppetuolo, Michael, MD",2/19/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/30/2024,Inactive,,
MMC OP INFUSION,76467,"Lee, Patrick C, MD",4/9/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,4/1/2024,Active,,
HAM OP INFUSION,60490,"Yogarajah, Meera, MD",5/20/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,5/1/2025,Active,Squamous cell carcinoma of esophagus (CMS/HCC),"C15.5 - Malignant neoplasm of lower third of esophagus; N18.9 - Chronic kidney disease, unspecified; D63.1 - Anemia in chronic kidney disease; R13.10 - Dysphagia, unspecified; I31.39 - Other pericardial effusion (noninflammatory); I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,29038,"Litvak, Anna M, MD",9/14/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,9/13/2023,Inactive,,
CMC 4B ONCOLOGY,62784,"Tang, Horace, MD",8/28/2023,CISplatin With Concurrent Radiation 7 Day Cycles,,8/28/2023,Inactive,,
CBMC OP INFUSION 2FL,47722,"Litvak, Anna M, MD",1/24/2025,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_1. First Line,1/24/2025,Active,,
SOM OUTPT INFUSION,8874,"Patel, Eshan, MD",8/2/2023,DOCEtaxel  28 Day Cycles - Prostate,,7/17/2023,Active,,
CBMC OP INFUSION 2FL,27885,"Dharmapuri, Sirish, MD",2/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/12/2025,Active,Biliary tract cancer (CMS/HCC),
CINJ OP INFUSION,76553,"Boland, Patrick M, MD",11/27/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,11/27/2023,Inactive,,
CINJ OP INFUSION,76553,"Boland, Patrick M, MD",2/2/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/1/2024,Inactive,,
CINJ OP INFUSION,40063,"Haigentz, Missak, MD",3/13/2023,CINJ 032108 (PRE0506) ARM A Durvalumab / PEMEtrexed / CARBOplatin 21 Day Cycles Research- Pleural Mesothelioma,First Line,3/10/2023,Inactive,,
CINJ OP INFUSION,40063,"Haigentz, Missak, MD",7/12/2024,PEMEtrexed/CARBOplatin + Bevacizumab 21 Day Cycles- Mesothelioma,_2. Second Line,7/4/2024,Inactive,,
CINJ OP INFUSION,40063,"Haigentz, Missak, MD",11/18/2024,Bevacizumab Maintenance 21 Day Cycles- Mesothelioma,Maintenance,11/18/2024,Active,,
CINJ OP INFUSION,40063,"Haigentz, Missak, MD",4/8/2025,Nivolumab/Ipilimumab 42 Day Cycles- Malignant Pleural Mesothelioma,_3. Third Line,4/8/2025,Active,"Malignant pleural mesothelioma (CMS/HCC)
Chronic fatigue",C45.0 - Mesothelioma of pleura; R97.20 - Elevated prostate specific antigen (PSA)
CINJ OP INFUSION,92520,"George, Mridula A, MD",2/17/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Adjuvant,2/16/2023,Inactive,,
CINJ OP INFUSION,92520,"George, Mridula A, MD",2/18/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,2/17/2023,Inactive,,
SOM OUTPT INFUSION,27509,"Patel, Eshan, MD",6/4/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,_1. First Line,5/22/2024,Inactive,,
CINJ OP INFUSION,27509,"Ghodoussipour, Saum Bobak, MD",8/9/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,8/8/2024,Inactive,,
CINJ OP INFUSION,27509,"Ghodoussipour, Saum Bobak, MD",10/25/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,10/24/2024,Active,,
SOM OUTPT INFUSION,37800,"Patel, Eshan, MD",7/31/2023,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,,7/23/2023,Inactive,,
CINJ OP INFUSION,46035,"Stephenson, Ryan D, DO",9/26/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,9/24/2024,Inactive,,
NBR 4N ONCOLOGY,83238,"Elsamra, Sammy, MD",1/8/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,1/8/2025,Active,,
CINJ OP INFUSION,70261,"Leiser, Aliza, MD",6/28/2024,PACLitaxel / CISplatin 21 Day Cycles - Cervical,_2. Second Line,6/25/2024,Inactive,,
CINJ OP INFUSION,70261,"Leiser, Aliza, MD",11/2/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,11/2/2024,Active,,
CBMC OP INFUSION 2FL,31472,"Dave, Manish, MD",5/9/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,5/8/2023,Active,,
CINJ OP INFUSION,99345,"Saraiya, Biren P, MD",3/21/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,3/20/2023,Inactive,,
CINJ OP INFUSION,99345,"Saraiya, Biren P, MD",10/4/2023,Nivolumab 28 Day Cycles - Bladder,Adjuvant,10/4/2023,Inactive,,
CINJ OP INFUSION,99345,"Saraiya, Biren P, MD",3/6/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_2. Second Line,2/21/2024,Inactive,,
CBMC OP INFUSION 2FL,76728,"Dharmapuri, Sirish, MD",11/25/2024,CINJ 072401 Quemliclustat / Zimberelimab / Gemcitabine / CISplatin 42 Day Cycles Research- Advanced Biliary Tract Cancers,_1. First Line,11/24/2024,Active,,
CINJ OP INFUSION,86382,"Toppmeyer, Deborah L, MD",3/31/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/31/2025,Active,Secondary adenocarcinoma of lymph node (CMS/HCC),"C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; Z90.11 - Acquired absence of right breast and nipple; Z79.899 - Other long term (current) drug therapy"
TRMC TCCC OP INFUSION,12020,"Capo, Gerardo, MD",3/27/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,3/5/2025,Active,Follicular lymphoma (CMS/HCC),
MMC OP VP INFUSION,57321,"Cohen, Seth D, MD",4/24/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,3/24/2024,Active,,
CBMC OP INFUSION 2FL,52345,"Grossman, I Robert, MD",8/2/2023,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,8/1/2023,Active,,
NBR 5N ONCOLOGY,53306,"Palmisiano, Neil David, MD",8/8/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,8/7/2023,Inactive,,
CINJ OP INFUSION,16473,"Haigentz, Missak, MD",7/12/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,7/11/2023,Inactive,,
CINJ OP INFUSION,23069,"Mayer, Tina M, MD",1/23/2023,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,1/18/2023,Inactive,,
CINJ OP INFUSION,23069,"Mayer, Tina M, MD",8/6/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_3. Third Line,8/5/2024,Active,,
NBR CINJ OP INFUSION,44405,"Mayer, Tina M, MD",3/4/2025,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,3/4/2025,Inactive,Prostate cancer (CMS/HCC),
CINJ OP INFUSION,53257,"Ghodoussipour, Saum Bobak, MD",2/9/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,2/8/2024,Inactive,,
CINJ OP INFUSION,53257,"Ghodoussipour, Saum Bobak, MD",7/3/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,7/1/2024,Inactive,,
CINJ OP INFUSION,53257,"Ghodoussipour, Saum Bobak, MD",10/3/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,9/30/2024,Inactive,,
CINJ OP INFUSION,53257,"Ghodoussipour, Saum Bobak, MD",10/14/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Adjuvant,10/13/2024,Active,,
CINJ OP INFUSION,53257,"Ghodoussipour, Saum Bobak, MD",3/13/2025,BCG (TICE) Intravesical Induction 42 Day Cycle - Bladder,Induction,3/13/2025,Inactive,Malignant neoplasm of urinary bladder (CMS/HCC),
MMC OP VP INFUSION,33606,"Meghal, Trishala, MD",4/9/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,4/7/2024,Inactive,,
MMC OP VP INFUSION,33606,"Meghal, Trishala, MD",7/9/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,7/2/2024,Inactive,,
MMC OP VP INFUSION,33606,"Meghal, Trishala, MD",7/9/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,7/9/2024,Inactive,,
MMC OP VP INFUSION,33606,"Meghal, Trishala, MD",8/19/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,8/19/2024,Inactive,,
SOM OUTPT INFUSION,76994,"Patel, Eshan, MD",5/23/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_1. First Line,5/19/2024,Active,,
NBR 5N ONCOLOGY,55686,"Tiger, Yun Kyoung, MD",12/2/2023,R-GCVP (Gemcitabine / Cyclophosphamide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/1/2023,Inactive,,
NBR 5N ONCOLOGY,55686,"Tiger, Yun Kyoung, MD",1/3/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/31/2023,Inactive,,
NBR CINJ OP INFUSION,55686,"Tiger, Yun Kyoung, MD",1/24/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/24/2024,Inactive,,
CMC OP INFUSION,91135,"Pompa, Tiffany Ann, MD",10/1/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,9/25/2024,Active,,
MSC OP INFUSION,16545,"Pompa, Tiffany Ann, MD",8/6/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/5/2024,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
HAM OP INFUSION,1561,"Yogarajah, Meera, MD",8/1/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,7/21/2024,Active,,
HAM OP INFUSION,1561,"Yogarajah, Meera, MD",4/14/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,4/14/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CBMC 2W ONCOLOGY,74391,"Grossman, I Robert, MD",4/16/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,4/15/2024,Inactive,,
CBMC OP INFUSION 2FL,5245,"Leitner, Stuart P, MD",12/5/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/4/2023,Inactive,,
CBMC OP INFUSION 2FL,5245,"Leitner, Stuart P, MD",5/7/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,5/5/2024,Inactive,,
CBMC OP INFUSION 2FL,5245,"Leitner, Stuart P, MD",10/15/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",Adjuvant,10/7/2024,Active,ATLL (adult T-cell leukemia/lymphoma) (CMS/HCC),
CBMC OP INFUSION 2FL,77657,"Brown, Andrew Bennett, MD",2/21/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/21/2024,Inactive,,
SOM OUTPT INFUSION,75038,"Patel, Eshan, MD",11/20/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,11/12/2023,Inactive,,
MMC OP VP INFUSION,65468,"Talwar, Sumit, MD",2/27/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/26/2024,Inactive,,
CINJ OP INFUSION,19390,"Haigentz, Missak, MD",9/20/2023,Nivolumab + PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,9/19/2023,Inactive,,
CINJ OP INFUSION,19390,"Haigentz, Missak, MD",10/14/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,10/13/2024,Inactive,,
CINJ OP INFUSION,19390,"Haigentz, Missak, MD",1/6/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,1/6/2025,Active,,
SOM OUTPT INFUSION,23350,"Patel, Eshan, MD",8/30/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,8/25/2024,Active,,
NBR CINJ OP INFUSION,23744,"Matasar, Matthew J, MD",10/31/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/30/2023,Inactive,,
NBR CINJ OP INFUSION,23744,"Matasar, Matthew J, MD",2/13/2024,Alemtuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,2/12/2024,Inactive,,
CBMC OP INFUSION 2FL,41705,"Dharmapuri, Sirish, MD",12/4/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/2/2024,Active,,
NBR CINJ OP INFUSION,7254,"Zayac, Adam, MD",4/16/2024,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_1. First Line,4/5/2024,Active,,
CINJ OP INFUSION,97144,"Stephenson, Ruth D, DO",2/21/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,2/20/2025,Active,Malignant neoplasm of exocervix (CMS/HCC),N95.0 - Post-menopausal bleeding
CINJ OP INFUSION,13683,"Stephenson, Ruth D, DO",3/24/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/24/2025,Inactive,Malignant neoplasm of exocervix (CMS/HCC),"C53.1 - Malignant neoplasm of exocervix; N95.0 - Postmenopausal bleeding; C53.9 - Malignant neoplasm of cervix uteri, unspecified"
CBMC OP INFUSION 2FL,33786,"Scoppetuolo, Michael, MD",6/19/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,6/18/2023,Inactive,,
CBMC OP INFUSION 2FL,42659,"Scoppetuolo, Michael, MD",5/20/2025,RiTUXimab 180 Day Cycles (Initial & Maintenance) - Hodgkin Lymphoma,_1. First Line,5/20/2025,Active,Nodular lymphocyte predom Hodgkin lymphoma intra-abdomin lymph nodes (CMS/HCC),
MSC OP INFUSION,42868,"Cohen, Seth D, MD",1/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/3/2024,Inactive,,
CINJ PEDS HEMONC ,91031,"Cole, Peter David, MD",3/13/2023,AALL0434 - Interim Maintenance Arm A (CMTX) and Arm B (CMTX + Nel) 56 Day Cycle - Acute Lymphoblastic Leukemia,,3/13/2023,Inactive,,
CINJ PEDS HEMONC ,91031,"Cole, Peter David, MD",5/8/2023,PEDS AALL0434 Arm B (CMTX + Nel) Delayed Intensification,,5/8/2023,Inactive,,
CINJ PEDS HEMONC ,91031,"Cole, Peter David, MD",7/17/2023,AALL0434 - Maintenance Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,7/17/2023,Inactive,,
CINJ PEDS HEMONC ,91031,"Cole, Peter David, MD",4/1/2024,AALL0434 - Maintenance Continued After Cycle Three Arm B (CMTX + Nel) and Arm D (HDMTX + Nel) 84 Day Cycle - Acute Lymphoblastic Leukemia,_1. First Line,4/1/2024,Active,,
CMC OP INFUSION,28999,"Tang, Horace, MD",5/3/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Head and Neck Cancer,Adjuvant,5/2/2023,Inactive,,
CMC OP INFUSION,28999,"Tang, Horace, MD",12/1/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- head and neck cancer,_2. Second Line,12/1/2023,Inactive,,
CMC OP INFUSION,28999,"Talwar, Sumit, MD",4/17/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,4/16/2024,Inactive,,
CMC OP INFUSION,28999,"Talwar, Sumit, MD",5/16/2024,Cetuximab Maintenance 14 Day Cycles- Head and Neck Cancers,_3. Third Line,5/15/2024,Inactive,,
SOM OUTPT INFUSION,43806,"George, Roshini, DO",4/28/2025,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,4/28/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); E11.9 - Type 2 diabetes mellitus without complications; Z85.72 - Personal history of non-Hodgkin lymphomas; Z79.4 - Long term (current) use of insulin
SOM OUTPT INFUSION,43806,"George, Roshini, DO",4/11/2025,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,4/11/2025,Inactive,Endometrial cancer (CMS/HCC),
NBR 4N ONCOLOGY,43721,"Elsamra, Sammy, MD",1/15/2025,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,1/15/2025,Active,,
CBMC OP INFUSION 2FL,45495,"Litvak, Anna M, MD",10/5/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,10/4/2023,Inactive,,
CBMC OP INFUSION 2FL,63123,"Dharmapuri, Sirish, MD",12/24/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/23/2024,Active,,
NBR CINJ OP INFUSION,56561,"Evens, Andrew M, DO",4/5/2023,RiTUXimab / Lenalidomide 28 Day Cycles - Follicular Lymphoma,,4/4/2023,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,52308,"Boland, Patrick M, MD",2/16/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/14/2024,Active,,
NBR 4N BMTU/IMCU,8080,"Patel, Vimal D, MD",9/27/2023,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,9/25/2023,Inactive,,
NBI OP INFUSION,87476,"Anderson, Patrick S, MD",2/29/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Endometrial( Carcinosarcoma),_1. First Line,2/28/2024,Inactive,,
NBI OP INFUSION,87476,"Anderson, Patrick S, MD",11/21/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_2. Second Line,11/20/2024,Active,,
NBR CINJ OP INFUSION,68568,"Rhodes, Joanna Meehan, MD",9/29/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,First Line,9/28/2023,Inactive,,
CMC OP INFUSION,37768,"Pompa, Tiffany Ann, MD",5/28/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/28/2025,Active,Malignant neoplasm metastatic to both lungs (CMS/HCC),
NBI VALERIE FND HEMONC,35828,"Ford, Maegan C, MD",1/31/2024,PEDS ACNS1123 Stratum 2,_1. First Line,1/31/2024,Inactive,,
JCMC CP INFUSION,41074,"Cruz, Allan Louie E, MD",4/30/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,4/23/2025,Active,Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC),
JCMC CP INFUSION,41074,"Cruz, Allan Louie E, MD",4/3/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_2. Second Line,4/3/2025,Inactive,Malignant neoplasm of upper-outer quadrant of right female breast (CMS/HCC),C79.51 - Secondary malignant neoplasm of bone; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
NBR CINJ OP INFUSION,3306,"Palmisiano, Neil David, MD",4/24/2023,Dasatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,Second Line,4/24/2023,Inactive,,
NBR 4N ONCOLOGY,32259,"Hinrichs, Christian, MD",6/13/2023,"CINJ 192004 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + KK-LC-TCR-T Cells 6 Day Cycle Research- Cancers of the Stomach, Breast, Cervix and Lung",Second Line,6/12/2023,Active,,
MMC OP INFUSION,83719,"Meghal, Trishala, MD",9/27/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,9/27/2024,Inactive,,
MMC OP INFUSION,83719,"Meghal, Trishala, MD",10/2/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,9/26/2024,Active,,
MMC OP INFUSION,83719,"Meghal, Trishala, MD",12/27/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,12/26/2024,Active,,
MMC OP VP INFUSION,83719,"Meghal, Trishala, MD",12/27/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,12/26/2024,Future,,
CMC OP INFUSION,2366,"Tang, Horace, MD",5/4/2023,"Topotecan / Bevacizumab Day 1, 8 , 15, every 28 Day Cycles - Ovarican cancer",Third Line,5/4/2023,Inactive,,
CMC OP INFUSION,2366,"Tang, Horace, MD",10/9/2023,"Gemcitabine (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",,10/9/2023,Inactive,,
CINJ OP INFUSION,83551,"Berim, Lyudmyla, MD",4/24/2023,SUNItinib 28 Day Cycles - Sarcoma,,4/24/2023,Inactive,,
NBR 4N ONCOLOGY,83551,"Berim, Lyudmyla, MD",10/2/2023,Everolimus 28 Day Cycles - NET,,10/2/2023,Inactive,,
NBR 4N ONCOLOGY,83551,"Berim, Lyudmyla, MD",10/6/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,10/5/2023,Inactive,,
CINJ OP INFUSION,83551,"Berim, Lyudmyla, MD",11/27/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,Maintenance,11/26/2023,Inactive,,
CINJ OP INFUSION,83551,"Berim, Lyudmyla, MD",3/21/2024,"PACLitaxel 80 mg/m2 D1, D8, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_5. Fifth Line,3/17/2024,Inactive,,
CINJ OP INFUSION,47745,"Groisberg, Roman, MD",10/13/2023,DOXOrubicin Liposomal 21 Day Cycles - Sarcoma,_1. First Line,10/12/2023,Inactive,,
JCMC CP INFUSION,61625,"Sekhri, Arunabh, MD",9/18/2023,Siltuximab 21 Day Cycles - Castleman Disease,Maintenance,9/10/2023,Active,Malignant neoplasm of rectum (CMS/HCC),
NBR 5N ONCOLOGY,23322,"Matasar, Matthew J, MD",1/11/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,1/11/2023,Inactive,,
NBR 4N BMTU/IMCU,23322,"Doraiswamy, Anupama, MD",1/26/2023,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,Third Line,1/26/2023,Inactive,,
NBR CINJ OP INFUSION,23322,"Doraiswamy, Anupama, MD",3/7/2023,High-Dose Cytarabine x 2 days - 28 Day Cycles - Acute Lymphoblastic Leukemia,,3/6/2023,Inactive,,
SOM OUTPT INFUSION,57336,"Yin, Faye, MD",9/26/2023,Capecitabine 21 Day Cycles - Breast,Second Line,9/26/2023,Inactive,,
CBMC OP INFUSION 2FL,78732,"Litvak, Anna M, MD",10/20/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,_1. First Line,10/19/2023,Inactive,,
CBMC OP INFUSION 2FL,78732,"Wagmiller, Jennifer Ann, MD",1/12/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,1/12/2024,Inactive,,
CBMC OP INFUSION 2FL,52876,"Brown, Andrew Bennett, MD",11/9/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,11/8/2023,Inactive,,
CINJ OP INFUSION,47553,"Weiss, Sarah, MD",8/28/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,8/27/2024,Active,,
TRMC TCCC OP INFUSION,83296,"Capo, Gerardo, MD",10/15/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_2. Second Line,10/7/2024,Active,,
NBR 5N ONCOLOGY,3203,"Tiger, Yun Kyoung, MD",6/12/2024,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,6/10/2024,Inactive,,
NBR CINJ OP INFUSION,3203,"Tiger, Yun Kyoung, MD",8/23/2024,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,8/22/2024,Inactive,,
NBR 4N ONCOLOGY,3203,"Matasar, Matthew J, MD",11/26/2024,BMT Autologous BEAM,_2. Second Line,11/26/2024,Active,,
NBR 4N ONCOLOGY,46704,"Tiger, Yun Kyoung, MD",3/6/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/5/2024,Inactive,,
NBR 4N ONCOLOGY,46704,"Tiger, Yun Kyoung, MD",3/29/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,3/29/2024,Inactive,,
NBR CINJ OP INFUSION,46704,"Zayac, Adam, MD",8/2/2024,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,_2. Second Line,8/2/2024,Inactive,,
MMC OP INFUSION,5819,"Meghal, Trishala, MD",3/19/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/17/2024,Inactive,,
CBMC OP INFUSION 2FL,77265,"Grossman, I Robert, MD",9/16/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,9/8/2024,Inactive,,
CBMC OP INFUSION 2FL,77265,"Grossman, I Robert, MD",10/14/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/13/2024,Active,,
HAM OP INFUSION,12580,"Patel, Malini M, MD",6/26/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,First Line,6/25/2023,Inactive,,
CINJ OP INFUSION,26175,"Haigentz, Missak, MD",2/13/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Lung Cancer,Adjuvant,2/12/2023,Inactive,,
CINJ OP INFUSION,26175,"Dasgeb, Bahar, MD",9/11/2024,Methotrexate Weekly- Basal Cell,_2. Second Line,9/10/2024,Active,,
CINJ OP INFUSION,26175,"Dasgeb, Bahar, MD",2/24/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/23/2025,Active,"Squamous cell carcinoma of multiple sites
Axillary lymphadenopathy
Essential (primary) hypertension",
CINJ OP INFUSION,31637,"Toppmeyer, Deborah L, MD",9/12/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/11/2024,Inactive,,
CINJ OP INFUSION,39194,"Toppmeyer, Deborah L, MD",3/24/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,3/24/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C50.812 - Malignant neoplasm of overlapping sites of left female breast; Z17.0 - Estrogen receptor positive status (ER+); K59.00 - Constipation, unspecified; Z90.12 - Acquired absence of left breast and nipple"
NBR CINJ OP INFUSION,94777,"Schaar, Dale, MD PhD",1/9/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,1/8/2023,Inactive,,
NBR CINJ OP INFUSION,94777,"Schaar, Dale, MD PhD",8/7/2024,"CINJ 022204 Cohort 3 Combination Agents Part 1 of 2 LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_2. Second Line,8/7/2024,Inactive,,
NBR 4N ONCOLOGY,94777,"Schaar, Dale, MD PhD",10/4/2024,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,10/3/2024,Inactive,,
CINJ OP INFUSION,39996,"Gulhati, Prateek, MD PhD",6/15/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,6/15/2023,Inactive,,
CINJ OP INFUSION,39996,"Gulhati, Prateek, MD PhD",12/21/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,12/21/2023,Inactive,,
CINJ OP INFUSION,39996,"Gulhati, Prateek, MD PhD",5/24/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,5/24/2024,Inactive,,
CINJ OP INFUSION,39996,"Gulhati, Prateek, MD PhD",8/8/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,8/8/2024,Inactive,,
CINJ OP INFUSION,82984,"Weiss, Sarah, MD",12/11/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,12/10/2023,Inactive,,
NBR CINJ OP INFUSION,27098,"Leiser, Aliza, MD",4/11/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,4/11/2025,Active,"Endometrial cancer (CMS/HCC)
Other specified hypothyroidism","Z51.89 - Encounter for other specified aftercare; C54.1 - Malignant neoplasm of endometrium; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; E07.9 - Disorder of thyroid, unspecified"
MMC OP VP INFUSION,43031,"Lee, Patrick C, MD",8/29/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,,8/24/2023,Inactive,,
CMC OP INFUSION,48288,"Easaw, Sarah, MD",3/24/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,3/23/2023,Inactive,,
NBR CINJ OP INFUSION,81818,"Tiger, Yun Kyoung, MD",1/10/2025,Daratumumab and Hyaluronidase-fihj /Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,1/2/2025,Active,,
MSC OP INFUSION,82389,"Eltoukhy, Hussam, MD",3/12/2025,Daratumumab and Hyaluronidase-fihj /Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,1/10/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CBMC OP INFUSION 2FL,55044,"Brown, Andrew Bennett, MD",8/26/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/25/2024,Active,,
NBR CINJ OP INFUSION,80230,"Doraiswamy, Anupama, MD",5/8/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,5/7/2023,Inactive,,
NBR 4N BMTU/IMCU,80230,"Assal, Amer, MD",8/18/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,8/18/2023,Inactive,,
NBR CINJ OP INFUSION,80230,"Chowaniec, Wayne B, NP",11/27/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,Adjuvant,11/26/2023,Active,,
CINJ OP INFUSION,71750,"Stephenson, Ryan D, DO",3/31/2025,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,3/31/2025,Active,"Renal cell carcinoma metastatic to pancreas (CMS/HCC)
Disorder of thyroid","C64.2 - Malignant neoplasm of left kidney, except renal pelvis; C78.89 - Secondary malignant neoplasm of other digestive organs; E11.9 - Type 2 diabetes mellitus without complications; B20 - Human immunodeficiency virus (HIV) disease; E07.9 - Disorder of thyroid, unspecified; C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; Z14.02 - Symptomatic hemophilia A carrier; Z90.5 - Acquired absence of kidney; Z79.4 - Long term (current) use of insulin"
NBR CINJ OP INFUSION,9974,"Evens, Andrew M, DO",9/25/2024,Brentuximab Vedotin / Nivolumab 21 Day Cycles - Hodgkin Lymphoma,_1. First Line,9/24/2024,Active,,
JCMC CP INFUSION,16149,"Cruz, Allan Louie E, MD",4/22/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/22/2025,Active,"Malignant neoplasm of rectum (CMS/HCC)
Malignant neoplasm of colon, unspecified (CMS/HCC)","C18.9 - Malignant neoplasm of colon, unspecified; C20 - Malignant neoplasm of rectum; C18.2 - Malignant neoplasm of ascending colon"
NBR CINJ OP INFUSION,28445,"Shah, Mansi R, MD",5/11/2023,Carfilzomib (High-Dose)/Pomalidomide 2mg/ Dexamethasone 28 Day Cycles- Multiple Myeloma,,5/10/2023,Inactive,,
NBR CINJ OP INFUSION,28445,"Shah, Mansi R, MD",9/7/2023,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,,9/7/2023,Inactive,,
NBR CINJ OP INFUSION,28445,"Shah, Mansi R, MD",11/6/2023,"Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles- Multiple Myeloma",_5. Fifth Line,11/6/2023,Inactive,,
NBR CINJ OP INFUSION,28445,"Shah, Mansi R, MD",3/7/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,3/6/2024,Inactive,,
CBMC OP INFUSION 2FL,19404,"Wagmiller, Jennifer Ann, MD",4/24/2024,CARBOplatin Weekly AUC 2 with radiation,Induction,4/24/2024,Active,,
CINJ OP INFUSION,21997,"Haigentz, Missak, MD",4/3/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/3/2024,Active,,
CINJ OP INFUSION,31918,"Muralikrishnan, Sivraj, MD",1/13/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,1/1/2025,Active,,
CINJ OP INFUSION,34018,"Boland, Patrick M, MD",4/9/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,3/31/2024,Inactive,,
NBR 5N ONCOLOGY,44237,"Schaar, Dale, MD PhD",9/7/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,9/3/2023,Active,"Diffuse large B-cell lymphoma, unspecified site (CMS/HCC)
H/O allogeneic bone marrow transplant (CMS/HCC)
Encounter for immunization",
MMC OP VP INFUSION,59572,"Cohen, Seth D, MD",6/12/2023,CISplatin 25 mg/m2 D1-D3/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,First Line,6/11/2023,Inactive,,
CINJ OP INFUSION,48618,"Saraiya, Biren P, MD",5/19/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/19/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
CINJ PEDS HEMONC ,23435,"Masterson, Margaret, MD",6/12/2024,Iron Desensitization (Venofer),Maintenance,6/12/2024,Active,,
CINJ OP INFUSION,11521,"Boland, Patrick M, MD",7/25/2023,Gemcitabine / OXALIplatin / Durva 21 Day Cycles - Cholangiocarcinoma,,7/24/2023,Inactive,,
CINJ OP INFUSION,11521,"Boland, Patrick M, MD",3/26/2024,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_2. Second Line,3/25/2024,Inactive,,
MMC OP VP INFUSION,9868,"Cohen, Seth D, MD",11/26/2024,CINJ 082401 Arm 2 Cohort A Nivolumab  / Relatlimab 28 Day Cycles Research- Urothelial Cancer,_2. Second Line,11/26/2024,Active,,
CINJ OP INFUSION,2292,"Gulhati, Prateek, MD PhD",3/10/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,3/10/2023,Inactive,,
CINJ OP INFUSION,2292,"Gulhati, Prateek, MD PhD",9/5/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,9/4/2024,Active,,
CBMC OP INFUSION 2FL,6578,"McKenna, Marshall, MD",5/9/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/8/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
CBMC OP INFUSION 2FL,6578,"McKenna, Marshall, MD",5/7/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/7/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
CBMC 2W ONCOLOGY,6578,"McKenna, Marshall, MD",4/3/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/3/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"A41.9 - Sepsis, unspecified organism; E88.3 - Tumor lysis syndrome; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; C83.36 - Diffuse large b-cell lymphoma, intrapelvic lymph nodes; B37.0 - Candidal stomatitis; D70.9 - Neutropenia, unspecified; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E03.9 - Hypothyroidism, unspecified; E66.9 - Obesity, unspecified; N18.9 - Chronic kidney disease, unspecified; D50.9 - Iron deficiency anemia, unspecified; I50.32 - Chronic diastolic (congestive) heart failure; E87.0 - Hyperosmolality and hypernatremia; E87.20 - Acidosis, unspecified; N39.0 - Urinary tract infection, site not specified; E87.1 - Hypo-osmolality and hyponatremia; I48.0 - Paroxysmal atrial fibrillation; Z11.52 - Encounter for screening for COVID-19; E83.39 - Other disorders of phosphorus metabolism; E83.51 - Hypocalcemia; R62.7 - Adult failure to thrive; D69.59 - Other secondary thrombocytopenia; D64.81 - Anemia due to antineoplastic chemotherapy; E56.1 - Deficiency of vitamin K; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; E87.6 - Hypokalemia; E83.42 - Hypomagnesemia; K64.9 - Unspecified hemorrhoids; H11.31 - Conjunctival hemorrhage, right eye; K12.30 - Oral mucositis (ulcerative), unspec..."
CBMC 2W ONCOLOGY,6578,"McKenna, Marshall, MD",4/2/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/2/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"A41.9 - Sepsis, unspecified organism; E88.3 - Tumor lysis syndrome; A04.72 - Enterocolitis due to Clostridium difficile, not specified as recurrent; C83.36 - Diffuse large b-cell lymphoma, intrapelvic lymph nodes; B37.0 - Candidal stomatitis; D70.9 - Neutropenia, unspecified; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E03.9 - Hypothyroidism, unspecified; E66.9 - Obesity, unspecified; N18.9 - Chronic kidney disease, unspecified; D50.9 - Iron deficiency anemia, unspecified; I50.32 - Chronic diastolic (congestive) heart failure; E87.0 - Hyperosmolality and hypernatremia; E87.20 - Acidosis, unspecified; N39.0 - Urinary tract infection, site not specified; E87.1 - Hypo-osmolality and hyponatremia; I48.0 - Paroxysmal atrial fibrillation; Z11.52 - Encounter for screening for COVID-19; E83.39 - Other disorders of phosphorus metabolism; E83.51 - Hypocalcemia; R62.7 - Adult failure to thrive; D69.59 - Other secondary thrombocytopenia; D64.81 - Anemia due to antineoplastic chemotherapy; E56.1 - Deficiency of vitamin K; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; E87.6 - Hypokalemia; E83.42 - Hypomagnesemia; K64.9 - Unspecified hemorrhoids; H11.31 - Conjunctival hemorrhage, right eye; K12.30 - Oral mucositis (ulcerative), unspec..."
HAM OP INFUSION,69484,"Patel, Malini M, MD",11/6/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,10/27/2023,Inactive,,
NBR CINJ OP INFUSION,20700,"Matasar, Matthew J, MD",5/24/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,First Line,5/23/2023,Inactive,,
NBR CINJ OP INFUSION,20700,"Matasar, Matthew J, MD",7/5/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,First Line,7/4/2023,Inactive,,
MSC OP INFUSION,20700,"Cohen, Seth D, MD",8/30/2023,CINJ 112305 AVD Arm E (Doxorubicin / Vinblastine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,8/29/2023,Inactive,,
NBI OP INFUSION,22647,"Anderson, Patrick S, MD",2/17/2025,Methotrexate 7 Day Cycles - Gestational Trophoblastic Neoplasia,_1. First Line,2/9/2025,Active,Molar pregnancy,
SOM OUTPT INFUSION,38944,"Patel, Eshan, MD",2/15/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_1. First Line,2/14/2024,Inactive,,
SOM OUTPT INFUSION,38944,"Patel, Eshan, MD",7/3/2024,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,7/3/2024,Inactive,,
SOM OUTPT INFUSION,38944,"Patel, Eshan, MD",9/10/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_3. Third Line,9/10/2024,Active,,
CINJ OP INFUSION,86539,"Goel, Sanjay, MD",11/13/2023,CINJ 052301 Dose Finding JZP341 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,11/10/2023,Inactive,,
NBI OP INFUSION,69845,"Jacoby, Sari H, MD",11/20/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/20/2023,Inactive,,
CINJ OP INFUSION,99168,"Ghodoussipour, Saum Bobak, MD",4/10/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,4/9/2024,Inactive,,
CINJ OP INFUSION,99168,"Ghodoussipour, Saum Bobak, MD",7/10/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,7/10/2024,Active,,
CBMC OP INFUSION 2FL,26678,"Grossman, I Robert, MD",10/15/2024,Brentuximab Vedotin 21 Day Cycles + DOXOrubicin / VinBLAStine / Dacarbazine 28 Day Cycles + Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,_1. First Line,10/13/2024,Active,,
CINJ OP INFUSION,9595,"Hochster, Howard S, MD",1/16/2025,CINJ 072401 Quemliclustat / Zimberelimab / Gemcitabine / CISplatin 42 Day Cycles Research- Advanced Biliary Tract Cancers,_1. First Line,1/15/2025,Active,,
CMC OP INFUSION,31648,"Cohen, Seth D, MD",2/28/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/26/2025,Active,"Non-small cell lung cancer (NSCLC) (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,41245,"Saraiya, Biren P, MD",7/22/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,7/14/2024,Inactive,,
HAM OP INFUSION,97755,"Patel, Malini M, MD",8/9/2023,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,8/8/2023,Inactive,,
HAM OP INFUSION,97755,"Patel, Malini M, MD",11/9/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,11/1/2023,Inactive,,
SOM OUTPT INFUSION,91285,"Patel, Eshan, MD",2/19/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,2/11/2024,Inactive,,
SOM OUTPT INFUSION,91285,"Patel, Eshan, MD",5/29/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,5/19/2024,Active,,
CINJ OP INFUSION,72948,"Saraiya, Biren P, MD",7/12/2024,CINJ 082101 (NRG-GU009) ARM 2 Androgen Deprivation Therapy 3 Month Cycles (84 Days) Research- Prostate Cancer,_1. First Line,3/7/2024,Active,,
CINJ OP INFUSION,21625,"Saraiya, Biren P, MD",10/21/2024,CINJ 082304 Cohort 2 ONC-392 / Lutetium Lu 177 Vipivotide Tetraxetan 42 Day Cycles Research- Prostate Cancer,_4. Fourth Line,10/20/2024,Active,,
NBI OP INFUSION,7647,"Shah, Shailja S, MD",9/26/2023,"DOCEtaxel D1, D8 21 Day Cycles-Non-Small Cell Lung Cancer",_2. Second Line,9/25/2023,Inactive,,
NBI OP INFUSION,7647,"Shah, Shailja S, MD",4/23/2024,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_5. Fifth Line,4/22/2024,Inactive,,
CBMC 2W ONCOLOGY,86722,"Meelheim, Brooke A, DO",11/5/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Advanced endometrial carcinoma,Adjuvant,10/27/2024,Active,,
CINJ OP INFUSION,86085,"George, Mridula A, MD",4/12/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_3. Third Line,4/9/2024,Active,,
NBI VALERIE FND HEMONC,64738,"de Benedictis, Marianna, MD",9/20/2023,ARST2032 Regimen VAC/VA,_1. First Line,9/19/2023,Inactive,,
NBR 4N ONCOLOGY,77433,"Braunschweig, Ira, MD",3/18/2023,HyperCVAD (Cycle B) Course (High Dose Methotrexate / Cytarabine) + RiTUXimab 21 Day Cycles - Mantle Cell Lymphoma,,3/17/2023,Inactive,,
CBMC OP INFUSION 2FL,57233,"Radovich, Delia, MD",11/2/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_3. Third Line,11/1/2023,Inactive,,
CINJ OP INFUSION,99531,"Omene, Coral Oghenerukevwe, MD",4/6/2023,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Neoadjuvant,4/3/2023,Inactive,,
CINJ OP INFUSION,99531,"Omene, Coral Oghenerukevwe, MD",2/5/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/22/2024,Inactive,,
CINJ OP INFUSION,99531,"Omene, Coral Oghenerukevwe, MD",3/25/2024,Neratinib 28 Day Cycles - Breast,Adjuvant,3/25/2024,Active,,
CINJ OP INFUSION,73416,"Weiss, Sarah, MD",4/22/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,4/19/2024,Active,,
NBR CINJ OP INFUSION,914,"Matasar, Matthew J, MD",4/5/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,Second Line,4/4/2023,Inactive,,
NBR CINJ OP INFUSION,914,"Matasar, Matthew J, MD",7/26/2023,Tazemetostat 30 Day Cycles - Follicular Lymphoma (Grade 1-2),Third Line,7/26/2023,Active,"Malignant melanoma of left upper limb, including shoulder (CMS/HCC)",
NBR 5N MED-SURG OVRF,38507,"Alexander, Henry Richard, MD",6/27/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,6/27/2024,Inactive,,
CINJ OP INFUSION,38507,"Hochster, Howard S, MD",8/1/2024,"Encorafenib + Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",Consolidation,7/24/2024,Active,,
CINJ OP INFUSION,799,"Stephenson, Ryan D, DO",5/28/2025,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_4. Fourth Line,5/28/2025,Active,Metastatic castration-resistant adenocarcinoma of prostate (CMS/HCC),C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; Z19.2 - Hormone resistant malignancy status
MMC OP VP INFUSION,73843,"Talwar, Sumit, MD",7/5/2023,Abemaciclib 28 Day Cycles - Breast,First Line,7/5/2023,Inactive,,
CINJ OP INFUSION,71446,"Saraiya, Biren P, MD",12/4/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,12/2/2024,Active,,
CBMC OP INFUSION 2FL,34816,"Raptis, George, MD",6/6/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,6/3/2024,Active,,
JCMC CP INFUSION,98741,"Cruz, Allan Louie E, MD",7/18/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,7/11/2023,Inactive,,
JCMC CP INFUSION,98741,"Maggi, Jason C, MD",3/14/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,3/14/2024,Inactive,,
JCMC CP INFUSION,98741,"Cruz, Allan Louie E, MD",11/20/2024,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/12/2024,Inactive,,
MMC OP VP INFUSION,83275,"Lee, Patrick C, MD",10/5/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,,10/4/2023,Inactive,,
CINJ OP INFUSION,84795,"Haigentz, Missak, MD",2/17/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,2/17/2025,Active,Nasopharyngeal carcinoma (CMS/HCC),"C11.9 - Malignant neoplasm of nasopharynx, unspecified"
CINJ OP INFUSION,20537,"Haigentz, Missak, MD",1/23/2023,CINJ 032201 ARM 3 Pembrolizumab / CARBOplatin / Fluorouracil Alternating with Pembrolizumab Alone 21 Day Cycles Research- Head and Neck Cancers,First Line,1/22/2023,Inactive,,
NBI OP INFUSION,88262,"Anderson, Patrick S, MD",11/2/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,11/1/2023,Inactive,,
NBI OP INFUSION,88262,"Anderson, Patrick S, MD",5/16/2024,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,5/15/2024,Active,,
NBI OP INFUSION,88262,"Anderson, Patrick S, MD",4/17/2025,Dostarlimab-gxly 42 Day Cycles- Gynecologic Cancers,_4. Fourth Line,4/17/2025,Active,Ovarian cancer (CMS/HCC),
CINJ OP INFUSION,70397,"Aikins, James K, MD",5/3/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,,4/20/2023,Inactive,,
JCMC CP INFUSION,54248,"Sekhri, Arunabh, MD",4/6/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/5/2023,Inactive,,
CINJ OP INFUSION,89982,"Omene, Coral Oghenerukevwe, MD",1/6/2023,TH+P (DOCEtaxel / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,First Line,1/2/2023,Inactive,,
CINJ OP INFUSION,89982,"Omene, Coral Oghenerukevwe, MD",9/5/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,8/13/2023,Inactive,,
CINJ OP INFUSION,89982,"Omene, Coral Oghenerukevwe, MD",11/26/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_3. Third Line,11/25/2024,Inactive,,
MMC OP VP INFUSION,36646,"Cohen, Seth D, MD",9/4/2024,Dabrafenib/Trametinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/4/2024,Inactive,,
MMC OP VP INFUSION,36646,"Cohen, Seth D, MD",1/13/2025,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/12/2025,Active,,
MMC OP VP INFUSION,36646,"Cohen, Seth D, MD",1/15/2025,Nivolumab/Ipilimumab 42 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/14/2025,Inactive,Malignant neoplasm of overlapping sites of right bronchus and lung (CMS/HCC),
CBMC OP INFUSION 2FL,72027,"Derosa, William T, DO",11/20/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/19/2024,Active,,
TRMC TCCC OP INFUSION,65221,"Capo, Gerardo, MD",4/17/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/16/2025,Active,Malignant neoplasm of transverse colon (CMS/HCC),"D64.9 - Anemia, unspecified; C18.4 - Malignant neoplasm of transverse colon; D49.0 - Neoplasm of unspecified behavior of digestive system; R97.0 - Elevated carcinoembryonic antigen (CEA); R97.8 - Other abnormal tumor markers; R10.84 - Generalized abdominal pain"
CBMC OP INFUSION 2FL,55702,"Brown, Andrew Bennett, MD",10/18/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/12/2023,Inactive,,
CBMC OP INFUSION 2FL,55702,"Brown, Andrew Bennett, MD",11/20/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,11/19/2023,Inactive,,
CINJ OP INFUSION,29725,"Toppmeyer, Deborah L, MD",4/8/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,4/8/2024,Inactive,,
CINJ OP INFUSION,29725,"Toppmeyer, Deborah L, MD",4/8/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,4/8/2024,Active,,
NBI OP INFUSION,81708,"Shah, Shailja S, MD",1/23/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,1/22/2024,Inactive,,
NBI OP INFUSION,4464,"Cohen, Alice, MD",12/27/2023,Ruxolitinib 30 Day Cycles - Myelofibrosis,_2. Second Line,12/27/2023,Active,"Adenosquamous carcinoma (CMS/HCC)
Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)
Other fatigue",
MMC OP VP INFUSION,72096,"Cohen, Seth D, MD",4/7/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,4/7/2025,Active,Malignant neoplasm of body of pancreas (CMS/HCC),
CMC OP INFUSION,32852,"Talwar, Sumit, MD",5/8/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,5/7/2024,Inactive,,
CINJ OP INFUSION,88702,"Haigentz, Missak, MD",2/22/2023,Bevacizumab 3-week interval - CNS/NF2 Palliation,First Line,2/20/2023,Inactive,,
MMC OP VP INFUSION,33403,"Cohen, Seth D, MD",12/7/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,11/22/2023,Inactive,,
CINJ OP INFUSION,36118,"Omene, Coral Oghenerukevwe, MD",2/17/2025,Abemaciclib 28 Day Cycles - Breast,_1. First Line,2/17/2025,Active,"Breast cancer metastasized to bone, left (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C79.51 - Secondary malignant neoplasm of bone; I48.91 - Unspecified atrial fibrillation
CBMC OP INFUSION 2FL,15147,"Raptis, George, MD",7/12/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,6/27/2024,Active,,
NBR 4N ONCOLOGY,38813,"Tiger, Yun Kyoung, MD",10/12/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,10/11/2024,Inactive,,
NBR CINJ OP INFUSION,38813,"Tiger, Yun Kyoung, MD",10/18/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,10/17/2024,Active,,
JCMC CP INFUSION,16536,"Cruz, Allan Louie E, MD",5/14/2025,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,5/14/2025,Active,Hepatocellular carcinoma (CMS/HCC),C22.0 - Liver cell carcinoma
JCMC CP INFUSION,49574,"Sekhri, Arunabh, MD",4/25/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - High-risk endometrial carcinoma (Serous Carcinoma),Adjuvant,4/25/2025,Active,Endometrial adenocarcinoma (CMS/HCC),"C54.1 - Malignant neoplasm of endometrium; E66.813 - Obesity, class 3; F41.9 - Anxiety disorder, unspecified; K59.09 - Other constipation; L65.8 - Other specified nonscarring hair loss; E66.01 - Morbid (severe) obesity due to excess calories; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z68.41 - Body mass index (BMI) 40.0-44.9, adult"
CINJ OP INFUSION,32351,"Stephenson, Ryan D, DO",1/2/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,12/29/2023,Inactive,,
CBMC OP INFUSION 2FL,52034,"Brown, Andrew Bennett, MD",6/19/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/18/2024,Inactive,,
TRMC TCCC OP INFUSION,9868,"Capo, Gerardo, MD",9/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,9/3/2024,Inactive,,
TRMC TCCC OP INFUSION,9868,"Capo, Gerardo, MD",10/30/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,10/29/2024,Active,,
TRMC TCCC OP INFUSION,96561,"Capo, Gerardo, MD",5/22/2025,PACLitaxel / CARBOplatin / Gemcitabine 21 Day Cycles - Unknown Primary,_1. First Line,5/22/2025,Active,Carcinoma of unknown primary (CMS/HCC),"C80.1 - Malignant (primary) neoplasm, unspecified; C61 - Malignant neoplasm of prostate"
HAM OP INFUSION,62342,"Yogarajah, Meera, MD",1/10/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,First Line,1/4/2023,Inactive,,
HAM OP INFUSION,62342,"Yogarajah, Meera, MD",4/27/2023,Pembrolizumab 21 Day Cycles - Bladder ,,4/27/2023,Active,,
CINJ PEDS HEMONC ,35411,"Moerdler, Scott, MD",9/5/2024,Dosing per AGCT1532 Arm A (Standard BEP),_1. First Line,9/3/2024,Active,,
CINJ OP INFUSION,64907,"Toppmeyer, Deborah L, MD",8/17/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,First Line,8/9/2023,Active,,
CINJ OP INFUSION,9286,"Toppmeyer, Deborah L, MD",5/8/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,5/8/2025,Active,Malignant neoplasm of breast metastatic to liver (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
NBR CINJ OP INFUSION,59632,"Egini, Ogechukwu, MD",6/15/2024,BMT Autologous BEAM,Consolidation,6/14/2024,Inactive,,
CMC OP INFUSION,52539,"Taff, Jessica, MD",12/21/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/10/2023,Inactive,,
CINJ OP INFUSION,10459,"Weiss, Sarah, MD",8/7/2024,Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,8/4/2024,Active,,
CINJ OP INFUSION,93519,"Berim, Lyudmyla, MD",1/13/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,1/7/2025,Active,,
CBMC OP INFUSION 2FL,3737,"Brown, Andrew Bennett, MD",11/18/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,11/18/2024,Active,,
CINJ OP INFUSION,69714,"Packiam, Vignesh, MD",10/24/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,10/22/2024,Active,,
CINJ OP INFUSION,63472,"Packiam, Vignesh, MD",2/12/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,2/11/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CBMC OP INFUSION 2FL,22922,"Brown, Andrew Bennett, MD",10/24/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/23/2023,Active,,
MMC OP VP INFUSION,62136,"Lee, Patrick C, MD",7/13/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,7/12/2023,Inactive,,
TRMC TCCC OP INFUSION,27265,"Capo, Gerardo, MD",9/17/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/16/2024,Active,,
TRMC TCCC OP INFUSION,27265,"Capo, Gerardo, MD",1/31/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,1/30/2025,Active,,
MMC BBR2 ONCOLOGY,80272,"Eltoukhy, Hussam, MD",2/20/2024,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,2/19/2024,Active,,
MMC BBR2 ONCOLOGY,80272,"Eltoukhy, Hussam, MD",3/6/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,3/3/2024,Active,,
MMC OP VP INFUSION,25793,"Meghal, Trishala, MD",7/15/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,7/8/2024,Active,,
MMC OP VP INFUSION,25793,"Meghal, Trishala, MD",8/20/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,8/18/2024,Inactive,,
MMC OP VP INFUSION,25793,"Meghal, Trishala, MD",12/17/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,12/17/2024,Active,,
HAM OP INFUSION,90776,"Yogarajah, Meera, MD",11/2/2023,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/29/2023,Inactive,,
NBR 5N ONCOLOGY,40632,"Leiser, Aliza, MD",7/30/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,7/23/2024,Inactive,,
CINJ OP INFUSION,40632,"Leiser, Aliza, MD",9/16/2024,Pembrolizumab 21 Day Cycles - Cervical,Maintenance,9/16/2024,Active,,
HAM OP INFUSION,93727,"Patel, Malini M, MD",10/18/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/16/2024,Active,,
JCMC CP INFUSION,64421,"Cruz, Allan Louie E, MD",10/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/16/2024,Active,,
SOM OUTPT INFUSION,47622,"Patel, Eshan, MD",1/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/4/2024,Inactive,,
SOM OUTPT INFUSION,47622,"Patel, Eshan, MD",4/17/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/16/2024,Inactive,,
CINJ OP INFUSION,44027,"Haigentz, Missak, MD",8/26/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/26/2024,Active,,
NBR CINJ OP INFUSION,43294,"Evens, Andrew M, DO",1/20/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,1/20/2023,Inactive,,
NBR CINJ OP INFUSION,43294,"Evens, Andrew M, DO",2/8/2023,RiTUXimab Rapid Infusion Single Day (Outpatient),,2/8/2023,Inactive,,
CINJ PEDS HEMONC ,10317,"Cole, Peter David, MD",3/18/2024,Trametinib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/18/2024,Inactive,,
CINJ PEDS HEMONC ,10317,"Moerdler, Scott, MD",3/20/2024,PEDS Trametinib - Plexiform Neurofibroma,_1. First Line,3/19/2024,Active,,
CBMC OP INFUSION 2FL,6822,"Litvak, Anna M, MD",9/20/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,9/19/2024,Active,,
CINJ OP INFUSION,58926,"Gulhati, Prateek, MD PhD",3/31/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,3/29/2023,Inactive,,
CINJ OP INFUSION,58926,"Gulhati, Prateek, MD PhD",2/15/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,2/14/2024,Active,,
CINJ OP INFUSION,15928,"Gulhati, Prateek, MD PhD",5/15/2025,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,5/15/2025,Active,Malignant neoplasm of other parts of pancreas (CMS/HCC),"G89.3 - Neoplasm related pain (acute) (chronic); M79.10 - Myalgia, unspecified site; K59.03 - Drug induced constipation; T40.2X5A - Adverse effect of other opioids, initial encounter; R11.0 - Nausea; R53.81 - Other malaise; C25.9 - Malignant neoplasm of pancreas, unspecified; C79.61 - Secondary malignant neoplasm of right ovary; C79.89 - Secondary malignant neoplasm of other specified sites; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; K86.81 - Exocrine pancreatic insufficiency; E11.9 - Type 2 diabetes mellitus without complications; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; G62.9 - Polyneuropathy, unspecified; I82.402 - Acute embolism and thrombosis of unspecified deep veins of left lower extremity; G89.29 - Other chronic pain; M79.2 - Neuralgia and neuritis, unspecified; C25.7 - Malignant neoplasm of other parts of pancreas; Z51.5 - Encounter for palliative care; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
CBMC OP INFUSION 2FL,62692,"Derosa, William T, DO",11/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,11/3/2024,Inactive,,
CINJ OP INFUSION,73243,"Haigentz, Missak, MD",8/6/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,7/24/2024,Active,,
CINJ OP INFUSION,73243,"Haigentz, Missak, MD",2/17/2025,Albumin-Bound PACLitaxel/CARBOplatin + Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/16/2025,Active,"Adenocarcinoma, lung, right (CMS/HCC)
Chronic fatigue","C34.91 - Adenocarcinoma, lung, right (CMS/HCC); C34.92 - Adenocarcinoma of lung, left (CMS/HCC); J91.0 - Malignant pleural effusion"
SOM OUTPT INFUSION,24242,"Toomey, Kathleen C, MD",5/23/2025,Bevacizumab/ PACLitaxel / CARBOplatin weekly (AUC 1.5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/23/2025,Active,"Ovarian cancer (CMS/HCC)
Peritoneal carcinoma (CMS/HCC)",
CMC OP INFUSION,33984,"Taff, Jessica, MD",6/5/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,First Line,6/4/2023,Inactive,,
JCMC CP INFUSION,37277,"Cruz, Allan Louie E, MD",2/24/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/24/2025,Active,Cancer of base of tongue (CMS/HCC),
HAM OP INFUSION,67572,"Patel, Malini M, MD",8/23/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,8/22/2023,Inactive,,
SOM OUTPT INFUSION,87828,"Toomey, Kathleen C, MD",3/28/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,3/28/2025,Inactive,Breast cancer of upper-outer quadrant of left female breast (CMS/HCC),
SOM OUTPT INFUSION,87828,"Toomey, Kathleen C, MD",3/13/2025,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,_1. First Line,3/13/2025,Inactive,Breast cancer of upper-outer quadrant of left female breast (CMS/HCC),
CBMC OP INFUSION 2FL,86261,"Wagmiller, Jennifer Ann, MD",11/7/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,11/6/2023,Active,,
JCMC CP INFUSION,1065,"Cruz, Allan Louie E, MD",11/25/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,11/25/2024,Active,,
MSC OP INFUSION,46082,"Cohen, Seth D, MD",6/26/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,6/26/2024,Inactive,,
MMC OP VP INFUSION,46082,"Cohen, Seth D, MD",1/21/2025,"FOLFIRI Inpatient Cycle 1, Outpatient Cycle 2+ (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/17/2025,Inactive,Primary malignant neoplasm of pancreas with metastasis to other site (CMS/HCC),
CINJ OP INFUSION,1555,"George, Mridula A, MD",12/18/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,11/12/2024,Active,,
CBMC OP INFUSION 2FL,85178,"Derosa, William T, DO",10/24/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/18/2024,Active,,
NBR BMSCH 2 PED HEMONC,68535,"Goyal-Khemka, Meenakshi, MD",2/1/2023,AALL1732 B-ALL Induction,Induction,2/1/2023,Inactive,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",3/14/2023,AALL1732 Consolidation,Consolidation,3/14/2023,Inactive,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",6/6/2023,AALL1732 Interim Maintenance I (IM I) with HDMTX,First Line,6/1/2023,Inactive,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",8/31/2023,AALL1732 Delayed Intensification,First Line,8/31/2023,Inactive,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",11/7/2023,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,11/7/2023,Inactive,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",1/25/2024,AALL1732 HR B-ALL Arm A & Arm B - Maintenance,Maintenance,1/24/2024,Active,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",10/4/2024,PEDS Blinatumomab,_1. First Line,10/3/2024,Inactive,,
CINJ PEDS HEMONC ,68535,"Botwinick, Marissa, DO",10/8/2024,PEDS Blinatumomab,_1. First Line,10/8/2024,Inactive,,
NBR CINJ OP INFUSION,91111,"Evens, Andrew M, DO",5/17/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,5/16/2023,Inactive,,
JCMC CP INFUSION,35441,"Sekhri, Arunabh, MD",4/17/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,4/10/2023,Inactive,,
CBMC OP INFUSION 2FL,35441,"Leitner, Stuart P, MD",5/8/2024,Hepatic Artery Infusion FUDR / Dexamethasone / Heparin NS alternating w/ Heparin or Glycerol HAI 28 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/8/2024,Inactive,,
CBMC OP INFUSION 2FL,35441,"Leitner, Stuart P, MD",5/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/21/2024,Inactive,,
CBMC OP INFUSION 2FL,35441,"Leitner, Stuart P, MD",10/23/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/22/2024,Active,,
CBMC OP INFUSION 2FL,69827,"Dave, Manish, MD",1/16/2024,RiTUXimab Initial Infusion ++ Day (Outpatient),Maintenance,1/16/2024,Inactive,,
CINJ OP INFUSION,29293,"Weiss, Sarah, MD",6/5/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,6/5/2023,Inactive,,
CINJ OP INFUSION,70126,"Haigentz, Missak, MD",8/5/2023,Lenvatinib 28 Day Cycles- Thyroid Cancer,First Line,8/5/2023,Active,,
JCMC CP INFUSION,64423,"Sekhri, Arunabh, MD",8/24/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,8/10/2023,Active,,
NBR 4N BMTU/IMCU,30901,"Palmisiano, Neil David, MD",6/2/2023,HyperCVAD (Cycle A) Course (Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone) 21 Day Cycles - Acute Lymphoblastic Leukemia,Induction,6/1/2023,Inactive,,
NBR CINJ OP INFUSION,30901,"Palmisiano, Neil David, MD",6/30/2023,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,Induction,6/15/2023,Inactive,,
NBR 4N BMTU/IMCU,30901,"Braunschweig, Ira, MD",11/9/2023,BMT Allogeneic TBF + Post Cy ,_2. Second Line,11/2/2023,Inactive,,
NBR CINJ OP INFUSION,30901,"Palmisiano, Neil David, MD",3/7/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,3/7/2024,Inactive,,
NBR CINJ OP INFUSION,30901,"Assal, Amer, MD",6/13/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,6/13/2024,Inactive,,
NBR 4N BMTU/IMCU,30901,"Palmisiano, Neil David, MD",7/10/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_2. Second Line,7/9/2024,Inactive,,
NBI OP INFUSION,81475,"Shah, Shailja S, MD",6/7/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,Induction,6/6/2024,Active,,
NBI OP INFUSION,10429,"Shah, Shailja S, MD",2/7/2025,Carfilzomib 56 mg/m2 Weekly / Lenalidomide Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,2/6/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CINJ OP INFUSION,5218,"Aikins, James K, MD",9/22/2023,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,8/24/2023,Inactive,,
CINJ OP INFUSION,81622,"Stephenson, Ryan D, DO",6/12/2024,Nivolumab 28 Day Cycles - Kidney or Bladder,Adjuvant,6/12/2024,Inactive,,
CINJ OP INFUSION,81622,"Stephenson, Ryan D, DO",10/16/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,10/8/2024,Active,,
CINJ OP INFUSION,86729,"Boland, Patrick M, MD",2/14/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/13/2023,Inactive,,
CINJ OP INFUSION,86729,"Boland, Patrick M, MD",2/14/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,2/13/2023,Inactive,,
CINJ OP INFUSION,86729,"Boland, Patrick M, MD",2/19/2023,CINJ 072201 Treatment ARM NBT-NM108 / FOLFIRI (Fluorouracil IVCI / Leucovorin / Irinotecan) 14 Day Cycles Research- Colorectal Cancer,,1/16/2023,Inactive,,
CINJ OP INFUSION,86729,"Boland, Patrick M, MD",4/28/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,,4/27/2023,Inactive,,
CINJ OP INFUSION,86729,"Boland, Patrick M, MD",4/28/2023,Irinotecan + Panitumumab 14 Day Cycles- Gastrointestinal Cancers,,4/27/2023,Inactive,,
CINJ OP INFUSION,86729,"Boland, Patrick M, MD",6/23/2023,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/22/2023,Inactive,,
SOM 1PAV ONCOLOGY,35736,"Patel, Eshan, MD",5/9/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,,5/9/2023,Inactive,,
MMC OP VP INFUSION,48913,"Cohen, Seth D, MD",1/6/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,12/25/2024,Active,,
MMC OP VP INFUSION,90703,"Cohen, Seth D, MD",4/8/2025,CINJ 032404 Control Group Durvalumab 28 Day Cycles Research- Small Cell Lung Cancer,_1. First Line,4/8/2025,Active,Metastasis to bone (CMS/HCC),
CINJ OP INFUSION,37880,"Stephenson, Ryan D, DO",12/9/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,12/9/2024,Active,,
MMC OP INFUSION,15765,"Meghal, Trishala, MD",5/24/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,5/22/2024,Inactive,,
TRMC TCCC OP INFUSION,60566,"Capo, Gerardo, MD",10/10/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,10/9/2024,Active,,
TRMC TCCC OP INFUSION,43986,"Capo, Gerardo, MD",5/14/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,5/14/2025,Active,"Malignant melanoma of left upper extremity including shoulder (CMS/HCC)
Secondary malignant neoplasm of both lungs (CMS/HCC)","D63.8 - Anemia in other chronic diseases classified elsewhere; D53.9 - Nutritional anemia, unspecified; C78.01 - Secondary malignant neoplasm of right lung; C78.02 - Secondary malignant neoplasm of left lung; C43.62 - Malignant melanoma of left upper limb, including shoulder"
CINJ OP INFUSION,23488,"Groisberg, Roman, MD",2/21/2025,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_2. Second Line,2/20/2025,Active,"Secondary malignant neoplasm of unspecified lung (CMS/HCC)
Synovial sarcoma (CMS/HCC)",C49.9 - Synovial sarcoma (CMS/HCC)
CINJ OP INFUSION,23488,"Groisberg, Roman, MD",5/23/2025,DOXOrubicin 21 Day Cycles - Sarcoma,_3. Third Line,5/23/2025,Active,Synovial sarcoma (CMS/HCC),
NBR 5N ONCOLOGY,11630,"Packiam, Vignesh, MD",7/25/2024,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,7/25/2024,Inactive,,
CINJ OP INFUSION,11630,"Ghodoussipour, Saum Bobak, MD",9/13/2024,BCG Induction (TICE) 42 Day Cycle,Adjuvant,9/6/2024,Inactive,,
CINJ OP INFUSION,11630,"Ghodoussipour, Saum Bobak, MD",12/13/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,12/13/2024,Active,,
SOM OUTPT INFUSION,19914,"Yin, Faye, MD",5/23/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/8/2023,Inactive,,
SOM OUTPT INFUSION,19914,"Yin, Faye, MD",9/27/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,9/26/2023,Inactive,,
SOM OUTPT INFUSION,53267,"George, Roshini, DO",5/28/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,5/28/2025,Active,Cervix cancer (CMS/HCC),"C53.8 - Malignant neoplasm of overlapping sites of cervix uteri; C57.7 - Malignant neoplasm of other specified female genital organs; D64.9 - Anemia, unspecified; R79.1 - Abnormal coagulation profile; E43 - Unspecified severe protein-calorie malnutrition; E53.8 - Deficiency of other specified B group vitamins; R45.89 - Other symptoms and signs involving emotional state; Z51.11 - Encounter for antineoplastic chemotherapy"
NBR 4N ONCOLOGY,16309,"Palmisiano, Neil David, MD",1/23/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,1/22/2024,Inactive,,
NBR 5N ONCOLOGY,16309,"Rhodes, Joanna Meehan, MD",11/6/2024,Cytarabine Cytoreduction for Hyperleukocytosis,Adjuvant,11/5/2024,Inactive,,
CINJ OP INFUSION,71139,"George, Mridula A, MD",12/20/2023,Ribociclib 28 Day Cycles - Breast,_1. First Line,12/20/2023,Active,"Breast cancer (CMS/HCC)
Endometrial cancer (CMS/HCC)",
MMC OP VP INFUSION,3185,"Cohen, Seth D, MD",7/22/2024,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_3. Third Line,7/18/2024,Inactive,,
MMC OP VP INFUSION,3185,"Cohen, Seth D, MD",11/5/2024,Gemcitabine 21 Day Cycles - Sarcoma,_3. Third Line,11/3/2024,Active,,
NBR 4N ONCOLOGY,70727,"Palmisiano, Neil David, MD",11/10/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,11/9/2023,Inactive,,
CINJ OP INFUSION,66966,"Berim, Lyudmyla, MD",2/5/2024,Olaparib 30 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,2/5/2024,Active,,
CINJ OP INFUSION,68029,"Berim, Lyudmyla, MD",5/5/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_3. Third Line,5/5/2025,Active,Malignant neoplasm of stomach (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C16.9 - Malignant neoplasm of stomach, unspecified"
CINJ OP INFUSION,68029,"Berim, Lyudmyla, MD",4/28/2025,CISplatin + Gemcitabine 28 Day Cycles - Pancreatic Adenocarcinoma,_2. Second Line,4/28/2025,Inactive,Malignant neoplasm of stomach (CMS/HCC),"C25.0 - Malignant neoplasm of head of pancreas; C16.9 - Malignant neoplasm of stomach, unspecified"
CBMC OP INFUSION 2FL,6902,"Leitner, Stuart P, MD",5/20/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/20/2025,Active,Cancer of overlapping sites of right lung (CMS/HCC),
TRMC TCCC OP INFUSION,97655,"Capo, Gerardo, MD",9/27/2024,OVA28 Bevacizumab + Topotecan 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/19/2024,Inactive,,
TRMC TCCC OP INFUSION,97655,"Capo, Gerardo, MD",10/10/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/26/2024,Inactive,,
CBMC OP INFUSION 2FL,45953,"Leitner, Stuart P, MD",9/30/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,9/25/2024,Active,,
CBMC OP INFUSION 2FL,3581,"Radovich, Delia, MD",8/1/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,7/31/2023,Inactive,,
CBMC OP INFUSION 2FL,3581,"Brown, Andrew Bennett, MD",9/23/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/22/2024,Inactive,,
CBMC OP INFUSION 2FL,88202,"Brown, Andrew Bennett, MD",3/19/2024,CINJ 042102 Block A Zanidatamab 14 Day Cycles Research- Breast Cancer,Neoadjuvant,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,88202,"Brown, Andrew Bennett, MD",6/18/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,6/17/2024,Inactive,,
CBMC OP INFUSION 2FL,88202,"Brown, Andrew Bennett, MD",12/2/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,12/1/2024,Active,,
NBR 5N ONCOLOGY,77160,"Groisberg, Roman, MD",5/19/2024,DOXOrubicin 21 Day Cycles - Sarcoma,_1. First Line,5/19/2024,Inactive,,
NBR CINJ OP INFUSION,30961,"Shah, Mansi R, MD",4/18/2023,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,,4/11/2023,Inactive,,
NBR CINJ OP INFUSION,30961,"Shah, Mansi R, MD",9/27/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,9/26/2023,Inactive,,
CINJ OP INFUSION,25125,"Berim, Lyudmyla, MD",2/12/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/5/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
CINJ OP INFUSION,13773,"Haigentz, Missak, MD",6/12/2023,"CISplatin D1/Vinorelbine D1, D8 21 Day Cycles- Head and Neck Cancers",First Line,6/11/2023,Inactive,,
CINJ OP INFUSION,13773,"Haigentz, Missak, MD",2/5/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Salivary Gland,_2. Second Line,2/5/2024,Inactive,,
CBMC OP INFUSION 2FL,96931,"Wagmiller, Jennifer Ann, MD",9/12/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/11/2024,Inactive,,
CBMC 2W ONCOLOGY,96931,"Wagmiller, Jennifer Ann, MD",9/13/2024,Decitabine (3 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/12/2024,Active,,
CINJ OP INFUSION,24899,"Toppmeyer, Deborah L, MD",1/19/2023,Palbociclib 28 Day Cycles - Breast,Second Line,1/19/2023,Inactive,,
CMC 4B ONCOLOGY,31789,"Eltoukhy, Hussam, MD",8/27/2024,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,8/27/2024,Inactive,,
NBR 4N ONCOLOGY,41372,"Boland, Patrick M, MD",4/10/2024,CISplatin/DOCEtaxel 21 Day Cycles- Head and Neck Cancers,_1. First Line,4/9/2024,Inactive,,
SOM OUTPT INFUSION,61561,"Toomey, Kathleen C, MD",10/11/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,10/1/2024,Active,,
NBR CINJ OP INFUSION,3689,"Eltoukhy, Hussam, MD",7/21/2023,Elotuzumab/Pomalidomide/Dexamethasone 28 Day Cycles- Multiple Myeloma,Third Line,7/20/2023,Inactive,,
NBR CINJ OP INFUSION,3689,"Eltoukhy, Hussam, MD",11/8/2023,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,11/7/2023,Inactive,,
NBR CINJ OP INFUSION,3689,"Shah, Mansi R, MD",7/3/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,7/2/2024,Inactive,,
NBR 4N ONCOLOGY,203,"Shah, Mansi R, MD",3/15/2025,High-Dose Methotrexate- CNS Lymphoma,_1. First Line,3/15/2025,Inactive,Peripheral T cell lymphoma of lymph nodes of multiple sites (CMS/HCC),"C84.49 - Peripheral t-cell lymphoma, not elsewhere classified, extranodal and solid organ sites; G93.6 - Cerebral edema; C79.31 - Secondary malignant neoplasm of brain; D80.1 - Nonfamilial hypogammaglobulinemia; C90.00 - Multiple myeloma not having achieved remission; R78.81 - Bacteremia; E87.0 - Hyperosmolality and hypernatremia; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; E83.51 - Hypocalcemia; E83.39 - Other disorders of phosphorus metabolism; Z94.84 - Stem cells transplant status; E87.3 - Alkalosis; D69.59 - Other secondary thrombocytopenia; K21.9 - Gastro-esophageal reflux disease without esophagitis; E78.5 - Hyperlipidemia, unspecified; E87.5 - Hyperkalemia; E87.70 - Fluid overload, unspecified; E87.6 - Hypokalemia; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R31.0 - Gross hematuria; B95.7 - Other staphylococcus as the cause of diseases classified elsewhere; D64.9 - Anemia, unspecified; K59.00 - Constipation, unspecified; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; R39.15 - Urgency of urination; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states; Z87.891 - Personal history of nicotine dependence; Z59.41 - Food insecurity; Z56.0 - Unemployment, unspecified"
CINJ OP INFUSION,28767,"Hochster, Howard S, MD",1/26/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,1/24/2023,Inactive,,
CINJ OP INFUSION,28767,"Hochster, Howard S, MD",7/20/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,7/18/2023,Inactive,,
CINJ OP INFUSION,28767,"Hochster, Howard S, MD",2/29/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,2/27/2024,Inactive,,
CINJ OP INFUSION,28767,"Berim, Lyudmyla, MD",10/31/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,10/30/2024,Active,,
JCMC CP INFUSION,19257,"Sekhri, Arunabh, MD",2/24/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,2/23/2025,Active,Hodgkin lymphoma (CMS/HCC),"C81.71 - Other Hodgkin lymphoma, lymph nodes of head, face, and neck; R13.10 - Dysphagia, unspecified; F41.9 - Anxiety disorder, unspecified; D64.9 - Anemia, unspecified; Z92.21 - Personal history of antineoplastic chemotherapy"
JCMC CP INFUSION,19257,"Sekhri, Arunabh, MD",3/12/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,3/12/2025,Active,Hodgkin lymphoma (CMS/HCC),"C81.71 - Other Hodgkin lymphoma, lymph nodes of head, face, and neck; R13.10 - Dysphagia, unspecified; F41.9 - Anxiety disorder, unspecified; D64.9 - Anemia, unspecified; Z92.21 - Personal history of antineoplastic chemotherapy"
CINJ OP INFUSION,19014,"Ghodoussipour, Saum Bobak, MD",9/16/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/12/2024,Active,,
CINJ OP INFUSION,76398,"Berim, Lyudmyla, MD",2/6/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/3/2023,Inactive,,
NBR CINJ OP INFUSION,60216,"Patel, Vimal D, MD",1/13/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,Maintenance,1/12/2023,Inactive,,
NBR CINJ OP INFUSION,60216,"Patel, Vimal D, MD",7/18/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,7/3/2023,Inactive,,
NBR CINJ OP INFUSION,60216,"Palmisiano, Neil David, MD",8/7/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,,8/6/2023,Inactive,,
CBMC OP INFUSION 2FL,26355,"Leitner, Stuart P, MD",10/26/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,10/25/2023,Active,,
CINJ OP INFUSION,93614,"Leiser, Aliza, MD",4/15/2024,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,4/14/2024,Inactive,,
CINJ OP INFUSION,93614,"Leiser, Aliza, MD",4/16/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,4/14/2024,Inactive,,
CINJ OP INFUSION,82333,"Saraiya, Biren P, MD",6/6/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,First Line,6/6/2023,Inactive,,
NBR CINJ OP INFUSION,18832,"Evens, Andrew M, DO",7/24/2024,RiTUXimab 28 -> 56  Day Cycle - Follicular Lymphoma ,_1. First Line,7/23/2024,Active,"Mass of head of pancreas
Malignant neoplasm of head of pancreas (CMS/HCC)",
CINJ OP INFUSION,81604,"Packiam, Vignesh, MD",8/22/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,8/7/2024,Inactive,,
CMC OP INFUSION,82030,"Pompa, Tiffany Ann, MD",4/30/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,Adjuvant,4/30/2025,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),C34.91 - Non-small cell cancer of right lung (CMS/HCC)
CINJ OP INFUSION,26866,"Mayer, Tina M, MD",8/31/2023,Apalutamide 30 Day Cycles - Prostate,,8/31/2023,Active,,
CINJ OP INFUSION,18403,"Toppmeyer, Deborah L, MD",2/16/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,First Line,1/19/2023,Active,,
CINJ OP INFUSION,18403,"Toppmeyer, Deborah L, MD",2/16/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",Neoadjuvant,2/15/2023,Inactive,,
CINJ OP INFUSION,18403,"Toppmeyer, Deborah L, MD",4/13/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,First Line,2/16/2023,Inactive,,
CINJ OP INFUSION,18403,"Toppmeyer, Deborah L, MD",5/11/2023,EA1181 / CINJ 042004 Post-Operative Trastuzumab / Pertuzumab 21 Day Cycles Research ARM A- Breast Cancer,,5/10/2023,Active,,
CINJ OP INFUSION,18403,"Toppmeyer, Deborah L, MD",5/11/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/10/2023,Inactive,,
MSC OP INFUSION,92216,"Eltoukhy, Hussam, MD",6/11/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,6/7/2024,Inactive,,
CMC 4B ONCOLOGY,92216,"Eltoukhy, Hussam, MD",8/2/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,8/1/2024,Inactive,,
CMC OP INFUSION,92216,"Eltoukhy, Hussam, MD",11/13/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,11/12/2024,Active,,
MSC OP INFUSION,86864,"Cohen, Seth D, MD",3/16/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,,3/15/2023,Inactive,,
NBR 4N ONCOLOGY,19931,"Tiger, Yun Kyoung, MD",1/2/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/31/2023,Inactive,,
NBR CINJ OP INFUSION,19931,"Tiger, Yun Kyoung, MD",1/24/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/21/2024,Inactive,,
CINJ OP INFUSION,9136,"Gulhati, Prateek, MD PhD",6/13/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,6/11/2024,Inactive,,
NBR 5N ONCOLOGY,9136,"Boland, Patrick M, MD",7/28/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,7/26/2024,Inactive,,
CINJ OP INFUSION,9136,"Gulhati, Prateek, MD PhD",8/15/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,8/14/2024,Inactive,,
SOM OUTPT INFUSION,30549,"George, Roshini, DO",1/17/2025,Palbociclib 28 Day Cycles - Breast,_2. Second Line,1/17/2025,Active,,
CBMC OP INFUSION 2FL,50476,"Wagmiller, Jennifer Ann, MD",11/9/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,50476,"Wagmiller, Jennifer Ann, MD",8/7/2024,Pertuzumab / Trastuzumab / VinORELBine 21 Day Cycles - Breast,_1. First Line,8/6/2024,Inactive,,
CINJ OP INFUSION,5169,"Aikins, James K, MD",11/24/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/23/2023,Inactive,,
CINJ OP INFUSION,5169,"Aikins, James K, MD",12/15/2023,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/29/2023,Inactive,,
CINJ OP INFUSION,5169,"Aikins, James K, MD",2/9/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/8/2024,Inactive,,
NBR 4N ONCOLOGY,98422,"Rhodes, Joanna Meehan, MD",11/6/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,11/6/2024,Inactive,,
NBR 4N ONCOLOGY,98422,"Rhodes, Joanna Meehan, MD",11/7/2024,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_2. Second Line,11/7/2024,Active,,
NBR CINJ OP INFUSION,98422,"Rhodes, Joanna Meehan, MD",3/5/2025,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,3/5/2025,Active,B-cell lymphoma (CMS/HCC),
CBMC 2W ONCOLOGY,93060,"Grossman, I Robert, MD",12/15/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,12/14/2023,Inactive,,
CINJ OP INFUSION,51802,"Patankar, Sonali, MD",12/12/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,12/9/2024,Active,,
CBMC OP INFUSION 2FL,80668,"Brown, Andrew Bennett, MD",11/9/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,11/8/2023,Inactive,,
TRMC TCCC OP INFUSION,79787,"Capo, Gerardo, MD",5/15/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/15/2025,Active,Malignant neoplasm of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; C16.1 - Malignant neoplasm of fundus of stomach; D50.0 - Iron deficiency anemia secondary to blood loss (chronic)"
CINJ OP INFUSION,25547,"Aikins, James K, MD",4/15/2024,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_1. First Line,4/14/2024,Inactive,,
CINJ OP INFUSION,25547,"Aikins, James K, MD",11/8/2024,Dostarlimab-gxly 42 Day Cycles- Gynecologic Cancers,Maintenance,11/7/2024,Active,,
JCMC CP INFUSION,64266,"Cruz, Allan Louie E, MD",9/24/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,9/24/2024,Active,"Aplastic anemia (CMS/HCC)
Donor specific antibody (DSA) positive",
CBMC OP INFUSION 2FL,19945,"Ligresti, Louise G, MD",2/5/2024,Ribociclib 28 Day Cycles - Breast,Adjuvant,2/5/2024,Active,"Malignant neoplasm of central portion of breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,77068,"Lee, Patrick C, MD",3/27/2025,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/27/2025,Active,"Malignant neoplasm of hilus of left lung (CMS/HCC)
Chemotherapy-induced fatigue",
NBI OP INFUSION,85610,"Jacoby, Sari H, MD",5/1/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/30/2024,Inactive,,
MSC OP INFUSION,85209,"Talwar, Sumit, MD",7/10/2024,Pembrolizumab 42 Day Cycles - Melanoma,Adjuvant,7/9/2024,Active,,
CINJ OP INFUSION,45226,"Boland, Patrick M, MD",7/19/2023,Belzutifan 28 Day Cycles,First Line,7/19/2023,Active,,
JCMC CP INFUSION,44258,"Cruz, Allan Louie E, MD",12/18/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/17/2023,Inactive,,
JCMC CP INFUSION,44258,"Cruz, Allan Louie E, MD",9/9/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/8/2024,Active,,
JCMC CP INFUSION,11979,"Cruz, Allan Louie E, MD",9/13/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,9/12/2023,Inactive,,
JCMC CP INFUSION,11979,"Cruz, Allan Louie E, MD",10/25/2023,Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/25/2023,Inactive,,
SOM OUTPT INFUSION,3651,"Toomey, Kathleen C, MD",7/7/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,,7/5/2023,Inactive,,
SOM OUTPT INFUSION,3651,"Toomey, Kathleen C, MD",3/28/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,3/26/2024,Active,Urothelial cancer (CMS/HCC),
JCMC CP INFUSION,72502,"Sekhri, Arunabh, MD",1/24/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,1/8/2025,Active,Endometrial cancer (CMS/HCC),
MMC OP VP INFUSION,42723,"Talwar, Sumit, MD",1/3/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/2/2023,Inactive,,
MMC OP VP INFUSION,42723,"Talwar, Sumit, MD",6/25/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/27/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,41443,"Botwinick, Marissa, DO",6/12/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,6/12/2024,Inactive,,
JCMC CP INFUSION,80455,"Sekhri, Arunabh, MD",5/23/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/23/2025,Active,Diffuse large B-cell lymphoma of extranodal site excluding spleen and other solid organs (CMS/HCC),C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites
CINJ OP INFUSION,18769,"Muralikrishnan, Sivraj, MD",5/5/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,5/5/2025,Active,Tonsil cancer (CMS/HCC),
CINJ OP INFUSION,8932,"Stein, Stacey",5/6/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/6/2025,Active,"Colorectal cancer, stage IV (CMS/HCC)",C19 - Malignant neoplasm of rectosigmoid junction
CINJ PEDS HEMONC ,11592,"Drachtman, Richard, MD",12/5/2023,CINJ 022304 1L / 2L Cohort Asciminib 28 Day Cycles Research- Chronic Myelogenous Leukemia,_1. First Line,12/4/2023,Active,,
TRMC TCCC OP INFUSION,13515,"Salerno, Vincent E, MD",1/13/2025,Gemcitabine with Concurrent Radiation Preceding Adjuvant Chemotherapy Weekly- Pancreatic Adenocarcinoma,_1. First Line,1/9/2025,Active,,
TRMC TCCC OP INFUSION,13515,"Salerno, Vincent E, MD",3/10/2025,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,3/10/2025,Inactive,Malignant neoplasm of tail of pancreas (CMS/HCC),
TRMC TCCC OP INFUSION,13515,"Salerno, Vincent E, MD",3/10/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/10/2025,Active,Malignant neoplasm of tail of pancreas (CMS/HCC),
NBR 5N ONCOLOGY,90214,"Rhodes, Joanna Meehan, MD",3/13/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,3/13/2024,Inactive,,
NBR 5N ONCOLOGY,90214,"Zayac, Adam, MD",3/14/2024,CINJ 022101 (EA9181) ARM A Dasatinib / Prednisone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,3/13/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",4/1/2024,CINJ 022101 (EA9181)  ARM B Cycle 1 Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,3/31/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",4/21/2024,CINJ 022101 (EA9181)  ARM B Cycle 2 Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,4/21/2024,Inactive,,
NBR 5N ONCOLOGY,90214,"Zayac, Adam, MD",5/13/2024,CINJ 022101 (EA9181)  ARM B Cycle 1 Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,5/13/2024,Inactive,,
NBR 5N ONCOLOGY,90214,"Zayac, Adam, MD",6/2/2024,CINJ 022101 (EA9181)  ARM B Cycle 2 Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,6/2/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",7/2/2024,CINJ 022101 (EA9181) ARM A Cycle 3 Dasatinib / Prednisone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,7/2/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",7/2/2024,CINJ 022101 (EA9181)  ARM B Cycle 1 Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,7/1/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",8/19/2024,CINJ 022101 (EA9181)  ARM B Cycle 4A Dasatinib / Cyclophosphamide / VinCRIStine / DOXOrubicin / Dexamethasone 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,8/12/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",9/6/2024,CINJ 022101 (EA9181)  ARM B Cycle 4B Dasatinib / Methotrexate / Cytarabine 21 Day Cycle Research- Acute Lymphoblastic Leukemia,_1. First Line,9/6/2024,Inactive,,
NBR CINJ OP INFUSION,90214,"Zayac, Adam, MD",10/9/2024,CINJ 022101 (EA9181) Arms B / C Maintenance Methotrexate Intrathecal / Dasatinib / VinCRIStine 28 Day Cycles Research- Acute Lymphoblastic Leukemia,Maintenance,10/7/2024,Active,,
CMC OP INFUSION,76816,"Pompa, Tiffany Ann, MD",10/3/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,9/30/2024,Inactive,,
CINJ OP INFUSION,11456,"Girda, Eugenia, MD",8/16/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,8/10/2023,Inactive,,
CINJ OP INFUSION,11456,"Girda, Eugenia, MD",11/14/2023,CINJ 102006 (GOG-3039) Abemaciclib + Letrozole 28 Day Cycles Research- Endometrial Cancer,_3. Third Line,11/14/2023,Inactive,,
CINJ OP INFUSION,11456,"Girda, Eugenia, MD",11/20/2023,Abemaciclib 28 Day Cycles - Breast ,_3. Third Line,11/20/2023,Active,,
CBMC OP INFUSION 1FL,987,"Leitner, Stuart P, MD",11/10/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,11/10/2023,Inactive,,
SOM OUTPT INFUSION,15608,"Toomey, Kathleen C, MD",9/21/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/29/2023,Inactive,,
NBI OP INFUSION,52984,"Jacoby, Sari H, MD",4/22/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/22/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon
NBI OP INFUSION,52343,"Cheng, Yan Ho, MD",5/26/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,5/26/2025,Active,Prostate cancer metastatic to bone (CMS/HCC),R10.9 - Unspecified abdominal pain; C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone
CINJ OP INFUSION,87436,"Packiam, Vignesh, MD",5/22/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Adjuvant,5/21/2024,Inactive,,
CINJ OP INFUSION,87436,"Packiam, Vignesh, MD",9/11/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,9/11/2024,Inactive,,
CINJ OP INFUSION,87436,"Packiam, Vignesh, MD",9/16/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,9/15/2024,Inactive,,
CINJ OP INFUSION,87436,"Packiam, Vignesh, MD",12/10/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,12/8/2024,Active,,
CINJ OP INFUSION,93929,"Packiam, Vignesh, MD",5/19/2025,Nadofaragene Firadenovec 84 Day Cycles - Bladder,Induction,5/19/2025,Active,"Malignant tumor of right ureter (CMS/HCC)
Urothelial cancer (CMS/HCC)","C67.9 - Malignant neoplasm of bladder, unspecified; C61 - Malignant neoplasm of prostate; C68.9 - Malignant neoplasm of urinary organ, unspecified; C66.1 - Malignant neoplasm of right ureter; Z90.79 - Acquired absence of other genital organ(s)"
CINJ OP INFUSION,49141,"George, Mridula A, MD",4/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,4/4/2024,Inactive,,
CINJ OP INFUSION,49141,"George, Mridula A, MD",11/22/2024,Olaparib 30 Day Cycles - Breast,Adjuvant,11/22/2024,Inactive,,
CINJ OP INFUSION,49141,"George, Mridula A, MD",12/20/2024,Talazoparib 28 Day Cycles ,Adjuvant,12/20/2024,Active,Prostate cancer metastatic to bone (CMS/HCC),
CMMC OP INFUSION,87991,"Freeman, Benjamin B, MD",3/17/2025,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,3/17/2025,Active,Small cell carcinoma of bladder (CMS/HCC),"C67.5 - Malignant neoplasm of bladder neck; N18.6 - End stage renal disease; R18.8 - Other ascites; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; E87.1 - Hypo-osmolality and hyponatremia; N13.8 - Other obstructive and reflux uropathy; D64.9 - Anemia, unspecified; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; Z99.2 - Dependence on renal dialysis; T82.41XA - Breakdown (mechanical) of vascular dialysis catheter, initial encounter; N17.9 - Acute kidney failure, unspecified; N13.30 - Unspecified hydronephrosis; Z43.6 - Encounter for attention to other artificial openings of urinary tract; E86.9 - Volume depletion, unspecified; Z85.46 - Personal history of malignant neoplasm of prostate; E87.5 - Hyperkalemia; Z92.3 - Personal history of irradiation; K59.00 - Constipation, unspecified; Z90.79 - Acquired absence of other genital organ(s); Z79.899 - Other long term (current) drug therapy; E78.5 - Hyperlipidemia, unspecified; R31.0 - Gross hematuria; H91.10 - Presbycusis, unspecified ear; J38.7 - Other diseases of larynx; N50.819 - Testicular pain, unspecified; N50.82 - Scrotal pain; Z59.41 - Food insecurity; Z60.3 - Acculturation difficulty; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
NBR CINJ OP INFUSION,6880,"Egini, Ogechukwu, MD",1/17/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_2. Second Line,1/3/2025,Active,,
CBMC OP INFUSION 2FL,41355,"Leitner, Stuart P, MD",3/13/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,3/13/2024,Inactive,,
NBI OP INFUSION,67443,"Jacoby, Sari H, MD",10/19/2023,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,_1. First Line,10/11/2023,Inactive,,
NBI OP INFUSION,67443,"Jacoby, Sari H, MD",1/29/2024,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,1/29/2024,Active,,
NBR CINJ OP INFUSION,75871,"Tiger, Yun Kyoung, MD",10/27/2023,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,10/26/2023,Inactive,,
NBR CINJ OP INFUSION,75871,"Tiger, Yun Kyoung, MD",10/27/2023,Ibrutinib 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/27/2023,Inactive,,
NBR CINJ OP INFUSION,75871,"Tiger, Yun Kyoung, MD",11/1/2023,RiTUXimab 168 Day Cycles - Indolent Lymphoma Maintenance,_1. First Line,10/31/2023,Inactive,,
NBR CINJ OP INFUSION,75871,"Tiger, Yun Kyoung, MD",11/1/2023,RiTUXimab / Ibrutinib 28 Day Cycles - CNS Lymphoma ,_1. First Line,10/29/2023,Inactive,,
CBMC OP INFUSION 2FL,92628,"Litvak, Anna M, MD",11/1/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,10/31/2023,Inactive,,
CINJ OP INFUSION,20298,"Hochster, Howard S, MD",7/23/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,7/22/2024,Inactive,,
CINJ OP INFUSION,12397,"Weiss, Sarah, MD",8/14/2024,CINJ 092302 Cohort 1 Propranolol + Nivolumab (1 mg/kg) / Ipilumumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research- Melanoma,_1. First Line,8/13/2024,Inactive,,
CINJ OP INFUSION,12397,"Weiss, Sarah, MD",8/14/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,8/13/2024,Inactive,,
CINJ OP INFUSION,12397,"Weiss, Sarah, MD",8/28/2024,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_2. Second Line,8/28/2024,Active,,
CBMC OP INFUSION 2FL,71130,"Radovich, Delia, MD",11/7/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_3. Third Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,71130,"Leitner, Stuart P, MD",12/26/2023,Bevacizumab 28 Day Cycles - CNS,_3. Third Line,12/26/2023,Inactive,,
CBMC OP INFUSION 2FL,71130,"Leitner, Stuart P, MD",6/18/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,6/10/2024,Inactive,,
CBMC OP INFUSION 2FL,71130,"Leitner, Stuart P, MD",12/12/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/11/2024,Active,,
SOM OUTPT INFUSION,87249,"Patel, Eshan, MD",9/24/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,9/15/2024,Active,,
SOM OUTPT INFUSION,87249,"Patel, Eshan, MD",2/18/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,2/17/2025,Active,Small cell lung cancer (CMS/HCC),C34.00 - Malignant neoplasm of unspecified main bronchus
TRMC TCCC OP INFUSION,39799,"Capo, Gerardo, MD",9/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/10/2024,Inactive,,
NBR CINJ OP INFUSION,13110,"Evens, Andrew M, DO",7/26/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/11/2023,Inactive,,
NBR CINJ OP INFUSION,13110,"Evens, Andrew M, DO",11/29/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,11/28/2023,Inactive,,
NBR CINJ OP INFUSION,13110,"Evens, Andrew M, DO",12/21/2023,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,_3. Third Line,12/20/2023,Inactive,,
NBR CINJ OP INFUSION,13110,"Evens, Andrew M, DO",2/28/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_3. Third Line,2/27/2024,Inactive,,
JCMC CP INFUSION,13110,"Sekhri, Arunabh, MD",5/20/2024,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,5/19/2024,Inactive,,
NBI OP INFUSION,18438,"Snyder, Rose, MD",4/22/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/22/2025,Active,Primary squamous cell carcinoma of right lung (CMS/HCC),"C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; R91.8 - Other nonspecific abnormal finding of lung field; I48.92 - Unspecified atrial flutter; R07.9 - Chest pain, unspecified"
CINJ OP INFUSION,117,"Leiser, Aliza, MD",11/14/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,11/12/2024,Active,,
NBR 5N ONCOLOGY,91435,"Tiger, Yun Kyoung, MD",5/11/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/11/2024,Inactive,,
NBI OP INFUSION,65475,"Cheng, Yan Ho, MD",10/10/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,10/9/2023,Inactive,,
NBR CINJ OP INFUSION,65475,"Rhodes, Joanna Meehan, MD",2/26/2024,GVD + Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_2. Second Line,2/1/2024,Inactive,,
NBR CINJ OP INFUSION,65475,"Rhodes, Joanna Meehan, MD",5/23/2024,BMT Autologous BEAM,_3. Third Line,5/23/2024,Inactive,,
NBR CINJ OP INFUSION,65475,"Rhodes, Joanna Meehan, MD",8/19/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,Maintenance,8/11/2024,Active,,
MMC OP VP INFUSION,7978,"Talwar, Sumit, MD",4/25/2023,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,,4/24/2023,Active,,
CINJ OP INFUSION,62366,"Goel, Sanjay, MD",3/22/2023,CINJ 052101 (TT420X1103) ARM A TT-00420 (tinengotinib) 12 mg 28 Day Cycles Research- Solid Tumors,Third Line,3/20/2023,Inactive,,
CINJ OP INFUSION,62366,"Goel, Sanjay, MD",3/12/2024,CINJ 052212 Phase 1b RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,_6. Sixth Line,3/12/2024,Inactive,,
CINJ OP INFUSION,43716,"Stephenson, Ruth D, DO",10/9/2023,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,Adjuvant,10/2/2023,Inactive,,
NBR 4N ONCOLOGY,21218,"Matasar, Matthew J, MD",4/7/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,4/7/2023,Inactive,,
CMC OP INFUSION,6953,"Cohen, Seth D, MD",4/16/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/8/2024,Inactive,,
CMC OP INFUSION,6953,"Cohen, Seth D, MD",6/18/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/17/2024,Inactive,,
CINJ OP INFUSION,84111,"Boland, Patrick M, MD",10/15/2024,CINJ 072401 Quemliclustat / Zimberelimab / Gemcitabine / CISplatin 42 Day Cycles Research- Advanced Biliary Tract Cancers,_1. First Line,10/14/2024,Inactive,,
CINJ OP INFUSION,84111,"Boland, Patrick M, MD",10/29/2024,Pembro + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/28/2024,Active,,
TRMC TCCC OP INFUSION,54902,"Capo, Gerardo, MD",9/19/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,9/18/2024,Active,,
JCMC CP INFUSION,17139,"Sekhri, Arunabh, MD",1/22/2025,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/14/2025,Active,,
CINJ OP INFUSION,42352,"Mayer, Tina M, MD",1/25/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,1/22/2024,Active,,
NBR CINJ OP INFUSION,90949,"Braunschweig, Ira, MD",9/6/2023,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,,9/4/2023,Inactive,,
NBR CINJ OP INFUSION,90949,"Chowaniec, Wayne B, NP",9/13/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,9/12/2023,Inactive,,
NBR CINJ OP INFUSION,90949,"Assal, Amer, MD",1/26/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_3. Third Line,1/26/2024,Inactive,,
NBR CINJ OP INFUSION,90949,"Assal, Amer, MD",3/27/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,3/26/2024,Inactive,,
NBR CINJ OP INFUSION,90949,"Shah, Mansi R, MD",8/26/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,8/21/2024,Inactive,,
NBR CINJ OP INFUSION,90949,"Shah, Mansi R, MD",9/25/2024,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,9/24/2024,Inactive,,
JCMC CP INFUSION,47734,"Sekhri, Arunabh, MD",7/12/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/11/2023,Inactive,,
JCMC CP INFUSION,47734,"Sekhri, Arunabh, MD",9/20/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/12/2023,Inactive,,
JCMC CP INFUSION,47734,"Sekhri, Arunabh, MD",10/23/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/22/2023,Inactive,,
SOM OUTPT INFUSION,6321,"Toomey, Kathleen C, MD",8/7/2024,EriBULin / Trastuzumab 21 Day Cycles - Breast,_7. Seventh Line,7/23/2024,Active,,
MSC OP INFUSION,93025,"Lee, Patrick C, MD",10/31/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/30/2023,Inactive,,
CINJ OP INFUSION,84406,"Gulhati, Prateek, MD PhD",10/10/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/2/2024,Active,,
CINJ OP INFUSION,84406,"Gulhati, Prateek, MD PhD",1/16/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/15/2025,Active,,
CINJ OP INFUSION,84406,"Gulhati, Prateek, MD PhD",1/16/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/15/2025,Inactive,Cholangiocarcinoma metastatic to liver (CMS/HCC),
CINJ OP INFUSION,84406,"Gulhati, Prateek, MD PhD",1/16/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/15/2025,Inactive,Cholangiocarcinoma metastatic to liver (CMS/HCC),
CMC OP INFUSION,20628,"Taff, Jessica, MD",6/1/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/31/2023,Inactive,,
HAM OP INFUSION,86207,"Yogarajah, Meera, MD",1/5/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,1/4/2023,Inactive,,
CINJ OP INFUSION,33839,"Saraiya, Biren P, MD",9/23/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/23/2024,Active,,
NBR CINJ OP INFUSION,54854,"Tiger, Yun Kyoung, MD",4/12/2024,Mini-Pola-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/11/2024,Active,,
NBR 4N ONCOLOGY,54854,"Tiger, Yun Kyoung, MD",4/25/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/25/2024,Inactive,,
NBR 5N ONCOLOGY,37862,"Tiger, Yun Kyoung, MD",3/19/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/19/2025,Active,Non-Hodgkin's lymphoma (CMS/HCC),"C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; D61.810 - Antineoplastic chemotherapy induced pancytopenia; U07.1 - COVID-19; J10.08 - Influenza due to other identified influenza virus with other specified pneumonia; J96.01 - Acute respiratory failure with hypoxia; J12.82 - Pneumonia due to coronavirus disease 2019; L89.322 - Pressure ulcer of left buttock, stage 2; J91.0 - Malignant pleural effusion; C83.35 - Diffuse large b-cell lymphoma, lymph nodes of inguinal region and lower limb; D70.9 - Neutropenia, unspecified; I11.0 - Hypertensive heart disease with heart failure; E03.9 - Hypothyroidism, unspecified; J45.909 - Unspecified asthma, uncomplicated; I50.20 - Unspecified systolic (congestive) heart failure; E87.3 - Alkalosis; R22.42 - Localized swelling, mass and lump, left lower limb; B37.9 - Candidiasis, unspecified; E83.52 - Hypercalcemia; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; R50.81 - Fever presenting with conditions classified elsewhere; E83.42 - Hypomagnesemia; E87.6 - Hypokalemia; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z90.49 - Acquired absence of other specified parts of digestive tract; Z90.710 - Acquired absence of both cervix and uterus; Z90.89 - Acquired absence of other organs; Z98.890 - Other specified postprocedural states; Z80.0 - Family history of malignant neoplasm of digestive organs; Z79.899 - Other long t..."
NBR 5N ONCOLOGY,46063,"Stephenson, Ryan D, DO",6/11/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,6/8/2024,Active,,
CINJ OP INFUSION,71473,"Toppmeyer, Deborah L, MD",2/7/2023,Palbociclib 28 Day Cycles - Breast,First Line,2/7/2023,Active,,
NBR CINJ OP INFUSION,91153,"Evens, Andrew M, DO",3/8/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,3/8/2023,Inactive,,
NBR CINJ OP INFUSION,91153,"Evens, Andrew M, DO",11/1/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,10/31/2023,Active,Primary malignant neoplasm of right kidney with metastasis from kidney to other site (CMS/HCC),
CINJ OP INFUSION,49794,"Omene, Coral Oghenerukevwe, MD",4/3/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,,3/27/2023,Inactive,,
CINJ OP INFUSION,49794,"Omene, Coral Oghenerukevwe, MD",6/1/2023,PACLitaxel Dose-Dense 14 Day Cycles - Breast,,5/29/2023,Inactive,,
CINJ OP INFUSION,49794,"Omene, Coral Oghenerukevwe, MD",10/2/2023,Abemaciclib 28 Day Cycles - Breast ,,10/2/2023,Active,,
NBR 5N ONCOLOGY,73331,"Palmisiano, Neil David, MD",8/14/2024,Cytarabine Cytoreduction for Hyperleukocytosis,Consolidation,8/14/2024,Inactive,,
NBR 4N ONCOLOGY,73331,"Zayac, Adam, MD",8/20/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,8/20/2024,Inactive,,
NBR CINJ OP INFUSION,73331,"Zayac, Adam, MD",10/14/2024,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_2. Second Line,10/14/2024,Inactive,,
NBR CINJ OP INFUSION,73331,"Zayac, Adam, MD",11/22/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,11/20/2024,Inactive,,
NBR 5N ONCOLOGY,73331,"Shah, Mansi R, MD",12/26/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_3. Third Line,12/26/2024,Inactive,,
MMC OP INFUSION,65144,"Cohen, Seth D, MD",10/31/2023,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_2. Second Line,10/30/2023,Inactive,,
SOM OUTPT INFUSION,59766,"Khalid, Aysha, MD",1/8/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/7/2024,Inactive,,
CINJ OP INFUSION,30496,"George, Mridula A, MD",6/5/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/4/2024,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),
CINJ OP INFUSION,31874,"Berim, Lyudmyla, MD",5/10/2023,CINJ 072205 Stage 1 (Run In Cycle) ALX148 (evorpacept) / Cetuximab / Pembrolizumab 21 Day Cycle Research- Colorectal Cancer,,4/11/2023,Inactive,,
CINJ OP INFUSION,31874,"Berim, Lyudmyla, MD",5/10/2023,CINJ 072205 Stage 2 Cohort B ALX148 (evorpacept) / Cetuximab / Pembrolizumab 21 Day Cycles Research- Colorectal Cancer,,4/11/2023,Inactive,,
CINJ OP INFUSION,31874,"Berim, Lyudmyla, MD",5/10/2023,CINJ 072205 Stage 1 (Run In Cycle) ALX148 (evorpacept) / Cetuximab / Pembrolizumab 21 Day Cycle Research- Colorectal Cancer,,4/11/2023,Inactive,,
CINJ OP INFUSION,31874,"Berim, Lyudmyla, MD",5/31/2023,CINJ 072205 Stage 2 Cohort B ALX148 (evorpacept) / Cetuximab / Pembrolizumab 21 Day Cycles Research- Colorectal Cancer,,5/2/2023,Inactive,,
CINJ OP INFUSION,31874,"Berim, Lyudmyla, MD",8/9/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,8/9/2023,Inactive,,
CINJ OP INFUSION,31874,"Berim, Lyudmyla, MD",9/18/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,9/17/2023,Inactive,,
CINJ OP INFUSION,31874,"Goel, Sanjay, MD",8/14/2024,CINJ 052008 / R7075-ONC-2009 Dose level 10A Schedule C Escalation Q3W REGN7075 / Cemiplimab 350 mg 42 Day Cycles Combination Research- Solid Tumors,_5. Fifth Line,7/24/2024,Inactive,,
NBR 5N ONCOLOGY,35865,"Rhodes, Joanna Meehan, MD",11/23/2023,Cytarabine / DAUNOrubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,11/23/2023,Inactive,,
NBR 5N ONCOLOGY,35865,"Rhodes, Joanna Meehan, MD",11/24/2023,Cytarabine Cytoreduction for Hyperleukocytosis,Lymphodepletion,11/24/2023,Inactive,,
CBMC OP INFUSION 2FL,65048,"Litvak, Anna M, MD",3/25/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,3/25/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)","N63.0 - Palpable mass of breast; C50.919, Z17.421 - Triple negative breast cancer (CMS/HCC)"
SOM OUTPT INFUSION,37178,"Patel, Eshan, MD",1/8/2025,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,1/5/2025,Active,,
SOM OUTPT INFUSION,35734,"Patel, Eshan, MD",1/27/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,1/27/2025,Inactive,Metastasis from breast cancer (CMS/HCC),
CBMC OP INFUSION 2FL,98388,"Wagmiller, Jennifer Ann, MD",11/7/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,98388,"Wagmiller, Jennifer Ann, MD",11/29/2023,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,11/29/2023,Inactive,,
NBR CINJ OP INFUSION,89028,"Shah, Mansi R, MD",5/15/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Consolidation,5/15/2025,Inactive,"Type 2 diabetes mellitus without complication, without long-term current use of insulin (CMS/HCC)
Amyloid like glomerulopathy
Monoclonal gammopathy","C90.00 - Multiple myeloma not having achieved remission; D47.2 - Monoclonal gammopathy; E85.81 - Light chain (AL) amyloidosis; N17.9 - Acute kidney failure, unspecified; I10 - Essential (primary) hypertension; E11.9 - Type 2 diabetes mellitus without complications; R79.1 - Abnormal coagulation profile; N05.9 - Unspecified nephritic syndrome with unspecified morphologic changes; Z90.81 - Acquired absence of spleen; Z86.79 - Personal history of other diseases of the circulatory system; Z79.84 - Long term (current) use of oral hypoglycemic drugs"
NBI OP INFUSION,38152,"Jacoby, Sari H, MD",11/11/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,11/11/2024,Active,Multiple myeloma (CMS/HCC),
CBMC OP INFUSION 2FL,3982,"Litvak, Anna M, MD",11/9/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,11/9/2023,Inactive,,
CINJ PEDS HEMONC ,93579,"Moerdler, Scott, MD",5/7/2025,PEDS DD-4A - Renal,_1. First Line,5/7/2025,Inactive,"Wilm's tumor (nephroblastoma), left (CMS/HCC)",
CINJ PEDS HEMONC ,93579,"Moerdler, Scott, MD",5/7/2025,AREN2231 Regimen DD-4A,_1. First Line,5/7/2025,Active,"Wilm's tumor (nephroblastoma), left (CMS/HCC)",
SOM OUTPT INFUSION,77484,"Yin, Faye, MD",6/16/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,6/16/2024,Active,,
CMC OP INFUSION,78621,"Taff, Jessica, MD",11/6/2023,Capecitabine 21 Day Cycles - Breast,_1. First Line,11/6/2023,Active,,
MSC OP INFUSION,86106,"Tang, Horace, MD",7/10/2023,RiTUXimab 14 Day Cycle x 2 cycles,,7/10/2023,Active,Colon cancer metastasized to multiple sites (CMS/HCC),
NBR CINJ OP INFUSION,30907,"Mayer, Tina M, MD",9/5/2024,Apalutamide 30 Day Cycles - Prostate,_1. First Line,9/5/2024,Active,,
SOM OUTPT INFUSION,36987,"Toomey, Kathleen C, MD",4/12/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,First Line,4/9/2023,Inactive,,
SOM OUTPT INFUSION,36987,"Toomey, Kathleen C, MD",7/6/2023,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,Neoadjuvant,6/29/2023,Inactive,,
SOM OUTPT INFUSION,36987,"Toomey, Kathleen C, MD",10/20/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Maintenance,10/20/2023,Inactive,,
NBR CINJ OP INFUSION,56691,"Patel, Vimal D, MD",2/7/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,First Line,2/6/2023,Inactive,,
HAM OP INFUSION,3703,"Patel, Malini M, MD",10/23/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,Third Line,10/18/2023,Inactive,,
HAM OP INFUSION,3703,"Patel, Malini M, MD",10/23/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Third Line,10/19/2023,Inactive,,
CBMC OP INFUSION 2FL,6124,"Leitner, Stuart P, MD",2/23/2024,Sipuleucel-T 14 Day Cycles - Prostate,_2. Second Line,2/23/2024,Inactive,,
CINJ OP INFUSION,43688,"Haigentz, Missak, MD",3/18/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/17/2024,Inactive,,
CINJ OP INFUSION,43688,"Haigentz, Missak, MD",6/4/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,6/4/2024,Active,,
CBMC 2W ONCOLOGY,33508,"Grossman, I Robert, MD",12/11/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/10/2024,Active,"Wolffian adnexal tumor
Secondary malignancy of omentum (CMS/HCC)",
CBMC OP INFUSION 2FL,33508,"Grossman, I Robert, MD",2/5/2025,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,2/5/2025,Active,T-cell/histiocyte-rich large B-cell lymphoma (CMS/HCC),
HAM OP INFUSION,24180,"Patel, Malini M, MD",3/18/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,3/18/2025,Active,Malignant neoplasm of floor of mouth (CMS/HCC),
MMC OP INFUSION,14337,"Lee, Patrick C, MD",1/31/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,1/30/2023,Inactive,,
MMC OP INFUSION,14337,"Lee, Patrick C, MD",6/20/2023,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,,6/19/2023,Active,"Malignant melanoma of right upper limb, including shoulder (CMS/HCC)",
MMC OP INFUSION,77041,"Lee, Patrick C, MD",4/21/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,4/21/2025,Active,Severe thrombocytopenia (CMS/HCC),
CINJ PEDS HEMONC ,90492,"Drachtman, Richard, MD",3/26/2024,PEDS AHOD1331 Bv-AVE-PC,_1. First Line,3/19/2024,Active,,
JCMC CP INFUSION,3516,"Cruz, Allan Louie E, MD",10/31/2024,Gemcitabine / CARBOplatin D1 and D8 21 Day Cycles - Breast,_1. First Line,10/30/2024,Active,,
JCMC CP INFUSION,3516,"Cruz, Allan Louie E, MD",2/6/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,2/5/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)",
JCMC CP INFUSION,3516,"Cruz, Allan Louie E, MD",3/4/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,2/6/2025,Inactive,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,68955,"Evens, Andrew M, DO",6/21/2023,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,First Line,6/20/2023,Inactive,,
NBR CINJ OP INFUSION,68955,"Evens, Andrew M, DO",6/5/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,6/5/2024,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
CMC OP INFUSION,173,"Taff, Jessica, MD",9/29/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,9/28/2023,Inactive,,
CINJ OP INFUSION,17928,"Ghodoussipour, Saum Bobak, MD",11/28/2023,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) - Bladder Cancer,Induction,11/26/2023,Inactive,,
CINJ OP INFUSION,17928,"Ghodoussipour, Saum Bobak, MD",3/20/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,3/11/2024,Active,,
CINJ OP INFUSION,93524,"Aikins, James K, MD",8/17/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/17/2023,Active,,
CINJ OP INFUSION,85341,"Stephenson, Ryan D, DO",10/9/2023,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Penile Cancer (Neoadjuvant or Adjuvant),Neoadjuvant,10/9/2023,Inactive,,
NBR 5N ONCOLOGY,85341,"Stephenson, Ryan D, DO",10/30/2023,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Penile Cancer (Neoadjuvant or Adjuvant),Neoadjuvant,10/30/2023,Inactive,,
CINJ OP INFUSION,85341,"Stephenson, Ryan D, DO",2/9/2024,Pembrolizumab 21 Day Cycles - Penile,_2. Second Line,2/9/2024,Inactive,,
CINJ OP INFUSION,57931,"Stephenson, Ruth D, DO",12/4/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,12/3/2024,Active,,
CINJ OP INFUSION,40446,"Haigentz, Missak, MD",4/3/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,4/3/2023,Inactive,,
CMC OP INFUSION,3342,"Talwar, Sumit, MD",6/16/2023,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,6/6/2023,Inactive,,
MMC BBR2 ONCOLOGY,39373,"Lee, Patrick C, MD",10/31/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,10/31/2024,Inactive,,
NBR 5N ONCOLOGY,39373,"Rhodes, Joanna Meehan, MD",10/31/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,10/31/2024,Inactive,,
NBR 5N ONCOLOGY,39373,"Rhodes, Joanna Meehan, MD",11/3/2024,EC (Etoposide / Hight-Dose Cytarabine) 28 Day Cycles - HLH/hematologic malignancy,_1. First Line,11/3/2024,Inactive,,
CINJ OP INFUSION,66509,"Haigentz, Missak, MD",4/24/2025,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/24/2025,Active,"Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Secondary malignant neoplasm of brain (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)
Small cell lung cancer, left upper lobe (CMS/HCC)
Chronic fatigue",
NBR 5N ONCOLOGY,79751,"Mayer, Tina M, MD",5/25/2023,VIP (Etoposide / Ifosfamide / Mesna / CISplatin) 21 Day Cycles - Gestational Trophoblastic Neoplasia,First Line,5/24/2023,Inactive,,
NBR 5N ONCOLOGY,79751,"George, Mridula A, MD",6/16/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - ",Second Line,6/15/2023,Inactive,,
HAM OP INFUSION,1063,"Patel, Malini M, MD",4/3/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/3/2023,Inactive,,
HAM OP INFUSION,1063,"Patel, Malini M, MD",6/26/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,6/25/2023,Inactive,,
CINJ OP INFUSION,23162,"Mayer, Tina M, MD",9/18/2023,Abiraterone 30 Day Cycles - Prostate,,9/18/2023,Inactive,,
CINJ OP INFUSION,99146,"Weiss, Sarah, MD",2/6/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/5/2023,Inactive,,
CINJ OP INFUSION,48977,"Haigentz, Missak, MD",12/9/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,12/9/2024,Active,,
JCMC CP INFUSION,35710,"Cruz, Allan Louie E, MD",5/20/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/20/2025,Active,Malignant neoplasm of overlapping sites of left lung (CMS/HCC),
NBR CINJ OP INFUSION,59004,"Egini, Ogechukwu, MD",8/30/2024,BMT Allogeneic TBF + Post Cy ,_1. First Line,8/29/2024,Active,,
HAM OP INFUSION,35661,"Patel, Malini M, MD",11/13/2024,Temozolomide 28 Day Cycles - CNS,_1. First Line,11/13/2024,Active,"Malignant neoplasm of overlapping sites of right bronchus and lung (CMS/HCC)
End stage renal disease (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,95412,"Boland, Patrick M, MD",11/15/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,11/14/2024,Active,,
CINJ OP INFUSION,22592,"Boland, Patrick M, MD",5/9/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,5/9/2025,Active,"Hepatocellular carcinoma (CMS/HCC)
Other specified diabetes mellitus with chronic kidney disease, without long-term current use of insulin, unspecified CKD stage (CMS/HCC)
Encounter for screening for other viral diseases
Other problems related to lifestyle","C22.0 - Liver cell carcinoma; E11.9 - Type 2 diabetes mellitus without complications; G62.9 - Polyneuropathy, unspecified; J90 - Pleural effusion, not elsewhere classified; E13.22 - Other specified diabetes mellitus with diabetic chronic kidney disease; R94.6 - Abnormal results of thyroid function studies; Z11.59 - Encounter for screening for other viral diseases; Z72.89 - Other problems related to lifestyle"
MMC OP VP INFUSION,41994,"Cohen, Seth D, MD",4/19/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,Second Line,4/18/2023,Inactive,,
NBI OP INFUSION,49727,"Jacoby, Sari H, MD",12/20/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,12/20/2023,Active,Malignant neoplasm of ovary (CMS/HCC),
CBMC OP INFUSION 2FL,50461,"Brown, Andrew Bennett, MD",7/24/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/24/2024,Inactive,,
CINJ OP INFUSION,96631,"Stephenson, Ryan D, DO",10/26/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_1. First Line,10/26/2023,Active,,
CBMC OP INFUSION 1FL,93654,"Meelheim, Brooke A, DO",1/21/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,1/15/2025,Active,,
CBMC OP INFUSION 1FL,48339,"Meelheim, Brooke A, DO",5/27/2025,Temsirolimus 28 Day Cycles - Uterine,_2. Second Line,5/27/2025,Inactive,"Wolffian adnexal tumor
Peritoneal carcinomatosis (CMS/HCC)","I82.411 - Acute embolism and thrombosis of right femoral vein; C56.1 - Malignant neoplasm of right ovary; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; R18.0 - Malignant ascites; I82.C12 - Acute embolism and thrombosis of left internal jugular vein; D63.8 - Anemia in other chronic diseases classified elsewhere; D51.9 - Vitamin B12 deficiency anemia, unspecified; I10 - Essential (primary) hypertension; D69.6 - Thrombocytopenia, unspecified; D68.59 - Other primary thrombophilia; I82.502 - Chronic embolism and thrombosis of unspecified deep veins of left lower extremity; I82.C22 - Chronic embolism and thrombosis of left internal jugular vein; D64.81 - Anemia due to antineoplastic chemotherapy; E78.00 - Pure hypercholesterolemia, unspecified; E87.5 - Hyperkalemia; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z63.4 - Disappearance and death of family member; Z90.710 - Acquired absence of both cervix and uterus; Z90.722 - Acquired absence of ovaries, bilateral; Z79.899 - Other long term (current) drug therapy; Z79.01 - Long term (current) use of anticoagulants; Z79.82 - Long term (current) use of aspirin; Z87.891 - Personal history of nicotine dependence; Z80.0 - Family history of malignant neoplasm of digestive organs; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z28.21 - Immunization not carried out because of patient refusal"
CBMC OP INFUSION 1FL,48339,"Meelheim, Brooke A, DO",4/15/2025,Albumin-bound Sirolimus 21 Day Cycles - Malignant Perivascular Epithelioid Cell Tumor (PEComa),_2. Second Line,4/15/2025,Inactive,"Wolffian adnexal tumor
Peritoneal carcinomatosis (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; D49.59 - Neoplasm of unspecified behavior of other genitourinary organ; C48.2 - Malignant neoplasm of peritoneum, unspecified"
CBMC OP INFUSION 1FL,48339,"Meelheim, Brooke A, DO",4/15/2025,Temsirolimus 28 Day Cycles - FATWO,_2. Second Line,4/15/2025,Active,"Wolffian adnexal tumor
Peritoneal carcinomatosis (CMS/HCC)",
NBR 5N ONCOLOGY,61360,"Stephenson, Ryan D, DO",4/15/2025,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,_1. First Line,4/15/2025,Active,"Urothelial carcinoma (CMS/HCC)
Malignant neoplasm metastatic to both lungs (CMS/HCC)","C67.9 - Malignant neoplasm of bladder, unspecified; G93.41 - Metabolic encephalopathy; I63.81 - Other cerebral infarction due to occlusion or stenosis of small artery; J18.9 - Pneumonia, unspecified organism; I26.99 - Other pulmonary embolism without acute cor pulmonale; J96.01 - Acute respiratory failure with hypoxia; E44.0 - Moderate protein-calorie malnutrition; C77.5 - Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes; C78.01 - Secondary malignant neoplasm of right lung; C78.02 - Secondary malignant neoplasm of left lung; C53.9 - Malignant neoplasm of cervix uteri, unspecified; C52 - Malignant neoplasm of vagina; D69.59 - Other secondary thrombocytopenia; Z99.11 - Dependence on respirator (ventilator) status; R65.10 - Systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction; D62 - Acute posthemorrhagic anemia; E87.1 - Hypo-osmolality and hyponatremia; E87.0 - Hyperosmolality and hypernatremia; E87.20 - Acidosis, unspecified; D68.69 - Other thrombophilia; J81.1 - Chronic pulmonary edema; T83.84XA - Pain due to genitourinary prosthetic devices, implants and grafts, initial encounter; N17.9 - Acute kidney failure, unspecified; Z11.52 - Encounter for screening for COVID-19; R13.10 - Dysphagia, unspecified; E83.39 - Other disorders of phosphorus metabolism; E83.51 - Hypocalcemia; D64.81 - Anemia due to antineoplastic chemotherapy; R74.01 - Elevation of levels of liver transaminase levels; R79.89 - Other sp..."
HAM OP INFUSION,2704,"Yogarajah, Meera, MD",10/31/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,10/27/2024,Active,,
CBMC 2W ONCOLOGY,60935,"Wagmiller, Jennifer Ann, MD",1/31/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/29/2025,Active,Malignant neoplasm of left renal pelvis (CMS/HCC),
CINJ OP INFUSION,30069,"Packiam, Vignesh, MD",12/12/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,12/11/2024,Active,,
CINJ OP INFUSION,30069,"Packiam, Vignesh, MD",2/13/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,2/12/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; R31.0 - Gross hematuria; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; Z95.5 - Presence of coronary angioplasty implant and graft; Z87.891 - Personal history of nicotine dependence; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
MMC OP VP INFUSION,57529,"Cohen, Seth D, MD",5/21/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,5/21/2024,Active,,
CINJ OP INFUSION,43071,"Hochster, Howard S, MD",7/25/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,7/22/2024,Active,,
CBMC OP INFUSION 2FL,83810,"Litvak, Anna M, MD",3/28/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/28/2025,Active,Carcinoma of breast metastatic to bone (CMS/HCC),
SOM OUTPT INFUSION,47199,"Yin, Faye, MD",9/24/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/9/2024,Active,Marginal zone lymphoma (CMS/HCC),
CMC OP INFUSION,89776,"Taff, Jessica, MD",5/18/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Third Line,5/17/2023,Inactive,,
JCMC CP INFUSION,93116,"Sekhri, Arunabh, MD",3/6/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/5/2023,Inactive,,
JCMC CP INFUSION,93116,"Sekhri, Arunabh, MD",1/9/2024,CINJ 032304 Arm B Pembrolizumab / Ramucirumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,1/9/2024,Inactive,,
JCMC CP INFUSION,93116,"Sekhri, Arunabh, MD",5/6/2024,PACLitaxel/CARBOplatin + Bevacizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,4/30/2024,Inactive,,
SOM OUTPT INFUSION,93808,"Patel, Eshan, MD",7/9/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,7/8/2024,Active,,
CINJ OP INFUSION,64006,"Hochster, Howard S, MD",2/18/2025,Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 480 mg D1 28 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/17/2025,Active,Cholangiocarcinoma at hepatic hilum (CMS/HCC),C24.0 - Malignant neoplasm of extrahepatic bile duct
CBMC OP INFUSION 2FL,10602,"Raptis, George, MD",5/3/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/2/2024,Inactive,,
CBMC OP INFUSION 2FL,10602,"Raptis, George, MD",10/1/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,10/1/2024,Active,,
CINJ OP INFUSION,53207,"Jang, Thomas L, MD",8/9/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,8/9/2023,Inactive,,
NBI OP INFUSION,54910,"Anderson, Patrick S, MD",4/4/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,4/4/2025,Active,Malignant neoplasm of endocervix (CMS/HCC),
NBI OP INFUSION,54910,"Anderson, Patrick S, MD",3/18/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/18/2025,Inactive,Malignant neoplasm of endocervix (CMS/HCC),
HAM OP INFUSION,61046,"Patel, Malini M, MD",2/27/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,First Line,2/27/2023,Inactive,,
CMC OP INFUSION,9822,"Talwar, Sumit, MD",10/23/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/23/2024,Active,,
SOM OUTPT INFUSION,10417,"Patel, Eshan, MD",9/30/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,9/17/2024,Inactive,,
CINJ OP INFUSION,10417,"Packiam, Vignesh, MD",12/31/2024,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Neoadjuvant,12/30/2024,Active,,
CINJ OP INFUSION,10417,"Packiam, Vignesh, MD",1/3/2025,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Neoadjuvant,1/2/2025,Inactive,Malignant neoplasm of dome of urinary bladder (CMS/HCC),
CBMC OP INFUSION 2FL,23527,"Brown, Andrew Bennett, MD",2/21/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/20/2024,Active,,
MMC OP INFUSION,98061,"Lee, Patrick C, MD",5/23/2023,Nivolumab/Ipilimumab + PACLitaxel/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/22/2023,Active,,
MMC OP INFUSION,98061,"Lee, Patrick C, MD",6/13/2023,Nivolumab 480 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,6/12/2023,Inactive,,
MMC OP VP INFUSION,21510,"Cohen, Seth D, MD",4/10/2024,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,Maintenance,4/9/2024,Active,,
MMC OP VP INFUSION,85265,"Cohen, Seth D, MD",4/29/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_3. Third Line,4/29/2025,Active,"Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC)
Hypothyroidism due to medication
Chemotherapy management, encounter for
Hypothyroxinemia",
CBMC OP INFUSION 2FL,29817,"Dharmapuri, Sirish, MD",1/24/2025,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,1/23/2025,Active,,
CBMC OP INFUSION 2FL,69062,"Wagmiller, Jennifer Ann, MD",11/27/2023,Pembrolizumab 42 Day Cycles - Uterine,Maintenance,11/27/2023,Active,,
NBR CINJ OP INFUSION,65767,"Rhodes, Joanna Meehan, MD",4/23/2025,Triangle Regimen R-I-CHOP / R-DHAX  (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Ibrutinib) / (Dexamethasone / Cytarabine / OXALIplatin) RiTUXimab Every 21 Days - Mantle Cell Lymphoma,_1. First Line,4/23/2025,Active,Mantle cell lymphoma (CMS/HCC),"C83.10 - Mantle cell lymphoma, unspecified site; N28.89 - Other specified disorders of kidney and ureter; C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site"
NBR CINJ OP INFUSION,65767,"Rhodes, Joanna Meehan, MD",3/17/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,3/13/2025,Active,Lymphoma (CMS/HCC),"C85.90 - Non-Hodgkin lymphoma, unspecified, unspecified site; C83.10 - Mantle cell lymphoma, unspecified site; D68.61 - Antiphospholipid syndrome; N28.89 - Other specified disorders of kidney and ureter; K63.89 - Other specified diseases of intestine; D68.51 - Activated protein C resistance; R59.1 - Generalized enlarged lymph nodes; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits"
CBMC OP INFUSION 2FL,83534,"Wagmiller, Jennifer Ann, MD",11/10/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,11/9/2023,Inactive,,
CMC OP INFUSION,57978,"Pompa, Tiffany Ann, MD",5/13/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/13/2025,Active,"Clear cell carcinoma of ovary, right (CMS/HCC)","C56.1 - Clear cell carcinoma of ovary, right (CMS/HCC)"
SOM OUTPT INFUSION,7379,"Toomey, Kathleen C, MD",1/7/2025,RiTUXimab Initial Infusion Single Day (Outpatient),Maintenance,1/7/2025,Inactive,Pemphigus vulgaris,
CBMC 2W ONCOLOGY,20395,"Grossman, I Robert, MD",8/23/2024,R-GemOX (Gemcitabine / OXALIplatin / RiTUXimab) 14 Day Cycles - Mantle Cell Lymphoma,_2. Second Line,8/22/2024,Active,Cancer of overlapping sites of tonsil (CMS/HCC),
NBR CINJ OP INFUSION,66658,"Schaar, Dale, MD PhD",2/28/2024,RiTUXimab 168 Day Cycles - Pemphigus,_1. First Line,2/27/2024,Active,"Malignant neoplasm of corpus uteri, unspecified (CMS/HCC)",
MMC OP VP INFUSION,70406,"Cohen, Seth D, MD",11/25/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,11/25/2024,Active,,
CINJ OP INFUSION,20856,"Saraiya, Biren P, MD",3/25/2025,Relugolix 30 day Cycles - Prostate,Neoadjuvant,3/25/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
NBR 5N MED-SURG OVRF,33528,"Alexander, Henry Richard, MD",1/30/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,1/30/2025,Active,,
CINJ OP INFUSION,2833,"Gulhati, Prateek, MD PhD",3/9/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,3/8/2023,Inactive,,
SOM 1PAV ONCOLOGY,55663,"Patel, Eshan, MD",2/12/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,2/12/2025,Inactive,Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC),"A41.9 - Sepsis, unspecified organism; D61.810 - Antineoplastic chemotherapy induced pancytopenia; J18.9 - Pneumonia, unspecified organism; R65.21 - Severe sepsis with septic shock; C79.51 - Secondary malignant neoplasm of bone; C83.33 - Diffuse large b-cell lymphoma, intra-abdominal lymph nodes; E87.3 - Alkalosis; E83.39 - Other disorders of phosphorus metabolism; C61 - Malignant neoplasm of prostate; J44.0 - Chronic obstructive pulmonary disease with (acute) lower respiratory infection; F03.90 - Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety; E66.01 - Morbid (severe) obesity due to excess calories; I50.9 - Heart failure, unspecified; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; I42.0 - Dilated cardiomyopathy; I47.20 - Ventricular tachycardia, unspecified; I48.92 - Unspecified atrial flutter; R45.851 - Suicidal ideations; N39.0 - Urinary tract infection, site not specified; E87.1 - Hypo-osmolality and hyponatremia; N17.9 - Acute kidney failure, unspecified; I48.0 - Paroxysmal atrial fibrillation; F41.9 - Anxiety disorder, unspecified; G89.29 - Other chronic pain; E78.5 - Hyperlipidemia, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; G47.33 - Obstructive sleep apnea (adult) (pediatric); R32 - Unspecified urinary incontinence; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounte..."
MMC OP VP INFUSION,24345,"Cohen, Seth D, MD",9/18/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,_1. First Line,8/21/2024,Inactive,,
MMC OP VP INFUSION,24345,"Cohen, Seth D, MD",12/4/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,_1. First Line,11/20/2024,Active,,
MMC OP VP INFUSION,99090,"Eltoukhy, Hussam, MD",3/12/2025,CINJ 042211 Arm A Sacituzumab govitecan / Pembrolizumab 21 Day Cycles Research- Breast Cancer,_1. First Line,3/12/2025,Inactive,Rectal cancer (CMS/HCC),Z51.11 - Encounter for antineoplastic chemotherapy; C20 - Malignant neoplasm of rectum
CMC 4B ONCOLOGY,7725,"Taff, Jessica, MD",5/8/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/7/2023,Inactive,,
CMC OP INFUSION,7725,"Taff, Jessica, MD",9/13/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/12/2024,Active,,
CMC OP INFUSION,7725,"Taff, Jessica, MD",4/25/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/25/2025,Active,Colon cancer (CMS/HCC),
CMC OP INFUSION,27568,"Pompa, Tiffany Ann, MD",1/14/2025,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/13/2025,Active,,
CINJ OP INFUSION,25260,"Golombos, David, MD",2/19/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/12/2024,Inactive,,
CINJ OP INFUSION,25260,"Golombos, David, MD",5/30/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,5/30/2024,Active,,
CINJ OP INFUSION,98467,"Weiss, Sarah, MD",5/8/2023,CINJ 092204 [Fianlimab (1600mg=arm A or 400mg=arm B) + Cemiplimab 350mg] or [pembrolizumab= arm C ] - 21 Day Cycles Research- Melanoma,Adjuvant,5/7/2023,Inactive,,
CINJ OP INFUSION,98467,"Weiss, Sarah, MD",2/26/2025,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,2/26/2025,Active,Malignant melanoma of overlapping sites of skin (CMS/HCC),C43.8 - Malignant melanoma of overlapping sites of skin (CMS/HCC)
MMC OP VP INFUSION,2571,"Meghal, Trishala, MD",10/2/2023,Enzalutamide 28 Day Cycles - Prostate,,10/2/2023,Active,,
CBMC OP INFUSION 2FL,80767,"Wagmiller, Jennifer Ann, MD",7/19/2024,Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,7/14/2024,Active,,
CINJ OP INFUSION,56489,"Boland, Patrick M, MD",10/1/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/30/2024,Active,,
CINJ OP INFUSION,86427,"Boland, Patrick M, MD",4/22/2025,"Gemcitabine D1, D8 21 Day Cycles + erlotinib - Gastrointestinal Cancers",_2. Second Line,4/22/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas
NBR 5N ONCOLOGY,99069,"Weiss, Sarah, MD",12/2/2024,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_1. First Line,12/2/2024,Inactive,,
CINJ OP INFUSION,99069,"Weiss, Sarah, MD",12/9/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/8/2024,Inactive,,
SOM OUTPT INFUSION,8279,"George, Roshini, DO",1/8/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_2. Second Line,1/7/2025,Active,,
CBMC 2W ONCOLOGY,36132,"Grossman, I Robert, MD",6/7/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,6/5/2024,Active,,
CBMC 2W ONCOLOGY,36132,"Grossman, I Robert, MD",6/10/2024,RiTUXimab Initial Infusion ++ Day (Outpatient),_1. First Line,6/10/2024,Active,Small cell lung cancer (CMS/HCC),
CBMC OP INFUSION 2FL,36132,"Grossman, I Robert, MD",2/26/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,2/2/2025,Active,"Mantle cell lymphoma (CMS/HCC)
Encounter for screening for other viral diseases",
CBMC OP INFUSION 2FL,22589,"Dharmapuri, Sirish, MD",7/29/2024,"Pembrolizumab + Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- dMMR Pancreatic Adenocarcinoma",_1. First Line,7/28/2024,Active,,
NBR BMSCH 2 PED HEMONC,21327,"Cole, Peter David, MD",12/4/2023,PEDS ANHL1131 Group B ,_8. Eighth Line,12/4/2023,Active,,
CMC OP INFUSION,19566,"Pompa, Tiffany Ann, MD",9/5/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,9/4/2024,Active,Malignant neoplasm of lower-outer quadrant of female breast (CMS/HCC),
CMC OP INFUSION,19566,"Pompa, Tiffany Ann, MD",1/23/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/22/2025,Active,,
CMMC 3SA MED-SURG/ONCO,64718,"Siu, Karleung, MD",3/20/2025,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,3/20/2025,Inactive,"Lung cancer, primary, with metastasis from lung to other site, unspecified laterality (CMS/HCC)","C7A.8 - Other malignant neuroendocrine tumors; E43 - Unspecified severe protein-calorie malnutrition; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; R53.2 - Functional quadriplegia; B37.0 - Candidal stomatitis; E87.1 - Hypo-osmolality and hyponatremia; C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung; R13.10 - Dysphagia, unspecified; J44.9 - Chronic obstructive pulmonary disease, unspecified; E11.51 - Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene; I10 - Essential (primary) hypertension; Z68.1 - Body mass index (BMI) 19.9 or less, adult; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; D72.829 - Elevated white blood cell count, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z95.1 - Presence of aortocoronary bypass graft; E78.5 - Hyperlipidemia, unspecified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z88.5 - Allergy status to narcotic agent; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; Z86.718 - Personal history of other venous thrombosis and embolism; J34.2 - Deviated nasal septum; J31.0 - Chronic rhinitis; H69.91 - Unspecified eustachian tube disorder, right ear; H91.11 - Presbycusis, right ear; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z28.82 - Immunization not carried out because of caregiver refusal; Z92.21 - Personal history of antineopl..."
SOM OUTPT INFUSION,38696,"Patel, Eshan, MD",5/20/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_1. First Line,5/19/2024,Active,,
CBMC OP INFUSION 2FL,63417,"Raptis, George, MD",3/11/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,3/4/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,43490,"Taff, Jessica, MD",6/23/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,6/22/2023,Active,Urothelial carcinoma (CMS/HCC),
CINJ OP INFUSION,25954,"Weiss, Sarah, MD",3/28/2023,Talimogene Laherparepvec 21 Day Cycle + Talimogene Laherparepvec 14 Day Cycles - Melanoma,Second Line,3/20/2023,Inactive,,
CINJ OP INFUSION,78858,"Saraiya, Biren P, MD",3/29/2023,CINJ 082002 Pre-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,First Line,3/28/2023,Inactive,,
NBR 4N ONCOLOGY,757,"Jang, Thomas L, MD",2/5/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/5/2025,Active,Primary transitional cell carcinoma of right ureter (CMS/HCC),
SOM OUTPT INFUSION,17634,"Toomey, Kathleen C, MD",6/19/2024,Ribociclib 28 Day Cycles - Breast,_2. Second Line,6/14/2024,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
SOM 1PAV ONCOLOGY,17634,"Toomey, Kathleen C, MD",3/24/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),Maintenance,3/24/2025,Inactive,"Breast carcinoma metastatic to multiple sites (CMS/HCC)
Cancer, metastatic to bone (CMS/HCC)","C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K72.00 - Acute and subacute hepatic failure without coma; Z66 - Do not resuscitate; C79.01 - Secondary malignant neoplasm of right kidney and renal pelvis; E87.20 - Acidosis, unspecified; C79.51 - Secondary malignant neoplasm of bone; D69.6 - Thrombocytopenia, unspecified; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; I10 - Essential (primary) hypertension; K59.01 - Slow transit constipation; M81.0 - Age-related osteoporosis without current pathological fracture; E78.2 - Mixed hyperlipidemia; Z11.52 - Encounter for screening for COVID-19; G89.29 - Other chronic pain; E16.2 - Hypoglycemia, unspecified; M19.041 - Primary osteoarthritis, right hand; M19.042 - Primary osteoarthritis, left hand; Z17.0 - Estrogen receptor positive status (ER+); Z17.21 - Progesterone receptor positive status; Z17.32 - Human epidermal growth factor receptor 2 negative status; Z63.4 - Disappearance and death of family member; F41.8 - Other specified anxiety disorders; Z90.710 - Acquired absence of both cervix and uterus; Z90.89 - Acquired absence of other organs; Z90.722 - Acquired absence of ovaries, bilateral; Z98.890 - Other specified postprocedural states; Z91.041 - Radiographic dye allergy status; Z88.2 - Allergy status to sulfonamides; Z88.0 - Allergy status to penicillin; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z92.3 - Personal history of irradiatio..."
CINJ OP INFUSION,41829,"Berim, Lyudmyla, MD",3/21/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/19/2025,Active,Carcinoma of pancreas metastatic to liver (CMS/HCC),"C25.1 - Malignant neoplasm of body of pancreas; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; G89.3 - Neoplasm related pain (acute) (chronic); G89.29 - Other chronic pain; C25.9 - Malignant neoplasm of pancreas, unspecified; K59.03 - Drug induced constipation; T40.2X5A - Adverse effect of other opioids, initial encounter; K86.89 - Other specified diseases of pancreas; R16.0 - Hepatomegaly, not elsewhere classified; R53.81 - Other malaise; Z51.5 - Encounter for palliative care; Z71.89 - Other specified counseling"
NBR CINJ OP INFUSION,28699,"Evens, Andrew M, DO",9/28/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,9/28/2024,Active,,
NBR CINJ OP INFUSION,28699,"Rhodes, Joanna Meehan, MD",9/28/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,9/28/2024,Inactive,,
NBR 5N ONCOLOGY,28699,"Evens, Andrew M, DO",10/3/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_1. First Line,10/2/2024,Inactive,,
NBR CINJ OP INFUSION,28699,"Rhodes, Joanna Meehan, MD",10/9/2024,Nivolumab-AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,10/8/2024,Inactive,,
CINJ OP INFUSION,14497,"Stephenson, Ryan D, DO",1/8/2024,Gemcitabine / CISplatin (1000/35) Split Dose 21 Day Cycles - Bladder,Neoadjuvant,1/7/2024,Inactive,,
CBMC OP INFUSION 2FL,98483,"Scoppetuolo, Michael, MD",11/14/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_2. Second Line,11/12/2023,Inactive,,
CINJ OP INFUSION,27237,"Stephenson, Ryan D, DO",2/26/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,2/26/2024,Active,,
CINJ OP INFUSION,27237,"Stephenson, Ryan D, DO",2/26/2024,Relugolix 30 day Cycles - Prostate,_1. First Line,2/26/2024,Active,ATLL (adult T-cell leukemia/lymphoma) (CMS/HCC),
MMC OP VP INFUSION,52444,"Talwar, Sumit, MD",5/2/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Maintenance,5/1/2023,Inactive,,
MSC OP INFUSION,52444,"Talwar, Sumit, MD",10/8/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,10/7/2024,Active,"B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)
Lymphomatous meningitis (CMS/HCC)",
NBR CINJ OP INFUSION,76858,"Palmisiano, Neil David, MD",5/30/2025,CINJ 022405 Part 1 Tagraxofusp 12 mcg/kg / Venetoclax / Azacitadine (Days 1-7) 28 Day Cycles Research- Acute Myeloid Leukemia,_1. First Line,5/30/2025,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Cerebral infarction due to embolism of bilateral anterior cerebral arteries (CMS/HCC)",
NBR CINJ OP INFUSION,92383,"Evens, Andrew M, DO",7/26/2023,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,,7/25/2023,Inactive,,
CINJ OP INFUSION,84199,"George, Mridula A, MD",3/31/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,3/30/2023,Inactive,,
CINJ OP INFUSION,84199,"George, Mridula A, MD",6/29/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,6/22/2023,Inactive,,
MMC OP VP INFUSION,37989,"Eltoukhy, Hussam, MD",6/20/2023,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles + Maintenance 28 Day Cycles - Multiple Myeloma,First Line,6/19/2023,Inactive,,
NBR 4N ONCOLOGY,37989,"Assal, Amer, MD",11/8/2023,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,11/6/2023,Inactive,,
MMC OP VP INFUSION,37989,"Eltoukhy, Hussam, MD",2/19/2024,Lenalidomide (D1-D21) Maintenance 28 Day Cycles - Multiple Myeloma,Maintenance,2/19/2024,Active,,
CINJ OP INFUSION,60374,"Stephenson, Ryan D, DO",5/14/2025,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Urothelial Cancer,_1. First Line,5/14/2025,Active,"Metastatic urothelial carcinoma (CMS/HCC)
Disorder of thyroid",
CINJ OP INFUSION,60374,"Stephenson, Ryan D, DO",4/2/2025,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_1. First Line,4/2/2025,Inactive,"Metastatic urothelial carcinoma (CMS/HCC)
Disorder of thyroid","D50.0 - Iron deficiency anemia secondary to blood loss (chronic); C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; C78.01 - Secondary malignant neoplasm of right lung; N17.9 - Acute kidney failure, unspecified; K82.8 - Other specified diseases of gallbladder; E87.1 - Hypo-osmolality and hyponatremia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G89.3 - Neoplasm related pain (acute) (chronic); R11.2 - Nausea with vomiting, unspecified; G89.29 - Other chronic pain; R59.0 - Localized enlarged lymph nodes; K59.03 - Drug induced constipation; R53.81 - Other malaise; T40.2X5A - Adverse effect of other opioids, initial encounter; R11.0 - Nausea; C64.2 - Malignant neoplasm of left kidney, except renal pelvis; K68.9 - Other disorders of retroperitoneum; R91.1 - Solitary pulmonary nodule; R52 - Pain, unspecified; E78.89 - Other lipoprotein metabolism disorders; D50.9 - Iron deficiency anemia, unspecified; K59.00 - Constipation, unspecified; N28.89 - Other specified disorders of kidney and ureter; Z51.5 - Encounter for palliative care; Z79.891 - Long term (current) use of opiate analgesic; Z71.89 - Other specified counseling"
CINJ OP INFUSION,60374,"Stephenson, Ryan D, DO",4/2/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,4/2/2025,Inactive,"Metastatic urothelial carcinoma (CMS/HCC)
Disorder of thyroid","D50.0 - Iron deficiency anemia secondary to blood loss (chronic); C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; C78.01 - Secondary malignant neoplasm of right lung; N17.9 - Acute kidney failure, unspecified; K82.8 - Other specified diseases of gallbladder; E87.1 - Hypo-osmolality and hyponatremia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G89.3 - Neoplasm related pain (acute) (chronic); R11.2 - Nausea with vomiting, unspecified; G89.29 - Other chronic pain; R59.0 - Localized enlarged lymph nodes; K59.03 - Drug induced constipation; R53.81 - Other malaise; T40.2X5A - Adverse effect of other opioids, initial encounter; R11.0 - Nausea; Z51.5 - Encounter for palliative care; C64.2 - Malignant neoplasm of left kidney, except renal pelvis; K68.9 - Other disorders of retroperitoneum; R91.1 - Solitary pulmonary nodule; R52 - Pain, unspecified; E78.89 - Other lipoprotein metabolism disorders; D50.9 - Iron deficiency anemia, unspecified; K59.00 - Constipation, unspecified; N28.89 - Other specified disorders of kidney and ureter; Z79.891 - Long term (current) use of opiate analgesic"
MMC OP INFUSION,5847,"Meghal, Trishala, MD",3/8/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,3/7/2023,Inactive,,
MMC OP INFUSION,5847,"Meghal, Trishala, MD",6/16/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,First Line,6/15/2023,Inactive,,
MMC OP INFUSION,5847,"Meghal, Trishala, MD",1/19/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/18/2024,Inactive,,
MMC OP VP INFUSION,5847,"Meghal, Trishala, MD",5/15/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,5/9/2024,Inactive,,
CINJ OP INFUSION,56244,"Weiss, Sarah, MD",11/30/2023,Nivolumab 28 Day Cycles - Melanoma,_1. First Line,11/29/2023,Inactive,,
CINJ OP INFUSION,56244,"Weiss, Sarah, MD",1/24/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,1/23/2024,Inactive,,
CINJ OP INFUSION,51723,"Patel, Eshan, MD",1/18/2024,CINJ 032105 Group A/B/C CISplatin / Etoposide + Pembrolizumab / Placebo 21 Day Cycles Followed by Pembrolizumab / Placebo + Olaparib / Placebo 42 Day Cycles Research- Small Cell Lung Cancer,_1. First Line,12/20/2023,Inactive,,
SOM OUTPT INFUSION,51723,"Patel, Eshan, MD",8/23/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,8/22/2024,Active,,
MMC OP VP INFUSION,94442,"Lee, Patrick C, MD",2/23/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,2/22/2023,Inactive,,
CMC OP INFUSION,5466,"Taff, Jessica, MD",7/16/2024,CISplatin 25 mg/m2 D1-D3/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,7/11/2024,Active,,
NBR CINJ OP INFUSION,26329,"Shah, Mansi R, MD",8/5/2024,CINJ 012310 Induction Linvoseltamab 28 Day Cycles Research- Multiple Myeloma,_1. First Line,8/5/2024,Inactive,,
NBR CINJ OP INFUSION,26329,"Shah, Mansi R, MD",11/21/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,11/7/2024,Active,,
NBR CINJ OP INFUSION,26329,"Shah, Mansi R, MD",4/28/2025,CINJ 012310 Inpatient Consolidation Linvolsetamab Post ASCT 28 Day Cycles Research- Multiple Myeloma,_1. First Line,4/28/2025,Active,"Multiple myeloma (CMS/HCC)
Multiple myeloma and immunoproliferative neoplasms (CMS/HCC)",
MMC OP VP INFUSION,76845,"Lee, Patrick C, MD",6/8/2023,Bevacizumab 21 Day Cycles x 4 for radiation necrosis,,6/7/2023,Inactive,,
CINJ OP INFUSION,57270,"Jang, Thomas L, MD",9/4/2024,BCG Induction (TICE) 42 Day Cycle,Induction,9/2/2024,Active,,
CBMC OP INFUSION 2FL,97263,"Brown, Andrew Bennett, MD",10/24/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Induction,10/23/2023,Active,,
CINJ OP INFUSION,91325,"Patel, Eshan, MD",8/23/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/15/2024,Inactive,,
CINJ OP INFUSION,91325,"Patel, Eshan, MD",9/25/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/17/2024,Inactive,,
SOM OUTPT INFUSION,91325,"Patel, Eshan, MD",12/20/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/12/2024,Active,,
SOM OUTPT INFUSION,10100,"Patel, Eshan, MD",4/24/2025,Amivantamab-vmjw Patients >/= 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/24/2025,Active,Malignant neoplasm of lower lobe of left lung (CMS/HCC),
CINJ OP INFUSION,19043,"Ghodoussipour, Saum Bobak, MD",5/7/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,4/29/2024,Inactive,,
CINJ OP INFUSION,19043,"Ghodoussipour, Saum Bobak, MD",9/9/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,9/9/2024,Active,,
MMC OP VP INFUSION,45773,"Cohen, Seth D, MD",8/20/2024,CINJ 082401 Arm 3 Cohort B Nivolumab 480 mg 28 Day Cycles Research- Urothelial Cancer,_1. First Line,8/20/2024,Active,,
NBR CINJ OP INFUSION,56523,"Evens, Andrew M, DO",12/11/2024,RiTUXimab Weekly x 4 for 28 Days -Marginal Zone Lymphoma,_1. First Line,12/10/2024,Active,Primary cancer of left upper lobe of lung (CMS/HCC),
NBR CINJ OP INFUSION,56718,"Evens, Andrew M, DO",5/28/2025,RiTUXimab 56 Day Cycles - Marginal Zone Lymphoma PRIMA Maintenance,Maintenance,5/28/2025,Active,Marginal zone lymphoma (CMS/HCC),
NBR 5N ONCOLOGY,20818,"Stephenson, Ruth D, DO",5/20/2025,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Ovarian carcinosarcoma,_2. Second Line,5/20/2025,Inactive,Carcinosarcoma of ovary (CMS/HCC),"A41.9 - Sepsis, unspecified organism; E43 - Unspecified severe protein-calorie malnutrition; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; L89.153 - Pressure ulcer of sacral region, stage 3; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; C79.89 - Secondary malignant neoplasm of other specified sites; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I47.20 - Ventricular tachycardia, unspecified; C56.3 - Malignant neoplasm of bilateral ovaries; D63.0 - Anemia in neoplastic disease; I10 - Essential (primary) hypertension; I71.21 - Aneurysm of the ascending aorta, without rupture; N13.6 - Pyonephrosis; K51.00 - Ulcerative (chronic) pancolitis without complications; E87.29 - Other acidosis; R18.8 - Other ascites; E87.1 - Hypo-osmolality and hyponatremia; N17.9 - Acute kidney failure, unspecified; Z93.3 - Colostomy status; E83.42 - Hypomagnesemia; E87.6 - Hypokalemia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; R34 - Anuria and oliguria; G89.3 - Neoplasm related pain (acute) (chronic); K59.03 - Drug induced constipation; E16.2 - Hypoglycemia, unspecified; T40.2X5A - Adverse effect of other opioids, initial encounter; E83.52 - Hypercalcemia; I95.9 - Hypotension, unspecified; R33.9 - Retention of urine, unspecified; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; F41.9 - Anxiety disorder, unspecified; R32 - Unspecified urinary incontine..."
CINJ OP INFUSION,20818,"Stephenson, Ruth D, DO",4/2/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,4/2/2025,Inactive,Carcinosarcoma of ovary (CMS/HCC),C56.9 - Malignant neoplasm of unspecified ovary
NBI OP INFUSION,43854,"Cohen, Alice, MD",12/1/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,11/30/2023,Inactive,,
CINJ OP INFUSION,71029,"Gulhati, Prateek, MD PhD",11/7/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,10/9/2024,Inactive,,
CINJ OP INFUSION,71029,"Gulhati, Prateek, MD PhD",12/19/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,12/18/2024,Active,,
CINJ OP INFUSION,71029,"Gulhati, Prateek, MD PhD",12/19/2024,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Pembro 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/19/2024,Active,,
CBMC OP INFUSION 2FL,42247,"Grossman, I Robert, MD",11/29/2024,HyperCVD Mini (RiTUXimab / High-Dose Methotrexate / Cytarabine / Inotuzumab / Cyclophosphamide / VinCRIStine / DexAMETHasone) 28 Day Cycles - Acute Lymphoblastic Leukemia,_1. First Line,11/28/2024,Active,,
CBMC 2W ONCOLOGY,42247,"Grossman, I Robert, MD",12/31/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,12/30/2024,Active,,
MMC OP VP INFUSION,99278,"Cohen, Seth D, MD",5/11/2023,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,Maintenance,5/10/2023,Inactive,,
CINJ OP INFUSION,49946,"Toppmeyer, Deborah L, MD",3/17/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Neoadjuvant,3/15/2023,Inactive,,
CINJ OP INFUSION,49946,"Toppmeyer, Deborah L, MD",12/18/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_1. First Line,12/18/2023,Inactive,,
NBR CINJ OP INFUSION,28801,"Braunschweig, Ira, MD",11/8/2023,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_1. First Line,11/7/2023,Inactive,,
NBR CINJ OP INFUSION,28801,"Egini, Ogechukwu, MD",2/23/2024,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,Consolidation,2/23/2024,Inactive,,
NBR CINJ OP INFUSION,28801,"Egini, Ogechukwu, MD",4/1/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,3/31/2024,Inactive,,
NBR CINJ OP INFUSION,28801,"Egini, Ogechukwu, MD",6/19/2024,CINJ 022204 LYT- 200 / Azacitadine 28 Day Cycles Research- Myelodysplastic Syndromes ,_2. Second Line,6/14/2024,Inactive,,
CBMC OP INFUSION 2FL,70742,"Leitner, Stuart P, MD",8/20/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Adjuvant,8/20/2024,Inactive,,
CBMC OP INFUSION 2FL,70742,"Leitner, Stuart P, MD",11/5/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,Adjuvant,10/28/2024,Inactive,,
CBMC 2W ONCOLOGY,65926,"Grossman, I Robert, MD",8/29/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/28/2024,Inactive,,
CINJ OP INFUSION,90746,"Haigentz, Missak, MD",8/7/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,8/6/2023,Inactive,,
NBR CINJ OP INFUSION,45071,"Matasar, Matthew J, MD",1/17/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,1/16/2023,Inactive,,
NBR CINJ OP INFUSION,45071,"Matasar, Matthew J, MD",4/10/2023,High-Dose Methotrexate - Diffuse Large B-Cell Lymphoma,Second Line,4/7/2023,Inactive,,
NBR CINJ OP INFUSION,45071,"Matasar, Matthew J, MD",8/23/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,30610,"Matasar, Matthew J, MD",5/28/2025,CINJ 012406 ARV-393 28 Day Cycles Research- Non-Hodgkin's Lymphoma,_3. Third Line,5/28/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,30610,"Matasar, Matthew J, MD",5/28/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_3. Third Line,5/28/2025,Active,"Diffuse large B-cell lymphoma (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)
Abnormal coagulation profile",
CBMC OP INFUSION 2FL,42234,"Raptis, George, MD",6/26/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,6/17/2024,Inactive,,
CBMC OP INFUSION 2FL,42234,"Raptis, George, MD",9/25/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,9/24/2024,Active,Cancer of sigmoid colon (CMS/HCC),
MMC OP VP INFUSION,31136,"Talwar, Sumit, MD",2/27/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/20/2024,Inactive,,
SOM OUTPT INFUSION,31410,"Yin, Faye, MD",4/24/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Neoadjuvant,4/21/2023,Inactive,,
SOM OUTPT INFUSION,31410,"Yin, Faye, MD",8/2/2023,Pembrolizumab 21 Day Cycles - Uterine,First Line,7/13/2023,Inactive,,
SOM OUTPT INFUSION,31410,"Toomey, Kathleen C, MD",12/18/2024,Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,12/17/2024,Active,,
CINJ OP INFUSION,4495,"Boland, Patrick M, MD",1/20/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,1/20/2023,Inactive,,
CINJ OP INFUSION,4495,"Boland, Patrick M, MD",5/29/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly - pancreatic cancer,,5/29/2023,Inactive,,
CINJ OP INFUSION,4495,"Boland, Patrick M, MD",1/19/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/18/2024,Inactive,,
CINJ OP INFUSION,4495,"Boland, Patrick M, MD",10/11/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,5/24/2024,Inactive,,
CINJ OP INFUSION,77179,"Hochster, Howard S, MD",1/3/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Third Line,1/3/2023,Inactive,,
CINJ OP INFUSION,77179,"Hochster, Howard S, MD",6/22/2023,FOLFIRI-NIVO = Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Third Line,6/21/2023,Inactive,,
CINJ OP INFUSION,77179,"Hochster, Howard S, MD",8/28/2024,Nivolumab 480 mg 28 Day Cycles- Gastrointestinal Cancers,Maintenance,8/28/2024,Inactive,,
CINJ OP INFUSION,51416,"Hochster, Howard S, MD",1/3/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,1/2/2025,Inactive,"Mucinous adenocarcinoma (CMS/HCC)
Secondary malignant neoplasm of liver and intrahepatic bile duct (CMS/HCC)
Elevated carcinoembryonic antigen (CEA)
Abnormal findings on diagnostic imaging of other specified body structures",
CMC OP INFUSION,6106,"Taff, Jessica, MD",1/3/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,1/2/2024,Active,,
CBMC OP INFUSION 2FL,61315,"Raptis, George, MD",12/11/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/10/2024,Active,Adenocarcinoma of upper lobe of left lung (CMS/HCC),
CBMC OP INFUSION 2FL,61315,"Raptis, George, MD",2/12/2025,TAC (DOCEtaxel / DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,2/11/2025,Inactive,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,61315,"Raptis, George, MD",3/6/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/6/2025,Inactive,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,61315,"Raptis, George, MD",3/5/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/5/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,40062,"Litvak, Anna M, MD",10/23/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_1. First Line,10/22/2023,Inactive,,
CMC OP INFUSION,33090,"Pompa, Tiffany Ann, MD",4/29/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/29/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,44539,"Toomey, Kathleen C, MD",10/31/2023,RiTUXimab 28 Day Cycle -idiopathic thrombocytopenic purpura,_1. First Line,10/30/2023,Inactive,,
CINJ OP INFUSION,71364,"Haigentz, Missak, MD",4/9/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,4/9/2024,Active,,
CINJ OP INFUSION,99757,"Mayer, Tina M, MD",9/25/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,9/23/2024,Active,,
CINJ OP INFUSION,52665,"Ghodoussipour, Saum Bobak, MD",5/13/2025,CINJ 082404 Group A TAR-210 6 Week / 12 Week Cycles Research- Bladder Cancer,Induction,5/13/2025,Active,Urothelial carcinoma (CMS/HCC),
NBR 4N ONCOLOGY,522,"Hochster, Howard S, MD",3/22/2024,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,3/21/2024,Inactive,,
NBR 4N ONCOLOGY,522,"Hochster, Howard S, MD",4/1/2024,Fluorouracil Continuous Infusion (Over 5 Days) with Concurrent Radiation 35 Day Cycle - Rectal Cancer,_1. First Line,4/1/2024,Inactive,,
CINJ OP INFUSION,76591,"Haigentz, Missak, MD",5/12/2025,PACLitaxel / CARBOplatin PLUS Ramucirumab - 21 Day Cycles - Thymic Carcinoma,Adjuvant,5/12/2025,Active,"Malignant neoplasm of thymus (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",C37 - Malignant neoplasm of thymus; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C61 - Malignant neoplasm of prostate; R97.21 - Rising PSA following treatment for malignant neoplasm of prostate; R74.8 - Abnormal levels of other serum enzymes; I48.91 - Unspecified atrial fibrillation; Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm; Z92.21 - Personal history of antineoplastic chemotherapy
CBMC OP INFUSION 2FL,52998,"Raptis, George, MD",5/7/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,5/6/2024,Inactive,,
CBMC OP INFUSION 2FL,52998,"Raptis, George, MD",7/5/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,6/27/2024,Inactive,,
CBMC OP INFUSION 2FL,52998,"Raptis, George, MD",8/30/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,8/29/2024,Inactive,,
CBMC 2W ONCOLOGY,28663,"Grossman, I Robert, MD",7/15/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,7/15/2024,Active,"Fallopian tube cancer, carcinoma (CMS/HCC)",
CBMC 2W ONCOLOGY,28663,"Grossman, I Robert, MD",7/17/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,7/15/2024,Active,,
SOM OUTPT INFUSION,42911,"Patel, Eshan, MD",1/18/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,1/17/2023,Inactive,,
CINJ OP INFUSION,97174,"Boland, Patrick M, MD",8/21/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,8/21/2023,Active,,
CINJ OP INFUSION,97174,"Boland, Patrick M, MD",2/24/2025,CINJ 192301 NT-175 21 Day Cycle Research- Advanced / Metastatic Solid Tumors,_3. Third Line,2/23/2025,Active,"Malignant neoplasm of rectum (CMS/HCC)
Abnormal coagulation profile
Bleeding diathesis (CMS/HCC)",
CINJ OP INFUSION,97174,"Boland, Patrick M, MD",3/3/2025,CINJ 192301 NT-175 21 Day Cycle Research- Advanced / Metastatic Solid Tumors,_3. Third Line,2/24/2025,Active,"Malignant neoplasm of rectum (CMS/HCC)
Abnormal coagulation profile
Bleeding diathesis (CMS/HCC)",
JCMC CP INFUSION,84555,"Sekhri, Arunabh, MD",4/15/2024,Bevacizumab + Capecitabine 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/7/2024,Inactive,,
JCMC CP INFUSION,84555,"Sekhri, Arunabh, MD",10/29/2024,5fu  + Bevacizumab  14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/29/2024,Active,,
CINJ OP INFUSION,94638,"Omene, Coral Oghenerukevwe, MD",6/4/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/3/2024,Inactive,,
CINJ OP INFUSION,94638,"Omene, Coral Oghenerukevwe, MD",10/22/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,10/22/2024,Inactive,,
CINJ OP INFUSION,94638,"Omene, Coral Oghenerukevwe, MD",12/24/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,12/23/2024,Active,,
CBMC OP INFUSION 2FL,31986,"Grossman, I Robert, MD",8/19/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,8/13/2024,Active,"Lung cancer metastatic to brain (CMS/HCC)
Other specified disorders involving the immune mechanism, not elsewhere classified (CMS/HCC)",
CMC OP INFUSION,64272,"Talwar, Sumit, MD",4/29/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/29/2024,Inactive,,
CMC OP INFUSION,64272,"Talwar, Sumit, MD",7/16/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,_1. First Line,7/1/2024,Inactive,,
NBR CINJ OP INFUSION,6971,"Shah, Mansi R, MD",6/6/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,6/5/2023,Inactive,,
NBR CINJ OP INFUSION,8051,"Shah, Mansi R, MD",12/4/2024,Teclistamab Weekly 28 Day Cycles,Lymphodepletion,12/3/2024,Inactive,,
HAM OP INFUSION,29479,"Yogarajah, Meera, MD",10/30/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,10/29/2023,Inactive,,
HAM OP INFUSION,38315,"Patel, Malini M, MD",4/4/2023,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Adjuvant,4/4/2023,Inactive,,
HAM OP INFUSION,38315,"Patel, Malini M, MD",5/22/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,5/22/2023,Active,Rectal adenocarcinoma (CMS/HCC),
HAM OP INFUSION,13061,"Patel, Malini M, MD",3/9/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,3/8/2023,Active,,
CINJ OP INFUSION,73460,"Boland, Patrick M, MD",4/10/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,4/6/2023,Inactive,,
CINJ OP INFUSION,73460,"Boland, Patrick M, MD",12/1/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/1/2023,Inactive,,
CINJ OP INFUSION,73460,"Boland, Patrick M, MD",7/19/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,7/18/2024,Inactive,,
NBR CINJ OP INFUSION,41990,"Rhodes, Joanna Meehan, MD",2/5/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,1/28/2024,Inactive,,
NBR CINJ OP INFUSION,41990,"Rhodes, Joanna Meehan, MD",4/16/2024,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,4/15/2024,Inactive,,
SOM OUTPT INFUSION,54116,"Patel, Eshan, MD",1/7/2025,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,1/5/2025,Active,,
CINJ OP INFUSION,17778,"George, Mridula A, MD",1/27/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/26/2023,Inactive,,
CINJ OP INFUSION,17778,"George, Mridula A, MD",3/24/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,3/23/2023,Inactive,,
CINJ OP INFUSION,17778,"George, Mridula A, MD",4/30/2025,Talazoparib 28 Day Cycles ,_1. First Line,4/30/2025,Active,"Malignant neoplasm of axillary tail of left breast in female, estrogen receptor negative (CMS/HCC)","C50.612 - Malignant neoplasm of axillary tail of left female breast; I82.C11 - Acute embolism and thrombosis of right internal jugular vein; E04.1 - Nontoxic single thyroid nodule; E80.7 - Disorder of bilirubin metabolism, unspecified; Z90.13 - Acquired absence of bilateral breasts and nipples; D50.8 - Other iron deficiency anemias; Z17.1 - Estrogen receptor negative status (ER-)"
JCMC CP INFUSION,77395,"Ghuman, Damanjit, MD",8/17/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,7/25/2023,Inactive,,
JCMC CP INFUSION,67690,"Sekhri, Arunabh, MD",1/20/2025,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Adjuvant,1/19/2025,Active,,
NBR 4N BMTU/IMCU,71189,"Patel, Vimal D, MD",2/17/2023,BMT Allogeneic TBF + Post Cy ,,2/16/2023,Inactive,,
NBR CINJ OP INFUSION,71189,"Braunschweig, Ira, MD",7/17/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,7/16/2023,Inactive,,
NBR CINJ OP INFUSION,71189,"Braunschweig, Ira, MD",10/18/2023,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,Reinduction,10/17/2023,Inactive,,
NBR CINJ OP INFUSION,71189,"Braunschweig, Ira, MD",12/4/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,Induction,12/3/2023,Inactive,,
CBMC OP INFUSION 2FL,18422,"Wagmiller, Jennifer Ann, MD",9/16/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,8/25/2024,Active,,
CINJ OP INFUSION,19341,"Haigentz, Missak, MD",9/16/2024,PACLitaxel 175 mg/m2 /CARBOplatin 21 Day Cycles - Salivary Gland Cancer,_1. First Line,9/15/2024,Inactive,,
CINJ OP INFUSION,19341,"Haigentz, Missak, MD",10/28/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,10/28/2024,Active,,
CINJ OP INFUSION,67188,"Patel, Eshan, MD",11/17/2023,Pemetrexed / CARBOplatin (AUC 5) / Nivolumab  21 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,11/9/2023,Inactive,,
CINJ OP INFUSION,22695,"Omene, Coral Oghenerukevwe, MD",3/18/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/18/2025,Active,Breast cancer of upper-inner quadrant of left female breast (CMS/HCC),
CINJ OP INFUSION,60886,"George, Mridula A, MD",4/14/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/13/2023,Inactive,,
CINJ OP INFUSION,60886,"George, Mridula A, MD",7/28/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,,7/6/2023,Inactive,,
CINJ OP INFUSION,97221,"Dasgeb, Bahar, MD",1/23/2023,Nivolumab 28 Day Cycles - Melanoma,Second Line,1/22/2023,Inactive,,
CINJ OP INFUSION,97221,"Dasgeb, Bahar, MD",2/12/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,2/9/2024,Inactive,,
HAM OP INFUSION,42332,"Yogarajah, Meera, MD",5/6/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/28/2025,Active,"Metastatic adenocarcinoma (CMS/HCC)
Malignant neoplasm of colon, unspecified part of colon (CMS/HCC)",
HAM OP INFUSION,42332,"Yogarajah, Meera, MD",4/28/2025,Encorafenib - Gastrointestinal Cancers,_1. First Line,4/28/2025,Active,Metastatic adenocarcinoma (CMS/HCC),
HAM OP INFUSION,42332,"Yogarajah, Meera, MD",4/15/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/4/2025,Inactive,"Metastatic adenocarcinoma (CMS/HCC)
Malignant neoplasm of colon, unspecified part of colon (CMS/HCC)",
CINJ OP INFUSION,55644,"Berim, Lyudmyla, MD",2/27/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,2/14/2023,Inactive,,
TRMC TCCC OP INFUSION,3513,"Capo, Gerardo, MD",10/7/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/6/2024,Inactive,,
TRMC TCCC OP INFUSION,3513,"Salerno, Vincent E, MD",12/9/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,12/8/2024,Inactive,,
TRMC TCCC OP INFUSION,3513,"Salerno, Vincent E, MD",12/16/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,12/9/2024,Active,,
CMC OP INFUSION,67643,"Taff, Jessica, MD",6/8/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Consolidation,6/7/2023,Inactive,,
CINJ OP INFUSION,76701,"Haigentz, Missak, MD",12/1/2023,NIVOLUMAB plus PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant),Neoadjuvant,11/23/2023,Inactive,,
CINJ OP INFUSION,76701,"Haigentz, Missak, MD",6/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,6/5/2024,Active,,
NBI OP INFUSION,55213,"Shah, Shailja S, MD",5/30/2025,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone Induction 21 Day Cycles - Multiple Myeloma,_1. First Line,5/30/2025,Inactive,Multiple myeloma (CMS/HCC),D47.2 - MGUS (monoclonal gammopathy of unknown significance)
NBI OP INFUSION,55213,"Shah, Shailja S, MD",5/30/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,5/30/2025,Active,Multiple myeloma (CMS/HCC),D47.2 - MGUS (monoclonal gammopathy of unknown significance)
NBI OP INFUSION,4735,"Anderson, Patrick S, MD",5/16/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar Cancer,_1. First Line,5/15/2024,Active,,
CBMC OP INFUSION 2FL,951,"Brown, Andrew Bennett, MD",7/13/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/12/2023,Inactive,,
CBMC OP INFUSION 2FL,951,"Brown, Andrew Bennett, MD",10/15/2024,"Cetuximab D1, D15 28 Day Cycles- Colon Cancer",_3. Third Line,10/14/2024,Active,,
NBI OP INFUSION,93678,"Cheng, Yan Ho, MD",8/23/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,8/23/2024,Active,,
MMC OP VP INFUSION,22653,"Cohen, Seth D, MD",6/15/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,,6/12/2023,Inactive,,
CBMC OP INFUSION 2FL,75843,"Wagmiller, Jennifer Ann, MD",3/3/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,3/2/2023,Inactive,,
CBMC OP INFUSION 2FL,75843,"Wagmiller, Jennifer Ann, MD",3/29/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_4. Fourth Line,3/29/2024,Active,,
NBR CINJ OP INFUSION,54276,"Tiger, Yun Kyoung, MD",6/19/2024,RiTUXimab 168 Day Cycles - Indolent Lymphoma Maintenance,_1. First Line,6/12/2024,Active,Gastric cancer (CMS/HCC),
CBMC OP INFUSION 2FL,45192,"Litvak, Anna M, MD",11/6/2023,CINJ 042208 Ribociclib / Endocrine Therapy of Choice 28 Day Cycles Research- Breast Cancer,_1. First Line,11/6/2023,Active,,
NBR CINJ OP INFUSION,28243,"Evens, Andrew M, DO",5/15/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/14/2024,Active,Small lymphocytic lymphoma (CMS/HCC),
CINJ PEDS HEMONC ,72554,"Botwinick, Marissa, DO",1/27/2025,AALL1731 Non-DS SR B-ALL Induction,_1. First Line,1/26/2025,Active,,
CINJ PEDS HEMONC ,72554,"Botwinick, Marissa, DO",5/12/2025,AALL1731 All Arms - Interim Maintenance I EscMTX,_1. First Line,5/12/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,72554,"Botwinick, Marissa, DO",4/4/2025,PEDS Blinatumomab as per AALL1731 SR-Avg B-ALL,_1. First Line,4/3/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),C91.01 - Acute lymphoid leukemia in remission (CMS/HCC)
CINJ PEDS HEMONC ,72554,"Botwinick, Marissa, DO",4/1/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,3/31/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),C91.01 - Acute lymphoid leukemia in remission (CMS/HCC)
CINJ PEDS HEMONC ,72554,"Botwinick, Marissa, DO",3/3/2025,AALL1731  SR-Avg B-ALL -  Consolidation,_1. First Line,3/3/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBI OP INFUSION,81224,"Schleicher, Lori, MD",6/23/2023,Asciminib 28 Day Cycles - Chronic Myeloid Leukemia (Two or More TKIs),_3. Third Line,6/23/2023,Inactive,,
NBI OP INFUSION,81224,"Schleicher, Lori, MD",9/19/2023,Dasatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,_4. Fourth Line,9/19/2023,Active,,
CINJ OP INFUSION,58787,"Omene, Coral Oghenerukevwe, MD",2/5/2024,CINJ 042208 Ribociclib / Endocrine Therapy of Choice 28 Day Cycles Research- Breast Cancer,Adjuvant,2/5/2024,Inactive,,
NBR CINJ OP INFUSION,24116,"Shah, Mansi R, MD",6/1/2023,"Bortezomib D1, D15 + Lenalidomide D1-21 Maintenance 28 Day Cycles- Multiple Myeloma",,5/31/2023,Inactive,,
NBR CINJ OP INFUSION,24116,"Shah, Mansi R, MD",7/11/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,7/11/2024,Active,,
CMC OP INFUSION,99731,"Talwar, Sumit, MD",6/14/2023,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,5/29/2023,Inactive,,
NBR CINJ OP INFUSION,20674,"Mayer, Tina M, MD",11/11/2024,CINJ 082101 (NRG-GU009) ARM 1 Androgen Deprivation Therapy 3 Month Cycles (84 Days) Research- Prostate Cancer,_1. First Line,7/7/2024,Inactive,,
CBMC OP INFUSION 2FL,26563,"Radovich, Delia, MD",11/7/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_3. Third Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,26563,"Leitner, Stuart P, MD",12/31/2024,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/30/2024,Active,,
CINJ OP INFUSION,90250,"Saraiya, Biren P, MD",4/8/2024,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_1. First Line,4/8/2024,Active,,
NBR CINJ OP INFUSION,10663,"Shah, Mansi R, MD",9/4/2023,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,,9/1/2023,Inactive,,
NBR 4N ONCOLOGY,62973,"Matasar, Matthew J, MD",7/9/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,7/7/2023,Inactive,,
NBR 5N ONCOLOGY,9443,"Berim, Lyudmyla, MD",9/14/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/13/2024,Active,,
CINJ PEDS HEMONC ,58405,"Drachtman, Richard, MD",9/19/2024,Dosing per AALL1731 Non-DS SR B-ALL Induction,_3. Third Line,9/19/2024,Inactive,,
CINJ PEDS HEMONC ,58405,"Drachtman, Richard, MD",10/29/2024,per AALL1732 Interim Maintenance II (IM II) with CMTX (no CALPeg)  for Bridging therapy to CAR-T,_3. Third Line,10/29/2024,Active,,
CINJ PEDS HEMONC ,58405,"Drachtman, Richard, MD",4/10/2025,PEDS Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia,_4. Fourth Line,4/10/2025,Active,ALL (acute lymphoid leukemia) in relapse (CMS/HCC),
CINJ PEDS HEMONC ,58405,"Drachtman, Richard, MD",3/6/2025,BRIDGE CHEMO TO BMT - ARAC/ETOP,Adjuvant,3/6/2025,Inactive,ALL (acute lymphoid leukemia) in relapse (CMS/HCC),
CINJ PEDS HEMONC ,58405,"Drachtman, Richard, MD",3/6/2025,BRIDGE CHEMO TO BMT - ARAC/ETOP,Adjuvant,3/6/2025,Inactive,ALL (acute lymphoid leukemia) in relapse (CMS/HCC),
CBMC OP INFUSION 2FL,85796,"Radovich, Delia, MD",10/31/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,10/29/2023,Inactive,,
JCMC CP INFUSION,12578,"Cruz, Allan Louie E, MD",4/10/2025,PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,4/10/2025,Inactive,"Malignant neoplasm of lower-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.312 - Malignant neoplasm of lower-inner quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,56087,"Sekhri, Arunabh, MD",4/15/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Endometrial serous carcinoma,_1. First Line,3/28/2024,Active,,
MMC OP VP INFUSION,11219,"Eltoukhy, Hussam, MD",8/21/2023,Bendamustine / RiTUXimab 28 Day Cycles,First Line,8/13/2023,Inactive,,
NBR 5N ONCOLOGY,31288,"Groisberg, Roman, MD",1/8/2025,AP (DOXOrubicin / CISplatin) - Bone Cancer,Neoadjuvant,1/8/2025,Active,,
CINJ OP INFUSION,86786,"Aikins, James K, MD",3/2/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,3/1/2023,Inactive,,
HAM OP INFUSION,87663,"Yogarajah, Meera, MD",8/15/2023,Ribociclib 28 Day Cycles - Breast,,8/15/2023,Inactive,,
HAM OP INFUSION,87663,"Yogarajah, Meera, MD",7/25/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,7/23/2024,Active,,
NBI OP INFUSION,56617,"Shah, Shailja S, MD",11/3/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,10/12/2023,Inactive,,
CINJ OP INFUSION,4233,"Omene, Coral Oghenerukevwe, MD",12/31/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,12/30/2024,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,38678,"Omene, Coral Oghenerukevwe, MD",5/6/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/6/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z90.12 - Acquired absence of left breast and nipple; Z51.81 - Encounter for therapeutic drug level monitoring; Z17.0 - Estrogen receptor positive status (ER+); Z79.899 - Other long term (current) drug therapy
CBMC OP INFUSION 2FL,69523,"Leitner, Stuart P, MD",6/26/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,6/20/2024,Active,,
CINJ OP INFUSION,84752,"Haigentz, Missak, MD",7/30/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,7/30/2024,Active,,
CBMC OP INFUSION 2FL,48569,"Litvak, Anna M, MD",11/20/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/19/2023,Inactive,,
SOM OUTPT INFUSION,67881,"Patel, Eshan, MD",6/4/2024,Durvalumab / CISplatin / Etoposide D1-D3 Day q21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/22/2024,Inactive,,
SOM OUTPT INFUSION,67881,"Patel, Eshan, MD",9/9/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/6/2024,Active,,
CINJ OP INFUSION,67881,"Patel, Eshan, MD",2/25/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,2/25/2025,Inactive,"Mass of lower lobe of right lung
Metastatic cancer to brain (CMS/HCC)
Other abnormal findings on diagnostic imaging of central nervous system
Advanced care planning/counseling discussion
Other problems related to lifestyle
Encounter for screening for viral disease",R91.8 - Other nonspecific abnormal finding of lung field; C79.31 - Secondary malignant neoplasm of brain; R90.89 - Other abnormal findings on diagnostic imaging of central nervous system; Z71.89 - Other specified counseling; Z11.59 - Encounter for screening for other viral diseases; Z72.89 - Other problems related to lifestyle
SOM OUTPT INFUSION,30020,"Patel, Eshan, MD",3/4/2025,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,3/4/2025,Active,"Mass of lower lobe of right lung
Metastatic cancer to brain (CMS/HCC)
Other abnormal findings on diagnostic imaging of central nervous system
Advanced care planning/counseling discussion
Other problems related to lifestyle
Encounter for screening for viral disease",C79.31 - Secondary malignant neoplasm of brain; C78.00 - Secondary malignant neoplasm of unspecified lung; R91.8 - Other nonspecific abnormal finding of lung field; R90.89 - Other abnormal findings on diagnostic imaging of central nervous system; Z85.3 - Personal history of malignant neoplasm of breast; Z78.0 - Asymptomatic menopausal state; Z11.59 - Encounter for screening for other viral diseases; Z72.89 - Other problems related to lifestyle; Z71.89 - Other specified counseling
NBI OP INFUSION,70755,"Anderson, Patrick S, MD",2/16/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_3. Third Line,2/15/2024,Inactive,,
JCMC CP INFUSION,5080,"Sekhri, Arunabh, MD",12/31/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/22/2024,Active,,
JCMC CP INFUSION,5080,"Sekhri, Arunabh, MD",1/13/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/22/2024,Active,,
CINJ OP INFUSION,27427,"Groisberg, Roman, MD",4/1/2024,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,4/1/2024,Inactive,,
CINJ OP INFUSION,20258,"Leiser, Aliza, MD",1/4/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/2/2024,Active,,
CINJ OP INFUSION,30372,"Haigentz, Missak, MD",7/8/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,Induction,7/7/2024,Inactive,,
CINJ OP INFUSION,30372,"Haigentz, Missak, MD",10/30/2024,Durvalumab 1500 mg 28 Day Cycles- SMALL CELL LUNG CANCER,Maintenance,10/28/2024,Active,,
MMC OP INFUSION,58586,"Talwar, Sumit, MD",2/20/2024,Bendamustine / RiTUXimab 28 Day Cycles- LPL,_1. First Line,2/19/2024,Inactive,,
CINJ OP INFUSION,22750,"Stephenson, Ryan D, DO",7/31/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,7/30/2024,Inactive,,
CMC OP INFUSION,17667,"Easaw, Sarah, MD",7/14/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/3/2023,Inactive,,
MMC OP VP INFUSION,12408,"Cohen, Seth D, MD",9/30/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,9/29/2024,Inactive,,
CINJ OP INFUSION,36105,"George, Mridula A, MD",6/14/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/13/2024,Active,Overlapping malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,36105,"George, Mridula A, MD",7/5/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,6/7/2024,Active,,
NBR CINJ OP INFUSION,18748,"Eltoukhy, Hussam, MD",6/30/2023,RiTUXimab / Lenalidomide + Lenalidomide 28 Day Cycles - Follicular Lymphoma,Second Line,6/29/2023,Active,Primary intra-abdominal sarcoma (CMS/HCC),
CINJ OP INFUSION,45229,"Leiser, Aliza, MD",3/8/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/7/2024,Inactive,,
CINJ OP INFUSION,96283,"Groisberg, Roman, MD",3/26/2025,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_1. First Line,3/26/2025,Active,"Leiomyosarcoma (CMS/HCC)
H/O surgical procedure","C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; I82.402 - Acute embolism and thrombosis of unspecified deep veins of left lower extremity; R19.00 - Intra-abdominal and pelvic swelling, mass and lump, unspecified site"
CINJ OP INFUSION,96283,"Groisberg, Roman, MD",3/25/2025,DOXOrubicin 21 Day Cycles - Sarcoma,_1. First Line,3/25/2025,Inactive,"Leiomyosarcoma (CMS/HCC)
H/O surgical procedure","C49.9 - Malignant neoplasm of connective and soft tissue, unspecified; I82.402 - Acute embolism and thrombosis of unspecified deep veins of left lower extremity; R19.00 - Intra-abdominal and pelvic swelling, mass and lump, unspecified site"
NBI OP INFUSION,12299,"Jacoby, Sari H, MD",10/28/2024,Cetuximab/DOCEtaxel with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,10/27/2024,Active,,
NBR CINJ OP INFUSION,36229,"Matasar, Matthew J, MD",9/26/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,9/25/2024,Active,,
NBR 5N ONCOLOGY,70690,"Saraiya, Biren P, MD",1/6/2023,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycle",Second Line,1/5/2023,Inactive,,
CINJ OP INFUSION,82004,"Stephenson, Ruth D, DO",12/2/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/29/2024,Active,,
CINJ OP INFUSION,82004,"Stephenson, Ruth D, DO",2/21/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_2. Second Line,2/21/2025,Active,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,82004,"Stephenson, Ruth D, DO",4/16/2025,Abemaciclib 28 Day Cycles - Breast,_3. Third Line,4/16/2025,Active,Malignant neoplasm of ovary (CMS/HCC),"C64.9 - Malignant neoplasm of unspecified kidney, except renal pelvis; C56.9 - Malignant neoplasm of unspecified ovary"
CBMC OP INFUSION 2FL,82773,"Brown, Andrew Bennett, MD",8/8/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,8/8/2024,Active,,
SOM OUTPT INFUSION,44613,"Patel, Eshan, MD",2/15/2023,Bendamustine / RiTUXimab 28 Day Cycles - Follicular  Lymphoma,,1/22/2023,Inactive,,
SOM OUTPT INFUSION,44613,"Patel, Eshan, MD",7/20/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,First Line,7/19/2023,Active,Malignant neoplasm of prostate (CMS/HCC),
NBR 4N BMTU/IMCU,78169,"Schaar, Dale, MD PhD",2/13/2025,BMT Allogeneic Mel / Thio / Flu + Post Cy,_2. Second Line,2/13/2025,Active,"MDS (myelodysplastic syndrome), high grade (CMS/HCC)","D46.9 - Myelodysplastic syndrome, unspecified; U07.1 - COVID-19; B20 - Human immunodeficiency virus (HIV) disease; E88.819 - Insulin resistance, unspecified; I42.0 - Dilated cardiomyopathy; E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; E53.8 - Deficiency of other specified B group vitamins; E78.00 - Pure hypercholesterolemia, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; H40.9 - Unspecified glaucoma; I25.2 - Old myocardial infarction; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z80.6 - Family history of leukemia; Z86.11 - Personal history of tuberculosis; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs"
NBR 4N BMTU/IMCU,59611,"Schaar, Dale, MD PhD",3/13/2025,BMT Allogeneic Mel / Thio / Flu + Post Cy,_2. Second Line,2/13/2025,Inactive,"MDS (myelodysplastic syndrome), high grade (CMS/HCC)","D46.9 - Myelodysplastic syndrome, unspecified; U07.1 - COVID-19; B20 - Human immunodeficiency virus (HIV) disease; E88.819 - Insulin resistance, unspecified; I42.0 - Dilated cardiomyopathy; E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; E53.8 - Deficiency of other specified B group vitamins; E78.00 - Pure hypercholesterolemia, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; H40.9 - Unspecified glaucoma; I25.2 - Old myocardial infarction; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z80.6 - Family history of leukemia; Z86.11 - Personal history of tuberculosis; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs"
CINJ OP INFUSION,34345,"George, Mridula A, MD",11/17/2023,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,11/16/2023,Active,,
CINJ OP INFUSION,43251,"George, Mridula A, MD",3/31/2023,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Neoadjuvant,3/30/2023,Inactive,,
CINJ OP INFUSION,43251,"George, Mridula A, MD",7/14/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,7/13/2023,Inactive,,
CINJ OP INFUSION,43251,"George, Mridula A, MD",2/2/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,2/2/2024,Active,,
NBR 4N ONCOLOGY,4108,"Schaar, Dale, MD PhD",11/21/2023,RiTUXimab 168 Day Cycles - Pemphigus,_2. Second Line,11/20/2023,Active,Malignant neoplasm of female breast (CMS/HCC),
CINJ OP INFUSION,10968,"Boland, Patrick M, MD",5/30/2023,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,,4/24/2023,Inactive,,
CINJ OP INFUSION,10968,"Boland, Patrick M, MD",7/28/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,,7/13/2023,Inactive,,
CINJ OP INFUSION,99616,"Boland, Patrick M, MD",1/27/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,1/26/2023,Inactive,,
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",7/3/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Third Line,7/3/2023,Inactive,,
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",11/27/2023,Alpelisib 28 Day Cycles - Breast,10. Tenth Line,11/27/2023,Inactive,,
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",9/7/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Third Line,9/7/2024,Inactive,,
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",9/19/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_7. Seventh Line,6/2/2024,Inactive,,
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",9/30/2024,CINJ 042402 Parts 1 and 2 RLY-2608 Single Agent 28 Day Cycles Research- Breast Cancer,_9. Ninth Line,9/30/2024,Inactive,,
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",12/19/2024,TCH (DOCEtaxel / CARBOplatin / Trastuzumab) 21 Day Cycles - Breast,_9. Ninth Line,12/16/2024,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
CINJ OP INFUSION,68376,"Toppmeyer, Deborah L, MD",2/17/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,10. Tenth Line,2/9/2025,Active,"Secondary malignant neoplasm of skin (CMS/HCC)
Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Hypokalemia",
CINJ OP INFUSION,59886,"Stephenson, Ruth D, DO",5/9/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/9/2025,Active,Carcinoma of fallopian tube (CMS/HCC),Z48.817 - Encounter for surgical aftercare following surgery on the skin and subcutaneous tissue; C57.00 - Malignant neoplasm of unspecified fallopian tube
CBMC OP INFUSION 2FL,58765,"Grossman, I Robert, MD",4/22/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,4/22/2024,Inactive,,
CBMC OP INFUSION 2FL,58765,"Grossman, I Robert, MD",5/2/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,5/2/2024,Inactive,,
CINJ OP INFUSION,93225,"Aikins, James K, MD",8/31/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,8/30/2023,Inactive,,
CBMC OP INFUSION 2FL,40549,"Litvak, Anna M, MD",3/17/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/17/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,72843,"Lee, Patrick C, MD",5/22/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/22/2025,Active,"Malignant neoplasm of head of pancreas (CMS/HCC)
Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,70133,"Lee, Patrick C, MD",7/22/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,7/18/2024,Inactive,,
MMC OP VP INFUSION,5850,"Cohen, Seth D, MD",2/14/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,2/14/2024,Inactive,,
MMC OP VP INFUSION,68042,"Cohen, Seth D, MD",5/31/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/29/2024,Active,,
NBI OP INFUSION,94540,"Anderson, Patrick S, MD",11/13/2023,Liposomal DOXOrubicin 28 Day Cycles - Endometrial adenocarcinoma,_3. Third Line,11/12/2023,Inactive,,
NBI OP INFUSION,94540,"Anderson, Patrick S, MD",12/21/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_4. Fourth Line,12/20/2023,Inactive,,
NBI OP INFUSION,94540,"Anderson, Patrick S, MD",10/10/2024,Dostarlimab-gxly  42 Day Cycles-  Endometrial  Cancer,_4. Fourth Line,9/25/2024,Inactive,,
CINJ OP INFUSION,3504,"Weiss, Sarah, MD",12/9/2024,CINJ 092402 Arm A Fianlimab and Cemiplimab 21 Day Cycles Research- Melanoma,_1. First Line,12/9/2024,Active,,
NBR BMSCH 2 PED HEMONC,4728,"Botwinick, Marissa, DO",8/31/2023,AALL1732 Induction,Induction,8/31/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,4728,"Botwinick, Marissa, DO",10/19/2023,Dosing per PEDS AALL1731 (Bridge therapy),Adjuvant,10/19/2023,Inactive,,
CINJ PEDS HEMONC ,4728,"Botwinick, Marissa, DO",1/11/2024,AALL1732 Consolidation,_1. First Line,1/11/2024,Inactive,,
CINJ PEDS HEMONC ,4728,"Botwinick, Marissa, DO",3/29/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,3/14/2024,Inactive,,
CINJ PEDS HEMONC ,4728,"Drachtman, Richard, MD",7/18/2024,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy: Delayed Intensification",_1. First Line,7/18/2024,Inactive,,
CINJ OP INFUSION,40571,"Haigentz, Missak, MD",9/18/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,9/18/2023,Inactive,,
CINJ OP INFUSION,40571,"Haigentz, Missak, MD",11/15/2023,Nivolumab 480 mg D1 28 Day Cycles- Head and Neck Cancers,_1. First Line,11/15/2023,Inactive,,
NBR CINJ OP INFUSION,15391,"Shah, Mansi R, MD",6/5/2023,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,6/4/2023,Inactive,,
NBR 5N ONCOLOGY,15391,"Shah, Mansi R, MD",7/27/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,7/26/2023,Inactive,,
NBR CINJ OP INFUSION,15391,"Shah, Mansi R, MD",2/15/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_6. Sixth Line,2/7/2024,Inactive,,
SOM OUTPT INFUSION,46812,"Patel, Eshan, MD",4/4/2023,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,3/28/2023,Active,,
CBMC OP INFUSION 2FL,58457,"Litvak, Anna M, MD",11/17/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,58457,"Litvak, Anna M, MD",1/12/2024,Gemcitabine 28 Day Cycles - Breast,_4. Fourth Line,1/11/2024,Inactive,,
CBMC OP INFUSION 2FL,58457,"Ligresti, Louise G, MD",4/5/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_5. Fifth Line,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,58457,"Ligresti, Louise G, MD",4/5/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_5. Fifth Line,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,58457,"Ligresti, Louise G, MD",5/1/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_6. Sixth Line,5/1/2024,Inactive,,
CINJ OP INFUSION,58457,"Goel, Sanjay, MD",8/26/2024,CINJ 052401 Part A Escalation GIM-122,_7. Seventh Line,8/26/2024,Inactive,,
CBMC OP INFUSION 2FL,58457,"Litvak, Anna M, MD",12/17/2024,EriBULin 21 Day Cycles - Breast,_5. Fifth Line,12/16/2024,Active,,
CBMC OP INFUSION 2FL,81746,"Litvak, Anna M, MD",4/25/2025,VinORELBine 21 Day Cycles - Breast,_1. First Line,4/25/2025,Inactive,"Triple negative breast cancer (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Chemotherapy induced neutropenia (CMS/HCC)","C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; D70.1 - Agranulocytosis secondary to cancer chemotherapy; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.421 - Hormone receptor negative with human epidermal growth factor receptor 2 negative status; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC OP INFUSION 2FL,81746,"Litvak, Anna M, MD",4/4/2025,EriBULin 21 Day Cycles - Breast,_1. First Line,4/4/2025,Inactive,"Triple negative breast cancer (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Chemotherapy induced neutropenia (CMS/HCC)","C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; C50.811 - Malignant neoplasm of overlapping sites of right female breast; D70.1 - Agranulocytosis secondary to cancer chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC OP INFUSION 2FL,81746,"Litvak, Anna M, MD",4/4/2025,VinORELBine 21 Day Cycles - Breast,_5. Fifth Line,4/4/2025,Inactive,"Triple negative breast cancer (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Chemotherapy induced neutropenia (CMS/HCC)",
CINJ OP INFUSION,15696,"Mayer, Tina M, MD",4/16/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,4/16/2024,Active,,
NBI OP INFUSION,25557,"Schleicher, Lori, MD",1/18/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,1/18/2024,Active,,
MMC OP INFUSION,93382,"Meghal, Trishala, MD",3/8/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,,3/7/2023,Inactive,,
MMC OP INFUSION,93382,"Meghal, Trishala, MD",5/31/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,,5/25/2023,Inactive,,
MMC OP INFUSION,93382,"Meghal, Trishala, MD",6/7/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,6/7/2023,Inactive,,
MMC OP INFUSION,93382,"Meghal, Trishala, MD",12/21/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,12/21/2023,Inactive,,
CINJ OP INFUSION,78164,"George, Mridula A, MD",2/3/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,2/2/2023,Inactive,,
CINJ OP INFUSION,78164,"George, Mridula A, MD",10/25/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,10/25/2023,Active,,
TRMC TCCC OP INFUSION,97231,"Salerno, Vincent E, MD",9/5/2024,"Ramucirumab D1, D15/PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,9/4/2024,Inactive,,
CINJ OP INFUSION,35824,"Toppmeyer, Deborah L, MD",4/29/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Neoadjuvant,4/26/2024,Active,,
NBR 4N ONCOLOGY,5257,"Egini, Ogechukwu, MD",4/5/2025,BMT Allogeneic TBF +Abatacept +Post Cy 40mg/kg (Reduced Intensity),_2. Second Line,3/22/2025,Active,"MDS/MPN (myelodysplastic/myeloproliferative neoplasms) (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
NBR 4N ONCOLOGY,5257,"Egini, Ogechukwu, MD",3/14/2025,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_2. Second Line,3/13/2025,Inactive,"MDS/MPN (myelodysplastic/myeloproliferative neoplasms) (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
SOM OUTPT INFUSION,5111,"Yin, Faye, MD",5/16/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,4/30/2024,Active,,
MMC OP INFUSION,62192,"Lee, Patrick C, MD",6/13/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,5/29/2023,Inactive,,
SOM OUTPT INFUSION,68191,"Patel, Eshan, MD",11/1/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/23/2024,Active,,
NBR 5N ONCOLOGY,60881,"Palmisiano, Neil David, MD",5/16/2023,ECOG - ACRIN E1910 (Step 1) Induction - Acute Lymphoblastic Leukemia,First Line,5/16/2023,Inactive,,
NBR CINJ OP INFUSION,60881,"Palmisiano, Neil David, MD",6/28/2023,HyperCVAD + RiTUXimab (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate / RiTUXimab) - Acute Lymphoblastic Leukemia,,6/27/2023,Inactive,,
NBR 5N ONCOLOGY,60881,"Palmisiano, Neil David, MD",8/15/2023,HyperCVAD (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate) - Acute Lymphoblastic Leukemia,,8/14/2023,Inactive,,
NBR CINJ OP INFUSION,60881,"Palmisiano, Neil David, MD",12/7/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,Consolidation,12/7/2023,Active,,
NBR CINJ OP INFUSION,60881,"Palmisiano, Neil David, MD",12/7/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,12/7/2023,Inactive,,
NBR 5N ONCOLOGY,60881,"Palmisiano, Neil David, MD",2/4/2024,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,Consolidation,2/4/2024,Inactive,,
MMC OP INFUSION,62869,"Lee, Patrick C, MD",9/17/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,9/16/2024,Active,,
CINJ OP INFUSION,52562,"Tiger, Yun Kyoung, MD",2/3/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,2/3/2025,Inactive,Mediastinal mass,"C85.22 - Mediastinal (thymic) large b-cell lymphoma, intrathoracic lymph nodes; J96.01 - Acute respiratory failure with hypoxia; I31.4 - Cardiac tamponade; Z99.11 - Dependence on respirator (ventilator) status; I31.39 - Other pericardial effusion (noninflammatory); J90 - Pleural effusion, not elsewhere classified; D70.9 - Neutropenia, unspecified; Z11.52 - Encounter for screening for COVID-19; F19.10 - Other psychoactive substance abuse, uncomplicated; J45.909 - Unspecified asthma, uncomplicated; R63.4 - Abnormal weight loss; K76.9 - Liver disease, unspecified; B34.8 - Other viral infections of unspecified site; R49.0 - Dysphonia; R20.2 - Paresthesia of skin; R61 - Generalized hyperhidrosis; E16.2 - Hypoglycemia, unspecified; J38.3 - Other diseases of vocal cords; R59.0 - Localized enlarged lymph nodes; K12.0 - Recurrent oral aphthae; K12.1 - Other forms of stomatitis; K59.00 - Constipation, unspecified; Z88.5 - Allergy status to narcotic agent; Z88.6 - Allergy status to analgesic agent; Z98.1 - Arthrodesis status; Z68.26 - Body mass index (BMI) 26.0-26.9, adult; Z79.891 - Long term (current) use of opiate analgesic; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z78.1 - Physical restraint status"
NBR 5N ONCOLOGY,52562,"Tiger, Yun Kyoung, MD",2/18/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,2/18/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.32 - Diffuse large b-cell lymphoma, intrathoracic lymph nodes; I21.A1 - Myocardial infarction type 2; K76.89 - Other specified diseases of liver; G25.3 - Myoclonus; E03.9 - Hypothyroidism, unspecified; J21.9 - Acute bronchiolitis, unspecified; R56.9 - Unspecified convulsions; J98.4 - Other disorders of lung; H53.2 - Diplopia; K59.00 - Constipation, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z88.5 - Allergy status to narcotic agent; Z91.018 - Allergy to other foods; Z91.048 - Other nonmedicinal substance allergy status; Z88.6 - Allergy status to analgesic agent; Z90.49 - Acquired absence of other specified parts of digestive tract; Z98.1 - Arthrodesis status; Z11.52 - Encounter for screening for COVID-19"
MMC OP VP INFUSION,75486,"Talwar, Sumit, MD",8/8/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/24/2023,Inactive,,
CINJ OP INFUSION,50362,"Weiss, Sarah, MD",1/8/2025,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,1/7/2025,Active,,
HAM OP INFUSION,4150,"Yogarajah, Meera, MD",1/23/2023,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,First Line,1/15/2023,Inactive,,
CBMC OP INFUSION 2FL,74911,"Scoppetuolo, Michael, MD",3/20/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/21/2024,Inactive,,
CBMC OP INFUSION 2FL,74911,"Scoppetuolo, Michael, MD",7/30/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_3. Third Line,7/15/2024,Inactive,,
CMC OP INFUSION,13211,"Taff, Jessica, MD",9/19/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,9/17/2023,Inactive,,
CINJ OP INFUSION,70255,"Weiss, Sarah, MD",9/13/2023,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,First Line,9/13/2023,Inactive,,
CINJ OP INFUSION,70255,"Weiss, Sarah, MD",1/24/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,1/23/2024,Inactive,,
CINJ OP INFUSION,70255,"Weiss, Sarah, MD",5/8/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_3. Third Line,5/7/2024,Active,,
CBMC OP INFUSION 2FL,32953,"Brown, Andrew Bennett, MD",9/17/2024,Pembrolizumab / Cetuximab 21 Day Cycles- Head and Neck Cancers,_1. First Line,9/10/2024,Active,,
SOM OUTPT INFUSION,84046,"Patel, Eshan, MD",1/30/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,1/29/2025,Active,,
JCMC CP INFUSION,69244,"Cruz, Allan Louie E, MD",3/26/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Endometrial Serous Carcinoma,Adjuvant,3/26/2025,Active,Primary serous adenocarcinoma of endometrium (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; G60.8 - Other hereditary and idiopathic neuropathies
EMH HEM ONC,36123,"Yin, Faye, MD",2/23/2023,"PACLitaxel D1, D15 28 Day Cycles - Breast",First Line,2/22/2023,Inactive,,
CINJ OP INFUSION,36123,"Toppmeyer, Deborah L, MD",3/7/2023,Sacituzumab Govitecan 21 Day Cycles - Breast,Second Line,3/5/2023,Inactive,,
CINJ OP INFUSION,36123,"Toppmeyer, Deborah L, MD",5/2/2023,EriBULin 21 Day Cycles - Breast,Third Line,5/1/2023,Inactive,,
NBR CINJ OP INFUSION,46222,"Palmisiano, Neil David, MD",2/14/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),Induction,2/14/2024,Inactive,,
NBR 4N ONCOLOGY,46222,"Matasar, Matthew J, MD",2/27/2024,Gemtuzumab Ozogamicin Induction and Consolidation 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,2/27/2024,Inactive,,
NBR CINJ OP INFUSION,46222,"Palmisiano, Neil David, MD",3/25/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,3/25/2024,Active,"Encounter for adjustment and management of vascular access device
Multiple myeloma not having achieved remission (CMS/HCC)
Coagulation defect, unspecified (CMS/HCC)",
CINJ OP INFUSION,73694,"Jang, Thomas L, MD",8/6/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,8/5/2024,Inactive,,
CINJ OP INFUSION,73694,"Jang, Thomas L, MD",1/10/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,1/9/2025,Active,,
MMC OP VP INFUSION,54493,"Cohen, Seth D, MD",2/15/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Third Line,2/14/2023,Inactive,,
CINJ OP INFUSION,27240,"Ghodoussipour, Saum Bobak, MD",3/15/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,3/15/2023,Inactive,,
CINJ OP INFUSION,27240,"Ghodoussipour, Saum Bobak, MD",6/28/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,6/28/2023,Inactive,,
MMC OP VP INFUSION,90881,"Cohen, Seth D, MD",5/19/2025,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,_1. First Line,5/19/2025,Active,Bladder cancer metastasized to pelvic region (CMS/HCC),C67.9 - Urothelial carcinoma of bladder (CMS/HCC)
CINJ OP INFUSION,69805,"Haigentz, Missak, MD",12/22/2023,CINJ 032003 PACLitaxel / CARBOplatin + Pembrolizumab 21 Day Cycle CYCLE 1 Groups A/B Research- Non-Small Cell Lung Cancer,Induction,12/22/2023,Inactive,,
CINJ OP INFUSION,69805,"Haigentz, Missak, MD",3/27/2024,CINJ 032003 Post RT Pembrolizumab + Olaparib / Placebo 21 Day Cycles Group A Research- Non-Small Cell Lung Cancer,Consolidation,3/26/2024,Active,,
CBMC OP INFUSION 2FL,77452,"Dharmapuri, Sirish, MD",12/23/2024,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,12/19/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
MMC OP VP INFUSION,85294,"Lee, Patrick C, MD",6/27/2023,CISplatin (Recurrent/Metastatic) 21 Day Cycles- Head and Neck Cancers,Induction,6/14/2023,Inactive,,
CINJ OP INFUSION,65840,"Gulhati, Prateek, MD PhD",2/2/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,2/1/2023,Inactive,,
CINJ OP INFUSION,31344,"Haigentz, Missak, MD",6/10/2024,CINJ 032212 COHORT 6 AMIVANTAMAB / LAZERTINIB PATIENTS 28 DAY CYCLES RESEARCH- NON-SMALL CELL LUNG CANCERS,_1. First Line,6/7/2024,Active,,
MMC OP VP INFUSION,47254,"Lee, Patrick C, MD",1/4/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/15/2023,Inactive,,
CBMC OP INFUSION 2FL,13570,"Raptis, George, MD",6/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/3/2024,Inactive,,
CBMC OP INFUSION 2FL,13570,"Raptis, George, MD",7/30/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,7/29/2024,Inactive,,
NBR CINJ OP INFUSION,76278,"Tiger, Yun Kyoung, MD",7/5/2024,Daratumumab and Hyaluronidase-fihj / Carfilzomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,6/27/2024,Inactive,,
NBR CINJ OP INFUSION,76278,"Tiger, Yun Kyoung, MD",8/29/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/28/2024,Inactive,,
NBR CINJ OP INFUSION,76278,"Egini, Ogechukwu, MD",10/18/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,_1. First Line,10/2/2024,Active,,
NBR CINJ OP INFUSION,76278,"Tiger, Yun Kyoung, MD",3/28/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,3/28/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,76278,"Tiger, Yun Kyoung, MD",3/28/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone Maintenance 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,3/28/2025,Active,"Multiple myeloma not having achieved remission (CMS/HCC)
CKD (chronic kidney disease)",
CMC OP INFUSION,25260,"Pompa, Tiffany Ann, MD",7/17/2024,Capecitabine 21 Day Cycles - Breast,_5. Fifth Line,7/17/2024,Active,,
CINJ OP INFUSION,59071,"Aikins, James K, MD",6/21/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,6/7/2023,Inactive,,
SOM OUTPT INFUSION,58570,"Patel, Eshan, MD",12/20/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,12/16/2024,Active,,
SOM OUTPT INFUSION,87391,"Patel, Eshan, MD",2/26/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,2/19/2025,Active,Invasive ductal carcinoma of breast (CMS/HCC),
MMC OP INFUSION,92067,"Lee, Patrick C, MD",1/28/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/27/2025,Active,Marginal zone lymphoma (CMS/HCC),
MMC OP INFUSION,45444,"Lee, Patrick C, MD",5/20/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,5/20/2025,Active,Malignant neoplasm of female breast (CMS/HCC),
CINJ OP INFUSION,1118,"Leiser, Aliza, MD",6/17/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,6/16/2024,Inactive,,
CINJ OP INFUSION,1118,"Leiser, Aliza, MD",7/30/2024,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,7/23/2024,Active,,
CBMC OP INFUSION 2FL,43878,"Leitner, Stuart P, MD",8/28/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/28/2023,Active,,
CINJ OP INFUSION,49820,"George, Mridula A, MD",7/12/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,7/9/2024,Active,,
CINJ OP INFUSION,49820,"George, Mridula A, MD",2/26/2025,Abemaciclib 28 Day Cycles - Breast,Adjuvant,2/26/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)","C50.811, Z17.0 - Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor positive (CMS/HCC)"
NBR CINJ OP INFUSION,92585,"Chen, Xiaoyi",11/18/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,11/17/2024,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
JCMC CP INFUSION,10712,"Sekhri, Arunabh, MD",1/3/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/2/2024,Inactive,,
JCMC CP INFUSION,10712,"Sekhri, Arunabh, MD",4/10/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,3/26/2024,Active,"Breast cancer, stage 4 (CMS/HCC)",
CBMC OP INFUSION 2FL,77959,"Brown, Andrew Bennett, MD",11/6/2023,Bevacizumab Maintenance 21 Day Cycles- GBM,Adjuvant,11/5/2023,Active,,
CINJ OP INFUSION,31834,"Leiser, Aliza, MD",12/28/2023,CISplatin 21 Day Cycles - Cervical,_1. First Line,12/27/2023,Inactive,,
CINJ OP INFUSION,89112,"Leiser, Aliza, MD",12/28/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Neoadjuvant,12/27/2023,Inactive,,
CINJ OP INFUSION,89112,"Leiser, Aliza, MD",1/2/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,20136,"Wagmiller, Jennifer Ann, MD",1/31/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,1/30/2024,Inactive,,
CBMC OP INFUSION 2FL,20136,"Wagmiller, Jennifer Ann, MD",8/16/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,8/15/2024,Inactive,,
CBMC OP INFUSION 2FL,20136,"Wagmiller, Jennifer Ann, MD",9/6/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/5/2024,Active,,
CINJ OP INFUSION,20124,"Jang, Thomas L, MD",3/21/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,3/21/2025,Active,Urothelial cancer (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; C68.9 - Malignant neoplasm of urinary organ, unspecified"
SOM OUTPT INFUSION,39431,"Patel, Eshan, MD",10/24/2023,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,10/24/2023,Inactive,,
CBMC OP INFUSION 2FL,91866,"Radovich, Delia, MD",12/8/2023,Sacituzumab Govitecan 21 Day Cycles - Bladder,_2. Second Line,12/7/2023,Inactive,,
CBMC OP INFUSION 2FL,91866,"Ligresti, Louise G, MD",8/5/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,8/5/2024,Inactive,,
CBMC OP INFUSION 2FL,91866,"Ligresti, Louise G, MD",9/3/2024,EriBULin 21 Day Cycles - Breast,_3. Third Line,8/28/2024,Active,,
CBMC OP INFUSION 2FL,91866,"Ligresti, Louise G, MD",3/7/2025,Gemcitabine 28 Day Cycles - Breast,_4. Fourth Line,3/6/2025,Active,"Estrogen receptor negative status (ER-)
Malignant neoplasm of upper-inner quadrant of right female breast (CMS/HCC)
Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes (CMS/HCC)",
CINJ OP INFUSION,32432,"Toppmeyer, Deborah L, MD",1/27/2025,Palbociclib 28 Day Cycles - Breast,_2. Second Line,1/27/2025,Active,,
CINJ OP INFUSION,98483,"Hochster, Howard S, MD",2/1/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,1/23/2023,Inactive,,
NBR 4N ONCOLOGY,37677,"Palmisiano, Neil David, MD",9/15/2024,Cytarabine (200 mg/m2) / DAUNOrubicin (60 mg/m2) (7 + 3) - Acute Myeloid Leukemia (Induction),Induction,9/15/2024,Inactive,,
NBR CINJ OP INFUSION,37677,"Palmisiano, Neil David, MD",11/13/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,11/13/2024,Active,,
CINJ PEDS HEMONC ,76095,"Moerdler, Scott, MD",6/18/2024,PEDS Carboplatin - Low Grade Glioma,_1. First Line,6/10/2024,Active,,
CINJ PEDS HEMONC ,6049,"Moerdler, Scott, MD",7/20/2024,PEDS VDC/IE extrapolated from AEWS0031,_1. First Line,7/19/2024,Active,,
CINJ PEDS HEMONC ,6049,"Moerdler, Scott, MD",10/11/2024,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_1. First Line,10/9/2024,Inactive,,
NBR CINJ OP INFUSION,3932,"Doraiswamy, Anupama, MD",3/6/2023,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,First Line,3/6/2023,Active,,
CINJ OP INFUSION,87244,"Groisberg, Roman, MD",1/6/2023,DOXOrubicin 21 Day Cycles - Sarcoma,First Line,1/5/2023,Inactive,,
CINJ OP INFUSION,69080,"Leiser, Aliza, MD",5/5/2023,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,,5/3/2023,Inactive,,
CINJ OP INFUSION,69080,"Leiser, Aliza, MD",11/30/2023,Ifosfamide / Mesna 21 Day Cycles - Sarcoma,_3. Third Line,11/29/2023,Inactive,,
CINJ OP INFUSION,69080,"Leiser, Aliza, MD",2/15/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_5. Fifth Line,2/11/2024,Inactive,,
NBR 5N ONCOLOGY,69080,"Leiser, Aliza, MD",4/22/2024,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,_6. Sixth Line,4/15/2024,Inactive,,
CINJ OP INFUSION,69080,"Leiser, Aliza, MD",7/17/2024,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_4. Fourth Line,6/26/2024,Inactive,,
CINJ OP INFUSION,69080,"Leiser, Aliza, MD",9/16/2024,PAZOPanib 30 Day Cycles - Uterine Sarcoma,_8. Eighth Line,9/16/2024,Inactive,,
SOM OUTPT INFUSION,63601,"Patel, Eshan, MD",11/2/2023,Amivantamab-vmjw Patients >/= 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/1/2023,Inactive,,
CINJ OP INFUSION,26959,"Aikins, James K, MD",6/30/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,6/29/2023,Inactive,,
CINJ OP INFUSION,26959,"Aikins, James K, MD",1/18/2024,CINJ 102310 Cohort B MK-4280A or Pembrolizumab / Lenvatinib 21 Day Cycles Research Solid Tumors,_2. Second Line,1/17/2024,Active,,
MMC OP VP INFUSION,87916,"Lee, Patrick C, MD",4/28/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Maintenance,4/26/2023,Active,,
MMC OP VP INFUSION,94182,"Meghal, Trishala, MD",5/8/2023,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Second Line,5/7/2023,Inactive,,
MMC OP VP INFUSION,94182,"Meghal, Trishala, MD",12/4/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,12/1/2024,Active,,
MMC OP VP INFUSION,89681,"Cohen, Seth D, MD",8/7/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",First Line,7/9/2023,Inactive,,
NBR CINJ OP INFUSION,28928,"Shah, Mansi R, MD",3/28/2023,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,,3/27/2023,Inactive,,
NBR CINJ OP INFUSION,28928,"Shah, Mansi R, MD",4/4/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,3/27/2023,Inactive,,
NBR CINJ OP INFUSION,28928,"Shah, Mansi R, MD",5/7/2023,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,,5/3/2023,Inactive,,
NBR CINJ OP INFUSION,28928,"Shah, Mansi R, MD",5/25/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,28928,"Shah, Mansi R, MD",6/1/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,5/24/2023,Inactive,,
NBR CINJ OP INFUSION,28928,"Schaar, Dale, MD PhD",6/24/2024,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,6/23/2024,Inactive,,
CINJ OP INFUSION,40212,"Mayer, Tina M, MD",10/1/2024,Pembrolizumab 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,9/22/2024,Inactive,,
NBR CINJ OP INFUSION,44139,"Shah, Mansi R, MD",4/15/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,4/15/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
SOM OUTPT INFUSION,66331,"Patel, Eshan, MD",11/19/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/18/2024,Active,,
SOM 1PAV ONCOLOGY,86822,"Patel, Eshan, MD",3/10/2025,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_2. Second Line,3/10/2025,Inactive,"Adenocarcinoma of pancreas, stage 4 (CMS/HCC)","C25.7 - Malignant neoplasm of other parts of pancreas; D61.810 - Antineoplastic chemotherapy induced pancytopenia; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; E43 - Unspecified severe protein-calorie malnutrition; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified; K31.1 - Adult hypertrophic pyloric stenosis; D73.5 - Infarction of spleen; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; E11.65 - Type 2 diabetes mellitus with hyperglycemia; D50.9 - Iron deficiency anemia, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C78.89 - Secondary malignant neoplasm of other digestive organs; I35.1 - Nonrheumatic aortic (valve) insufficiency; F41.9 - Anxiety disorder, unspecified; E87.6 - Hypokalemia; F12.90 - Cannabis use, unspecified, uncomplicated; Z68.20 - Body mass index (BMI) 20.0-20.9, adult; K57.30 - Diverticulosis of large intestine without perforation or abscess without bleeding; Z60.3 - Acculturation difficulty; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K21.9 - Gastro-esophageal reflux disease without esophagitis; K59.00 - Constipation, unspecified; Z88.0 - Allergy status to penicillin; Z98.890 - Other specified postprocedural states; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.42 - Family history of malignant neoplasm of prostate"
CINJ OP INFUSION,34529,"Weiss, Sarah, MD",6/26/2023,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,6/26/2023,Inactive,,
CINJ OP INFUSION,34529,"Weiss, Sarah, MD",8/25/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,8/24/2023,Active,,
JCMC CP INFUSION,38647,"Sekhri, Arunabh, MD",4/12/2024,Pembrolizumab 42 Day Cycles - Endometrial Cancer Stage IVB,_1. First Line,3/31/2024,Active,,
CBMC OP INFUSION 2FL,19221,"Litvak, Anna M, MD",11/2/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,19221,"Litvak, Anna M, MD",12/28/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,12/27/2023,Active,,
JCMC CP INFUSION,68303,"Cruz, Allan Louie E, MD",5/3/2023,Pembrolizumab 21 Day Cycles - Cervical,First Line,5/2/2023,Inactive,,
JCMC CP INFUSION,68303,"Cruz, Allan Louie E, MD",7/5/2023,Pembrolizumab 42 Day Cycles - Cervical,Maintenance,7/5/2023,Inactive,,
NBR 4N ONCOLOGY,68303,"Girda, Eugenia, MD",11/22/2023,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_2. Second Line,11/20/2023,Inactive,,
MMC OP VP INFUSION,30387,"Meghal, Trishala, MD",5/7/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,4/29/2024,Inactive,,
MMC OP VP INFUSION,30387,"Meghal, Trishala, MD",5/14/2024,CINJ 042301 Nab-PACLitaxel 28 Day Cycles Research- Breast Cancer,Adjuvant,5/13/2024,Inactive,,
MMC OP VP INFUSION,30387,"Meghal, Trishala, MD",8/13/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,8/1/2024,Active,,
CMC OP INFUSION,87616,"Taff, Jessica, MD",5/9/2023,Nivolumab 28 Day Cycles - Melanoma,First Line,5/8/2023,Inactive,,
JCMC CP INFUSION,36540,"Sekhri, Arunabh, MD",5/5/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/5/2025,Inactive,Adenocarcinoma (CMS/HCC),
NBR CINJ OP INFUSION,75176,"Braunschweig, Ira, MD",2/8/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,,2/7/2023,Inactive,,
CBMC OP INFUSION 2FL,87995,"Leitner, Stuart P, MD",9/8/2023,Avelumab 14 Day Cycles - Merkel Cell Carcinoma,_1. First Line,9/7/2023,Active,,
CBMC OP INFUSION 2FL,40944,"Dharmapuri, Sirish, MD",2/26/2025,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/25/2025,Active,Malignant ascites,C25.0 - Malignant neoplasm of head of pancreas; R18.0 - Malignant ascites
CBMC OP INFUSION 2FL,40944,"Wagmiller, Jennifer Ann, MD",3/10/2025,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,3/10/2025,Active,"Malignant ascites
Other abnormal tumor markers
Anemia associated with chemotherapy",
CINJ OP INFUSION,76546,"George, Mridula A, MD",12/6/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/5/2024,Active,Malignant neoplasm of left female breast (CMS/HCC),
CINJ OP INFUSION,76546,"George, Mridula A, MD",12/27/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,11/29/2024,Active,,
MMC OP INFUSION,47686,"Lee, Patrick C, MD",9/7/2023,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,9/6/2023,Inactive,,
CINJ OP INFUSION,85294,"Weiss, Sarah, MD",8/2/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,8/1/2023,Inactive,,
CINJ OP INFUSION,85294,"Stephenson, Ryan D, DO",8/15/2023,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,Second Line,8/15/2023,Inactive,,
CINJ OP INFUSION,85294,"Weiss, Sarah, MD",7/2/2024,Pembrolizumab / Lenvatinib 21 Day Cycles - Melanoma,_4. Fourth Line,6/19/2024,Inactive,,
CINJ OP INFUSION,75250,"Patel, Eshan, MD",6/10/2024,CINJ 032204 Dose Escalation Dose Level 3 Ipatasertib / Cisplatin Weekly 28 Day Cycles Research- Head and Neck Cancers,Induction,6/9/2024,Active,,
CINJ OP INFUSION,20774,"Saraiya, Biren P, MD",12/16/2024,CISplatin Weekly with Concurrent Radiation-  High grade Neuroendocrine,Induction,12/13/2024,Active,,
CBMC OP INFUSION 2FL,65676,"Litvak, Anna M, MD",4/3/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,4/3/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C50.112 - Malignant neoplasm of central portion of left female breast; Z11.59 - Encounter for screening for other viral diseases; Z17.0 - Estrogen receptor positive status (ER+)
MSC OP INFUSION,27326,"Cohen, Seth D, MD",12/3/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_2. Second Line,12/2/2024,Active,,
MMC OP VP INFUSION,94361,"Cohen, Seth D, MD",5/8/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles +Velcade monthly (DVd started 8/17/20),First Line,5/8/2023,Active,,
CINJ OP INFUSION,52520,"Dasgeb, Bahar, MD",2/1/2023,Nivolumab 28 Day Cycles - Melanoma,Third Line,1/17/2023,Inactive,,
CINJ OP INFUSION,52520,"Dasgeb, Bahar, MD",1/8/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,1/1/2024,Inactive,,
NBR 5N ONCOLOGY,47737,"Matasar, Matthew J, MD",5/17/2023,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),,5/17/2023,Inactive,,
NBR CINJ OP INFUSION,47737,"Shah, Mansi R, MD",6/6/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,6/5/2023,Inactive,,
CMC OP INFUSION,10717,"Eltoukhy, Hussam, MD",5/30/2024,RiTUXimab 28 Day Cycle,_1. First Line,5/14/2024,Active,Malignant neoplasm of ovary (CMS/HCC),
CBMC 2W ONCOLOGY,62646,"Grossman, I Robert, MD",4/11/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,4/10/2024,Inactive,,
CBMC 2W ONCOLOGY,38354,"Grossman, I Robert, MD",5/11/2024,Hydroxyurea 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,5/11/2024,Active,,
CBMC 2W ONCOLOGY,38354,"McKenna, Marshall, MD",9/13/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,9/11/2024,Active,,
NBR 4N ONCOLOGY,42838,"Saraiya, Biren P, MD",2/11/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,2/10/2023,Inactive,,
CBMC OP INFUSION 2FL,48927,"Brown, Andrew Bennett, MD",2/26/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,2/25/2024,Inactive,,
CINJ OP INFUSION,6365,"Toppmeyer, Deborah L, MD",10/26/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,10/23/2023,Active,,
CINJ OP INFUSION,75055,"George, Mridula A, MD",4/14/2023,Palbociclib 28 Day Cycles - Breast,First Line,4/14/2023,Inactive,,
CBMC OP INFUSION 2FL,53477,"Wagmiller, Jennifer Ann, MD",3/17/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/17/2025,Active,Malignant neoplasm of bilateral ovaries (CMS/HCC),
MMC OP VP INFUSION,18340,"Cohen, Seth D, MD",10/7/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,10/6/2024,Active,,
CMC OP INFUSION,85918,"Talwar, Sumit, MD",8/21/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/21/2023,Active,,
CBMC OP INFUSION 2FL,38166,"Scoppetuolo, Michael, MD",12/16/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,12/8/2024,Active,,
NBI OP INFUSION,45070,"Shah, Shailja S, MD",10/17/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,10/16/2023,Active,,
CBMC OP INFUSION 2FL,8319,"Radovich, Delia, MD",11/16/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,11/15/2023,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,76524,"Anderson, Patrick S, MD",11/14/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar/ Groin,_1. First Line,11/13/2024,Active,,
JCMC CP INFUSION,37272,"Cruz, Allan Louie E, MD",8/17/2023,Pembrolizumab 42 Day Cycles- Gastrointestinal Cancers,Second Line,4/10/2023,Inactive,,
SOM OUTPT INFUSION,42915,"Toomey, Kathleen C, MD",4/20/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/6/2023,Inactive,,
CINJ OP INFUSION,52843,"Mayer, Tina M, MD",10/15/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,10/15/2024,Active,,
CINJ OP INFUSION,33785,"Boland, Patrick M, MD",5/26/2023,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,,5/26/2023,Active,"Adenocarcinoma, appendix (CMS/HCC)",
HAM OP INFUSION,18425,"Patel, Malini M, MD",10/10/2023,"Gemcitabine 1000 mg/m2 D1, D8/ CISplatin 80 mg/m2 D1 21 Day Cycles- Head and Neck Cancers",First Line,10/9/2023,Active,,
TRMC TCCC OP INFUSION,38544,"Salerno, Vincent E, MD",2/12/2025,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/11/2025,Active,Lung cancer (CMS/HCC),
TRMC TCCC OP INFUSION,38544,"Salerno, Vincent E, MD",5/8/2025,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/8/2025,Active,Lung cancer (CMS/HCC),
MMC OP VP INFUSION,33283,"Cohen, Seth D, MD",3/15/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,3/14/2023,Inactive,,
CINJ OP INFUSION,33813,"Toppmeyer, Deborah L, MD",1/13/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,1/12/2025,Active,,
CINJ OP INFUSION,33813,"Toppmeyer, Deborah L, MD",5/27/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,5/26/2025,Active,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",Z79.69 - On antineoplastic chemotherapy
CINJ OP INFUSION,33813,"Toppmeyer, Deborah L, MD",4/14/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Neoadjuvant,4/14/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
HAM OP INFUSION,89552,"Patel, Malini M, MD",8/14/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,8/12/2024,Active,,
MMC OP INFUSION,47894,"Meghal, Trishala, MD",3/29/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,,3/28/2023,Inactive,,
MMC OP INFUSION,47894,"Meghal, Trishala, MD",6/23/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,,6/22/2023,Inactive,,
MMC OP INFUSION,47894,"Meghal, Trishala, MD",6/23/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,6/23/2023,Inactive,,
MMC OP INFUSION,47894,"Meghal, Trishala, MD",8/4/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Neoadjuvant,8/4/2023,Inactive,,
HAM OP INFUSION,70537,"Patel, Malini M, MD",6/22/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,6/22/2023,Inactive,,
HAM OP INFUSION,70537,"Patel, Malini M, MD",9/25/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/22/2023,Inactive,,
CINJ OP INFUSION,12328,"Stephenson, Ryan D, DO",7/19/2023,CINJ 051709 BRCA1 / BRCA2 Mutations Pembrolizumab 200 mg IV D1 21 Day Cycles Research- Basket Trial for Advanced Solid Tumors,Third Line,7/18/2023,Inactive,,
NBI OP INFUSION,83967,"Snyder, Rose, MD",5/12/2025,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophosphamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintenance Q21 Days,_1. First Line,5/12/2025,Inactive,"Invasive ductal carcinoma of breast, female, left (CMS/HCC)","C50.912 - Malignant neoplasm of unspecified site of left female breast; N63.0 - Unspecified lump in unspecified breast; C50.112 - Malignant neoplasm of central portion of left female breast; R58 - Hemorrhage, not elsewhere classified; N64.89 - Other specified disorders of breast; D53.9 - Nutritional anemia, unspecified; R23.4 - Changes in skin texture; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures; Z17.1 - Estrogen receptor negative status (ER-)"
NBI OP INFUSION,83967,"Snyder, Rose, MD",5/12/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,5/12/2025,Active,"Invasive ductal carcinoma of breast, female, left (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C50.912 - Malignant neoplasm of unspecified site of left female breast; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures
NBI OP INFUSION,26091,"Anderson, Patrick S, MD",6/23/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,6/22/2023,Inactive,,
SOM OUTPT INFUSION,59624,"Toomey, Kathleen C, MD",6/7/2024,Capecitabine 21 Day Cycles - Breast,_5. Fifth Line,6/7/2024,Inactive,,
EMH HEM ONC,59624,"Toomey, Kathleen C, MD",8/23/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,8/7/2024,Inactive,,
SOM OUTPT INFUSION,59624,"Toomey, Kathleen C, MD",8/30/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_2. Second Line,8/29/2024,Active,,
SOM OUTPT INFUSION,59624,"Toomey, Kathleen C, MD",4/18/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/18/2025,Active,"Secondary malignant neoplasm of pleura (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
NBR CINJ OP INFUSION,55617,"Shah, Mansi R, MD",4/29/2025,Daratumumab and Hyaluronidase-fihj 28/Selinexor weekly/dex Day Cycles- Multiple Myeloma (STORM TRIAL),_8. Eighth Line,4/29/2025,Active,Multiple myeloma (CMS/HCC),
NBR CINJ OP INFUSION,39807,"Shah, Mansi R, MD",2/21/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/20/2023,Active,,
CINJ OP INFUSION,2141,"Haigentz, Missak, MD",10/4/2024,Cetuximab/CARBOplatin/Fluorouracil Continuous Infusion 21 Day Cycles- Head and Neck Cancers,_1. First Line,10/3/2024,Active,,
NBR CINJ OP INFUSION,61943,"Rhodes, Joanna Meehan, MD",2/27/2025,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,2/26/2025,Active,Hodgkin lymphoma of lymph nodes of multiple regions (CMS/HCC),
CINJ OP INFUSION,89292,"Hochster, Howard S, MD",5/1/2025,CINJ 072405 Arm B FOLFOX / Cetuximab 28 Day Cycles Research- Colorectal Cancer,_1. First Line,5/1/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
NBR 5N ONCOLOGY,91183,"Palmisiano, Neil David, MD",2/22/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,Consolidation,2/22/2023,Inactive,,
NBR CINJ OP INFUSION,91183,"Palmisiano, Neil David, MD",4/7/2023,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,,4/7/2023,Inactive,,
NBR 4N BMTU/IMCU,91183,"Patel, Vimal D, MD",6/2/2023,BMT Allogeneic Flu (D-7) / TBI + Post Cy - Myeloablative,,6/2/2023,Inactive,,
NBR 4N ONCOLOGY,82113,"Kennedy, Timothy, MD",10/16/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,10/16/2023,Inactive,,
NBR CINJ OP INFUSION,65280,"Evens, Andrew M, DO",7/12/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,7/11/2023,Inactive,,
NBR CINJ OP INFUSION,65280,"Evens, Andrew M, DO",11/8/2023,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,,11/8/2023,Active,"Squamous cell carcinoma of lung, left (CMS/HCC)
Malignant neoplasm of upper lobe of left lung (CMS/HCC)
Chronic fatigue",
NBR CINJ OP INFUSION,3458,"Tiger, Yun Kyoung, MD",1/31/2025,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,1/30/2025,Inactive,Follicular lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,3458,"Tiger, Yun Kyoung, MD",2/7/2025,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,2/4/2025,Active,Follicular lymphoma (CMS/HCC),"C82.90 - Follicular lymphoma, unspecified, unspecified site; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; R59.1 - Generalized enlarged lymph nodes"
CINJ OP INFUSION,83998,"Boland, Patrick M, MD",1/5/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,1/4/2023,Inactive,,
CINJ OP INFUSION,83998,"Boland, Patrick M, MD",6/2/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,Second Line,5/31/2023,Inactive,,
CINJ OP INFUSION,17232,"Groisberg, Roman, MD",5/19/2023,DOXOrubicin 21 Day Cycles - Sarcoma,First Line,5/18/2023,Inactive,,
NBR CINJ OP INFUSION,17232,"Patel, Eshan, MD",6/23/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,6/22/2023,Inactive,,
CINJ OP INFUSION,17232,"Patel, Eshan, MD",9/15/2023,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcomatoid squamous cell cancer ",,9/14/2023,Inactive,,
CINJ OP INFUSION,23569,"Berim, Lyudmyla, MD",3/21/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/19/2024,Inactive,,
NBR CINJ OP INFUSION,23569,"Berim, Lyudmyla, MD",5/14/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,5/10/2024,Active,,
CINJ OP INFUSION,23569,"Berim, Lyudmyla, MD",2/24/2025,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,2/17/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas (CMS/HCC)
NBI VALERIE FND HEMONC,81359,"Rao, Harini, MD",6/28/2024,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,6/28/2024,Inactive,,
NBI VALERIE FND HEMONC,81359,"Rao, Harini, MD",12/10/2024,CARBOplatin 21 Day Cycle- Head and Neck Cancers,_3. Third Line,12/9/2024,Inactive,,
NBI OP INFUSION,90270,"Cohen, Alice, MD",1/22/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,1/22/2024,Active,,
TRMC TCCC OP INFUSION,34565,"Capo, Gerardo, MD",8/27/2024,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,8/26/2024,Active,,
CINJ OP INFUSION,71396,"George, Mridula A, MD",4/25/2025,Abemaciclib 28 Day Cycles - Breast,Neoadjuvant,4/25/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor positive (CMS/HCC)",C50.112 - Malignant neoplasm of central portion of left female breast; Z79.811 - Long term (current) use of aromatase inhibitors; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,42009,"Grossman, I Robert, MD",5/21/2025,CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,5/21/2025,Active,Peripheral T cell lymphoma of lymph nodes of multiple sites (CMS/HCC),
CBMC OP INFUSION 2FL,78455,"Brown, Andrew Bennett, MD",1/21/2025,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,Induction,1/6/2025,Active,,
CBMC 2W ONCOLOGY,85343,"Brown, Andrew Bennett, MD",11/2/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/1/2023,Inactive,,
CBMC 2W ONCOLOGY,85343,"Brown, Andrew Bennett, MD",11/3/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,78693,"Dharmapuri, Sirish, MD",5/9/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/7/2025,Active,Colon cancer metastasized to lung (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; C18.5 - Malignant neoplasm of splenic flexure; C78.00 - Secondary malignant neoplasm of unspecified lung"
CINJ OP INFUSION,78839,"Ghodoussipour, Saum Bobak, MD",2/23/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,2/23/2023,Inactive,,
NBR CINJ OP INFUSION,26311,"Evens, Andrew M, DO",5/31/2023,Lymphodepletion Breyanzi with Fludarabine/Cyclophosphamide 9 Day Cycle - Non-Hodgkin's Lymphoma,Second Line,5/16/2023,Inactive,,
CINJ PEDS HEMONC ,87869,"Moerdler, Scott, MD",9/25/2023,Selumetinib (Koselugo) ,First Line,9/20/2023,Active,Adenocarcinoma of bile duct (CMS/HCC),
CBMC OP INFUSION 2FL,65423,"Leitner, Stuart P, MD",1/29/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/27/2025,Active,Primary cancer of left upper lobe of lung (CMS/HCC),
CINJ OP INFUSION,12463,"Stephenson, Ruth D, DO",8/11/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,8/6/2023,Inactive,,
CINJ OP INFUSION,12463,"Stephenson, Ruth D, DO",11/13/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/13/2023,Inactive,,
CINJ OP INFUSION,12463,"Stephenson, Ruth D, DO",5/1/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,4/30/2024,Active,,
CINJ OP INFUSION,12463,"Stephenson, Ruth D, DO",5/23/2024,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,5/23/2024,Inactive,,
CMC OP INFUSION,87009,"Talwar, Sumit, MD",4/19/2023,Pembrolizumab 21 Day Cycles- Gastrointestinal Cancers,Second Line,4/17/2023,Active,,
CMC OP INFUSION,71023,"Tang, Horace, MD",8/31/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,,8/31/2023,Inactive,,
NBI OP INFUSION,84670,"Schleicher, Lori, MD",5/29/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/29/2024,Active,,
MMC BBR2 ONCOLOGY,52820,"Lee, Patrick C, MD",12/1/2023,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 - Breast",_1. First Line,12/1/2023,Inactive,,
CINJ OP INFUSION,62220,"Stephenson, Ruth D, DO",9/23/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,9/13/2024,Inactive,,
CMC OP INFUSION,59317,"Taff, Jessica, MD",3/13/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,3/13/2025,Active,Endometrial carcinoma (CMS/HCC),
NBR 5N ONCOLOGY,55121,"Zayac, Adam, MD",10/4/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,10/4/2024,Inactive,,
NBR CINJ OP INFUSION,55121,"Zayac, Adam, MD",11/18/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,11/17/2024,Active,Hodgkin lymphoma (CMS/HCC),
CBMC OP INFUSION 2FL,91045,"Derosa, William T, DO",5/16/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,5/16/2025,Active,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission; I82.4Y1 - Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity; I82.551 - Chronic embolism and thrombosis of right peroneal vein
CMC OP INFUSION,38179,"Pompa, Tiffany Ann, MD",8/27/2024,Pembrolizumab 21 Day Cycles - Melanoma,Neoadjuvant,8/26/2024,Active,,
CINJ OP INFUSION,25187,"Mayer, Tina M, MD",5/24/2023,Apalutamide 30 Day Cycles - Prostate,,5/24/2023,Active,,
HAM OP INFUSION,50315,"Yogarajah, Meera, MD",6/27/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles - Breast,_1. First Line,6/23/2024,Inactive,,
HAM OP INFUSION,50315,"Yogarajah, Meera, MD",10/17/2024,Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles - Breast,_1. First Line,9/15/2024,Active,,
HAM OP INFUSION,50315,"Yogarajah, Meera, MD",5/9/2025,Capecitabine 21 Day Cycles - Breast,_2. Second Line,3/31/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,20136,"Brown, Andrew Bennett, MD",2/22/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,2/21/2024,Inactive,,
CBMC OP INFUSION 2FL,20136,"Brown, Andrew Bennett, MD",5/30/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/29/2024,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,20136,"Brown, Andrew Bennett, MD",7/12/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,7/11/2024,Inactive,,
CBMC OP INFUSION 2FL,9138,"Leitner, Stuart P, MD",11/7/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/5/2023,Inactive,,
CINJ OP INFUSION,14209,"Leiser, Aliza, MD",1/30/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,1/23/2023,Inactive,,
CINJ OP INFUSION,15609,"Ghodoussipour, Saum Bobak, MD",4/11/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,4/11/2023,Inactive,,
MSC OP INFUSION,75381,"Cohen, Seth D, MD",7/25/2023,Pembrolizumab 200 mg / Ipilimumab (1 mg/kg) 21 Day Cycles + Pembrolizumab 21 Day Cycles - Melanoma,Maintenance,7/25/2023,Inactive,,
NBR 4N ONCOLOGY,64198,"Rhodes, Joanna Meehan, MD",11/9/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,11/9/2023,Inactive,,
NBR CINJ OP INFUSION,64198,"Rhodes, Joanna Meehan, MD",11/24/2023,PEDS ANHL1131 R-da-EPOCH,_1. First Line,11/23/2023,Inactive,,
NBR 4N ONCOLOGY,64198,"Rhodes, Joanna Meehan, MD",12/4/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/1/2023,Inactive,,
MMC OP VP INFUSION,73288,"Cohen, Seth D, MD",6/16/2023,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,Maintenance,6/16/2023,Inactive,,
CINJ OP INFUSION,5398,"Berim, Lyudmyla, MD",7/13/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/3/2024,Inactive,,
NBR 5N ONCOLOGY,5398,"Berim, Lyudmyla, MD",10/21/2024,"Encorafenib + Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,10/20/2024,Inactive,,
CINJ OP INFUSION,31974,"Weiss, Sarah, MD",1/30/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,1/29/2023,Inactive,,
NBR 4N BMTU/IMCU,29612,"Braunschweig, Ira, MD",5/1/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,4/30/2023,Inactive,,
CBMC OP INFUSION 2FL,26954,"Radovich, Delia, MD",10/16/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/27/2023,Inactive,,
CBMC OP INFUSION 2FL,26954,"Niranjan, Usha, MD",8/13/2024,"Trifluridine and Tipiracil D1-5; D8-12 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,8/13/2024,Inactive,,
CMC OP INFUSION,28933,"Pompa, Tiffany Ann, MD",4/25/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/25/2025,Active,Malignant neoplasm of body of stomach (CMS/HCC),
CBMC OP INFUSION 2FL,74452,"Ligresti, Louise G, MD",1/21/2024,Capecitabine 21 Day Cycles - Breast,Adjuvant,1/21/2024,Inactive,,
CBMC OP INFUSION 2FL,69519,"McKenna, Marshall, MD",4/22/2025,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,4/22/2025,Active,"Follicular lymphoma, unspecified, lymph nodes of multiple sites (CMS/HCC)",
SOM OUTPT INFUSION,39990,"Toomey, Kathleen C, MD",2/9/2023,Pembrolizumab / PACLitaxel / CISplatin + Bevacizumab 21 Day Cycles - Cervical,First Line,2/8/2023,Active,,
CINJ OP INFUSION,46892,"Gulhati, Prateek, MD PhD",3/16/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,3/15/2023,Inactive,,
CINJ OP INFUSION,46892,"Gulhati, Prateek, MD PhD",7/20/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,7/18/2023,Active,,
HAM OP INFUSION,98324,"Patel, Malini M, MD",8/1/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/28/2024,Active,Endometrial cancer (CMS/HCC),
CINJ OP INFUSION,61916,"George, Mridula A, MD",2/28/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/27/2024,Active,,
NBI OP INFUSION,25195,"Anderson, Patrick S, MD",10/10/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles -Uterine Cancer,_1. First Line,10/9/2024,Inactive,,
NBI OP INFUSION,25195,"Anderson, Patrick S, MD",12/26/2024,CARBOplatin 21 Day Cycles - Uterine,_1. First Line,12/26/2024,Active,,
CINJ OP INFUSION,82255,"Girda, Eugenia, MD",1/23/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,_1. First Line,1/22/2024,Active,,
CINJ OP INFUSION,82255,"Girda, Eugenia, MD",3/26/2024,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Adjuvant,3/22/2024,Inactive,,
CINJ OP INFUSION,82255,"Girda, Eugenia, MD",3/21/2025,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,3/21/2025,Inactive,Recurrent carcinoma of endometrium (CMS/HCC),
CINJ OP INFUSION,82255,"Girda, Eugenia, MD",3/21/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_2. Second Line,3/21/2025,Active,Recurrent carcinoma of endometrium (CMS/HCC),
CBMC 2W ONCOLOGY,71092,"Grossman, I Robert, MD",2/2/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,2/1/2024,Active,,
CBMC OP INFUSION 2FL,28288,"Wagmiller, Jennifer Ann, MD",4/12/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,4/11/2024,Inactive,,
MSC OP INFUSION,72647,"Eltoukhy, Hussam, MD",12/30/2024,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,12/30/2024,Active,,
MMC BBR2 ONCOLOGY,72647,"Eltoukhy, Hussam, MD",2/18/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,2/16/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),"C92.01 - Acute myeloblastic leukemia, in remission; D61.810 - Antineoplastic chemotherapy induced pancytopenia; E43 - Unspecified severe protein-calorie malnutrition; J90 - Pleural effusion, not elsewhere classified; E87.1 - Hypo-osmolality and hyponatremia; E83.39 - Other disorders of phosphorus metabolism; R16.2 - Hepatomegaly with splenomegaly, not elsewhere classified; Z99.81 - Dependence on supplemental oxygen; D46.9 - Myelodysplastic syndrome, unspecified; J44.9 - Chronic obstructive pulmonary disease, unspecified; I10 - Essential (primary) hypertension; I08.1 - Rheumatic disorders of both mitral and tricuspid valves; D63.8 - Anemia in other chronic diseases classified elsewhere; J96.11 - Chronic respiratory failure with hypoxia; I48.0 - Paroxysmal atrial fibrillation; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; I49.3 - Ventricular premature depolarization; E78.5 - Hyperlipidemia, unspecified; R59.1 - Generalized enlarged lymph nodes; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; K52.9 - Noninfective gastroenteritis and colitis, unspecified; E87.6 - Hypokalemia; Z98.890 - Other specified postprocedural states; Z79.51 - Long term (current) use of inhaled steroids; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; Z90.49 - Acquired absence of other specified parts of digestive tract; Z68.20 - Body mass index (BMI) 20.0-20.9, adult"
JCMC CP INFUSION,81610,"Sekhri, Arunabh, MD",10/16/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell  Cancer,_1. First Line,10/15/2023,Inactive,,
JCMC CP INFUSION,81610,"Sekhri, Arunabh, MD",10/23/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,First Line,10/22/2023,Inactive,,
NBI D7 MED-SURG/TELE,54866,"Anderson, Patrick S, MD",9/20/2024,Pembrolizumab / PACLitaxel  21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,9/19/2024,Active,,
MMC BBR2 ONCOLOGY,4772,"Lee, Patrick C, MD",7/24/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/23/2024,Active,,
CINJ OP INFUSION,3151,"Goel, Sanjay, MD",11/13/2024,CINJ 052401 Part A Enrichment GIM-122,_3. Third Line,11/13/2024,Active,,
CBMC OP INFUSION 2FL,94154,"Dharmapuri, Sirish, MD",2/19/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,2/10/2025,Active,Anal squamous cell carcinoma (CMS/HCC),
CINJ OP INFUSION,27381,"Berim, Lyudmyla, MD",10/5/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,10/4/2023,Inactive,,
CINJ OP INFUSION,91656,"Gulhati, Prateek, MD PhD",1/16/2025,DOXOrubicin Conventional TACE - Hepatocellular Cancer,_1. First Line,1/16/2025,Inactive,Hepatocellular carcinoma (CMS/HCC),
CINJ OP INFUSION,91656,"Gulhati, Prateek, MD PhD",1/21/2025,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,1/21/2025,Active,,
CINJ OP INFUSION,91656,"Gulhati, Prateek, MD PhD",3/13/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,3/13/2025,Active,Hepatocellular carcinoma (CMS/HCC),
CINJ OP INFUSION,25937,"Saraiya, Biren P, MD",4/18/2023,Enzalutamide 28 Day Cycles - Prostate,Maintenance,4/18/2023,Inactive,,
CINJ OP INFUSION,25937,"Saraiya, Biren P, MD",10/9/2023,CINJ 082211 Dose Escalation HB-302 / HB-301 Alternating 2-Vector Therapy 42 Day Cycles Research- Prostate Cancer,_3. Third Line,10/9/2023,Inactive,,
CINJ OP INFUSION,25937,"Saraiya, Biren P, MD",1/16/2024,CINJ 081908 (NCI/CTEP 10096) Phase 2 ARM A Radium-223 / Olaparib 28 Day Cycles Research- Prostate Cancer,_3. Third Line,12/19/2023,Active,,
NBR CINJ OP INFUSION,56175,"Assal, Amer, MD",2/22/2024,BMT Autologous Thio / Mel,_3. Third Line,2/22/2024,Inactive,,
CINJ OP INFUSION,7286,"Hochster, Howard S, MD",3/21/2025,CINJ 072311 Durvalumab / Bevacizumab 21 Day Cycles Research- Hepatocellular Carcinoma,_1. First Line,3/21/2025,Active,"Hepatocellular carcinoma (CMS/HCC)
Prediabetes",C22.0 - Liver cell carcinoma; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; R73.03 - Prediabetes
CINJ OP INFUSION,59276,"Berim, Lyudmyla, MD",5/29/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,5/29/2023,Inactive,,
CINJ OP INFUSION,59276,"Berim, Lyudmyla, MD",12/8/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/8/2023,Inactive,,
CINJ OP INFUSION,59276,"Berim, Lyudmyla, MD",4/15/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/14/2024,Inactive,,
CINJ OP INFUSION,8723,"Dasgeb, Bahar, MD",2/15/2023,Pembrolizumab 21 Day Cycles - Numerous mixed Basal cell and Squamous cell carcinoma more than 200,Second Line,2/14/2023,Inactive,,
CINJ OP INFUSION,20339,"Dasgeb, Bahar, MD",3/4/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,3/4/2025,Active,"Basal cell carcinoma (BCC) of multiple sites
Squamous cell carcinoma of multiple sites",
CMC OP INFUSION,23463,"Talwar, Sumit, MD",5/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/30/2024,Inactive,,
MMC OP VP INFUSION,1712,"Lee, Patrick C, MD",9/19/2023,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,Third Line,9/12/2023,Inactive,,
MMC OP INFUSION,60269,"Meghal, Trishala, MD",5/24/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,5/24/2024,Active,,
NBR CINJ OP INFUSION,46693,"Shah, Mansi R, MD",3/2/2024,Carfilzomib 56 mg/m2 q2 weeks maintenance ,Maintenance,3/2/2024,Inactive,,
HAM OP INFUSION,78425,"Yogarajah, Meera, MD",2/3/2023,Enzalutamide 30 Day Cycles - Prostate,First Line,2/3/2023,Inactive,,
HAM OP INFUSION,78425,"Yogarajah, Meera, MD",3/21/2023,Apalutamide 30 Day Cycles - Prostate,,3/21/2023,Active,,
NBR 4N BMTU/IMCU,78392,"Schaar, Dale, MD PhD",8/9/2023,BMT Allogeneic TBF + Post Cy (Reduced Intensity),,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,60203,"Shah, Mansi R, MD",1/28/2025,CINJ 012301 Arm B Pomalidomide / Daratumumab 28 Day Cycles Research-Multiple Myeloma,_2. Second Line,1/26/2025,Active,,
HAM OP INFUSION,15317,"Yogarajah, Meera, MD",6/1/2023,DOCEtaxel/CARBOplatin 21 Day Cycles- Head and Neck Cancers,First Line,5/31/2023,Inactive,,
HAM OP INFUSION,15317,"Yogarajah, Meera, MD",9/28/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,6/1/2023,Inactive,,
CBMC 2W ONCOLOGY,72042,"Brown, Andrew Bennett, MD",7/31/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,7/31/2024,Inactive,,
CBMC OP INFUSION 2FL,72042,"Brown, Andrew Bennett, MD",11/20/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/19/2024,Active,,
CMC OP INFUSION,22819,"Eltoukhy, Hussam, MD",2/13/2025,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,2/13/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
CINJ OP INFUSION,15833,"Aikins, James K, MD",1/12/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,First Line,1/11/2023,Active,,
CINJ OP INFUSION,57425,"Haigentz, Missak, MD",10/3/2023,CINJ 032201 ARM 1 Paclitaxel / CARBOplatin + Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,10/3/2023,Inactive,,
CINJ OP INFUSION,53950,"Haigentz, Missak, MD",3/31/2024,Lenvatinib 28 Day Cycles- Thyroid Carcinoma,_1. First Line,3/31/2024,Active,,
CINJ OP INFUSION,87934,"Mayer, Tina M, MD",7/20/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,7/20/2023,Active,,
CMC OP INFUSION,49943,"Tang, Horace, MD",3/17/2023,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/10/2023,Inactive,,
CMC OP INFUSION,49943,"Tang, Horace, MD",12/11/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/11/2023,Inactive,,
MMC OP VP INFUSION,49943,"Cohen, Seth D, MD",5/2/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_2. Second Line,5/1/2024,Inactive,,
CMC OP INFUSION,49943,"Cohen, Seth D, MD",9/12/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_3. Third Line,9/12/2024,Inactive,,
CMC OP INFUSION,49943,"Cohen, Seth D, MD",12/27/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,12/26/2024,Active,,
NBR CINJ OP INFUSION,11374,"Matasar, Matthew J, MD",2/14/2024,SCIG (Hyqvia) and Hyaluronidase-fihj 28 Day Cycles,Maintenance,1/8/2024,Active,Pancreatic adenocarcinoma (CMS/HCC),
SOM OUTPT INFUSION,24191,"Patel, Eshan, MD",4/10/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,,4/6/2023,Inactive,,
CINJ OP INFUSION,65864,"Muralikrishnan, Sivraj, MD",5/30/2025,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,Adjuvant,5/30/2025,Active,Adenosquamous carcinoma of right lung (CMS/HCC),C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung
CINJ OP INFUSION,15036,"Stephenson, Ryan D, DO",4/5/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_2. Second Line,4/5/2024,Active,,
CINJ OP INFUSION,47907,"Stephenson, Ruth D, DO",4/7/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,4/7/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium; Z51.89 - Encounter for other specified aftercare
CINJ OP INFUSION,27219,"Saraiya, Biren P, MD",1/30/2023,CINJ 082106 Pembrolizumab / Belzutifan or Placebo 42 Day Cycles Research- Renal Cell Carcinoma,Adjuvant,1/29/2023,Active,,
NBI OP INFUSION,95375,"Jacoby, Sari H, MD",5/5/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/5/2025,Active,Malignant neoplasm of colon (CMS/HCC),
NBI OP INFUSION,95375,"Jacoby, Sari H, MD",4/23/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2025,Inactive,Malignant neoplasm of colon (CMS/HCC),
CINJ OP INFUSION,32243,"Patel, Eshan, MD",11/13/2023,CARBOplatin / Gemcitabine 21 Day Cycles and Keytruda- Bladder Primary,_1. First Line,11/12/2023,Inactive,,
CMC OP INFUSION,42180,"Cohen, Seth D, MD",3/19/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,28667,"Brown, Andrew Bennett, MD",1/15/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,1/12/2025,Active,,
CBMC OP INFUSION 2FL,16100,"Brown, Andrew Bennett, MD",4/22/2025,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Adjuvant,4/22/2025,Active,Primary malignant neoplasm of bronchus of right lower lobe (CMS/HCC),
CINJ OP INFUSION,30732,"Groisberg, Roman, MD",11/12/2024,PACLitaxel weekly 28 Day Cycles - Angiosarcoma (Weekly),_1. First Line,11/11/2024,Active,,
CINJ OP INFUSION,28391,"Gulhati, Prateek, MD PhD",1/30/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,1/30/2023,Inactive,,
CMC OP INFUSION,35951,"Cohen, Seth D, MD",5/20/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,5/20/2025,Active,"Malignant melanoma (CMS/HCC)
Hypothyroidism due to medication",
SOM OUTPT INFUSION,1383,"Toomey, Kathleen C, MD",6/26/2023,PACLitaxel / CARBOplatin / Trastuzumab 21 Day Cycles + Trastuzumab 21 Day Cycles - Uterine,Second Line,6/19/2023,Inactive,,
SOM OUTPT INFUSION,1383,"Toomey, Kathleen C, MD",3/14/2024,CINJ 102310 Cohort B MK-4280A or Pembrolizumab / Lenvatinib 21 Day Cycles Research Solid Tumors,_3. Third Line,3/13/2024,Inactive,,
SOM OUTPT INFUSION,57301,"Toomey, Kathleen C, MD",2/6/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/4/2025,Active,"Neoplasm of endometrium
Secondary carcinoma of lung (CMS/HCC)",
NBR CINJ OP INFUSION,38201,"Shah, Mansi R, MD",8/15/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,8/15/2023,Active,,
CINJ OP INFUSION,41971,"Mayer, Tina M, MD",2/27/2023,DOCEtaxel 21 Day Cycles - Prostate,,2/26/2023,Inactive,,
CINJ OP INFUSION,41971,"Mayer, Tina M, MD",4/18/2023,Olaparib 30 Day Cycles - Prostate Ca,_5. Fifth Line,4/18/2023,Inactive,,
CINJ OP INFUSION,41971,"Mayer, Tina M, MD",1/12/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_5. Fifth Line,1/12/2024,Inactive,,
CINJ OP INFUSION,77467,"Haigentz, Missak, MD",1/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,1/22/2024,Inactive,,
MMC BBR2 ONCOLOGY,7701,"Lee, Patrick C, MD",12/12/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,12/11/2024,Active,,
SOM OUTPT INFUSION,80576,"Patel, Eshan, MD",6/25/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/17/2024,Active,,
SOM OUTPT INFUSION,80576,"Patel, Eshan, MD",4/30/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/30/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),
TRMC TCCC OP INFUSION,6615,"Salerno, Vincent E, MD",1/8/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/7/2025,Active,,
NBI OP INFUSION,56667,"Shah, Shailja S, MD",4/30/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,4/29/2024,Active,,
CBMC OP INFUSION 2FL,22996,"Wagmiller, Jennifer Ann, MD",1/9/2024,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,1/9/2024,Inactive,,
HAM OP INFUSION,59399,"Gendy, Mina, DO",2/17/2025,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,2/11/2025,Active,MDS (myelodysplastic syndrome) (CMS/HCC),
HAM OP INFUSION,77300,"Patel, Malini M, MD",1/24/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,1/23/2023,Inactive,,
SOM OUTPT INFUSION,28493,"Patel, Eshan, MD",6/17/2024,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/16/2024,Active,,
CINJ OP INFUSION,15140,"Stephenson, Ryan D, DO",12/17/2024,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_1. First Line,12/17/2024,Active,,
NBI OP INFUSION,7019,"Shah, Shailja S, MD",4/22/2025,Pembrolizumab 21 Day Cycles - Squamous cell carcinoma of unknown primary,_1. First Line,4/22/2025,Active,Squamous cell carcinoma of neck,"D04.9 - Carcinoma in situ of skin, unspecified; R22.31 - Localized swelling, mass and lump, right upper limb; R59.1 - Generalized enlarged lymph nodes"
CMC OP INFUSION,46189,"Eltoukhy, Hussam, MD",7/19/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,7/16/2024,Active,,
NBR 4N ONCOLOGY,85231,"Rhodes, Joanna Meehan, MD",2/14/2024,High-Dose Cytarabine / Rituximab 21 Day Cycles - Mantle Cell Lymphoma,_4. Fourth Line,2/14/2024,Inactive,,
NBR CINJ OP INFUSION,85231,"Rhodes, Joanna Meehan, MD",2/15/2024,"Obinutuzumab, Glofitamab 21 Day Cycles - Diffuse Large B-Cell Lymphoma",_6. Sixth Line,2/14/2024,Inactive,,
NBR CINJ OP INFUSION,85231,"Rhodes, Joanna Meehan, MD",8/26/2024,Venetoclax 28 Day Cycles - MCL,_6. Sixth Line,8/21/2024,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
NBR CINJ OP INFUSION,85231,"Rhodes, Joanna Meehan, MD",10/14/2024,Obinutuzumab 28 Day Cycles - Low Grade Indolent Lymphoma ,10. Tenth Line,10/13/2024,Active,,
NBR CINJ OP INFUSION,1661,"Rhodes, Joanna Meehan, MD",2/17/2025,CINJ 012408 Cohort 2A  AZD0486 Monotherapy 28 Day Cycles Research- Non-Hodgkin's Lymphoma,10. Tenth Line,2/16/2025,Active,Mantle cell lymphoma (CMS/HCC),
CINJ OP INFUSION,8810,"Mayer, Tina M, MD",10/19/2023,CINJ 081910 (A031704) Induction Therapy Nivolumab / Ipilimumab 21 Day Cycles Research- Renal Cell Carcinoma,_1. First Line,10/18/2023,Inactive,,
CINJ OP INFUSION,8810,"Mayer, Tina M, MD",2/20/2024,RiTUXimab Subsequent Infusion Single Day (Outpatient),Consolidation,2/20/2024,Inactive,,
CINJ OP INFUSION,57997,"Weiss, Sarah, MD",8/7/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,8/6/2024,Active,,
NBI OP INFUSION,90857,"Jacoby, Sari H, MD",6/24/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/23/2024,Active,,
NBI OP INFUSION,90857,"Jacoby, Sari H, MD",1/7/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/6/2025,Active,,
NBI OP INFUSION,35171,"Jacoby, Sari H, MD",5/28/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/28/2025,Active,"Rectal cancer metastasized to liver (CMS/HCC)
Metastasis from rectal cancer (CMS/HCC)",
NBI OP INFUSION,35171,"Jacoby, Sari H, MD",4/23/2025,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,_2. Second Line,4/23/2025,Active,Rectal cancer metastasized to liver (CMS/HCC),C20 - Malignant neoplasm of rectum; N13.30 - Unspecified hydronephrosis; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
MMC OP INFUSION,89728,"Meghal, Trishala, MD",12/31/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,12/18/2024,Active,,
MMC OP VP INFUSION,81817,"Talwar, Sumit, MD",5/6/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,5/6/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
NBI OP INFUSION,88108,"Anderson, Patrick S, MD",11/27/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/21/2024,Active,,
CBMC OP INFUSION 2FL,91795,"Raptis, George, MD",8/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/28/2024,Inactive,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,91795,"Raptis, George, MD",1/3/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/3/2025,Active,,
CINJ OP INFUSION,26880,"Patankar, Sonali, MD",9/4/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,9/3/2024,Active,,
NBI OP INFUSION,15200,"Snyder, Rose, MD",2/24/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,2/23/2025,Active,Malignant neoplasm of supraglottis (CMS/HCC),"A41.9 - Sepsis, unspecified organism; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; I21.A1 - Myocardial infarction type 2; J15.69 - Pneumonia due to other gram-negative bacteria; J96.01 - Acute respiratory failure with hypoxia; N17.0 - Acute kidney failure with tubular necrosis; R65.21 - Severe sepsis with septic shock; G93.41 - Metabolic encephalopathy; I31.39 - Other pericardial effusion (noninflammatory); E87.0 - Hyperosmolality and hypernatremia; D69.6 - Thrombocytopenia, unspecified; E87.1 - Hypo-osmolality and hyponatremia; C32.1 - Malignant neoplasm of supraglottis; I75.013 - Atheroembolism of bilateral upper extremities; E11.51 - Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene; I10 - Essential (primary) hypertension; D64.9 - Anemia, unspecified; I75.023 - Atheroembolism of bilateral lower extremities; K92.2 - Gastrointestinal hemorrhage, unspecified; Z79.4 - Long term (current) use of insulin; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; E78.5 - Hyperlipidemia, unspecified; E87.6 - Hypokalemia; I25.2 - Old myocardial infarction; J01.90 - Acute sinusitis, unspecified; K05.329 - Chronic periodontitis, generalized, unspecified severity; K08.3 - Retained dental root; R62.7 - Adult failure to thrive; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z85.21 - Personal history of malignant neoplasm of larynx; Z87.891 - Personal history of nicot..."
CMC OP INFUSION,93205,"Taff, Jessica, MD",5/6/2024,DOCEtaxel 21 Day Cycles - Extranodal Pagets Disease,_1. First Line,5/5/2024,Active,,
CMC OP INFUSION,74022,"Taff, Jessica, MD",5/30/2025,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,5/30/2025,Active,Hepatocellular carcinoma (CMS/HCC),
MMC BBR2 ONCOLOGY,87209,"Lee, Patrick C, MD",6/16/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,6/16/2023,Inactive,,
CMC OP INFUSION,2185,"Tang, Horace, MD",7/7/2023,GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,Second Line,6/28/2023,Inactive,,
CMC OP INFUSION,2185,"Tang, Horace, MD",9/25/2023,ICE (Ifosfamide / CARBOplatin / Etoposide) + Nivolumab 21 Day Cycles - Hodgkin Lymphoma,,9/24/2023,Inactive,,
NBR 4N ONCOLOGY,2185,"Schaar, Dale, MD PhD",12/1/2023,BMT Autologous BEAM,_4. Fourth Line,11/30/2023,Inactive,,
CBMC OP INFUSION 2FL,558,"Scoppetuolo, Michael, MD",12/5/2023,RiTUXimab Initial Infusion ++ Day (Outpatient),_2. Second Line,11/21/2023,Inactive,,
CINJ OP INFUSION,73429,"George, Mridula A, MD",5/21/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/21/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z90.11 - Acquired absence of right breast and nipple; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,23330,"Girda, Eugenia, MD",4/11/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/9/2023,Inactive,,
CINJ OP INFUSION,23330,"Girda, Eugenia, MD",8/22/2023,Pembrolizumab 21 Day Cycles - Uterine,,8/20/2023,Active,,
CBMC OP INFUSION 2FL,19533,"Leitner, Stuart P, MD",12/12/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/11/2023,Inactive,,
CBMC OP INFUSION 2FL,19533,"Leitner, Stuart P, MD",2/25/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/24/2025,Active,"Cancer of bronchus of left lower lobe (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)
Long-term current use of immunosuppressive biologic agent",
SOM OUTPT INFUSION,50532,"Yin, Faye, MD",4/1/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,3/31/2024,Inactive,,
SOM OUTPT INFUSION,50532,"Yin, Faye, MD",5/13/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin)  14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2024,Inactive,,
SOM OUTPT INFUSION,50532,"Patel, Eshan, MD",9/30/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,9/29/2024,Active,,
SOM OUTPT INFUSION,4047,"Patel, Eshan, MD",3/17/2025,Durvalumab Maintenance 28 Day Cycles- Biliary Tract Cancers,_1. First Line,3/17/2025,Inactive,Cholangiocarcinoma (CMS/HCC),C22.1 - Intrahepatic bile duct carcinoma
CMC OP INFUSION,49427,"Cohen, Seth D, MD",3/24/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,_1. First Line,3/24/2025,Active,"Malignant neoplasm of cervix (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,98438,"Boland, Patrick M, MD",12/19/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/19/2023,Inactive,,
CINJ OP INFUSION,98438,"Boland, Patrick M, MD",1/12/2024,"Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/8/2024,Inactive,,
NBR 5N ONCOLOGY,79025,"Shah, Mansi R, MD",2/14/2025,V-CED (Bortezomib/Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_1. First Line,2/13/2025,Active,Multiple myeloma (CMS/HCC),"C90.00 - Multiple myeloma not having achieved remission; I10 - Essential (primary) hypertension; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; D63.0 - Anemia in neoplastic disease; D84.9 - Immunodeficiency, unspecified; M89.9 - Disorder of bone, unspecified; M76.00 - Gluteal tendinitis, unspecified hip; E80.6 - Other disorders of bilirubin metabolism; E78.00 - Pure hypercholesterolemia, unspecified; B19.10 - Unspecified viral hepatitis B without hepatic coma; R76.8 - Other specified abnormal immunological findings in serum; Z86.2 - Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism; Z71.89 - Other specified counseling"
CINJ OP INFUSION,6623,"Weiss, Sarah, MD",6/26/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Second Line,6/25/2023,Active,,
CINJ OP INFUSION,65437,"Leiser, Aliza, MD",4/14/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,4/14/2025,Active,"Malignant neoplasm of cervix uteri, unspecified (CMS/HCC)",
SOM OUTPT INFUSION,81281,"Patel, Eshan, MD",5/11/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,5/10/2023,Active,,
TRMC TCCC OP INFUSION,1826,"Salerno, Vincent E, MD",2/5/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/4/2025,Active,"Lung cancer, primary, with metastasis from lung to other site, right (CMS/HCC)",
SOM OUTPT INFUSION,17340,"Patel, Eshan, MD",9/10/2024,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",_1. First Line,9/8/2024,Active,,
SOM OUTPT INFUSION,17340,"Patel, Eshan, MD",4/8/2025,dara/velcade/dex,_2. Second Line,4/8/2025,Active,Light chain deposition disease,"Z94.0 - Kidney transplant status; N28.9 - Disorder of kidney and ureter, unspecified; R77.9 - Abnormality of plasma protein, unspecified"
MMC OP INFUSION,37544,"Eltoukhy, Hussam, MD",6/20/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,6/17/2024,Inactive,,
MMC OP INFUSION,37544,"Eltoukhy, Hussam, MD",7/15/2024,DHAP (Dexamethasone / CISplatin / Cytarabine) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,6/17/2024,Inactive,,
MMC OP INFUSION,37544,"Eltoukhy, Hussam, MD",12/2/2024,RiTUXimab / Acalabrutinib 56 Day Cycles - Mantle Cell Lymphoma (Maintenance),Maintenance,12/1/2024,Active,Anal squamous cell carcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,98267,"Wagmiller, Jennifer Ann, MD",5/20/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,5/13/2024,Inactive,,
CBMC OP INFUSION 2FL,98267,"Wagmiller, Jennifer Ann, MD",5/30/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,5/20/2024,Inactive,,
CBMC OP INFUSION 2FL,98267,"Wagmiller, Jennifer Ann, MD",8/22/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,8/21/2024,Active,,
NBI OP INFUSION,31509,"Shah, Shailja S, MD",2/18/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,2/10/2025,Active,SCC (squamous cell carcinoma of esophagus) (CMS/HCC),
NBI OP INFUSION,43472,"Shah, Shailja S, MD",1/31/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,1/30/2025,Inactive,SCC (squamous cell carcinoma of esophagus) (CMS/HCC),
CBMC OP INFUSION 2FL,27531,"Brown, Andrew Bennett, MD",12/6/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/26/2023,Inactive,,
SOM OUTPT INFUSION,33308,"Patel, Eshan, MD",3/11/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,3/8/2024,Inactive,,
NBR CINJ OP INFUSION,30762,"Schaar, Dale, MD PhD",3/20/2023,AzaCITIDine 28 Day Cycle - Acute Myeloid Leukemia / MDS,,3/19/2023,Inactive,,
CINJ OP INFUSION,54073,"Boland, Patrick M, MD",11/19/2024,CINJ 072401 Quemliclustat / Zimberelimab / Gemcitabine / CISplatin 42 Day Cycles Research- Advanced Biliary Tract Cancers,_1. First Line,11/18/2024,Active,,
CINJ OP INFUSION,44489,"Packiam, Vignesh, MD",5/13/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,5/13/2024,Active,,
CBMC OP INFUSION 2FL,2720,"Wagmiller, Jennifer Ann, MD",8/15/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,8/14/2023,Inactive,,
SOM OUTPT INFUSION,33858,"Yin, Faye, MD",3/21/2023,Atezolizumab/Carboplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,3/14/2023,Inactive,,
SOM OUTPT INFUSION,33858,"Yin, Faye, MD",5/22/2023,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,First Line,5/22/2023,Inactive,,
SOM OUTPT INFUSION,33858,"Yin, Faye, MD",7/3/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,First Line,6/28/2023,Inactive,,
CBMC OP INFUSION 2FL,36824,"Wagmiller, Jennifer Ann, MD",3/20/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,3/17/2024,Inactive,,
CINJ OP INFUSION,21298,"Boland, Patrick M, MD",8/1/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,,7/31/2023,Inactive,,
CINJ OP INFUSION,26177,"Berim, Lyudmyla, MD",8/1/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,,7/31/2023,Inactive,,
CINJ PEDS HEMONC ,84906,"Drachtman, Richard, MD",12/28/2023,112304 GBT440-041 Voxelotor (Cohorts B & C),_1. First Line,12/28/2023,Active,,
CINJ OP INFUSION,32047,"Omene, Coral Oghenerukevwe, MD",2/3/2025,Capivasertib 28 Day Cycles - Breast,_1. First Line,2/3/2025,Active,Stage IV breast cancer in female (CMS/HCC),C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,28243,"Omene, Coral Oghenerukevwe, MD",4/21/2025,Abemaciclib 28 Day Cycles - Breast,_2. Second Line,4/21/2025,Active,Stage IV breast cancer in female (CMS/HCC),"C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; M85.80 - Other specified disorders of bone density and structure, unspecified site; R20.2 - Paresthesia of skin; E11.9 - Type 2 diabetes mellitus without complications; Z90.12 - Acquired absence of left breast and nipple; C50.812 - Malignant neoplasm of overlapping sites of left female breast; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.0 - Estrogen receptor positive status (ER+); Z86.79 - Personal history of other diseases of the circulatory system; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs"
CBMC OP INFUSION 2FL,51958,"Radovich, Delia, MD",11/10/2023,Tremelimumab-actl / Durvalumab 1500 mg 28 Day Cycles- Hepatocellular Cancer,_1. First Line,11/9/2023,Active,"Multiple myeloma (CMS/HCC)
Encounter for pre-transplant evaluation for stem cell transplant",
CBMC OP INFUSION 1FL,51958,"Dharmapuri, Sirish, MD",2/27/2025,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer (LC Beads),_1. First Line,2/27/2025,Active,Liver cell carcinoma (CMS/HCC),"C22.0 - Liver cell carcinoma; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; M19.90 - Unspecified osteoarthritis, unspecified site; G20.A1 - Parkinson's disease without dyskinesia, without mention of fluctuations; Z86.16 - Personal history of COVID-19; Z85.820 - Personal history of malignant melanoma of skin; Z85.46 - Personal history of malignant neoplasm of prostate; Z90.49 - Acquired absence of other specified parts of digestive tract; Z95.1 - Presence of aortocoronary bypass graft; Z95.5 - Presence of coronary angioplasty implant and graft; Z98.890 - Other specified postprocedural states; Z87.891 - Personal history of nicotine dependence; Z88.0 - Allergy status to penicillin; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy"
CMC OP INFUSION,77028,"Talwar, Sumit, MD",1/23/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/22/2024,Inactive,,
HAM OP INFUSION,72853,"Patel, Malini M, MD",9/14/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Second Line,9/14/2023,Active,,
CBMC OP INFUSION 2FL,83060,"Litvak, Anna M, MD",5/9/2025,CINJ 042403 Tirzepatide Weekly 28 Day Cycles Research- Breast Cancer,_1. First Line,5/9/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,95955,"Hochster, Howard S, MD",7/1/2024,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,7/1/2024,Inactive,,
CINJ OP INFUSION,95955,"Boland, Patrick M, MD",7/26/2024,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,_1. First Line,6/17/2024,Inactive,,
CINJ OP INFUSION,64097,"Berim, Lyudmyla, MD",2/20/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/17/2023,Inactive,,
CINJ OP INFUSION,64097,"Kennedy, Timothy, MD",3/26/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,3/26/2024,Active,,
CINJ OP INFUSION,64097,"Berim, Lyudmyla, MD",10/24/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,10/22/2024,Active,,
CMC OP INFUSION,49033,"Pompa, Tiffany Ann, MD",9/10/2024,R-GCVP (Gemcitabine / Cyclophosphamide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/9/2024,Active,Primary squamous cell carcinoma of upper lobe of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,93043,"Brown, Andrew Bennett, MD",1/21/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,1/21/2025,Active,,
HAM OP INFUSION,14417,"Yogarajah, Meera, MD",11/3/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/25/2023,Inactive,,
JCMC CP INFUSION,31386,"Sekhri, Arunabh, MD",12/5/2024,Hydroxyurea 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,12/5/2024,Inactive,,
CBMC OP INFUSION 2FL,31716,"Leitner, Stuart P, MD",12/13/2024,"Nivolumab D1, D15 28 Day Cycles - Kidney or Bladder",_1. First Line,11/26/2024,Active,,
CINJ PEDS HEMONC ,68867,"Moerdler, Scott, MD",5/20/2024,Bevacizumab Maintenance 21 Day Cycles- Recurrent Papillomatosis,Adjuvant,5/20/2024,Active,,
NBI OP INFUSION,73324,"Anderson, Patrick S, MD",11/2/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/1/2023,Active,,
TRMC TCCC OP INFUSION,29594,"Capo, Gerardo, MD",6/5/2024,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,5/28/2024,Active,,
TRMC TCCC OP INFUSION,35369,"Salerno, Vincent E, MD",4/17/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,4/17/2025,Active,"Malignant neoplasm of central portion of right breast, estrogen receptor positive (CMS/HCC)",
HAM OP INFUSION,82250,"Yogarajah, Meera, MD",9/3/2024,Capivasertib 28 Day Cycles - Breast,_3. Third Line,12/30/2024,Active,,
TRMC TCCC OP INFUSION,38901,"Capo, Gerardo, MD",10/1/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,9/30/2024,Active,,
MMC OP VP INFUSION,56748,"Talwar, Sumit, MD",4/23/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,3/22/2024,Inactive,,
NBI OP INFUSION,76893,"Schleicher, Lori, MD",11/15/2023,Bevacizumab Maintenance 21 Day Cycles- HHT,Maintenance,11/15/2023,Inactive,,
CBMC 2W ONCOLOGY,82148,"Grossman, I Robert, MD",1/16/2025,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_1. First Line,1/16/2025,Active,,
TRMC TCCC OP INFUSION,4773,"Capo, Gerardo, MD",9/13/2024,VinORELBine 21 Day Cycles - Breast,_3. Third Line,9/12/2024,Active,Malignant neoplasm of uterus (CMS/HCC),
TRMC TCCC OP INFUSION,4773,"Capo, Gerardo, MD",4/18/2025,Capecitabine 21 Day Cycles - Breast,_2. Second Line,4/18/2025,Active,Malignant neoplasm of left female breast (CMS/HCC),
JCMC CP INFUSION,66992,"Cruz, Allan Louie E, MD",10/24/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/16/2024,Active,,
NBR CINJ OP INFUSION,46535,"Eltoukhy, Hussam, MD",2/9/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,2/8/2024,Inactive,,
NBR CINJ OP INFUSION,46535,"Tiger, Yun Kyoung, MD",1/3/2025,Talquetamab 28 Day Cycles,_6. Sixth Line,1/3/2025,Active,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),
NBR 4N BMTU/IMCU,96842,"Rhodes, Joanna Meehan, MD",10/20/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Adjuvant,10/20/2023,Inactive,,
NBR CINJ OP INFUSION,96842,"Evens, Andrew M, DO",10/22/2023,Lymphodepletion Yescarta with Fludarabine/Cyclophosphamide 6 Day Cycle - Refractory Large B-Cell Lymphoma,_2. Second Line,10/22/2023,Inactive,,
NBR CINJ OP INFUSION,96842,"Evens, Andrew M, DO",8/21/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_3. Third Line,8/20/2024,Active,,
CBMC OP INFUSION 2FL,93448,"Litvak, Anna M, MD",11/26/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,11/26/2024,Active,"Breast cancer in female (CMS/HCC)
Breast cancer, stage 4, unspecified laterality (CMS/HCC)",
CBMC OP INFUSION 2FL,54493,"Grossman, I Robert, MD",10/17/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/9/2024,Inactive,,
NBR CINJ OP INFUSION,96335,"Patel, Eshan, MD",11/10/2023,Bevacizumab / Pembrolizumab 28 Day Cycles - CNS,Maintenance,11/2/2023,Active,,
CINJ OP INFUSION,84249,"Weiss, Sarah, MD",7/22/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,7/21/2024,Inactive,,
CINJ OP INFUSION,84249,"Weiss, Sarah, MD",8/5/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,8/4/2024,Active,,
CINJ OP INFUSION,44205,"Toppmeyer, Deborah L, MD",5/15/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,5/15/2025,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor positive (CMS/HCC)",C50.512 - Malignant neoplasm of lower-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
CBMC OP INFUSION 2FL,36970,"Brown, Andrew Bennett, MD",10/10/2023,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/9/2023,Active,,
CBMC OP INFUSION 2FL,68342,"Grossman, I Robert, MD",11/2/2023,Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,78846,"Radovich, Delia, MD",1/26/2024,Simplified BiWeekly Infusional Fluorouracil/Leucovorin + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/26/2024,Inactive,,
CBMC OP INFUSION 2FL,78846,"Brown, Andrew Bennett, MD",11/1/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,10/24/2024,Active,,
SOM OUTPT INFUSION,11889,"Patel, Eshan, MD",3/13/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/10/2024,Inactive,,
SOM OUTPT INFUSION,11889,"Patel, Eshan, MD",8/12/2024,"Encorafenib + Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,7/26/2024,Inactive,,
MMC OP VP INFUSION,36690,"Lee, Patrick C, MD",11/13/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,,9/19/2023,Inactive,,
CINJ OP INFUSION,84044,"Dasgeb, Bahar, MD",2/27/2023,Nivolumab 28 Day Cycles - Melanoma,Third Line,2/26/2023,Inactive,,
MMC OP VP INFUSION,96953,"Lee, Patrick C, MD",5/29/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,5/19/2025,Active,Malignant neoplasm of overlapping sites of right female breast (CMS/HCC),
CINJ OP INFUSION,79886,"Boland, Patrick M, MD",5/5/2023,FOLFIRI + Ram (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,5/4/2023,Inactive,,
CINJ OP INFUSION,79886,"Goel, Sanjay, MD",10/3/2023,CINJ 052103 (TJ033721STM101) Dose Expansion Cohort 1 TJ033721 12 mg/kg 28 Day Cycles Research- Gastric Cancer / Gastroesophageal Junction Carcinoma / Esophageal Adenocarcinoma,Third Line,9/28/2023,Inactive,,
CBMC OP INFUSION 2FL,27897,"Dharmapuri, Sirish, MD",1/24/2025,CINJ 072311 Durvalumab / Bevacizumab 21 Day Cycles Research- Hepatocellular Carcinoma,_1. First Line,1/23/2025,Active,,
CBMC OP INFUSION 2FL,74291,"Dharmapuri, Sirish, MD",3/13/2025,CINJ 072311 Durvalumab / Bevacizumab 21 Day Cycles Research- Hepatocellular Carcinoma,_1. First Line,3/13/2025,Active,HCC (hepatocellular carcinoma) (CMS/HCC),
CMC OP INFUSION,22398,"Taff, Jessica, MD",6/12/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,First Line,6/11/2023,Inactive,,
CINJ PEDS HEMONC ,26845,"Cole, Peter David, MD",12/18/2023,Selumetinib (Koselugo),_1. First Line,12/17/2023,Inactive,,
CINJ PEDS HEMONC ,26845,"Moerdler, Scott, MD",7/8/2024,PEDS Carboplatin - Low Grade Glioma,_1. First Line,7/7/2024,Active,,
CINJ OP INFUSION,90962,"Stephenson, Ryan D, DO",8/14/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,First Line,8/13/2023,Inactive,,
MMC OP VP INFUSION,91222,"Cohen, Seth D, MD",2/24/2025,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,2/21/2025,Active,Cancer of tonsillar fossa (CMS/HCC),
NBR 4N ONCOLOGY,82829,"Aikins, James K, MD",6/4/2024,"PACLitaxel D1, D8, D15 / CARBOplatin D1, D8, D15 28 Day Cycles - Ovarian Cancer",_1. First Line,5/30/2024,Inactive,,
MMC OP VP INFUSION,82829,"Meghal, Trishala, MD",11/7/2024,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,11/7/2024,Active,,
CBMC OP INFUSION 2FL,24238,"Wagmiller, Jennifer Ann, MD",10/24/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,10/23/2023,Inactive,,
CBMC OP INFUSION 2FL,24238,"Wagmiller, Jennifer Ann, MD",1/2/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/1/2024,Inactive,,
CBMC OP INFUSION 2FL,24238,"Wagmiller, Jennifer Ann, MD",8/1/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,7/31/2024,Inactive,,
CBMC OP INFUSION 2FL,24238,"Wagmiller, Jennifer Ann, MD",8/8/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,8/7/2024,Active,,
CINJ OP INFUSION,66668,"Packiam, Vignesh, MD",5/12/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,Maintenance,4/28/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C67.8 - Malignant neoplasm of overlapping sites of bladder; C67.9 - Malignant neoplasm of bladder, unspecified"
MMC OP VP INFUSION,36688,"Talwar, Sumit, MD",7/28/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),Second Line,7/28/2023,Inactive,,
TRMC TCCC OP INFUSION,74488,"Salerno, Vincent E, MD",10/28/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/24/2024,Active,,
CINJ OP INFUSION,64033,"Muralikrishnan, Sivraj, MD",5/13/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/13/2025,Active,Cancer of left lung parenchyma (CMS/HCC),
CINJ OP INFUSION,64033,"Girda, Eugenia, MD",5/13/2025,GY022 / CINJ 102003 Iohexol/CARBOplatin PK Research Study- CARBOplatin Clearance Predictors,Non-Oncology Research,5/13/2025,Active,Cancer of left lung parenchyma (CMS/HCC),
CINJ OP INFUSION,51204,"Stephenson, Ryan D, DO",9/27/2023,CINJ 082002 Pre-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,First Line,9/26/2023,Inactive,,
CINJ OP INFUSION,51204,"Stephenson, Ryan D, DO",1/22/2024,CINJ 082002 Post-Nephrectomy Cabozantinib / Nivolumab 28 Day Cycles Research- Renal Cell Cancer,_1. First Line,11/26/2023,Active,,
CMC OP INFUSION,73223,"Taff, Jessica, MD",6/13/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,6/12/2023,Inactive,,
CINJ OP INFUSION,43603,"Saraiya, Biren P, MD",2/3/2023,CINJ 082107 (CURLU177PSM001) Enzalutamide 28 Day Cycles Research Prostate Cancer,Second Line,12/13/2022,Active,,
CBMC OP INFUSION 2FL,43998,"Brown, Andrew Bennett, MD",4/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/22/2024,Inactive,,
CBMC OP INFUSION 2FL,43998,"Brown, Andrew Bennett, MD",9/24/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/24/2024,Active,,
MMC OP VP INFUSION,37499,"Lee, Patrick C, MD",11/29/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,11/21/2023,Inactive,,
MMC OP VP INFUSION,37499,"Lee, Patrick C, MD",11/27/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,11/7/2024,Active,,
MMC OP VP INFUSION,5575,"Lee, Patrick C, MD",2/26/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,2/20/2025,Active,"Malignant melanoma of left upper limb, including shoulder (CMS/HCC)",
MSC OP INFUSION,73787,"Easaw, Sarah, MD",3/29/2023,Cemiplimab-rwlc 21 Day Cycles - NSCLC,First Line,3/28/2023,Inactive,,
MSC OP INFUSION,73787,"Easaw, Sarah, MD",3/29/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,First Line,3/21/2023,Inactive,,
MSC OP INFUSION,73787,"Easaw, Sarah, MD",5/10/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,5/2/2023,Inactive,,
MSC OP INFUSION,42437,"Easaw, Sarah, MD",3/29/2023,PEMEtrexed/CARBOplatin + Libtaya 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/21/2023,Inactive,,
CMC OP INFUSION,42437,"Talwar, Sumit, MD",5/10/2023,Cemiplimab-rwlc 21 Day Cycles - NSCLC,First Line,5/9/2023,Active,,
MSC OP INFUSION,42437,"Easaw, Sarah, MD",6/21/2023,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,6/13/2023,Inactive,,
SOM OUTPT INFUSION,94809,"Patel, Eshan, MD",5/14/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,4/28/2024,Inactive,,
CBMC OP INFUSION 2FL,6350,"Ligresti, Louise G, MD",1/22/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_4. Fourth Line,1/19/2024,Inactive,,
CINJ OP INFUSION,56433,"Mayer, Tina M, MD",1/17/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,,1/17/2023,Inactive,,
CBMC OP INFUSION 2FL,53936,"Scoppetuolo, Michael, MD",5/6/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,5/5/2024,Inactive,,
MMC OP INFUSION,71046,"Meghal, Trishala, MD",3/29/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,3/28/2023,Inactive,,
CINJ OP INFUSION,4017,"Aikins, James K, MD",7/19/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,7/18/2024,Active,,
NBR 4N ONCOLOGY,4017,"Aikins, James K, MD",1/30/2025,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_2. Second Line,1/29/2025,Active,,
NBR 4N ONCOLOGY,4017,"Aikins, James K, MD",2/6/2025,AIM (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,_2. Second Line,1/29/2025,Active,"Carcinosarcoma of body of uterus (CMS/HCC)
Fallopian tube cancer, carcinoma, left (CMS/HCC)","C54.9 - Malignant neoplasm of corpus uteri, unspecified; C57.02 - Malignant neoplasm of left fallopian tube; E05.90 - Thyrotoxicosis, unspecified without thyrotoxic crisis or storm; Z51.11 - Encounter for antineoplastic chemotherapy; Z29.89 - Encounter for other specified prophylactic measures"
MMC OP VP INFUSION,24556,"Cohen, Seth D, MD",1/8/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,1/5/2025,Active,,
CBMC OP INFUSION 2FL,52925,"Scoppetuolo, Michael, MD",11/29/2023,CAV (Cyclophosphamide/DOXOrubicin/VinCRIStine) 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,11/6/2023,Inactive,,
CINJ OP INFUSION,21991,"Jang, Thomas L, MD",5/24/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,5/24/2025,Active,Urothelial cancer (CMS/HCC),
CINJ OP INFUSION,21991,"Jang, Thomas L, MD",4/25/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Maintenance,4/25/2025,Inactive,Urothelial cancer (CMS/HCC),
SOM 1PAV ONCOLOGY,59536,"Patel, Eshan, MD",12/2/2024,PACLitaxel / CARBOplatin  7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,12/1/2024,Active,,
SOM OUTPT INFUSION,59536,"Patel, Eshan, MD",12/31/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/30/2024,Active,,
NBI OP INFUSION,89320,"Schleicher, Lori, MD",9/22/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,9/21/2023,Inactive,,
NBI OP INFUSION,89320,"Schleicher, Lori, MD",4/19/2024,"TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast, Pembrolizumab for Colon cancer",_2. Second Line,4/18/2024,Inactive,,
NBI OP INFUSION,89320,"Schleicher, Lori, MD",8/27/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,8/27/2024,Active,,
NBR 4N BMTU/IMCU,68359,"Braunschweig, Ira, MD",1/9/2024,BMT Autologous Melphalan Day -1 140MG/M2,_3. Third Line,1/8/2024,Inactive,,
NBR CINJ OP INFUSION,68359,"Shah, Mansi R, MD",10/3/2024,Elotuzumab / Bortezomib weekly 3 on 1 off / Dexamethasone 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,10/2/2024,Inactive,,
NBR CINJ OP INFUSION,68359,"Shah, Mansi R, MD",12/5/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,12/2/2024,Inactive,,
NBR CINJ OP INFUSION,68359,"Shah, Mansi R, MD",12/26/2024,Talquetamab 28 Day Cycles,_6. Sixth Line,12/26/2024,Active,ALL (acute lymphoid leukemia) in remission (CMS/HCC),
NBR CINJ OP INFUSION,68359,"Shah, Mansi R, MD",2/27/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,2/12/2025,Active,"Multiple myeloma (CMS/HCC)
Multiple myeloma not having achieved remission (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
NBR CINJ OP INFUSION,95219,"Shah, Mansi R, MD",5/19/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Consolidation,5/19/2025,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,23032,"Stephenson, Ruth D, DO",9/12/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,9/11/2024,Active,,
CINJ OP INFUSION,76107,"Stephenson, Ryan D, DO",12/24/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,12/24/2024,Inactive,,
CINJ OP INFUSION,74471,"Groisberg, Roman, MD",9/18/2023,DOXOrubicin 21 Day Cycles - Sarcoma,,9/14/2023,Inactive,,
CINJ OP INFUSION,74471,"Groisberg, Roman, MD",2/16/2024,Pembrolizumab 42 Day Cycles - Melanoma,_1. First Line,2/15/2024,Inactive,,
CINJ OP INFUSION,74471,"Groisberg, Roman, MD",5/22/2024,Ifosfamide / Mesna 21 Day Cycles - Sarcoma,_2. Second Line,5/20/2024,Inactive,,
CINJ OP INFUSION,74471,"Groisberg, Roman, MD",11/1/2024,Gemcitabine 21 Day Cycles - Sarcoma,_3. Third Line,10/31/2024,Active,,
CBMC OP INFUSION 2FL,3387,"Litvak, Anna M, MD",7/6/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,7/5/2023,Inactive,,
CBMC OP INFUSION 2FL,3387,"Litvak, Anna M, MD",10/1/2024,Tucatinib / Capecitabine / Trastuzumab 21 Day Cycles - Breast,_1. First Line,9/30/2024,Inactive,,
CBMC OP INFUSION 2FL,3387,"Ligresti, Louise G, MD",10/3/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,10/2/2024,Inactive,,
CBMC OP INFUSION 2FL,3387,"Litvak, Anna M, MD",10/4/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,10/3/2024,Active,,
SOM OUTPT INFUSION,37510,"Yin, Faye, MD",7/19/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/27/2024,Active,Neoplasm of uncertain behavior of left ovary,
CINJ OP INFUSION,85560,"Berim, Lyudmyla, MD",2/20/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/17/2023,Inactive,,
CBMC OP INFUSION 2FL,5396,"Grossman, I Robert, MD",5/10/2024,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_1. First Line,5/9/2024,Active,,
CINJ OP INFUSION,44950,"Haigentz, Missak, MD",9/6/2024,PEMEtrexed/CISplatin 21 Day Cycles- Malignant Pleural Mesothelioma,Neoadjuvant,8/29/2024,Active,,
CBMC OP INFUSION 2FL,48702,"Wagmiller, Jennifer Ann, MD",8/23/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,8/22/2024,Active,,
CMC OP INFUSION,17605,"Meghal, Trishala, MD",6/27/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,,6/20/2023,Inactive,,
CINJ OP INFUSION,61532,"Talwar, Sumit, MD",1/9/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,1/9/2023,Active,,
CBMC OP INFUSION 2FL,70359,"Brown, Andrew Bennett, MD",1/16/2024,Bevacizumab 28 Day Cycles - GBM,Induction,1/16/2024,Inactive,,
CINJ OP INFUSION,34623,"Dasgeb, Bahar, MD",4/30/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_2. Second Line,4/29/2024,Active,,
CINJ OP INFUSION,95360,"Omene, Coral Oghenerukevwe, MD",1/17/2023,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,1/16/2023,Inactive,,
CINJ OP INFUSION,95360,"Omene, Coral Oghenerukevwe, MD",2/6/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,,1/9/2023,Inactive,,
CINJ OP INFUSION,95360,"Omene, Coral Oghenerukevwe, MD",4/10/2023,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",,3/27/2023,Inactive,,
CINJ OP INFUSION,95360,"Omene, Coral Oghenerukevwe, MD",5/15/2023,CINJ 042102 (I-SPY 2 105139) DOXOrubicin / Cyclophosphamide 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,,5/14/2023,Inactive,,
CINJ OP INFUSION,95360,"Omene, Coral Oghenerukevwe, MD",7/11/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,7/10/2023,Inactive,,
CINJ OP INFUSION,86118,"Stephenson, Ryan D, DO",1/10/2025,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,1/9/2025,Inactive,Malignant neoplasm of dome of urinary bladder (CMS/HCC),
NBI OP INFUSION,4751,"Shah, Shailja S, MD",2/11/2025,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/11/2025,Active,Adenocarcinoma of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C90.00 - Multiple myeloma not having achieved remission"
NBI OP INFUSION,19843,"Shah, Shailja S, MD",3/18/2025,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_2. Second Line,3/18/2025,Inactive,Adenocarcinoma of pancreas (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified; C90.00 - Multiple myeloma not having achieved remission"
NBI OP INFUSION,91164,"Shah, Shailja S, MD",1/28/2025,Ibrutinib 28 Day Cycles - Waldenstrom Macroglobulinemia / Lymphoplasmacytic Lymphoma,_1. First Line,1/28/2025,Active,,
CBMC OP INFUSION 2FL,15808,"Litvak, Anna M, MD",11/3/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,15808,"Litvak, Anna M, MD",11/3/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,11/2/2023,Inactive,,
NBR CINJ OP INFUSION,71688,"Shah, Mansi R, MD",2/2/2023,Daratumumab and Hyaluronidase-fihj/Pom /Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,Consolidation,2/1/2023,Inactive,,
NBR CINJ OP INFUSION,71688,"Shah, Mansi R, MD",3/21/2024,Carfilzomib 70 mg/m2 / Cyclophosphamide IV Plus Dexamethasone 28 Day Cycles - Multiple Myeloma,_3. Third Line,3/20/2024,Inactive,,
NBR CINJ OP INFUSION,71688,"Shah, Mansi R, MD",9/27/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,9/25/2024,Active,,
NBR 4N BMTU/IMCU,98171,"Rhodes, Joanna Meehan, MD",8/29/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,8/29/2024,Inactive,,
CBMC OP INFUSION 2FL,92261,"Phillips, Adrienne A, MD",11/30/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,Maintenance,11/28/2023,Active,Urothelial carcinoma (CMS/HCC),
SOM OUTPT INFUSION,66177,"George, Roshini, DO",10/9/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,10/8/2024,Active,Primary high grade serous adenocarcinoma of ovary (CMS/HCC),
MMC OP VP INFUSION,31643,"Eltoukhy, Hussam, MD",9/19/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,9/17/2024,Active,,
CMC OP INFUSION,97664,"Taff, Jessica, MD",8/21/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,8/16/2023,Inactive,,
CMC OP INFUSION,97664,"Taff, Jessica, MD",2/26/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/22/2024,Inactive,,
CMC OP INFUSION,97664,"Taff, Jessica, MD",5/24/2024,"Encorafenib + Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,5/19/2024,Inactive,,
NBR CINJ OP INFUSION,58047,"Egini, Ogechukwu, MD",6/21/2024,BMT Allogeneic TBF + Post Cy (Reduced Intensity),Consolidation,6/20/2024,Inactive,,
NBR CINJ OP INFUSION,58047,"Egini, Ogechukwu, MD",8/14/2024,RiTUXimab 375 mg/m2 Weekly for Autoimmune Hemolysis,_1. First Line,8/13/2024,Inactive,,
NBR CINJ OP INFUSION,58047,"Egini, Ogechukwu, MD",9/20/2024,Daratumumab for ABO incompatability/ Red cell aplasia 28 Day Cycles,_2. Second Line,9/19/2024,Active,,
CINJ OP INFUSION,49063,"Stephenson, Ryan D, DO",1/27/2025,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,1/24/2025,Active,,
CBMC OP INFUSION 2FL,52777,"Leitner, Stuart P, MD",2/16/2024,CINJ 042102 (I-SPY 2 105139) Block A ARX788 21 Day Cycles Research- Breast Cancer,Neoadjuvant,2/15/2024,Inactive,,
CBMC OP INFUSION 2FL,52777,"Leitner, Stuart P, MD",6/14/2024,CINJ 042102 Block B Pertuzumab / Trastuzumab Weekly / PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer,Neoadjuvant,6/13/2024,Inactive,,
CBMC OP INFUSION 2FL,52777,"Leitner, Stuart P, MD",9/20/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,9/19/2024,Inactive,,
CBMC OP INFUSION 2FL,52777,"Leitner, Stuart P, MD",11/1/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,10/31/2024,Active,,
CMC 4B ONCOLOGY,2239,"Tang, Horace, MD",6/16/2023,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,,6/16/2023,Inactive,,
HAM OP INFUSION,14646,"Yogarajah, Meera, MD",11/12/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/3/2024,Active,,
CINJ OP INFUSION,96073,"Berim, Lyudmyla, MD",5/8/2025,Pembro/Trastuzumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/8/2025,Active,Primary malignant neoplasm of esophagogastric junction (CMS/HCC),"C15.9 - Malignant neoplasm of esophagus, unspecified; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; K22.89 - Other specified disease of esophagus; C16.0 - Malignant neoplasm of cardia"
NBR CINJ OP INFUSION,19871,"Shah, Mansi R, MD",4/11/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/10/2024,Inactive,,
HAM OP INFUSION,80495,"Yogarajah, Meera, MD",5/10/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,5/8/2024,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
CMC OP INFUSION,44113,"Pompa, Tiffany Ann, MD",11/7/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,11/7/2024,Active,,
CBMC OP INFUSION 2FL,734,"Leitner, Stuart P, MD",10/1/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,9/30/2024,Active,,
NBR MEDICAL SAME DAY,734,"Ghodoussipour, Saum Bobak, MD",2/12/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/12/2025,Active,Cancer of left renal pelvis (CMS/HCC),
HAM OP INFUSION,77250,"Yogarajah, Meera, MD",10/12/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,10/9/2023,Inactive,,
SOM OUTPT INFUSION,28799,"Toomey, Kathleen C, MD",2/14/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,2/4/2024,Inactive,,
CINJ OP INFUSION,78487,"George, Mridula A, MD",10/25/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,10/24/2024,Active,,
CINJ OP INFUSION,20057,"Weiss, Sarah, MD",10/21/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,10/15/2024,Active,,
CMC OP INFUSION,25366,"Talwar, Sumit, MD",6/7/2024,XELIRI 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/6/2024,Inactive,,
MMC OP VP INFUSION,3259,"Cohen, Seth D, MD",11/21/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,_1. First Line,11/18/2024,Active,,
CINJ OP INFUSION,52489,"Toppmeyer, Deborah L, MD",8/6/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,7/31/2024,Inactive,,
CINJ OP INFUSION,52489,"Toppmeyer, Deborah L, MD",8/15/2024,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,7/18/2024,Active,,
CINJ OP INFUSION,52489,"Toppmeyer, Deborah L, MD",11/21/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Neoadjuvant,11/20/2024,Active,,
CBMC OP INFUSION 2FL,783,"Wagmiller, Jennifer Ann, MD",12/21/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/17/2023,Inactive,,
CMC OP INFUSION,1109,"Taff, Jessica, MD",11/14/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,11/12/2024,Active,,
JCMC CP INFUSION,65102,"Sekhri, Arunabh, MD",7/13/2023,"PACLitaxel D1, D8 / CARBOplatin D1, D8 21 Day Cycles - Anal",First Line,7/12/2023,Inactive,,
JCMC CP INFUSION,65102,"Sekhri, Arunabh, MD",10/6/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_2. Second Line,10/5/2023,Inactive,,
MMC OP INFUSION,40142,"Lee, Patrick C, MD",12/3/2024,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/3/2024,Active,,
NBI OP INFUSION,18723,"Jacoby, Sari H, MD",11/25/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,11/25/2024,Active,,
SOM OUTPT INFUSION,22583,"Patel, Eshan, MD",11/29/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/28/2023,Inactive,,
SOM OUTPT INFUSION,22583,"Patel, Eshan, MD",3/5/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/4/2024,Inactive,,
SOM OUTPT INFUSION,22583,"Patel, Eshan, MD",5/16/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/15/2024,Active,,
HAM OP INFUSION,18058,"Patel, Malini M, MD",8/5/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,8/4/2024,Inactive,,
HAM OP INFUSION,18058,"Patel, Malini M, MD",9/30/2024,Imetelstat 28 Day Cycles - Myelodysplastic Syndromes,_3. Third Line,9/23/2024,Active,,
MMC OP VP INFUSION,52668,"Cohen, Seth D, MD",3/11/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/11/2025,Active,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Hypothyroidism due to medication",
CINJ OP INFUSION,49697,"Packiam, Vignesh, MD",11/13/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Adjuvant,11/12/2024,Active,,
CINJ OP INFUSION,49697,"Packiam, Vignesh, MD",1/27/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,1/26/2025,Active,,
CINJ OP INFUSION,99982,"Haigentz, Missak, MD",6/11/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/6/2024,Inactive,,
NBI OP INFUSION,11640,"Jacoby, Sari H, MD",6/17/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,6/17/2024,Active,Malignant melanoma of vulva (CMS/HCC),
CINJ OP INFUSION,17719,"Stephenson, Ryan D, DO",3/3/2025,Relugolix 30 day Cycles - Prostate,Adjuvant,3/3/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; M35.3 - Polymyalgia rheumatica; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis"
CINJ OP INFUSION,72178,"Saraiya, Biren P, MD",5/21/2024,Abiraterone (Low Dose) / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/21/2024,Active,,
HAM OP INFUSION,4750,"Patel, Malini M, MD",7/26/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,First Line,7/25/2023,Inactive,,
CBMC OP INFUSION 2FL,72008,"Brown, Andrew Bennett, MD",3/1/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/29/2024,Inactive,,
CBMC OP INFUSION 2FL,72008,"Brown, Andrew Bennett, MD",8/26/2024,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Gastrointestinal Cancers",_2. Second Line,8/25/2024,Inactive,,
MMC OP VP INFUSION,60575,"Talwar, Sumit, MD",9/23/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,9/23/2024,Inactive,,
MMC OP VP INFUSION,60575,"Talwar, Sumit, MD",11/12/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/4/2024,Active,,
CINJ OP INFUSION,64871,"George, Mridula A, MD",4/21/2023,Palbociclib 28 Day Cycles - Breast,Third Line,4/21/2023,Inactive,,
CINJ OP INFUSION,64871,"George, Mridula A, MD",9/25/2024,Elacestrant 28 Day Cycles - Breast,_4. Fourth Line,9/25/2024,Active,,
CINJ OP INFUSION,96847,"Stephenson, Ryan D, DO",9/11/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,9/10/2023,Inactive,,
CINJ OP INFUSION,96847,"Stephenson, Ryan D, DO",10/11/2023,CINJ 082210 Arm C Durvalumab / Gemcitabine 21 Day Cycles Research- Urothelial Cancer,Neoadjuvant,10/10/2023,Inactive,,
CINJ OP INFUSION,80406,"Haigentz, Missak, MD",1/30/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,1/30/2023,Inactive,,
CINJ OP INFUSION,80406,"Haigentz, Missak, MD",3/11/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/10/2024,Inactive,,
CINJ OP INFUSION,80406,"Haigentz, Missak, MD",5/7/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,5/7/2024,Active,,
NBR CINJ OP INFUSION,73411,"Tiger, Yun Kyoung, MD",5/24/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/21/2024,Inactive,,
NBR CINJ OP INFUSION,73411,"Tiger, Yun Kyoung, MD",10/26/2024,Pirtobrutininb 30 Day Cycles -,_2. Second Line,10/26/2024,Active,,
NBR CINJ OP INFUSION,47941,"Zayac, Adam, MD",8/19/2024,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Newly Diagnosed),_1. First Line,8/12/2024,Inactive,,
MMC OP VP INFUSION,64684,"Cohen, Seth D, MD",2/16/2023,Acalabrutinib 30 Day Cycles - CLL,Maintenance,2/16/2023,Inactive,,
MMC OP INFUSION,64684,"Cohen, Seth D, MD",11/28/2023,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,11/28/2023,Inactive,,
MMC OP VP INFUSION,64684,"Cohen, Seth D, MD",6/19/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,6/18/2024,Inactive,,
CMC 4B ONCOLOGY,35999,"Taff, Jessica, MD",11/18/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,11/17/2024,Active,,
CMC OP INFUSION,31484,"Taff, Jessica, MD",3/10/2025,Atezolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/10/2025,Inactive,Lung cancer (CMS/HCC),
SOM OUTPT INFUSION,23425,"Patel, Eshan, MD",6/3/2024,"PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 28 Day Cycles- Non small cell Cancer",_1. First Line,5/29/2024,Active,,
CINJ OP INFUSION,73799,"Hochster, Howard S, MD",6/21/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Second Line,6/20/2023,Inactive,,
CINJ OP INFUSION,73799,"Hochster, Howard S, MD",8/28/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Maintenance,8/28/2024,Inactive,,
CINJ OP INFUSION,36842,"Hochster, Howard S, MD",1/30/2025,Gemcitabine / CISplatin 21 Day Cycles- Panc Cancers-,_3. Third Line,1/29/2025,Active,,
CBMC OP INFUSION 2FL,19091,"Scoppetuolo, Michael, MD",6/10/2024,Bortezomib / RiTUXimab 28 Day Cycles - Waldenstrom Macroglobulinemia / Lymphoplasmacytic Lymphoma,_2. Second Line,6/9/2024,Inactive,,
CBMC OP INFUSION 2FL,81700,"Grossman, I Robert, MD",6/12/2023,VDC / IE (VinCRIStine / DOXOrubicin / Cyclophosphamide / Ifosfamide / Etoposide) 14 Day Cycles - Sarcoma,_1. First Line,6/11/2023,Active,Hodgkin lymphoma (CMS/HCC),
CBMC OP INFUSION 2FL,81700,"Grossman, I Robert, MD",8/19/2024,Irinotecan / Temozolomide 21 Day Cycles - Sarcoma,Maintenance,8/18/2024,Active,,
NBR 5N ONCOLOGY,42741,"Evens, Andrew M, DO",5/2/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/2/2024,Inactive,,
NBR CINJ OP INFUSION,42741,"Evens, Andrew M, DO",10/30/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,10/29/2024,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
NBR CINJ OP INFUSION,96485,"Braunschweig, Ira, MD",2/8/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,2/6/2023,Inactive,,
NBR CINJ OP INFUSION,96485,"Braunschweig, Ira, MD",2/22/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,2/5/2023,Inactive,,
CINJ OP INFUSION,76731,"Muralikrishnan, Sivraj, MD",2/11/2025,PACLitaxel/CARBOplatin + Cemiplimab 21 Day Cycles- Non-Small Cell Lung Cancer EMPOWER NSC121,_1. First Line,2/10/2025,Active,NSCLC of left lung (CMS/HCC),
CMC OP INFUSION,94144,"Taff, Jessica, MD",8/19/2024,DOCEtaxel 21 Day Cycles - Prostate,_3. Third Line,8/11/2024,Inactive,,
CBMC OP INFUSION 2FL,41026,"Kulkarni, Aditya A, MD",11/18/2024,"DOCETAXEL / DAROLUTAMIDE, 21 DAY CYCLES - PROSTATE CANCER",_1. First Line,11/17/2024,Inactive,,
NBR CINJ OP INFUSION,52528,"Braunschweig, Ira, MD",12/18/2023,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_1. First Line,12/17/2023,Inactive,,
NBI OP INFUSION,14850,"Shah, Shailja S, MD",11/26/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/26/2024,Active,,
CINJ OP INFUSION,81603,"Saraiya, Biren P, MD",9/11/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,First Line,9/11/2023,Inactive,,
NBR CINJ OP INFUSION,5707,"Assal, Amer, MD",9/13/2023,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),,9/13/2023,Inactive,,
MMC OP INFUSION,30304,"Meghal, Trishala, MD",6/7/2023,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,,6/6/2023,Inactive,,
MMC OP INFUSION,30304,"Meghal, Trishala, MD",7/14/2023,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,,7/13/2023,Inactive,,
MMC BBR2 ONCOLOGY,30304,"Meghal, Trishala, MD",7/6/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/13/2024,Inactive,,
CBMC OP INFUSION 2FL,33181,"Litvak, Anna M, MD",9/1/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,_1. First Line,8/31/2023,Inactive,,
TRMC TCCC OP INFUSION,20489,"Salerno, Vincent E, MD",12/18/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/17/2024,Active,,
NBR 4N ONCOLOGY,84019,"Zayac, Adam, MD",4/25/2025,FLAG-Ven-TKI (Fludarabine / Cytarabine / IDArubicin / Filgrastim) - CML- Blast Phase (Induction),_2. Second Line,4/24/2025,Active,Blast crisis phase of chronic myeloid leukemia (CMS/HCC),"A41.9 - Sepsis, unspecified organism; E88.3 - Tumor lysis syndrome; D61.810 - Antineoplastic chemotherapy induced pancytopenia; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; J18.9 - Pneumonia, unspecified organism; C91.10 - Chronic lymphocytic leukemia of B-cell type not having achieved remission; D84.821 - Immunodeficiency due to drugs; D63.1 - Anemia in chronic kidney disease; I50.22 - Chronic systolic (congestive) heart failure; C92.10 - Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; D70.9 - Neutropenia, unspecified; N18.9 - Chronic kidney disease, unspecified; I42.9 - Cardiomyopathy, unspecified; N13.6 - Pyonephrosis; E83.39 - Other disorders of phosphorus metabolism; E86.1 - Hypovolemia; D69.59 - Other secondary thrombocytopenia; E87.1 - Hypo-osmolality and hyponatremia; J34.2 - Deviated nasal septum; K21.9 - Gastro-esophageal reflux disease without esophagitis; K82.8 - Other specified diseases of gallbladder; K52.1 - Toxic gastroenteritis and colitis; N17.9 - Acute kidney failure, unspecified; N28.1 - Cyst of kidney, acquired; Q92.8 - Other specified trisomies and partial trisomies of autosomes; R50.81 - Fever presenting with conditions classified elsewhere; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z79.899 - Other long term (current) drug therapy; Z80.6 - Family history of ..."
CINJ OP INFUSION,11045,"Weiss, Sarah, MD",11/29/2023,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,11/28/2023,Active,,
JCMC CP INFUSION,27457,"Cruz, Allan Louie E, MD",1/6/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/2/2025,Active,,
CINJ OP INFUSION,22983,"Boland, Patrick M, MD",10/8/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,10/8/2024,Active,,
CINJ OP INFUSION,22983,"Boland, Patrick M, MD",1/31/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,1/30/2025,Active,,
CBMC OP INFUSION 2FL,67909,"Raptis, George, MD",10/8/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,9/24/2024,Active,,
MMC OP VP INFUSION,2650,"Eltoukhy, Hussam, MD",12/26/2024,Triangle Regimen R-I-CHOP / R-DHAX  (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / Acalabrutinib) / (Dexamethasone / Cytarabine / OXALIplatin) RiTUXimab Every 21 Days - Mantle Cell Lymphoma,_1. First Line,12/18/2024,Active,APL (acute promyelocytic leukemia) (CMS/HCC),
HAM OP INFUSION,43135,"Patel, Malini M, MD",5/21/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,5/16/2025,Active,Non-small cell cancer of left lung (CMS/HCC),C34.32 - Primary malignant neoplasm of left lower lobe of lung (CMS/HCC)
CINJ OP INFUSION,70883,"Saraiya, Biren P, MD",8/28/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,8/28/2023,Active,,
NBR 4N ONCOLOGY,38574,"Tiger, Yun Kyoung, MD",4/8/2024,CINJ 012303 Odronextamab + REGN5837 - NHL,_1. First Line,3/27/2024,Active,,
CMC OP INFUSION,12532,"Taff, Jessica, MD",1/28/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,1/27/2025,Active,,
CMC OP INFUSION,12532,"Taff, Jessica, MD",2/19/2025,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,1/27/2025,Active,Malignant neoplasm of female breast (CMS/HCC),
SOM OUTPT INFUSION,27692,"Patel, Eshan, MD",3/18/2025,Pembrolizumab 21 Day Cycles - GU,_1. First Line,3/18/2025,Active,Adenocarcinoma of prostate (CMS/HCC),
CINJ OP INFUSION,61098,"Stephenson, Ruth D, DO",1/6/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,1/3/2023,Inactive,,
CINJ OP INFUSION,61098,"Stephenson, Ruth D, DO",12/13/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/14/2023,Inactive,,
CMC OP INFUSION,83899,"Tang, Horace, MD",6/12/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,First Line,6/12/2023,Inactive,,
NBR 4N ONCOLOGY,75953,"Braunschweig, Ira, MD",7/21/2023,BMT Autologous BEAM,,7/20/2023,Inactive,,
NBR CINJ OP INFUSION,75953,"Matasar, Matthew J, MD",5/29/2024,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,5/28/2024,Inactive,,
NBR CINJ OP INFUSION,75953,"Matasar, Matthew J, MD",7/24/2024,"Nivolumab (D1, D15) 28 Day Cycles - Hodgkin Lymphoma",_4. Fourth Line,7/23/2024,Active,,
CINJ OP INFUSION,34056,"George, Mridula A, MD",10/25/2024,Capecitabine 21 Day Cycles - Breast,_1. First Line,10/25/2024,Active,,
CBMC OP INFUSION 2FL,52530,"Leitner, Stuart P, MD",11/17/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,11/17/2023,Inactive,,
CINJ OP INFUSION,55947,"Girda, Eugenia, MD",2/22/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Stage IV Uterine cancer ,_1. First Line,2/21/2024,Inactive,,
CINJ OP INFUSION,55947,"Girda, Eugenia, MD",8/1/2024,CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,7/19/2024,Inactive,,
CBMC OP INFUSION 2FL,64211,"Phillips, Adrienne A, MD",7/24/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,7/23/2024,Active,,
CINJ OP INFUSION,98533,"Haigentz, Missak, MD",2/15/2023,Methotrexate Weekly- Head and Neck Cancers,,2/15/2023,Inactive,,
CINJ OP INFUSION,98533,"Haigentz, Missak, MD",3/15/2023,"DOCEtaxel D1, D8, D15 21 Day Cycles- Head and Neck Cancers",,3/14/2023,Inactive,,
CMC OP INFUSION,40026,"Cohen, Seth D, MD",2/20/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,2/19/2024,Inactive,,
CMC OP INFUSION,40026,"Cohen, Seth D, MD",3/5/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,2/26/2024,Inactive,,
CMC OP INFUSION,34793,"Cohen, Seth D, MD",4/4/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,4/4/2025,Active,Multiple myeloma (CMS/HCC),
CBMC OP INFUSION 2FL,96243,"Radovich, Delia, MD",11/30/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,11/21/2023,Inactive,,
JCMC CP INFUSION,48937,"Cruz, Allan Louie E, MD",6/18/2024,PACLitaxel 21 Day Cycles - Recurrent Ovarian Germ Cell,_1. First Line,6/10/2024,Active,,
NBR 5N ONCOLOGY,8385,"Zayac, Adam, MD",4/8/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,4/5/2024,Inactive,,
NBR CINJ OP INFUSION,23337,"Assal, Amer, MD",4/12/2023,Cyclophosphamide for Stem Cell Mobilization,Neoadjuvant,4/12/2023,Inactive,,
CBMC OP INFUSION 2FL,98264,"Grossman, I Robert, MD",3/14/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/7/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,15168,"Mayer, Tina M, MD",8/30/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,8/30/2024,Inactive,,
SOM OUTPT INFUSION,19968,"Toomey, Kathleen C, MD",10/18/2023,"Gemcitabine D1, D8 /Albumin-Bound PACLItaxel D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,10/17/2023,Inactive,,
CINJ OP INFUSION,16882,"Girda, Eugenia, MD",7/8/2024,Trastuzumab 21 Day Cycles,_1. First Line,7/7/2024,Inactive,,
CINJ OP INFUSION,16882,"Girda, Eugenia, MD",10/11/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,10/10/2024,Active,,
CINJ OP INFUSION,33720,"Girda, Eugenia, MD",4/28/2025,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles,_3. Third Line,4/28/2025,Active,"Malignant neoplasm of uterus, part unspecified (CMS/HCC)","C55 - Malignant neoplasm of uterus, part unspecified; I26.99 - Other pulmonary embolism without acute cor pulmonale; K56.609 - Unspecified intestinal obstruction, unspecified as to partial versus complete obstruction; R31.9 - Hematuria, unspecified; Z90.710 - Acquired absence of both cervix and uterus"
CBMC OP INFUSION 2FL,34089,"Brown, Andrew Bennett, MD",4/22/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Consolidation,4/22/2025,Active,Primary squamous cell carcinoma of esophagus (CMS/HCC),
CMC OP INFUSION,86228,"Talwar, Sumit, MD",9/18/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles,_1. First Line,9/17/2023,Inactive,,
CMC OP INFUSION,31192,"Talwar, Sumit, MD",5/28/2025,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,Neoadjuvant,5/28/2025,Active,"Malignant neoplasm of lower-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,81577,"Meghal, Trishala, MD",4/10/2023,Pembrolizumab 21 Day Cycles -  Breast,Adjuvant,4/10/2023,Inactive,,
HAM OP INFUSION,41296,"Patel, Malini M, MD",9/27/2023,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",First Line,9/27/2023,Active,,
CMC OP INFUSION,48494,"Taff, Jessica, MD",4/19/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,9/1/2022,Inactive,,
CMC OP INFUSION,48494,"Taff, Jessica, MD",5/10/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,5/9/2023,Inactive,,
TRMC TCCC OP INFUSION,50077,"Salerno, Vincent E, MD",1/30/2025,RiTUXimab Initial Infusion Single Day (Outpatient) for sarcoidosis,_1. First Line,1/30/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
TRMC TCCC OP INFUSION,50077,"Salerno, Vincent E, MD",1/30/2025,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,_1. First Line,1/29/2025,Inactive,Sarcoidosis,
CINJ OP INFUSION,5894,"Toppmeyer, Deborah L, MD",2/22/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/21/2024,Inactive,,
CINJ OP INFUSION,5894,"Toppmeyer, Deborah L, MD",7/12/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,6/26/2024,Active,,
CBMC OP INFUSION 2FL,54961,"Ligresti, Louise G, MD",11/12/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,11/11/2024,Active,"Acute leukemia not having achieved remission (CMS/HCC)
Anticoagulated",
CINJ OP INFUSION,94885,"Saraiya, Biren P, MD",7/9/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,7/8/2024,Inactive,,
SOM OUTPT INFUSION,16331,"Toomey, Kathleen C, MD",2/16/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles,Neoadjuvant,2/6/2024,Inactive,,
SOM OUTPT INFUSION,16331,"Toomey, Kathleen C, MD",11/8/2024,Capecitabine 21 Day Cycles - Breast,_1. First Line,11/8/2024,Inactive,,
CBMC OP INFUSION 2FL,76717,"Scoppetuolo, Michael, MD",11/29/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,11/26/2023,Inactive,,
CINJ OP INFUSION,50966,"Girda, Eugenia, MD",5/8/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors - 10091805,,5/7/2023,Inactive,,
CINJ OP INFUSION,50966,"Girda, Eugenia, MD",8/30/2023,CINJ 052102 (AN2025S0101) Observation III AN2025 50 mg / AN0025 125 mg / Atezolizumab 21 Day Cycles Research- Advanced Solid Tumors,,7/17/2023,Inactive,,
CBMC 2W ONCOLOGY,22050,"Grossman, I Robert, MD",7/9/2024,Venetoclax / Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_1. First Line,7/8/2024,Active,Malignant tumor of breast (CMS/HCC),
CINJ OP INFUSION,26010,"Patel, Eshan, MD",8/13/2024,carbo etoposide q3 weeks,_1. First Line,8/11/2024,Inactive,,
SOM OUTPT INFUSION,26010,"Patel, Eshan, MD",12/6/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/5/2024,Active,,
CINJ OP INFUSION,42077,"Gulhati, Prateek, MD PhD",1/17/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",,12/19/2022,Inactive,,
CINJ OP INFUSION,42077,"Gulhati, Prateek, MD PhD",2/2/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,2/2/2023,Inactive,,
CINJ OP INFUSION,42077,"Gulhati, Prateek, MD PhD",4/17/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,4/17/2023,Inactive,,
CINJ OP INFUSION,42077,"Gulhati, Prateek, MD PhD",11/30/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_3. Third Line,11/29/2023,Inactive,,
JCMC CP INFUSION,32977,"Sekhri, Arunabh, MD",7/15/2024,"Pembrolizumab 21 Day Cycles- Poorly differentiated Carcinoma, suggestive of pulmonary origin",_1. First Line,7/12/2024,Active,,
MMC OP INFUSION,68249,"Lee, Patrick C, MD",5/23/2023,Enzalutamide 28 Day Cycles - Prostate,,5/23/2023,Active,,
CINJ OP INFUSION,22023,"Ghodoussipour, Saum Bobak, MD",2/12/2024,CINJ 082303 Arm B BCG - Bladder Cancer,Adjuvant,2/11/2024,Inactive,,
CINJ OP INFUSION,22023,"Packiam, Vignesh, MD",6/10/2024,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Adjuvant,6/10/2024,Active,,
MSC OP INFUSION,12883,"Talwar, Sumit, MD",12/11/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,12/10/2024,Active,"Secondary malignant neoplasm of brain and spinal cord (CMS/HCC)
Metastatic lung cancer (metastasis from lung to other site) (CMS/HCC)",
CMC OP INFUSION,22193,"Talwar, Sumit, MD",4/16/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,4/16/2025,Inactive,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,25062,"Tang, Horace, MD",7/10/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles,First Line,7/9/2023,Inactive,,
CMC OP INFUSION,25062,"Tang, Horace, MD",9/15/2023,"Keytruda PACLitaxel D1, D8, D15/CARBOplatin D1, D8, D15 Day Cycles- Non-Small Cell Lung Cancer",,9/15/2023,Inactive,,
CMC OP INFUSION,56178,"Taff, Jessica, MD",2/19/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,2/12/2024,Active,,
CMC OP INFUSION,97384,"Talwar, Sumit, MD",11/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,11/3/2024,Inactive,,
CINJ OP INFUSION,65019,"Leiser, Aliza, MD",4/18/2023,Olaparib 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,4/18/2023,Active,,
CINJ OP INFUSION,22499,"Berim, Lyudmyla, MD",11/13/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - GEJ Cancer,Neoadjuvant,11/12/2023,Inactive,,
CINJ OP INFUSION,21895,"Boland, Patrick M, MD",3/28/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,3/27/2023,Inactive,,
NBR CINJ OP INFUSION,838,"Rhodes, Joanna Meehan, MD",8/29/2024,P-GemOX (Gemcitabine / OXALIplatin / Pegaspargase) 14 Day Cycles - T-Cell Lymphoma,_1. First Line,8/28/2024,Inactive,,
NBR CINJ OP INFUSION,838,"Rhodes, Joanna Meehan, MD",9/16/2024,Carboplatin With Concurrent Radiation 7 Day Cycles - N-KTcell lymphoma,_1. First Line,9/15/2024,Inactive,,
NBR 5N ONCOLOGY,838,"Rhodes, Joanna Meehan, MD",11/29/2024,VIPD  (Etoposide / Mesna / Ifosfamide/ Cisplatin or Carboplatin / DexAMETHasone)  21 Day Cycles - (NK) / T-Cell Lymphoma,_1. First Line,11/20/2024,Active,Prostate cancer (CMS/HCC),
CMC 4B ONCOLOGY,28758,"Tang, Horace, MD",3/8/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,11/16/2021,Inactive,,
CMC OP INFUSION,28758,"Tang, Horace, MD",7/15/2023,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,Second Line,7/15/2023,Inactive,,
CMC OP INFUSION,28758,"Tang, Horace, MD",8/7/2023,FOLFIRI + Cetuximab D1 (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles-Gastrointestinal Cancers,,8/6/2023,Inactive,,
NBR CINJ OP INFUSION,26884,"Matasar, Matthew J, MD",10/30/2024,CINJ 022401 Arm A Sonrotoclax / Zanubrutinib 28 Day Cycles Research- Chronic Lymphocytic Leukemia,_1. First Line,10/29/2024,Active,,
HAM OP INFUSION,84547,"Gendy, Mina, DO",2/13/2025,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,Induction,2/12/2025,Inactive,"Urothelial carcinoma of bladder (CMS/HCC)
Abnormal results of thyroid function studies",
HAM OP INFUSION,84547,"Gendy, Mina, DO",3/13/2025,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,Induction,3/12/2025,Active,Urothelial carcinoma of bladder (CMS/HCC),
HAM OP INFUSION,84547,"Gendy, Mina, DO",3/4/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,3/4/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
NBR CINJ OP INFUSION,94569,"Palmisiano, Neil David, MD",1/18/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,1/18/2023,Inactive,,
NBR CINJ OP INFUSION,94569,"Palmisiano, Neil David, MD",4/29/2023,FLAG + Ven (Fludarabine / Cytarabine / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),Consolidation,4/29/2023,Inactive,,
NBR CINJ OP INFUSION,94569,"Palmisiano, Neil David, MD",6/10/2023,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),,6/10/2023,Inactive,,
NBR CINJ OP INFUSION,94569,"Palmisiano, Neil David, MD",8/7/2023,Decitabine (Induction Phase) 28 Day Cycles - Acute Myeloid Leukemia,,8/6/2023,Inactive,,
NBR 4N ONCOLOGY,94569,"Palmisiano, Neil David, MD",10/2/2023,Cytarabine Cytoreduction for Hyperleukocytosis,,10/2/2023,Inactive,,
NBR CINJ OP INFUSION,94569,"Palmisiano, Neil David, MD",10/12/2023,CINJ 022303 Phase 1 DSP-5336 - Leukemia,Consolidation,10/12/2023,Inactive,,
NBR CINJ OP INFUSION,94569,"Palmisiano, Neil David, MD",1/12/2024,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_4. Fourth Line,1/12/2024,Inactive,,
NBR 5N ONCOLOGY,94569,"Palmisiano, Neil David, MD",2/19/2024,CINJ 022305 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_4. Fourth Line,2/14/2024,Inactive,,
NBR 4N ONCOLOGY,94569,"Shah, Mansi R, MD",3/19/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_5. Fifth Line,3/19/2024,Inactive,,
NBR 4N ONCOLOGY,92211,"Palmisiano, Neil David, MD",1/30/2025,Intraommaya Treatment  - Hematological Malignancies,_1. First Line,1/30/2025,Active,,
NBR 4N ONCOLOGY,92211,"Palmisiano, Neil David, MD",2/1/2025,HyperCVAD + RiTUXimab + Ponatinib (Cyclophosphamide / DOXOrubicin / VinCRIStine / DexAMETHasone / Cytarabine / High-Dose Methotrexate / RiTUXimab) - Acute Lymphoblastic Leukemia,_1. First Line,2/1/2025,Active,Acute lymphoblastic leukemia (ALL) not having achieved remission (CMS/HCC),"C92.10 - Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission; K86.2 - Cyst of pancreas; C91.00 - Acute lymphoblastic leukemia not having achieved remission; N17.9 - Acute kidney failure, unspecified; G51.0 - Bell's palsy; N50.9 - Disorder of male genital organs, unspecified; N28.89 - Other specified disorders of kidney and ureter; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; M43.06 - Spondylolysis, lumbar region; K82.4 - Cholesterolosis of gallbladder; N28.1 - Cyst of kidney, acquired; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,86610,"Jang, Thomas L, MD",1/12/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,1/11/2024,Inactive,,
CINJ OP INFUSION,86610,"Jang, Thomas L, MD",7/12/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Mantenance 28 Day Cycles - Bladder,_1. First Line,6/20/2024,Active,,
CBMC OP INFUSION 2FL,87469,"Leitner, Stuart P, MD",5/1/2024,CINJ 042102 (I-SPY 2 105139) PACLitaxel 7 Day Cycles- HER2 Negative Tumors- Breast Cancer,Neoadjuvant,4/23/2024,Active,,
CINJ OP INFUSION,3322,"Weiss, Sarah, MD",5/15/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,5/14/2023,Inactive,,
CBMC OP INFUSION 2FL,94236,"Litvak, Anna M, MD",12/24/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,12/23/2024,Active,,
CBMC OP INFUSION 2FL,94236,"Litvak, Anna M, MD",1/15/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,12/23/2024,Active,,
CBMC OP INFUSION 2FL,94236,"Litvak, Anna M, MD",3/12/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,_1. First Line,3/12/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP INFUSION,96351,"Meghal, Trishala, MD",2/15/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,,2/14/2023,Inactive,,
NBR 4N ONCOLOGY,8183,"Braunschweig, Ira, MD",1/6/2024,BMT Autologous Melphalan Day -1  200mg/m2,_1. First Line,1/4/2024,Inactive,,
NBR CINJ OP INFUSION,8183,"Assal, Amer, MD",4/27/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,4/25/2024,Inactive,,
CINJ OP INFUSION,85493,"Saraiya, Biren P, MD",10/28/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/28/2024,Active,,
CBMC OP INFUSION 2FL,5392,"Wagmiller, Jennifer Ann, MD",9/20/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,9/17/2024,Active,,
CBMC OP INFUSION 2FL,5392,"Wagmiller, Jennifer Ann, MD",10/23/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,10/21/2024,Active,,
CBMC OP INFUSION 2FL,5392,"Litvak, Anna M, MD",2/7/2025,Ribociclib 28 Day Cycles - Breast,_1. First Line,2/7/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
CINJ OP INFUSION,92466,"Leiser, Aliza, MD",1/22/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,1/14/2024,Inactive,,
CINJ OP INFUSION,92466,"Stephenson, Ruth D, DO",8/5/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,8/5/2024,Active,,
NBI OP INFUSION,22252,"Schleicher, Lori, MD",5/30/2024,Capecitabine 21 Day Cycles - Breast,_3. Third Line,5/30/2024,Inactive,,
NBI OP INFUSION,22252,"Schleicher, Lori, MD",10/21/2024,Capivasertib 28 Day Cycles - Breast,_4. Fourth Line,10/21/2024,Active,,
TRMC TCCC OP INFUSION,9850,"Capo, Gerardo, MD",5/3/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/2/2024,Inactive,,
TRMC TCCC OP INFUSION,9850,"Capo, Gerardo, MD",11/14/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/13/2024,Inactive,,
CBMC OP INFUSION 2FL,99716,"Radovich, Delia, MD",7/19/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_1. First Line,7/18/2023,Inactive,,
CBMC OP INFUSION 2FL,99716,"Wagmiller, Jennifer Ann, MD",3/13/2024,FLOX (Fluorouracil/Leucovorin/OXALIplatin) 56 Day Cycles- Colon Cancer,_2. Second Line,3/6/2024,Inactive,,
CBMC 2W ONCOLOGY,99716,"Wagmiller, Jennifer Ann, MD",3/13/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/12/2024,Inactive,,
MMC OP VP INFUSION,75866,"Lee, Patrick C, MD",3/19/2024,CISplatin With Concurrent Radiation 7 Day Cycles ,_1. First Line,3/17/2024,Inactive,,
CINJ OP INFUSION,10611,"Stein, Stacey",5/6/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/30/2025,Active,Ampullary carcinoma (CMS/HCC),Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm; Z85.09 - Personal history of malignant neoplasm of other digestive organs
NBR 5N ONCOLOGY,51081,"Palmisiano, Neil David, MD",3/22/2023,Cytarabine / IDArubicin / Midostaurin (7 + 3) - Acute Myeloid Leukemia FLT3+ (Induction),,3/21/2023,Inactive,,
NBR 4N ONCOLOGY,51081,"Palmisiano, Neil David, MD",5/17/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,5/17/2023,Inactive,,
NBR 4N BMTU/IMCU,51081,"Schaar, Dale, MD PhD",7/29/2023,BMT Allogeneic TBF + Post Cy ,,7/28/2023,Inactive,,
NBR CINJ OP INFUSION,51081,"Palmisiano, Neil David, MD",11/27/2023,CINJ 022301 Iadademstat / Gilteritinib 28 Day Cycles Research- Acute Myeloid Leukemia,_2. Second Line,11/20/2023,Inactive,,
NBR 4N ONCOLOGY,51081,"Palmisiano, Neil David, MD",1/19/2024,Venetoclax / Decitabine / Gilteritinib 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_4. Fourth Line,1/19/2024,Inactive,,
NBR 5N ONCOLOGY,51081,"Palmisiano, Neil David, MD",4/11/2024,Cytarabine Cytoreduction for Hyperleukocytosis,Lymphodepletion,4/11/2024,Inactive,,
NBR 5N ONCOLOGY,51081,"Palmisiano, Neil David, MD",4/18/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_6. Sixth Line,4/18/2024,Inactive,,
NBR 5N ONCOLOGY,51081,"Palmisiano, Neil David, MD",4/18/2024,CINJ 022305 Ziftomenib / Venetoclax / Azacitadine 28 Day Cycles Research- Acute Myeloid Leukemia,_3. Third Line,4/17/2024,Inactive,,
NBR 5N ONCOLOGY,51081,"Palmisiano, Neil David, MD",4/25/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,4/25/2024,Inactive,,
JCMC CP INFUSION,16478,"Sekhri, Arunabh, MD",11/4/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,10/31/2024,Active,,
CINJ OP INFUSION,88509,"Goel, Sanjay, MD",10/9/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,10/8/2023,Inactive,,
CINJ OP INFUSION,88509,"Goel, Sanjay, MD",11/21/2024,CINJ 052310 Dose Escalation / Pharmacodynamic AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_6. Sixth Line,11/21/2024,Active,,
NBR 4N ONCOLOGY,11137,"George, Mridula A, MD",1/26/2025,mFOLFOX6 Inpatient (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/25/2025,Active,,
SOM OUTPT INFUSION,40828,"George, Roshini, DO",4/16/2025,R-CDOP (Cyclophosphamide /Liposomal DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/16/2025,Inactive,Diffuse large B-cell lymphoma of intra-abdominal lymph nodes (CMS/HCC),
CINJ OP INFUSION,75967,"Boland, Patrick M, MD",8/6/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,8/5/2024,Active,,
CINJ OP INFUSION,1805,"Saraiya, Biren P, MD",9/27/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/27/2024,Inactive,,
CINJ OP INFUSION,1805,"Saraiya, Biren P, MD",12/17/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,12/17/2024,Active,,
CINJ OP INFUSION,1805,"Saraiya, Biren P, MD",1/14/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,1/14/2025,Active,,
NBR CINJ OP INFUSION,74773,"Evens, Andrew M, DO",4/26/2023,Brentuximab Vedotin 21 Day Cycles + DOXOrubicin / VinBLAStine / Dacarbazine 28 Day Cycles + Brentuximab Vedotin 21 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/25/2023,Inactive,,
CBMC OP INFUSION 2FL,52700,"Grossman, I Robert, MD",3/29/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,3/28/2023,Active,,
CMC OP INFUSION,73184,"Pompa, Tiffany Ann, MD",11/6/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Adjuvant,11/6/2024,Inactive,,
CINJ OP INFUSION,4492,"Stephenson, Ryan D, DO",1/30/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,First Line,1/29/2023,Inactive,,
CINJ OP INFUSION,4492,"Stephenson, Ryan D, DO",3/6/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,Adjuvant,3/5/2023,Inactive,,
HAM OP INFUSION,98968,"Patel, Malini M, MD",1/6/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_2. Second Line,12/22/2024,Active,,
SOM OUTPT INFUSION,19757,"Toomey, Kathleen C, MD",12/31/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,12/30/2024,Active,Serous adenocarcinoma of uterus (CMS/HCC),
SOM OUTPT INFUSION,19757,"Toomey, Kathleen C, MD",5/7/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,5/7/2025,Active,Breast cancer (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C50.122 - Malignant neoplasm of central portion of left male breast; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; K52.1 - Toxic gastroenteritis and colitis; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; E86.0 - Dehydration; R53.83 - Other fatigue; Z17.0 - Estrogen receptor positive status (ER+)"
MSC OP INFUSION,34517,"Boland, Patrick M, MD",11/30/2023,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,10/12/2023,Active,,
CBMC OP INFUSION 2FL,56676,"Grossman, I Robert, MD",8/19/2024,RiTUXimab Initial Infusion +++  Day (Outpatient),_1. First Line,8/12/2024,Active,Breast cancer (CMS/HCC),
NBR 5N ONCOLOGY,94501,"Shah, Mansi R, MD",11/12/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,11/12/2024,Inactive,,
NBR CINJ OP INFUSION,94501,"Rhodes, Joanna Meehan, MD",12/2/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/1/2024,Active,,
CBMC OP INFUSION 2FL,39104,"Scoppetuolo, Michael, MD",10/19/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_3. Third Line,10/11/2023,Inactive,,
CBMC OP INFUSION 2FL,39104,"Scoppetuolo, Michael, MD",1/11/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_3. Third Line,1/4/2024,Inactive,,
CBMC OP INFUSION 2FL,39104,"Scoppetuolo, Michael, MD",2/22/2024,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,2/14/2024,Inactive,,
CINJ OP INFUSION,53382,"Hochster, Howard S, MD",8/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/20/2024,Active,,
CINJ OP INFUSION,44721,"Mayer, Tina M, MD",12/11/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,12/10/2023,Inactive,,
JCMC CP INFUSION,51671,"Sekhri, Arunabh, MD",1/8/2024,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_1. First Line,1/7/2024,Inactive,,
JCMC CP INFUSION,51671,"Sekhri, Arunabh, MD",1/18/2024,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles + Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,1/7/2024,Inactive,,
JCMC CP INFUSION,51671,"Sekhri, Arunabh, MD",2/8/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/7/2024,Inactive,,
HAM OP INFUSION,39887,"Yogarajah, Meera, MD",3/21/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/12/2024,Inactive,,
HAM OP INFUSION,39887,"Yogarajah, Meera, MD",4/15/2024,CISplatin/Etoposide with Concurrent Radiation 28 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,4/14/2024,Inactive,,
HAM OP INFUSION,39887,"Yogarajah, Meera, MD",5/30/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/22/2024,Active,,
CINJ OP INFUSION,36956,"Stephenson, Ryan D, DO",10/31/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/31/2024,Inactive,,
CINJ OP INFUSION,65036,"Aikins, James K, MD",6/29/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,6/7/2023,Inactive,,
NBR 5N ONCOLOGY,65036,"Aikins, James K, MD",3/27/2024,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,3/27/2024,Inactive,,
CINJ OP INFUSION,65036,"Aikins, James K, MD",5/10/2024,DOCEtaxel / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,4/24/2024,Inactive,,
CINJ OP INFUSION,65036,"Aikins, James K, MD",8/23/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,8/11/2024,Inactive,,
CINJ OP INFUSION,31886,"Haigentz, Missak, MD",9/11/2023,CINJ 032212 Cohort 2 Pemetrexed / CARBOplatin / Amivantamab Patients 21 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,9/10/2023,Active,,
CINJ OP INFUSION,23816,"Haigentz, Missak, MD",5/9/2025,Osimertinib 160mg - 28 Day Cycles- EGFR Exon 20 insertion positive Non-Small Cell Lung Cancer,_3. Third Line,5/9/2025,Active,"Adenocarcinoma of right lung, stage 4 (CMS/HCC)
Malignant neoplasm metastatic to brain (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)",
CINJ OP INFUSION,23816,"Haigentz, Missak, MD",3/11/2025,PACLitaxel/CARBOplatin + Bevacizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,3/11/2025,Inactive,"Adenocarcinoma of right lung, stage 4 (CMS/HCC)
Malignant neoplasm metastatic to brain (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)",C34.91 - Malignant neoplasm of unspecified part of right bronchus or lung; C79.31 - Secondary malignant neoplasm of brain; C79.51 - Secondary malignant neoplasm of bone; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C34.01 - Malignant neoplasm of right main bronchus
HAM OP INFUSION,31456,"Yogarajah, Meera, MD",6/12/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,First Line,6/4/2023,Inactive,,
NBR CINJ OP INFUSION,31456,"Palmisiano, Neil David, MD",12/9/2024,HAM-Ven (High-Dose Cytarabine/ MitoXANTRONE / Venetoclax) - Acute Myeloid Leukemia,_2. Second Line,12/9/2024,Inactive,,
MMC OP VP INFUSION,44972,"Cohen, Seth D, MD",5/8/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles -Breast (started 6/1/21),,5/7/2023,Active,,
NBR MEDICAL SAME DAY,39019,"Golombos, David, MD",2/20/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,2/20/2025,Active,"Urothelial carcinoma of kidney, left (CMS/HCC)",
NBR MEDICAL SAME DAY,39019,"Golombos, David, MD",4/22/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/22/2025,Active,"Urothelial carcinoma of kidney, left (CMS/HCC)",
HAM OP INFUSION,31694,"Yogarajah, Meera, MD",12/19/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,12/18/2023,Inactive,,
NBI OP INFUSION,23000,"Anderson, Patrick S, MD",10/10/2023,Topotecan 21 Day Cycles - Uterine,_3. Third Line,10/9/2023,Inactive,,
CINJ OP INFUSION,69527,"George, Mridula A, MD",2/12/2024,Palbociclib 28 Day Cycles - Breast,,2/12/2024,Active,,
CINJ OP INFUSION,47159,"Weiss, Sarah, MD",4/21/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,4/18/2025,Inactive,Malignant melanoma of left lower extremity including hip (CMS/HCC),"C43.72 - Malignant melanoma of left lower limb, including hip"
CINJ OP INFUSION,95696,"Weiss, Sarah, MD",4/8/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,4/8/2025,Active,Metastatic melanoma (CMS/HCC),"C43.39 - Malignant melanoma of other parts of face; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified; C43.9 - Malignant melanoma of skin, unspecified"
CINJ OP INFUSION,65152,"Toppmeyer, Deborah L, MD",4/20/2023,Palbociclib 28 Day Cycles - Breast,First Line,4/20/2023,Active,,
CBMC OP INFUSION 2FL,29525,"Leitner, Stuart P, MD",7/23/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_3. Third Line,7/22/2024,Active,,
MMC OP VP INFUSION,85626,"Meghal, Trishala, MD",8/21/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,8/20/2023,Inactive,,
MMC OP INFUSION,85626,"Meghal, Trishala, MD",10/6/2023,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,Adjuvant,10/5/2023,Inactive,,
CBMC OP INFUSION 2FL,36125,"Brown, Andrew Bennett, MD",6/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,6/5/2024,Active,,
JCMC CP INFUSION,93703,"Sekhri, Arunabh, MD",9/18/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,9/17/2024,Inactive,,
NBI OP INFUSION,4280,"Schleicher, Lori, MD",2/13/2024,PEMBROLIZUMAB + GEMCITABINE + CARBOPLATIN 21 DAY CYCLES - Lung CANCER,_1. First Line,2/12/2024,Inactive,,
NBR CINJ OP INFUSION,4473,"Shah, Mansi R, MD",6/30/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_3. Third Line,6/30/2024,Inactive,,
NBR CINJ OP INFUSION,4473,"Shah, Mansi R, MD",7/11/2024,Daratumumab and Hyaluronidase-fihj/velcade/ Dex 28 Day Cycles- Multiple Myeloma,_2. Second Line,7/10/2024,Inactive,,
NBR 5N ONCOLOGY,4473,"Shah, Mansi R, MD",7/13/2024,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_3. Third Line,7/13/2024,Inactive,,
MMC OP VP INFUSION,97975,"Meghal, Trishala, MD",3/14/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,3/14/2024,Inactive,,
MMC OP VP INFUSION,97975,"Meghal, Trishala, MD",11/25/2024,Abemaciclib 28 Day Cycles - Breast,_2. Second Line,11/25/2024,Active,,
MMC OP VP INFUSION,50772,"Cohen, Seth D, MD",3/20/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,3/20/2025,Active,"Invasive carcinoma of breast (CMS/HCC)
Encounter for screening for viral disease",
CINJ OP INFUSION,73589,"Goel, Sanjay, MD",4/21/2025,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,4/21/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),
CBMC OP INFUSION 2FL,2072,"Litvak, Anna M, MD",12/20/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,12/19/2024,Active,"Hodgkin lymphoma, unspecified, unspecified site (CMS/HCC)",
CBMC OP INFUSION 2FL,2072,"Litvak, Anna M, MD",5/20/2025,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,5/20/2025,Active,Malignant neoplasm of central portion of right breast (CMS/HCC),C50.111 - Malignant neoplasm of central portion of right female breast
CBMC OP INFUSION 2FL,2072,"Litvak, Anna M, MD",5/20/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,5/20/2025,Active,Malignant neoplasm of central portion of right breast (CMS/HCC),"C50.111 - Malignant neoplasm of central portion of right female breast; C50.911 - Malignant neoplasm of unspecified site of right female breast; L81.9 - Disorder of pigmentation, unspecified; R23.4 - Changes in skin texture; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; Z65.8 - Other specified problems related to psychosocial circumstances; Z17.0 - Estrogen receptor positive status (ER+)"
CINJ OP INFUSION,17973,"Toppmeyer, Deborah L, MD",7/17/2023,Palbociclib 28 Day Cycles - Breast,First Line,7/17/2023,Active,,
CINJ OP INFUSION,65083,"Packiam, Vignesh, MD",11/6/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,Induction,11/5/2024,Active,,
CINJ OP INFUSION,65921,"Packiam, Vignesh, MD",2/5/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Maintenance,2/4/2025,Active,Bladder cancer (CMS/HCC),
CINJ OP INFUSION,23661,"Omene, Coral Oghenerukevwe, MD",1/14/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,1/13/2025,Active,,
MMC OP INFUSION,11548,"Cohen, Seth D, MD",1/4/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,First Line,1/3/2023,Inactive,,
CINJ OP INFUSION,40382,"Saraiya, Biren P, MD",4/10/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,4/10/2023,Active,,
CMC OP INFUSION,32688,"Taff, Jessica, MD",5/4/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Unknown Primary,Neoadjuvant,5/3/2023,Inactive,,
CMC OP INFUSION,63642,"Taff, Jessica, MD",5/5/2023,Nivolumab/Ipilimumab + PACLitaxel/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,Neoadjuvant,5/4/2023,Inactive,,
MMC OP INFUSION,79464,"Meghal, Trishala, MD",5/17/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,4/25/2023,Inactive,,
MMC OP INFUSION,79464,"Meghal, Trishala, MD",10/16/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,9/25/2024,Active,,
CBMC OP INFUSION 2FL,85440,"Derosa, William T, DO",1/28/2025,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_2. Second Line,1/23/2025,Active,,
CINJ OP INFUSION,67110,"Stephenson, Ryan D, DO",6/12/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,6/12/2024,Active,,
NBI OP INFUSION,56653,"Jacoby, Sari H, MD",1/31/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/30/2024,Active,,
TRMC TCCC OP INFUSION,53802,"Capo, Gerardo, MD",5/23/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,5/22/2024,Active,"Cancer of ovary (CMS/HCC)
Malignant neoplasm of both ovaries (CMS/HCC)",
CBMC OP INFUSION 2FL,44296,"Leitner, Stuart P, MD",4/22/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/22/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
CMC OP INFUSION,7401,"Taff, Jessica, MD",8/12/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,8/10/2024,Inactive,,
CMC OP INFUSION,7401,"Taff, Jessica, MD",9/10/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/8/2024,Active,,
CINJ OP INFUSION,98896,"Boland, Patrick M, MD",6/14/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/31/2024,Active,,
SOM OUTPT INFUSION,76015,"Yin, Faye, MD",3/27/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,3/21/2023,Inactive,,
SOM OUTPT INFUSION,76015,"Yin, Faye, MD",12/4/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/1/2023,Inactive,,
SOM OUTPT INFUSION,76015,"Yin, Faye, MD",1/29/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,1/28/2024,Inactive,,
SOM OUTPT INFUSION,76015,"Yin, Faye, MD",2/6/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_3. Third Line,2/6/2024,Inactive,,
SOM OUTPT INFUSION,76015,"Patel, Eshan, MD",5/6/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/3/2024,Active,,
CINJ OP INFUSION,8604,"Berim, Lyudmyla, MD",1/9/2025,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/8/2025,Active,,
CINJ OP INFUSION,8604,"Berim, Lyudmyla, MD",2/20/2025,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,2/19/2025,Active,Malignant neoplasm of upper third of esophagus (CMS/HCC),C15.3 - Malignant neoplasm of upper third of esophagus
SOM OUTPT INFUSION,58629,"Toomey, Kathleen C, MD",11/15/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,11/12/2024,Active,Malignant neoplasm of female breast (CMS/HCC),
CBMC OP INFUSION 2FL,73066,"Wagmiller, Jennifer Ann, MD",12/7/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,12/6/2023,Inactive,,
CBMC OP INFUSION 2FL,73066,"Wagmiller, Jennifer Ann, MD",12/5/2024,Everolimus / exemestane 28 Day Cycles - Uterine,_3. Third Line,12/5/2024,Active,,
CMC OP INFUSION,22906,"Easaw, Sarah, MD",5/1/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,Maintenance,5/1/2023,Inactive,,
CMC OP INFUSION,22906,"Easaw, Sarah, MD",5/26/2023,Pembrolizumab / Cetuximab 21 Day Cycles- Head and Neck Cancers,Maintenance,5/1/2023,Inactive,,
HAM OP INFUSION,50193,"Yogarajah, Meera, MD",5/8/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gallbladder cancer,First Line,5/8/2023,Inactive,,
HAM OP INFUSION,14705,"Yogarajah, Meera, MD",4/24/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,First Line,4/4/2023,Inactive,,
CINJ OP INFUSION,58438,"Dasgeb, Bahar, MD",4/29/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,4/29/2025,Active,Squamous cell carcinoma of multiple sites,
CINJ OP INFUSION,87263,"Mayer, Tina M, MD",2/14/2023,CINJ 082106 Pembrolizumab / Belzutifan or Placebo 42 Day Cycles Research- Renal Cell Carcinoma,Adjuvant,2/13/2023,Inactive,,
CINJ OP INFUSION,87263,"Mayer, Tina M, MD",3/2/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,,3/2/2023,Inactive,,
CINJ OP INFUSION,49982,"Stephenson, Ryan D, DO",11/20/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,11/20/2023,Active,,
MSC OP INFUSION,7436,"Easaw, Sarah, MD",5/4/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/23/2023,Inactive,,
NBI D7 MED-SURG/TELE,45774,"Jacoby, Sari H, MD",7/27/2024,RiTUXimab Rapid Infusion Single Day (Outpatient),_1. First Line,7/27/2024,Inactive,,
MMC OP VP INFUSION,25654,"Lee, Patrick C, MD",10/19/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,10/19/2023,Inactive,,
MMC OP INFUSION,25654,"Lee, Patrick C, MD",1/16/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,1/8/2024,Inactive,,
HAM OP INFUSION,37620,"Yogarajah, Meera, MD",11/8/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,11/3/2024,Active,,
HAM OP INFUSION,37620,"Yogarajah, Meera, MD",3/27/2025,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,3/27/2025,Active,"Metastatic hepatocellular carcinoma to bone (CMS/HCC)
Hypothyroidism due to drugs
Other problems related to lifestyle
Encounter for screening for other viral diseases",
JCMC CP INFUSION,8295,"Sekhri, Arunabh, MD",4/1/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_1. First Line,4/1/2024,Active,,
CMC OP INFUSION,98748,"Eltoukhy, Hussam, MD",10/14/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,10/13/2024,Active,,
CMC OP INFUSION,37134,"Eltoukhy, Hussam, MD",2/27/2025,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,2/26/2025,Active,"MDS (myelodysplastic syndrome) (CMS/HCC)
Encounter for screening for other viral diseases
Multiple myeloma (CMS/HCC)",
CMC OP INFUSION,37134,"Eltoukhy, Hussam, MD",2/27/2025,Isatuximab-irfc- Multiple Myeloma,_1. First Line,2/25/2025,Active,Multiple myeloma (CMS/HCC),
CMC OP INFUSION,37134,"Eltoukhy, Hussam, MD",4/2/2025,Isatuximab-irfc- Multiple Myeloma,_1. First Line,2/27/2025,Inactive,Multiple myeloma (CMS/HCC),
CMC OP INFUSION,37134,"Eltoukhy, Hussam, MD",3/20/2025,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,2/27/2025,Active,"MDS (myelodysplastic syndrome) (CMS/HCC)
Encounter for screening for other viral diseases
Multiple myeloma (CMS/HCC)",
JCMC CP INFUSION,39949,"Sekhri, Arunabh, MD",5/26/2023,Bevacizumab Maintenance 21 Day Cycles- Gastrointestinal Cancers,Third Line,4/10/2023,Inactive,,
CINJ OP INFUSION,39949,"Gulhati, Prateek, MD PhD",10/11/2023,CINJ 072304 Cohort 1 ME-344 + Bevacizumab - Colorectal Cancer,_4. Fourth Line,10/11/2023,Inactive,,
CINJ OP INFUSION,39949,"Gulhati, Prateek, MD PhD",2/22/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_4. Fourth Line,2/22/2024,Inactive,,
CINJ OP INFUSION,39949,"Gulhati, Prateek, MD PhD",3/28/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,2/27/2024,Inactive,,
CBMC OP INFUSION 2FL,13191,"Brown, Andrew Bennett, MD",4/3/2024,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,4/3/2024,Inactive,,
CINJ OP INFUSION,73900,"Boland, Patrick M, MD",12/1/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/24/2023,Inactive,,
CINJ OP INFUSION,73900,"Boland, Patrick M, MD",2/16/2024,"Encorafenib + Panitumumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,2/15/2024,Inactive,,
CINJ PEDS HEMONC ,81004,"Drachtman, Richard, MD",4/18/2025,PEDS R-CHOP - B-Cell Lymphoma,_1. First Line,4/18/2025,Inactive,Nodular lymphocyte predominant Hodgkin lymphoma of lymph nodes of neck (CMS/HCC),
CINJ PEDS HEMONC ,81004,"Drachtman, Richard, MD",4/3/2025,"PEDS CHOP- B-Cell Lymphoma, following as per AHOD03P1",_1. First Line,4/3/2025,Inactive,Nodular lymphocyte predominant Hodgkin lymphoma of lymph nodes of neck (CMS/HCC),"C81.01 - Nodular lymphocyte predominant hodgkin lymphoma, lymph nodes of head, face, and neck; C81.40 - Lymphocyte-rich Hodgkin lymphoma, unspecified site"
TRMC TCCC OP INFUSION,44058,"Salerno, Vincent E, MD",9/18/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,9/18/2024,Active,,
NBR 4N ONCOLOGY,9894,"Boland, Patrick M, MD",12/1/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/30/2023,Inactive,,
CINJ OP INFUSION,75110,"Omene, Coral Oghenerukevwe, MD",7/12/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,7/11/2023,Inactive,,
CINJ OP INFUSION,75110,"Omene, Coral Oghenerukevwe, MD",11/21/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,11/20/2023,Inactive,,
CINJ OP INFUSION,75110,"Omene, Coral Oghenerukevwe, MD",1/23/2024,Adjuvant Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/22/2024,Active,,
NBR 5N ONCOLOGY,40966,"Palmisiano, Neil David, MD",6/14/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,6/14/2024,Inactive,,
NBR 5N ONCOLOGY,40966,"Zayac, Adam, MD",6/14/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Neoadjuvant,6/14/2024,Inactive,,
CBMC OP INFUSION 2FL,29257,"Wagmiller, Jennifer Ann, MD",11/20/2023,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,11/19/2023,Inactive,,
NBR CINJ OP INFUSION,26172,"Egini, Ogechukwu, MD",4/11/2025,BMT Allogeneic Flu / Cy / TBI + Post Cy,_6. Sixth Line,4/10/2025,Active,"Diffuse large B-cell lymphoma, unspecified site (CMS/HCC)",
CBMC OP INFUSION 2FL,79459,"Raptis, George, MD",9/11/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,9/10/2024,Inactive,,
CINJ OP INFUSION,31312,"Weiss, Sarah, MD",10/14/2024,CINJ 092204 ((Fianlimab (1600 mg = Arm A or 400 mg = Arm B) + Cemiplimab 350 mg)) or (Pembrolizumab = Arm C) 21 Day Cycles Research- Melanoma,Adjuvant,10/13/2024,Active,,
CINJ OP INFUSION,31312,"Weiss, Sarah, MD",2/5/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,2/2/2025,Active,Malignant melanoma of left breast (CMS/HCC),"C43.52 - Malignant melanoma of skin of breast; E78.5 - Hyperlipidemia, unspecified; M81.0 - Age-related osteoporosis without current pathological fracture; R73.03 - Prediabetes; Z79.83 - Long term (current) use of bisphosphonates; Z79.899 - Other long term (current) drug therapy; Z88.5 - Allergy status to narcotic agent; Z88.6 - Allergy status to analgesic agent"
CINJ OP INFUSION,21982,"Berim, Lyudmyla, MD",2/16/2023,CINJ 071702 (MK-3475-535) Pembrolizumab 21 Day Cycles Pre-Operative Research- Gastric Cancer,,2/14/2023,Inactive,,
CINJ OP INFUSION,21982,"Berim, Lyudmyla, MD",7/7/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,,7/5/2023,Inactive,,
MMC OP VP INFUSION,53820,"Cohen, Seth D, MD",5/19/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,5/15/2023,Inactive,,
JCMC CP INFUSION,41827,"Sekhri, Arunabh, MD",7/24/2024,PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,7/14/2024,Active,,
CINJ OP INFUSION,96512,"Girda, Eugenia, MD",3/18/2024,Megestrol / Tamoxifen (GOG 3007) 42 Day Cycles - Uterine,_4. Fourth Line,3/18/2024,Inactive,,
CINJ OP INFUSION,96512,"Girda, Eugenia, MD",5/1/2024,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,3/28/2024,Active,,
CINJ OP INFUSION,96512,"Girda, Eugenia, MD",1/30/2025,Abemaciclib 28 Day Cycles - Uterine,_5. Fifth Line,1/30/2025,Active,,
CINJ OP INFUSION,96512,"Stephenson, Ruth D, DO",1/30/2025,Letrozole 30 Day Cycles - Uterine,_5. Fifth Line,1/30/2025,Active,,
CINJ OP INFUSION,63203,"Stephenson, Ruth D, DO",10/9/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,10/8/2024,Active,,
MMC OP VP INFUSION,65825,"Cohen, Seth D, MD",7/10/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,Third Line,7/9/2023,Inactive,,
MMC OP VP INFUSION,65825,"Cohen, Seth D, MD",5/28/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/27/2024,Inactive,,
MMC OP VP INFUSION,65825,"Cohen, Seth D, MD",6/5/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_4. Fourth Line,6/5/2024,Inactive,,
MMC OP VP INFUSION,84788,"Cohen, Seth D, MD",8/22/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,8/21/2024,Inactive,,
MMC OP VP INFUSION,84788,"Cohen, Seth D, MD",12/9/2024,Gemcitabine with Concurrent Radiation Preceding Adjuvant Chemotherapy Weekly- Pancreatic Adenocarcinoma,_2. Second Line,12/8/2024,Inactive,,
JCMC CP INFUSION,1508,"Cruz, Allan Louie E, MD",10/11/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,10/4/2023,Inactive,,
JCMC CP INFUSION,1508,"Cruz, Allan Louie E, MD",11/1/2023,"CARBOplatin, Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",Neoadjuvant,11/1/2023,Inactive,,
JCMC CP INFUSION,1508,"Cruz, Allan Louie E, MD",6/6/2024,"Albumin-Bound PACLitaxel, (D1, D8, D15) 28 Day Cycles - serous ovarian cancer",_1. First Line,5/30/2024,Inactive,,
JCMC CP INFUSION,1508,"Cruz, Allan Louie E, MD",10/16/2024,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,10/15/2024,Active,,
NBI OP INFUSION,59132,"Anderson, Patrick S, MD",5/9/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/9/2024,Active,,
MMC OP VP INFUSION,9294,"Patel, Nell Maloney, MD",10/24/2023,PACLitaxel weekly 28 Day Cycles - Bladder,_5. Fifth Line,10/23/2023,Inactive,,
CMC 4B ONCOLOGY,92648,"Taff, Jessica, MD",7/18/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,7/16/2023,Inactive,,
CMC OP INFUSION,92648,"Taff, Jessica, MD",11/13/2023,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,11/12/2023,Active,,
CBMC OP INFUSION 2FL,80293,"Leitner, Stuart P, MD",9/26/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_2. Second Line,9/25/2023,Inactive,,
CBMC OP INFUSION 2FL,80293,"Leitner, Stuart P, MD",5/10/2024,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,5/7/2024,Active,Carcinoma of prostate (CMS/HCC),
HAM OP INFUSION,52936,"Yogarajah, Meera, MD",1/26/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,1/18/2023,Inactive,,
CINJ OP INFUSION,20664,"In, Haejin, MD",4/21/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,4/21/2025,Active,Low grade mucinous neoplasm of appendix,
CINJ OP INFUSION,53107,"Mayer, Tina M, MD",2/5/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,2/5/2024,Active,,
CBMC 2W ONCOLOGY,34216,"McKenna, Marshall, MD",5/2/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,5/2/2025,Active,CNS lymphoma (CMS/HCC),"C83.31 - Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck; G93.6 - Cerebral edema; J18.9 - Pneumonia, unspecified organism; T86.19 - Other complication of kidney transplant; D47.Z1 - Post-transplant lymphoproliferative disorder (PTLD); D84.821 - Immunodeficiency due to drugs; D69.6 - Thrombocytopenia, unspecified; E83.39 - Other disorders of phosphorus metabolism; E11.65 - Type 2 diabetes mellitus with hyperglycemia; C83.390 - Primary central nervous system lymphoma; E03.9 - Hypothyroidism, unspecified; I10 - Essential (primary) hypertension; E66.812 - Obesity, class 2; D63.0 - Anemia in neoplastic disease; Z79.4 - Long term (current) use of insulin; E78.5 - Hyperlipidemia, unspecified; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; M48.061 - Spinal stenosis, lumbar region without neurogenic claudication; G89.29 - Other chronic pain; R26.2 - Difficulty in walking, not elsewhere classified; Z74.09 - Other reduced mobility; R07.2 - Precordial pain; Z79.890 - Hormone replacement therapy; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.624 - Long term (current) use of inhibitors of nucleotide synthesis; Z79.621 - Long term (current) use of calcineurin inhibitor; Z79.899 - Other long term (current) drug therapy; Z22.7 - Latent tuberculosis; Z68.35 - Body mass index (BMI) 35.0-35.9, adult"
CBMC OP INFUSION 2FL,51274,"Brown, Andrew Bennett, MD",11/6/2023,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,_1. First Line,11/5/2023,Inactive,,
CBMC OP INFUSION 2FL,51274,"Wagmiller, Jennifer Ann, MD",12/26/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,12/25/2023,Inactive,,
CINJ OP INFUSION,61643,"Berim, Lyudmyla, MD",5/13/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,4/28/2024,Inactive,,
CINJ OP INFUSION,88226,"Aikins, James K, MD",7/6/2023,Rucaparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,7/6/2023,Inactive,,
CINJ OP INFUSION,88226,"Aikins, James K, MD",1/10/2025,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,12/27/2024,Active,,
CINJ OP INFUSION,33599,"Aikins, James K, MD",5/13/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,5/12/2025,Active,"Drug-induced polyneuropathy (CMS/HCC)
Malignant ascites
Malignant neoplasm of unspecified ovary (CMS/HCC)",
CINJ OP INFUSION,33599,"Aikins, James K, MD",5/9/2025,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_4. Fourth Line,5/9/2025,Inactive,"Drug-induced polyneuropathy (CMS/HCC)
Malignant ascites
Malignant neoplasm of unspecified ovary (CMS/HCC)","G62.0 - Drug-induced polyneuropathy (CMS/HCC); R18.0 - Malignant ascites; C56.9 - Malignant neoplasm of ovary, unspecified laterality (CMS/HCC)"
CINJ OP INFUSION,8277,"Aikins, James K, MD",2/11/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,2/10/2023,Inactive,,
CINJ OP INFUSION,8277,"Aikins, James K, MD",8/24/2023,Trastuzumab 21 Day Cycles (Continuation) - Uterine Carcinosarcoma-HER2+,Maintenance,8/23/2023,Inactive,,
CINJ OP INFUSION,8277,"Aikins, James K, MD",12/29/2023,"DOCEtaxel D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",_2. Second Line,12/28/2023,Inactive,,
CINJ OP INFUSION,58703,"Girda, Eugenia, MD",2/27/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,2/24/2023,Inactive,,
CINJ OP INFUSION,58703,"Girda, Eugenia, MD",7/31/2023,Pembrolizumab 21 Day Cycles - Uterine,,7/29/2023,Inactive,,
CINJ OP INFUSION,58703,"Girda, Eugenia, MD",1/16/2024,Pembrolizumab 42 Day Cycles - Uterine,Maintenance,1/15/2024,Active,,
CINJ OP INFUSION,22886,"Weiss, Sarah, MD",6/30/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,6/29/2023,Inactive,,
CBMC OP INFUSION 2FL,6478,"Leitner, Stuart P, MD",12/11/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,12/10/2023,Inactive,,
CBMC 2W ONCOLOGY,89038,"Grossman, I Robert, MD",6/21/2024,Hydroxyurea 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,6/21/2024,Active,,
NBR CINJ OP INFUSION,39365,"Tiger, Yun Kyoung, MD",4/1/2024,CINJ 012320 Group 3 CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE) 21 Day Cycles Research- Peripheral T-Cell Lymphoma,_1. First Line,3/28/2024,Active,,
NBR CINJ OP INFUSION,39365,"Egini, Ogechukwu, MD",8/20/2024,BMT Autologous BEAM,_1. First Line,8/20/2024,Active,,
NBR CINJ OP INFUSION,39365,"Tiger, Yun Kyoung, MD",1/29/2025,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,_2. Second Line,1/23/2025,Active,,
NBR CINJ OP INFUSION,39365,"Egini, Ogechukwu, MD",3/12/2025,BMT Allogeneic Flu / Cy / TBI + Post Cy,_4. Fourth Line,3/11/2025,Active,Peripheral T cell lymphoma of lymph nodes of multiple sites (CMS/HCC),
CINJ OP INFUSION,32423,"Ghodoussipour, Saum Bobak, MD",4/5/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,4/5/2023,Inactive,,
CINJ OP INFUSION,32423,"Ghodoussipour, Saum Bobak, MD",1/2/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,1/2/2023,Inactive,,
MMC BBR2 ONCOLOGY,32423,"Cohen, Seth D, MD",3/11/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,3/11/2024,Inactive,,
NBI VALERIE FND HEMONC,73436,"Batra, Surabhi, MD",12/10/2024,AALL1732 Consolidation,_1. First Line,12/5/2024,Active,,
NBI VALERIE FND HEMONC,75413,"Rao, Harini, MD",4/7/2025,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,4/6/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
NBI VALERIE FND HEMONC,75413,"Rao, Harini, MD",3/4/2025,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,2/21/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),
CBMC OP INFUSION 2FL,56268,"Litvak, Anna M, MD",9/20/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,9/20/2024,Active,"Malignant neoplasm of unspecified site of unspecified female breast (CMS/HCC)
Malignant neoplasm of nipple in female, estrogen receptor positive (CMS/HCC)
Other problems related to lifestyle
Encounter for screening for other viral diseases",
NBI OP INFUSION,65748,"Jacoby, Sari H, MD",12/5/2023,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/4/2023,Inactive,,
CINJ OP INFUSION,97407,"Girda, Eugenia, MD",1/18/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,1/10/2024,Inactive,,
CINJ OP INFUSION,12311,"Leiser, Aliza, MD",10/11/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,9/29/2024,Active,,
MMC OP INFUSION,13304,"Meghal, Trishala, MD",6/21/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,6/19/2023,Inactive,,
CINJ OP INFUSION,97860,"George, Mridula A, MD",12/5/2023,CINJ 042303 Part 1 Dose Escalation RLY-5836 Single Agent 28 Day Cycles Research- Breast Cancer,_4. Fourth Line,12/5/2023,Inactive,,
MMC OP INFUSION,97860,"Meghal, Trishala, MD",1/24/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,1/18/2024,Inactive,,
MMC OP VP INFUSION,97860,"Meghal, Trishala, MD",7/31/2024,Sacituzumab Govitecan 21 Day Cycles - Breast,_5. Fifth Line,7/25/2024,Inactive,,
MMC OP VP INFUSION,97860,"Meghal, Trishala, MD",11/13/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_4. Fourth Line,11/6/2024,Active,,
MMC OP INFUSION,68915,"Talwar, Sumit, MD",4/25/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_4. Fourth Line,4/25/2025,Active,Carcinoma of breast metastatic to axillary lymph node (CMS/HCC),
CINJ OP INFUSION,18455,"Girda, Eugenia, MD",6/23/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/13/2023,Inactive,,
NBR CINJ OP INFUSION,86208,"Tiger, Yun Kyoung, MD",7/26/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,7/25/2024,Active,,
JCMC CP INFUSION,28088,"Sekhri, Arunabh, MD",4/23/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
MMC OP VP INFUSION,39162,"Cohen, Seth D, MD",5/22/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Second Line,5/21/2023,Inactive,,
MMC OP VP INFUSION,39162,"Cohen, Seth D, MD",1/8/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/7/2024,Inactive,,
MMC OP VP INFUSION,39162,"Cohen, Seth D, MD",5/13/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_4. Fourth Line,5/12/2024,Inactive,,
MMC OP VP INFUSION,39162,"Cohen, Seth D, MD",7/15/2024,EriBULin 21 Day Cycles - Breast,_5. Fifth Line,7/14/2024,Inactive,,
NBR 4N ONCOLOGY,36697,"Matasar, Matthew J, MD",6/2/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),First Line,6/2/2023,Inactive,,
NBR 5N ONCOLOGY,36697,"Matasar, Matthew J, MD",7/11/2023,Dose-Adjusted EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/10/2023,Inactive,,
NBR 4N ONCOLOGY,36697,"Assal, Amer, MD",11/2/2023,BMT Autologous BEAM,_1. First Line,11/1/2023,Inactive,,
MSC OP INFUSION,50921,"Cohen, Seth D, MD",2/12/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/6/2025,Active,Malignant neoplasm of splenic flexure (CMS/HCC),
JCMC CP INFUSION,15396,"Cruz, Allan Louie E, MD",7/19/2023,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,Adjuvant,7/19/2023,Inactive,,
HAM OP INFUSION,45307,"Yogarajah, Meera, MD",6/10/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles-pancraetic cancer,_2. Second Line,6/10/2024,Inactive,,
HAM OP INFUSION,45307,"Yogarajah, Meera, MD",8/12/2024,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",_1. First Line,8/11/2024,Active,,
JCMC CP INFUSION,12197,"Sekhri, Arunabh, MD",12/2/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/19/2024,Inactive,,
JCMC CP INFUSION,12197,"Sekhri, Arunabh, MD",12/2/2024,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/1/2024,Active,,
MMC OP VP INFUSION,48642,"Talwar, Sumit, MD",6/12/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,5/6/2024,Inactive,,
MMC OP VP INFUSION,48642,"Talwar, Sumit, MD",8/20/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,8/5/2024,Active,,
CBMC OP INFUSION 2FL,7588,"Leitner, Stuart P, MD",10/27/2023,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_2. Second Line,10/26/2023,Inactive,,
CBMC OP INFUSION 2FL,7588,"Leitner, Stuart P, MD",8/2/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_2. Second Line,8/1/2024,Active,,
NBR 5N ONCOLOGY,46174,"Palmisiano, Neil David, MD",6/6/2023,CINJ 022105 (Part 1 of 2) Magrolimab or Placebo 28 Day Cycles Research- Acute Myeloid Leukemia,,6/4/2023,Inactive,,
NBR 5N ONCOLOGY,46174,"Palmisiano, Neil David, MD",6/6/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,6/6/2023,Inactive,,
CINJ OP INFUSION,21108,"Leiser, Aliza, MD",10/16/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,10/14/2024,Active,,
CBMC OP INFUSION 2FL,42681,"Scoppetuolo, Michael, MD",2/20/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,2/4/2024,Inactive,,
CBMC OP INFUSION 2FL,42681,"Scoppetuolo, Michael, MD",7/1/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,6/30/2024,Active,,
CBMC OP INFUSION 2FL,5355,"Wagmiller, Jennifer Ann, MD",7/31/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/21/2024,Active,,
CINJ OP INFUSION,9957,"Gulhati, Prateek, MD PhD",2/10/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,2/10/2024,Inactive,,
NBR 5N ONCOLOGY,75102,"Rhodes, Joanna Meehan, MD",11/26/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,11/26/2024,Inactive,,
NBR 5N ONCOLOGY,75102,"Tiger, Yun Kyoung, MD",12/3/2024,Vincristine- Acute Lymphoblastic Leukemia,_1. First Line,12/3/2024,Inactive,,
NBR 5N ONCOLOGY,75102,"Zayac, Adam, MD",12/11/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,12/10/2024,Inactive,,
NBR 5N ONCOLOGY,75102,"Zayac, Adam, MD",12/16/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/16/2024,Inactive,,
NBR CINJ OP INFUSION,75102,"Chen, Xiaoyi",12/23/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,12/23/2024,Active,,
NBR CINJ OP INFUSION,68732,"Chen, Xiaoyi",4/28/2025,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,_1. First Line,4/28/2025,Active,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),"C91.01 - Acute lymphoblastic leukemia, in remission; B45.7 - Disseminated cryptococcosis; E55.9 - Vitamin D deficiency, unspecified"
NBR CINJ OP INFUSION,68732,"Chen, Xiaoyi",3/25/2025,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,3/24/2025,Inactive,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),
NBR CINJ OP INFUSION,68732,"Chen, Xiaoyi",3/17/2025,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,3/17/2025,Inactive,Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),"C91.01 - Acute lymphoblastic leukemia, in remission; D61.818 - Other pancytopenia; Z79.899 - Other long term (current) drug therapy"
CBMC OP INFUSION 2FL,55650,"Leitner, Stuart P, MD",11/2/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,11/2/2023,Active,,
MMC OP VP INFUSION,32969,"Meghal, Trishala, MD",5/29/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,5/28/2024,Inactive,,
MSC OP INFUSION,71760,"Cohen, Seth D, MD",5/8/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,5/8/2025,Active,Diffuse follicle center lymphoma of lymph nodes of axilla (CMS/HCC),
SOM OUTPT INFUSION,95556,"Toomey, Kathleen C, MD",10/1/2024,Pembrolizumab 21 Day Cycles - Neoadjuvant Sarcoma,Neoadjuvant,9/3/2024,Active,,
NBI OP INFUSION,17142,"Schleicher, Lori, MD",5/17/2023,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,_3. Third Line,1/8/2023,Inactive,,
NBI D7 MED-SURG/TELE,17142,"Schleicher, Lori, MD",2/2/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Leptomeningal disease breast cancer,_1. First Line,2/2/2024,Inactive,,
NBR 5N ONCOLOGY,12528,"Shah, Mansi R, MD",2/11/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,2/10/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"U07.1 - COVID-19; J10.01 - Influenza due to other identified influenza virus with the same other identified influenza virus pneumonia; N18.6 - End stage renal disease; J96.01 - Acute respiratory failure with hypoxia; J12.82 - Pneumonia due to coronavirus disease 2019; C90.00 - Multiple myeloma not having achieved remission; D69.6 - Thrombocytopenia, unspecified; E87.20 - Acidosis, unspecified; D63.1 - Anemia in chronic kidney disease; D84.9 - Immunodeficiency, unspecified; Z99.2 - Dependence on renal dialysis; E66.9 - Obesity, unspecified; N17.9 - Acute kidney failure, unspecified; D53.9 - Nutritional anemia, unspecified; E79.0 - Hyperuricemia without signs of inflammatory arthritis and tophaceous disease; E83.52 - Hypercalcemia; R04.0 - Epistaxis; E87.70 - Fluid overload, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; E78.5 - Hyperlipidemia, unspecified; E80.6 - Other disorders of bilirubin metabolism; D63.0 - Anemia in neoplastic disease; Z80.3 - Family history of malignant neoplasm of breast; Z87.891 - Personal history of nicotine dependence; Z68.37 - Body mass index (BMI) 37.0-37.9, adult"
NBR CINJ OP INFUSION,743,"Evens, Andrew M, DO",3/15/2023,Cladribine / RiTUXimab 56 Day Cycle - Hairy Cell Leukemia,,3/15/2023,Inactive,,
CINJ OP INFUSION,99883,"Omene, Coral Oghenerukevwe, MD",1/31/2023,CINJ 042102 Block B TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles Research Breast Cancer,,1/30/2023,Inactive,,
CINJ OP INFUSION,99883,"Omene, Coral Oghenerukevwe, MD",6/27/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,6/26/2023,Inactive,,
CINJ OP INFUSION,42925,"Omene, Coral Oghenerukevwe, MD",4/29/2025,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_1. First Line,4/29/2025,Active,Stage IV breast cancer in female (CMS/HCC),
CINJ OP INFUSION,63777,"Boland, Patrick M, MD",6/7/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Adjuvant,6/7/2023,Inactive,,
CINJ OP INFUSION,86474,"Berim, Lyudmyla, MD",3/9/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",,3/8/2023,Inactive,,
CINJ OP INFUSION,86474,"Berim, Lyudmyla, MD",1/24/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/23/2024,Inactive,,
MMC OP INFUSION,63258,"Talwar, Sumit, MD",3/14/2025,DOXOrubicin / Trabectedin followed by Trabectedin 21 Day Cycles - Sarcoma,_1. First Line,3/14/2025,Active,Leiomyosarcoma (CMS/HCC),C49.9 - Leiomyosarcoma (CMS/HCC)
CINJ OP INFUSION,17853,"Hochster, Howard S, MD",8/8/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/6/2024,Active,,
CINJ OP INFUSION,17853,"Hochster, Howard S, MD",2/17/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Adjuvant,2/17/2025,Active,Gastric adenocarcinoma (CMS/HCC),
CINJ OP INFUSION,68733,"Mayer, Tina M, MD",3/25/2025,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,3/25/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
CBMC OP INFUSION 2FL,30795,"Grossman, I Robert, MD",10/31/2023,Topotecan Daily 28 Day Cycles - Cervical,_5. Fifth Line,10/30/2023,Inactive,,
CBMC OP INFUSION 2FL,71731,"Phillips, Adrienne A, MD",3/26/2025,GVD (Gemcitabine / VinORELBine / Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,3/26/2025,Active,Hodgkin's lymphoma (CMS/HCC),
CBMC OP INFUSION 2FL,71731,"Phillips, Adrienne A, MD",3/26/2025,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,_3. Third Line,3/26/2025,Active,Hodgkin's lymphoma (CMS/HCC),
NBI OP INFUSION,24287,"Cheng, Yan Ho, MD",4/25/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_3. Third Line,4/24/2023,Inactive,,
NBI OP INFUSION,24287,"Cheng, Yan Ho, MD",12/10/2024,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_3. Third Line,12/9/2024,Active,,
CBMC OP INFUSION 2FL,57635,"Gallinson, David Herschel, DO",1/13/2025,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,1/6/2025,Inactive,AML (acute myeloblastic leukemia) (CMS/HCC),
CINJ OP INFUSION,27255,"Hochster, Howard S, MD",2/8/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,2/7/2024,Inactive,,
CINJ OP INFUSION,27255,"Hochster, Howard S, MD",8/8/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,8/7/2024,Active,,
MMC OP VP INFUSION,50826,"Lee, Patrick C, MD",3/30/2023,Atezolizumab 28 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,3/29/2023,Inactive,,
TRMC TCCC OP INFUSION,30020,"Salerno, Vincent E, MD",7/28/2023,Avelumab 28 Day Cycles - Merkel Cell Carcinoma or Endometrial Carcinoma or Gestational Trophoblastic Neoplasia or Bladder Cancer,Maintenance,7/27/2023,Inactive,,
SOM OUTPT INFUSION,43073,"Patel, Eshan, MD",10/7/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,10/4/2024,Inactive,,
CINJ OP INFUSION,3975,"Stephenson, Ryan D, DO",5/22/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,5/22/2023,Inactive,,
CMC OP INFUSION,4607,"Taff, Jessica, MD",5/5/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,5/4/2023,Inactive,,
CMC OP INFUSION,4607,"Taff, Jessica, MD",10/18/2023,"Irinotecan D1/Cetuximab D1, D8 14 Day Cycles- Gastrointestinal Cancers",_4. Fourth Line,10/17/2023,Inactive,,
CMC OP INFUSION,4607,"Taff, Jessica, MD",10/26/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_4. Fourth Line,10/25/2023,Active,,
CMC OP INFUSION,4607,"Taff, Jessica, MD",8/9/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_5. Fifth Line,8/8/2024,Active,,
CINJ PEDS HEMONC ,22459,"Drachtman, Richard, MD",1/4/2025,PEDS Blinatumomab,Consolidation,1/3/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBR BMSCH 2 PED HEMONC,22459,"Drachtman, Richard, MD",1/6/2025,AALL1731 DS B-ALL Induction,Consolidation,1/5/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Drachtman, Richard, MD",1/7/2025,PEDS Blinatumomab,Consolidation,1/6/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Drachtman, Richard, MD",1/7/2025,PEDS AALL1331 Blinatumomab,Consolidation,1/6/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Drachtman, Richard, MD",1/7/2025,AALL1732 Induction,Consolidation,1/6/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBR BMSCH 2 PED HEMONC,22459,"Drachtman, Richard, MD",1/7/2025,PEDS Blinatumomab,Consolidation,1/6/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Shah, Niketa, MD",1/14/2025,PEDS BMT Allogeneic TBI / Cy ,Consolidation,1/6/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Drachtman, Richard, MD",1/22/2025,AALL1732 Induction,Consolidation,1/21/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Moerdler, Scott, MD",1/23/2025,ARST2032 Regimen VA,Consolidation,1/22/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
CINJ PEDS HEMONC ,22459,"Drachtman, Richard, MD",1/29/2025,AALL1731 Non-DS SR B-ALL Induction,Consolidation,1/28/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBR BMSCH 2 PED HEMONC,22459,"Drachtman, Richard, MD",2/7/2025,PEDS AOST0331 MAP Arm (DOXOrubicin / CISplatin / Methotrexate),Consolidation,2/5/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
NBR CINJ OP INFUSION,62610,"Zayac, Adam, MD",2/6/2025,Temsirolimus 28 Day Cycles - Kidney,_1. First Line,2/5/2025,Inactive,"CML (chronic myelocytic leukemia) (CMS/HCC)
Bladder cancer (CMS/HCC)
Malignant neoplasm of urinary bladder (CMS/HCC)
NSCLC of left lung (CMS/HCC)",
CINJ PEDS HEMONC ,33793,"Shah, Niketa, MD",1/16/2025,PEDS BMT Allogeneic TBI / Cy ,_4. Fourth Line,1/8/2025,Inactive,Acute lymphoid leukemia in remission (CMS/HCC),
CINJ PEDS HEMONC ,42420,"Shah, Niketa, MD",1/16/2025,PEDS BMT Allogeneic TBI / Cy ,_4. Fourth Line,1/8/2025,Inactive,Acute lymphoid leukemia in remission (CMS/HCC),
NBR CINJ OP INFUSION,35484,"Rhodes, Joanna Meehan, MD",3/3/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,3/3/2025,Active,Bladder cancer (CMS/HCC),
CINJ OP INFUSION,26006,"Haigentz, Missak, MD",3/27/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,3/26/2023,Inactive,,
CINJ OP INFUSION,47731,"Stephenson, Ryan D, DO",5/5/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,5/5/2025,Active,"Renal pelvis transitional cell malignant neoplasm, left (CMS/HCC)","C68.9 - Malignant neoplasm of urinary organ, unspecified; C65.2 - Malignant neoplasm of left renal pelvis"
CINJ OP INFUSION,9008,"Berim, Lyudmyla, MD",5/16/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/16/2025,Active,Colon cancer (CMS/HCC),
CINJ OP INFUSION,9008,"Berim, Lyudmyla, MD",5/3/2025,mFOLFOX6 Inpatient (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/3/2025,Inactive,Colon cancer (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified"
CINJ OP INFUSION,64858,"Patel, Eshan, MD",4/15/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,4/14/2024,Active,,
CBMC OP INFUSION 2FL,8600,"Leitner, Stuart P, MD",9/10/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,11/7/2023,Active,,
NBR 5N ONCOLOGY,32202,"Rhodes, Joanna Meehan, MD",8/30/2024,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,_1. First Line,8/28/2024,Active,,
NBR CINJ OP INFUSION,32202,"Rhodes, Joanna Meehan, MD",9/5/2024,CHOPE (Cyclophosphamide / DOXOrubicin / VinCRIStine / Prednisone / Etoposide) 21 Day Cycles - Non-Hodgkin's Lymphoma,_1. First Line,9/4/2024,Inactive,,
SOM OUTPT INFUSION,82357,"Toomey, Kathleen C, MD",5/12/2023,"PACLitaxel Weekly / CARBOplatin weekly, Trazimera 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",First Line,5/11/2023,Inactive,,
SOM OUTPT INFUSION,82357,"Toomey, Kathleen C, MD",6/9/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,First Line,6/8/2023,Inactive,,
SOM OUTPT INFUSION,82357,"Toomey, Kathleen C, MD",9/22/2023,Trastuzumab 21 Day Cycles (Continuation) - Uterine,Maintenance,9/21/2023,Inactive,,
SOM OUTPT INFUSION,82357,"Toomey, Kathleen C, MD",10/4/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_2. Second Line,10/3/2024,Inactive,,
SOM OUTPT INFUSION,82357,"Toomey, Kathleen C, MD",11/21/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/20/2024,Inactive,,
SOM OUTPT INFUSION,22627,"Patel, Eshan, MD",2/12/2024,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,1/9/2024,Inactive,,
SOM OUTPT INFUSION,22627,"Patel, Eshan, MD",9/3/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,9/2/2024,Inactive,,
SOM OUTPT INFUSION,22627,"Patel, Eshan, MD",10/1/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,9/30/2024,Inactive,,
CINJ OP INFUSION,90973,"Mayer, Tina M, MD",1/16/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,1/16/2023,Active,"Bladder cancer (CMS/HCC)
End stage renal disease (CMS/HCC)
Hypothyroidism due to medication",
NBR CINJ OP INFUSION,42301,"Matasar, Matthew J, MD",10/3/2023,Brentuximab Vedotin 21 Day Cycles - T-Cell Lymphoma,,10/2/2023,Inactive,,
CINJ OP INFUSION,46346,"Stephenson, Ryan D, DO",6/5/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Adjuvant,6/5/2024,Active,,
CBMC OP INFUSION 2FL,25482,"Dave, Manish, MD",8/23/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/22/2023,Inactive,,
CBMC OP INFUSION 2FL,25482,"Leitner, Stuart P, MD",3/13/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/13/2024,Inactive,,
JCMC CP INFUSION,41718,"Ghuman, Damanjit, MD",6/6/2023,"Bortezomib D1, D8, D15 28 Day Cycles- Multiple Myeloma",First Line,6/5/2023,Inactive,,
JCMC CP INFUSION,41718,"Sekhri, Arunabh, MD",1/17/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,1/16/2025,Active,,
NBI OP INFUSION,75546,"Jacoby, Sari H, MD",2/8/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_5. Fifth Line,2/7/2023,Inactive,,
NBI OP INFUSION,75546,"Jacoby, Sari H, MD",2/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/6/2024,Inactive,,
NBI OP INFUSION,75546,"Jacoby, Sari H, MD",7/3/2024,VinORELBine 21 Day Cycles - Breast,_4. Fourth Line,7/2/2024,Inactive,,
NBI OP INFUSION,75546,"Jacoby, Sari H, MD",9/18/2024,Elacestrant (ORSERDU) Oral Chemo 28 Day Cycles - HER2 Negative,_3. Third Line,9/17/2024,Active,,
NBI OP INFUSION,75546,"Jacoby, Sari H, MD",2/26/2025,Datopotamab deruxtecan-dlnk 21 Day Cycles- Breast Cancer,_6. Sixth Line,2/25/2025,Active,Stage IV breast cancer in female (CMS/HCC),C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; R35.0 - Frequency of micturition; N30.01 - Acute cystitis with hematuria
NBI D7 MED-SURG/TELE,54414,"Jacoby, Sari H, MD",3/6/2025,Albumin-Bound PACLitaxel / CARBOplatin 28 Day Cycles - breast,_6. Sixth Line,3/6/2025,Inactive,Stage IV breast cancer in female (CMS/HCC),"C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; E43 - Unspecified severe protein-calorie malnutrition; Z51.5 - Encounter for palliative care; N17.9 - Acute kidney failure, unspecified; C79.51 - Secondary malignant neoplasm of bone; R62.7 - Adult failure to thrive; R18.8 - Other ascites; E87.1 - Hypo-osmolality and hyponatremia; D63.0 - Anemia in neoplastic disease; C50.811 - Malignant neoplasm of overlapping sites of right female breast; F32.0 - Major depressive disorder, single episode, mild; N18.9 - Chronic kidney disease, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; Z68.1 - Body mass index (BMI) 19.9 or less, adult; E86.9 - Volume depletion, unspecified; F41.9 - Anxiety disorder, unspecified; Z98.890 - Other specified postprocedural states; G89.3 - Neoplasm related pain (acute) (chronic); G47.00 - Insomnia, unspecified; K59.00 - Constipation, unspecified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; Z90.11 - Acquired absence of right breast and nipple; Z79.899 - Other long term (current) drug therapy; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z86.16 - Personal history of COVID-19; Z85.72 - Personal history of non-Hodgkin lymphomas; Z92.21 - Personal history of antineoplastic chemotherapy; Z92.3 - Personal history of irradiation; Z81.3 - Family history of other psychoactive substance abuse and d..."
NBR CINJ OP INFUSION,23652,"Evens, Andrew M, DO",5/15/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,Lymphodepletion,5/14/2024,Inactive,,
CMC OP INFUSION,1739,"Taff, Jessica, MD",6/12/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,6/11/2023,Active,,
NBR CINJ OP INFUSION,63118,"Evens, Andrew M, DO",5/8/2024,CINJ 012315 Arm A MK-4280A Single Agent 21 Day Cycles Research- Hodgkin Lymphoma,_3. Third Line,5/7/2024,Active,,
CINJ OP INFUSION,74381,"Stephenson, Ruth D, DO",12/20/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,12/12/2023,Inactive,,
NBI OP INFUSION,62966,"Shah, Maya M, MD",5/22/2025,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles + Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,5/22/2025,Inactive,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
JCMC CP INFUSION,38310,"Cruz, Allan Louie E, MD",8/22/2023,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",,8/15/2023,Inactive,,
CBMC 2W ONCOLOGY,27830,"Wagmiller, Jennifer Ann, MD",3/24/2025,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,3/24/2025,Inactive,"Malignant neoplasm of endometrium metastatic to lung (CMS/HCC)
On antineoplastic chemotherapy
Long term use of drug","C78.01 - Secondary malignant neoplasm of right lung; N18.6 - End stage renal disease; I31.4 - Cardiac tamponade; I31.31 - Malignant pericardial effusion in diseases classified elsewhere; J91.0 - Malignant pleural effusion; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; Z11.52 - Encounter for screening for COVID-19; E87.1 - Hypo-osmolality and hyponatremia; D63.1 - Anemia in chronic kidney disease; C78.02 - Secondary malignant neoplasm of left lung; C57.8 - Malignant neoplasm of overlapping sites of female genital organs; Z99.2 - Dependence on renal dialysis; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; F32.A - Depression, unspecified; I71.21 - Aneurysm of the ascending aorta, without rupture; I95.9 - Hypotension, unspecified; G47.00 - Insomnia, unspecified; K59.00 - Constipation, unspecified; I49.3 - Ventricular premature depolarization; R59.0 - Localized enlarged lymph nodes; E78.5 - Hyperlipidemia, unspecified; Z79.899 - Other long term (current) drug therapy; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs; Z91.018 - Allergy to other foods; Z90.722 - Acquired absence of ovaries, bilateral; Z90.710 - Acquired absence of both cervix and uterus; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z74.01 - Bed confinement status; Z92.21 - Personal history of antineoplastic chemotherapy"
CBMC OP INFUSION 2FL,27830,"Wagmiller, Jennifer Ann, MD",3/24/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/24/2025,Active,"Malignant neoplasm of endometrium metastatic to lung (CMS/HCC)
On antineoplastic chemotherapy
Long term use of drug","C78.01 - Secondary malignant neoplasm of right lung; N18.6 - End stage renal disease; I31.4 - Cardiac tamponade; I31.31 - Malignant pericardial effusion in diseases classified elsewhere; J91.0 - Malignant pleural effusion; I12.0 - Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease; Z11.52 - Encounter for screening for COVID-19; E87.1 - Hypo-osmolality and hyponatremia; D63.1 - Anemia in chronic kidney disease; C78.02 - Secondary malignant neoplasm of left lung; C57.8 - Malignant neoplasm of overlapping sites of female genital organs; Z99.2 - Dependence on renal dialysis; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; F32.A - Depression, unspecified; I71.21 - Aneurysm of the ascending aorta, without rupture; I95.9 - Hypotension, unspecified; G47.00 - Insomnia, unspecified; K59.00 - Constipation, unspecified; I49.3 - Ventricular premature depolarization; R59.0 - Localized enlarged lymph nodes; E78.5 - Hyperlipidemia, unspecified; Z79.899 - Other long term (current) drug therapy; Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs; Z91.018 - Allergy to other foods; Z90.722 - Acquired absence of ovaries, bilateral; Z90.710 - Acquired absence of both cervix and uterus; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z74.01 - Bed confinement status; Z92.21 - Personal history of antineoplastic chemotherapy"
JCMC CP INFUSION,76678,"Sekhri, Arunabh, MD",1/22/2025,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,_1. First Line,1/21/2025,Active,,
JCMC CP INFUSION,76678,"Sekhri, Arunabh, MD",1/22/2025,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,12/22/2024,Inactive,"Malignant lymphoma, Hodgkin's type (CMS/HCC)",
JCMC CP INFUSION,76678,"Sekhri, Arunabh, MD",4/2/2025,CINJ 112305 AVD Arm E (Doxorubicin / Vinblastine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,4/2/2025,Active,"Hodgkin lymphoma, unspecified, unspecified site (CMS/HCC)",
NBR 5N MED-SURG OVRF,10256,"Alexander, Henry Richard, MD",9/19/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_2. Second Line,9/19/2024,Active,,
CBMC OP INFUSION 2FL,68446,"Scoppetuolo, Michael, MD",12/5/2023,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,_1. First Line,12/3/2023,Inactive,,
JCMC CP INFUSION,24371,"Cruz, Allan Louie E, MD",4/28/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,,4/28/2023,Inactive,,
JCMC CP INFUSION,24371,"Cruz, Allan Louie E, MD",9/27/2023,Carfilzomib 27 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,,9/13/2023,Inactive,,
MMC OP VP INFUSION,43887,"Meghal, Trishala, MD",4/10/2023,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,First Line,4/9/2023,Inactive,,
NBI OP INFUSION,29999,"Jacoby, Sari H, MD",10/9/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/8/2023,Inactive,,
CINJ OP INFUSION,13320,"Boland, Patrick M, MD",5/26/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,5/24/2023,Inactive,,
CINJ OP INFUSION,13320,"Goel, Sanjay, MD",11/6/2023,CINJ 052008 / R7075-ONC-2009 Dose Level 9aW REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,_3. Third Line,10/16/2023,Inactive,,
CINJ OP INFUSION,29143,"Mayer, Tina M, MD",1/18/2024,CINJ 082104 (EA8191) ARM A Short Term Androgen Deprivation GnRH Therapy 84 Cycles Research- Prostate Cancer,_1. First Line,12/21/2023,Active,,
SOM OUTPT INFUSION,55099,"Toomey, Kathleen C, MD",2/9/2023,"EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / PACLitaxel D1, D8, D15 21 Day Cycles Research- Breast Cancer",Neoadjuvant,2/8/2023,Inactive,,
SOM OUTPT INFUSION,55099,"Toomey, Kathleen C, MD",4/13/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,4/11/2023,Inactive,,
SOM OUTPT INFUSION,55099,"Toomey, Kathleen C, MD",8/16/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,8/15/2023,Inactive,,
CINJ OP INFUSION,65787,"Weiss, Sarah, MD",12/4/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,11/19/2024,Active,,
NBR 4N ONCOLOGY,75530,"Weiss, Sarah, MD",1/19/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,1/18/2024,Inactive,,
NBR 4N ONCOLOGY,75530,"Boland, Patrick M, MD",1/24/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/24/2024,Inactive,,
JCMC CP INFUSION,12269,"Cruz, Allan Louie E, MD",3/21/2024,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,3/20/2024,Inactive,,
CBMC OP INFUSION 2FL,46611,"Brown, Andrew Bennett, MD",9/7/2023,Bendamustine 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_3. Third Line,9/6/2023,Inactive,,
HAM OP INFUSION,1202,"Patel, Malini M, MD",9/5/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,9/4/2023,Inactive,,
HAM OP INFUSION,1202,"Patel, Malini M, MD",12/12/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Consolidation,12/11/2023,Active,,
CBMC OP INFUSION 2FL,67603,"Wagmiller, Jennifer Ann, MD",11/3/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,11/3/2023,Inactive,,
CBMC OP INFUSION 2FL,67603,"Wagmiller, Jennifer Ann, MD",12/29/2023,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,12/28/2023,Inactive,,
CINJ OP INFUSION,40977,"Weiss, Sarah, MD",12/22/2023,CINJ 092302 Cohort 1 Propranolol + Nivolumab (1 mg/kg) / Ipilumumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research- Melanoma,_1. First Line,12/21/2023,Inactive,,
CINJ OP INFUSION,40977,"Weiss, Sarah, MD",2/6/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,2/1/2024,Inactive,,
HAM OP INFUSION,43221,"Patel, Malini M, MD",6/14/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,First Line,6/11/2023,Inactive,,
SOM OUTPT INFUSION,28760,"Toomey, Kathleen C, MD",1/29/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,1/28/2025,Active,,
SOM OUTPT INFUSION,28760,"Toomey, Kathleen C, MD",2/6/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Adjuvant,1/28/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Metastasis to lymph nodes (CMS/HCC)",
CINJ OP INFUSION,89695,"Haigentz, Missak, MD",8/26/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,8/26/2024,Active,,
SOM OUTPT INFUSION,53613,"Patel, Eshan, MD",10/2/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,10/1/2024,Active,,
CINJ OP INFUSION,89524,"Toppmeyer, Deborah L, MD",7/10/2023,Ribociclib 28 Day Cycles - Breast,Adjuvant,7/10/2023,Active,"Mass of spine
Clear cell renal cell carcinoma, unspecified laterality (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)",
CBMC OP INFUSION 1FL,37034,"Gallinson, David Herschel, DO",1/16/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,1/10/2025,Active,,
CBMC OP INFUSION 2FL,37034,"Gallinson, David Herschel, DO",2/27/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_1. First Line,1/17/2025,Active,"CLL (chronic lymphocytic leukemia) (CMS/HCC)
Acquired hemophilia A (CMS/HCC)",
CINJ OP INFUSION,56594,"Toppmeyer, Deborah L, MD",8/10/2023,Palbociclib 28 Day Cycles - Breast,,8/10/2023,Inactive,,
CINJ OP INFUSION,31019,"Patel, Eshan, MD",5/16/2023,CINJ 032105 Group A/B/C CARBOplatin / Etoposide + Pembrolizumab / Placebo 21 Day Cycles Followed by Pembrolizumab / Placebo + Olaparib / Placebo 42 Day Cycles- Small Cell Lung Cancer,,4/17/2023,Active,,
CBMC OP INFUSION 2FL,72201,"Scoppetuolo, Michael, MD",2/26/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/30/2024,Inactive,,
CBMC OP INFUSION 2FL,72201,"Scoppetuolo, Michael, MD",9/13/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_4. Fourth Line,9/10/2024,Active,,
CMC OP INFUSION,64151,"Taff, Jessica, MD",6/9/2023,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,5/31/2023,Inactive,,
CMC OP INFUSION,73555,"Taff, Jessica, MD",4/10/2024,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,4/3/2024,Inactive,,
NBI VALERIE FND HEMONC,78252,"Batra, Surabhi, MD",12/30/2024,PEDS AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Nivolumab 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,12/29/2024,Active,,
JCMC CP INFUSION,74368,"Cruz, Allan Louie E, MD",12/27/2023,durvalumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell esophageal/Lung Cancer,_1. First Line,12/27/2023,Inactive,,
JCMC CP INFUSION,74368,"Sekhri, Arunabh, MD",1/11/2024,"CISplatin/Irinotecan D1, D8, 15 28 Day Cycles- small cell cancer",_1. First Line,1/11/2024,Inactive,,
JCMC CP INFUSION,74368,"Cruz, Allan Louie E, MD",3/27/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_2. Second Line,3/26/2024,Inactive,,
MMC OP VP INFUSION,18819,"Talwar, Sumit, MD",2/12/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,2/10/2025,Active,Malignant neoplasm of rectum (CMS/HCC),
MMC BBR2 ONCOLOGY,28044,"Talwar, Sumit, MD",3/24/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,3/24/2025,Inactive,Malignant neoplasm of rectum (CMS/HCC),"A41.89 - Other specified sepsis; J10.00 - Influenza due to other identified influenza virus with unspecified type of pneumonia; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; J69.0 - Pneumonitis due to inhalation of food and vomit; J96.01 - Acute respiratory failure with hypoxia; E44.0 - Moderate protein-calorie malnutrition; J90 - Pleural effusion, not elsewhere classified; B37.0 - Candidal stomatitis; E87.0 - Hyperosmolality and hypernatremia; E87.4 - Mixed disorder of acid-base balance; D62 - Acute posthemorrhagic anemia; D69.6 - Thrombocytopenia, unspecified; C19 - Malignant neoplasm of rectosigmoid junction; J44.0 - Chronic obstructive pulmonary disease with (acute) lower respiratory infection; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; K76.9 - Liver disease, unspecified; K52.1 - Toxic gastroenteritis and colitis; N17.9 - Acute kidney failure, unspecified; J98.11 - Atelectasis; Z79.4 - Long term (current) use of insulin; I48.0 - Paroxysmal atrial fibrillation; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; Z99.81 - Dependence on supplemental oxygen; I44.0 - Atrioventricular block, first degree; Z11.52 - Encounter for screening for COVID-19; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.49 - Family history ..."
MMC BBR2 ONCOLOGY,28044,"Talwar, Sumit, MD",3/24/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,3/24/2025,Inactive,Malignant neoplasm of rectum (CMS/HCC),"A41.89 - Other specified sepsis; J10.00 - Influenza due to other identified influenza virus with unspecified type of pneumonia; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; J69.0 - Pneumonitis due to inhalation of food and vomit; J96.01 - Acute respiratory failure with hypoxia; E44.0 - Moderate protein-calorie malnutrition; J90 - Pleural effusion, not elsewhere classified; B37.0 - Candidal stomatitis; E87.0 - Hyperosmolality and hypernatremia; E87.4 - Mixed disorder of acid-base balance; D62 - Acute posthemorrhagic anemia; D69.6 - Thrombocytopenia, unspecified; C19 - Malignant neoplasm of rectosigmoid junction; J44.0 - Chronic obstructive pulmonary disease with (acute) lower respiratory infection; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; K76.9 - Liver disease, unspecified; K52.1 - Toxic gastroenteritis and colitis; N17.9 - Acute kidney failure, unspecified; J98.11 - Atelectasis; Z79.4 - Long term (current) use of insulin; I48.0 - Paroxysmal atrial fibrillation; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; Z99.81 - Dependence on supplemental oxygen; I44.0 - Atrioventricular block, first degree; Z11.52 - Encounter for screening for COVID-19; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.49 - Family history ..."
MMC BBR2 ONCOLOGY,28044,"Talwar, Sumit, MD",3/24/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,3/24/2025,Inactive,Malignant neoplasm of rectum (CMS/HCC),"A41.89 - Other specified sepsis; J10.00 - Influenza due to other identified influenza virus with unspecified type of pneumonia; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; J69.0 - Pneumonitis due to inhalation of food and vomit; J96.01 - Acute respiratory failure with hypoxia; E44.0 - Moderate protein-calorie malnutrition; J90 - Pleural effusion, not elsewhere classified; B37.0 - Candidal stomatitis; E87.0 - Hyperosmolality and hypernatremia; E87.4 - Mixed disorder of acid-base balance; D62 - Acute posthemorrhagic anemia; D69.6 - Thrombocytopenia, unspecified; C19 - Malignant neoplasm of rectosigmoid junction; J44.0 - Chronic obstructive pulmonary disease with (acute) lower respiratory infection; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; K76.9 - Liver disease, unspecified; K52.1 - Toxic gastroenteritis and colitis; N17.9 - Acute kidney failure, unspecified; J98.11 - Atelectasis; Z79.4 - Long term (current) use of insulin; I48.0 - Paroxysmal atrial fibrillation; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; Z99.81 - Dependence on supplemental oxygen; I44.0 - Atrioventricular block, first degree; Z11.52 - Encounter for screening for COVID-19; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.49 - Family history ..."
CBMC OP INFUSION 2FL,81311,"Scoppetuolo, Michael, MD",2/20/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,2/17/2025,Active,Malignant melanoma of neck (CMS/HCC),
CBMC OP INFUSION 2FL,22745,"Raptis, George, MD",10/30/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,10/29/2024,Active,,
CINJ OP INFUSION,89086,"Ghodoussipour, Saum Bobak, MD",5/9/2024,MitoMYcin (Jelmyto) for Pyelocalyceal Instillation Via Nephrostomy Tube,Induction,5/8/2024,Inactive,,
NBI OP INFUSION,3088,"Anderson, Patrick S, MD",9/28/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - High Grade Endometrial adenocarcinoma,_2. Second Line,9/27/2023,Inactive,,
NBI OP INFUSION,3088,"Anderson, Patrick S, MD",1/18/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/17/2024,Inactive,,
NBI OP INFUSION,3088,"Anderson, Patrick S, MD",4/25/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,4/24/2024,Active,,
MSC OP INFUSION,98528,"Talwar, Sumit, MD",5/1/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/30/2024,Inactive,,
MMC OP VP INFUSION,98528,"Talwar, Sumit, MD",10/30/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,10/29/2024,Active,,
HAM OP INFUSION,19936,"Yogarajah, Meera, MD",6/5/2023,5FU + Oxaliplatin concurrent with radiaiton ,First Line,6/4/2023,Inactive,,
HAM OP INFUSION,19936,"Yogarajah, Meera, MD",10/13/2023,"Nivolumab D1, D15 28 Day Cycles - post operative GE junction",First Line,10/10/2023,Inactive,,
CINJ OP INFUSION,39725,"Berim, Lyudmyla, MD",1/11/2023,Irinotecan 14 Day Cycles- Gastrointestinal Cancers,,12/27/2022,Inactive,,
CINJ OP INFUSION,39725,"Berim, Lyudmyla, MD",2/23/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,2/21/2023,Inactive,,
CINJ OP INFUSION,39725,"Berim, Lyudmyla, MD",10/24/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_4. Fourth Line,10/16/2024,Active,,
CINJ OP INFUSION,39725,"Berim, Lyudmyla, MD",10/24/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,10/24/2024,Active,Hx of autologous stem cell transplant (CMS/HCC),
CINJ OP INFUSION,79375,"George, Mridula A, MD",10/25/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/24/2024,Active,Follicular lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,5856,"Yogarajah, Meera, MD",8/14/2023,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,,8/6/2023,Inactive,,
NBR 4N ONCOLOGY,5856,"Palmisiano, Neil David, MD",9/11/2024,Gemtuzumab / Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_2. Second Line,9/10/2024,Inactive,,
HAM OP INFUSION,5856,"Yogarajah, Meera, MD",10/21/2024,Gemtuzumab Ozogamicin Relapsed / Refractory 8 Day Cycle - Acute Myeloid Leukemia,_2. Second Line,10/20/2024,Active,,
HAM OP INFUSION,5856,"Yogarajah, Meera, MD",10/21/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,_2. Second Line,10/20/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,5856,"Palmisiano, Neil David, MD",10/30/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,Consolidation,10/30/2024,Active,,
CBMC OP INFUSION 2FL,81334,"Brown, Andrew Bennett, MD",11/2/2023,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_2. Second Line,11/2/2023,Active,,
CBMC OP INFUSION 1FL,84544,"Gallinson, David Herschel, DO",2/20/2025,"Encorafenib + Cetuximab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,2/2/2025,Active,Cancer of transverse colon (CMS/HCC),
CBMC OP INFUSION 2FL,1987,"Brown, Andrew Bennett, MD",10/2/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",Maintenance,9/26/2023,Active,,
NBR CINJ OP INFUSION,33909,"Evens, Andrew M, DO",1/24/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/23/2024,Inactive,,
NBR CINJ OP INFUSION,33909,"Evens, Andrew M, DO",7/3/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,7/2/2024,Active,Malignant neoplasm of bile ducts (CMS/HCC),
CINJ OP INFUSION,25504,"Boland, Patrick M, MD",8/8/2023,FOLFOXIRI + Bevacizumab  --> capecitabine + bev maintenance,_1. First Line,8/7/2023,Inactive,,
CINJ OP INFUSION,25504,"Boland, Patrick M, MD",1/4/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/3/2024,Active,,
CINJ OP INFUSION,25504,"Boland, Patrick M, MD",1/30/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/28/2025,Active,,
CINJ OP INFUSION,28032,"Weiss, Sarah, MD",7/17/2023,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,7/16/2023,Inactive,,
CINJ OP INFUSION,28032,"Weiss, Sarah, MD",2/21/2024,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,Adjuvant,2/21/2024,Inactive,,
CINJ OP INFUSION,28032,"Weiss, Sarah, MD",3/13/2025,Encorafenib / Binimetinib 30 Day Cycles - Melanoma,_2. Second Line,3/13/2025,Active,Malignant melanoma of right foot (CMS/HCC),
MMC OP VP INFUSION,67517,"Lee, Patrick C, MD",2/8/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,2/7/2024,Inactive,,
JCMC CP INFUSION,7203,"Sekhri, Arunabh, MD",6/29/2023,PACLitaxel / CISplatin 21 Day Cycles - Cervical,First Line,6/28/2023,Inactive,,
JCMC CP INFUSION,7203,"Sekhri, Arunabh, MD",11/28/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/27/2023,Inactive,,
NBR CINJ OP INFUSION,64687,"Shah, Mansi R, MD",7/31/2023,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,,7/31/2023,Inactive,,
NBR 4N BMTU/IMCU,56757,"Braunschweig, Ira, MD",6/15/2023,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,,6/15/2023,Inactive,,
NBR CINJ OP INFUSION,56757,"Chowaniec, Wayne B, NP",10/3/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,10/2/2023,Inactive,,
NBR 4N ONCOLOGY,56757,"Braunschweig, Ira, MD",12/23/2023,DAUNOrubicin Liposomal - Cytarabine (VYXEOS) - Induction 14 Day Cycle - Acute Myeloid Leukemia,_3. Third Line,12/23/2023,Inactive,,
HAM OP INFUSION,36951,"Gendy, Mina, DO",12/13/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,12/3/2024,Active,,
NBR 5N ONCOLOGY,65599,"Shah, Mansi R, MD",6/5/2023,"CINJ 012309 Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles Research- Multiple Myeloma",,6/5/2023,Inactive,,
NBR CINJ OP INFUSION,65599,"Shah, Mansi R, MD",7/31/2023,"CINJ 012309 Talquetamab D1, D3, D5, D7 Step-Up 28 Day Cycles Research- Multiple Myeloma",,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,65599,"Shah, Mansi R, MD",11/7/2023,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",10. Tenth Line,11/7/2023,Inactive,,
NBR CINJ OP INFUSION,65599,"Shah, Mansi R, MD",3/26/2024,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,_9. Ninth Line,3/25/2024,Inactive,,
NBR CINJ OP INFUSION,65599,"Shah, Mansi R, MD",5/8/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,5/7/2024,Inactive,,
JCMC CP INFUSION,70822,"Sekhri, Arunabh, MD",3/12/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,3/3/2024,Inactive,,
CBMC OP INFUSION 2FL,73279,"Litvak, Anna M, MD",4/23/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,4/23/2025,Active,Breast cancer metastasized to intrathoracic lymph node (CMS/HCC),
NBR CINJ OP INFUSION,18247,"Leiser, Aliza, MD",2/5/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,2/4/2024,Inactive,,
CINJ OP INFUSION,5129,"Leiser, Aliza, MD",8/23/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,8/22/2024,Active,,
NBI OP INFUSION,50600,"Anderson, Patrick S, MD",3/29/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/28/2024,Active,,
CINJ OP INFUSION,348,"George, Mridula A, MD",9/8/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/7/2023,Active,Metastatic malignant neuroendocrine tumor to liver (CMS/HCC),
CINJ OP INFUSION,348,"George, Mridula A, MD",9/29/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,9/1/2023,Active,,
NBR CINJ OP INFUSION,32951,"Evens, Andrew M, DO",4/12/2023,CHP (Cyclophosphamide / DOXOrubicin / Prednisone) + Brentuximab Vedotin 21 Day Cycles - Peripheral T-Cell Lymphoma,First Line,4/11/2023,Inactive,,
NBR 4N BMTU/IMCU,32951,"Assal, Amer, MD",8/19/2023,BMT Autologous BEAM,,8/18/2023,Inactive,,
NBR CINJ OP INFUSION,20524,"Evens, Andrew M, DO",1/2/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,1/2/2025,Inactive,Marginal zone lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,20524,"Evens, Andrew M, DO",1/3/2025,Rituximab for Marginal Zone Lymphoma weekly x4,_2. Second Line,1/2/2025,Active,Malignant neoplasm of cervix (CMS/HCC),
NBR CINJ OP INFUSION,20524,"Evens, Andrew M, DO",1/8/2025,RiTUXimab Subsequent Infusion Single Day (Outpatient),_1. First Line,1/8/2025,Inactive,Marginal zone lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,20524,"Evens, Andrew M, DO",4/23/2025,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,Maintenance,4/23/2025,Active,Marginal zone lymphoma (CMS/HCC),"C88.40 - Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue (malt-lymphoma) not having achieved remission; C85.80 - Other specified types of non-hodgkin lymphoma, unspecified site"
MMC OP VP INFUSION,18861,"Lee, Patrick C, MD",7/22/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,7/12/2023,Inactive,,
NBR 4N ONCOLOGY,6657,"Zayac, Adam, MD",1/11/2024,Methotrexate Intrathecal IT 1 Day Cycle- Hematological Malignancies,Neoadjuvant,1/11/2024,Inactive,,
NBR 4N ONCOLOGY,6657,"Zayac, Adam, MD",1/17/2024,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,Induction,1/16/2024,Inactive,,
NBR CINJ OP INFUSION,6657,"Zayac, Adam, MD",5/1/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,_1. First Line,4/30/2024,Inactive,,
NBR 4N ONCOLOGY,6657,"Zayac, Adam, MD",5/8/2024,Methotrexate Intrathecal 6 mg & Cytarabine Intrathecal 70mg IT via Ommaya- CNS Leukemia - Hematological Malignancies,_1. First Line,4/30/2024,Active,,
NBR CINJ OP INFUSION,6657,"Zayac, Adam, MD",5/28/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,5/28/2024,Inactive,,
NBR CINJ OP INFUSION,6657,"Zayac, Adam, MD",8/20/2024,ECOG - ACRIN E1910 (Step 3) Consolidation (Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,8/20/2024,Active,,
NBR CINJ OP INFUSION,6657,"Zayac, Adam, MD",4/21/2025,ECOG - ACRIN E1910 (Step 4) Maintenance (VinCRIStine / Prednisone / Mercaptopurine / Methotrexate Oral / Methotrexate IT) - Acute Lymphoblastic Leukemia,Maintenance,4/21/2025,Active,B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),"C95.00 - Acute leukemia not having achieved remission (CMS/HCC); G96.9, C91.00 - Disorder of central nervous system concurrent with and due to acute lymphoblastic leukemia (ALL) (CMS/HCC); C91.00 - Pre B-cell acute lymphoblastic leukemia (CMS/HCC); C91.00 - B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC)"
CBMC OP INFUSION 2FL,80051,"Brown, Andrew Bennett, MD",10/2/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,9/26/2023,Inactive,,
CINJ OP INFUSION,82259,"Patankar, Sonali, MD",1/6/2025,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,1/5/2025,Active,,
CINJ PEDS HEMONC ,17319,"Moerdler, Scott, MD",12/12/2024,PEDS VAC (as Per D9803),_1. First Line,12/10/2024,Active,,
MSC OP INFUSION,73925,"Pompa, Tiffany Ann, MD",3/5/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/5/2025,Inactive,Malignant neoplasm of unspecified site of left female breast (CMS/HCC),
MSC OP INFUSION,63877,"Talwar, Sumit, MD",10/30/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/24/2023,Inactive,,
MSC OP INFUSION,63877,"Talwar, Sumit, MD",6/26/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide 21 Day Cycles- Multiple Myeloma,_1. First Line,6/25/2024,Active,,
NBI OP INFUSION,45104,"Schleicher, Lori, MD",5/9/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,5/8/2023,Active,,
SOM OUTPT INFUSION,86853,"Patel, Eshan, MD",3/20/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,3/5/2024,Inactive,,
MMC OP VP INFUSION,91218,"Lee, Patrick C, MD",10/26/2023,Pembrolizumab 21 Day Cycles - Melanoma,,8/27/2023,Inactive,,
CINJ OP INFUSION,59328,"Mayer, Tina M, MD",9/14/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,_1. First Line,9/6/2023,Inactive,,
CMC OP INFUSION,44400,"Taff, Jessica, MD",8/2/2023,"Gemcitabine D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma- Unresectable/Locally Advanced/Metastatic",First Line,8/1/2023,Inactive,,
JCMC CP INFUSION,12618,"Sekhri, Arunabh, MD",12/18/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- vulvar Cancers,_1. First Line,12/3/2023,Inactive,,
JCMC CP INFUSION,12618,"Sekhri, Arunabh, MD",7/8/2024,Cemiplimab-rwlc 21 Day Cycles - Vulvar Cancer,_2. Second Line,6/23/2024,Active,,
CBMC OP INFUSION 2FL,50099,"Scoppetuolo, Michael, MD",2/16/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_2. Second Line,1/15/2024,Inactive,,
SOM OUTPT INFUSION,81293,"Yin, Faye, MD",7/8/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/20/2024,Active,Malignant neoplasm of posterior wall of urinary bladder (CMS/HCC),
NBR 5N ONCOLOGY,90697,"Packiam, Vignesh, MD",1/23/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,1/22/2025,Active,,
CINJ OP INFUSION,52766,"Groisberg, Roman, MD",9/1/2023,Gemcitabine 21 Day Cycles - Sarcoma,First Line,8/31/2023,Inactive,,
CINJ OP INFUSION,52766,"Groisberg, Roman, MD",9/8/2023,AD (DOXOrubicin / Dacarbazine) 21 Day Cycles - Sarcoma,First Line,3/30/2023,Inactive,,
CINJ OP INFUSION,52766,"Groisberg, Roman, MD",11/10/2023,PAZOPanib 30 Day Cycles - Sarcoma,_3. Third Line,11/10/2023,Active,,
CMC OP INFUSION,5977,"Talwar, Sumit, MD",5/31/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/16/2023,Inactive,,
CBMC OP INFUSION 2FL,80923,"Raptis, George, MD",6/14/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,6/13/2024,Inactive,,
NBR CINJ OP INFUSION,11623,"Evens, Andrew M, DO",5/10/2023,Lymphodepletion Breyanzi 9 Day Cycle - Non-Hodgkin's Lymphoma,Second Line,5/9/2023,Inactive,,
NBR CINJ OP INFUSION,11623,"Evens, Andrew M, DO",10/23/2024,OBINUTUZUMAB / GLOFITAMAB 21 DAY CYCLES - DIFFUSE LARGE B-CELL LYMPHOMA,_3. Third Line,10/15/2024,Active,,
TRMC TCCC OP INFUSION,50583,"Capo, Gerardo, MD",9/11/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_1. First Line,9/10/2024,Active,,
TRMC TCCC OP INFUSION,50583,"Salerno, Vincent E, MD",11/6/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),_1. First Line,10/23/2024,Active,,
NBR 4N ONCOLOGY,78839,"Matasar, Matthew J, MD",7/25/2023,R-IVAC (Ifosfamide / Etoposide / Cytarabine / Intrathecal Methotrexate) + RiTUXimab 21 Day Cycle - DLBCL,Second Line,7/25/2023,Inactive,,
NBR 4N BMTU/IMCU,78839,"Rhodes, Joanna Meehan, MD",10/25/2023,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_2. Second Line,10/25/2023,Inactive,,
SOM OUTPT INFUSION,38362,"Yin, Faye, MD",7/10/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/9/2024,Inactive,,
CINJ OP INFUSION,29977,"George, Mridula A, MD",8/2/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,8/1/2023,Active,Aplastic anemia (CMS/HCC),
CBMC OP INFUSION 2FL,12536,"Brown, Andrew Bennett, MD",11/29/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Neoadjuvant,11/28/2023,Inactive,,
CBMC OP INFUSION 2FL,12536,"Brown, Andrew Bennett, MD",12/13/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,12/13/2023,Inactive,,
CBMC OP INFUSION 2FL,12536,"Brown, Andrew Bennett, MD",5/29/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/28/2024,Inactive,,
CBMC OP INFUSION 2FL,12536,"Brown, Andrew Bennett, MD",10/14/2024,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,10/13/2024,Inactive,,
MMC OP INFUSION,80132,"Lee, Patrick C, MD",9/26/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,9/25/2023,Inactive,,
CBMC OP INFUSION 2FL,87249,"Wagmiller, Jennifer Ann, MD",6/20/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,6/9/2024,Active,,
CMC OP INFUSION,81618,"Taff, Jessica, MD",1/19/2023,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,First Line,1/4/2023,Active,,
CINJ OP INFUSION,96909,"Berim, Lyudmyla, MD",5/31/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/30/2024,Active,"Buccal mucosa squamous cell carcinoma (CMS/HCC)
Autoinflammatory syndrome, unspecified (CMS/HCC)",
MMC OP VP INFUSION,50729,"Talwar, Sumit, MD",5/5/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,First Line,5/4/2023,Inactive,,
CBMC OP INFUSION 2FL,15115,"Litvak, Anna M, MD",11/12/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,11/11/2024,Active,,
CINJ OP INFUSION,43727,"Leiser, Aliza, MD",2/24/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,2/2/2023,Inactive,,
NBR 5N ONCOLOGY,5250,"Goel, Sanjay, MD",4/21/2025,Gemcitabine with Concurrent Radiation,_1. First Line,4/21/2025,Inactive,Metastatic cholangiocarcinoma (CMS/HCC),"C22.1 - Intrahepatic bile duct carcinoma; A41.52 - Sepsis due to Pseudomonas; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; E43 - Unspecified severe protein-calorie malnutrition; R57.8 - Other shock; R57.1 - Hypovolemic shock; K72.00 - Acute and subacute hepatic failure without coma; J96.01 - Acute respiratory failure with hypoxia; K83.1 - Obstruction of bile duct; G93.41 - Metabolic encephalopathy; R65.21 - Severe sepsis with septic shock; R64 - Cachexia; E87.0 - Hyperosmolality and hypernatremia; E83.51 - Hypocalcemia; C54.1 - Malignant neoplasm of endometrium; I50.32 - Chronic diastolic (congestive) heart failure; I13.0 - Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; D68.9 - Coagulation defect, unspecified; N18.31 - Chronic kidney disease, stage 3a; J43.9 - Emphysema, unspecified; F32.9 - Major depressive disorder, single episode, unspecified; Z68.37 - Body mass index (BMI) 37.0-37.9, adult; I35.0 - Nonrheumatic aortic (valve) stenosis; D63.0 - Anemia in neoplastic disease; K56.699 - Other intestinal obstruction unspecified as to partial versus complete obstruction; K83.09 - Other cholangitis; E87.20 - Acidosis, unspecified; D62 - Acute posthemorrhagic anemia; E87.1 - Hypo-osmolality and hyponatremia; N17.9 - Acute kidney failure, unspecified; K92.1 - Melena; Z92.3 - Personal history of irradiation; K21.9 - Gastro-esophageal reflux disease wit..."
NBR CINJ OP INFUSION,29871,"Shah, Mansi R, MD",6/27/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,,6/26/2023,Inactive,,
NBR 4N ONCOLOGY,29871,"Patel, Vimal D, MD",6/29/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,,6/28/2023,Inactive,,
NBR 4N ONCOLOGY,29871,"Patel, Vimal D, MD",6/29/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,6/28/2023,Inactive,,
NBR 4N ONCOLOGY,29871,"Patel, Vimal D, MD",6/29/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone 21 Day Cycles- Multiple Myeloma,,6/28/2023,Inactive,,
NBR CINJ OP INFUSION,29871,"Shah, Mansi R, MD",6/27/2024,Carfilzomib 56 mg/m2 (High-Dose) Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,6/26/2024,Inactive,,
NBR CINJ OP INFUSION,29871,"Shah, Mansi R, MD",7/24/2024,Lymphodepletion Abecma with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,7/23/2024,Inactive,,
CINJ OP INFUSION,54257,"Boland, Patrick M, MD",6/2/2023,Temozolomide 28 Day Cycles - Melanoma,,6/2/2023,Inactive,,
CINJ OP INFUSION,58044,"Haigentz, Missak, MD",1/6/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,1/5/2025,Inactive,Primary oral squamous cell carcinoma (CMS/HCC),
CINJ OP INFUSION,14283,"Hochster, Howard S, MD",9/20/2023,CINJ 072012 (BTCRC-GI20-457) Atezolizumab / Bevacizumab 21 Day Cycles Research- Hepatocellular Carcinoma,First Line,9/19/2023,Inactive,,
CINJ OP INFUSION,14283,"Hochster, Howard S, MD",8/28/2024,CINJ 072213 Nivolumab / Ipilimumab 21 Day Cycles Followed by Nivolumab 28 Day Cycles Research- Hepatocellular Carcinoma,_2. Second Line,7/30/2024,Inactive,,
CINJ OP INFUSION,14283,"Hochster, Howard S, MD",10/30/2024,Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers--Gemcitabine-CISplatin Sequencing,_2. Second Line,10/29/2024,Active,,
CINJ OP INFUSION,92470,"Patankar, Sonali, MD",2/7/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/6/2024,Inactive,,
NBR BMSCH 2 PED HEMONC,78371,"Masterson, Margaret, MD",6/10/2023,AALL1732 Induction,Induction,6/8/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,78371,"Goyal-Khemka, Meenakshi, MD",7/13/2023,AALL1732 Consolidation,Consolidation,7/13/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,78371,"Moerdler, Scott, MD",8/9/2023,PEDS Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia,Third Line,8/9/2023,Inactive,,
CBMC OP INFUSION 2FL,8403,"Dharmapuri, Sirish, MD",9/24/2024,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,9/23/2024,Active,,
CBMC OP INFUSION 1FL,10631,"Siu, Karleung, MD",1/14/2025,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/6/2025,Inactive,Malignant neoplasm of lower lobe of right lung (CMS/HCC),
CBMC 2W ONCOLOGY,70676,"Siu, Karleung, MD",4/15/2025,Amivantamab-vmjw + Lazertinib 2L,_2. Second Line,4/15/2025,Inactive,Malignant neoplasm of lower lobe of right lung (CMS/HCC),
CINJ OP INFUSION,98400,"Gulhati, Prateek, MD PhD",5/18/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,5/11/2023,Inactive,,
CINJ OP INFUSION,98400,"Gulhati, Prateek, MD PhD",9/28/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,9/27/2023,Inactive,,
CINJ OP INFUSION,24522,"Berim, Lyudmyla, MD",4/26/2024,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/24/2024,Inactive,,
CINJ PEDS HEMONC ,31267,"Moerdler, Scott, MD",4/26/2023,Pembrolizumab 21 Day Cycles- progressive sarcoma,Third Line,4/23/2023,Inactive,,
CINJ OP INFUSION,38283,"Stephenson, Ryan D, DO",2/2/2024,Durvalumab / CISplatin / Etoposide D1-D3 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/28/2024,Inactive,,
CINJ OP INFUSION,38283,"Stephenson, Ryan D, DO",5/20/2024,Topotecan 21 Day Cycles- Small Cell Bladder,_2. Second Line,5/17/2024,Inactive,,
CINJ OP INFUSION,55061,"Aikins, James K, MD",6/5/2023,Letrozole 30 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,6/5/2023,Active,,
CINJ OP INFUSION,23530,"Hochster, Howard S, MD",12/31/2024,DOXOrubicin Drug Eluting Bead TACE - Hepatocellular Cancer,_1. First Line,12/31/2024,Active,,
NBI OP INFUSION,95648,"Cheng, Yan Ho, MD",2/4/2025,Abemaciclib and Anastrazole 28 Day Cycles - Breast,_1. First Line,2/4/2025,Active,"Malignant neoplasm of right female breast (CMS/HCC)
Secondary malignant neoplasm of brain (CMS/HCC)","C79.31 - Secondary malignant neoplasm of brain; G93.6 - Cerebral edema; C78.02 - Secondary malignant neoplasm of left lung; E87.1 - Hypo-osmolality and hyponatremia; D62 - Acute posthemorrhagic anemia; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C79.51 - Secondary malignant neoplasm of bone; C50.911 - Malignant neoplasm of unspecified site of right female breast; C50.912 - Malignant neoplasm of unspecified site of left female breast; F32.9 - Major depressive disorder, single episode, unspecified; D63.0 - Anemia in neoplastic disease; R62.7 - Adult failure to thrive; Z11.52 - Encounter for screening for COVID-19; R74.01 - Elevation of levels of liver transaminase levels; F41.9 - Anxiety disorder, unspecified; Z59.71 - Insufficient health insurance coverage; Z68.22 - Body mass index (BMI) 22.0-22.9, adult; Z17.0 - Estrogen receptor positive status (ER+); Z17.21 - Progesterone receptor positive status; Z17.32 - Human epidermal growth factor receptor 2 negative status"
CINJ OP INFUSION,11235,"Jang, Thomas L, MD",2/16/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,2/16/2023,Inactive,,
CINJ OP INFUSION,11235,"Jang, Thomas L, MD",9/21/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,9/21/2023,Active,,
CINJ OP INFUSION,11235,"Jang, Thomas L, MD",4/17/2025,BCG (TICE) Maintenance 3/6/12 Schedule - Upper Tract,Maintenance,4/17/2025,Active,Malignant neoplasm of urinary bladder (CMS/HCC),
CINJ OP INFUSION,26913,"Packiam, Vignesh, MD",4/15/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Induction,4/15/2025,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),"C67.8 - Malignant neoplasm of overlapping sites of bladder; C67.9 - Malignant neoplasm of bladder, unspecified; R30.0 - Dysuria"
CINJ OP INFUSION,58376,"Mayer, Tina M, MD",3/6/2023,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,,3/6/2023,Inactive,,
CINJ OP INFUSION,98462,"Stephenson, Ryan D, DO",2/19/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,2/19/2024,Inactive,,
CINJ OP INFUSION,98462,"Stephenson, Ryan D, DO",2/19/2025,Darolutamide 28 Day Cycles - Prostate,_1. First Line,2/19/2025,Active,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; C79.51 - Secondary malignant neoplasm of bone; R39.9 - Unspecified symptoms and signs involving the genitourinary system; M54.50 - Low back pain, unspecified; I48.91 - Unspecified atrial fibrillation; N18.31 - Chronic kidney disease, stage 3a; C44.92 - Squamous cell carcinoma of skin, unspecified; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; Z19.1 - Hormone sensitive malignancy status; I50.33 - Acute on chronic diastolic (congestive) heart failure; I49.5 - Sick sinus syndrome; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E78.5 - Hyperlipidemia, unspecified; Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels; Z95.0 - Presence of cardiac pacemaker"
NBR 5N ONCOLOGY,75252,"Berim, Lyudmyla, MD",3/18/2023,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,3/17/2023,Inactive,,
CINJ OP INFUSION,75252,"Berim, Lyudmyla, MD",6/22/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,6/20/2023,Inactive,,
SOM OUTPT INFUSION,47454,"Yin, Faye, MD",10/16/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,10/15/2023,Inactive,,
SOM OUTPT INFUSION,47454,"Yin, Faye, MD",10/24/2023,CMF PO (Cyclophosphamide PO / Methotrexate / Fluorouracil) 28 Day Cycles - Breast,Adjuvant,10/23/2023,Inactive,,
CBMC OP INFUSION 2FL,71668,"Wagmiller, Jennifer Ann, MD",11/22/2023,Albumin-Bound PACLitaxel 21 Day Cycles - Breast,_2. Second Line,11/20/2023,Inactive,,
MMC OP VP INFUSION,58716,"Cohen, Seth D, MD",1/4/2023,CISplatin 80 mg/m2/ Etoposide 80 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,,1/3/2023,Inactive,,
MMC OP VP INFUSION,68277,"Cohen, Seth D, MD",8/21/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,8/20/2023,Inactive,,
MMC OP VP INFUSION,68277,"Cohen, Seth D, MD",9/20/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/19/2023,Active,,
NBR CINJ OP INFUSION,61029,"Shah, Mansi R, MD",2/17/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/3/2025,Active,Multiple myeloma in remission (CMS/HCC),
CINJ OP INFUSION,51598,"Berim, Lyudmyla, MD",3/11/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Colon Cancer,,3/3/2023,Inactive,,
CINJ OP INFUSION,51598,"Berim, Lyudmyla, MD",9/20/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Colon Cancer,,9/19/2023,Inactive,,
CINJ OP INFUSION,51598,"Berim, Lyudmyla, MD",10/10/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colon Cancer,_3. Third Line,10/6/2023,Inactive,,
CINJ OP INFUSION,51598,"Berim, Lyudmyla, MD",5/13/2024,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Colon Cancer,_3. Third Line,5/6/2024,Inactive,,
CINJ OP INFUSION,51598,"Berim, Lyudmyla, MD",10/9/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Colon Cancer,_3. Third Line,9/25/2024,Inactive,,
CINJ OP INFUSION,51598,"Berim, Lyudmyla, MD",1/10/2025,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Colon Cancer,_3. Third Line,1/3/2025,Active,,
CINJ OP INFUSION,97729,"Berim, Lyudmyla, MD",3/6/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,3/6/2025,Inactive,Cancer of sigmoid colon (CMS/HCC),C18.7 - Cancer of sigmoid colon (CMS/HCC)
SOM OUTPT INFUSION,4268,"Patel, Eshan, MD",1/18/2024,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - head and neck,_1. First Line,1/17/2024,Active,,
MMC OP INFUSION,94107,"Eltoukhy, Hussam, MD",6/22/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,First Line,6/19/2023,Inactive,,
MMC OP INFUSION,94107,"Eltoukhy, Hussam, MD",12/18/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,Maintenance,12/10/2023,Active,,
CBMC OP INFUSION 2FL,74236,"Brown, Andrew Bennett, MD",12/28/2023,PACLitaxel 200 mg/m2 /CARBOplatin 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,_1. First Line,12/21/2023,Inactive,,
NBR CINJ OP INFUSION,87948,"Evens, Andrew M, DO",4/5/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,,4/4/2023,Inactive,,
MMC OP INFUSION,11463,"Talwar, Sumit, MD",9/25/2023,RiTUXimab 168 Day Cycles - Rheumatoid Arthritis,,9/24/2023,Active,Malignant neoplasm of central portion of left female breast (CMS/HCC),
MMC OP VP INFUSION,52388,"Meghal, Trishala, MD",8/15/2023,Abemaciclib 28 Day Cycles - Breast ,,8/15/2023,Inactive,,
MSC OP INFUSION,84135,"Cohen, Seth D, MD",3/5/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,3/1/2024,Active,,
MMC OP VP INFUSION,84135,"Cohen, Seth D, MD",9/3/2024,Capecitabine 21 Day Cycles - Breast,_1. First Line,9/3/2024,Active,,
CINJ OP INFUSION,54391,"Stephenson, Ryan D, DO",11/18/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,11/15/2024,Active,,
NBR 4N ONCOLOGY,96643,"Muralikrishnan, Sivraj",12/30/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,_1. First Line,12/27/2024,Active,,
NBR 5N ONCOLOGY,61391,"Sridharan, Ashwin, MD",9/15/2023,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),First Line,9/15/2023,Inactive,,
CINJ OP INFUSION,61391,"Patel, Eshan, MD",4/12/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,_2. Second Line,4/4/2024,Inactive,,
NBR 4N ONCOLOGY,50367,"Zayac, Adam, MD",1/22/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,1/21/2025,Active,AML (acute myeloid leukemia) in remission (CMS/HCC),
TRMC TCCC OP INFUSION,58265,"Salerno, Vincent E, MD",1/9/2025,RiTUXimab 168 Day Cycles - Indolent Lymphoma Maintenance,_1. First Line,1/9/2025,Active,Cholangiocarcinoma determined by biopsy of biliary tract (CMS/HCC),
CINJ OP INFUSION,6792,"Girda, Eugenia, MD",5/29/2025,CISplatin With Concurrent Radiation Weekly + Pembrolizumab - Cervical,Induction,5/29/2025,Active,Cervical intraepithelial neoplasia grade III with severe dysplasia,
CBMC OP INFUSION 2FL,89224,"Wagmiller, Jennifer Ann, MD",10/22/2024,CISplatin/Pembrolizumab with radiation/ cervical cancer,Adjuvant,10/14/2024,Inactive,,
CBMC OP INFUSION 2FL,89224,"Wagmiller, Jennifer Ann, MD",12/19/2024,Pembrolizumab 21 Day Cycles - Cervical,Adjuvant,12/18/2024,Active,,
CBMC OP INFUSION 2FL,89224,"Wagmiller, Jennifer Ann, MD",2/26/2025,"Taxol 80, carbo 6, bev",_1. First Line,2/25/2025,Active,"Cervical cancer (CMS/HCC)
On antineoplastic chemotherapy
Elevated cancer antigen 125 (CA 125)
Elevated carcinoembryonic antigen (CEA)",
MMC OP VP INFUSION,93656,"Cohen, Seth D, MD",7/8/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,7/7/2024,Inactive,,
MMC OP VP INFUSION,93656,"Cohen, Seth D, MD",7/10/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles,_1. First Line,7/7/2024,Inactive,,
CINJ OP INFUSION,32559,"Toppmeyer, Deborah L, MD",10/11/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/9/2024,Active,,
NBR 4N ONCOLOGY,14470,"Evens, Andrew M, DO",7/14/2023,Prephase Cyclophosphamide / VinCRIStine / Methylprednisolone - Lymphoma,Neoadjuvant,7/14/2023,Inactive,,
NBR 4N ONCOLOGY,14470,"Evens, Andrew M, DO",7/26/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),,7/26/2023,Inactive,,
NBR CINJ OP INFUSION,14470,"Evens, Andrew M, DO",8/23/2023,CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,8/22/2023,Inactive,,
CMC OP INFUSION,34376,"Ferretti, Mark J, MD",9/9/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,_1. First Line,8/27/2024,Active,,
CMC OP INFUSION,34376,"Ferretti, Mark J, MD",1/6/2025,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,1/5/2025,Active,,
CINJ OP INFUSION,82970,"Weiss, Sarah, MD",12/18/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,12/15/2023,Inactive,,
CINJ OP INFUSION,82970,"Weiss, Sarah, MD",4/18/2024,Dabrafenib / Trametinib 30 Day Cycles - Melanoma,_2. Second Line,4/18/2024,Active,,
SOM OUTPT INFUSION,89508,"Patel, Eshan, MD",11/29/2023,"AHOD2131 Arms B,D,F and H Brentuximab + Nivolumab",_1. First Line,11/29/2023,Inactive,,
SOM OUTPT INFUSION,89508,"Patel, Eshan, MD",11/30/2023,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,11/28/2023,Inactive,,
CINJ OP INFUSION,3690,"Leiser, Aliza, MD",7/17/2023,CINJ 102203 ARM 1 Nemvaleukin / Pembrolizumab 21 Day Cycles Research- Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Third Line,7/16/2023,Inactive,,
CINJ OP INFUSION,3690,"Stephenson, Ruth D, DO",9/15/2023,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Third Line,9/14/2023,Inactive,,
CINJ OP INFUSION,2421,"Stephenson, Ryan D, DO",9/25/2023,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,Neoadjuvant,9/24/2023,Inactive,,
NBR 4N ONCOLOGY,58589,"Rhodes, Joanna Meehan, MD",7/19/2024,Acalabrutinib 30 Day Cycles,_1. First Line,7/19/2024,Inactive,,
JCMC CP INFUSION,20912,"Sekhri, Arunabh, MD",1/23/2023,ABVD (DOXOrubicin / BLEOmycin / VinBLAStine / Dacarbazine) 28 Day Cycles - Hodgkin Lymphoma,First Line,1/22/2023,Inactive,,
CINJ OP INFUSION,75234,"Saraiya, Biren P, MD",3/10/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,3/10/2025,Active,Malignant neoplasm of prostate (CMS/HCC),"C61 - Malignant neoplasm of prostate; N28.89 - Other specified disorders of kidney and ureter; E66.9 - Obesity, unspecified; Z68.41 - Body mass index (BMI) 40.0-44.9, adult"
MMC OP VP INFUSION,18663,"Meghal, Trishala, MD",1/6/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,12/8/2024,Active,,
CBMC OP INFUSION 2FL,79433,"Brown, Andrew Bennett, MD",11/4/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/3/2024,Active,,
CINJ OP INFUSION,54901,"Toppmeyer, Deborah L, MD",2/16/2023,Palbociclib 28 Day Cycles - Breast,,2/16/2023,Active,,
TRMC TCCC OP INFUSION,3020,"Capo, Gerardo, MD",10/9/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/8/2024,Active,,
CINJ OP INFUSION,96780,"Stephenson, Ruth D, DO",6/19/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Neoadjuvant,6/11/2024,Inactive,,
CBMC OP INFUSION 2FL,67049,"Brown, Andrew Bennett, MD",3/17/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,3/17/2025,Inactive,"Primary squamous cell carcinoma of lung, left (CMS/HCC)",
MMC OP VP INFUSION,15665,"Cohen, Seth D, MD",10/25/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/18/2023,Inactive,,
CINJ OP INFUSION,78558,"Berim, Lyudmyla, MD",7/24/2023,Atezolizumab/Bevacizumab-Maintenance 21 Day Cycles- HCC,,7/23/2023,Inactive,,
NBR CINJ OP INFUSION,74711,"Tiger, Yun Kyoung, MD",6/24/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,6/23/2024,Active,"Malignant neoplasm of cervix, unspecified site (CMS/HCC)",
CBMC OP INFUSION 2FL,89113,"Kulkarni, Aditya A, MD",4/21/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,4/21/2025,Inactive,Prostate cancer metastatic to bone (CMS/HCC),C61 - Malignant neoplasm of prostate
JCMC CP INFUSION,98916,"Cruz, Allan Louie E, MD",12/5/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,12/3/2023,Inactive,,
JCMC CP INFUSION,98916,"Cruz, Allan Louie E, MD",3/4/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,2/26/2024,Active,,
CINJ OP INFUSION,52047,"Omene, Coral Oghenerukevwe, MD",12/30/2024,CINJ 042403 Tirzepatide Weekly 28 Day Cycles Research- Breast Cancer,Adjuvant,12/30/2024,Active,,
CINJ OP INFUSION,78222,"Saraiya, Biren P, MD",1/8/2024,Gemcitabine with Concurrent Radiation 35 Day Cycle - Bladder,Induction,12/10/2023,Inactive,,
NBR 4N ONCOLOGY,24725,"Braunschweig, Ira, MD",4/1/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,3/31/2023,Inactive,,
NBR CINJ OP INFUSION,24725,"Braunschweig, Ira, MD",5/11/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,5/10/2023,Inactive,,
JCMC CP INFUSION,24725,"Cruz, Allan Louie E, MD",5/8/2025,Talquetamab 28 Day Cycles,_6. Sixth Line,5/8/2025,Active,"Hx of multiple myeloma
Multiple myeloma (CMS/HCC)","Z51.12 - Encounter for antineoplastic immunotherapy; C90.02 - Multiple myeloma in relapse; D61.9 - Aplastic anemia, unspecified; I48.92 - Unspecified atrial flutter; M84.48XA - Pathological fracture, other site, initial encounter for fracture; D50.0 - Iron deficiency anemia secondary to blood loss (chronic); E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; K25.9 - Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation; E11.65 - Type 2 diabetes mellitus with hyperglycemia; I48.91 - Unspecified atrial fibrillation; Z79.4 - Long term (current) use of insulin; E83.42 - Hypomagnesemia; E88.2 - Lipomatosis, not elsewhere classified; H35.30 - Unspecified macular degeneration; K31.819 - Angiodysplasia of stomach and duodenum without bleeding; M47.896 - Other spondylosis, lumbar region; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; E87.5 - Hyperkalemia; R74.01 - Elevation of levels of liver transaminase levels; K21.00 - Gastro-esophageal reflux disease with esophagitis, without bleeding; Z79.01 - Long term (current) use of anticoagulants; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z80.3 - Family history of malignant neoplasm of breast; Z87.891 - ..."
CBMC OP INFUSION 2FL,55986,"Litvak, Anna M, MD",10/16/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,10/15/2023,Inactive,,
CBMC OP INFUSION 2FL,55986,"Ligresti, Louise G, MD",5/13/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,5/13/2024,Inactive,,
NBR CINJ OP INFUSION,25987,"Shah, Mansi R, MD",5/1/2023,Teclistamab Q 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,4/30/2023,Inactive,,
NBR CINJ OP INFUSION,25987,"Shah, Mansi R, MD",8/22/2024,"Bortezomib/Pom/Dex D1, D8, D15 28 Day Cycles- Multiple Myeloma",_5. Fifth Line,8/21/2024,Active,,
NBR CINJ OP INFUSION,25987,"Shah, Mansi R, MD",9/3/2024,Talquetamab 28 Day Cycles,_8. Eighth Line,9/3/2024,Inactive,,
NBR CINJ OP INFUSION,25987,"Shah, Mansi R, MD",5/23/2025,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,_5. Fifth Line,5/23/2025,Active,Multiple myeloma in relapse (CMS/HCC),
NBR CINJ OP INFUSION,25987,"Shah, Mansi R, MD",4/26/2025,Talquetamab 28 Day Cycles,_7. Seventh Line,4/26/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),
NBR CINJ OP INFUSION,25987,"Shah, Mansi R, MD",4/17/2025,Carfilzomib 70 mg/m2 (High-Dose) Plus Selinexor Plus Dexamethasone 28 Day Cycles- Multiple Myeloma Gasparetto et al. BR J Cancer 2022.,_5. Fifth Line,4/17/2025,Inactive,Multiple myeloma in relapse (CMS/HCC),
NBR 5N ONCOLOGY,25987,"Shah, Mansi R, MD",4/9/2025,CED (Cyclophosphamide/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,4/8/2025,Inactive,"H/O of chimeric antigen receptor T-cell therapy
Multiple myeloma in relapse (CMS/HCC)
Hypogammaglobulinemia (CMS/HCC)
Immunocompromised (CMS/HCC)",
SOM OUTPT INFUSION,82810,"Patel, Eshan, MD",5/27/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/27/2025,Inactive,Malignant neoplasm of bronchus and lung (CMS/HCC),"C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; R16.0 - Hepatomegaly, not elsewhere classified"
CMC OP INFUSION,49428,"Pompa, Tiffany Ann, MD",8/22/2024,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",Adjuvant,8/21/2024,Active,,
CINJ OP INFUSION,109,"Stephenson, Ryan D, DO",1/24/2025,DOCEtaxel / Darolutamide 21 Day Cycles - Prostate,_1. First Line,12/12/2024,Active,,
CINJ OP INFUSION,42256,"Haigentz, Missak, MD",3/13/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/12/2024,Inactive,,
CINJ OP INFUSION,73759,"Dasgeb, Bahar, MD",5/6/2025,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,_1. First Line,5/6/2025,Inactive,"Complication of lung transplant (CMS/HCC)
Squamous cell carcinoma of multiple sites
Squamous cell carcinoma of overlapping sites of skin",
CINJ OP INFUSION,73759,"Dasgeb, Bahar, MD",4/23/2025,Cetuximab 7 Day Cycles (Recurrent/Metastatic)- Head and Neck Cancers,_1. First Line,4/22/2025,Active,"Complication of lung transplant (CMS/HCC)
Squamous cell carcinoma of multiple sites
Squamous cell carcinoma of overlapping sites of skin",
NBR CINJ OP INFUSION,40470,"Matasar, Matthew J, MD",4/9/2024,Obinutuzumab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma,_3. Third Line,4/8/2024,Inactive,,
CINJ OP INFUSION,35388,"Haigentz, Missak, MD",10/30/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/30/2023,Active,,
CBMC OP INFUSION 2FL,39958,"Brown, Andrew Bennett, MD",4/21/2025,Pembrolizumab 21 Day Cycles - Lung,_1. First Line,4/21/2025,Inactive,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Other autoinflammatory syndromes (CMS/HCC)",
HAM OP INFUSION,68890,"Yogarajah, Meera, MD",4/14/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,4/14/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor negative (CMS/HCC)","C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; M17.12 - Unilateral primary osteoarthritis, left knee; E55.9 - Vitamin D deficiency, unspecified; Z87.891 - Personal history of nicotine dependence; Z91.09 - Other allergy status, other than to drugs and biological substances; Z79.899 - Other long term (current) drug therapy; Z17.1 - Estrogen receptor negative status (ER-); R79.1 - Abnormal coagulation profile"
CINJ OP INFUSION,45884,"Boland, Patrick M, MD",4/18/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/18/2025,Inactive,Cancer of ascending colon (CMS/HCC),"C18.2 - Malignant neoplasm of ascending colon; K76.9 - Liver disease, unspecified"
NBI OP INFUSION,78398,"Anderson, Patrick S, MD",12/18/2024,Paclitaxel/Cisplatin+Mvasi Q21day,_2. Second Line,12/17/2024,Active,,
HAM OP INFUSION,77835,"Patel, Malini M, MD",4/4/2025,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,3/14/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified body region (CMS/HCC)"
NBR CINJ OP INFUSION,26252,"Palmisiano, Neil David, MD",2/10/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Second Line,2/9/2023,Inactive,,
MMC OP VP INFUSION,66775,"Eltoukhy, Hussam, MD",8/15/2024,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/14/2024,Inactive,,
MMC OP INFUSION,66775,"Eltoukhy, Hussam, MD",10/2/2024,MMC--Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,10/1/2024,Inactive,,
HAM OP INFUSION,9147,"Patel, Malini M, MD",1/16/2025,RiTUXimab 28 Day Cycle - warm autoimmunee hemolytic anemia,_2. Second Line,1/1/2025,Active,Carcinoma in situ of bladder,
HAM OP INFUSION,23320,"Yogarajah, Meera, MD",5/1/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,5/1/2025,Inactive,"Uterine carcinosarcoma (CMS/HCC)
Malignant neoplasm of endometrium (CMS/HCC)",
SOM OUTPT INFUSION,82584,"Yin, Faye, MD",11/22/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,11/21/2023,Inactive,,
MMC OP VP INFUSION,21495,"Lee, Patrick C, MD",12/24/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,Induction,12/24/2024,Active,Malignant neoplasm of rectum (CMS/HCC),
MMC OP INFUSION,48520,"Lee, Patrick C, MD",3/18/2025,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,3/17/2025,Active,Primary malignant glioma of temporal lobe (CMS/HCC),
MMC OP INFUSION,48520,"Lee, Patrick C, MD",3/17/2025,Temozolomide 28 Day Cycles - CNS,_1. First Line,3/17/2025,Inactive,Primary malignant glioma of temporal lobe (CMS/HCC),"C71.2 - Malignant neoplasm of temporal lobe; R56.9 - Unspecified convulsions; Z98.890 - Other specified postprocedural states; D43.0 - Neoplasm of uncertain behavior of brain, supratentorial; Q85.01 - Neurofibromatosis, type 1; F10.121 - Alcohol abuse with intoxication delirium; Z98.51 - Tubal ligation status; Z79.899 - Other long term (current) drug therapy; Z78.0 - Asymptomatic menopausal state; Z87.891 - Personal history of nicotine dependence; Z92.3 - Personal history of irradiation; Z80.8 - Family history of malignant neoplasm of other organs or systems; Z91.048 - Other nonmedicinal substance allergy status; Z79.52 - Long term (current) use of systemic steroids; Z79.630 - Long term (current) use of alkylating agent; G93.89 - Other specified disorders of brain; Z92.21 - Personal history of antineoplastic chemotherapy; Z79.2 - Long term (current) use of antibiotics; R53.82 - Chronic fatigue, unspecified"
HAM OP INFUSION,47967,"Yogarajah, Meera, MD",3/30/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/22/2023,Inactive,,
HAM OP INFUSION,47967,"Yogarajah, Meera, MD",6/22/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,,6/14/2023,Inactive,,
CINJ OP INFUSION,98774,"Jang, Thomas L, MD",10/24/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Induction - Bladder Cancer,Induction,10/23/2024,Active,,
CINJ OP INFUSION,24030,"Jang, Thomas L, MD",4/29/2025,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,4/29/2025,Active,Urothelial cancer (CMS/HCC),
CINJ OP INFUSION,57782,"Packiam, Vignesh, MD",7/22/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle - Bladder,Adjuvant,7/21/2024,Inactive,,
CINJ OP INFUSION,57782,"Packiam, Vignesh, MD",10/14/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles,Maintenance,10/11/2024,Active,,
CBMC OP INFUSION 2FL,60879,"Leitner, Stuart P, MD",9/30/2024,CINJ 042102 Block A Zanidatamab 14 Day Cycles Research- Breast Cancer,Neoadjuvant,9/29/2024,Active,,
CBMC OP INFUSION 2FL,60879,"Leitner, Stuart P, MD",2/17/2025,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,Adjuvant,2/10/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,45703,"Brown, Andrew Bennett, MD",6/3/2024,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Reinduction,6/3/2024,Active,,
NBR CINJ OP INFUSION,97121,"Shah, Mansi R, MD",11/28/2023,Elotuzumab/Pomalidomide 2mg/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,11/27/2023,Inactive,,
NBR CINJ OP INFUSION,97121,"Shah, Mansi R, MD",11/28/2023,"Carfilzomib 56 mg/m2, Pomalidomide 4mg x 21 days, Plus Dexamethasone 28 Day Cycles- Multiple Myeloma",_3. Third Line,11/27/2023,Inactive,,
NBR CINJ OP INFUSION,97121,"Shah, Mansi R, MD",2/13/2024,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,2/12/2024,Inactive,,
NBR CINJ OP INFUSION,97121,"Shah, Mansi R, MD",3/12/2024,Teclistamab Weekly 28 Day Cycles - Multiple Myeloma,_5. Fifth Line,3/11/2024,Inactive,,
NBR CINJ OP INFUSION,97121,"Shah, Mansi R, MD",8/7/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,8/6/2024,Inactive,,
NBR CINJ OP INFUSION,97121,"Shah, Mansi R, MD",2/18/2025,CAR-T,Maintenance,2/18/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,16094,"Shah, Mansi R, MD",5/15/2025,Talquetamab 28 Day Cycles,_8. Eighth Line,5/15/2025,Active,Multiple myeloma in remission (CMS/HCC),"C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; C90.01 - Multiple myeloma in remission; K74.3 - Primary biliary cirrhosis; C90.00 - Multiple myeloma not having achieved remission; D80.1 - Nonfamilial hypogammaglobulinemia; Z00.00 - Encounter for general adult medical examination without abnormal findings; D84.9 - Immunodeficiency, unspecified; I77.89 - Other specified disorders of arteries and arterioles; D47.2 - Monoclonal gammopathy; Z86.69 - Personal history of other diseases of the nervous system and sense organs; Z87.19 - Personal history of other diseases of the digestive system; Z85.3 - Personal history of malignant neoplasm of breast; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC OP INFUSION 2FL,89187,"Wagmiller, Jennifer Ann, MD",5/30/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_2. Second Line,5/20/2024,Active,,
CBMC OP INFUSION 2FL,61841,"Wagmiller, Jennifer Ann, MD",3/27/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_2. Second Line,3/24/2025,Inactive,"Malignant neoplasm of right kidney, except renal pelvis (CMS/HCC)
Elevated cancer antigen 125 (CA 125)
On antineoplastic chemotherapy",
HAM OP INFUSION,25187,"Patel, Malini M, MD",2/4/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,1/26/2025,Active,Oropharyngeal carcinoma (CMS/HCC),"C10.0 - Malignant neoplasm of vallecula; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; E11.9 - Type 2 diabetes mellitus without complications; E03.9 - Hypothyroidism, unspecified; Z90.49 - Acquired absence of other specified parts of digestive tract; Z79.82 - Long term (current) use of aspirin; Z79.890 - Hormone replacement therapy; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z96.651 - Presence of right artificial knee joint"
NBI OP INFUSION,96266,"Shah, Shailja S, MD",7/31/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/30/2024,Inactive,,
NBI OP INFUSION,19147,"Cheng, Yan Ho, MD",3/10/2025,FOLFOXIRI (Fluorouracil Continuous Infusion 1200 mg/m2/day /Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/10/2025,Inactive,Malignant neoplasm of splenic flexure (CMS/HCC),
NBR CINJ OP INFUSION,92903,"Shah, Mansi R, MD",1/25/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,1/24/2023,Active,,
CINJ OP INFUSION,71989,"Boland, Patrick M, MD",6/13/2023,Gemcitabine/CISplatin 21 Day Cycles- Hepatobiliary Cancers- Gemcitabine-CISplatin Sequencing,,6/5/2023,Inactive,,
CINJ OP INFUSION,71989,"Boland, Patrick M, MD",12/14/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Adjuvant,12/14/2023,Inactive,,
CINJ OP INFUSION,71989,"Boland, Patrick M, MD",2/21/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/23/2025,Active,"Cholangiocarcinoma at hepatic hilum (CMS/HCC)
Other abnormal tumor markers
Anemia associated with nutritional deficiency",
MMC OP VP INFUSION,88718,"Cohen, Seth D, MD",4/10/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,4/9/2023,Inactive,,
MMC OP VP INFUSION,78481,"Cohen, Seth D, MD",9/5/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,9/4/2024,Inactive,,
CINJ OP INFUSION,56332,"Haigentz, Missak, MD",3/7/2024,CARBOplatin / Etoposide 21 Day Cycles - Sinonasal Cancer,_1. First Line,3/7/2024,Inactive,,
CINJ OP INFUSION,56332,"Haigentz, Missak, MD",7/16/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,7/16/2024,Active,,
CBMC OP INFUSION 1FL,90676,"Maggi, Jason C, MD",8/7/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,8/7/2024,Active,,
SOM OUTPT INFUSION,71738,"Toomey, Kathleen C, MD",6/26/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/18/2024,Inactive,,
CBMC OP INFUSION 2FL,91314,"Raptis, George, MD",6/26/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/25/2024,Inactive,,
CINJ OP INFUSION,43822,"Stephenson, Ruth D, DO",3/28/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,3/26/2023,Active,,
CINJ PEDS HEMONC ,56925,"Moerdler, Scott, MD",9/5/2024,AGCT1532 Arm A (Standard BEP),_1. First Line,9/4/2024,Active,,
NBI OP INFUSION,30166,"Shah, Maya M, MD",9/27/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,9/26/2023,Inactive,,
NBI OP INFUSION,30166,"Shah, Maya M, MD",11/22/2023,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_1. First Line,11/21/2023,Inactive,,
NBI OP INFUSION,30166,"Shah, Maya M, MD",12/6/2023,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,_1. First Line,11/29/2023,Inactive,,
CBMC OP INFUSION 2FL,28660,"Grossman, I Robert, MD",2/27/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,2/4/2024,Inactive,,
NBR 5N ONCOLOGY,25776,"Berim, Lyudmyla, MD",11/15/2024,mFOLFOX6 Inpatient (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/14/2024,Active,,
JCMC CP INFUSION,99901,"Cruz, Allan Louie E, MD",6/13/2024,Keytruda Q3W / PACLitaxel D1 21 Day Cycles - Bilateral Breast Cancer (R) TNBC (L) Hormone(+),_1. First Line,5/31/2024,Active,,
NBR CINJ OP INFUSION,39874,"Shah, Mansi R, MD",6/6/2024,"Talquetamab D1, D4, D7, D10 Step-Up 28 Day Cycles- Multiple Myeloma",_9. Ninth Line,6/6/2024,Active,Acute lymphoid leukemia in remission (CMS/HCC),
SOM OUTPT INFUSION,61912,"Yin, Faye, MD",2/19/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,2/11/2024,Inactive,,
CINJ OP INFUSION,94001,"Berim, Lyudmyla, MD",8/12/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,8/8/2024,Active,,
CINJ OP INFUSION,84990,"Weiss, Sarah, MD",2/22/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,2/21/2023,Inactive,,
HAM OP INFUSION,14354,"Yogarajah, Meera, MD",7/3/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,First Line,7/2/2023,Inactive,,
SOM OUTPT INFUSION,86262,"Patel, Eshan, MD",5/22/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,5/22/2024,Active,,
SOM OUTPT INFUSION,86262,"Patel, Eshan, MD",9/10/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,9/9/2024,Active,,
CBMC OP INFUSION 2FL,99716,"Litvak, Anna M, MD",4/17/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,4/17/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)","C50.211, Z17.0 - Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC); R92.8 - Abnormal magnetic resonance imaging of left breast"
CBMC OP INFUSION 2FL,47428,"Dharmapuri, Sirish, MD",10/24/2024,Durvalumab + Gemcitabine / Carboplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/23/2024,Active,,
TRMC TCCC OP INFUSION,83501,"Capo, Gerardo, MD",6/11/2024,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin)  21 Day Cycles- Gastrointestinal Cancers,_1. First Line,6/10/2024,Active,,
CINJ OP INFUSION,41681,"George, Mridula A, MD",10/13/2023,EA1181 / CINJ 042004 Preoperative Trastuzumab / Pertuzumab / DOCEtaxel 21 Day Cycles Research- Breast Cancer,Neoadjuvant,10/13/2023,Inactive,,
NBR CINJ OP INFUSION,41681,"George, Mridula A, MD",1/5/2024,EA1181 / CINJ 042004 Post-Operative Trastuzumab / Pertuzumab 21 Day Cycles Research ARM A- Breast Cancer,Adjuvant,1/4/2024,Inactive,,
CINJ OP INFUSION,41681,"George, Mridula A, MD",1/9/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/8/2024,Active,,
NBI OP INFUSION,15107,"Anderson, Patrick S, MD",2/20/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,2/5/2025,Active,Malignant neoplasm of cervix (CMS/HCC),"C53.9 - Malignant neoplasm of cervix, unspecified site (CMS/HCC)"
CINJ OP INFUSION,62067,"Omene, Coral Oghenerukevwe, MD",4/17/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,,4/14/2023,Inactive,,
CINJ OP INFUSION,42451,"Stephenson, Ruth D, DO",10/17/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,_1. First Line,10/16/2024,Active,,
CINJ OP INFUSION,42451,"Stephenson, Ruth D, DO",10/18/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,_1. First Line,10/17/2024,Inactive,,
CINJ OP INFUSION,15165,"Stephenson, Ruth D, DO",4/2/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,Maintenance,4/2/2025,Active,Malignant neoplasm of overlapping sites of body of uterus (CMS/HCC),C54.8 - Malignant neoplasm of overlapping sites of corpus uteri
CINJ OP INFUSION,55605,"Stephenson, Ryan D, DO",12/2/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,11/24/2024,Active,,
NBI OP INFUSION,51578,"Schleicher, Lori, MD",10/21/2024,Paclitaxel/Pembro-Breast,_1. First Line,10/20/2024,Active,,
NBI OP INFUSION,51578,"Schleicher, Lori, MD",3/10/2025,Sacituzumab Govitecan 28 Day Cycles D1 & 15 - Breast or Bladder,_2. Second Line,3/10/2025,Active,"Malignant neoplasm of central portion of left breast in female, estrogen receptor negative (CMS/HCC)",Z51.11 - Encounter for antineoplastic chemotherapy; C50.112 - Malignant neoplasm of central portion of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
SOM OUTPT INFUSION,52504,"Toomey, Kathleen C, MD",7/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,_1. First Line,7/21/2024,Inactive,,
SOM OUTPT INFUSION,52504,"Toomey, Kathleen C, MD",11/29/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,11/27/2024,Active,,
SOM OUTPT INFUSION,76945,"Toomey, Kathleen C, MD",4/4/2025,Sacituzumab Govitecan 21 Day Cycles - Breast,_2. Second Line,4/4/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",
CBMC OP INFUSION 2FL,32868,"Litvak, Anna M, MD",4/1/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,4/1/2025,Active,Malignant neoplasm of central portion of right female breast (CMS/HCC),
NBI OP INFUSION,33812,"Anderson, Patrick S, MD",5/6/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,5/5/2024,Active,,
MMC OP INFUSION,37180,"Meghal, Trishala, MD",7/26/2023,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,,7/24/2023,Inactive,,
MMC OP VP INFUSION,69549,"Lee, Patrick C, MD",7/18/2023,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers ,,7/17/2023,Inactive,,
CINJ OP INFUSION,58698,"Saraiya, Biren P, MD",1/22/2024,Gemcitabine / CISplatin (1000/70) 21 Day Cycles - Bladder,Neoadjuvant,1/20/2024,Inactive,,
CMC OP INFUSION,92047,"Taff, Jessica, MD",1/6/2025,PEMEtrexed/CISplatin/Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer (Adjuvant),Adjuvant,12/29/2024,Active,,
CMC OP INFUSION,92047,"Taff, Jessica, MD",4/28/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,4/28/2025,Active,Adenocarcinoma of upper lobe of left lung (CMS/HCC),
HAM OP INFUSION,93808,"Patel, Malini M, MD",7/3/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,7/2/2023,Inactive,,
HAM OP INFUSION,93808,"Yogarajah, Meera, MD",6/27/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/24/2024,Active,,
HAM OP INFUSION,93808,"Yogarajah, Meera, MD",1/20/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,1/20/2025,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Stem cells transplant status (CMS/HCC)",
HAM OP INFUSION,93808,"Yogarajah, Meera, MD",1/21/2025,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,1/21/2025,Inactive,"Colorectal cancer, stage IV (CMS/HCC)",
HAM OP INFUSION,93808,"Yogarajah, Meera, MD",5/16/2025,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_4. Fourth Line,5/16/2025,Active,"Colorectal cancer, stage IV (CMS/HCC)","C19 - Colorectal cancer, stage IV (CMS/HCC)"
NBR 5N ONCOLOGY,15208,"Packiam, Vignesh, MD",4/2/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/2/2025,Inactive,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,50853,"Omene, Coral Oghenerukevwe, MD",10/10/2023,Abemaciclib 150 mg BID 28 Day Cycles - Breast ,_1. First Line,10/10/2023,Active,,
CINJ OP INFUSION,76302,"Berim, Lyudmyla, MD",4/20/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,,4/10/2023,Inactive,,
SOM OUTPT INFUSION,41760,"Toomey, Kathleen C, MD",5/10/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/9/2023,Inactive,,
SOM OUTPT INFUSION,41760,"Toomey, Kathleen C, MD",12/11/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,12/11/2023,Inactive,,
MSC OP INFUSION,97712,"Taff, Jessica, MD",7/14/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Second Line,7/4/2023,Inactive,,
CMC OP INFUSION,97712,"Taff, Jessica, MD",10/6/2023,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/28/2023,Inactive,,
CMC OP INFUSION,97712,"Taff, Jessica, MD",10/27/2023,"Gemcitabine 1000 mg/m2 D1, D8, D15  28 Day Cycles- Non-Small Cell Lung Cancer",_3. Third Line,10/26/2023,Inactive,,
MSC OP INFUSION,97712,"Taff, Jessica, MD",5/3/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_4. Fourth Line,5/2/2024,Inactive,,
SOM OUTPT INFUSION,15663,"Patel, Eshan, MD",3/18/2025,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,3/18/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission
CINJ OP INFUSION,21342,"Toppmeyer, Deborah L, MD",1/13/2023,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,1/12/2023,Inactive,,
CINJ OP INFUSION,21342,"Toppmeyer, Deborah L, MD",7/20/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,7/20/2023,Inactive,,
MMC OP INFUSION,90854,"Lee, Patrick C, MD",4/25/2023,Gemcitabine 21 Day Cycles - Day 1 and 8,,4/24/2023,Inactive,,
MMC OP INFUSION,90854,"Lee, Patrick C, MD",9/19/2023,Capecitabine 650 mg/m2 21 Day Cycles- Hepatobiliary cancer ,,9/19/2023,Inactive,,
MMC OP INFUSION,90854,"Lee, Patrick C, MD",11/21/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Maintenance,11/20/2023,Inactive,,
MMC OP INFUSION,90854,"Lee, Patrick C, MD",2/13/2024,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,2/12/2024,Inactive,,
MMC OP INFUSION,90854,"Lee, Patrick C, MD",7/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_4. Fourth Line,7/22/2024,Active,,
NBI OP INFUSION,9139,"Jacoby, Sari H, MD",7/23/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/8/2024,Active,"Metastasis to mediastinum (CMS/HCC)
Colon cancer metastasized to lung (CMS/HCC)",
NBI OP INFUSION,99984,"Jacoby, Sari H, MD",2/13/2025,CINJ 042403 Tirzepatide Weekly 28 Day Cycles Research- Breast Cancer,_2. Second Line,2/13/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,87227,"Omene, Coral Oghenerukevwe, MD",5/20/2024,Abemaciclib 28 Day Cycles - Breast,_2. Second Line,5/20/2024,Inactive,,
CINJ OP INFUSION,73921,"George, Mridula A, MD",8/1/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,8/1/2023,Active,,
CBMC OP INFUSION 2FL,7514,"Grossman, I Robert, MD",8/12/2024,RiTUXimab Initial Infusion ++Day (Outpatient),_1. First Line,8/12/2024,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
SOM OUTPT INFUSION,91297,"Toomey, Kathleen C, MD",1/22/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,1/21/2025,Active,,
SOM OUTPT INFUSION,91297,"Toomey, Kathleen C, MD",2/20/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,1/21/2025,Active,"Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)
Metastasis to lymph nodes (CMS/HCC)",C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; C50.411 - Malignant neoplasm of upper-outer quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
SOM OUTPT INFUSION,27944,"Yin, Faye, MD",2/7/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/14/2024,Inactive,,
SOM OUTPT INFUSION,27944,"Toomey, Kathleen C, MD",5/1/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/30/2024,Active,Nodular sclerosis Hodgkin lymphoma of intrathoracic lymph nodes (CMS/HCC),
NBI OP INFUSION,54766,"Shah, Shailja S, MD",7/9/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/8/2024,Active,,
NBI A5 PEDIATRICS,26771,"de Benedictis, Marianna, MD",7/23/2024,AALL1732 Induction,_1. First Line,7/22/2024,Inactive,,
NBI VALERIE FND HEMONC,26771,"de Benedictis, Marianna, MD",9/3/2024,AALL1732 Consolidation,_1. First Line,9/3/2024,Inactive,,
NBI VALERIE FND HEMONC,26771,"de Benedictis, Marianna, MD",9/20/2024,PEDS Asparaginase Erwinia (Rylaze),_1. First Line,9/20/2024,Active,,
NBI VALERIE FND HEMONC,26771,"de Benedictis, Marianna, MD",11/22/2024,"AALL1731 ALL SR-Avg B-ALL Arm B (including DS patients), SR-High B-ALL Arm D, DS-High B-ALL - Blinatumomab Block 1",_1. First Line,11/15/2024,Inactive,,
NBI VALERIE FND HEMONC,26771,"de Benedictis, Marianna, MD",11/26/2024,AALL1732 Interim Maintenance I (IM I) with HDMTX,_1. First Line,11/26/2024,Active,,
NBI VALERIE FND HEMONC,26771,"de Benedictis, Marianna, MD",2/6/2025,"AALL1732 HR Fav B-ALL, HR B-ALL Arm A, MPAL, B-LLy Delayed Intensification",_1. First Line,2/6/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),
NBI VALERIE FND HEMONC,26771,"de Benedictis, Marianna, MD",4/25/2025,AALL1732 Interim Maintenance II (IM II) with CMTX,_1. First Line,4/25/2025,Active,Pre B-cell acute lymphoblastic leukemia (ALL) in remission (CMS/HCC),"C91.01 - Acute lymphoblastic leukemia, in remission"
JCMC CP INFUSION,95257,"Sekhri, Arunabh, MD",1/15/2025,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,1/14/2025,Active,,
CINJ OP INFUSION,76768,"George, Mridula A, MD",1/10/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_3. Third Line,1/5/2025,Inactive,"Triple negative breast cancer (CMS/HCC)
Metastasis to lung (CMS/HCC)",
CINJ OP INFUSION,76768,"George, Mridula A, MD",2/24/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,2/16/2025,Active,"Triple negative breast cancer (CMS/HCC)
Metastasis to lung (CMS/HCC)",C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; Z17.421 - Hormone receptor negative with human epidermal growth factor receptor 2 negative status; C78.01 - Secondary malignant neoplasm of right lung; C78.02 - Secondary malignant neoplasm of left lung
NBR 4N BMTU/IMCU,59037,"Palmisiano, Neil David, MD",4/20/2024,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),Induction,4/19/2024,Inactive,,
NBR CINJ OP INFUSION,59037,"Palmisiano, Neil David, MD",6/17/2024,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,6/17/2024,Active,,
NBR CINJ OP INFUSION,59037,"Palmisiano, Neil David, MD",2/24/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_2. Second Line,2/24/2025,Active,Acute myeloid leukemia in remission (CMS/HCC),
CMC OP INFUSION,37692,"Pompa, Tiffany Ann, MD",12/24/2024,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,12/23/2024,Active,,
NBR 4N ONCOLOGY,12434,"Shah, Mansi R, MD",8/3/2024,CyBorD Twice Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,8/2/2024,Inactive,,
NBR CINJ OP INFUSION,12434,"Shah, Mansi R, MD",9/26/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/20/2024,Inactive,,
SOM OUTPT INFUSION,5680,"Toomey, Kathleen C, MD",6/28/2024,CARBOplatin AUC 1.5 weekly 21 Day Cycles - Endometrial Cancer,_1. First Line,6/27/2024,Inactive,,
SOM OUTPT INFUSION,5680,"Toomey, Kathleen C, MD",7/5/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,7/4/2024,Inactive,,
MMC OP VP INFUSION,19163,"Meghal, Trishala, MD",12/17/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,12/17/2024,Active,,
MSC OP INFUSION,15809,"Easaw, Sarah, MD",4/14/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,4/13/2023,Inactive,,
CMC OP INFUSION,15809,"Cohen, Seth D, MD",7/21/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,7/17/2023,Inactive,,
CMC OP INFUSION,50896,"Ferretti, Mark J, MD",11/13/2024,Gemcitabine Intravesical Single Dose - Bladder,_1. First Line,11/13/2024,Active,,
CMC OP INFUSION,50896,"Ferretti, Mark J, MD",12/3/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,_1. First Line,12/3/2024,Inactive,,
CMC OP INFUSION,50896,"Ferretti, Mark J, MD",12/5/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,_1. First Line,12/4/2024,Active,,
CMC OP INFUSION,50896,"Ferretti, Mark J, MD",2/17/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,_1. First Line,2/16/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
CMC OP INFUSION,50896,"Ferretti, Mark J, MD",4/15/2025,BCG (TICE) Intravesical Maintenance 3/6/12 Schedule - Bladder,_1. First Line,4/15/2025,Inactive,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
CMC OP INFUSION,50896,"Ferretti, Mark J, MD",4/15/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,_1. First Line,4/15/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
CMC OP INFUSION,53920,"Cohen, Seth D, MD",5/16/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,5/16/2025,Active,Malignant neoplasm of prostate (CMS/HCC),
CMC OP INFUSION,53920,"Cohen, Seth D, MD",4/30/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,4/29/2025,Inactive,Malignant neoplasm of prostate (CMS/HCC),
NBR CINJ OP INFUSION,89746,"Chowaniec, Wayne B, NP",11/11/2024,"ROPEGINTERFERON, MPN (not on hydrea)",_1. First Line,11/10/2024,Active,Urothelial cancer (CMS/HCC),
CMC OP INFUSION,25907,"Tang, Horace, MD",6/6/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Second Line,5/30/2023,Inactive,,
CMC OP INFUSION,25907,"Tang, Horace, MD",8/29/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,,8/29/2023,Inactive,,
JCMC CP INFUSION,89450,"Sekhri, Arunabh, MD",8/15/2024,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,8/14/2024,Active,,
CINJ OP INFUSION,85590,"Hochster, Howard S, MD",3/1/2023,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,First Line,2/28/2023,Inactive,,
CINJ OP INFUSION,85590,"Hochster, Howard S, MD",9/28/2023,CINJ 072214 CTX-009 / PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,_3. Third Line,9/28/2023,Inactive,,
CINJ OP INFUSION,85590,"Hochster, Howard S, MD",9/28/2023,CINJ 072214 PACLitaxel 28 Day Cycles Research- Biliary Tract Cancers,Second Line,9/28/2023,Inactive,,
CINJ OP INFUSION,85590,"Hochster, Howard S, MD",5/30/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,5/30/2024,Active,,
CBMC OP INFUSION 2FL,6528,"Leitner, Stuart P, MD",11/1/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_2. Second Line,11/1/2023,Active,,
CBMC OP INFUSION 2FL,87824,"Leitner, Stuart P, MD",4/21/2025,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,_3. Third Line,4/21/2025,Active,"Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes (CMS/HCC)
Secondary malignant neoplasm of left lung (CMS/HCC)
Renal cell cancer (CMS/HCC)
Metastatic renal cell carcinoma to lung, right (CMS/HCC)
Thyroiditis",
CINJ OP INFUSION,54480,"Jang, Thomas L, MD",9/18/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,9/17/2023,Inactive,,
CINJ OP INFUSION,54480,"Jang, Thomas L, MD",1/29/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,1/28/2024,Active,,
CINJ OP INFUSION,8193,"Boland, Patrick M, MD",10/31/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,10/30/2023,Inactive,,
CINJ OP INFUSION,80334,"Stephenson, Ruth D, DO",7/24/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/20/2023,Inactive,,
MMC OP VP INFUSION,29955,"Lee, Patrick C, MD",12/11/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/4/2023,Inactive,,
CBMC OP INFUSION 2FL,77295,"Brown, Andrew Bennett, MD",4/2/2025,Cetuximab Weekly 28 Day Cycles- Colon Cancer,Induction,4/2/2025,Active,"Head and neck cancer (CMS/HCC)
Other abnormal tumor markers",
CINJ OP INFUSION,76843,"Goel, Sanjay, MD",5/22/2024,"CINJ 052208 Part 1c,e,f,g,h AMG-193 28 Day Cycles Research- Solid Tumors",_3. Third Line,5/21/2024,Active,,
CINJ OP INFUSION,96496,"Boland, Patrick M, MD",4/11/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,4/10/2023,Inactive,,
CINJ OP INFUSION,28479,"Dasgeb, Bahar, MD",7/25/2023,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,Second Line,7/24/2023,Inactive,,
MMC OP VP INFUSION,24931,"Cohen, Seth D, MD",6/5/2024,Capecitabine 21 Day Cycles - Breast,_2. Second Line,6/5/2024,Inactive,,
MMC OP VP INFUSION,24931,"Cohen, Seth D, MD",7/18/2024,"PACLitaxel D1, D8 21 Day Cycles - Breast",_2. Second Line,7/16/2024,Inactive,,
MMC OP VP INFUSION,91740,"Cohen, Seth D, MD",1/6/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/5/2025,Inactive,"Malignant neoplasm of left breast in female, estrogen receptor positive (CMS/HCC)",
HAM OP INFUSION,27351,"Yogarajah, Meera, MD",7/29/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,_1. First Line,7/21/2024,Active,Malignant neoplasm of middle third of esophagus (CMS/HCC),
CINJ OP INFUSION,10134,"Girda, Eugenia, MD",1/9/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,1/7/2024,Inactive,,
CINJ OP INFUSION,10134,"Girda, Eugenia, MD",1/11/2024,Bevacizumab Q 2 weeks Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,1/11/2024,Inactive,,
CINJ OP INFUSION,10134,"Girda, Eugenia, MD",4/9/2024,CINJ 052102 (AN2025S0101) Observation III AN2025 50 mg / AN0025 125 mg / Atezolizumab 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,3/4/2024,Inactive,,
CINJ OP INFUSION,10134,"Girda, Eugenia, MD",4/23/2024,CINJ 102203 Pre-Treatment Assessments Research- Ovarian Cancer / Fallopian Tube Cancer / Primary Peritoneal Cancer,_4. Fourth Line,4/23/2024,Inactive,,
CINJ OP INFUSION,82026,"Haigentz, Missak, MD",1/9/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,1/9/2023,Inactive,,
MMC OP VP INFUSION,34829,"Cohen, Seth D, MD",5/8/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,5/7/2025,Active,"Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,22017,"Brown, Andrew Bennett, MD",8/1/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/1/2024,Active,,
CMC OP INFUSION,2735,"Talwar, Sumit, MD",11/8/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/31/2023,Inactive,,
CMC OP INFUSION,2735,"Tang, Horace, MD",1/31/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/23/2024,Inactive,,
CMC OP INFUSION,2735,"Cohen, Seth D, MD",3/5/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/4/2024,Inactive,,
CINJ OP INFUSION,66814,"Omene, Coral Oghenerukevwe, MD",1/13/2023,NeoAdjuvant TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,1/12/2023,Inactive,,
CINJ OP INFUSION,97783,"Tiger, Yun Kyoung, MD",5/28/2025,Methotrexate Intrathecal - Hematological Malignancies,Adjuvant,5/28/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
NBR 4N ONCOLOGY,97783,"Tiger, Yun Kyoung, MD",4/28/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,4/28/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; E88.3 - Tumor lysis syndrome; J96.01 - Acute respiratory failure with hypoxia; C79.51 - Secondary malignant neoplasm of bone; E44.0 - Moderate protein-calorie malnutrition; E87.4 - Mixed disorder of acid-base balance; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K80.21 - Calculus of gallbladder without cholecystitis with obstruction; C83.70 - Burkitt lymphoma, unspecified site; J90 - Pleural effusion, not elsewhere classified; F11.10 - Opioid abuse, uncomplicated; B18.2 - Chronic viral hepatitis C; J45.909 - Unspecified asthma, uncomplicated; N17.9 - Acute kidney failure, unspecified; R18.8 - Other ascites; E87.1 - Hypo-osmolality and hyponatremia; E87.3 - Alkalosis; I87.1 - Compression of vein; K74.60 - Unspecified cirrhosis of liver; E83.39 - Other disorders of phosphorus metabolism; R79.89 - Other specified abnormal findings of blood chemistry; E87.70 - Fluid overload, unspecified; T50.2X5A - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter; N50.89 - Other specified disorders of the male genital organs; E86.1 - Hypovolemia; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; E87.5 - Hyperkalemia; E86.9 - Volume depletion, unspecified; F41.9 - Anxiety disorder, unspecified; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z68..."
NBR 4N ONCOLOGY,97783,"Chen, Xiaoyi",4/26/2025,Cyclophosphamide -cytoreduction - Diffuse Large B-Cell Lymphoma,Lymphodepletion,4/26/2025,Inactive,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),"C83.398 - Diffuse large b-cell lymphoma of other extranodal and solid organ sites; E88.3 - Tumor lysis syndrome; J96.01 - Acute respiratory failure with hypoxia; C79.51 - Secondary malignant neoplasm of bone; E44.0 - Moderate protein-calorie malnutrition; E87.4 - Mixed disorder of acid-base balance; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; K80.21 - Calculus of gallbladder without cholecystitis with obstruction; C83.70 - Burkitt lymphoma, unspecified site; J90 - Pleural effusion, not elsewhere classified; F11.10 - Opioid abuse, uncomplicated; B18.2 - Chronic viral hepatitis C; J45.909 - Unspecified asthma, uncomplicated; N17.9 - Acute kidney failure, unspecified; R18.8 - Other ascites; E87.1 - Hypo-osmolality and hyponatremia; E87.3 - Alkalosis; I87.1 - Compression of vein; K74.60 - Unspecified cirrhosis of liver; E83.39 - Other disorders of phosphorus metabolism; R79.89 - Other specified abnormal findings of blood chemistry; E87.70 - Fluid overload, unspecified; T50.2X5A - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter; N50.89 - Other specified disorders of the male genital organs; E86.1 - Hypovolemia; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; E87.5 - Hyperkalemia; E86.9 - Volume depletion, unspecified; F41.9 - Anxiety disorder, unspecified; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z68..."
NBR 5N ONCOLOGY,3516,"George, Mridula A, MD",7/7/2023, PACLitaxel 160 mg/m2 / CARBOplatin AUC 4 - 21 Day Cycles- Head and Neck Cancers,,7/6/2023,Inactive,,
CINJ OP INFUSION,3516,"Haigentz, Missak, MD",8/1/2023,PACLitaxel 160 mg/m2 /CARBOplatin (AUC 4) 21 Day Cycles Neoadjuvant - Head and neck cancer,Neoadjuvant,8/1/2023,Inactive,,
CINJ OP INFUSION,3516,"Haigentz, Missak, MD",9/11/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,,9/11/2023,Inactive,,
JCMC CP INFUSION,77522,"Cruz, Allan Louie E, MD",4/29/2025,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,4/29/2025,Active,Cancer of temporal lobe (CMS/HCC),
CBMC OP INFUSION 2FL,84694,"Dharmapuri, Sirish, MD",1/14/2025,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,1/13/2025,Active,,
NBR CINJ OP INFUSION,38679,"Chen, Xiaoyi",1/21/2025,Cytarabine (200 mg/m2) / DAUNOrubicin (60 mg/m2) (7 + 3) - Acute Myeloid Leukemia (Induction),_2. Second Line,1/21/2025,Active,,
CINJ OP INFUSION,45717,"Groisberg, Roman, MD",2/10/2023,DOXOrubicin Liposomal 21 Day Cycles - Sarcoma,,2/9/2023,Inactive,,
NBI OP INFUSION,57767,"Snyder, Rose, MD",5/27/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/27/2025,Active,Adenocarcinoma of sigmoid colon (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified part of colon (CMS/HCC)"
CINJ OP INFUSION,20187,"Saraiya, Biren P, MD",11/19/2024,DOCEtaxel 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/18/2024,Active,,
CMC OP INFUSION,9922,"Tang, Horace, MD",3/23/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,3/22/2023,Inactive,,
CMC OP INFUSION,9922,"Tang, Horace, MD",8/1/2023,Avelumab 14 Day Cycles,Maintenance,8/1/2023,Inactive,,
MSC OP INFUSION,69123,"Talwar, Sumit, MD",5/10/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,5/9/2023,Inactive,,
HAM OP INFUSION,46136,"Gendy, Mina, DO",3/14/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/7/2025,Active,"Diffuse large B-cell lymphoma (CMS/HCC)
Diffuse follicle center lymphoma, intrathoracic lymph nodes (CMS/HCC)","C83.30 - Diffuse large B-cell lymphoma, unspecified site; C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; Z87.891 - Personal history of nicotine dependence; Z86.718 - Personal history of other venous thrombosis and embolism; Z91.041 - Radiographic dye allergy status; Z88.2 - Allergy status to sulfonamides; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,52880,"Girda, Eugenia, MD",9/10/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,9/10/2024,Active,,
CINJ OP INFUSION,20308,"Haigentz, Missak, MD",7/1/2023,Alectinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/1/2023,Active,,
CINJ OP INFUSION,99192,"Boland, Patrick M, MD",2/28/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,2/27/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),C25.0 - Malignant neoplasm of head of pancreas
CINJ OP INFUSION,87195,"Saraiya, Biren P, MD",5/29/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,5/29/2025,Active,Prostate cancer (CMS/HCC),C61 - Malignant neoplasm of prostate
CINJ OP INFUSION,56380,"Patel, Eshan, MD",12/8/2023,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) - lung ,_1. First Line,12/7/2023,Inactive,,
CINJ OP INFUSION,56380,"Patel, Eshan, MD",12/15/2023,PACLitaxel Weekly / CARBOplatin Weekly 21 Day Cycles - lung cancer ,_1. First Line,12/14/2023,Inactive,,
CBMC OP INFUSION 2FL,10187,"Wagmiller, Jennifer Ann, MD",9/19/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,8/11/2024,Active,,
CINJ OP INFUSION,23276,"George, Mridula A, MD",5/19/2025,Capecitabine 21 Day Cycles - Breast,Adjuvant,5/19/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,41509,"Girda, Eugenia, MD",9/12/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - CERVIX,_5. Fifth Line,9/11/2023,Inactive,,
CINJ OP INFUSION,41509,"Girda, Eugenia, MD",5/7/2024,CINJ 052310 Dose Escalation AB598 Monotherapy 21 Day Cycles Research- Advanced Solid Tumors,_4. Fourth Line,5/7/2024,Inactive,,
CINJ OP INFUSION,41509,"Girda, Eugenia, MD",6/18/2024,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_6. Sixth Line,6/17/2024,Inactive,,
CINJ OP INFUSION,82770,"George, Mridula A, MD",9/20/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,9/19/2024,Active,,
CBMC OP INFUSION 2FL,94807,"Litvak, Anna M, MD",9/21/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,9/20/2023,Inactive,,
CINJ OP INFUSION,67222,"Saraiya, Biren P, MD",9/5/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_2. Second Line,9/2/2024,Active,,
CINJ OP INFUSION,71222,"Groisberg, Roman, MD",1/13/2023,"DOCEtaxel D1, D8 / Gemcitabine D1, D8 21 Day Cycles - Sarcoma",,1/12/2023,Inactive,,
CINJ OP INFUSION,71222,"Groisberg, Roman, MD",6/8/2023,Ifosfamide / Mesna 21 Day Cycles - Sarcoma,Third Line,6/2/2023,Inactive,,
CINJ OP INFUSION,71222,"Groisberg, Roman, MD",10/6/2023,Trabectedin 21 Day Cycles - Soft Tissue Sarcoma,,10/5/2023,Inactive,,
CINJ OP INFUSION,71222,"Groisberg, Roman, MD",12/1/2023,Pembrolizumab 42 Day Cycles - Uterine,_5. Fifth Line,11/30/2023,Inactive,,
NBR 4N BMTU/IMCU,55266,"Patel, Vimal D, MD",2/22/2023,BMT Allogeneic TBF + Post Cy ,,2/21/2023,Inactive,,
NBR CINJ OP INFUSION,37202,"Evens, Andrew M, DO",1/10/2025,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,1/9/2025,Active,,
NBR 5N ONCOLOGY,37202,"Evens, Andrew M, DO",3/19/2025,Glofitamab-GemOx (Glofitamab / Oxaliplatin / Gemctiabine / Obinutuzumab) - Diffuse Large B-Cell Lymphoma,_2. Second Line,3/19/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site; C90.00 - Multiple myeloma not having achieved remission; E88.819 - Insulin resistance, unspecified; J96.11 - Chronic respiratory failure with hypoxia; I27.21 - Secondary pulmonary arterial hypertension; E11.65 - Type 2 diabetes mellitus with hyperglycemia; M34.9 - Systemic sclerosis, unspecified; D64.9 - Anemia, unspecified; I10 - Essential (primary) hypertension; I35.0 - Nonrheumatic aortic (valve) stenosis; J84.9 - Interstitial pulmonary disease, unspecified; E86.0 - Dehydration; Z11.52 - Encounter for screening for COVID-19; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z79.52 - Long term (current) use of systemic steroids; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z82.3 - Family history of stroke; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z82.5 - Family history of asthma and other chronic lower respiratory diseases; Z83.3 - Family history of diabetes mellitus; Z83.438 - Family history of other disorder of lipoprotein metabolism and other lipidemia; Z86.16 - Personal history of COVID-19; Z99.81 - Dependence on supplemental oxygen; Z87.01 - Personal history of pneumonia (recurrent); Z87.442 - Personal history of urinary calculi; M10.9 - Gout, unspecified; Z79.899 - Other long term (current) drug therapy; Z98.890 - Other specified postprocedural states"
CINJ OP INFUSION,43315,"Haigentz, Missak, MD",4/3/2023,PEMEtrexed/CARBOplatin (AUC 5) PLUS Osimertinib 21 Day Cycles- Non-Small Cell Lung Cancer ,Second Line,3/26/2023,Inactive,,
CINJ OP INFUSION,43315,"Haigentz, Missak, MD",6/26/2023,PEMEtrexed PLUS Osimertinib 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,6/18/2023,Inactive,,
CINJ OP INFUSION,43315,"Haigentz, Missak, MD",8/15/2023,Crizotinib 28 Day Cycles- Non-Small Cell Lung Cancer,Third Line,8/15/2023,Inactive,,
CINJ OP INFUSION,43315,"Haigentz, Missak, MD",2/19/2024,"DOCEtaxel D1, D8, D15 /Ramucirumab 28 Day Cycles- Non-Small Cell Lung Cancer",_5. Fifth Line,2/19/2024,Inactive,,
TRMC TCCC OP INFUSION,24545,"Capo, Gerardo, MD",3/19/2025,"Nivolumab D1,15,29 q 42 Day Cycles - Malignant Pleural Mesothelioma",_2. Second Line,3/5/2025,Active,Malignant neoplasm metastatic to genital organ (CMS/HCC),C79.82 - Secondary malignant neoplasm of genital organs
TRMC TCCC OP INFUSION,48878,"Salerno, Vincent E, MD",3/27/2025,Albumin-Bound PACLitaxel weekly 28 Day Cycles - Breast,_3. Third Line,3/27/2025,Active,"Adenocarcinoma of left breast (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C79.51 - Secondary malignant neoplasm of bone
CINJ OP INFUSION,36160,"Girda, Eugenia, MD",8/5/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,7/14/2024,Inactive,,
CINJ OP INFUSION,36160,"Girda, Eugenia, MD",12/5/2024,Pembrolizumab 42 Day Cycles - Cervical,_1. First Line,12/4/2024,Active,,
CBMC OP INFUSION 2FL,21657,"Dharmapuri, Sirish, MD",3/7/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,3/7/2025,Active,Biliary tract cancer (CMS/HCC),"C24.9 - Malignant neoplasm of biliary tract, unspecified"
CINJ OP INFUSION,69959,"Haigentz, Missak, MD",11/3/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/3/2023,Inactive,,
CINJ OP INFUSION,94399,"Toppmeyer, Deborah L, MD",8/16/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,8/14/2024,Inactive,,
CINJ OP INFUSION,94399,"Toppmeyer, Deborah L, MD",12/19/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Neoadjuvant,12/18/2024,Active,,
CINJ OP INFUSION,22766,"Stephenson, Ryan D, DO",2/5/2025,Pembrolizumab 42 Day Cycles - Kidney Cancer,Adjuvant,2/5/2025,Active,"Malignant neoplasm of right kidney (CMS/HCC)
Disorder of thyroid","C64.1 - Malignant neoplasm of right kidney, except renal pelvis; E07.9 - Disorder of thyroid, unspecified"
CMC OP INFUSION,66580,"Talwar, Sumit, MD",12/6/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,11/26/2024,Active,,
NBR CINJ OP INFUSION,794,"Shah, Mansi R, MD",7/18/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,7/17/2024,Inactive,,
NBI OP INFUSION,59459,"Anderson, Patrick S, MD",10/11/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,9/29/2024,Active,,
JCMC CP INFUSION,70620,"Cruz, Allan Louie E, MD",1/5/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,1/4/2023,Inactive,,
JCMC CP INFUSION,70620,"Cruz, Allan Louie E, MD",9/6/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,9/6/2023,Inactive,,
JCMC CP INFUSION,70620,"Cruz, Allan Louie E, MD",10/25/2023,Gemcitabine 21 Day Cycles - Uterine cancer,_3. Third Line,10/25/2023,Inactive,,
JCMC CP INFUSION,70620,"Cruz, Allan Louie E, MD",1/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Endometrial,_4. Fourth Line,1/25/2024,Active,,
JCMC CP INFUSION,21727,"Cruz, Allan Louie E, MD",5/21/2025,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,_5. Fifth Line,5/21/2025,Active,Malignant neoplasm of endometrium (CMS/HCC),C54.1 - Malignant neoplasm of endometrium
NBR 4N ONCOLOGY,93580,"Zayac, Adam, MD",8/3/2024,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,8/1/2024,Active,,
CINJ OP INFUSION,1403,"Aikins, James K, MD",3/1/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,2/29/2024,Inactive,,
CINJ OP INFUSION,2033,"Saraiya, Biren P, MD",4/20/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,4/20/2023,Inactive,,
CINJ OP INFUSION,2033,"Saraiya, Biren P, MD",12/5/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_2. Second Line,11/5/2024,Active,,
CINJ OP INFUSION,28200,"Saraiya, Biren P, MD",2/20/2025,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_4. Fourth Line,2/18/2025,Active,Malignant neoplasm of prostate (CMS/HCC),
HAM OP INFUSION,56875,"Patel, Malini M, MD",1/9/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,First Line,1/8/2023,Inactive,,
TRMC TCCC OP INFUSION,69826,"Meghal, Trishala, MD",3/31/2025,Palbociclib 28 Day Cycles - Breast,_2. Second Line,3/31/2025,Active,Malignant neoplasm of overlapping sites of right female breast (CMS/HCC),C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; C50.811 - Malignant neoplasm of overlapping sites of right female breast
CINJ OP INFUSION,73314,"Leiser, Aliza, MD",10/30/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Endometrial,Neoadjuvant,10/24/2023,Inactive,,
CINJ OP INFUSION,73314,"Leiser, Aliza, MD",10/30/2023,CARBOplatin Weekly ,_1. First Line,10/24/2023,Inactive,,
CINJ OP INFUSION,73314,"Leiser, Aliza, MD",3/22/2024,Albumin-Bound PACLitaxel / CARBOplatin/pembrolizumab 21 Day Cycles- Uterine,Adjuvant,3/21/2024,Inactive,,
CINJ OP INFUSION,73314,"Leiser, Aliza, MD",4/12/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,4/11/2024,Inactive,,
HAM OP INFUSION,81501,"Patel, Malini M, MD",11/30/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,11/27/2023,Inactive,,
CMC OP INFUSION,47436,"Pompa, Tiffany Ann, MD",10/29/2024,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",Adjuvant,10/24/2024,Active,,
CMC OP INFUSION,90695,"Pompa, Tiffany Ann, MD",5/13/2025,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,5/13/2025,Active,"Malignant melanoma of left lateral thigh (CMS/HCC)
Malignant melanoma of other part of trunk (CMS/HCC)",
NBI OP INFUSION,98757,"Jacoby, Sari H, MD",12/5/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_2. Second Line,12/4/2023,Inactive,,
NBI OP INFUSION,98757,"Jacoby, Sari H, MD",7/22/2024,Cetuximab / PACLitaxel 80 mg/m2 / CARBOplatin AUC 2 28 Day Cycles- Head and Neck Cancers,_2. Second Line,6/3/2024,Active,,
NBR CINJ OP INFUSION,54243,"Palmisiano, Neil David, MD",2/14/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),,2/10/2023,Inactive,,
NBR CINJ OP INFUSION,54243,"Palmisiano, Neil David, MD",8/15/2024,CINJ 022301 Iadademstat / Gilteritinib 28 Day Cycles Research- Acute Myeloid Leukemia,_2. Second Line,8/15/2024,Inactive,,
NBR CINJ OP INFUSION,13618,"Palmisiano, Neil David, MD",1/7/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,1/3/2025,Inactive,AML (acute myeloid leukemia) in relapse (CMS/HCC),
CINJ OP INFUSION,99467,"Ghodoussipour, Saum Bobak, MD",6/5/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,6/5/2023,Inactive,,
CINJ OP INFUSION,99467,"Ghodoussipour, Saum Bobak, MD",10/13/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 42 Day Cycle - Bladder,Induction,10/5/2023,Inactive,,
CINJ OP INFUSION,99467,"Ghodoussipour, Saum Bobak, MD",1/26/2024,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,1/18/2024,Active,,
NBI OP INFUSION,74803,"Schleicher, Lori, MD",12/20/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/5/2024,Active,,
HAM OP INFUSION,57672,"Yogarajah, Meera, MD",5/27/2024,Trametinib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,5/27/2024,Active,Malignant neoplasm of ovary (CMS/HCC),
CINJ OP INFUSION,96092,"Dasgeb, Bahar, MD",1/3/2023,Nivolumab 28 Day Cycles - Melanoma,Second Line,1/2/2023,Inactive,,
CINJ OP INFUSION,96092,"Dasgeb, Bahar, MD",10/31/2023,Dostarlimab-gxly  42 Day Cycles- Colon Cancer,_4. Fourth Line,10/30/2023,Inactive,,
CINJ OP INFUSION,76783,"Weiss, Sarah, MD",10/7/2024,"CINJ 092303 Arms A, B, C, or D Pembrolizumab / Fianlimab / Cemiplimab 21 Day Cycles Research- Melanoma",Neoadjuvant,10/7/2024,Active,,
CINJ OP INFUSION,18452,"Golombos, David, MD",11/1/2024,BCG Induction (TICE) 42 Day Cycle,Induction,10/31/2024,Inactive,,
CINJ OP INFUSION,70799,"Gulhati, Prateek, MD PhD",3/29/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/27/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified"
NBR 5N ONCOLOGY,70799,"Mayer, Tina M, MD",3/5/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,3/5/2025,Inactive,Gastric adenocarcinoma (CMS/HCC),"C16.2 - Malignant neoplasm of body of stomach; E43 - Unspecified severe protein-calorie malnutrition; C16.1 - Malignant neoplasm of fundus of stomach; R18.0 - Malignant ascites; C78.6 - Secondary malignant neoplasm of retroperitoneum and peritoneum; E87.1 - Hypo-osmolality and hyponatremia; E86.1 - Hypovolemia; E86.0 - Dehydration; D72.829 - Elevated white blood cell count, unspecified; Z68.1 - Body mass index (BMI) 19.9 or less, adult; K59.00 - Constipation, unspecified; D75.839 - Thrombocytosis, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; Z79.899 - Other long term (current) drug therapy; Z59.71 - Insufficient health insurance coverage; Z80.8 - Family history of malignant neoplasm of other organs or systems"
NBR BMSCH 2 PED HEMONC,79762,"Drachtman, Richard, MD",12/24/2024,AALL1732 Induction,_1. First Line,12/24/2024,Active,,
NBR BMSCH 2 PED HEMONC,79762,"Drachtman, Richard, MD",12/24/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,12/24/2024,Inactive,,
CINJ PEDS HEMONC ,79762,"Drachtman, Richard, MD",2/3/2025,AALL1732 Consolidation,Consolidation,1/29/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),"C91.00 - Acute lymphoblastic leukemia not having achieved remission; E88.3 - Tumor lysis syndrome; D61.818 - Other pancytopenia; E27.3 - Drug-induced adrenocortical insufficiency; D84.821 - Immunodeficiency due to drugs; E27.40 - Unspecified adrenocortical insufficiency; I47.20 - Ventricular tachycardia, unspecified; N17.9 - Acute kidney failure, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; I15.8 - Other secondary hypertension; I49.1 - Atrial premature depolarization; I49.3 - Ventricular premature depolarization; J45.909 - Unspecified asthma, uncomplicated; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; T80.89XA - Other complications following infusion, transfusion and therapeutic injection, initial encounter; Z60.3 - Acculturation difficulty; R74.01 - Elevation of levels of liver transaminase levels; Z83.3 - Family history of diabetes mellitus; Z82.5 - Family history of asthma and other chronic lower respiratory diseases"
CINJ PEDS HEMONC ,79762,"Drachtman, Richard, MD",4/8/2025,PEDS Blinatumomab,_1. First Line,4/7/2025,Inactive,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C91.02 - Acute lymphoblastic leukemia, in relapse; I15.8 - Other secondary hypertension; E11.65 - Type 2 diabetes mellitus with hyperglycemia; Z79.4 - Long term (current) use of insulin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z82.5 - Family history of asthma and other chronic lower respiratory diseases; Z83.3 - Family history of diabetes mellitus; Z98.890 - Other specified postprocedural states"
CINJ PEDS HEMONC ,79762,"Botwinick, Marissa, DO",4/8/2025,AALL1732 Interim Maintenance I (IM I) with HDMTX,_2. Second Line,4/7/2025,Active,Pre B-cell acute lymphoblastic leukemia (CMS/HCC),
MSC OP INFUSION,83992,"Cohen, Seth D, MD",1/20/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/14/2025,Active,,
CINJ OP INFUSION,32479,"In, Haejin, MD",9/21/2023,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,,9/21/2023,Inactive,,
CINJ OP INFUSION,32479,"Boland, Patrick M, MD",11/12/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_4. Fourth Line,11/11/2024,Active,,
CINJ OP INFUSION,64867,"Toppmeyer, Deborah L, MD",5/29/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Third Line,5/29/2023,Inactive,,
CINJ OP INFUSION,64867,"Toppmeyer, Deborah L, MD",5/29/2023,Alpelisib 28 Day Cycles - Breast,Third Line,5/26/2023,Inactive,,
CINJ OP INFUSION,64867,"Toppmeyer, Deborah L, MD",3/14/2024,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",_3. Third Line,3/14/2024,Inactive,,
CINJ OP INFUSION,64867,"Toppmeyer, Deborah L, MD",10/21/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,10/16/2024,Inactive,,
NBR 5N ONCOLOGY,64867,"Toppmeyer, Deborah L, MD",10/23/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_5. Fifth Line,10/22/2024,Active,,
CINJ OP INFUSION,64867,"Toppmeyer, Deborah L, MD",12/3/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_3. Third Line,12/2/2024,Active,,
CINJ OP INFUSION,37397,"Omene, Coral Oghenerukevwe, MD",10/28/2024,Abemaciclib 28 Day Cycles - Breast,_4. Fourth Line,10/28/2024,Active,,
HAM OP INFUSION,59939,"Yogarajah, Meera, MD",5/22/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/21/2023,Active,,
NBR 4N BMTU/IMCU,59981,"Palmisiano, Neil David, MD",10/23/2023,FLAG-IDA + Ven (Fludarabine / Cytarabine / IDArubicin / Filgrastim / Venetoclax) - Acute Myeloid Leukemia (Relapsed / Refractory),_3. Third Line,10/23/2023,Inactive,,
CINJ OP INFUSION,13484,"Stephenson, Ruth D, DO",4/28/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,4/25/2023,Active,,
CINJ OP INFUSION,13484,"Stephenson, Ruth D, DO",2/19/2025,CINJ 102405 Dose Escalation APG-1252 (Pelcitoclax) / Cobimetinib 28 Day Cycles Research- Ovarian / Endometrial Cancers,_4. Fourth Line,2/18/2025,Active,"Malignant neoplasm of left ovary (CMS/HCC)
Essential hypertension, benign
Bloating",C56.3 - Malignant neoplasm of bilateral ovaries; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; C56.9 - Malignant neoplasm of unspecified ovary
CBMC OP INFUSION 2FL,14288,"Raptis, George, MD",8/29/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,8/27/2024,Inactive,,
CBMC OP INFUSION 2FL,14288,"Raptis, George, MD",10/25/2024,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,10/25/2024,Active,,
CMC OP INFUSION,89724,"Talwar, Sumit, MD",5/12/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,5/12/2025,Active,Rectal cancer (CMS/HCC),
MSC OP INFUSION,89724,"Talwar, Sumit, MD",5/7/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,5/7/2025,Active,Rectal cancer (CMS/HCC),
JCMC CP INFUSION,50451,"Cruz, Allan Louie E, MD",10/7/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,Induction,10/6/2024,Inactive,,
NBR CINJ OP INFUSION,50451,"Rhodes, Joanna Meehan, MD",10/16/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_2. Second Line,10/16/2024,Inactive,,
NBR CINJ OP INFUSION,50451,"Rhodes, Joanna Meehan, MD",10/28/2024,DHAX (Dexamethasone / Cytarabine / OXALIplatin) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,10/28/2024,Active,,
JCMC CP INFUSION,50451,"Cruz, Allan Louie E, MD",3/24/2025,RiTUXimab  56 Day Cycles - Mantle Cell Lymphoma (Maintenance),Maintenance,3/24/2025,Active,Mantle cell lymphoma (CMS/HCC),"C83.18 - Mantle cell lymphoma, lymph nodes of multiple sites"
CBMC OP INFUSION 2FL,93252,"Wagmiller, Jennifer Ann, MD",12/5/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,11/26/2023,Inactive,,
CBMC OP INFUSION 2FL,93252,"Wagmiller, Jennifer Ann, MD",1/11/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,12/4/2023,Inactive,,
MSC OP INFUSION,2622,"Tang, Horace, MD",5/22/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,,5/21/2023,Inactive,,
JCMC CP INFUSION,39224,"Sekhri, Arunabh, MD",1/26/2023,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,First Line,1/25/2023,Inactive,,
JCMC CP INFUSION,39224,"Sekhri, Arunabh, MD",5/16/2024,Pembrolizumab 21 Day Cycles- History of Head and neck carcinoma,_2. Second Line,5/15/2024,Inactive,,
JCMC CP INFUSION,39224,"Sekhri, Arunabh, MD",10/28/2024,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_2. Second Line,10/27/2024,Active,,
CINJ OP INFUSION,69620,"Mayer, Tina M, MD",9/10/2024,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,_1. First Line,9/8/2024,Active,,
HAM OP INFUSION,75960,"Yogarajah, Meera, MD",1/9/2023,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,First Line,1/8/2023,Inactive,,
CBMC 2W ONCOLOGY,20768,"Grossman, I Robert, MD",4/28/2025,RiTUXimab Initial Infusion Single Day (Outpatient),_1. First Line,4/25/2025,Active,Other acquired hemolytic anemias (CMS/HCC),"D59.8 - Other acquired hemolytic anemias; K51.90 - Ulcerative colitis, unspecified, without complications; K76.89 - Other specified diseases of liver; I10 - Essential (primary) hypertension; Z86.16 - Personal history of COVID-19; Z83.3 - Family history of diabetes mellitus; Z63.4 - Disappearance and death of family member; Z83.0 - Family history of human immunodeficiency virus (hiv) disease; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system"
NBR CINJ OP INFUSION,83216,"Doraiswamy, Anupama, MD",3/20/2023,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,,3/19/2023,Inactive,,
CINJ OP INFUSION,70973,"Stephenson, Ruth D, DO",8/15/2024,Everolimus / Letrozole 28 Day Cycles - Uterine,_9. Ninth Line,8/15/2024,Active,,
JCMC CP INFUSION,40964,"Sekhri, Arunabh, MD",4/23/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days {{Tripe Negative Breast Cancer Stage 2b}},Neoadjuvant,4/23/2025,Active,"Malignant neoplasm of lower-outer quadrant of right breast of female, estrogen receptor negative (CMS/HCC)",C50.511 - Malignant neoplasm of lower-outer quadrant of right female breast; E11.9 - Type 2 diabetes mellitus without complications; R45.89 - Other symptoms and signs involving emotional state; Z92.21 - Personal history of antineoplastic chemotherapy; Z17.1 - Estrogen receptor negative status (ER-)
CBMC OP INFUSION 2FL,50341,"Raptis, George, MD",11/1/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 175 mg/m2 14 Day Cycles,Neoadjuvant,10/31/2024,Active,,
MMC OP INFUSION,91655,"Meghal, Trishala, MD",10/27/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,10/26/2023,Inactive,,
MMC OP INFUSION,91655,"Meghal, Trishala, MD",11/8/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,10/11/2023,Inactive,,
MMC OP VP INFUSION,91655,"Meghal, Trishala, MD",3/29/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,3/28/2024,Inactive,,
CBMC OP INFUSION 2FL,63818,"Leitner, Stuart P, MD",10/9/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,10/8/2023,Inactive,,
CBMC 2W ONCOLOGY,33299,"Siu, Karleung, MD",4/15/2025,Sacituzumab Govitecan 21 Day Cycles - Breast (+ trastuzumab),_5. Fifth Line,4/15/2025,Inactive,Malignant neoplasm of breast metastatic to brain (CMS/HCC),"C79.89 - Secondary malignant neoplasm of other specified sites; A41.9 - Sepsis, unspecified organism; Z51.5 - Encounter for palliative care; Z66 - Do not resuscitate; I60.9 - Nontraumatic subarachnoid hemorrhage, unspecified; J96.01 - Acute respiratory failure with hypoxia; J69.0 - Pneumonitis due to inhalation of food and vomit; I61.5 - Nontraumatic intracerebral hemorrhage, intraventricular; J18.9 - Pneumonia, unspecified organism; E44.0 - Moderate protein-calorie malnutrition; I31.4 - Cardiac tamponade; D84.81 - Immunodeficiency due to conditions classified elsewhere; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C50.912 - Malignant neoplasm of unspecified site of left female breast; C79.31 - Secondary malignant neoplasm of brain; C78.02 - Secondary malignant neoplasm of left lung; C79.51 - Secondary malignant neoplasm of bone; J91.0 - Malignant pleural effusion; E11.42 - Type 2 diabetes mellitus with diabetic polyneuropathy; G40.909 - Epilepsy, unspecified, not intractable, without status epilepticus; D63.0 - Anemia in neoplastic disease; I31.31 - Malignant pericardial effusion in diseases classified elsewhere; I47.10 - Supraventricular tachycardia, unspecified; D62 - Acute posthemorrhagic anemia; J93.82 - Other air leak; J93.9 - Pneumothorax, unspecified; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E87.6 - Hypokalemia; N95.1 - Menopausal and female climacteric states; I95.9 - Hypotension, unspecified; Z98.890 - Other specified pos..."
NBR CINJ OP INFUSION,20010,"Evens, Andrew M, DO",11/1/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,10/31/2023,Inactive,,
NBR CINJ OP INFUSION,20010,"Evens, Andrew M, DO",4/24/2024,RiTUXimab 56 Day Cycles - Follicular Lymphoma PRIMA Maintenance,_2. Second Line,4/23/2024,Active,Salivary gland malignant neoplasm (CMS/HCC),
CINJ OP INFUSION,96537,"Leiser, Aliza, MD",6/3/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar,_1. First Line,5/31/2024,Active,,
NBR CINJ OP INFUSION,37004,"Leiser, Aliza, MD",3/27/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,3/27/2025,Active,Malignant neoplasm of overlapping sites of vulva (CMS/HCC),
SOM OUTPT INFUSION,83734,"Patel, Eshan, MD",4/24/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,,4/9/2023,Inactive,,
SOM OUTPT INFUSION,83734,"Patel, Eshan, MD",7/17/2023,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,,7/16/2023,Inactive,,
CINJ OP INFUSION,47086,"Girda, Eugenia, MD",6/22/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,6/21/2023,Inactive,,
CINJ OP INFUSION,47086,"Girda, Eugenia, MD",8/28/2023,HIPEC CISplatin Intraperitoneal - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,,8/28/2023,Inactive,,
CINJ OP INFUSION,47086,"Girda, Eugenia, MD",10/2/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,10/2/2023,Inactive,,
CINJ OP INFUSION,47086,"Girda, Eugenia, MD",3/29/2024,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,3/28/2024,Inactive,,
CINJ OP INFUSION,47086,"Girda, Eugenia, MD",5/28/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles,_3. Third Line,5/27/2024,Inactive,,
CINJ OP INFUSION,47086,"Girda, Eugenia, MD",6/1/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,5/30/2024,Inactive,,
CINJ OP INFUSION,78157,"Boland, Patrick M, MD",6/6/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,5/21/2023,Inactive,,
CINJ OP INFUSION,78157,"Boland, Patrick M, MD",10/16/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles,_2. Second Line,10/16/2023,Inactive,,
CINJ OP INFUSION,78157,"Boland, Patrick M, MD",11/6/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,10/24/2023,Inactive,,
CINJ OP INFUSION,78157,"Boland, Patrick M, MD",4/12/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,3/28/2024,Inactive,,
CINJ OP INFUSION,78157,"Boland, Patrick M, MD",7/5/2024,"Gemcitabine 1000 mg/m2 D1, D8 21 Day Cycles- Pancreatic Adenocarcinoma",Maintenance,6/27/2024,Inactive,,
CMC OP INFUSION,70893,"Taff, Jessica, MD",5/5/2023,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",First Line,5/4/2023,Active,,
CINJ OP INFUSION,37333,"Mayer, Tina M, MD",9/24/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,9/23/2024,Inactive,,
NBR 4N ONCOLOGY,67250,"Schaar, Dale, MD PhD",9/8/2023,GAMMUNEX FOR HOME INFUSION,,8/24/2023,Inactive,,
SOM OUTPT INFUSION,60318,"Patel, Eshan, MD",1/4/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,12/15/2022,Inactive,,
SOM OUTPT INFUSION,60318,"Patel, Eshan, MD",5/2/2023,PACLitaxel / Topotecan / Bevacizumab 21 Day Cycles - Cervical,Second Line,5/1/2023,Inactive,,
SOM OUTPT INFUSION,60318,"Patel, Eshan, MD",1/2/2024,"Gemcitabine (D1, D8) 21 Day Cycles - neuroendocrine tumor",_3. Third Line,12/29/2023,Inactive,,
SOM OUTPT INFUSION,60318,"Patel, Eshan, MD",4/5/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_4. Fourth Line,4/1/2024,Inactive,,
CINJ OP INFUSION,49341,"Berim, Lyudmyla, MD",4/12/2023,CINJ 072108 (A021806) ARM 1 FOLFIRINOX (Fluorouracil / Leucovorin / Irinotecan / OXALiplatin) 14 Day Cycles Research- Pancreatic Adenocarcinoma,,3/28/2023,Inactive,,
CINJ OP INFUSION,49341,"Berim, Lyudmyla, MD",10/20/2023,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",_2. Second Line,10/19/2023,Inactive,,
JCMC CP INFUSION,35339,"Sekhri, Arunabh, MD",7/10/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/9/2023,Inactive,,
CINJ OP INFUSION,40487,"George, Mridula A, MD",8/16/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/7/2024,Active,,
CBMC OP INFUSION 2FL,44582,"Derosa, William T, DO",1/21/2025,DOXOrubicin Liposomal 21 Day Cycles - Sarcoma,_1. First Line,1/9/2025,Active,,
CINJ OP INFUSION,38649,"Groisberg, Roman, MD",4/1/2024,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,4/1/2024,Inactive,,
CINJ OP INFUSION,841,"Haigentz, Missak, MD",2/13/2025,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/13/2025,Active,"NSCLC with EGFR mutation (CMS/HCC)
Secondary malignant neoplasm of brain (CMS/HCC)
Secondary malignant neoplasm of mediastinal lymph nodes (CMS/HCC)",
CBMC OP INFUSION 2FL,50940,"Brown, Andrew Bennett, MD",2/14/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/13/2024,Inactive,,
CINJ OP INFUSION,74859,"Berim, Lyudmyla, MD",2/4/2023,Everolimus 28 Day Cycles - NET,,2/4/2023,Inactive,,
CINJ OP INFUSION,74859,"Berim, Lyudmyla, MD",8/14/2023,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",,8/14/2023,Inactive,,
MMC OP INFUSION,74859,"Eltoukhy, Hussam, MD",3/7/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,3/4/2024,Inactive,,
CBMC OP INFUSION 2FL,47995,"Brown, Andrew Bennett, MD",9/5/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,9/4/2023,Inactive,,
CBMC OP INFUSION 2FL,47995,"Brown, Andrew Bennett, MD",1/3/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,1/2/2024,Active,,
NBI OP INFUSION,9431,"Anderson, Patrick S, MD",3/8/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,3/8/2024,Active,,
CINJ OP INFUSION,28445,"Leiser, Aliza, MD",7/9/2024,Pembrolizumab 21 Day Cycles - Cervical,_2. Second Line,7/2/2024,Active,,
NBR 5N ONCOLOGY,24359,"Berim, Lyudmyla, MD",5/12/2024,DOCEtaxel/CARBOplatin 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/7/2024,Inactive,,
CINJ OP INFUSION,24359,"Haigentz, Missak, MD",7/1/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,6/30/2024,Active,,
CINJ OP INFUSION,88465,"Ghodoussipour, Saum Bobak, MD",3/15/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,3/14/2023,Active,,
CINJ OP INFUSION,88465,"Ghodoussipour, Saum Bobak, MD",2/18/2025,CINJ 082403 PHASE 2 (4 INSTILLATION REGIMEN) EG-70,Adjuvant,2/18/2025,Active,Urothelial carcinoma (CMS/HCC),C68.9 - Urothelial carcinoma (CMS/HCC)
NBR CINJ OP INFUSION,11867,"Shah, Mansi R, MD",10/19/2023,Daratumumab and Hyaluronidase-fihj - Multiple Myeloma,Reinduction,10/19/2023,Inactive,,
NBR CINJ OP INFUSION,11867,"Shah, Mansi R, MD",10/9/2024,Lymphodepletion Carvykti with Fludarabine / Cyclophosphamide - Multiple Myeloma,Lymphodepletion,9/25/2024,Inactive,,
CINJ OP INFUSION,77143,"Haigentz, Missak, MD",7/22/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,7/22/2024,Active,,
NBR BMSCH 2 PED HEMONC,1225,"Cole, Peter David, MD",4/26/2023,per AALL1731 Non-DS SR B-ALL Induction,Induction,4/25/2023,Inactive,,
CINJ PEDS HEMONC ,1225,"Masterson, Margaret, MD",6/1/2023,AALL1731 SR-High B-ALL and DS-High B-ALL Consolidation,First Line,6/1/2023,Inactive,,
CINJ PEDS HEMONC ,1225,"Masterson, Margaret, MD",7/13/2023,Asparaginase Erwinia (Rylaze) ,First Line,7/13/2023,Inactive,,
CINJ PEDS HEMONC ,1225,"Masterson, Margaret, MD",8/18/2023,AALL1731 SR-High B-ALL Interim Maintenance I (IM I) with HDMTX,First Line,8/1/2023,Inactive,,
CINJ PEDS HEMONC ,1225,"Masterson, Margaret, MD",11/15/2023,AALL1731 SR-High B-ALL Arms C & D Delayed Intensification,_1. First Line,11/15/2023,Inactive,,
CINJ PEDS HEMONC ,1225,"Masterson, Margaret, MD",1/24/2024,AALL1731 SR-High B-ALL Arms C & D - Interim Maintenance II CMTX,_1. First Line,1/24/2024,Inactive,,
CINJ PEDS HEMONC ,1225,"Masterson, Margaret, MD",4/3/2024,AALL1731 SR-High B-ALL Arm C - Maintenance,_1. First Line,4/3/2024,Active,,
CINJ PEDS HEMONC ,1225,"Botwinick, Marissa, DO",1/3/2025,PEDS Blinatumomab,_1. First Line,1/2/2025,Active,,
NBR CINJ OP INFUSION,98559,"Matasar, Matthew J, MD",3/4/2025,CINJ 012319 Mosunetuzumab 21 Day Cycles (Cycles 1 through 4) Research- Non-Hodgkin's Lymphoma,_1. First Line,3/4/2025,Inactive,Marginal zone lymphoma (CMS/HCC),
CINJ OP INFUSION,55089,"Omene, Coral Oghenerukevwe, MD",1/23/2024,Elacestrant 28 Day Cycles - Breast,_2. Second Line,1/23/2024,Inactive,,
CINJ OP INFUSION,55089,"Omene, Coral Oghenerukevwe, MD",10/25/2024,Capivasertib 28 Day Cycles - Breast,_4. Fourth Line,10/25/2024,Active,,
NBR CINJ OP INFUSION,97155,"Zayac, Adam, MD",1/8/2025,Cytarabine / DAUNOrubicin (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,1/8/2025,Active,,
NBR CINJ OP INFUSION,25234,"Zayac, Adam, MD",2/24/2025,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,2/24/2025,Inactive,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Pancytopenia (CMS/HCC)",
SOM OUTPT INFUSION,64086,"Patel, Eshan, MD",11/12/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/7/2024,Inactive,,
NBR CINJ OP INFUSION,81438,"Shah, Mansi R, MD",5/18/2023,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,,5/17/2023,Inactive,,
NBR CINJ OP INFUSION,81438,"Shah, Mansi R, MD",1/9/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,1/8/2024,Active,,
NBR CINJ OP INFUSION,81438,"Shah, Mansi R, MD",5/13/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,4/29/2024,Inactive,,
TRMC TCCC OP INFUSION,65270,"Salerno, Vincent E, MD",7/8/2024,PCbTP (Paclitaxel / Carboplatin / Trastuzumab / Pertuzumab) 21 Day Cycle - HER2 Breast Cancer,_1. First Line,7/8/2024,Inactive,,
TRMC TCCC OP INFUSION,65270,"Salerno, Vincent E, MD",12/2/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,12/1/2024,Inactive,,
TRMC TCCC OP INFUSION,65270,"Salerno, Vincent E, MD",1/8/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_1. First Line,1/1/2025,Active,,
JCMC CP INFUSION,25802,"Cruz, Allan Louie E, MD",5/3/2023,CINJ 042109 SGNTUC-028 Trastuzumab / Pertuzumab + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,,5/3/2023,Inactive,,
JCMC CP INFUSION,25802,"Cruz, Allan Louie E, MD",8/16/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,8/16/2023,Active,,
TRMC TCCC OP INFUSION,5502,"Capo, Gerardo, MD",3/6/2025,Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,3/6/2025,Active,"Malignant neoplasm of overlapping sites of unspecified bronchus and lung (CMS/HCC)
Drug-induced hypothyroidism",
MMC OP VP INFUSION,19434,"Lee, Patrick C, MD",7/13/2023,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,,7/12/2023,Inactive,,
CINJ OP INFUSION,87725,"Gulhati, Prateek, MD PhD",3/24/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,3/23/2023,Inactive,,
CINJ OP INFUSION,87725,"Gulhati, Prateek, MD PhD",6/15/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,6/14/2023,Inactive,,
CMC OP INFUSION,93180,"Talwar, Sumit, MD",1/25/2024,RiTUXimab -Hemolytic anemia,Non-Oncology Research,1/24/2024,Inactive,,
CMC OP INFUSION,57946,"Cohen, Seth D, MD",8/16/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,7/28/2023,Active,,
CMC OP INFUSION,52123,"Cohen, Seth D, MD",4/22/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,_1. First Line,4/22/2025,Active,Malignant neoplasm of colon (CMS/HCC),
CBMC OP INFUSION 2FL,30992,"Brown, Andrew Bennett, MD",12/7/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,12/6/2023,Active,,
MMC OP INFUSION,87962,"Eltoukhy, Hussam, MD",6/1/2023,Imatinib (Chronic Phase) 30 Day Cycles - Chronic Myeloid Leukemia,,6/1/2023,Active,,
CINJ OP INFUSION,58067,"Gulhati, Prateek, MD PhD",4/17/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,4/17/2025,Active,Malignant neoplasm of head of pancreas (CMS/HCC),
JCMC CP INFUSION,58067,"Cruz, Allan Louie E, MD",4/8/2025,"Gemcitabine D1, D8 /Albumin-Bound PACLitaxel D1, D8, 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/8/2025,Inactive,Malignant neoplasm of head of pancreas (CMS/HCC),K86.89 - Other specified diseases of pancreas; I81 - Portal vein thrombosis; C25.0 - Malignant neoplasm of head of pancreas
NBR 4N ONCOLOGY,13281,"Zayac, Adam, MD",5/19/2024,Tretinoin (ATRA) / Arsenic 60 Day Cycle - Acute Promyelocytic Leukemia (Induction),_1. First Line,5/19/2024,Inactive,,
NBR 4N ONCOLOGY,13281,"Zayac, Adam, MD",6/17/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,6/17/2024,Active,Multiple myeloma not having achieved remission (CMS/HCC),
CINJ OP INFUSION,3943,"Stephenson, Ryan D, DO",2/7/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,2/7/2025,Active,Metastatic castration-sensitive adenocarcinoma of prostate (CMS/HCC),R97.20 - Elevated prostate specific antigen (PSA); C61 - Malignant neoplasm of prostate
NBI OP INFUSION,64563,"Schleicher, Lori, MD",3/11/2024,Tretinoin (ATRA) / IDArubicin / Arsenic 36 Day Cycle (Induction) - Acute Promyelocytic Leukemia,_1. First Line,3/11/2024,Inactive,,
NBR 4N ONCOLOGY,64563,"Rhodes, Joanna Meehan, MD",3/13/2024,Tretinoin (ATRA) / Arsenic / Gemtuzumab  - Acute Promyelocytic Leukemia (Induction),Induction,3/13/2024,Inactive,,
NBR 5N ONCOLOGY,64563,"Sridharan, Ashwin, MD",4/8/2024,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,4/8/2024,Inactive,,
NBR 5N ONCOLOGY,64563,"Schleicher, Lori, MD",4/15/2024,Tretinoin (ATRA) / Arsenic (Consolidation) - Acute Promyelocytic Leukemia,Consolidation,4/10/2024,Active,Hodgkin lymphoma (CMS/HCC),
MMC OP INFUSION,43408,"Lee, Patrick C, MD",3/14/2023,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,Second Line,3/13/2023,Active,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,8314,"Omene, Coral Oghenerukevwe, MD",1/23/2023,Sacituzumab Govitecan 21 Day Cycles - Breast,,1/20/2023,Inactive,,
CINJ OP INFUSION,8314,"Omene, Coral Oghenerukevwe, MD",5/28/2024,Elacestrant 28 Day Cycles - Breast,_5. Fifth Line,5/28/2024,Inactive,,
NBR 5N ONCOLOGY,88707,"Schaar, Dale, MD PhD",2/20/2023,HyperCVD Mini (Cycle 4) (RiTUXimab / High Dose Methotrexate / Cytarabine / Inotuzumab) 28 Day Cycles - Acute Lymphoblastic Leukemia,,2/20/2023,Inactive,,
NBR 4N ONCOLOGY,88707,"Schaar, Dale, MD PhD",5/22/2023,Blinatumomab 42 Day Cycles - (MRD+) Acute Lymphoblastic Leukemia,,5/22/2023,Inactive,,
NBR CINJ OP INFUSION,88707,"Schaar, Dale, MD PhD",4/8/2024,CALGB 9111 (Maintenance Therapy) 28 Day Cycles - Acute Lymphoblastic Leukemia,Maintenance,4/7/2024,Active,,
MSC OP INFUSION,24023,"Meghal, Trishala, MD",3/6/2023,Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,3/5/2023,Inactive,,
MSC OP INFUSION,24023,"Meghal, Trishala, MD",6/7/2023,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,6/5/2023,Inactive,,
MSC OP INFUSION,24023,"Meghal, Trishala, MD",2/20/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,2/19/2024,Inactive,,
MMC OP VP INFUSION,24023,"Meghal, Trishala, MD",8/6/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_4. Fourth Line,7/22/2024,Active,,
NBR 5N ONCOLOGY,20288,"Palmisiano, Neil David, MD",2/23/2024,Fractionated cyclophosphamide,_1. First Line,2/23/2024,Inactive,,
CINJ OP INFUSION,95172,"Boland, Patrick M, MD",2/6/2024,Atezolizumab/Bevacizumab 21 Day Cycles- Hepatobiliary Cancers,_1. First Line,1/31/2024,Inactive,,
CINJ OP INFUSION,95172,"Boland, Patrick M, MD",5/1/2024,SORAfenib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,5/1/2024,Inactive,,
CINJ OP INFUSION,95172,"Boland, Patrick M, MD",5/22/2024,"Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,5/21/2024,Inactive,,
NBR CINJ OP INFUSION,38328,"Matasar, Matthew J, MD",5/6/2025,CINJ 012207 Arm 1 Dose Level 3 Tazemetostat / Rituximab / Bendamustine 28 Day Cycles Research- Follicular Lymphoma,_1. First Line,5/6/2025,Active,Follicular lymphoma (CMS/HCC),
NBR CINJ OP INFUSION,17093,"Evens, Andrew M, DO",1/4/2023,Tafasitamab-cxix / Lenalidomide 28 Day Cycles + Tafasitamab-cxix 28 Day Cycles - Diffuse Large B-Cell Lymphoma,,1/3/2023,Inactive,,
NBR CINJ OP INFUSION,17093,"Evens, Andrew M, DO",2/15/2023,Bendamustine / Polatuzumab vedotin / RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Third Line,2/14/2023,Inactive,,
NBR CINJ OP INFUSION,23397,"Palmisiano, Neil David, MD",8/5/2024,ECOG - ACRIN E1910 (Step 1) Induction (RiTUXimab / Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,Induction,8/5/2024,Inactive,,
MMC BBR2 ONCOLOGY,23397,"Eltoukhy, Hussam, MD",10/21/2024,ECOG - ACRIN E1910 (Step 2) Intensification (High-Dose Methotrexate / Pegaspargase) - Acute Lymphoblastic Leukemia,Consolidation,10/20/2024,Inactive,,
NBR CINJ OP INFUSION,23397,"Palmisiano, Neil David, MD",11/19/2024,ECOG - ACRIN E1910 (Step 3) Blinatumomab - Acute Lymphoblastic Leukemia,Consolidation,11/19/2024,Active,,
MMC OP INFUSION,23397,"Palmisiano, Neil David, MD",2/17/2025,ECOG - ACRIN E1910 (Step 3) Consolidation (RiTUXimab / Cytarabine / Methotrexate IT / Etoposide / DAUNOrubicin / VinCRIStine / Cyclophosphamide / Mercaptopurine / Blinatumomab) - ALL,Consolidation,2/17/2025,Active,ALL (acute lymphocytic leukemia) (CMS/HCC),C91.01 - Acute lymphoblastic leukemia (ALL) in remission (CMS/HCC)
CMC OP INFUSION,91994,"Taff, Jessica, MD",5/16/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,5/7/2023,Inactive,,
CMC OP INFUSION,91994,"Taff, Jessica, MD",8/16/2023,CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Adjuvant,8/15/2023,Inactive,,
NBI OP INFUSION,44512,"Jacoby, Sari H, MD",4/12/2024,Bevacizumab 28 Day Cycles - CNS Radiation Necrosis ,_1. First Line,4/12/2024,Inactive,,
NBI OP INFUSION,44512,"Jacoby, Sari H, MD",1/7/2025,Amivantamab-vmjw Patients >/= 80 kg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,1/5/2025,Active,,
CMC 4B ONCOLOGY,69115,"Cohen, Seth D, MD",9/26/2023,PEDS ACNS0332 - Other than Average Risk Medulloblastoma / PNET ,Adjuvant,9/22/2023,Active,,
MMC OP VP INFUSION,33087,"Talwar, Sumit, MD",5/12/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,First Line,5/11/2023,Active,,
SOM OUTPT INFUSION,59187,"Patel, Eshan, MD",4/22/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/21/2024,Active,,
CMC OP INFUSION,23138,"Easaw, Sarah, MD",7/20/2023,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",Adjuvant,7/12/2023,Inactive,,
CMC OP INFUSION,23138,"Tang, Horace, MD",2/15/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_2. Second Line,2/14/2024,Inactive,,
CINJ OP INFUSION,49663,"Stephenson, Ryan D, DO",3/27/2023,CINJ 082106 Pembrolizumab / Belzutifan or Placebo 42 Day Cycles Research- Renal Cell Carcinoma,Adjuvant,3/24/2023,Inactive,,
NBR 4N ONCOLOGY,47836,"Shah, Mansi R, MD",8/21/2024,HLH-94 (Etoposide / Dexamethasone) - Hemophagocytic Lymphohistiocytosis (Induction),_1. First Line,8/21/2024,Inactive,,
NBR 5N ONCOLOGY,47836,"Rhodes, Joanna Meehan, MD",8/23/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) + RiTUXimab 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_2. Second Line,8/23/2024,Inactive,,
NBR 4N BMTU/IMCU,47836,"Rhodes, Joanna Meehan, MD",10/31/2024,BMT Autologous BEAM,_3. Third Line,10/30/2024,Active,,
CINJ OP INFUSION,68883,"Toppmeyer, Deborah L, MD",10/22/2024,CINJ 042102 EOP E ARV-471 and Abemaciclib 28 Day Cycles Research,Neoadjuvant,10/21/2024,Active,,
CINJ OP INFUSION,11531,"Patel, Eshan, MD",2/10/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,,2/9/2023,Inactive,,
SOM OUTPT INFUSION,11531,"Patel, Eshan, MD",6/30/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,6/29/2023,Inactive,,
JCMC CP INFUSION,38122,"Cruz, Allan Louie E, MD",2/26/2024,Nivo / 5FU (Fluorouracil Continuous Infusion / Leucovorin) + Nivolumab 14 Day Cycles - metastatic gastric cancer adenocarcinoma HER2(-),_1. First Line,2/15/2024,Inactive,,
CBMC OP INFUSION 2FL,37736,"Brown, Andrew Bennett, MD",6/28/2023,DOCEtaxel 21 Day Cycles - Prostate,Second Line,6/27/2023,Inactive,,
CBMC OP INFUSION 2FL,37736,"Brown, Andrew Bennett, MD",3/6/2024,CABAZItaxel / PredniSONE 21 Day Cycles - Prostate,_3. Third Line,3/5/2024,Inactive,,
JCMC CP INFUSION,30709,"Sekhri, Arunabh, MD",4/22/2024,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,4/21/2024,Inactive,,
NBR CINJ OP INFUSION,45435,"Evens, Andrew M, DO",12/6/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/5/2023,Inactive,,
NBR CINJ OP INFUSION,45435,"Evens, Andrew M, DO",2/8/2024,ICE (Ifosfamide / CARBOplatin / Etoposide) 21 Day Cycles - T-Cell Lymphoma (Inpatient Regimen),_2. Second Line,2/8/2024,Inactive,,
NBR CINJ OP INFUSION,45435,"Evens, Andrew M, DO",2/28/2024,RiTUXimab Rapid Infusion Single Day (Outpatient),Maintenance,2/28/2024,Inactive,,
CINJ OP INFUSION,39596,"Patankar, Sonali, MD",5/10/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,5/6/2024,Inactive,,
CINJ OP INFUSION,7918,"George, Mridula A, MD",12/4/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,12/3/2024,Active,,
CINJ OP INFUSION,14023,"Ganesan, Shridar, MD PhD",1/17/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,,1/17/2023,Inactive,,
NBI OP INFUSION,86403,"Anderson, Patrick S, MD",2/26/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,2/23/2025,Active,"Metastatic malignant neoplasm, unspecified site (CMS/HCC)",
CBMC OP INFUSION 2FL,6266,"Scoppetuolo, Michael, MD",12/27/2023,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,11/28/2023,Active,,
CINJ OP INFUSION,86472,"Mayer, Tina M, MD",2/28/2023,Apalutamide 30 Day Cycles - Prostate,,2/28/2023,Inactive,,
CINJ OP INFUSION,86472,"Mayer, Tina M, MD",9/5/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,,9/5/2023,Inactive,,
NBI OP INFUSION,55528,"Anderson, Patrick S, MD",10/10/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,10/9/2024,Active,,
NBR CINJ OP INFUSION,94173,"Rhodes, Joanna Meehan, MD",11/22/2024,CINJ 012307 Part 2 Rituximab / CHOP 21 Day Cycles Research- Diffuse Large B-Cell Lymphoma,_1. First Line,11/21/2024,Inactive,,
CBMC OP INFUSION 2FL,597,"Brown, Andrew Bennett, MD",11/2/2023,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/1/2023,Inactive,,
CBMC OP INFUSION 2FL,47028,"Phillips, Adrienne A, MD",10/7/2024,CINJ 012207 Arm 1 Dose Level 3 Tazemetostat / Rituximab / Bendamustine 28 Day Cycles Research- Follicular Lymphoma,_1. First Line,10/6/2024,Active,,
CBMC OP INFUSION 2FL,47028,"Phillips, Adrienne A, MD",12/30/2024,RiTUXimab Rapid Infusion Single Day (Outpatient),_1. First Line,12/30/2024,Active,Malignant neoplasm of overlapping sites of bladder (CMS/HCC),
CINJ OP INFUSION,75776,"Boland, Patrick M, MD",11/3/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/19/2023,Inactive,,
CINJ OP INFUSION,75776,"Boland, Patrick M, MD",11/14/2023,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,11/13/2023,Inactive,,
CINJ OP INFUSION,75776,"Boland, Patrick M, MD",12/21/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/20/2023,Inactive,,
CINJ OP INFUSION,75776,"Boland, Patrick M, MD",10/25/2024,5-FU + bevacizumab,_1. First Line,10/17/2024,Active,,
CBMC 2W ONCOLOGY,7867,"Leitner, Stuart P, MD",11/25/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,11/24/2024,Active,,
CMC OP INFUSION,99381,"Tang, Horace, MD",7/27/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,7/17/2023,Inactive,,
CBMC OP INFUSION 2FL,22587,"Grossman, I Robert, MD",3/15/2024,Bortezomib / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,3/12/2024,Inactive,,
CBMC 2W ONCOLOGY,22587,"Grossman, I Robert, MD",8/29/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,8/22/2024,Active,,
CBMC 2W ONCOLOGY,22587,"Grossman, I Robert, MD",10/18/2024,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,10/18/2024,Active,,
CBMC 2W ONCOLOGY,93811,"Grossman, I Robert, MD",1/29/2025,Teclistamab Weekly 28 Day Cycles,_5. Fifth Line,1/28/2025,Active,"Breast cancer (CMS/HCC)
Malignant neoplasm of upper-outer quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",
MMC OP VP INFUSION,83774,"Cohen, Seth D, MD",5/21/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/21/2025,Inactive,Malignant neoplasm of overlapping sites of right lung (CMS/HCC),
MMC OP VP INFUSION,83774,"Cohen, Seth D, MD",5/21/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/21/2025,Active,Malignant neoplasm of overlapping sites of right lung (CMS/HCC),
CBMC OP INFUSION 2FL,1043,"Litvak, Anna M, MD",11/7/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,1043,"Ligresti, Louise G, MD",3/14/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_5. Fifth Line,3/13/2024,Active,,
CBMC OP INFUSION 2FL,1043,"Litvak, Anna M, MD",1/28/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,1/27/2025,Active,,
SOM OUTPT INFUSION,79430,"Patel, Eshan, MD",4/14/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,Neoadjuvant,4/14/2025,Active,Malignant neoplasm of trigone of urinary bladder (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified"
SOM OUTPT INFUSION,79430,"Patel, Eshan, MD",4/14/2025,CISplatin with Concurrent Radiation 21 Day Cycles - Bladder,_1. First Line,4/14/2025,Inactive,Malignant neoplasm of trigone of urinary bladder (CMS/HCC),"C67.0 - Malignant neoplasm of trigone of bladder; E78.00 - Pure hypercholesterolemia, unspecified; I10 - Essential (primary) hypertension; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; Z96.652 - Presence of left artificial knee joint; Z98.52 - Vasectomy status; Z79.82 - Long term (current) use of aspirin; Z79.01 - Long term (current) use of anticoagulants; Z79.899 - Other long term (current) drug therapy; F17.290 - Nicotine dependence, other tobacco product, uncomplicated; N40.1 - Benign prostatic hyperplasia with lower urinary tract symptoms; C67.9 - Malignant neoplasm of bladder, unspecified; N28.89 - Other specified disorders of kidney and ureter; R35.0 - Frequency of micturition"
CMC OP INFUSION,40333,"Taff, Jessica, MD",4/11/2024,CISplatin 60 mg/m2/Etoposide 120 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/7/2024,Inactive,,
CMC OP INFUSION,40333,"Taff, Jessica, MD",7/26/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/25/2024,Active,,
NBI OP INFUSION,96559,"Shah, Shailja S, MD",12/12/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/11/2023,Active,,
SOM OUTPT INFUSION,72419,"Patel, Eshan, MD",2/21/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,2/20/2024,Inactive,,
NBI OP INFUSION,92866,"Jacoby, Sari H, MD",5/9/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/8/2023,Inactive,,
NBI OP INFUSION,92866,"Jacoby, Sari H, MD",12/10/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/9/2024,Active,,
CINJ OP INFUSION,82663,"Haigentz, Missak, MD",6/18/2024,PEMEtrexed/CARBOplatin (AUC 5) PLUS Pembrolizumab (Starting C2) - 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/15/2024,Inactive,,
CBMC OP INFUSION 2FL,93168,"Leitner, Stuart P, MD",1/6/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,12/16/2024,Active,,
CMC OP INFUSION,11219,"Eltoukhy, Hussam, MD",11/18/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,Induction,11/17/2024,Active,,
CMC OP INFUSION,11219,"Eltoukhy, Hussam, MD",1/27/2025,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,1/27/2025,Active,,
NBR CINJ OP INFUSION,66093,"Palmisiano, Neil David, MD",2/9/2023,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,2/9/2023,Inactive,,
NBR CINJ OP INFUSION,66093,"Palmisiano, Neil David, MD",6/22/2023,AzaCITIDine Oral 28 Day Cycles - Acute Myeloid Leukemia,Maintenance,6/22/2023,Active,,
TRMC TCCC OP INFUSION,2723,"Capo, Gerardo, MD",2/6/2025,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/5/2025,Active,Colon cancer metastasized to liver (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C18.2 - Malignant neoplasm of ascending colon"
CMC OP INFUSION,25765,"Easaw, Sarah, MD",5/15/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,Maintenance,4/25/2023,Inactive,,
CMC OP INFUSION,25765,"Eltoukhy, Hussam, MD",10/2/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,Maintenance,9/27/2023,Active,,
CBMC OP INFUSION 2FL,88372,"Brown, Andrew Bennett, MD",5/12/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Consolidation,5/12/2025,Active,Squamous cell carcinoma of head and neck,
CBMC OP INFUSION 2FL,69626,"Raptis, George, MD",4/30/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,4/29/2024,Inactive,,
CBMC OP INFUSION 2FL,69626,"Raptis, George, MD",6/25/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/24/2024,Inactive,,
CINJ OP INFUSION,40810,"Boland, Patrick M, MD",6/20/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,,6/14/2023,Inactive,,
CINJ OP INFUSION,40810,"Boland, Patrick M, MD",2/21/2025,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,2/20/2025,Active,Cancer of rectosigmoid (colon) (CMS/HCC),C19 - Cancer of rectosigmoid (colon) (CMS/HCC)
MSC OP INFUSION,32590,"Cohen, Seth D, MD",3/12/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,3/4/2024,Active,,
CINJ OP INFUSION,404,"Weiss, Sarah, MD",2/19/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,2/18/2025,Active,Squamous cell carcinoma of skin,C07 - Malignant neoplasm of parotid gland
SOM OUTPT INFUSION,54472,"Patel, Eshan, MD",12/19/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,12/9/2024,Active,,
CBMC OP INFUSION 2FL,16091,"Litvak, Anna M, MD",10/30/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,10/29/2023,Inactive,,
CINJ OP INFUSION,16955,"Weiss, Sarah, MD",1/29/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,Neoadjuvant,1/21/2024,Active,,
CINJ OP INFUSION,29549,"Toppmeyer, Deborah L, MD",12/31/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,12/30/2024,Active,"Non-small cell cancer of left lung (CMS/HCC)
Encounter for screening for other viral diseases",
CINJ OP INFUSION,10903,"Haigentz, Missak, MD",12/11/2023,CISplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,_1. First Line,12/10/2023,Inactive,,
CBMC OP INFUSION 2FL,70939,"Grossman, I Robert, MD",9/6/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,,9/5/2023,Active,,
CBMC OP INFUSION 2FL,5085,"Brown, Andrew Bennett, MD",7/22/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,7/21/2024,Inactive,,
CINJ OP INFUSION,12972,"Omene, Coral Oghenerukevwe, MD",7/16/2024,CINJ 042102 EOP E ARV-471 and Abemaciclib 28 Day Cycles Research,Neoadjuvant,7/15/2024,Inactive,,
NBR CINJ OP INFUSION,34132,"Shah, Mansi R, MD",4/27/2023,Lymphodepletion Abecma 6 Day Cycle - Multiple Myeloma,,3/28/2023,Inactive,,
NBR CINJ OP INFUSION,34132,"Shah, Mansi R, MD",7/13/2023,Lymphodepletion Abecma with Fludarabine/Cyclophosphamide 6 Day Cycle - Multiple Myeloma,,7/12/2023,Inactive,,
HAM OP INFUSION,81198,"Yogarajah, Meera, MD",9/11/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,First Line,9/11/2023,Active,,
CINJ OP INFUSION,62644,"Goel, Sanjay, MD",7/27/2023,CINJ 052216 Stage 2 Ulixertinib / Hydroxychloroquine 28 Day Cycles Research- Gastrointestinal Malignancies,Third Line,7/27/2023,Inactive,,
CINJ OP INFUSION,16973,"Gulhati, Prateek, MD PhD",5/8/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,5/4/2023,Inactive,,
CINJ OP INFUSION,16973,"Gulhati, Prateek, MD PhD",7/12/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,,7/7/2023,Inactive,,
CINJ OP INFUSION,27447,"Ghodoussipour, Saum Bobak, MD",12/19/2023,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) - Bladder Cancer,Induction,12/17/2023,Inactive,,
CINJ OP INFUSION,27447,"Ghodoussipour, Saum Bobak, MD",3/29/2024,CINJ 082303 Arm A GEMDOCE (Gemcitabine + DOCEtaxel) Maintenance - Bladder Cancer,Maintenance,3/25/2024,Active,,
CINJ OP INFUSION,27447,"Ghodoussipour, Saum Bobak, MD",2/19/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Adjuvant,2/18/2025,Active,Urothelial carcinoma (CMS/HCC),
CINJ OP INFUSION,71859,"Ghodoussipour, Saum Bobak, MD",3/11/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,Adjuvant,2/19/2025,Active,Urothelial carcinoma (CMS/HCC),
CMC OP INFUSION,50123,"Talwar, Sumit, MD",3/1/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,2/29/2024,Inactive,,
NBR 4N BMTU/IMCU,56568,"Saraiya, Biren P, MD",2/13/2025,CINJ 192204 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + E7 TCR Cells 6 Day Cycle Research- HPV Associated Cancers,_3. Third Line,2/10/2025,Active,Primary squamous cell carcinoma of base of tongue (CMS/HCC),
NBR CINJ OP INFUSION,64316,"Braunschweig, Ira, MD",7/26/2023,Lymphodepletion Tecartus with Fludarabine/Cyclophosphamide 6 Day Cycle - Mantle Cell Lymphoma,,7/25/2023,Inactive,,
CINJ OP INFUSION,95062,"Haigentz, Missak, MD",4/26/2023,CISplatin / Etoposide (75/100) 21 Day Cycles - High Grade Neuroendocrine,Adjuvant,4/26/2023,Inactive,,
MMC OP VP INFUSION,64798,"Cohen, Seth D, MD",3/7/2024,RiTUXimab Rapid Infusion Single Day (Outpatient),_1. First Line,3/7/2024,Inactive,,
CMC OP INFUSION,9455,"Pompa, Tiffany Ann, MD",10/18/2024,Nivolumab 28 Day Cycles - Melanoma,Adjuvant,10/17/2024,Active,,
JCMC CP INFUSION,2566,"Sekhri, Arunabh, MD",12/16/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/12/2024,Active,,
HAM OP INFUSION,58915,"Patel, Malini M, MD",7/16/2024,Atezolizumab/Bevacizumab/PACLitaxel/CARBOplatin 21 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,7/9/2024,Active,,
HAM OP INFUSION,58915,"Patel, Malini M, MD",11/19/2024,Atezolizumab/Bevacizumab-Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/18/2024,Active,,
HAM OP INFUSION,61877,"Patel, Malini M, MD",4/21/2025,PEMEtrexed 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,4/21/2025,Active,Non-small cell cancer of left lung (CMS/HCC),"C34.92 - Non-small cell cancer of left lung (CMS/HCC); R80.9 - Proteinuria, unspecified type; F17.200 - Tobacco dependence"
CBMC OP INFUSION 2FL,72487,"Leitner, Stuart P, MD",5/15/2024,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,_1. First Line,5/13/2024,Active,,
CBMC OP INFUSION 2FL,86031,"Leitner, Stuart P, MD",5/22/2025,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_2. Second Line,5/21/2025,Active,"Prostate cancer (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)",
CINJ OP INFUSION,42217,"Berim, Lyudmyla, MD",5/11/2023,Lenvatinib 28 Day Cycles- Hepatobiliary Cancers,,5/11/2023,Active,,
CINJ OP INFUSION,42217,"Berim, Lyudmyla, MD",6/15/2024,Cabozantinib 28 Day Cycles- Hepatobiliary Cancers,_2. Second Line,6/15/2024,Active,,
CINJ OP INFUSION,42217,"Berim, Lyudmyla, MD",4/21/2025,SORAfenib 28 Day Cycles- Hepatobiliary Cancers,_3. Third Line,4/21/2025,Active,Liver cell carcinoma (CMS/HCC),C22.0 - Liver cell carcinoma
CINJ OP INFUSION,42217,"Berim, Lyudmyla, MD",4/14/2025,Ramucirumab 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,4/14/2025,Inactive,Liver cell carcinoma (CMS/HCC),C22.0 - Liver cell carcinoma (CMS/HCC)
CBMC OP INFUSION 2FL,74571,"Leitner, Stuart P, MD",11/2/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,11/2/2023,Active,,
CBMC OP INFUSION 2FL,74571,"Leitner, Stuart P, MD",11/2/2023,Enfortumab Vedotin 28 Day Cycles - Bladder,_1. First Line,11/1/2023,Active,,
NBI OP INFUSION,26043,"Cohen, Alice, MD",1/29/2024,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,1/28/2024,Inactive,,
CMC OP INFUSION,91933,"Tang, Horace, MD",11/29/2023,PEGinterferon alfa-2a 28 Day Cycle - Myeloproliferative Neoplasms,_2. Second Line,11/28/2023,Inactive,,
NBR 5N ONCOLOGY,59533,"Salacz, Michael E, MD",1/5/2023,Temozolomide (Continuous Twice Daily) 28 Day Cycles - CNS,Second Line,1/5/2023,Inactive,,
CINJ OP INFUSION,72349,"Haigentz, Missak, MD",9/17/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,9/16/2024,Inactive,,
CINJ OP INFUSION,72349,"Haigentz, Missak, MD",12/30/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,12/29/2024,Active,,
CINJ OP INFUSION,18273,"Salacz, Michael E, MD",1/20/2023,Temozolomide 28 Day Cycles - CNS,Adjuvant,1/18/2023,Inactive,,
CINJ OP INFUSION,18273,"Salacz, Michael E, MD",1/23/2023,Bevacizumab 28 Day Cycles - CNS,Second Line,1/23/2023,Inactive,,
CINJ OP INFUSION,18273,"Salacz, Michael E, MD",3/6/2023,Etoposide Oral 28 Day Cycles - CNS,Third Line,3/6/2023,Active,,
CMC OP INFUSION,44590,"Talwar, Sumit, MD",9/3/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,9/2/2024,Inactive,,
CMC OP INFUSION,44590,"Talwar, Sumit, MD",9/4/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,8/30/2024,Active,,
CBMC OP INFUSION 2FL,2410,"Leitner, Stuart P, MD",11/10/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/9/2023,Active,,
NBR CINJ OP INFUSION,61899,"Tiger, Yun Kyoung, MD",9/25/2024,CINJ 012207 Arm 1 Dose Level 3 Tazemetostat / Rituximab / Bendamustine 28 Day Cycles Research- Follicular Lymphoma,_1. First Line,9/24/2024,Active,,
CBMC OP INFUSION 2FL,10803,"Grossman, I Robert, MD",9/27/2023,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/19/2023,Inactive,,
CBMC OP INFUSION 2FL,10803,"Grossman, I Robert, MD",3/14/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/10/2024,Inactive,,
NBI A5 PEDIATRICS,30455,"Bhatla, Teena, MD",6/20/2024,PEDS ANHL1131 Group C1,_1. First Line,6/20/2024,Active,,
NBI VALERIE FND HEMONC,30455,"Bhatla, Teena, MD",6/20/2024,PEDS ANHL1131 Group C3,_1. First Line,6/20/2024,Inactive,,
NBR 5N ONCOLOGY,8207,"Chen, Xiaoyi",5/30/2025,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),_1. First Line,5/30/2025,Active,Acute myeloid leukemia not having achieved remission (CMS/HCC),C92.00 - Acute myeloid leukemia not having achieved remission (CMS/HCC)
CINJ OP INFUSION,46938,"George, Mridula A, MD",10/26/2023,Palbociclib 28 Day Cycles - Breast,_1. First Line,10/26/2023,Inactive,,
CINJ OP INFUSION,46938,"George, Mridula A, MD",11/18/2024,Palbociclib 28 Day Cycles - Breast,_1. First Line,11/18/2024,Active,,
NBI OP INFUSION,70089,"Anderson, Patrick S, MD",12/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Endometrial Cancer,_1. First Line,12/4/2024,Active,,
HAM OP INFUSION,62337,"Yogarajah, Meera, MD",9/9/2024,Fluorouracil Continuous Infusion/MitoMYcin 10 mg/m2 with Concurrent Radiation 35 Day Cycle- Anal Carcinoma,_1. First Line,8/28/2024,Active,,
CBMC OP INFUSION 2FL,79705,"Brown, Andrew Bennett, MD",9/6/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,9/6/2024,Active,,
CMC OP INFUSION,79377,"Cohen, Seth D, MD",5/29/2025,PACLitaxel / CARBOplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_1. First Line,5/29/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)
Elevated cancer antigen 125 (CA 125)",
CINJ OP INFUSION,24289,"Dasgeb, Bahar, MD",12/2/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,12/1/2024,Active,,
CINJ OP INFUSION,7047,"Goel, Sanjay, MD",4/17/2023,"CINJ 052203 Phase 2 Cohort A, B, C E7386 / Pembrolizumab 21 Day Cycles Research- Solid Malignancies",Third Line,3/16/2023,Inactive,,
CINJ OP INFUSION,7047,"Goel, Sanjay, MD",2/12/2024,CINJ 052008 / R7075-ONC-2009 Dose Level 9W REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,_4. Fourth Line,1/17/2024,Inactive,,
CINJ OP INFUSION,54353,"Mayer, Tina M, MD",6/1/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Maintenance,6/1/2023,Inactive,,
NBR CINJ OP INFUSION,45987,"Egini, Ogechukwu, MD",7/24/2024,Lymphodepletion Yescarta with Fludarabine / Cyclophosphamide - Refractory Large B-Cell Lymphoma,_3. Third Line,7/23/2024,Active,,
CINJ OP INFUSION,81048,"George, Mridula A, MD",6/12/2024,DOXOrubicin Liposomal / CARBOplatin 28 Day Cycles - Breast,Adjuvant,5/28/2024,Inactive,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)",
CINJ OP INFUSION,81048,"George, Mridula A, MD",1/17/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,1/10/2025,Active,"Rectal malignant neoplasm (CMS/HCC)
Encounter for screening for other viral diseases",
CBMC OP INFUSION 2FL,16500,"Leitner, Stuart P, MD",11/6/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,11/5/2023,Inactive,,
CBMC OP INFUSION 2FL,16500,"Leitner, Stuart P, MD",8/26/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,8/25/2024,Active,,
CBMC OP INFUSION 2FL,54648,"Grossman, I Robert, MD",11/20/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,11/14/2023,Inactive,,
CBMC OP INFUSION 2FL,54648,"Grossman, I Robert, MD",9/17/2024,Daratumumab/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/16/2024,Active,,
NBI OP INFUSION,36002,"Schleicher, Lori, MD",12/22/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,12/22/2023,Active,,
CBMC OP INFUSION 2FL,73620,"Radovich, Delia, MD",2/20/2023,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",,2/20/2023,Active,"Myeloid sarcoma, not having achieved remission (CMS/HCC)",
CBMC OP INFUSION 2FL,58585,"Kulkarni, Aditya A, MD",3/19/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,3/19/2025,Active,Renal cell carcinoma (CMS/HCC),
NBI VALERIE FND HEMONC,90762,"Rao, Harini, MD",3/20/2025,PEDS DD-4A - Renal,_1. First Line,3/20/2025,Active,Wilm's tumor (nephroblastoma) (CMS/HCC),
CBMC OP INFUSION 2FL,51476,"Raptis, George, MD",3/19/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,51476,"Raptis, George, MD",5/14/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,5/13/2024,Inactive,,
TRMC TCCC OP INFUSION,56312,"Capo, Gerardo, MD",11/21/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/20/2024,Active,,
CMC OP INFUSION,78005,"Taff, Jessica, MD",8/2/2023,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,8/1/2023,Active,,
CINJ OP INFUSION,71519,"Muralikrishnan, Sivraj, MD",2/14/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/20/2025,Active,"NSCLC metastatic to bone (CMS/HCC)
Other fatigue",C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; R91.1 - Solitary pulmonary nodule; C79.51 - Secondary malignant neoplasm of bone; I82.411 - Acute embolism and thrombosis of right femoral vein; Z51.5 - Encounter for palliative care
CINJ OP INFUSION,50005,"Muralikrishnan, Sivraj, MD",4/3/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/3/2025,Active,"NSCLC metastatic to bone (CMS/HCC)
Other fatigue","C34.90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung; C79.51 - Secondary malignant neoplasm of bone; E88.3 - Tumor lysis syndrome; N17.9 - Acute kidney failure, unspecified; I82.411 - Acute embolism and thrombosis of right femoral vein; E03.9 - Hypothyroidism, unspecified; K11.8 - Other diseases of salivary glands; R53.83 - Other fatigue"
HAM OP INFUSION,70197,"Patel, Malini M, MD",1/29/2025,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,1/29/2025,Active,,
HAM OP INFUSION,70197,"Patel, Malini M, MD",5/7/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/23/2025,Active,"Non-small cell cancer of left lung (CMS/HCC)
Abnormal findings on diagnostic imaging of other specified body structures",
CBMC OP INFUSION 2FL,91616,"Radovich, Delia, MD",11/20/2023,Sacituzumab Govitecan 21 Day Cycles - Breast ,_5. Fifth Line,11/12/2023,Inactive,,
CBMC OP INFUSION 2FL,91616,"Ligresti, Louise G, MD",4/16/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_5. Fifth Line,3/4/2024,Inactive,,
CMC OP INFUSION,22171,"Taff, Jessica, MD",5/12/2023,Pembrolizumab 21 Day Cycles - Hodgkin Lymphoma,Third Line,5/11/2023,Active,,
CINJ OP INFUSION,23524,"Berim, Lyudmyla, MD",1/9/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,Maintenance,1/6/2023,Active,,
CINJ OP INFUSION,23524,"Berim, Lyudmyla, MD",3/24/2025,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles followed by Durvalumab 28 Day Cycles- Biliary Tract Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_3. Third Line,3/24/2025,Active,"Malignant neoplasm of pancreas, unspecified location of malignancy (CMS/HCC)","C25.9 - Malignant neoplasm of pancreas, unspecified; K86.81 - Exocrine pancreatic insufficiency; K76.0 - Fatty (change of) liver, not elsewhere classified; B02.9 - Zoster without complications; N17.9 - Acute kidney failure, unspecified; I26.99 - Other pulmonary embolism without acute cor pulmonale; I82.409 - Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity; E11.9 - Type 2 diabetes mellitus without complications; G62.0 - Drug-induced polyneuropathy; T43.025A - Adverse effect of tetracyclic antidepressants, initial encounter; C25.7 - Malignant neoplasm of other parts of pancreas"
CINJ OP INFUSION,27583,"Stephenson, Ryan D, DO",10/30/2023,BEP (Bleomycin / Etoposide / CISplatin) 21 Day Cycles - Testicular,Adjuvant,10/27/2023,Inactive,,
HAM OP INFUSION,92313,"Patel, Malini M, MD",3/27/2025,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,3/27/2025,Active,Non-small cell cancer of right lung (CMS/HCC),"C34.90 - Malignant neoplasm of lung, unspecified laterality, unspecified part of lung (CMS/HCC)"
CMC OP INFUSION,88757,"Taff, Jessica, MD",10/25/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/22/2024,Active,,
CMC OP INFUSION,88757,"Taff, Jessica, MD",12/27/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,12/13/2024,Active,,
HAM OP INFUSION,12763,"Yogarajah, Meera, MD",3/7/2023,Atezolizumab 21 Day Cycles- Small Cell Lung Cancer,First Line,3/6/2023,Active,,
JCMC CP INFUSION,26909,"Sekhri, Arunabh, MD",11/13/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/10/2023,Inactive,,
JCMC CP INFUSION,26909,"Sekhri, Arunabh, MD",4/23/2024,5FU+ Bevacizumab (Fluorouracil Continuous Infusion) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/22/2024,Inactive,,
JCMC CP INFUSION,26909,"Sekhri, Arunabh, MD",6/18/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/9/2024,Inactive,,
JCMC CP INFUSION,26909,"Sekhri, Arunabh, MD",8/19/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,8/12/2024,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Pancytopenia (CMS/HCC)",
JCMC CP INFUSION,26909,"Sekhri, Arunabh, MD",5/20/2025,Irinotecan single agent --- 14 Day Cycles - Colorectal cancer,_4. Fourth Line,5/6/2025,Active,Malignant neoplasm of descending colon (CMS/HCC),E86.0 - Dehydration; C18.6 - Malignant neoplasm of descending colon
MMC OP VP INFUSION,3353,"Cohen, Seth D, MD",9/16/2024,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,_1. First Line,9/15/2024,Inactive,,
CMC OP INFUSION,67286,"Tang, Horace, MD",9/7/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,,9/7/2023,Inactive,,
CINJ OP INFUSION,3697,"Haigentz, Missak, MD",11/6/2024,Pemetrexed / CARBOplatin + Amivantamab Patients < 80 kg 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/29/2024,Active,,
SOM OUTPT INFUSION,23455,"Toomey, Kathleen C, MD",12/9/2024,PACLitaxel / CISplatin 21 Day Cycles - Cervical,_1. First Line,12/6/2024,Active,,
JCMC CP INFUSION,74564,"Sekhri, Arunabh, MD",7/27/2023,TH+P (DOCEtaxel  / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/2/2023,Inactive,,
JCMC CP INFUSION,74564,"Sekhri, Arunabh, MD",1/22/2024,Trastuzumab / Pertuzumab 21 Day Cycles - Metastatic HER 2 (+) Breast Cancer,Maintenance,1/17/2024,Inactive,,
JCMC CP INFUSION,74564,"Sekhri, Arunabh, MD",9/3/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,9/3/2024,Active,,
NBR CINJ OP INFUSION,27839,"Shah, Mansi R, MD",2/28/2023,Decitabine (weekly) 28 Day Cycles,,2/27/2023,Inactive,,
NBR CINJ OP INFUSION,27839,"Shah, Mansi R, MD",4/26/2023,Low-Dose Melphalan Oral 28 Day Cycles - Acute Myeloid Leukemia,Third Line,4/26/2023,Inactive,,
SOM OUTPT INFUSION,75805,"Patel, Eshan, MD",3/5/2023,CINJ 032003 PACLitaxel / CARBOplatin 21 Day Cycles CYCLES 2 & 3 Group C Research- Non-Small Cell Lung Cancer,,3/5/2023,Inactive,,
CINJ OP INFUSION,75805,"Patel, Eshan, MD",4/10/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,4/9/2023,Inactive,,
NBR CINJ OP INFUSION,75805,"Patel, Eshan, MD",5/1/2023,DOCEtaxel/keytruda  21 Day Cycles- Non-Small Cell Lung Cancer,,4/27/2023,Inactive,,
CINJ OP INFUSION,62078,"Toppmeyer, Deborah L, MD",3/7/2024,AC (DOXOrubicin / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/6/2024,Inactive,,
CINJ OP INFUSION,62078,"Toppmeyer, Deborah L, MD",7/11/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,7/10/2024,Active,Transitional cell carcinoma of left ureter (CMS/HCC),
CBMC OP INFUSION 2FL,35023,"Raptis, George, MD",4/12/2024,"PACLitaxel D1, D15 28 Day Cycles - Breast",_1. First Line,4/11/2024,Inactive,,
CBMC OP INFUSION 2FL,35023,"Raptis, George, MD",7/19/2024,"PACLitaxel D1, D8, D15 28 Day Cycles - Breast",_1. First Line,7/18/2024,Inactive,,
CBMC OP INFUSION 2FL,35023,"Raptis, George, MD",2/19/2025,Pembrolizumab 21 Day Cycles - Bladder or Breast,_3. Third Line,2/19/2025,Active,"Breast cancer, stage 4, left (CMS/HCC)",
CBMC OP INFUSION 2FL,81805,"Leitner, Stuart P, MD",10/10/2024,Nivolumab / Ipilimumab (Induction) 21 Day Cycles Followed By Nivolumab 28 Day Cycles - Kidney,_1. First Line,10/8/2024,Active,,
SOM OUTPT INFUSION,60238,"Yin, Faye, MD",2/22/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,2/21/2023,Inactive,,
NBR CINJ OP INFUSION,75898,"Evens, Andrew M, DO",1/17/2024,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_4. Fourth Line,1/16/2024,Inactive,,
NBR CINJ OP INFUSION,75898,"Evens, Andrew M, DO",5/1/2024,Lymphodepletion Breyanzi with Fludarabine / Cyclophosphamide - Non-Hodgkin's Lymphoma,_4. Fourth Line,4/9/2024,Inactive,,
CINJ OP INFUSION,49823,"Toppmeyer, Deborah L, MD",3/7/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,3/6/2024,Inactive,,
CINJ OP INFUSION,49823,"Toppmeyer, Deborah L, MD",11/4/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,11/4/2024,Active,Metastatic malignant neoplasm of unknown primary site (CMS/HCC),
CBMC OP INFUSION 2FL,50972,"Wagmiller, Jennifer Ann, MD",10/24/2023,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,10/23/2023,Inactive,,
CBMC OP INFUSION 2FL,50972,"Wagmiller, Jennifer Ann, MD",4/10/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,4/9/2024,Inactive,,
CBMC OP INFUSION 2FL,50972,"Wagmiller, Jennifer Ann, MD",12/12/2024,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,_4. Fourth Line,12/11/2024,Active,,
HAM OP INFUSION,62563,"Yogarajah, Meera, MD",6/3/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/2/2024,Inactive,,
NBI OP INFUSION,56514,"Snyder, Rose, MD",1/28/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,1/28/2025,Active,,
NBR 5N ONCOLOGY,2309,"Saraiya, Biren P, MD",3/25/2024,TI-CE (PACLitaxel / Ifosfamide) 14 Day Cycles - Germ Cell Tumors,_2. Second Line,3/25/2024,Inactive,,
CINJ OP INFUSION,2309,"Saraiya, Biren P, MD",6/18/2024,Gemcitabine / OXALIplatin 21 Day Cycles - Testicular,_3. Third Line,6/15/2024,Inactive,,
MMC OP VP INFUSION,80585,"Lee, Patrick C, MD",2/4/2025,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,2/3/2025,Active,Rectal cancer metastasized to liver (CMS/HCC),
CINJ OP INFUSION,65271,"Goel, Sanjay, MD",1/17/2024,CINJ 052208 Part 1K AMG-193 28 Day Cycles Research  - Solid Tumors,_2. Second Line,1/17/2024,Inactive,,
CBMC OP INFUSION 2FL,80820,"Leitner, Stuart P, MD",1/14/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/5/2025,Active,,
CINJ OP INFUSION,87985,"Goel, Sanjay, MD",9/11/2023,CINJ 052214 Single Agent Part 1a XTX202 21 Day Cycles Research- Advanced Solid Tumors,Third Line,9/10/2023,Active,,
CINJ OP INFUSION,32847,"George, Mridula A, MD",5/24/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/23/2024,Inactive,,
CINJ OP INFUSION,32847,"George, Mridula A, MD",9/13/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,9/13/2024,Active,"Malignant neoplasm of endometrium (CMS/HCC)
Mediastinal adenopathy",
JCMC CP INFUSION,92829,"Sekhri, Arunabh, MD",12/30/2024,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell anal,_2. Second Line,12/27/2024,Active,,
CBMC OP INFUSION 2FL,93305,"Ligresti, Louise G, MD",4/8/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,4/8/2024,Active,,
CBMC 2W ONCOLOGY,8679,"Scoppetuolo, Michael, MD",8/7/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,8/6/2024,Inactive,,
CBMC OP INFUSION 2FL,8679,"Scoppetuolo, Michael, MD",2/4/2025,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,2/3/2025,Active,"Malignant neoplasm of upper lobe of right lung (CMS/HCC)
Non-small cell lung cancer (CMS/HCC)",
SOM OUTPT INFUSION,44468,"George, Roshini, DO",2/5/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,1/31/2025,Active,"Cancer of sigmoid colon (CMS/HCC)
Metastasis to lung (CMS/HCC)","C18.9 - Malignant neoplasm of colon, unspecified; C18.7 - Malignant neoplasm of sigmoid colon; C78.01 - Secondary malignant neoplasm of right lung; C78.02 - Secondary malignant neoplasm of left lung"
CINJ OP INFUSION,97016,"Aikins, James K, MD",11/25/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,11/24/2024,Inactive,,
JCMC CP INFUSION,64340,"Sekhri, Arunabh, MD",11/27/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,11/26/2023,Inactive,,
JCMC CP INFUSION,64340,"Sekhri, Arunabh, MD",12/13/2023,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,12/7/2023,Active,,
CBMC OP INFUSION 2FL,41633,"Radovich, Delia, MD",11/7/2023,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,41633,"Mack, Alleda Eileen, MD",4/9/2024,"Trifluridine and Tipiracil D1-5; D15-19 / Bevacizumab D1, D15 28 Day Cycles- Gastrointestinal Cancers",_3. Third Line,3/5/2024,Inactive,,
CBMC 2W ONCOLOGY,41633,"Dharmapuri, Sirish, MD",7/30/2024,CAPEOX (Capecitabine 1000 mg/m2 / OXALiplatin 85 mg/m2) + Bevacizumab 5 mg/kg 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,7/29/2024,Inactive,,
CINJ OP INFUSION,41633,"Goel, Sanjay, MD",10/28/2024,CINJ 052401 Part B Dose Expansion GIM-122 ,_3. Third Line,10/28/2024,Active,,
SOM OUTPT INFUSION,52767,"Yin, Faye, MD",8/28/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,First Line,8/27/2023,Inactive,,
SOM OUTPT INFUSION,52767,"Yin, Faye, MD",9/25/2023,Pembrolizumab 21 Day Cycles - Cervical,Second Line,9/24/2023,Inactive,,
SOM OUTPT INFUSION,75875,"Yin, Faye, MD",6/13/2023,Alpelisib 28 Day Cycles - Breast,Third Line,6/13/2023,Inactive,,
NBR CINJ OP INFUSION,63970,"Evens, Andrew M, DO",1/19/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),First Line,1/18/2023,Inactive,,
NBR 4N ONCOLOGY,63970,"Palmisiano, Neil David, MD",1/25/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,,1/25/2023,Inactive,,
CINJ OP INFUSION,37265,"Toppmeyer, Deborah L, MD",7/18/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,7/17/2024,Inactive,,
CINJ OP INFUSION,37265,"Toppmeyer, Deborah L, MD",12/27/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,12/27/2024,Active,Seminoma (CMS/HCC),
CBMC OP INFUSION 2FL,13110,"Litvak, Anna M, MD",11/3/2023,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,13110,"Litvak, Anna M, MD",11/3/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,_1. First Line,11/2/2023,Inactive,,
CBMC OP INFUSION 2FL,13110,"Litvak, Anna M, MD",11/3/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,_1. First Line,11/2/2023,Inactive,,
NBR 5N ONCOLOGY,15036,"Packiam, Vignesh, MD",2/4/2025,Gemcitabine Intravesical Single Dose - Bladder,Consolidation,2/4/2025,Inactive,Ureteral mass,"N28.9 - Disorder of kidney and ureter, unspecified; R00.1 - Bradycardia, unspecified; R73.03 - Prediabetes; Z87.81 - Personal history of (healed) traumatic fracture; Z86.018 - Personal history of other benign neoplasm; Z87.891 - Personal history of nicotine dependence"
CMC OP INFUSION,15036,"Cohen, Seth D, MD",4/2/2025,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,4/2/2025,Active,Transitional cell carcinoma metastatic to left renal pelvis (CMS/HCC),
CMC OP INFUSION,15604,"Tang, Horace, MD",2/6/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Adjuvant,2/6/2024,Active,,
CINJ OP INFUSION,2889,"Toppmeyer, Deborah L, MD",8/25/2023,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,8/23/2023,Inactive,,
CBMC OP INFUSION 2FL,22331,"Raptis, George, MD",11/14/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,11/13/2024,Active,Cholangiocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,26059,"Raptis, George, MD",4/18/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,4/11/2025,Active,"Malignant neoplasm of left breast in female, estrogen receptor negative (CMS/HCC)",
HAM OP INFUSION,76043,"Yogarajah, Meera, MD",1/3/2023,DOCEtaxel 21 Day Cycles - Prostate,First Line,12/21/2022,Inactive,,
CINJ OP INFUSION,99619,"Ghodoussipour, Saum Bobak, MD",2/11/2025,CINJ 082403 PHASE 2 (4 INSTILLATION REGIMEN) EG-70,Adjuvant,2/11/2025,Active,Urothelial cancer (CMS/HCC),
CINJ OP INFUSION,22574,"Mayer, Tina M, MD",1/9/2023,Sipuleucel-T 14 Day Cycles - Prostate,,1/9/2023,Inactive,,
CINJ OP INFUSION,22574,"Mayer, Tina M, MD",9/7/2023,DOCEtaxel 21 Day Cycles - Prostate,,8/29/2023,Inactive,,
CINJ OP INFUSION,22574,"Mayer, Tina M, MD",4/18/2024,CABAZItaxel / PredniSONE / CARBOplatin 21 Day Cycles - Prostate,_3. Third Line,4/2/2024,Inactive,,
CINJ OP INFUSION,22574,"Mayer, Tina M, MD",3/26/2025,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_4. Fourth Line,3/26/2025,Active,Prostate cancer (CMS/HCC),"C61 - Malignant neoplasm of prostate; G62.9 - Polyneuropathy, unspecified; D64.9 - Anemia, unspecified; C77.8 - Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions; Z79.899 - Other long term (current) drug therapy"
NBR CINJ OP INFUSION,82994,"Tiger, Yun Kyoung, MD",12/20/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_2. Second Line,12/19/2024,Active,,
CBMC OP INFUSION 2FL,10525,"Radovich, Delia, MD",12/6/2023,Ribociclib 28 Day Cycles - Breast,_1. First Line,12/6/2023,Inactive,,
CBMC OP INFUSION 2FL,10525,"Wagmiller, Jennifer Ann, MD",2/2/2024,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_1. First Line,1/28/2024,Inactive,,
CBMC OP INFUSION 2FL,10525,"Wagmiller, Jennifer Ann, MD",11/15/2024,Capivasertib 28 Day Cycles - Breast,_3. Third Line,11/15/2024,Inactive,,
CBMC OP INFUSION 2FL,31493,"Wagmiller, Jennifer Ann, MD",4/17/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,4/11/2025,Inactive,Breast cancer (CMS/HCC),"C50.919 - Malignant neoplasm of unspecified site of unspecified female breast; C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; D64.81 - Anemia due to antineoplastic chemotherapy; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.0 - Estrogen receptor positive status (ER+)"
CBMC 2W ONCOLOGY,45121,"Brown, Andrew Bennett, MD",2/26/2024,"VinORELBine D1, D8, D15, D22  28 Day Cycles- Non-Small Cell Lung Cancer",_2. Second Line,2/26/2024,Active,Endometrial ca (CMS/HCC),
NBR CINJ OP INFUSION,48310,"Shah, Mansi R, MD",5/15/2025,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,5/15/2025,Active,"Lymphadenopathy
Multiple myeloma not having achieved remission (CMS/HCC)
Immunocompromised patient (CMS/HCC)","D47.2 - Monoclonal gammopathy; C90.00 - Multiple myeloma not having achieved remission; B27.00 - Gammaherpesviral mononucleosis without complication; N17.9 - Acute kidney failure, unspecified; N18.9 - Chronic kidney disease, unspecified; Z94.0 - Kidney transplant status; N28.9 - Disorder of kidney and ureter, unspecified; Z94.83 - Pancreas transplant status; R59.1 - Generalized enlarged lymph nodes; D84.9 - Immunodeficiency, unspecified; Z86.39 - Personal history of other endocrine, nutritional and metabolic disease"
SOM OUTPT INFUSION,48948,"Patel, Eshan, MD",12/11/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/3/2023,Inactive,,
SOM OUTPT INFUSION,48948,"Patel, Eshan, MD",3/11/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/8/2024,Active,,
CMC OP INFUSION,38938,"Cohen, Seth D, MD",12/15/2023,CARBOplatin / Etoposide 21 Day Cycles - High Grade Neuroendocrine,_1. First Line,12/14/2023,Inactive,,
CMC OP INFUSION,38938,"Cohen, Seth D, MD",4/3/2024,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/2/2024,Inactive,,
CMC OP INFUSION,38938,"Cohen, Seth D, MD",6/26/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,6/24/2024,Inactive,,
JCMC CP INFUSION,81136,"Sekhri, Arunabh, MD",5/21/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,5/21/2025,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
CINJ OP INFUSION,60878,"Berim, Lyudmyla, MD",1/5/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,12/27/2023,Inactive,,
MMC BBR2 ONCOLOGY,10848,"Lee, Patrick C, MD",10/24/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Non-Small Cell Lung Cancer",_1. First Line,10/23/2023,Inactive,,
JCMC CP INFUSION,40307,"Sekhri, Arunabh, MD",7/3/2023,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,7/2/2023,Inactive,,
HAM OP INFUSION,64741,"Yogarajah, Meera, MD",2/6/2023,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,First Line,2/6/2023,Inactive,,
HAM OP INFUSION,64741,"Yogarajah, Meera, MD",3/13/2023,Single agent 5FU  14 Day Cycles- Gastrointestinal Cancers,Adjuvant,3/8/2023,Inactive,,
CBMC OP INFUSION 2FL,28316,"Leitner, Stuart P, MD",12/7/2023,Sipuleucel-T 14 Day Cycles - Prostate,_2. Second Line,12/7/2023,Inactive,,
CINJ OP INFUSION,10923,"Berim, Lyudmyla, MD",7/1/2024,FOLFIRI +Panitumumab,_2. Second Line,6/27/2024,Active,,
CINJ OP INFUSION,9654,"Haigentz, Missak, MD",1/14/2025,CINJ 032309 Arm 2 Pemetrexed / CARBOplatin 21 Day Cycles Research- Non-Small Cell Lung Cancer,Induction,1/14/2025,Active,,
CMC OP INFUSION,58073,"Saraiya, Biren P, MD",2/28/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,First Line,2/28/2023,Inactive,,
CINJ OP INFUSION,61061,"Boland, Patrick M, MD",8/11/2023,mFOLFOX6 + trastuzumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- GE Junction Cancers,_1. First Line,8/3/2023,Inactive,,
CINJ OP INFUSION,61061,"Boland, Patrick M, MD",1/14/2025,Ramucirumab / FOLFIRI (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan) 14 Day Cycles- GE Junction Cancers,_2. Second Line,1/6/2025,Active,,
NBI OP INFUSION,52452,"Jacoby, Sari H, MD",4/19/2024,Daratumumab and Hyaluronidase-fihj / Carfilzomib / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,4/8/2024,Active,,
NBI A5 PEDIATRICS,43508,"Batra, Surabhi, MD",12/23/2023,PEDS ANHL1131 Group B ,_1. First Line,12/23/2023,Inactive,,
NBI A5 PEDIATRICS,43508,"Batra, Surabhi, MD",5/20/2024,PEDS ANHL0121 ICE-R,_2. Second Line,5/19/2024,Inactive,,
NBR CINJ OP INFUSION,80800,"Palmisiano, Neil David, MD",1/15/2025,"CINJ 022204 Cohort 5 Single Agent LYT- 200 28 Day Cycles Research - Acute Myeloid Leukemia (AML), & MDS",_2. Second Line,1/15/2025,Inactive,Acute myeloid leukemia not having achieved remission (CMS/HCC),
CMC OP INFUSION,83979,"Talwar, Sumit, MD",1/31/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,1/23/2024,Inactive,,
SOM OUTPT INFUSION,46184,"George, Roshini, DO",5/2/2025,Pembrolizumab / Axitinib 21 Day Cycles - Kidney,_1. First Line,5/2/2025,Inactive,Malignant neoplasm of left kidney (CMS/HCC),
SOM OUTPT INFUSION,46184,"George, Roshini, DO",5/2/2025,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_1. First Line,5/2/2025,Active,Malignant neoplasm of left kidney (CMS/HCC),
CINJ OP INFUSION,5477,"Omene, Coral Oghenerukevwe, MD",6/25/2024,CINJ 042209 Arm B Endocrine Therapy of Physician's Choice 5 Year Treatment Research- Breast Cancer,Adjuvant,6/25/2024,Active,,
HAM OP INFUSION,46577,"Yogarajah, Meera, MD",12/6/2024,Selpercatinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/6/2024,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
CBMC OP INFUSION 2FL,178,"Wagmiller, Jennifer Ann, MD",7/20/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,7/19/2023,Inactive,,
HAM OP INFUSION,95825,"Patel, Malini M, MD",5/8/2023,PEMEtrexed/CARBOplatin (AUC 6) 21 Day Cycles- Non-Small Cell Lung Cancer ,Second Line,4/30/2023,Inactive,,
NBI OP INFUSION,39679,"Rao, Harini, MD",12/6/2023,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/6/2023,Active,,
NBI VALERIE FND HEMONC,79848,"Rao, Harini, MD",11/15/2023,Bevacizumab 28 Day Cycles - Kidney,Maintenance,11/15/2023,Active,,
NBI OP INFUSION,78668,"Cheng, Yan Ho, MD",5/28/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/27/2024,Inactive,,
NBI OP INFUSION,78668,"Cheng, Yan Ho, MD",6/11/2024,Pembrolizumab Q42 day / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,5/27/2024,Inactive,,
NBI OP INFUSION,78668,"Cheng, Yan Ho, MD",12/17/2024,Trifluridine and Tipiracil 28 Day Cycles- Gastrointestinal Cancers,_2. Second Line,12/17/2024,Active,Multiple myeloma without remission (CMS/HCC),
CBMC OP INFUSION 2FL,44272,"Wagmiller, Jennifer Ann, MD",4/26/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/25/2023,Inactive,,
NBR 4N ONCOLOGY,3989,"Zayac, Adam, MD",7/9/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Induction,7/9/2024,Inactive,,
NBR 5N ONCOLOGY,3989,"Tiger, Yun Kyoung, MD",7/13/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,7/13/2024,Inactive,,
CINJ OP INFUSION,53843,"Girda, Eugenia, MD",4/8/2025,PACLitaxel / CARBOplatin (AUC 5)/ AVASTIN added 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Neoadjuvant,4/8/2025,Active,Primary high grade serous adenocarcinoma of ovary (CMS/HCC),
MSC OP INFUSION,63316,"Cohen, Seth D, MD",1/23/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,1/17/2024,Inactive,,
MSC OP INFUSION,63316,"Cohen, Seth D, MD",5/8/2024,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,5/6/2024,Active,Adenocarcinoma of unknown primary (CMS/HCC),
CMC OP INFUSION,47081,"Talwar, Sumit, MD",7/31/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,7/30/2024,Active,,
CINJ OP INFUSION,96422,"Hochster, Howard S, MD",11/6/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,10/28/2024,Active,,
CINJ OP INFUSION,74253,"Weiss, Sarah, MD",4/11/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,4/11/2025,Active,Melanoma metastatic to lymph node (CMS/HCC),"C43.9 - Malignant melanoma of skin, unspecified; C77.3 - Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes; C77.9 - Secondary and unspecified malignant neoplasm of lymph node, unspecified"
MSC OP INFUSION,95162,"Cohen, Seth D, MD",3/8/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,3/7/2024,Inactive,,
MSC OP INFUSION,95162,"Cohen, Seth D, MD",3/8/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,3/8/2024,Inactive,,
MMC OP VP INFUSION,95162,"Cohen, Seth D, MD",5/21/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,_2. Second Line,5/17/2024,Inactive,,
MMC OP VP INFUSION,95162,"Cohen, Seth D, MD",5/21/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_2. Second Line,5/21/2024,Inactive,,
MSC OP INFUSION,95162,"Cohen, Seth D, MD",7/22/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,7/21/2024,Inactive,,
MMC OP VP INFUSION,95162,"Cohen, Seth D, MD",9/26/2024,Capecitabine / Ixabepilone 21 Day Cycles - Breast,_3. Third Line,9/25/2024,Inactive,,
MSC OP INFUSION,95162,"Cohen, Seth D, MD",1/23/2025,"Ixabepilone weekly Day 1,8,15 - 28 Day Cycles- Breast",Maintenance,1/22/2025,Active,,
CINJ OP INFUSION,46448,"Packiam, Vignesh, MD",9/23/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,9/16/2024,Inactive,,
CBMC OP INFUSION 2FL,65812,"Wagmiller, Jennifer Ann, MD",11/8/2023,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Neoadjuvant,11/6/2023,Inactive,,
CBMC OP INFUSION 2FL,65812,"Wagmiller, Jennifer Ann, MD",2/28/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,2/27/2024,Inactive,,
CBMC OP INFUSION 2FL,11571,"Wagmiller, Jennifer Ann, MD",1/20/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,1/19/2025,Active,Primary malignant neoplasm of pancreas with metastasis to other site (CMS/HCC),
CBMC OP INFUSION 2FL,11571,"Wagmiller, Jennifer Ann, MD",1/24/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,_1. First Line,1/20/2025,Active,Adenocarcinoma of prostate (CMS/HCC),
CBMC OP INFUSION 2FL,11571,"Wagmiller, Jennifer Ann, MD",2/14/2025,Trastuzumab 21 Day Cycles (Initiation) - Breast,_1. First Line,1/19/2025,Active,"Malignant neoplasm of corpus uteri, unspecified (CMS/HCC)","C50.011, Z17.0 - Malignant neoplasm of nipple of right breast in female, estrogen receptor positive (CMS/HCC)"
HAM OP INFUSION,77763,"Patel, Malini M, MD",1/14/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,1/13/2025,Active,,
CBMC OP INFUSION 2FL,60176,"Brown, Andrew Bennett, MD",11/15/2023,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer or CNS,_2. Second Line,11/14/2023,Active,,
NBR 5N MED-SURG OVRF,94084,"Alexander, Henry Richard, MD",1/9/2025,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,_1. First Line,1/9/2025,Active,,
CMC OP INFUSION,92213,"Taff, Jessica, MD",12/5/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/4/2023,Active,,
CBMC OP INFUSION 2FL,95253,"Dharmapuri, Sirish, MD",11/5/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,10/22/2024,Active,,
CINJ OP INFUSION,64664,"Gulhati, Prateek, MD PhD",3/13/2025,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,3/13/2025,Active,Colon cancer (CMS/HCC),"R97.0 - Elevated carcinoembryonic antigen (CEA); T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; C18.9 - Malignant neoplasm of colon, unspecified"
CBMC OP INFUSION 2FL,86897,"Dharmapuri, Sirish, MD",11/8/2024,FOLFOX,_1. First Line,10/6/2024,Active,,
NBI OP INFUSION,85586,"Shah, Shailja S, MD",4/15/2025,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,4/15/2025,Inactive,Small cell lung cancer (CMS/HCC),R91.8 - Other nonspecific abnormal finding of lung field; C79.31 - Secondary malignant neoplasm of brain; R53.83 - Other fatigue
NBI OP INFUSION,22733,"Shah, Shailja S, MD",10/31/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Maintenance,10/30/2023,Inactive,,
NBI OP INFUSION,22733,"Shah, Shailja S, MD",4/23/2024,"Roswell Park Leucovorin/Fluorouracil 42 Day Cycles, 4 Weeks On, 2 Weeks Off - Colon Cancer",Maintenance,4/22/2024,Inactive,,
NBI OP INFUSION,22733,"Shah, Shailja S, MD",8/13/2024,Irinotecan and Bevacizumab(Mvasi ) q14days,_3. Third Line,8/12/2024,Active,,
NBI OP INFUSION,35999,"Shah, Shailja S, MD",2/4/2025,Irinotecan + Bevacizumab( MVASI) 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,2/3/2025,Active,Colon cancer metastasized to liver (CMS/HCC),"C18.9 - Malignant neoplasm of colon, unspecified; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct"
CINJ OP INFUSION,74299,"Haigentz, Missak, MD",1/22/2024,"PACLitaxel / CARBOplatin, PLUS PEMBROLIZUMAB  21 Day Cycles - Head Neck",_1. First Line,1/22/2024,Inactive,,
CINJ OP INFUSION,74299,"Haigentz, Missak, MD",5/14/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,5/13/2024,Active,,
CINJ OP INFUSION,74299,"Haigentz, Missak, MD",1/15/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Head and Neck Cancer,Maintenance,1/15/2025,Active,,
CINJ OP INFUSION,74299,"Haigentz, Missak, MD",4/15/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Maintenance,4/15/2025,Inactive,"Secondary malignant neoplasm of lung (CMS/HCC)
Malignant neoplasm oropharynx (CMS/HCC)
Chronic fatigue","Z51.11 - Encounter for antineoplastic chemotherapy; C08.9 - Malignant neoplasm of major salivary gland, unspecified; C78.01 - Secondary malignant neoplasm of right lung; C78.02 - Secondary malignant neoplasm of left lung; C10.9 - Malignant neoplasm of oropharynx, unspecified; C79.51 - Secondary malignant neoplasm of bone; E11.9 - Type 2 diabetes mellitus without complications; I10 - Essential (primary) hypertension; Z92.21 - Personal history of antineoplastic chemotherapy; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence"
MMC OP INFUSION,73702,"Meghal, Trishala, MD",3/26/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Neoadjuvant,3/25/2024,Inactive,,
MMC OP VP INFUSION,73702,"Meghal, Trishala, MD",6/18/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Adjuvant,6/16/2024,Inactive,,
MMC OP VP INFUSION,73702,"Meghal, Trishala, MD",12/20/2024,CINJ 042312 Arm A Endocrine Therapy Investigator's Choice +/- Abemaciclib +/- LHRH Agonist 90 / 180 Day Cycles Research- Breast Cancer,Adjuvant,12/20/2024,Active,,
MMC OP INFUSION,73702,"Meghal, Trishala, MD",1/22/2025,Abemaciclib 28 Day Cycles - Breast,Adjuvant,1/22/2025,Active,,
CINJ OP INFUSION,70308,"Hochster, Howard S, MD",6/21/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,6/20/2023,Inactive,,
CINJ OP INFUSION,70308,"Hochster, Howard S, MD",12/6/2023,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,12/5/2023,Inactive,,
CINJ OP INFUSION,70308,"Hochster, Howard S, MD",4/10/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,4/10/2024,Active,,
CINJ OP INFUSION,77492,"Hochster, Howard S, MD",2/6/2025,CINJ 072404 Stage 1 ABBV-400 2 mg/kg 21 Day Cycles Research- Colorectal Cancer,_3. Third Line,2/6/2025,Active,"Adenocarcinoma of rectosigmoid junction (CMS/HCC)
Abnormal findings on diagnostic imaging of other parts of digestive tract
Abnormal coagulation profile
Hypercholesterolemia",
NBR MEDICAL SAME DAY,99250,"Ghodoussipour, Saum Bobak, MD",4/22/2025,Gemcitabine Intravesical Single Dose - Bladder,Adjuvant,4/22/2025,Active,Urothelial carcinoma (CMS/HCC),
CINJ OP INFUSION,99142,"Goel, Sanjay, MD",1/6/2025,CINJ 052212 Phase 1b Expansion RO7502175 / Atezolizumab 21 Day Cycles- Advanced or Metastatic Solid Tumors,_5. Fifth Line,1/6/2025,Inactive,Non-small cell cancer of right lung (CMS/HCC),
MMC OP INFUSION,98585,"Meghal, Trishala, MD",4/28/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,4/27/2023,Inactive,,
MMC OP INFUSION,98585,"Meghal, Trishala, MD",5/19/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,5/19/2023,Inactive,,
CINJ OP INFUSION,74454,"George, Mridula A, MD",10/23/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,10/23/2024,Active,,
MMC OP VP INFUSION,87283,"Cohen, Seth D, MD",8/30/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",,8/29/2023,Inactive,,
MMC OP VP INFUSION,87283,"Cohen, Seth D, MD",9/20/2023,Albumin-Bound PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,First Line,9/19/2023,Inactive,,
MMC OP VP INFUSION,87283,"Cohen, Seth D, MD",12/13/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/12/2023,Inactive,,
MMC OP VP INFUSION,10489,"Meghal, Trishala, MD",10/13/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,10/12/2023,Inactive,,
CMC OP INFUSION,31360,"Talwar, Sumit, MD",10/2/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Adjuvant,10/1/2023,Inactive,,
CBMC OP INFUSION 2FL,80565,"Scoppetuolo, Michael, MD",2/14/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,2/13/2023,Active,,
SOM OUTPT INFUSION,96330,"Matasar, Matthew J, MD",2/19/2024,Zanubrutinib (160 mg) 30 Day Cycles - Marginal cell Lymphoma,_2. Second Line,2/19/2024,Active,Malignant neoplasm of overlapping sites of left bronchus and lung (CMS/HCC),
MMC OP INFUSION,68808,"Meghal, Trishala, MD",9/5/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,9/5/2024,Active,,
NBI OP INFUSION,7885,"Anderson, Patrick S, MD",9/12/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles-  cervicalk cancer,_1. First Line,9/11/2024,Active,,
CINJ OP INFUSION,47627,"Boland, Patrick M, MD",4/21/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,4/21/2025,Active,Malignant neoplasm of rectum (CMS/HCC),C20 - Malignant neoplasm of rectum
NBI OP INFUSION,53025,"Schleicher, Lori, MD",4/19/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,4/18/2023,Inactive,,
JCMC CP INFUSION,75621,"Sekhri, Arunabh, MD",10/4/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Second Line,9/21/2023,Inactive,,
JCMC CP INFUSION,75621,"Sekhri, Arunabh, MD",5/16/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Metastatic Ovarian Cancer,_2. Second Line,5/7/2024,Inactive,,
NBI OP INFUSION,68568,"Jacoby, Sari H, MD",3/4/2025,Bendamustine / RiTUXimab 28 Day Cycles - Mantle Cell Lymphoma,_1. First Line,3/4/2025,Active,Mantle cell lymphoma of lymph nodes of multiple regions (CMS/HCC),"C83.18 - Mantle cell lymphoma, lymph nodes of multiple sites"
CINJ OP INFUSION,36734,"Weiss, Sarah, MD",8/30/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,8/27/2024,Active,,
CINJ OP INFUSION,622,"Boland, Patrick M, MD",7/11/2023,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,,7/11/2023,Inactive,,
CINJ OP INFUSION,622,"Boland, Patrick M, MD",5/10/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,5/9/2024,Inactive,,
CINJ OP INFUSION,21972,"Berim, Lyudmyla, MD",11/30/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/29/2023,Active,,
CINJ OP INFUSION,21972,"Berim, Lyudmyla, MD",2/24/2025,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,_2. Second Line,2/24/2025,Active,Rectal cancer (CMS/HCC),C20 - Rectal cancer (CMS/HCC)
CINJ OP INFUSION,91653,"Berim, Lyudmyla, MD",5/30/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,5/30/2025,Active,Rectal cancer (CMS/HCC),C20 - Rectal cancer (CMS/HCC)
CINJ OP INFUSION,66126,"Stephenson, Ryan D, DO",8/8/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,7/31/2024,Active,,
CINJ OP INFUSION,28277,"Mayer, Tina M, MD",9/27/2024,EP (CISplatin / Etoposide) 21 Day Cycles - Testicular,_1. First Line,9/26/2024,Active,,
MMC BBR2 ONCOLOGY,81529,"Lee, Patrick C, MD",7/14/2023,TIP (PACLitaxel / Ifosfamide / CISplatin) 21 Day Cycles - Testicular,,7/13/2023,Inactive,,
CBMC OP INFUSION 2FL,53287,"Leitner, Stuart P, MD",6/24/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,6/23/2024,Inactive,,
NBR 5N ONCOLOGY,93047,"Desai, Sahaj, MD",7/31/2024,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,_1. First Line,7/31/2024,Inactive,,
CINJ OP INFUSION,89494,"Saraiya, Biren P, MD",4/18/2023,CINJ 051709 BRCA1 / BRCA2 Mutations Pembrolizumab 200 mg IV D1 21 Day Cycles Research- Basket Trial for Advanced Solid Tumors,Third Line,4/17/2023,Inactive,,
JCMC CP INFUSION,15776,"Sekhri, Arunabh, MD",12/31/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- head and neck,_1. First Line,12/30/2024,Inactive,,
JCMC CP INFUSION,15776,"Sekhri, Arunabh, MD",1/6/2025,Pembrolizumab/CARBOplatin/Fluorouracil 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/5/2025,Active,,
CBMC OP INFUSION 2FL,97325,"Raptis, George, MD",2/11/2025,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/30/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",
CBMC OP INFUSION 2FL,97325,"Raptis, George, MD",5/8/2025,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,5/8/2025,Active,"Malignant neoplasm of right breast in female, estrogen receptor positive (CMS/HCC)",
JCMC CP INFUSION,798,"Cruz, Allan Louie E, MD",2/27/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Induction,2/26/2025,Active,"Malignant neoplasm of anus, unspecified (CMS/HCC)",
JCMC CP INFUSION,798,"Cruz, Allan Louie E, MD",3/3/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Induction,3/3/2025,Inactive,"Malignant neoplasm of anus, unspecified (CMS/HCC)",
JCMC CP INFUSION,798,"Cruz, Allan Louie E, MD",3/3/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Induction,2/27/2025,Inactive,"Malignant neoplasm of anus, unspecified (CMS/HCC)",
CINJ OP INFUSION,18393,"Stephenson, Ruth D, DO",4/14/2023,Cyclophosphamide Oral / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,4/13/2023,Inactive,,
CINJ OP INFUSION,18393,"Stephenson, Ruth D, DO",8/3/2023,Liposomal Doxorubicin / CISplatin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,8/2/2023,Inactive,,
CINJ OP INFUSION,18393,"Stephenson, Ruth D, DO",1/31/2024,CINJ 102303 ARM A Relacorilant / Nab-PACLitaxel 28 Day Cycles Research- Gynecological Malignancies,_4. Fourth Line,1/18/2024,Inactive,,
CINJ OP INFUSION,18393,"Stephenson, Ruth D, DO",6/18/2024,"CINJ 102302 ARM 1 Phase 2 ACR-368 - Ovarian, Endometrial, Urothelial Cancer",_5. Fifth Line,6/18/2024,Inactive,,
CINJ OP INFUSION,18393,"Stephenson, Ruth D, DO",12/4/2024,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_4. Fourth Line,12/3/2024,Active,,
CINJ OP INFUSION,42306,"Haigentz, Missak, MD",2/24/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,2/23/2025,Active,Squamous cell cancer of skin of nose,C44.321 - Squamous cell carcinoma of skin of nose; Z48.89 - Encounter for other specified surgical aftercare
MMC OP INFUSION,23794,"Lee, Patrick C, MD",4/4/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,Induction,3/31/2024,Inactive,,
MMC OP INFUSION,23794,"Lee, Patrick C, MD",7/2/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,7/1/2024,Inactive,,
MMC OP INFUSION,23794,"Lee, Patrick C, MD",12/24/2024,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/16/2024,Active,,
MMC OP INFUSION,23794,"Lee, Patrick C, MD",1/14/2025,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,12/16/2024,Active,,
HAM OP INFUSION,25716,"Yogarajah, Meera, MD",5/19/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/19/2025,Active,Cancer of antrum of stomach (CMS/HCC),"C16.9 - Malignant neoplasm of stomach, unspecified; K31.89 - Other diseases of stomach and duodenum; K21.9 - Gastro-esophageal reflux disease without esophagitis; H40.9 - Unspecified glaucoma; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,82374,"Mayer, Tina M, MD",11/14/2023,Enzalutamide 28 Day Cycles - Prostate,_2. Second Line,11/14/2023,Active,,
CINJ OP INFUSION,20768,"George, Mridula A, MD",2/28/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,2/28/2025,Active,"Malignant neoplasm involving both nipple and areola of right breast in female, estrogen receptor positive (CMS/HCC)","C50.011, Z17.0 - Malignant neoplasm involving both nipple and areola of right breast in female, estrogen receptor positive (CMS/HCC)"
HAM OP INFUSION,99051,"Yogarajah, Meera, MD",9/24/2024,PACLitaxel / CARBOplatin 21 Day Cycles - Cervical ,_2. Second Line,9/16/2024,Active,,
HAM OP INFUSION,714,"Yogarajah, Meera, MD",2/27/2025,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_3. Third Line,2/26/2025,Active,Vulvar cancer (CMS/HCC),
HAM OP INFUSION,714,"Yogarajah, Meera, MD",3/13/2025,Tisotumab vedotin-tftv 21 Day Cycles - Cervical,_3. Third Line,3/13/2025,Active,Vulvar cancer (CMS/HCC),
CBMC OP INFUSION 2FL,98735,"Phillips, Adrienne A, MD",3/20/2024,Mosunetuzumab-axgb 21 Day Cycles - Follicular Lymphoma,_3. Third Line,3/19/2024,Inactive,,
CINJ OP INFUSION,36169,"Ghodoussipour, Saum Bobak, MD",7/26/2023,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,7/26/2023,Inactive,,
CINJ OP INFUSION,36169,"Ghodoussipour, Saum Bobak, MD",11/7/2023,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,11/7/2023,Inactive,,
MMC OP VP INFUSION,94982,"Cohen, Seth D, MD",1/23/2024,CINJ 072301 CTX-009 28 Day Cycles Research- Colon Cancer,_3. Third Line,1/23/2024,Inactive,,
MMC OP VP INFUSION,94982,"Cohen, Seth D, MD",8/12/2024,Regorafenib 28 Day Cycles- Gastrointesinal Cancers,_4. Fourth Line,8/12/2024,Inactive,,
NBR 4N ONCOLOGY,92204,"Goel, Sanjay, MD",4/5/2023,R7075-ONC-2009 / CINJ 052008 Dose Level 9* REGN7075 / Cemiplimab 350 mg 21 Day Cycles Combination Research- Solid Tumors,Third Line,2/22/2023,Active,,
CINJ OP INFUSION,98650,"Weiss, Sarah, MD",4/17/2023,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,Adjuvant,4/9/2023,Inactive,,
NBI OP INFUSION,50583,"Cheng, Yan Ho, MD",8/15/2023,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,8/14/2023,Inactive,,
NBI OP INFUSION,50583,"Cheng, Yan Ho, MD",1/6/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,1/6/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),
NBI OP INFUSION,6063,"Cheng, Yan Ho, MD",5/13/2025,Capecitabine 21 Day Cycles - Breast,_3. Third Line,5/13/2025,Active,Metastasis from malignant neoplasm of breast (CMS/HCC),
SOM OUTPT INFUSION,65039,"Patel, Eshan, MD",3/16/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,,3/13/2023,Inactive,,
NBI OP INFUSION,41259,"Cheng, Yan Ho, MD",9/12/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,9/12/2023,Active,,
MMC OP VP INFUSION,97037,"Lee, Patrick C, MD",7/23/2024,Temozolomide with Concurrent Radiation 42 Day Cycle - CNS,_1. First Line,7/23/2024,Inactive,,
MMC OP INFUSION,97037,"Lee, Patrick C, MD",10/9/2024,Bevacizumab 28 Day Cycles - CNS,_1. First Line,10/9/2024,Active,,
NBI OP INFUSION,98588,"Schleicher, Lori, MD",7/12/2023,Pembrolizumab 21 Day Cycles - Bladder or Kidney,Adjuvant,7/12/2023,Active,"Malignant neoplasm of breast in female, estrogen receptor positive (CMS/HCC)",
HAM OP INFUSION,71611,"Gendy, Mina, DO",5/20/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,5/20/2025,Active,Malignant neoplasm of other parts of pancreas (CMS/HCC),
HAM OP INFUSION,71611,"Gendy, Mina, DO",3/25/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,3/25/2025,Inactive,Malignant neoplasm of other parts of pancreas (CMS/HCC),
HAM OP INFUSION,71611,"Hochster, Howard S, MD",3/19/2025,"CINJ 072011 (ALTPANC) FOLFOXIRI D1, D15 Odd Cycles / Gemcitabine and Nab-PACLitaxel Even Cycles D1, D15 28 Day Cycles Research- Pancreatic Adenocarcinoma",_1. First Line,3/19/2025,Inactive,Malignant neoplasm of other parts of pancreas (CMS/HCC),
CINJ OP INFUSION,89015,"Stephenson, Ryan D, DO",2/5/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,2/4/2024,Active,,
CINJ OP INFUSION,9689,"Omene, Coral Oghenerukevwe, MD",9/18/2023,Palbociclib 28 Day Cycles - Breast,,9/18/2023,Active,,
CINJ OP INFUSION,20523,"Girda, Eugenia, MD",4/29/2024,Pembrolizumab 21 Day Cycles - Cervical,_1. First Line,4/9/2024,Inactive,,
CINJ OP INFUSION,20523,"Girda, Eugenia, MD",4/29/2024,CARBOplatin Weekly / RT,_1. First Line,4/26/2024,Inactive,,
CINJ OP INFUSION,20523,"Girda, Eugenia, MD",1/23/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_2. Second Line,1/13/2025,Active,,
MMC OP VP INFUSION,62871,"Lee, Patrick C, MD",6/13/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,6/11/2024,Active,,
CBMC OP INFUSION 2FL,3825,"Wagmiller, Jennifer Ann, MD",10/31/2023,Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,12/17/2019,Active,,
NBR 5N ONCOLOGY,22784,"Girda, Eugenia, MD",8/16/2023,"CINJ 192004 (Inpatient) Lymphodepletion Fludarabine / Cyclophosphamide + KK-LC-TCR-T Cells 6 Day Cycle Research- Cancers of the Stomach, Breast, Cervix and Lung",Third Line,8/7/2023,Inactive,,
CBMC OP INFUSION 2FL,58900,"Litvak, Anna M, MD",5/8/2025,Albumin-Bound PACLitaxel 28 Day Cycles - Breast,_1. First Line,5/3/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",
CMC OP INFUSION,43535,"Cohen, Seth D, MD",6/6/2024,Enfortumab vedotin-ejfv + Pembrolizumab 21 Day Cycles- Bladder Cancer,_1. First Line,6/2/2024,Inactive,,
SOM OUTPT INFUSION,45919,"Patel, Eshan, MD",7/3/2023,mFu- Outpatient (Fluorouracil Continuous Infusion/Leucovorin/) 14 Day Cycles- Gastrointestinal Cancers,First Line,5/28/2023,Inactive,,
CBMC OP INFUSION 2FL,90268,"Dave, Manish, MD",9/29/2023,Carfilzomib 27 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,9/28/2023,Inactive,,
CINJ OP INFUSION,49233,"Saraiya, Biren P, MD",3/15/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,First Line,3/15/2023,Inactive,,
NBR BMSCH 2 PED HEMONC,49349,"Goyal-Khemka, Meenakshi, MD",11/13/2023,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,11/13/2023,Inactive,,
TRMC TCCC OP INFUSION,9292,"Capo, Gerardo, MD",1/5/2024,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/4/2024,Active,,
CMC OP INFUSION,93483,"Cohen, Seth D, MD",3/11/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,3/5/2024,Inactive,,
MMC OP VP INFUSION,93483,"Cohen, Seth D, MD",12/11/2024,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,11/18/2024,Active,,
CINJ OP INFUSION,44811,"Boland, Patrick M, MD",1/28/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,1/20/2025,Active,,
CBMC OP INFUSION 2FL,38968,"Scoppetuolo, Michael, MD",11/9/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,11/9/2023,Active,,
SOM OUTPT INFUSION,9896,"Yin, Faye, MD",8/14/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,8/13/2023,Inactive,,
CMC OP INFUSION,3841,"Easaw, Sarah, MD",7/25/2023,DOCEtaxel / PredniSONE 21 Day Cycles - Prostate,First Line,7/24/2023,Inactive,,
NBR 4N ONCOLOGY,23796,"Rhodes, Joanna Meehan, MD",3/14/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,3/13/2024,Inactive,,
NBR 4N ONCOLOGY,23796,"Rhodes, Joanna Meehan, MD",3/14/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,_1. First Line,3/13/2024,Inactive,,
NBR 4N BMTU/IMCU,72731,"Assal, Amer, MD",12/22/2023,BMT Autologous Melphalan Day -1 140MG/M2,_2. Second Line,12/20/2023,Inactive,,
CINJ OP INFUSION,28081,"Weiss, Sarah, MD",9/19/2024,CINJ 092302 Cohort 2 Propranolol / Naltrexone 4.5 mg + Nivolumab (1 mg/kg) / Ipilimumab (3 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles Research Melanoma,_1. First Line,9/18/2024,Inactive,,
CINJ OP INFUSION,28081,"Weiss, Sarah, MD",9/20/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,9/18/2024,Inactive,,
HAM OP INFUSION,49599,"Patel, Malini M, MD",8/13/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,8/12/2024,Active,,
HAM OP INFUSION,15818,"Patel, Malini M, MD",1/17/2023,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,First Line,1/16/2023,Inactive,,
HAM OP INFUSION,15818,"Patel, Malini M, MD",6/16/2023,"Nivolumab 240 mg D1, D15 28 Day Cycles- Head and Neck Cancers",Second Line,6/12/2023,Inactive,,
CINJ OP INFUSION,74236,"Muralikrishnan, Sivraj, MD",1/24/2025,Paclitaxel 200 mg/m2 / CARBOplatin (AUC 5) / Cemiplimab-rwlc 21 Day Cycles- Non-Small Cell Lung Cancer NSC 121,_1. First Line,1/8/2025,Active,,
JCMC CP INFUSION,7028,"Cruz, Allan Louie E, MD",3/25/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/25/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,7028,"Cruz, Allan Louie E, MD",3/25/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,3/25/2025,Inactive,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,37688,"Cruz, Allan Louie E, MD",10/23/2023,CINJ 032201 ARM 2 Pemetrexed / CARBOplatin / Pembrolizumab Alternating with Pembrolizumab Alone 21 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,10/18/2023,Inactive,,
JCMC CP INFUSION,37688,"Cruz, Allan Louie E, MD",11/9/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,11/8/2023,Inactive,,
CBMC OP INFUSION 2FL,16355,"Scoppetuolo, Michael, MD",5/15/2024,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/15/2024,Inactive,,
CBMC OP INFUSION 2FL,16355,"Scoppetuolo, Michael, MD",5/15/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/7/2024,Inactive,,
CMC OP INFUSION,60692,"Cohen, Seth D, MD",5/31/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Advanced, Recurrent, Metastatic)",_1. First Line,5/20/2024,Inactive,,
HAM OP INFUSION,74779,"Yogarajah, Meera, MD",6/19/2023,Capecitabine 21 Day Cycles - Breast,Second Line,6/19/2023,Inactive,,
NBI OP INFUSION,33781,"Shah, Maya M, MD",1/10/2024,Daratumumab / Bortezomib / Lenalidomide / Dexamethasone 21 Day Cycles + Maintenance 28 Day Cycles - Multiple Myeloma,_1. First Line,1/2/2024,Active,,
JCMC CP INFUSION,35488,"Sekhri, Arunabh, MD",7/12/2024,Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,7/7/2024,Active,,
JCMC CP INFUSION,35488,"Sekhri, Arunabh, MD",2/19/2025,Capecitabine 21 Day Cycles - Breast,Adjuvant,2/19/2025,Active,Malignant neoplasm of unspecified site of right female breast (CMS/HCC),"C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; I63.9 - Cerebral infarction, unspecified; C50.911 - Malignant neoplasm of unspecified site of right female breast; Z17.1 - Estrogen receptor negative status (ER-)"
CBMC 2W ONCOLOGY,66591,"Grossman, I Robert, MD",7/24/2024,R-GCVP (Gemcitabine / Cyclophosphamide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/23/2024,Inactive,,
CBMC OP INFUSION 2FL,65633,"Dharmapuri, Sirish, MD",8/20/2024,CISplatin + Gemcitabine + Durvalumab 21 Day Cycles - Cholangiocarcinoma,_1. First Line,8/14/2024,Active,,
NBI VALERIE FND HEMONC,31075,"de Benedictis, Marianna, MD",10/16/2024,RiTUXimab Initial Infusion Single Day (Outpatient),_2. Second Line,10/16/2024,Active,Malignant neoplasm of upper lobe of right lung (CMS/HCC),
CINJ OP INFUSION,31276,"Ghodoussipour, Saum Bobak, MD",1/18/2023,Gemcitabine Intravesical / DOCEtaxel Intravesical 28 Day Cycles - Bladder,Maintenance,1/17/2023,Inactive,,
CINJ OP INFUSION,52959,"Haigentz, Missak, MD",1/13/2025,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Salivary Duct Carcinoma,Adjuvant,1/13/2025,Active,,
MMC OP VP INFUSION,23808,"Eltoukhy, Hussam, MD",7/25/2023,Bortezomib Weekly/Dexamethasone/Cyclophosphamide Oral 28 Day Cycles- Multiple Myeloma,First Line,7/24/2023,Inactive,,
MMC OP VP INFUSION,23808,"Eltoukhy, Hussam, MD",9/22/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,First Line,9/21/2023,Active,,
CBMC OP INFUSION 2FL,75538,"Phillips, Adrienne A, MD",7/10/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,6/18/2024,Active,,
NBR CINJ OP INFUSION,99986,"Assal, Amer, MD",4/15/2024,Bortezomib / RiTUXimab / IVIG- For Donor Specific Anti-HLA Antibodies (DSA),_1. First Line,4/14/2024,Inactive,,
NBR CINJ OP INFUSION,99986,"Assal, Amer, MD",6/21/2024,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_2. Second Line,6/20/2024,Inactive,,
NBR 5N ONCOLOGY,25886,"Haigentz, Missak, MD",6/15/2024,DOCEtaxel 75 mg/m2/ CISplatin 75 mg/m2/ Fluorouracil Continuous Infusion (4 Days) 21 Day Cycles- Head and Neck Cancers,_1. First Line,6/15/2024,Active,,
CINJ OP INFUSION,25886,"Haigentz, Missak, MD",9/23/2024,CARBOplatin with Concurrent Radiation 7 Day Cycles- Head and Neck Cancers,Consolidation,9/22/2024,Active,,
NBR 4N ONCOLOGY,13665,"Braunschweig, Ira, MD",2/11/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,2/10/2023,Inactive,,
NBR CINJ OP INFUSION,13665,"Braunschweig, Ira, MD",5/4/2023,Lymphodepletion Abecma 6 Day Cycle - Multiple Myeloma,,4/25/2023,Inactive,,
CBMC OP INFUSION 2FL,75333,"Derosa, William T, DO",1/16/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,1/12/2025,Active,,
JCMC CP INFUSION,50815,"Sekhri, Arunabh, MD",3/21/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,69926,"Dharmapuri, Sirish, MD",4/7/2025,"Capecitabine + Temozolomide 28 Day Cycles - Neuroendocrine Tumor of the GI, Lung, and Thymus",_1. First Line,4/7/2025,Active,Neuroendocrine tumor,D3A.8 - Neuroendocrine tumor
CINJ OP INFUSION,42487,"Berim, Lyudmyla, MD",11/15/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,11/2/2023,Active,,
CINJ OP INFUSION,51788,"Boland, Patrick M, MD",5/5/2023,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",,5/3/2023,Inactive,,
CINJ OP INFUSION,51788,"Boland, Patrick M, MD",3/11/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Consolidation,3/11/2024,Inactive,,
MMC OP VP INFUSION,22399,"Lee, Patrick C, MD",5/5/2025,Capecitabine 1250 mg/m2 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,5/5/2025,Inactive,Carcinoma of gall bladder (CMS/HCC),"D72.829 - Leukocytosis, unspecified type; D64.9 - Anemia, unspecified type"
CINJ OP INFUSION,86239,"Groisberg, Roman, MD",7/24/2023,AIM Intensified (DOXOrubicin / Ifosfamide / Mesna) 21 Day Cycles - Sarcoma,Neoadjuvant,7/24/2023,Inactive,,
CBMC OP INFUSION 2FL,80031,"Dharmapuri, Sirish, MD",11/8/2024,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,11/7/2024,Inactive,,
JCMC CP INFUSION,57941,"Cruz, Allan Louie E, MD",4/24/2025,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/17/2025,Active,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,57941,"Cruz, Allan Louie E, MD",4/24/2025,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Neoadjuvant,4/24/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of right breast in female, estrogen receptor positive (CMS/HCC)",C50.211 - Malignant neoplasm of upper-inner quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+)
JCMC CP INFUSION,43489,"Cruz, Allan Louie E, MD",4/20/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Neoadjuvant,4/19/2023,Inactive,,
TRMC TCCC OP INFUSION,83305,"Capo, Gerardo, MD",11/15/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/22/2024,Inactive,,
CBMC OP INFUSION 2FL,27593,"Litvak, Anna M, MD",10/6/2023,Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel weekly 21 Day Cycles - Breast,_2. Second Line,10/5/2023,Inactive,,
CBMC OP INFUSION 2FL,27593,"Leitner, Stuart P, MD",1/11/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,1/10/2024,Active,"Pulmonary embolism (CMS/HCC)
Peritoneal carcinomatosis (CMS/HCC)
Metastatic disease (CMS/HCC)
Iron deficiency anemia
Carcinomatosis (CMS/HCC)",
SOM OUTPT INFUSION,20716,"Toomey, Kathleen C, MD",7/6/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,First Line,6/6/2023,Inactive,,
SOM OUTPT INFUSION,20716,"Toomey, Kathleen C, MD",8/25/2023,"Durvalumab D1, D15  28 Day Cycles- Non-Small Cell Lung Cancer",,8/23/2023,Inactive,,
SOM OUTPT INFUSION,20716,"Toomey, Kathleen C, MD",10/5/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,Neoadjuvant,10/4/2023,Inactive,,
CMC OP INFUSION,72367,"Pompa, Tiffany Ann, MD",10/25/2024,Pembrolizumab 21 Day Cycles - Melanoma,Adjuvant,10/3/2024,Active,,
CMC OP INFUSION,72367,"Pompa, Tiffany Ann, MD",3/6/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,3/6/2025,Active,Malignant melanoma of other part of trunk (CMS/HCC),
NBI OP INFUSION,47163,"Schleicher, Lori, MD",1/3/2024,Pembrolizumab + PACLitaxel + CARBOplatin Every 21 Day X 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day X 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,1/2/2024,Active,,
NBI OP INFUSION,47163,"Schleicher, Lori, MD",5/30/2025,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,5/30/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor negative (CMS/HCC)",
NBI OP INFUSION,51124,"Jacoby, Sari H, MD",9/20/2024,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_1. First Line,9/19/2024,Active,,
CMC OP INFUSION,69517,"Talwar, Sumit, MD",5/2/2023,"Gemcitabine (D1, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",Maintenance,4/21/2023,Inactive,,
CMC OP INFUSION,69517,"Tang, Horace, MD",1/30/2024,Gemcitabine 21 Day Cycles,_2. Second Line,1/30/2024,Active,,
CINJ OP INFUSION,4224,"Saraiya, Biren P, MD",8/29/2023,DOCEtaxel / CARBOplatin 21 Day Cycles - Prostate,Second Line,8/28/2023,Inactive,,
NBI OP INFUSION,31343,"Cheng, Yan Ho, MD",3/25/2024,CINJ 032304 Arm B Pembrolizumab / Ramucirumab 21 Day Cycles Research- Non-Small Cell Lung Cancer,_2. Second Line,3/24/2024,Active,,
NBI OP INFUSION,72366,"Cheng, Yan Ho, MD",2/1/2024,Enzalutamide 28 Day Cycles - Prostate,_1. First Line,2/1/2024,Active,,
SOM OUTPT INFUSION,45384,"Toomey, Kathleen C, MD",4/6/2023,Pembrolizumab 21 Day Cycles - Bladder or Breast,Adjuvant,4/5/2023,Inactive,,
MMC OP VP INFUSION,37230,"Talwar, Sumit, MD",10/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Adjuvant,10/22/2024,Inactive,,
CMC OP INFUSION,37230,"Pompa, Tiffany Ann, MD",11/21/2024,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,11/20/2024,Inactive,,
CMC OP INFUSION,37230,"Pompa, Tiffany Ann, MD",11/21/2024,Trastuzumab 21 Day Cycles (Initiation) - Breast,Adjuvant,11/20/2024,Active,Urothelial cancer (CMS/HCC),
CBMC OP INFUSION 2FL,37491,"Dharmapuri, Sirish, MD",4/23/2025,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) 21 Day Cycles- Gastrointestinal Cancers,Adjuvant,4/23/2025,Active,Malignant neoplasm of ascending colon (CMS/HCC),C18.2 - Malignant neoplasm of ascending colon
NBI OP INFUSION,49435,"Shah, Shailja S, MD",5/19/2025,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,5/19/2025,Inactive,Myelodysplastic syndrome (CMS/HCC),"D46.9 - Myelodysplastic syndrome, unspecified"
NBI OP INFUSION,49435,"Shah, Shailja S, MD",5/19/2025,AzaCITIDine (Post Transplant) 28 Day Cycle - Acute Myeloid Leukemia / MDS,_1. First Line,5/19/2025,Inactive,Myelodysplastic syndrome (CMS/HCC),"D46.9 - Myelodysplastic syndrome, unspecified"
SOM OUTPT INFUSION,2819,"Patel, Eshan, MD",4/20/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,4/19/2023,Inactive,,
SOM OUTPT INFUSION,2819,"Patel, Eshan, MD",8/24/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,8/23/2023,Inactive,,
SOM OUTPT INFUSION,2819,"Patel, Eshan, MD",11/30/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/24/2023,Active,,
NBR 4N ONCOLOGY,1594,"Braunschweig, Ira, MD",9/7/2023,BMT Autologous Melphalan Day -1  200mg/m2,,9/5/2023,Inactive,,
NBR CINJ OP INFUSION,1594,"Shah, Mansi R, MD",12/2/2023,Daratumumab and Hyaluronidase-fihj/Bortezomib/Dexamethasone (Weekly Regimen) 21 Day Cycles- Multiple Myeloma,Maintenance,12/2/2023,Inactive,,
NBR 4N ONCOLOGY,1594,"Shah, Mansi R, MD",12/14/2023,Maintenance Revlimid + Bortezomib Bi-Weekly 28 Day Cycles- Multiple Myeloma,_2. Second Line,12/1/2023,Active,,
CBMC OP INFUSION 2FL,75364,"Grossman, I Robert, MD",8/4/2023,Daratumumab and Hyaluronidase-fihj/Dexamethasone 28 Day Cycles - Multiple Myeloma,Maintenance,8/4/2023,Inactive,,
CBMC OP INFUSION 2FL,75364,"Grossman, I Robert, MD",2/2/2024,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,2/1/2024,Inactive,,
CBMC 2W ONCOLOGY,75364,"Grossman, I Robert, MD",2/23/2024,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_4. Fourth Line,2/23/2024,Inactive,,
CBMC OP INFUSION 2FL,75364,"Grossman, I Robert, MD",5/31/2024,Carfilzomib 70 mg/m2 Plus Dexamethasone 28 Day Cycles- Multiple Myeloma,_5. Fifth Line,5/27/2024,Inactive,,
NBR 5N ONCOLOGY,75364,"Shah, Mansi R, MD",8/6/2024,Elranatamab-bcmm Cycle 1 Inpatient 28 Day Cycles- Multiple Myeloma,_8. Eighth Line,8/1/2024,Active,,
NBI OP INFUSION,57345,"Shah, Shailja S, MD",11/21/2023,CapeOX (Capecitabine 1000 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/15/2023,Inactive,,
NBI OP INFUSION,57345,"Shah, Shailja S, MD",5/7/2024,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,_2. Second Line,5/6/2024,Inactive,,
NBI OP INFUSION,57345,"Shah, Shailja S, MD",7/23/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/22/2024,Active,,
MMC OP INFUSION,34239,"Meghal, Trishala, MD",1/29/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,1/28/2024,Inactive,,
MMC OP VP INFUSION,34239,"Meghal, Trishala, MD",4/22/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,4/21/2024,Active,Waldenstrom macroglobulinemia,
CBMC OP INFUSION 2FL,76252,"Wagmiller, Jennifer Ann, MD",9/21/2023,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,9/20/2023,Inactive,,
CBMC OP INFUSION 2FL,76252,"Wagmiller, Jennifer Ann, MD",7/18/2024,DOXOrubicin Liposomal 28 Day Cycles - Breast,_2. Second Line,6/30/2024,Active,,
HAM OP INFUSION,62814,"Yogarajah, Meera, MD",3/6/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,First Line,3/5/2023,Inactive,,
CBMC OP INFUSION 2FL,84282,"Wagmiller, Jennifer Ann, MD",3/26/2024,Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Maintenance,3/25/2024,Active,,
CINJ OP INFUSION,89539,"Toppmeyer, Deborah L, MD",2/6/2025,Palbociclib 28 Day Cycles - Breast,_1. First Line,1/27/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.0 - Estrogen receptor positive status (ER+)
MMC OP VP INFUSION,55557,"Lee, Patrick C, MD",10/2/2023,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,First Line,9/26/2023,Inactive,,
MMC OP VP INFUSION,55557,"Lee, Patrick C, MD",4/8/2024,Lurbinectedin 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,4/7/2024,Inactive,,
MMC OP VP INFUSION,55557,"Lee, Patrick C, MD",8/28/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_3. Third Line,8/28/2024,Inactive,,
MMC OP VP INFUSION,55557,"Lee, Patrick C, MD",9/23/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_3. Third Line,9/23/2024,Inactive,,
NBR 4N ONCOLOGY,47928,"Groisberg, Roman, MD",7/23/2024,VDC  (Vincristine / Doxorubicin / Cyclophsophamide) - Alveolar rhabdomyosarcoma,_1. First Line,7/23/2024,Inactive,,
CBMC OP INFUSION 2FL,43126,"Wagmiller, Jennifer Ann, MD",6/10/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,6/9/2024,Inactive,,
CBMC OP INFUSION 2FL,43126,"Wagmiller, Jennifer Ann, MD",5/14/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_4. Fourth Line,5/13/2025,Active,"Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC)","C50.812, Z17.0 - Malignant neoplasm of overlapping sites of left breast in female, estrogen receptor positive (CMS/HCC); Z79.899 - Long term use of drug"
JCMC CP INFUSION,79052,"Cruz, Allan Louie E, MD",9/17/2024,TCHP (DOCEtaxel / CARBOplatin / Trastuzumab/pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,9/13/2024,Active,Malignant neoplasm metastatic to bone (CMS/HCC),
JCMC CP INFUSION,1470,"Cruz, Allan Louie E, MD",3/4/2025,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,3/4/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.912 - Malignant neoplasm of unspecified site of left female breast; C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
CINJ OP INFUSION,96801,"Omene, Coral Oghenerukevwe, MD",12/9/2024,Abemaciclib 28 Day Cycles - Breast,Adjuvant,12/9/2024,Active,,
CINJ OP INFUSION,96801,"Omene, Coral Oghenerukevwe, MD",12/10/2024,CINJ 042312 Arm A Endocrine Therapy Investigator's Choice +/- Abemaciclib +/- LHRH Agonist 90 / 180 Day Cycles Research- Breast Cancer,Adjuvant,12/9/2024,Active,,
CINJ OP INFUSION,96801,"Omene, Coral Oghenerukevwe, MD",3/6/2025,Ribociclib 28 Day Cycles - Breast,Adjuvant,3/6/2025,Active,Malignant neoplasm of central portion of right male breast (CMS/HCC),
SOM OUTPT INFUSION,68171,"Yin, Faye, MD",6/6/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,6/4/2023,Inactive,,
SOM OUTPT INFUSION,68171,"Yin, Faye, MD",8/1/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,7/27/2023,Inactive,,
JCMC CP INFUSION,17871,"Sekhri, Arunabh, MD",4/23/2025,Sacituzumab Govitecan 21 Day Cycles - Breast or Bladder,_2. Second Line,4/16/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor negative (CMS/HCC)","B37.0 - Candidal stomatitis; C50.412 - Malignant neoplasm of upper-outer quadrant of left female breast; R06.02 - Shortness of breath; C50.911 - Malignant neoplasm of unspecified site of right female breast; R45.89 - Other symptoms and signs involving emotional state; I63.9 - Cerebral infarction, unspecified; Z17.1 - Estrogen receptor negative status (ER-)"
NBI OP INFUSION,16473,"Jacoby, Sari H, MD",4/17/2024,Pembrolizumab 21 Day Cycles-Small Cell Lung Cancer,_2. Second Line,4/16/2024,Inactive,,
NBI OP INFUSION,73448,"Anderson, Patrick S, MD",12/27/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,12/26/2024,Active,,
NBR CINJ OP INFUSION,71442,"Evens, Andrew M, DO",4/23/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/23/2025,Active,DLBCL (diffuse large B cell lymphoma) (CMS/HCC),
NBR 5N ONCOLOGY,71442,"Rhodes, Joanna Meehan, MD",4/11/2025,CVP (Cyclophosphamide / VinCRIStine / PredniSONE) 21 Day Cycles - Indolent Lymphoma,_1. First Line,4/11/2025,Inactive,"Non-Hodgkin lymphoma (CMS/HCC)
DLBCL (diffuse large B cell lymphoma) (CMS/HCC)","C83.31 - Diffuse large b-cell lymphoma, lymph nodes of head, face, and neck; C79.51 - Secondary malignant neoplasm of bone; E11.9 - Type 2 diabetes mellitus without complications; M84.58XA - Pathological fracture in neoplastic disease, other specified site, initial encounter for fracture; M48.02 - Spinal stenosis, cervical region; M47.812 - Spondylosis without myelopathy or radiculopathy, cervical region; E83.42 - Hypomagnesemia; R07.2 - Precordial pain; Z87.891 - Personal history of nicotine dependence; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z80.3 - Family history of malignant neoplasm of breast; R59.0 - Localized enlarged lymph nodes"
JCMC CP INFUSION,16882,"Cruz, Allan Louie E, MD",5/16/2023,Trastuzumab 21 Day Cycles (Continuation) - Breast,,4/25/2023,Inactive,,
CBMC OP INFUSION 1FL,50301,"Meelheim, Brooke A, DO",12/16/2024,CARBOPLATIN AUC2 With Concurrent Radiation 7 Day Cycles - Cervical,_1. First Line,12/8/2024,Active,,
NBI OP INFUSION,91592,"Anderson, Patrick S, MD",11/6/2023,"Gemcitabine (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",_2. Second Line,11/5/2023,Inactive,,
CINJ OP INFUSION,9610,"Leiser, Aliza, MD",6/18/2024,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,6/17/2024,Inactive,,
CINJ OP INFUSION,9610,"Leiser, Aliza, MD",10/8/2024,Niraparib 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Maintenance,10/8/2024,Active,,
CMC OP INFUSION,48670,"Talwar, Sumit, MD",12/11/2023,Pembrolizumab / Lenvatinib 21 Day Cycles - Kidney,_1. First Line,12/6/2023,Inactive,,
MMC OP VP INFUSION,48670,"Talwar, Sumit, MD",6/4/2024,Pembrolizumab 42 Day Cycles - Bladder or Kidney or Breast,_1. First Line,6/4/2024,Active,,
MSC OP INFUSION,20258,"Cohen, Seth D, MD",12/21/2023,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,_3. Third Line,12/20/2023,Active,,
MSC OP INFUSION,73054,"Cohen, Seth D, MD",2/10/2025,Daratumumab and Hyaluronidase-fihj/Carfilzomib/Dexamethasone 28 Day Cycles- Multiple Myeloma,Maintenance,2/9/2025,Active,"Multiple myeloma (CMS/HCC)
End stage renal disease (CMS/HCC)",
MMC OP VP INFUSION,96858,"Cohen, Seth D, MD",4/2/2025,CINJ 042316 Neoadjuvant Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles x 4 Cycles followed by Pembrolizumab / DOXOrubicin / Cyclophosphamide 21 Day Cycles x 4 Cycles Research- Breast Cancer,_1. First Line,4/2/2025,Active,"Malignant neoplasm of breast in female, estrogen receptor negative (CMS/HCC)",
MMC OP VP INFUSION,4803,"Talwar, Sumit, MD",2/18/2025,Durvalumab / Gemcitabine / CISplatin 21 Day Cycles- Biliary Tract Cancers- Durvalumab- Gemcitabine- CISplatin Sequencing,Neoadjuvant,2/17/2025,Active,"Malignant neoplasm of bladder, unspecified (CMS/HCC)",
CINJ OP INFUSION,78628,"Stephenson, Ruth D, DO",9/13/2024,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,9/12/2024,Active,,
MMC OP VP INFUSION,5350,"Cohen, Seth D, MD",5/10/2024,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,_1. First Line,5/8/2024,Inactive,,
CBMC OP INFUSION 2FL,98931,"Dharmapuri, Sirish, MD",8/28/2024,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,8/26/2024,Active,,
CBMC OP INFUSION 2FL,98931,"Dharmapuri, Sirish, MD",2/13/2025,5FU/Cisplatin + Zolbetuximab-clzb 14 Day Cycles,_2. Second Line,2/12/2025,Active,Gastric adenocarcinoma (CMS/HCC),
CBMC OP INFUSION 2FL,59282,"Radovich, Delia, MD",8/22/2023,Gemcitabine D1/OXALIplatin D2 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,8/21/2023,Inactive,,
NBI OP INFUSION,26729,"Anderson, Patrick S, MD",11/30/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,11/29/2023,Inactive,,
CBMC OP INFUSION 2FL,99170,"Brown, Andrew Bennett, MD",6/7/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,First Line,6/6/2023,Inactive,,
CBMC OP INFUSION 2FL,99170,"Brown, Andrew Bennett, MD",8/21/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,8/20/2024,Active,,
CINJ OP INFUSION,23533,"Omene, Coral Oghenerukevwe, MD",5/20/2025,CINJ 042208 Ribociclib / Endocrine Therapy of Choice 28 Day Cycles Research- Breast Cancer,Adjuvant,5/20/2025,Active,Malignant neoplasm of upper-inner quadrant of right female breast (CMS/HCC),
NBR CINJ OP INFUSION,13662,"Matasar, Matthew J, MD",10/4/2023,RiTUXimab 28 Day Cycle - Follicular Lymphoma ,,10/3/2023,Inactive,,
JCMC CP INFUSION,61338,"Sekhri, Arunabh, MD",11/13/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,11/12/2024,Inactive,,
JCMC CP INFUSION,61338,"Cruz, Allan Louie E, MD",11/29/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,11/29/2024,Inactive,,
JCMC CP INFUSION,61338,"Cruz, Allan Louie E, MD",1/7/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/7/2025,Active,,
NBR 4N ONCOLOGY,24336,"Chen, Xiaoyi",3/12/2025,CALGB 10403 (Course I) Remission Induction - Acute Lymphocytic Leukemia,_1. First Line,3/12/2025,Inactive,Adult T-cell lymphoma/leukemia (CMS/HCC),"O9A.12 - Malignant neoplasm complicating childbirth; C91.00 - Acute lymphoblastic leukemia not having achieved remission; Z37.0 - Single live birth; C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission; D61.818 - Other pancytopenia; O99.12 - Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth; O99.52 - Diseases of the respiratory system complicating childbirth; O89.4 - Spinal and epidural anesthesia-induced headache during the puerperium; O99.62 - Diseases of the digestive system complicating childbirth; J45.30 - Mild persistent asthma, uncomplicated; Z91.040 - Latex allergy status; Z87.891 - Personal history of nicotine dependence; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z79.51 - Long term (current) use of inhaled steroids; Z79.899 - Other long term (current) drug therapy; Z80.6 - Family history of leukemia; Z88.2 - Allergy status to sulfonamides; K59.00 - Constipation, unspecified; Z3A.33 - 33 weeks gestation of pregnancy"
NBR 4N ONCOLOGY,24336,"Tiger, Yun Kyoung, MD",3/4/2025,Cytarabine Intrathecal (IT) 1 Day Cycle- Hematological Malignancies,_1. First Line,3/4/2025,Inactive,Adult T-cell lymphoma/leukemia (CMS/HCC),"O9A.12 - Malignant neoplasm complicating childbirth; C91.00 - Acute lymphoblastic leukemia not having achieved remission; Z37.0 - Single live birth; C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission; D61.818 - Other pancytopenia; O99.12 - Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth; O99.52 - Diseases of the respiratory system complicating childbirth; O89.4 - Spinal and epidural anesthesia-induced headache during the puerperium; O99.62 - Diseases of the digestive system complicating childbirth; J45.30 - Mild persistent asthma, uncomplicated; Z91.040 - Latex allergy status; Z87.891 - Personal history of nicotine dependence; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z79.51 - Long term (current) use of inhaled steroids; Z79.899 - Other long term (current) drug therapy; Z80.6 - Family history of leukemia; Z88.2 - Allergy status to sulfonamides; K59.00 - Constipation, unspecified; Z3A.33 - 33 weeks gestation of pregnancy"
NBR 4N ONCOLOGY,24336,"Tiger, Yun Kyoung, MD",3/3/2025,Vincristine 2 mg- T cell leukemia,_1. First Line,3/3/2025,Inactive,Adult T-cell lymphoma/leukemia (CMS/HCC),"O9A.12 - Malignant neoplasm complicating childbirth; C91.00 - Acute lymphoblastic leukemia not having achieved remission; Z37.0 - Single live birth; C91.50 - Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission; D61.818 - Other pancytopenia; O99.12 - Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating childbirth; O99.52 - Diseases of the respiratory system complicating childbirth; O89.4 - Spinal and epidural anesthesia-induced headache during the puerperium; O99.62 - Diseases of the digestive system complicating childbirth; J45.30 - Mild persistent asthma, uncomplicated; Z91.040 - Latex allergy status; Z87.891 - Personal history of nicotine dependence; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z79.51 - Long term (current) use of inhaled steroids; Z79.899 - Other long term (current) drug therapy; Z80.6 - Family history of leukemia; Z88.2 - Allergy status to sulfonamides; K59.00 - Constipation, unspecified; Z3A.33 - 33 weeks gestation of pregnancy"
HAM OP INFUSION,19103,"Yogarajah, Meera, MD",3/21/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/21/2024,Inactive,,
HAM OP INFUSION,19103,"Yogarajah, Meera, MD",6/13/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,6/12/2024,Inactive,,
CINJ OP INFUSION,26845,"Haigentz, Missak, MD",12/24/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Induction,12/22/2024,Active,,
HAM OP INFUSION,21124,"Yogarajah, Meera, MD",12/2/2024,Bendamustine / RiTUXimab 28 Day Cycles - Follicular Lymphoma,_1. First Line,11/21/2024,Active,,
MMC OP VP INFUSION,21799,"Cohen, Seth D, MD",10/29/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",_1. First Line,10/10/2024,Active,,
CINJ OP INFUSION,84552,"Dasgeb, Bahar, MD",5/21/2024,Pembrolizumab 42 Day Cycles- Head and Neck Cancers,_1. First Line,5/20/2024,Inactive,,
JCMC CP INFUSION,4394,"Cruz, Allan Louie E, MD",5/15/2025,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,5/15/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)","C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; Z17.1 - Estrogen receptor negative status (ER-)"
JCMC CP INFUSION,4394,"Cruz, Allan Louie E, MD",4/24/2025,CINJ 042304 Liposomal DOXOrubicin / CARBOplatin 28 Day Cycles Research- Breast Cancer,Adjuvant,4/24/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z00.6 - Encounter for examination for normal comparison and control in clinical research program; Z17.1 - Estrogen receptor negative status (ER-)
JCMC CP INFUSION,4394,"Cruz, Allan Louie E, MD",4/22/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,4/22/2025,Inactive,"Malignant neoplasm of upper-inner quadrant of left breast in female, estrogen receptor negative (CMS/HCC)",C50.212 - Malignant neoplasm of upper-inner quadrant of left female breast; Z17.1 - Estrogen receptor negative status (ER-)
MMC OP INFUSION,4768,"Meghal, Trishala, MD",2/22/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,,2/21/2023,Inactive,,
MMC OP INFUSION,4768,"Meghal, Trishala, MD",11/15/2023,Capecitabine 21 Day Cycles - Breast,Adjuvant,11/15/2023,Inactive,,
SOM OUTPT INFUSION,29021,"Patel, Eshan, MD",2/1/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/31/2024,Active,,
SOM OUTPT INFUSION,29021,"Patel, Eshan, MD",2/1/2024,Durvalumab + Gemcitabine / CISplatin 21 Day Cycles- Hepatobiliary Cancers- Durvalumab-Gemcitabine-CISplatin Sequencing,_1. First Line,1/31/2024,Inactive,,
NBR 5N ONCOLOGY,81011,"Palmisiano, Neil David, MD",7/31/2023,Cytarabine / IDArubicin / Gemtuzumab Ozogamicin - Acute Myeloid Leukemia (Induction),,7/31/2023,Inactive,,
NBR CINJ OP INFUSION,81011,"Palmisiano, Neil David, MD",9/27/2023,HiDAC-123 + GO (High-Dose Cytarabine / Gemtuzumab Ozogamicin) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),,9/27/2023,Inactive,,
SOM OUTPT INFUSION,77978,"Patel, Eshan, MD",10/16/2023,Bortezomib 21 Day Cycles - Multiple Myeloma,_2. Second Line,10/15/2023,Inactive,,
CBMC OP INFUSION 2FL,51260,"Wagmiller, Jennifer Ann, MD",9/21/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_2. Second Line,9/20/2023,Active,,
CBMC OP INFUSION 2FL,51260,"Wagmiller, Jennifer Ann, MD",2/12/2025,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,2/12/2025,Active,Endometrial cancer (CMS/HCC),C54.1 - Malignant neoplasm of endometrium
CINJ OP INFUSION,12555,"George, Mridula A, MD",5/26/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,5/26/2023,Active,,
CINJ OP INFUSION,30053,"Omene, Coral Oghenerukevwe, MD",8/13/2024,"CINJ 042314 Cohort 2 BB-1701 D1, D8 21 Day Cycles Research- Breast Cancer",_4. Fourth Line,8/13/2024,Inactive,,
CINJ OP INFUSION,30053,"Omene, Coral Oghenerukevwe, MD",10/1/2024,CINJ 042402 Parts 1 and 2 RLY-2608 / Fulvestrant 28 Day Cycles Research- Breast Cancer,_5. Fifth Line,10/1/2024,Inactive,,
CINJ OP INFUSION,30053,"Omene, Coral Oghenerukevwe, MD",10/1/2024,CINJ 042402 Parts 1 and 2 RLY-2608 Single Agent 28 Day Cycles Research- Breast Cancer,_6. Sixth Line,10/1/2024,Inactive,,
CINJ OP INFUSION,30053,"Omene, Coral Oghenerukevwe, MD",12/18/2024,Capivasertib 28 Day Cycles - Breast,_6. Sixth Line,12/18/2024,Active,,
NBR 4N ONCOLOGY,30053,"Omene, Coral Oghenerukevwe, MD",1/31/2025,"CARBOplatin D1, D8, D15 28 Day Cycles - Breast",_8. Eighth Line,1/30/2025,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,1370,"Omene, Coral Oghenerukevwe, MD",5/1/2025,Gemcitabine 28 Day Cycles - Breast,_8. Eighth Line,5/1/2025,Inactive,Carcinoma of breast metastatic to liver (CMS/HCC),
CINJ OP INFUSION,70762,"Omene, Coral Oghenerukevwe, MD",11/11/2024,CINJ 042403 Tirzepatide Weekly 28 Day Cycles (3 Month Dispense Cycle 6 and Beyond) Research- Breast Cancer,Adjuvant,11/11/2024,Active,,
CINJ OP INFUSION,32803,"Toppmeyer, Deborah L, MD",11/3/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,11/2/2023,Inactive,,
CINJ OP INFUSION,46828,"Stephenson, Ryan D, DO",8/21/2023,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,8/20/2023,Inactive,,
CINJ OP INFUSION,46828,"Stephenson, Ryan D, DO",9/18/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Neoadjuvant,9/17/2023,Inactive,,
CINJ OP INFUSION,46828,"Stephenson, Ryan D, DO",11/15/2023,Gemcitabine / CISplatin (1000/35) 21 Day Cycles - Bladder,Adjuvant,11/14/2023,Inactive,,
CMC OP INFUSION,65357,"Pompa, Tiffany Ann, MD",11/14/2024,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,Adjuvant,11/12/2024,Active,,
CBMC OP INFUSION 2FL,66989,"Raptis, George, MD",3/21/2024,CMF IV (Cyclophosphamide IV / Methotrexate / Fluorouracil) 21 Day Cycles - Breast,Adjuvant,3/21/2024,Active,,
CMC OP INFUSION,63656,"Ferretti, Mark J, MD",11/11/2024,BCG Induction (TICE) 42 Day Cycle,_1. First Line,11/10/2024,Inactive,,
CMC OP INFUSION,63656,"Ferretti, Mark J, MD",11/15/2024,GEMDOCE (Gemcitabine + DOCEtaxel) Intravesical Induction 42 Day Cycle,_1. First Line,11/14/2024,Active,,
CMC OP INFUSION,63656,"Ferretti, Mark J, MD",2/10/2025,GEM/DOCE (Gemcitabine + DOCEtaxel) Intravesical Maintenance 28 Day Cycles - Bladder,_1. First Line,2/9/2025,Active,Malignant neoplasm of lateral wall of urinary bladder (CMS/HCC),
CINJ OP INFUSION,69583,"Salacz, Michael E, MD",4/20/2023,Selinexor 28 Day Cycles - MPNST,Third Line,4/20/2023,Active,"Primary lung adenocarcinoma, unspecified laterality (CMS/HCC)",
CINJ OP INFUSION,94338,"Berim, Lyudmyla, MD",5/30/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Pancreatic Adenocarcinoma",Neoadjuvant,5/23/2024,Active,,
NBR 5N ONCOLOGY,7108,"Matasar, Matthew J, MD",2/18/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,2/16/2023,Inactive,,
CINJ OP INFUSION,51864,"Gulhati, Prateek, MD PhD",2/27/2023,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,,2/27/2023,Inactive,,
CINJ OP INFUSION,51864,"Gulhati, Prateek, MD PhD",8/3/2023,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Pancreatic Adenocarcinoma",,8/2/2023,Active,,
SOM OUTPT INFUSION,41063,"Toomey, Kathleen C, MD",6/21/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,Adjuvant,6/13/2023,Inactive,,
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",9/26/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_2. Second Line,9/25/2023,Inactive,,
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",4/30/2024,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,Induction,4/29/2024,Inactive,,
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",5/13/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_3. Third Line,5/5/2024,Inactive,,
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",5/14/2024,Albumin-Bound PACLitaxel/CARBOplatin with Concurrent Radiation Therapy 7 Day Cycles- Non-Small Cell Lung Cancer,Induction,5/13/2024,Inactive,,
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",6/18/2024,Albumin-Bound PACLitaxel / Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,6/9/2024,Inactive,,
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",7/9/2024,Bevacizumab Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,7/8/2024,Inactive,Malignant neoplasm of endometrium (CMS/HCC),
CBMC OP INFUSION 2FL,15548,"Wagmiller, Jennifer Ann, MD",12/16/2024,Imatinib 30 Day Cycles - Dermatofibrosarcoma Protuberans,_2. Second Line,12/16/2024,Active,,
MMC OP VP INFUSION,41974,"Lee, Patrick C, MD",4/6/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,First Line,4/5/2023,Inactive,,
JCMC CP INFUSION,88685,"Sekhri, Arunabh, MD",5/30/2025,Pertuzumab / Trastuzumab / PACLitaxel weekly 21 Day Cycles Followed By Pertuzumab / Trastuzumab 21 Day Cycles - Breast,Neoadjuvant,5/30/2025,Active,"Malignant neoplasm of upper-outer quadrant of left breast in female, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,25136,"Girda, Eugenia, MD",3/13/2025,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,3/13/2025,Active,Malignant neoplasm of both ovaries (CMS/HCC),
HAM OP INFUSION,57144,"Yogarajah, Meera, MD",5/29/2025,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/28/2025,Active,Metastatic adenocarcinoma to esophagus (CMS/HCC),
CINJ OP INFUSION,58877,"Aikins, James K, MD",6/28/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,6/20/2024,Active,,
TRMC TCCC OP INFUSION,21111,"Capo, Gerardo, MD",5/29/2025,mFOLFOX6 + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/29/2025,Active,Malignant neoplasm of sigmoid colon (CMS/HCC),C18.7 - Malignant neoplasm of sigmoid colon; E53.8 - Deficiency of other specified B group vitamins
CINJ OP INFUSION,20617,"Berim, Lyudmyla, MD",1/4/2023,Irinotecan Liposome/Fluorouracil Continuous Infusion/Leucovorin 14 Day Cycles- Pancreatic Adenocarcinoma,,1/3/2023,Inactive,,
CINJ OP INFUSION,20617,"Berim, Lyudmyla, MD",2/20/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,2/19/2023,Inactive,,
CBMC OP INFUSION 2FL,55699,"Litvak, Anna M, MD",11/6/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,11/6/2024,Active,,
CBMC OP INFUSION 2FL,46959,"Litvak, Anna M, MD",9/24/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,9/24/2024,Active,GBM (glioblastoma multiforme) (CMS/HCC),
CINJ OP INFUSION,5082,"Goel, Sanjay, MD",2/12/2025,CINJ 052404 Dose Escalation XL309 28 Day Cycles Research- Advanced Solid Tumors,_3. Third Line,2/12/2025,Active,"Cancer of head of pancreas (CMS/HCC)
Malabsorption due to intolerance, not elsewhere classified",
SOM OUTPT INFUSION,11300,"Yin, Faye, MD",3/19/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/10/2024,Inactive,,
SOM OUTPT INFUSION,11300,"Yin, Faye, MD",7/23/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,7/23/2024,Inactive,,
SOM OUTPT INFUSION,11300,"Toomey, Kathleen C, MD",10/15/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,_2. Second Line,10/14/2024,Active,,
NBR 5N ONCOLOGY,21836,"Palmisiano, Neil David, MD",8/8/2023,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),First Line,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,21836,"Shah, Mansi R, MD",8/15/2023,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Lenalidomide MODIFIED 28 Day Cycles- Multiple Myeloma,_1. First Line,8/8/2023,Inactive,,
NBR CINJ OP INFUSION,21836,"Shah, Mansi R, MD",12/7/2023,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Adjuvant,11/23/2023,Inactive,,
CINJ OP INFUSION,39732,"Stephenson, Ryan D, DO",12/18/2024,Darolutamide 28 Day Cycles - Prostate,_1. First Line,12/18/2024,Active,,
CBMC OP INFUSION 2FL,28823,"Dave, Manish, MD",3/6/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,Maintenance,3/5/2023,Inactive,,
CMC OP INFUSION,39352,"Pompa, Tiffany Ann, MD",2/25/2025,PACLitaxel Weekly / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,2/24/2025,Active,Malignant neoplasm of ovary (CMS/HCC),C56.3 - Malignant neoplasm of both ovaries (CMS/HCC)
NBR CINJ OP INFUSION,81581,"Patel, Eshan, MD",7/19/2023,CINJ 032003 PACLitaxel / CARBOplatin + Pembrolizumab 21 Day Cycle CYCLE 1 Groups A/B Research- Non-Small Cell Lung Cancer,,7/18/2023,Inactive,,
CINJ OP INFUSION,81581,"Patel, Eshan, MD",8/6/2023,CINJ 032003 PACLitaxel / CARBOplatin + Pembrolizumab 21 Day Cycles CYCLES 2 & 3 Groups A/B Research- Non-Small Cell Lung Cancer,,8/6/2023,Inactive,,
CINJ OP INFUSION,81581,"Patel, Eshan, MD",10/18/2023,CINJ 032003 Post RT Pembrolizumab + Olaparib / Placebo 21 Day Cycles Group A Research- Non-Small Cell Lung Cancer,Maintenance,10/17/2023,Active,,
NBR 4N ONCOLOGY,43925,"Chen, Xiaoyi",1/23/2025,Atgam / CycloSPORINE / Eltrombopag - Aplastic Anemia,_1. First Line,1/23/2025,Active,,
NBR CINJ OP INFUSION,83355,"Egini, Ogechukwu, MD",4/16/2025,Allogeneic rATG / Flu / Cy / TBI + Post Cy 40/Abatacept,_2. Second Line,4/14/2025,Active,Aplastic anemia (CMS/HCC),Z01.818 - Encounter for pre-transplant evaluation for stem cell transplant
CBMC OP INFUSION 2FL,54238,"Grossman, I Robert, MD",9/21/2023,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,,9/20/2023,Inactive,,
JCMC CP INFUSION,88573,"Cruz, Allan Louie E, MD",9/30/2024,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/29/2024,Inactive,,
CBMC 2W ONCOLOGY,13925,"Grossman, I Robert, MD",11/7/2023,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_1. First Line,11/7/2023,Inactive,Peripheral T cell lymphoma of extranodal and solid organ sites (CMS/HCC),
CBMC OP INFUSION 2FL,13925,"Grossman, I Robert, MD",1/15/2024,EA (Etoposide / High-Dose Cytarabine) 28 Day Cycle - CNS Lymphoma,Consolidation,1/15/2024,Inactive,Peripheral T cell lymphoma of extranodal and solid organ sites (CMS/HCC),
CBMC 2W ONCOLOGY,13925,"Grossman, I Robert, MD",1/13/2025,MT-R (High-Dose Methotrexate / Temozolomide / RiTUXimab) 14 Day Cycles - CNS Lymphoma,_3. Third Line,1/12/2025,Active,,
NBR CINJ OP INFUSION,37595,"Schaar, Dale, MD PhD",2/6/2023,Decitabine (Post Transplant Maintenance) q8 weeks - Acute Myeloid Leukemia,,2/6/2023,Inactive,,
CINJ OP INFUSION,12574,"Goel, Sanjay, MD",6/11/2023,CINJ 052103 (TJ033721STM101) Dose Expansion Cohort 1 TJ033721 12 mg/kg 28 Day Cycles Research- Gastric Cancer / Gastroesophageal Junction Carcinoma / Esophageal Adenocarcinoma,Third Line,6/2/2023,Inactive,,
CINJ OP INFUSION,50303,"Girda, Eugenia, MD",10/13/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,Adjuvant,10/11/2023,Inactive,,
CINJ OP INFUSION,50303,"Girda, Eugenia, MD",5/23/2024,trastuzumab - Uterine,_1. First Line,5/23/2024,Active,Endometrial cancer (CMS/HCC),
NBR CINJ OP INFUSION,65011,"Matasar, Matthew J, MD",5/20/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,5/20/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"C83.30 - Diffuse large B-cell lymphoma, unspecified site"
CMC OP INFUSION,48367,"Pompa, Tiffany Ann, MD",10/2/2024,Gemcitabine / CARBOplatin 21 Day Cycles - Breast,_1. First Line,9/26/2024,Active,,
CMC OP INFUSION,48367,"Pompa, Tiffany Ann, MD",10/23/2024,Pembrolizumab 21 Day Cycles - Bladder or Breast,_1. First Line,10/23/2024,Active,,
MMC OP VP INFUSION,44280,"Lee, Patrick C, MD",4/6/2023,Nivolumab/Ipilimumab + PEMEtrexed/CARBOplatin (AUC 6) 42 Day Cycles- Non-Small Cell Lung Cancer,First Line,3/29/2023,Inactive,,
MMC OP VP INFUSION,44280,"Lee, Patrick C, MD",10/10/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,10/9/2024,Active,,
MMC OP VP INFUSION,23843,"Lee, Patrick C, MD",7/20/2023,FOLFIRI + Panitumumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,7/19/2023,Inactive,,
CINJ OP INFUSION,93729,"Berim, Lyudmyla, MD",10/17/2024,Imatinib 30 Day Cycles - Sarcoma,Neoadjuvant,10/17/2024,Active,,
CBMC 2W ONCOLOGY,69665,"Grossman, I Robert, MD",10/31/2023,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,10/31/2023,Inactive,,
CBMC 2W ONCOLOGY,69665,"Grossman, I Robert, MD",11/3/2023,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,11/3/2023,Inactive,,
MMC OP INFUSION,42428,"Eltoukhy, Hussam, MD",7/24/2024,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,7/23/2024,Inactive,,
MMC OP VP INFUSION,36717,"Cohen, Seth D, MD",2/19/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,2/18/2024,Inactive,,
MMC OP VP INFUSION,36717,"Cohen, Seth D, MD",6/10/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,6/10/2024,Inactive,,
MMC OP VP INFUSION,36717,"Cohen, Seth D, MD",9/18/2024,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,_3. Third Line,9/15/2024,Active,,
MMC OP VP INFUSION,22256,"Cohen, Seth D, MD",4/30/2025,Pembrolizumab 21 Day Cycles - Melanoma,_2. Second Line,4/30/2025,Active,Malignant melanoma of overlapping sites (CMS/HCC),
MMC OP VP INFUSION,60925,"Cohen, Seth D, MD",6/14/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,Third Line,6/9/2023,Inactive,,
HAM OP INFUSION,28647,"Yogarajah, Meera, MD",5/8/2023,PACLitaxel/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,,5/1/2023,Inactive,,
HAM OP INFUSION,28647,"Yogarajah, Meera, MD",7/31/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,7/30/2023,Active,,
NBR CINJ OP INFUSION,63140,"Palmisiano, Neil David, MD",7/9/2024,Decitabine Oral and Cedazuridine 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,7/9/2024,Active,,
CINJ OP INFUSION,43665,"Weiss, Sarah, MD",2/5/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_1. First Line,2/4/2025,Active,Melanoma metastatic to lung (CMS/HCC),
CINJ OP INFUSION,86231,"Ghodoussipour, Saum Bobak, MD",3/5/2024,CINJ 082303 Arm B BCG - Bladder Cancer,Induction,3/4/2024,Inactive,,
CINJ OP INFUSION,86231,"Ghodoussipour, Saum Bobak, MD",6/6/2024,CINJ 082303 BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Maintenance,6/6/2024,Active,,
MMC OP VP INFUSION,88703,"Lee, Patrick C, MD",4/16/2024,"PEMEtrexed/CISplatin 21 Day Cycles- Non-Small Cell Lung Cancer (Neoadjuvant, Adjuvant)",Adjuvant,4/1/2024,Inactive,,
CBMC OP INFUSION 2FL,57054,"Leitner, Stuart P, MD",3/20/2024,PACLitaxel / CARBOplatin / Gemcitabine 21 Day Cycles - Unknown Primary,_1. First Line,3/18/2024,Inactive,,
CBMC OP INFUSION 2FL,57054,"Leitner, Stuart P, MD",4/22/2024,Pembrolizumab 21 Day Cycles - Bladder or Kidney,_2. Second Line,4/22/2024,Active,,
CINJ OP INFUSION,4947,"Berim, Lyudmyla, MD",11/30/2023,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,,9/10/2023,Inactive,,
CINJ OP INFUSION,64251,"Weiss, Sarah, MD",4/25/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_3. Third Line,4/23/2024,Inactive,,
HAM OP INFUSION,78892,"Yogarajah, Meera, MD",2/13/2023,mFOLFOX6 (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) + Nivolumab14 Day Cycles- Gastrointestinal Cancers,Second Line,1/29/2023,Inactive,,
CMC OP INFUSION,98283,"Easaw, Sarah, MD",5/4/2023,Loncastuximab Tesirine-lpyl 21 Day Cycles - Diffuse Large B-Cell Lymphoma,Maintenance,4/29/2023,Inactive,,
HAM OP INFUSION,23093,"Gendy, Mina, DO",1/21/2025,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,Adjuvant,1/20/2025,Active,,
HAM OP INFUSION,23093,"Gendy, Mina, DO",3/18/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,3/18/2025,Active,"Squamous cell carcinoma of mandible (CMS/HCC)
Abnormal results of thyroid function studies",C41.1 - Squamous cell carcinoma of mandible (CMS/HCC)
NBR 5N ONCOLOGY,32271,"Palmisiano, Neil David, MD",1/22/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),Induction,1/21/2023,Inactive,,
MMC OP VP INFUSION,17040,"Cohen, Seth D, MD",10/15/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,_1. First Line,10/14/2024,Inactive,,
MSC OP INFUSION,17040,"Cohen, Seth D, MD",1/8/2025,Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Maintenance,1/7/2025,Active,Multiple myeloma (CMS/HCC),
CINJ OP INFUSION,28784,"Toppmeyer, Deborah L, MD",2/20/2023,DOXOrubicin Liposomal 28 Day Cycles - Breast,Third Line,2/17/2023,Inactive,,
CINJ OP INFUSION,28784,"Toppmeyer, Deborah L, MD",3/20/2023,"PACLitaxel D1, D8 21 Day Cycles - Breast",Third Line,3/19/2023,Inactive,,
TRMC TCCC OP INFUSION,43684,"Capo, Gerardo, MD",4/23/2025,CapeOX (Capecitabine 850 mg/m2/OXALIplatin) + Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/23/2025,Active,"Malignant neoplasm of descending colon (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
TRMC TCCC OP INFUSION,43684,"Capo, Gerardo, MD",4/9/2025,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/9/2025,Inactive,"Malignant neoplasm of descending colon (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",C18.6 - Malignant neoplasm of descending colon; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
TRMC TCCC OP INFUSION,43684,"Capo, Gerardo, MD",4/9/2025,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,4/9/2025,Inactive,"Malignant neoplasm of descending colon (CMS/HCC)
Secondary malignant neoplasm of liver (CMS/HCC)",
MSC OP INFUSION,55354,"Cohen, Seth D, MD",12/13/2023,Pembrolizumab 21 Day Cycles - Gastrointestinal Cancers,_1. First Line,12/12/2023,Inactive,,
JCMC CP INFUSION,75988,"Cruz, Allan Louie E, MD",6/18/2024,Maintenance Durvalumab - cholangiocarcinoma,_1. First Line,6/4/2024,Active,,
HAM OP INFUSION,56942,"Patel, Malini M, MD",2/20/2025,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_2. Second Line,2/19/2025,Active,Multiple myeloma (CMS/HCC),C90.00 - Multiple myeloma not having achieved remission (CMS/HCC)
CINJ OP INFUSION,85636,"Stephenson, Ryan D, DO",3/27/2023,Abiraterone (Low Dose) / PredniSONE 28 Day Cycles - Prostate,Adjuvant,3/27/2023,Active,,
NBR 4N ONCOLOGY,18923,"Chen, Xiaoyi",4/29/2025,ECOG - ACRIN E1910 (Step 1) Induction (Cytarabine IT / Methotrexate IT / DAUNOrubicin / VinCRIStine / DexAMETHasone / Pegaspargase / Cyclophosphamide / Cytarabine / Mercaptopurine) - ALL,_1. First Line,4/29/2025,Active,Philadelphia chromosome-negative pre B-cell acute lymphoblastic leukemia (ALL) (CMS/HCC),"O9A.12 - Malignant neoplasm complicating childbirth; E87.3 - Alkalosis; Z37.0 - Single live birth; C91.00 - Acute lymphoblastic leukemia not having achieved remission; O99.284 - Endocrine, nutritional and metabolic diseases complicating childbirth; O48.0 - Post-term pregnancy; O70.1 - Second degree perineal laceration during delivery; O76 - Abnormality in fetal heart rate and rhythm complicating labor and delivery; O72.1 - Other immediate postpartum hemorrhage; O92.29 - Other disorders of breast associated with pregnancy and the puerperium; O90.89 - Other complications of the puerperium, not elsewhere classified; K08.89 - Other specified disorders of teeth and supporting structures; Z3A.40 - 40 weeks gestation of pregnancy; Z91.040 - Latex allergy status; Z90.49 - Acquired absence of other specified parts of digestive tract"
CINJ OP INFUSION,76144,"Weiss, Sarah, MD",4/17/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,4/16/2024,Inactive,,
CINJ OP INFUSION,76144,"Weiss, Sarah, MD",7/29/2024,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_2. Second Line,7/28/2024,Inactive,,
CINJ OP INFUSION,76144,"Weiss, Sarah, MD",9/9/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,9/4/2024,Active,,
CINJ OP INFUSION,86552,"Weiss, Sarah, MD",3/18/2025,Nivolumab and Relatlimab-rmbw 28 Day Cycles - Cutaneous Melanoma,_2. Second Line,3/18/2025,Inactive,Melanoma of left posterior calf (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C43.71 - Malignant melanoma of right lower limb, including hip; D89.89 - Other specified disorders involving the immune mechanism, not elsewhere classified; C43.9 - Malignant melanoma of skin, unspecified; C43.72 - Malignant melanoma of left lower limb, including hip"
NBR 4N ONCOLOGY,11768,"Stephenson, Ruth D, DO",1/4/2023,PACLitaxel / CARBOplatin 21 Day Cycles - Cervical ,First Line,1/3/2023,Inactive,,
MMC OP VP INFUSION,90340,"Cohen, Seth D, MD",2/19/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,2/13/2024,Inactive,,
MMC OP VP INFUSION,90340,"Cohen, Seth D, MD",5/16/2024,DOCEtaxel/Ramucirumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/15/2024,Inactive,,
NBI OP INFUSION,11502,"Jacoby, Sari H, MD",9/27/2023,"Albumin-Bound PACLitaxel (D1, D8, D15) 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ",_3. Third Line,9/26/2023,Active,,
CINJ OP INFUSION,57828,"Boland, Patrick M, MD",4/22/2025,Capecitabine / MitoMYcin 10 mg/m2 with Concurrent Radiation 42 Day Cycle - Anal Carcinoma,Neoadjuvant,4/22/2025,Active,"Malignant neoplasm of anus, unspecified (CMS/HCC)","C21.0 - Malignant neoplasm of anus, unspecified"
CBMC OP INFUSION 2FL,93462,"Wagmiller, Jennifer Ann, MD",9/12/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_1. First Line,9/10/2024,Active,,
CBMC OP INFUSION 2FL,9201,"Leitner, Stuart P, MD",7/18/2024,Pembrolizumab + PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by Pembrolizumab + DOXOrubicin + Cyclophoshamide 21 Day x 4 Cycles Followed By Pembrolizumab Maintance Q21 Days,Neoadjuvant,7/7/2024,Active,,
TRMC TCCC OP INFUSION,88421,"Capo, Gerardo, MD",8/5/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,8/4/2024,Inactive,,
TRMC TCCC OP INFUSION,88421,"Salerno, Vincent E, MD",8/5/2024,Bortezomib/Dexamethasone/Cyclophosphamide IV 28 Day Cycles- Multiple Myeloma,_1. First Line,8/4/2024,Inactive,,
TRMC TCCC OP INFUSION,88421,"Salerno, Vincent E, MD",10/7/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,10/6/2024,Inactive,,
TRMC TCCC OP INFUSION,88421,"Salerno, Vincent E, MD",12/13/2024,Daratumumab and Hyaluronidase-fihj / Lenalidomide / Dexamethasone 28 Day Cycles - Multiple Myeloma,_1. First Line,12/12/2024,Active,,
MMC OP VP INFUSION,3820,"Cohen, Seth D, MD",2/20/2023,Mirvetuximab Soravtansine 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Second Line,2/19/2023,Inactive,,
MMC OP VP INFUSION,3820,"Cohen, Seth D, MD",5/17/2023,Gemcitabine / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Third Line,5/16/2023,Inactive,,
MMC OP VP INFUSION,3820,"Cohen, Seth D, MD",9/11/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,,8/15/2023,Inactive,,
CINJ OP INFUSION,51901,"Mayer, Tina M, MD",4/22/2025,DDMVAC (Methotrexate / VinBLAStine / DOXOrubicin / CISplatin) Dose-Dense 14 Day Cycles - Bladder,Neoadjuvant,4/21/2025,Active,Urothelial carcinoma (CMS/HCC),"C67.9 - Malignant neoplasm of bladder, unspecified; N42.89 - Other specified disorders of prostate; C68.9 - Malignant neoplasm of urinary organ, unspecified; D49.4 - Neoplasm of unspecified behavior of bladder; D49.9 - Neoplasm of unspecified behavior of unspecified site"
CINJ OP INFUSION,57662,"Groisberg, Roman, MD",9/15/2023,AD (DOXOrubicin / Dacarbazine) 21 Day Cycles - Sarcoma,Neoadjuvant,9/14/2023,Inactive,,
CINJ OP INFUSION,47007,"Mayer, Tina M, MD",10/24/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,10/24/2023,Active,,
CINJ OP INFUSION,92841,"Ghodoussipour, Saum Bobak, MD",8/28/2024,BCG Induction (TICE) 42 Day Cycle,Induction,8/27/2024,Active,,
SOM OUTPT INFUSION,22897,"Yin, Faye, MD",2/13/2023,CISplatin / Etoposide (80/80) 21 Day Cycles - High Grade Neuroendocrine,First Line,2/12/2023,Inactive,,
CINJ OP INFUSION,51361,"George, Mridula A, MD",6/19/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/18/2024,Inactive,,
CINJ OP INFUSION,51361,"George, Mridula A, MD",12/18/2024,CINJ 042106 (A011801)  Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,Adjuvant,12/17/2024,Active,,
CMC OP INFUSION,13389,"Pompa, Tiffany Ann, MD",4/30/2025,FLOT (Fluorouracil IVCI 2400 mg/m2 over 46 Hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/30/2025,Active,Malignant neoplasm of body of stomach (CMS/HCC),
SOM OUTPT INFUSION,30714,"Patel, Eshan, MD",12/17/2024,DOCEtaxel / PredniSONE 28 Day Cycles - Prostate,_1. First Line,12/16/2024,Active,,
CMC OP INFUSION,55539,"Meghal, Trishala, MD",3/21/2023,CISplatin With Concurrent Radiation + PACLitaxel / CARBOplatin 21 Day Cycles - Uterine,First Line,3/20/2023,Inactive,,
CMC OP INFUSION,55539,"Meghal, Trishala, MD",5/23/2023,Pembrolizumab 21 Day Cycles - Uterine,First Line,5/23/2023,Inactive,,
MMC OP INFUSION,38572,"Eltoukhy, Hussam, MD",3/15/2025,CyBorD Weekly (Bortezomib / Dexamethasone / Cyclophosphamide) 28 Day Cycles - Multiple Myeloma (Inpatient Regimen),_1. First Line,3/14/2025,Active,Multiple myeloma not having achieved remission (CMS/HCC),"I48.91 - Unspecified atrial fibrillation; C90.00 - Multiple myeloma not having achieved remission; D61.818 - Other pancytopenia; E44.1 - Mild protein-calorie malnutrition; E87.20 - Acidosis, unspecified; N13.1 - Hydronephrosis with ureteral stricture, not elsewhere classified; N18.4 - Chronic kidney disease, stage 4 (severe); D63.1 - Anemia in chronic kidney disease; I12.9 - Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease; N25.81 - Secondary hyperparathyroidism of renal origin; I48.3 - Typical atrial flutter; Z90.6 - Acquired absence of other parts of urinary tract; D50.9 - Iron deficiency anemia, unspecified; E78.5 - Hyperlipidemia, unspecified; M10.9 - Gout, unspecified; Z90.79 - Acquired absence of other genital organ(s); Z59.41 - Food insecurity; D53.9 - Nutritional anemia, unspecified; G89.29 - Other chronic pain; Z68.21 - Body mass index (BMI) 21.0-21.9, adult; E87.5 - Hyperkalemia; I89.0 - Lymphedema, not elsewhere classified; Z88.8 - Allergy status to other drugs, medicaments and biological substances; Z79.899 - Other long term (current) drug therapy; Z79.01 - Long term (current) use of anticoagulants; Z92.3 - Personal history of irradiation; Z87.442 - Personal history of urinary calculi; Z85.51 - Personal history of malignant neoplasm of bladder; Z85.46 - Personal history of malignant neoplasm of prostate"
CBMC OP INFUSION 2FL,72444,"Grossman, I Robert, MD",3/4/2024,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,Maintenance,3/3/2024,Active,,
MMC BBR2 ONCOLOGY,64344,"Lee, Patrick C, MD",8/1/2023,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,,7/31/2023,Inactive,,
CINJ OP INFUSION,64357,"Boland, Patrick M, MD",10/20/2023,FOLFOXIRI + Bevacizumab (Fluorouracil Continuous Infusion 1200 mg/m2/day/ Leucovorin/OXALIplatin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,10/19/2023,Active,,
CINJ OP INFUSION,8340,"Weiss, Sarah, MD",1/18/2023,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,1/17/2023,Inactive,,
CINJ OP INFUSION,99245,"Berim, Lyudmyla, MD",7/27/2024,Modified FOLFIRINOX (Fluorouracil Continuous Infusion / Leucovorin / Irinotecan 150 mg/m2 / OXALiplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,7/16/2024,Inactive,,
CINJ OP INFUSION,99245,"Berim, Lyudmyla, MD",9/9/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/8/2024,Inactive,,
SOM OUTPT INFUSION,13187,"Patel, Eshan, MD",7/17/2024,Bevacizumab 28 Day Cycles - Kidney or CNS,_1. First Line,7/17/2024,Active,,
CINJ OP INFUSION,38214,"Girda, Eugenia, MD",3/7/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,_1. First Line,2/21/2024,Inactive,,
CINJ OP INFUSION,38214,"Leiser, Aliza, MD",5/9/2024,CISplatin 21 Day Cycles - Uterine,_1. First Line,5/8/2024,Inactive,,
CINJ OP INFUSION,38214,"Girda, Eugenia, MD",6/18/2024,CINJ 052202 Dose Expansion Cohort 1 RGX104 / Ipilimumab 28 Day Cycles Research- Solid Tumor Malignancies,_3. Third Line,5/27/2024,Inactive,,
CBMC OP INFUSION 2FL,60378,"Kulkarni, Aditya A, MD",1/24/2025,Pembrolizumab 21 Day Cycles- Head and Neck Cancers,_1. First Line,1/9/2025,Active,,
CINJ PEDS HEMONC ,67756,"Botwinick, Marissa, DO",3/6/2025,CINJ 012103 ARM 1 CC-486 + MINI-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / RiTUXimab) 21 Day Cycles Research- Non-Hodgkin Lymphoma,_1. First Line,2/27/2025,Inactive,Hodgkin lymphoma (CMS/HCC),
CINJ OP INFUSION,41652,"Boland, Patrick M, MD",5/6/2025,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 + Herceptin (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) 28 Day Cycles- Gastroesophageal Cancer",_1. First Line,4/22/2025,Active,Malignant neoplasm of lower third of esophagus (CMS/HCC),"C15.5 - Malignant neoplasm of lower third of esophagus; C15.9 - Malignant neoplasm of esophagus, unspecified; R93.89 - Abnormal findings on diagnostic imaging of other specified body structures"
CINJ OP INFUSION,84499,"Berim, Lyudmyla, MD",9/27/2024,"CINJ 072204 FOLFOX D1, 15 Alternating with FOLFIRI D1, D15 (Fluorouracil / Leucovorin / OXALiplatin / Irinotecan) +Nivolumab 28 Day Cycles- Gastroesophageal Cancers",_1. First Line,9/26/2024,Active,,
CINJ OP INFUSION,84499,"Berim, Lyudmyla, MD",1/16/2025,FOLFIRI Outpatient (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/15/2025,Active,,
CINJ OP INFUSION,84499,"Berim, Lyudmyla, MD",2/27/2025,mFOLFOX6 + Zolbetuximab-clzb (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles,_1. First Line,2/26/2025,Active,Primary gastric signet ring cell carcinoma (CMS/HCC),"C16.3 - Malignant neoplasm of pyloric antrum; C16.9 - Malignant neoplasm of stomach, unspecified"
CMC OP INFUSION,15567,"Cohen, Seth D, MD",10/5/2023,PACLitaxel weekly 28 Day Cycles - Breast (Metastatic),_3. Third Line,10/5/2023,Active,,
MMC OP INFUSION,89845,"Eltoukhy, Hussam, MD",12/28/2023,R-CDOP (Cyclophosphamide / liposomal DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,12/25/2023,Inactive,,
MMC OP INFUSION,89845,"Eltoukhy, Hussam, MD",3/4/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,3/3/2024,Inactive,,
CINJ OP INFUSION,45554,"Dasgeb, Bahar, MD",5/2/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,First Line,5/1/2023,Inactive,,
CINJ OP INFUSION,61583,"Haigentz, Missak, MD",2/21/2025,Atezolizumab/Bevacizumab/PACLitaxel - 21 Day Cycles - Non-Small Cell Lung Cancer,_3. Third Line,2/21/2025,Active,"Adenocarcinoma of lung, stage 4 (CMS/HCC)
Secondary malignant neoplasm of bone (CMS/HCC)
Secondary malignant neoplasm of adrenal gland (CMS/HCC)
Malignant pleural effusion
Chronic fatigue
Elevated cancer antigen 125 (CA 125)",
CBMC OP INFUSION 2FL,1217,"Wagmiller, Jennifer Ann, MD",3/4/2024,CINJ 042102 (I-SPY 2 105139) Block A VV1 / Cemiplimab 21 Day Cycles Research- Breast Cancer,Neoadjuvant,3/3/2024,Inactive,,
CBMC OP INFUSION 2FL,1217,"Wagmiller, Jennifer Ann, MD",6/3/2024,CINJ 042102  (I-SPY 2 105139)  PACLitaxel Weekly 21 Day Cycles Research- Breast Cancer HER2 Negative Tumors,Neoadjuvant,5/29/2024,Active,,
CINJ OP INFUSION,97357,"Toppmeyer, Deborah L, MD",3/31/2025,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,3/31/2025,Active,"Malignant neoplasm of lower-inner quadrant of right breast of female, estrogen receptor positive (CMS/HCC)",C50.311 - Malignant neoplasm of lower-inner quadrant of right female breast; Z17.0 - Estrogen receptor positive status (ER+); Z79.899 - Other long term (current) drug therapy
CBMC OP INFUSION 2FL,50838,"Wagmiller, Jennifer Ann, MD",7/19/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,Adjuvant,7/18/2023,Inactive,,
CINJ OP INFUSION,72595,"Patankar, Sonali, MD",2/3/2025,PACLitaxel / CARBOplatin 21 Day Cycles - Ovarian and Uterine,Adjuvant,1/23/2025,Active,"Endometrial cancer (CMS/HCC)
Malignant neoplasm of both ovaries (CMS/HCC)",C56.3 - Malignant neoplasm of bilateral ovaries; Z48.816 - Encounter for surgical aftercare following surgery on the genitourinary system; C54.1 - Malignant neoplasm of endometrium
CINJ OP INFUSION,57966,"George, Mridula A, MD",3/17/2023,Abemaciclib 28 Day Cycles - Breast ,Adjuvant,3/17/2023,Inactive,,
CINJ OP INFUSION,55133,"Dasgeb, Bahar, MD",9/17/2024,Pembrolizumab 21 Day Cycles - Merkel Cell Carcinoma,_1. First Line,9/16/2024,Inactive,,
CINJ OP INFUSION,55133,"Dasgeb, Bahar, MD",12/31/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_3. Third Line,12/30/2024,Active,,
CINJ OP INFUSION,40808,"Dasgeb, Bahar, MD",4/1/2025,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_4. Fourth Line,4/1/2025,Inactive,"Merkel cell carcinoma of left lower limb, including hip (CMS/HCC)
Secondary malignant neoplasm of bone and bone marrow (CMS/HCC)","Z51.11 - Encounter for antineoplastic chemotherapy; C7B.1 - Secondary Merkel cell carcinoma; C4A.72 - Merkel cell carcinoma of left lower limb, including hip; C79.51 - Secondary malignant neoplasm of bone; C79.52 - Secondary malignant neoplasm of bone marrow; R53.83 - Other fatigue; C4A.9 - Merkel cell carcinoma, unspecified; R53.81 - Other malaise; M79.2 - Neuralgia and neuritis, unspecified; Z51.5 - Encounter for palliative care"
NBR 4N BMTU/IMCU,58873,"Patel, Vimal D, MD",2/21/2023,BMT Allogeneic TBF + Post Cy ,Consolidation,2/21/2023,Inactive,,
CINJ OP INFUSION,89960,"Haigentz, Missak, MD",1/21/2023,"PACLitaxel/CARBOplatin,(addition of BEVACIZUMAB/ATEZOLIZUMAB in Cycle 3)21 Day Cycles Metastatic/Recurrent - Non-Small Cell Lung Cancer",First Line,1/20/2023,Inactive,,
CINJ OP INFUSION,89960,"Haigentz, Missak, MD",3/6/2023,Atezolizumab/Bevacizumab/PACLitaxel/CARBOplatin 21 Day Cycles - Non-Small Cell Lung Cancer,First Line,3/5/2023,Inactive,,
NBR CINJ OP INFUSION,27651,"Evens, Andrew M, DO",1/10/2024,AVD (DOXOrubicin / VinBLAStine / Dacarbazine) + Brentuximab Vedotin 28 Day Cycles - Hodgkin Lymphoma,_1. First Line,1/9/2024,Inactive,,
SOM 1PAV ONCOLOGY,2921,"Patel, Eshan, MD",5/23/2023,CARBOplatin/Etoposide D1-D3 21 Day Cycles- Small-Cell Lung Cancer,First Line,5/22/2023,Inactive,,
CINJ OP INFUSION,210,"Haigentz, Missak, MD",12/11/2023,CISplatin / Etoposide (60/100) 21 Day Cycles - Thymoma,Adjuvant,12/11/2023,Inactive,,
MMC OP INFUSION,10152,"Cohen, Seth D, MD",5/16/2023,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,,5/15/2023,Active,,
MMC OP VP INFUSION,10152,"Cohen, Seth D, MD",6/17/2024,Abemaciclib 28 Day Cycles - Breast,_2. Second Line,6/17/2024,Active,,
MMC OP VP INFUSION,10152,"Cohen, Seth D, MD",5/28/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,5/28/2025,Active,Breast cancer (CMS/HCC),
SOM OUTPT INFUSION,44729,"Toomey, Kathleen C, MD",11/12/2024,Ribociclib 28 Day Cycles - Breast,_1. First Line,11/12/2024,Active,Diffuse large B-cell lymphoma of lymph nodes of multiple regions (CMS/HCC),
CINJ OP INFUSION,48644,"Berim, Lyudmyla, MD",12/7/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,12/5/2023,Inactive,,
CINJ OP INFUSION,48644,"Berim, Lyudmyla, MD",12/11/2023,mFOLFOX6 (Fluorouracil Continuous Infusion / Leucovorin / OXALiplatin) + Nivolumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/6/2023,Inactive,,
CINJ OP INFUSION,48644,"Berim, Lyudmyla, MD",9/5/2024,"Nivolumab/Ipilimumab 21 Day Cycles Followed By Nivolumab 240 mg D1, D15 28 Day Cycles- Gastrointestinal Cancers",_2. Second Line,9/4/2024,Inactive,,
CBMC OP INFUSION 2FL,29366,"Wagmiller, Jennifer Ann, MD",9/7/2024,PACLitaxel / CARBOplatin (AUC 6) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,Adjuvant,7/14/2024,Inactive,,
CBMC 2W ONCOLOGY,29366,"Wagmiller, Jennifer Ann, MD",1/7/2025,Liposomal DOXOrubicin 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,1/6/2025,Active,,
CINJ OP INFUSION,17161,"Saraiya, Biren P, MD",5/28/2024,CISplatin 80 mg/m2/ Etoposide 80 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,5/27/2024,Inactive,,
CINJ OP INFUSION,17161,"Saraiya, Biren P, MD",10/8/2024,Durvalumab 1500 mg 28 Day Cycles- Small Cell Cancer of Bladder,Consolidation,9/23/2024,Inactive,,
NBR 5N ONCOLOGY,74081,"Zayac, Adam, MD",2/28/2025,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,2/27/2025,Active,"Acute myeloid leukemia not having achieved remission (CMS/HCC)
Pancytopenia (CMS/HCC)","D46.9 - MDS (myelodysplastic syndrome) (CMS/HCC); C95.92 - Leukemia in relapse, unspecified leukemia type (CMS/HCC)"
CINJ OP INFUSION,36249,"Toppmeyer, Deborah L, MD",4/6/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,First Line,4/5/2023,Inactive,,
CINJ OP INFUSION,36249,"Toppmeyer, Deborah L, MD",11/6/2023,"Capecitabine D1-7, D15-21 28 Day Cycles - Breast",Adjuvant,11/6/2023,Active,,
NBR 4N ONCOLOGY,5647,"Braunschweig, Ira, MD",2/11/2023,CED (Cyclophosphamde/Etoposide/Dexamethasone) 28 Day Cycles- Multiple Myeloma,,2/10/2023,Inactive,,
TRMC TCCC OP INFUSION,62519,"Capo, Gerardo, MD",7/11/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,_1. First Line,7/10/2024,Active,,
CINJ OP INFUSION,83231,"George, Mridula A, MD",5/29/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/28/2024,Inactive,,
CINJ OP INFUSION,83231,"George, Mridula A, MD",12/4/2024,Pertuzumab and Trastuzumab and Hyaluronidase 21 Day Cycles - Breast,Adjuvant,12/4/2024,Active,,
NBR CINJ OP INFUSION,26528,"Zayac, Adam, MD",9/10/2024,Cytarabine (100 mg/m2) / DAUNOrubicin (90 mg/m2) (7 + 3) - Acute Myeloid Leukemia (Induction),_1. First Line,9/9/2024,Inactive,,
NBR CINJ OP INFUSION,26528,"Zayac, Adam, MD",11/4/2024,HiDAC-123 (High-Dose Cytarabine) 28 Day Cycles - Acute Myeloid Leukemia (Consolidation),Consolidation,11/4/2024,Inactive,,
NBR 5N ONCOLOGY,26528,"Zayac, Adam, MD",11/18/2024,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_2. Second Line,11/18/2024,Inactive,,
CINJ OP INFUSION,30507,"Haigentz, Missak, MD",7/10/2023,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,First Line,7/10/2023,Active,,
CBMC OP INFUSION 2FL,83722,"Leitner, Stuart P, MD",11/3/2023,CARBOplatin / Gemcitabine 21 Day Cycles - Bladder,Adjuvant,11/2/2023,Active,,
CINJ OP INFUSION,75502,"Ghodoussipour, Saum Bobak, MD",3/4/2025,CINJ 082303 Arm B Indcution BCG - Bladder Cancer,Induction,3/4/2025,Inactive,Urothelial carcinoma (CMS/HCC),
CINJ OP INFUSION,44347,"Groisberg, Roman, MD",3/24/2023,Liposomal DOXOrubicin 28 Day Cycles - Uterine Sarcoma,,3/23/2023,Inactive,,
MMC OP VP INFUSION,26290,"Cohen, Seth D, MD",8/28/2024,CISplatin with Concurrent Radiation 21 Day Cycles- Head and Neck Cancers,_1. First Line,8/27/2024,Active,,
SOM OUTPT INFUSION,12186,"Patel, Eshan, MD",5/25/2023,Pembrolizumab 21 Day Cycles -  Kidney,,5/25/2023,Inactive,,
JCMC CP INFUSION,6235,"Sekhri, Arunabh, MD",5/5/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,5/4/2023,Inactive,,
JCMC CP INFUSION,6235,"Sekhri, Arunabh, MD",12/8/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Maintenance,12/7/2023,Inactive,,
CINJ OP INFUSION,45950,"Saraiya, Biren P, MD",5/16/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Second Line,5/16/2023,Inactive,,
NBR 5N ONCOLOGY,43010,"Goel, Sanjay, MD",5/4/2025,PACLitaxel weekly / CARBOplatin 21 Day Cycles - Breast,_1. First Line,5/4/2025,Active,Carcinoma of unknown primary (CMS/HCC),"C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; B37.81 - Candidal esophagitis; E22.2 - Syndrome of inappropriate secretion of antidiuretic hormone; R18.8 - Other ascites; E86.9 - Volume depletion, unspecified; C80.1 - Malignant (primary) neoplasm, unspecified; E11.9 - Type 2 diabetes mellitus without complications; I48.0 - Paroxysmal atrial fibrillation; E78.00 - Pure hypercholesterolemia, unspecified; E87.70 - Fluid overload, unspecified; K21.9 - Gastro-esophageal reflux disease without esophagitis; K29.70 - Gastritis, unspecified, without bleeding; R09.02 - Hypoxemia; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; M81.0 - Age-related osteoporosis without current pathological fracture; Z79.01 - Long term (current) use of anticoagulants; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z80.0 - Family history of malignant neoplasm of digestive organs; Z82.3 - Family history of stroke; Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system; Z83.3 - Family history of diabetes mellitus; Z83.438 - Family history of other disorder of lipoprotein metabolism and other lipidemia; Z86.19 - Personal history of other infectious and parasitic diseases; Z98.41 - Cataract extraction status, right eye; Z98.890 - Other specified postprocedural states; Z88.2 - Allergy status to sulfonamides; Z88.8 - Allergy status to other drugs..."
SOM OUTPT INFUSION,28153,"Toomey, Kathleen C, MD",8/27/2024,Daratumumab and Hyaluronidase-fihj / Bortezomib / Dexamethasone / Pomalidomide 21 Day Cycles- Multiple Myeloma transplant candidate,_1. First Line,8/18/2024,Active,,
NBR CINJ OP INFUSION,28153,"Shah, Mansi R, MD",1/2/2025,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Maintenance,12/19/2024,Active,,
CINJ OP INFUSION,41174,"Berim, Lyudmyla, MD",9/30/2024,Pembrolizumab / mFOLFOX (Fluorouracil IVCI / Leucovorin / OXALiplatin) / Trastuzumab 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,9/26/2024,Active,,
CBMC OP INFUSION 2FL,44214,"Leitner, Stuart P, MD",6/21/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,6/12/2024,Inactive,,
CBMC 2W ONCOLOGY,44214,"Leitner, Stuart P, MD",9/27/2024,Pertuzumab / Trastuzumab / Albumin-Bound PACLitaxel weekly 21 Day Cycles - Breast,Neoadjuvant,9/26/2024,Inactive,,
CBMC OP INFUSION 2FL,44214,"Leitner, Stuart P, MD",12/12/2024,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Neoadjuvant,12/11/2024,Active,,
CBMC OP INFUSION 2FL,44214,"Leitner, Stuart P, MD",3/18/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,3/18/2025,Active,"Malignant neoplasm of overlapping sites of right breast in female, estrogen receptor negative (CMS/HCC)
Breast cancer metastasized to axillary lymph node, right (CMS/HCC)",
CMC OP INFUSION,87170,"Taff, Jessica, MD",5/5/2023,FOLFIRI (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,5/4/2023,Inactive,,
CMC OP INFUSION,87170,"Taff, Jessica, MD",12/12/2023,CINJ 072303 TAS-102 / OXALiplatin ODD Cycles / Irinotecan EVEN Cycles / Bevacizumab 14 Day Cycles Research- Colorectal Cancer,_3. Third Line,12/5/2023,Active,,
HAM OP INFUSION,41495,"Yogarajah, Meera, MD",10/11/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/10/2024,Inactive,,
CBMC OP INFUSION 2FL,81108,"Wagmiller, Jennifer Ann, MD",1/26/2024,PACLitaxel + CARBOplatin Weekly (21 Day) x 4 Cycles Followed by DOXOrubicin + Cyclophoshamide Day x 4 Cycles ,Adjuvant,1/26/2024,Active,,
NBI OP INFUSION,46113,"Anderson, Patrick S, MD",3/27/2025,Dostarlimab-gxly / Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles+ Dostarlimab-gxly 42 Day Cycles- Uterine,_2. Second Line,3/27/2025,Active,"Malignant neoplasm of uterus, part unspecified (CMS/HCC)
Malignant neoplasm of endometrium (CMS/HCC)",
CINJ OP INFUSION,54755,"Saraiya, Biren P, MD",10/3/2024,Pembrolizumab 21 Day Cycles - Kidney,Adjuvant,10/3/2024,Active,,
CBMC OP INFUSION 2FL,65776,"Dave, Manish, MD",12/11/2023,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,12/11/2023,Inactive,,
MMC OP VP INFUSION,29633,"Cohen, Seth D, MD",4/8/2024,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,4/2/2024,Inactive,,
CINJ OP INFUSION,58886,"Haigentz, Missak, MD",5/22/2023,CINJ 032013 (EA5181) ARM A Durvalumab / PACLitaxel / CARBOplatin 7 Day Cycles Research- Non-Small Cell Lung Cancer,First Line,5/22/2023,Inactive,,
CINJ OP INFUSION,58886,"Haigentz, Missak, MD",7/19/2023,CINJ 032013 (EA5181) ARM C Durvalumab 28 Day Cycles Consolidative Research- Non-Small Cell Lung Cancer,Consolidation,7/18/2023,Active,,
CBMC OP INFUSION 2FL,14182,"Raptis, George, MD",3/26/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,3/25/2024,Inactive,,
CBMC OP INFUSION 2FL,14182,"Raptis, George, MD",4/17/2024,Pertuzumab Trastuzumab (Initiation) 21 Day Cycles - Breast,_1. First Line,4/15/2024,Inactive,,
CBMC OP INFUSION 2FL,65880,"Raptis, George, MD",1/6/2025,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,_2. Second Line,12/23/2024,Active,,
NBR CINJ OP INFUSION,97233,"Tiger, Yun Kyoung, MD",4/10/2024,R-CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,4/9/2024,Inactive,,
HAM OP INFUSION,78883,"Patel, Malini M, MD",11/5/2024,Lenalidomide D1-D28 Maintenance 28 Day Cycles - Multiple Myeloma,_2. Second Line,11/5/2024,Active,,
HAM OP INFUSION,78883,"Patel, Malini M, MD",12/10/2024,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,_1. First Line,12/3/2024,Active,,
NBR CINJ OP INFUSION,38446,"Zayac, Adam, MD",7/29/2024,Venetoclax / Decitabine 28 Day Cycles - Relapsed Myelodysplastic Syndrome,_2. Second Line,7/28/2024,Inactive,,
NBR CINJ OP INFUSION,38446,"Zayac, Adam, MD",11/25/2024,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_3. Third Line,11/25/2024,Active,Malignant neoplasm of ascending colon (CMS/HCC),
NBR CINJ OP INFUSION,38446,"Zayac, Adam, MD",1/6/2025,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_3. Third Line,11/25/2024,Active,"Malignant neoplasm of lower-outer quadrant of left breast of female, estrogen receptor negative (CMS/HCC)",
NBR CINJ OP INFUSION,98191,"Zayac, Adam, MD",3/17/2025,Venetoclax / Decitabine Subcutaneous Low-Dose Weekly 28 Day Cycles - Myelodysplastic Syndromes / Acute Myeloid Leukemia,_3. Third Line,11/25/2024,Active,"Myelodysplastic syndrome, unspecified (CMS/HCC)
Pancytopenia (CMS/HCC)",
CBMC OP INFUSION 2FL,25729,"Raptis, George, MD",4/5/2024,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles - Breast,Neoadjuvant,4/4/2024,Inactive,,
CBMC OP INFUSION 2FL,25729,"Raptis, George, MD",5/31/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,Adjuvant,5/30/2024,Inactive,,
CBMC OP INFUSION 2FL,25729,"Raptis, George, MD",10/9/2024,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,10/8/2024,Inactive,,
CBMC OP INFUSION 2FL,25729,"Raptis, George, MD",10/25/2024,PACLitaxel Dose-Dense 14 Day Cycles - Breast,_2. Second Line,10/24/2024,Inactive,,
CINJ OP INFUSION,27630,"Saraiya, Biren P, MD",5/8/2023,PACLitaxel 175 mg/m2 /CARBOplatin 21 Day Cycles ,,5/7/2023,Inactive,,
CINJ OP INFUSION,27630,"Saraiya, Biren P, MD",10/3/2023,"Gemcitabine D1, D8/Vinorelbine D1, D8 21 Day Cycles- Head and Neck Cancers",Third Line,10/1/2023,Inactive,,
CINJ OP INFUSION,27630,"Goel, Sanjay, MD",10/23/2023,CINJ 052008 / R7075-ONC-2009 Dose Level 9W REGN7075 / Cemiplimab 350 mg 42 Day Day Cycles Combination Research- Solid Tumors,,9/3/2023,Inactive,,
CINJ OP INFUSION,46618,"Ghodoussipour, Saum Bobak, MD",8/2/2024,BCG Induction (TICE) 42 Day Cycle - Bladder,Induction,8/1/2024,Inactive,,
CINJ OP INFUSION,46618,"Ghodoussipour, Saum Bobak, MD",11/8/2024,BCG Maintenance (TICE) 3/6/12 Schedule - Bladder,Adjuvant,11/8/2024,Active,,
CINJ OP INFUSION,45568,"Leiser, Aliza, MD",4/3/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,_2. Second Line,4/3/2025,Active,Squamous cell carcinoma of vulva (CMS/HCC),
TRMC TCCC OP INFUSION,18752,"Capo, Gerardo, MD",10/9/2024,Gemcitabine 1250 mg/m2 /CISplatin 75 mg/m2  21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,10/8/2024,Active,,
TRMC TCCC OP INFUSION,43885,"Capo, Gerardo, MD",5/14/2025,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/14/2025,Active,Primary squamous cell carcinoma of lower lobe of left lung (CMS/HCC),"D64.9 - Anemia, unspecified; C34.32 - Malignant neoplasm of lower lobe, left bronchus or lung"
JCMC CP INFUSION,5411,"Sekhri, Arunabh, MD",5/16/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,Adjuvant,5/16/2025,Active,"Cervical cancer, FIGO stage IB1 (CMS/HCC)","C53.9 - Malignant neoplasm of cervix uteri, unspecified; R45.89 - Other symptoms and signs involving emotional state; R56.9 - Unspecified convulsions; Z01.818 - Encounter for other preprocedural examination"
CMC OP INFUSION,25174,"Pompa, Tiffany Ann, MD",11/6/2024,"Nivolumab (D1, D15) 28 Day Cycles - Melanoma",Adjuvant,11/5/2024,Active,,
SOM 1PAV ONCOLOGY,93065,"Patel, Eshan, MD",4/14/2025,CISplatin 75 mg/m2 / Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Cancers,_1. First Line,4/14/2025,Active,Small cell carcinoma of upper lobe of right lung (CMS/HCC),"C7A.1 - Malignant poorly differentiated neuroendocrine tumors; R65.11 - Systemic inflammatory response syndrome (sirs) of non-infectious origin with acute organ dysfunction; J96.21 - Acute and chronic respiratory failure with hypoxia; Z66 - Do not resuscitate; J91.0 - Malignant pleural effusion; J44.1 - Chronic obstructive pulmonary disease with (acute) exacerbation; E11.65 - Type 2 diabetes mellitus with hyperglycemia; E03.9 - Hypothyroidism, unspecified; F32.A - Depression, unspecified; I10 - Essential (primary) hypertension; Z95.828 - Presence of other vascular implants and grafts; E11.9 - Type 2 diabetes mellitus without complications; Z79.4 - Long term (current) use of insulin; E87.8 - Other disorders of electrolyte and fluid balance, not elsewhere classified; G47.00 - Insomnia, unspecified; E87.5 - Hyperkalemia; J98.11 - Atelectasis; J98.4 - Other disorders of lung; E78.5 - Hyperlipidemia, unspecified; Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits; Z98.890 - Other specified postprocedural states; Z99.81 - Dependence on supplemental oxygen; Z87.891 - Personal history of nicotine dependence; Z79.899 - Other long term (current) drug therapy; Z79.890 - Hormone replacement therapy; Z59.811 - Housing instability, housed, with risk of homelessness; Z79.02 - Long term (current) use of antithrombotics/antiplatelets; Z80.0 - Family history of malignant neoplasm of digestive organs; Z80.3 - Family history of mali..."
HAM OP INFUSION,40962,"Yogarajah, Meera, MD",4/8/2024,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_1. First Line,4/7/2024,Active,,
CINJ OP INFUSION,39881,"Kennedy, Timothy, MD",9/9/2024,HIPEC MitoMYcin Intraperitoneal - Peritoneal Metastases,Adjuvant,9/9/2024,Active,,
CBMC OP INFUSION 2FL,25733,"Radovich, Delia, MD",11/6/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,11/5/2023,Inactive,"Adenocarcinoma, appendix (CMS/HCC)",
CBMC OP INFUSION 2FL,25733,"Mack, Alleda Eileen, MD",6/12/2024,Capecitabine/Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_2. Second Line,6/10/2024,Inactive,"Adenocarcinoma, appendix (CMS/HCC)",
CBMC OP INFUSION 2FL,25733,"Dharmapuri, Sirish, MD",1/6/2025,Irinotecan + Bevacizumab 14 Day Cycles- Gastrointestinal Cancers,_3. Third Line,1/5/2025,Active,,
SOM OUTPT INFUSION,32599,"Patel, Eshan, MD",5/12/2025,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/12/2025,Active,Rectal cancer (CMS/HCC),C20 - Malignant neoplasm of rectum; Z78.0 - Asymptomatic menopausal state; I10 - Essential (primary) hypertension; Z12.11 - Encounter for screening for malignant neoplasm of colon
SOM OUTPT INFUSION,32599,"Patel, Eshan, MD",3/17/2025,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,_1. First Line,3/17/2025,Inactive,Rectal cancer (CMS/HCC),
CINJ OP INFUSION,94733,"Hochster, Howard S, MD",9/27/2024,Fam-Trastuzumab Deruxtecan-nxki 21 Day Cycles- Gastrointestinal Cancer,_3. Third Line,9/24/2024,Active,,
NBR CINJ OP INFUSION,42589,"Matasar, Matthew J, MD",2/24/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,First Line,2/20/2023,Inactive,,
CINJ OP INFUSION,6622,"Saraiya, Biren P, MD",3/28/2023,Cabozantinib / Nivolumab 28 Day Cycles - Kidney,First Line,3/28/2023,Inactive,,
CINJ OP INFUSION,6622,"Saraiya, Biren P, MD",8/20/2024,Lenvatinib everolimus - Kidney,_2. Second Line,8/20/2024,Active,,
SOM OUTPT INFUSION,64168,"Patel, Eshan, MD",8/27/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/20/2024,Inactive,,
NBR 5N ONCOLOGY,94619,"Palmisiano, Neil David, MD",11/28/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,11/28/2023,Inactive,,
NBR 4N BMTU/IMCU,94619,"Assal, Amer, MD",5/24/2024,BMT Allogeneic TBF + Post Cy (Reduced Intensity),_1. First Line,5/23/2024,Inactive,,
JCMC CP INFUSION,9983,"Cruz, Allan Louie E, MD",6/6/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,6/5/2023,Inactive,,
NBR CINJ OP INFUSION,88443,"Rhodes, Joanna Meehan, MD",4/2/2024,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - B-Cell Lymphoma,_1. First Line,4/2/2024,Inactive,,
JCMC CP INFUSION,91437,"Cruz, Allan Louie E, MD",5/7/2024,PACLitaxel 175 mg/m2 /CARBOplatin 5 AUC 21 Day Cycles Neoadjuvant/Adjuvant- Non-Small Cell Lung Cancer,_1. First Line,5/2/2024,Inactive,,
NBR 4N ONCOLOGY,19827,"Egini, Ogechukwu, MD",3/19/2025,BMT Allogeneic rATG / Flu / Cy / TBI + Post Cy,_3. Third Line,3/9/2025,Active,Stem cells transplant status (CMS/HCC),
SOM OUTPT INFUSION,85535,"Toomey, Kathleen C, MD",9/29/2023,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,First Line,9/26/2023,Inactive,,
CBMC OP INFUSION 2FL,22420,"Dharmapuri, Sirish, MD",10/18/2024,"Gemcitabine D1, D15 /Albumin-Bound PACLItaxel D1, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,10/13/2024,Active,,
TRMC TCCC OP INFUSION,8988,"Capo, Gerardo, MD",10/8/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,9/30/2024,Active,,
NBR 5N ONCOLOGY,34219,"Gulhati, Prateek, MD PhD",3/22/2023,Conventional Transarterial Chemoembolization (cTACE) with DOXOrubicin - Hepatocellular Cancer,,3/22/2023,Inactive,,
CINJ OP INFUSION,34219,"Gulhati, Prateek, MD PhD",4/27/2023,CINJ 072105 Tislelizumab Consolidation Cycle 1 (Pre-Radiation) Research- Hepatocellular Carcinoma,,3/23/2023,Inactive,,
CBMC OP INFUSION 2FL,79768,"Grossman, I Robert, MD",9/9/2024,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,_2. Second Line,9/8/2024,Inactive,,
MMC OP VP INFUSION,5146,"Meghal, Trishala, MD",7/17/2024,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,Neoadjuvant,7/8/2024,Inactive,,
MMC OP VP INFUSION,5146,"Meghal, Trishala, MD",11/22/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Adjuvant,11/14/2024,Active,,
MMC OP VP INFUSION,5146,"Meghal, Trishala, MD",1/24/2025,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,1/23/2025,Active,,
SOM OUTPT INFUSION,46671,"Patel, Eshan, MD",2/16/2023,TCH+P (DOCEtaxel / CARBOplatin / Trastuzumab / Pertuzumab) 21 Day Cycles - Breast,,2/15/2023,Inactive,,
CBMC OP INFUSION 2FL,92239,"Leitner, Stuart P, MD",4/1/2024,CINJ 082201 (NRG-GU010) ARM 4 Androgen Deprivation Therapy / Darolutamide 3 Month Cycles (90 Days) Research- Prostate Cancer,Adjuvant,3/3/2024,Inactive,,
CINJ OP INFUSION,4369,"Patel, Eshan, MD",3/29/2024,CISplatin with Concurrent Radiation 49 Day Cycle- Head and Neck Cancers,_1. First Line,3/28/2024,Inactive,Malignant neoplasm of nasal cavity (CMS/HCC),
CINJ OP INFUSION,4369,"Patel, Eshan, MD",9/9/2024,CISplatin 25 mg/m2 D1-D3 /Etoposide 80 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,9/8/2024,Inactive,Malignant neoplasm of nasal cavity (CMS/HCC),
CINJ OP INFUSION,4369,"Muralikrishnan, Sivraj, MD",1/17/2025,"DOCEtaxel / Irinotecan ad hoc order set D1, D8, D15  28 Day Cycles-olfactory neuroblastoma per https://doi.org/10.1002/cncr.23246",_3. Third Line,12/17/2024,Active,,
CBMC OP INFUSION 2FL,80858,"Raptis, George, MD",9/27/2024,TC (DOCEtaxel / Cyclophosphamide) 21 Day Cycles - Breast,Adjuvant,9/24/2024,Active,Glioblastoma (CMS/HCC),
CINJ OP INFUSION,88375,"Patankar, Sonali, MD",12/5/2024,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar Cancer,_1. First Line,11/24/2024,Active,,
CINJ OP INFUSION,8012,"Berim, Lyudmyla, MD",4/28/2025,PACLitaxel/CARBOplatin with Concurrent Radiation 35 Day Cycle- Esophageal and Esophagogastric Junction Cancers,Neoadjuvant,4/28/2025,Active,Malignant neoplasm of esophagus (CMS/HCC),"C15.4 - Malignant neoplasm of middle third of esophagus; E11.22 - Type 2 diabetes mellitus with diabetic chronic kidney disease; N18.9 - Chronic kidney disease, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; I25.10 - Atherosclerotic heart disease of native coronary artery without angina pectoris; E66.9 - Obesity, unspecified; Z68.37 - Body mass index (BMI) 37.0-37.9, adult; Z98.49 - Cataract extraction status, unspecified eye; Z90.5 - Acquired absence of kidney; Z79.82 - Long term (current) use of aspirin; Z79.84 - Long term (current) use of oral hypoglycemic drugs; Z79.899 - Other long term (current) drug therapy; Z87.891 - Personal history of nicotine dependence; Z51.11 - Encounter for antineoplastic chemotherapy; C15.9 - Malignant neoplasm of esophagus, unspecified"
CINJ OP INFUSION,72437,"Stephenson, Ruth D, DO",7/13/2023,"Gemcitabine (D1, D8) 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer",Third Line,7/11/2023,Inactive,,
CINJ OP INFUSION,71587,"Omene, Coral Oghenerukevwe, MD",11/6/2023,PACLitaxel weekly 28 Day Cycles - Breast (Adjuvant / Neoadjuvant),Adjuvant,11/5/2023,Inactive,,
CINJ OP INFUSION,71587,"Omene, Coral Oghenerukevwe, MD",11/21/2023,PACLitaxel weekly / Trastuzumab weekly 28 Day Cycles - Breast,Adjuvant,11/5/2023,Inactive,,
CINJ OP INFUSION,71587,"Omene, Coral Oghenerukevwe, MD",11/21/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,Adjuvant,10/24/2023,Inactive,,
CINJ OP INFUSION,71587,"Omene, Coral Oghenerukevwe, MD",2/27/2024,Trastuzumab 21 Day Cycles (Continuation) - Breast,Adjuvant,2/26/2024,Inactive,,
NBR CINJ OP INFUSION,84778,"Palmisiano, Neil David, MD",6/26/2023,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,,6/11/2023,Inactive,,
NBR CINJ OP INFUSION,84778,"Palmisiano, Neil David, MD",2/27/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,_1. First Line,2/26/2024,Inactive,,
NBR CINJ OP INFUSION,84778,"Palmisiano, Neil David, MD",3/1/2024,AzaCITIDine 28 Day Cycles - Myelodysplastic Syndromes,Induction,2/26/2024,Inactive,,
CMC OP INFUSION,62031,"Taff, Jessica, MD",4/15/2024,CISplatin / Etoposide (60/120) 21 Day Cycles - High Grade Neuroendocrine,Neoadjuvant,4/14/2024,Inactive,,
CINJ OP INFUSION,41792,"Hochster, Howard S, MD",5/9/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/7/2024,Inactive,,
CINJ OP INFUSION,41792,"Hochster, Howard S, MD",10/31/2024,Capecitabine/Bevacizumab 21 Day Cycles- Gastrointestinal Cancers,Maintenance,10/31/2024,Active,,
CINJ OP INFUSION,41792,"Hochster, Howard S, MD",1/30/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,1/29/2025,Active,,
CINJ OP INFUSION,41792,"Hochster, Howard S, MD",1/30/2025,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_2. Second Line,1/29/2025,Inactive,Adenocarcinoma of unknown primary (CMS/HCC),
NBR CINJ OP INFUSION,60426,"Shah, Mansi R, MD",5/31/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,5/15/2024,Active,,
NBR CINJ OP INFUSION,60426,"Egini, Ogechukwu, MD",7/10/2024,BMT Autologous Melphalan Day -1  200mg/m2,Consolidation,7/1/2024,Inactive,,
CMC OP INFUSION,41856,"Tang, Horace, MD",6/21/2023,Nivolumab+ PACLitaxel/CARBOplatin (AUC 5) Checkmate 816 Non-Small Cell Lung Cancer,Neoadjuvant,6/21/2023,Inactive,,
CMC OP INFUSION,41856,"Tang, Horace, MD",1/15/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_2. Second Line,1/14/2024,Inactive,,
NBR CINJ OP INFUSION,28671,"Shah, Mansi R, MD",10/13/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Non-Oncology Research,10/3/2024,Inactive,,
CINJ OP INFUSION,86900,"Ghodoussipour, Saum Bobak, MD",1/26/2023,Mitomycin for Pyelocalyceal Instillation (Ureteral Gel) - Urothelial ,Induction,1/25/2023,Inactive,,
NBR CINJ OP INFUSION,40077,"Shah, Mansi R, MD",3/21/2024,CINJ 011910 Loratadine / Placebo 15 Day Cycle Research- Multiple Myeloma,Maintenance,3/21/2024,Inactive,,
HAM OP INFUSION,26830,"Yogarajah, Meera, MD",3/16/2023,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer ,First Line,2/26/2023,Inactive,,
HAM OP INFUSION,26830,"Yogarajah, Meera, MD",9/12/2023,adjuvant NSCLC after resection,Maintenance,7/23/2023,Inactive,,
HAM OP INFUSION,26830,"Yogarajah, Meera, MD",9/10/2024,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,8/21/2024,Inactive,,
HAM OP INFUSION,26830,"Yogarajah, Meera, MD",12/3/2024,Pembrolizumab/PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,11/25/2024,Active,,
CMC OP INFUSION,49139,"Taff, Jessica, MD",1/8/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,12/17/2023,Inactive,,
CMC OP INFUSION,49139,"Taff, Jessica, MD",6/10/2024,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Consolidation,6/9/2024,Active,,
NBR CINJ OP INFUSION,47496,"Egini, Ogechukwu, MD",8/14/2024,BMT Allogeneic Flu / Mel (100 mg/m2) + Post Cy,_2. Second Line,8/10/2024,Inactive,,
NBR 4N ONCOLOGY,47496,"Schaar, Dale, MD PhD",12/18/2024,Decitabine (Maintenance Phase) 28 Day Cycles - Acute Myeloid Leukemia,_3. Third Line,12/17/2024,Inactive,,
NBR 4N ONCOLOGY,47496,"Schaar, Dale, MD PhD",12/18/2024,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_4. Fourth Line,12/17/2024,Active,Prostate cancer metastatic to intraabdominal lymph node (CMS/HCC),
NBR CINJ OP INFUSION,47496,"Egini, Ogechukwu, MD",1/17/2025,Venetoclax / AzaCITIDine 28 Day Cycles - Acute Myeloid Leukemia,_5. Fifth Line,1/16/2025,Active,Acute erythroid leukemia not having achieved remission (CMS/HCC),
NBR CINJ OP INFUSION,47496,"Chen, Xiaoyi",4/2/2025,CINJ 022305 Non-Intensive Outpatient Ziftomenib / Venetoclax / Azacitidine,_5. Fifth Line,4/2/2025,Inactive,"Acute monocytic leukemia not having achieved remission (CMS/HCC)
Other secondary thrombocytopenia",
CBMC OP INFUSION 2FL,74432,"Brown, Andrew Bennett, MD",1/21/2025,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,1/21/2025,Active,,
CBMC OP INFUSION 2FL,74432,"Brown, Andrew Bennett, MD",5/28/2025,Bevacizumab 28 Day Cycles - CNS,_2. Second Line,5/28/2025,Active,GBM (glioblastoma multiforme) (CMS/HCC),C71.9 - Glioblastoma (CMS/HCC)
NBR CINJ OP INFUSION,85773,"Matasar, Matthew J, MD",9/26/2023,GVD (Gemcitabine / VinORELBine / NO Liposomal DOXOrubicin) 21 Day Cycles - Hodgkin Lymphoma,,9/25/2023,Inactive,,
CINJ OP INFUSION,96451,"Patel, Eshan, MD",7/3/2023,PACLitaxel / CARBOplatin with Concurrent Radiation  7 Day Cycles - salivary gland Cancer,,7/2/2023,Inactive,,
CBMC OP INFUSION 2FL,2441,"Wagmiller, Jennifer Ann, MD",10/6/2023,Pembrolizumab 21 Day Cycles - Uterine,_1. First Line,10/5/2023,Active,,
CINJ OP INFUSION,47105,"Patel, Eshan, MD",9/22/2023,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,,9/21/2023,Inactive,,
CINJ OP INFUSION,47105,"Patel, Eshan, MD",12/1/2023,Durvalumab 1500 mg 28 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,11/30/2023,Inactive,,
NBR CINJ OP INFUSION,47105,"Patel, Eshan, MD",4/19/2024,"DOCEtaxel D1, D8, D15  28 Day Cycles-Non-Small Cell Lung Cancer",_1. First Line,4/18/2024,Inactive,,
CINJ OP INFUSION,55844,"Haigentz, Missak, MD",3/15/2023,PEMEtrexed Maintenance 21 Day Cycles- Non-Small Cell Lung Cancer,Maintenance,3/15/2023,Inactive,,
CINJ OP INFUSION,55844,"Haigentz, Missak, MD",5/2/2023,PEMEtrexed 21 Day Cycles (Maintenance)- Non-Small Cell Lung Cancer,Maintenance,5/1/2023,Inactive,,
CINJ OP INFUSION,95882,"George, Mridula A, MD",12/30/2024,CINJ 042312 Arm B Camizestrant +/- Abemaciclib +/- LHRH Agonist 90 / 180 Day Cycles Research- Breast Cancer,Adjuvant,12/30/2024,Active,,
NBI OP INFUSION,7049,"Cohen, Alice, MD",10/11/2023,Daratumumab and Hyaluronidase-fihj / Pomalidomide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_4. Fourth Line,10/10/2023,Active,,
MMC OP INFUSION,65814,"Meghal, Trishala, MD",3/11/2024,Albumin-Bound PACLitaxel / CARBOplatin 21 Day Cycles- Uterine,Adjuvant,3/10/2024,Active,,
CBMC OP INFUSION 1FL,70772,"Meelheim, Brooke A, DO",1/14/2025,Dostarlimab-gxly / PACLitaxel / CARBOplatin 21 Day Cycles + Dostarlimab-gxly 42 Day Cycles - Uterine,Adjuvant,12/25/2024,Active,,
CBMC OP INFUSION 2FL,82263,"Derosa, William T, DO",1/17/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,1/13/2025,Active,,
CINJ OP INFUSION,85218,"Weiss, Sarah, MD",12/11/2024,Nivolumab (3 mg/Kg) / Ipilimumab (1 mg/kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,Neoadjuvant,12/10/2024,Active,,
NBI OP INFUSION,58219,"Anderson, Patrick S, MD",11/9/2023,Liposomal DOXOrubicin / Bevacizumab 28 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_2. Second Line,11/1/2023,Inactive,,
MMC OP VP INFUSION,54995,"Cohen, Seth D, MD",9/26/2023,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,,9/25/2023,Inactive,,
MMC OP VP INFUSION,54995,"Cohen, Seth D, MD",5/23/2024,Abemaciclib 28 Day Cycles - Breast,_1. First Line,5/23/2024,Active,,
CBMC OP INFUSION 2FL,76204,"Litvak, Anna M, MD",11/16/2023,Capecitabine 21 Day Cycles - Breast,_2. Second Line,11/16/2023,Inactive,,
CBMC OP INFUSION 2FL,76204,"Ligresti, Louise G, MD",10/3/2024,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_3. Third Line,9/30/2024,Inactive,,
TRMC TCCC OP INFUSION,65239,"Capo, Gerardo, MD",2/28/2024,CINJ 032006 (BTCRC-LUN18-153) ARM A Pembrolizumab 42 Day Cycles Research- Non-Small Cell Lung Cancer,_1. First Line,1/30/2024,Active,,
NBR CINJ OP INFUSION,1912,"Evens, Andrew M, DO",7/6/2023,CINJ 112305 ADULT Initial Cycles (ALL ARMS) ABVD (DOXOrubicin / Bleomycin / VinBLAStine / Dacarbazine) 28 Day Cycle Research- Hodgkin Lymphoma,,7/5/2023,Inactive,,
NBR CINJ OP INFUSION,1912,"Evens, Andrew M, DO",9/6/2023,"CINJ 112305 Arms B,D,F,H (Brentuximab Vendotin + Nivolumab) 21 Day Cycles - Hodgkin Lymphoma",Consolidation,9/5/2023,Active,,
CBMC 2W ONCOLOGY,88715,"Grossman, I Robert, MD",2/25/2025,Pola-R-CHP (Cyclophosphamide / DOXOrubicin / Polatuzumab Vedotin / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_1. First Line,2/24/2025,Active,Diffuse large B-cell lymphoma (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; C83.32 - Diffuse large b-cell lymphoma, intrathoracic lymph nodes; I10 - Essential (primary) hypertension; E78.00 - Pure hypercholesterolemia, unspecified; Z63.4 - Disappearance and death of family member; Z79.899 - Other long term (current) drug therapy; Z87.442 - Personal history of urinary calculi; Z92.3 - Personal history of irradiation; Z85.3 - Personal history of malignant neoplasm of breast"
CBMC OP INFUSION 2FL,98981,"Brown, Andrew Bennett, MD",10/17/2023,FOLFIRINOX (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan/OXALIplatin) 14 Day Cycles- Pancreatic Adenocarcinoma,_1. First Line,10/16/2023,Active,,
CBMC OP INFUSION 2FL,63739,"Brown, Andrew Bennett, MD",4/3/2025,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",_1. First Line,4/3/2025,Inactive,Malignant neoplasm of overlapping sites of pancreas (CMS/HCC),
JCMC CP INFUSION,63135,"Sekhri, Arunabh, MD",2/6/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,First Line,2/5/2023,Inactive,,
JCMC CP INFUSION,63135,"Sekhri, Arunabh, MD",5/1/2023,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,Second Line,4/30/2023,Inactive,,
CINJ OP INFUSION,25466,"Leiser, Aliza, MD",3/30/2023,PACLitaxel / CARBOplatin (AUC 5) 21 Day Cycles - Endometrial Cancer,,3/13/2023,Inactive,,
CINJ OP INFUSION,25466,"Leiser, Aliza, MD",8/15/2023,Pembrolizumab 21 Day Cycles - Uterine,,8/14/2023,Inactive,,
CINJ OP INFUSION,25466,"Leiser, Aliza, MD",10/5/2023,Lenvatinib / Pembrolizumab 21 Day Cycles - Uterine,,9/12/2023,Inactive,,
CINJ OP INFUSION,25466,"Leiser, Aliza, MD",8/27/2024,Liposomal DOXOrubicin / CARBOplatin 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer ,_3. Third Line,8/12/2024,Active,,
CBMC OP INFUSION 2FL,88319,"Brown, Andrew Bennett, MD",3/24/2025,Bevacizumab 28 Day Cycles - CNS,Induction,3/24/2025,Active,Astrocytoma brain tumor (CMS/HCC),"C71.9 - Malignant neoplasm of brain, unspecified; G93.41 - Metabolic encephalopathy; G93.5 - Compression of brain; G93.6 - Cerebral edema; D63.0 - Anemia in neoplastic disease; R47.01 - Aphasia; R73.9 - Hyperglycemia, unspecified; T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter; Z79.899 - Other long term (current) drug therapy; Z92.3 - Personal history of irradiation; Z91.013 - Allergy to seafood; Z98.890 - Other specified postprocedural states"
HAM OP INFUSION,73188,"Yogarajah, Meera, MD",3/14/2025,"Gemcitabine D1, D8 21 Day Cycles- Gastrointestinal Cancers",_1. First Line,3/10/2025,Inactive,"Cholangiocarcinoma (CMS/HCC)
Elevated carcinoembryonic antigen (CEA)",
MMC OP INFUSION,84354,"Lee, Patrick C, MD",2/13/2024,Atezolizumab/CARBOplatin/Etoposide 21 Day Cycles- Small Cell Lung Cancer,_1. First Line,2/4/2024,Inactive,,
MMC OP INFUSION,84354,"Lee, Patrick C, MD",9/23/2024,Tarlatamab 28 Day Cycles - Small Cell Lung Cancer,_2. Second Line,9/23/2024,Active,"Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (CMS/HCC)",
CMC OP INFUSION,47692,"Pompa, Tiffany Ann, MD",1/21/2025,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell / Basal Cell Skin Cancer,_1. First Line,1/20/2025,Active,,
SOM OUTPT INFUSION,25106,"Patel, Eshan, MD",11/5/2024,Low-Dose Gemcitabine w / Concurrent Radiation Induction 28 Day Cycle / Consolidation 21 Day Cycle- Bladder,_1. First Line,10/31/2024,Active,,
CINJ OP INFUSION,73830,"Haigentz, Missak, MD",1/4/2024,CARBOplatin/Etoposide D1-D3 28 Day Cycles- Small Cell Lung Cancer,_1. First Line,1/4/2024,Inactive,,
CINJ OP INFUSION,73830,"Haigentz, Missak, MD",9/6/2024,Pembrolizumab 21 Day Cycles- Small Cell Lung Cancer,_2. Second Line,9/5/2024,Active,,
CINJ OP INFUSION,73830,"Haigentz, Missak, MD",9/6/2024,Durvalumab 1500 mg 28 Day Cycles- Small Cell Lung Cancer,Consolidation,9/6/2024,Inactive,,
CINJ OP INFUSION,79521,"Saraiya, Biren P, MD",4/3/2023,Abiraterone / PredniSONE 30 Day Cycles - Prostate,Second Line,4/3/2023,Inactive,,
CINJ OP INFUSION,79521,"Saraiya, Biren P, MD",1/2/2024,Enzalutamide 30 Day Cycles - Prostate,_2. Second Line,1/2/2024,Active,,
SOM OUTPT INFUSION,83197,"Yin, Faye, MD",3/5/2024,PACLitaxel / CARBOplatin with Concurrent Radiation Induction 7 Day Cycles - Non-Small Cell Lung Cancer,_1. First Line,3/4/2024,Inactive,,
CINJ OP INFUSION,72734,"Boland, Patrick M, MD",12/12/2023,mFOLFOX6 + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,12/11/2023,Active,,
NBI OP INFUSION,57586,"Jacoby, Sari H, MD",2/26/2025,Roswell Park Leucovorin/Fluorouracil 56 Day Cycles- Colon Cancer,_1. First Line,1/28/2025,Active,Colon adenocarcinoma (CMS/HCC),"C16.2 - Malignant neoplasm of body of stomach; I50.43 - Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure; E44.0 - Moderate protein-calorie malnutrition; C78.5 - Secondary malignant neoplasm of large intestine and rectum; D68.9 - Coagulation defect, unspecified; D62 - Acute posthemorrhagic anemia; E88.09 - Other disorders of plasma-protein metabolism, not elsewhere classified; J91.8 - Pleural effusion in other conditions classified elsewhere; I27.20 - Pulmonary hypertension, unspecified; E87.20 - Acidosis, unspecified; E87.1 - Hypo-osmolality and hyponatremia; Z68.1 - Body mass index (BMI) 19.9 or less, adult; I82.462 - Acute embolism and thrombosis of left calf muscular vein; R19.5 - Other fecal abnormalities; Z11.52 - Encounter for screening for COVID-19; K59.00 - Constipation, unspecified; Z17.32 - Human epidermal growth factor receptor 2 negative status; I95.9 - Hypotension, unspecified; F17.210 - Nicotine dependence, cigarettes, uncomplicated; R00.0 - Tachycardia, unspecified; K57.10 - Diverticulosis of small intestine without perforation or abscess without bleeding; K22.89 - Other specified disease of esophagus; K64.8 - Other hemorrhoids; Z98.0 - Intestinal bypass and anastomosis status; Z75.1 - Person awaiting admission to adequate facility elsewhere"
CBMC 2W ONCOLOGY,79600,"Scoppetuolo, Michael, MD",5/31/2024,Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_2. Second Line,5/29/2024,Inactive,,
SOM OUTPT INFUSION,53938,"Patel, Eshan, MD",6/10/2024,Abiraterone / PredniSONE 30 Day Cycles - Prostate,_1. First Line,6/10/2024,Active,,
SOM OUTPT INFUSION,56860,"Yin, Faye, MD",12/1/2023,Fedratinib 30 Day Cycles - Myelofibrosis,_2. Second Line,12/1/2023,Inactive,,
CINJ OP INFUSION,8515,"Patel, Eshan, MD",1/17/2023,CARBOplatin/Etoposide D1-D3 + Durvalumab 21 Day Cycles- Small Cell Lung Cancer,,1/16/2023,Inactive,,
CINJ OP INFUSION,3479,"Haigentz, Missak, MD",5/4/2024,Osimertinib 28 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/4/2024,Active,,
CINJ OP INFUSION,3479,"Haigentz, Missak, MD",5/22/2024,PEMEtrexed/CARBOplatin (AUC 5) 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/14/2024,Inactive,,
CINJ OP INFUSION,3479,"Haigentz, Missak, MD",8/14/2024,PEMEtrexed 21 Day Cycles (Maintenance)- Non-Small Cell Lung Cancer,Maintenance,8/6/2024,Active,,
CINJ OP INFUSION,60819,"Berim, Lyudmyla, MD",8/10/2023,FLOT (Fluorouracil IVCI 2400 mg/m2 over 24 hours/Leucovorin/OXALIplatin/DOCEtaxel) 14 Day Cycles- Gastrointestinal Cancers,Adjuvant,8/1/2023,Inactive,,
NBR 4N ONCOLOGY,69936,"Rhodes, Joanna Meehan, MD",2/17/2025,CEOP (Cyclophosphamide / Etoposide / VinCRIStine / PredniSONE) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,_2. Second Line,2/17/2025,Active,Diffuse large B cell lymphoma (CMS/HCC),; C83.30 - Diffuse large B cell lymphoma (CMS/HCC)
NBR 4N ONCOLOGY,8628,"Chen, Xiaoyi",3/11/2025,Dose-Adjusted R-EPOCH (Etoposide / DOXOrubicin / VinCRIStine / Cyclophosphamide / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma (Inpatient Regimen),_1. First Line,3/11/2025,Inactive,Diffuse large B cell lymphoma (CMS/HCC),
CINJ OP INFUSION,19911,"George, Mridula A, MD",8/16/2023,Palbociclib 28 Day Cycles - Breast,First Line,8/16/2023,Inactive,,
HAM OP INFUSION,95310,"Yogarajah, Meera, MD",6/24/2024,NEoadjuvant Pembrolizuamb + radition and adjuvant treatment,_1. First Line,6/21/2024,Active,,
SOM OUTPT INFUSION,67018,"Patel, Eshan, MD",1/7/2025,DOCEtaxel 21 Day Cycles - Prostate,_1. First Line,12/30/2024,Active,,
HAM OP INFUSION,35414,"Yogarajah, Meera, MD",8/17/2023,Pertuzumab / Trastuzumab / DOCEtaxel 21 Day Cycles - Breast,First Line,8/14/2023,Active,,
HAM OP INFUSION,35414,"Yogarajah, Meera, MD",4/10/2025,Fam-trastuzumab Deruxtecan 21 Day Cycles - Breast,_2. Second Line,4/10/2025,Active,Carcinoma of left breast metastatic to liver (CMS/HCC),"C50.912 - Malignant neoplasm of unspecified site of left female breast; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; Z79.82 - Long term (current) use of aspirin; Z79.899 - Other long term (current) drug therapy; Z88.0 - Allergy status to penicillin; Z17.0 - Estrogen receptor positive status (ER+)"
CINJ OP INFUSION,47922,"Gulhati, Prateek, MD PhD",5/15/2025,CINJ 072402 Quemliclustat or Placebo / Nab-PACLitaxel / Gemcitabine 28 Day Cycles Research- Pancreatic Adenocarcinoma,_1. First Line,5/15/2025,Active,Overlapping malignant neoplasm of pancreas (CMS/HCC),Z48.815 - Encounter for surgical aftercare following surgery on the digestive system; C25.2 - Malignant neoplasm of tail of pancreas; C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct; C25.8 - Malignant neoplasm of overlapping sites of pancreas; R79.1 - Abnormal coagulation profile
CBMC 2W ONCOLOGY,55596,"Scoppetuolo, Michael, MD",2/16/2024,CyBorD + Daratumumab-fihj:  Daratumumab-fihj / Bortezomib / Cyclophosphamide / Dexamethasone 28 Day Cycles- Multiple Myeloma,_1. First Line,2/11/2024,Inactive,,
CBMC 2W ONCOLOGY,55596,"Scoppetuolo, Michael, MD",5/31/2024,DCEP (Cyclophosphamide / Etoposide / CISplatin / Dexamethasone) 28 Day Cycles - Multiple Myeloma,_2. Second Line,5/23/2024,Inactive,,
CBMC 2W ONCOLOGY,49508,"Grossman, I Robert, MD",11/24/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia,Induction,11/23/2023,Inactive,,
CBMC 2W ONCOLOGY,49508,"Grossman, I Robert, MD",11/27/2023,Cytarabine Cytoreduction for Hyperleukocytosis,_1. First Line,11/27/2023,Inactive,,
CBMC 2W ONCOLOGY,49508,"Grossman, I Robert, MD",12/27/2023,Venetoclax / Decitabine 28 Day Cycles - Acute Myeloid Leukemia (Cycle 1 Inpatient),_1. First Line,12/25/2023,Active,Pancreatic adenocarcinoma (CMS/HCC),
CBMC 2W ONCOLOGY,49508,"McKenna, Marshall, MD",9/13/2024,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,_1. First Line,9/13/2024,Inactive,,
CBMC 2W ONCOLOGY,49508,"Grossman, I Robert, MD",12/24/2024,Cytarabine Cytoreduction for Hyperleukocytosis,_3. Third Line,12/24/2024,Active,,
CBMC 2W ONCOLOGY,49508,"Grossman, I Robert, MD",2/4/2025,Methotrexate Intrathecal 12 mg IT 1 Day Cycle- Hematological Malignancies,Maintenance,2/4/2025,Active,AML (acute myeloid leukemia) in relapse (CMS/HCC),"Z51.11 - Encounter for antineoplastic chemotherapy; D61.810 - Antineoplastic chemotherapy induced pancytopenia; C92.02 - Acute myeloblastic leukemia, in relapse; C22.0 - Liver cell carcinoma; G54.6 - Phantom limb syndrome with pain; D63.0 - Anemia in neoplastic disease; B19.20 - Unspecified viral hepatitis C without hepatic coma; Z16.21 - Resistance to vancomycin; D69.59 - Other secondary thrombocytopenia; F41.9 - Anxiety disorder, unspecified; N40.0 - Benign prostatic hyperplasia without lower urinary tract symptoms; G47.00 - Insomnia, unspecified; Z87.891 - Personal history of nicotine dependence; T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter; H54.3 - Unqualified visual loss, both eyes; L30.9 - Dermatitis, unspecified; H90.3 - Sensorineural hearing loss, bilateral; K52.9 - Noninfective gastroenteritis and colitis, unspecified; Z98.890 - Other specified postprocedural states; Z79.899 - Other long term (current) drug therapy; Z88.8 - Allergy status to other drugs, medicaments and biological substances"
MSC OP INFUSION,93475,"Cohen, Seth D, MD",11/27/2024,CINJ 042106 (A011801)  Ado-Trastuzumab Emtansine + Tucatinib / Placebo 21 Day Cycles Research- Breast Cancer,_2. Second Line,11/26/2024,Active,,
NBR CINJ OP INFUSION,31879,"Assal, Amer, MD",6/12/2023,"Bendamustine D1, D4 / Bortezomib / Dexamethasone D1, D4, D8, D11 28 Day Cycles - Multiple Myeloma",,6/11/2023,Inactive,,
NBR CINJ OP INFUSION,31879,"Assal, Amer, MD",6/27/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,6/25/2023,Inactive,,
NBR CINJ OP INFUSION,31879,"Assal, Amer, MD",6/30/2023,Daratumumab and Hyaluronidase-fihj 28 Day Cycles- Multiple Myeloma,,6/29/2023,Inactive,,
NBR CINJ OP INFUSION,31879,"Assal, Amer, MD",6/30/2023,Bendamustine / RiTUXimab 28 Day Cycles - Chronic Lymphocytic Leukemia / Small Lymphatic Lymphoma,,6/29/2023,Inactive,,
NBR CINJ OP INFUSION,31879,"Assal, Amer, MD",6/30/2023,RiTUXimab Initial Infusion Single Day (Outpatient),,6/30/2023,Inactive,,
NBR 4N BMTU/IMCU,31879,"Assal, Amer, MD",7/6/2023,BMT Allogeneic TBF + Post Cy ,,7/5/2023,Inactive,,
CINJ OP INFUSION,10888,"Leiser, Aliza, MD",3/4/2024,Pembrolizumab / PACLitaxel / CARBOplatin 21 Day Cycles + Pembrolizumab 42 Day Cycles - Uterine,Adjuvant,2/28/2024,Active,,
MMC OP VP INFUSION,88388,"Cohen, Seth D, MD",8/14/2023,CINJ 072014 Expanded Access Ulixertinib (BVD-523) - MAPK Pathway Altered Malignancies,,8/14/2023,Active,,
SOM OUTPT INFUSION,30298,"Yin, Faye, MD",4/11/2023,PACLitaxel / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,First Line,4/10/2023,Inactive,,
SOM OUTPT INFUSION,30298,"Yin, Faye, MD",11/10/2023,Bevacizumab 21 Day Cycles - Uterine Cancer maintenance ,_1. First Line,11/9/2023,Inactive,,
CINJ OP INFUSION,80910,"Berim, Lyudmyla, MD",10/21/2024,"Gemcitabine D1, D8, D15/Albumin-Bound PACLitaxel D1, D8, D15 28 Day Cycles- Gastrointestinal Cancers",Neoadjuvant,10/18/2024,Inactive,,
CINJ OP INFUSION,80910,"Berim, Lyudmyla, MD",2/26/2025,"Gemcitabine 1000 mg/m2 D1, D8/Capecitabine 650 mg/m2 21 Day Cycles- Pancreatic Adenocarcinoma",Adjuvant,2/16/2025,Active,Pancreatic adenocarcinoma (CMS/HCC),"C25.9 - Malignant neoplasm of pancreas, unspecified"
NBR 4N ONCOLOGY,29857,"Aikins, James K, MD",9/22/2023,CISplatin With Concurrent Radiation 7 Day Cycles - Cervical,,9/21/2023,Inactive,,
NBR 4N ONCOLOGY,29857,"Girda, Eugenia, MD",9/22/2023,PEMEtrexed With Prior Radiation 21 Day Cycles - Cervical,,9/14/2023,Inactive,,
NBR 5N ONCOLOGY,29857,"Stephenson, Ruth D, DO",10/5/2023,PACLitaxel / CARBOplatin / Bevacizumab / Pembrolizumab 21 Day Cycles - Cervical,First Line,10/3/2023,Inactive,,
MMC OP VP INFUSION,56968,"Cohen, Seth D, MD",5/8/2023,Pembrolizumab 21 Day Cycles - Uterine,,5/7/2023,Inactive,,
NBR CINJ OP INFUSION,92570,"Assal, Amer, MD",4/24/2023,Decitabine (5 day) 28 Day Cycles - Myelodysplastic Syndromes,,4/23/2023,Inactive,,
MMC OP VP INFUSION,57163,"Talwar, Sumit, MD",6/27/2023,CISplatin 75 mg/m2/Etoposide 100 mg/m2 D1-D3 21 Day Cycles- Small Cell Lung Cancer,First Line,6/26/2023,Inactive,,
MMC OP VP INFUSION,84297,"Lee, Patrick C, MD",5/9/2024,FOLFIRI + Bevacizumab (Fluorouracil Continuous Infusion/Leucovorin/Irinotecan) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,5/8/2024,Inactive,,
CMC OP INFUSION,72568,"Tang, Horace, MD",11/30/2023,Cemiplimab-rwlc 21 Day Cycles - Squamous Cell Skin Cancer,_2. Second Line,11/30/2023,Inactive,,
CINJ OP INFUSION,99722,"Omene, Coral Oghenerukevwe, MD",1/27/2023,Abemaciclib 28 Day Cycles - Breast ,,1/27/2023,Inactive,,
MMC OP VP INFUSION,2893,"Eltoukhy, Hussam, MD",5/18/2023,Mini-R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - Diffuse Large B-Cell Lymphoma,First Line,5/17/2023,Inactive,,
HAM OP INFUSION,38944,"Yogarajah, Meera, MD",10/12/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,_1. First Line,9/12/2023,Active,,
HAM OP INFUSION,38944,"Yogarajah, Meera, MD",3/19/2024,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,_1. First Line,3/18/2024,Active,,
CINJ PEDS HEMONC ,15073,"Drachtman, Richard, MD",4/26/2023,R-CHOP (Cyclophosphamide / DOXOrubicin / VinCRIStine / PredniSONE / RiTUXimab) 21 Day Cycles - -Lymphocyte predominant Hodgkin Lymphoma,First Line,4/25/2023,Inactive,,
CINJ OP INFUSION,39075,"Ganesan, Shridar, MD PhD",11/28/2023,Abemaciclib 28 Day Cycles - Breast ,_5. Fifth Line,11/28/2023,Inactive,,
CINJ OP INFUSION,51978,"Boland, Patrick M, MD",4/19/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,Neoadjuvant,4/3/2024,Inactive,,
CINJ OP INFUSION,96678,"Saraiya, Biren P, MD",1/31/2023,Abiraterone / DEX 30 Day Cycles - Prostate,First Line,1/31/2023,Active,,
HAM OP INFUSION,72268,"Yogarajah, Meera, MD",4/17/2025,CISplatin With Concurrent Radiation 7 Day Cycles - Vulvar,_1. First Line,4/17/2025,Active,Malignant neoplasm of overlapping sites of vulva (CMS/HCC),"C51.8 - Malignant neoplasm of overlapping sites of vulva; I10 - Essential (primary) hypertension; E78.5 - Hyperlipidemia, unspecified; Z79.899 - Other long term (current) drug therapy"
CINJ OP INFUSION,79428,"Saraiya, Biren P, MD",12/17/2024,Belzutifan 28 Day Cycles,_3. Third Line,12/17/2024,Inactive,,
CINJ OP INFUSION,69975,"Haigentz, Missak, MD",1/11/2024,mFOLFOX6 Outpatient (Fluorouracil Continuous Infusion/Leucovorin/OXALIplatin) 14 Day Cycles- Gastrointestinal Cancers,_1. First Line,1/11/2024,Inactive,,
CINJ OP INFUSION,69975,"Haigentz, Missak, MD",7/24/2024,Capecitabine 1000 mg/m2 21 Day Cycles- Gastrointestinal Cancers,_2. Second Line,7/24/2024,Active,,
SOM OUTPT INFUSION,85071,"Patel, Eshan, MD",11/7/2024,Nivolumab (1 mg/kg) / Ipilimumab (3 mg/Kg) 21 Day Cycles + Nivolumab 28 Day Cycles - Melanoma,_1. First Line,10/28/2024,Active,,
HAM OP INFUSION,65536,"Patel, Malini M, MD",1/11/2023,CINJ 042201 Lipitor 84 Day Cycles Research Breast Cancer,First Line,12/14/2022,Active,,
HAM OP INFUSION,65536,"Patel, Malini M, MD",5/17/2023,Pertuzumab / Trastuzumab (Continuation) 21 Day Cycles - Breast,Neoadjuvant,5/16/2023,Inactive,,
HAM OP INFUSION,65536,"Patel, Malini M, MD",6/21/2023,Ado-Trastuzumab Emtansine 21 Day Cycles - Breast,Adjuvant,6/21/2023,Inactive,,
MMC OP VP INFUSION,34992,"Cohen, Seth D, MD",3/13/2024,Gemcitabine / CARBOplatin / Bevacizumab 21 Day Cycles + Bevacizumab 21 Day Cycles - Ovarian Cancer/ Fallopian Tube Cancer/ Primary Peritoneal Cancer,_3. Third Line,3/12/2024,Active,,
CINJ OP INFUSION,73033,"Mayer, Tina M, MD",7/10/2023,Apalutamide 30 Day Cycles - Prostate,,7/10/2023,Active,,
MMC OP VP INFUSION,76664,"Cohen, Seth D, MD",5/19/2025,PEMEtrexed/CARBOplatin + Pembrolizumab 21 Day Cycles- Non-Small Cell Lung Cancer,_1. First Line,5/19/2025,Active,"Malignant neoplasm of lower lobe of left lung (CMS/HCC)
Hypothyroidism due to medication",
MMC OP VP INFUSION,57083,"Cohen, Seth D, MD",3/24/2025,AC (DOXOrubicin / Cyclophosphamide) Dose-Dense 14 Day Cycles Followed By PACLitaxel 7 Day Cycles - Breast,_1. First Line,3/24/2025,Active,"Malignant neoplasm of right breast, estrogen receptor positive (CMS/HCC)",
CINJ OP INFUSION,92197,"Boland, Patrick M, MD",5/20/2024,Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation Weekly 7 Day Cycles- Rectal Cancer,Neoadjuvant,5/20/2024,Inactive,,
CINJ OP INFUSION,92197,"Boland, Patrick M, MD",6/19/2024,CINJ 072202 Chemoradiation Therapy Capecitabine 825 mg/m2 D1-D5 with Concurrent Radiation- Rectal Cancer,Neoadjuvant,5/21/2024,Inactive,,
CINJ OP INFUSION,92197,"Boland, Patrick M, MD",9/3/2024,CINJ 072202 FOLFOXIRI (OXALiplatin / Irinotecan / Leucovorin / Fluorouracil) 14 Day Cycles Research- Rectal Cancer,Neoadjuvant,8/20/2024,Active,,
CINJ OP INFUSION,41657,"Stephenson, Ryan D, DO",2/7/2024,CINJ 082101 (NRG-GU009) ARM 3 Androgen Deprivation Therapy 3 Month Cycles (84 Days) Research Prostate Cancer,Neoadjuvant,10/3/2023,Active,,
CINJ OP INFUSION,55894,"Patel, Vimal D, MD",1/21/2025,CINJ 192301 NT-175 21 Day Cycle Research- Advanced / Metastatic Solid Tumors,_2. Second Line,1/20/2025,Inactive,Acquired hypothyroidism,
